"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01556347","Multi-Drug Desensitization Protocol for Heart Transplant Candidates",,"Terminated","Has Results","Heart Transplantation","Drug: Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis","Percentage of Patients With a Reduction in CPRA to Less Than 20%|Percentage of Patients Transplanted|Percentage of Patients Who Suffer Mortality, a Serious Adverse Event, or Other Adverse Event During the Study Period|Percentage of Patients Who Experience Grade 3 and Above Non-Hematologic Toxicities|The Percentage of Patients Who Experience Any Grade of Peripheral Neuropathy|Percentage of Patients Who Experience CMV, PTLD, and PML|The Percentage of Patients Who Experience Either a Respiratory Tract Infection or a Urinary Tract Infection|The Percentage of Patients Who Experience Exacerbations Cardiac Dysrhythmias or Heart Failure|Percentage of Patients With Grade 4 Hematologic Toxicities|The Percentage of Patients With Antibody Mediated Rejection After Transplantation|Percentage of Patients Who Develop De Novo Alloantibody or DSA Alloantibody After Transplant|Percentage of Patients Post-Transplant That Are DSA Negative|Percentage of Allograft Survival|The Percentage of Allografts That Endure Acute Rejection Within One Year of Transplantation|Percentage of Patients With a CPRA <20%, But Were Not Transplanted During the Study Period|Percentage of Patients Who Receive Transplants Who Then Suffer Serious Post-transplant Complications","Providence Health & Services","All","18 Years to 67 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IND110875","July 2012","May 2016","May 2016","March 16, 2012","June 15, 2018","June 15, 2018","Providence Sacred Heart Medical Center, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01556347"
2,"NCT03629340","Metformin for Pulmonary Hypertension HFpEF",,"Active, not recruiting","No Results Available","Pulmonary Hypertension|Heart Failure","Drug: Metformin|Drug: Placebo oral capsule","The primary endpoint of the trial will be mean pulmonary artery pressure (mPAP) during submaximal exercise as compared between placebo and metformin at 12 weeks (i.e. the week 12 RHC of placebo vs week 12 RHC of metformin).","Marc A. Simon|National Institute on Aging (NIA)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO18030354|R01AG058659","February 26, 2019","June 2023","December 2023","August 14, 2018",,"April 1, 2020","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03629340"
3,"NCT02408432","Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines",,"Recruiting","No Results Available","Cardiomyopathy|Heart Failure","Biological: Mesenchymal Stem Cell Transplantation|Drug: Standard of Care for Heart Failure","Adverse Events of Allogeneic Human Mesenchymal Stem Cells (hMSCs) Determined by CTCAE version 4|Change in Left Ventricular Ejection Fraction (LVEF)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0519|NCI-2015-00969|P30CA016672","January 11, 2016","January 31, 2023","January 31, 2023","April 3, 2015",,"August 22, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02408432"
4,"NCT03122730","VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB",,"Completed","No Results Available","Pulmonary Hypertension","Combination Product: VentaProst","Determination of the equivalent dose of VentaProst necessary to achieve a pharmacodynamic response that is comparable to Standard of Care|Treatment-Emergent Adverse Events (TEAEs)|Effects on pulmonary vascular resistance|Effects on oxygenation status|Effects on fraction of inspired oxygen (FiO2)|Effects on cardiovascular medication usage","Aerogen Pharma Limited","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APC-VP-CLN-001","August 23, 2017","March 1, 2019","May 30, 2019","April 21, 2017",,"May 31, 2019","Stanford University Medical Center, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03122730"
5,"NCT00944229","The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure",,"Terminated","Has Results","Heart Failure","Drug: LOVAZA (Omega-3)|Drug: Placebo","Change in Peak VO2|Change in Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) After 8 Weeks of Omega 3 Supplementation.|Change in Base Line Oxidized Low Density Lipoprotein (LDL) Level and in Response to Exercise","Columbia University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAD7501|LVZ112854","January 2010","March 2014","March 2014","July 23, 2009","April 22, 2016","May 25, 2016","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00944229"
6,"NCT01103843","Plavix, Prasugrel and Drug Eluting Stents Pilot Trial","PPD","Unknown status","No Results Available","Coronary Artery Disease|Platelet Aggregation Inhibitors|PCI- Percutaneous Coronary Intervention","Drug: Loading Dose Arm|Drug: Maintenance Dose Arm","Change in platelet reactivity after switching medication regimen of two thienopyridines- clopidogrel and prasugrel|Occurrence of all bleeding events for subjects enrolled into the trial|Occurrence of all MACE events for subjects enrolled into the trial","St. Francis Hospital, New York","All","21 Years to 75 Years   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-006","April 2010","April 2011","May 2011","April 15, 2010",,"April 15, 2010","St. Francis Hospital, Roslyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT01103843"
7,"NCT03939923","Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery",,"Active, not recruiting","No Results Available","Surgery|Coronary Artery Disease","Drug: Rocuronium|Drug: Neostigmine|Drug: Glycopyrrolate|Drug: Sugammadex","Time to Extubation|Heart rate|Blood Pressure|Tidal Volume|Peak Flow Rate|Swallowing Capacity","West Virginia University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","WVU Protocol #: 1806161309","May 1, 2019","December 2022","December 2022","May 7, 2019",,"May 7, 2019","WVU Medicine, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03939923"
8,"NCT01234870","Comprehensive Evaluation of Ischemic Heart Disease Using MRI",,"Completed","Has Results","Heart Disease, Ischemic|Atherosclerosis, Coronary","Drug: Gadolinium|Drug: Adenosine","Magnetic Resonance Image Quality Rating|Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol","Northwestern University|Astellas Pharma US, Inc.|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CR1_STU00006013|ASCA-9J02","June 2010","January 2012","January 2012","November 4, 2010","September 26, 2014","September 26, 2014","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01234870"
9,"NCT01932606","Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction",,"Completed","Has Results","Heart Disease|Heart Failure With Preserved Ejection Fraction|Exercise Intolerance|Pulmonary Hypertension","Drug: Nitrite|Drug: Saline Placebo for Nitrite","Exercise Pulmonary Capillary Wedge Pressure (PCWP)|Change in Central Pressures After Study Drug (Resting)|Change in Heart Rate After Study Drug (Resting)|Change in Blood Pressure After Study Drug (Resting)|Change in Pulmonary Vascular Resistance (PVR) After Study Drug (Resting)|Change in Pulmonary Artery (PA) Compliance After Study Drug (Resting)|Change in Systemic Vascular Resistance (SVR) After Study Drug (Resting)|Change in Left Ventricular Stroke Work (LVSW) After Study Drug (Resting)|Change in Oxygen Consumption (VO_2) After Study Drug (Resting)|Change in Arteriovenous Oxygen Content Difference After Study Drug (Resting)|Change in Cardiac Output After Study Drug (Resting)|Change in Stroke Volume After Study Drug (Resting)|Change in Central Pressures After Study Drug (Exercise)|Change in Heart Rate After Study Drug (Exercise)|Change in Blood Pressure After Study Drug (Exercise)|Change in PVR After Study Drug (Exercise)|Change in PA Compliance After Study Drug (Exercise)|Change in SVR After Study Drug (Exercise)|Change in LVSW After Study Drug (Exercise)|Change in Oxygen Consumption (VO_2) After Study Drug (Exercise)|Change in Arteriovenous Oxygen Difference After Study Drug (Exercise)|Change in Cardiac Output After Study Drug (Exercise)|Change in Stroke Volume After Study Drug (Exercise)","Barry Borlaug|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","13-004077","August 2013","October 2014","October 2014","August 30, 2013","February 15, 2016","March 14, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01932606"
10,"NCT03146741","Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)","USHER","Completed","Has Results","Heart Failure","Drug: Zepatier","Number of Participants With Post-treatment Sustained Virologic Response (SVR)|Number of Severe Adverse Events (SAE) Attributable to HCV Therapy Post-heart Transplant","University of Pennsylvania|Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","826708","May 16, 2017","September 10, 2019","November 30, 2019","May 10, 2017","February 5, 2020","February 26, 2020","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03146741/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03146741/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03146741"
11,"NCT03702829","24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients",,"Recruiting","No Results Available","Amyloidosis","Drug: Inotersen","Systolic strain imaging by echocardiographic|Systolic strain evaluation by echocardiography|LV mass measurement by Cardiac MRI (cMRI) (units = grams)|ECV-extracellular volume by Cardiac MRI (cMRI) (unit=percentage)","Brigham and Women's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P001436","February 28, 2019","January 2022","March 2022","October 11, 2018",,"August 2, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03702829"
12,"NCT03944577","Impact of Evolocumab in Cardiac Transplant Patients With CAV",,"Recruiting","No Results Available","Heart Transplant","Drug: Evolocumab (Repatha)","To measure the effect of evolocumab on serum LDL as measured in mL/dL after 12 weeks of therapy in heart transplant patients.","University of Nebraska|Amgen","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20177584","July 15, 2019","July 1, 2021","September 1, 2021","May 9, 2019",,"July 29, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT03944577"
13,"NCT02637193","A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects",,"Completed","No Results Available","Healthy Subjects","Drug: Venlafaxine|Drug: Moxifloxacin|Drug: Drug - placebo","Postdose QTcF (Fridericia's correction) intervals|Averse events, vital signs, physical examinations and abnormal laboratory for safety assessments (safety and tolerability)|Relationship between QTc prolongation and the measured venlafaxine/desvenlafaxine plasma concentration","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","B2411360|TQTC","December 2015","July 2016","July 2016","December 22, 2015",,"June 21, 2018","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02637193"
14,"NCT03035227","Catheter Ablation of Arrhythmias to Improve CRT Response","ABLATE-CRT","Terminated","No Results Available","Arrhythmia, Cardiac","Procedure: Catheter Ablation|Drug: Anti-Arrhythmics","Change in Ejection Fraction (EF)|Bi-ventricular pacing improvement|Cardiovascular mortality|All-cause mortality|Hospital admissions for heart failure exacerbation|New York Heart Association (NYHA) class change|Change in 6 minute walk test|Change in Quality of Life - SF-36|Change in Quality of Life Kansas City Cardiomyopathy Questionnaire (KCCQ)","Kansas City Heart Rhythm Institute|Biosense Webster, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003861","January 23, 2017","May 1, 2018","May 1, 2018","January 27, 2017",,"September 30, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT03035227"
15,"NCT01960153","Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage","PITCH-ER","Withdrawn","No Results Available","Heart Failure|Pulmonary Hypertension","Drug: Tadalafil|Drug: Placebo","Change in renal function|Incidence of acute kidney injury (AKI) events (clinical and subclinical)|Changes in renal function stratified by diabetes/no diabetes|Incidence of AKI events stratified by diabetes/no diabetes","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)|HealthCore-NERI","All","21 Years and older   (Adult, Older Adult)","Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2013P001412|R01HL119155-01A1","October 2013","December 2017","May 2018","October 10, 2013",,"September 12, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01960153"
16,"NCT01763996","The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina",,"Completed","Has Results","Coronary Artery Disease","Drug: Febuxostat|Drug: Febuxostat placebo","Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo|Change in Coronary Artery Cross-Sectional Area From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo|Change in Coronary Flow Velocity From Rest to IHG Exercise at the End of the Administration of Febuxostat and Placebo|Change in Coronary Artery Flow Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo|Change in Coronary Artery Cross Sectional Area Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo|Change in Coronary Flow Velocity Following the Administration of Sublingual Nitroglycerin at the End of the Administration of Febuxostat and Placebo|Change in Time to Onset of ≥1 mm ST-Segment Depression During Exercise Treadmill Test (ETT)|Change in Maximum ST-segment Depression During Exercise Treadmill Test|Percentage of Participants Stopping Exercise Treadmill Test Due to Angina at the End of the Administration of Febuxostat and Placebo|Time to Onset of Angina During Exercise Treadmill Test at the End of the Administration of Febuxostat and Placebo|Exercise Duration","Takeda","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CCR-FEB-002|U1111-1136-2270","May 2013","March 2015","April 2015","January 9, 2013","April 13, 2016","April 13, 2016","Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01763996"
17,"NCT03392740","Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.",,"Unknown status","No Results Available","Cardiomyopathy Due to Drug|Heart Failure, Systolic","Drug: Lisinopril|Drug: Placebo Oral Tablet","Change in strain rate from baseline|Heart failure and left ventricular dysfunction","Ascension Genesys Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","GHIGHCI2018","March 15, 2018","March 15, 2019","March 15, 2020","January 8, 2018",,"February 22, 2018","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03392740"
18,"NCT01157949","A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)",,"Withdrawn","No Results Available","Cardiac Allograft Vasculopathy","Drug: Thymoglobulin",,"Cedars-Sinai Medical Center|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MA-1007-1","November 2010","November 2013","January 10, 2018","July 8, 2010",,"March 14, 2019","Cedars-Sinai Medical Center, Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT01157949"
19,"NCT02359227","Safety Study of Cenderitide in Stable Chronic Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: Cenderitide","Safety and tolerability as assessed by changes in vital signs (blood pressure, heart rate, and body temperature), clinical laboratory tests, adverse events, 12-lead ECGs, and physical examinations compared to pre-dose, baseline measurements.|Pharmacokinetic (PK) profile of cenderitide as measured in area under the blood concentration-curve (AUC) from time zero to 48 hours post each infusion rate start, maximum blood concentration (Cmax), and time of maximum blood concentration (Tmax).|Pharmacodynamic (PD) response as assessed by changes in blood pressure, heart rate, weight, fluid balance (intake/output), plasma cGMP, ANP, NT-proBNP, and aldosterone, and urine cGMP compared to pre-dose baseline assessments.","Capricor Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDNP-578-01","January 2015","April 2, 2015","April 2, 2015","February 9, 2015",,"February 11, 2020","Orange County Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT02359227"
20,"NCT03222531","Expanding the Pool in Orthotopic Heart Transplantation",,"Recruiting","No Results Available","Hepatitis C|Heart Transplant|Cardiac Transplant","Drug: sofosbuvir/velpatasvir","Adverse Events|HCV free at 1 year|Transmission rate of HCV from HCVAb+/NAT- donors to HCVAb- recipients|Incidence of allograft rejection|Incidence of graft loss|All-cause mortality|Waitlist time after enrollment","University of Pittsburgh","All","18 Years to 71 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRO17020069","August 1, 2017","July 1, 2023","July 1, 2023","July 19, 2017",,"October 14, 2019","UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03222531"
21,"NCT01979965","Effect of Ranolazine on Valvular Disease in Patients With Pacemakers","REIN-MR","Unknown status","No Results Available","Ischemic Mitral Regurgitation","Drug: Ranolazine (Active drug)|Drug: Placebo","effective regurgitant orifice by echocardiography|proximal isovelocity surface area by echocardiography|Seattle Angina Questionnaire|Rose Dyspnea Scale","University Cardiology","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","IN-US-259-0173","November 2013","May 2014","September 2014","November 8, 2013",,"November 8, 2013","University Cardiology, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01979965"
22,"NCT02252783","BFPET for Regional Myocardial Perfusion Imaging",,"Not yet recruiting","No Results Available","Coronary Artery Disease","Drug: BFPET","Sensitivity and specificity of BFPET|Primary safety endpoints - ECG, physical examinations, vital signs, laboratory and adverse event assessments","Fluoropharma, Inc.","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BFPET P-02","October 1, 2018","May 30, 2019","September 30, 2019","September 30, 2014",,"August 1, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02252783"
23,"NCT02366091","Inflammation and Coronary Endothelial Function",,"Active, not recruiting","No Results Available","Coronary Artery Disease","Drug: Methotrexate|Drug: Colchicine|Drug: Placebo","Coronary segment endothelial function, measured by MRI as the change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest and as mm2).|Change in coronary segment endothelial function, measured by MRI as the change in coronary cross sectional area (CSA) from rest to that during isometric handgrip exercise (IHE) (as % rest and as mm2).|Change in coronary blood velocity (CBV), measured by MRI as the change in CBV from rest to IHE stress (as cm/s and as % rest).|Change in coronary blood flow (CBF), measured by MRI as the change from rest to IHE stress (as cm/s and as % rest).|Serum high-sensitivity C reactive protein (hs-CRP), measured by laboratory assessment as the change in hs-CRP between baseline and 8 and 24 weeks.|Serum interleukin-6 (IL-6), measured by laboratory assessment as the change in IL-6 between baseline and 8 and 24 weeks..|Brachial flow mediated dilation (FMD), measured by ultrasound as the change in brachial FMD between baseline and 8 and 24 weeks.|Safety as determined by physical exam and monitoring laboratory values. Measured by assessment for side-effects and laboratory assessment including complete metabolic panel, liver function tests, and complete blood count.","Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years and older   (Adult, Older Adult)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","IRB00047206|R01HL120905","January 2015","August 2020","February 2021","February 19, 2015",,"September 12, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02366091"
24,"NCT02603614","Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment",,"Completed","No Results Available","Heart Failure|Renal Insufficiency","Drug: Cenderitide|Drug: Placebo","Safety and tolerability as evaluated by incidence and severity of treatment-emergent adverse events, concomitant medications, and changes from baseline in lab assessments, vital signs, physical exams, and ECGs per subject and for the study as a whole.|Pharmacokinetics of cenderitide by assessing Cmax|Pharmacokinetics of cenderitide by assessing tmax|Pharmacokinetics of cenderitide by assessing AUC(0-discharge)|Pharmacodynamics as assessed by observed vital signs and changes from baseline.|Pharmacodynamics as assessed by observed weight and changes from baseline.|Pharmacodynamics as assessed by daily volume difference between liquid intake and urine output (i.e., daily fluid balance) and changes from baseline.|Pharmacodynamics as assessed by observed plasma cystatin C and changes from baseline.|Pharmacodynamics as assessed by observed plasma cGMP and changes from baseline.|Pharmacodynamics as assessed by observed urinary cGMP and changes from baseline.","Capricor Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDNP-578-02","December 2015","March 31, 2016","March 31, 2016","November 13, 2015",,"February 11, 2020","Orange County Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT02603614"
25,"NCT01170338","Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome",,"Unknown status","No Results Available","Smoking|Acute Coronary Syndrome","Drug: Varenicline 100 mg by mouth twice daily|Drug: control","nicotine levels|recurrent myocardial ischemia","Newark Beth Israel Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2008.68","January 2008","July 2011",,"July 27, 2010",,"July 27, 2010","Newark Beth Israel Medical Center, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01170338"
26,"NCT02674204","STOP Heart Disease in Breast Cancer Survivors Trial","STOP","Terminated","Has Results","Breast Cancer|Heart Disease|Cardiotoxicity|Myocardial Dysfunction","Drug: Atorvastatin|Drug: Placebo","Change in Global Circumferential Strain (GCS) Measured by Cardiac MRI (CMRI)|Change in Global Longitudinal Strain as Measured by CMRI|Change in Peak Left Ventricular Twist as Measured by CMRI|Change in Peak Left Ventricular Torsion as Measured by CMRI|Change in Left Ventricular Untwisting Rate as Measured by CMRI|Change in Left Ventricular Ejection Fraction as Measured by CMRI|Change in Left Ventricular End Diastolic Volume as Measured by CMRI|Change in Left Ventricular End Systolic Volume as Measured by CMRI|Change in Cardiac Output as Measured by CMRI|Change in Left Ventricular Mass as Measured by CMRI|Change in Left Ventricular Concentricity as Measured by CMRI|Change in Native T1 as Measured by CMRI|Change in Post Contrast T1 as Measured by CMRI|Change in Extracellular Volume as Measured by CMRI|Change in Native T2 as Measured by CMRI","Cedars-Sinai Medical Center|California Breast Cancer Research Program","Female","18 Years and older   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IIT2015-12-Goodman-STOP","May 5, 2016","May 25, 2018","May 25, 2018","February 4, 2016","April 30, 2019","May 15, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02674204/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02674204/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02674204"
27,"NCT03168529","Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit","OBSERVE-IVA","Recruiting","No Results Available","Heart Failure","Drug: Ivabradine|Drug: Placebo","Change in Heart Rate|Change in Heart Rate in self-identified African Americans","Phillip Levy|Amgen|iRhythm Technologies, Inc.|Wayne State University","All","19 Years to 89 Years   (Adult, Older Adult)","Phase 4","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1701000235","July 1, 2018","December 31, 2019","June 30, 2020","May 30, 2017",,"October 4, 2018","Wayne State University, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03168529"
28,"NCT03208244","DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant",,"Recruiting","No Results Available","End Stage Heart Disease|Hepatitis C","Drug: Clinically prescribed direct acting antiviral","Undetectable HCV RNA|Safety and tolerability (based on number of adverse events and out of range lab values) of DAA therapy in patients undergoing cardiac transplantation","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017P001427","November 9, 2017","December 31, 2021","April 1, 2022","July 5, 2017",,"March 5, 2019","Masschusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03208244"
29,"NCT01767987","Ranolazine Cardioprotection in PCI",,"Terminated","Has Results","Acute Coronary Syndrome","Drug: Ranolazine|Drug: Placebo","Troponin|CK-MB|TIMI Flow Rate (Grade)|Incidence of Atrial Fibrillation, Ventricular Tachycardia, or Ventricular Fibrillation in Coronary Cath Lab|Incidence of Non-sustained Ventricular Tachycardia or Atrial Fibrillation Post PCI|Left Ventricular End Diastolic Pressure (LVEDP)|Death, Myocardial Infarction (Biomarker Greater Than 2x Normal), CHF, Cardiac Arrest|Death, MI, Revascularization, CHF|Successful PCI","Harvey Hahn|Gilead Sciences|Kettering Health Network","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","ISR IN-US-259-0139","November 2012","April 2014","April 2014","January 15, 2013","November 20, 2015","September 14, 2017","Kettering Medical Center, Kettering, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01767987"
30,"NCT03138603","Metoprolol to Reduce Perioperative Myocardial Injury","ORION","Active, not recruiting","No Results Available","Heart Diseases","Drug: Metoprolol Tartrate|Drug: Placebo","myocardial injury|MACE|Myocardial ischemia (ST-depression/elevation duration)|Stroke|Cumulative vasopressor requirements in PACU|Incidence rate bradycardia duration (HR <50/min)|cumulative rate bradycardia duration (HR <50/min)|Unplanned ICU admission|Length of hospital stay|Length of ICU stay","Washington University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Phase 3","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201610156|5R01HL126892","December 2016","December 31, 2021","December 31, 2022","May 3, 2017",,"April 23, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03138603"
31,"NCT01352416","Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery",,"Terminated","Has Results","Heart; Dysfunction Postoperative, Cardiac Surgery","Drug: Ranolazine|Drug: Placebo","Freedom From Any Episode of Post Operative Atrial Fibrillation Longer Than 6 Hours Duration Occurring During the Study Period.","William Beaumont Hospitals|Beaumont Foundation of America|Gilead Sciences","All","22 Years and older   (Adult, Older Adult)","Phase 3","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009-101, IN-US-259-0114","September 2010","November 2012","November 2012","May 11, 2011","January 6, 2017","January 6, 2017","William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01352416"
32,"NCT03383419","Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients","TROJAN-C","Recruiting","No Results Available","Heart Failure","Drug: Epclusa","Sustained virologic response after 12 weeks of treatment|1-year post-transplant survival","Baylor Research Institute","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","018-009","March 20, 2018","January 30, 2021","February 28, 2021","December 26, 2017",,"April 24, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Duke University Medical Center, Durham, North Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03383419"
33,"NCT02579057","Sub-Q Versus IV Furosemide in Acute Heart Failure",,"Completed","Has Results","Congestive Heart Failure","Drug: Furosemide Injection Solution (SCP-101)|Drug: Furosemide Injection Solution, USP","Urine Output|Heart Failure Symptom Scoring/Symptom Improvement|Number of Participants With Side Effects|Urine Sodium","Johns Hopkins University|scPharmaceuticals, Inc.","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00068019","February 2016","June 2017","July 2017","October 19, 2015","November 17, 2017","December 18, 2017","Johns Hopkins Hospital Heart Failure Bridge Clinic, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02579057/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02579057"
34,"NCT01842035","Heart Rate Response to Regadenoson and Sudden Cardiac Death",,"Active, not recruiting","No Results Available","Left Ventricular Systolic Dysfunction|Sudden Cardiac Death","Drug: regadenoson","Sudden cardiac death|all-cause death|First appropriate ICD therapy|Inappropriate ICD therapy|All-cause death or first appropriate ICD therapy|supraventricular tachycardia","University of Alabama at Birmingham|Astellas Scientific & Medical Affairs, Inc.","All","19 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","REGA 12D05","February 2013","January 2020","June 2020","April 29, 2013",,"June 14, 2019","UAB, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01842035"
35,"NCT03814317","Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension","SAPPHIRE","Recruiting","No Results Available","Sarcoidosis|Precapillary Pulmonary Hypertension|Interstitial Lung Disease","Drug: Inhaled Treprostinil","PVR by Right heart catheterization (RHC)|mPAP by Right heart catheterization (RHC)|Change in 6-Minute Walk Test (6MWT)|Change in Cardiac MRI parameters|Change in Pulmonary Function Testing|Change in Brain Natriuretic Peptide (BNP)|Change in WHO Functional Class (WHO FC)","University of Florida|United Therapeutics","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCR19684|20192572","January 30, 2020","September 2020","March 2021","January 24, 2019",,"February 13, 2020","University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03814317"
36,"NCT02840799","Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)",,"Active, not recruiting","No Results Available","Heart Failure","Drug: Potassium Nitrate (KNO3)|Drug: Potassium Chloride (KCl)","Change in peak oxygen consumption (Vo2) from phase 1 to phase 2|Change in total work performed during a maximal-effort exercise test from phase 1 to phase 2|Effect of potassium nitrate (KNO3) on quality of life (QOL)|Effect of KNO3 on the systemic vasodilatory response to exercise: The change in systemic vascular resistance reserve during exercise during a maximal effort exercise test|Effect of potassium nitrate (KNO3) on muscle blood flow during exercise: Muscle blood flow during exercise, measured with arterial MRI spin labeling during a standardized plantar flexion exercise test|Effect of potassium nitrate (KNO3) on muscle phosphocreatine (PCr) recovery kinetics following a standardized plantar flexor exercise protocol|Effect of potassium nitrate (KNO3) on left ventricle (LV) diastolic function: E/e' ratio|Effect of potassium nitrate (KNO3) on left ventricle (LV) diastolic function: left atrial volume index|Effect of potassium nitrate (KNO3) on myocardial systolic strain: peak global systolic myocardial longitudinal strain|Effect of potassium nitrate (KNO3) on myocardial systolic strain: peak global systolic myocardial circumferential strain|Effect of potassium nitrate (KNO3) on late systolic wall stress as assessed by the Arts formula using echocardiographic and tonometry recordings|Effect of potassium nitrate (KNO3) on arterial wave reflections as assessed by wave separation analysis using tonometry and Doppler flow data|Effect of potassium nitrate (KNO3) on augmentation index","University of Pennsylvania|Northwestern University","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","76","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","824290","August 2016","August 2020","February 2021","July 21, 2016",,"March 24, 2020","Northwestern Medical Center, Evanston, Illinois, United States|Corporal Michael J Crescenz Veterans Affairs Medical Center (VA), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02840799"
37,"NCT03051711","Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions",,"Terminated","No Results Available","Cardio-pulmonary Function","Drug: GBT440","The change in oxygen saturation (%) at rest and exercise, under hypoxic conditions|Maximal oxygen uptake VO2 max (mL/kg/min) under normoxic and hypoxic conditions|Cardiac output (L/min) under normoxic and hypoxic conditions|Oxy-hemoglobin dissociation curve p50, under hypoxic conditions|Perceived dyspnea score (1-10), under normoxic and hypoxic conditions|Frequency and severity of treatment-emergent adverse events (TEAEs) as assessed by (NCI CTCAE Version 4.03)","Global Blood Therapeutics|Mayo Clinic","All","18 Years to 50 Years   (Adult)","Phase 1","14","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GBT440-0111","December 2016","December 1, 2017","February 21, 2018","February 14, 2017",,"October 4, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03051711"
38,"NCT04112316","Developing Oral LT3 Therapy for Heart Failure - HFrEF","DOT3HF-HFrEF","Active, not recruiting","No Results Available","Heart Failure With Reduced Ejection Fraction|Low Triiodothyronine Syndrome","Drug: liothyronine or placebo","Cardiac Rhythm Monitoring by 14 day Patch Rhythm Assessment|T3 Level|Peak Maximal Rate of Oxygen Consumption During Exercise (VO2 Max)|Measure of Quality of Life|Actigraphy|NT-proBNP levels","University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","833681r|1R61HL146390-01","February 11, 2020","April 30, 2023","April 30, 2023","October 2, 2019",,"March 24, 2020","PennMedicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04112316"
39,"NCT04111536","Developing Oral LT3 Therapy for Heart Failure - HFpEF","DOT3HF-HFpEF","Active, not recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction|Low Triiodothyronine Syndrome","Drug: liothyronine or placebo","Cardiac Rhythm Monitoring by 14 day Patch Rhythm Assessment|T3 Level|Peak Maximal Rate of Oxygen Consumption During Exercise (VO2 Max)|Measure of Quality of Life|Actigraphy|NT-proBNP Levels","University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","833681p|1R61HL146390-01","March 8, 2020","April 30, 2023","April 30, 2023","October 1, 2019",,"March 24, 2020","Penn Medicine, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04111536"
40,"NCT03015402","Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction","PH-HFpEF","Active, not recruiting","No Results Available","Pulmonary Hypertension Secondary|Heart Failure","Drug: Sodium Nitrite|Drug: Placebo Oral Capsule","Pulmonary artery pressure (mPAP) during submaximal exercise as compared between placebo and nitrite|Difference in 6-minute walk test|Change in right heart catheterization (RHC) hemodynamics|Change in severity of heart failure|Change in endurance exercise time","Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO16110594|5P01HL103455","October 30, 2017","March 2021","March 2021","January 10, 2017",,"April 1, 2020","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03015402"
41,"NCT01815957","Impact of Ranolazine on Coronary Microcirculatory Resistance",,"Unknown status","No Results Available","Coronary Microcirculation|Coronary Artery Disease|Myocardial Disease|Ischemia","Drug: Rnalozine","Relative change in IMR before and after Ranolazine therapy.|Absolute change in SAQ and DASI scores before and after Ranolazine therapy.|Compare relative change in IMR among patients with and without symptomatic improvement in angina burden based on SAQ and DASI scores.","University of New Mexico|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-069 MICRO Study","May 2012","June 2016",,"March 21, 2013",,"June 3, 2015","University of New Mexico Health Science Center, Albuquerque, New Mexico, United States",,"https://ClinicalTrials.gov/show/NCT01815957"
42,"NCT01013714","Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias","PREVENT VT","Not yet recruiting","No Results Available","Sudden Cardiac Death|Ventricular Tachycardia|Ventricular Fibrillation|Cardiomyopathy","Procedure: Cardiac Sympathetic Denervation (CSD)|Drug: Routine Care","Time to ICD shock, death, or cardiac transplantation|Number of ICD shocks|Number of appropriate ICD therapies (including ATPs ) and sustained VT below ICD detection|Serious adverse events|Number and etiology of hospitalizations|Number of deaths or cardiac transplantations","University of California, Los Angeles|Johns Hopkins University|Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UCLA09-07-100-01","July 2020","July 2023","July 2023","November 16, 2009",,"October 22, 2019","UCLA Health, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01013714"
43,"NCT01354613","Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)",,"Completed","No Results Available","Heart Failure With Preserved Ejection Fraction|Pulmonary Disease|Left Ventricular Hypertrophy/Hypertension","Drug: Dobutamine|Drug: Amlodipine","Change in ejection fraction with 5mcg/kg/min dobutamine|Change in pulse wave velocity","University of Wisconsin, Madison|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","14","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H-2010-0061|R21HL106103-01","April 2011","December 2013","December 2013","May 17, 2011",,"April 11, 2019","UW - Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01354613"
44,"NCT01468571","Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension",,"Unknown status","No Results Available","Pulmonary Hypertension","Drug: Spironolactone|Drug: Placebo","Change in biomarker levels in the spironolactone treated as compared to placebo treated group.|Number of adverse events in patients treated with spironolactone as compared to placebo.|Change in six-minute walk distance from baseline to week 8 and week 16.|Composite end-point","Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","H24178|K23HL093214","July 2011","July 2015","December 2015","November 9, 2011",,"May 8, 2015","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01468571"
45,"NCT01756495","A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin",,"Completed","No Results Available","Acute Coronary Syndrome","Drug: Losmapimod|Drug: Moxifloxacin|Drug: Losmapimod matched Placebo|Drug: Moxifloxacin Placebo","Change from baseline in QT interval corrected for heart rate by Fridericia's formula (QTcF) at each time point for losmapimod 20 mg QD on Day 5 as compared with time matched placebo|Change from baseline in QTcF at each time point for losmapimod 7.5 mg BID on Day 5 as compared with time-matched placebo|Change from baseline in QTcF at each time point for moxifloxacin 400 mg single dose as compared with time-matched placebo|Change from baseline in QT interval corrected for heart rate by Bazett's formula (QTcB) at each time point for losmapimod (7.5 mg BID and 20 mg QD) and moxifloxacin (400 mg) on Day 5 as compared with time matched placebo|Change from baseline at each time point on Day 5 for other cardiac electrophysiological parameters: QT, PR, QRS, heart rate (HR) and ECG waveform morphology for losmapimod (7.5 mg BID and 20 mg QD) and moxifloxacin|Area under the plasma concentration-time curve (AUC) of losmapimod and its metabolite GSK198602 at doses of 7.5 mg BID and 20 mg QD, as well as 400 mg single dose of moxifloxacin|Maximum observed plasma concentration (Cmax) of losmapimod and its metabolite GSK198602 at doses of 7.5 mg BID and 20 mg QD, as well as 400 mg single dose of moxifloxacin|Time to Cmax (Tmax) of losmapimod and its metabolite GSK198602 at doses of 7.5 mg BID and 20 mg QD, as well as 400 mg single dose of moxifloxacin|Model parameters appropriate for concentration-QT analysis of losmapimod, metabolite and moxifloxacin (e.g. slope and intercept)|Physical examination findings to assess safety and tolerability of losmapimod and moxifloxacin|12-lead ECGs measurements to assess safety and tolerability of losmapimod and moxifloxacin|Clinical laboratory test measurements to assess safety and tolerability of losmapimod and moxifloxacin|Clinical monitoring/observation|Number of subjects with adverse events|Blood pressure measurements to assess safety and tolerability of losmapimod and moxifloxacin|HR measurements to assess safety and tolerability of losmapimod and moxifloxacin","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","116628","January 10, 2013","April 23, 2013","April 23, 2013","December 27, 2012",,"June 7, 2017","GSK Investigational Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01756495"
46,"NCT01375361","Nebulized Albuterol for Congestive Heart Failure Exacerbation","ACHE","Withdrawn","No Results Available","Congestive Heart Failure","Drug: Albuterol|Drug: Normal Saline","Borg Dyspnea Score|Admission","University of California, San Francisco","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RandomizedAlbuterolCHF","April 2009","July 2010",,"June 17, 2011",,"October 10, 2013","University of California, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01375361"
47,"NCT01869309","Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor","HEIGHTEN","Unknown status","No Results Available","Coronary Artery Disease","Drug: Prasugrel|Drug: Ticagrelor","Pharmacodynamic (PD) Vasodilator Stimulated Phosphoprotein-Phosphorylation(VASP-P) in High On Prasugrel Platelet Reactivity(HPPR) stable CAD patients|Prevalence of HPPR|CYP2C19 relation to occurence of HPPR|PD VerifyNow in HPPR stable CAD patients|PD LTA in HPPR stable CAD patients|Frequency of HPR|PD effect(Prasugrel) relation to CYP2C19","LifeBridge Health|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015|ISSBRIL0149","January 2014","December 2015","December 2016","June 5, 2013",,"November 21, 2014","Sinai Center for Thrombosis Research, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01869309"
48,"NCT00868855","Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease",,"Terminated","No Results Available","Coronary Artery Disease","Drug: Bradykinin","Mortality","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB# 030473|5P5OHL081009-02","December 2003","December 2010","December 2010","March 25, 2009",,"December 13, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00868855"
49,"NCT01681095","Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent",,"Completed","Has Results","Coronary Artery Disease|Myocardial Ischemia|Coronary Disease|Heart Diseases|Valvular Heart Disease","Drug: Custodiol HTK|Drug: Cold Blood Cardioplegia","Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB)|Change in Troponin I|Changes in Left Ventricular (LV) Ejection Fraction (EF) by Transthoracic Echocardiogram (TTE)|Cardiac Dysrhythmias|All Cause Mortality|Cardiovascular Mortality|Time on Mechanically Assisted Ventilation|Duration of Vasopressor / Inotropic Agent|Postoperative Inotropic Infusion >20 Minutes|Intensive Care Unit (ICU) Length of Stay|Myocardial Infarction|Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)|Cardiac Marker - Troponin-I","Marc Sakwa, MD|Essential Pharmaceuticals, LLC|William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-125","August 2012","August 2014","April 2016","September 7, 2012","March 1, 2017","August 6, 2019","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01681095"
50,"NCT02767024","Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure","PRIORITY-ADHF","Withdrawn","No Results Available","Acute Heart Failure","Drug: Sodium nitroprusside|Drug: Dobutamine|Drug: Furosemide","Arrhythmia incidence|Serum troponin T release|Hypotension incidence|≥2 point improvement in the 5 point Likert dyspnea scale|≥ 30% improvement in the 100 point global patient assessment scale|Reduction in the Cardiac Care Unit length of stay|Reduction in the hospitalization length of stay|Assessment of difference in restrictive filling pattern by echocardiogram","Montefiore Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-3586","May 1, 2018","May 1, 2018","June 1, 2018","May 10, 2016",,"October 31, 2018","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT02767024"
51,"NCT02585843","Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance",,"Completed","Has Results","Heart Failure","Drug: Spironolactone 100mg|Drug: Spironolactone 25mg","Change in Body Weight|Change in Estimated Jugular Venous Pressure (cmH2O)|Change in 6-minute Walk Test Distance (6MWT)|Change in Score on the Visual Analogue Scale (VAS)|Change From Baseline to Day 7 on the Seven-Level Likert Scale","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AAAO9102","November 2015","March 31, 2017","March 31, 2017","October 23, 2015","July 23, 2019","August 8, 2019","Columbia University Medical Center, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02585843/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02585843/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02585843"
52,"NCT01787851","Study of the Acute Effects of Triheptanoin in Heart Failure","ACETO-TCA","Withdrawn","No Results Available","Congestive Heart Failure|Non-ischemic Cardiomyopathy","Drug: Triheptanoin oil","Cardiac output/index|Cardiac Output/index and pulmonary capillary wedge pressure","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UTSW 65827-1","February 2013","February 2014","February 2014","February 11, 2013",,"December 14, 2018","University of Texas-Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01787851"
53,"NCT03702582","Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation","NEW-AF","Active, not recruiting","No Results Available","Atrial Fibrillation|Stroke|Bleeding","Drug: Rivaroxaban|Drug: Warfarin","Postoperative Length of Stay|Episode of Major Bleeding (Defined as the occurrence of any of several events listed in the description. No specific scale, questionnaire or instrument will be used)|Cerebrovascular accident (CVA)|Other systemic embolism|Deep venous thrombosis (DVT) and/or Pulmonary Embolism (PE)|Minor Bleeding|Number of Transfusions|Hospital Readmission|Therapy related costs of anticoagulation|Performance on the EUROQOL (EQ-5D) Quality of Life Instrument|Average score on the Perception of Anticoagulant Treatment Questionnaire (PACT-Q2)|Rate of ongoing atrial fibrillation|Rate of Mortality|Rates of adverse clinical outcomes","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018P002307","April 30, 2019","April 1, 2022","May 1, 2022","October 11, 2018",,"March 18, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03702582"
54,"NCT02943590","STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)",,"Recruiting","No Results Available","Heart Failure","Drug: Placebo|Drug: Atorvastatin","Left ventricular Ejection Fraction (LVEF)|Number of Cardiac Events|Myocardial Fibrosis|Troponin T and Global Longitudinal Strain","Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16-440","January 13, 2017","June 2021","May 2022","October 24, 2016",,"August 13, 2019","Massachusetts general Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02943590"
55,"NCT03043742","Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease",,"Recruiting","No Results Available","Chronic Ischemic Heart Disease","Drug: Bone Marrow Derived Autologous CD133+ Selected Cell Product","Occurrence of Treatment-emergent serious adverse events (SAE) and adverse events|Change in left ventricular ejection fraction compared to baseline|Change in myocardial regional function compared to baseline|Change in myocardial regional viability compared to baseline|Change in distance walked compared to baseline|Change in quality of life associated with heart failure compared to baseline|Change in class of angina compared to baseline|Change in class of heart failure compared to baseline|Change in regional left ventricular wall motion compared to baseline|Change in quality of life associated with angina compared to baseline","Michael Sekela|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-1051","July 12, 2016","March 2020","March 2021","February 6, 2017",,"April 9, 2019","University of Kentucky Healthcare, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03043742"
56,"NCT02004613","Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery","Decade","Active, not recruiting","No Results Available","Heart Disease","Drug: Dexmedetomidine|Drug: Placebo","Sedation Outcome of patients assigned to dexmedetomidine or placebo.|Sedation Outcome of patients assigned to dexmedetomidine or placebo","The Cleveland Clinic|Hospira, now a wholly owned subsidiary of Pfizer","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","965","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","12-1379","June 2013","December 2018","December 31, 2020","December 9, 2013",,"January 31, 2020","Cleveland Clinic Main, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02004613"
57,"NCT01165931","Coronary Vasomotor Response After Riociguat Exposure","CORONARIES","Withdrawn","No Results Available","Coronary Artery Disease","Drug: Riociguat (BAY63-2521)","The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administration|Adverse event collection","Bayer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14550","May 2012","January 2013","January 2013","July 20, 2010",,"October 23, 2013","Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01165931"
58,"NCT02918552","Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction","ONOH","Completed","Has Results","Heart Failure","Drug: sodium nitrite|Drug: Control","Cardiorespiratory Fitness|Perceived Fatigability|Bioenergetics: In-Vivo 31P MRS Respirations|Bioenergetics: Ex-Vivo Mitochondrial Respiration Analysis|Exercise-induced Changes in Pulmonary Arterial Pressure|Exercise-induced Changes in Pulmonary Capillary Wedge Pressure|Patients With Pulmonary Hypertension|Steps From Accelerometry Assessment of Daily Activity|Sedentary Events From Accelerometry Assessment of Daily Activity|Light Activity Duration From Accelerometry Assessment of Daily Activity|Moderate to Vigorous Physical Activity From Accelerometry Assessment of Daily Activity|Vector Magnitude Counts From Accelerometry Assessment of Daily Activity|Sedentary Event Duration From Accelerometry Assessment of Daily Activity|Light Activity Events Percentage of Day From Accelerometry Assessment of Daily Activity|Moderate to Vigorous Physical Activity Percentage From Accelerometry Assessment of Daily Activity","Gladwin, Mark, MD|National Institute on Aging (NIA)|University of Pittsburgh","All","70 Years and older   (Older Adult)","Phase 2","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY19070450|1R56AG051637-01A1","April 3, 2017","December 2, 2018","December 31, 2018","September 29, 2016","January 22, 2020","January 22, 2020","UPMC Montefiore Hospital, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02918552/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02918552"
59,"NCT01136876","Kidney Damage in Patients With Moderate Fall in eGFR",,"Completed","Has Results","Coronary Artery Stenosis","Drug: Iopamidol|Drug: Iodixanol-320","Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media in Comparison to a Non-ionic, Iso-osmolar Contrast Media","Bracco Diagnostics, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 4","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","IOP-117","November 2010","November 2012","November 2012","June 4, 2010","December 30, 2013","December 30, 2013","Priarie Cardiovascular Consultants, Springfield, Illinois, United States|Springfield, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01136876"
60,"NCT00996021","Study to Assess Cardiac Conduction of GSK1349572",,"Completed","No Results Available","Healthy Subjects","Drug: GSK1349572 250 mg|Drug: Placebo Suspension|Drug: Moxifloxacin 400 mg","Change from baseline in QTcF for GSK1349572.|Safety and tolerability of GSK1349572 as assessed by 12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.|Change from baseline in QTcB, QTci, QT, and HR for GSK1349572|Change from baseline in QTcF, QTcB, QTci, QT, and HR for placebo|Change from baseline in QTcF, QTcB, QTci, QT, and HR for moxifloxacin|AUC(0-24), AUC(0-t), AUC(0-tau), Cmax, tmax, CL/F, Vdz/F, and t1/2 from plasma concentrations of GSK1349572 and moxifloxacin (if needed)","GlaxoSmithKline|Shionogi","All","18 Years to 55 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","111856","September 2009","November 2009","December 2009","October 16, 2009",,"January 25, 2010","GSK Investigational Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00996021"
61,"NCT01789814","Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation",,"Completed","Has Results","Coronary Artery Disease","Drug: Prasugrel|Drug: Clopidogrel","Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF.","Tufts Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PraCloBiv2013CK|TMCcardintervCK2013","July 2013","July 2014","July 2014","February 12, 2013","April 4, 2017","April 4, 2017","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01789814"
62,"NCT01432626","Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG",,"Completed","Has Results","Stress Induced Cardiomyopathy","Drug: I-123 radiolabeled metaiodobenzylguanidine cardiac imaging","Number of Participants Who Had an Abnormal Regional Uptake of I-123 mIBG at Baseline (Acute Phase) and the Number of Participants Who Had an Abnormal I-123 mIBG Uptake on Follow up (Recovery Phase)","University of Pittsburgh|GE Healthcare","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PRO10080198","September 2011","December 2014","June 2015","September 13, 2011","March 22, 2016","March 22, 2016","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01432626"
63,"NCT01311518","A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction",,"Suspended","No Results Available","Acute Myocardial Infarction|ST Elevation Myocardial Infarction|STEMI","Drug: Drug: Placebo|Drug: Drug: Injectable Thymosin beta 4","Total MRI infarct zone derived from cardiac MRI scan|MRI-derived myocardial salvage index, mass, Left Ventricle (LV) ejection fraction,systolic and end diastolic volumes","RegeneRx Biopharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RGN-MI-201","March 2016","March 2019","August 2019","March 9, 2011",,"March 24, 2015","St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|The Valley Hospital, Ridgewood, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01311518"
64,"NCT03560323","Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors",,"Recruiting","No Results Available","Heart Failure|Type 2 Diabetes Mellitus","Drug: Beta-hydroxy-butyrate","Cardiac Function|Myocardial energetics","The University of Texas Health Science Center at San Antonio","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HSC20180077H","January 7, 2019","December 31, 2021","December 31, 2022","June 18, 2018",,"August 2, 2019","Texas Diabetes Institute - University Health System, San Antonio, Texas, United States|University of Texas Health Science Center San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03560323"
65,"NCT04197570","Opioid-free Anesthesia for Open Cardiac Surgery: A Prospective Randomized Controlled Trial",,"Recruiting","No Results Available","Opioid Use|Heart; Surgery, Heart, Functional Disturbance as Result|Anesthesia","Drug: Opioid Anesthetics|Drug: Non Opioid Analgesics","Mean arterial blood pressure-time integral|Blood pressure variability pre-cardiopulmonary bypass|Heart rate variability pre-cardiopulmonary bypass|Vasopressor usage intra- and post-operatively|Arrhythmias or EKG changes|Delirium medications|Delirium|Postoperative pain scores|Opioid consumption|Postoperative nausea/vomiting|Time to extubation|ICU length of stay|Hospital length of stay|Reintubation or readmission to ICU|major adverse cardiovascular event or mortality|Postoperative pain questionnaire","Benaroya Research Institute|Virginia Mason Hospital/Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","158","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","IRB19-024","February 4, 2020","May 1, 2021","March 30, 2022","December 13, 2019",,"February 18, 2020","Virginia Mason Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04197570"
66,"NCT00924014","Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure",,"Unknown status","No Results Available","Heart Failure","Drug: Conivaptan|Drug: Furosemide|Drug: Conivaptan and furosemide","renal hemodynamics renal blood flow and glomerular filtration rate|measure plasma neurohormone levels","Hennepin County Medical Center, Minneapolis|Astellas Pharma Inc","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","001|IND 104, 334","July 2009","December 2009","March 2010","June 18, 2009",,"June 18, 2009","Hennepin county Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00924014"
67,"NCT02624180","Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV",,"Active, not recruiting","No Results Available","Coronary Artery Disease|Human Immunodeficiency Virus","Drug: Colchicine|Drug: Placebo","Coronary endothelial function at 8 weeks|Coronary endothelial function at 24 weeks;|Change in coronary artery cross-sectional area (CSA) at 8 weeks|Change in coronary artery cross-sectional area (CSA) at 24 weeks|High-sensitivity C-reactive protein (hsCRP) at 8 and 24 weeks|Brachial flow mediated dilatation (FMD) at 8 and 24 weeks|Interleukin-6 (IL-6) at 8 and 24 weeks|Change in hs-CRP at 8 and 24 weeks|Change in FMD at 8 and 24 weeks|Change in IL-6 at 8 and 24 weeks","Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years and older   (Adult, Older Adult)","Phase 2","102","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","IRB00070892|1R01HL125059","November 2015","August 2020","February 2021","December 8, 2015",,"September 12, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02624180"
68,"NCT01342029","Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia","RWISE","Completed","Has Results","Microvascular Coronary Dysfunction (MCD)","Drug: Ranolazine|Drug: Placebo","Seattle Angina Questionnaire (SAQ)|Cardiac Magnetic Resonance (CMRs)","Cedars-Sinai Medical Center|University of Florida","All","18 Years and older   (Adult, Older Adult)","Not Applicable","142","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IN-US-259-0124 - RWISE","May 2011","December 2016","December 2016","April 26, 2011","December 12, 2017","April 24, 2019","127 S. San Vicente Blvd, Suite A9303, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01342029"
69,"NCT03228823","Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)","PAPS","Recruiting","No Results Available","Ventricular Premature Beats, Contractions, or Systoles|Cardiomyopathies","Procedure: Radiofrequency ablation|Drug: Amiodarone (Antiarrhythmic drug)","Improvement of left ventricular ejection fraction after PVC suppression|Responders to PVC suppression strategy|Successful PVC suppression|Composite Adverse Events|Composite Arrhythmia Burden","Hunter Holmes Mcguire Veteran Affairs Medical Center|Virginia Commonwealth University|University of California, San Francisco|University of Calgary|Washington University School of Medicine|Wake Forest University Health Sciences|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","U.S. Fed|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NIH ID 9372611|R34HL138110-01","August 1, 2018","August 31, 2021","August 31, 2021","July 25, 2017",,"June 12, 2019","University of California Los Angeles Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|James A. Haley Veterans' Hospital, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Roxbury VA Medical Center, West Roxbury, Massachusetts, United States|Northwell Health System-Staten Island University Hospital, Staten Island, New York, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03228823/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03228823/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03228823"
70,"NCT01586156","PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)","PAHTCH","Completed","Has Results","Pulmonary Hypertension","Drug: Carvedilol|Drug: placebo","Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography)|Urinary cAMP (Cyclic Adenosine Monophosphate)/Creatinine|Beta-Adrenergic Receptor (Alprenolol Binding Assay)","The Cleveland Clinic|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-1198|R01HL115008","December 2012","July 2016","July 2016","April 26, 2012","November 30, 2017","December 5, 2018","Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01586156/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01586156"
71,"NCT03026023","Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant",,"Withdrawn","No Results Available","Cardiac Transplant Disorder|Hepatitis C","Drug: Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin","Undetectable HCV|Safety and tolerability (based on number of adverse events and out of range lab values) of grazoprevir and elbasvir (with or without ribavirin) in patients who have undergone cardiac transplantation","Raymond T. Chung, MD|Merck Sharp & Dohme Corp.|Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017P000074","August 1, 2018","December 31, 2020","June 30, 2021","January 20, 2017",,"December 20, 2018","Masschusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03026023"
72,"NCT03644576","Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate",,"Completed","No Results Available","Healthy Volunteers","Drug: ozanimod|Drug: Pseudoephedrine|Drug: ozanimod placebo","Cardiovascular analysis|Pharmacokinetics- Cmax|Pharmacokinetics- Cmin|Pharmacokinetics- Tmax|Pharmacokinetics- AUC0-24|Pharmacokinetics- Ctrough|Adverse events (AEs)|Pharmacokinetics- % total drug related AUC0-24 for each analyte|Pharmacokinetics- % total active drug related AUC0-24 for each active analyte|Cardiovascular analysis for DBP|Cardiovascular analysis for heart rate|Cardiovascular analysis for blood pressure|Cardiovascular analysis for Heart Rate","Celgene","All","18 Years to 55 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","RPC01-1914|U1111-1215-6267","July 11, 2018","September 12, 2018","September 12, 2018","August 23, 2018",,"May 30, 2019","ICON Early Phase Services, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03644576"
73,"NCT02096588","Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin",,"Active, not recruiting","Has Results","Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer","Drug: Simvastatin|Drug: Doxorubicin/cyclophosphamide","Change in Echocardiographic Global Longitudinal Strain (GLS)|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Recurrence Free Survival (RFS) With Concurrent Simvastatin","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Avon Foundation","Female","18 Years and older   (Adult, Older Adult)","Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J13160|NA_00091900","May 20, 2014","April 25, 2017","March 1, 2022","March 26, 2014","June 26, 2019","June 26, 2019","Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital, Washington, District of Columbia, United States|Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02096588/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02096588"
74,"NCT04206865","Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output","PARAVLO-HF","Recruiting","No Results Available","Cardiogenic Shock","Drug: Sacubitril-Valsartan|Drug: Standard Oral Vasodilators","Proportion of patients on ARNI therapy at one-month follow-up|Length of time of in the Intensive Care Unit|Length of Hospital Stay|Change in NT-proBNP from admission at one-month follow-up|30 day HF readmissions|180 day telephone follow up to determine: ARNI yes or no, hospitalizations, mortality, LVAD or transplant","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 4","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-1133","November 25, 2019","December 31, 2021","March 31, 2022","December 20, 2019",,"December 20, 2019","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04206865"
75,"NCT02353312","Rhode Island Diastolic Dysfunction - Heart Failure","RIDD-HF","Completed","No Results Available","Heart Failure|Cardiovascular Disease","Drug: Kuvan","Change from baseline in VO2 consumption|Change from baseline in echocardiographic parameters of diastolic dysfunction|Change from baseline in Quality of life measured by Kansas City Cardiomyopathy Questionnaire","Providence VA Medical Center|BioMarin Pharmaceutical|Lifespan","All","18 Years and older   (Adult, Older Adult)","Not Applicable","28","U.S. Fed|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-051","March 2015","December 2018","December 2018","February 2, 2015",,"January 30, 2019","Providence VAMC, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02353312"
76,"NCT03634969","An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants",,"Completed","No Results Available","Cardiac Failure|Myocardial Failure","Drug: BMS-986224","Maximum observed plasma concentration (Cmax) of BMS-986224|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986224|Area under the plasma concentration-time curve from time zero to 72 h post dose [AUC(0-72)] of BMS-986224|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986224|Time of maximum observed plasma concentration (Tmax) of BMS-986224|Terminal elimination half-life (T-HALF) of BMS-986224 derived from plasma concentration|Fraction of unbound drug in plasma (fu) of BMS-986224|Apparent oral clearance (CL/F) of BMS-986224 derived from plasma concentration|Apparent volume of distribution (Vz/F) of BMS-986224 derived from plasma concentration|Cumulative amount of unchanged drug excreted into the urine at a given time (Aet) of BMS-986224|Fraction of dose excreted in urine (Fe%) of BMS-986224|Renal clearance of BMS-986224 derived from urine concentration|Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation|Maximum observed plasma concentration (Cmax) of metabolite|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of metabolite|Area under the plasma concentration-time curve from time zero to 72 h post dose [AUC(0-72)] of metabolite|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of metabolite|Time of maximum observed plasma concentration (Tmax) of metabolite|Terminal elimination half-life (T-HALF) of metabolite derived from plasma concentration|Metabolite-to-parent (MR) ratio for cMax|Metabolite-to-parent (MR) ratio for AUC(0-T)|Metabolite-to-parent (MR) ratio for AUC(0-72)|Metabolite-to-parent (MR) ratio for AUC(INF)|Number of clinically significant changes in vital signs, ECGs, physical examinations, or clinical laboratory tests","Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CV016-010","August 14, 2018","April 30, 2019","April 30, 2019","August 17, 2018",,"February 25, 2020","Clinical Pharmacology of Miami, Miami, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Prism Research, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03634969"
77,"NCT00869869","Melatonin Supplementation to Improve Sleep in Patients With Heart Failure",,"Withdrawn","No Results Available","Heart Failure|Sleep Disorders","Drug: melatonin|Drug: placebo","Change in sleep quantity assessed by actigraphy|Change in quality of life and heart failure biomarkers","Brigham and Women's Hospital|American Academy of Sleep Medicine","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASMF-Scheer","March 2009","March 2010","March 2011","March 26, 2009",,"January 19, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00869869"
78,"NCT02925923","Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel",,"Completed","No Results Available","Acute Coronary Syndrome|Angina, Unstable","Drug: Ticagrelor|Drug: Eptifibatide|Drug: Clopidogrel","High-on treatment platelet reactivity (HPR)|Periprocedural myocardial infarction and injury (PMI)|Platelet aggregation levels|Hemoglobin/hematocrit levels|Heparin dose, Unit/Kg|Activated clotting time (ACT), Seconds|Bleeding complications|Clinical outcomes","University of Alabama at Birmingham","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F151006002","November 1, 2016","January 30, 2018","December 1, 2018","October 6, 2016",,"November 26, 2019","University of Alabama, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02925923"
79,"NCT01542502","Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction",,"Completed","Has Results","Heart Failure","Drug: Anakinra|Drug: Placebo","Peak Oxygen Consumption (Peak VO2)|Exercise Time","Virginia Commonwealth University|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM14079","February 2012","June 2013","June 2013","March 2, 2012","April 7, 2016","February 6, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01542502"
80,"NCT03331861","Metformin in Heart Failure Without Diabetes","Met-HeFT","Recruiting","No Results Available","Heart Failure","Drug: Metformin hydrochloride|Drug: Placebo","Change in Minute Ventilation to Carbon Dioxide Production (VE/VCO2) Slope|Change in Dyspnea Assesment Score|Minnesota Health Living with Heart Failure Questionnaire|Left Ventricular Function Evaluated by Ejection Fraction and Diastolic Function on Echocardiography|Global Longitudinal Strain and Strain Rate Measured on Echocardiography|B Type Natriuretic Peptide (BNP) level|Body Weight|Peak Myocardial Oxygen Consumption (VO2)|Quantitative 18F-FDG Activity in 9 Myocardial Segments|Quantitative N13-NH3 Activity in 9 Myocardial Segments|Heart Failure Hospitalizations","Columbia University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAAR5389","February 15, 2019","August 2021","February 2022","November 6, 2017",,"March 10, 2020","New York Hospital - Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03331861"
81,"NCT01312935","Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)",,"Terminated","No Results Available","Percutaneous Coronary Intervention|Coronary Artery Disease (CAD)|Angioplasty","Drug: PMX-60056","The primary outcome measure of this study is the ability to reverse the anticoagulant effects of heparin (as measured by ACT) to the same extent as is known for protamine. intravenous infusion of PMX-60056.","PolyMedix, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMX56-203","April 2011","June 2012","August 2012","March 11, 2011",,"May 17, 2012","South Bend, Indiana, United States|Detroit, Michigan, United States|Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01312935"
82,"NCT02173548","Interleukin-1 Blockade in HF With Preserved EF","D-HART2","Completed","Has Results","Heart Failure With Normal Ejection Fraction","Drug: Anakinra|Drug: Placebo","Change in Aerobic Exercise Capacity|Change in Ventilatory Eefficiency|Echocardiographic Assessment of Diastolic and Systolic Function (Left Ventricular Ejection Fraction)|Change in Diastolic and Contractile Reserve (e' Velocity and E/e' Ratio)|Change in Inflammation (C Reactive Protein Levels)|Change in Quality of Life Questionnaire-Minnesota Living With Heart Failure Questionnaire (MLWHF)|Change in Quality of Life Questionnaire-Duke Activity Status Index (DASI)|Hospital Admission for Acute Decompensated Heart Failure","Virginia Commonwealth University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years and older   (Adult, Older Adult)","Phase 2","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20000118|1R34HL118348-01A1","September 2014","April 11, 2017","June 1, 2017","June 25, 2014","June 19, 2018","June 19, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02173548/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02173548"
83,"NCT01306292","Safety of SonoVue on Pulmonary Hemodynamics",,"Completed","Has Results","Pulmonary Hypertension","Drug: SonoVue|Drug: Placebo","Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Systolic Pulmonary Artery Pressure (mmHg) - Mean Change From Baseline|Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Diastolic Pulmonary Artery Pressure (mmHg) - Mean Change From Baseline|Effects of SonoVue and Placebo on Pulmonary Hemodynamics: Pulmonary Vascular Resistance (Dyne*Sec/cm^5) - Mean Change From Baseline","Bracco Diagnostics, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","BR1-133","April 2011","November 2011","November 2011","March 1, 2011","February 8, 2016","December 7, 2016","Holy Name Medical Center, Teaneck, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01306292"
84,"NCT01248104","Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery",,"Unknown status","No Results Available","Cardiopulmonary Bypass","Drug: Tranexamic Acid|Drug: Aminocaproic Acid","The primary outcome of the Tranexamic Acid Study is the amount of blood loss per patient in the study.","Loma Linda University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","5100064","March 2010","March 2013","February 2015","November 25, 2010",,"April 23, 2014","Loma Linda University Medical Center, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT01248104"
85,"NCT03843060","A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers",,"Completed","No Results Available","Heart Failure With Preserved Ejection Fraction (HFpEF)","Drug: AZD9977|Drug: Itraconazole","Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) for AZD9977|Maximum observed plasma concentration (Cmax) for AZD9977|Time to reach Maximum Observed Plasma Concentration (tMax)|Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)|Mean residence time of the unchanged drug in the systemic circulation from time zero to infinity (MRT)|Terminal elimination rate constant (λz)|Apparent total body clearance of drug from plasmsa after extravascular administration (CL/F)|Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)|Number of participants with adverse events (AEs)|Number of participants with abnormal blood pressure (both systolic and diastolic blood pressure)|Number of participants with abnormal pulse rate|Number of participants with abnormal 12-lead Electrocardiograms (ECG)|Number of participants with abnormal physical examination findings|Number of participants with abnormal laboratory assessments: Hematology- White blood cell (WBC) count|Number of participnats with abnormal laboratory assessments: Hematology- Red blood cell (RBC) count|Number of paticipants with abnormal laboratory assessments: Hematology - Hemoglobin (Hb)|Number of participants with abnormal laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count|Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)|Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular volume (MCV)|Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)|Number of participants with abnormal laboratory assessments: Hematology- Neutrophils absolute count|Number of participants with abnotmal laboratory assessments: Hematology- Lymphocytes absolute count|Number of participants with abnormal laboratory assessments: Hematology- Monocytes absolute count|Number of participants with abnormal laboratory assessments: Hematology- Eosinophils absolute count|Number of participants with abnormal laboratory assessments: Hematology- Basophils absolute count|Number of participants with abnormal laboratory assessments: Hematology- Platelets count|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Liver enzymes|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Albumin|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP)|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK)|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatinine|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Glucose (fasting)|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- Uric acid|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- BUN|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Total Bilirubin (TBL)|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Indirect bilirubin|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin I ((hsTnI)|Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)|Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Protein|Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Blood|Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Glucose","AstraZeneca","All","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6401C00003","February 22, 2019","April 1, 2019","April 1, 2019","February 15, 2019",,"April 22, 2019","Research Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03843060"
86,"NCT01246011","Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion",,"Terminated","Has Results","Coronary Artery Bypass Graft Surgery|Presence of Heparin/Platelet Factor 4 Antibody","Drug: Argatroban and warfarin","Coronary Artery Bypass Vein Graft Patency|Major Bleeding Events.","Massachusetts General Hospital|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other","2010P001386","November 2010","July 2011","July 2011","November 23, 2010","March 12, 2012","November 17, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01246011"
87,"NCT01710254","Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients","RECAD-AF","Completed","Has Results","Atrial Fibrillation|Coronary Artery Disease","Drug: Regadenoson MRI|Drug: Gadobenate dimeglumine","Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)|Specificity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)|Accuracy of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD)","University of Utah","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","REGA-12F08","January 2013","October 2016","October 2016","October 19, 2012","November 7, 2017","December 13, 2017","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01710254"
88,"NCT01241903","Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions",,"Completed","Has Results","Acute Coronary Syndrome|Angioplasty, Transluminal, Percutaneous Coronary|Hydroxymethylglutaryl-CoA Reductase Inhibitors|Blood Platelets","Drug: rosuvastatin|Drug: placebo","Platelet - Leukocyte Aggregates|Biomarkers of Platelet Function and Myocardial Necrosis","Susan Smyth|University of Kentucky","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-208-F1V","June 2011","August 2013","February 2014","November 16, 2010","June 24, 2014","March 28, 2017","University of Kentucky Dept of Cardiology, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT01241903"
89,"NCT01218802","Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks",,"Completed","Has Results","HIV Infections|Heart Disease","Drug: Rosuvastatin 10 mg. daily for 96 weeks|Drug: Placebo","Bone Mineral Density (BMD)|Carotid IMT","University Hospitals Cleveland Medical Center|National Institutes of Health (NIH)|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","147","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1R01NR012642-01","February 2011","May 2014","May 2014","October 11, 2010","March 8, 2016","March 8, 2016","University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01218802"
90,"NCT02552238","Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142",,"Completed","No Results Available","Coronary Artery Disease","Drug: Lumason","Sensitivity and Specificity of Lumason enhanced Dobutamine Stress Echo (DSE) for Detection and Exclusion of Coronary Artery Disease (CAD)|Critical shift from suboptimal to optimal echocardiographic images|Change in total LV EBD|Safety (adverse events, labs,vital signs, ECGs and pulse oxygen)","Bracco Diagnostics, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","174","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BR1-142","October 2015","April 14, 2017","February 25, 2018","September 17, 2015",,"August 9, 2018","Alfieri Cardiology, Wilmington, Delaware, United States",,"https://ClinicalTrials.gov/show/NCT02552238"
91,"NCT02522481","Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141",,"Completed","No Results Available","Coronary Artery Disease","Drug: Lumason","Sensitivity and Specificity for Detection and Exclusion of CAD|Critical shift from suboptimal to optimal echocardiographic images|Change in total LV EBD|Safety Assessed by monitoring adverse events, labs,vital signs, ECGs and pulse oxygen","Bracco Diagnostics, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","175","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BR1-141","September 2015","May 31, 2017","February 2018","August 13, 2015",,"August 9, 2018","St Luke's Hospital of Kansas City, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02522481"
92,"NCT03534297","Study of Dapansutrile Capsules in Heart Failure",,"Completed","No Results Available","Systolic Heart Failure","Drug: dapansutrile capsules|Drug: Placebo capsules","Adverse events|Cardiopulmonary exercise test|Transthoracic Doppler ECG - Left Ventricle Ejection Fraction|Transthoracic Doppler ECG - Left Ventricular Filling Pressure|Bioimpedance analysis|Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score|Kansas City Cardiomyopathy Questionnaire - Overall Summary Score|Duke Activity Status Index|Vital signs - Pulse|Vital signs - Blood Pressure|Vital signs - Temperature|Vital signs - Respiratory Rate|Safety Laboratory Measurements - Chemistry|Safety Laboratory Measurements - Hematology|Physical Examination|12-lead electrocardiogram","Olatec Therapeutics LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","OLT1177-06","May 16, 2018","November 21, 2019","November 21, 2019","May 23, 2018",,"January 9, 2020","Virginia Commonwealth University - Pauley Heart Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03534297"
93,"NCT03708588","Chewed Versus Integral Pill of Ticagrelor",,"Active, not recruiting","No Results Available","Percutaneous Coronary Intervention","Drug: Ticagrelor","Concentration of pharmacodynamics|Number of Participants with Major adverse cardiac and cerebrovascular event MACCE","Aurora Health Care","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-078_18-911","September 19, 2018","December 31, 2019","July 31, 2020","October 17, 2018",,"January 7, 2020","Aurora Health Care, St. Luke's Medical Center, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03708588"
94,"NCT02669563","An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients",,"Completed","No Results Available","Cardiomyopathy","Drug: [18F]4F-MHPG|Drug: [18F]3F-PHPG|Drug: [13N]ammonia|Drug: [11C]HED","Composite measures based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, minutes) of [18F]4F-MHPG and [18F]3F-PHPG in patients with heart failure.|Quantitative measures of regional cardiac sympathetic nerve density in patients with heart failure using tracer kinetic analyses.|Number of study participants with adverse events as a measure of safety and tolerability following intravenous administration of [18F]4F-MHPG or [18F]3F-PHPG.","University of Michigan","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00105110","December 2015","August 2016","December 2016","February 1, 2016",,"February 27, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02669563"
95,"NCT01948518","Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease",,"Completed","Has Results","Diffuse Parenchymal Lung Disease|Pulmonary Hypertension","Drug: Oral sildenafil 20 mg","Change in Diffusion Capacity Measured at Baseline and One Hour.|Change in 6 Minute Walk Distance","The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-993","June 2009","June 2012","June 2012","September 23, 2013","September 30, 2014","September 30, 2014","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01948518"
96,"NCT00881218","Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson",,"Completed","No Results Available","Ischemic Heart Disease","Drug: Regadenoson","Feasibility of use of regadenoson during cardiac perfusion MRI to visualize regions of myocardial ischemia as demonstrated on SPECT-MPI.","Washington University School of Medicine|Astellas Pharma US, Inc.","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","REGADENOSON.MRI.WUSTL","June 2009","December 2011","December 2011","April 15, 2009",,"April 10, 2012","Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT00881218"
97,"NCT01848106","A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI","Regulate","Terminated","No Results Available","Coronary Artery Disease","Drug: pegnivacogin/anivamersen|Drug: Bivalirudin","Ischemic composite","Regado Biosciences, Inc.|The Cleveland Clinic|Duke Clinical Research Institute|Canadian VIGOUR Centre|Icahn School of Medicine at Mount Sinai|Parexel","All","18 Years and older   (Adult, Older Adult)","Phase 3","3232","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REG1-CLIN310|2013-001384-23","September 2013","August 2014","August 2014","May 7, 2013",,"October 23, 2014","Black Hills Cardiovascular Research, Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01848106"
98,"NCT00842023","Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy","ABC-HFT","Completed","Has Results","Acute Decompensated Heart Failure","Drug: Nesiritide|Drug: Nitroglycerin","Renal Function by Serum Creatinine","Western University of Health Sciences|American College of Clinical Pharmacy","All","18 Years and older   (Adult, Older Adult)","Phase 4","89","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACCP-26060","July 2006","July 2008","February 2009","February 12, 2009","August 30, 2013","August 30, 2013","Centinela Hospital Medical Center, Inglewood, California, United States",,"https://ClinicalTrials.gov/show/NCT00842023"
99,"NCT01852214","Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes",,"Completed","Has Results","Diabetes Mellitus|Coronary Artery Disease","Drug: Prasugrel|Drug: Ticagrelor","P2Y12 Reaction Units|Platelet Reactivity Index","University of Florida","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UFJ 2011-184","February 2013","July 2015","August 2015","May 13, 2013","October 17, 2016","October 17, 2016","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01852214"
100,"NCT03150667","Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD","CPRS-CKD","Unknown status","No Results Available","Chronic Kidney Diseases|Acute Coronary Syndrome","Drug: Ticagrelor|Drug: Clopidogrel","Occurrence of all-cause mortality, non-fatal myocardial infarction (MI), or ischemic stroke|Occurrence of bleeding|Need for ischemia driven urgent coronary revascularization|Occurrence of MACE events|Length of hospital stay and readmission","North Texas Veterans Healthcare System","All","18 Years and older   (Adult, Older Adult)","Phase 4","220","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","16-041","April 10, 2017","April 30, 2019","April 30, 2020","May 12, 2017",,"May 25, 2018","Durham VA Medical Center, Durham, North Carolina, United States|VA North Texas Health Care System, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03150667"
101,"NCT01186250","Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation",,"Completed","Has Results","Cardiac Allograft Vasculopathy","Drug: Pioglitazone|Drug: Placebo","Insulin Levels Area Under Curve(AUC)|Change in Intimal Volume|Change in Levels of Fasting Glucose at Baseline and 1 Year|Change From Baseline in TG/HDL Ratio at One Year|Change in Maximal Intimal Thickness(MIT) by Intravascular Unltrasound(IVUS)|Change From Baseline in ADMA (Asymmetric Dimethylarginine) at One Year.|Change From Baseline in High-sensitivity C-reactive Protein (HsCRP) at One Year","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SU-05282010-6202|CTRU protocol 1314|IRB protocol 19373","July 2010","August 2013","December 2013","August 23, 2010","August 18, 2016","August 18, 2016","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01186250"
102,"NCT03797001","Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2","REDHART2","Active, not recruiting","No Results Available","Heart Failure, Systolic|Inflammation","Drug: Anakinra|Drug: Placebo","changes in peak oxygen consumption (VO2)|changes in peak VO2 at earlier endpoints|echocardiography assessments|hemodynamic assessments|Quality of Life Assessments|Biomarker - high sensitivity C-reactive protein (CRP)|Biomarker - N-terminal pro b-type Natriuretic Peptide (NT-proBNP)|Clinical Outcome - cardiac death|Clinical Outcome - hospitalization for heart failure","Virginia Commonwealth University","All","21 Years and older   (Adult, Older Adult)","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REDHART2 HM20014686","January 4, 2019","September 2023","September 2024","January 8, 2019",,"March 25, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03797001"
103,"NCT03837470","Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction","ERES-HFpEF","Recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: 0.9% Sodium Chloride|Drug: Furosemide 40 mg","Urinary Sodium Excretion|Urine Volume|Change in NT-proBNP|Serum Aldosterone|Plasma Renin Activity|Plasma Nor-epinephrine","Adhish Agarwal|University of Utah Center for Clinical and Translational Science|University of Utah","All","21 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB_00112270","May 6, 2019","August 31, 2020","August 31, 2020","February 12, 2019",,"April 29, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03837470"
104,"NCT01706510","Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients",,"Completed","No Results Available","Coronary Artery Disease","Drug: Ticagrelor|Drug: Clopidogrel","Compare ticagrelor's versus clopidogrel's inhibition of the P2Y12 receptor as measured by the decrease in P2Y12 Reaction Units (PRU) using VerifyNow TM.|Compare the decrease of P2Y12 Reaction Units (PRU) by VerifyNow TM from ticagrelor and clopidogrel.|Compare the decrease in P2Y l2 Reaction Units (PRU) by VerifyNow™ from ticagrelor's and clopidogrel's morning dose on Day 7|To evaluate and compare the pharmacodynamic effects, measured by the vasodilator-stimulated phosphoprotein (VASP) assay (platelet reactivity index [PRI]), in all subjects|Assess and to compare the percentage of subjects with High on-treatment Platelet Reactivity (HPR) at all time points after randomized study treatment.","Rapid City Regional Hospital, Inc|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 4","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISSBRIL0076","December 2012","March 2014","April 2014","October 15, 2012",,"May 5, 2015","Regional Heart Doctors/Black Hills Cardiovascular Research, Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01706510"
105,"NCT01814319","Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure","ReProsperHF","Completed","No Results Available","Systolic Heart Failure","Drug: Probenecid 1 gr oral twice daily|Drug: Placebo","6 minute walk test|shortness of breath|Ejection fraction|beta naturietic peptide|serum electrolytes","University of Cincinnati","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Re-Prosper HF","March 2013","June 2015","June 2015","March 19, 2013",,"August 26, 2015","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01814319"
106,"NCT03988634","Changes in NT-proBNP and Outcomes, Safety, and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)",,"Suspended","No Results Available","Heart Failure With Preserved Ejection Fraction (HFpEF)","Drug: sacubitril/valsartan|Drug: valsartan","Proportional change in NT-proBNP from baseline to the average of weeks 4 and 8|Composite hierarchical outcome|Cumulative number of recurrent composite overtime|Incidences of a composite endpoint of worsening renal function|Proportional change in NT-proBNP from baseline to Week 8|Proportional change from baseline in hs-Troponin (high sensitivity) at Weeks 4 and 8","Novartis Pharmaceuticals|Novartis","All","40 Years and older   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696DUS01","June 27, 2019","September 30, 2021","September 30, 2021","June 17, 2019",,"April 15, 2020","Novartis Investigative Site, Camp Hill, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03988634"
107,"NCT01300650","Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure",,"Completed","Has Results","Heart Failure","Drug: Anakinra","Median Interval Change From Baseline in Peak VO2|Median Interval Change From Baseline in the Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)|Interval Change From Baseline in Heart Failure Symptoms as Measured by Duke Activity Status Index (DASI)","Virginia Commonwealth University|National Institutes of Health (NIH)|National Center for Research Resources (NCRR)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIR-HF Pilot Study|1KL2RR031989-01","February 2011","August 2011","August 2011","February 21, 2011","May 16, 2013","November 30, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01300650"
108,"NCT01935622","Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy","DOXY-HF","Terminated","Has Results","Non-ischemic Cardiomyopathy|Systolic Heart Failure (NYHA II-III)","Drug: Doxycycline|Drug: placebo","Peak Aerobic Exercise Capacity","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VCU HM14393","July 2012","June 2014","June 2014","September 5, 2013","August 20, 2014","August 20, 2014","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01935622"
109,"NCT01980979","Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension",,"Withdrawn","No Results Available","Congenital Heart Disease","Drug: Remodulin","Improved cardiopulmonary exercise test|Improved overall cardiopulmonary variables","University of California, Los Angeles|United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Remodulin in ACHD|IRB#12-001968","November 2013","December 2015","December 2015","November 11, 2013",,"September 21, 2017","UCLA Medical Center, Los Angeles, California, United States|Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01980979"
110,"NCT01122316","Management of Diabetes With Metformin In Patients With Chronic Heart Failure",,"Completed","No Results Available","Heart Failure|Diabetes","Drug: Metformin","QOL|HbA1c|LVEF|renal function","University of California, Los Angeles","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-06-086-02","September 2009","January 2012","January 2012","May 13, 2010",,"April 2, 2012","Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01122316"
111,"NCT01779869","Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson","PET/MR-P","Completed","Has Results","Ischemic Heart Disease","Drug: Regadenoson","Diagnostic Accuracy of Cardiac PET/MRI Examination","Washington University School of Medicine|Astellas Pharma US, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PET/MR-Perfusion","January 2013","June 2015","June 2015","January 30, 2013","June 15, 2018","June 15, 2018","Center for Clinical Imaging Research at Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01779869"
112,"NCT01072643","Sedation With Dexmedetomidine During Cardiac Catheterization",,"Terminated","Has Results","Pulmonary Hypertension","Drug: Dexmedetomidine","The Primary Endpoint Will be the Change in PVR in Wood Units|Efficacy of Sedation With DEX|Quantify the Effect of DEX on PVR in Pediatric Subjects With Pulmonary Hypertension (PHTN) and Its Dependence on Baseline PVR|Obtain Pharmacokinetic Data in This Population|Demonstrate That DEX is a Safe Sedative in Pediatric Subjects With PHTN","Aruna Nathan|Children's Hospital of Philadelphia","All","8 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-007076","March 2010","March 2013","April 2013","February 22, 2010","September 8, 2014","April 16, 2019","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01072643"
113,"NCT02304705","Sildenafil in Heart Failure With Reactive Pulmonary Hypertension","Sildenafil-HF","Terminated","Has Results","Heart Failure With Reactive Pulmonary Hypertension","Drug: Sildenafil|Drug: Placebo","Change in Exercise Tolerance","Maya Guglin|University of Kentucky","All","18 Years and older   (Adult, Older Adult)","Phase 4","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-0628-F3R","January 2015","June 2017","June 2017","December 2, 2014","March 13, 2019","November 7, 2019","University of Kentucky Medical Center, Lexington, Kentucky, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02304705/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02304705"
114,"NCT03154476","Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study","SiFALD","Completed","No Results Available","Cirrhosis|Congenital Heart Disease","Drug: Sildenafil|Drug: Placebo","Change in liver stiffness as measured by magnetic resonance elastography (MRE)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","16-008985","July 5, 2017","June 30, 2019","June 30, 2019","May 16, 2017",,"April 7, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03154476"
115,"NCT01901809","Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction","ROPA-DOP","Completed","Has Results","Heart Failure, Diastolic","Drug: Furosemide|Drug: Dopamine","Percent Change in Serum Creatinine at 72 Hours.|Percent Change in Serum Creatinine at 72 Hours - Continuous vs Intermittent Diuretic|Percent Change in Serum Creatinine at 72 Hours - Dopamine vs No Dopamine","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NA 00083629","August 2013","June 2017","May 2018","July 17, 2013","May 17, 2018","August 16, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/09/NCT01901809/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01901809"
116,"NCT01482169","Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)",,"Completed","Has Results","Coronary Artery Disease","Drug: FFR Measurement with IV Adenoscan® then with Regadenoson","Comparing Measurement of Fractional Flow Reserve (FFR)|Duration to Baseline Hyperemia After Aminophylline Injection","Ochsner Health System|Astellas Pharma Global Development, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","48","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10012012","March 2012","May 2014","September 2014","November 30, 2011","May 11, 2018","May 11, 2018","Ochsner Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01482169"
117,"NCT02560467","Perfusion Imaging With Myocardial Contrast Echocardiography in HCM",,"Active, not recruiting","No Results Available","Hypertrophic Cardiomyopathy","Drug: Echo and myocardial contrast echocardiography perfusion imaging","Myocardial perfusion (ml/min/g) in the hypertrophied segment on myocardial contrast echo|Myocardial blood flow reserve in the hypertrophied segment on myocardial contrast echo|Spatial distribution of blood flow on myocardial contrast echocardiography","Oregon Health and Science University","All","19 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15158","December 1, 2015","September 1, 2019","September 15, 2019","September 25, 2015",,"June 6, 2019","Oregon Health & Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02560467"
118,"NCT01663662","The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study",,"Withdrawn","No Results Available","Heart Failure","Drug: Tolvaptan|Drug: placebo","Renal dysfunction|Weight|Urine output|Hospitalization length of stay","University of Michigan|Otsuka Pharmaceuticals","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11-PAF06621","August 2012","November 2013","November 2013","August 13, 2012",,"December 11, 2015","University of Michigan Health Systems, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01663662"
119,"NCT02424695","Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome",,"Unknown status","No Results Available","Restless Legs Syndrome","Drug: Gabapentin Enacarbil (GEn)|Drug: Placebo","The mean change from baseline to week 4 in intensity of cortical arousals associated with periodic limb movements (PLMs)|The mean change from baseline to week 4 in heart rate variability associated with arousals secondary to periodic limb movements (PLMs)|The mean change from baseline to week 4 in blood pressure associated with arousals secondary to periodic limb movements (PLMs)|The mean change from baseline to week 4 in periodic limb movement (PLM) intensity|The mean change from Baseline to week 4 in Rechtschaffen and Kales polysomnography parameters|The mean change from baseline to week 4 in International Restless Legs Syndrome (IRLS) Rating Scale total score|The mean change from Baseline to week 4 in proportion of responders (""much""/ ""very much"" improved) on the investigator-rated Clinical Global Impression-Improvement (CGI-I) scale|The mean change from Baseline to week 4 in proportion of responders (""moderately better"" to ""a great deal better"") on the patient Global Impression of Change (PGIC) scale|The mean change from Baseline to week 4 in Post Sleep Questionnaire (PSQ)scores|The mean change from Baseline to week 4 in Subjective Sleep Questionnaire (SSQ) scores|The mean change from Baseline to week 4 in Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL) scores|The mean change from Baseline to week 4 in Restless Legs Syndrome- Next Day Impact Questionnaire (RLS-NDI) scores|The mean change from Baseline to week 4 in the Epworth Sleepiness Scale (ESS) scores|Number of subjects with treatment emergent adverse events|Number of subjects with mild, moderate and severe adverse events","Cleveland Sleep Research Center|XenoPort, Inc.|YRT Limited","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XP-IIT-0031","June 2015","June 2016","July 2016","April 23, 2015",,"April 23, 2015","Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02424695"
120,"NCT03453151","Abdominal Nerve Blockade in Chronic Heart Failure.",,"Completed","No Results Available","Heart Failure","Drug: splanchnic nerve anesthesia with a local anesthetic","Change in exercise capacity|Change in pulmonary arterial mean pressure|Change in pulmonary wedge pressure|Change in cardiac output|Improvement in urine output|Improvement in renal biomarkers","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00090299","May 1, 2018","June 27, 2019","December 27, 2019","March 5, 2018",,"February 5, 2020","Duke, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03453151"
121,"NCT01252810","Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure",,"Completed","Has Results","Chronic Renal Insufficiency|Diabete Mellitus|Congestive Heart Failure","Drug: GE-145","Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader.|To Determine Incidence Rates of the Overall AEs, Organ-specific AEs (i.e., Delayed Skin Reactions, General Subject Comfort, and Allergic/Immunologic Reactions, Etc.) and SAEs Following Administration|Assessing the Incidence of Renal Biomarker-based Contrast-induced Acute Kidney Injury (CI-AKI) in Subjects Post Administration of Ioforminol or Iopamidol Injections","GE Healthcare|i3 Statprobe|Medpace, Inc.|Biomedical Systems|Rules-Based Medicine, Inc.","All","65 Years and older   (Older Adult)","Phase 2","284","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","GE 145-002","November 2010","December 2012","December 2012","December 3, 2010","May 2, 2014","August 29, 2018","GE Healthcare, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01252810"
122,"NCT01573949","A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)",,"Completed","No Results Available","Diabetes|Heart Failure","Drug: Metformin","QOL|Change from baseline HgA1c at 3 months|Change from baseline left ventricular ejection fraction (LVEF) at 3 months|Change from baseline in creatinine (Cr) level at 3 months","University of California, Los Angeles","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-002909","December 2011","December 2012","December 2012","April 10, 2012",,"June 24, 2013","Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01573949"
123,"NCT03460470","Sildenafil in US Heart Failure Patients (SilHF-US)","SilHF-US","Unknown status","No Results Available","Heart Failure|Pulmonary Hypertension","Drug: Sildenafil|Drug: Placebo oral capsule","Six minute walk test|Patient Global Assessment (PGA)|1.Quality of Life (QoL) evaluation by EuroQol5D|Kansas City Cardiomyopathy Questionnaire (KCCQ)|New York Heart Association (NYHA) function class","Hartford Hospital|Helse Stavanger HF","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HHC-2016-0152","February 14, 2018","December 2018","December 2018","March 9, 2018",,"March 9, 2018","Hartford Hospital 80 Seymour street, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03460470"
124,"NCT02546583","Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure",,"Recruiting","No Results Available","Heart Failure","Drug: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|Drug: IV Chlorothiazide","Accuracy of sodium prediction equation in predicting suboptimal natriuretic response to a dose of diuretics|Prevalence of mechanistic sub types of Diuretic Resistance (DR) as defined by cutoff values of change in fractional excretion of lithium|Accuracy of prediction of mechanistic sub types of DR using universally available laboratory tests|Change in total 6-hour sodium output between observational and randomized intervention study days|Prediction of mechanistic sub types of DR","Yale University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1505015805|1R01HL128973-01","August 2015","July 2025","July 2025","September 11, 2015",,"March 26, 2020","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02546583"
125,"NCT03081052","Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes","INSPIRE-FLO","Suspended","No Results Available","Heart Transplant Surgery|Lung Transplant Surgery","Drug: iNO|Drug: iEPO","Incidence of Grade 3 Primary Graft Dysfunction (PGD) for Lung Transplant subjects.|Incidence of moderate or severe RV failure for the LVAD implantation subjects.|Incidence of severe RV failure for Heart Transplantation subjects.|Duration of postoperative mechanical ventilation|Per patient cost|Length of ICU stay|Length of hospital stay|Incidence of Acute Kidney Injury|Incidence of in-hospital mortality|Incidence of postoperative mortality within 30 days|Incidence of post-operative mortality within 90 days|Incidence of post-operative mortality within 1 year","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 4","424","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Pro00078035","May 4, 2017","September 2020","September 2021","March 15, 2017",,"April 21, 2020","Duke Health, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03081052"
126,"NCT02620384","Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.","MELT-HF","Terminated","Has Results","Acute Decompensated Heart Failure","Drug: Experimental: Placebo|Drug: Experimental: Metolazone","Total Urinary Output at 48 Hours|Fluid Balance at 48 Hours|Change in Weight First 48 Hours|Degree of Improvement in Dyspnea at 6, 12, 24, 36 and 48 Hours.|Total Dose Diuretics First 48 Hours|Number of Participants With Inotrope Administration During First 48 Hours|All Cause Mortality at 30 Days","Aultman Health Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","147","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2015.03.26.F2","October 1, 2015","November 29, 2017","December 29, 2017","December 3, 2015","February 15, 2019","February 15, 2019","Aultman Health Foundation, Canton, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02620384/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02620384/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02620384"
127,"NCT03027960","Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects","EMPA","Completed","No Results Available","Heart Failure|Type II; Diabetes","Drug: Empagliflozin|Drug: Placebo Oral Capsule","urine sodium concentrations via ion selective electrodes|blood volume","Yale University|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2000020019","June 27, 2017","May 14, 2019","June 1, 2019","January 23, 2017",,"June 5, 2019","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03027960"
128,"NCT02349152","Remifentanil and Glycemic Response in Cardiac Surgery",,"Completed","Has Results","Heart Diseases|Hyperglycemia","Drug: Remifentanil|Drug: Fentanyl","Blood Glucose Values (More Than One ) > 180 mg%|Insulin Requirement|Number of Blood Glucose Values > 180 mg%|Mean, Peak and Trough Intraoperative Blood Glucose (mg/dl)|Postoperative Blood Glucose|Total Postoperative Regular Insulin|Intraoperative Pre-cardiopulmonary Bypass Hemodynamic Stability|Stress Hormone Levels-Cortisol (µg/dl)|Inflammatory Mediator Levels, Interleukin-1b, Interleukin 6 and Tumor Necrosis Factor (TNF) (pg/ml)|Stress Hormone Levels-ACTH, GH, Glucagon (pg/ml)|Society of Thoracic Surgery Patient Outcomes|Postoperative Pain|Emergence From Anesthesia|Wound Hyperalgesia|Development of Chronic Pain|Glycemic Variability","Kathirvel Subramaniam|Mylan Inc.|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 4","116","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO14110258","January 2016","December 2016","December 2017","January 28, 2015","May 14, 2018","April 21, 2020","UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02349152"
129,"NCT03574857","Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance",,"Enrolling by invitation","No Results Available","Heart Failure|Heart Failure With Reduced Ejection Fraction|Heart Failure Acute|Cardiovascular Diseases","Drug: Metolazone Oral Tablet|Drug: Chlorothiazide Injection","Net urine output at 24 hours|Net urine output at 48 hours|Net fluid balance over 12 hours|Net fluid balance over 24 hours|Weight change","University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20455","June 2018","August 2018","August 2018","July 2, 2018",,"July 2, 2018","University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03574857"
130,"NCT02329834","Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: Fursemide Injection Solution for subcutaneous administration (80 mg)|Drug: Furosemide Injection, USP","Pharmacokinetic Parameters","scPharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","scP-01-002","April 2015","October 2015","October 2015","January 1, 2015",,"June 27, 2018","Avail Clinical Research, LLC, DeLand, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02329834"
131,"NCT02053246","Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure",,"Active, not recruiting","No Results Available","Pulmonary Hypertension|Diastolic Heart Failure|Heart Failure With Preserved Ejection Fraction","Drug: Nebivolol","Changes in pulmonary vascular pressure|Changes in 6-minute walk distance","University of Florida|National Institute of General Medical Sciences (NIGMS)","All","18 Years and older   (Adult, Older Adult)","Phase 4","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201501144 -N|K23GM112014","January 2014","March 2021","March 2021","February 3, 2014",,"March 17, 2020","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02053246"
132,"NCT01505179","The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction","RAZE","Completed","Has Results","Heart Failure With Preserved Ejection Fraction","Drug: Ranolazine|Drug: Placebo","Change in Exercise Capacity at 6 Weeks|Change in Oxygen Consumption (VO2) at 6 Weeks|Change in Quality of Life (QOL) Score|Change in Doppler Echocardiographic Parameters, Septal E/e' Ratio (E/e')","University of California, San Diego|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IN-US-259-0109|110344","February 2011","December 2014","January 2015","January 6, 2012","January 18, 2020","January 18, 2020","University of California, San Diego, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01505179"
133,"NCT01765400","Platelet Inhibition in Patients With Systolic Heart Failure",,"Completed","No Results Available","Systolic Heart Failure","Drug: Prasugrel 10 mg daily x 2 weeks|Drug: Clopidogrel 75 mg daily x 2 weeks","The change in platelet aggregation measured by the Accumetrics (VerifyNow P2Y12) assay between baseline and each antiplatelet medication|The change in light transmission aggregometry (LTA)between baseline and each antiplatelet medication|The change in platelet activation assay (VASP)between baseline and each antiplatelet medication","University of Nebraska|Daiichi Sankyo, Inc.|Eli Lilly and Company","All","19 Years to 75 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","574-11-FB","February 2013","December 1, 2015","December 28, 2015","January 10, 2013",,"October 2, 2017","University of Nebaska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01765400"
134,"NCT01936909","Interleukin-1 Blockade in Recently Decompensated Heart Failure","RED-HART","Completed","Has Results","Heart Failure","Drug: Anakinra (weeks 1-2)|Drug: Anakinra (weeks 3-12)|Drug: Placebo","Interval Changes in Peak Oxygen Consumption (VO2)|Quality of Life Improvement|Death or Hospital Admission for Heart Failure","Virginia Commonwealth University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 130 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RED-HART (HM15339)|1R34HL117026","February 2014","September 23, 2016","September 23, 2016","September 6, 2013","December 22, 2017","December 22, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01936909"
135,"NCT00904488","Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure",,"Terminated","Has Results","Acute Decompensated Heart Failure","Drug: Addition of oral Metolazone|Drug: Furosemide dose escalation","Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)|Daily Net Fluid Output on Days 1, 3, and 4|Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)|Daily Weight|Patient Global Assessment Scale|Physician Global Assessment Scale|Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure)|Time to Return to Baseline Weight|Length of Hospitalization|30-day All-cause Mortality|Rehospitalization at 30 Days|Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic|Blood Urea Nitrogen (BUN)","University of North Carolina, Chapel Hill|University of Illinois at Chicago|Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 4","11","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-1292","October 2008","May 28, 2016","November 14, 2017","May 19, 2009","February 13, 2018","March 13, 2018","UNC_Chapel Hill, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00904488"
136,"NCT01337349","Effects of Pentoxiphylline on Left Ventricular (LV) Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure (CHF)","PENT-CHF","Unknown status","No Results Available","Congestive Heart Failure","Drug: Placebo|Drug: Pentoxifylline","Improvement in Left Ventricular Ejection Fraction > 5%|Left Ventricular End Systolic Volume Index|Left Ventricular End Diastolic Volume Index|Quality of Life Improvement|Circulating Inflammatory Biomarkers|Change in VO2 Max","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2192010","July 2010","July 2014","July 2014","April 18, 2011",,"August 29, 2013","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01337349"
137,"NCT03249272","Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve",,"Completed","No Results Available","Hypertrophic Cardiomyopathy|Non-ischemic Dilated Cardiomyopathy|Microvascular Ischaemia of Myocardium","Drug: Regadenoson|Drug: Adenosine","Prevalence of microvascular dysfunction (MVD) by a CMR measurement of whole-heart (global) perfusion reserve ratio in patients with hypertrophic cardiomyopathy, non-ischemic cardiomyopathy, and atypical chest pain.|CMR measurement of global perfusion reserve ratio|The association between global perfusion reserve ratio and other CMR metrics including regional myocardial scarring and perfusion as measured by odds ratio as appropriate.","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","Pro00082447","September 5, 2017","March 31, 2019","March 31, 2019","August 15, 2017",,"December 13, 2019","Duke Cardiovascular Magnetic Resonance Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03249272"
138,"NCT01645826","Efficacy Study of Cardizem in Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Idiopathic Pulmonary Arterial Hypertension|Primary Pulmonary Hypertension|Pulmonary Arterial Hypertension|Familial Primary Pulmonary Hypertension","Drug: Diltiazem Hydrochloride|Drug: Sugar Pill","Six Minute Walk Distance|Dyspnea Score|Quality of Life Score|Pulse Oximetry","University of South Florida","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pro00004379","July 2012","September 2014","September 2014","July 20, 2012",,"November 20, 2018","University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01645826"
139,"NCT02625558","Riociguat for Sarcoidosis Associated Pulmonary Hypertension","RioSAPH","Unknown status","No Results Available","Sarcoidosis","Drug: Riociguat|Drug: Placebo","Time until clinical worsening|Safety: adverse events|Pulmonary function|Quality of life|Six minute walk","University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-7130","April 2015","April 2018","October 2018","December 9, 2015",,"December 9, 2015","University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02625558"
140,"NCT02961946","Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality",,"Completed","Has Results","Coronary Artery Disease","Drug: Nitroglycerin","Coronary Artery Diameter Change","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","2016P002417","March 15, 2017","October 31, 2017","August 2, 2018","November 11, 2016","September 17, 2019","September 17, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02961946/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02961946/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02961946"
141,"NCT01230307","Vitamin D Supplementation for Treatment of Heart Failure","DELIGHTFUL","Terminated","Has Results","Heart Failure","Drug: Vitamin D3|Drug: Placebo","Biomarkers|Exercise Capacity Measured by 6 Minute Walk Test|Quality of Life Measured by Kansas City Cardiomyopathy Questionnaire|Vitamin D Genomics","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 4","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","VitD3","October 2010","December 2014","December 2014","October 29, 2010","November 18, 2016","November 18, 2016","University of Michigan Medical Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01230307"
142,"NCT04017936","Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis","MAGiC-ART","Not yet recruiting","No Results Available","Cardiac Sarcoidosis","Drug: Anakinra|Drug: Placebos","Change in inflammation marker|Change in cardiac functioning|Change in cardiac damage|Number of serious cardiac events","Virginia Commonwealth University|American Heart Association","All","21 Years and older   (Adult, Older Adult)","Phase 2","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20015843","August 2020","August 2023","December 2023","July 12, 2019",,"March 26, 2020","University of Michigan Sarcoidosis Clinic, Ann Arbor, Michigan, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04017936"
143,"NCT02177266","Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation",,"Terminated","Has Results","Atrial Fibrillation|Post-pericardiotomy Syndrome|Constriction","Drug: Colchicine|Drug: Placebo","Number of Patients With Post Cardiac Surgery Atrial Fibrillation or Post-pericardiotomy Syndrome.|Trans-thoracic Echocardiography for Constriction","Mayo Clinic","All","40 Years and older   (Adult, Older Adult)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-008553","May 2015","November 2016","November 2016","June 27, 2014","June 21, 2017","June 21, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02177266"
144,"NCT01598740","Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease",,"Completed","Has Results","Heart Failure","Drug: CLP|Drug: Spironolactone","Change in Fecal Sodium Content|Change in Fecal Weight","Sorbent Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTST-25","June 2012","September 2012","September 2012","May 15, 2012","May 8, 2013","July 19, 2013","Orange Country Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT01598740"
145,"NCT01150461","Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy",,"Completed","Has Results","Hypertrophic Cardiomyopathy","Drug: losartan|Drug: placebo","Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging.|Percentage Change From Baseline in Left Ventricular Mass at 1 Year as Assessed by Magnetic Resonance Imaging.","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2006P002232/7","February 2007","July 2010","July 2010","June 25, 2010","September 5, 2013","September 5, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01150461"
146,"NCT01261065","Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure",,"Completed","No Results Available","Heart Failure|Cardiomyopathy","Drug: carvedilol","Load independent measure of contractility: Left ventricular velocity of circumferential shortening to left ventricular end systolic stress ratio|Left ventricular end diastolic and end systolic volumes, left ventricular end systolic stress, effective arterial elastance","Michael Debakey Veterans Affairs Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","55","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VA-CDA","December 2001","October 2005","October 2005","December 16, 2010",,"December 16, 2010","Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01261065"
147,"NCT01377987","Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients","HF-ACZ","Completed","Has Results","Heart Failures","Drug: Acetazolamide|Drug: Placebo","The Severity of Sleep Disordered Breathing (Apnea-hypopnea Index, AHI)|Ventilatory Chemoreflex Sensitivity, ""Loop Gain"" Using Carbon Dioxide Pulses|Sympathetic Activity (Urinary Norepinephrine)|Left-atrial Volume|Brain Natriuretic Peptide (NT-proBNP)|Pittsburgh Sleep Quality Index","David Andrew Wellman|American Heart Association|National Institutes of Health (NIH)|Brigham and Women's Hospital","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","29","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2011-P-000049/1","August 2011","December 2016","December 2016","June 22, 2011","June 13, 2018","June 13, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01377987"
148,"NCT03743805","Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination",,"Recruiting","No Results Available","Brain Death|Anoxic Brain Injury|Cardiac Arrest|Sedative Intoxication|Narcotic Intoxication","Drug: Flumazenil|Drug: Naloxone","Improved GCS scores or return of cerebral or brainstem functions in comatosed subjects","Sameh Hanna, MD|Prisma Health-Midlands","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00077995","January 1, 2019","December 31, 2019","June 30, 2020","November 16, 2018",,"March 26, 2019","PRISMA Health Midlands, Columbia, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03743805"
149,"NCT01097785","Targeting Sympathetic Overactivity in Heart Failure Patients With Statins",,"Completed","Has Results","Heart Failure","Drug: Simvastatin|Drug: Placebo","Change in Muscle Sympathetic Nerve Activity in Bursts Per 100 Heartbeats|Change in Measures of Reactive Oxygen Species in the Blood","University of Missouri-Columbia|University of Nebraska","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","IRB-1135098","March 2009","July 2014","July 2014","April 2, 2010","November 21, 2016","November 21, 2016","University of Missouri, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01097785"
150,"NCT01522378","Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging",,"Terminated","No Results Available","Congestive Heart Failure","Drug: 123 iodine metaiodobenzylguanidine","Change in 123I-MIBG parameters|Change in submaximal exercise gas exchange|Change in Autonomic function","Mayo Clinic|GE Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-006296","February 2012","February 2016","February 2016","January 31, 2012",,"April 26, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01522378"
151,"NCT01067339","Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans",,"Completed","Has Results","Endothelial Dysfunction","Drug: darapladib|Drug: placebo","Percentage Change in Coronary Artery Diameter|Percentage Change in Coronary Blood Flow (CBF)","Mayo Clinic|GlaxoSmithKline|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","70","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10-000044|5R01HL092954|5R01AG031750","February 4, 2010","November 2015","November 2015","February 11, 2010","March 15, 2017","April 18, 2017","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01067339"
152,"NCT03471611","Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis",,"Active, not recruiting","No Results Available","Atherosclerosis, Coronary","Drug: Autologous CD34+ Cells|Drug: Granulocyte Colony-Stimulating Factor (G-CSF)","Number of subjects experiencing adverse events|Number of subjects experiencing serious adverse events|Number of subjects experiencing Major Adverse Cardiovascular Events (MACE)","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-005743","June 15, 2018","May 1, 2022","May 1, 2022","March 20, 2018",,"March 9, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03471611"
153,"NCT02980068","A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction","PMED","Recruiting","No Results Available","Pulmonary; Hypertension|Heart Failure|Preserved Ejection Fraction","Drug: 15N Nitrate|Drug: 14N Nitrate","Change in nitrate level in urine|Change in nitrate level in plasma|Bacterial content of gut microbiome|Bacterial content of the oral microbiome|Change in nitrite level in urine|Change in nitrite level in plasma|Change in blood pressure|Change in heart rate|Change in respiratory rate|Change in hemoglobin concentration","Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO16090149|5P01HL103455","August 28, 2017","July 2020","July 2021","December 2, 2016",,"November 13, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02980068"
154,"NCT01516372","A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers",,"Completed","No Results Available","Restless Legs Syndrome","Drug: GEn 1200mg|Drug: Gen 6000 mg|Drug: GEn Placebo|Drug: Moxifloxacin Placebo|Drug: Moxifloxacin","Change in QTcF (QT duration corrected for heart rate by Fridericia's formula) interval at Each time point for 6000 mg GEn and Placebo measured by ECG|Change in QTcF interval at Each time point for 1200 mg GEn and Placebo measured by ECG|Change from baseline in QTcF interval at each time point for moxifloxacin 400 mg and placebo measured by ECG|Change from baseline in QTcB (QT duration corrected for heart rate by Bazett's formula), QT for GEn (1200 mg and 6000 mg) and moxifloxacin (400 mg) and placebo measured by ECG|Change from baseline in PR, QRS intervals, heart rate and ECG waveform morphology for GEn (1200 mg and 6000 mg) and placebo measured by ECG|Change from baseline in heart rate and ECG waveform morphology for moxifloxacin (400 mg)|Pharmacokinetic parameters for gabapentin and moxifloxacin|Safety parameters: AEs, vital signs, ECGs, Columbia Suicide Severity Rating Scale (C-SSRS) and clinical laboratory parameters","XenoPort, Inc.","All","18 Years to 50 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","114112","January 2012","March 2012","March 2012","January 24, 2012",,"July 16, 2013","GSK Investigational Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01516372"
155,"NCT04134078","Improving Outcomes in Cardiac Arrest With Inhaled Nitric Oxide",,"Recruiting","No Results Available","Cardiac Arrest","Drug: inhaled nitric oxide","Rate of return of spontanueous circulation (ROSC)|Change in cerebral oxygenation (rSO2)|Neurologic outcomes at hospital discharge|short term survival","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","648019","August 2016","July 2020","July 2022","October 21, 2019",,"October 21, 2019","Stony Brook University, S. Setauket, New York, United States",,"https://ClinicalTrials.gov/show/NCT04134078"
156,"NCT02183792","Aquaresis Utility for Hyponatremic Acute Heart Failure Study","AQUA-AHF","Completed","Has Results","Heart Failure","Drug: Tolvaptan|Drug: Furosemide","Median Urine Output at 24 Hours Post Randomization|Median Change in Serum Creatinine at 24 Hours Post Randomization","University of Southern California|Otsuka America Pharmaceutical","All","18 Years and older   (Adult, Older Adult)","Phase 4","33","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-13-00705","December 2014","February 2018","March 2018","July 8, 2014","May 28, 2019","May 28, 2019","Keck Medical Center of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02183792/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02183792"
157,"NCT02077010","Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population","iMilrinone","Not yet recruiting","No Results Available","Heart Failure|Cardiomyopathy","Drug: Inhaled nebulized milrinone","Safety Analysis|Pharmacokinetic analysis|All cause mortality","University of Kansas Medical Center|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170530","April 1, 2020","December 1, 2020","December 1, 2020","March 4, 2014",,"March 17, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02077010"
158,"NCT01028170","Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure","REaCH","Completed","No Results Available","Congestive Heart Failure|Renal Insufficiency","Drug: furosemide and hypertonic saline solution|Drug: furosemide","Renal function (GFR)|Diuretic response (defined as achievement of weight within 2% of previously determined dry body weight or reaching a clinically compensated state including return of functional level to prior NYHA class as determined by the primary treating physician)|Length of hospital stay|Readmission rate|Weight loss|BNP Levels|Hospitalization cost analysis","Aspirus Heart and Vascular Institute-Research and Education|Aspirus Wausau Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REaCH-23.07.09","November 2009","July 2011","January 2012","December 9, 2009",,"February 9, 2012","Aspirus Wausau Hospital, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01028170"
159,"NCT03184155","Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine",,"Not yet recruiting","No Results Available","Coronary Artery Disease","Drug: Nicardipine|Drug: Sterile Saline","Change in Index of Microcirculatory Resistance (IMR)|Post-Procedure myocardial Infarction (PMI)|Major Adverse Cardiac Event","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17D.172","June 2019","July 2019","July 2020","June 12, 2017",,"February 12, 2019","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03184155"
160,"NCT02189889","Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery","APART","Terminated","No Results Available","Anemia|Cardiovascular Disease","Drug: EPO|Drug: Feraheme","Assessment of adherence rate to the dosing protocol per surveillance strategy.|Change from Baseline hemoglobin level assessed at different time points within the 2 arms.|Change from Baseline reticulocyte count assessed at different time points within the 2 arms.|Number of blood products utilized per patient receiving erythrocyte transfusions.|Incidence of pre-defined clinical events in each of the study arms.","University of Texas Southwestern Medical Center|AMAG Pharmaceuticals, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APART.V1.2013","April 9, 2013","July 26, 2019","July 26, 2019","July 15, 2014",,"September 26, 2019","Clements University Hospital, Dallas, Texas, United States|Clements University Hospital, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02189889"
161,"NCT02429388","High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure",,"Withdrawn","No Results Available","Heart Failure","Drug: Spironolactone","Efficacy of adjunctive high-dose Spironolactone on weight loss.|Efficacy of adjunctive high-dose Spironolactone on dyspnea.|Risk of hyperkalemia and renal dysfunction with use of adjunctive high-dose Spironolactone.|Length of hospitalization","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20140274H","May 2014","October 2015","October 2015","April 29, 2015",,"April 20, 2016","University Hospital, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02429388"
162,"NCT01489176","Regadenoson Real Time Perfusion Imaging Trial-Optison",,"Unknown status","No Results Available","Coronary Artery Disease|Myocardial Perfusion Abnormalities","Drug: Regadenoson; Optison","Identification of Coronary Stenosis","Thomas R. Porter, MD|Astellas Pharma US, Inc.|GE Healthcare|University of Nebraska","All","30 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","555-11-FB","September 2012","September 2013","September 2013","December 9, 2011",,"September 26, 2012","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01489176"
163,"NCT02124824","Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: BQ-123","Blood Flow","VA Office of Research and Development|University of Utah","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","30","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","F1418-P","September 1, 2014","March 31, 2019","March 31, 2019","April 28, 2014",,"May 2, 2019","VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02124824"
164,"NCT02008370","Exparel in Minimally Invasive Cardiac Surgery",,"Terminated","Has Results","Cardiac Disease","Drug: Exparel infiltration","Total Use of Analgesics|Patient Satisfaction|Pain Scores","Maimonides Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-07-18","November 2013","June 2016","June 2016","December 11, 2013","October 4, 2019","October 4, 2019","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT02008370"
165,"NCT01479010","Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension",,"Terminated","Has Results","Pulmonary Hypertension","Drug: Anakinra 100 mg subcutaneously daily","Median Interval Change From Baseline in Peak VO2|Median Interval Change From Baseline in the Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)|Interval Change From Baseline in Biomarkers (High-sensitivity C-reactive Protein, Whole Blood Assay, Brain Natriuretic Peptide)|Interval Change From Baseline in Heart Failure Symptoms as Measured by Duke Activity Status Index (DASI)|Correlation Between Interval Changes in Biomarkers, Peak VO2, and VE/VCO2|Rate of Adverse Events and Hospitalizations|Total Exercise Time|Oxygen Uptake Efficiency Slope","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM13729","November 2011","November 2013","November 2013","November 24, 2011","June 8, 2015","November 13, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01479010"
166,"NCT03515304","Evolocumab in Acute Coronary Syndrome","EVACS","Recruiting","No Results Available","Acute Coronary Syndrome","Drug: Evolocumab|Drug: Placebo","Change in LDL-Cholesterol|PET Imaging for inflammation|Change in left ventricular volume as assessed by echocardiography|Change in ejection fraction as assessed by echocardiography|Change in plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels (ng/ml)|Change in plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)|PET-FDG assessed vascular inflammation|Change in New York Heart Association (NYHA) Class|Change in high sensitivity C-reactive protein (hs-CRP) serum levels|Change in tumor necrosis factor (TNF)-alpha serum levels|Change in plasma levels of Interleukin 1|Change in serum levels of Interleukin 6|Change in serum levels of Interleukin 10|Change in Canadian Angina Class","Johns Hopkins University|Washington University School of Medicine","All","25 Years to 90 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00156313","May 20, 2018","February 1, 2021","August 1, 2021","May 3, 2018",,"January 2, 2020","Steven Paul Schulman, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03515304"
167,"NCT03611153","MPO Inhibitor A_Zeneca for HFpEF",,"Recruiting","No Results Available","Heart Failure","Drug: Oral Myeloperoxidase Inhibitor|Drug: Placebo oral capsule","Exercise Pulmonary capillary wedge pressure (PCWP)","Mayo Clinic","All","30 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17-002907|UL1TR000135","July 1, 2018","December 31, 2020","January 31, 2021","August 2, 2018",,"February 5, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03611153"
168,"NCT01415921","Safety Study of Pyridostigmine in Heart Failure","APP-HF","Completed","Has Results","Heart Failure","Drug: Pyridostigmine Bromide","Baseline Heart Rate Recovery|Post Exercise Heart Rate Recovery","NYU Langone Health|Nathan Kline Institute for Psychiatric Research|Oklahoma State University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-02167|1R01HL103988","October 2011","July 2015","July 2015","August 12, 2011","October 25, 2016","July 31, 2017","New York University Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01415921"
169,"NCT03787082","Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension",,"Not yet recruiting","No Results Available","Pulmonary Hypertension|Heart Failure With Normal Ejection Fraction|Pulmonary Heart Disease and Diseases of Pulmonary Circulation","Drug: Nitrates|Drug: Chlorhexidine Gluconate Mouthwash|Drug: Placebo Mouthwash","Change in Plasma Nitrate|Change in Urine Nitrate|Change in Pulmonary Vascular Resistance (PVR)","Gladwin, Mark, MD|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO18080517|5P01HL103455","July 2020","February 2021","February 2021","December 26, 2018",,"April 6, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03787082"
170,"NCT01530464","The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers","GQ01","Completed","Has Results","High Altitude Pulmonary Hypertension","Drug: Aminophylline|Drug: Ambrisentan|Drug: Aminophylline plus ambrisentan","Mean Number of Adverse Events Following Each Dose|Plasma Halflife of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Time Until Maximum Plasma Concentration (Tmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Maximum Plasma Concentration (Cmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Area Under the Curve Within 24 Hours Post Dosing (AUC_0-24 Hours) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|Area Under the Curve Post Dosing (AUC_0-infinity) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination","Thies Schroeder|Duke University","All","18 Years to 40 Years   (Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00028417","February 2012","April 2012","April 2012","February 10, 2012","January 16, 2014","January 16, 2014","Duke Clinical Research Unit, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01530464"
171,"NCT03103061","Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System",,"Completed","Has Results","Cardiovascular Diseases|Coronary Artery Disease","Drug: Lexiscan","Number of Treatment-related Adverse Events|Diagnostic Accuracy Using Quantitative Objective Image Quality Assessment","Medical University of South Carolina|Astellas Pharma US, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00051308","February 9, 2016","June 14, 2018","June 14, 2018","April 6, 2017","August 9, 2019","August 9, 2019","Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03103061/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03103061"
172,"NCT02762331","High Dose Vitamin C in Cardiac Surgery Patients",,"Terminated","Has Results","Disorder of Vitamin C|Atrial Fibrillation|Complications Due to Coronary Artery Bypass Graft|Heart Valve Disease","Drug: Ascorbic Acid|Drug: Placebo","Plasma Inflammatory Biomarkers|Urinary Inflammatory Biomarker|Occurence of Atrial Fibrillation|Coagulation Biomarkers|Lipidomic Biomarkers|Development of Renal Calculi","Virginia Commonwealth University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","HM20000539","January 1, 2017","March 13, 2018","March 13, 2018","May 4, 2016","June 24, 2019","June 24, 2019","Virginia Commonwealth University Health System, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02762331/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02762331"
173,"NCT00818701","Study of Low Dose Nesiritide With or Without Sildenafil in Congestive Heart Failure Patients With Renal Dysfunction","BNP+PDEVI","Terminated","No Results Available","Congestive Heart Failure|Renal Dysfunction","Drug: low dose Nesiritide|Drug: nesiritide, Sildenafil","To determine the efficacy of low dose BNP alone vs low dose BNP + PDE V inhibition in improving renal function in patients with CHF and renal dysfunction. (Calculated creatinine clearance = or < than 60 ml/min and > 30 ml/min, within 12 months.)|We also want to characterize both plasma and urinary humoral profile in these patients.","Mayo Clinic","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","08-004797|BNP + PDEVI","February 2009","August 2010","August 2010","January 8, 2009",,"September 24, 2010","Mayo Clinic, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00818701"
174,"NCT00860340","Hemodynamic Effects of Spironolactone in Patients With Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Drug: Spironolactone","Echocardiogram|Measure of Kidney function and potassium levels","University of Toledo Health Science Campus","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","xMUO-02","February 2003","October 2006","October 2006","March 12, 2009",,"December 10, 2014","Medical University of Ohio, Toledo, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00860340"
175,"NCT02920918","Treatment of Diabetes in Patients With Systolic Heart Failure",,"Completed","Has Results","Heart Failure, Systolic|Diabetes Mellitus, Type 2","Drug: Canagliflozin|Drug: Sitagliptin","Change From Baseline Aerobic Exercise Capacity at 12 Weeks|Change From Baseline Ventilatory Efficiency at 12 Weeks","Virginia Commonwealth University|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HM20007043|28431754DIATBD","October 2016","September 2018","September 2018","September 30, 2016","October 29, 2019","October 29, 2019","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02920918/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02920918"
176,"NCT03506412","Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction","CNEPi","Recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: Entresto™ 49Mg-51 mg tablet","Change From Baseline of Biomarkers Based on NEP Levels with Entresto™ Administration|Change From Baseline in NT-proANP, NT-proBNP and NT-proCNP|Change From Baseline in Plasma Cyclic Guanine Monophosphate (cGMP)","Mayo Clinic|National Institute on Aging (NIA)","All","50 Years and older   (Adult, Older Adult)","Phase 4","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000044|R21AG053512","June 25, 2018","December 2020","December 2020","April 24, 2018",,"April 22, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03506412"
177,"NCT01102140","The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study","ImPrOVE","Terminated","Has Results","Cardiomyopathy|Heart Failure","Drug: POMx, pomegranate polyphenol extract|Drug: Sugar Pill","Thiobarbituric Reactive Substances (TBARS)|F-8 Isoprostanes|Procollagen Types I (PINP) and III (PIIINP)|Asymmetric Dimethylarginine (ADMA)","Jennifer Cowger , MD, MS|POM Wonderful LLC|University of Michigan","All","21 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IMPROVEHF","July 2010","May 31, 2013","May 31, 2013","April 13, 2010","July 14, 2017","July 14, 2017","University of Michigan Health Systems, Ann Arbor, Michigan, United States|University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01102140"
178,"NCT01852175","Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease",,"Completed","Has Results","Coronary Artery Disease","Drug: Prasugrel|Drug: Ticagrelor","Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP)|Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)","University of Florida","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","UFJ 2011-143","January 2012","June 2014","July 2014","May 13, 2013","June 10, 2015","June 10, 2015","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01852175"
179,"NCT03307005","Improving Sleep Quality in Heart Failure",,"Completed","Has Results","Sleep Disturbance|Heart Failure","Drug: Zolpidem Tartrate|Drug: Placebo oral capsule","Sleep Latency|Total Sleep Time|Sleep Efficiency","Johns Hopkins University","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 4","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IRB00142395","November 1, 2017","January 25, 2019","January 25, 2019","October 11, 2017","February 10, 2020","February 11, 2020","Johns Hopkins Bayview Campus, Asthma and Allergy Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03307005/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03307005"
180,"NCT01826851","Parasternal Nerve Block in Cardiac Patients",,"Completed","Has Results","Coronary Artery Disease|Pain, Postoperative","Drug: Exparel|Drug: Placebo","Median Cumulative Morphine Equivalent|Median Pain Levels|Time to Extubation (Hours)|ICU Length of Stay (Hours)|Time to First Bowel Movement (Days)|Hospital Length of Stay (Days)|Time to Return to Work or Daily Activities","Peter A Knight|University of Rochester","All","18 Years and older   (Adult, Older Adult)","Phase 2","79","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RSRB 00044181","March 2013","June 2017","June 2017","April 9, 2013","August 1, 2018","August 1, 2018","University of Rochester Medical Center, Rochester, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT01826851/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01826851"
181,"NCT01464671","Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention","STATUS PCI","Terminated","No Results Available","Coronary Artery Disease","Drug: Bivalirudin|Drug: Heparin","Bleeding events|MACE","Stony Brook University","All","18 Years and older   (Adult, Older Adult)","Phase 4","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","119778 (IRB ID)","July 2009","September 2014","September 2014","November 3, 2011",,"November 20, 2014","Stony Brook University Medical Center, Stony Brook, New York, United States",,"https://ClinicalTrials.gov/show/NCT01464671"
182,"NCT00990795","Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery","CYCLO1","Terminated","No Results Available","Cardiac Surgical Procedures","Drug: cyclosporine|Drug: saline solution","Length of Stay (LOS)|Left Ventricular Ejection Fraction (TTE)|Cardiac Index|SVO2|Systemic Vascular Resistance (SVR)","The University of Texas Health Science Center, Houston","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","72","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CYCLO1","April 2010","October 2010","October 2010","October 7, 2009",,"November 2, 2010","University of Texas Medical School Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00990795"
183,"NCT00965055","Ezetimibe in Patients Hypo-responsive to Statins",,"Terminated","Has Results","High Cholesterol|Coronary Artery Disease","Drug: Ezetimibe|Drug: Atorvastatin","LDL-C Reduction|LDL-C Reduction as Well as Changes in TG, HDL, and Non-HDL Cholesterol.","University of California, San Diego|Merck Sharp & Dohme Corp.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","090948","September 2009","September 2011","September 2012","August 25, 2009","August 21, 2019","August 21, 2019","UCSD Medical Center in Hillcrest Clinical Trials Facility, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT00965055"
184,"NCT02514642","Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease",,"Unknown status","No Results Available","Coronary Artery Disease","Drug: low-dose ticagrelor|Drug: Clopidogrel","P2Y12 reaction units (PRU)|inhibition of platelet aggregation (IPA)","First Affiliated Hospital of Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","SCAD-201523","July 2015","October 2015","November 2015","August 4, 2015",,"September 30, 2015","VerifyNow, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02514642"
185,"NCT02287909","Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease","SWAP-4","Completed","No Results Available","Coronary Artery Disease","Drug: Clopidogrel|Drug: Ticagrelor","Platelet reactivity Unit","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UFJ 2014-153","December 2014","October 2017","March 2018","November 11, 2014",,"March 15, 2018","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02287909"
186,"NCT01358409","Regression of Myocardial Steatosis by Nebivolol",,"Completed","No Results Available","Cardiac Steatosis and Lipotoxicity","Drug: Nebivolol","Myocardial triglyceride content|Cardiac function|Regression of concentric cardiac remodeling|Regression of steatosis in other non-adipocyte tissue|Regression of subcutaneous fat","Lidia Szczepaniak|Forest Laboratories|Cedars-Sinai Medical Center","All","18 Years to 59 Years   (Adult)","Early Phase 1","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MTG_Neb01","April 1, 2011","February 11, 2013","February 11, 2013","May 23, 2011",,"July 14, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01358409"
187,"NCT01431313","Inhaled Nitrite in Subjects With Pulmonary Hypertension",,"Completed","Has Results","Pulmonary Hypertension|Heart Failure, Diastolic","Drug: Inhaled Nitrite","Change in Pulmonary Vascular Resistance (PVR)|Time to Maximum Pulmonary Vascular Resistance (PVR) Decrease|Change in Systemic Blood Pressure (Mean Arterial Pressure, MAP)|Change in Systemic Vascular Resistance (SVR)|Change in Pulmonary Vascular Impedance / Wave Intensity|Change in Plasma Nitrite Concentrations in Mixed Venous Blood|Change in Pulmonary Artery Occlusion (Capillary) Pullback Nitrite|Change in Mitochondrial Oxygen Consumption Compared to Baseline After Each Dose of Nitrite","Schmidhofer, Mark, MD|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO11080686","June 2012","October 2017","October 2017","September 9, 2011","March 12, 2019","March 28, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01431313/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01431313"
188,"NCT00818337","Aspirin Responsiveness in Women at Risk for Cardiac Events",,"Completed","Has Results","Heart Disease","Drug: Aspirin","Number of Women Aspirin Resistant|Number of Aspirin Resistant Who Became Responders After Increase to Aspirin 325 mg","Creighton University","Female","19 Years and older   (Adult, Older Adult)","Phase 4","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","08-14888","November 2008","June 2009","June 2009","January 7, 2009","December 4, 2012","December 4, 2012","The Cardiac Center at Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00818337"
189,"NCT02486211","Amantadine to Speed Awakening After Cardiac Arrest","AWAKE","Completed","Has Results","Coma|Heart Arrest|Anoxia","Drug: Amantadine|Drug: Placebo","Rate of Awakening (Number of Patients Who Are Able to Follow Commands)|Time to Awakening|Seizures (Number of Patients Who Experience Seizures as Detected by EEG Monitoring With or Without Clinical Correlate)|Nausea or Vomiting|Number of Participants With Severe or Intracranial Bleeding","Jon Rittenberger, MD|American Heart Association|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15GRNT25680021","September 2015","June 30, 2018","June 30, 2018","July 1, 2015","December 4, 2019","December 4, 2019","Main Medical Center, Portland, Maine, United States|Beth Israel Deacconness, Boston, Massachusetts, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02486211/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02486211"
190,"NCT01855360","Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy",,"Completed","No Results Available","Amyloidosis; Heart (Manifestation)|Senile Cardiac Amyloidosis","Drug: Tauroursodeoxycholic Acid and Doxycycline","The rate of progression of transthyretin cardiac amyloidosis, as measured by changes in strain echocardiography, in a group of patients taking a combination of doxycycline and TUDCA.|Number of patients with adverse events to the medications over the period of therapy (18 months)|To evaluate general and health related quality of life (QoL) in SSA and ATTR subjects.","Brigham and Women's Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BWHAMY1","June 2013","May 31, 2015","May 31, 2015","May 16, 2013",,"June 20, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01855360"
191,"NCT02322892","Thiamine as an Adjunctive Therapy in Cardiac Surgery",,"Completed","Has Results","Coronary Artery Bypass|Cardiac Surgical Procedures","Drug: Thiamine|Drug: Normal saline solution","Lactate Levels|Percentage Change From Baseline in Pyruvate Dehydrogenase (PDH) Enzyme Activity|Patients With Post-operative Complications|Length of Stay|Mortality","Beth Israel Deaconess Medical Center|American Heart Association|University of Aarhus","All","21 Years and older   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014P000257","January 2015","August 2015","August 2015","December 23, 2014","March 30, 2017","March 30, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02322892"
192,"NCT01185067","Physiological Effects of Grape Seed Extract in Diastolic Heart Failure","GRAPEVINE-HF","Completed","No Results Available","Diastolic Heart Failure|Hypertensive Heart Disease|Heart Failure With Preserved Ejection Fraction|Hypertension|Oxidative Stress","Drug: grape seed extract (MegaNatural BP, Polyphenolics, Inc.)","Brachial artery flow-mediated dilation (FMD)|24-hour blood pressure|EndoPAT arterial endothelial function|Carotid-femoral pulse wave velocity|Maximal exercise capacity and oxygen consumption|Resting and post-exercise ventricular systolic and diastolic function|Urinary 8-isoprostanes|Heart failure related quality of life","University of Michigan","All","50 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00029626","October 2010","November 4, 2013","February 24, 2014","August 19, 2010",,"June 6, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01185067"
193,"NCT02497937","A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure",,"Completed","Has Results","Heart Failure","Drug: GSK2798745|Drug: Placebo","Change From Baseline in the Diffusing Capacity of the Lung for Carbon Monoxide (DLco) on Pulmonary Gas Transfer (Site: Mayo)|Change From Baseline in the Diffusing Capacity of the Lung for DLco on Pulmonary Gas Transfer (Site: Hennepin)|Change From Baseline in Diffusing Capacity of the Lung for Nitric Oxide (DLno) and Membrane Conductance (DM)|Change From Baseline in Capillary Blood Volume (Vc)|Change From Baseline in DLco Following Exercise and Following an Intravenous Saline Infusion (Site: Mayo)|Change From Baseline in DLco Following Exercise and Following an Intravenous Saline Infusion (Site: Hennepin)|Change From Baseline in the Ventilation/Volume of Carbon Dioxide Production (VE/VCO2) Ratio|Change From Baseline in Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 Second (FEV1), Forced Expiratory Flows (FEF) 25-75, FEF50 and FEF75|Change From Baseline in Functional Residual Capacity (FRC)|Change From Baseline in End-expiratory Lung Volume (EELV) Measured by Body Plethysmograph|Change From Baseline in Dyspnea Score|Respiratory Rate Over Time Continuously Measured by Body Sensor (Site: Mayo Only)|Change From Baseline in Systolic Blood Pressure(SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Heart Rate|Change From Baseline in Respiration Rate|Change From Baseline in Temperature|Change From Baseline in Percent Oxygen in Blood|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase, Gamma Glutamyl Transferase (GGT) Values|Change From Baseline in Albumin and Total Protein Values|Change From Baseline in Chemistry: Calcium, Chloride, Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN)|Change From Baseline in Creatinine, Direct Bilirubin, Total Bilirubin, Uric Acid|Change From Baseline in Digoxin Level|Change From Baseline in Troponin I Levels and Type I Collagen Cross-linked C-telopeptide|Change From Baseline in Chemistry: N-terminal Pro-Brain Natriuretic Peptide|Change From Baseline in Hematology: Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, White Blood Cell (WBC) Count, Total Neutrophils|Change From Baseline in Hematocrit|Change From Baseline in Hemoglobin|Change From Baseline in Mean Corpuscle Volume|Change From Baseline in Red Blood Cell Count (RBC) and Reticulocytes|Change From Baseline in Mean Corpuscle Hemoglobin Concentration|Change From Baseline in Mean Corpuscle Hemoglobin|Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE)|Change From Baseline in Participant Reported Health Status (SF-36) Acute Score|Area Under the Concentration Time Curve (AUC) Time Zero to the Last Time of the Last Quantifiable Concentration (AUC(0-t)), AUC Over the Dosing Interval After First and Last Dose (AUC(0-tau)) and AUCall for GSK2798745|Maximum Drug Concentration (Cmax) for GSK2798745|Time to Maximum Observed Plasma Concentration (Tmax) for GSK2798745|Elimination Half Life (T½) for GSK2798745","GlaxoSmithKline","All","21 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201881","April 13, 2016","August 21, 2017","August 21, 2017","July 15, 2015","September 5, 2018","September 5, 2018","GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02497937/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02497937/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02497937"
194,"NCT02257398","Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers",,"Completed","No Results Available","Infections, Respiratory Tract","Drug: GSK2140944|Drug: GSK2140944 placebo|Drug: Moxifloxacin|Drug: Moxifloxacin placebo","Change from baseline in corrected QT interval, using the Fridericia formula (QTcF) for GSK2140944 (1000 mg and 1800 mg)|Change from baseline in ECG parameters for GSK2140944 (1000 mg and 1800 mg)|Categorical outliers in ECG parameters for GSK2140944 (1000 mg and 1800 mg)|Change from baseline in ECG parameters for moxifloxacin|Composite of pharmacokinetic (PK) parameters for GSK2140944 (1000 mg and 1800 mg)|Composite of PK parameters for moxifloxacin|Plasma concentrations and change in QTcF for GSK2140944 and moxifloxacin|Amount excreted (Ae) in urine of unchanged GSK2140944 (1000 mg and 1800 mg)|Fraction of the dose (fe) excreted in urine|Renal clearance|Assessment of ECG|Change from baseline in vital sign measurements|Number of subjects with adverse events (AEs)|Toxicity grading of clinical laboratory test results","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","115775","October 6, 2014","March 2, 2015","March 2, 2015","October 6, 2014",,"July 13, 2017","GSK Investigational Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02257398"
195,"NCT01319045","Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease",,"Terminated","Has Results","Pulmonary Arterial Hypertension|Congenital Heart Disease|Eisenmenger's Syndrome","Drug: Iloprost","Safety and Tolerability|Exercise Capacity|Serum Brain Natriuretic Peptide (BNP)|Quality of Life","University of California, Los Angeles|Actelion","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Iloprost ACHD","June 2011","May 2013","May 2013","March 21, 2011","December 29, 2014","January 26, 2015","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01319045"
196,"NCT03062462","Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity",,"Unknown status","No Results Available","Coronary Artery Disease|Clopidogrel, Poor Metabolism of","Drug: Clopidogrel|Drug: ticagrelor","The platelet aggregation rate|Side effects including bleeding,dyspnea and arrhythmia|Adverse events including myocardial infarction, death, stroke, re-hospitalization for cardiovascular diseases and ischemia events","First Affiliated Hospital of Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SCAD-20170220","February 10, 2017","July 31, 2019","December 31, 2019","February 23, 2017",,"May 7, 2018","whole blood lumi-aggregometer type 560 VS, Havertown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03062462"
197,"NCT03102125","Stress Cardiac MRI in Heart Transplant",,"Recruiting","No Results Available","Heart Transplant Failure and Rejection","Drug: Regadenoson","Myocardial Perfusion Reserve|Myocardial ischemia/infarction|Hospitalization for cardiac related causes|Re-transplantation|Death from cardiovascular causes|All cause mortality|Late gadolinium enhancement|Mean segmental T1 values of the left ventricle","Paul Kim|Astellas Pharma Inc|University of California, San Diego","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","160808","August 1, 2018","April 2020","April 2020","April 5, 2017",,"July 9, 2019","UC San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT03102125"
198,"NCT00982423","The Effects of Decreasing the Lasix Dose on the Cardiorenal System","Aim1","Completed","Has Results","Heart Failure|Kidney Dysfunction","Drug: Furosemide","Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose|Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose|Aldosterone at Baseline and in Response to Decreasing Furosemide Dose|Plasma Renin Activity at Baseline and in Response to Decreasing Furosemide Dose|Angiotensin II at Baseline and in Response to Decreasing Furosemide Dose|Plasma Cyclic Guanosine Monophosphate (cGMP) at Baseline and in Response to Decreasing Furosemide Dose","Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-003210|R01HL084155|P01HL076611|UL1TR000135","July 2009","July 2014","July 2014","September 23, 2009","July 20, 2015","July 20, 2015","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00982423"
199,"NCT03294707","Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10",,"Completed","No Results Available","Amyloid Cardiomyopathy, Transthyretin-Related","Drug: AG10 oral tablet|Drug: Placebo Oral Tablet","Safety & tolerability: individual and summary blood pressures, heart rate, ECG and lab data presented in tabular form with descriptive statistics. Adverse events will be tabulated and summarized by Part A (SAD) vs. B (MAD), and treatment.|Pharmacokinetic Assessments: T1/2|Pharmacokinetic Assessments: Tmax|Pharmacokinetic Assessments: Cmax|Pharmacokinetic Assessments: Cmin|Pharmacokinetic Assessments: AUC|Pharmacokinetic Assessments: Clearance|Pharmacokinetic Assessments: volume of distribution|Pharmacodynamic Assessments: Assessments of TTR stabilization will be listed and summarized by part, treatment, and time point using appropriate descriptive statistics.|Pharmacodynamic Assessments: Western blot|Pharmacodynamic Assessments: prealbumin|Food effect: AUC|Food effect: Cmax","Eidos Therapeutics|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG10-001","September 11, 2017","February 5, 2018","May 18, 2018","September 27, 2017",,"May 23, 2018","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03294707"
200,"NCT00839891","A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers","TQT","Completed","No Results Available","Torsades de Pointes","Drug: VI-0521","The primary objective of this study is to assess whether treatment with a potential therapeutic dose or a supra-therapeutic dose of VI-0521 has the potential to cause QT/QTc prolongation in healthy volunteers.|A secondary objective is to demonstrate assay sensitivity by showing that the active control (moxifloxacin 400 mg) treatment, corrected for placebo, produces a QTc change >5 msec.","VIVUS, Inc.","All","19 Years to 50 Years   (Adult)","Phase 1","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","OB-118","February 2009","April 2009","April 2009","February 10, 2009",,"January 21, 2010","MDS Pharma Services, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00839891"
201,"NCT01440517","Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction",,"Terminated","Has Results","Diabetes Mellitus|Heart Failure","Drug: Tc99m-Maraciclatide","Evidence of Active Myocardial Angiogenesis/Remodeling|Uptake of 99mTc-maraciclatide Agent in Diabetic Subjects With Heart Failure With Preserved Left Ventricular Fraction and Subjects With Diabetes Mellitus and Asymptomatic Diastolic Dysfunction","GE Healthcare","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-078-101","August 2011","March 2012","March 2012","September 26, 2011","February 4, 2014","February 4, 2014","GE Healthcare, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01440517"
202,"NCT01544036","Monitoring Renal Blood Flow With Contrast Enhanced Ultrasound During Coronary Angiogram",,"Unknown status","No Results Available","Contrast Induced Acute Kidney Injury","Drug: perflutren","Acute Kidney Injury|Change in novel biomarkers of AKI","University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15591|K23DK074616","February 2012","February 2014",,"March 5, 2012",,"December 19, 2013","University of Virginia Health System, Charlottesville, Virginia, United States|University of Virginia Health System, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01544036"
203,"NCT03606057","A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)",,"Completed","No Results Available","Healthy","Drug: JNJ-64565111|Drug: Moxifloxacin|Drug: JNJ-64565111-matching Placebo|Drug: Moxifloxacin-matching Placebo","Placebo-Corrected Change from Baseline in QT Interval Corrected for Individual Heart Rate (QTcI) on Day 26 Time-Matched Time Points|Change from Time-Matched Baseline in QTc Interval|Change from Time-Matched Baseline in Heart Rate (HR)|Change from Time-Matched Baseline in QRS Interval|Change from Time-Matched Baseline in PR Interval|Cardiac Repolarization as Determined by Mean Change from Time-Matched Baseline in QT Interval Corrected for Individual HR (QTcI) on Day 5|Cardiac Repolarization as Determined by Mean Change from Time-Matched Baseline in QT Interval Corrected For HR Using Fridericia's Formula (QTcF) on Day 5 and Day 26|Maximum Observed Serum Concentration (Cmax)|Time to Reach Maximum Observed Serum Concentration (Tmax)|Average Serum Analyte Concentration (Cavg)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|QTcI Changes Evaluated Using ECG Assessments versus Serum Concentrations of JNJ-64565111","Janssen Research & Development, LLC","All","18 Years to 55 Years   (Adult)","Phase 1","188","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108477|64565111OBE1002","July 13, 2018","February 8, 2019","February 28, 2019","July 30, 2018",,"March 3, 2020","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03606057"
204,"NCT01812434","Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients",,"Withdrawn","No Results Available","Cardiac Allograft Vasculopathy","Drug: Sildenafil|Drug: Placebo","Mean change in SAE and in the number of endothelial progenitor cells after 4 weeks of treatment between placebo and sildenafil|Determine variability of SAE and large artery elasticity (LAE) in heart transplant recipients in order to plan a multi-center trial that will use arterial elasticity as a primary outcome","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","1001M76094","October 2010","March 2015","March 2015","March 18, 2013",,"November 1, 2019","University of Minnesota Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01812434"
205,"NCT00939237","Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease",,"Completed","No Results Available","Coronary Heart Disease","Drug: Ateronon|Drug: Placebo","Carotid intima-media thickness|Biomarkers for coronary heart disease","Brigham and Women's Hospital|CamNutra Ltd.|Cambridge Theranostics Ltd","All","50 Years and older   (Adult, Older Adult)","Phase 3","213","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009-P-000202 BWH","July 2009","May 2011","May 2011","July 14, 2009",,"August 19, 2014","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00939237"
206,"NCT01440335","Initial Study of Fenoterol as a Treatment for Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Drug: Oral R,R'-Fenoterol|Drug: Oral Racemic Fenoterol","Safety assessment|Pharmacokinetics|Bioavailability|Pharmacodynamic effects of heart rate|Blood Pressure|Echocardiographic indices of cardiac structure and function|B2-AR lymphocyte binding and function during drug exposure","National Institute on Aging (NIA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 60 Years   (Adult)","Phase 1","29","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","999911153|11-AG-N153","July 10, 2011","April 15, 2014","April 15, 2014","September 26, 2011",,"July 5, 2018","National Institute of Aging, Clinical Research Unit, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01440335"
207,"NCT01758744","Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1","TAPIT-1","Completed","No Results Available","Pulmonary Hypertension|COPD","Drug: Inhaled Treprostinil Therapy","To assess the safety of Tyvaso ® as assessed by changes or stability of acute oxygenation (pulse oximetry) and spirometry (FEV1).|New York Heart Association (NYHA) functional class|Six minute walk distance|Clinical Worsening|Peripheral Blood Mononuclear Cells (PBMC) phagocytic index (PI) and PBMC gene expression|St. George's Chronic Obstructive Pulmonary Disease (COPD) questionnaire","University of Colorado, Denver","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-0560","December 2012","July 2016","July 2016","January 1, 2013",,"July 20, 2016","University of Colorado Denver, Aurora, Colorado, United States|University of Florida College of Medicine, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01758744"
208,"NCT02769611","Ruboxistaurin in New York Heart Failure Classification III-IV Patients",,"Recruiting","No Results Available","Heart Failure","Drug: Ruboxistaurin","Percent of patients with a new onset, clinically significant arrhythmia or conduction system disease,|Percent of patients with significant prolongation in the corrected QT (QTc) interval|Percent of patients with significant increase in liver function tests|Percent of patients with a significant increase in serum creatinine not explained by diuretic use.|Percent of patient with a significant increase in serum creatine phosphokinase (CPK) levels|Percent of patients experiencing at least one adverse event|Change in cardiac contractility as assessed by echocardiography.|Change in self-reported well-being, fatigue and dyspnea","University of Tennessee|The Christ Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-7007","June 28, 2017","December 2020","March 2021","May 11, 2016",,"June 12, 2019","The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02769611"
209,"NCT01161121","Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia",,"Completed","Has Results","Coronary Artery Disease","Drug: adenosine|Drug: regadenoson","Difference in FFR Between IV Adenosine and IV Regadenoson|Heart Rate Changes With Drug|Side Effects of Medication Administration","St. Louis University|University of Florida|Astellas Pharma US, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Rega-9I06","July 2010","April 2013","April 2013","July 13, 2010","June 19, 2017","June 23, 2017","University of Florida, Jacksonville, Florida, United States|St. Louis University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01161121"
210,"NCT01862536","Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease","TADA-PHILD","Active, not recruiting","No Results Available","Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease (COPD)","Drug: Tadalafil|Drug: placebo","Change in 6 minute walk test|Maximum volume of oxygen extraction on exercise testing|Pulmonary vascular resistance|Mean pulmonary artery pressure|Tricuspid annular plane excursion (TAPSE)|Dyspnea and health related quality of life (HRQL)|N-type brain natriuretic peptide (BNP) concentration|Resting Hypoxemia|Exercise-induced hypoxemia","VA Office of Research and Development","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","64","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLIN-008-12F","October 1, 2013","August 31, 2019","June 30, 2020","May 24, 2013",,"December 13, 2019","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|VA Eastern Colorado Health Care System, Denver, CO, Denver, Colorado, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Providence VA Medical Center, Providence, RI, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01862536"
211,"NCT02230891","Biomarker Guided Therapies in Stage A/B Heart Failure",,"Active, not recruiting","No Results Available","Hypertension|Diabetes|Cardiovascular Disease","Drug: Carvedilol|Drug: Spironolactone","Cardiac Strain|Change in biomarkers|arterial stiffness","VA Office of Research and Development|Baylor College of Medicine","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 2","210","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CLNB-009-13F","October 1, 2014","July 1, 2020","December 31, 2020","September 3, 2014",,"April 7, 2020","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02230891"
212,"NCT01178359","Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients",,"Completed","No Results Available","Cardiac Arrest","Drug: nitrite","Blood pressure|nitrite concentration levels in blood","University of Washington|Medic One Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","STUDY00001499","January 2010","April 2016","April 2016","August 10, 2010",,"May 18, 2017","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01178359"
213,"NCT02594111","Colchicine in Percutaneous Coronary Intervention","Colchicine-PCI","Active, not recruiting","No Results Available","Coronary Artery Disease|Acute Coronary Syndrome","Drug: Colchicine vs Placebo","Peri-procedural myocardial necrosis|all-cause mortality, non-fatal MI, or target vessel revascularization (TVR)|all-cause mortality, non-fatal MI, or TVR|Peri-procedural myocardial infarction (MI)","VA Office of Research and Development|NYU Langone Health","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","714","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CARB-025-15S","May 30, 2013","August 30, 2019","August 30, 2024","November 1, 2015",,"March 5, 2020","Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02594111/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02594111/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02594111"
214,"NCT04208997","Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation","AFTER-VT","Recruiting","No Results Available","Tachycardia, Ventricular|Catheter Ablation","Drug: Antiarrhythmic drug","VT-free survival|All-cause mortality|VT recurrence|VT/electrical storm|Readmission for heart failure","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","191113","December 21, 2019","September 30, 2022","September 30, 2022","December 23, 2019",,"December 23, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04208997"
215,"NCT00851929","Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension",,"Completed","No Results Available","Sarcoidosis|Pulmonary Hypertension","Drug: Ambrisentan","Change in 6 minute walk distance.","Medical University of South Carolina|Gilead Sciences","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17747","November 2008","April 2011","November 2011","February 26, 2009",,"August 2, 2018","University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|Medical Univerrsity of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00851929"
216,"NCT02606253","Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure",,"Completed","Has Results","Heart Failure","Drug: tolvaptan|Drug: Chlorothiazide|Drug: Metolazone","Weight Change Over 48 Hours|Net Urine Output|Mean Change in Serum Creatinine|Mean Change in Glomerular Filtration Rate at Discharge|Mean Change in Serum Potassium|Potassium Supplementation|Number of Patients With Hypokalemia|Number of Patients With Escalation of Loop Diuretic Therapy|Number of Patients With Cardiac Arrhythmias|Number of Patients With Symptomatic Hypotension|Change in eGFR From Baseline to 48 Hours|Mean Change in Serum Sodium","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VU-IRB-TBD","February 2016","September 27, 2018","October 31, 2018","November 17, 2015","November 8, 2019","November 8, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02606253/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02606253"
217,"NCT01085175","Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing","LMI1195-201","Withdrawn","No Results Available","Heart Failure","Drug: LMI 1195","Dose acquisition time product, target and non-target F18 count density|Assess Image Quality Data Variability across age & sex stratification Determine Retention Index Values Determine Heart to Mediastinal Ratio Evaluate additional image derived markers that may have predictive value","Lantheus Medical Imaging","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LMI 1195-201","May 2010","February 2011","February 2011","March 11, 2010",,"October 14, 2015","Columbia University Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01085175"
218,"NCT01667744","Citalopram for Sx/Util in Acute Coronary Syndrome Patients",,"Withdrawn","No Results Available","Acute Coronary Syndrome","Drug: Citalopram","Frequency of ACS Symptoms|Treatment usage|Emotional Distress","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","11146121","January 2018","February 2021","February 2021","August 17, 2012",,"February 19, 2016","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01667744"
219,"NCT01630408","The Effects of Active VItamin D on Left Atrial Volume Index","AVID-LAVI","Withdrawn","No Results Available","Heart Failure","Drug: Paricalcitol","Change in left atrial volume index (LAVI) by transthoracic echocardiography.|Number of and time-to-first heart failure-related hospitalizations|Overall cardiac and non-cardiac mortality rates|Changes in biological, inflammatory, LVH and strain biomarkers that have been linked to cardiovascular disease.|Changes in standard mineral metabolite parameters (calcium, phosphorus, calcium-phosphate-product and PTH)|Changes in self-reported Patient Global Assessment|Change in diastolic function parameters (including E, A, IVRT, DT)|Change in tissue doppler parameters (including Ea, Aa)|Change in pulmonary venous inflow (including S, D, a reversal)|Change in cardiac ejection fraction|Change in end-diastolic and end-systolic left ventricular internal dimension","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVID-LAVI","March 2014","May 2014","June 2014","June 28, 2012",,"August 16, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01630408"
220,"NCT01175018","Anakinra to Prevent Adverse Post-infarction Remodeling (2)","VCU-ART2","Completed","Has Results","Acute Myocardial Infarction|Heart Failure","Drug: Anakinra|Drug: Placebo","Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices|Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-diastolic Volume Indices From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging|Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi >5%)|Median Difference Between the 2 Arms in the Peak Oxygen Consumption (VO2) at 10-14 Weeks|Incidence of Heart Failure|Number of Adverse Events in Each Group|Difference Between the 2 Arm in the Interval Change in Right Ventricular Ejection Fraction (RVEF)|Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular Ejection Fraction Values From Baseline to Follow up Exam at Cardiac Magnetic Resonance Imaging|Median Difference Between the 2 Arms in the Ratio of Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope) at 10-14 Weeks|Percentage of Patients in Each Group With Reverse Remodeling (Reduction in LVESVi >10%)|Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase >5%) Based Upon Cardiac Magnetic Resonance Imaging|Percentage of Patients in Each Group With Adverse Remodeling (LVESVi Increase >10%)|Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change >5%|Percentage of Patients in Each Group With Left Ventricular Ejection Fraction Change >10%|Number of Deaths in Each Group|Number of Adverse Events Requiring Withdrawal in Each Group","Virginia Commonwealth University|American Heart Association","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHA 10SDG3030051","July 2010","September 2012","December 2012","August 4, 2010","May 23, 2016","May 23, 2016","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01175018"
221,"NCT01330654","Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers",,"Withdrawn","No Results Available","Cardiac Event Risk","Drug: metoprolol","Heart Rate Variability","University of California, San Francisco","All","40 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)","2010030","March 2011","March 2012","March 2012","April 7, 2011",,"June 27, 2012","Community Regional Medical Center, Fresno, California, United States",,"https://ClinicalTrials.gov/show/NCT01330654"
222,"NCT00994253","Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics",,"Withdrawn","No Results Available","Hypertension|Diabetes Type 2","Drug: Aliskiren|Drug: Hydrochlorothiazide","The primary objective is to assess the effect of a multimodal drug therapy regimen including the renin inhibitor Tekturna (aliskiren), an ACE inhibitor, and a calcium channel blocker on coronary flow reserve (CFR) in hypertensive Type II diabetics.|Secondary measures include evaluation of serum and urine biomarkers related to endothelial function, the renin-angiotensin system, oxidative stress, and inflammation.","William Beaumont Hospitals|Novartis Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-083","August 2009","December 2012","December 2012","October 14, 2009",,"October 2, 2017","William Beaumont Hospital, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00994253"
223,"NCT02987088","Phase 1 Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest",,"Completed","No Results Available","Out-Of-Hospital Cardiac Arrest","Drug: Sodium Nitrite","plasma level of sodium nitrite at hospital arrival|Rate of re-arrest|Need for pressor support before hospital arrival","University of Washington","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","51605-A","December 2016","April 5, 2017","May 2, 2017","December 8, 2016",,"May 7, 2018","University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02987088"
224,"NCT02065479","A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:",,"Completed","No Results Available","Coronary Artery Disease","Drug: Prasugrel|Drug: Ticagrelor","Platelet reactivity","University of Florida","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UFJ 2014-12|IRB201702750","March 2014","April 22, 2019","April 22, 2019","February 19, 2014",,"April 25, 2019","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02065479"
225,"NCT02841774","High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV","HILLCLIMBER","Recruiting","No Results Available","HIV Infection|Coronary Heart Disease","Drug: Pravastatin|Drug: Rosuvastatin","Mean percent change in fasting LDL-cholesterol|Treatment-emergent adverse events|Mean percent change in fasting HDL-cholesterol|Mean percent change in fasting Total Cholesterol|Mean percent change in fasting Triglycerides","Matthew Feinstein|Northwestern University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSC01","November 2016","March 2020","March 2020","July 22, 2016",,"May 17, 2019","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02841774"
226,"NCT03044314","Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension","OVATION","Recruiting","No Results Available","Pulmonary Hypertension","Drug: Illoprost and nitric oxide administration","Change in invasively measured pulmonary artery pressures after challenge with NO and iloprost|Change in echocardiographic and invasively measured parameters after vasodilator challenge|Change in PA pressure and mean pressure determined invasively after vasodilator challenge|Clinical response to vasodilator challenge by echo|Association of change in pressures after vasodilator challenge with clinical outcomes","Duke University|Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00075840","July 21, 2017","December 1, 2020","December 1, 2020","February 7, 2017",,"February 20, 2020","Duke University Health System, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03044314"
227,"NCT01212874","Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery",,"Completed","Has Results","Hypertension","Drug: nitroglycerin|Drug: esmolol","Diastolic Blood Pressure Excursions Beyond Predetermined Lower Limits, Normalized Per Hour|Title: Systolic Hypertension","Loma Linda University","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5100218","December 2010","June 2014","June 2014","October 1, 2010","August 17, 2016","March 1, 2019","Loma Linda University, Loma Linda, California, United States",,"https://ClinicalTrials.gov/show/NCT01212874"
228,"NCT01030328","AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis","AFRICA","Terminated","No Results Available","Coronary Atherosclerosis","Drug: Placebo|Drug: TriLipix","Change in calcified plaque volume/percent, non-calcified high-density plaque volume/percent, and low-density plaque volume/percent|The secondary endpoint of the study will be the change in PAV of the ""Study Lesion"" from baseline to follow-up. PAV will be expressed as a ratio of the plaque volume/total vessel volume.","Piedmont Healthcare","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","PH09001","November 2009","July 2011","July 2011","December 11, 2009",,"April 15, 2014","Piedmont Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01030328"
229,"NCT01366976","Inhibition of Lipid Peroxidation During Cardiac Surgery",,"Completed","Has Results","Cardiopulmonary Bypass Induced Lipid Peroxidation","Drug: Acetaminophen","Plasma Isofuran Concentrations|Plasma F2-isoprostane Concentrations|Urinary NGAL (Neutrophil Gelatinase-associated Lipocalin)|Serum Creatinine","Vanderbilt University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110423","July 2011","June 2013","June 2013","June 6, 2011","January 14, 2015","January 27, 2015","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01366976"
230,"NCT01837823","YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering",,"Completed","Has Results","Obstructive Coronary Artery Disease|Coronary Artery Disease","Drug: rosuvastatin","Correlation Between Plaque Morphology and HDL Functionality|Correlation Between the Change in Fibrous Cap Thickness and Hs-CRP|Maximal 4mm Lipid Core Burden Index (LCBI 4mm Max)|Fibrous Cap Thickness (FCT) by OCT|IVUS Imaging Measures|Inflammatory and Lipid Parameters|Lesion LCBI|LCBI 4mm at Same Anatomical Site|Change in Atheroma Volume|Biomarker Release|Correlation of Baseline Lipid Parameters With Baseline LCBI4mm Max|Plaque Morphology as Related to Haptoglobin|Mechanism of Reverse Cholesterol Transport|Correlation of Changes in Plaque Morphology|MACE","Icahn School of Medicine at Mount Sinai|Texas Heart Institute (Wafic Said Molecular Cardiology Research Lab)|AstraZeneca|InfraReDx (indirect)","All","18 Years and older   (Adult, Older Adult)","Phase 2","91","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-1507|HS#: 12-00741","July 2013","April 2015","April 2015","April 23, 2013","February 13, 2018","February 13, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01837823"
231,"NCT01370265","Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress",,"Completed","Has Results","Coronary Artery Disease","Drug: Regadenoson|Drug: Adenosine|Drug: N-13 ammonia","Global Hyperemic Myocardial Blood Flow (MBF)|Resting Global MBF and Resting Segmental MBF|Global Cardiac Flow Rate|Hyperemic Segmental MBF|Segmental CFR|Heart Rate (Beats Per Minute (BPM))|Hyperemic Blood Pressure (mmHg)","Mayo Clinic|Astellas Pharma Inc","All","30 Years and older   (Adult, Older Adult)","Not Applicable","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-006377","February 2011","February 2012","June 2012","June 9, 2011","September 5, 2013","September 5, 2013","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01370265"
232,"NCT01936844","Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)",,"Completed","Has Results","Heart Failure","Drug: Anakinra (high dose)|Drug: Anakinra (standard dose)|Drug: Placebo","C Reactive Protein|Left Ventricular Ejection Fraction|Brachial Artery Vasoreactivity","Virginia Commonwealth University|American Heart Association","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VCU HM15347","February 2014","May 2015","May 2015","September 6, 2013","March 22, 2016","May 5, 2016","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01936844"
233,"NCT01051960","Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan",,"Completed","No Results Available","Systemic Sclerosis|Shortness of Breath|Pulmonary Hypertension","Drug: Ambrisentan","Change in multipoint exercise total pulmonary resistance (TPR)from baseline to week 24.|Change in distance walked in six minutes from baseline to 24 week|SF-36 (short form 36)|HAQ-DI (health assessment questionnaire disability index)|St. George's respiratory questionnaire","University of California, Los Angeles|Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-000567","March 2009","June 2010","January 2011","January 20, 2010",,"March 7, 2018","David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01051960"
234,"NCT01936480","Genetics of QT Response to Moxifloxacin","MOXIGEN","Enrolling by invitation","No Results Available","Cardiac Arrhythmias","Drug: Moxifloxacin 400mg once time|Drug: Placebo","QT interval duration","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2009A059013","October 2013","September 2019","October 2019","September 6, 2013",,"August 28, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01936480"
235,"NCT02058095","Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)","Aim 3","Completed","No Results Available","Cardiomyopathy|Renal Impairment","Drug: Tadalafil|Drug: Placebo","Change in urinary sodium excretion|Change in Glomerular Filtration Rate (GFR)","Mayo Clinic","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","11-006194|HL76611-07P3","March 2014","June 2019","December 2019","February 7, 2014",,"January 18, 2020","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02058095"
236,"NCT01970176","Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)","Aim2","Completed","No Results Available","Cardiomyopathy|Renal Impairment","Drug: Tadalafil|Drug: Placebo","Na excretion|Change in GFR from baseline|Change in urinary cGMP excretion","Mayo Clinic","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","11-004644|HL76611-07P3","March 2013","September 2019","September 2019","October 25, 2013",,"October 10, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01970176"
237,"NCT03985384","Semaglutide Treatment On Coronary Progression","STOP","Recruiting","No Results Available","Type 2 Diabetes|Coronary Artery Disease","Drug: Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Drug: Placebo","Rate of change in non-calcified plaque volume|Rate of change in total plaque volume","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","40 Years and older   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","22174-01","April 30, 2019","September 2020","September 2020","June 13, 2019",,"April 9, 2020","Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT03985384"
238,"NCT00891241","A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: LMI 1195-101","Safety|Dosimetry","Lantheus Medical Imaging","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LMI 1195 -101","August 2009","November 2009","November 2009","May 1, 2009",,"August 18, 2011","Hartford Hospital, Hartford, Connecticut, United States|Yale University Medical Center, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT00891241"
239,"NCT02454426","Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease",,"Withdrawn","No Results Available","Major Depressive Disorder|Coronary Artery Disease","Drug: Vortioxetine","Severity of depressive episodes measured using the Montgomery-Asberg Depression Rating Scale (MADRS)","Thomas Jefferson University|Takeda","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TakedaHRV","April 2016","June 2016","June 2016","May 27, 2015",,"August 25, 2016","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02454426"
240,"NCT01863511","Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure","TUF","Completed","No Results Available","Acute Decompensated Heart Failure","Drug: loop diuretic|Drug: tolvaptan|Procedure: ultrafiltration","Net change in weight|net volume loss|urinary NGAL|dyspnea score|BNP change from admission to discharge|serum creatinine change|serum sodium and potassium changes|Quality of Life|all cause readmission|all cause death","The Christ Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUF-01","May 2013","December 2015","December 2015","May 29, 2013",,"January 28, 2016","The Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01863511"
241,"NCT02220634","Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension","RHINO","Terminated","No Results Available","Pulmonary Hypertension","Drug: Regadenoson","Number of people","National Jewish Health|Astellas Pharma Inc","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-2820","August 2014","May 25, 2017","May 25, 2017","August 20, 2014",,"August 24, 2018","National Jewish Health, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT02220634"
242,"NCT01011257","Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.","Dual-Dosing","Withdrawn","No Results Available","Coronary Artery Disease","Drug: Asprin|Drug: Clopidogrel","To look if dual dosing of aspirin and/or clopidogrel will augment antiplatelet efficacy in patients with elevated reticulated platelet turnover.","Neil Kleiman, MD|The Methodist Hospital System","All","18 Years to 64 Years   (Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00001863","September 2009","August 2011","September 2011","November 11, 2009",,"January 31, 2018","The Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01011257"
243,"NCT03489863","Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study",,"Completed","No Results Available","Coronary Artery Disease","Drug: Prasugrel|Drug: Ticagrelor","P2Y12 Reaction Unit (PRU)","University of Florida|Scott R MacKenzie Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201703338 -A","May 30, 2018","March 20, 2019","March 20, 2019","April 6, 2018",,"March 25, 2019","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03489863"
244,"NCT01887353","The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure","RAD HF","Terminated","Has Results","Atrial Fibrillation|Heart Failure","Drug: Ranolazine|Drug: Placebo","Time to First Atrial Fibrillation (AF) Recurrence","Intermountain Health Care, Inc.|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1024475","June 2013","February 2014","February 2014","June 26, 2013","July 20, 2015","July 20, 2015","Intermountain Medical Center, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01887353"
245,"NCT03088345","Early Use of Vasopressin in Post-Fontan Management","VAMP","Completed","No Results Available","Circulatory Perfusion Disorder|Congenital Heart Disease|Single-ventricle","Drug: Vasopressin, Arginine|Drug: Placebos","Hemodynamics as characterized by vasoactive inotrope score (VIS)|Hemodynamics as characterized by organ perfusion pressure|Hemodynamics as characterized by transpulmonary pressure gradient|Hemodynamics as characterized by regional oximetry differences|Renal function characterized by the presence of oliguria|Renal dysfunction as characterized by cystatin level|Liver dysfunction as characterized by transaminase levels|Fluid Balance","Medical College of Wisconsin","All","up to 18 Years   (Child, Adult)","Phase 2|Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRBNet 885148","March 6, 2017","November 1, 2018","January 28, 2019","March 23, 2017",,"August 8, 2019","Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03088345"
246,"NCT03476369","Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention","FACTPCI","Recruiting","No Results Available","Percutaneous Coronary Intervention","Drug: Fentanyl|Drug: Ticagrelor 90Mg Tablet","Platelet Function Testing|Stent thrombosis|Recurrent myocardial infarction|All-cause mortality|Stroke|TIMI minor and major","The Guthrie Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1801-05","April 18, 2018","August 2020","August 2020","March 26, 2018",,"February 12, 2020","The Guthrie Clinic, Sayre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03476369"
247,"NCT00954707","CYPRESS - CYPHER for Evaluating Sustained Safety",,"Unknown status","Has Results","Coronary Artery Disease","Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin|Drug: Placebo & Aspirin","Phase I: the Rate of Target Lesion Failure (TLF)|Rate of Device Success|Rate of Lesion Success|Rate of Procedure Success|Rate of Clinically-driven Target Lesion Revascularization (TVR)|Rate of Clinically Driven Target Vessel Revascularization (TVR)|Rate of Target Vessel Failure (TVF)|Rate of Major Adverse Cardiac Events (MACE)|Rate of Protocol Defined Stent Thrombosis (ST)|Rate of Academic Research Consortium (ARC) Defined Stent Thrombosis (ST)|Rate of Protocol Defined Major Bleeding Complications|Rate of Cardiac Death|Rate of Non-cardiac Death","Cordis Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","2509","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P09-6301","August 2009","January 2012","March 2016","August 7, 2009","October 9, 2013","February 7, 2014","University Hospitals, Case Medical Center (Cleveland), Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00954707"
248,"NCT02545972","Once-a-day Tacrolimus Conversion Study: The OneTAC Trial","OneTAC","Unknown status","No Results Available","Heart Failure","Drug: tacrolimus extended release","The change in glomerular filtration rate slope between the 6 months prior to study enrollment and 6 months post-study enrollment.|The change in glomerular filtration rate slope between the 6 months prior to study enrollment and 12 months post-study enrollment.","Newark Beth Israel Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OneTAC","February 2016","November 2018","February 2019","September 10, 2015",,"September 21, 2016","Newark Beth Israel Medical Center, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02545972"
249,"NCT01324999","Tadalafil for Sarcoidosis Associated Pulmonary Hypertension","SAPH","Completed","Has Results","Pulmonary Hypertension","Drug: Tadalafil","6 Minute Walk Distance|Resting Oxygen Saturation|Oxygen Desaturation During 6 Minute Walk Test|Maximum Borg Dyspnea Score During 6 Minute Walk Test|Brain Natriuretic Peptide Level|Short Form-36 Global Score|St. George's Respiratory Questionnaire (SGRQ) Score|Number of Participants With Change in WHO Functional Class (WHO FC)","University of North Carolina, Chapel Hill|Eli Lilly and Company|United Therapeutics|University of Cincinnati","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-2326","March 2011","July 2013","October 2013","March 29, 2011","July 24, 2017","July 24, 2017","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01324999"
250,"NCT01379573","Preventive Approach to Congenital Heart Block With Hydroxychloroquine","PATCH","Active, not recruiting","Has Results","Congenital Heart Block|Neonatal Lupus|Autoantibody-Associated Heart Block","Drug: Hydroxychloroquine","Recurrence of Advanced Heart Block|Prolonged PR Interval (>150msec)|Any Sign of Myocardial Injury, Without Change in Cardiac Rate or Rhythm|Echocardiographic Densities Consistent With EFE Confirmed Postnatally|Fetal Death Not Related to Cardiac Dysfunction|Cutaneous Neonatal Lupus|Prematurity|Birth Weight <10% in the Context of Gestational Age|Abnormal Fluid Collection","NYU Langone Health","Female","18 Years to 45 Years   (Adult)","Phase 2","74","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","11-00369","January 2011","March 2, 2019","August 2020","June 23, 2011","March 16, 2020","March 30, 2020","New York University School of Medicine, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT01379573/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01379573"
251,"NCT01521546","Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy","E-SCAR DMD","Completed","Has Results","Duchenne Muscular Dystrophy","Drug: eplerenone|Drug: placebo","12-month Change in Myocardial Strain","Subha Raman|Ballou Skies|Ohio State University","Male","7 Years and older   (Child, Adult, Older Adult)","Not Applicable","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011H0251","February 2012","June 2016","June 2016","January 30, 2012","May 27, 2015","November 8, 2016","Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01521546"
252,"NCT01413399","A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest",,"Completed","No Results Available","Out-of-Hospital Cardiac Arrest","Drug: 4 degree chilled saline","Survival to hospital discharge|Number of patients who achieve prehospital return of spontaneous circulation|Total volume of chilled saline infused","Carolinas Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","363","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MeckHypo2011","August 2011","June 2012","June 2012","August 10, 2011",,"August 7, 2012","Carolinas Medical Center; Center for Prehospital MEdicine, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01413399"
253,"NCT01852019","Cangrelor Prasugrel Transition Study",,"Completed","Has Results","Coronary Artery Disease","Drug: Cangrelor|Drug: Prasugrel","Extent of Preservation of Inhibitory Effect After Transition From Cangrelor to Prasugrel Compared With Effect Observed With Prasugrel Alone (Reference Timepoint)|Extent of Preservation of Inhibitory Effect of Cangrelor Treatment After Prasugrel, Compared to Treatment With Cangrelor Alone|Bleeding Events in Accordance With the GUSTO Scale","The Medicines Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","MDCO-CAN-13-01","June 2013","July 2013","July 2013","May 13, 2013","May 28, 2015","June 24, 2015","Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01852019"
254,"NCT01766466","Cangrelor Ticagrelor Transition Study",,"Completed","Has Results","Coronary Artery Disease","Drug: cangrelor|Drug: Ticagrelor","Extent of Preservation of Inhibitory Effect Compared With Effect Observed With Cangrelor Alone (at Timepoint 1, Either at 0.5 Hours or 1.25 Hours) or Ticagrelor Alone (Measured 5.25 Hours After Initiation of Cangrelor on Day 1)|Extent of Preservation of Inhibitory Effect Compared With Effect Observed During Cangrelor Treatment After Ticagrelor|Extent of Aggregation Response During Ticagrelor Treatment","The Medicines Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)","MDCO-CAN-12-03","January 2013","February 2013","February 2013","January 11, 2013","May 19, 2014","May 19, 2014","Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01766466"
255,"NCT01564485","Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome","CTRAD","Completed","No Results Available","Diabetes|Metabolic Syndrome","Procedure: Cardiac CT|Drug: Usual medical care","Systolic BP pressure|Control of LDL cholesterol|Hemoglobin A1c","University of California, Irvine","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","198","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20086170","July 2008","December 2016","December 2016","March 27, 2012",,"December 8, 2016","University of California, Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT01564485"
256,"NCT03123107","Vitamin C in Cardiac Surgery Patients",,"Active, not recruiting","No Results Available","Coronary Artery Bypass Graft Surgery","Drug: Ascorbic Acid","Ascorbate maximum serum concentration (Cmax)|Half-life of serum ascorbate (T1/2)|Elimination rate constant of ascorbate (Ke)|Area under the concentration-time curve for serum ascorbate (AUC)|Change in biomarker concentrations","Geisinger Clinic|Wilkes University","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2016-0463","July 6, 2017","August 31, 2020","August 31, 2020","April 21, 2017",,"September 4, 2019","Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03123107"
257,"NCT02693002","Estrogen Diastolic Heart Failure",,"Terminated","Has Results","Menopause","Drug: Estradiol/Norethindrone acetate|Drug: Placebo","Diastolic Function Assessed by Echocardiography|Activity Level Assessed by Duke Activity Status Index (DASI)|Quality of Life Score Assessed by Utian Quality of Life Scale (UQoLS)|B-type Natriuretic Peptide (BNP) Levels","Gretchen Wells|University of Kentucky","Female","45 Years to 55 Years   (Adult)","Phase 4","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","15-0798-F6A","February 2016","November 2016","November 2016","February 26, 2016","July 11, 2018","August 8, 2018","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02693002"
258,"NCT03746002","Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing",,"Terminated","No Results Available","Fluid Overload|Heart Failure Acute","Drug: Metolazone 60 minutes prior to furosemide|Drug: Metolazone concurrently with furosemide","24-Hour Urine Output|Change in total body weight|Change in serum creatinine|Change in blood urea nitrogen|Acute Kidney Injury|Hypokalemia|Severe Hypokalemia|Hypomagnesemia|Severe Hypomagnesemia|Hyponatremia|Severe Hyponatremia","University of Maryland, Baltimore","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00082982","January 1, 2019","January 10, 2020","January 10, 2020","November 19, 2018",,"January 14, 2020","University of Maryland Medical Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03746002"
259,"NCT01283282","Investigation of the Athero-Protective Effects of Clopidogrel","APECS","Completed","Has Results","Coronary Artery Disease","Drug: Clopidogrel|Drug: Placebo","Flow-mediated Dilation (FMD)|Nitroglycerin-mediated Vasodilation|Endothelial Progenitor Cells (EPCs)|Pulse Wave Velocity (PWV)|Oxidative Stress Markers|Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP)|Inflammatory Marker CD40 Ligand","Emory University","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 4","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00005145|APECS","January 2008","December 2010","December 2010","January 25, 2011","May 1, 2015","May 1, 2015","Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01283282"
260,"NCT03243942","Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement",,"Completed","No Results Available","Cardiac Catheterization|Blood Pressure|Heart Ventricles|Echocardiography|Heart Failure","Drug: Definity","Agreement between SHAPE and pressure catheter measurements|Error between SHAPE and pressure catheter measurements","Thomas Jefferson University|American Heart Association|Lantheus Medical Imaging","All","21 Years and older   (Adult, Older Adult)","Phase 2","56","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15SDG25740015","June 1, 2017","June 26, 2019","June 26, 2019","August 9, 2017",,"July 10, 2019","Thomas Jefferson University and Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03243942"
261,"NCT03333551","Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy",,"Not yet recruiting","No Results Available","Cardiac Amyloidosis","Drug: F18 Florbetapir (amyvid) cardiac PET/CT imaging","Relative change in cardiac uptake of 18F florbetapir prior to chemotherapy and after six months of chemotherapy.|six minute walk test|Hematologic response|Cardiac response|Patient related outcomes","Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","29197","July 1, 2020","July 2021","July 2021","November 7, 2017",,"April 10, 2020","Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03333551"
262,"NCT03446599","Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery",,"Withdrawn","No Results Available","Vasoplegia|Hypotension|Coronary Artery Disease|Cardiac Valve Disease","Drug: Hydroxocobalamin|Drug: Methylene Blue|Drug: Normal saline","ΔMAP (baseline to 30 min after CPB separation) in OH-CO and placebo groups.|ΔMAP (baseline to 30 min after CPB separation) in OH-CO and MB groups.|ΔMAP between baseline and all time points (30 and 60 minutes after CPB initiation, and 30 and 60 minutes after CPB separation) between all 3 groups.|ΔSVR (baseline to 30 min after CPB separation) in OH-CO and placebo groups.|ΔSVR (baseline to 30 min after CPB separation) in OH-CO and MB groups.|ΔSVR between baseline and all time points (30 and 60 minutes after CPB initiation, and 30 and 60 minutes after CPB separation) between all 3 groups.|Differences in phenylephrine requirements during CPB between all 3 groups during CPB|Differences in Norepinephrine requirements during CPB between all 3 groups during and after CPB|Differences in Vasopressin requirements during CPB between all 3 groups during and after CPB","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D17173","November 2019","May 2020","June 30, 2020","February 27, 2018",,"March 2, 2020","Dartmouth-Hitchcock, Lebanon, New Hampshire, United States",,"https://ClinicalTrials.gov/show/NCT03446599"
263,"NCT02256345","Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF",,"Completed","Has Results","Heart Failure|Diastolic Heart Failure","Drug: KNO3|Drug: KCl","Change in Peak Oxygen Uptake (VO2) From Baseline Upto 1 Week of Administration for Each Dose|Change in Vasodilatory Reserve for Each Dose|Change in Mitochondrial Oxidative Capacity for Each Dose|Change in Aortic Augmentation Index","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","01340","January 2015","June 2016","June 2016","October 3, 2014","October 3, 2017","October 3, 2017","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02256345"
264,"NCT03500302","Effect of Evolocumab on Coronary Endothelial Function","EVOLVE","Completed","No Results Available","Human Immunodeficiency Virus|Coronary Artery Disease","Drug: evolocumab","Coronary endothelial function measured on MRI: coronary artery area change with isometric handgrip exercise|Serum PCSK9 levels","Johns Hopkins University|American Heart Association","All","21 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00127952","May 4, 2018","November 30, 2019","November 30, 2019","April 18, 2018",,"February 10, 2020","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03500302"
265,"NCT01919723","Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion",,"Completed","Has Results","Acute Coronary Syndrome","Drug: Ticagrelor|Drug: Eptifibatide","Change in Percent Inhibition of Platelet Aggregation (%IPA)|High On-treatment Platelet Reactivity (HPR)|Bleeding Complications|Periprocedural Myocardial Infarction (PMI)","University of Alabama at Birmingham|AstraZeneca","All","19 Years and older   (Adult, Older Adult)","Phase 2","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISSBRIL0077","February 2014","December 2015","December 2015","August 9, 2013","February 28, 2017","February 28, 2017","University of Alabama, Birmingham, Alabama, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01919723"
266,"NCT03270332","Effect of Inhaled Albuterol in Pulmonary Hypertension",,"Recruiting","No Results Available","Pulmonary Hypertension","Drug: albuterol first then placebo|Drug: placebo first then albuterol","Mean Pulmonary Artery Pressure|Pulmonary Vascular Resistance","University of Miami","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20170552","October 12, 2017","June 30, 2020","September 30, 2020","September 1, 2017",,"November 8, 2019","Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03270332"
267,"NCT01798992","Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart","BORG","Completed","Has Results","Idiopathic Dilated Cardiomyopathy","Drug: Carvedilol|Drug: Metoprolol succinate|Drug: Metoprolol succinate + doxazosin","Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months|Improvement in LVEF at 3 Months|Composite of All-cause Mortality, Need for Heart Transplant or Need for Ventricular Assist Device.","University of Colorado, Denver|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 4","56","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","00-0242|2R01HL048013","September 2000","March 2009","March 2009","February 26, 2013","February 20, 2017","August 14, 2018","University of Colorado Hospital, Denver, Colorado, United States|University of Utah Medical Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01798992"
268,"NCT02721511","A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen","DIVERSION-HF","Withdrawn","No Results Available","Acute Decompensated Heart Failure","Drug: Furosemide Injection Solution 8mg/mL","Efficacy endpoint: Urine output per 24 hours|Safety endpoint: Composite of Severe hypokalemia, severe hyperkalemia, moderate to severe worsening of renal function, fever, sepsis, intravenous catheter infection, cardiac dysrhythmia causing syncope or requiring therapy or death|Functional Status|Quality of life|Congestion Scale|Breathlessness","Todd M Koelling, MD|scPharmaceuticals, Inc.|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00107057","May 2016","March 7, 2017","March 7, 2017","March 29, 2016",,"March 24, 2017","University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02721511"
269,"NCT01989195","Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease",,"Completed","Has Results","ISCHEMIC CARDIOMYOPATHY","Drug: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT","COMPARISON OF MYOCARDIAL INFARCTION SIZE MEASUREMENTS USING INVESTIGATIONAL MANGANESE-ENHANCED MRI (MEMRI) OR DELAYED GADOLINIUM ENHANCED MRI (DEMRI)|SAFETY AND TOLERABILITY OF MANGANESE CONTRAST REAGENT|Significant Cardiovascular Event|Heart Rate: SAFETY AND TOLERABILITY OF MANGANESE CONTRAST REAGENT","Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","24224","May 2013","June 2013","June 2013","November 20, 2013","January 2, 2017","January 2, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01989195"
270,"NCT02646540","AiDing Diuresis wIth Tolvaptan (ADD-IT)","ADD-IT","Completed","No Results Available","Cardiomyopathy|Congestive Heart Failure","Drug: Tolvaptan 30 mg + IV Diuretics|Drug: Metolazone 5 mg + IV Diuretics|Drug: 2.5 times the Diuretics Dose","Length of Hospitalization Measured in Days|Change in Body Weight|Total Diuretic Dose|Change in estimated glomerular filtration rate (eGFR)|Number of Days Alive|Rate of Re-Hospitalization|Number of Electrolyte Imbalance Related Adverse Events|Number of Participants Requiring Electrolyte Repletion|Change in Sodium Level","Emory University","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00080051","January 2016","December 30, 2018","December 30, 2018","January 5, 2016",,"March 27, 2019","Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02646540"
271,"NCT00818779","Direct Renin Inhibition Effects on Atherosclerotic Biomarkers",,"Completed","Has Results","Coronary Artery Disease|Type 2 Diabetes Mellitus","Drug: Aliskiren|Drug: Amlodipine","Plasminogen Activator Inhibitor 1|Serum Level of Vascular Cell Adhesion Molecule|Serum Level of Intracellular Cell Adhesion Molecule|Serum Level of C-reactive Protein|Serum Level of Nitric Oxide","Texas Tech University Health Sciences Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Tekturna 1","January 2008","August 2011","August 2011","January 8, 2009","November 19, 2012","December 5, 2017","Texas Tech University Health Sciences Center, Lubbock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00818779"
272,"NCT02448550","Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial","CALIFORNIA","Terminated","No Results Available","Percutaneous Coronary Intervention","Drug: Bivalirudin|Drug: Unfractionated heparin","Net adverse clinical events (composite of efficacy and safety [bleeding] endpoints)|all cause mortality, myocardial infarction, or unplanned revascularization for ischemia|Bleeding Academic Research Consortium grade III or V bleeding events","Kaiser Permanente","All","18 Years and older   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","KP-RRC-CE1","May 2015","May 6, 2016","June 16, 2016","May 19, 2015",,"May 24, 2018","Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02448550"
273,"NCT02880137","Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy",,"Completed","Has Results","Cardiac Allograft Vasculopathy","Drug: Perflutren Lipid Microsphere|Procedure: RTMPE","Number of Subjects With a Perfusion Defect","Mayo Clinic|University of Calgary","All","1 Year and older   (Child, Adult, Older Adult)","Phase 4","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-007825","September 2016","June 2018","June 30, 2018","August 26, 2016","June 20, 2019","June 20, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02880137/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02880137"
274,"NCT01731041","Impact of Ticagrelor Re-load on Pharmacodynamic Profiles",,"Completed","Has Results","Coronary Artery Disease","Drug: Ticagrelor 180mg|Drug: Ticagrelor 90mg","Platelet Reactivity Index (PRI) by Vasodilator-stimulated Phosphoprotein (VASP)|P2Y12 Reaction Units (PRU) Determined by VerifyNow P2Y12","University of Florida|AstraZeneca","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UFJ 2012-096","January 2013","June 2014","June 2014","November 21, 2012","June 10, 2015","June 10, 2015","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01731041"
275,"NCT02457260","Oral Nitrite for Older Heart Failure Patients","ONTx+HF","Completed","Has Results","Heart Failure","Drug: 14 N Sodium Nitrite","Skeletal Muscle Bioenergetics- Polymerase Chain Reaction (PCR)|Skeletal Muscle Bioenergetics - Mitochondrial Function|Serology-platelet Bioenergetics|Measures of Physical Function- Cardiopulmonary Exercise Test (CPX)|Measures of Physical Function- Gait Speed|Measures of Physical Function- Handgrip|Measures of Physical Function- Balance|Quality of Life Assessment- In Heart Failure|Serology-Inflammatory Marker|Serology-plasma Nitrite and Nitrate|Serology-platelet Bioenergetics-1","Gladwin, Mark, MD|University of Pittsburgh","All","70 Years and older   (Older Adult)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO15020481","January 8, 2016","March 6, 2017","March 6, 2017","May 29, 2015","July 17, 2018","September 18, 2018","UPMC Montefiore Hospital, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02457260/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02457260"
276,"NCT01925703","Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure",,"Completed","Has Results","Heart Failure|Iron Deficiency Anemia","Drug: Sodium ferric gluconate","Serum Hemoglobin Concentration|Transferrin Saturation|Serum Ferritin Level","University of North Carolina, Chapel Hill","All","18 Years and older   (Adult, Older Adult)","Phase 4","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-0551","April 2011","December 2013","December 2013","August 20, 2013","August 10, 2015","August 25, 2015","University of North Carolina Hospitals & Clinics, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01925703"
277,"NCT03232918","Oxytocin and Fetal Heart Rate Changes",,"Recruiting","No Results Available","Fetal Bradycardia Complicating Labor and Delivery|Fetal Bradycardia During Labor|Fetal Heart Rate or Rhythm Abnormality Affecting Fetus","Drug: Half dose Oxytocin","Incidence of non-reassuring fetal heart rate tracings|Effect of oxytocin dose on duration of 1st and 2nd stage of labor|Mode of delivery","Unyime Ituk|University of Iowa","Female","18 Years to 55 Years   (Adult)","Phase 4","730","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201609722","February 20, 2019","April 30, 2021","April 30, 2021","July 28, 2017",,"March 9, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03232918"
278,"NCT01981863","Fibrinolysis Before Cardiopulmonary Bypass?",,"Completed","Has Results","Pathologic Fibrinolysis","Drug: Epsilonaminocaproic acid|Drug: Placebo","Di-Dimer Increase Before Cardiopulmonary Bypass|Value of Thromboelastography as Monitor of Fibrinolysis","Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Fibrinolysis","July 2013","February 2014","February 2014","November 13, 2013","June 30, 2016","June 30, 2016","Stanford Hospital & Clinics, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01981863"
279,"NCT03569085","Inhaled Anesthetics and Myocardial Strain",,"Recruiting","No Results Available","Heart Diseases","Drug: Sevoflurane|Drug: Isoflurane","Global longitudinal strain of myocardium, unitless (Comparison between two inhalational anesthetics, isoflurane and sevoflurane)|Global longitudinal strain of myocardium, unitless (Dose dependent effect of sevoflurane)|Global longitudinal strain of myocardium, unitless (Dose dependent effect of isoflurane)","Kathirvel Subramaniam|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","PRO17080624","June 27, 2018","June 2020","June 2020","June 26, 2018",,"April 14, 2020","UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03569085"
280,"NCT02933034","Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury",,"Completed","Has Results","ISCHEMIC CARDIOMYOPATHY","Drug: Manganese-enhanced MRI contrast reagent|Drug: Gadolinium-enhanced MRI contrast reagent","Infarct Size of MEMRI Versus DEMRI Scans|Systolic Blood Pressure|Diastolic Blood Pressure|Heart Rate|QT Interval|Corrected QT (QTc)|Alanine Aminotransferase (ALT)|Aspartate Aminotransferase (AST)|Alkaline Phosphatase (ALP)|Total Bilirubin|Creatinine|Estimated Glomerular Filtration Rate (eGFR)","Stanford University|General Electric","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","28508","April 2015","February 3, 2019","February 3, 2019","October 14, 2016","February 17, 2020","February 17, 2020","Stanford University School of Medicine, Stanford, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02933034/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02933034"
281,"NCT02099331","Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin","DREAM","Active, not recruiting","No Results Available","Atrial Fibrillation","Drug: Melatonin|Drug: Placebo (for Melatonin)","Incidence of atrial fibrillation|Levels of Reactive Oxygen Species (ROS)","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NA_00090647","September 2014","November 2020","November 2020","March 28, 2014",,"November 12, 2019","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02099331"
282,"NCT02539160","Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease",,"Active, not recruiting","No Results Available","Coronary Artery Disease|Diabetes Mellitus","Drug: ticagrelor","Platelet reactivity measured by vasodilator stimulated phosphoprotein (VASP) platelet reactivity index (PRI)|Platelet reactivity measured by VerifyNow P2Y12","University of Florida","All","18 Years and older   (Adult, Older Adult)","Phase 4","92","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESR-15-10953","February 2016","November 14, 2019","May 2020","September 2, 2015",,"March 3, 2020","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02539160"
283,"NCT03079102","Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest","iNOOHCA","Recruiting","No Results Available","Heart Arrest, Out-Of-Hospital","Drug: Nitric Oxide|Drug: Nitrogen","Death or significant neurological or cardiac impairment|Death|Cerebral performance category (CPC)|Cerebral performance category - extended (CPC-E)|Modified Rankin Score (mRS)|Discharge destination|Barthel Index (activities of daily living)|Time to awakening|Methemoglobin level|ECHOcardiogram|Reactive hyperemia|Systolic blood pressure|Diastolic blood pressure|Heart rate","Cameron Dezfulian|Mallinckrodt|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO16100408","August 21, 2017","June 30, 2021","December 1, 2021","March 14, 2017",,"May 29, 2019","UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC East, Monroeville, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03079102"
284,"NCT02260258","Neuromuscular Blockade for Post-Cardiac Arrest Care","NMB_in_CA","Completed","No Results Available","Cardiac Arrest","Drug: Rocuronium|Drug: Normal Saline","Lactate levels 24 hours after initiation of study drug|Lactate change over time|Survival|Good neurological outcome|Length of intensive care unit (ICU) stay","Beth Israel Deaconess Medical Center|University of Pittsburgh Medical Center|Brigham and Women's Hospital|University of Alabama at Birmingham|Beaumont Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","2014P000204|14GRNT20010002","October 2014","May 29, 2019","May 29, 2019","October 9, 2014",,"August 19, 2019","Michael Kurz, Birmingham, Alabama, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Robert Swor, Royal Oak, Michigan, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02260258/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02260258"
285,"NCT01353729","A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers",,"Completed","No Results Available","Influenza, Human","Drug: 600 mg zanamivir + moxifloxacin placebo|Drug: 1200 mg zanamivir + moxifloxacin placebo|Drug: zanamivir placebo + moxifloxacin placebo|Drug: zanamivir placebo + 400 mg moxifloxacin","Change from baseline in QTcF for zanamivir|Change from baseline in QTcB|Change from baseline in QTci|Change from baseline in QT|Change from baseline in Heart Rate|Pharmacokinetic parameters of Area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration from serum zanamivir concentration-time data|Pharmacokinetic parameters of Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time from serum zanamivir concentration-time data|Pharmacokinetic parameters of maximum observed concentration from serum zanamivir concentration-time data|Pharmacokinetic parameters of time of occurrence of cmax from serum zanamivir concentration-time data|Pharmacokinetic parameters of systemic clearance of parent drug from serum zanamivir concentration-time data|Pharmacokinetic parameters of volume of distribution in terminal phase from serum zanamivir concentration-time data|Pharmacokinetic parameters of terminal phase half-life from serum zanamivir concentration-time data|Pharmacokinetic parameters of Area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (if needed) from plasma moxifloxacin concentration-time data|Pharmacokinetic parameters of area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (if needed) from plasma moxifloxacin concentration-time data|Pharmacokinetic parameters of maximum observed concentration (if needed) from plasma moxifloxacin concentration-time data|Pharmacokinetic parameters of time of occurrence of cmax (if needed) from plasma moxifloxacin concentration-time data|Pharmacokinetic parameters of systemic clearance of parent drug (if needed) from plasma moxifloxacin concentration-time data|Pharmacokinetic parameters of volume of distribution in terminal phase (if needed) from plasma moxifloxacin concentration-time data|Pharmacokinetic parameters of terminal phase half-life (if needed) from plasm moxifloxacin concentration-time data|Safety and tolerability of zanamivir as assessed by change from baseline in 12-lead Electrocardiograms (ECG)|Safety and tolerability of zanamivir as assessed by change from baseline in blood pressure and heart rate|Safety and tolerability of zanamivir as assessed by change from baseline in the collection of adverse events|Safety and tolerability of zanamivir as assessed by change from baseline in toxicity grading of clinical laboratory tests","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","114346","May 19, 2011","August 2, 2011","August 2, 2011","May 16, 2011",,"July 21, 2017","GSK Investigational Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01353729"
286,"NCT01852162","Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy",,"Completed","Has Results","Coronary Artery Disease","Drug: Dabigatran|Drug: Placebo","TRAP-induced Platelet Aggregation|Platelet Reactivity Measured by LTA|Platelet Reactivity Measured by Multiple Electrode Aggregometry.|Clot Kinetic: Thrombin Activity|Clot Kinetic: Clot Stength","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UFJ 2011-112","February 2012","January 2014","February 2014","May 13, 2013","March 17, 2015","March 17, 2015","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01852162"
287,"NCT04082442","Evolocumab in Patients With STEMI","EVACS II","Recruiting","No Results Available","Acute Coronary Syndrome","Drug: Evolocumab|Drug: Placebos","Change in LDL-Cholesterol|Change in PET Imaging for inflammation","Johns Hopkins University","All","25 Years to 90 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00206305","September 1, 2019","August 2021","August 2021","September 9, 2019",,"September 9, 2019","The Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04082442"
288,"NCT04094857","Phase 1 Study of HBN-1",,"Not yet recruiting","No Results Available","Cardiac Arrest","Drug: HBN-1","Characterize the safety and recommended Phase 2 loading dose infusion rate of HBN-1|Determine the incidence of the need for implementation of treatment to offset shivering","Hibernaid, Inc","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBN-1-001-US","October 30, 2019","November 1, 2020","December 31, 2020","September 19, 2019",,"October 7, 2019","Maine Medical Center, Portland, Maine, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04094857"
289,"NCT01847391","A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects",,"Completed","No Results Available","Ischemic Heart Disease","Drug: GS-6615|Drug: Placebo","Safety and tolerability of GS-6615|Pharmacokinetic (PK) profile of GS-6615","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GS-US-279-0102","May 2013","November 2013","November 2013","May 6, 2013",,"November 13, 2013","Investigational Site, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01847391"
290,"NCT01636570","Vitamin D3 Supplementation for Heart Failure Patients",,"Completed","No Results Available","Heart Failure|Vitamin D Deficiency|Cardiomyopathy|Congestive Heart Failure","Drug: Placebo Comparator: Sugar Pill|Drug: Vitamin D3 (cholecalciferol)","B type Natriuretic Peptide (BNP)|Cardiopulmonary exercise test (CPX)|25 hydroxyvitamin D [25 (OH)D]|C reactive protein (CRP)|Serum Calcium|6 minute walk test|Kansas City Cardiomyopathy Questionnaire","Heidi Moretti, MS, RD|Saint Patrick Hospital","All","Child, Adult, Older Adult","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VitD3HF","August 2012","April 2015","April 2015","July 10, 2012",,"April 26, 2017","International Heart Institute of Montana, Missoula, Montana, United States|Saint Patrick Hosptial, Missoula, Montana, United States",,"https://ClinicalTrials.gov/show/NCT01636570"
291,"NCT01752842","Lipid Biomarkers for Diabetic Heart Disease",,"Completed","Has Results","Type II Diabetes Mellitus|Diabetes Complications","Drug: Fenofibrate|Drug: Placebo for fenofibrate","Change in Cardiac Diastolic Function as Measured by E' (cm/s)|Change in Cardiac Systolic Function as Measured by Fractional Shortening Percent|Change in C24:0/C16:0 Ceramide Ratio","Washington University School of Medicine|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|Leducq Foundation","All","30 Years to 65 Years   (Adult, Older Adult)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","201112122|P20HL113444-01","March 2013","February 23, 2018","February 23, 2018","December 19, 2012","February 26, 2019","March 15, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01752842/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01752842"
292,"NCT01058018","Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease","ASSERT","Completed","No Results Available","Atherosclerosis|Coronary Artery Disease","Drug: RVX000222|Drug: Placebo","The percent change in ApoA1 from baseline to 12 weeks post-randomization for each treatment arm compared to placebo.|Compare the dose and time response relationships for major lipids (ApoA1, total cholesterol, HDL-C, LDL-C, non-HDL-C, TG, ApoB, LDL, and HDL-subclasses) over 4, 8 and 12 weeks time course.","Resverlogix Corp","All","18 Years and older   (Adult, Older Adult)","Phase 2","299","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RVX222-CS-005","December 2009","June 2010",,"January 28, 2010",,"July 22, 2016","Orange County Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT01058018"
293,"NCT03452917","Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest","SNOCAT","Recruiting","No Results Available","Out-Of-Hospital Cardiac Arrest","Drug: Placebo|Drug: sodium nitrite 45 mg|Drug: sodium nitrite 60 mg","Survival to hospital admission|Re-arrest or use of pressors in the field by paramedics|Survival to discharge|Number of days in ICU|survival to 24 h","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","51605-B|R01HL129722","February 8, 2018","February 8, 2021","June 30, 2021","March 2, 2018",,"March 26, 2019","Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03452917"
294,"NCT01952834","Effect of Probiotic Supplementation on Endothelial Function",,"Completed","Has Results","Coronary Artery Disease","Dietary Supplement: GoodBelly Probiotic|Drug: Vancomycin","Brachial Artery Flow Mediated Dilation|Interleukin 8|Interleukin-12","Medical College of Wisconsin","Male","40 Years to 75 Years   (Adult, Older Adult)","Phase 4","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00019610|FP00004156","June 2013","March 2015","March 2015","September 30, 2013","January 21, 2016","January 21, 2016","Medical College of Wisconsin, Milwauke, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01952834"
295,"NCT01319110","Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation",,"Completed","Has Results","Cardiac Arrest|Sudden Cardiac Arrest","Drug: Coenzyme Q10|Dietary Supplement: Placebo","Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients|Comparison of Serum CoQ10 Levels Randomized to Supplementation vs. Placebo","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010P000362","February 2011","December 31, 2011","December 31, 2011","March 21, 2011","April 28, 2017","July 31, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01319110"
296,"NCT03119558","PET/MRI Evaluation of Cardiac Amyloid",,"Completed","No Results Available","Cardiac Amyloidosis","Drug: 18F‑Florbetaben (Neuraceq®) PET/MRI","Number of participants with 18F‑Florbetaben (Neuraceq®) uptake on Fused PET/MRI Images","Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-35049","May 26, 2016","August 23, 2018","August 28, 2018","April 18, 2017",,"July 17, 2019","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03119558"
297,"NCT01137786","Kidney Damage in Patients With Normal eGFR",,"Completed","Has Results","Coronary Artery Stenosis","Drug: Non ionic contrast media comparator","Impact on the Trajectory of Serum and Urinary NGAL Following the Administration of Non-ionic Low Osmolar Contrast Media.","Bracco Diagnostics, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 4","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","IOP-116","December 2010","April 2012","April 2012","June 4, 2010","September 30, 2013","September 30, 2013","Prairie Cardiovascular Consultants, Ltd., Springfield, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01137786"
298,"NCT02669407","Splanchnic Nerve Anesthesia in Heart Failure",,"Completed","Has Results","Heart Failure","Procedure: splanchnic nerve anesthesia with a local anesthetic|Drug: regional nerve block with a local anesthetic (Lidocaine)","Central Venous Pressure|Pulmonary Arterial Mean Pressure|Pulmonary Capillary Wedge Pressure|Cardiac Index|Ejection Fraction (LVEF)|Pulmonary Artery Systolic Pressure|Right Ventricular Diameter|Left Ventricular Diameter|N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Level|Urine Output Measured in ml Over 3 Hours|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine Level|Dyspnea as Measured on Likert Scale|Change in Clinical Symptoms, as Measured by 6 Minute Walk Test","Duke University","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00066528","January 1, 2017","October 2018","October 2018","February 1, 2016","December 6, 2019","December 6, 2019","Duke, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02669407/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02669407"
299,"NCT01345188","Ranolazine in Ischemic Cardiomyopathy",,"Completed","Has Results","Cardiomyopathy|Chest Pain|Dyspnea","Drug: Ranexa|Drug: Placebo","Anginal Frequency|Quality of Life|Dyspnea Assessed by the Rose Dyspnea Questionnaire (RDQ)","Midwest Cardiovascular Research Foundation|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IN-US-259-D032","April 2011","April 2014","April 2014","April 29, 2011","September 6, 2018","March 4, 2020","Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01345188"
300,"NCT02361944","Risk of Oxygen During Cardiac Surgery Trial","ROCS","Active, not recruiting","No Results Available","Cardiac Surgery","Drug: Oxygen","oxidative damage is the primary outcome of aim 2 (mechanism of organ injury)|acute kidney injury is the primary outcome of aim 1 (organ injury)|vascular reactivity / endothelial function|mitochondrial function|arrythmia|myocardial injury or infarction|stroke|postoperative cognitive dysfunction, pain, and depression|mortality|respiratory failure|chronic kidney disease|inflammation|hemolysis|reactive oxygen species production|acute brain dysfunction (delirium)|oxygenation and perfusion","Vanderbilt University|National Institute of General Medical Sciences (NIGMS)|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","131128|R01GM112871","April 5, 2016","October 3, 2019","April 3, 2021","February 12, 2015",,"January 31, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02361944"
301,"NCT00998218","Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction",,"Completed","No Results Available","Sudden Cardiac Death|Ventricular Arrythmias","Drug: Ranolazine|Drug: Placebo","The effect of ranolazine compared to placebo on MVTWA and reproducibility of MVTWA will be demonstrated. A p value of < 0.05 will be considered significant","Aspirus Heart and Vascular Institute-Research and Education","All","18 Years and older   (Adult, Older Adult)","Phase 3","7","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RAN-Twave alt","September 2009","December 2010","December 2010","October 20, 2009",,"February 9, 2012","Aspirus Wausau Hospital, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00998218"
302,"NCT03040427","The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis",,"Terminated","No Results Available","Cardiac Amyloidosis","Drug: F-18 florbetapir","Frequency of positive studies as determined by the tracer uptake by the heart.|Development of clinical symptoms of cardiac amyloidosis by conventional cardiac testing.|Correlation of F-18 florbetapir PET scan with TcPYP scan.","Wael Jaber|Avid Radiopharmaceuticals|The Cleveland Clinic","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 4","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-960","January 2017","August 21, 2019","August 21, 2019","February 2, 2017",,"January 9, 2020","Cleveland Clinic Foundation (Main Campus), Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03040427"
303,"NCT01996618","Study to Reduce Symptoms of Premature Beats With Ranolazine","RSVP","Unknown status","No Results Available","Premature Ventricular Beats","Drug: Ranolazine","Reduction in Premature Ventricular Beats|Changes in transthoracic echocardiographic parameters|Frequency of palpitations|Reduction of Premature Atrial Beats|Measure Temperature Rebound Rate (TRR)","Walter Reed National Military Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","72","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20043-7","January 2014","June 2016","July 2016","November 27, 2013",,"May 1, 2015","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01996618"
304,"NCT03423342","Nicotinamide Riboside in Systolic Heart Failure",,"Completed","No Results Available","Heart Failure, Systolic","Dietary Supplement: nicotinamide riboside|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Effect of NR on Whole Blood NAD+ Levels|Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment|Effect of NR on Mitochondrial Function","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","STUDY00001830|1R21HL126209-01","May 19, 2016","April 11, 2019","June 30, 2019","February 6, 2018",,"August 1, 2019","University of Washington, Seattle, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03423342/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT03423342/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03423342"
305,"NCT01014624","Prasugrel/Clopidogrel Maintenance Dose Washout Study",,"Completed","Has Results","Coronary Artery Disease","Drug: prasugrel|Drug: clopidogrel","The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline|The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline.|Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population.|Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population.|Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population.|Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population.|Percentage of Platelet Inhibition on Washout Day 1|Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose.","Daiichi Sankyo, Inc.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS747S-B-U4001","February 2010","May 2010","June 2010","November 17, 2009","September 9, 2011","February 13, 2012","Scripps Clinic, La Jolla, California, United States|University of Florida Health Science Center Shands Jacksonville, Jacksonville, Florida, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States|Black Hills Clinical Research Center, Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01014624"
306,"NCT02802592","EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)","EPORT","Terminated","Has Results","Cardiac Surgery-CABG|Cardiac Valve Replacement","Drug: Epogen|Drug: Normal Saline","Total Number of Packed Red Blood Cells Transfused During the Intraoperative and Immediate Postoperative Period|Length of Stay (# of Total Days Hospitalized)|Overall Hospitalization Cost|Change in Quality of Life as Assessed by Short Form-36 Quality of Life Survey","Johns Hopkins University","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00050961","May 2015","June 15, 2016","February 27, 2017","June 16, 2016","September 14, 2017","February 26, 2019","Suburban Hospital, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02802592"
307,"NCT02119806","Decreasing the Incidence of Delirium After Cardiac Surgery",,"Withdrawn","No Results Available","C.Surgical Procedure; Cardiac|Delirium","Drug: Benzodiazepine|Drug: Fentanyl|Drug: Propofol","Delirium","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Delirium 13-001412","August 2017","August 2017","August 2017","April 22, 2014",,"June 12, 2018","Ronald Reagan UCLA Medical Center, Department of Anesthesiology, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02119806"
308,"NCT03270514","Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride",,"Completed","No Results Available","Coronary Artery Disease|Coronary Artery Stenoses|Valve Regurgitation, Mitral|Valve Regurgitation, Tricuspid","Drug: Exparel Injectable Product|Drug: Bupivacaine Hydrochloride","Post-operative Pain Intensity|Total Narcotic Consumption|Time to Extubation|Time to Mobilization|Time to Out of Bed to Chair|Time to Oral Intake|Non-invasive ventilation (NIV) requirement|Re-intubation|Use of Incentive Spirometry|Post-operative nausea and vomiting|Major organ dysfunction|Length of Hospital and ICU Stay|Hospital readmission|Mortality","Kathirvel Subramaniam|Pacira Pharmaceuticals, Inc|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 3","63","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO17060305","November 15, 2018","December 13, 2019","February 25, 2020","September 1, 2017",,"April 15, 2020","UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03270514"
309,"NCT02383563","Metformin for HIV Inflammation",,"Unknown status","No Results Available","HIV|Coronary Artery Disease","Drug: metformin extended release","Coronary plaques by CT angiography|Monocyte subsets by multiparametric flow cytometry|Monocyte secretory function by intracellular cytokine staining release assay|Sub-types of coronary plaques by CT angiography","University of Hawaii|National Institute of General Medical Sciences (NIGMS)","All","45 Years and older   (Adult, Older Adult)","Phase 2","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H028|P30GM103341","February 2015","February 2016","February 2016","March 9, 2015",,"March 9, 2015","Hawaii Center for AIDS, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT02383563"
310,"NCT02003456","Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging",,"Completed","No Results Available","Ischemic Heart Disease|Myocardial Infarction","Drug: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82","Equivalence of Images from Rest Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously|Equivalence of Quantitative Estimates of Global Myocardial Blood Flow using Rubidium-82 Perfusion PET Obtained Separately versus Simultaneously|Equivalence of Images from FDG PET Obtained Separately versus Simultaneously","University of Michigan","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00080193","December 2013","August 2014","August 2014","December 6, 2013",,"February 23, 2017","University of Michigan Hospital, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02003456"
311,"NCT01840696","Phase Analysis and Obstructive CAD on Rubidium PET",,"Withdrawn","No Results Available","Coronary Artery Disease","Drug: Regadenoson","Stress/rest differences in global left ventricular mechanical contraction bandwidth.|Stress/rest differences in segmental left ventricular mechanical contraction bandwidth.","Emory University","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00062632|REGA12I11","October 2013","May 2014","May 2014","April 26, 2013",,"June 2, 2014","Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01840696"
312,"NCT03019653","Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome","ANX-042 Aim 1","Enrolling by invitation","No Results Available","Heart Failure|Cardiorenal Disease|Renal Disfunction","Drug: ANX-042|Drug: Placebo","Change in Glomerular Filtration Rate|Change in Sodium Excretion|Change in Urine Flow|Change in Blood Pressure|Change in Renin-angiotensin-aldosterone system (RAAS)|Change in Urine Annexin A1 (AnxA1) Protein Levels|Number of Subjects with Hypotension","Mayo Clinic|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","16-001847|UL1TR000135|R01HL084155-06A1","January 2017","July 2023","September 2023","January 12, 2017",,"April 8, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03019653"
313,"NCT01921829","Protocolized Diuretic Strategy in Cardiorenal Failure","ProDiuS","Terminated","Has Results","Cardiac Failure|Renal Failure|Kidney Failure","Drug: Protocolized Diuretic Strategy","Change in Body Weight (kg) From Randomization to Day 4 or Date of Discharge (Whichever Comes First)|Length of Hospitalization|Number of Rehospitalizations for Heart Failure (HF)|Number of Total Rehospitalizations|All-cause Mortality|Difference From Baseline to 1 Month in Change in Right Internal Jugular Vein (RIJV) Cross-sectional Area (CSA) Pre- and Post-Valsalva|Fluid Balance|Acute Kidney Injury|Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Score Change at 1 Month|Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Score Change at 1 Month|SF-36 Mental Component Score (MCS) Change at 1 Month|SF-36 Physical Component Score (PCS) Change at 1 Month|PHQ-9 Depression Index Change at 1 Month|PSQI Total Score Change at 1 Month|Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Score Change at 3 Months|Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Score Change at 3 Months|SF-36 Mental Component Score (MCS) Change at 3 Months|SF-36 Physical Component Score (PCS) Change at 3 Months|PHQ-9 Depression Index Change at 3 Months|PSQI Total Score Change at 3 Months","Kelly V. Liang, MD|University of Pittsburgh","Male","21 Years and older   (Adult, Older Adult)","Phase 4","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PRO13040071","November 2013","November 2015","November 2015","August 13, 2013","July 17, 2017","August 21, 2017","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01921829"
314,"NCT02133352","Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction",,"Completed","Has Results","Pulmonary Hypertension|Diastolic Left Ventricular Dysfunction","Drug: Ranolazine","Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)|Percent Change in Other Hemodynamic Parameters|6 Minute Walk Test (6MWT)|Change in Cardiac Size and Function|Change in Echocardiogram Parameters (LVEF)|Change in BNP Cardiac Biomarker","Boston University|Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30217","July 2011","May 2013","May 2014","May 8, 2014","May 17, 2017","May 17, 2017","Boston University Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02133352"
315,"NCT02498769","Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery",,"Completed","Has Results","Atrial Fibrillation","Drug: Botulinum Toxin Type A|Drug: Placebo","Time to In-hospital Post-operative Atrial Fibrillation (POAF)|Number of Participants With In-hospital POAF|Length of Stay|Number of Participants With Adverse Events","Joseph Mathew, M.D.|Foundation for Anesthesia Education and Research|American Heart Association|Duke University","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00061607","September 2015","September 28, 2017","December 1, 2018","July 15, 2015","December 7, 2018","February 22, 2019","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02498769/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02498769"
316,"NCT02307864","Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Tramadol HCl|Drug: Moxifloxacin 400 mg|Drug: Tramadol HCl Placebo|Drug: Moxifloxacin Placebo","Change From Baseline in QTc Interval|Change From Baseline in HR, QRS, and PR Intervals|Number of Participants with T-wave and U-wave Morphological Changes|Maximum Plasma Concentration During a Dosing Interval at Steady State (Cmax,ss)|Trough Plasma Concentration Before Dosing (pre-dose) At Steady State (Ctrough,ss)|Time to Reach the Maximum Plasma Concentration at Steady State (Tmax,ss)|Area Under the Plasma Concentration-Time Curve During a Dosing Interval (tau) at Steady State (AUCtau,ss)|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)","Janssen Scientific Affairs, LLC|Bausch Health Americas, Inc.|Cipher Pharmaceuticals Inc.","All","18 Years to 55 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR106355|TRAMPAI1003|V01-TRAA-401|2014-01-00","December 4, 2014","August 22, 2015","August 27, 2015","December 4, 2014",,"August 29, 2018","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02307864"
317,"NCT02546765","Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery","DEXACET","Completed","Has Results","Delirium","Drug: IV acetaminophen & IV propofol|Drug: IV acetaminophen & IV dexmedetomidine|Drug: IV propofol & placebo|Drug: IV dexmedetomidine & placebo","Incidence of Delirium|Duration of Delirium|Severity of Delirium|Postoperative Opioid Consumption in Morphine Equivalents|Montreal Cognitive Assessment (MoCA)|Hospital Length of Stay|ICU Length of Stay|Follow up Incidence of Cognitive Dysfunction","Beth Israel Deaconess Medical Center","All","60 Years and older   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2014P000413","October 2015","May 2018","July 2019","September 11, 2015","January 7, 2020","April 9, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02546765/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02546765"
318,"NCT02206204","Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects",,"Completed","No Results Available","Cardiodynamics|Safety|Tolerability|Pharmacokinetics","Drug: selexipag|Drug: placebo for selexipag|Drug: moxifloxacin|Drug: moxifloxacin-matching placebo","Baseline adjusted placebo corrected change in corrected QTc interval (time interval from beginning of the Q wave until end of the T wave) (ΔΔQTcI) at various time points|Baseline adjusted placebo corrected change in heart rate at various time points|Baseline adjusted placebo corrected change in RR interval (interval from the peak of one QRS complex to the peak of the next) at various time points|Baseline adjusted placebo corrected change in PR interval (time interval from the beginning of the P wave to the beginning of the QRS complex) at various time points|Baseline adjusted placebo corrected change in QRS interval (time interval from the beginning of the Q wave to the end of the S wave) at various time points|Number of time points at which T-wave morphology changes were observed|Maximum plasma concentration (Cmax) for selexipag|Time to reach maximum plasma concentration (tmax) for selexipag|Area under the plasma concentration-time curve (AUCt) for selexipag|Trough plasma concentration (Ctrough) for selexipag|Maximum plasma concentration (Cmax) for ACT-333679|Time to reach maximum plasma concentration (tmax) for ACT-333679|Area under the plasma concentration-time curve (AUCt) for ACT-333679|Trough plasma concentration (Ctrough) for ACT-333679|Change in systolic blood pressure from baseline up to end of study|Change in diastolic blood pressure from baseline up to end of study|Change in pulse rate from baseline up to end of study|Change in body weight from baseline up to end of study|Number of participants with treatment-related electrocardiogram abnormalities up to the end of study","Actelion","All","18 Years to 45 Years   (Adult)","Phase 1","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","AC-065-106","June 2012","November 2012","November 2012","August 1, 2014",,"August 1, 2014","Covance Clinical Research Unit, Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02206204"
319,"NCT01537926","Hypertrophic Regression With N-Acetylcysteine in HCM","HALT","Completed","No Results Available","Hypertrophic Cardiomyopathy","Drug: N-acetylcysteine|Drug: Placebo","Recruitment rate|indices of cardiac mass and function","The University of Texas Health Science Center, Houston|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HALT-HCM","January 2012","December 31, 2016","December 31, 2016","February 23, 2012",,"May 4, 2017","UTHSC, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01537926"
320,"NCT02423265","Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries",,"Withdrawn","No Results Available","Myocardial Ischemia|Coronary Artery Disease|Arteriosclerosis|Chronic Stable Angina","Drug: Ranolazine|Drug: Placebo","Cardiac MRI (CMR) strain|Dobutamine wall motion scoring index (WMSI)|Quality of Life/burden of angina|Treadmill ECG exercise distance|Time to ECG changes (ST depression) on exercise ECG","East Carolina University|Gilead Sciences","All","21 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IN-US-259-0172 Buch ISR|UMCIRB 13-001574","June 2015","December 2016","March 2017","April 22, 2015",,"May 30, 2018","East Carolina Heart Institute at Vidant Medical Center, Greenville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02423265"
321,"NCT01914926","Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter","DiME","Completed","Has Results","Heart Rate and Rhythm Disorders","Drug: Metoprolol|Drug: Diltiazem","Percent of Patients Reaching Target HR<100bpm Within 30 Minutes","Antonios Likourezos|Maimonides Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09/01/VA02","June 2009","November 2010","November 2010","August 2, 2013","December 16, 2013","May 15, 2014","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT01914926"
322,"NCT01642238","Antithrombotic Effects of Ticagrelor Versus Clopidogrel",,"Completed","Has Results","Acute Coronary Syndrome","Drug: Ticagrelor + ASA + Bivalirudin|Drug: Clopidogrel + ASA + Bivalirudin","Platelet-thrombus Formation in an ex Vivo Model of Thrombosis|Platelet Reactivity|Blood Thrombogenicity","Juan J Badimon|AstraZeneca|Icahn School of Medicine at Mount Sinai","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-0732|ISSBRIL0067","July 2012","March 2013","April 2013","July 17, 2012","July 11, 2016","July 11, 2016","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01642238"
323,"NCT03349775","Cardiometabolic Disease and Pulmonary Hypertension",,"Recruiting","No Results Available","Obesity","Drug: Metformin|Drug: Placebo","Pulmonary vascular hemodynamics (rest)|Pulmonary vascular hemodynamics (exercise)|Effect on pulmonary artery endothelial cell phenotypes","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","30 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","2017P001020|1R01HL134893-01A1","November 27, 2017","September 1, 2022","September 1, 2024","November 22, 2017",,"February 19, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03349775"
324,"NCT02081443","In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients",,"Completed","Has Results","Coronary Artery Disease","Drug: Ticagrelor 180mg|Drug: Ticagrelor 90mg","Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP)|PRI Measured by VASP","University of Florida|The Medicines Company","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","CIT","April 2014","October 2015","October 2015","March 7, 2014","March 3, 2017","April 4, 2017","Dominick Angiolillo, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02081443"
325,"NCT03097120","The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.","ERA","Completed","No Results Available","Heart Disease","Drug: 0.625 mg of conjugated equine estrogen|Drug: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|Drug: placebo tablets","mean minimal coronary-artery diameter|stenosis as a percentage of the reference diameter|development of new lesions in a patient|Models focusing on change in diameter were also examined","Wake Forest University Health Sciences|National Heart, Lung, and Blood Institute (NHLBI)","Female","55 Years and older   (Adult, Older Adult)","Phase 3","309","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","U01HL45488","January 1995","January 2001","January 2001","March 31, 2017",,"August 1, 2018","Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03097120"
326,"NCT03155893","A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: ODV Placebo (Matching 25 mg ODV)|Drug: ODV Placebo (Matching 200 mg ODV)|Drug: ODV Placebo (Matching 125 mg ODV)|Drug: ODV Placebo (Matching 100 mg ODV)|Drug: SMV Placebo (Matching 150 mg SMV)|Drug: AL-335 Placebo (matching 1200 mg AL-335)|Drug: Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Drug: ODV 25 mg|Drug: ODV 200 mg|Drug: ODV 125 mg|Drug: ODV 100 mg|Drug: SMV 150 mg|Drug: AL-335 1200 mg","Panel 1:Effect of AL-335 Single Supratherapeutic Dose on QT/QTc Interval Change on top of Multiple Doses of ODV and SMV Vs. Placebo Using IUT Analysis at Day 16|Panel 2: Effect of ODV on QT/QTc Interval Change From Baseline After Multiple Supratherapeutic Doses of ODV Using ER Approach at Day 14|Panel 2: Effect of ODV on QT/QTc Interval Change From Baseline After Multiple Supratherapeutic Doses of ODV Using ER Approach at Day 15|Panel 2: Effect of ODV on QT/QTc Interval Change From Baseline After Multiple Supratherapeutic Doses of ODV Using ER Approach at Day 16|Panel 2: Effect of ODV on PR Interval Change From Baseline After Multiple Supratherapeutic Doses of ODV Using ER Approach at Day 14|Panel 2: Effect of ODV on PR Interval Change From Baseline After Multiple Supratherapeutic Doses of ODV Using ER Approach at Day 15|Panel 2: Effect of ODV on PR Interval Change From Baseline After Multiple Supratherapeutic Doses of ODV Using ER Approach at Day 16|Panel 2: Effect of Multiple Supratherapeutic Doses of ODV on Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) at Day 10|Panel 2: Effect of Multiple Supratherapeutic Doses of ODV on Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) at Day 14|Panel 2: Effect of Multiple Supratherapeutic Doses of ODV on Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) at Day 28|Panel 1: Maximum Observed Analyte Concentration (Cmax) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1: Time to Reach the Maximum Observed Analyte Concentration (Tmax) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1: Area Under the Analyte Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC24) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1: Area Under the Analyte Concentration-time Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1: Apparent Terminal Elimination Half-life (t1/2term) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1: Apparent Terminal Elimination Rate Constant (Lambda[z]) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1: Area Under the Analyte Concentration-time Curve From Time 0 to Infinite Time (AUC[0-infinity]) of AL-335 and its 2 metabolites ALS-022399 and ALS-022227|Panel 1 and 2: Maximum Observed Analyte Concentration (Cmax) of ODV|Panel 1 and 2: Time to Reach the Maximum Observed Analyte Concentration (Tmax) of ODV|Panel 1 and 2: Minimum Observed Analyte Concentration (Cmin) of ODV|Panel 1 and 2: Observed Analyte Concentration Just Prior to the Beginning of a Dosing Interval (Ctrough) of ODV|Panel 1 and 2: Area Under the Analyte Concentration-time Curve From Time 0 to 24 hours Postdose (AUC24) of ODV|Panel 2: Observed Analyte Concentration of ODV|Panel 1: Maximum Observed Analyte Concentration (Cmax) of SMV|Panel 1: Time to Reach the Maximum Observed Analyte Concentration (Tmax) of SMV|Panel 1: Minimum Observed Analyte Concentration (Cmin) of SMV|Panel 1: Observed Analyte Concentration Just Prior to the Beginning of a Dosing Interval (Ctrough) of SMV|Panel 1: Area Under the Analyte Concentration-time Curve From Time 0 to 24 hours Postdose (AUC24) of SMV|Panel 1 and 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Panel 1: Effect of Moxifloxacin on the QT/QTc Interval Change From Baseline at Day 2 and 16","Janssen Research & Development, LLC","All","18 Years to 55 Years   (Adult)","Phase 1","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CR108332|64294178HPC1012","May 12, 2017","October 27, 2017","October 27, 2017","May 16, 2017",,"November 14, 2017","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03155893"
327,"NCT03341156","Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation","OPSTAHT","Recruiting","No Results Available","Heart Disease End Stage|Heart Failure，Congestive","Drug: Kcentra|Drug: Frozen Plasma Product, Human","Amount of Chest Tube Drainage|Postoperative INR|Blood Product Use|Red Blood Cell Use|Need for circulatory support|Mechanical Ventilation|Tracheostomy|Renal Failure|Sepsis|Death|Stroke or postoperative neurological dysfunction|Gastrointestinal complication requiring bowel resection|Peripheral vascular complication|Deep Vein Thrombosis and Pulmonary Thromboembolism|Plasma Coagulation Factor levels|Thrombin Generation Assay|Surgical Re-exploration","Kathirvel Subramaniam|University of Maryland, College Park|CSL Behring|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO17080509","July 11, 2018","July 1, 2021","August 1, 2021","November 14, 2017",,"October 25, 2019","University of Maryland, Baltimore, Maryland, United States|Upmc Presbyterian Montefiore Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Shadyside, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03341156"
328,"NCT01648296","Fatty Acid Radiotracer Comparison Study in Heart Failure Patients",,"Completed","Has Results","Heart Failure|Obesity|Type 2 Diabetes Mellitus|Health Normal Volunteer Subjects","Drug: [18F]FluorbetaOx","The Primary Endpoint is to Determine if PET/CT Measurements of Myocardial FA Metabolism Performed With [18F]FluorbetaOx Correlated With Those Performed With [11C]Palmitate and Calculation of Human Dosimetry.|To Determine Human Dosimetry Based on the Human Biodistribution of [18F](+/-)NOS in Both Normal Healthy Volunteers and Dilated Non-ischemic Cardiomyopathy Patients.","Washington University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IND113344|IRB#201208087","September 13, 2012","June 4, 2014","June 4, 2014","July 24, 2012","November 27, 2019","February 24, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01648296"
329,"NCT02500628","Heart Rate Variability in Response to Metformin Challenge",,"Completed","Has Results","Fibromyalgia|Mitochondrial Diseases|Movement Disorders|Diabetes Mellitus, Type 2","Drug: Metformin","Heart Rate Variability (Time Domain)|Heart Rate Variability (Frequency Domain)|Number of Patients Reporting Side Effects From the Medication","Woodinville Psychiatric Associates","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20150618","July 2015","February 2016","February 2016","July 16, 2015","January 3, 2018","January 3, 2018","Woodinville Psychiatric Associates, Woodinville, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02500628"
330,"NCT00879060","Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy",,"Unknown status","No Results Available","Myocardial Fibrosis|Hypertrophic Cardiomyopathy","Drug: spironolactone","changes in serum markers of collagen turnover|measures of diastolic function by echocardiography|cardiac mass and fibrosis by cardiac magnetic resonance imaging (CMR)|exercise tolerance by exercise VO2max and Holter","Tufts Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","K23HL086745-01A1","November 2007","November 2011","November 2012","April 9, 2009",,"April 9, 2009","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00879060"
331,"NCT03437044","Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI","OPTIMUS-6","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 2|Coronary Artery Disease","Drug: Ticagrelor|Drug: Clopidogrel","P2Y12 reaction units (PRU)|Platelet reactivity index (PRI)","University of Florida|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ESR 13396","March 14, 2018","June 27, 2019","August 2020","February 19, 2018",,"April 30, 2020","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03437044"
332,"NCT01806077","Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors",,"Completed","No Results Available","Vascular Disease|Coronary Artery Disease Risk Factors Multiple","Drug: PZ-128","Summary of Participants Experience with Safety and Tolerability|Pharmacokinetic profile of PZ-128|Evaluate inhibition of ex vivo platelet function in response to multiple agonists|Correlate PZ-128 plasma levels with inhibition of platelet aggregation|Evaluate changes in clotting characteristics at each dose level of PZ-128 relative to baseline","Tufts Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|Sinai Hospital of Baltimore","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TMC-A2012-04|P50HL110789","April 2013","November 2014","November 2014","March 7, 2013",,"April 21, 2016","Sinai Hospital of Baltimore (Sinai Center for Thrombosis Research), Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01806077"
333,"NCT03844191","A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4",,"Completed","No Results Available","Coronary Disease","Drug: RUC-4 Compound","Platelet Inhibition|Platelet inhibition","CeleCor Therapeutics|Precision For Medicine|CirQuest Labs|CRL","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","44","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CEL-01","February 18, 2019","November 1, 2019","December 1, 2019","February 18, 2019",,"February 19, 2020","The Lindner Research Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03844191"
334,"NCT00878878","Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).",,"Completed","Has Results","Pulmonary Hypertension","Drug: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|Drug: Dextrose","Observed the Change of Pulmonary Artery Systolic Pressure (PASP) Measured by Millimeters of Mercury (mm hg) Within Certain Time Periods. This is Per Sequence and Not a Cross-over Study.|Observed the Change of Pulmonary Vascular Resistance (PVR) Measured by Wood Units Within Certain Time Periods. This is Per Sequence and Not a Cross-over Study.|Recorded Any Adverse Events From the Optison and Control Solution (5% Dextrose) Used in Subjects With Normal and Elevated Pulmonary Artery Systolic Pressure (PASP. This is Per Sequence and Not a Cross-over Study.","GE Healthcare|ICON Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","GE-191-004","March 2009","July 2010","July 2010","April 9, 2009","August 24, 2012","August 24, 2012","ICON Development Solutions, Elliott City, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00878878"
335,"NCT01590979","Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation",,"Terminated","Has Results","Atrial Fibrillation New Onset|Hemorrhage|Prolonged QTc Interval|Ventricular Tachycardia|Medical Care; Complications, Late Effect of Complications","Drug: Ranolazine|Drug: Placebo","Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients","Northwell Health|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Not Applicable","54","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Bekheit-Ranolazine","April 2012","June 2015","June 2015","May 3, 2012","March 23, 2017","March 23, 2017","Staten Island University Hosptial, Staten Island, New York, United States",,"https://ClinicalTrials.gov/show/NCT01590979"
336,"NCT01109992","Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET","IDEALPET","Completed","Has Results","Coronary Artery Disease","Drug: Exercise plus Regadenoson (Lexercise)|Drug: Regadenoson (Lexiscan)","Safety and Tolerability of Combined Exercise and Regadenoson Stress|Image Quality: Heart to Liver Ratio of Counts|Changes in Left Ventricular Function With Dual Exercise and Regadenoson PET|Peak Stress Myocardial Blood Flow","Brigham and Women's Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","43","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BWH","February 2011","June 6, 2017","June 6, 2017","April 23, 2010","October 25, 2018","October 25, 2018","Brigham and Womens' Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT01109992/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01109992"
337,"NCT02120339","Carvedilol PAH A Pilot Study of Efficacy and Safety",,"Terminated","No Results Available","Pulmonary Hypertension|Cardiac MRI <40","Drug: Carvedilol","Mean change in RVEF|Absence of Adverse Events","University of Minnesota","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PAH","May 2014","June 2015","June 2016","April 22, 2014",,"July 12, 2019","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02120339"
338,"NCT01546454","Relationship Between the Menstrual Cycle and Heart Disease in Women",,"Completed","Has Results","Coronary Heart Disease","Drug: Ethinyl Estradiol-Levonorgestrel combination|Drug: leuprolide acetate|Drug: Estradiol|Drug: Progesterone","Total to HDL Cholesterol Ratio","Oregon Health and Science University|Medical Research Foundation, Oregon","Female","21 Years to 40 Years   (Adult)","Not Applicable","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB8023","February 2012","June 2012","January 2013","March 7, 2012","October 23, 2014","March 22, 2017","Oregon Health & Sciences University, Department of Obstetrics and Gynecology, Women's Health Research Unit, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01546454"
339,"NCT00979940","Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)","ESTATE","Terminated","Has Results","Coronary Artery Disease","Drug: Atorvastatin","Periprocedural Myonecrosis","Indiana University School of Medicine|National Center for Research Resources (NCRR)|Indiana University","All","21 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0712-15|1470","November 2008","June 2014","August 2014","September 18, 2009","September 22, 2015","September 22, 2015","Methodist Hospital, Indianapolis, Indiana, United States|Wishard Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT00979940"
340,"NCT01078363","Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy",,"Completed","Has Results","Cardiac Allograft Vasculopathy","Drug: ramipril|Drug: Placebo","Cardiac Allograft Vasculopathy(CAV) Defined as Change in IVUS-assessed Plaque Volume From Baseline to One Year|Percentage of Participants With ≥20% Coronary Artery Diameter Reduction After Acetylcholine|ADMA Level at One Year Post Transplant|The Percentage of Endothelial Progenitor Cells ( EPC) in Peripheral Blood in Patients One Year After Transplant|Fractional Flow Reserve (FFR) at One Year Post Transplant|Index of Microcirculatory Resistance at One Year Post Heart Transplant","Stanford University|VA Palo Alto Health Care System|Cedars-Sinai Medical Center","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","96","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","SU-12162009-4562|16155 (William Fuller Fearon)","June 2009","April 2015","April 2015","March 2, 2010","July 27, 2016","January 26, 2017","VA Palo Alto Health Care System, Palo Alto, California, United States|Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01078363"
341,"NCT02932969","Study With Healthy Japanese and Non-Asian Participants With BMS-986231",,"Completed","No Results Available","Heart Decompensation, Acute","Drug: BMS-986231|Drug: BMS-986231 Placebo","Safety and tolerability of single continuous IV infusion of BMS-986231 in healthy Japanese and Non-Asian participants based on Adverse events, clinical laboratory values, vital signs, ECGs, and physical examinations","Bristol-Myers Squibb","All","18 Years to 40 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV013-018","October 4, 2016","May 26, 2017","May 26, 2017","October 13, 2016",,"May 31, 2017","West Coast Clinical Trials, Llc, Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT02932969"
342,"NCT01721967","Ranolazine for the Treatment of Chest Pain in HCM Patients","RHYME","Completed","Has Results","Hypertrophic Cardiomyopathy","Drug: Ranolazine","QT Interval|Number of Adverse Events Considered Probably or Possibly Related to Study Drug|Drug Tolerability|Improvement in Number of Episodes of Angina Per Week|Seattle Angina Questionnaire (SAQ)|Kansas City Cardiomyopathy Questionnaire (KCCQ)","Duke University|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00039302|3938381","November 2012","November 2015","May 2016","November 6, 2012","January 18, 2017","March 3, 2017","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01721967"
343,"NCT02889549","Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease",,"Unknown status","No Results Available","Coronary Artery Disease","Drug: ticagrelor|Drug: clopidogrel","Inhibition of platelet aggregation|Endothelial Function","First Affiliated Hospital of Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","SCAD-20160901","August 2016","October 2017",,"September 5, 2016",,"February 23, 2017","VerifyNow, San Diego, California, United States|Endothelial Function detection by brachial artery ultrasound, Harbin, China",,"https://ClinicalTrials.gov/show/NCT02889549"
344,"NCT02013037","The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation","DUET","Active, not recruiting","No Results Available","Antibody-mediated Rejection|Hyperacute Rejection of Cardiac Transplant|Left Ventricular Dysfunction|Cardiac Allograft Vasculopathy|Heart Graft Dysfunction","Drug: Eculizumab","Incidence of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction|Incidence of Hemodynamic Compromise at 6 months post transplant|Incidence of Hemodynamic Compromise at 1 year post transplant|Incidence of Acute Cellular Rejection (ACR) and/or Antibody Mediated Rejection (AMR)|Patient Survival at 12 months Post Heart Transplantation|Development of Cardiac Allograft Vasculopathy (CAV) at 1 year post transplant|Presence of Inflammatory and Complement Biomarkers at routine endomyocardial biopsies|Change in Panel Reactive Antibody (PRA) from baseline to 1 year post transplant|Presence of Donor Specific Antibody (DSA)","Cedars-Sinai Medical Center|Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSR 205237|Pro00028970","November 2012","August 30, 2019","December 31, 2019","December 17, 2013",,"August 22, 2019","Cedars Sinai Medical Center, Heart Institute, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02013037"
345,"NCT01052428","Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)","P1A1","Completed","Has Results","Mitral Regurgitation","Drug: metoprolol succinate (Toprol XL)|Drug: Placebo","Left Ventricular End Diastolic Volume Indexed to Body Surface Area|Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume|Left Ventricular End-Diastolic Radius to Wall Thickness|Left Ventricular End Systolic Volume Indexed to Body Surface Area|Left Ventricular Ejection Fraction|Systolic Longitudinal Strain|Peak Early Filling Rate: Rate of Change Over Time","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","38","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","F040601008","August 2004","July 2010","July 2010","January 20, 2010","April 16, 2012","November 22, 2012","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01052428"
346,"NCT02651272","Macitentan in Pulmonary Hypertension of Sickle Cell Disease","MENSCH","Completed","No Results Available","Pulmonary Hypertension|Sickle Cell Disease","Drug: macitentan","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assess change in Right atrial pressure (RAP), Right ventricular pressure (RVP), Systolic pulmonary artery pressure (SPAP), and Diastolic pulmonary artery pressure (PADP), measured in mmHg.|Assess change in Cardiac output (CO) measured in L/min|Assess change in Cardiac index (CI) measured in L/min/m^2|Assess change in systemic vascular resistance measured by the following formula: Systemic Vascular Resistance (SVR) = 80x(Mean Arterial Pressure - Mean Venous Pressure or CVP) / Cardiac Output|Assess change in Right ventricular function assessed by pressure-volume loop measurements|Assess change in 6 minute walk test|Assess change of Borg Dyspnea Index|Assess change in NYHA/WHO functional classification|Assess change in cardiac biomarkers (BNP, NT-pro-BNP)","Boston University|Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","H-33165","July 2015","December 18, 2019","December 18, 2019","January 8, 2016",,"February 11, 2020","Boston University School of Medicine, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02651272"
347,"NCT01554800","Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease",,"Completed","No Results Available","Coronary Artery Disease|Atherosclerosis","Drug: ACP-501","Summary of Participants Experience with Safety and Tolerability|Pharmacokinetic profile|Change in High-Density Lipoprotein-Cholesterol (HDL-C) value following a single dose","MedImmune LLC|National Heart, Lung, and Blood Institute (NHLBI)","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACP 501-01|12-H-0092","March 2012","September 2012","September 2012","March 15, 2012",,"March 14, 2019","Cardiovascular and Pulmonary Branch (CPB) of NIH, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01554800"
348,"NCT00955266","A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass",,"Terminated","Has Results","Diastolic Dysfunction","Drug: Calcium Chloride|Drug: Placebo","Diastolic Dysfunction|Return to Cardiopulmonary Bypass Secondary to Hemodynamic Instability|Need for Inotropic or Vasopressor Support Upon Leaving the OR|Length of Hospital Stay (Days)|Length of ICU Stay (Days)","Brigham and Women's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2009-P-000052","July 2009","February 2010","February 2010","August 10, 2009","May 22, 2017","May 22, 2017","Brigham and Womens Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00955266"
349,"NCT02462941","Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart",,"Completed","No Results Available","Sinus Bradycardia|Atrioventricular Block","Drug: Adenosine|Procedure: Cardiac catheterization","Incidence of sinus bradycardia or atrioventricular block with low-dose adenosine administration that is greater than 12 seconds and requires hemodynamic intervention (ventricular escape pacing).|Prevalence of inducing atrioventricular block (defined as a single non-conducted P wave) at adenosine doses lower than suggested starting dose (100µg/kg) in PALS algorithm.","Columbia University","All","6 Months to 25 Years   (Child, Adult)","Phase 1","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAO8054","July 2015","April 2016","July 2017","June 4, 2015",,"February 8, 2018","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02462941"
350,"NCT01201785","Aspirin Dosing in Diabetic Patients",,"Completed","Has Results","Type 2 Diabetes Mellitus|Coronary Artery Disease","Drug: Aspirin","Collagen Induced Aggregation","University of Florida","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UFJ 2008-88","January 2009","September 2010","September 2010","September 15, 2010","March 6, 2012","March 6, 2012","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01201785"
351,"NCT03005184","Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2",,"Withdrawn","No Results Available","Heart Failure NYHA Class I|Heart Failure NYHA Class II|Heart Failure NYHA Class III","Drug: Valsartan 80 mg bid|Drug: Enalapril 10 mg bid|Drug: Sacubitril-Valsartan 200 mg bid|Drug: Icatibant|Drug: Placebo","change in systolic blood pressure|change in plasma cGMP|heart rate|renal plasma flow|glomerular filtration rate|change in diastolic blood pressure|fractional excretion of sodium|urine albumin-to-creatinine ratio|brain natriuretic peptide (BNP) to N-terminal pro-BNP ratio|plasminogen activator inhibitor-1|tissue plasminogen activator|aldosterone|urine cGMP","Vanderbilt University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB#161306","September 2017","January 2020","January 2020","December 29, 2016",,"January 11, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03005184"
352,"NCT01156571","A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)","CHAMPION","Completed","Has Results","Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome","Drug: cangrelor P2Y12 (platelet) inhibitor|Drug: Clopidogrel - 300 or 600 mg (study arm)|Drug: Clopidogrel 600 mg post cangrelor","The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)|Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)|Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild","The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","11145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMC-CAN-10-01","September 2010","December 2012","December 2012","July 5, 2010","June 18, 2013","February 4, 2014","Anderson Area Medical Center, Anderson, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01156571"
353,"NCT01567826","Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy","YELLOW","Completed","Has Results","Coronary Artery Disease","Drug: standard of care lipid therapy|Drug: Aggressive lipid therapy","Lipiscan - Lipid Core Burden Index (LCBI)|LCBI4mm Max|Change in LCBI4mm Max|Change in LCBI, Lesion|Intravascular Ultrasound (IVUS) Parameters|Fractional Flow Reserve (FFR) Value|Diameter Stenosis|Post PCI Cardiac Enzymes|Major Adverse Cardiac Events (MACE)|Blood Chemistry - HsCRP","Annapoorna Kini|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 4","87","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","GCO 09-1294|IF1292822","May 2010","February 2012","February 2012","March 30, 2012","February 27, 2017","May 19, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01567826"
354,"NCT03772613","The Randomized OPTIMAL-ACT Trial",,"Recruiting","No Results Available","Coronary Artery Disease|Ischemic Heart Disease|Anticoagulant-induced Bleeding|Coronary Syndrome","Drug: Unfractionated heparin","Primary Study Endpoint: Bleeding|Primary Safety Endpoint: Composite of Net Adverse Clinical Events (NACE)|Stent Thrombosis","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","546","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","18-005209","February 8, 2019","January 2021","January 2022","December 11, 2018",,"October 15, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03772613"
355,"NCT01260584","The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease",,"Completed","Has Results","Coronary Artery Disease","Drug: Prasugrel|Drug: Clopidogrel","Inhibition of Platelet Aggregation (IPA) in Prasugrel-treated and Clopidogrel-treated Smokers and Non-smokers Following 9 Days of Maintenance Therapy.|Assessment of P2Y12 Reaction Units (PRU) by Treatment and Smoking Status|Assessment of Vasodilator Stimulated Phosphoprotein (VASP) by Treatment and Smoking Status|Responder Rate by Treatment and Smoking Status Based on P2Y12 Reaction Units (PRU) <= 235|Responder Rate by Treatment and Smoking Status Based on Platelet Reactivity Index (PRI) <= 50%|Characterization of the Pharmacokinetics (PK) Area Under Curve (AUC)(0-Last) of the Active Metabolite of Prasugrel and the Active Metabolite of Clopidogrel in Smokers and Non-smokers|Characterization of the Pharmacokinetics (PK) Cmax of the Active Metabolite of Prasugrel and the Active Metabolite of Clopidogrel in Smokers and Non-smokers","Daiichi Sankyo, Inc.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CS747S-B-U4002","November 2010","September 2011","September 2011","December 15, 2010","December 12, 2012","January 9, 2019","Sanai Center for Thrombosis Research, Baltimore, Maryland, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States|The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01260584"
356,"NCT01158703","Aspirin and Plavix Following Coronary Artery Bypass Grafting","ASAP-CABG","Terminated","Has Results","Coronary Graft Patency","Drug: clopidogrel|Drug: sugar pill|Drug: Aspirin","Incidence of More Than 50% Stenosis in Graft With Combination Therapy With Aspirin and Clopidogrel vs. Aspirin Alone|Incidence of Bleeding Between the Two Treatment Arms|Number of Major Adverse Cardiovascular Events With Combination Therapy|Number of Angina Events|Number of Myocardial Infarction Events|Number of Thrombotic Events","Ahmad Slim|Bristol-Myers Squibb|Brooke Army Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C.2009.120","July 2010","December 2014","December 2014","July 8, 2010","May 19, 2015","May 19, 2015","Brooke Army Medical Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01158703"
357,"NCT03265431","Evaluation of PET/MR in Patients Selected for Ablation Therapy",,"Recruiting","No Results Available","Arrhythmias, Cardiac","Drug: 18F-TPP","TPP imaging in Ventricular Arrhythmia","Massachusetts General Hospital","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016P002123","July 1, 2016","June 1, 2022","June 1, 2023","August 29, 2017",,"April 1, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03265431"
358,"NCT01848899","Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography",,"Completed","Has Results","Coronary Artery Disease","Drug: Iodixanol|Drug: Ioxaglate|Drug: Bivalirudin","Thrombin Generation Test: Baseline|Thrombin Generation Test: After Coronary Angiography|Percent Change in Maximal Platelet Aggregation: Epinephrine|Percent Change in Maximal Platelet Aggregation: Arachidonic Acid|Percent Change in Maximal Platelet Aggregation: ADP","NYU Langone Health|Guerbet","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","12-02409","February 2013","November 2013","November 2014","May 8, 2013","April 6, 2016","April 6, 2016","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01848899"
359,"NCT01330589","Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort","INDUCE-it","Withdrawn","No Results Available","Acute Coronary Syndrome","Drug: Placebo|Drug: St. Johns Wort","Mean platelet reactivity (as measured in platelet reactivity units) on day 7 and day 21","Lancaster General Hospital|H G Barsumian MD Memorial Fund|Louise von Hess Medical Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2010-56-LGH","April 2011","March 2015","March 2015","April 7, 2011",,"October 5, 2017","Lancaster General Hospital, Lancaster, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01330589"
360,"NCT03137537","Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.",,"Recruiting","No Results Available","Lymphoma|Autonomic Imbalance|Cancer Survivorship","Drug: Ivabradine|Drug: Placebo Oral Tablet","To Investigate Whether Ivabradine Lowers Resting HR, Compared To Placebo, In Survivors Of Lymphoma|To Evaluate Whether Ivabradine Improves Exercise Duration, Compared To Placebo, In Survivors Of Lymphoma","Dana-Farber Cancer Institute|Amgen","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17-022","February 27, 2018","April 30, 2021","April 30, 2023","May 2, 2017",,"December 18, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03137537"
361,"NCT03940651","Cardiac and Renal Biomarkers in Arthroplasty Surgery",,"Recruiting","No Results Available","Renal Injury|Anesthesia|Myocardial Injury|Arthropathy of Knee|Arthropathy of Hip","Drug: Spinal Anesthesia|Drug: General Anesthetics","Incidence of myocardial injury defined by new Hs-cTnI elevation postoperatively|Investigate the effect of spinal anesthesia on biomarker levels in hip arthroplasty population|Investigate the effect of spinal anesthesia on biomarker levels in knee arthroplasty population|Investigate the effect of general anesthesia on biomarker levels in hip arthroplasty population|Investigate the effect of general anesthesia on biomarker levels in knee arthroplasty population|Incidence of postoperative renal injury using investigational renal biomarkers|Difference renal biomarkers levels according to anesthesia groups - Pain scores and the incidence of intraoperative hypotension|Difference renal biomarkers levels according to anesthesia groups - Pain medication consumption and the incidence of intraoperative hypotension|Difference in cardiac biomarker levels according to surgical groups - Pain scores, pain medications consumption and the incidence of intraoperative hypotension|Difference in cardiac biomarker levels according to surgical groups - Pain scores and the incidence of intraoperative hypotension|Difference in renal biomarker levels according to surgical groups - Pain medication consumption and the incidence of intraoperative hypotension|The effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on renal biomarkers - Pain scores and the incidence of intraoperative hypotension|The effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on renal biomarkers - Pain medication consumption and the incidence of intraoperative hypotension","Washington University School of Medicine|Abbott|BioMérieux","All","60 Years and older   (Adult, Older Adult)","Phase 4","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201812100","September 4, 2019","May 2020","December 2020","May 7, 2019",,"September 9, 2019","Washington University, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03940651"
362,"NCT03934905","Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction",,"Recruiting","No Results Available","Anthracycline Related Cardiotoxicity in Breast Cancer","Drug: sulforaphane|Drug: Placebo Oral Tablet","Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies|Elevation of troponin levels as a surrogate evidence of DOX related cardiotoxicity will be checked at baseline, prior to each DOX therapy and then at 1 year from baseline assessment (Each cycle is 14 days).|Tumor size in patients on DOX therapy with or without sulforaphane treatment will be assessed at baseline, at completion of DOX chemotherapy (4 cycles planned with each cycle being 14 days) and at 1 year from baseline assessment.","Texas Tech University Health Sciences Center","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","L19-065","December 1, 2019","June 1, 2021","June 1, 2022","May 2, 2019",,"December 13, 2019","Texas Tech University Health Sciences Center, Lubbock, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03934905/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03934905/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03934905"
363,"NCT01012414","Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease","VINCA-CKD","Terminated","Has Results","Coronary Artery Disease|Chronic Kidney Disease|Hypovitaminosis D|Secondary Hyperparathyroidism","Drug: paricalcitol|Drug: placebo","Change in High Sensitivity-C Reactive Protein (Serum)|Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A|Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure.|Effect on Carotid Intima-media Thickening (CIMT)","Thomas Jefferson University|Abbott","All","18 Years and older   (Adult, Older Adult)","Phase 3","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09C.110","January 2010","May 2011","May 2011","November 13, 2009","November 11, 2013","May 20, 2014","Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01012414"
364,"NCT03888066","Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)","DIAMOND","Recruiting","No Results Available","Hyperkalemia","Drug: Patiromer|Drug: Placebos","Time to first occurrence of CV death or CV hospitalization (or equivalent in outpatient clinic)|Proportion of subjects on ≥ 50% of guideline-recommended target dose of RAASi medications|Total HF hospitalizations|Kansas City Cardiomyopathy Questionnaire (KCCQ)","Relypsa, Inc.|Vifor Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","2388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Relypsa","April 25, 2019","December 31, 2021","March 31, 2022","March 25, 2019",,"April 20, 2020","Investigator Site 11-080, Alexander City, Alabama, United States|Investigator Site 11-041, Huntsville, Alabama, United States|Investigator Site 11-048, La Mesa, California, United States|Investigator Site 11-017, Long Beach, California, United States|Investigator Site 11-035, Pasadena, California, United States|Investigator Site 11-047, Thousand Oaks, California, United States|Investigator Site 11-058, West Hills, California, United States|Investigator Site 11-007, Littleton, Colorado, United States|Investigator Site 11-020, Bradenton, Florida, United States|Investigator Site 11-028, Brandon, Florida, United States|Investigator Site 11-011, Daytona Beach, Florida, United States|Investigator Site 11-003, Doral, Florida, United States|Investigator Site 11-014, Hialeah, Florida, United States|Investigator Site 11-078, Homestead, Florida, United States|Investigator Site 11-004, Jacksonville, Florida, United States|Research Site 11-001, Miami Lakes, Florida, United States|Research Site 11-002, Miami Lakes, Florida, United States|Investigator Site 11-006, Miami, Florida, United States|Investigator Site 11-005, Miami, Florida, United States|Investigator Site 11-032, North Miami Beach, Florida, United States|Investigator Site 11-039, Ocala, Florida, United States|Investigator Site 11-025, Orlando, Florida, United States|Investigator Site 11-015, Columbus, Georgia, United States|Investigator Site 11-031, Arlington Heights, Illinois, United States|Investigator Site 11-051, Hazel Crest, Illinois, United States|Investigator Site 11-063, Peoria, Illinois, United States|Investigator Site 11-069, Richmond, Indiana, United States|Investigator Site 11-061, Owensboro, Kentucky, United States|Investigator Site 11-026, Baton Rouge, Louisiana, United States|Investigator Site 11-022, West Monroe, Louisiana, United States|Investigator Site 11-027, Baltimore, Maryland, United States|Investigator Site 11-008, Saint Louis, Missouri, United States|Investigator Site 11-054, Linden, New Jersey, United States|Investigator Site 11-040, Manhasset, New York, United States|Investigator Site 11-053, Richmond Hill, New York, United States|Investigator Site 11-021, Stony Brook, New York, United States|Investigator Site 11-075, Charlotte, North Carolina, United States|Investigator Site 11-019, Fayetteville, North Carolina, United States|Investigator Site 11-064, Lorain, Ohio, United States|Investigator Site 11-042, Marion, Ohio, United States|Investigator Site 11-056, Hillsboro, Oregon, United States|Investigator Site 11-091, Jackson, Tennessee, United States|Investigator Site 11-092, Dallas, Texas, United States|Investigator Site 11-060, Fort Worth, Texas, United States|Investigator Site 11-072, Gonzales, Texas, United States|Investigator Site 11-009, Houston, Texas, United States|Investigator Site 11-016, Houston, Texas, United States|Investigator Site 11-033, Houston, Texas, United States|Investigator Site 11-079, Houston, Texas, United States|Investigator Site 11-034, Katy, Texas, United States|Investigator Site 11-029, Lampasas, Texas, United States|Investigator Site 11-010, McKinney, Texas, United States|Investigator Site 11-046, McKinney, Texas, United States|Investigator Site 11-045, Milwaukee, Wisconsin, United States|Investigator Site 61-002, Pleven, Bulgaria|Investigator Site 62-010, Mariánské Lázně, Czechia|Investigator Site 32-002, La Tronche, France|Investigator Site 32-005, Montpellier, France|Investigator Site 32-001, Nancy, France|Investigator Site 32-004, Paris, France|Investigator Site 32-003, Pau, France|Investigator Site 32-006, Toulon, France|Investigator Site 63-007, Tbilisi, Georgia|Investigator Site 63-011, Tbilisi, Georgia|Investigator Site 63-004, Tbilisi, Georgia|Investigator Site 63-002, Tbilisi, Georgia|Investigator Site 63-006, Tbilisi, Georgia|Investigator Site 63-008, Tbilisi, Georgia|Investigator Site 63-010, Tbilisi, Georgia|Investigator Site 63-003, Tbilisi, Georgia|Investigator Site 63-009, Tbilisi, Georgia|Investigator Site 63-001, Tbilisi, Georgia|Investigator Site 63-005, Tbilisi, Georgia|Investigator Site 64-002, Budapest, Hungary|Investigator Site 64-011, Budapest, Hungary|Investigator Site 64-005, Nyiregyhaza, Hungary|Investigator Site 65-014, Katowice, Poland|Investigator Site 65-016, Kraków, Poland|Investigator Site 65-002, Kraków, Poland|Investigator Site 65-012, Kędzierzyn-Koźle, Poland|Investigator Site 65-019, Olsztyn, Poland|Investigator Site 65-015, Ostrowiec Świętokrzyski, Poland|Investigator Site 65-013, Oława, Poland|Investigator Site 65-021, Pomorskie, Poland|Investigator Site 65-003, Poznań, Poland|Investigator Site 65-008, Rzeszów, Poland|Investigator Site 65-009, Tychy, Poland|Investigator Site 65-010, Wrocław, Poland|Investigator Site 65-005, Wrocław, Poland|Investigator Site 65-011, Zgierz, Poland|Investigator Site 65-001, Łódź, Poland|Investigator Site 37-007, Barcelona, Spain|Investigator Site 37-002, Barcelona, Spain|Investigator Site 37-008, Valencia, Spain|Investigator Site 39-006, Chesterfield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03888066"
365,"NCT03218384","Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency",,"Recruiting","No Results Available","Iron-deficiency","Drug: Ferric Carboxymaltose|Drug: Placebo","Effects of ferric carboxymaltose 750 mg vs. placebo on change in skeletal muscle mitochondrial oxidative capacity|Change in 6-minute walk test distance from baseline to 4 weeks|Change in Kansas City Cardiomyopathy Questionnaire score from baseline to 4 weeks","NYU Langone Health","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","17-00444","September 7, 2017","August 2020","August 2020","July 14, 2017",,"October 4, 2019","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03218384"
366,"NCT01792830","Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","CABG-D/C","Completed","Has Results","Poor Glycemic Control","Drug: Metformin|Drug: Glargine insulin|Drug: Glulisine","Efficacy, Measured by a Change in HbA1c Levels|Number of Participants Readmitted to the Hospital|The Number of Participants Experiencing a Hypoglycemic Event|The Number of Participants Experiencing a Severe Hypoglycemic Event|Number of Participants Experiencing a Hyperglycemic Event","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","175","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00056365","October 2012","February 2014","February 2014","February 15, 2013","October 29, 2015","September 24, 2018","Grady Memorial Hospital, Atlanta, Georgia, United States|Emory Midtown Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01792830"
367,"NCT00832572","Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy",,"Terminated","Has Results","Coronary Artery Disease|Pain|Peripheral Nervous System Diseases|Polyneuropathy","Drug: Ranolazine|Drug: Placebo","Reduction in Neuropathic Pain|Assess Participant Quality of Life Utilizing the Short Form 36 Health Survey (SF-36v2) Questionnaire|Response to Thermal and Mechanical Stimuli","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CVT 3042","January 2009","June 2009","June 2009","January 30, 2009","June 30, 2014","June 30, 2014","Cardiovascular Institute of the South Clinical Research Corporation, Houma, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00832572"
368,"NCT01754259","Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD","RAND-CFR","Completed","Has Results","Diabetes, Type I|Diabetes, Type II|Angina|Coronary Artery Disease","Drug: Ranolazine|Drug: Placebo","Change in Post-exercise Coronary Vasodilator Reserve|Change in LV Diastolic Function","Brigham and Women's Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","47","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","2012P002537","April 2013","October 2015","December 2015","December 21, 2012","July 24, 2017","July 24, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01754259"
369,"NCT02635542","Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery",,"Completed","Has Results","Neuromuscular Blockade|Postoperative Complications","Drug: Succinylcholine|Drug: Cisatracurium","Number of Participants With Postoperative Pulmonary Complications|Surgical Conditions","University of Chicago","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","15-1016","March 2016","September 15, 2017","September 15, 2017","December 21, 2015","July 17, 2018","July 17, 2018","University of Chicago Medicine, Chicago, Illinois, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02635542/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02635542"
370,"NCT02954510","Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney Disease",,"Enrolling by invitation","No Results Available","Coronary Artery Disease","Drug: ferumoxytol","Detect the absence of ≥50% stenosis in the coronary artery tree|Detect stenosis in proximal and distal segments of the coronary artery tree|Compare ferumoxtyol enhanced magnetic resonance angiography with stress echocardiography","Brigham and Women's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","185","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016P000250","February 1, 2017","November 1, 2021","February 27, 2022","November 3, 2016",,"February 15, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02954510"
371,"NCT03549598","d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis",,"Recruiting","No Results Available","Cardiac Sarcoidosis","Drug: 68Ga-DOTATATE PET/CT|Drug: 18FDG PET/CT scan|Drug: 13NH3 PET/CT scan","68Ga-DOTATATE uptake with Cardia Sarcoidosis (CS)|18FDG uptake with Cardia Sarcoidosis (CS)|13NH3 PET/CT uptake with Cardia Sarcoidosis (CS)|Physician confidence in study interpretation|Patient Satisfaction","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18-000393","July 20, 2018","June 1, 2019","May 20, 2020","June 8, 2018",,"August 15, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03549598"
372,"NCT02934555","Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest",,"Recruiting","No Results Available","Cardiac Arrest","Drug: Ubiquinol|Dietary Supplement: Ensure","Oral ubiquinol absorption|Decreased neurological injury|Cellular oxygen consumption|Global oxygen consumption|Mortality|Neurological outcome","Beth Israel Deaconess Medical Center|Kaneka Pharma America LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","2015P000319","March 2016","December 2019","December 2019","October 17, 2016",,"April 26, 2019","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02934555"
373,"NCT03289481","Treatment of HFpEF With Nitrate Supplement",,"Completed","Has Results","Heart Failure With Normal Ejection Fraction","Dietary Supplement: Active lozenge|Drug: Placebo","Time on Treadmill|Metabolic Equivalents|E/E Prime|Estimated Right Ventricular Systolic Pressure","Penobscot Bay Medical Center|HumanN","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","13","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Neo40 Study","June 29, 2017","August 22, 2018","August 22, 2018","September 21, 2017","August 26, 2019","August 26, 2019","Penobscot Bay Medical Center, Rockport, Maine, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03289481/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT03289481/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03289481"
374,"NCT01001767","Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease",,"Completed","Has Results","HIV Infections|Heart Disease","Drug: Lovaza|Drug: Placebo","Change in Flow Mediated Dilation (FMD) of the Brachial Artery","University Hospitals Cleveland Medical Center|The Campbell Foundation|Case Western Reserve University|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","35","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","AIDS 10-08-24","April 2009","March 2010","June 2010","October 27, 2009","April 9, 2012","January 7, 2015","University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01001767"
375,"NCT00989911","Endothelin Blockade in Patients With Single Ventricle Physiology",,"Completed","Has Results","Congenital Heart Disease","Drug: Bosentan","Pulmonary Blood Flow as Determined by MRI Velocity Encoding at 3-6 Months","University of California, Los Angeles|Actelion","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Actelion - 1","May 2010","March 2013","March 2013","October 6, 2009","January 13, 2015","February 27, 2015","UCLA Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00989911"
376,"NCT03485222","Are the ""Cardiac Benefits"" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).","EMPA-TROPISM","Completed","No Results Available","Cardiovascular Diseases","Drug: Empagliflozin|Drug: Placebos","Left Ventricle-end systolic volume (ESV)|LV-end diastolic volume (EDV)|LV-Ejection Fraction index|VO2 Consumption|6 min walk test|Kansas Cardiomyopathy questionnaire (KCCQ-12)","Icahn School of Medicine at Mount Sinai|Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 4","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 17-2457","May 21, 2018","February 13, 2020","February 13, 2020","April 2, 2018",,"February 25, 2020","Mount Sinai Heart - Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03485222"
377,"NCT03574337","Residual Neuromuscular Blockade in Cardiac Surgery Patients",,"Not yet recruiting","No Results Available","Residual Neuromuscular Blockade","Drug: Sugammadex|Drug: neostigmine/glycopyrolate","Time from arrival in CVICU until extubation|Tidal volumes prior to extubation|Need for unplanned noninvasive positive pressure ventilation or high flow nasal cannula|Lowest documented pulse oximetry|Number of participants requiring re-intubation|Bronchoscopy|Pneumonia|Intensive care unit length of stay|Mortality","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Henryford","August 1, 2018","December 30, 2018","March 30, 2019","July 2, 2018",,"July 2, 2018","Henry Ford Health Systems, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03574337"
378,"NCT03387605","Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine",,"Recruiting","No Results Available","Heart Failure|Cardiogenic Shock|Tachycardia","Drug: Ivabradine|Drug: Placebo","Heart rate|cardiac index|plasma brain natriuretic peptide (BNP) level","Loyola University|Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","209939","March 15, 2018","January 2020","June 2020","January 2, 2018",,"May 23, 2019","Loyola University Medical Center, Maywood, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03387605"
379,"NCT04023110","Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab","CCTGuide Pilot","Recruiting","No Results Available","Cardiotoxicity|Risk Factor, Cardiovascular|Toxicity Due to Chemotherapy|Breast Cancer|Cardiomyopathies|Heart Failure","Drug: Carvedilol","Left Ventricular Ejection Fraction (LVEF)|Treatment adherence as measured by pill count|Adverse Events|Diastolic function (E/e') by echocardiogram|Ventricular-arterial coupling measured by echocardiogram|Cardiac Strain measurements by echocardiogram|Frequency of individuals with clinical heart failure|High-sensitivity Troponin (hsTnT) level|N-terminal pro B-type natriuetic peptide (NTproBNP) level","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Older Adult)","Phase 1","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","UPCC12118","August 9, 2019","February 2022","February 2023","July 17, 2019",,"October 4, 2019","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04023110"
380,"NCT01979445","Cangrelor to Clopidogrel or Prasugrel Transition Study","BRIDGE","Completed","Has Results","Coronary Artery Disease (CAD)","Drug: Cangrelor|Drug: Clopidogrel|Drug: Prasugrel","Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor To Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or Clopidogrel Alone|Extent Of Preservation Of Platelet Inhibitory Effect Of Cangrelor Treatment After Prasugrel Or Clopidogrel Compared To Treatment With Cangrelor Alone|Extent of Preservation Of Platelet Inhibitory Effect After Transition From Cangrelor to Prasugrel Or Clopidogrel Compared With Effect Observed With Prasugrel Or Clopidogrel Alone Determined By VerifyNow P2Y12 Assay|Extent of Preservation of Platelet Inhibitory Effect of Cangrelor Treatment After Prasugrel or Clopidogrel Compared to Treatment With Cangrelor Alone Determined By VerifyNow P2Y12 Assay|Bleeding Events In Accordance With GUSTO Scale","The Medicines Company","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","MDCO-CAN-13-02","December 2, 2013","January 20, 2014","January 20, 2014","November 8, 2013","March 5, 2018","February 26, 2020","Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01979445"
381,"NCT01655524","The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion","ASSUAGE-MPI","Suspended","No Results Available","Coronary Artery Disease","Drug: ASSUAGE Protocol","Summed Difference Score (SDS); a measure of size and severity of ischemia (heart muscle in jeopardy) detected with regadenoson nuclear stress of the heart (standard vs. ASSUAGE protocol).|Agreement rate in the SDS burden category (normal/mild, moderate or severe)","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","ASSUAGE-MPI Trial","July 2012","August 2014","December 2014","August 2, 2012",,"March 18, 2014","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01655524"
382,"NCT01690884","Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake",,"Completed","No Results Available","Coronary Artery Disease","Drug: Adenosine","Interstitial levels of adenosine","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","120477","August 2012","January 2017","January 2017","September 24, 2012",,"February 28, 2018","Autonomic Dysfunction Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01690884"
383,"NCT01036802","Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease",,"Terminated","Has Results","Pulmonary Hypertension","Drug: Warfarin|Drug: Placebo","Effect of Anticoagulation on Pulmonary Artery Systolic Pressure Was Obtained by Doppler Echocardiography|6-minute Walk Test|Thrombin Generation|Platelet Activation|Endothelial Activation|All-cause Mortality|Major and Minor Bleeding Complications","University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI)","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","3","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","09-1596|R01HL094592-01A1","December 2009","September 2012","September 2012","December 21, 2009","February 21, 2014","May 9, 2016","University of North Carolina, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01036802"
384,"NCT01046604","Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery",,"Unknown status","No Results Available","Mitral Valve Regurgitation|Left Atrium Dilatation and Hypertrophy|Mitochondrial Dysfunction in the Heart|Cardiomyocyte Apoptosis|Cardiac Inflammation","Drug: Lovaza group","Specific Aim 1: To determine if Lovaza treatment reduces markers of inflammation and improves mitochondrial function in atrial myocardium|Specific Aim 2: To determine if Lovaza treatment alters the biophysical and biochemical organization of cardiac mitochondrial membranes. The following questions will be addressed using the blood and cardiac tissue samples collected as described above:","East Carolina University|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ECUomega3-01","January 2010","October 2013","December 2013","January 12, 2010",,"September 10, 2013","Brody School of Medicine, Greenville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01046604"
385,"NCT03210909","Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants",,"Completed","No Results Available","Heart Decompensation, Acute","Drug: BMS-986231","Area Under the Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC[0-T])|Percent of Total Radioactivity Recovered in All Excreta (% total)|Half-Life (T-HALF)|Total Body Clearance (CLT)|Volume of Distribution during Terminal Elimination Phase (Vz/F)|Time to Maximum Observed Concentration (Tmax)|Incidence of adverse events (AEs)|Results of electrocardiogram tests (ECGs)|Results of vital sign measurements|Results of clinical laboratory tests","Bristol-Myers Squibb","Male","18 Years to 50 Years   (Adult)","Phase 1","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CV013-022","June 22, 2017","July 20, 2017","July 20, 2017","July 7, 2017",,"August 1, 2017","Covance Clinical Research Unit, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03210909"
386,"NCT00893984","Alternative in Beta Blocker Intolerance: The ABBI Trial","ABBI","Terminated","Has Results","Coronary Artery Disease","Drug: Nebivolol","Number of Participants With Intolerance of Bystolic, Measured by Side Effect(s) That Lead to Discontinuance of Bystolic by the Patient and/or the Physician|Number of Participants With Termination of Bystolic Stratified by Reason|Incidence of Same Symptom Stopping Bystolic as Previous Beta Blocker|Number of Participants With Mild Symptoms","Minneapolis Heart Institute Foundation|Forest Laboratories","All","21 Years and older   (Adult, Older Adult)","Phase 4","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","pre001","May 2009","June 2012","June 2012","May 6, 2009","July 17, 2019","August 6, 2019","Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00893984"
387,"NCT01874561","Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization",,"Completed","No Results Available","Cardiac Conduction and Repolarization","Drug: Custirsen|Drug: Placebo|Drug: Moxifloxacin","Individually-corrected QT interval (QTcI)|Fridericia-corrected QT interval (QTcF)|Heart rate, PR interval, QRS interval and uncorrected QT interval|ECG morphological patterns|QTc (QTcI and QTcF) Intervals|Assay sensitivity|Maximum observed plasma concentration (Cmax)|Time to maximum observed plasma concentration (Tmax)|Area under the plasma concentration-time curve (AUC0-t)|Area under the curve from time 0 to infinity (AUC0-∞)|Percentage of AUC0-∞ due to extrapolation from the time of last measurable concentration to infinity|Area under the curve from time 0 to 24 hours (AUC0-24)|Terminal elimination rate constant (kel)|Apparent terminal half life (t½)|Apparent volume of distribution (Vz)|Apparent total body clearance (CL)|Occurrence of Adverse Events","Achieve Life Sciences|Teva Pharmaceutical Industries","Male","18 Years to 45 Years   (Adult)","Phase 1","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TV1011-TQT-108","May 2013","December 2013","January 2014","June 11, 2013",,"October 10, 2016","Teva Investigational Site 10565, Lenexa, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01874561"
388,"NCT02697448","Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: propofol|Drug: sevoflurane","procedure duration","Medical University of South Carolina","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00044072","February 2016","February 2021","February 2021","March 3, 2016",,"April 24, 2020","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02697448"
389,"NCT01927640","Dexmedetomidine for Reversal of Cocaine's Effects on the Heart",,"Completed","No Results Available","Chest Pain|Acute Coronary Syndrome","Drug: Dexmedetomidine|Drug: Normal Saline|Drug: Intranasal cocaine","Myocardial Perfusion","Cedars-Sinai Medical Center|Lincy Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pro19549","February 1, 2013","January 15, 2014","January 15, 2014","August 22, 2013",,"January 14, 2020","Cedars-Sinai, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01927640"
390,"NCT02829034","Targeting Right Ventricle in Pulmonary Hypertension Gilead",,"Completed","Has Results","Pulmonary Hypertension","Drug: Ranolazine|Drug: Placebo","Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)|Percent Change in 6min-walk-test Distance|Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)","University of Pennsylvania|Brigham and Women's Hospital|University of Maryland, College Park|Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","824808","July 2016","December 2017","January 2018","July 12, 2016","February 26, 2019","February 26, 2019","University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02829034/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02829034"
391,"NCT02121184","Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes",,"Recruiting","No Results Available","Pregnancy|Labor Pain","Drug: Routine oxytocin|Drug: Half-dose oxytocin","Incidence of non-reassuring fetal heart rate tracings during the first 60 minutes after the placement of epidural analgesia","Northwestern University","Female","18 Years to 60 Years   (Adult)","Not Applicable","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","STU00074673","April 2014","April 2021","April 2021","April 23, 2014",,"April 11, 2019","Prentice Women's Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02121184"
392,"NCT03354273","An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)",,"Recruiting","No Results Available","Coronary Artery Disease (CAD)","Drug: PET MPI|Drug: SPECT MPI|Drug: Pharmacological stress agents","Diagnostic efficacy of Flurpiridaz (18F) Injection PET MPI in the detection of significant CAD|Diagnostic efficacy of Flurpiridaz (18F) Injection PET MPI compared with SPECT MPI in the detection of CAD","GE Healthcare|Pharmaceutical Product Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","552","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-265-303|2017-005011-14","June 8, 2018","September 2020","September 2020","November 27, 2017",,"October 30, 2019","Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California- Los Angeles, Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Health Care System, Los Angeles, California, United States|VA San Diego Health System, San Diego, California, United States|Tower Saint John's Imaging, Santa Monica, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Alfieri Cardiology, Newark, Delaware, United States|Cardiology Physicians PA/Red Clay Research LLC, Newark, Delaware, United States|University of Florida, Gainesville, Florida, United States|Indago Research and Health Center, Hialeah, Florida, United States|Amavita Clinical Research, LLC, North Miami Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Mercy Medical Center, Des Moines, Iowa, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|VA St. Louis Health Care System, Saint Louis, Missouri, United States|St Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University Medical Center/New York Presbyterian Hospital - Milstein Hospital Building, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OhioHealth Research Institute, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Berks Cardiologists, LTD, Wyomissing, Pennsylvania, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Vital Heart & Vein, Humble, Texas, United States|Memorial City and Katy Cardiology Associates, Katy, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|Turku University Hospital, Turku, Finland|Hopital Cote de Nacre, Caen, France|Groupe Hospitalier Bichat Claude Bernard, Paris, France|Universitätsklinikum der RWTH Aachen, Aachen, Germany|Universitätsklinikum Essen, Essen, Germany|VU Medisch Centrum, Amsterdam, Netherlands|Amphia Ziekenhuis - WCN - PPDS, Breda, Netherlands|Catharina Hospital, Eindhoven, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT03354273"
393,"NCT01839110","Targeting the Right Ventricle in Pulmonary Hypertension",,"Completed","Has Results","Pulmonary Hypertension","Drug: Ranolazine|Drug: Placebo","Changes in Right Ventricular Ejection Fraction","University of Pennsylvania|The Cardiovascular Medical Research and Education Fund|Brigham and Women's Hospital|University of Maryland, College Park|Yale University|Washington University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","817785","July 2013","January 2018","January 2018","April 24, 2013","December 19, 2018","February 5, 2019","University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT01839110/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01839110"
394,"NCT02347111","Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: Flecainide|Drug: Sotalol","AF burden (Percent of time subject is in atrial fibrillation)","University of Illinois at Chicago|Medtronic","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VR9644","February 2015","June 2020","June 2020","January 27, 2015",,"May 3, 2018","University of Illinois at Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02347111"
395,"NCT02415803","Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS",,"Unknown status","No Results Available","Non ST Segment Elevation Acute Coronary Syndrome","Drug: low-dose ticagrelor|Drug: conventional-dose ticagrelor|Drug: Clopidogrel","the differences in mean inhibition of platelet aggregation or inhibition ratio (%)|Number of bleeding events|Number of difficulty breathing events|number of ventricular pauses|number of myocardial infarction events|number of death events|number of stroke events|number of severe recurrent ischemia events","First Affiliated Hospital of Harbin Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","ACS-1","December 2014","December 2016",,"April 14, 2015",,"April 14, 2015","VerifyNow, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT02415803"
396,"NCT01917721","Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease",,"Recruiting","No Results Available","Kawasaki Disease|Coronary Aneurysm","Drug: Doxycycline|Drug: Placebo","Coronary artery diameter change|Assess the change in MMP-9 level|Assess a change in TIMP level","Hawaii Pacific Health","All","1 Month to 21 Years   (Child, Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013-005","October 2013","November 2022","November 2022","August 7, 2013",,"August 28, 2019","Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT01917721"
397,"NCT01823510","Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients",,"Completed","Has Results","Type-2 Diabetes Mellitus|Coronary Artery Disease","Drug: Ticagrelor + Aspirin|Drug: Clopidogrel + Aspirin","Thrombus Formation|Platelet Reactivity|P2Y12 Reaction Unit (PRU)|Platelet Reactivity Index (PRI)","Juan J Badimon|AstraZeneca|Icahn School of Medicine at Mount Sinai","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","GCO 13-0208","July 2013","May 10, 2016","May 10, 2016","April 4, 2013","September 1, 2017","December 8, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01823510"
398,"NCT01505296","Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation","CABAL","Withdrawn","No Results Available","Atrial Fibrillation","Drug: Antiarrhythmic drug|Procedure: Catheter ablation","Percentage of AF burden|All-death death","Valley Health System|Biosense Webster, Inc.","All","Child, Adult, Older Adult","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BWI-IIS-0143","December 2011","January 2014","January 2014","January 6, 2012",,"December 16, 2014","Valley Health System, Ridgewood, New Jersey, United States|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01505296"
399,"NCT02265796","Ranolazine Among Unrevascularized Chronic Stable Angina Patients","IMWELL","Completed","Has Results","Angina","Drug: Ranolazine|Drug: Sugar pill","Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks|Subjective Well Being|Ischemia Driven Revascularization or Hospitalization","North Florida Foundation for Research and Education|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","149-2013","September 2014","May 2016","September 2016","October 16, 2014","December 4, 2017","August 22, 2019","North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02265796"
400,"NCT02925546","A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets",,"Completed","No Results Available","Heart Failure, Congestive","Drug: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|Drug: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|Drug: GSK2798745 milled API without SLS and hypermellose (Tablet C)","Area under the curve (AUC) of GSK2798745|Maximum plasma concentration (Cmax) of GSK2798745|Time to maximum observed concentration (Tmax) of GSK2798745|Elimination half-life (T1/2) of GSK2798745|AUC of GSK2798745 following a standard Food Drug Administration (FDA) high fat, high calorie meal|Cmax of GSK2798745 following a standard FDA high fat, high calorie meal|Systolic and diastolic blood pressure as a measure of safety and tolerability of GSK2798745|Pulse rate as a measure of safety and tolerability of GSK2798745|Respiratory rate as a measure of safety and tolerability of GSK2798745|Safety and tolerability of single dose of GSK2798745 as assessed by electorcardiograms (ECGs)|Safety and tolerability of single dose of GSK2798745 as assessed by hematology|Safety and tolerability of single dose of GSK2798745 as assessed by clinical chemistry|Safety and tolerability of single dose of GSK2798745 as assessed by urinalysis|Safety and tolerability of single dose of GSK2798745 as assessed by liver function tests (LFTs)|Safety and tolerability of single dose of GSK2798745 as assessed by weight assessments|Safety and tolerability of single dose of GSK2798745 as assessed by appetite assessments|Safety and tolerability of single dose of GSK2798745 as assessed by troponin measurement|Number of subjects with any adverse events (AEs) as a measure of safety and tolerability of GSK2798745","GlaxoSmithKline","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","204725","October 2016","December 2016","December 2016","October 6, 2016",,"January 25, 2017","GSK Investigational Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02925546"
401,"NCT01215253","Ranolazine Implantable Cardioverter-Defibrillator Trial","RAID","Completed","Has Results","Ischemic Cardiomyopathy|Nonischemic Cardiomyopathy|Heart Failure","Drug: Ranolazine","Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death|Number of Patients With VT or VF Requiring ICD Shock or Death|Number of Recurrent Episodes of VT or VF Requiring Antitachycardia Pacing (ATP) or ICD Shock Therapies|Number of Patients With First Inappropriate ICD Shock|Number of Patients With Hospitalization for Cardiac Causes or Death, Whichever Occurred First.|Number of Patients With Heart Failure Hospitalization or Death, Whichever Occurred First|Death|Mean Meters Walked in 6 Minutes|Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)|Number of Recurrent Inappropriate ICD Shocks","University of Rochester","All","21 Years and older   (Adult, Older Adult)","Phase 3","1012","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U01HL096607","September 2011","February 28, 2017","February 28, 2017","October 6, 2010","June 15, 2018","August 27, 2018","University of Arizona, Tucson, Arizona, United States|Arkansas Cardiology, Little Rock, Arkansas, United States|Sequoia Hospital, East Palo Alto, California, United States|Good Samaritan Hospital, Los Angeles, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Regional Cardiology Associates, Sacramento, California, United States|Delta Heart and Medical Clinic, Stockton, California, United States|University of Colorado Health - MHS, Colorado Springs, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|Washington Electrophysiology/Cardiovascular Research Institute, Washington, District of Columbia, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|University of Florida/Cardiovascular Medicine, Gainesville, Florida, United States|University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States|Watson Clincia Center for Research Inc., Lakeland, Florida, United States|Florida Hospital, Orlando, Florida, United States|Tallahassee Research Institute, Inc., Tallahassee, Florida, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Georgia Arrhythmia Consultants, Macon, Georgia, United States|University of Chicago Hospital, Chicago, Illinois, United States|Peakview Research Center, Fort Wayne, Indiana, United States|LaPorte Hospital, Hobart, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|MedStar Southern Maryland Hospital Center, Clinton, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Massachusetts-Worchester, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|William Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri, Columbia, Missouri, United States|Kansas City Heart Foundation, Kansas City, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Morristown Memorial Hospital- Gagnon Cardiovascular Institute, Morristown, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|St. Luke's-Roosevelt Hospital, New York, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|The Valley Hospital, Ridgewood, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center,, Stony Brook, New York, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Center for Research & Education, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The MetroHealth System - Heart and Vascular Dept., Cleveland, Ohio, United States|The Toledo Hospital/Northwest Ohio Cardiology Consultants, Toledo, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Portland VA Medical Ctr, Portland, Oregon, United States|Abington Medical Specialists, Abington, Pennsylvania, United States|Doylestown Cardiology Associates - VIAA, Doylestown, Pennsylvania, United States|Doylestown Health Cardiology/Central Bucks, Doylestown, Pennsylvania, United States|Lancaster Heart & Stroke Foundation, Lancaster, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center-Presbyterian, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare Center, Pittsburgh, Pennsylvania, United States|Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United States|Brigham and Women's Cardiovascular Associates, Warwick, Rhode Island, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|Cardiopulmonary Research Science and Technology Inst., Dallas, Texas, United States|Medicus Alliance CRO, Inc, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Cardiovascular Associates Ltd., Chesapeake, Virginia, United States|Walter Reed NMMC, Portsmouth, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Cardiac Study Center, Tacoma, Washington, United States|CAMC Institute, Charleston, West Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Wheaton Franciscan All Saints, Racine, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Queen's University, Kingston, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|CHUS (Sherbrooke University), Sherbrooke, Quebec, Canada|IUCPQ, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01215253/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT01215253/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01215253"
402,"NCT03188705","CES1 Carriers in the PAPI Study",,"Enrolling by invitation","No Results Available","Heart Diseases|Coronary Disease|Coronary Artery Disease|Cardiovascular Diseases|Myocardial Ischemia|Artery Occlusion|Aspirin Sensitivity|Clopidogrel, Poor Metabolism of|Platelet Dysfunction|Platelet Thrombus","Drug: Clopidogrel|Drug: Aspirin","Changes in Platelet Function in Response to Clopidogrel|Changes in Platelet Function in Response to Clopidogrel Plus Aspirin","University of Maryland, Baltimore","All","20 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HP-00075567","October 14, 2019","September 2020","September 2020","June 15, 2017",,"November 12, 2019","Amish Research Clinic, Lancaster, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03188705"
403,"NCT03237546","The Use of Serratus Block for Cardiac Surgery",,"Completed","No Results Available","Cardiac Surgery","Procedure: Anesthetic regimen including SB|Procedure: Anesthetic regimen including SB or no block","Amount of intravenous opiates used during the immediate postoperative period","NYU Langone Health","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-00070","July 17, 2017","November 13, 2017","November 13, 2017","August 2, 2017",,"March 29, 2018","New York University School of Medicine, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03237546"
404,"NCT01709981","Anti-inflammatory Effects of Colchicine in PCI",,"Active, not recruiting","No Results Available","Coronary Artery Disease","Drug: Colchicine|Drug: Placebo","Post-procedural IL-6 concentration|Post-procedural mean fluorescence intensity of cell-associated L- selectin as measured by flow cytometry|Post-procedural mean fluorescence intensity of cell-associated beta-2 integrin as measured by flow cytometry|Post-procedural concentration of interleukin-1B|Post-procedural concentration of soluble E-selectin|Post-procedural concentration of soluble L-selectin|Post-procedural concentration of intercellular adhesion molecule-1|Post-procedural concentration of vascular cell adhesion molecule|Post-procedural concentration of NGAL|Post-procedural concentration of MPO|Post-procedural concentration of neutrophil elastase|Post-procedural concentration of tumor necrosis factor-α|Post-procedural level of white blood cell count|Post-procedural peripheral neutrophil lymphocyte ratio|30-day MACE","NYU Langone Health|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 4","478","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11-02573","May 30, 2013","August 30, 2019","August 30, 2024","October 18, 2012",,"September 30, 2019","Manhattan VA Hospital, New York, New York, United States|Bellevue Hospital Center, New York, New York, United States|New York Langone Medical Center, New York, New York, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT01709981/SAP_002.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/81/NCT01709981/Prot_003.pdf","https://ClinicalTrials.gov/show/NCT01709981"
405,"NCT01201772","Prasugrel Re-load Strategies",,"Completed","Has Results","Coronary Artery Disease","Drug: Prasugrel","PRI Levels at 4 Hours","University of Florida","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UFJ 2010-49","August 2010","May 2011","September 2011","September 15, 2010","January 18, 2013","January 18, 2013","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01201772"
406,"NCT03231371","Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients","CFR-OHT","Completed","Has Results","Orthotopic Heart Transplant","Drug: Adenosine","Coronary Flow Reserve (CFR)|Gadolinium Enhancement by Cardiac MRI","Bryan Goldstein|University of Michigan","All","1 Year to 25 Years   (Child, Adult)","Phase 3","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM23585","November 2008","January 2011","January 2011","July 27, 2017","September 26, 2017","September 26, 2017","University of MIchigan-Congenital Heart Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03231371"
407,"NCT02597543","Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction",,"Completed","Has Results","Heart Transplant|Acute Graft Rejection|Chronic Graft Rejection","Drug: Regadenoson|Drug: Gadolinium|Procedure: Cardiac MRI","Myocardial Perfusion Reserve|Myocardial Ischemia/Infarction|Hospitalization for Cardiac Related Causes|Re-transplantation|Late Gadolinium Enhancement|Mean Segmental T1 Values of the Left Ventricle","Paul Kim|Astellas Pharma Inc|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","1186278","November 2015","June 30, 2016","June 30, 2016","November 5, 2015","August 22, 2017","August 22, 2017","UC San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02597543"
408,"NCT01336140","Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging","ASSUAGE-CKD","Completed","Has Results","Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson (Lexiscan ®).","Drug: Aminophylline|Drug: Placebo","Diarrhea (as Reported by the Patient)|Number of Patients With Any (One or More) Regadenoson-related Adverse-effect|Global Symptom Score (GSS) of Regadenoson Related Adverse-effects|Patients With Recorded Aminophylline Related Major Adverse Events","Rush University Medical Center|John H. Stroger Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ASSUAGE-CKD|110129","June 2011","May 2012","May 2012","April 15, 2011","February 13, 2013","February 13, 2013","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01336140"
409,"NCT02746575","Pilot - Peri-operative Beta Blockade",,"Completed","Has Results","Adrenergic Beta-Receptor Blockader|Troponin Levels|Cardiomyopathy, Post-surgical","Drug: metoprolol","Difference in hscTnI Values","Washington University School of Medicine","All","51 Years and older   (Adult, Older Adult)","Phase 4","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","201507010","November 2015","October 2016","October 2017","April 21, 2016","January 30, 2020","January 30, 2020","Barnes-Jewish Hospital/Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02746575/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02746575"
410,"NCT01232413","A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects",,"Completed","No Results Available","Healthy Subjects|Cardiac Repolarization","Drug: Placebo|Drug: ASP1941|Drug: Moxifloxacin","QTcF evaluated through electrocardiogram analysis (ECG)|Evaluation of Electrocardiogram (ECG)|QTcI evaluated through electrocardiogram analysis|QTcB evaluated through electrocardiogram analysis (ECG)","Astellas Pharma Inc","All","18 Years to 50 Years   (Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","1941-CL-0058","September 2010","February 2011","February 2011","November 2, 2010",,"February 28, 2011","West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01232413"
411,"NCT03073668","Pericardial Resection to Treat Heart Failure",,"Completed","No Results Available","Heart Failure","Procedure: Anterior pericardiotomy|Drug: Saline","Change in Pulmonary Artery Wedge Pressure (PAWP)|Change in Pulmonary Artery Pressure (PAP)|Change in Right Arterial Pressure (RAP)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-000261","March 20, 2017","January 23, 2018","February 2, 2019","March 8, 2017",,"May 14, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03073668"
412,"NCT00966654","Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery","GLP-1 CABG","Terminated","Has Results","CABG","Drug: Placebo|Drug: GLP-1 (7-36) amide","Left Ventricular Systolic Function: Pulmonary Capillary Wedge Pressure|Insulin Infusion Requirements","Johns Hopkins University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NA_00013802","September 2008","August 2009","September 2012","August 27, 2009","July 12, 2017","July 12, 2017","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00966654"
413,"NCT01794091","Detection of Diffuse Scar in Patients With Diabetes",,"Unknown status","No Results Available","Diabetes Mellitus, Type II","Drug: Eplerenone|Drug: Placebo","All cause mortality, cardiovascular death, myocardial infarction or stroke","Brigham and Women's Hospital","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","Fibrotic Index in Diabetics","August 2013","August 2017",,"February 18, 2013",,"February 18, 2013","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01794091"
414,"NCT01822821","Pain Control After Cardiac Surgery Using Intravenous Acetaminophen",,"Completed","Has Results","Pain","Drug: IV Acetaminophen|Drug: Placebo","Cumulative Opioid Consumption|Pain Intensity|Postoperative Nausea and Vomiting|Postoperative Sedation|Duration of Mechanical Ventilation (Minutes)|Intensive Care Unit (ICU) Length of Stay|Hospital Length of Stay|Alanine Aminotransferase (ALT); U/L|Aspartate Aminotransferase (AST); U/L|Total Bilirubin (mg/dL)","The Cleveland Clinic","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","13-269","March 2013","December 2014","March 2015","April 2, 2013","May 15, 2017","May 15, 2017","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01822821"
415,"NCT01544062","IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery","CarDolMev","Completed","Has Results","Acute Pain|Hyperalgesia","Drug: IV acetaminophen|Drug: Placebo","24 Hour Postoperative Opioid Consumption|48 Hour Postoperative Opioid Consumption|24 Hour Postoperative Pain Scores at Rest|48 Hour Postoperative Pain Scores at Rest|24 Hour Postoperative Pain Scores With Movement|48 Hour Postoperative Pain Scores With Movement|24 Hour Wound Hyperalgesia|48 Hour Wound Hyperalgesia|Length of Mechanical Ventilation|Length of ICU Stay|48 Hour Patient Satisfaction|24 Hour Nausea|48 Hour Nausea|24 Hour Pruritus|48 Hour Pruritus|24 Hour Sedation|48 Hour Sedation|24 Hour Respiratory Depression|48 Hour Respiratory Depression|24 Hour Dizziness|48 Hour Dizziness","University of Washington|Mallinckrodt","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","68","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","42204-D","July 2012","December 2013","August 2014","March 5, 2012","June 21, 2016","June 21, 2016","University of Washington Medical Center, Department of ANesthesiology and Pain Medicine, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01544062"
416,"NCT00953212","Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery",,"Completed","Has Results","Atrial Fibrillation|Atrial Flutter","Drug: beta blockers|Drug: amiodarone|Drug: ascorbic acid","Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery|Number of Participants With Mortality|Hospital Length of Stay|ICU Length of Stay|Number of Participants With Stroke|Number of Participants With Low Output Heart Failure|Number of Participants With Postoperative Vasoplegia|Number of Participants With Respiratory Failure Requiring Reintubation|Number of Participants With Bradycardia Necessitating Permanent Pacemaker Placement|Number of Participants With Acute Kidney Injury|Number of Participants With Readmission to ICU for Treatment of Atrial Fibrillation|Number of Participants With Readmission to Hospital for Treatment of Atrial Fibrillation","Maine Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","304","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MMC-3514","August 2009","January 2012","February 2012","August 6, 2009","March 29, 2018","April 26, 2018","Maine Medical Center, Portland, Maine, United States",,"https://ClinicalTrials.gov/show/NCT00953212"
417,"NCT02918877","Anesthetics to Prevent Lung Injury in Cardiac Surgery","APLICS","Active, not recruiting","No Results Available","Inflammatory Lung Injury|Ischemia-Reperfusion Lung Injury|Postoperative Pulmonary Complications","Drug: Sevoflurane|Drug: Propofol","Bronchoalveolar Lavage (BAL) Concentration of TNF alpha (ng/L)|Postoperative Pulmonary Complications|BAL concentration of IL1b (ng/L)|BAL concentration of IL6 (ng/L)|BAL concentration of IL8 (ng/L)|BAL concentration of MCP1 (ng/L)|BAL concentration of sRAGE (ng/L)|BAL concentration of angiopoietin 2 (ng/L)","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","2016P000306","June 9, 2017","July 1, 2020","September 1, 2020","September 29, 2016",,"March 30, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02918877"
418,"NCT01026012","Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing","Rega Stress","Completed","Has Results","Cardiac Function","Drug: regadenoson","Number of Participants With Side Effects, Including Dyspnea, Headache, Dizziness, Chest Pain, Nausea, Abdominal Discomfort, Dysgeusia, Flushing, and Symptomatic Hypotension and Others.","University of Maryland, Baltimore|Astellas Pharma US, Inc.","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HP-00040189","December 2009","September 2010","September 2010","December 4, 2009","December 19, 2014","December 23, 2019","University of MD Cardiology Physicians, Westminster, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01026012"
419,"NCT01544998","Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure",,"Completed","Has Results","Congestive Heart Failure","Drug: Nesiritide|Drug: Tadalafil|Drug: Placebo|Drug: Saline load","Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group|Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group|Change in Glomerular Filtration Rate (GFR) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group|Change in Glomerular Filtration Rate (GFR) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group|Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group|Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group","Mayo Clinic|National Center for Research Resources (NCRR)|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","43","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","11-004257|UL1RR024150|5P01HL076611","February 2012","August 2013","August 2014","March 6, 2012","March 4, 2015","March 22, 2018","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01544998"
420,"NCT03259165","Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial","N-FURIOUS","Recruiting","No Results Available","Heart Failure|Heart Failure Acute|Acute Cardiac Failure|Acute Cardiac Pulmonary Edema","Drug: Nitrates|Drug: Loop Diuretics","The total number of B-lines at the conclusion of ED AHF management|Dyspnea assessment|B-lines <= 15 at the conclusion of ED AHF management","Indiana University|Vanderbilt University","All","21 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17IRG33411129","December 14, 2017","September 2020","December 2020","August 23, 2017",,"August 28, 2019","Eskenazi Health, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03259165"
421,"NCT01916902","Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study",,"Withdrawn","No Results Available","Acute Coronary Syndrome|Coronary Artery Disease","Drug: Ticagrelor- Delayed Administration|Drug: Ticagrelor- Immediate Administration|Procedure: Optical Coherence Tomography","Total thrombus burden as measured by the volume of in-stent thrombus quantified by planimetry.|PRI (platelet reactivity index) as measured bu the PLT-VASP assay.|P2Y12 Reaction Units as measured by the VerifyNow P2Y12 assay.","Massachusetts General Hospital|AstraZeneca","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)","2013P001322","February 2014","February 2015",,"August 6, 2013",,"May 26, 2014","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01916902"
422,"NCT02016170","Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor","SWAP3","Completed","Has Results","Coronary Artery Disease|Acute Coronary Syndrome","Drug: Ticagrelor 180mg|Drug: Prasugrel 10mg|Drug: Ticagrelor 90mg","Platelet Reactivity Measured as P2Y12 Reaction Units (PRU) Determined by Verify Now-P2Y12 Assay|Platelet Reactivity Index (PRI) Measured by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP).","University of Florida","All","18 Years to 74 Years   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SWAP3","March 2014","October 2015","October 2015","December 19, 2013","October 18, 2016","October 18, 2016","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02016170"
423,"NCT00977938","The Dual Antiplatelet Therapy Study (DAPT Study)",,"Completed","Has Results","Coronary Artery Disease","Drug: Placebo & Aspirin|Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin","MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT|Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT|GUSTO Severe or Moderate Bleeding - Randomized DES ITT|MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS|Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS|MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT|Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT|GUSTO Severe or Moderate Bleeding - Randomized BMS ITT","Baim Institute for Clinical Research|Abbott|Boston Scientific Corporation|Bristol-Myers Squibb|Sanofi-Synthelabo|Cordis Corporation|Eli Lilly and Company|Daiichi Sankyo, Inc.|Medtronic","All","18 Years and older   (Adult, Older Adult)","Phase 4","25682","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HCRIG080186","October 2009","June 2014","June 2014","September 16, 2009","October 22, 2015","June 9, 2017","Thomas Hospital, Fairhope, Alabama, United States|Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Heart & Vascular Center of Arizona, Phoenix, Arizona, United States|Scottsdale Health Care, Scottsdale, Arizona, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|University of Arkansas (Central VA) for Medical Science, Little Rock, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|California Cardiovascular Consultants/ Washington Hospital, Fremont, California, United States|The Foundation for Cardiovascular Medicine, La Jolla, California, United States|Mercy General Hospital, Sacramento, California, United States|UC San Diego Medical Center, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|St. Joseph's Medical Center- CA, Stockton, California, United States|Torrance Memorial Medical Center / Vasek Polak Research Program, Torrance, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|St. Vincent's Medical Center, Stamford, Connecticut, United States|Washington Hospital Center, Washington, D.C., District of Columbia, United States|Palm Beach Heart Research Institute, Atlantis, Florida, United States|Bay Area Cardiology Associates/ Brandon Regional Hospital, Brandon, Florida, United States|Jacksonville Heart Center, Jacksonville, Florida, United States|Watson Clinic Center for Research, Lakeland, Florida, United States|Diagnostic Cardiology Associates, Lauderdale Lakes, Florida, United States|Melbourne Internal Medicine Assoc, Melbourne, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Munroe Regional Medical Center, Ocala, Florida, United States|Ocala Regional Medical Center, Ocala, Florida, United States|Florida Hospital, Orlando, Florida, United States|Baptist Hospital, Pensacola, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|Pepin Heart Hospital, Tampa, Florida, United States|Winter Haven Hospital, Winter Haven, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital Research Institute, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Medical Center Central Georgia, Macon, Georgia, United States|Redmond Regional Hospital, Rome, Georgia, United States|Advocate Good Shephard Hospital, Barrington, Illinois, United States|Jesse Brown VA Medical Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Good Samaritan Hospital- IL, Downers Grove, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|Heartland Education and Research Foundation, Joliet, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Heart Care Research Foundation, Mokena, Illinois, United States|Edward Heart Hospital, Naperville, Illinois, United States|Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana, United States|St. Vincent Heart Center of Indiana, LLC, Indianapolis, Indiana, United States|Northwest Indiana Cardiovascular Physicians, P.C., Valparaiso, Indiana, United States|McFarland Clinic PC, Ames, Iowa, United States|St. Luke's Hospital - Cedar Rapids, Cedar Rapids, Iowa, United States|Iowa Heart Center, West Des Moines, Iowa, United States|Kings Daughters Medical Center, Ashland, Kentucky, United States|Tulane University Medical School, New Orleans, Louisiana, United States|Northeast Cardiology Associates, Bangor, Maine, United States|Maine Medical Center, Portland, Maine, United States|Sinai Hospital at Baltimore, Baltimore, Maryland, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Shah Associates, LLC, Prince Frederick, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Washington Adventist Hospital, Takoma Park, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Bay Regional Medical Center, Bay City, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital Heart & Vascular Institute, Detroit, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|St. Joseph Mercy-PTCMI, Pontiac, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Covenant Medical Center, Saginaw, Michigan, United States|Great Lakes Heart & Vascular Institute, PC, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Beaumont Hospital Troy, Troy, Michigan, United States|Mayo Clinic - Saint Marys Hospital, Rochester, Minnesota, United States|Central Minnesota Heart Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Cardiology Associates Research LLC, Tupelo, Mississippi, United States|St. Luke's Hospital Mid America Heart Institute, Kansas City, Missouri, United States|Kansas City Heart Foundation, Kansas City, Missouri, United States|North Kansas City Hospital, North Kansas City, Missouri, United States|Washington University Hospital, Saint Louis, Missouri, United States|St. Louis University Hospital, Saint Louis, Missouri, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|St. John's Medical Institute, Springfield, Missouri, United States|Nebraska Heart Institute, Lincoln, Nebraska, United States|Alegent Health / Bergan Mercy Hospital, Omaha, Nebraska, United States|Creighton University, Omaha, Nebraska, United States|Catholic Medical Center, Manchester, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Cardiovascular Associates of the Delaware Valley, PA, Haddon Heights, New Jersey, United States|Hamilton Cardiology Associates, Hamilton, New Jersey, United States|Valley Hospital, Hawthorne, New Jersey, United States|UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|St. Michaels Hospital, Newark, New Jersey, United States|Presbyterian Heart Group, Albuquerque, New Mexico, United States|SJH Cardiology Associates, Liverpool, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|St. Elizabeth's Medical Center- NY, Utica, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Carolina Heart Specialists, Gastonia, North Carolina, United States|Carolina Cardiology Associates, High Point, North Carolina, United States|Wake Heart Association, Raleigh, North Carolina, United States|Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest Health Sciences, Winston-Salem, North Carolina, United States|MeritCare Medical Center, Fargo, North Dakota, United States|Altru Health System, Grand Forks, North Dakota, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Riverside Methodist, Columbus, Ohio, United States|Elyria Memorial Hospital, Elyria, Ohio, United States|Frederick C Smith Clinic dba Smith Clinic, Marion, Ohio, United States|Northwest Ohio Cardiology, Toledo, Ohio, United States|Midwest Regional Medical Center, Midwest City, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Foundation for CV Research, Oklahoma City, Oklahoma, United States|St. Vincent Hospital/ Providence Heart Hospital, Portland, Oregon, United States|Oregon Health & Sciences University Hospital, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Geisinger Clinic, Danville, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Pinnacle Health Hospital, Harrisburg, Pennsylvania, United States|Conemaugh Memorial Medical Center, Johnstown, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation for Education and Research, Sayre, Pennsylvania, United States|Berks Cardiologists, Wyomissing, Pennsylvania, United States|York Hospital (PA), York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Miriam Hospital, Providence, Rhode Island, United States|AnMed Health, Anderson, South Carolina, United States|Black Hills Research- Rapid City Regional, Rapid City, South Dakota, United States|North Central Heart Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Chattanooga Heart - East Third Street, Chattanooga, Tennessee, United States|Chattanooga Heart Institute, Chattanooga, Tennessee, United States|Centennial Heart Medical Center, Nashville, Tennessee, United States|Austin Heart, Austin, Texas, United States|Capital Cardiovascular Research Institute, Austin, Texas, United States|Texas Cardiovascular, Austin, Texas, United States|Veteran's Affairs Medical Center- Dallas, Dallas, Texas, United States|CRSTI Research, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Methodist DeBakey Heart & Vascular Center, Houston, Texas, United States|North Dallas Research Associates, McKinney, Texas, United States|North Dallas Research Associate, McKinney, Texas, United States|The Heart Hospital / Baylor Plano, Plano, Texas, United States|Scott and White Healthcare - Round Rock, Round Rock, Texas, United States|TexSan Heart Hospital, San Antonio, Texas, United States|Mother Frances Hospital, Tyler, Texas, United States|Providence Healthcare Network, Waco, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Rockingham Memorial Hospital, Harrisonburg, Virginia, United States|Lynchburg General Hospital, Lynchburg, Virginia, United States|Sentara, Norfolk General Hospital, Norfolk, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Cardiovascular Associates, Ltd., Virginia Beach, Virginia, United States|Winchester Medical Center, Winchester, Virginia, United States|Providence St. Peter Hospital, Olympia, Washington, United States|University of Washington, Seattle, Washington, United States|Inland Cardiology Associates, Spokane, Washington, United States|Sacred Heart Medical Center, Spokane, Washington, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|CaRE Foundation, Inc., Wausau, Wisconsin, United States|St. Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia|Prince of Wales Eastern Heart, Randwick, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|The Mount Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Monash Heart, Clayton, Australia|St Vincents Hospital Melbourne, Fitzroy, Australia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Krajska karlovarska nemocnice a.s., Karlovy Vary, Czechia|Centrum pro choroby srdce a cev, Kromeriz, Czechia|Mestska nemocnice Ostrava, Ostrava, Czechia|Krajska nemocnice T. Bati a.s., Zlin, Czechia|Centre Hospitalier Saint Louis, La Rochelle, France|Hospital Saint Philibert, Lomme, France|Nouvelles Cliniques Nantaises, Nantes, France|Clinique les Franciscaines, Nimes, France|Hopital Bichat, Paris, France|Groupe Hospitalier Sud, Pessac, France|CH Chatiliez Tourcoing, Tourcoing, France|Helios Klinikum Emil von Behring, Berlin, BE, Germany|Universitaetsklinikum Schleswig-Holstein - PS, Luebeck, SH, Germany|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Vivantes-Klinikum Neukoelin, Berlin, Germany|Vivantes-Klinikum Neukoelln, Berlin, Germany|Vivantes-Humboldt Klinikum, Berlin, Germany|Elbe-Kliniken Stade-Buxtehude GmbH, Buxtehude, Germany|Universitaetsklinikum Dresden, Dresden, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Elbe-Kliniken Stade-Buxtehude GmbH, Stade, Germany|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Josa Andras Oktato Korhaz Nonprofit Kft, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Klinikai Kozpont, Szeged, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Mercy Angiography, Epsom, Auckland, New Zealand|North Shore Hospital, Auckland, New Zealand|Ascot Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Nelson Hospital, Nelson, New Zealand|Wellington Hospital, Wellington, New Zealand|Wakefield Hospital, Wellington, New Zealand|Uniwersyteck Szpital Klin. w Bialymstoku, Bialystok, Poland|Wielospecj. Szpital Miejski im.dr.E.Warminskiego-SPZOZ, Bydgoszcz, Poland|NZOZ Centrum Medyczne Beluga-Med, Krakow, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|SPSK nr 2 Pomorskiej Akademii Medycznej w Szczecinie, Szczecin, Poland|Polsko-Amerykanskie Kliniki Serca.American Heart of Poland S, Ustron, Poland|Instytut Kardiologii im. Kardynala St. Wyszynskiego, Warszawa, Poland|Centrul Clinic de Urgenta de Boli Cardiovasculare al Armatei, Bucuresti, Romania|Spitalul Clinic de Urgenta Bucuresti, Bucuresti, Romania|Inst. Urgenta Boli Cardiovasculare Prof. Dr. C.C. Iliescu, Bucuresti, Romania|Institutul de Urgenta pentru Boli Cardiovasculare Prof. Dr., Bucuresti, Romania|Spitalul Clinic Universitar de Urgenta Bucuresti, Bucuresti, Romania|Institutul Inimii Niculae Stancioiu Cluj-Napoca, Cluj-Napoca, Romania|Institutul de Boli Cardiovasculare si Transplant Targu Mures, Targu Mures, Romania|Wycombe General Hospital, High Wycombe, Bucks, United Kingdom|Papworth Hospital, Cambridge, Cambs, United Kingdom|Torbay hospital, Torquay, Devon, United Kingdom|Royal Bournemouth General Hospital, Bournemouth, Dorset, United Kingdom|Basildon University Hospital, Basildon, Essex, United Kingdom|Barnet Hospital, Barnet, Herts, United Kingdom|James Cook Hospital, Middlesborough, N York, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Weston General Hospital, Weston Super Mare, Somerset, United Kingdom|Golden Jubilee National Hospital, Glasgow, Strath, United Kingdom|St Peter's Hospital, Chertsey, United Kingdom|University Hospital of Coventry and Warwickshire, Coventry, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|University Hospital of Leicester Glenfield Hospital, Leicester, United Kingdom|The London Chest Hospital, London, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00977938"
424,"NCT00910299","Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)","TRIGGER-PCI","Terminated","Has Results","Coronary Artery Disease (CAD)","Drug: Prasugrel|Drug: Clopidogrel","Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI)|Number of Participants With Stent Thrombosis (ST)|Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI)","Eli Lilly and Company|Daiichi Sankyo Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","423","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12323|H7T-MC-TACW","July 2009","April 2011","April 2011","May 29, 2009","June 8, 2012","June 8, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clearwater, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moline, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rapid City, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Berka, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Krozingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Segeberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bremen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dortmund, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fulda, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pforzheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stuttgart, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tuebingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villingen-Schwenningen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany",,"https://ClinicalTrials.gov/show/NCT00910299"
425,"NCT01737866","Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency",,"Completed","No Results Available","Heart Failure","Drug: AMG 423","AMG 423 Pharmacokinetic Parameters|Other Total AMG 423 PK Parameters|AMG 423 Dialysis Clearance|AMG 423 Metabolites|Safety","Amgen|Cytokinetics","All","18 Years and older   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080676","November 2012","January 2013","May 2013","November 30, 2012",,"August 13, 2013","Research Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01737866"
426,"NCT02120014","Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Procedure: blood volume measurement|Procedure: venous plethysmography","Total Blood Volume Measurement|venous plethysmography","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-003912","April 21, 2014","July 6, 2018","July 6, 2018","April 22, 2014",,"October 24, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02120014"
427,"NCT02053493","Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction","NEAT-HFpeF","Completed","Has Results","Heart Failure","Drug: Isosorbide Mononitrate|Drug: Placebo","Arbitrary Accelerometry Units (AAU) (Phase I)|Arbitrary Accelerometry Units (AAU) (Phase II)|Six Minute Walk Distance (Phase I)|Six Minute Walk Distance (Phase II)|Patient Preference for Isosorbide Mononitrate Treatment at the End of Study.|Borg Score During 6 Minute Walk Test (Phase I)|Borg Score During 6 Minute Walk Test (Phase II)|Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase I)|Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase II)|N-terminal Pro-B-type Natriuretic Peptide Level (Phase I)|N-terminal Pro-B-type Natriuretic Peptide Level (Phase II)|Improvement in Daily Activity - Hours Active Per Day (Phase I)|Improvement in Daily Activity - Hours Active Per Day (Phase II)|Improvement in Daily Activity - Slope of Daily Average (Phase I)|Improvement in Daily Activity - Slope of Daily Average (Phase II)|Improvement in Daily Activity - Area Under the Curve (Phase I)|Improvement in Daily Activity - Area Under the Curve (Phase II)","Adrian Hernandez|National Heart, Lung, and Blood Institute (NHLBI)|Mayo Clinic|University of Vermont|Duke University","All","50 Years and older   (Adult, Older Adult)","Phase 2","110","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00050042|4U10HL084904-10","April 2014","February 2015","March 2015","February 3, 2014","November 28, 2016","November 28, 2016","Christiana Care Health Services, Newark, Delaware, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston V.A. Healthcare System, West Roxbury, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Metro Health System, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Jefferson Medical College, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|V.A. Medical Center, Salt Lake CIty, Utah, United States|The University of Vermont - Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02053493"
428,"NCT02472353","Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer",,"Terminated","Has Results","Breast Cancer|Breast Tumors","Drug: Metformin|Drug: Doxorubicin","Number of Participants With Less Than or Equal to 5% Decrease in Left Ventricle Ejection Fraction (LVEF) on Echocardiogram","Avera McKennan Hospital & University Health Center","All","21 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AMEM-2014-MET001","July 2014","May 23, 2018","May 23, 2018","June 15, 2015","October 16, 2019","October 16, 2019","Avera Cancer Institute, Sioux Falls, South Dakota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT02472353/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02472353"
429,"NCT03879629","TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol","TACTIC","Recruiting","No Results Available","Breast Cancer","Drug: Carvedilol","Rate of asymptomatic and symptomatic cardiac dysfunction|Rate of reversible cardiac function decline|Cardiac function changes after completion of HER2-directed therapy|Gene variants and risk of cardiotoxicity and response to therapy","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","450","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-006090|R01CA233610","August 21, 2019","August 31, 2024","December 31, 2024","March 19, 2019",,"April 29, 2020","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03879629"
430,"NCT03744702","Impact of Ascorbic Acid Treatment on the Development and Treatment of Vasodilation in Cardiac Surgery",,"Enrolling by invitation","No Results Available","Vasoplegia","Drug: Ascorbic Acid","Vasopressor duration in hours|Vasopressor dose","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-003358","June 28, 2019","December 2020","June 2021","November 16, 2018",,"April 3, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03744702"
431,"NCT01274481","Iloprost Effects on Gas Exchange and Pulmonary Mechanics",,"Completed","No Results Available","Acute Respiratory Distress Syndrome|Acute Lung Injury|Pulmonary Hypertension","Drug: Iloprost","Arterial oxygenation|Lung compliance","University of Oklahoma|Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15123","March 2011","July 2012","July 2012","January 11, 2011",,"August 10, 2012","OU Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01274481"
432,"NCT01773512","The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques","PREDICT","Unknown status","No Results Available","Coronary Artery Disease","Drug: Rosuvastatin","The prediction of plaque volume and plaque composition.|Prediction of changes in plaque volume and plaque composition","General University Hospital, Prague|Ministry of Health, Czech Republic|Czech Ministry of Education|University of Iowa|Loyola University Chicago","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UK2012|IGA 2012 NT/13224","June 2012","December 2014","June 2015","January 23, 2013",,"January 23, 2013","Loyola University Hospital, Maywood, Illinois, United States|The University of Iowa, Iowa City, Iowa, United States|General University Hospital, Prague, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01773512"
433,"NCT01898442","High Ticagrelor Loading Dose in STEMI",,"Completed","Has Results","Coronary Artery Disease","Drug: Ticagrelor 180mg|Drug: Ticagrelor 270mg|Drug: Ticagrelor 360mg","Platelet Reactivity by VerifyNow P2Y12|Platelet Reactivity by VerifyNow P2Y12 at Other Time Points|Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) at All Time Points|Pharmacokinetic Profiles of Ticagrelor (Tmax)|Pharmacokinetic Profiles of Ticagrelor (Cmax)|Pharmacokinetic Profiles of Ticagrelor (AUC0-t)","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TicagSTEMI","September 2013","June 2014","June 2014","July 12, 2013","June 8, 2015","June 8, 2015","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01898442"
434,"NCT03245255","Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound",,"Recruiting","No Results Available","Cardiac Catheterization|Blood Pressure|Heart Ventricles|Echocardiography|Heart Failure","Drug: Sonazoid","Agreement between SHAPE and pressure catheter measurements|Error between SHAPE and pressure catheter measurements|Accuracy of ventricular relaxation rate and relaxation time constant","Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|GE Healthcare","All","21 Years and older   (Adult, Older Adult)","Phase 2","80","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R21HL130899","December 4, 2017","March 31, 2021","March 31, 2021","August 10, 2017",,"April 1, 2020","Thomas Jefferson University and Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03245255"
435,"NCT02830360","Antiarrhythmics or Ablation for Ventricular Tachycardia 2","VANISH2","Recruiting","No Results Available","Ventricular Tachycardia (VT)","Drug: Antiarrythmic Drug Therapy|Procedure: Catheter ablation","All-cause mortality|Appropriate ICD shock at least 14 days post randomization|VT storm at least 14 days post randomization|Sustained VT requiring treatment at least 14 days post randomziation|Incessant VT at least 14 days post randomization|Appropriate ICD ATP at any time or after 14 days|Appropriate shocks|VT storm at any time or after 14 days|Sustained VT not treated by ICD at any time or after 14 days|Incessant VT at any time or after 14 days|Time to sustained VT treated with appropriate any type of manual cardioversion after 14 days|Inappropriate ICD shocks at any time or after 14 days|Any ICD shock at any time or after 14 days|Any ventricular arrhythmia event at any time or after 14 days (composite of appropriate ATP, appropriate shock, sustained VT not treated by ICD, external cardioversion, or pharmacologic cardioversion)|Number of ICD shocks (all cause)|Number of Anti-tachycardia pacing (ATP)|Number of ICD appropriate therapy|Number of VT storm events|Number of sustained VT events|Number of ventricular arrhythmia events|Hospital admission for cardiac causes|.Ablation procedural complications or antiarrhythmic drug adverse effects (this may require a separate substudy, depending on data complexity)|Time to any serious adverse events|Side effects from anti-arrhythmic medication|Quality of life - SF36|Quality of life - EQ5D|Quality of life - HADS|Cost-effectiveness|Escalation and De-escalation of antiarrhythmic medication","John Sapp|Heart and Stroke Foundation of Canada|Abbott Medical Devices|Biosense Webster, Inc.|Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR)|Cardiac Arrhythmia Network of Canada|Abbott|Nova Scotia Health Authority","All","18 Years and older   (Adult, Older Adult)","Phase 4","366","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAPP004","October 2016","October 2021","October 2022","July 12, 2016",,"April 25, 2019","Hartford Hospital, Hartford, Connecticut, United States|Vanderbilt University Hospital, Nashville, Tennessee, United States|Foothills Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Fraser Health Authority - Royal Columbian Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|Hamilton Health Sciences Center, Hamilton, Ontario, Canada|Queen's University Health Sciences Centre, Kingston, Ontario, Canada|St. Mary's Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|Centre Hospitalier de l'Universitaire de Montreal, Montréal, Quebec, Canada|Institut Universitaire de cardiologie et pneumologie de Quebec - Laval University Hosptial, Quebec CIty, Quebec, Canada|Centre Hospitalier Univesitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Hopitaux de Bordeaux, Bordeaux, Acquitaine, France|CHU - University Hospital Nancy, Nancy, Meurthe-et-Moselle, France",,"https://ClinicalTrials.gov/show/NCT02830360"
436,"NCT02046135","Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery",,"Completed","No Results Available","Acute Kidney Injury|Congenital Heart Disease","Drug: Sodium Bicarbonate|Drug: Sodium Chloride","Acute Kidney Injury|Duration of acute kidney injury|Cumulative fluid balance|Hospital and intensive care unit length of stay|Need for dialysis|Incidence of acute kidney injury according to changes in serum NGAL.|Length of mechanical ventilation|Change in acid-base status","Northwell Health","All","up to 21 Years   (Child, Adult)","Phase 2","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-007B","September 2013","June 2017","July 22, 2017","January 27, 2014",,"December 8, 2017","Cohen Children's Medical Center of New York, New Hyde Park, New York, United States",,"https://ClinicalTrials.gov/show/NCT02046135"
437,"NCT04059679","Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy",,"Recruiting","No Results Available","Coronary Artery Disease|Peripheral Artery Disease","Drug: Rivaroxaban 2.5 Mg Oral Tablet|Drug: Aspirin 81 mg","Relative Difference in maximal ADP-induced Platelet Aggregation|Relative differences in TF-thrombin-induced platelet aggregation|Relative differences in alpha- thrombin-induced platelet aggregation|Relative differences in inflammation biomarkers|Relative differences in platelet-fibrin clot characteristics|Relative differences in shear-induced platelet aggregation|Relative differences in lag time|Relative differences in peak thrombin production|Relative differences in mean velocity rate index|Relative differences in endogenous thrombin potential","LifeBridge Health|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1436289","January 30, 2020","March 2020","March 2020","August 16, 2019",,"February 25, 2020","Sinai Hospital of Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04059679"
438,"NCT01936649","Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.",,"Completed","Has Results","Heart Failure (HF)|Ventricular Dysfunction, Left","Drug: AdreView (Iobenguane I 123 Injection)","To Assess Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake in Heart Failure (HF) Participants on Planar Imaging at 3 Hours 50 Minutes Following I.V. Injection of AdreView (Iobenguane I 123 Injection)|To Assess the Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake on Planar Imaging at 15 Minutes Following Administration of AdreView (Iobenguane I 123 Injection)","GE Healthcare|H2O Clinical LLC|Quintiles, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","63","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-122-015","August 2013","February 2014","February 2014","September 6, 2013","January 26, 2015","December 8, 2016","GE Healthcare, Princeton, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01936649"
439,"NCT01655043","Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI",,"Completed","Has Results","Myocardial Ischemia","Drug: Regadenoson|Drug: gadofoveset trisodium","Quantification of Myocardial Blood Volume","Northwestern University|Astellas Pharma Global Development, Inc.","All","19 Years to 89 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic","STU00050900|000598","September 2012","February 2014","February 2014","August 1, 2012","March 27, 2015","August 28, 2019","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01655043"
440,"NCT03774394","Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus",,"Recruiting","No Results Available","Chronic Kidney Disease (CKD)|Type 2 Diabetes Mellitus (T2DM)|Coronary Artery Disease (CAD)","Drug: Clopidogrel|Drug: Clopidogrel active metabolite","Platelet reactivity index (PRI)|Clopidogrel active metabolite concentration","University of Florida|Scott R MacKenzie Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201801870 -A","August 22, 2019","August 2020","December 2020","December 13, 2018",,"April 20, 2020","University of Florida Jacksonville, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03774394"
441,"NCT02217683","Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion",,"Withdrawn","No Results Available","Hypertension, Pulmonary|Hemolysis","Drug: Nitric Oxide","Pulmonary vascular resistance index|Hemolysis|Nitric oxide metabolites|Inflammation","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BloodiNO","March 2016","December 2016","April 2017","August 15, 2014",,"March 18, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02217683"
442,"NCT02664922","Anesthetic Techniques in EP Patients",,"Terminated","No Results Available","Cardiac Disease","Drug: Propofol|Drug: Ketamine|Drug: Remifentanil|Drug: Sevoflurane","Effectiveness of anesthetic drugs in terms of adverse effects.|Effectiveness of anesthetic drugs in terms of pain relief.|Effectiveness of anesthetic drugs in terms of patient comfort and satisfaction.|Effectiveness of anesthetic drugs in terms of identification and treatment of arrhythmias.","University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Phase 4","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Other","Anes Tech 11-003514","May 2012","September 2013","December 2013","January 27, 2016",,"January 14, 2020","Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02664922"
443,"NCT03258281","Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention","ISS-DMII","Terminated","No Results Available","Diabetes Mellitus, Type 2|Dyslipidemia Associated With Type II Diabetes Mellitus|Percutaneous Coronary Intervention","Drug: Evolocumab|Drug: Placebo","Absolute difference in ADP-stimulated P-selectin expression|Absolute differences in unstimulated and ADP-stimulated p-selectin and GPIIb/IIIa receptor expression and unstimulated CD36, and LOX-1|Absolute differences in lipid profile including LDL-C, oxLDL, fibrinogen|Prevalence of high on-clopidogrel platelet reactivity by the VerifyNow P2Y12 assa","Inova Health Care Services","All","Child, Adult, Older Adult","Phase 4","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","17-2639","May 1, 2018","September 1, 2019","September 1, 2019","August 23, 2017",,"October 10, 2019","Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03258281"
444,"NCT01120769","Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction","APRIORI Pilot","Withdrawn","No Results Available","Acute Myocardial Infarction","Drug: Acetaminophen|Drug: Placebo","Plasma isoprostane level|Index of microcirculatory resistance","Vanderbilt University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","100001","July 2011","July 2012","July 2012","May 11, 2010",,"December 7, 2015","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01120769"
445,"NCT04065919","Evaluation of Liposomal Bupivacaine Compared to Usual Care and Its Effects on Pain for Cardiac Surgery","EXPAREL","Enrolling by invitation","No Results Available","Cardiothoracic Surgery","Drug: Liposomal bupivacaine|Drug: 0.25% Bupivacaine with epinephrine","20% change in opioids use|Time to extubation|Time to ICU|Pain Scores on Post op day 2,3 and 4|Total narcotic use on Post op Day 2,3, and 4|Time to Hospital Discharge|Major Adverse Cardiac Effects of Liposomal Bupivacaine","Florida Heart and Lung Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IIT#2018-137","October 1, 2019","October 30, 2020","November 30, 2020","August 22, 2019",,"February 6, 2020","Florida Heart and Lung Institute, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04065919"
446,"NCT02973594","Pulse Reduction On Beta-blocker and Ivabradine Therapy","PROBE-IT","Recruiting","No Results Available","Dilated Cardiomyopathies, Idiopathic|Heart Failure, Systolic|Ventricular Remodeling|Electrical Remodeling","Drug: Ivabradine|Drug: Placebo","Left ventricular reverse remodeling according to heart rate response|Comparison of gene expression abundances by heart rate response|Left ventricular reverse remodeling by treatment group (ivabradine vs. placebo)","University of Colorado, Denver|American Heart Association|Ohio State University","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","16-1363","November 2016","July 2020","July 2020","November 25, 2016",,"June 13, 2019","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02973594"
447,"NCT01330108","Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension","SCOBA-PH","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: ambrisentan","Number of Subjects Not Able to Tolerate Ambrisentan|Mean Change in Distance for a Six Minute Walk at 12 Weeks Post Start of Ambrisentan","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 4","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCOBA-PH","May 2011","June 2012","June 2012","April 6, 2011","August 11, 2014","August 11, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01330108"
448,"NCT01048905","Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension",,"Completed","No Results Available","Pulmonary Hypertension|Sickle Cell Disease|Thalassemia","Drug: L-Glutamine","Change in erythrocyte glutamine/glutamate ratio, a novel biomarker of oxidative stress,post therapy compared to pre-therapy steady-state values.|Plasma Glutamine|Tricuspid Regurgitant Jet velocity on Doppler Echocardiography|6 minute walk distance|Liver function tests|Renal function tests","UCSF Benioff Children’s Hospital Oakland","All","4 Years and older   (Child, Adult, Older Adult)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R01FD003531-01|IRB 2008-059","March 2009","March 2014","March 2014","January 14, 2010",,"July 18, 2014","Children's Hospital & Research Center Oakland, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT01048905"
449,"NCT02858180","Hepatitis C Virus(HCV) Heart and Lung Study",,"Completed","Has Results","Hepatitis C, Chronic|Heart Failure|Pulmonary Disease, Chronic Obstructive|Lung Diseases, Interstitial","Drug: Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)","Number of Subjects Who Completed 24 Weeks of Therapy|Number of Subjects With Sustained Virologic Response (SVR) 12|Number of Subjects With Sustained Virologic Response (SVR) 4","Duke University|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00069602","December 2016","April 11, 2019","July 4, 2019","August 8, 2016","April 21, 2020","April 21, 2020","Henry Ford Health System, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center - Dept of Gastroenterology, Durham, North Carolina, United States|Harborview Medical Center, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02858180/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02858180"
450,"NCT03254485","A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)","CAPACITY-HFpEF","Completed","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: IW-1973|Drug: Placebo Oral Tablet","Incidence of Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs|Change From Baseline in Peak VO2 (CPET) at Week 12|Change From Baseline in 6-Minute Walk Test (6MWT) Distance at Week 12|Change From Baseline in Ventilatory Efficiency at Week 12|Number of CPET Responders at Week 12","Cyclerion Therapeutics","All","45 Years and older   (Adult, Older Adult)","Phase 2","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C1973-204","November 7, 2017","August 19, 2019","August 19, 2019","August 18, 2017",,"September 23, 2019","Arizona Arrhythmia Research Center, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Cardiology and Medicine Clinic, Little Rock, Arkansas, United States|JEHM, La Mesa, California, United States|Axis Clinical Trials, Los Angeles, California, United States|JEHM, National City, California, United States|Valley Clinical Trials, Northridge, California, United States|Stanford University, Palo Alto, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Aurora Denver Cardiology, Denver, Colorado, United States|South Denver Cardiology Associates, Littleton, Colorado, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|New Generation of Medical Research, Hialeah, Florida, United States|East Coast Institute for Research, Jacksonville, Florida, United States|PCRS Network, LLC, Miami, Florida, United States|Broward Research Center, Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|St. Luke's Regional Medical Center, Boise, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Unity Point Health - Methodist Hospital, Peoria, Illinois, United States|Franciscan Physician Network - Indiana Heart Physicians, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Lousiana Heart Center, Bogalusa, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Michigan Heart, Ypsilanti, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|VA Healthcare John Cochran Medical Center, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Medical Center (OSUMC), Columbus, Ohio, United States|ProMedica Toledo Hospital, Toledo, Ohio, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|Newton Clinical Research, Oklahoma City, Oklahoma, United States|Oklahoma Heart Institute, Tulsa, Oklahoma, United States|Oregon Health & Science University (OHSU), Portland, Oregon, United States|PeaceHealth, Sacred Heart Physicians, Springfield, Oregon, United States|Research Institute of Lancaster General Health, Lancaster, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|North Dallas Research Associates, Dallas, Texas, United States|Texas Health Research and Education Insitute, Dallas, Texas, United States|Southwest Family Medicine Associates, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Schnitzler Cardiovascular Consultants, San Antonio, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Virginia Commonwealth University Medical College of Virginia, Richmond, Virginia, United States|Madigan Army Medical Center, Tacoma, Washington, United States|Unity Point Health, Madison, Wisconsin, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|London Health Sciences Centre, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|CIUSSS de l'Estrie - CHUS, Sherbrooke, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie De Quebec, Québec, Canada",,"https://ClinicalTrials.gov/show/NCT03254485"
451,"NCT04203927","Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes","EJB051","Recruiting","No Results Available","Type2 Diabetes|Insulin Sensitivity","Drug: Empagliflozin 25 MG|Drug: Placebo oral tablet","Myocardial microvascular perfusion|Flow Mediated Dilation (FMD) Vascular measure of conduit artery stiffness Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp Vascular measure of conduit artery stiffness Flow Mediated Dilation ( FMD)|Augmentation Index ( AI)|Pulse Wave Velocity ( PWV)","University of Virginia|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 60 Years   (Adult)","Early Phase 1","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","21403|1R01HL142250-01A1","February 1, 2020","October 22, 2022","November 30, 2022","December 18, 2019",,"February 24, 2020","University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04203927"
452,"NCT02147834","Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents","IMWELL3","Terminated","Has Results","Angina","Drug: Ranolazine|Drug: Sugar pill","Seattle Angina Questionnaire Score Change From Baseline to Month 4|Subjective Well Being|Ischemia Driven Revascularization or Hospitalization","North Florida Foundation for Research and Education|Gilead Sciences|University of Florida","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","5","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201400100","August 2015","March 2016","September 2016","May 28, 2014","June 11, 2019","June 11, 2019","North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02147834"
453,"NCT02212028","Pharmacological Effects of Crushing Prasugrel in STEMI Patients",,"Completed","Has Results","Coronary Artery Disease","Drug: prasugrel","P2Y12 Reaction Units (PRU)|Platelet Reactivity Index (PRI)","University of Florida","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Prasugrel-CRUSH","October 2014","August 2015","August 2015","August 8, 2014","December 28, 2016","December 28, 2016","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02212028"
454,"NCT04083339","Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy",,"Recruiting","No Results Available","Diabetic Cardiomyopathies","Drug: AT-001|Drug: Placebo","Peak VO2 during cardio-pulmonary exercise test (CPET)|Changes in NT-proBNP|Changes in the modified Kansas City Cardiomyopathy Questionnaire (KCCQ) score|Percentages of patients with clinically significant changes in Peak VO2","Applied Therapeutics, Inc.","All","40 Years and older   (Adult, Older Adult)","Phase 3","675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AT-001-2001","September 20, 2019","September 2021","September 2023","September 10, 2019",,"October 16, 2019","Mountain View Clinical Research, Greer, South Carolina, United States|Juno Research, LLC - Northwest Site, Houston, Texas, United States|Juno Research, LLC - Southwest Houston Site, Houston, Texas, United States|Juno Research, LLC - Katy, Katy, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04083339"
455,"NCT02556918","Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","SITA-CABGDM","Completed","Has Results","Hyperglycemia","Drug: Sitagliptin|Drug: Placebo|Drug: Regular Human Insulin|Drug: Insulin glargine|Drug: Supplemental insulin (Insulin lispro)|Drug: Supplemental insulin (Insulin aspart)","Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU)|Number of Patients With Persistent Hyperglycemia|Number of Patients Requiring Continuous Intravenous Insulin Infusion (CII)|Mean Blood Glucose (BG) Concentration in the Intensive Care Unit (ICU)|Total IV Insulin in ICU|Mean Insulin Dose Per Day During Intensive Care Unit (ICU) Recovery|Duration of Continuous Intravenous Insulin Infusion (CII)|Number of Patients Requiring Subcutaneous (SQ) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)|Median Number of Days of Subcutaneous (SC) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)|Mean Post-operative Blood Glucose (BG) Concentration|Amount of Subcutaneous (SC) Insulin Taken in Intensive Care Unit (ICU)|Amount of Subcutaneous (SC) Insulin in Intensive Care Unit (ICU) 48 Hours|Number of Subjects With Hyperglycemia in Intensive Care Unit (ICU)|Number of Subjects With Hyperglycemia (Blood Glucose Greater Than or Equal to 300 mg/dL) in Non-ICU|Number of Patients With Hypoglycemic Events in Intensive Care Unit (ICU)|Number of Patients With Hypoglycemic Events in Non-intensive Care Unit (ICU)|Number of Patients With Severe Hypoglycemic Events in Intensive Care Unit (ICU)|Number of Patients With Severe Hypoglycemic Events in Non-intensive Care Unit (ICU)|Composite of Perioperative Complications|Duration of Intubation|Length of Intensive Care Unit (ICU) Stay|Total Length of Hospital Stay|Number of Intensive Care Unit (ICU) Readmission|Number of Cerebrovascular Events|Number of Subjects Readmitted to the Hospital|Number of Subjects Returning to the ER Within 30 Days","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","IRB00082180","January 2016","November 6, 2018","November 6, 2018","September 22, 2015","December 23, 2019","December 23, 2019","Grady Health System, Atlanta, Georgia, United States|Emory Univeristy Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02556918/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02556918"
456,"NCT01151579","Effect of Nebulized Bronchodilators on Heart Rate",,"Completed","Has Results","COPD|Sepsis|Shock","Drug: Levalbuterol|Drug: Albuterol","Heart Rate in Beats Per Minute|Arrhythmias|Total Number of Participants With Arrhythmias","Fahim Khorfan, MD|Ascension Genesys Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","89","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ME 07-0011","December 2008","November 2009","November 2009","June 28, 2010","October 23, 2015","October 23, 2015","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01151579"
457,"NCT00921518","Prevention of Acute Kidney Injury in Cardiac Surgery Patients",,"Completed","Has Results","Kidney Injury","Drug: 0.9% Sodium Chloride (Placebo)|Drug: Sodium Bicarbonate","Number of Participants With Acute Kidney Injury","Community Medical Center, Scranton, PA","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CMC AKICS","January 2009","January 2012","January 2012","June 16, 2009","March 11, 2014","April 15, 2014","Community Medical Center, Scranton, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00921518"
458,"NCT03109015","Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing","ASSET","Completed","No Results Available","Carcinoma, Renal Cell","Drug: Sunitinib","Change in VO2 peak from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in difference between Rest and Stress Left Ventricular Ejection Fraction (LVEF) and Cardiac Function by 2-D echocardiography (2DE) from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in difference between Rest and Stress Left Ventricular Ejection Fraction (LVEF) and Cardiac Function by 3-D echocardiography (3DE) from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in one repetition maximum (1RM) in upper and lower extremity muscular strength from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in Muscular Endurance in upper and lower extremity muscular strength from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in Muscle cross-sectional area (CSA) of the major muscles near Lumbar3 (CT scans and Slice-O-Matic® software) from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in time taken to complete the 5-repititionChair-stand test from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in time taken to complete the Timed up and Go test from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in distance walked during the 6 minute walk test from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale score from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in Functional Assessment of Cancer Therapy - Kidney Symptom Index - 19 (FKSI-19) score from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in Hospital Anxiety and Depression Survey (HADS) score from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules|Change in leisure activity score from the Godin-Leisure questionnaire from baseline to week 12 in the 4/2 and 2/1 sunitinib administration schedules","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00072588","September 27, 2017","October 8, 2019","October 8, 2019","April 11, 2017",,"October 14, 2019","Duke Cancer Institute, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03109015"
459,"NCT01760304","Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo","AZCO","Terminated","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Budesonide / Formoterol|Drug: Placebo","Cardiac Output|Lung Hyperinflation|Evaluation of O2 Pulse","Brigham and Women's Hospital|AstraZeneca","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","5","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011-P-001576/1|D589BL00021/ISSSYMB0033","January 2012","July 2012","October 2012","January 4, 2013","June 14, 2017","June 14, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01760304"
460,"NCT01185249","Congestive Heart Failure Weight Study",,"Completed","Has Results","Congestive Heart Failure","Procedure: Weigh subjects on a scale in the standing position","The Measurement of the Difference Between Early Morning and Evening Weights for CHF Patients","Central DuPage Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","10-010","August 2009","May 2010","May 2011","August 19, 2010","July 25, 2013","July 25, 2013","Central DuPage Hospital, Winfield, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01185249"
461,"NCT02133573","Randomized Trial of Maternal Progesterone Therapy",,"Active, not recruiting","No Results Available","Congenital Heart Disease|Periventricular Leucomalacia|Brain Development|Cardiac Surgery|Neurodevelopmental Disability|Fetal Neuroprotection","Drug: Progesterone|Drug: Vaginal lubricant","Motor Scale of the Bayley Scales of Infant and Toddler Development-III|Cognitive and Language Scales of the Bayley Scale of Infant and Toddler Development-III|Fetal brain growth and maturation by MRI|Myelination during fetal brain development by MRI|Brain white matter injury by MRI","Children's Hospital of Philadelphia","All","Child, Adult, Older Adult","Phase 2","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13-010710","May 2014","December 2021","December 2021","May 8, 2014",,"March 9, 2020","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02133573"
462,"NCT02577614","FEIBA and Use of Blood Products in Cardiac Surgery","FEIBA","Active, not recruiting","No Results Available","Cardiovascular Disease","Drug: FEIBA|Drug: Normal Saline","Volume of blood products transfused (mL)|Number of thrombotic or thromboembolic events|Number of patients with post-operative bleeding requiring surgical hemostasis|Duration of post-operative ventilation, ICU and hospital length of stay|Number of deaths","Oregon Health and Science University","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11975","February 2016","December 2019","March 2020","October 16, 2015",,"April 9, 2019","Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT02577614"
463,"NCT02360397","Ranolazine Mediated PVC Reduction in Ischemic Heart Disease",,"Completed","Has Results","Ventricular Premature Complexes|Myocardial Ischemia","Drug: ranolazine","The Effect of Ranolazine on the PVC Burden Over 30 Days|The Effect of Ranolazine on Cardiac Ischemia|Score on Seattle Angina Questionnaire at Baseline and at Day 30|Number of Non-sustained Ventricular Tachycardia and Sustained Ventricular Arrhythmia Episodes on Holter Monitoring","Kent Hospital, Rhode Island|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IN-US-259-1341","December 2014","December 31, 2017","February 23, 2018","February 10, 2015","January 29, 2020","January 29, 2020","Kent Hospital, Warwick, Rhode Island, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT02360397/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02360397"
464,"NCT01875185","Hormones Inflammation and Thrombosis","HIT2","Terminated","Has Results","Acute Coronary Syndrome|Thrombosis","Drug: Aspirin 81 mg","Level of Urinary Thromboxane (UTXB2) in pg/mg Creatinine|The Change in the Level of UTXB2 in pg/mg Creatinine: Estrogen and Progesterone|Level of UTXB2 in pg/mg Creatinine|Relative Change of UTXB2 in pg/mg Creatinine in Response to Aspirin","Johns Hopkins University","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NA_00079522","December 2012","November 2013","November 2013","June 11, 2013","May 7, 2018","May 7, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01875185"
465,"NCT01970462","Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery",,"Terminated","Has Results","Diabetes Mellitus, Type 2|Hyperglycemia","Drug: Sitagliptin|Drug: Placebo","Difference in Fasting Glucose","Kathleen Dungan|Ohio State University","All","18 Years and older   (Adult, Older Adult)","Phase 4","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2013H0328","January 2014","August 2016","August 2016","October 28, 2013","May 17, 2018","June 18, 2018","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01970462"
466,"NCT01815008","Pharmacogenomics of Antiplatelet Response - I","PARes-I","Completed","Has Results","Platelet Aggregation|Platelet Transcriptome|Coronary Artery Disease","Drug: Clopidogrel|Drug: Aspirin","Difference in ADP-induced Platelet Aggregation|Difference in Arachidonic Acid-induced Platelet Aggregation|Difference in Collagen-induced Platelet Aggregation|Changes in Platelet Transcriptome With Clopidogrel","Johns Hopkins University","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 4","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","K23HL105897-PARes-I|K23HL105897","October 2012","June 2014","June 2014","March 20, 2013","January 9, 2017","January 9, 2017","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01815008"
467,"NCT03241485","Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery",,"Recruiting","No Results Available","Pain","Drug: Intrathecal morphine|Drug: Placebo","Postoperative morphine consumption|Pain Score|Patient Satisfaction|Adverse effects|Cardiac arrhythmia/cardiac event|Pulmonary complication","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB17-1103","June 19, 2018","August 2021","October 2021","August 7, 2017",,"March 26, 2020","University of Chicago Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03241485"
468,"NCT03331146","Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass",,"Withdrawn","No Results Available","Acute Kidney Injury","Drug: Saline|Drug: Sodium Nitrite","Nitrite Metabolome Levels|Biomarkers of Hemolysis|Biomarkers of Kidney Injury|Cell Cycle Stress|Biomarkers of Hepatic injury|Biomarkers of Myocardial Injury|Urine Output|Vasopressors Usage","University of Alabama at Birmingham","All","19 Years to 100 Years   (Adult, Older Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","1709284471","October 1, 2018","June 1, 2019","December 1, 2020","November 6, 2017",,"September 27, 2018","UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03331146"
469,"NCT00837369","Regadenoson R-T Perfusion Imaging Trial",,"Completed","No Results Available","Coronary Artery Disease|Myocardial Perfusion Abnormalities","Drug: Regadenoson","more feasible and accurate way to detect significant coronary artery disease","University of Nebraska|Mayo Clinic|Astellas Pharma Inc","All","30 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","566-08-FB","May 2009","March 2011","December 2011","February 5, 2009",,"July 23, 2012","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medicial Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00837369"
470,"NCT01375699","Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",,"Completed","No Results Available","Breast Cancer|Gastrointestinal Cancer|Genitourinary Cancer|Sarcoma|Gynecologic Cancer","Drug: Doxorubicin|Drug: Sildenafil","Safety of concurrent sildenafil with doxorubicin-based chemotherapy|The difference in left ventricular ejection fraction (LVEF) between arms|Comparison of candidate early markers of cardiac injury","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-13419|NCI-2011-0098","August 11, 2011","August 4, 2017","January 19, 2018","June 17, 2011",,"August 26, 2019","Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01375699"
471,"NCT00938964","Lidocaine For Neuroprotection During Cardiac Surgery",,"Completed","Has Results","Cognitive Decline","Drug: Lidocaine|Drug: Placebo","Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change|Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome|Transcerebral Activation Gradients of Platelets|Transcerebral Activation Gradients of Neutrophils|Transcerebral Activation Gradients of Monocytes|Transcerebral Activation Gradient of Platelet-neutrophil Conjugates|Change in Cognitive Function From Baseline|Change in Duke Activity Status Index (DASI)|Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)|Change in Center for Epidemiological Studies Depression Scale (CES-D)|Change in Spielberger State Anxiety Inventory (STAI)|Change in Symptom Limitations|Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)|Change in the Cognitive Difficulties Scale|Change in Perceived Social Support|Change in Social Activity|Change in Study 36-Item Short Form Health Survey (SF-36)|Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)","Duke University|National Heart, Lung, and Blood Institute (NHLBI)|CAS Medical Systems, Inc.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","550","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00015641|R01HL096978","July 2009","July 18, 2016","May 23, 2017","July 14, 2009","August 24, 2017","May 10, 2019","Duke University Medical Center, Durham, North Carolina, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00938964"
472,"NCT01066637","iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.","F-NOS","Completed","No Results Available","Patients With Post Orthotopic Heart Transplantation Status","Drug: [18F](+/-)NOS","To demonstrate the feasibility of imaging patients with increased levels of iNOS using [18F](+/-)NOS.|To determine human dosimetry based on the human biodistribution of [18F](+/-)NOS in both normal adult healthy volunteers and heart transplant patients.","Washington University School of Medicine","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09-0986|201106273","September 2009","June 2017","June 2017","February 10, 2010",,"February 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01066637"
473,"NCT01474434","Efficacy of LCQ908 on Cardiovascular Risk",,"Terminated","Has Results","Coronary Artery Disease|Hypertriglyceridemia","Drug: pradigastat (LCQ908)|Drug: Placebo","Change From Baseline in Myocardial Perfusion Reserve Index (MPRi) Overall Mean (Part A, Cohort 1)|Change From Baseline in Total Exercise Duration (Part A, Cohort 1)|Time to Onset of Angina (Part A, Cohort 1)|Time to Onset of Exercise-induced Ischemia(Part A, Cohort 1)|Aortic Plaque Inflammation (Part B)|Number of Participants With Adverse Events (Part A, Cohort 1)|Number of Participants With Adverse Events (Part A, Cohort 2)|Postprandial Triglycerides (Part A, Cohort 1)|Postprandial Triglycerides (Part A, Cohort 2)|Pharmacokinetics of Pradigastat (LCQ908): Plasma Concentration (Part A)|Other Related Lipid Parameters (Part A)|Interleukin-6 (IL-6) Level (Part A)|C-reactive Protein (CRP) Level (Part A)|Adiponectin Level ( Part B)","Novartis Pharmaceuticals|Novartis","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCQ908A2213","December 2011","June 2014","June 2014","November 18, 2011","April 14, 2016","April 14, 2016","Novartis Investigative Site, Pasadena, California, United States",,"https://ClinicalTrials.gov/show/NCT01474434"
474,"NCT01245595","Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery","KIDPROAM","Completed","Has Results","Acute Kidney Injury","Drug: Aminophylline|Drug: Placebo","Acute Kidney Injury Measured by Kidney Diseases: Improving Global Outcomes (KDIGO) AKI Serum Creatinine Criteria","Stanford University","All","up to 18 Years   (Child, Adult)","Not Applicable","144","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18977","November 2010","May 2014","May 2014","November 22, 2010","June 8, 2015","June 8, 2015","Lucile Packard Childrens' Hospital, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT01245595"
475,"NCT02422446","Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects",,"Terminated","Has Results","Type 2 Diabetes|Coronary Artery Disease","Drug: Icosapent ethyl","Change From Baseline in Endothelial Function at 12 Weeks Using Reactive Hyperemia Index (RHI)","Brigham and Women's Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","2013D003968","April 2015","March 1, 2017","March 1, 2017","April 21, 2015","June 6, 2018","June 6, 2018","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02422446/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT02422446/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02422446"
476,"NCT00930631","Study of [3H] BMS747158 in Healthy Male Subjects","PPA103","Completed","No Results Available","Coronary Artery Disease","Drug: [3H] BMS747158","To assess safety and the extent and route of [3H] radioactivity eliminated (mass balance) in urine and feces following a single intravenous (IV) dose of approximately 100 (±20) µCi of [3H] BMS747158 in healthy male subjects.|To assess the pharmacokinetics (PK) of [3H] radioactivity and of [3H] BMS747158 in blood. To identify the major metabolites of [3H] BMS747158 present in blood, urine, and feces","Lantheus Medical Imaging","Male","18 Years to 45 Years   (Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BMS747158-103","June 2009","July 2009","January 2010","June 30, 2009",,"October 17, 2011","Covance Clinical Laboratory Unit, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00930631"
477,"NCT01547728","Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery",,"Terminated","Has Results","Thrombophilia Due to Acquired Antithrombin III Deficiency","Drug: Recombinant antithrombin (rhAT)","Percentage of Patients Whose Activated Clotting Time (ACT) is Prolonged Beyond 480 Seconds With Recombinant Human Antithrombin Concentrate (rhAT) Administration","Mayo Clinic|rEVO Biologics","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","42","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-004125","February 2012","February 2014","February 2014","March 8, 2012","July 15, 2015","July 15, 2015","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01547728"
478,"NCT02926027","Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy","EVAPORATE","Active, not recruiting","No Results Available","Hypertriglyceridemia","Drug: Vascepa|Drug: placebo","Progression rates of low attenuation plaque under influence of Vascepa as compared to placebo.|The morphology of non-calcified coronary atherosclerotic plaque (NCP)|markers of inflammation (Lp-PLA2)|changes in markers of LDL and HDL cholesterol|The composition of non-calcified coronary atherosclerotic plaque (NCP)","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Intermountain Research and Medical Foundation","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","21733-01","March 28, 2017","May 15, 2020","August 15, 2020","October 6, 2016",,"April 9, 2020","Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States|Intermountain Medical Center, Intermountain Heart Institute, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02926027"
479,"NCT03818776","Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC",,"Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Durvalumab|Radiation: Proton beam therapy RT","Safety of intervention as defined by number of participants with Dose Limiting Toxicities (DLT) between first dose of Durvalumab and 30 days following completion of radiotherapy.|Feasibility of intervention defined by number of participants receiving full course of RT treatment and minimum of two doses of Durvalumab|Number of participants with Adverse Events according to CTCAE v5.0","Case Comprehensive Cancer Center","All","19 Years and older   (Adult, Older Adult)","Early Phase 1","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1518","August 30, 2019","April 1, 2021","May 1, 2022","January 28, 2019",,"September 11, 2019","University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03818776"
480,"NCT04164732","Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy",,"Recruiting","No Results Available","Cardiomyopathy, Hypertrophic","Drug: LCZ696|Drug: Placebo","Change from baseline in peak VO2 as measured by cardiopulmonary exercise test (CPET)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696I12201|2019-003098-24","January 8, 2020","February 22, 2022","February 22, 2022","November 15, 2019",,"April 10, 2020","Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04164732"
481,"NCT04190433","AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR)Trial",,"Not yet recruiting","No Results Available","Lymphoma","Drug: Carvedilol|Drug: Lisinopril|Drug: Pravastatin|Drug: Spironolactone","Cardiac function changes","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-007547","January 1, 2020","June 1, 2022","December 31, 2022","December 9, 2019",,"December 9, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04190433"
482,"NCT02376010","Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium",,"Completed","No Results Available","Atherosclerosis","Drug: rivaroxaban|Drug: Warfarin","coronary artery calcium (serial calcium scans)|atherosclerotic plaque (measures of total atherosclerosis plaque on serial CCTA)","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 4","110","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","21429","April 2, 2015","April 1, 2018","April 1, 2018","March 3, 2015",,"August 6, 2018","Los Angeles Biomedical Research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT02376010"
483,"NCT03097419","Ischemic Conditioning in STEMI Patients","EDICT","Active, not recruiting","No Results Available","Cardiac Arrest","Procedure: Remote post-ischemic conditioning","Changes in the Metabolomic Profile","Beth Israel Deaconess Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012P000095","November 28, 2012","June 2021","June 2021","March 31, 2017",,"January 18, 2020","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03097419"
484,"NCT02220023","Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI","iNO","Completed","No Results Available","Pulmonary Vascular Disorder","Drug: INOmax Inhalation","Right ventricular ejection fraction (RVEF) before and after inhaled nitric oxide exposure|Pulmonary flow|Pulmonary perfusion|Estimates of pulmonary vascular resistance|Pulmonary transit time|Pulmonary artery compliance","Vanderbilt University|Mallinckrodt|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140068","July 2014","February 2017","February 2017","August 19, 2014",,"February 13, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02220023"
485,"NCT01736735","Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects","STEPWISE","Unknown status","No Results Available","Heart Failure","Drug: CLP|Drug: placebo","Composite endpoint comprised of: 6-Minute Walk Test, Body weight, KCCQ Score, Log2 NT-proBNP, time to first occurrence of heart/renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart/renal failure or death|Change in 6-Minute Walk Test distance from baseline to Week 8.|Time to heart failure or renal failure hospitalization, unscheduled outpatient intravenous or mechanical therapy for heart failure or renal failure, or death","Sorbent Therapeutics","All","21 Years and older   (Adult, Older Adult)","Phase 2","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CTST-24","January 2013","June 2014","June 2014","November 29, 2012",,"March 5, 2014","Orange Country Research Center, Tustin, California, United States|Buenos Aires, Argentina|Ashkelon, Israel",,"https://ClinicalTrials.gov/show/NCT01736735"
486,"NCT01260285","The Safety of Vardenafil in Patients Undergoing Cardiac Surgery",,"Completed","No Results Available","Ischemia-reperfusion Injury.","Drug: Vardenafil","Hypotension|Ejection Fraction","McGuire Research Institute","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01703","December 2010","October 2011","October 2011","December 15, 2010",,"November 4, 2011","McGuire VAMC, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01260285"
487,"NCT03014830","Alirocumab and Reverse Cholesterol Transport",,"Completed","No Results Available","Atherosclerosis|Coronary Heart Disease","Drug: Alirocumab|Drug: Placebos","Change from baseline in percent cholesterol excretion per day.|Change from baseline in removal rate of esterified cholesterol from plasma per day.|Change from baseline in LDL cholesterol|Change from baseline in percent cholesterol absorption","Washington University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","28","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","201612021","June 1, 2017","June 4, 2018","July 30, 2018","January 9, 2017",,"November 7, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT03014830"
488,"NCT02546388","Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis",,"Completed","Has Results","Sarcoidosis","Drug: Indium-111 Pentreotide|Drug: Gallium-68 DOTATATE","Number of Participants Characterized by Abnormal or Negative Uptake|Effect of Treatment","Marcelo F. Di Carli, MD, FACC|Mallinckrodt|Brigham and Women's Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015P001421","October 2015","August 2018","August 2018","September 10, 2015","March 25, 2020","April 9, 2020","Brigham and Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02546388/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02546388"
489,"NCT02048085","Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis","TACAT","Withdrawn","No Results Available","Acute ST Segment Elevation Myocardial Infarction|Acute Coronary Syndrome","Drug: Ticagrelor|Drug: Clopidogrel","Pharmacodynamics (PRU and IPA) of ticagrelor vs Clopidogrel using VASP and VerifyNow|Pharmacokinetic (AUC, Cmax, Tmax)","Medical Center of South Arkansas","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","ISSBRIL0224","January 2, 2014","May 2015","March 2018","January 29, 2014",,"April 4, 2018","Medical Center of South Arkansas, El Dorado, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT02048085"
490,"NCT03685175","Effect of Cardiotoxic Anticancer Chemotherapy on the Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria","HPCardiotox","Suspended","No Results Available","Breast Neoplasms","Drug: Formal study using hyperpolarized 13C-pyruvate injection|Drug: Feasible study using hyperpolarized 13C-pyruvate injection","Detect subclinical anthracycline induced cardiotoxicity using hyperpolarized carbon-13 pyruvate","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","110","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 072016-058","July 1, 2018","March 2022","March 2022","September 26, 2018",,"April 10, 2020","UT Southwestern - Advanced Imaging Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03685175"
491,"NCT02654782","Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients",,"Terminated","Has Results","Hemodynamic Stability","Drug: Lactated Ringer's|Drug: 5% Human Albumin","Total Fluid Administered Indexed to Weight|Alveolar-arterial Gradient","William C. Oliver|Mayo Clinic","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","15-000858","January 2016","October 9, 2017","October 9, 2017","January 13, 2016","April 16, 2019","April 16, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02654782/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02654782"
492,"NCT01186289","Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery",,"Withdrawn","No Results Available","Neurocognitive Dysfunction","Drug: atorvastatin","Neurocognitive Dysfunction","Duke University|Pfizer","All","50 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","PRO00020165","October 2010","October 2011","October 2012","August 23, 2010",,"October 14, 2015","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01186289"
493,"NCT03013751","A Extension Study of Udenafil in Adolescents","FUELExten","Active, not recruiting","No Results Available","Functional Single Ventricle Heart Disease","Drug: Udenafil","Safety (Adverse Events)|Exercise (Change in maximal oxygen consumption)|Echo (Change in myocardial performance Index)|Endothelial function (Change in log-transformed Reactive Hyperemia Index)|Function Health Status (Change in full scale Peds QL)|Biomarkers (Change in serum BNP level)","Mezzion Pharma Co. Ltd|National Heart, Lung, and Blood Institute (NHLBI)","All","12 Years to 18 Years   (Child, Adult)","Phase 3","300","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHN-Udenafil-03|U01HL068270","January 2017","July 2020","July 2020","January 6, 2017",,"January 13, 2020","Phoenix Children's Hospital/Children's Heart Center at Phoenix Children's Hospital, Phoenix, Arizona, United States|Cedars/Sinai Heart Institute, Los Angeles, California, United States|Rady Children's Hospital, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Cardiac Center/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Johns Hopkins All Children's Heart Institute, Saint Petersburg, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Riley Hospital for Children/Herman B. Wells Center for Pediatric Research, Indianapolis, Indiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan Congenital Heart Center/C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States|Washington University St. Louis/St.Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital of New York, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's Medical Hospital/Dept. of Pediatric Cardiology, Salt Lake City, Utah, United States|Seattle Children's Hosptial, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Sejong General Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Seoul National University Children's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03013751"
494,"NCT01867879","Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors (Excluding Breast Cancer)","Drug: TAS-102|Drug: Placebo","QTc interval|Quantitative and Qualitative ECG parameters|Relationship between TAS-102 pharmacokinetics and its effect on cardiac repolarization|Safety monitoring including adverse events, vital signs, and laboratory assessments|Tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST)","Taiho Oncology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TPU-TAS-102-103|2013-000650-21","June 2013","August 2014","April 2015","June 4, 2013",,"November 9, 2015","Sarah Cannon Research Institute, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01867879"
495,"NCT01539590","Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack",,"Terminated","Has Results","Myocardial Infarction","Drug: BB3|Drug: Normal saline","Evaluation of Reduction in Infarct Size|Evaluation of the Degree of Late Ventricular Remodeling|Change in CK-MB and Troponin|Change in BNP Levels|Change in Symptoms and Clinical Signs of CHF|Change in LVEDVI, LVESVI and LV Ejection Fraction (EF) After MI Assessed by Cine MR (SSFP Imaging)|LVEDVI, LVESVI and LVEF After MI Assessed by 2D and 3D Echocardiography|Change Between Initial Semi-quantitative Regional Wall Motion Score (17 Segment Model) by Echocardiography|Change in Regional Myocardial Radial, Circumferential and Longitudinal Strain|Frequency of MACE|Frequency of New Onset CHF Through 6 Months|Number of Hospitalizations for CHF Through 6 Months|Incidence of Complete ST Segment Resolution 60 ± 30 Minutes After Last Angiogram|Frequency of AE, SAEs|Frequency of MACCE|All-cause Mortality|Development of Ventricular Fibrillation or Other Life-threatening Arrhythmia|Change From Baseline eCrCl|Change in Body Weight|Symptoms and Clinical Signs of CHF","Angion Biomedica Corp|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 2","5","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","001-10|5R44HL091699","July 2012","July 2013","November 2013","February 27, 2012","November 4, 2014","November 21, 2014","Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Yale University Medical Center, New Haven, New York, United States",,"https://ClinicalTrials.gov/show/NCT01539590"
496,"NCT01910389","Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure","PITCH-HF","Terminated","Has Results","Heart Failure|Pulmonary Hypertension","Drug: Tadalafil|Drug: Placebo for tadalafil","Composite Outcome of Cardiovascular (CV) Mortality or Heart Failure (HF) Hospitalization|Cardiovascular Mortality|Heart Failure Hospitalization|All-cause Mortality|Composite Outcome of All-cause Mortality or CV Hospitalization (Myocardial Infarction, Acute Coronary Syndrome, Stroke, Arrhythmia, or Heart Failure)|Frequency of CV Hospitalizations|Frequency of HF Hospitalizations|Change in 6 Minute Walk Distance From Baseline to 3 Months|Change in MLHFQ Score From Baseline to 3 Months|Change in 6 Minute Walk Distance From Baseline to 18 Months|Trend in 6 Minute Walk Distance From Baseline Through 18 Months|Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score From Baseline to 18 Months|Trend in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score From Baseline Through 18 Months","HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 3","23","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U01HL105463","November 2013","February 2014","February 2014","July 29, 2013","May 4, 2015","May 4, 2015","Heart Center Inc - Research, Huntsville, Alabama, United States|Baptist Health Transplant Institute, Little Rock, Arkansas, United States|Allianz Medical and Research Center, Fountain Valley, California, United States|Christiana Care Health System, Newark, Delaware, United States|Broward Health, Ft. Lauderdale, Florida, United States|Miller School of Medicine University of Miami, Miami, Florida, United States|Orlando Health, Orlando, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Brevard Cardiovascular Research Associates, Rockledge, Florida, United States|University Cardiology Associates LLC, Augusta, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|Methodist Medical Group Cardiology, Peoria, Illinois, United States|Baptist Hospital East, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Primary Care Cardiology Research, Inc., Ayer, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MGH West, Waltham, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Covenant Center for the Heart, Saginaw, Michigan, United States|Essentia Health East, Duluth, Minnesota, United States|Metropolitan Heart and Vascular Institute, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Missouri Cardiovascular Specialists, Columbia, Missouri, United States|St. Luke's Health System, Kansas City, Missouri, United States|Glacier View Research Institute, Kalispell, Montana, United States|Advanced Heart Care, LLC, Bridgewater, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Heart & Vascular Center of NJ/Cardio Metabolic Institute, Somerset, New Jersey, United States|Bronx - Lebanon Hospital Center, Bronx, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Cardiology Associates of Schenectady, Schenectady, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States|The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, Ohio, United States|Oklahoma City VA, Oklahoma City, Oklahoma, United States|Warren Cancer Research Foundation, Tulsa, Oklahoma, United States|Lancaster Heart and Stroke Foundation, Lancaster, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Grand View - Lehigh Valley Health Service, Sellersville, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|CIVA/CArdiovascular Research Institute of Dallas, Dallas, Texas, United States|Michael E. Debakey VA Medical Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Jewish General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01910389"
497,"NCT01485757","Prospective L-arginine Study",,"Terminated","No Results Available","Heart Transplant","Drug: L-arginine","Change in peripheral endothelial function from baseline following 12 week treatment course of L-arginine.|Change from baseline in serum levels of oxidative stress markers|Change in exercise tolerance from baseline following a 12 week treatment course of L-arginine","University of Michigan","All","8 Years and older   (Child, Adult, Older Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00035716","July 2011","July 2015","July 2015","December 5, 2011",,"January 10, 2017","University of Michigan Pediatric Heart Transplant Clinic, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01485757"
498,"NCT02236026","A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers",,"Completed","No Results Available","Healthy","Drug: Supratherapuetic dose of Nestorone|Drug: Placebo|Drug: Moxifloxacin","To evaluate the effect of Nestorone (NES) administered as an IV solution on the corrected QT interval using Fridericia's formula (QTcF).","Population Council|Parexel","Female","18 Years to 40 Years   (Adult)","Phase 1","44","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","648","September 2014","December 2015","December 2015","September 10, 2014",,"August 15, 2017","Harbor Hospital, 3001 South Hanover Street, 7th Floor, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02236026"
499,"NCT01800968","Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)","FIGHT","Completed","Has Results","Acute Heart Failure","Drug: Liraglutide|Drug: Placebo","Global Ranking of Predefined Events|Change in Left Ventricular End-Diastolic Volume Index|Change in Left Ventricular End-systolic Volume Index|Change in Left Ventricular Ejection Fraction|Change in Medial Filling Pressure|Change in Lateral Filling Pressure|Change in 6 Minute Walk Distance|Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)|Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score|Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.|Individual Component of the Primary Endpoint- Mortality|Individual Component of the Primary Endpoint- Heart Failure Hospitalization|Individual Component of the Primary Endpoint- Time-averaged Proportional Change in NT-proBNP","Duke University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pro00042633|5U10HL084904-09","April 2013","October 2015","October 2015","February 28, 2013","February 15, 2017","February 15, 2017","Christiana Care Health Services, Newark, Delaware, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston VA Healtcare System, West Roxbury, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|Saint Louis University Hospital, St. Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|Southeast Regional Medical Center, Lumberton, North Carolina, United States|University Hospitals- Case Medical Center, Cleveland, Ohio, United States|Metro Health System, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lancaster Heart and Stroke Foundation, Lancaster, Pennsylvania, United States|University of Pennsylvaina, Philadelphia, Pennsylvania, United States|Jefferson Medical College, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Michael Debakey VA Medical Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Utah VA Medical Center, Salt Lake City, Utah, United States|The University of Vermont- Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT01800968"
500,"NCT01250496","Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients Undergoing Myocardial Perfusion Imaging","ASSUAGE","Completed","No Results Available","Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson (Lexiscan ®).","Drug: Aminophylline|Drug: Placebo","Composite endpoints of abdominal cramps and diarrhea.|Global symptomatic burden of regadenoson","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","248","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ASSUAGETrial","November 2010","September 2011","September 2011","November 30, 2010",,"November 28, 2012","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01250496"
501,"NCT03718429","Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies",,"Recruiting","No Results Available","Coronary Artery Disease|Peripheral Arterial Disease|Atrial Fibrillation","Drug: Rivaroxaban 2.5Mg Tablet","Platelet aggregation measured by VerifyNow PRU|Thrombin generation|Platelet aggregation measured by VASP PRI|Clot strength","University of Florida|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS-RIVA01|20180155","January 14, 2019","August 2020","December 2020","October 24, 2018",,"February 25, 2020","Cardiovascular Research Center,, Jacksonville, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03718429"
502,"NCT01444872","Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction",,"Completed","No Results Available","Heart Failure|Kidney Disease","Drug: TRV120027|Drug: Normal Saline","Change from Baseline Glomerular Filtration Rate|Change from Baseline in Vital Signs (Blood pressure, heart rate)","Trevena Inc.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","CP120027.1002","August 2011","May 2012","June 2012","October 3, 2011",,"August 27, 2012","Orlando Clinical Research Center, Orlando, Florida, United States|DaVita Clinical Research, Minneapolis, Minnesota, United States|Duke Clinical Research Unit, Durham, North Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01444872"
503,"NCT03025087","Hydroxychloroquine and Cognitive Function After Surgery",,"Suspended","No Results Available","Individuals Undergoing Cardiac and General Surgery","Drug: Hydroxychloroquine","Ratio of T1 relaxivity difference","Duke University","All","50 Years and older   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00046611","June 19, 2017","March 2021","March 2021","January 19, 2017",,"April 21, 2020","Duke Health, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03025087"
504,"NCT02020226","A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors",,"Unknown status","No Results Available","Solid Tumors","Drug: TH-302","Evaluate the potential for QT/QTc interval prolongation of TH-302 in patients with solid tumors|Evaluate association between plasma exposure to TH-302 and its active metabolite, Br-IPM, and effects on cardiac repolarization|Safety and antitumor activity of TH-302 in patients with advanced solid tumors","Threshold Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-CR-414","November 2013","July 2016","December 2016","December 24, 2013",,"June 2, 2016","The University of Arizona Cancer Center, Tucson, Arizona, United States|Yuma Regional Cancer Center, Yuma, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02020226"
505,"NCT01658553","A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212",,"Completed","No Results Available","Cancer","Drug: GSK1120212","Compare the effect of GSK1120212 on the baseline-adjusted, placebo-corrected, time-matched QTcF(QT interval corrected for heart rate by Fridericia's formula) interval duration in subjects with solid tumor cancers|Evidence of the relationships between the change in QTc(Corrected QT interval) from baseline and the plasma concentrations of GSK1120212 and predicted change in QTc(Corrected QT interval)|Plasma concentrations and PK (Pharmacokinetic) parameters of GSK1120212, including AUC(Area under concentration-time curve)(0‑24), concentration at time t (Ct), Cmax (Maximum observed concentration) and time to Cmax (tmax).|Safety parameters: AEs, vital sign (blood pressure, pulse rate and temperature), ECGs, and clinical laboratory assessments|Change in blood pressure parameters, including PP(Pulse pressure) and MABP(Mean arterial blood pressure)","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","114655","September 19, 2012","April 5, 2014","April 5, 2014","August 7, 2012",,"November 13, 2017","GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01658553"
506,"NCT02629094","Cardiometabolic Effects of Eplerenone in HIV Infection",,"Terminated","Has Results","Cardiac Steatosis|Hepatic Steatosis","Drug: Inspra /Eplerenone","Improvement of Cardiac Steatosis: Mean Change in Intraventricular Septum Percentage of Lipid by MR Spectroscopy.|Improvement of Hepatic Steatosis: Mean Change in Hepatic Percentage of Lipid by MR Spectroscopy","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","5","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160030|16-I-0030","December 2, 2015","September 11, 2017","September 11, 2017","December 14, 2015","July 17, 2018","July 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02629094/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02629094"
507,"NCT03373227","Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen","Veloxis","Active, not recruiting","No Results Available","Heart Transplant Rejection|Graft Failure|Compliance, Patient","Drug: Envarsus","Rejection and Graft Failure|Effect of Compliance on Rejection and Graft Failure","Baylor Research Institute","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRI 017-178","December 4, 2017","December 2022","December 2022","December 14, 2017",,"July 11, 2019","Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03373227"
508,"NCT02832115","Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention","TNT-RASP","Completed","No Results Available","Radial Artery Spasm|Angina|Coronary Artery Disease","Drug: Topical Nitroglycerine|Drug: Topical Lidocaine","Radial artery spasm|Change in Radial artery dimension measured in mm.|Procedural failure|Patient discomfort or pain during procedure (Visual analog scale 0-10)|Radial pulse at end of procedure","Aultman Health Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","2016.04.PG","September 2016","May 2, 2019","May 2, 2019","July 14, 2016",,"October 18, 2019","Aultman Hospital, Canton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02832115"
509,"NCT01169402","Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)",,"Completed","No Results Available","Cardiopulmonary Arrest|Fungal Infection","Drug: Fluconazole","Pharmacokinetics/Pharmacodynamics","Michael Cohen-Wolkowiez|Duke University","All","up to 18 Years   (Child, Adult)","Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00022822","July 2010","February 20, 2013","February 20, 2013","July 26, 2010",,"November 22, 2017","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01169402"
510,"NCT02003638","Assessment Of Vascular Health After Niacin Therapy (AVANT)","AVANT","Completed","Has Results","Coronary Artery Disease|Carotid Artery Disease|Peripheral Artery Disease","Drug: Niacin|Drug: Placebo","Change From Baseline in Arterial Fluorodeoxyglucose (FDG) Uptake Assessed by FDG-PET/CT","University of Pennsylvania","All","45 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","812962","March 2012","January 2013","January 2013","December 6, 2013","June 25, 2014","June 25, 2014","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02003638"
511,"NCT01376076","Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: Cariprazine|Drug: Risperidone/Moxifloxacin","Heart rate-corrected QT interval (QTc)","Forest Laboratories","All","18 Years to 50 Years   (Adult)","Phase 1","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RGH-MD-02","June 2011","February 2012","February 2012","June 20, 2011",,"February 8, 2012","Forest Investigative Site 001, Glendale, California, United States|Forest Investigative Site 004, Long Beach, California, United States|Forest Investigative Site 002, Willingboro, New Jersey, United States|Forest Investigative Site 003, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01376076"
512,"NCT01499654","Half-Dose Radiopharmaceutical in Wide Beam Reconstruction","REGA-1102","Terminated","Has Results","Myocardial Infarction|Ischemic Heart Disease","Drug: Half-dose of the Tc99-m sestamibi (Cardiolite)","Sum Rest Score|Segments With Resting Perfusion Defect|Image Quality Score|Diagnostic Confidence Score","Edwin Wu|Astellas Pharma Global Development, Inc.|Northwestern University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU53243","October 2011","December 2014","December 2014","December 26, 2011","February 24, 2016","February 24, 2016","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01499654"
513,"NCT03252093","Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG",,"Terminated","No Results Available","Coronary Artery Bypass Surgery|Cognitive Impairment","Drug: Angiotensin-(1-7)|Drug: Placebo for Angiotensin-(1-7)","Demonstrate 21 days daily administration of Ang-(1-7) in participants undergoing 1st time CABG surgery is safe and efficacious as assessed by the number of related AEs grade 3 or > and change in composite neuropsychological score up to Day 90.|Demonstrated change in the neuropsychological component scores assessed at baseline, Day 21 and Day 90 in the treatment and placebo arms.|Evidence of change in fractional anisotropy from diffusion tensor imaging on Brain MRI at baseline versus post operative Day 21 will be assessed in the treatment and placebo arms as a measure of efficacy.|Demonstrated change in PBR28 VT/fP, a quantitative measure of TSPO receptor density, in a composite cerebral region-of-interest (ROI) derived from brain PET imaging in the treatment and placebo arms.|Demonstrated associations between neuropsychogical test results, MRI findings and PBR28 binding in all participants.","University of Arizona|National Heart, Lung, and Blood Institute (NHLBI)|Suburban Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","6","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HL131014|1U01HL131014-01A1","July 20, 2017","March 15, 2019","March 15, 2019","August 17, 2017",,"April 16, 2019","Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona Sarver Heart Center, Tucson, Arizona, United States|Suburban Hospital, Bethesda, Maryland, United States|National Institutes of Health, Bethesda, Maryland, United States|INOVA Heart & Vascular Research, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03252093"
514,"NCT02192502","Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients","SHARP","Active, not recruiting","No Results Available","Postoperative Kidney Injury","Drug: human albumin 5%|Drug: HES 130/0.4 (Voluven)","Urine neutrophil gelatinase-associated lipocalin (NGAL) [Time Frame: 24 hours after surgery] [Designated as safety issue: Yes]|coagulation parameters and measures of platelet aggregation","The Cleveland Clinic|Fresenius Kabi","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","012-973","March 2015","December 2019","December 2020","July 16, 2014",,"January 30, 2020","Cleveland Clinic Foundation, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02192502"
515,"NCT02485938","HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)","HOPE","Completed","No Results Available","Duchenne Muscular Dystrophy|Cardiomyopathy","Drug: Allogeneic Cardiosphere-Derived Cells (CAP-1002)","Safety and tolerability composite of CAP-1002 will be established as described below.|Cardiac Structural composite assessed as: Absolute and relative change in parameters measured by cardiac MRI|Functional composite assessed as: Serial change in mobility measurements and Performance of Upper Limb (PUL) scale, spirometry, and 6-minute walk test (6MWT) when deemed appropriate by the Investigator.|Quality of Life composite assessed as: Change in PedsQL (Pediatric Quality of Life Inventory), including the cardiac module, and PODCI Adolescent Questionnaire.|Biomarkers composite assessed as: Osteopontin, ST2, IL-10, Galectin-3, and exploratory biomarkers (if consented/provided assent).","Capricor Inc.","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAP-1002-DMD-01","January 2016","September 2017","September 2017","June 30, 2015",,"July 20, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Florida, Gainesville, Florida, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02485938"
516,"NCT01230892","Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques",,"Completed","Has Results","Atherosclerosis|Endothelial Function","Drug: Nebivolol|Drug: Atenolol","Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS","Emory University|Georgia Institute of Technology","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 4","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00027953|Emory #00000681","February 2010","September 2013","September 2013","October 29, 2010","February 27, 2015","February 27, 2015","Emory University Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01230892"
517,"NCT01607983","Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients",,"Withdrawn","No Results Available","Congenital Heart Disease|Fontan","Drug: inhaled nitric oxide","Effective arterial elastance (Ea)","University of California, San Francisco","All","4 Years to 60 Years   (Child, Adult)","Phase 3","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-06070","June 2012","December 2017","December 2017","May 30, 2012",,"May 4, 2018","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01607983"
518,"NCT02668952","Fluid Chloride and AKI in Cardiopulmonary Bypass",,"Completed","Has Results","Acute Kidney Injury","Drug: 0.9% Normal Saline (0.9% Sodium Chloride) injection|Drug: Isolyte S injection","Change in [TIMP2]*[IGFBP7] Biomarker|Serum Creatinine Level at 24 Hours|Serum Chloride Level at 24 Hours|Proportion of Patients With Need for Dialysis|Postoperative Arterial pH|Serum Creatinine Level at 48 Hours|Serum Chloride at 48 Hours","University of New Mexico","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15-572","January 2016","February 4, 2017","February 2018","January 29, 2016","March 19, 2018","May 14, 2018","University of New Mexico Hospital, Albuquerque, New Mexico, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02668952/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02668952"
519,"NCT01819922","Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters",,"Completed","Has Results","Healthy","Drug: PF-05175157|Drug: Placebo","Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 20 Minutes Pre-dose|Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 1 Hour 30 Minutes Post-dose|Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 2 Hours 5 Minutes Post-dose|Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Abnormalities|Number of Participants With Categorical Post-dose Cardiovascular Monitoring Data|Number of Participants With Categorical Post-dose Cardiovascular Monitoring Data: Electrocardiogram (ECG) Parameters|Cardiopulmonary Exercise Test: Peak Volume of Oxygen (VO2)|Cardiopulmonary Exercise Test: Respiratory Exchange Ratio (RER)|Cardiopulmonary Exercise Test: Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)|Cardiopulmonary Exercise Test: Volume of Oxygen (VO2) at Anaerobic Threshold (AT)|Cardiopulmonary Exercise Test: Oxygen (O2) Pulse|Cardiopulmonary Exercise Test: Oxygen (O2) Kinetics|Cardiopulmonary Exercise Test: Aerobic Efficiency|Cardiopulmonary Exercise Test: Physical Work Capacity at a Heart Rate of 130 Beats Per Minute (PWC 130)|Cardiac Structure: Left Ventricular Volume|Change From Baseline in the Left Ventricular Volume|Cardiac Structure: Left Ventricular Wall Thickness|Cardiac Structure: Left Ventricular Geometry|Cardiac Structure: Right Ventricular Dimension|Change From Baseline in Right Ventricular Dimension|Cardiac Structure: Atrial Volume|Change From Baseline in Atrial Volumes|Systolic Function: Ejection Fraction|Change From Baseline in Ejection Fraction|Systolic Function: Peak Contractile Velocity|Change From Baseline in Peak Contractile Velocity|Systolic Function: Rotation/Torsion|Systolic Function: Global Strain Rate|Change From Baseline in Systolic Global Strain Rate|Trans-mitral Doppler: Ratio|Change From Baseline in Trans-mitral Doppler Ratio|Trans-mitral Doppler: Time|Change From Baseline in Trans-mitral Doppler Time|Early and Late Peak Tissue Velocity|Change From Baseline in Early and Late Peak Velocity|Diastolic Strain Rate|Peak Diastolic Untwisting Rate|Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise","Pfizer","All","18 Years to 40 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","B1731008","April 2013","October 2013","October 2013","March 28, 2013","May 2, 2016","May 2, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01819922"
520,"NCT01587651","Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease","SWAP-2","Completed","Has Results","Coronary Artery Disease","Drug: Prasugrel Loading Dose|Drug: Prasugrel Maintenance Dose|Drug: Ticagrelor Maintenance Dose","P2Y12 Reaction Units|Platelet Reactivity Index|PRU Percent Inhibition (Device-reported)|PRU Percent Inhibition (Calculated)|Percentage of Subjects With High On-treatment Platelet Reactivity","Daiichi Sankyo, Inc.|Eli Lilly and Company","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS747s-B-U4003","March 2012","February 2013","February 2013","April 30, 2012","April 29, 2014","January 9, 2019","Univ. of Florida College Medicine, Jacksonville, Florida, United States|Clinical Pharmacology Unit of Miami, Miami, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Sinai Center for Thrombosis Research, Baltimore, Maryland, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|West Houston Area Clinical Trial Consultants, Houston, Texas, United States|Cardiology Center of Houston, Katy, Texas, United States|University Hospital of Wales, Heath Park, Cardiff, United Kingdom|Bristol Heart Institute, Bristol, United Kingdom|University Hospital Leicester, Leicester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01587651"
521,"NCT03496168","Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER","PIONEER-OLE","Active, not recruiting","No Results Available","Hypertrophic Cardiomyopathy","Drug: mavacamten","Frequency and severity of adverse events and serious adverse events.","MyoKardia, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MYK-461-008","April 26, 2018","January 2022","March 2022","April 12, 2018",,"December 18, 2019","Mayo Clinic Arizona, Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Duke Cardiology at Southpoint, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03496168"
522,"NCT01235351","Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56","ELEVATE","Completed","Has Results","Myocardial Infarction|Percutaneous Coronary Intervention","Drug: Clopidogrel","Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI)","The TIMI Study Group|Bristol-Myers Squibb|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","335","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TIMI 56","October 2010","September 2011","September 2011","November 5, 2010","November 15, 2019","November 15, 2019","TIMI Study Group, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01235351"
523,"NCT03777761","Effects of Tucatinib on Cardiac Repolarization in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: tucatinib|Drug: placebo|Drug: moxifloxacin","Placebo-corrected change-from-baseline in QTcF|Change from baseline in heart rate (HR)|Change from baseline in QTcF|Change from baseline in PR interval|Change from baseline in QRS interval|Placebo-corrected change from baseline in HR|Placebo-corrected change from baseline in PR interval|Placebo-corrected change from baseline in QRS interval|• Number of participants who experience increases in absolute QTcF interval values >450 msec|• Number of participants who experience QTcF interval changes from predose baseline of >30msec|• Number of participants who experience an increase in PR interval from predose baseline of >25% to a PR >200 msec|• Number of participants who experience an increase in QRS interval from predose baseline >25% to a QRS >120 msec|• Number of participants who experience a decrease in heart rate >25% from baseline to a heart rate <50|• Number of participants who experience an increase in heart rate >25% from baseline to a heart rate >100|Frequency of treatment-emergent changes of T-wave morphology and U-wave presence|Area under the concentration-time curve (AUC) from time 0 extrapolated to infinity (AUC[0-inf]) for tucatinib and ONT-993|AUC from time 0 to the time of the last quantifiable concentration for tucatinib and ONT-993|Percentage of AUC[0-inf] due to extrapolation for tucatinib and ONT-993|Maximum observed concentration for tucatinib and ONT-993|Time of maximum observed concentration for tucatinib and ONT-993|Apparent terminal elimination half-life for tucatinib and ONT-993|Apparent total clearance for tucatinib|Apparent volume of distribution during the terminal phase for tucatinib|Metabolic ratio based on AUC for ONT-993|Incidence of adverse events (AEs)","Seattle Genetics, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ONT-380-011","December 6, 2018","March 11, 2019","March 11, 2019","December 17, 2018",,"April 12, 2019","Covance Clinical Research Unit - Dallas, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03777761"
524,"NCT03956017","Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery","ACE","Active, not recruiting","No Results Available","Myocardial Injury","Drug: Ubiquinone|Drug: Placebo","BNP levels following surgery|Cardiac Troponin levels following surgery|Change in Troponin levels from baseline to peak|Number of participants with adverse cardiac outcomes following surgery|Number of participants who died|Number of participants requiring coronary revascularization|Number of participants with new heart failure|Number of participants with new onset Atrial Fibrillation (A-Fib)|Number of participants with infection|Number of participants with a surgical graft failure|Length of stay|Rate of readmission at 1 year following discharge","Minneapolis Veterans Affairs Medical Center","All","Child, Adult, Older Adult","Early Phase 1","341","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IND 119600 Coenzyme Q10","August 5, 2013","August 4, 2021","August 4, 2022","May 20, 2019",,"May 30, 2019","Va Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03956017"
525,"NCT02561000","Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention","TRIP-PCI","Completed","No Results Available","Arterial Occlusive Diseases|Coronary Artery Disease|Coronary Disease|Arteriosclerosis|Heart Diseases|Myocardial Ischemia|Vascular Diseases|Acute Coronary Syndrome","Drug: PZ-128|Drug: Placebo","Incidence of bleeding through 30 days following treatment in subjects undergoing cardiac catheterization/percutaneous coronary intervention|Incidence of major adverse cardiac events","Tufts Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|RTI International|Inova Fairfax Hospital|University of Massachusetts, Worcester","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TMC-PZ128-02|P50HL110789","May 27, 2016","September 17, 2019","September 17, 2019","September 25, 2015",,"September 24, 2019","Tufts Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02561000"
526,"NCT00872170","Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension",,"Completed","Has Results","Thalassemia|Hypertension, Pulmonary","Drug: Sildenafil","Change in Six-minute Walk Test (6MWT) Distance From Baseline to Week 12 Among Sildenafil Group|Change in Tricuspid Regurgitant Jet Velocity (TRV) From Baseline to Week 12 Among Sildenafil Group|Change in Echo Left Ventricular End Systolic Volume (LVESV) From Baseline to Week 12 Among Sildenafil Group|Change in Echo Left Ventricular End Diastolic Volume (LVEDV) From Baseline to Week 12 Among Sildenafil Group|Change in Plasma Arginine From Baseline to Week 12 Among Sildenafil Group|Change in Red Blood Cell (RBC) Arginine From Baseline to Week 12 Among Sildenafil Group|Change in Soluble Platelet Selectin (sP-SELECTIN) From Baseline to Week 12 Among Sildenafil Group|Change in Lactate Dehydrogenase (LDH) From Baseline to Week 12 Among Sildenafil Group|Change in Cell Free Hemoglobin From Baseline to Week 12 Among Sildenafil Group|Change in Arginase Concentration From Baseline to Week 12 Among Sildenafil Group|Change in Arginase Activity From Baseline to Week 12 Among Sildenafil Group","HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)","All","7 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","27","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","638|U01HL065238","March 2009","June 2010","November 2010","March 31, 2009","February 21, 2014","February 21, 2014","Children's Hospital and Research Institute Oakland, Oakland, California, United States",,"https://ClinicalTrials.gov/show/NCT00872170"
527,"NCT03985410","Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers",,"Completed","No Results Available","Acinetobacter Baumannii-calcoaceticus Complex Infections","Drug: ETX2514|Drug: Placebo|Drug: moxifloxacin","Placebo-corrected change from Baseline in Fridericia-corrected QTc (QTcF) (ΔΔQTcF)|Change from baseline in heart rate (HR) (ΔHR)|Change from Baseline in QTcF (ΔQTcF)|Change from Baseline in the PR interval (ΔPR)|Change from Baseline in the QRS interval (ΔQRS)|Placebo-corrected change from Baseline in HR (ΔΔHR)|Placebo-corrected change from Baseline in PR (ΔΔPR)|Placebo-corrected change from Baseline in QRS (ΔΔQRS)|Number of participants with categorical outliers for QTcF, HR, PR, and QRS|Number of participants with treatment-emergent changes of T-wave morphology and U-wave presence","Entasis Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS2514-2018-0003","May 23, 2019","July 24, 2019","July 24, 2019","June 13, 2019",,"August 30, 2019","Pharmaron Clinical Pharmacology Center, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03985410"
528,"NCT01770236","Pain Control After Minimally Invasive Coronary Artery Bypass Grafting",,"Terminated","No Results Available","Postoperative Pain|Medication Side Effects|Narcotic Requirement","Drug: IV acetaminophen","Pain score|Medication side effects","Gundersen Lutheran Medical Foundation","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2-12-12-001","January 2013","November 2015","November 2015","January 17, 2013",,"December 21, 2016","Gundersen Lutheran Health System, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01770236"
529,"NCT01305395","Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients","STOPCAV","Withdrawn","No Results Available","Cardiac Allograft Vasculopathy","Drug: Sirolimus","1. Change in maximal intimal thickness|Mean maximal intima thickness|Percent atheroma volume|Death from CAV, death from any cause, myocardial infarction, need for percutaneous coronary intervention (PCI), number of hospitalizations, infection rates, evidence of restrictive physiology, arrhythmic event related to CAV or pulmonary hypertension|Change in small artery elasticity|Change in endothelial progenitor cell count|Change in biomarkers","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1007M85473","November 2010","January 2015","January 2015","February 28, 2011",,"January 24, 2017","Cardiology Division, University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01305395"
530,"NCT01556568","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy",,"Withdrawn","No Results Available","Cardiomegaly","Drug: MEK162","Change from baseline in Left ventricular mass (LVM)|Change from baseline in Cardiac energetics state at 3 months and 6 months|Number of patients with adverse events, serious adverse events and death|Pharmacokinetics of MEK162 and metabolite (AR00426032): The trough plasma concentration (Ctrough) just prior to drug administration|Pharmacokinetics of MEK162 and metabolite (AR00426032): maximum drug exposure of MEK162 and its metabolite (AR00426032) in plasma|Pharmacokinetics of MEK162 and metabolite (AR00426032): time to reach peak concentration (Tmax) in plasma|Pharmacokinetics of MEK162 and metabolite (AR00426032): Area under the plasma concentration-time profile from time zero to 12 hours post dose (AUC0-12h)|Pharmacokinetics of MEK162 and metabolite (AR00426032): Area under the plasma concentration-time profile from time zero to the last quantifiable sample (AUClast)|Pharmacokinetics of MEK162 and metabolite (AR00426032): accumulation ratio (Racc)|Pharmacokinetics of MEK162: The degree of fluctuation of MEK162 and its metabolite (AR00426032) in plasma at steady state (on Day 8)|Pharmacokinetics of MEK162: The ratio of Metabolite (AR00426032) to MEK162 in plasma on Days 1 and 8|Change from baseline in end systolic and end diastolic right and left vetricular volumes in 3 and 6 months|Pharmacokinetics of MEK162 and metabolite (AR00426032):observed maximum plasma concentration (Cmax) following drug adminstration|Change from baseline in stroke volume and stroke output during 3 and 6 months|Ejection fraction|Cardiac index","Array BioPharma","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMEK162Y2201|2011-003392-10","February 2012","May 2017",,"March 16, 2012",,"December 29, 2015","Array BioPharma Investigative Site, Boston, Massachusetts, United States|Array BioPharma Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01556568"
531,"NCT02820311","Thorough QT (TQT) Study of TD-4208 in Healthy Subjects",,"Completed","No Results Available","Cardiac Repolarization in Healthy Subjects","Drug: TD-4208 175 mcg|Drug: TD-4208 700 mcg|Drug: Placebo for TD-4208|Drug: Moxifloxacin 400 mg","Change-from-baseline in corrected QT|Maximum Plasma Concentration Cmax|Adverse Events","Theravance Biopharma","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","0136","May 2016","July 2016","July 2016","June 30, 2016",,"November 19, 2019","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02820311"
532,"NCT02201394","Reversing Ticagrelor's Effects With Fresh Platelets",,"Completed","Has Results","Coronary Artery Disease","Drug: Ticagrelor loading dose|Drug: Aspirin loading dose|Drug: Ticagrelor maintenance dose|Drug: Aspirin maintenance dose","P2Y12 Reaction Unit (PRU)|Platelet Aggregation Using Multiplate Analyzer","Icahn School of Medicine at Mount Sinai|AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 13-1802","July 2014","June 2016","June 2016","July 28, 2014","December 5, 2017","December 5, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02201394"
533,"NCT03726398","CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH","CRUSADE","Recruiting","No Results Available","Interstitial Lung Disease|Scleroderma|Pulmonary Hypertension","Drug: Opsumit 10 Mg Tablet","Change in exercise pulmonary vascular resistance (PVR)|Change in right ventricular pulmonary vascular hemodynamic coupling (RVPA).|Change in maximal oxygen consumption (V02 max).|Change in pulmonary impedance.","Franz Rischard, DO|National Jewish Health|University of Pittsburgh|University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IIS-02801","September 1, 2018","January 31, 2020","December 1, 2020","October 31, 2018",,"April 2, 2019","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03726398"
534,"NCT03521934","Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)",,"Active, not recruiting","No Results Available","Heart Failure-Type 2 Diabetes Mellitus","Drug: Sotagliflozin (SAR439954)|Drug: Placebo","Cardiovascular (CV) death or hospitalization for heart failure (HHF)|Total number of heart failure events|Time to first composite renal event|Cardiovascular (CV) death|All cause mortality","Lexicon Pharmaceuticals|Sanofi","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","4000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15156|2017-003510-16|U1111-1190-7891","June 11, 2018","May 2020","May 2020","May 11, 2018",,"April 24, 2020","Investigational Site Number 8400128, Alexander City, Alabama, United States|Investigational Site Number 8400109, Cottonwood, Arizona, United States|Investigational Site Number 8400032, Little Rock, Arkansas, United States|Investigational Site Number 8400080, Little Rock, Arkansas, United States|Investigational Site Number 8400075, Bakersfield, California, United States|Investigational Site Number 8400069, Fresno, California, United States|Investigational Site Number 8400008, Los Angeles, California, United States|Investigational Site Number 8400063, Los Angeles, California, United States|Investigational Site Number 8400127, National City, California, United States|Investigational Site Number 8400007, Redondo Beach, California, United States|Investigational Site Number 8400036, Stockton, California, United States|Investigational Site Number 8400033, Sylmar, California, United States|Investigational Site Number 8400049, Torrance, California, United States|Investigational Site Number 8400028, Walnut Creek, California, United States|Investigational Site Number 8400029, Bridgeport, Connecticut, United States|Investigational Site Number 8400037, New Haven, Connecticut, United States|Investigational Site Number 8400046, DeLand, Florida, United States|Investigational Site Number 8400009, Gainesville, Florida, United States|Investigational Site Number 8400079, Homestead, Florida, United States|Investigational Site Number 8400031, Jacksonville, Florida, United States|Investigational Site Number 8400022, Jacksonville, Florida, United States|Investigational Site Number 8400098, Lake Mary, Florida, United States|Investigational Site Number 8400058, Miami Beach, Florida, United States|Investigational Site Number 8400105, Orlando, Florida, United States|Investigational Site Number 8400082, Pensacola, Florida, United States|Investigational Site Number 8400057, Port Charlotte, Florida, United States|Investigational Site Number 8400006, Sarasota, Florida, United States|Investigational Site Number 8400035, Tampa, Florida, United States|Investigational Site Number 8400042, Tampa, Florida, United States|Investigational Site Number 8400004, Wellington, Florida, United States|Investigational Site Number 8400073, Atlanta, Georgia, United States|Investigational Site Number 8400118, Tucker, Georgia, United States|Investigational Site Number 8400067, Arlington Heights, Illinois, United States|Investigational Site Number 8400043, Chicago, Illinois, United States|Investigational Site Number 8400072, Elk Grove Village, Illinois, United States|Investigational Site Number 8400055, Indianapolis, Indiana, United States|Investigational Site Number 8400020, Muncie, Indiana, United States|Investigational Site Number 8400122, Richmond, Indiana, United States|Investigational Site Number 8400091, Waterloo, Iowa, United States|Investigational Site Number 8400030, Covington, Louisiana, United States|Investigational Site Number 8400065, Annapolis, Maryland, United States|Investigational Site Number 8400012, Boston, Massachusetts, United States|Investigational Site Number 8400001, Cambridge, Massachusetts, United States|Investigational Site Number 8400077, Detroit, Michigan, United States|Investigational Site Number 8400062, Kalamazoo, Michigan, United States|Investigational Site Number 8400017, Kalamazoo, Michigan, United States|Investigational Site Number 8400107, Duluth, Minnesota, United States|Investigational Site Number 8400056, Jackson, Mississippi, United States|Investigational Site Number 8400019, Columbia, Missouri, United States|Investigational Site Number 8400103, Lee's Summit, Missouri, United States|Investigational Site Number 8400132, Grand Island, Nebraska, United States|Investigational Site Number 8400130, Lincoln, Nebraska, United States|Investigational Site Number 8400083, Omaha, Nebraska, United States|Investigational Site Number 8400071, Omaha, Nebraska, United States|Investigational Site Number 8400015, Ridgewood, New Jersey, United States|Investigational Site Number 8400050, Voorhees, New Jersey, United States|Investigational Site Number 8400131, Albuquerque, New Mexico, United States|Investigational Site Number 8400097, Bronx, New York, United States|Investigational Site Number 8400061, Bronx, New York, United States|Investigational Site Number 8400051, Brooklyn, New York, United States|Investigational Site Number 8400111, Buffalo, New York, United States|Investigational Site Number 8400045, Greensboro, North Carolina, United States|Investigational Site Number 8400085, Raleigh, North Carolina, United States|Investigational Site Number 8400078, Winston-Salem, North Carolina, United States|Investigational Site Number 8400087, Cincinnati, Ohio, United States|Investigational Site Number 8400047, Cincinnati, Ohio, United States|Investigational Site Number 8400095, Maumee, Ohio, United States|Investigational Site Number 8400099, Toledo, Ohio, United States|Investigational Site Number 8400121, Zanesville, Ohio, United States|Investigational Site Number 8400054, Arlington, Oregon, United States|Investigational Site Number 8400134, Doylestown, Pennsylvania, United States|Investigational Site Number 8400044, Natrona Heights, Pennsylvania, United States|Investigational Site Number 8400115, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400039, Sayre, Pennsylvania, United States|Investigational Site Number 8400114, Providence, Rhode Island, United States|Investigational Site Number 8400100, Warwick, Rhode Island, United States|Investigational Site Number 8400059, Charleston, South Carolina, United States|Investigational Site Number 8400092, Columbia, South Carolina, United States|Investigational Site Number 8400104, Greenville, South Carolina, United States|Investigational Site Number 8400040, Rapid City, South Dakota, United States|Investigational Site Number 8400088, Greenville, Tennessee, United States|Investigational Site Number 8400089, Memphis, Tennessee, United States|Investigational Site Number 8400053, Nashville, Tennessee, United States|Investigational Site Number 8400041, Brownsville, Texas, United States|Investigational Site Number 8400074, Dallas, Texas, United States|Investigational Site Number 8400016, Houston, Texas, United States|Investigational Site Number 8400123, McKinney, Texas, United States|Investigational Site Number 8400101, New Braunfels, Texas, United States|Investigational Site Number 8400066, Victoria, Texas, United States|Investigational Site Number 8400093, Manassas, Virginia, United States|Investigational Site Number 8400003, Richmond, Virginia, United States|Investigational Site Number 8400126, Clarksburg, West Virginia, United States|Investigational Site Number 8400038, Morgantown, West Virginia, United States|Investigational Site Number 8400048, Manitowoc, Wisconsin, United States|Investigational Site Number 0320031, Caba, Argentina|Investigational Site Number 0320009, Caba, Argentina|Investigational Site Number 0320016, Capital Federal, Argentina|Investigational Site Number 0320002, Ciudad De Buenos Aires, Argentina|Investigational Site Number 0320011, Cordoba, Argentina|Investigational Site Number 0320010, Cordoba, Argentina|Investigational Site Number 0320022, Corrientes, Argentina|Investigational Site Number 0320001, Corrientes, Argentina|Investigational Site Number 0320024, Córdoba, Argentina|Investigational Site Number 0320003, Córdoba, Argentina|Investigational Site Number 0320025, Córdoba, Argentina|Investigational Site Number 0320029, La Plata, Argentina|Investigational Site Number 0320007, La Plata, Argentina|Investigational Site Number 0320006, Merlo, Argentina|Investigational Site Number 0320005, Moron, Argentina|Investigational Site Number 0320012, Olivos, Argentina|Investigational Site Number 0320023, Quilmes, Argentina|Investigational Site Number 0320018, Rosario, Argentina|Investigational Site Number 0320013, Rosario, Argentina|Investigational Site Number 0320008, Salta, Argentina|Investigational Site Number 0320020, San Martin, Argentina|Investigational Site Number 0320028, San Miguel De Tucuman, Argentina|Investigational Site Number 0320019, San Miguel De Tucuman, Argentina|Investigational Site Number 0320017, Santa Fe, Argentina|Investigational Site Number 0320015, Santa Fe, Argentina|Investigational Site Number 0320030, Tucuman, Argentina|Investigational Site Number 0320004, Villa Belgrano, Argentina|Investigational Site Number 0320014, Villa Maria, Argentina|Investigational Site Number 0360007, Murdoch, Australia|Investigational Site Number 0360001, Wollongong, Australia|Investigational Site Number 0400006, Braunau, Austria|Investigational Site Number 0400002, Feldkirch, Austria|Investigational Site Number 0400007, Graz, Austria|Investigational Site Number 0400005, Linz, Austria|Investigational Site Number 0400004, Salzburg, Austria|Investigational Site Number 0400003, Wien, Austria|Investigational Site Number 0400001, Wien, Austria|Investigational Site Number 0560002, Aalst, Belgium|Investigational Site Number 0560007, Gent, Belgium|Investigational Site Number 0560004, Kortrijk, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Liège, Belgium|Investigational Site Number 0560005, Mol, Belgium|Investigational Site Number 0560006, Mons, Belgium|Investigational Site Number 0560008, Roeselare, Belgium|Investigational Site Number 0760009, Belo Horizonte, Brazil|Investigational Site Number 0760024, Belo Horizonte, Brazil|Investigational Site Number 0760002, Blumenau, Brazil|Investigational Site Number 0760011, Brasilia, Brazil|Investigational Site Number 0760005, Campinas, Brazil|Investigational Site Number 0760006, Campinas, Brazil|Investigational Site Number 0760023, Fortaleza, Brazil|Investigational Site Number 0760018, Goiania, Brazil|Investigational Site Number 0760010, Passo Fundo, Brazil|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760020, Porto Alegre, Brazil|Investigational Site Number 0760021, Porto Alegre, Brazil|Investigational Site Number 0760007, Porto Alegre, Brazil|Investigational Site Number 0760013, Porto Alegre, Brazil|Investigational Site Number 0760004, Recife, Brazil|Investigational Site Number 0760001, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 0760012, Sao Paulo, Brazil|Investigational Site Number 0760008, Sao Paulo, Brazil|Investigational Site Number 0760017, Votuporanga, Brazil|Investigational Site Number 1240013, Cambridge, Canada|Investigational Site Number 1240006, Granby, Canada|Investigational Site Number 1240015, Halifax, Canada|Investigational Site Number 1240002, Montreal, Canada|Investigational Site Number 1240019, Montreal, Canada|Investigational Site Number 1240018, Montreal, Canada|Investigational Site Number 1240004, Peterborough, Canada|Investigational Site Number 1240014, Quebec, Canada|Investigational Site Number 1240007, Scarborough, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 1240011, Toronto, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1240009, Trois-Rivières, Canada|Investigational Site Number 1520009, Concepción, Chile|Investigational Site Number 1520011, Santiago, Chile|Investigational Site Number 1520006, Santiago, Chile|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520005, Santiago, Chile|Investigational Site Number 1520012, Santiago, Chile|Investigational Site Number 1520013, Santiago, Chile|Investigational Site Number 1520002, Temuco, Chile|Investigational Site Number 1520010, Vina Del Mar, Chile|Investigational Site Number 1520001, Viña Del Mar, Chile|Investigational Site Number 2030001, Brno, Czechia|Investigational Site Number 2030003, Brno, Czechia|Investigational Site Number 2030004, Brno, Czechia|Investigational Site Number 2030014, Kolin 3, Czechia|Investigational Site Number 2030010, Kromeriz, Czechia|Investigational Site Number 2030005, Liberec, Czechia|Investigational Site Number 2030013, Mestec Kralove, Czechia|Investigational Site Number 2030018, Praha 10, Czechia|Investigational Site Number 2030002, Praha 2, Czechia|Investigational Site Number 2030007, Praha 5 - Motol, Czechia|Investigational Site Number 2030017, Praha 5, Czechia|Investigational Site Number 2030011, Prerov, Czechia|Investigational Site Number 2030015, Pribram I, Czechia|Investigational Site Number 2030006, Slany, Czechia|Investigational Site Number 2080003, Aarhus N, Denmark|Investigational Site Number 2080002, Glostrup, Denmark|Investigational Site Number 2080001, Herlev, Denmark|Investigational Site Number 2080005, København Nv, Denmark|Investigational Site Number 2080004, Ålborg, Denmark|Investigational Site Number 2460004, Espoo, Finland|Investigational Site Number 2460001, Helsinki, Finland|Investigational Site Number 2460002, Jyväskylä, Finland|Investigational Site Number 2460003, Oulu, Finland|Investigational Site Number 2460005, Seinäjoki, Finland|Investigational Site Number 2500009, Chambray Les Tours, France|Investigational Site Number 2500008, La Tronche, France|Investigational Site Number 2500004, Le Chesnay, France|Investigational Site Number 2500002, Le Coudray, France|Investigational Site Number 2500001, Lille, France|Investigational Site Number 2500007, Nantes Cedex 1, France|Investigational Site Number 2500012, Nice Cedex 1, France|Investigational Site Number 2500003, Paris Cedex 18, France|Investigational Site Number 2500006, Paris, France|Investigational Site Number 2500005, Toulouse Cedex 9, France|Investigational Site Number 2500013, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 2760020, Bad Nauheim, Germany|Investigational Site Number 2760016, Bad Oeynhausen, Germany|Investigational Site Number 2760013, Berlin, Germany|Investigational Site Number 2760019, Berlin, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Berlin, Germany|Investigational Site Number 2760025, Bielefeld, Germany|Investigational Site Number 2760005, Bonn, Germany|Investigational Site Number 2760021, Bremen, Germany|Investigational Site Number 2760035, Coburg, Germany|Investigational Site Number 2760032, Dortmund, Germany|Investigational Site Number 2760006, Dortmund, Germany|Investigational Site Number 2760029, Erfurt, Germany|Investigational Site Number 2760018, Essen, Germany|Investigational Site Number 2760033, Frankfurt Am Main, Germany|Investigational Site Number 2760009, Greifswald, Germany|Investigational Site Number 2760022, Heidelberg, Germany|Investigational Site Number 2760031, Heidelberg, Germany|Investigational Site Number 2760027, Köln, Germany|Investigational Site Number 2760034, Lahr, Germany|Investigational Site Number 2760030, Langen, Germany|Investigational Site Number 2760014, Leverkusen, Germany|Investigational Site Number 2760036, Limburg, Germany|Investigational Site Number 2760012, Ludwigshafen, Germany|Investigational Site Number 2760028, Merseburg, Germany|Investigational Site Number 2760011, Rotenburg An Der Fulda, Germany|Investigational Site Number 2760015, Rüsselsheim, Germany|Investigational Site Number 2760007, Witten, Germany|Investigational Site Number 2760026, Würzburg, Germany|Investigational Site Number 3000012, Athens, Greece|Investigational Site Number 3000004, Athens, Greece|Investigational Site Number 3000002, Chalkida, Greece|Investigational Site Number 3000009, Elefsina, Greece|Investigational Site Number 3000003, Haidari, Greece|Investigational Site Number 3000005, Heraklion, Greece|Investigational Site Number 3000007, Ioannina, Greece|Investigational Site Number 3000006, Larissa, Greece|Investigational Site Number 3000001, N. Ionia, Greece|Investigational Site Number 3000008, Thessaloniki, Greece|Investigational Site Number 3480018, Berettyóújfalu, Hungary|Investigational Site Number 3480012, Budapest, Hungary|Investigational Site Number 3480016, Budapest, Hungary|Investigational Site Number 3480010, Budapest, Hungary|Investigational Site Number 3480019, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480015, Budapest, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480014, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480007, Debrecen, Hungary|Investigational Site Number 3480002, Dombóvár, Hungary|Investigational Site Number 3480017, Gyula, Hungary|Investigational Site Number 3480008, Hódmezövásárhely, Hungary|Investigational Site Number 3480020, Kistarcsa, Hungary|Investigational Site Number 3480009, Komárom, Hungary|Investigational Site Number 3480013, Pécs, Hungary|Investigational Site Number 3480003, Szekesfehervar, Hungary|Investigational Site Number 3480006, Zalaegerszeg, Hungary|Investigational Site Number 3760013, Ashkelon, Israel|Investigational Site Number 3760004, Hadera, Israel|Investigational Site Number 3760005, Haifa, Israel|Investigational Site Number 3760006, Jerusalem, Israel|Investigational Site Number 3760003, Jerusalem, Israel|Investigational Site Number 3760008, Jerusalem, Israel|Investigational Site Number 3760010, Nahariya, Israel|Investigational Site Number 3760002, Petah-Tikva, Israel|Investigational Site Number 3760011, Rehovot, Israel|Investigational Site Number 3760009, Safed, Israel|Investigational Site Number 3760001, Tel Aviv, Israel|Investigational Site Number 3760012, Tiberias, Israel|Investigational Site Number 3800006, Arzignano (Vi), Italy|Investigational Site Number 3800011, Brescia, Italy|Investigational Site Number 3800017, Brescia, Italy|Investigational Site Number 3800005, Cortona, Italy|Investigational Site Number 3800009, Ferrara, Italy|Investigational Site Number 3800020, Gallipoli, Italy|Investigational Site Number 3800003, Legnago, Italy|Investigational Site Number 3800023, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800012, Milano, Italy|Investigational Site Number 3800008, Milano, Italy|Investigational Site Number 3800013, Monza, Italy|Investigational Site Number 3800022, Napoli, Italy|Investigational Site Number 3800018, Pavia, Italy|Investigational Site Number 3800004, Perugia, Italy|Investigational Site Number 3800016, Pozzilli, Italy|Investigational Site Number 3800014, Rimini, Italy|Investigational Site Number 3800010, Roma, Italy|Investigational Site Number 3800021, Roma, Italy|Investigational Site Number 3800019, Scorrano, Italy|Investigational Site Number 3800007, Udine, Italy|Investigational Site Number 4100008, Bucheon-Si, Korea, Republic of|Investigational Site Number 4100010, Busan, Korea, Republic of|Investigational Site Number 4100004, Daegu, Korea, Republic of|Investigational Site Number 4100001, Hwaseong-Si, Korea, Republic of|Investigational Site Number 4100003, Incheon, Korea, Republic of|Investigational Site Number 4100005, Seongnam-Si, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100007, Seoul, Korea, Republic of|Investigational Site Number 4100011, Seoul, Korea, Republic of|Investigational Site Number 4100009, Seoul, Korea, Republic of|Investigational Site Number 4280004, Daugavpils, Latvia|Investigational Site Number 4280002, Liepaja, Latvia|Investigational Site Number 4280001, Riga, Latvia|Investigational Site Number 4280003, Riga, Latvia|Investigational Site Number 4400002, Kaunas, Lithuania|Investigational Site Number 4400005, Kaunas, Lithuania|Investigational Site Number 4400004, Klaipeda, Lithuania|Investigational Site Number 4400006, Siauliai, Lithuania|Investigational Site Number 4400001, Vilnius, Lithuania|Investigational Site Number 4400003, Vilnius, Lithuania|Investigational Site Number 5280003, Amsterdam, Netherlands|Investigational Site Number 5280001, Breda, Netherlands|Investigational Site Number 5280007, Delft, Netherlands|Investigational Site Number 5280002, Doetinchem, Netherlands|Investigational Site Number 5280004, Hertogenbosch, Netherlands|Investigational Site Number 5280006, Rotterdam, Netherlands|Investigational Site Number 5280008, Sneek, Netherlands|Investigational Site Number 5280005, Veldhoven, Netherlands|Investigational Site Number 5540007, Auckland, New Zealand|Investigational Site Number 5540006, Christchurch, New Zealand|Investigational Site Number 5540002, Hamilton, New Zealand|Investigational Site Number 5540004, Lower Hutt, New Zealand|Investigational Site Number 5540005, New Plymouth, New Zealand|Investigational Site Number 5540003, Rotorua, New Zealand|Investigational Site Number 6160007, Bialystok, Poland|Investigational Site Number 6160017, Gdansk, Poland|Investigational Site Number 6160002, Grodzisk Mazowiecki, Poland|Investigational Site Number 6160014, Katowice, Poland|Investigational Site Number 6160021, Krakow, Poland|Investigational Site Number 6160001, Krakow, Poland|Investigational Site Number 6160003, Krakow, Poland|Investigational Site Number 6160012, Krakow, Poland|Investigational Site Number 6160011, Leczna, Poland|Investigational Site Number 6160016, Lubin, Poland|Investigational Site Number 6160005, Miechow, Poland|Investigational Site Number 6160022, Poznan, Poland|Investigational Site Number 6160006, Torun, Poland|Investigational Site Number 6160013, Warszawa, Poland|Investigational Site Number 6160004, Warszawa, Poland|Investigational Site Number 6160020, Warszawa, Poland|Investigational Site Number 6160024, Warszawa, Poland|Investigational Site Number 6160008, Warszawa, Poland|Investigational Site Number 6160015, Zamosc, Poland|Investigational Site Number 6200012, Braga, Portugal|Investigational Site Number 6200001, Coimbra, Portugal|Investigational Site Number 6200011, Guilhufe - Penafiel, Portugal|Investigational Site Number 6200004, Guimarães, Portugal|Investigational Site Number 6200006, Lisboa, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200008, Porto, Portugal|Investigational Site Number 6200007, Vila Franca De Xira, Portugal|Investigational Site Number 6200003, Vila Nova Gaia, Portugal|Investigational Site Number 6200005, Vila Real, Portugal|Investigational Site Number 6420014, Arad, Romania|Investigational Site Number 6420006, Baia Mare, Romania|Investigational Site Number 6420015, Braila, Romania|Investigational Site Number 6420013, Bucharest, Romania|Investigational Site Number 6420019, Bucuresti, Romania|Investigational Site Number 6420011, Bucuresti, Romania|Investigational Site Number 6420008, Bucuresti, Romania|Investigational Site Number 6420007, Bucuresti, Romania|Investigational Site Number 6420002, Cluj Napoca, Romania|Investigational Site Number 6420003, Cluj Napoca, Romania|Investigational Site Number 6420016, Craiova, Romania|Investigational Site Number 6420005, Oradea, Romania|Investigational Site Number 6420004, Oradea, Romania|Investigational Site Number 6420018, Satu Mare, Romania|Investigational Site Number 6420001, Targu Mures, Romania|Investigational Site Number 6420012, Tg-Mures, Romania|Investigational Site Number 6420009, Timisoara, Romania|Investigational Site Number 6420010, Timisoara, Romania|Investigational Site Number 6430026, Ivanovo, Russian Federation|Investigational Site Number 6430023, Kazan, Russian Federation|Investigational Site Number 6430002, Kemerovo, Russian Federation|Investigational Site Number 6430006, Kemerovo, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430022, Moscow, Russian Federation|Investigational Site Number 6430024, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430010, Moscow, Russian Federation|Investigational Site Number 6430018, Nizhniy Novgorod, Russian Federation|Investigational Site Number 6430013, Rostov-Na-Donu, Russian Federation|Investigational Site Number 6430011, Saint-Petersburg, Russian Federation|Investigational Site Number 6430017, Sochi, Russian Federation|Investigational Site Number 6430025, St-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430012, St-Petersburg, Russian Federation|Investigational Site Number 6430009, St-Petersburg, Russian Federation|Investigational Site Number 6430016, Tomsk, Russian Federation|Investigational Site Number 7030003, Bratislava 3 - Kramare, Slovakia|Investigational Site Number 7030004, Bratislava 37, Slovakia|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7030010, Brezno, Slovakia|Investigational Site Number 7030009, Dolny Kubin, Slovakia|Investigational Site Number 7030002, Kosice, Slovakia|Investigational Site Number 7030011, Nitra, Slovakia|Investigational Site Number 7030008, Trnava, Slovakia|Investigational Site Number 7240016, Alicante, Spain|Investigational Site Number 7240015, Badalona, Spain|Investigational Site Number 7240020, Hospitalet De Llobregat, Spain|Investigational Site Number 7240006, La Coruña, Spain|Investigational Site Number 7240005, Las Palmas De Gran Canaria, Spain|Investigational Site Number 7240021, Madrid, Spain|Investigational Site Number 7240008, Madrid, Spain|Investigational Site Number 7240022, Manises, Spain|Investigational Site Number 7240007, Murcia, Spain|Investigational Site Number 7240004, Málaga, Spain|Investigational Site Number 7240014, Olot, Spain|Investigational Site Number 7240009, San Sebastián De Los Reyes, Spain|Investigational Site Number 7240003, Sanlúcar De Barrameda, Spain|Investigational Site Number 7240001, Sevilla, Spain|Investigational Site Number 7240019, Sevilla, Spain|Investigational Site Number 7240012, Valencia, Spain|Investigational Site Number 7240011, Valencia, Spain|Investigational Site Number 7240010, Valencia, Spain|Investigational Site Number 7240002, Villamartín, Spain|Investigational Site Number 7240013, Zaragoza, Spain|Investigational Site Number 7240018, Úbeda, Spain|Investigational Site Number 7520004, Jönköping, Sweden|Investigational Site Number 7520002, Malmö, Sweden|Investigational Site Number 7520006, Skellefteå, Sweden|Investigational Site Number 7520007, Stockholm, Sweden|Investigational Site Number 7520008, Stockholm, Sweden|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 7560001, Basel, Switzerland|Investigational Site Number 7560003, Lugano, Switzerland|Investigational Site Number 7920008, Antalya, Turkey|Investigational Site Number 7920006, Corum, Turkey|Investigational Site Number 7920005, Eskisehir, Turkey|Investigational Site Number 7920002, Haseki/ Istanbul, Turkey|Investigational Site Number 7920011, Istanbul, Turkey|Investigational Site Number 7920012, Izmir, Turkey|Investigational Site Number 7920003, Kocaeli, Turkey|Investigational Site Number 7920004, Mersin, Turkey|Investigational Site Number 7920001, Sivas, Turkey|Investigational Site Number 7920010, Trabzon, Turkey|Investigational Site Number 8260005, Bournemouth, United Kingdom|Investigational Site Number 8260010, Bristol, United Kingdom|Investigational Site Number 8260008, Chelmsford, United Kingdom|Investigational Site Number 8260009, Hull, United Kingdom|Investigational Site Number 8260002, Newcastle, United Kingdom|Investigational Site Number 8260001, Oldham, United Kingdom|Investigational Site Number 8260003, Swansea, United Kingdom|Investigational Site Number 8260006, Swindon, United Kingdom|Investigational Site Number 8260004, Torquay, United Kingdom|Investigational Site Number 8260007, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03521934"
535,"NCT01730417","Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG","mIBG","Completed","No Results Available","Neuroendocrine Tumors|Heart Failure","Drug: no carrier added metaiodobenzylguanidine","Radiation dosimetry","Bennett Chin|National Cancer Institute (NCI)|Molecular Insights Pharmaceuticals|Duke University","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00019124 (MIP-CA130394-01)|5R44CA130394-03","November 2009","June 2011","July 2011","November 21, 2012",,"November 21, 2012","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01730417"
536,"NCT01174173","Ranolazine and Pulmonary Hypertension",,"Completed","Has Results","Angina|Pulmonary Arterial Hypertension","Drug: Ranolazine","Improve Angina Symptoms|6-Minute Walk Test|Improve Quality of Life|RV Perfusion on Cardiac MRI|Absolute RV Longitudinal Strain|Right Ventricular Hemodynamics","Northwestern University|Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00030314","June 2010","January 2014","October 2014","August 3, 2010","April 23, 2015","May 11, 2018","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01174173"
537,"NCT02052635","Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.","NSTE-ACS","Terminated","Has Results","Non-ST Elevation Acute Coronary Syndrome","Drug: ticagrelor|Drug: clopidogrel","P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose|P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 4","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5130L00065","September 2014","April 2015","April 2015","February 3, 2014","April 6, 2016","May 27, 2016","Research Site, Jacksonville, Florida, United States|Research Site, Lake Mary, Florida, United States|Research Site, Macon, Georgia, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT02052635"
538,"NCT02565485","Pulse Pressure and Post-epidural Fetal Heart Rate Changes",,"Completed","Has Results","Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery","Drug: Lactated Ringer's","Incidence of New-onset Category II or III Fetal Heart Rate Tracings|New Onset Hypotension (>20% Decrease in Systolic and/or Diastolic Blood Pressure)|Interventions to Correct Maternal Hypotension or Fetal Heart Rate Abnormalities (Position Change, Supplemental Oxygen, Vasopressor Support, Emergent Operative Delivery)|Adverse Events (Pulmonary Edema)","MetroHealth Medical Center","Female","18 Years to 50 Years   (Adult)","Not Applicable","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","IRB15-00366","September 1, 2015","November 1, 2016","November 1, 2016","October 1, 2015","June 8, 2018","July 9, 2018","MetroHealth Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02565485"
539,"NCT02741115","Fontan Udenafil Exercise Longitudinal Assessment Trial","FUEL","Completed","No Results Available","Single Ventricle Heart Disease","Drug: Udenafil|Drug: Placebo","Change in Exercise Capacity|Change in Myocardial Performance Index (MPI)|Change in log-transformed reactive hyperemia index (InRH)|Change in Level of Serum serum brain-type natriuretic peptide BNP","Mezzion Pharma Co. Ltd|National Heart, Lung, and Blood Institute (NHLBI)","All","12 Years to 18 Years   (Child, Adult)","Phase 3","400","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PHN-Udenafil-02|U01HL068270","July 22, 2016","December 27, 2018","April 30, 2019","April 18, 2016",,"January 14, 2020","Phoenix Children's Hospital/Children's Heart Center at Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars/Sinai Heart Institute, Los Angeles, California, United States|Rady Children's Hospital, San Diego, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Cardiac Center/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Johns Hopkins All Children's Heart Institute, Saint Petersburg, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Riley Hospital for Children/Herman B. Wells Center for Pediatric Research, Indianapolis, Indiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan Congenital Heart Center/C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States|Washington University St. Louis/St.Louis Children's Hospital, Saint Louis, Missouri, United States|University of Nebraska Children's Hospital and Medical Center, Omaha, Nebraska, United States|Children's Hospital of New York, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hosptial, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's Medical Hospital/Dept. of Pediatric Cardiology, Salt Lake City, Utah, United States|Seattle Children's Hosptial, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Stollery Children's Hospital - University of Alberta, Edmonton, Alberta, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Sejong General Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of|Seoul National University Children's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02741115"
540,"NCT02553733","Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD","HeartBeet","Recruiting","No Results Available","Peripheral Arterial Disease","Drug: Beetroot juice|Drug: Beetroot juice placebo","Exercise performance|Coronary vascular function|Leg vascular function","David N. Proctor, PhD|Milton S. Hershey Medical Center|Wake Forest University Health Sciences|Penn State University","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00003242","December 2015","December 2020","December 2022","September 18, 2015",,"January 13, 2020","Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02553733"
541,"NCT02485366","Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery",,"Withdrawn","No Results Available","Heart Defects, Congenital","Drug: Rejuvesol|Procedure: Cardiac surgery","Change in tissue oxygenation/perfusion during cardiac surgery, measured by whole blood lactate concentration|Change in ischemic organ injury during cardiac surgery, measured by urinary neutrophil gelatinase associated lipocalin (NGAL)|Change in hemolysis during cardiac surgery, as measured by plasma free hemoglobin levels","Duke University","All","up to 18 Years   (Child, Adult)","Phase 4","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00021487","June 2020","June 2021","June 2021","June 30, 2015",,"April 27, 2020","Duke Univerisity Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02485366"
542,"NCT03318809","AMG 986 20150186 Renal Impairment Study",,"Completed","No Results Available","Heart Failure","Drug: AMG 986","AMG 986 PK parameters - Area under the plasma concentration time curve from time 0 to the time of the last quantifiable sample|AMG 986 PK parameters - Maximum observed plasma concentration after dosing|AMG 986 PK parameters -Terminal phase half-life|AMG 986 PK parameters - Time of maximum plasma concentration|AMG 986 PK parameters - AUC from time 0 to infinity|Adverse Event assessment|Change in Heart rate|Physical Examination Assessment|Change in total Creatine kinase|ECG assessments|Change in Blood Pressure|Change in Respiratory rate|Change in Troponin 1|Change in total bilirubin|Change in alanine aminotransferase|Change in Aspartate aminotransferase","Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150186","December 12, 2017","March 12, 2018","April 5, 2018","October 24, 2017",,"October 22, 2019","Research Site, Tustin, California, United States|Research Site, Orlando, Florida, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03318809"
543,"NCT00850746","A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults",,"Completed","No Results Available","Functional Dyspepsia","Drug: YM443|Drug: Placebo|Drug: Moxifloxacin","Mean change in the QTcF (Fridericia's correction) between each active treatment and placebo|The mean change of the QTcI (Individual correction) and QTcB (Bazett's correction) between each active treatment and placebo.|The pharmacokinetics of YM443 in these subjects|The safety and tolerability of YM443","Astellas Pharma Inc","All","18 Years to 50 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","443-CL-048","February 2009","April 2009","April 2009","February 25, 2009",,"March 24, 2014","Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00850746"
544,"NCT00932100","A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome","RADAR","Completed","No Results Available","Acute Coronary Syndrome (ACS)","Drug: REG1|Drug: Heparin","The composite incidence of major and minor bleeding","Regado Biosciences, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","640","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","REG-CLIN211","July 2009","January 2011","January 2011","July 3, 2009",,"March 2, 2012","Heart Center Research LLC, Huntsville, Alabama, United States|Mercy Heart & Vascular Institute, Sacramento, California, United States|Sutter Medical Center - Sacramento, Sacramento, California, United States|Scripps Mercy Hospital, San Diego, California, United States|Heart & Vascular Institute of Florida, Clearwater, Florida, United States|Jim Moran Heart & Vascular Research Institute, Fort Lauderdale, Florida, United States|University of Florida-Medicine Cardiology Research, Gainsville, Florida, United States|University of Florida at Jacksonville, Jacksonville, Florida, United States|Northeast Georgia Heart Center, Gainesville, Georgia, United States|St. Luke's Idaho Cardiology Associates, Boise, Idaho, United States|St. Luke's Idaho Cardiology Associates, Meridian, Idaho, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|The Care Group LLC, Indianapolis, Indiana, United States|Cardiovascular Institute of the South - Houma, Houma, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Buffalo Heart Group, Buffalo, New York, United States|University of North Carolina - School of Medicine, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Black Hills Clinical Research Center, Rapid City, South Dakota, United States|North Cypress Medical Center, Cypress, Texas, United States|Swedish Medical Center - Cardiovascular, Seattle, Washington, United States|Heart Clinics Northwest, Spokane, Washington, United States|Aurora Cardiovascular Services, Milwaukee, Wisconsin, United States|Vancouver Hospital, Vancouver, British Columbia, Canada|Hamilton Health Science, Hamilton, Ontario, Canada|Montreal Heart Institute Research Center, Montreal, Quebec, Canada|Nouvelles Cliniques Nantaises, Nantes cedex 2, France|Kerckhoff-Klinik GmbH, Bad Nauheim, Germany|Kardiologische Praxis, Bad Soden, Germany|MVZ am Kuechwald GmbH Ambulantes Herzzentrum, Chemnitz, Germany|Klinikum Coburg GmbH 2. Med. Klinik Ebene 3 Studienbuero, Coburg, Germany|Universitatsklinikum Freiburg Abt. Innere Medizin III, Freiburg, Germany|Klinikum Fulda gAG Medizinische Klinik I, Fulda, Germany|Universitaetsklinikum Halle/Saale Klinik fÃ¼r Innere Medizin III, Halle/ Saale, Germany|UniversitÃ¤tsklinikum Schleswig-Holstein Kiel, Kiel, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Universitaetsklinik Magdeburg Klinik fÃ¼r Kardiologie Angiologie und Pneumologie, Magdeburg, Germany|Carl-von-Basedow Klinikum, Merseburg, Germany|Klinikum der Universitaet Muenchen GroÃŸhadern Medizinische Klinik und Poliklinik I der LMU, Muenchen, Germany|Klinikum Quedlinburg GmbH Klinik fuer Innere Medizin und Kardiologie, Quedlinburg, Germany",,"https://ClinicalTrials.gov/show/NCT00932100"
545,"NCT03767855","A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects",,"Completed","No Results Available","Symptomatic Obstructive Hypertrophic Cardiomyopathy|Healthy Subjects","Drug: CK-3773274 - Granules in Capsule|Drug: Placebo - Granules in Capsule|Drug: CK-3773274 - Tablets","Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects.|Cmax of CK-3773274 after single and multiple ascending doses|Change in absolute reduction in ejection fraction relative to baseline with doses of CK-3773274|Assess the effect of CYP2D6 genetic variants on the PK of CK-3773274|Assess the effect of a meal on how much CK-3773274 is in the blood in healthy subjects|Relative bioavailability of CK-3773274 formulated as granules in capsule versus a tablet in healthy adult subjects","Cytokinetics","All","18 Years to 55 Years   (Adult)","Phase 1","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CY 6011","December 4, 2018","January 3, 2020","January 3, 2020","December 7, 2018",,"January 29, 2020","Clinical Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT03767855"
546,"NCT04006288","Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","SWAP-AC","Recruiting","No Results Available","Coronary Artery Disease","Drug: Clopidogrel|Drug: Prasugrel|Drug: ticagrelor|Drug: aspirin|Drug: rivaroxaban","Maximal platelet aggregation (MPA%) by light transmittance aggregometry (LTA)","University of Florida|Janssen, LP","All","18 Years and older   (Adult, Older Adult)","Phase 4","90","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS-RIVA02","September 6, 2019","December 2020","April 2021","July 5, 2019",,"September 10, 2019","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04006288"
547,"NCT03292861","The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients",,"Active, not recruiting","No Results Available","Heart Transplantation","Drug: Thymoglobulin|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Drug: Sirolimus|Drug: Corticosteroids","Percentage of Participants With Composite Efficacy Failure at 12 Months|Changes in immune cell profiles|Changes in biomarkers|Number of patients who experience rejection|Number of episodes per patient|First rejection by ISHLT biopsy grading scale|Time to first rejection|Incidence of primary graft dysfunction (PGD)|Patient and graft survival|Types of patients with fatal infectious complications|Number of patients with fatal infectious complications|Types of patients with non-fatal infectious complications|Number of patients with non-fatal infectious complications|Freedom from development of circulating antibodies|Change in coronary maximal intimal thickness|Change in coronary intimal area|Change in coronary intimal volume|Change in coronary vessel area|Change in coronary intimal index|Change in coronary percent atheroma volume|Maintenance doses of mycophenolate mofetil, tacrolimus, sirolimus, and dose of corticosteroids|Number of hospital days per patient|Number of patients requiring hospitalization|Death/Re-transplant|Hemodynamic compromise rejection|Graft dysfunction|Cellular rejection|Antibody mediated rejected|Cardiac Allograft Vasculopathy (CAV)|Any treated rejection","Cedars-Sinai Medical Center|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ATG Pilot Study","September 13, 2018","October 1, 2020","June 30, 2021","September 26, 2017",,"April 10, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03292861"
548,"NCT01304095","Ranolazine, Ethnicity and the Metabolic Syndrome","REMS","Unknown status","No Results Available","Coronary Artery Disease|Angina|Metabolic Syndrome","Drug: Ranolazine","Exercise Duration|fasting glucose|Angina|Concomitant medications|lipid profile|HgbA1c","Atlanta Heart Specialists, LLC|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHS-REMS-001","January 2011","July 2013","November 2013","February 25, 2011",,"July 11, 2013","Atlanta Heart Specialist, LLC, Cumming, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01304095"
549,"NCT02351856","A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy",,"Active, not recruiting","No Results Available","LMNA-Related Dilated Cardiomyopathy","Drug: ARRY-371797, p38 inhibitor, oral","Assess the safety of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.|Assess the efficacy of study drug in terms of change in 6-minute walk test.|Assess the efficacy of study drug in terms of left ventricular function.|Assess the efficacy of study drug in terms of right ventricular function.|Assess the efficacy of the study drug in terms of quality of life.|Characterize the pharmacokinetics (PK) of study drug and metabolites in terms of plasma concentration-time profiles and model-based PK parameters.","Array BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARRAY-797-001","February 2015","February 2022","February 2022","January 30, 2015",,"March 20, 2020","University of Colorado, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Meriter Wisconsin Heart, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02351856"
550,"NCT03891108","A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants",,"Completed","No Results Available","Heart Failure","Drug: BMS-986231 Formulation A|Drug: BMS-986231 Formulation B|Drug: BMS-986231 Formulation C|Drug: BMS-986231 Formulation D","Maximum Plasma Concentration (Cmax) of BMS-986231 and its Metabolites (BMT-284730, BMT-279554, and CAR-000463)|Average Concentration Over a Dosing Interval (Css-av) of BMS-986231 and its Metabolites (BMT-284730, BMT-279554, and CAR-000463)|Area Under the Plasma Concentration-Time Curve From Time 0 (Dosing) Extrapolated to Infinity (AUC(INF)) of BMS-986231 and its Metabolites (BMT-284730, BMT-279554, and CAR-000463)|Area Under the Concentration-Time Curve From Time 0 (Dosing) to the Time of the Last Quantifiable Concentration Observed (AUC(0-T)) of BMS-986231 and its Metabolites (BMT-284730, BMT-279554, and CAR-000463)|Terminal Elimination Phase Half-Life (T-HALF) of BMS-986231 and its Metabolites (BMT-284730, BMT-279554, and CAR-000463)|Time to Reach Cmax in Plasma (Tmax) of BMS-986231 and its Metabolites (BMT-284730, BMT-279554, and CAR-000463)|Metabolite to Parent Molar Ratio of AUC(INF) (MRAUC[INF]) and Metabolite to Parent Molar Ratio of Css-av (MRCssav) of Metabolites of BMS-986231 (BMT-284730, BMT-279554, and CAR-000463)|Total Systemic Clearance (CLT) of BMS-986231|Apparent Volume of Distribution During the Terminal Phase (Vz) of BMS-986231|Volume of Distribution at Steady State (Vss) of BMS-986231|Number of Participants with Adverse Events (AEs)|Number of Participants with Serious AEs (SAEs)|Number of Participants With Significant Changes in Clinical Laboratory Values|Number of Participants with Significant Changes in Vital Signs|Number of Participants with Significant Changes in Electrocardiograms (ECGs)|Number of Participants with Significant Changes in Physical Examinations","Bristol-Myers Squibb","All","18 Years to 40 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CV013-038","February 28, 2019","July 29, 2019","July 29, 2019","March 26, 2019",,"October 1, 2019","PRA Health Sciences, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03891108"
551,"NCT02901587","Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: Lu AF35700 (10 mg/day)|Drug: Lu AF35700 (30 mg/day)|Drug: Quetiapine (Seroquel XR® 800 mg/day)","Change from time-matched baseline on day 1, 21, and 42 in QTcF","H. Lundbeck A/S","All","21 Years to 60 Years   (Adult)","Phase 1","119","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16323A","September 2016","April 18, 2018","April 18, 2018","September 15, 2016",,"September 12, 2019","US1104, Long Beach, California, United States",,"https://ClinicalTrials.gov/show/NCT02901587"
552,"NCT00914121","Study Evaluating The Effect of Bosutinib (SKI-606) On Cardiac Repolarization (Rhythms Of The Heart)",,"Completed","No Results Available","Healthy Subjects","Drug: SKI-606|Drug: Placebo|Drug: Moxifloxacin","Corrected QT interval, including QTcN, QTcB, and QTcF|Laboratory evaluations, Vital Sign measurements, Adverse Event reports","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years to 50 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3160A4-105","June 2009","August 2009","August 2009","June 4, 2009",,"September 2, 2009","Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00914121"
553,"NCT02027454","Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction",,"Completed","No Results Available","Infection, Human Immunodeficiency Virus","Drug: GSK1265744|Drug: GSK1265744 matching placebo|Drug: Moxifloxacin","Change from baseline in QT duration corrected for heart rate by Fridericia's formulas (QTcF) for GSK1265744|Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), individual corrected QTc ( QTci) values, QT, QRS, and PR for GSK1265744|Change from baseline in heart rate (HR) for GSK1265744|Change from baseline in QTcF, QTcB, QTci, QT, QRS, and PR for placebo|Change from baseline in HR for placebo|Change from baseline in QTcF, QTcB, QTci, QT, QRS, and PR for Moxifloxacin|Change from baseline in HR for Moxifloxacin.|Composite of pharmacokinetic (PK) parameters for GSK1265744.|Composite of PK parameters for Moxifloxacin (if needed).|12-lead ECG as a measure of safety and tolerability.|Vital sign as a measure of safety and tolerability.|Number participants with adverse events as a measure of safety and tolerability.|Clinical laboratory parameters assessment as a measure of safety and tolerability.|Change from baseline in QTcF, QTcB and QTci for GSK1265744|Difference between GSK1265744 and placebo in terms of change from baseline in QTcF, QTcB and QTci.|Plasma concentration profile as assessed from composite of PK parameters of GSK1265744.","ViiV Healthcare|GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","117009","January 2014","June 2014","June 2014","January 6, 2014",,"June 16, 2014","GSK Investigational Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02027454"
554,"NCT00868439","Evaluation of Patiromer in Heart Failure Patients","PEARL-HF","Completed","Has Results","Hyperkalemia|Heart Failure","Drug: patiromer|Drug: placebo","Change From Baseline in Serum Potassium to the End of the 28-day Treatment Period.|Proportion of Participants With a Serum Potassium Level During the 28-day Treatment Period That Was > 5.5 mEq/L.|Proportion of Participants Discontinuing the Study Due to Serum Potassium Elevation (Serum K+ > 5.5 mEq/L).|Proportion of Participants Whose Spironolactone Dose Was Increased.|Proportion of Participants With an Increase in Serum Potassium Level From Baseline to the End of the 28-day Treatment Period That Was ≥ 0.5 mEq/L|Time to First Elevated Serum K+ > 5.5 mEq/L.","Relypsa, Inc.|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RLY5016-202","April 2009","November 2009","December 2009","March 25, 2009","December 15, 2015","February 25, 2016","Investigator Site 029, Miami, Florida, United States|Investigator Site 031, Port Charlotte, Florida, United States|Investigator Site 009, Peoria, Illinois, United States|Investigator Site 018, Minneapolis, Minnesota, United States|Investigator Site 020, Buffalo, New York, United States|Investigator Site 005, Northport, New York, United States|Investigator Site 022, Columbus, Ohio, United States|Investigator Site 001, Dallas, Texas, United States|Investigator Site 019, Salt Lake City, Utah, United States|Investigator Site 102, Brno, Czech Republic|Investigator Site 104, Prague, Czech Republic|Investigator Site 103, Prague, Czech Republic|Investigator Site 605, Tblisi, Georgia|Investigator Site 602, Tblisi, Georgia|Investigator Site 604, Tblisi, Georgia|Investigator Site 603, Tblisi, Georgia|Investigator Site 201, Gottingen, Germany|Investigator Site 202, Heidelberg, Germany|Investigator Site 305, Warsaw, Poland|Investigator Site 409, Barnaul, Russian Federation|Investigator Site 407, Kemerovo, Russian Federation|Investigator Site 406, Moscow, Russian Federation|Investigator Site 402, Moscow, Russian Federation|Investigator Site 403, Moscow, Russian Federation|Investigator Site 404, St Petersburg, Russian Federation|Investigator Site 412, St Petersburg, Russian Federation|Investigator Site 405, St Petersburg, Russian Federation|Investigator Site 507, Dnipropetrovsk, Ukraine|Investigator Site 502, Kharkiv, Ukraine|Investigator Site 509, Kharkiv, Ukraine|Investigator Site 504, Kiev, Ukraine|Investigator Site 506, Kiev, Ukraine|Investigator Site 501, Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT00868439"
555,"NCT02808585","Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)",,"Completed","No Results Available","Heart Failure","Drug: PB1046 Injection|Drug: Placebo Injection","Adverse events|Telemetry|12-Lead ECG Assessment|12-Lead ECG - Categorical analysis of QT/QTc interval|Laboratory parameters - Serum chemistry|Laboratory parameters - Plasma chemistry|Laboratory parameters - Hematology|Laboratory parameters - Urinalysis|Laboratory parameters - eGFR|Laboratory parameters - Lipid profile|Vital signs - Blood pressure|Vital signs - Heart rate|Vital signs - Temperature|Vital signs - Respiratory rate|Pharmacokinetic profile - Area under the curve over the dosing interval [AUC(0-t)]|Pharmacokinetic profile - Area under the curve concentration-time profile|Pharmacokinetic profile - Maximum serum concentration (Cmax)|Pharmacokinetic profile - Time to Cmax (Tmax)|Pharmacokinetic profile - Elimination rate constant (lambda z)|Pharmacokinetic profile - Elimination half-life (t½)|Pharmacokinetic profile - Clearance (CL/F), uncorrected for bioavailability|Pharmacokinetic profile - Volume of Distribution (Vz/F), uncorrected for bioavailability (F)|Immunogenicity","PhaseBio Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PB1046-PT-CL-0003-P1","June 2016","December 6, 2017","December 6, 2017","June 22, 2016",,"March 29, 2019","Pinnacle Research Group, LLC, Anniston, Alabama, United States|Phoenix Medical Research, Peoria, Arizona, United States|Cardiology Associates Research Company, Daytona Beach, Florida, United States|Revivial Research, Miami, Florida, United States|North Dallas Research Associates, McKinney, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02808585"
556,"NCT03207451","Influence of Vorapaxar on Thrombin Generation and Coagulability",,"Completed","No Results Available","Coronary Artery Disease|Peripheral Vascular Disease|Myocardial Infarction","Drug: Vorapaxar|Drug: Vorapaxar and Aspirin|Drug: Vorapaxar and Clopidogrel|Drug: Vorapaxar, Aspirin, and Clopidogrel","Effects of Vorapaxar on Platelet Aggregation as measured by Light Transmission Aggregometry. Final and Maximum percent of aggregation will be measured in response to ADP, Collagen, and Thrombin Receptor Activating Protein (TRAP or SFFLRN).|Effects of Vorapaxar on Clot Formation as measured by thrombelastography.|Effects of Vorapaxar on Thrombin Generation as measured by Calibrated Automatic Thrombogram Assay.|Effects of Vorapaxar on plasma C-reactive protein (CRP).|Effects of Vorapaxar on plasma fibrinogen.|Effects of Vorapaxar on plasma von Willebrand factor (vWF).|Effects of Vorapaxar on plasma interleukin (IL)-6.|Effects of Vorapaxar on plasma p-selectin.|Effects of Vorapaxar on plasma plasminogen activator inhibitor (PAI)-1.|Effects of Vorapaxar on plasma matrix metalloproteinase (MMP)-9.|Effects of Vorapaxar on Urinary TxB2.","Inova Health Care Services|Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","15-2051","January 1, 2016","July 1, 2018","August 1, 2018","July 2, 2017",,"August 22, 2018","Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03207451"
557,"NCT04113109","Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2",,"Recruiting","No Results Available","Heart Failure","Drug: LCZ 696|Drug: Icatibant|Drug: placebo|Drug: Para-aminohippurate|Drug: Iohexol","mean arterial pressure|Urine sodium excretion|Heart rate|Urine volume|Renal plasma flow|Glomerular filtration rate|Urine albumin-to-creatinine ratio","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","#191228","November 1, 2019","April 2022","October 2022","October 2, 2019",,"March 17, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04113109"
558,"NCT03795428","Long-Term, Open Label Extension Study of PB1046 in PAH Subjects Following Completion of Study PB1046-PT-CL-0004","VIP Extend","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: PB1046 Injection","Incidence and Severity of Adverse Events|Incidence of Clinical Laboratory Abnormalities|Change in Diastolic Blood Pressure from baseline|Change in Systolic Blood Pressure from baseline|Change in Oral Body Temperature from baseline|Change in Respiratory Rate from baseline|Change in Heart Rate from baseline|12-Lead ECG - Incidence of clinically significant abnormal ECG findings as measured by 12 Lead ECG|Incidence of Immunogenicity|Survival|Change from baseline in 6MWD (6 minute walk distance test)|Change from baseline in NT-proBNP|Change from baseline in NYHA/WHO Functional Class (FC)|Change from baseline in emPHasis-10 (Health Related Quality of Life) score|Change from baseline in Borg Dyspnea Index (BDI)|Incidence of Clinical Worsening|Change in REVEAL Registry Risk Calculator Score","PhaseBio Pharmaceuticals Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB1046-PT-CL-0006","April 10, 2019","January 15, 2024","February 15, 2024","January 7, 2019",,"February 25, 2020","Emory University, The Emory Clinic, Atlanta, Georgia, United States|University of Rochester Medical Center, Rochester, New York, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03795428"
559,"NCT02119091","Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers",,"Unknown status","No Results Available","Cardiac Toxicity","Drug: Moxifloxacin","ΔΔQTcF","Haiyan Li|Food and Drug Administration (FDA)|Spaulding Clinical Research LLC|BioClinica, Inc.|Peking University|Peking University Third Hospital","All","18 Years to 45 Years   (Adult)","Phase 1","80","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUTH_CTC_2013_001","April 2014","June 2014","December 2014","April 21, 2014",,"April 21, 2014","Spaulding Clinical Research LLC, West Bend, Wisconsin, United States|Peking University Third Hospital Clinical Trial Center, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02119091"
560,"NCT02889367","A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Odalasvir 100 mg|Drug: Placebo|Drug: Odalasvir 500 mg|Drug: Odalasvir (Up to maximum 1000 mg)","The Relationship Between the Plasma Concentrations of Odalasvir and Changes in the QT/QTc Interval Using Exposure-response (ER) Analysis|Maximum Plasma Concentration (Cmax) of Odalasvir|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of Odalasvir|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of Odalasvir|PR Interval Changes and the Relationship Between the Plasma Concentrations of Odalasvir and PR Interval Changes Using ER Analysis|Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Janssen Research & Development, LLC","All","18 Years to 50 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CR108163|64294178HPC1002","September 12, 2016","March 4, 2017","March 4, 2017","September 5, 2016",,"April 10, 2017","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02889367"
561,"NCT00894387","Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure","ASTRONAUT","Completed","Has Results","Acute Decompensated Heart Failure|Congestive Heart Failure","Drug: Aliskiren|Drug: Placebo","Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6 Months|Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 12 Months|Change From Baseline in the Clinical Summary Score to 1 Month, 6 Months and 12 Months|Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 6 Months|Time to Event Analysis: Number of Patients With All-cause Mortality Hospitalized for an AHF Event Within 12 Months|Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Level at 1 Month, 6 Months, and 12 Months|Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 12 Months","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","1639","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPP100A2368|2009-010236-18","May 2009","August 2012","August 2012","May 7, 2009","October 10, 2013","November 7, 2013","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Sylmar, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Oakbrook Terrace, Illinois, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Cherry Hill, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Saratoga Springs, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Springfield, Tennessee, United States|Novartis Investigative Site, Brownsville, Texas, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, San Nicolas, Buenos Aires, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Mechelen, Belgium|Novartis Investigative Site, Mol, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, St. John's, Newfoundland and Labrador, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Florida Blanca, Colombia|Novartis Investigative Site, Hradec Kralove, CZE, Czech Republic|Novartis Investigative Site, Brno - Bohunice, Czech Republic|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Prague 4, Czech Republic|Novartis Investigative Site, Prague 5, Czech Republic|Novartis Investigative Site, Praha 10, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Slany, Czech Republic|Novartis Investigative Site, Teplice, Czech Republic|Novartis Investigative Site, Znojmo, Czech Republic|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pontoise, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Bevensen, Germany|Novartis Investigative Site, Bad Nauheim, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bischofswerda, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Cloppenburg, Germany|Novartis Investigative Site, Cottbus, Germany|Novartis Investigative Site, Dessau, Germany|Novartis Investigative Site, Detmold, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Halle/'Saale, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Herne, Germany|Novartis Investigative Site, Herrsching, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Konstanz, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Langen, Germany|Novartis Investigative Site, Ludwigslust, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Merseburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nordhorn, Germany|Novartis Investigative Site, Paderborn, Germany|Novartis Investigative Site, Quedlinburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Sömmerda, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Pecs, Baranya, Hungary|Novartis Investigative Site, Balatonfured, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Hodmezovasarhely, Hungary|Novartis Investigative Site, Nagykanizsa, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Zalaegerszeg, Hungary|Novartis Investigative Site, Secunderabad, Andhra Pradesh, India|Novartis Investigative Site, Vadodara, Gujrat, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Mangalore, Karnataka, India|Novartis Investigative Site, Kochi, Kerala, India|Novartis Investigative Site, Indore, M.p., India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Nazareth, Israel|Novartis Investigative Site, Safed, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Pavia, (pv), Italy|Novartis Investigative Site, Verona, (vr), Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Lagosanto, FE, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Grosseto, GR, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Casarano, LE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Scorrano, LE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Legnano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Albano Laziale, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Rimini, RN, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Legnago, VR, Italy|Novartis Investigative Site, Quezon City, Metro Manila, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Grodzisk Wielkopolski, Poland|Novartis Investigative Site, Klodzko, Poland|Novartis Investigative Site, Kraków, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Lódz, Poland|Novartis Investigative Site, Ruda Slaska, Poland|Novartis Investigative Site, Swidnica, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Walbrzych, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Zabrze, Poland|Novartis Investigative Site, Zamosc, Poland|Novartis Investigative Site, Bucuresti, District 1, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Tirgoviste, Romania|Novartis Investigative Site, Lubertsi, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Sankt-Peterburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St.Petersburg, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Liptovsky Mikulas, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Komarno, Slovakia|Novartis Investigative Site, Kosice-Saca, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Sanlúcar de Barrameda, Andalucia, Spain|Novartis Investigative Site, Villamartin, Andalucia, Spain|Novartis Investigative Site, Palma de Mallorca, Baleares, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Majadanonda, Madrid, Spain|Novartis Investigative Site, Pozuelo de Alarcón, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Keelung City, Taiwan|Novartis Investigative Site, Lin-Ko, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Atakum / Samsun, Turkey|Novartis Investigative Site, Etlik / Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kirikkale, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT00894387"
562,"NCT02201342","Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents",,"Completed","No Results Available","Single Ventricle Heart Disease After Fontan Surgery","Drug: Udenafil","Number of subjects with Serious Adverse Events|Plasma clearance of parent drug and active metabolite|Measurement of maximum oxygen consumption (VO2)|PAT Index|Myocardial Performance Index (MPI)","Mezzion Pharma Co. Ltd|National Heart, Lung, and Blood Institute (NHLBI)|Pediatric Heart Network","All","14 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","36","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHN-Udenafil-01|U01HL068270","July 2014","April 2015","April 2015","July 28, 2014",,"April 27, 2015","Riley Hospital for Children, Indianapolis, Indiana, United States|University of Michigan Congenital Heart Center, Ann Arbor, Michigan, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02201342"
563,"NCT02833831","Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: ALS-008176|Drug: Placebo|Drug: Moxifloxacin","Change from baseline in Corrected QT intervals (QTc)|Number of participants with adverse events as a measure of safety and tolerability|Change from baseline in ECG parameters: RR interval, PR interval and QRS interval|ALS-008112 and ALS 008144 plasma concentration-effect relationship for changes in QT/QTc (Panels 1 and 2)|Change from Baseline in QT/QTc interval in healthy subjects (Panel 2)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0- last])|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0- infinity])|Elimination Half-Life (t1/2)|Elimination Rate Constant (Lambda[z])|Plasma Concentration at 24 hours post dosing|Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])|Change from baseline in Heart Rate|Change from baseline in T wave morphology|Frequency of T wave morphology changes","Janssen Research & Development, LLC","All","18 Years to 50 Years   (Adult)","Phase 1","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR108169|64041575RSV1003","June 2, 2016","February 17, 2017","February 24, 2017","July 14, 2016",,"September 18, 2017","Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT02833831"
564,"NCT01762839","A Study to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: Single-Dose IV Oritavancin Diphosphate|Drug: Placebo|Drug: Moxifloxacin","Placebo-adjusted change from Baseline in QTcF|Placebo-adjusted change from baseline in QTcB, HR, RR, PR, and QRS interval analyses.|Placebo adjusted change from Baseline in the appearance or worsening of ST, T and U-wave morphology.|Effects on the QTc interval related to plasma concentration levels of oritavancin|Evaluate the number of volunteers with adverse events or abnormalities in lab/urine results and safety ECGs as measures of safety and tolerability","The Medicines Company","All","18 Years to 60 Years   (Adult)","Phase 1","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MDCO-ORI-12-02","January 2013","January 2013","March 2013","January 8, 2013",,"April 17, 2013","Spaulding Clinical, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01762839"
565,"NCT02283788","Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization",,"Completed","Has Results","Epilepsy","Drug: BIA 2-093|Drug: Moxifloxacin|Drug: Placebo","QTcI - QT Interval Individually Corrected for Heart Rate - Day 5|QTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula|QTcF - QT Interval Corrected Using Fridericia's Formula","Bial - Portela C S.A.","All","18 Years to 45 Years   (Adult)","Phase 1","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIA-2093-116","March 2007","June 2007","June 2007","November 5, 2014","December 22, 2014","December 22, 2014","Comprehensive Phase OneTM, Miramar, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02283788"
566,"NCT02293148","Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers",,"Completed","No Results Available","Anaemia","Drug: GSK1278863 75 mg|Drug: GSK1278863 500 mg|Drug: Moxifloxacin 400 mg|Drug: Placebo matching GSK1278863|Drug: Placebo matching Moxifloxacin","Composite of pharmacokinetic (PK) parameters for GSK1278863 and its metabolites for Part A|Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) interval for Part B|Assessment of 12-lead ECG for Part A|Assessment of Vital Signs for Part A|Number of participants with Adverse Events (AE) for Part A|Assessment of Clinical Laboratory Tests for Part A|Change from baseline in QT duration corrected for heart rate by Bazett's formula (QTcB), heart rate (HR), PR, QRS, and QT interval corrected for heart rate (QTci/QTciL interval) for GSK1278863 for Part B|Change from baseline in QTcB, HR, PR, QRS, and QTci/QTciL interval for moxifloxacin for Part B|Composite of PK parameters for GSK1278863, its metabolites and moxifloxacin for Part B|Maximal change from baseline in ECG parameters for Part B|Change from baseline for other ECG parameters for Part B|Change in QTc Cmax for Part B|Assessment of Vital Signs for Part B|Number of participants with Adverse Events in Part B|Assessment of Clinical Laboratory Tests for Part B|ECG assessment as a safety measure in Part B","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","113635","November 17, 2014","March 10, 2015","March 10, 2015","November 18, 2014",,"July 24, 2018","GSK Investigational Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02293148"
567,"NCT01565720","Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization",,"Completed","No Results Available","Pharmacokinetics of Isavuconazole|Healthy Volunteers","Drug: Isavuconazole|Drug: Placebo|Drug: Moxifloxacin","Change from baseline in QT interval corrected for heart rate using Fridericia's correction (QTcF)|Change from baseline in Electrocardiogram (ECG) variables: QT, PR, RR intervals, QRS, and Heart Rate","Astellas Pharma Global Development, Inc.|Basilea Pharmaceutica International Ltd|Astellas Pharma Inc","All","18 Years to 55 Years   (Adult)","Phase 1","161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","9766-CL-0017","March 2012","June 2012","June 2012","March 29, 2012",,"July 9, 2012","Parexel, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT01565720"
568,"NCT02877095","Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot","SUBQ-Pilot","Completed","Has Results","Acute Heart Failure","Drug: Furosemide","Overall Safety of a Strategy Based on Subcutaneous Delivery of Furosemide in Inpatients and Outpatients as Measured by Number of Adverse Events","Adrian Hernandez|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00070399","December 19, 2016","November 7, 2017","November 7, 2017","August 24, 2016","March 15, 2019","March 15, 2019","Emory University Hospital, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|Metro Health System, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02877095/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02877095"
569,"NCT02522208","Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets",,"Completed","No Results Available","Heart Failure","Drug: BiDil XR|Drug: BiDil Immediate Release (IR)","Pulmonary Artery (PA) Systolic Pressure change from baseline to each post dose timepoint for 28 hours|Comparison of Maximum observed effect (Emax) on PA systolic pressure vs maximum blood concentration (Cmax)|Comparison of the area under the effect curve (AUEC) on PA systolic pressure versus AUC (the area under the curve) for blood","Arbor Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AR06.009","September 2015","April 2016","April 2016","August 13, 2015",,"November 8, 2016","Pinnacle Research Group, LLC, Anniston, Alabama, United States|Linfritz Research Institue Inc, Coral Gables, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Center for Medical Research, LLC, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT02522208"
570,"NCT02270242","Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention","TWILIGHT","Completed","No Results Available","Cardiovascular Disease|Interventional Cardiology","Drug: Aspirin|Drug: Placebo|Drug: ticagrelor","Bleeding episode|Ischemic episode","Icahn School of Medicine at Mount Sinai|AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 4","9006","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GCO 14-1383","July 2015","July 10, 2019","July 10, 2019","October 21, 2014",,"September 11, 2019","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02270242"
571,"NCT01365221","The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel","SWITCH 600/60","Completed","No Results Available","Acute Coronary Syndrome","Drug: Prasugrel","The primary objective is to compare platelet reactivity, as assessed by the VerifyNow P2Y12 assay, between patients receiving a loading dose of clopidogrel and a reloading dose of prasugrel to patients receiving only a loading dose of prasugrel.|The secondary objective of this study is to describe rates of bleeding events associated with a loading dose of prasugrel in patients who have already received a loading dose of clopidogrel.","Rebecca Torguson|Medstar Health Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","77","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SWITCH 600/60","October 2010","January 2014","January 2014","June 3, 2011",,"January 2, 2020","The Heart Center, Huntsville, Alabama, United States|Washington Hospital Center, Washington, District of Columbia, United States|Sinai Center for Thrombosis Research, Baltimore, Maryland, United States|Saint Luke's Hospital, Kansas City, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01365221"
572,"NCT01831154","The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery",,"Completed","Has Results","Diabetes|Hyperglycemia|Surgical Site Infection","Drug: Tight Glycemic|Drug: Conventional Glycemic|Drug: Standard Glycemic","Number of Participants Undergoing Open Heart Surgery With Postoperative Surgical Site Infection|The Effect of Intraoperative Tight Glycemic Control on Postoperative Procalcitonin Plasma Levels in Patients Undergoing Open Heart Surgery|The Effect of Intraoperative Tight Glycemic Control on Postoperative C-Reactive Protein Plasma Levels in Patients Undergoing Open Heart Surgery|Intraoperative Blood Glucose Levels in Patients Undergoing Open Heart Surgery|The Effect of Tight Glycemic Control on Intensive Care Unit Length of Stay in Patients Undergoing Open Heart Surgery|Intraoperative Glycemic Stability in Patients Undergoing Open Heart Surgery Compared Between Three Glycemic Protocols.","James A. Haley Veterans Administration Hospital|University of South Florida","All","21 Years and older   (Adult, Older Adult)","Not Applicable","37","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","106219","May 2010","July 2011","October 2011","April 15, 2013","April 24, 2017","April 24, 2017","James A. Haley VAH, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01831154"
573,"NCT03735316","Vitamin B12a Vasoplegic Syndrome",,"Recruiting","No Results Available","Vasoplegic Syndrome","Drug: Hydroxocobalamin|Procedure: Cardiopulmonary Bypass|Drug: Placebos","Change in Mean Arterial Pressure|Change in Vasopressor infusion rates|Change in Systolic Blood Pressure|Death|Duration of hospital stay|Duration of intensive care stay","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","17-011130","April 25, 2019","April 30, 2021","December 31, 2021","November 8, 2018",,"June 12, 2019","Mayo Clinic Saint Mary's Hospital, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03735316"
574,"NCT03432884","A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: BGB-3111|Drug: Placebo|Drug: Moxifloxacin","Part A: Incidence of treatment-emergent adverse events (safety and tolerability)|Part B: Corrected QT interval [QTc]|Part A: PK Parameters|Part B: Heart Rate (HR)|Part B: PR Intervals|Part B: QRS Intervals|Part B: PK Parameters|Part B: Incidence of treatment-emergent adverse events (safety and tolerability)","BeiGene","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","BGB-3111-106","January 25, 2018","April 16, 2018","April 16, 2018","February 14, 2018",,"April 24, 2020","Frontage Clinical Services, Inc., Secaucus, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03432884"
575,"NCT02467387","A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure",,"Completed","Has Results","Non-Ischemic Heart Failure","Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Drug: Lactated Ringer's Solution","Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.","CardioCell LLC|Stemedica Cell Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM-104-M-CHF","June 1, 2014","May 11, 2017","May 11, 2017","June 10, 2015","January 7, 2020","January 7, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Centers for Heart Failure Therapy, Chicago, Illinois, United States|Stony Brook Heart Institute, Stony Brook, New York, United States|Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02467387/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02467387"
576,"NCT00838383","Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery","FCAD02","Completed","No Results Available","Cardiac Surgery Subjects|Subjects Undergoing CABG and/or Cardiac Valve Replacement","Drug: sitaxsentan (Thelin)|Drug: Placebo","The primary efficacy endpoint is the reduction in PVR.|Other safety endpoints.","Pfizer","All","Child, Adult, Older Adult","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1321004","August 2006","March 2008","March 2008","February 6, 2009",,"February 7, 2012","Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Chattanooga, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00838383"
577,"NCT02684786","A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension",,"Withdrawn","No Results Available","Pulmonary Artery Hypertension","Drug: reserpine|Procedure: stellate ganglion block|Drug: lidocaine","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of participants with successful stellate ganglion block|Effect of stellate ganglion block on heart rate|Change in 6 minute walk distance from one month of reserpine therapy|Change in brain natriuretic peptide (BNP) from one month of reserpine therapy|Change in Doppler derived mean pulmonary artery pressure from one month of reserpine therapy|Change in blood pressure from one month of reserpine therapy|Change in Minnesota Living with heart failure questionnaire from one month of reserpine therapy|Hemodynamic effect of stellate ganglion block|Change in heart rate from one month of reserpine therapy","Mayo Clinic","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-000928","July 2016","July 2016","July 2016","February 18, 2016",,"May 22, 2019","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02684786"
578,"NCT01199523","A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females",,"Completed","No Results Available","Healthy Subjects","Drug: Placebo|Drug: mirabegron|Drug: moxifloxacin","QTcl evaluated through electrocardiogram analysis|Pharmacodynamic assessment through electrocardiogram analysis","Astellas Pharma Inc","All","18 Years to 55 Years   (Adult)","Phase 1","352","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","178-CL-077","May 2010","November 2010","November 2010","September 13, 2010",,"July 3, 2013","Glendale, California, United States|Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01199523"
579,"NCT02884206","Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction","PERSPECTIVE","Active, not recruiting","No Results Available","Chronic Heart Failure (CHF)","Drug: LCZ696|Drug: Valsartan|Drug: Placebo of LCZ696|Drug: Placebo of Valsartan","Change from baseline in the CogState Global Cognitive Composite Score (GCCS)|Change from baseline in cortical composite standardized uptake value ratio (SUVr)|Change from baseline in individual cognitive domains (memory, executive function, and attention)|Change from baseline in the summary score of the instrumental activities of daily living (IADL)","Novartis Pharmaceuticals|Novartis","All","60 Years and older   (Adult, Older Adult)","Phase 3","593","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696B2320|2016-001254-17","November 23, 2016","March 28, 2022","March 28, 2022","August 30, 2016",,"April 10, 2020","Novartis Investigative Site, Andalusia, Alabama, United States|Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Fort Payne, Alabama, United States|Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Glendale, Arizona, United States|Novartis Investigative Site, Mesa, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Surprise, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Newport Beach, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Danbury, Connecticut, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Edgewater, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Homestead, Florida, United States|Novartis Investigative Site, Inverness, Florida, United States|Novartis Investigative Site, Jacksonville Beach, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Naples, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Lombard, Illinois, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Eunice, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Kalispell, Montana, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Reno, Nevada, United States|Novartis Investigative Site, Reno, Nevada, United States|Novartis Investigative Site, Elmer, New Jersey, United States|Novartis Investigative Site, Haddon Heights, New Jersey, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Manhasset, New York, United States|Novartis Investigative Site, Gastonia, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Oregon City, Oregon, United States|Novartis Investigative Site, Springfield, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Fort Mill, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Rock Hill, South Carolina, United States|Novartis Investigative Site, Summerville, South Carolina, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Gonzales, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lufkin, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Everett, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Buenos Aires, ARG, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Ramos Mejia, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Chemside, Queensland, Australia|Novartis Investigative Site, Milton, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Sofia, BGR, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Rijeka, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Villeurbanne, France|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Leverkusen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Berlin Buch, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bitburg, Germany|Novartis Investigative Site, Dessau-Roßlau, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Stadtlohn, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Wuppertal, Germany|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Wonju, Gangwon-Do, Korea, Republic of|Novartis Investigative Site, Seongnam Si, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Hertogenbosch, Netherlands|Novartis Investigative Site, Lodz, Lodzkie, Poland|Novartis Investigative Site, Tarnow, Malopolskie, Poland|Novartis Investigative Site, Krakow, Maloposkie, Poland|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Santa Coloma De Gramanet, Cataluna, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Eskisehir, Meselik, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Axbridge, Somerset, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Cardiff, Wales, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newport, United Kingdom|Novartis Investigative Site, Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02884206"
580,"NCT01961323","Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart",,"Completed","Has Results","Hypertension|Left Ventricular Diastolic Dysfunction","Drug: Nebivolol","Improvement in Exercise Tolerance|E Velocity Indexed to e' (E/e' Ratio) of the Left Ventricle|Untwist Rate of the Left Ventricle","Icahn School of Medicine at Mount Sinai|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 4","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-0493","March 2012","March 2016","March 2016","October 11, 2013","November 24, 2017","November 24, 2017","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01961323"
581,"NCT01155336","The Effects of Lovaza® in Acute Myocardial Infarction","OmegaMI","Terminated","Has Results","Myocardial Infarction","Drug: Lovaza®|Drug: The placebo contained 1 gram of corn oil in each capsule.","Platelet Function|Cardiac Electrophysiology","University of Rochester|GlaxoSmithKline|Albany College of Pharmacy and Health Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LVZ114193","June 2010","May 2011","May 2011","July 1, 2010","March 11, 2013","November 6, 2017","University or Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01155336"
582,"NCT01211808","Effect of Diltiazem on Pharmacokinetics of BMS-914392",,"Completed","No Results Available","Atrial Fibrillation","Drug: BMS-914832|Drug: Diltiazem","Pharmacokinetics of single dose of BMS-914393 derived from serial measurements of BMS-914392 plasma concentrations|The effect of multiple doses of BMS-914392 on PR, QRS, RR, and QTc intervals derived from serial electrocardiograms (ECGs)|Number of subjects with adverse events as a measure of safety and tolerability of BMS-914392","Bristol-Myers Squibb|PRA Health Sciences","All","18 Years to 45 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","CV203-002","September 2010","October 2010","October 2010","September 30, 2010",,"February 2, 2011","Pra International, Lenexa, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01211808"
583,"NCT01090661","A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: mipomersen sodium|Drug: moxifloxacin hydrochloride (Avelox®)|Drug: placebo","change from baseline in QTcF (corrected Frederica's CT interval)|ECG intervals (QTcB (corrected Bazett's QT interval), HR (heart rate, PR, QRS, and QT)|change in ECG morphological patterns|Correlation between delta delta QTc interval and plasma mipomersen concentrations|Incidence of treatment-emergent Adverse Events|mipomersen plasma pharmacokinetic (PK) parameters: Area Under the Curve (AUC 0-22.5h), Maximum Concentration (Cmax), Time to Maximum Concentration (Tmax)","Kastle Therapeutics, LLC|Ionis Pharmaceuticals, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MIPO2800209","March 2010","May 2010","May 2010","March 22, 2010",,"August 3, 2016","PPD Development, LP, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01090661"
584,"NCT03502499","Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation",,"Recruiting","No Results Available","Ventricular Arrythmia","Drug: Half-normal saline|Drug: Normal saline","total radiofrequency ablation time, and total procedure time|acute success|long-term success","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","TCAI_HNS_VA","May 16, 2018","May 2020","May 2020","April 18, 2018",,"February 6, 2019","University of Colorado Hospital, Aurora, Colorado, United States|Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03502499"
585,"NCT03496623","A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD",,"Recruiting","No Results Available","Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease","Drug: Inhaled treprostinil solution|Drug: Placebo solution","Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 12|Change in Borg dyspnea score from Baseline to Week 12|Change in quality of life (QOL) measured by St. George's Respiratory Questionnaire (SGRQ) from Baseline to Week 12|Change in QOL measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) from Baseline to Week 12|Change in plasma concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) levels from Baseline to Week 12","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIN-PH-304","June 27, 2018","September 30, 2020","September 30, 2020","April 12, 2018",,"February 13, 2020","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Southern California, Los Angeles, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|St. Francis Medical Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Pulmonary Disease Specialists, Kissimmee, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Advocate Aurora Health Care, Elmhurst, Illinois, United States|Advocate Condell Medical Center, Libertyville, Illinois, United States|Advocate Heart Institute & Pulmonology, Normal, Illinois, United States|Edward Heart Hospital, Oakbrook Terrace, Illinois, United States|Indiana University Healh North Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health, Troy, Michigan, United States|Albany Medical College, Albany, New York, United States|The Mount Sinai Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple Lung Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center - Montefiore, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CardioPulmonary Research Center, Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03496623"
586,"NCT00970489","Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation","OPERA","Completed","Has Results","Atrial Fibrillation","Drug: Omega -3 fatty acids|Drug: Placebo","Any First Post-op Atrial Fibrillation or Flutter (AF)|Post-op Af|Other Arrhythmias|Other Endpoints","Brigham and Women's Hospital|The OPERA Investigators","All","18 Years and older   (Adult, Older Adult)","Phase 3","1516","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IND-104364","August 2010","May 2012","June 2012","September 2, 2009","April 10, 2017","April 10, 2017","US, Italy and Argentina, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00970489"
587,"NCT01318811","A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation",,"Terminated","Has Results","Acute Kidney Injury|Acute Renal Failure|Heart Failure","Drug: Dilute unfractionated heparin|Drug: Standard concentration unfractionated heparin","Filter Life|Number of Major Bleeding Complications","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VU 110162","March 2011","April 3, 2016","April 3, 2016","March 18, 2011","January 29, 2019","February 22, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01318811"
588,"NCT01065051","Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics","HEARTWORK","Terminated","Has Results","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Change in Peak Power Index at Rest|Change in Left Ventricular Stroke Work Index (LVSWI) at Rest|Change in Left Ventricular Ejection Fraction (LVEF) at Rest|Change in End-systolic Elastance at Rest|Change in Peak Power Index During the Cardiopulmonary Exercise Tests|Change in Lateral Mitral Annular Peak Systolic Velocity (Sm) During the Cardiopulmonary Exercise Tests|Change in Peak Systolic Tricuspid Annular Velocity (RV-Sm) During the Cardiopulmonary Exercise Tests|Change in Tricuspid Annular Plane Systolic Excursion (TAPSE) During the Cardiopulmonary Exercise Tests|Change in Lateral Mitral Annular Peak Early Diastolic Velocity (E') During the Cardiopulmonary Exercise Tests|Change in the Slope of the Relationship Between Work Rate and Mean Pulmonary Arterial Pressure (PAPmean) During the Cardiopulmonary Exercise Tests|Change in the Ventilatory Efficiency (V'E/V'CO2) Measured From Baseline to the Anaerobic Threshold (AT) During the Cardiopulmonary Exercise Tests (CPET)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14549","November 2010","January 2011","January 2011","February 9, 2010","January 6, 2014","January 6, 2014","Boston, Massachusetts, United States|Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01065051"
589,"NCT01603758","Physiological Study of Human Cholesterol Metabolism and Excretion",,"Completed","No Results Available","Coronary Heart Disease|Cardiovascular Disease|Dyslipidemia|Disorder of Cholesterol Metabolism","Drug: Ezetimibe","Fractional Excretion of Endogenous Cholesterol","Richard E. Ostlund Jr., MD|National Heart, Lung, and Blood Institute (NHLBI)|Washington University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","132","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","201110042|R01HL108160","January 2014","June 2015","June 2015","May 23, 2012",,"May 6, 2016","Washington University School of Medicine, St. Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01603758"
590,"NCT01260454","The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain",,"Completed","Has Results","Pulmonary Hypertension|Pulmonary Arterial Hypertension","Drug: Qutenza (8% capsaicin)","Pain Score on a Visual Analogue Scale|Number of Participants Who Experienced Greater Than 6 Pain Level Using the 10 Point Visual Analog Score|Number of Participants Who Used of Narcotics Following a Treprostinil Infusion Site Change","University of Rochester|United Therapeutics","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Qutenza White","November 2010","December 2011","April 2012","December 15, 2010","February 22, 2016","April 21, 2016","Mary M. Parkes Asthma Center, University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01260454"
591,"NCT01881971","Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center","SPARC","Completed","No Results Available","HIV Seropositivity","Drug: Placebo|Drug: Rouvastatin calcium","change in inflammatory markers - hsCRP|effect of rosuvastatin on pulmonary and cardiac status by use of cIMT/FMD/ Vascular studies are a measure of preclinical atherosclerosis and predicts future cardiovascular events and mortality","Alison Morris|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","23","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PRO12100503|RFA-HL-12-034","May 2013","November 2015","January 2016","June 20, 2013",,"August 14, 2019","University of California, Los Angelos, Los Angeles, California, United States|University of California, SF, San Francisco, California, United States|University of Pittsburgh department of medicine division of Pulmonary, Allergy and Critical Care medicine, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01881971"
592,"NCT02533505","Phase IV O2 Consumption Study in COPD Patients.",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Drug: Matching Placebo pMDI 160/4.5 μg","Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Oxygen Consumption (VO2; Obtained Via a Metabolic Cart)|Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Oxygen Pulse (Defined as VO2/Heart Rate [HR]; VO2 is Obtained Via a Metabolic Cart; Used as a Surrogate for Stroke Volume)|Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Gas Exchange Parameter HR|Change From Pre-dose (Visit 2)to Post-dose (Visit 5) Assessment in Spirometry.|Change in Vt/Ti|Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in the Modified Borg Scale for Dyspnea|Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Gas Exchange Parameter VCO2|Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Gas Exchange Parameter SaO2|Change in RR|Change in Ti/Ttot|Change in Vt|Change in Ve|Change From Pre-dose (Visit 2) to Post-dose (Visit 5) Assessment in Spirometry.","AstraZeneca","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D589CC00014","August 25, 2015","August 12, 2016","August 12, 2016","August 26, 2015","July 30, 2018","July 30, 2018","Research Site, Hartford, Connecticut, United States|Research Site, Boston, Massachusetts, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02533505"
593,"NCT01523366","A Pharmacodynamic Study With Ticagrelor in Hispanic Patients",,"Completed","Has Results","Stable Coronary Artery Disease","Drug: Ticagrelor|Drug: Clopidogrel","Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose|Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose|Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8|Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses|AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 4","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5130L00012","April 2012","May 2013","May 2013","February 1, 2012","August 5, 2014","August 18, 2014","Research Site, Los Angeles, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Linden, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01523366"
594,"NCT03646643","Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial","PRECAF","Recruiting","No Results Available","Atrial Fibrillation|Arrhythmias, Cardiac","Procedure: Standard Atrial fibrillation ablation|Procedure: Coronary sinus to left atrium connection elimination","Time to recurrence of atrial arrhythmias|Atrial fibrillation burden","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","829990","August 18, 2018","August 2020","August 2021","August 24, 2018",,"September 10, 2019","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03646643"
595,"NCT01780727","Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery",,"Completed","No Results Available","Ventricular Dysfunction, Left|Major Adverse Cardiac Events","Procedure: EGHEM","Number of Patients who undergo dynamic heart function changes during surgery|Safety of Echo-Guided Hemodynamic Management during surgery","University of Nebraska","All","70 Years and older   (Older Adult)","Not Applicable","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","630-12-FB","September 2014","May 31, 2018","August 27, 2018","January 31, 2013",,"August 28, 2018","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01780727"
596,"NCT03037580","Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction",,"Terminated","No Results Available","Pulmonary Hypertension|Heart Failure With a Preserved Ejection Fraction","Drug: Oral treprostinil|Drug: Placebo","Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 24|Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels from Baseline to Week 24|Time to the First Clinical Worsening Event Over the 24-week Treatment Period|Change in WHO Functional Class from Baseline to Week 24","United Therapeutics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDE-HF-301","August 15, 2017","December 3, 2019","December 3, 2019","January 31, 2017",,"April 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|University of California Los Angeles Pulmonary Division, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Medical Faculty Associates, George Washington University, Washington, District of Columbia, United States|Bay Area Cardiology Associates, Brandon, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|University of South Florida ; Tampa General Hospital, Tampa, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont Physicians Georgia Lung, Austell, Georgia, United States|WellStar Medical Group, Marietta, Georgia, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|OSF HealthCare, Peoria, Illinois, United States|Indiana University Health Methodist Research Institute, INC, Indianapolis, Indiana, United States|Community Physician Network, Heart and Vascular Care, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Iowa Heart Center, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|St. Luke's Hospital, Chesterfield, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Barnabas Health Lung Center, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Pulmonary Health Physicians, PC, Syracuse, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|The Lindner Research Center The Christ Hospital Health Network, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|VitaLink Research - Anderson, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Summit Medical Group, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03037580"
597,"NCT01019486","Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)","RABIT1D","Completed","Has Results","Coronary Artery Disease|Type 1 Diabetes Mellitus","Drug: Regadenoson myocardial perfusion imaging|Drug: Regadenoson MRI myocardial blood flow","Coronary Blood Flow Assessment With Regadenoson Stress by Cardiac MRI Between Non-diabetic and Type 1 Diabetic Subjects.|Measured Coronary Blood Flow is Directly Correlated With Coronary Flow Reserve Measured Invasively in the Cardiac Catheterization Laboratory After Regadenoson Pharmacologic Stress.|Myocardial Perfusion Index","University of Colorado, Denver","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 4","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-0426","November 2009","December 2011","December 2011","November 25, 2009","December 14, 2015","December 14, 2015","Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01019486"
598,"NCT01578772","A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease",,"Completed","Has Results","Endothelial Dysfunction","Drug: Telmisartan","6-week Change in Diameter and Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy|6-week Change in Maximum Relative Flow Mediated Dilatation (FMD) of the Brachial Artery With Telmisartan Therapy","University of California, Los Angeles|The Campbell Foundation","All","50 Years and older   (Adult, Older Adult)","Phase 2","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","miFMD","August 2012","March 2013","March 2013","April 17, 2012","December 8, 2014","December 8, 2014","UCLA CARE Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01578772"
599,"NCT02370680","Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease","DURATION","Completed","No Results Available","Cardiovascular Disease","Drug: Aspirin|Drug: Durlaza™","change in platelet aggregation|Reactive Hyperemia Index|Safety as measured by the number and system class of adverse events reported in each treatment arm","New Haven Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NHP-ASP-102","February 2015","July 2015","July 2015","February 25, 2015",,"August 6, 2015","Platelet and Thrombosis Research, LLC, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02370680"
600,"NCT01721447","Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage","DOLOP","Completed","Has Results","Atrial Fibrillation","Drug: Optison echocardiography contrast agent","Percent Confidence in Assessment of Left Atrial Appendage Thrombus|Concordance Between Echo Readers in Determining Presence or Absence of Thrombus in the Left Atrial Appendage","University of Utah","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11-OPT-018 GE","June 2013","May 2018","May 2018","November 4, 2012","June 4, 2019","August 20, 2019","University of Utah, Salt Lake City, Utah, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT01721447/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01721447"
601,"NCT03292653","Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients With Worsening Heart Failure",,"Suspended","No Results Available","Cardiac Failure Aggravated","Drug: Sotagliflozin (SAR439954)|Drug: Placebo|Drug: Heavy Water|Drug: 131-Iodine-Albumin","Adverse events (AEs)|Change in plasma volume|Change in hemoconcentration|Change in erythropoietin|Change in N-terminal pro b-type natriuretic peptide (NT-proBNP)","Lexicon Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","PDY15079|2017-002774-39|U1111-1190-7962","December 4, 2017","November 2020","November 2020","September 25, 2017",,"February 24, 2020","Investigational Site Number 8400005, La Jolla, California, United States|Investigational Site Number 8400001, New Haven, Connecticut, United States|Investigational Site Number 8400007, Rochester, Minnesota, United States|Investigational Site Number 8400002, Cleveland, Ohio, United States|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 5280001, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03292653"
602,"NCT02812238","Study to Evaluate the Effect of Nicotinamide Riboside on Immunity",,"Completed","Has Results","Atherosclerosis|Diabetes|Coronary Artery Disease","Dietary Supplement: Nicotinamide riboside (NR)|Drug: Placebo","Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 39 Years   (Adult)","Not Applicable","38","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","160129|16-H-0129","June 23, 2016","August 28, 2018","August 28, 2018","June 24, 2016","September 17, 2019","September 17, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02812238/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02812238"
603,"NCT02644057","Dobutamaine Versus Milrinone in Cardiorenal Syndrome","DOMICAS","Withdrawn","No Results Available","Cardiorenal Syndrome","Drug: Milrinone|Drug: Dobutamine","Serum creatinine measured in mg/dl(milligram/decilitre)|Length of hospitalisation|Readmission rate|Global visual analog score|Dyspnea visual analog score|Urine output measured in milliliters in a 24 hour period","Maimonides Medical Center","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-05-11-MMC","March 2016","September 2016","September 2016","December 31, 2015",,"August 10, 2018","Maimonides Medical Center, Brooklyn, New York, United States",,"https://ClinicalTrials.gov/show/NCT02644057"
604,"NCT01775761","A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)",,"Completed","No Results Available","TTR Cardiomyopathy","Drug: Period 1|Drug: Period 2|Drug: Period 3","QTc interval using Fridericia's correction method (QTcF) of tafamidis and placebo (baseline-adjusted) at each post-dose time|QTcF of moxifloxacin and placebo at historical moxifloxacin median Tmax of 3 hours.|Tmax|Cmax|AUC0-24","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","B3461031","January 2013","April 2013","April 2013","January 25, 2013",,"May 21, 2013","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01775761"
605,"NCT01480336","The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot",,"Completed","No Results Available","Arrhythmia","Drug: Amiodarone Plus Ranolazine|Drug: Amiodarone with Placebo","Pharmacokinetic Parameter Estimates|Electrocardiogram (ECG)","Hartford Hospital|Gilead Sciences","All","Child, Adult, Older Adult","Not Applicable","19","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)","KLUG003330HE","February 2011","January 2013","January 2013","November 28, 2011",,"March 19, 2013","Hartford Hospital, Hartford, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01480336"
606,"NCT04105998","Effects of IM Oxytocin on Pupil Diameter and HRV",,"Active, not recruiting","No Results Available","Chronic Pain Due to Injury","Drug: Oxytocin|Drug: Placebo","Fluctuation in Pupil Diameter (Hippus) -Pre drug administration|Fluctuation in Pupil Diameter (Hippus) -Post drug administration|Heart rate variability in the high frequency range (HF-HRV) as a reflection of level of parasympathetic nervous system tone","Wake Forest University Health Sciences","All","18 Years to 66 Years   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00060838","October 24, 2019","December 2020","December 2020","September 26, 2019",,"April 17, 2020","Wake Forest Baptist Health, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04105998"
607,"NCT00939913","Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy","NAC","Unknown status","No Results Available","Nephropathy","Drug: intravenous NAC|Drug: Placebo","Incidence of CIN|in-hospital mortality|30 day mortality|duration of hospitalization|serum cystatin C","Ochsner Health System|Cumberland Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB#2006.212.A","January 2007","May 2010","May 2010","July 15, 2009",,"September 18, 2009","Ochsner Medical Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT00939913"
608,"NCT01951651","Effect of Exenatide on Liver and Heart Fat and Inflammation",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Exenatide|Drug: Glipizide","Myocardial Fat Content|Hepatic Fat Content|Left Ventricular Ejection Fraction (LVEF)(%).|Monocyte Inflammatory Protein Nuclear Factor Kappa-B (NFkappaB) (%)","Baylor College of Medicine","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-26030","April 2010","October 2012","March 2013","September 26, 2013","April 15, 2016","May 16, 2016","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01951651"
609,"NCT04210375","Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)",,"Not yet recruiting","No Results Available","Heart Failure With Reduced Ejection Fraction","Drug: JK07|Drug: Matching Placebo","Incidence and severity of treatment-emergent adverse events [safety and tolerability]|Pharmacokinetics (area under the concentration versus time curve) of JK07","Salubris Biotherapeutics Inc","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JK07.1.01","March 15, 2020","September 15, 2021","March 15, 2022","December 24, 2019",,"December 26, 2019","University of Arizona College of Medicine, Tucson, Arizona, United States|Stanford University Medical Center, Stanford, California, United States|Harvard Medical School/ Massachusetts General Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health Science University Hospital, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04210375"
610,"NCT02228408","Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD","HIDE","Active, not recruiting","No Results Available","Chronic Hemodialysis (ESRD)","Drug: Hydralazine/Isorsorbide Dinitrate|Drug: Placebo","Rate of hypotension, serious adverse events, gi events and cardiovascular death|Efficacy-Change in coronary flow reserve (CFR) from 0-6 months|Change in E' on TDI Echo from 0-6 months|Reduction in drug dose or discontinuation of study drug|Number of patients completing study from 0 to 6 months|Change in circulating fibrosis markers and angiogenesis markers|Change in LVMI","Brigham and Women's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DK100772-01","August 28, 2017","April 15, 2019","May 15, 2019","August 29, 2014",,"February 15, 2019","Brigham & Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02228408"
611,"NCT03649711","Chronic Kidney Disease (CKD) Platelet Study",,"Recruiting","No Results Available","Chronic Kidney Diseases|Heart Attack|Stroke, Ischemic","Drug: Ticagrelor 90mg|Drug: Clopidogrel 75mg|Drug: Aspirin 81 mg","ADP induced platelet aggregation|Platelet surface P-selectin expression","University of Arkansas|American Society of Nephrology","All","18 Years to 91 Years   (Adult, Older Adult)","Phase 3","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","227997|1241997","November 1, 2018","June 30, 2020","June 30, 2021","August 28, 2018",,"November 19, 2019","Central Arkansas Veterans Affairs Hospital, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,"https://ClinicalTrials.gov/show/NCT03649711"
612,"NCT03619213","Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.","DELIVER","Recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: Dapagliflozin|Drug: Placebo","Time to the first occurrence of any of the components of this composite: 1) CV death; 2) Hospitalisation for HF; 3) Urgent HF visit (e.g., emergency department or outpatient visit)|Total number of (first and recurrent) hospitalisations for HF and CV death|Change from baseline in the total symptom score (TSS) of the KCCQ at 8 months|Proportion of patients with worsened NYHA class from baseline to 8 months|Time to the occurrence of death from any cause","AstraZeneca","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","6100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D169CC00001|2018-000802-46","August 27, 2018","June 22, 2021","June 22, 2021","August 7, 2018",,"March 24, 2020","Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Loma Linda, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Munster, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Hammond, Louisiana, United States|Research Site, Houma, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Mentor, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Falls Church, Virginia, United States|Research Site, Leesburg, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Catamarca, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Ciudad Autonomade Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Bruxelles, Belgium|Research Site, Huy, Belgium|Research Site, Leuven, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Votuporanga, Brazil|Research Site, Dimitrovgrad, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Winnipeg, Manitoba, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Port Perry, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Stoney Creek, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Cangzhou, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Chifeng, China|Research Site, Daqing, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Jinan, China|Research Site, Lanzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Yinchuan, China|Research Site, Zhuhai, China|Research Site, Benesov, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Dobrany, Czechia|Research Site, Jaromer, Czechia|Research Site, Kladno, Czechia|Research Site, Louny, Czechia|Research Site, Nachod, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Pardubice, Czechia|Research Site, Pisek, Czechia|Research Site, Plzen, Czechia|Research Site, Prachatice, Czechia|Research Site, Praha 2, Czechia|Research Site, Tabor, Czechia|Research Site, Bayonne, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, La Tronche, France|Research Site, Le Coudray Cedex, France|Research Site, Lille, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pau Cedex, France|Research Site, Pessac, France|Research Site, Rennes Cedex 9, France|Research Site, Saint Brieuc, France|Research Site, Toulon, France|Research Site, Toulouse Cedex 9, France|Research Site, TOURCOING cedex, France|Research Site, Valenciennes, France|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Békéscsaba, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Adachi-ku, Japan|Research Site, Asahi-shi, Japan|Research Site, Azumino-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Higashiohmi-shi, Japan|Research Site, Ichinomiya-shi, Japan|Research Site, Iizuka-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kuki-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Mito-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Nakagami-gun, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasago-shi, Japan|Research Site, Toride-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Aguascalientes, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mazatlán, Mexico|Research Site, Mexico, Mexico|Research Site, Monclova, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Querétaro, Mexico|Research Site, Tijuana, Mexico|Research Site, Veracruz, Mexico|Research Site, Veracruz, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Meppel, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bellavista, Peru|Research Site, Callao, Peru|Research Site, Chancay, Peru|Research Site, Chorrillos, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Urb. El Chipe, Peru|Research Site, Białystok, Poland|Research Site, Bochnia, Poland|Research Site, Chojnice, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Lublin, Poland|Research Site, Opole, Poland|Research Site, Oława, Poland|Research Site, Płock, Poland|Research Site, Rzeszów, Poland|Research Site, Torun, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Brasov, Romania|Research Site, Brasov, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Targu Mures, Romania|Research Site, Tg Mures, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sanlúcar De Barrameda (Cádiz), Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Villamartín (Cádiz), Spain|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03619213"
613,"NCT02557672","PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding",,"Enrolling by invitation","No Results Available","Bleeding|Blood Loss, Surgical|Cardiovascular Surgical Procedures|Prothrombin Complex Concentrates|Fresh Frozen Plasma","Drug: Prothrombin complex concentrate (Human)|Biological: Fresh frozen plasma (FFP)","Blood loss|Blood product transfusion","Mayo Clinic|CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-009579","August 2016","December 2020","May 2021","September 23, 2015",,"January 30, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02557672"
614,"NCT03834883","Reducing the Risk of Drug-Induced QT Interval Lengthening in Women",,"Recruiting","No Results Available","Long QT Syndrome|Abnormalities, Drug-Induced","Drug: Progesterone|Drug: Ibutilide","Baseline (pre-ibutilide) QT-F and QT-Fram intervals|Maximum post-ibutilide QT-F and QT-Fram intervals|% change from baseline (pre-ibutilide) in maximum QT-F and QT-Fram intervals|Area under the QT-F and QT-Fram versus time curves during and for 1 hour following ibutilide infusion|Area under the QT-F and QT-Fram versus time curves during and for 8 hours following ibutilide infusion|Baseline (pre-ibutilide) heart rate-corrected J-Tpeak (J-Tpeakc) intervals|Maximum post-ibutilide J-Tpeakc intervals|% change from baseline (pre-ibutilide) in maximum J-Tpeakc intervals|Area under the J-Tpeakc versus time curve during and for 1 hour following ibutilide infusion|Area under the J-Tpeakc versus time curve during and for 8 hours following ibutilide infusion|Baseline (pre-ibutilide) Tpeak-Tend intervals|Maximum post-ibutilide Tpeak-Tend intervals|% change from baseline (pre-ibutilide) maximum Tpeak-Tend intervals|Area under the Tpeak-Tend versus time curves during and for 1 hour following ibutilide infusion|Area under the Tpeak-Tend versus time curves during and for 8 hours following ibutilide infusion","Indiana University|American Heart Association|Purdue University","Female","21 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1806935117","March 26, 2019","June 30, 2022","June 30, 2022","February 8, 2019",,"May 7, 2019","Indiana University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03834883"
615,"NCT02771509","Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass",,"Recruiting","No Results Available","Acute Kidney Injury","Drug: ANG-3777|Drug: Placebo","The mean AUC of the percent increase in serum creatinine above baseline","Angion Biomedica Corp|Everest Clinical Research|CTI Clinical Trial and Consulting Services","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","002-15","February 24, 2017","March 2021","June 2021","May 13, 2016",,"February 10, 2020","University of Southern California, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|California Institute of Renal Reseach, San Diego, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|UF Health at Unviersity of Florida, Gainesville, Florida, United States|River City Clinical Research, Jacksonville, Florida, United States|Indiana Ohio Heart, Fort Wayne, Indiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|MidMichigan Medical Center Midland, Midland, Michigan, United States|Cardiac & Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|Bryan Heart, Lincoln, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|TriHealth, Cincinnati, Ohio, United States|Cleveland Clinic Fairview, Cleveland, Ohio, United States|Ohio State Wexner Medical Center, Columbus, Ohio, United States|Baylor Jack and Jane Hamilton Heart and Vascular center- Soltero Cardiovascular Research Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, Brazil|Instituto de Cardiologia do Rio Grande do Sul / Fundação Universitária de Cardiologia (IC - FUC), Porto Alegre, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP), Ribeirão Preto, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José Do Rio Preto, Brazil|Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (InCor - HCFMUSP), São Paulo, Brazil|London Health Sciences Center, London, Ontario, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Canada|CHUM - Hôtel Dieu, Québec, Canada|MUHC - Royal Victoria Hospital, Québec, Canada|St. John Regional Hospital, Saint John, Canada|Saint Michael's Hospital, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT02771509"
616,"NCT03043651","Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)",,"Terminated","No Results Available","Pulmonary Hypertension Associated With HFpEF","Drug: Oral Treprostinil","Long-term Safety of Oral Treprostinil in Subjects with PH Associated with HFpEF as assessed by number of subjects with treatment-related adverse events|Long-term Safety of Oral Treprostinil in Subjects with PH Associated with HFpEF as assessed by clinical laboratory parameters|Long-term Safety of Oral Treprostinil in Subjects with PH Associated with HFpEF as assessed by number of subjects with heart failure signs and symptoms|Effect of Continued Long-term Oral Treprostinil Therapy on the 6-Minute Walk Distance (6MWD)|Effect of Continued Long-term Oral Treprostinil Therapy on the Borg Dyspnea Score|Effect of Continued Long-term Oral Treprostinil Therapy on World Health Organization (WHO) Functional Class|Effect of Continued Long-term Oral Treprostinil Therapy on the N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP)","United Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-HF-302","August 15, 2017","March 2, 2020","March 2, 2020","February 6, 2017",,"April 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Banner University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|University of California Los Angeles Pulmonary Division, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|South Denver Cardiology, Littleton, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Medical Faculty Associates, George Washington University, Washington, District of Columbia, United States|Bay Area Cardiology Associates, Brandon, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|University of South Florida ; Tampa General Hospital, Tampa, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont Physicians Georgia Lung, Austell, Georgia, United States|WellStar Medical Group, Marietta, Georgia, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|OSF HealthCare, Peoria, Illinois, United States|Indiana University Health Methodist Research Institute, INC, Indianapolis, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Iowa Heart Center, West Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|St. Luke's Hospital, Chesterfield, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Barnabas Health Lung Center, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Pulmonary Health Physicians, PC, Syracuse, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Pinehurst, North Carolina, United States|The Lindner Research Center The Christ Hospital Health Network, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|University of Toldedo Medical Center, Toledo, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|VitaLink Research - Anderson, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Summit Medical Group, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Clinic, Roanoke, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03043651"
617,"NCT02837328","Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias",,"Completed","Has Results","Premature Atrial Contraction","Drug: Oral Magnesium Supplement|Drug: Placebo","Change in Premature Atrial Contractions (PACs)|Change in Magnesium Concentration","University of Minnesota","All","55 Years and older   (Adult, Older Adult)","Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1605M87323","March 1, 2017","September 15, 2017","September 15, 2017","July 19, 2016","April 30, 2019","November 1, 2019","University of Minnesota - Twin Cities, Minneapolis, Minnesota, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02837328/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02837328/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02837328"
618,"NCT03036124","Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure","DAPA-HF","Completed","No Results Available","Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","Drug: Dapagliflozin|Drug: Placebo","Time to the first occurrence of any of the components of the composite: CV death or hospitalization for HF or an urgent HF visit.|Time to the first occurrence of either of the components of the composite: CV death or hospitalization for HF.|Total number of (first and recurrent) HF hospitalizations and CV death.|Change from baseline measured at 8 months in the total symptom score of the Kansas City Cardiomyopathy Questionnaire (KCCQ), a specific HF patient reported outcome questionnaire.|Time to the first occurrence of any of the components of the composite: ≥50% sustained decline in eGFR or reaching End Stage Renal Disease (ESRD) or renal death.|Time to death from any cause.","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","4744","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1699C00001|2016-003897-41","February 8, 2017","July 17, 2019","July 17, 2019","January 30, 2017",,"August 15, 2019","Research Site, Alexander City, Alabama, United States|Research Site, Fairhope, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Vista, California, United States|Research Site, Wilmington, Delaware, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Chalmette, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New York, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Burlington, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Falls Church, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Esperanza, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Quilmes, Argentina|Research Site, Quilmes, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Martin, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Vicente Lopez, Argentina|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Brasillia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Uberlandia, Brazil|Research Site, Votuporanga, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Abbotsford, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, North Vancouver, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Port Perry, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chifeng, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Lanzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xuzhou, China|Research Site, Xuzhou, China|Research Site, Yinchuan, China|Research Site, Zhuhai, China|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Kolin, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha, Czechia|Research Site, Trebic, Czechia|Research Site, Hellerup, Denmark|Research Site, Herlev, Denmark|Research Site, Hvidovre, Denmark|Research Site, København Ø, Denmark|Research Site, Odense C, Denmark|Research Site, Svendborg, Denmark|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Homburg, Germany|Research Site, Kassel, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Papenburg, Germany|Research Site, Stuttgart, Germany|Research Site, Wermsdorf, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Kecskemét, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Szentes, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ahmedabad, India|Research Site, Aurangabad, India|Research Site, Bangalore, India|Research Site, Belagavi, India|Research Site, Ernakulam, India|Research Site, Gurgaon, India|Research Site, Kanpur, India|Research Site, Karamsad, India|Research Site, Kolkata, India|Research Site, Maharashtra, India|Research Site, Nadiad, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Adachi-ku, Japan|Research Site, Aki-gun,, Japan|Research Site, Azumino-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hiratsuka-shi, Japan|Research Site, Hitachinaka-shi, Japan|Research Site, Iizuka-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kakamigahara-shi, Japan|Research Site, Kasama-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kitakyusyu-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kusatsu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Mito-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi,Kita-ku, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sanyoonoda-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shimonoseki-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Tachikawa-shi, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Toride-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Apeldoorn, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bochnia, Poland|Research Site, Gdynia, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Kędzierzyn Koźle, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Oława, Poland|Research Site, Płock, Poland|Research Site, Sokółka, Poland|Research Site, Torun, Poland|Research Site, Wierzchosławice, Poland|Research Site, Łódź, Poland|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Changhua City, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Airdrie, United Kingdom|Research Site, Clydebank, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Paisley, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03036124"
619,"NCT02062203","Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: AKB-6548 (therapeutic dose)|Drug: AKB-6548 (supratherapeutic dose)|Drug: Placebo|Drug: Moxifloxacin","Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) following AKB-6548 administration.|Placebo-corrected change-from-baseline heart rate (HR), PR interval, QRS interval|Categorical outliers defined as QTcF >450 msec, 480 msec and 500 msec at any timepoint and change-from-baseline QTcF (ΔQTcF) >30 msec (increased by 30 msec) and >60 msec|Categorical outliers for HR, PR interval, QRS interval|Frequency of T wave morphology changes|Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) following moxifloxacin administration|Safety parameters to include adverse events; changes in routine clinical laboratory measures including chemistry, hematology, and urinalysis; and clinically significant changes noted during physical examinations or in vital signs","Akebia Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","AKB-6548-CI-0010","January 2014","April 2014","April 2014","February 13, 2014",,"November 14, 2018","Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02062203"
620,"NCT00829296","Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries","EFFORT","Completed","Has Results","Hypertension|Diabetes","Drug: nebivolol|Drug: Metoprolol","Change in Central Systolic Blood Pressure (SBP)|Change in Pulse Wave Velocity (PWV)|Change in Augmentation Index|Change in Pulse Pressure Amplification","University of Chicago|Forest Laboratories","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2|Phase 3","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","16310B (EFFORT trial)","January 2009","April 2012","April 2013","January 27, 2009","November 5, 2014","February 5, 2016","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00829296"
621,"NCT01325415","A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects",,"Completed","No Results Available","Amount of NKTR-118 in Blood|Variation in the Heart's Electrical Cycle","Drug: NKTR-118|Drug: moxifloxacin|Drug: Placebo","To evaluate the effect of a single dose of NKTR-118 25 mg and 150 mg on the change in time-matched QTcF intervals compared with placebo|The effect of a single dose of NKTR-118 25 mg and 150 mg on the change in time-matched QTcF intervals compared with placebo|To evaluate the effect of a single oral dose of moxifloxacin 400 mg on the changes in time-match QTcF intervals compared with placebo, which will be used as supporting data.|Collect adverse events to assess the safety after dosing of NKTR-118 25mg and 150 mg in healthy male subjects.|Collect adverse events to assess the safety after dosing of NKTR-118 25mg and 150mg in healthy male subjects.","AstraZeneca","Male","18 Years to 50 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","D3820C00014","April 2011","July 2011","July 2011","March 29, 2011",,"October 15, 2014","Research Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01325415"
622,"NCT03030235","Dapagliflozin in PRESERVED Ejection Fraction Heart Failure","PRESERVED-HF","Recruiting","No Results Available","Chronic Heart Failure With Preserved Systolic Function","Drug: Dapagliflozin 10Mg Oral Tablet|Drug: Dapagliflozin matching placebo","Change from baseline in NTproBNP at 6 and 12 weeks|Change from baseline in heart failure related quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score over the treatment period|Change from baseline in 6 minute walk test over the treatment period|Change from baseline in BNP over the treatment period|Change from baseline in HbA1c over the treatment period (evaluated separately in patients with and without type 2 diabetes)|Proportion of patients with a ≥ 5pts increase in KCCQ|Proportion of patients with a ≥ 20% decrease in NTproBNP|Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP|Change in weight over 12 weeks|Change in systolic blood pressure over 12 weeks","Saint Luke's Health System","All","19 Years to 119 Years   (Adult, Older Adult)","Phase 4","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00053","March 1, 2017","October 2020","February 2021","January 24, 2017",,"September 13, 2019","Heart Group of the Eastern Shore, Fairhope, Alabama, United States|University of Southern California, Los Angeles, California, United States|First Coast Cardiovascular Institute, Jacksonville, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Emory University, Atlanta, Georgia, United States|NorthShore University HealthSystem Research Insititute, Evanston, Illinois, United States|Northwestern University, Evanston, Illinois, United States|Chicago Medical Research, Hazel Crest, Illinois, United States|OSF HealthCare Cardiovascular Institute, Peoria, Illinois, United States|Massachusetts Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|St. Francis Hospital, New York, New York, United States|Eastern Nephrology Associates, New Bern, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Scott and White Research Institute, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03030235"
623,"NCT03448419","This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms",,"Completed","No Results Available","Heart Failure","Drug: Empagliflozin|Drug: Placebo","The primary endpoint is the change from baseline to week 12 in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions|Change from baseline to week 12 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)|Change from baseline to week 12 in Chronic Heart Failure Questionnaire Self- Administered Standardized format (CHQ-SAS) dyspnea score|Change from baseline to week 6 in exercise capacity as measured by the distance walked in 6 minutes|Change from baseline in Clinical Congestion Score at week 12|Change from baseline in Patient Global Impression of Severity (PGI-S) of Heart Failure Symptoms at week 12|Change from baseline in Patient Global Impression of Dyspnea Severity at week 12|Patient Global Impression of Change (PGI-C) in Heart Failure Symptoms at week 12|Patient Global Impression of Change in Dyspnea at week 12|Change from baseline in N-terminal pro-brain natriuretic peptide (NTproBNP) at week 12","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1245-0168|2017-004073-14","March 20, 2018","October 7, 2019","October 7, 2019","February 28, 2018",,"November 21, 2019","Mobile Heart Specialists, PC, Mobile, Alabama, United States|The Center for Clinical Trials, Inc., Saraland, Alabama, United States|California Heart Specialists, Huntington Beach, California, United States|Manshadi Heart Institute, Inc, Stockton, California, United States|University of California Los Angeles, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Western Connecticut Health Network, Danbury, Connecticut, United States|Bio1 Clinical Research, Miami Beach, Florida, United States|Infinite Clinical Research, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Pharmacology Research, LLC, North Miami Beach, Florida, United States|Palm Beach Gardens Research Center, LLC, Palm Beach Gardens, Florida, United States|East Coast Institute for Research, LLC, Saint Augustine, Florida, United States|Cozy Research LLC, Zephyrhills, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Georgia Arrhythmia Consultants and Research Institute, Warner Robins, Georgia, United States|St Luke's Clinic - Idaho Cardiology Associates, Boise, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States|Chicago Medical Research, Hazel Crest, Illinois, United States|Midwest Heart and Vascular Specialists, Overland Park, Kansas, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Grace Research, LLC, Shreveport, Louisiana, United States|Clinical Trials of America LA, LLC, West Monroe, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|John D. Dingell VA Medical Center, Detroit, Michigan, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Med Research One, Florissant, Missouri, United States|Cox Medical Center South, Springfield, Missouri, United States|The DOCS, Las Vegas, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|New York Heart Research Foundation, Inc., Mineola, New York, United States|UNC REX Healthcare, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Rama Research LLC, Marion, Ohio, United States|Columbia Heart Clinic, Columbia, South Carolina, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|Angiocardiac Care of Texas, Houston, Texas, United States|Acacia Medical Research Institute,LLC, Sugar Land, Texas, United States|Mary Washington Hospital Research Department, Fredericksburg, Virginia, United States|York Clinical Research, LLC, Norfolk, Virginia, United States|Aspirus Research Institute, Wausau, Wisconsin, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Cairns Base Hospital, Cairns, Queensland, Australia|Peninsular Health CV Research Unit, Frankston, Victoria, Australia|University of Calgary, Calgary, Alberta, Canada|KMH Cardiology Centres Inc., Mississauga, Ontario, Canada|Toronto Heart Centre, Toronto, Ontario, Canada|Sameh Fikry Medicine Professional Corporation, Waterloo, Ontario, Canada|CIMS Studienzentrum Bamberg GmbH, Bamberg, Germany|Klinische Forschung Berlin GbR, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Bremer Institut für Herz- und Kreislaufforschung (BIHKF) am Klinikum Links der Weser, Bremen, Germany|Cardiologicum Dresden und Pirna, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Klinikum Esslingen GmbH, Esslingen, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany|Universitäts-Herzzentrum Freiburg, Bad Krozingen GmbH, Freiburg, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Ulm, Ulm, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|General Hospital of Athens Konstantopoulio-Agia Olga, Athens, Greece|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|General University Hospital ""Attikon"", Haidari, Athens, Greece|University General Hospital of Heraklion, Herakleion, Crete, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|University Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Centro Cardiologico Monzino-IRCCS, Milano, Italy|Asst Santi Paolo E Carlo, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Università Federico II, Napoli, Italy|Università degli studi di Palermo, Palermo, Italy|IRCCS San Raffaele, Roma, Italy|Sykehuset Østfold Kalnes, Grålum, Norway|Vestre Viken, Ringerike Sykehus HF, Hønefoss, Norway|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Helse Stavanger, Stavanger Universitetssykehus, Stavanger, Norway|St. Olavs Hospital, Universitetssykehuset i Trondheim, Trondheim, Norway|INTERCORE Medical Center, Bydgoszcz, Poland|Leszek Bryniarski Specialized Medical Cabinet, Krakow, Poland|Card.Cli.Mil.Med.Ac.Uni.Cli.Hosp. Cent.Vetera.Hosp.Lodz, Lodz, Poland|Cent.Clin.Hosp.Med.Univ.Lodz,Electrocard, Lodz, Poland|Provincial Specialist M. Kopernik Hospital, Lodz, Poland|Independent Public Healthcare, Dept. of Cardiology, Pulawy, Pulawy, Poland|The Provincial Polyclinical Hospital in Torun, Torun, Poland|Central Hospital of Medical Academy, Warsaw, Warsaw, Poland|4. Military Clinical Hospital with Polyclinic SP ZOZ, Wroclaw, Poland|CHLO, EPE - Hospital de Santa Cruz, Carnaxide, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Centro Hosp. de Leiria-Pombal, Leiria, Portugal|CHLC, EPE - Hospital de Santa Marta, Lisboa, Portugal|CHLO, EPE - Hospital S. Francisco Xavier, Lisboa, Portugal|CHULN, EPE - Hospital de Santa Maria, Lisboa, Portugal|CHTS, EPE - Hospital Padre Américo, Penafiel, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital San Rafael, Granada, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain|Hospital La Princesa, Madrid, Spain|Hospital Clínico de Valencia, Valencia, Spain|Sahlgrenska US, Göteborg, Göteborg, Sweden|Sahlgrenska Universitetssjukhuset, Östra, Göteborg, Sweden|Akardo Med Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03448419"
624,"NCT03448406","This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.",,"Completed","No Results Available","Heart Failure","Drug: Empagliflozin|Drug: Placebo","the change from baseline to week 12 in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions|Change from baseline to week 12 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)|Change from baseline to week 12 in Chronic Heart Failure Questionnaire Self- Administered Standardized format (CHQ-SAS) dyspnea score|Change from baseline to week 6 in exercise capacity as measured by the distance walked in 6 minutes|Change from baseline in Clinical Congestion Score at week 12|Change from baseline in Patient Global Impression of Severity (PGI-S) of Heart Failure Symptoms at week 12|Change from baseline in Patient Global Impression of Dyspnea Severity at week 12|Patient Global Impression of Change (PGI-C) in Heart Failure Symptoms at week 12|Patient Global Impression of Change in Dyspnea at week 12|Change from baseline in N-terminal pro-brain natriuretic peptide (NTproBNP) at week 12","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1245-0167|2017-004072-59","March 20, 2018","October 9, 2019","October 9, 2019","February 28, 2018",,"November 5, 2019","Mobile Heart Specialists, PC, Mobile, Alabama, United States|The Center for Clinical Trials, Inc., Saraland, Alabama, United States|California Heart Specialists, Huntington Beach, California, United States|Manshadi Heart Institute, Inc, Stockton, California, United States|University of California Los Angeles, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Western Connecticut Health Network, Danbury, Connecticut, United States|Bio1 Clinical Research, Miami Beach, Florida, United States|Infinite Clinical Research, Miami, Florida, United States|Advance Medical Research Center, Miami, Florida, United States|Pharmacology Research, LLC, North Miami Beach, Florida, United States|Palm Beach Gardens Research Center, LLC, Palm Beach Gardens, Florida, United States|East Coast Institute for Research, LLC, Saint Augustine, Florida, United States|Cozy Research LLC, Zephyrhills, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Georgia Arrhythmia Consultants and Research Institute, Warner Robins, Georgia, United States|St Luke's Clinic - Idaho Cardiology Associates, Boise, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States|Chicago Medical Research, Hazel Crest, Illinois, United States|Midwest Heart and Vascular Specialists, Overland Park, Kansas, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Grace Research, LLC, Shreveport, Louisiana, United States|Clinical Trials of America LA, LLC, West Monroe, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|John D. Dingell VA Medical Center, Detroit, Michigan, United States|Med Research One, Florissant, Missouri, United States|Cox Medical Center South, Springfield, Missouri, United States|The DOCS, Las Vegas, Nevada, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Albany Stratton VA Medical Center Albany, NY, Albany, New York, United States|UNC REX Healthcare, Raleigh, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|Rama Research LLC, Marion, Ohio, United States|Columbia Heart Clinic, Columbia, South Carolina, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|DiscoveResearch, Inc., Beaumont, Texas, United States|Angiocardiac Care of Texas, Houston, Texas, United States|Acacia Medical Research Institute,LLC, Sugar Land, Texas, United States|Mary Washington Hospital Research Department, Fredericksburg, Virginia, United States|York Clinical Research, LLC, Norfolk, Virginia, United States|Canberra Hospital, Garran, Australian Capital Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Peninsular Health CV Research Unit, Frankston, Victoria, Australia|University of Calgary, Calgary, Alberta, Canada|KMH Cardiology Centres Inc., Mississauga, Ontario, Canada|Toronto Heart Centre, Toronto, Ontario, Canada|Sameh Fikry Medicine Professional Corporation, Waterloo, Ontario, Canada|CIMS Studienzentrum Bamberg GmbH, Bamberg, Germany|Klinische Forschung Berlin GbR, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Cardiologicum Dresden und Pirna, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany|Universitäts-Herzzentrum Freiburg, Bad Krozingen GmbH, Freiburg, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Ulm, Ulm, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|General Hospital of Athens Konstantopoulio-Agia Olga, Athens, Greece|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|General Hospital of Chalkida, Chalkida, Greece|University General Hospital of Heraklion, Herakleion, Crete, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|University Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Centro Cardiologico Monzino-IRCCS, Milano, Italy|Asst Santi Paolo E Carlo, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Ospedale Regina Montis Regalis, Mondovì (CN), Italy|Università Federico II, Napoli, Italy|Università degli studi di Palermo, Palermo, Italy|IRCCS San Raffaele, Roma, Italy|Sykehuset Østfold Kalnes, Grålum, Norway|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Helse Stavanger, Stavanger Universitetssykehus, Stavanger, Norway|St. Olavs Hospital, Universitetssykehuset i Trondheim, Trondheim, Norway|INTERCORE Medical Center, Bydgoszcz, Poland|10.Military Clin.Hospital&Polyclinic, Bydgoszcz, Poland|Leszek Bryniarski Specialized Medical Cabinet, Krakow, Poland|Card.Cli.Mil.Med.Ac.Uni.Cli.Hosp. Cent.Vetera.Hosp.Lodz, Lodz, Poland|Cent.Clin.Hosp.Med.Univ.Lodz,Electrocard, Lodz, Poland|Provincial Specialist M. Kopernik Hospital, Lodz, Poland|Independent Public Healthcare, Dept. of Cardiology, Pulawy, Pulawy, Poland|Central Hospital of Medical Academy, Warsaw, Warsaw, Poland|4. Military Clinical Hospital with Polyclinic SP ZOZ, Wroclaw, Poland|CHLO, EPE - Hospital de Santa Cruz, Carnaxide, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Centro Hosp. de Leiria-Pombal, Leiria, Portugal|CHLC, EPE - Hospital de Santa Marta, Lisboa, Portugal|CHLO, EPE - Hospital S. Francisco Xavier, Lisboa, Portugal|CHULN, EPE - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital San Rafael, Granada, Spain|Hospital de la Inmaculada Concepción, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico de Valencia, Valencia, Spain|Sahlgrenska US, Göteborg, Göteborg, Sweden|Sahlgrenska Universitetssjukhuset, Östra, Göteborg, Sweden|Skånes universitetssjukhus, Lund, Lund, Sweden|Akardo Med Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03448406"
625,"NCT03192215","AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke","ARCADIA","Suspended","No Results Available","Stroke","Drug: Apixaban|Drug: Aspirin","Incidence of recurrent stroke|Incidence of recurrent ischemic stroke or systemic embolism|Incidence of recurrent stroke of any type plus death from any cause|Incidence of symptomatic intracranial hemorrhage (including symptomatic hemorrhagic transformation of an ischemic stroke).|Incidence of major hemorrhage other than intracranial hemorrhage|Incidence of death from any cause","Columbia University|National Institute of Neurological Disorders and Stroke (NINDS)|University of Cincinnati|Medical University of South Carolina|Bristol-Myers Squibb|Pfizer|Roche Pharma AG|Weill Medical College of Cornell University|University of Washington","All","45 Years and older   (Adult, Older Adult)","Phase 3","1100","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAR4607|1U01NS095869-01A1","January 19, 2018","January 18, 2022","April 30, 2022","June 20, 2017",,"April 17, 2020","University of Alabama, Birmingham, Alabama, United States|University of South Alabama University Hospital, Mobile, Alabama, United States|Chandler Regional Medical Center Chandler, AZ, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|UAMS Medical Center, Little Rock, Arkansas, United States|Mercy San Juan Medical Center (Dignity Health), Carmichael, California, United States|Eden Medical Center, Castro Valley, California, United States|Rancho Los Amigos National Rehabilitation Center, Downey, California, United States|Community Regional Medical Center, Fresno, California, United States|UCSD Health La Jolla, La Jolla, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Los Alamitos Medical Center, Los Alamitos, California, United States|Kaiser Permanente, Los Angeles, California, United States|Keck Hospital Of USC, Los Angeles, California, United States|Los Angeles County- USC Medical Center, Los Angeles, California, United States|VA Greater Los Angeles - West LA VA Medical Center, Los Angeles, California, United States|Salinas Valley Memorial Hospital, Salinas, California, United States|Scripps Mercy, San Diego, California, United States|UCSD Medical Center - Hillcrest Hospital, San Diego, California, United States|Kaiser Permanent San Diego Medical Center, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States|San Francisco General, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Good Samaritan, San Jose, California, United States|Stanford University Medical Center, Stanford, California, United States|Swedish Medical Center, Englewood, Colorado, United States|St. Mary's Medical Center, Grand Junction, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|Med-star Georgetown Univ., Washington, District of Columbia, United States|Medstar Washington, Washington, District of Columbia, United States|UF Health Shands, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Jackson Memorial, Miami, Florida, United States|Univ. Miami Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Intercoastal Medical Group - Hyde Park, Sarasota, Florida, United States|Tampa General, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Grady Memorial, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Southern Illinois University Memorial Medical Center, Springfield, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|U Mass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|VA Ann Arbor Healthcare System, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health St. Mary's, Grand Rapids, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|McLaren Macomb, Mount Clemens, MI, Mount Clemens, Michigan, United States|Abbot Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County, Minneapolis, Minnesota, United States|Univ. of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, St. Paul, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|St. Louis University Hospital, Saint Louis, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cox Medical Center South, Springfield, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Robert Wood Johnson, New Brunswick, New Jersey, United States|Capital Health Medical Center Hopewell, Pennington, New Jersey, United States|Univ. New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Kings County Hospital, Brooklyn, New York, United States|New York Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Beth Israel Brooklyn, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|North Shore University Hospital, Manhasset, New York, United States|NYU Langone, New York, New York, United States|Mount Sinai West, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Strong Memorial Hospital, Rochester, New York, United States|Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Sanford Medical Center Fargo, Fargo, North Dakota, United States|University of Cincinnati, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, Ohio, United States|UH Cleveland Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|OSU Wexner, Columbus, Ohio, United States|Ohio Health Riverside - Riverside Methodist Hospital, Columbus, Ohio, United States|Miami Valley Hospita, Dayton, Ohio, United States|Mercy Health St Vincent, Toledo, Ohio, United States|OU Medical Center Oklahoma, Oklahoma City, Oklahoma, United States|Legacy Emanuel, Portland, Oregon, United States|Oregon Health and Sciences, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital (formerly Palmetto Health), Columbia, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Valley Bapist, Harlingen, Texas, United States|Baylor College College of Medicine, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|Univ of Texas Health Science Center San Antonio, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Univ of Utah, Salt Lake City, Utah, United States|George E Whalen VA, Salt Lake City, Utah, United States|UVA Medical Center, Charlottesville, Virginia, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Puget Sound VA, Seattle, Washington, United States|Swedish Medical Center - Cherry Hill Campus, Seattle, Washington, United States|WVU Healthcare Ruby Memorial, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03192215"
626,"NCT03057977","EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)",,"Active, not recruiting","No Results Available","Heart Failure","Drug: Empagliflozin|Drug: Placebo","Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with reduced Ejection Fraction (HFrEF)|Occurrence of adjudicated HHF (Hospitalisation for Heart Failure) (first and recurrent)|eGFR (Estimated Glomerular Filtration Rate) (CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration Equation))cr slope of change from baseline|Time to first occurrence of chronic dialysis or renal transplant or sustained reduction of eGFR|Time to first adjudicated HHF (Hospitalisation for Heart Failure)|Time to adjudicated CV (Cardiovascular) death|Time to all-cause mortality|Time to onset of DM (Diabetes Mellitus)|Change from baseline in clinical summary score (HF (Chronic Heart Failure) symptoms and physical limitations domains) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) at week 52|Occurrence of all-cause hospitalisation (first and recurrent)","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","3730","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1245.121|2016-002280-34","March 6, 2017","June 19, 2020","July 20, 2020","February 20, 2017",,"April 24, 2020","Long Beach Center for Clinical Research, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Merced Vein and Vascular Center, Merced, California, United States|University of California Irvine, Orange, California, United States|Covigilant Research, LLC, Riverside, California, United States|University of California, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Blue Coast Cardiology, Vista, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Integrated Heart Care, Boca Raton, Florida, United States|Morton Plant Mease Health Care, Clearwater, Florida, United States|Nature Coast Clinical Research, Crystal River, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Integrative Research Associates, Fort Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|Cardiology Consultants, Inc, Pensacola, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Grady Clinical Research Center, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Cardiovascular Group PC, Lawrenceville, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, United States|Rockford Cardiovascular Associates, Rockford, Illinois, United States|Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana, United States|St. Francis Medical Group-Indiana Heart Physicians, Inc, Indianapolis, Indiana, United States|Reid Hospital, Richmond, Indiana, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|Krishnan Challappa M.D. PSC, Elizabethtown, Kentucky, United States|Research Integrity, LLC, Owensboro, Kentucky, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Louisiana Heart Center, Covington, Louisiana, United States|Clinical Trials of America LA, LLC, Monroe, Louisiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins University Hospital School of Medicine, Baltimore, Maryland, United States|MedStar Health Research Institute, Baltimore, Maryland, United States|Metropolitan Cardiovascular Consultants, Beltsville, Maryland, United States|Spectrum Clinical Research, Towson, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|East Mountain Medical Associates, PC, Great Barrington, Massachusetts, United States|Alpena General Hospital, Alpena, Michigan, United States|HealthPartners Institute, Saint Paul, Minnesota, United States|Saint Louis University, Saint Louis, Missouri, United States|SLHV, Saint Louis, Missouri, United States|Palm Research Center, Las Vegas, Nevada, United States|Advanced Heart Care, LLC, Bridgewater, New Jersey, United States|Cardiac Care and Vascular Medicine, PLLC, Bronx, New York, United States|Trinity Medical WNY, PC, Cheektowaga, New York, United States|Northwell Health, Great Neck, New York, United States|Mount Sinai School of Medicine, Lake Success, New York, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|Harlem Cardiology, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Kernodle Clinic West, Burlington, North Carolina, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Research of Gastonia, Gastonia, North Carolina, United States|Clinical Trials of America, Inc, Lenoir, North Carolina, United States|Rama Research LLC, Marion, Ohio, United States|University of Toledo, Toledo, Ohio, United States|South Oklahoma Heart Research Group, Oklahoma City, Oklahoma, United States|Doylestown Health Cardiology, Doylestown, Pennsylvania, United States|York Hospital, WellSpan Health, York, Pennsylvania, United States|AnMed Health Clinical Research, Anderson, South Carolina, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Palmetto Health, Columbia, South Carolina, United States|William Jennings Bryan Dorn VA Medical Center, Columbia, South Carolina, United States|Clinical Research of Rock Hill, Rock Hill, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|Methodist University Hospital, Memphis, Tennessee, United States|Baylor Heart and Vascular Hospital, Dallas, Texas, United States|Soltero Cardiovascular Research Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital, Houston, Texas, United States|The Heart Hospital, Plano, Texas, United States|Alpine Research Organization, Farmington, Utah, United States|Cardiac Health Management Network, P.C., Chester, Virginia, United States|Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Roanoke Heart Institute PLC, Roanoke, Virginia, United States|Salem VA Medical Center, Salem, Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Bahia Blanca, Argentina|CIPREC, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Centro Medico Dra Laura Maffei, Ciudad Autonoma Buenos Aires, Argentina|Instituto Cardiovascular de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Glenny Corp. S.A. Bioclinica Argentina, Ciudad Autonoma Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Bs As, Argentina|Sanatorio Güemes, Ciudad Autónoma de Bs As, Argentina|Instituto Medico Elsa Perez SRL (IMEP), Ciudadela, Argentina|Clínica Colombo, Cordoba, Argentina|Instituto Médico DAMIC S.R.L., Cordoba, Argentina|Clinica Coronel Suarez SA, Coronel Suarez, Argentina|Instituto de Cardiología de Corrientes, Corrientes, Argentina|Sanatorio Mayo Privado SA, Córdoba, Argentina|Centro de Investigaciones Clinicas Instituto del Corazon, Córdoba, Argentina|Sanatorio Allende S.A., Córdoba, Argentina|Hospital Privado, Córdoba, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|Centro de Investigaciones Médicas, Mar del Plata, Argentina|Hospital Privado de Comunidad, Mar del Plata, Argentina|Clínica Olivos, Olivos, Argentina|CER Instituto Médico, Quilmes, Argentina|Instituto de Investigaciones Clínicas de Quilmes, Quilmes, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Argentina|Instituto Medico Fundación Grupo Colaborativo Rosario, Rosario, Argentina|Sanatorio Británico, Rosario, Argentina|Sanatorio Plaza, Rosario, Argentina|Sanatorio Parque, Rosario, Argentina|Instituto CAICI, Rosario, Argentina|CORDIS S.A., Salta, Salta, Argentina|Centro Cardiovascular Salta, Salta, Argentina|Corporacion Medica de Gral. San Martin S.A., San Martin, Argentina|Clinica Mayo, San Miguel de Tucuman, Argentina|Investigaciones Clinicas Tucuman, San Miguel de Tucumán, Argentina|Centro Medico Luquez, San Vicente, Argentina|Centro de Investigaciones Clínicas del Litoral, Santa Fe, Argentina|Hospital ""Dr. José Maria Cullen "", Santa Fé, Argentina|Instituto de Cardiología, Tucumán, Argentina|CEMEDIC - Centro de Especialidades Medicas, Villa Luro, Argentina|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Mater Hospital Brisbane, Brisbane, Queensland, Australia|CORE Research Group, Milton, Queensland, Australia|SA-Heart Ashford Specialist Centre, Ashford, South Australia, Australia|Heart and Vascular Research, Fullarton, South Australia, Australia|The Northern Hospital, Epping, Victoria, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|University Hospital Geelong, Geelong, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|AZ Sint-Jan Brugge, Brugge, Belgium|C.H.U. de Charleroi, Charleroi, Belgium|AZ Sint-Blasius, Dendermonde, Belgium|Ziekenhuis Oost-Limburg - Campus Sint-Jan, Genk, Belgium|AZ Sint-Lucas - Campus Sint Lucas, Gent, Belgium|Grand Hôpital de Charleroi, Gilly, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Belgium|La Louvière - UNIV CHU Tivoli, La Louvière, Belgium|UZ Leuven, Leuven, Belgium|AZ Sint-Maarten, Mechelen, Belgium|Hospital Felicio Rocho, Belo Horizonte, Brazil|Hospital Vera Cruz, Belo Horizonte, Brazil|Cardresearch Cardiologia Assistencial e de Pesquisas Ltda, Belo Horizonte, Brazil|L2IP -Instituto de Pesquisas Clínicas Ltda., Brasília, Brazil|ICDF - Instituto de Cardiologia do Distrito Federal, Brasília, Brazil|CECAP - Centro de Cardiologia Clínica, Brasília, Brazil|Hospital Angelina Caron, Campina Grande do Sul, Brazil|Centro Especializado em Cardiol Loema Instituto de Pesq Clin, Campinas, Brazil|IPCC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|CAEP - Centro Avançado de Estudos e Pesquisas Ltda.,Campinas, Campinas, Brazil|Hospital Universitário, Canoas, Brazil|IPCEM - Instituto de Pesquisa Clínica para Estudos Multicêntricos - Universidade de Caxias do Sul, Caxias do Sul, Brazil|PUC Trials - Núcleo de Pesquisa Clínica da Escola de Medicina da PUC-PR, Curitiba, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Via Medica, Goiânia, Brazil|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil|ICM - Instituto do Coracao de Marilia, Marília, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto de Cardiologia Rio Grande do Sul, Porto Alegre, Brazil|Hospital Agamenon Magalhaes, Recife, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, Brazil|Hospital Universitário Pedro Ernesto UERJ, Rio De Janeiro - RJ, Brazil|CCBR - Rio de Janeiro - BR, Rio de Janeiro, Brazil|Pesquisare, Santo André, Brazil|Praxis Pesquisa Médica, Santo André, Brazil|Fundacao Faculdade Regional de Medicina, Sao Jose, Sao Jose do Rio Preto, Brazil|Centro de Pesquisa Clinica - CPCLIN, Sao Paulo, Brazil|FGM - Clínica Paulista de Doenças Cardiovasculares, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigacao Clinica, Sao Paulo, Brazil|INCOR e Hospital das Clínicas da Universidade de São Paulo, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, Brazil|CDEC BRASIL - Centro de Desenvolvimento em Estudos Clínicos Brasil, São Paulo, Brazil|Dr. Consulta, São Paulo, Brazil|CEDOES - Diagnóstico e Pesquisa,Vitória, Vitória, Brazil|Santa Casa de Votuporanga, Votuporanga, Brazil|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd, Moncton, New Brunswick, Canada|QEII Health Sciences Centre (Dalhousie University), Halifax, Nova Scotia, Canada|Brampton Cardio Pulmonary Clinic, Brampton, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Cambridge Cardiac Care Inc., Cambridge, Ontario, Canada|Curnew Medicine Professional Corporation, Hamilton, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|PACE (Partners in Advanced Cardiac Evaluation), Newmarket, Ontario, Canada|M Heffernan Medicine Professional Corp., Oakville, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Heart Health Institute, Scarborough, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Cardiovascular Contract Research Organization LTD, Sudbury, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|North York Diagnostic and Cardiac Centre, Toronto, Ontario, Canada|Diabetes Heart Research Centre, Toronto, Ontario, Canada|Mohan Babapulle Medicine Professional Medicine, Waterloo, Ontario, Canada|Dr. Louis C.H. Yao, York, Ontario, Canada|ViaCar Recherche Clinique Inc, Greenfield Park, Quebec, Canada|Centre de Dépistage et Recherche Cardiovasculaire Rive-Sud, Longeuil, Quebec, Canada|Clinique Santé Cardio MC, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|Centre de sante et de services sociaux de Beauce, Saint George-de-Beauce, Quebec, Canada|IUCPQ (Laval University), Quebec, Canada|Cardiovascular Institute and Fu Wai Hospital, Beijing, China|Beijing Friendship Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Hunan Provincial People's Hospital, Changsha, China|2nd Xiangya Hospital of Central South University, Changsha, China|The Third Hospital of Changsha, Changsha, China|Dongguan People's Hospital, Dongguan, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|The First Afiliated Hospital, Sun Yet-sen University, Guangzhou, China|Guangzhou First Municipal People's Hospital, Guangzhou, China|Haikou People's Hospital, Haikou, China|HaiNan Provincial People's Hospital, Haikou, China|The First Affiliated Hospital of Lanzhou University, Lanzhou, China|The Second Affiliated Hospital of Lanzhou Medical University, Lanzhou, China|The Affiliated Hospital of Southwest Medical University, Luzhou, China|Nanchang University Affiliated 3rd Hospital, Nanchang, China|First Hospital Affiliated with Nanjing Medical University, Nanjing, China|Huashan Hospital, Fudan University, Shanghai, China|General Hospital of Shenyang Military Region, Shenyang, China|Shengjing Hospital of China Medical University, Shenyang, China|Tianjin Union Medical Center Nankai University Affiliated Hospital, Tianjin, China|Tongji Hospital, Tongji University, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China|Yanbian University Hospital, Yanji, China|the first people hospital of Yue Yang, Yueyang, China|Affiliated Hospital of Jiangsu University, Zhenjiang, China|Poliklinika Humanitas, Bilovec, Czechia|Medicus Services Ltd., Brandys Nad, Czechia|Internal and Cardiology Practice, MUDr. Karel Kamenik, Brno, Brno, Czechia|Privatni interni ambulance, Brno, Czechia|Vojenska nemocnice Brno, Brno, Czechia|Nemocnice Milosrdnych bratri, Brno, Czechia|Edumed s.r.o, Broumov, Czechia|MUDr. Jan Hubac, s.r.o. Kardiologicka ambulance, Chrudim, Czechia|Nemocnice ve Frydku-Mistku, prispevkova organizace, Frydek-Mistek, Czechia|KardioLouny s.r.o., Louny, Czechia|Zdenek Vomacka, Olomouc, Czechia|PV-Kardiologie s.r.o., Pardubice, Czechia|University Hospital Motol, Prag 5, Czechia|General Faculty Hospital, Prague, Prague 2, Czechia|Thomayer Hospital, Praha 4 - Krc, Czechia|Kardio Vaclavik s.r.o., Prerov, Czechia|Kardiologicka ambulance s.r.o., Pribram VIII, Czechia|Hospital Trebic, p.o., Trebic, Czechia|Masaryk Hospital, Usti nad Labem, Usti nad Labem, Czechia|Angiocor s.r.o, Zlin, Czechia|KIGE s.r.o, Znojmo, Czechia|HOP de Bayonne, Bayonne, France|HOP Jean Minjoz, Besançon, France|HOP Louis Pradel, Bron, France|HOP Côte de Nacre, Caen, France|HOP Arnaud de Villeneuve, Montpellier, France|HOP La Pitié Salpêtrière, Paris, France|Centre Hospitalier de Pau, Pau, France|HOP Haut-Lévêque, Pessac, France|HOP Rangueil, Toulouse, France|INS Louis Mathieu, Vandoeuvre-lès-Nancy, France|Universitätsklinikum Aachen, AöR, Aachen, Germany|Praxis Dr. Rieker, Berlin, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Bielefeld gGmbH, Bielefeld, Germany|Praxis Dr. Menzel, Dessau-Roßlau, Germany|St. Johannes Hospital Dortmund, Dortmund, Germany|Städtisches Klinikum Dresden, Dresden, Germany|GWT-TUD GmbH, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Studienzentrum Bocholderstraße, Essen, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Frankfurt, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Asklepios Klinik Langen-Seligenstadt GmbH, Langen, Germany|Märkische Gesundheitsholding GmbH & Co. KG, Klinikum Lüdenscheid, Lüdenscheid, Germany|Praxis Dr. Sarnighausen, Lüneburg, Lüneburg, Germany|St. Vincenz- und Elisabeth-Hospital, Mainz, Mainz, Germany|Deutsches Herzzentrum München, München, Germany|Kardiologische Gemeinschaftspraxis Nienburg, Nienburg, Germany|Kardiologische Praxis Papenburg, Papenburg, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Praxis Dr. Stenzel, Riesa, Riesa, Germany|Zentrum für Klinische Forschung, Wangen, Germany|Josephs-Hospital Warendorf, Warendorf, Germany|Petrus-Krankenhaus, Wuppertal, Germany|Lausmed Kft. Outpatient Unit of Internal Medicine, Baja, Hungary|Belgyogyaszati es Kardiologiai Maganrendelo, Bekescsaba, Hungary|Clinexpert Kft., Budapest, Hungary|Gottsegen Gyorgy Hungarian Instit.of Cardiology,Budapest, Budapest, Hungary|Bajcsy-Zsilinszky Hospital and Clinic, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Uzsoki Street Hospital, Budapest, Budapest, Hungary|Nehezlegzes Ambulancia, Debrecen, Hungary|Bugat Pal Hospital, Gyongyos, Gyongyos, Hungary|Selye Janos Hospital Komarom, Komarom, Hungary|Dorottya Kanizsai Hospital, Nagykanizsa, Hungary|Dr. Nagy Laszlo Kardiologiai Maganrendeles, Oroshaza, Hungary|Da Vinci Maganklinika, Pecs, Hungary|Pecsi Tudomanyegyetem, Pécs, Hungary|Fejer County Saint George University Teaching Hospital, Szekesfehervar, Hungary|Veszpremi Sziv es Egeszseg Centrum, Veszprem, Hungary|Doctor Jivraj Mehta Smarak Health Foundation, Ahmedabad, India|Kamalnayan Bajaj Hospital, Aurangabad, India|Narayana Institute of Cardiac Sciences, Bangalore, India|Rajarajeswari Medical College, Bengaluru, India|Madras Medical Mission,, Chennai, India|Apollo Speciality Hospital, Chennai, India|Medanta-The Medicity, Gurgaon, India|B.M. Birla Heart research Centre, Kolkatta, India|Siddhi Hospital, Nashik, India|Vijan Cardiac and Critical Care Centre, Nasik, India|Batra Hospital and Medical Research Centre, New Delhi, India|GB Pant Hospital, New Delhi, India|Fortis Escorts Heart Institute, New Delhi, India|Sir Gangaram Hospital, New Delhi, India|Azienda Ospedaliera G. Rummo, Benevento, Italy|ASST Papa Giovanni XXIII - A.O. Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Cona (FE), Italy|Ospedale della Val di Chiana Santa Margherita, Cortona (AR), Italy|Centro Cardiologico Monzino-IRCCS, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|Azienda Servizi Sanitari 1 Triestina, Trieste, Italy|Kasugai Municipal Hospital, Aichi, Kasugai, Japan|Nagoya Kyoritsu Hospital, Aichi, Nagoya, Japan|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Toyota Memorial Hospital, Aichi, Toyota, Japan|Chiba Heart Clinic, Chiba, Chiba, Japan|Kimitsu Chuo Hospital, Chiba, Kisarazu, Japan|Seikeikai New Tokyo Heart Clinic, Chiba, Matsudo, Japan|Ehime Prefectural Central Hospital, Ehime, Matsuyama, Japan|Matsuyama Shimin Hospital, Ehime, Matsuyama, Japan|Uwajima City Hospital, Ehime, Uwajima, Japan|Fukuiken Saiseikai Hospital, Fukui, Fukui, Japan|Fukuoka University Chikushi Hospital, Fukuoka, Chikushino, Japan|Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka, Chikushino, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Fukuoka, Japan|Aso Co.,Ltd Iizuka Hospital, Fukuoka, Iizuka, Japan|Steel Memorial Yawata Hospital, Fukuoka, Kitakyushu, Japan|Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Kitakyushu, Japan|Ogaki Municipal Hospital, Gifu, Ogaki, Japan|Chuno Kosei Hospital, Gifu, Seki, Japan|Fukuyama City Hospital, Hiroshima, Fukuyama, Japan|JA Hiroshima General Hospital, Hiroshima, Hatsukaichi, Japan|Shobara Red Cross Hospital, Hiroshima, Shobara, Japan|National Hospital Organization Hakodate Hospital, Hokkaido, Hakodate, Japan|Teine Keijinkai Clinic, Hokkaido, Sapporo, Japan|Tomakomai City Hospital, Hokkaido, Tomakomai, Japan|Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Amagasaki, Japan|Hyogo Brain and Heart Center, Hyogo, Himeji, Japan|National Hospital Organization Kobe Medical Center, Hyogo, Kobe, Japan|Mito Medical Center, Ibaraki, Higashiibaraki-gun, Japan|National Hospital Organization Kanazawa Medical Center, Ishikawa, Kanazawa, Japan|Mitoyo General Hospital, Kagawa, Kanonji, Japan|Kagawa Prefectural Central Hospital, Kagawa, Takamatsu, Japan|Yamamoto Clinic, Kanagawa, Sagamihara, Japan|Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Yokohama, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto, Japan|Seiwakai Suizenji Touya Hospital, Kumamoto, Kumamoto, Japan|Kumamoto Rosai Hospital, Kumamoto, Yatsushiro, Japan|Uji-Tokushukai Medical Center, Kyoto, Uji, Japan|Sendai Kousei Hospital, Miyagi, Sendai, Japan|Sendai Tokushukai Hospital, Miyagi, Sendai, Japan|The Cardiovascular Center of Sendai, Miyagi, Sendai, Japan|National Hospital Organization Sendai Medical Center, Miyagi, Sendai, Japan|Miyazaki Medical Association Hospital, Miyazaki, Miyazaki, Japan|Hokushin General Hospital, Nagano, Nakano, Japan|Nagasaki Medical Center, Nagasaki, Omura, Japan|Okayama City General Medical Center, Okayama, Okayama, Japan|Naha City Hospital, Okinawa, Naha, Japan|Nanbu Tokushukai Hospital, Okinawa, Shimajiri-gun, Japan|Urasoe General Hospital, Okinawa, Urasoe, Japan|Higashiosaka City Medical Center, Osaka, Higashiosaka, Japan|Kitano Hospital, Osaka, Osaka, Japan|Yodogawa Christian Hospital, Osaka, Osaka, Japan|Seichokai Bell Land General Hospital, Osaka, Sakai, Japan|Hokusetsu General Hospital, Osaka, Takatsuki, Japan|San-Ai Hospital, Saitama, Saitama, Japan|Kosekai Iwatsuki-minami Hospital, Saitama, Saitama, Japan|Kusatsu General Hospital, Shiga, Kusatsu, Japan|Tokushima Prefectural Central Hospital, Tokushima, Tokushima, Japan|National Hospital Organization Tokyo Medical Center, Tokyo, Meguro-ku, Japan|Ome Municipal General Hospital, Tokyo, Ome, Japan|Tokyo Rosai Hospital, Tokyo, Ota-ku, Japan|Sekino Hospital, Tokyo, Toshima-ku, Japan|Minami Wakayama Medical Center, Wakayama, Tanabe, Japan|Kanmon Medical Center, Yamaguchi, Shimonoseki, Japan|Dong-A University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Seoul National University Bundang Hospital, Sungnam, Korea, Republic of|Wonju Severance Christian Hosp, Wonju, Korea, Republic of|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico|Centro de Investigacion Biomedica y Farmaceutica, S.C., Distrito Federal, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occident, Guadalajara, Mexico|Diseño y Planeación en Investigación Médica SC, Guadalajara, Mexico|Cardiologia Clinica e Intervencionista, Guadalajara, Mexico|Centro de Investigación Clinica Acelerada, S.C., Mexico, Mexico|Instituto Cardiovascular de Monclova, S de RL de CV, Monclova, Mexico|CEDOPEC-Ctro Esp en Diab, Obesidad y Prev de Enf Cardiovasc, México, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Nuevo Leon, Mexico|Centro Integral Medico SJR S.C., San Juan del Rio, Mexico|Cardioarritmias e Investigación S.C, San Luis Potosi, Mexico|Centro de Investigacion Cardiovascular y Metabolica, Tijuana, Mexico|Centro de Investigacion Alberto Bazzoni S.A. de C.V., Torreon, Mexico|Hospital Dr Angel Leano, Zapopan, Mexico|Ziekenhuisgroep Twente locatie Almelo, Almelo, Netherlands|BovenIJ Ziekenhuis, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Locatie West, Amsterdam, Netherlands|Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands|Rode Kruis Ziekenhuis Beverwijk, Beverwijk, Netherlands|Tergooiziekenhuizen locatie Blaricum, Blaricum, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|HMC Bronovo, Den Haag, Netherlands|Ziekenhuis Gelderse Vallei, EDE, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Vasculair Onderzoek Centrum, Hoorn, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Diaconessenhuis Meppel, Meppel, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Ziekenhuis Bernhoven Uden, Uden, Netherlands|Vie Curi Medisch Centrum, Venlo, Netherlands|De Heel - Zaans Medisch Centrum, Zaandam, Netherlands|Gelre Ziekenhuis Zutphen, Zutphen, Netherlands|KLIMED Marek Klimkiewicz, Bialystok, Poland|Univ. Clinic Hosp, Bialystok, Bialystok, Poland|American Heart of Poland Sp. z o.o., Bielsko-Biala, Poland|Polsko-Amerykanskie Kliniki Serca, Chorzow, Poland|American Heart of Poland Sp. z o.o., Dabrowa Gornicza, Poland|Poradnia Kardiologiczna Jaroslaw Jurowiecki, Gdansk, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Indywidualna Specjalistyczna Praktyka Lekarska, Gdynia, Poland|NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog., Gdynia, Poland|Szpital Zakonu Bonifratow Sp. z o.o., Katowice, Poland|Specialistic Cardiology&Hypertension Out-patient Clin,Kielce, Kielce, Poland|Leszek Bryniarski Specialized Medical Cabinet, Krakow, Poland|Krakow Specialistic Hospital of John Paul II, Krakow, Poland|SANTA FAMILIA Centrum Badan, Profilaktyki i Leczenia, Lodz, Poland|Nzoz Salus, Lodz, Poland|Individual Specialized Practice, Lodz, Poland|Lowickie Cardiology Center, Lowicz, Poland|American Heart of Poland Sp. z o.o., Nysa, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Specialized Practice Dr. Janusz Spyra, Ruda Slaska, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Lukmed Lukasz Wozniak, Siedlce, Poland|Clinmedica Research Omc sp. z o.o. sp.k., Skierniewice, Skierniewice, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|The Provincial Polyclinical Hospital in Torun, Torun, Poland|American Heart of Poland Sp. z o.o., Tychy, Poland|American Heart of Poland Sp. z o.o., Ustron, Poland|Central Hospital of Medical Academy, Warsaw, Warsaw, Poland|McM Polimedica, Warszawa, Poland|4. Military Clinical Hospital with Polyclinic SP ZOZ, Wroclaw, Poland|Zgierskie Center of Cardiology MED-PRO, Zgierz, Poland|Specialist Hospital J. Dietla NZOZ Specialized Clinic ""Gemini"", Zychlin, Poland|Hospital Quiron. I.C.U., Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain|Hospital de Bellvitge, L'Hospitalet de Llobregat, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Complejo Hospitalario Universitario de Orense, Orense, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Barnet General Hospital, Barnet, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Park & St Francis Surgery, Eastleigh, United Kingdom|Wycombe General Hospital, High Wycombe, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Luton and Dunstable University Hospital, Luton, United Kingdom|St Mary's Hospital, Newport, United Kingdom|Morriston Hospital, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03057977"
627,"NCT03057951","EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)",,"Active, not recruiting","No Results Available","Heart Failure","Drug: Empagliflozin|Drug: Placebo","Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with preserved Ejection Fraction (HFpEF)|Occurrence of adjudicated HHF (Hospitalisation for Heart Failure) (first and recurrent)|eGFR (Estimated Glomerular Filtration Rate) (CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration Equation))cr slope of change from baseline|Time to first occurrence of chronic dialysis or renal transplant sustained reduction of eGFR|Time to first adjudicated HHF (Hospitalisation for Heart Failure)|Time to adjudicated CV (Cardiovascular) death|Time to all-cause mortality|Time to onset of DM (Diabetes Mellitus)|Change from baseline in clinical summary score (HF (Chronic Heart Failure) symptoms and physical limitations domains) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) at week 52|Occurrence of all-cause hospitalisation (first and recurrent)","Boehringer Ingelheim|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","5987","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1245.110|2016-002278-11","March 2, 2017","October 9, 2020","November 9, 2020","February 20, 2017",,"April 24, 2020","Pinnacle Research Group, LLC, Anniston, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Heart Center Research, LLC, Huntsville, Alabama, United States|University of California San Francisco, Fresno, California, United States|La Mesa Cardiac Center, La Mesa, California, United States|Purushotham, Akther & Roshan Kotha, MD Inc., La Mesa, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Merced Vein and Vascular Center, Merced, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|University of California Irvine, Orange, California, United States|Covigilant Research, LLC, Riverside, California, United States|University of California San Francisco, San Francisco, California, United States|University of California, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Blue Coast Cardiology, Vista, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Integrated Heart Care, Boca Raton, Florida, United States|Southeast Clinical Research, LLC, Chiefland, Florida, United States|Morton Plant Mease Health Care, Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Integrative Research Associates, Fort Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Elite Clinical Research, Miami, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|Orlando Health Inc., Orlando, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Clearwater Cardiovascular Consultants, Safety Harbor, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|University of South Florida, Tampa, Florida, United States|Advent Health Medical Group, Tampa, Florida, United States|Grady Clinical Research Center, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Cardiovascular Group PC, Lawrenceville, Georgia, United States|Meridian Clinical Research, LLC, Savannah, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Advocate Health and Hospitals Corporation, Naperville, Illinois, United States|Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, United States|Rockford Cardiovascular Associates, Rockford, Illinois, United States|Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana, United States|St. Francis Medical Group-Indiana Heart Physicians, Inc, Indianapolis, Indiana, United States|Reid Hospital, Richmond, Indiana, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|Iowa Heart Center, Des Moines, Iowa, United States|Norton Heart Specialists, Louisville, Kentucky, United States|Research Integrity, LLC, Owensboro, Kentucky, United States|Grace Research, LLC, Bossier City, Louisiana, United States|Clinical Trials of America LA, LLC, Monroe, Louisiana, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Maine Research Associates, Lewiston, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|MedStar Health Research Institute, Baltimore, Maryland, United States|Metropolitan Cardiovascular Consultants, Beltsville, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Spectrum Clinical Research, Towson, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|East Mountain Medical Associates, PC, Great Barrington, Massachusetts, United States|Alpena General Hospital, Alpena, Michigan, United States|McLaren Northern Michigan Hospital, Petoskey, Michigan, United States|Regions Hospital, Saint Paul, Minnesota, United States|Jackson Heart Clinic, P.A., Jackson, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|St. Louis Center for Clinical Research, Saint Louis, Missouri, United States|St. Louis Heart and Vascular, P.C., Saint Louis, Missouri, United States|Deaconess Billings Clinic Research Center, Billings, Montana, United States|Bozeman Health Clinical Research, Bozeman, Montana, United States|Nebraska Heart Institute, Grand Island, Nebraska, United States|CHI Health Midlands, Papillion, Nebraska, United States|Healthcare Partners LLC, Las Vegas, Nevada, United States|Palm Research Center, Las Vegas, Nevada, United States|Advanced Heart Care, LLC, Bridgewater, New Jersey, United States|Garden State Heart Care, PC, Manalapan, New Jersey, United States|Capital Cardiology Associates, PC, Albany, New York, United States|CHEAR Center LLC, Bronx, New York, United States|Cardiac Care and Vascular Medicine, PLLC, Bronx, New York, United States|Trinity Medical WNY, PC, Cheektowaga, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Cardiovascular Consultants, New Hyde Park, New York, United States|Mount Sinai - PRIME, New York, New York, United States|Harlem Cardiology, New York, New York, United States|Laurelton Heart Specialist, PC, Rosedale, New York, United States|Saratoga Clinical Research, LLC, Saratoga Springs, New York, United States|Northwell Health, Southampton, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Kernodle Clinic West, Burlington, North Carolina, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|Clinical Research of Gastonia, Gastonia, North Carolina, United States|Clinical Trials of America, Inc, Lenoir, North Carolina, United States|VA Northeast Ohio Healthcare System, Cleveland, Ohio, United States|Rama Research LLC, Marion, Ohio, United States|South Oklahoma Heart Research Group, Oklahoma City, Oklahoma, United States|Doylestown Health Cardiology, Doylestown, Pennsylvania, United States|Lycoming Internal Medicine, Inc, Jersey Shore, Pennsylvania, United States|Richard M Kastelic and Associates, Johnstown, Pennsylvania, United States|York Hospital, WellSpan Health, York, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Palmetto Health, Columbia, South Carolina, United States|Clinical Research of Rock Hill, Rock Hill, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|Sanford Research, Sioux Falls, South Dakota, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Apex Cardiology/ Research Associates of Jackson, Jackson, Tennessee, United States|Methodist University Hospital, Memphis, Tennessee, United States|Seton Heart Institute, Austin, Texas, United States|Baylor Heart and Vascular Hospital, Dallas, Texas, United States|Soltero Cardiovascular Research Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Angiocardiac Care of Texas, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Biopharma Informatic, Inc. Research Center, Houston, Texas, United States|Private Practice Leadership, LLC, Katy, Texas, United States|Baylor Scott and White Health, Plano, Texas, United States|Alpine Research Organization, Farmington, Utah, United States|Cardiac Health Management Network, P.C., Chester, Virginia, United States|Cardiology Consultants of Danville, Inc, Danville, Virginia, United States|Carient Heart and Vascular, Manassas, Virginia, United States|Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Medical College of Virginia Hospitals, Richmond, Virginia, United States|Roanoke Heart Institute PLC, Roanoke, Virginia, United States|Salem VA Medical Center, Salem, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Meriter Wisconsin Heart, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Aspirus Research Institute, Wausau, Wisconsin, United States|Hospital Interzonal General de Agudos Dr Jose Penna, Bahia Blanca, Argentina|Hospital Italiano Regional del Sur, Bahia Blanca, Bahia Blanca, Argentina|CIPREC, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Consultorios Asociados de Endocrinología e Invest Clínica, Ciudad Autonoma Buenos Aires, Argentina|Instituto Cardiovascular de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|CCBR - Buenos Aires - AR, Ciudad Autonoma Buenos Aires, Argentina|Centro Médico Viamonte, Ciudad Autonoma de Bs As, Argentina|Sanatorio Güemes, Ciudad Autónoma de Bs As, Argentina|Instituto Medico Elsa Perez SRL (IMEP), Ciudadela, Argentina|Clínica Colombo, Cordoba, Argentina|Instituto Médico DAMIC S.R.L., Cordoba, Argentina|Clinica Coronel Suarez SA, Coronel Suarez, Argentina|Instituto de Cardiología de Corrientes, Corrientes, Argentina|Sanatorio Mayo Privado SA, Córdoba, Argentina|Centro de Investigaciones Clinicas Instituto del Corazon, Córdoba, Argentina|Sanatorio Allende S.A., Córdoba, Argentina|Hospital Privado, Córdoba, Argentina|Hospital Italiano de La Plata, La Plata, Argentina|Centro de Investigaciones Médicas, Mar del Plata, Argentina|Hospital Privado de Comunidad, Mar del Plata, Argentina|Clínica Olivos, Olivos, Argentina|CER Instituto Médico, Quilmes, Argentina|Instituto de Investigaciones Clínicas de Quilmes, Quilmes, Argentina|Instituto de Investigaciones Clinicas de Rosario, Rosario, Argentina|Instituto Medico Fundación Grupo Colaborativo Rosario, Rosario, Argentina|Sanatorio Británico, Rosario, Argentina|Sanatorio Plaza, Rosario, Argentina|Instituto CAICI, Rosario, Argentina|CORDIS S.A., Salta, Salta, Argentina|Centro Cardiovascular Salta, Salta, Argentina|Corporacion Medica de Gral. San Martin S.A., San Martin, Argentina|Investigaciones Clinicas Tucuman, San Miguel de Tucumán, Argentina|CCBR Tucuman, San Miguel de Tucumán, Argentina|Centro Medico Luquez, San Vicente, Argentina|Centro de Investigaciones Clínicas del Litoral, Santa Fe, Argentina|Hospital ""Dr. José Maria Cullen "", Santa Fé, Argentina|Instituto de Cardiología, Tucumán, Argentina|CEMEDIC - Centro de Especialidades Medicas, Villa Luro, Argentina|Pendlebury Research, Adamstown, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|CORE Research Group, Milton, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Heart and Vascular Research, Fullarton, South Australia, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|The Northern Hospital, Epping, Victoria, Australia|Peninsula Private Hospital, Frankston, Victoria, Australia|University Hospital Geelong, Geelong, Victoria, Australia|Mount Hospital, Perth, Western Australia, Australia|C.H.U. de Charleroi, Charleroi, Belgium|AZ Sint-Blasius, Dendermonde, Belgium|Ziekenhuis Oost-Limburg - Campus Sint-Jan, Genk, Belgium|AZ Maria Middelares, Gent, Belgium|Grand Hôpital de Charleroi, Gilly, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Belgium|La Louvière - UNIV CHU Tivoli, La Louvière, Belgium|UZ Leuven, Leuven, Belgium|Liège - HOSP CHR de la Citadelle, Liège, Belgium|Hospital Felicio Rocho, Belo Horizonte, Brazil|Hospital Vera Cruz, Belo Horizonte, Brazil|Cardresearch Cardiologia Assistencial e de Pesquisas Ltda, Belo Horizonte, Brazil|CCBR - Brasília, Brasília, Brazil|ICDF - Instituto de Cardiologia do Distrito Federal, Brasília, Brazil|CECAP - Centro de Cardiologia Clínica, Brasília, Brazil|Hospital Angelina Caron, Campina Grande do Sul, Brazil|Centro Especializado em Cardiol Loema Instituto de Pesq Clin, Campinas, Brazil|IPCC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil|CAEP - Centro Avançado de Estudos e Pesquisas Ltda.,Campinas, Campinas, Brazil|Hospital Universitário, Canoas, Brazil|IPCEM - Instituto de Pesquisa Clínica para Estudos Multicêntricos - Universidade de Caxias do Sul, Caxias do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Curitiba, Curitiba, Brazil|Via Medica, Goiania, Brazil|HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil|ICM - Instituto do Coracao de Marilia, Marília, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Brazil|Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Pesquisas em Diabetes, Porto Alegre, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto de Cardiologia Rio Grande do Sul, Porto Alegre, Brazil|Hospital Agamenon Magalhaes, Recife, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, Brazil|Hospital Universitário Pedro Ernesto UERJ, Rio De Janeiro - RJ, Brazil|CCBR - Rio de Janeiro - BR, Rio de Janeiro, Brazil|Pesquisare, Santo André, Brazil|Praxis Pesquisa Médica, Santo André, Brazil|Hospital de Base - Fac Med de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil|Centro de Pesquisa Clinica - CPCLIN, Sao Paulo, Brazil|FGM - Clínica Paulista de Doenças Cardiovasculares, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigacao Clinica, Sao Paulo, Brazil|INCOR e Hospital das Clínicas da Universidade de São Paulo, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos, São Bernardo do Campo, Brazil|CDEC BRASIL - Centro de Desenvolvimento em Estudos Clínicos Brasil, São Paulo, Brazil|Dr. Consulta, São Paulo, Brazil|CEDOES - Diagnóstico e Pesquisa,Vitória, Vitória, Brazil|Santa Casa de Votuporanga, Votuporanga, Brazil|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Medical Arts Health Research Group, North Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd, Moncton, New Brunswick, Canada|QEII Health Sciences Centre (Dalhousie University), Halifax, Nova Scotia, Canada|Brampton Cardio Pulmonary Clinic, Brampton, Ontario, Canada|Brampton Research Associates, Brampton, Ontario, Canada|JBN Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Cambridge Cardiac Care Inc., Cambridge, Ontario, Canada|Dr. Saul Vizel, Cambridge, Ontario, Canada|Curnew Medicine Professional Corporation, Hamilton, Ontario, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|University Hospital (LHSC), London, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|M Heffernan Medicine Professional Corp., Oakville, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Heart Health Institute, Scarborough, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|North York Diagnostic and Cardiac Centre, Toronto, Ontario, Canada|Mohan Babapulle Medicine Professional Medicine, Waterloo, Ontario, Canada|Dr. Louis C.H. Yao, York, Ontario, Canada|ViaCar Recherche Clinique Inc, Brossard, Quebec, Canada|ViaCar Recherche Clinique Inc, Greenfield Park, Quebec, Canada|Centre de Dépistage et Recherche Cardiovasculaire Rive-Sud, Longeuil, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Clinique Santé Cardio MC, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|Centre de sante et de services sociaux de Beauce, Saint George-de-Beauce, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|IUCPQ (Laval University), Quebec, Canada|Cardiovascular Institute and Fu Wai Hospital, Beijing, China|Beijing Friendship Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Hunan Provincial People's Hospital, Changsha, China|2nd Xiangya Hospital of Central South University, Changsha, China|The Third Hospital of Changsha, Changsha, China|Dongguan People's Hospital, Dongguan, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|The First Afiliated Hospital, Sun Yet-sen University, Guangzhou, China|Guangzhou First Municipal People's Hospital, Guangzhou, China|Haikou People's Hospital, Haikou, China|HaiNan Provincial People's Hospital, Haikou, China|The First Affiliated Hospital of Lanzhou University, Lanzhou, China|The Second Affiliated Hospital of Lanzhou Medical University, Lanzhou, China|The Affiliated Hospital of Southwest Medical University, Luzhou, China|Nanchang University Affiliated 3rd Hospital, Nanchang, China|First Hospital Affiliated with Nanjing Medical University, Nanjing, China|Huashan Hospital, Fudan University, Shanghai, China|General Hospital of Shenyang Military Region, Shenyang, China|Shengjing Hospital of China Medical University, Shenyang, China|Tianjin Union Medical Center Nankai University Affiliated Hospital, Tianjin, China|Tongji Hospital, Tongji University, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China|Yanbian University Hospital, Yanji, China|the first people hospital of Yue Yang, Yueyang, China|Affiliated Hospital of Jiangsu University, Zhenjiang, China|Corazon IPS S.A.S., Barranquilla, Colombia|Centro de Reumatologia y Ortopedia SAS, Barranquilla, Barranquilla, Colombia|IPS Centro Cientifico Asistencia, Barranquilla, Colombia|CardioColombia S.A.S., Bogota D.C, Colombia|Endocare Research Institute, Bogota, Colombia|IPS Centro Medico Julián Coronel S.A., Cali, Colombia|Fundación Valle del Lili, Cali, Colombia|Centro de Investigaciones Clinicas S.A.S, Cali, Colombia|Centro de Diagnostico Cardilogico, Cartagena, Colombia|Centro cardiovascular Aristides, Cartagena, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia|Promotora Medica Las Americas SA, Medellin, Colombia|Poliklinika Humanitas, Bilovec, Czechia|Internal and Cardiology Practice, MUDr. Karel Kamenik, Brno, Brno, Czechia|MUDr. Alexandra Ludkova, Brno, Czechia|University Hospital Brno, Brno, Czechia|Vojenska nemocnice Brno, Brno, Czechia|Nemocnice Milosrdnych bratri, Brno, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Univ.Hosp U Svate Anny, I.Internal Clinic-Cardiology,Brno, Brno, Czechia|Edumed s.r.o, Broumov, Czechia|MUDr. Jan Hubac, s.r.o. Kardiologicka ambulance, Chrudim, Czechia|Nemocnice ve Frydku-Mistku, prispevkova organizace, Frydek-Mistek, Czechia|Nemocnice Havlickuv Brod p.o., Havlickuv Brod, Czechia|Gepamed s.r.o., Pulm. Outpat. Office, Hradec Kralove, Hradec Kralove, Czechia|KardioLouny s.r.o., Louny, Czechia|InterKardioML s.r.o., Marianske Lazne, Czechia|Zdenek Vomacka, Olomouc, Czechia|PV-Kardiologie s.r.o., Pardubice, Czechia|Corintez s.r.o., Prague, Czechia|University Hospital Motol, Prag, Czechia|Vseobecna fakultni nemocnice V Praze, Praha 2, Czechia|Thomayer Hospital, Praha 4 - Krc, Czechia|Institute for Clinical and Experimental Medicine, Praha 4, Czechia|Kardio Vaclavik s.r.o., Prerov, Czechia|Nemocnice Trebic p.o., Trebic, Czechia|Kardiologicka ambulance, Tremosna, Czechia|Kardiologicka ambulance MUDr. Ferkl s.r.o., Trutnov, Czechia|Clinical Trials Services s.r.o, Uherske Hradiste, Czechia|Cardiology Private Practice, Unicov, Czechia|Angiocor s.r.o, Zlin, Czechia|KIGE s.r.o, Znojmo, Czechia|Universitätsklinikum Aachen, AöR, Aachen, Germany|Praxis Dr. Rieker, Berlin, Berlin, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Bielefeld gGmbH, Bielefeld, Germany|Augusta-Kranken-Anstalt gGmbH, Bochum, Germany|Praxis Dr. Menzel, Dessau-Roßlau, Germany|St. Johannes Hospital Dortmund, Dortmund, Germany|Städtisches Klinikum Dresden, Dresden, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Studienzentrum Bocholderstraße, Essen, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Frankfurt, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Asklepios Klinik Langen-Seligenstadt GmbH, Langen, Germany|Märkische Gesundheitsholding GmbH & Co. KG, Klinikum Lüdenscheid, Lüdenscheid, Germany|Praxis Dr. Sarnighausen, Lüneburg, Lüneburg, Germany|St. Vincenz- und Elisabeth-Hospital, Mainz, Mainz, Germany|Gemeinschaftspraxis Drs. Kohler/Salbach, Mannheim, Mannheim, Germany|Deutsches Herzzentrum München, München, Germany|Gemeinschaftspraxis Dres Haggenmiller/Jeserich, Nürnberg, Germany|Kardiologische Praxis Papenburg, Papenburg, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Praxis Dr. Stenzel, Riesa, Riesa, Germany|Zentrum für Klinische Forschung, Wangen, Germany|Josephs-Hospital Warendorf, Warendorf, Germany|Kardiologische Praxis, Wermsdorf, Wermsdorf, Germany|Petrus-Krankenhaus, Wuppertal, Germany|Lausmed Kft. Outpatient Unit of Internal Medicine, Baja, Hungary|Belgyogyaszati es Kardiologiai Maganrendelo, Bekescsaba, Hungary|Budai Irgalmasrendi Korhaz, Budapest, Hungary|Clinexpert Kft., Budapest, Hungary|Bajcsy-Zsilinszky Hospital and Clinic, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Milit.Hosp.-State Health Cent., Budapest, Hungary|Uzsoki Street Hospital, Budapest, Budapest, Hungary|Nehezlegzes Ambulancia, Debrecen, Hungary|University Debrecen Hospital, Debrecen, Hungary|Bugat Pal Hospital, Gyongyos, Gyongyos, Hungary|Studium Egeszseghaz Kft., Kalocsa, Hungary|Selye Janos Hospital Komarom, Komarom, Hungary|Dorottya Kanizsai Hospital, Nagykanizsa, Hungary|Medifarma-98 Kft., Nyiregyhaza, Hungary|Dr. Nagy Laszlo Kardiologiai Maganrendeles, Oroshaza, Hungary|University of Pecs, Invasive Cardiology, Pecs, Hungary|Da Vinci Maganklinika, Pecs, Hungary|Fejer County Saint George University Teaching Hospital, Szekesfehervar, Hungary|Veszpremi Sziv es Egeszseg Centrum, Veszprem, Hungary|Doctor Jivraj Mehta Smarak Health Foundation, Ahmedabad, India|Kamalnayan Bajaj Hospital, Aurangabad, India|Narayana Institute of Cardiac Sciences, Bangalore, India|Rajarajeswari Medical College, Bengaluru, India|Madras Medical Mission,, Chennai, India|Apollo Speciality Hospital, Chennai, India|Medanta-The Medicity, Gurgaon, India|GNRC Hospital, Guwahati, India|B.M. Birla Heart research Centre, Kolkatta, India|Siddhi Hospital, Nashik, India|Vijan Cardiac and Critical Care Centre, Nasik, India|Batra Hospital and Medical Research Centre, New Delhi, India|GB Pant Hospital, New Delhi, India|Fortis Escorts Heart Institute, New Delhi, India|Sir Gangaram Hospital, New Delhi, India|Azienda Ospedaliera G. Rummo, Benevento, Italy|ASST Papa Giovanni XXIII - A.O. Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Cona (FE), Italy|Ospedale della Val di Chiana Santa Margherita, Cortona (AR), Italy|Milano Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico, Milano, Italy|Centro Cardiologico Monzino-IRCCS, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|IRCCS Gruppo Multimedica, Sesto San Giovanni (MI), Italy|Azienda Servizi Sanitari 1 Triestina, Trieste, Italy|Kasugai Municipal Hospital, Aichi, Kasugai, Japan|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Chiba Heart Clinic, Chiba, Chiba, Japan|Kimitsu Chuo Hospital, Chiba, Kisarazu, Japan|Seikeikai New Tokyo Heart Clinic, Chiba, Matsudo, Japan|Ehime Prefectural Central Hospital, Ehime, Matsuyama, Japan|Matsuyama Shimin Hospital, Ehime, Matsuyama, Japan|Uwajima City Hospital, Ehime, Uwajima, Japan|Fukuiken Saiseikai Hospital, Fukui, Fukui, Japan|Fukuoka University Chikushi Hospital, Fukuoka, Chikushino, Japan|Fukuokaken Saiseikai Futsukaichi Hospital, Fukuoka, Chikushino, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Fukuoka, Japan|Steel Memorial Yawata Hospital, Fukuoka, Kitakyushu, Japan|Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Kitakyushu, Japan|Shirakawa Kosei General Hospital, Fukushima, Shirakawa, Japan|Ogaki Municipal Hospital, Gifu, Ogaki, Japan|Chuno Kosei Hospital, Gifu, Seki, Japan|Fukuyama City Hospital, Hiroshima, Fukuyama, Japan|Shobara Red Cross Hospital, Hiroshima, Shobara, Japan|Matsuda Cardiovascular Clinic, Hokkaido, Sapporo, Japan|Teine Keijinkai Clinic, Hokkaido, Sapporo, Japan|Tomakomai City Hospital, Hokkaido, Tomakomai, Japan|Otaru Kyokai Hospital, Hokkaido,Otaru, Japan|Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Amagasaki, Japan|Hyogo Brain and Heart Center, Hyogo, Himeji, Japan|National Hospital Organization Kobe Medical Center, Hyogo, Kobe, Japan|Mito Medical Center, Ibaraki, Higashiibaraki-gun, Japan|Tokushukai Koga General Hospital, Ibaraki, Koga, Japan|National Hospital Organization Kanazawa Medical Center, Ishikawa, Kanazawa, Japan|Mitoyo General Hospital, Kagawa, Kanonji, Japan|Kagawa Prefectural Central Hospital, Kagawa, Takamatsu, Japan|Sekishinkai Second Kawasaki Saiwai Clinic, Kanagawa, Kawasaki, Japan|Yamamoto Clinic, Kanagawa, Sagamihara, Japan|Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Yokohama, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto, Japan|Seiwakai Suizenji Touya Hospital, Kumamoto, Kumamoto, Japan|Kumamoto Rosai Hospital, Kumamoto, Yatsushiro, Japan|Uji-Tokushukai Medical Center, Kyoto, Uji, Japan|Sendai Kousei Hospital, Miyagi, Sendai, Japan|Sendai Tokushukai Hospital, Miyagi, Sendai, Japan|National Hospital Organization Sendai Medical Center, Miyagi, Sendai, Japan|Miyazaki Medical Association Hospital, Miyazaki, Miyazaki, Japan|Hokushin General Hospital, Nagano, Nakano, Japan|Nagasaki Medical Center, Nagasaki, Omura, Japan|Oita Medical Center, Oita, Oita, Japan|Okayama City General Medical Center, Okayama, Okayama, Japan|Naha City Hospital, Okinawa, Naha, Japan|Nanbu Tokushukai Hospital, Okinawa, Shimajiri-gun, Japan|Urasoe General Hospital, Okinawa, Urasoe, Japan|Higashiosaka City Medical Center, Osaka, Higashiosaka, Japan|Kitano Hospital, Osaka, Osaka, Japan|Yodogawa Christian Hospital, Osaka, Osaka, Japan|Hokusetsu General Hospital, Osaka, Takatsuki, Japan|San-Ai Hospital, Saitama, Saitama, Japan|Kosekai Iwatsuki-minami Hospital, Saitama, Saitama, Japan|Kusatsu General Hospital, Shiga, Kusatsu, Japan|Tokushima Prefectural Central Hospital, Tokushima, Tokushima, Japan|National Hospital Organization Tokyo Medical Center, Tokyo, Meguro-ku, Japan|Ome Municipal General Hospital, Tokyo, Ome, Japan|Tokyo Rosai Hospital, Tokyo, Ota-ku, Japan|Sekino Hospital, Tokyo, Toshima-ku, Japan|Minami Wakayama Medical Center, Wakayama, Tanabe, Japan|Kanmon Medical Center, Yamaguchi, Shimonoseki, Japan|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-Do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hosp, Wonju, Korea, Republic of|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Centro de Investigacion Biomedica y Farmaceutica, S.C., Distrito Federal, Mexico|Unidad de Investigacion Clinica Cardiometabolica de Occident, Guadalajara, Mexico|Diseño y Planeación en Investigación Médica SC, Guadalajara, Mexico|Cardiologia Clinica e Intervencionista, Guadalajara, Mexico|Instituto Cardiovascular de Monclova, S de RL de CV, Monclova, Mexico|CEDOPEC-Ctro Esp en Diab, Obesidad y Prev de Enf Cardiovasc, México, Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Nuevo Leon, Mexico|Centro Integral Medico SJR S.C., San Juan del Rio, Mexico|Cardioarritmias e Investigación S.C, San Luis Potosi, Mexico|Centro de Investigacion Cardiovascular y Metabolica, Tijuana, Mexico|Centro de Investigacion Alberto Bazzoni S.A. de C.V., Torreon, Mexico|Hospital Dr Angel Leano, Zapopan, Mexico|Ziekenhuisgroep Twente locatie Almelo, Almelo, Netherlands|BovenIJ Ziekenhuis, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Locatie West, Amsterdam, Netherlands|Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands|Rode Kruis Ziekenhuis Beverwijk, Beverwijk, Netherlands|Tergooiziekenhuizen locatie Blaricum, Blaricum, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Ziekenhuis Gelderse Vallei, EDE, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Diaconessenhuis Meppel, Meppel, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|De Heel - Zaans Medisch Centrum, Zaandam, Netherlands|Gelre Ziekenhuis Zutphen, Zutphen, Netherlands|KLIMED Marek Klimkiewicz, Bialystok, Poland|ClinicMed Badurski i wspolnicy Spolka Jawna, Bialystok, Bialystok, Poland|Univ. Clinic Hosp, Bialystok, Bialystok, Poland|American Heart of Poland Sp. z o.o., Bielsko-Biala, Poland|NZOZ Centrum Medyczne KERmed, Bydgoszcz, Poland|Polsko-Amerykanskie Kliniki Serca, Chorzow, Poland|American Heart of Poland Sp. z o.o., Dabrowa Gornicza, Poland|Poradnia Kardiologiczna Jaroslaw Jurowiecki, Gdansk, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Indywidualna Specjalistyczna Praktyka Lekarska, Gdynia, Poland|NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog., Gdynia, Poland|Szpital Zakonu Bonifratow Sp. z o.o., Katowice, Poland|Specialistic Cardiology&Hypertension Out-patient Clin,Kielce, Kielce, Poland|Leszek Bryniarski Specialized Medical Cabinet, Krakow, Poland|Krakow Specialistic Hospital of John Paul II, Krakow, Poland|ETG Lodz, Lodz, Poland|Nzoz Salus, Lodz, Poland|Individual Specialized Practice, Lodz, Poland|Lowickie Cardiology Center, Lowicz, Poland|American Heart of Poland Sp. z o.o., Nysa, Poland|Medicome Sp. z o.o., Oswiecim, Poland|NZOZ HEUREKA, Piaseczno, Piaseczno, Poland|Specialized Practice Dr. Janusz Spyra, Ruda Slaska, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Lukmed Lukasz Wozniak, Siedlce, Poland|ETG Skierniewice, Skierniewice, Poland|KO-MED Centra Kliniczne Staszow, Staszow, Poland|The Provincial Polyclinical Hospital in Torun, Torun, Poland|American Heart of Poland Sp. z o.o., Tychy, Poland|American Heart of Poland Sp. z o.o., Ustron, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Warszawa, Poland|ETG Warszawa, Warszawa, Poland|4. Military Clinical Hospital with Polyclinic SP ZOZ, Wroclaw, Poland|Zgierskie Center of Cardiology MED-PRO, Zgierz, Poland|Specialist Hospital J. Dietla NZOZ Specialized Clinic ""Gemini"", Zychlin, Poland|C.M.D.T.A. NEOMED, Brasov, Brasov, Romania|CMDTA Washington, Bucharest, Bucharest, Romania|Emergency Clinical Hospital 'Sf. Panteliomon', Bucharest, Romania|Prof.C.C.Iliescu Hospital, National Institute of Cardiology, Bucharest, Romania|Emergency University Hospital, Bucharest, Bucharest, Romania|Emergency University Hospital, Bucharest, Bucharest, Romania|Spitalul Clinic De Urgenta ""Prof. Dr. Agrippa Ionescu"", Bucuresti, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Spitalul Clinic ""Prof. Dr. Theodor Burghele"", Bucuresti, Romania|Clinica Medicala Data Plus SRL, Bucuresti, Romania|S.C Cardiomed S.R.L, Craiova, Romania|Spital Judetean Deva, Deva, Romania|S.C Medicali's S.R.L, Timisoara, Romania|Spitalul Clinic Judetean de Urgenta, Timisoara, Timisoara, Romania|National University Hospital, Singapore, Singapore|National Heart Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Khoo Teck Puat Hospital, Singapore, Singapore|Cardiology Clinical Research, Alberton, South Africa|Iatros International, Bloemfontein, South Africa|Universitas Hospital Cardiology Research, Bloemfontein, South Africa|Dr JM Engelbrecht Practice, Cape Town, South Africa|TREAD Research, Cape Town, South Africa|Tiervlei Trial Centre, Cape Town, South Africa|Excellentis Clinical Trials, George, South Africa|Clinresco, Johannesburg, South Africa|Peermed Clinical Trial Centre, Kempton Park, South Africa|Corbod Research, Panorama, South Africa|Into Research, Pretoria, South Africa|Chris Hani Baragwanath Hospital: Cardiology Department, Soweto, South Africa|Clinical Projects Research, Worcester, South Africa|Hospital Quiron. I.C.U., Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Sanitas CIMA, Barcelona, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Barnet General Hospital, Barnet, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Park & St Francis Surgery, Eastleigh, United Kingdom|Wycombe General Hospital, High Wycombe, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|St Mary's Hospital, Newport, United Kingdom|Morriston Hospital, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03057951"
628,"NCT02012140","Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI",,"Unknown status","No Results Available","Cardiovascular Disease|Stable Angina|Myocardial Infarction|Coronary Artery Disease","Drug: ticagrelor","Inhibition of platelet aggregation","LifeBridge Health","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AZSC01","January 2014","January 2015",,"December 16, 2013",,"December 16, 2013","Sinai Center for Thrombosis Research, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02012140"
629,"NCT01965730","Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery","EACA","Terminated","No Results Available","Aortic Disease","Drug: epsilon-aminocaproic acid (EACA)","degree of fibrinolysis as measured by thromboelastography","University of Pennsylvania","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","816724","January 2013","June 2014","June 2014","October 18, 2013",,"May 2, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01965730"
630,"NCT01514929","A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers",,"Completed","No Results Available","Cardiac Effects in Normal Healthy Volunteers","Drug: ACHN-490 Injection|Drug: Moxifloxacin|Drug: Placebo","Safety|Effect of ACHN-490 Injection on QTcF|PK Parameters|ECG Parameters|Correlation between drug concentration and QTc|Safety and tolerability","Achaogen, Inc.|Department of Health and Human Services","All","18 Years to 50 Years   (Adult)","Phase 1","64","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACHN-490-006","October 2011",,"March 2012","January 23, 2012",,"May 9, 2012","Investigational Site, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01514929"
631,"NCT01702376","This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.",,"Completed","No Results Available","Obstetric Labour, Premature","Drug: Retosiban 100 mg|Drug: Retosiban 800 mg|Drug: Placebo|Drug: Moxifloxacin 400 mg","Change from baseline in QT duration corrected for heart rate by Fridericia's formula (QTcF) interval at each timepoint for retosiban as compared with time-matched placebo|Change from baseline in QTcF, QT duration corrected for heart rate by Bazett's formula (QTcB), and QT interval corrected for heart rate (QTci) /QTciL interval at each timepoint for 100 mg and 800 mg retosiban as compared with time-matched placebo|Change from baseline in QTcF, QTcB, and QTci/QTciL interval at each timepoint for moxifloxacin as compared with time-matched placebo|Plasma concentrations of retosiban and GSK2847065|Maximum observed concentration (Cmax) for retosiban and GSK2847065|Time to maximum concentration (tmax) for retosiban and GSK2847065|Area under the concentration-time curve over the dosing interval (AUC(0-τ)) for retosiban and GSK2847065|Maximal change from baseline for QTcF and QTcB|Change from baseline for other cardiac electrophysiological parameters: QT, QRS, RR, PR and ventricular rate at each timepoint|Safety and tolerability of retosiban as assessed by change from baseline in 12-lead ECGs|Safety and tolerability of retosiban as assessed by change from baseline in systolic and diastolic blood pressure|Safety and tolerability of retosiban as assessed by change from baseline in pulse rate|Safety and tolerability of retosiban as assessed number of adverse events|Safety and tolerability of retosiban as assessed by change from baseline in clinical laboratory tests","GlaxoSmithKline","All","18 Years to 45 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","113789","October 3, 2012","January 14, 2013","January 14, 2013","October 8, 2012",,"June 12, 2017","GSK Investigational Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01702376"
632,"NCT01920711","Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction","PARAGON-HF","Completed","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: LCZ696|Drug: Valsartan","Cumulative number of primary composite events of cardiovascular (CV) death and total (first and recurrent) HF hospitalizations.|Change in the clinical summary score from baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)|Change from baseline to Month 8 in New York Heart Association (NYHA) functional class|Time to first occurance of a composite renal endpoint|Time to all-cause mortality","Novartis Pharmaceuticals|Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 3","4822","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696D2301|2013-001747-31","July 18, 2014","June 7, 2019","June 7, 2019","August 12, 2013",,"March 13, 2020","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Carmichael, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, West Haven, Connecticut, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, DeFuniak Springs, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Lake Worth, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Tallahassee, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Covington, Georgia, United States|Novartis Investigative Site, Cumming, Georgia, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Hazel Crest, Illinois, United States|Novartis Investigative Site, Lombard, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Oakbrook Terrace, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Quincy, Illinois, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Hammond, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Shreveport, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Biddeford, Maine, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Haverhill, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Grand Blanc, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Belzoni, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Kalispell, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Flushing, New York, United States|Novartis Investigative Site, Kingston, New York, United States|Novartis Investigative Site, Northport, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Saratoga Springs, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Bartlesville, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Yardley, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Warwick, Rhode Island, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Livingston, Texas, United States|Novartis Investigative Site, McKinney, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Tomball, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, White River Junction, Vermont, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Ramos Mejia, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, Argentina|Novartis Investigative Site, Tucuman, San Miguel De Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Salta, Argentina|Novartis Investigative Site, San Luis, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Gosford, New South Wales, Australia|Novartis Investigative Site, North Ryde, New South Wales, Australia|Novartis Investigative Site, Auchenflower, Queensland, Australia|Novartis Investigative Site, Southport, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Bundoora, Victoria, Australia|Novartis Investigative Site, Epping, Victoria, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Braunau, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Großgmain, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, De Pinte, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Uberlandia, Minas Gerais, Brazil|Novartis Investigative Site, Curitiba, Parana, Brazil|Novartis Investigative Site, Campina Grande do Sul, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Liberdade, Sao Paulo, Brazil|Novartis Investigative Site, Blumenau, SC, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Burgas, Bulgaria|Novartis Investigative Site, Pazardzhik, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Silistra, Bulgaria|Novartis Investigative Site, Sliven, Bulgaria|Novartis Investigative Site, Smolian, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Veliko Tarnovo, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, St. John, Newfoundland and Labrador, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Thetford Mines, Quebec, Canada|Novartis Investigative Site, Trois Rivieres, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chongqing, Chongqing, China|Novartis Investigative Site, Lanzhou, Gansu, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Nanning, Guangxi, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Wuxi, Jiangsu, China|Novartis Investigative Site, Nanchang, Jiangxi, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Jilin, Jilin, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Shanghai City, Shanghai, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Xian, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Chongqing, China|Novartis Investigative Site, Jinan, China|Novartis Investigative Site, Nanjing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Urumqi, China|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Florida Blanca, Colombia|Novartis Investigative Site, Varazdin, HRV, Croatia|Novartis Investigative Site, Rijeka, Croatia|Novartis Investigative Site, Zadar, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brandys nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Chomutov, Czech Republic, Czechia|Novartis Investigative Site, Ivancice, Czech Republic, Czechia|Novartis Investigative Site, Kladno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Louny, Czech Republic, Czechia|Novartis Investigative Site, Ostrava, Czech Republic, Czechia|Novartis Investigative Site, Plzen, Czech Republic, Czechia|Novartis Investigative Site, Praha 11, Czech Republic, Czechia|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Roznov pod Radhostem, Czech Republic, Czechia|Novartis Investigative Site, Svitavy, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Usti nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Znojmo, Czech Republic, Czechia|Novartis Investigative Site, Policska, CZE, Czechia|Novartis Investigative Site, Praha 2, CZE, Czechia|Novartis Investigative Site, Usti nad Labem, CZE, Czechia|Novartis Investigative Site, CZE, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Marianske lazne, Czechia|Novartis Investigative Site, Uherske Hradiste, Czechia|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Glostrup, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Randers, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Espoo, Finland|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Oulu, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Bayonne, Bayonne Cedex, France|Novartis Investigative Site, Montpellier cedex 5, Herault, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Beziers Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Paris cedex 10, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Pontoise, France|Novartis Investigative Site, Rennes Cedex 9, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Bad Homburg, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Berlin Buch, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Dessau-Roßlau, Germany|Novartis Investigative Site, Dietzenbach, Germany|Novartis Investigative Site, Dinkelsbühl, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duisburg, Germany|Novartis Investigative Site, Eilenburg, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hassloch, Germany|Novartis Investigative Site, Heidenau, Germany|Novartis Investigative Site, Heide, Germany|Novartis Investigative Site, Heppenheim, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Ingelheim, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kleve, Germany|Novartis Investigative Site, Koblenz, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Loehne, Germany|Novartis Investigative Site, Ludwigsburg, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Lutherstadt Wittenberg, Germany|Novartis Investigative Site, Lüneburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Markkleeberg, Germany|Novartis Investigative Site, Meißen, Germany|Novartis Investigative Site, Memmingen, Germany|Novartis Investigative Site, Muehldorf Am Inn, Germany|Novartis Investigative Site, Muehldorf, Germany|Novartis Investigative Site, Muehlheim An Der Ruhr, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Munchen, Germany|Novartis Investigative Site, Munich, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Northeim, Germany|Novartis Investigative Site, Nuremberg, Germany|Novartis Investigative Site, Oschatz, Germany|Novartis Investigative Site, Papenburg, Germany|Novartis Investigative Site, Reinfeld, Germany|Novartis Investigative Site, Riesa, Germany|Novartis Investigative Site, Rodgau, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Vilshofen, Germany|Novartis Investigative Site, Wangen, Germany|Novartis Investigative Site, Wermsdorf, Germany|Novartis Investigative Site, Weyhe, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, Attica, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Quetzaltenango, Guatemala|Novartis Investigative Site, Zalaegerszeg, Zala, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Cegled, Hungary|Novartis Investigative Site, Kistarcsa, Hungary|Novartis Investigative Site, Mako, Hungary|Novartis Investigative Site, Nyiregyháza, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Pécs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, Guntur, Andhra Pradesh, India|Novartis Investigative Site, Vishakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Surat, Gujarat, India|Novartis Investigative Site, Chandigarh, Haryana, India|Novartis Investigative Site, Gurgaon, Haryana, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Kochi, Kerala, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Chennai, Tamil NADU, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Madurai, Tamil NADU, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Lower Galilee, Israel|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Giborim, Holon, Israel|Novartis Investigative Site, Aosta, AO, Italy|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Treviglio, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, San Fermo della Battaglia, CO, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Vimercate, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Piacenza, PC, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Ariccia, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Vittorio Veneto, TV, Italy|Novartis Investigative Site, Palmanova, UD, Italy|Novartis Investigative Site, San Daniele Del Friuli, UD, Italy|Novartis Investigative Site, Saronno, Va, Italy|Novartis Investigative Site, Venezia, VE, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Seto-city, Aichi, Japan|Novartis Investigative Site, Chikushino-city, Fukuka, Japan|Novartis Investigative Site, Ogaki-city, Gifu, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Amagasaki city, Hyogo, Japan|Novartis Investigative Site, Kanazawa, Ishikawa, Japan|Novartis Investigative Site, Morioka, Iwate, Japan|Novartis Investigative Site, Kanonji-city, Kagawa, Japan|Novartis Investigative Site, Takamatsu city, Kagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Sendai city, Miyagi, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Kashihara city, Nara, Japan|Novartis Investigative Site, Oita-city, Oita, Japan|Novartis Investigative Site, Sayama-city, Saitama, Japan|Novartis Investigative Site, Kusatsu city, Shiga, Japan|Novartis Investigative Site, Chiyoda-ku, Tokyo, Japan|Novartis Investigative Site, Hachioji-city, Tokyo, Japan|Novartis Investigative Site, Itabashi-ku, Tokyo, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan|Novartis Investigative Site, Gyeonggi do, Bucheon Si, Korea, Republic of|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Wonju, Gangwon-do, Korea, Republic of|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Incheon, KOR, Korea, Republic of|Novartis Investigative Site, Seoul, KOR, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Torreon, Coahulia, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Leon, Guanajuato, Mexico|Novartis Investigative Site, Zapopan, Jalisco, Mexico|Novartis Investigative Site, San Juan del Rio, Queretaro, Mexico|Novartis Investigative Site, San Luis Potosi, San Luis Potosí, Mexico|Novartis Investigative Site, Culiacan, Sinaloa, Mexico|Novartis Investigative Site, Aguascalientes, Mexico|Novartis Investigative Site, Queretaro, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, San Luis Potosí, Mexico|Novartis Investigative Site, Apeldoorn, DZ, Netherlands|Novartis Investigative Site, Den Haag, NL, Netherlands|Novartis Investigative Site, Almelo, PP, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hardenberg, Netherlands|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sneek, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Hønefoss, Norway|Novartis Investigative Site, Loerenskog, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Tromsoe, Norway|Novartis Investigative Site, Bellavista, Lima, Peru|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Lipa City, Batangas, Philippines|Novartis Investigative Site, Quezon City, Manila, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Lodz, Lodzkie, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Grodzisk Mazowiecki, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Piaseczno, Poland|Novartis Investigative Site, Sandomierz, Poland|Novartis Investigative Site, Staszów, Poland|Novartis Investigative Site, Torun, Poland|Novartis Investigative Site, Warszawa/Anin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Zabrze, Poland|Novartis Investigative Site, Zamosc, Poland|Novartis Investigative Site, Pitesti, Arges, Romania|Novartis Investigative Site, Bucuresti, District 1, Romania|Novartis Investigative Site, Craiova, Jud. Dolj, Romania|Novartis Investigative Site, Sibiu, Jud. Iasi, Romania|Novartis Investigative Site, Braila, ROM, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Arad, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Oradea, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Izhevsk, Russian Federation|Novartis Investigative Site, Izhevsk, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Rostov on Don, Russian Federation|Novartis Investigative Site, Rostov-on-Don, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St.- Petersburg, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Belgrade, Serbia|Novartis Investigative Site, Beograd, Serbia|Novartis Investigative Site, Niska Banja, Serbia|Novartis Investigative Site, Nis, Serbia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Brezno, Slovak Republic, Slovakia|Novartis Investigative Site, Komarno, Slovak Republic, Slovakia|Novartis Investigative Site, Levice, Slovak Republic, Slovakia|Novartis Investigative Site, Namestovo, Slovak Republic, Slovakia|Novartis Investigative Site, Povazska Bystrica, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Velky Krtis, Slovak Republic, Slovakia|Novartis Investigative Site, Bardejov, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Piestany, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Svidnik, Slovakia|Novartis Investigative Site, Trebisov, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Novartis Investigative Site, Golnik, Slovenia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Mthatha, Eastern Cape, South Africa|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Durban, Kwa-Zulu Natal, South Africa|Novartis Investigative Site, Paarl, Western Cape, South Africa|Novartis Investigative Site, Alberton, South Africa|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Tongaat, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Sanlúcar de Barrameda, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Aranda de Duero, Castilla Y Leon, Spain|Novartis Investigative Site, Leon, Castilla Y Leon, Spain|Novartis Investigative Site, Lerida, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Merida, Extremadura, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Olot, Girona, Spain|Novartis Investigative Site, Mostoles, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Ciudad Real, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Danderyd, Sweden|Novartis Investigative Site, Falun, Sweden|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Karlstad, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Orebro, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Biel, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, New Taipei, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Yilan, Taiwan|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Haydarpasa Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, High Wycombe, Buckinghamshire, United Kingdom|Novartis Investigative Site, Stockton on Tees, Cleveland, United Kingdom|Novartis Investigative Site, Darlington, Co Durham, United Kingdom|Novartis Investigative Site, Durham, County Durham, United Kingdom|Novartis Investigative Site, Torquay, Devon, United Kingdom|Novartis Investigative Site, Dorchester, Dorset, United Kingdom|Novartis Investigative Site, Peterborough, GBR, United Kingdom|Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom|Novartis Investigative Site, Portsmouth, Hampshire, United Kingdom|Novartis Investigative Site, Oldham, Lancashire, United Kingdom|Novartis Investigative Site, Harrow, Middlesex, United Kingdom|Novartis Investigative Site, Whitby, North Yorkshire, United Kingdom|Novartis Investigative Site, Portadown, Nothern Ireland, United Kingdom|Novartis Investigative Site, Wansford, Peterborough, United Kingdom|Novartis Investigative Site, Glasgow, Scotland, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, Gateshead, Tyne And Wear, United Kingdom|Novartis Investigative Site, South Shields, Tyne And Wear, United Kingdom|Novartis Investigative Site, Clydebank, West Dumbartonshire, United Kingdom|Novartis Investigative Site, Bath, United Kingdom|Novartis Investigative Site, Cheshire, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Dundee, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Hull, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newport, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom|Novartis Investigative Site, Wiltshire, United Kingdom|Novartis Investigative Site, Wrexham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01920711"
633,"NCT03611374","Regional Anesthesia for Cardiothoracic Enhanced Recovery (RACER) Study",,"Recruiting","No Results Available","Congenital Heart Defect|Congenital Heart Disease|Anesthesia, Local|Opioid Use","Procedure: Bilateral Erector Spinae Plane Block (ESPB)","Median time to extubation in patients with ESPB|Median Cardiovascular Intensive Care Unit (CVICU) LOS in patients with ESPB|Determine average post-operative pain scores in patients with ESPB|Determine opioid consumption","Stanford University","All","up to 99 Years   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","47032","June 6, 2019","June 6, 2020","June 6, 2021","August 2, 2018",,"June 19, 2019","Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT03611374"
634,"NCT03190798","Effects of Canagliflozin on Intravascular Volume and Hemodynamics",,"Withdrawn","No Results Available","Type2 Diabetes Mellitus|Cardiovascular Diseases","Drug: Canagliflozin 300mg|Drug: Placebo","Change in Pulmonary capillary wedge pressure (PCWP)","The University of Texas Health Science Center at San Antonio|Janssen Scientific Affairs, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","HSC20170151H|DIA4028","September 1, 2017","August 1, 2018","August 1, 2018","June 19, 2017",,"October 12, 2017","The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03190798"
635,"NCT00935766","Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries",,"Terminated","Has Results","Metabolic Diseases|Endocrine System Diseases|Heart Disease|Vascular Diseases|Diabetes|Cardiovascular Disease|Glucose Metabolism Disorders|Hypertension","Drug: Omega-3|Drug: Placebo","Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.|Change in Lipoprotein-associated Phospholipase A2 (LpPLA2)|Change in hsCRP","Denver Health and Hospital Authority|National Heart, Lung, and Blood Institute (NHLBI)|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","76","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","08-0722 LUCHAR AIM 4","September 2009","March 2012","March 2012","July 9, 2009","September 29, 2014","September 29, 2014","Denver Health and Hospital Authority, Denver, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT00935766"
636,"NCT01250912","Imaging With a Radio Tracer to Guide VT Ablations",,"Completed","No Results Available","Ventricular Tachycardia|Arrhythmia","Drug: 123I-metaiodobenzylguanidine","Imaging of Nerve distribution in heart","University of Maryland, College Park|GE Healthcare|University of Maryland, Baltimore","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00043324","March 2010","August 2015","August 2015","December 1, 2010",,"April 6, 2018","University of Maryland Medical Center, EP Lab, Rm. N3W77, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01250912"
637,"NCT01560780","Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis",,"Completed","Has Results","Coronary Artery Bypass","Drug: Prasugrel|Drug: Placebo","Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging|Number of Patients With Severe Bleeding Using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Criteria|Number of Patients With Angiographic Saphenous Vein Graft Failure|Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography|Saphenous Vein Graft Lipid Core Burden Index, as Assessed at Near-infrared Intracoronary Spectroscopy|Major Adverse Cardiac Events, Defined as the Composite of Death, Acute Coronary Syndrome, or Coronary Revascularization) During Follow-up|Normalized Total Target Saphenous Vein Graft Atheroma Volume, as Assessed by Intravascular Ultrasonography","VA Office of Research and Development","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","84","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLIN-007-11F","February 1, 2013","April 30, 2018","May 31, 2018","March 22, 2012","October 9, 2019","October 30, 2019","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago, Illinois, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT01560780/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01560780"
638,"NCT03030222","Empagliflozin Impact on Hemodynamics in Patients With Heart Failure","EMBRACE-HF","Active, not recruiting","No Results Available","Heart Failure","Drug: Empagliflozin 10Mg Tab|Drug: Placebo Oral Tablet","To compare the change in pulmonary artery diastolic pressure from baseline to end of treatment period between empagliflozin and placebo|To compare change from baseline in pulmonary artery diastolic pressure between empagliflozin and placebo at each interim time point|To compare change in pulmonary artery systolic pressure from baseline to end of treatment period between empagliflozin and placebo|To compare change from baseline in pulmonary artery systolic pressure between empagliflozin and placebo at each interim time point|To compare change in mean pulmonary artery pressure from baseline to end of treatment period between empagliflozin and placebo|To compare change from baseline in mean pulmonary artery pressure between empagliflozin and placebo at each interim time point|To compare change from baseline to follow-up in heart failure related quality of life between empagliflozin and placebo, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score.|To compare proportion of patients with a ≥ 5pts increase from baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo|To compare change in 6 minute walk test from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo|To compare change in NTproBNP from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo|To compare change in BNP from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo|To compare proportion of patients with a ≥ 20% decrease from baseline in NTproBNP at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo.|To compare proportion of patients with a ≥ 20% decrease from baseline in BNP at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo.|To compare proportion of patients with both a ≥ 5pts increase from baseline in KCCQ and a ≥ 20% decrease from baseline in NTproBNP at either 6 weeks or 12 weeks of follow-up between empagliflozin and placebo|To compare the number of diuretic medication adjustments during the treatment period between empagliflozin and placebo|To compare change in Hemoglobin A1c from baseline to follow-up (defined as average of measurements at 6 and 12 weeks) between empagliflozin and placebo, evaluated separately in patients with and without type 2 diabetes","Saint Luke's Health System","All","19 Years to 119 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1245.129","July 5, 2017","March 10, 2020","June 30, 2020","January 24, 2017",,"April 2, 2020","University of Southern California, Los Angeles, California, United States|First Coast Cardiovascular Institute, Jacksonville, Florida, United States|NorthShore University Health System Research Institute, Evanston, Illinois, United States|CentraCare Heart and Vascular Center, Saint Cloud, Minnesota, United States|St. Francis Hospital, Roslyn, New York, United States|Ohio State University, Columbus, Ohio, United States|Sanford Research, Sioux Falls, South Dakota, United States|Austin Heart Clinical Research, Austin, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03030222"
639,"NCT02741284","Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings","O2C2","Active, not recruiting","Has Results","Electronic Fetal Monitoring|Fetal Hypoxia|Fetal-Placental Circulation","Drug: Room air|Drug: 10L Oxygen by nonrebreather mask","Mean Umbilical Artery Lactate at Delivery|Umbilical Artery pH|Mode of Delivery|Umbilical Artery pCO2|Umbilical Artery pO2|Umbilical Artery Base Deficit","Washington University School of Medicine","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","114","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","201602164","June 2016","June 2017","June 2020","April 18, 2016","November 2, 2018","February 10, 2020","Barnes Jewish Hospital, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02741284/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02741284"
640,"NCT02932007","Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: Chloroquine Phosphate","Proportion of patients with termination of AF|Percentage of AF burden|QT intervals|Time to AF termination|Percentages of classifications of rhythms identified|PR interval|QRS duration","University of South Florida","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Chloroquine AF","March 28, 2017","March 2020","September 2020","October 13, 2016",,"August 19, 2019","University of South Florida, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02932007"
641,"NCT02653482","Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure","DEFINE-HF","Active, not recruiting","No Results Available","Chronic Heart Failure With Reduced Systolic Function","Drug: Dapagliflozin|Drug: Dapagliflozin matching placebo","Difference in mean NTproBNP between the treatment and placebo study arms at 6 and 12 weeks.|Proportion of patients that achieve a ≥ 5pts increase in heart failure disease specific quality of life (assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score) or a ≥ 20% decrease in NTproBNP over 12 weeks|Proportion of patients with a ≥ 5pts increase in KCCQ|Proportion of patients with a ≥ 20% decrease in NTproBNP|Proportion of patients with a ≥ 5pts increase in KCCQ and a ≥ 20% decrease in NTproBNP|Change in KCCQ score over 12 weeks.|Change in 6 minute walk score over 12 weeks.|Change in BNP over 12 weeks.|Change in HbA1c over 12 weeks. (evaluated separately in patients with and without type 2 diabetes)|Change in weight over 12 weeks|Change in systolic blood pressure over 12 weeks","Saint Luke's Health System","All","19 Years to 119 Years   (Adult, Older Adult)","Phase 4","263","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00032","March 3, 2016","May 31, 2019","May 31, 2020","January 12, 2016",,"April 2, 2020","Heart Group of the Eastern Shore, Fairhope, Alabama, United States|University of Southern Califiornia, Los Angeles, California, United States|First Coast Cardiovascular Institute, Jacksonville, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Emory University, Atlanta, Georgia, United States|NorthShore University HealthSystem Research Institute, Evanston, Illinois, United States|Northwestern University, Evanston, Illinois, United States|Advocate Health and Hospitals, Oakbrook Terrace, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Freeman Health System, Joplin, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|New York University, New York, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Duke University, Durham, North Carolina, United States|Eastern Nephrology Associates, New Bern, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02653482"
642,"NCT02307006","The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection","PREVTAROLINE","Unknown status","No Results Available","Surgical Site Infection","Drug: Ceftaroline|Drug: Cefazolin / Vancomycin","Surgical site infection|Other infection|Drug intolerance|Repeat surgery","University of Cincinnati|Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 4","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","IDC 56 / IIT-USA-000585/","January 2015","December 2016","June 2017","December 3, 2014",,"December 2, 2015","University of Cincinnati Medical Center, Cincinnati, Ohio, United States|West Chester Hospital, West Chester, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02307006"
643,"NCT01092325","Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: CXL-1020|Drug: Placebo for CXL-1020 Cohort 1|Drug: Placebo for CXL-1020 Cohort 2|Drug: CXL-1020 Dose for Echo Cohort A|Drug: CXL-1020 Doses for Echo Cohort B","Safety and Tolerability|Hemodynamic Effects as Measured by Impedance Cardiography and Echocardiography|Plasma and Urinary Pharmacokinetics","Bristol-Myers Squibb|Cardioxyl Pharmaceuticals, Inc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CXL-1020-01","June 2009","May 2010","May 2010","March 24, 2010",,"July 1, 2016","Orange County Clinical Research Center, Tustin, California, United States",,"https://ClinicalTrials.gov/show/NCT01092325"
644,"NCT01678794","CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function",,"Active, not recruiting","No Results Available","Cardiorenal Syndrome (CRS)","Drug: Candesartan|Drug: Placebo","Change in Glomerular Filtration Rate (mL/min/1.73 m2)|change in urinary Sodium excretion","Mayo Clinic|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","76","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","09-003284|1R01HL084155-01A2","February 2012","December 30, 2020","December 30, 2021","September 5, 2012",,"October 10, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01678794"
645,"NCT03270644","A Study of Lasmiditan and Propranolol in Healthy Participants",,"Completed","Has Results","Healthy","Drug: Lasmiditan|Drug: Propranolol","Change From Baseline (Day 8) in Mean Hourly Heart Rate Following Propranolol Administered Alone and When Coadministered With Lasmiditan|Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan Alone and When Coadministered With Propranolol|Pharmacokinetic: Maximum Observed Drug Concentration (Cmax) of Propranolol Alone and When Coadministered With Lasmiditan|Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Last Measurable Concentration [AUC(0-tlast)] of Lasmiditan Alone and When Administered With Propranolol|Pharmacokinetic: Area Under the Concentration Versus Time Curve (AUC) of Propranolol During One Dosing Interval Alone and When Administered With Lasmiditan|Change From Baseline (Day 8) in PR Interval Following Propranolol Administered Alone and When Coadministered With Lasmiditan|Change From Baseline (Day 8) in Systolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan|Change From Baseline (Day 8) in Diastolic Blood Pressure Following Propranolol Administered Alone and When Coadministered With Lasmiditan","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16857|H8H-MC-LAHD","August 31, 2017","November 22, 2017","November 22, 2017","September 1, 2017","December 2, 2019","December 16, 2019","Covance Daytona Beach, Daytona Beach, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03270644/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03270644/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03270644"
646,"NCT03593902","Cardiac Safe Transplants for Systemic Sclerosis","CAST","Active, not recruiting","No Results Available","Systemic Sclerosis|Scleroderma","Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Drug: rATG|Drug: Methylprednisolone|Drug: G-CSF|Biological: IVIg|Biological: Autologous Stem Cells","Change in skin score by mRSS|Change in FVC on pulmonary function test|Treatment related mortality|Survival|Cardiac function, LVEF|Cardiac function, RVEF|Cardiac function, PASP|Cardiac function, mPAP|Cardiac function, ECV|Renal outcome, creatinine clearance|Renal outcome, episodes of renal crisis|Renal outcome, dialysis|Pulmonary function tests, TLC|Pulmonary function tests, DLCO","Northwestern University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIAD.CAST.2018","September 7, 2018","January 2025","January 2026","July 20, 2018",,"July 25, 2019","Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03593902"
647,"NCT02253394","The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Ambrisentan plus Spironolactone|Drug: Ambrisentan plus Placebo","Effect of Combination Ambrisentan + Spironolactone on Peak Volume of Oxygen Consumption (pVO2) and Cardiac Output","Brigham and Women's Hospital|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","CAPS_PAH","September 2015","February 2018","February 2018","October 1, 2014","November 15, 2019","November 15, 2019","Brigham & Women's Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02253394/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02253394"
648,"NCT01584557","Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management","Secret of CHF","Completed","No Results Available","Heart Failure","Drug: Tolvaptan or Samsca|Drug: placebo or sugar pill","To evaluate the short term efficacy and safety of tolvaptan in subjects hospitalized for worsening heart failure who have volume overload and one of the following: renal insufficiency, or hyponatremia or inadequate response to diuretic therapy.|Change from baseline in body weight measured daily while hospitalized up to 7 days.|Diuretic dose measured daily while hospitalized up to 7 days.|Change from baseline in estimated glomerular filtration rate (eGFR) at discharge or day 7, whichever comes first.|Days alive and out of the hospital over 30 days|Change from baseline in cognitive function at 48 hours or discharge, whichever comes first|Re-hospitalization for worsening heart failure or death at 30 days","Cardiovascular Clinical Science Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCSF-2011-001","June 2012","July 2016","August 2016","April 25, 2012",,"September 27, 2016","University of Alabama at Birmingham, Birmingham, Alabama, United States|The Heart Center Research, Huntsville, Alabama, United States|Greater Los Angeles VA Medical Center, Los Angeles, California, United States|University of Florida Health Science Ctr. Jacksonville, Jacksonville, Florida, United States|MIMA Century Research Associates, Melbourne, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|University Cardiology Associates, LLC, Augusta, Georgia, United States|Mercer University School of Medicine, Macon, Georgia, United States|Advocate Medical Group - Oakbrook, Naperville, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|CardioSpecialists Group, Munster, Indiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Advanced Cardiovascular Specialists, Shreveport, Louisiana, United States|Louisiana Heart Center and Research, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Crittenton Hospital Medical Center, Rochester, Michigan, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Bryan Heart Institute, Lincoln, Nebraska, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Caromont Heart/Gaston Memorial Hospital, Gastonia, North Carolina, United States|Duke Cardiology of Lumberton Research/Southeastern Regional Medical Cente, Lumberton, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|University of Cincinnati, Cincinnatti, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|The Sisters of Mercy of Hamilton, Ohio dba Mercy Hospital Fairfield, Fairfield, Ohio, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Memorial Hospital of RI, Pawtucket, Rhode Island, United States|The Miriam Hosptial, Providence, Rhode Island, United States|University of Texas Health Science Center, Houston, Texas, United States|The Heart Hospital Baylor Plano - Research Insititute, Plano, Texas, United States|CV Group Central Lynchburg/Stroobants Heart Center, Lynchburg, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01584557"
649,"NCT01800292","Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.","LV strain","Completed","No Results Available","Hypertension, Pulmonary Artery|Ventricular Dysfunction, Left","Drug: sildenafil","exercise capacity not on/on sildenafil therapy|Echo parameters:left ventricular septal and lateral wall longitudinal strain and strain rate, RV strain and strain rate, and LV lateral wall/septal strain and strain rate","University of Arizona","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-0006-01|986-12","February 2013","December 2013","December 2014","February 27, 2013",,"November 4, 2015","University of Arizona Medical Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT01800292"
650,"NCT00957034","Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure","CORDELIA","Terminated","Has Results","Heart Failure","Drug: placebo|Drug: testosterone","Percent Change From Baseline in Six Minute Walking Test (6MWT), Meters|Percent Change From Baseline in Severity of Heart Failure (HF) as Measured by New York Heart Association (NYHA) Classification|Mortality or Hospitalizations|Percent Change Minnesota Living With Heart Failure Questionnaire (MLHFQ) Overall Score and Domain Scores|Percent Change Patient Global Assessment of Heart Failure Status|Percent Change Physician Global Assessment of Heart Failure Status","Warner Chilcott","Female","50 Years and older   (Adult, Older Adult)","Phase 2","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2009015","July 2009","April 2010","May 2010","August 12, 2009","January 13, 2012","January 13, 2012","Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Lakewood, California, United States|Research Site, Riverside, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Melbourne, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Munster, Indiana, United States|Research Site, Brooklyn, New York, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00957034"
651,"NCT03340675","Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy","DMD","Recruiting","No Results Available","Duchenne Muscular Dystrophy Cardiomyopathy|Cardiomyopathy, Dilated","Drug: Ifetroban|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events (safety & tolerability)|Pharmacokinetics Area under the curve|Pharmacokinetics maximum serum concentration (Cmax)|Pharmacokinetics time to reach Cmax (Tmax) concentration|Pharmacokinetics plasma terminal half-life concentration|Change from baseline in left ventricular ejection fraction|Change from baseline in pulmonary function|Change from baseline in quality-of-life","Cumberland Pharmaceuticals|Vanderbilt University Medical Center","Male","7 Years and older   (Child, Adult, Older Adult)","Phase 2","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CPI-IFE-007|FD-R-6371","June 2020","July 2023","July 2023","November 13, 2017",,"April 7, 2020","Mattel Children's Hospital, Los Angeles, California, United States|Children's National Hospital, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Riley Children's Hospital, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT03340675"
652,"NCT02203630","Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients",,"Terminated","Has Results","Septic Shock|Sepsis|Shock|Tachycardia|Arrhythmia","Drug: Phenylephrine|Drug: Norepinephrine","Maximum Heart Rate|Number of Participants With Arrhythmia Events|Total Time in Arrhythmia|Number of Patients With ST-segment Abnormalities on ECG|Number of Uses of Rate-controlling Agent|Number of Times an Anti-arrhythmic Agent is Used|Use of Corticosteroid|Number of Direct Current (DC) Cardioversion Events|Number of Days Mechanical Ventilation Needed|Number of Days Hemodialysis Needed|Mean Sequential Organ Failure Assessment (SOFA) Score|Number of Participants Developing Peripheral Limb Ischemia|Number of Participants With Cardiac Arrest Events|Number of Days Without Vasopressor Use|Number of Days Without Mechanical Ventilation|Days Without Dialysis|Hospital Days Not in ICU|Days Spent Out of the Hospital|Readmission to ICU|Number of Participants Rehospitalized After Discharge|Length of ICU Stay|Length of Hospital Stay|28-day Mortality|Location of Death|Cause of Death|Mean Troponin-I|CK-MB|Creatinine Kinase (CK)|Number of Participants Receiving Non-study Vasopressors|Amount of Time Non-study Vasopressors Used","Vanderbilt University Medical Center|National Center for Research Resources (NCRR)|National Center for Advancing Translational Science (NCATS)","All","18 Years and older   (Adult, Older Adult)","Phase 4","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 140141|UL1RR024975-01|UL1TR000445-06","August 2014","January 2016","January 2016","July 30, 2014","June 13, 2018","June 13, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02203630"
653,"NCT01522417","Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention","SAVI-PCI","Completed","No Results Available","Myocardial Infarction|Acute Coronary Syndromes|Unstable Angina","Drug: Short Tirofiban|Drug: Eptifibatide|Drug: Long Tirofiban","The composite incidence of death, PCI-related myocardial infarction, urgent target vessel revascularization or major bleeding|The composite incidence of death, PCI-related myocardial infarction or urgent target vessel revascularization","Medicure|SCRI Development Innovations, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","535","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Medicure 11002","April 2012","December 2018","March 2019","January 31, 2012",,"August 13, 2019","Osceola Regional Medical Center, Kissimmee, Florida, United States|Northside Hospital, Saint Petersburg, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|North Georgia Heart Center, Gainesville, Georgia, United States|Redmond Regional Medical Center, Rome, Georgia, United States|Archbold Medical Center, Thomasville, Georgia, United States|Lenox Hill Hospital, New York, New York, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Centennial Heart, Nashville, Tennessee, United States|Chippenham Hospital, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01522417"
654,"NCT01574703","Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.","CATS","Completed","Has Results","Smoking Cessation","Drug: placebo|Drug: varenicline tartrate|Drug: bupropion hydrochloride|Drug: Nicotine Replacement Therapy Patch","Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.|Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.|Time to MACE Until the End of Study NCT01574703.|Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.|Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.|Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.|Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.|Incidence of MACE Assessed Until End of Study NCT01574703.|Incidence of MACE+ Assessed Until End of Study NCT01574703.","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","4595","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","A3051148|2011-005513-37|CATS","May 2012","July 2015","July 2015","April 10, 2012","December 29, 2016","December 29, 2016","Coastal Clinical Research, Inc., Mobile, Alabama, United States|Pharmacology Research Institute, Encino, California, United States|Synergy Clinical Research Center of Escondido, Escondido, California, United States|Sun Valley Research Center, Imperial, California, United States|Omega Clinical Trials, La Habra, California, United States|Pacific Treatment and Research Center, La Jolla, California, United States|Pharmacology Research Institute, Los Alamitos, California, United States|Pharmacology Research Institute (PRI), Newport Beach, California, United States|North County Clinical Research, Oceanside, California, United States|NRC Research Institute, Orange, California, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States|University of Colorado Anschutz Medical Campus Behavioral Health and Wellness Program, Aurora, Colorado, United States|Western Affiliated Research Institute, Denver, Colorado, United States|Comprehensive Psychiatric Care, Norwich, Connecticut, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Broward Research Group, Hollywood, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Jacksonville, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Ocala Psychiatric Associates, Ocala, Florida, United States|Clinical Neuroscience Solutions Inc., Orlando, Florida, United States|Meridien Research, Tampa, Florida, United States|Northwest Behavioral Research Center, Marietta, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Baber Research Group Incorporated, Naperville, Illinois, United States|Davis Clinic, Incorporated, Indianapolis, Indiana, United States|American Health Network of IN, LLC, Indianapolis, Indiana, United States|Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States|Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States|Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States|Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Central Kentucky Research Associates, Incorporated, Lexington, Kentucky, United States|Kentucky Research Group, Louisville, Kentucky, United States|The Center for Sexual Health, Metairie, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Milford Emergency Associates, Incorporated, Milford, Massachusetts, United States|University of Minnesota - TC, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Precise Research Centers, Flowood, Mississippi, United States|The Center for Pharmaceutical Research, PC, Kansas City, Missouri, United States|Mercy Health Research, St. Louis, Missouri, United States|CRI Worldwide, LLC, Marlton, New Jersey, United States|Global Medicinal Institutes, LLC; Princeton Medical Institute, Princeton, New Jersey, United States|SPRI Clinical Trails LLC, Brooklyn, New York, United States|Regional Clinical Research, Incorporated, Endwell, New York, United States|PMG Research of Raleigh, LLC, Cary, North Carolina, United States|Wake Internal Medicine Consultants, Inc, Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Midwest Clinical Research Center, Dayton, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Southeastern PA Medical Institute, Broomall, Pennsylvania, United States|Belmont Center for Comprehensive Treatment, Philadelphia, Pennsylvania, United States|Lincoln Research, LLC, Lincoln, Rhode Island, United States|Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions,Inc, Memphis, Tennessee, United States|Clinical Research Associates, Inc., Nashville, Tennessee, United States|James G. Kyser, MD, Nashville, Tennessee, United States|Future Search Clinical Trials, Austin, Texas, United States|InSite Clinical Research, DeSoto, Texas, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Clinical Research Associates of Tidewater, Inc, Norfolk, Virginia, United States|Centro de Investigacion Clinica WM, Capital Federal, Buenos Aires, Argentina|Centro Medico Dra. De Salvo, Buenos Aires, Capital Federal, Argentina|Monash Alfred Psychiatry Research Centre, Melbourne, Victoria, Australia|Hospital Sao Lucas da PUCRS - Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RS, Brazil|Hospital e Maternidade Celso Pierro - Pontifícia Universidade Católica de Campinas - Campus II, Campinas, São Paulo, Brazil|Jaqueline Scholz Issa e Mario Issa de cardiologia Ltda, Sao Paulo, Brazil|Mental Health Center ""Prof. Dr. Ivan Temkov-Bourgas"" Ltd., Bourgas, Bulgaria|MHAT ""Dr. Hristo Stambolski"" Ltd., Kazanlak, Bulgaria|NPH ""Sv. Ivan Rilski"", Novi Iskar, Bulgaria|UMHAT ""Dr. Georgi Stranski"" Ltd., Pleven, Bulgaria|UMHAT ""Sveti Georgi"" Ltd., Plovdiv, Bulgaria|SHATPPD - Ruse Ltd., Ruse, Bulgaria|Mental Health Center - Ruse Ltd., Ruse, Bulgaria|MHATNP ""Sveti Naum"" Ltd., Sofia, Bulgaria|MHATNP Sveti Naum SJsc., Sofia, Bulgaria|SHATPD - Troyan Ltd., Troyan, Bulgaria|Hamilton Medical Research Group, Hamilton, Ontario, Canada|Medical Research Associates, Mississauga, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Canadian Phase Onward Inc., Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Hospital Regional de Talca, Unidad de Enfermedades Respiratorias, Talca, Maule, Chile|Centro Respiratorio Integral (CENRESIN Ltda.), Quillota, Valparaiso, V Region, Chile|CCBR A/S, Ballerup, Denmark|CCBR A/S, Vejle, Denmark|Mehiläinen Leppävaara, Espoo, Finland|Savon Psykiatripalvelu Oy, Kuopio, Finland|Mehiläinen Nummela, Nummela, Finland|Oulu Mentalcare Oy, Oulu, Finland|Porin Lääkäritalo Oy, Pori, Finland|PEL, Psykiatrian ErikoisLääkärit, Turku, Finland|Universitaetsklinikum Freiburg, Freiburg, Baden-wuerttemberg, Germany|Ludwig Maximilians-Universitaet Muenchen, Muenchen, Bayern, Germany|Klinische Forschung Berlin-Mitte GmbH, Berlin, Germany|emovis GmbH, Berlin, Germany|Klinische Forschung Hamburg GmbH, Hamburg, Germany|ZSL - Zentrum fuer Medizinische Studien Leipzig GmbH, Leipzig, Germany|Universitaetsklinik Tuebingen, Klinik fuer Psychiatrie und Psychotherapie, Tuebingen, Germany|Consultorios de Medicina Especializada del Sector Privado, Mexico, Mexico Df, Mexico|Centro de Estudios Clinicos y Especialidades Medicas S.C., Monterrey, Nuevo Leon, Mexico|Lakeland Clinical Trials, Rotorua, New Zealand|FSBI ""Federal Medical Research Center of Psychiatry and Addiction Medicine"", Moscow, Russian Federation|Moscow State Public Healthcare Institution Mental Clinical Hospital #1 n.a. N.A. Alexeeva, Moscow, Russian Federation|Clinical Mental Hospital #12 of Moscow Healthcare Department, Moscow, Russian Federation|Clinical Psychiatric Hospital #1 of Nizhni Novgorod, Nizhni Novgorod, Russian Federation|FSBI ""Saint-Petersburg Scientific Research Psychoneurological Institute n.a. V.M. Bekhterev"", Saint Petersburg, Russian Federation|St. Petersburg State Healthcare Institution, St. Nikolay Chudotvorets Mental Hospital, St. Petersburg, Russian Federation|State Healthcare Institution of St.Petersburg ""Psychoneurological Dispensary #2, St. Petersburg, Russian Federation|Psychiatricka ambulancia, Mentum, s.r.o., Bratislava, Slovakia|Nestatna psychiatricka ambulancia, MUDr. Livia Vavrusova, PhD, Bratislava, Slovakia|Psychiatricka ambulancia MUDr. Nada Kuriackova, s.r.o., Levice, Slovakia|Psychiatricka ambulancia, PsychoLine s.r.o., Rimavska Sobota, Slovakia|Nemocnica s poliklinikou sv. Barbory Roznava a.s., Roznava, Slovakia|Flexivest Fourteen Research Center, Bellville, Cape Town, South Africa|Worthwhile Clinical Trials, Benoni, Johannesburg, Gauteng, South Africa|Soweto Clinical Trials Centre, Johannesburg, Gauteng, South Africa|Midrand Medical Centre, Midrand, Gauteng, South Africa|I Engelbrecht Research Pty. Ltd, Pretoria, Gauteng, South Africa|Vista Clinic, Pretoria, Gauteng, South Africa|Private Practice, Durban, Kwa-zulu Natal, South Africa, South Africa|Randles Road Medical Centre, Durban, Kwazulu Natal, South Africa|Dr John O'Brien Incorporated, Cape Town, Western Cape, South Africa|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital General Universitari Vall D'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital San Pedro de Alcantara, Caceres, Spain|Unidad Especializada En Tabaquismo de La Comunidad de Madrid, Madrid, Spain|Centro de Salud Torrero-La Paz., Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01574703"
655,"NCT02025621","Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass","LEVO-CTS","Completed","Has Results","Coronary Artery Bypass Grafting|Mitral Valve Surgery|Low Cardiac Output Syndrome","Drug: Levosimendan|Drug: Placebo","Number of Dual Efficacy Endpoint Events|Number of Quad Efficacy Endpoint Events|Duration of Intensive Care Unit/Critical or Coronary Care Unit (ICU/CCU) (Days)|Incidence of Low Cardiac Output Syndrome (LCOS)|Postoperative Use of Secondary Inotrope","Tenax Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","882","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TNX-LVO-01","July 2014","November 2016","November 2016","January 1, 2014","May 22, 2018","June 21, 2018","University of Alabama at Burlington Hospital, Burlington, Alabama, United States|Huntsville Hospital, Huntsville, Alabama, United States|Mercy General Hospital, Sacramento, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Stanford University School of Medicine, Stanford, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Boca Raton Community Hospital, Boca Raton, Florida, United States|Shands Hospital at the University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Redmond Regional Medical Center, Rome, Georgia, United States|Northwestern University Hospital, Evanston, Illinois, United States|Lutheran Hospital of Indiana, Fort Wayne, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Iowa Heart Center/ Mercy Medical Center, West Des Moines, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|St. Joseph's Mercy Hospital, Ann Arbor, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|St. Luke's Hospital, Kansas City, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Nebraska Heart Institute, Lincoln, Nebraska, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Morristown Medical Center, Morristown, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Columbia University Medical Center, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Saint Francis Hospital/The Heart Center, Roslyn, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States|Duke University Hospital, Raleigh, North Carolina, United States|The Christ's Hospital; Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|ProMedica Toledo Hospital, Toledo, Ohio, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Thomas Heart, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Hospital, Dallas, Texas, United States|The Heart Hospital Baylor Plano, Plano, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Franciscan Health System Res. Center, Tacoma, Washington, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|Royal Jubilee Hospital (Vancouver Island Health Authority), Victoria, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|St. Boniface Hospital, Winnepeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Sciences Center, University Hospital, London, Ontario, Canada|Southlake Regional Health Center, Newmarket, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|McGill University Health Centre-Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Institute universitaire de cardiologie et pneumologie de Quebec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02025621"
656,"NCT01035255","This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure","PARADIGM-HF","Terminated","Has Results","Heart Failure With Reduced Ejection Fraction","Drug: LCZ696 200 mg BID|Drug: Enalapril 10 mg BID","Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization|Number of Patients - All-cause Mortality|Number of Patients Reported With Adjudicated Primary Causes of Death|Change From Baseline to Month 8 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score|Number of Patients With First Confirmed Renal Dysfunction|Percentage of Participants With New Onset of Atrial Fibrillation (AF)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","8442","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696B2314|2009-015834-31","December 2009","May 2014","May 2014","December 18, 2009","September 7, 2015","August 15, 2016","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Bellflower, California, United States|Novartis Investigative Site, Berkley, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Mather, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, Pomona, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Santa Rosa, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Tustin, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boynton Beach, Florida, United States|Novartis Investigative Site, Davie, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Leesburg, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Tamarac, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Covington, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Melrose Park, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Quincy, Illinois, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Pratt, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Lafayette, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Biddeford, Maine, United States|Novartis Investigative Site, South Portland, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Beltsville, Maryland, United States|Novartis Investigative Site, Columbia, Maryland, United States|Novartis Investigative Site, Nottingham, Maryland, United States|Novartis Investigative Site, Ayer, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Haverhill, Massachusetts, United States|Novartis Investigative Site, Natick, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Lapeer, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, St. Paul, Minnesota, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Rolling Fork, Mississippi, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Fremont, Nebraska, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Nashua, New Hampshire, United States|Novartis Investigative Site, Elizabeth, New Jersey, United States|Novartis Investigative Site, Hamilton, New Jersey, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Ocean, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Cordtlandt Manor, New York, United States|Novartis Investigative Site, Laurelton, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Northport, New York, United States|Novartis Investigative Site, Asheboro, North Carolina, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Cary, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Wilmington, North Carolina, United States|Novartis Investigative Site, Cadiz, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Bartlesville, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Stillwater, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Aliquippa, Pennsylvania, United States|Novartis Investigative Site, Beaver, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Amarillo, Texas, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Brownsville, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Grapevine, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Kingwood, Texas, United States|Novartis Investigative Site, Livingston, Texas, United States|Novartis Investigative Site, Lufkin, Texas, United States|Novartis Investigative Site, Odessa, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Layton, Utah, United States|Novartis Investigative Site, Fredericksburg, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Waukesha, Wisconsin, United States|Novartis Investigative Site, Wausau, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Lanus, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Munro, Buenos Aires, Argentina|Novartis Investigative Site, Pilar, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, San Isidro, Buenos Aires, Argentina|Novartis Investigative Site, Zarate, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Trelew, Chubut, Argentina|Novartis Investigative Site, San Salvador de Jujuy, Jujuy, Argentina|Novartis Investigative Site, Cipolletti, Rio Negro, Argentina|Novartis Investigative Site, Buenos Aires, San Juan, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Córdoba, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Salta, Argentina|Novartis Investigative Site, San Juan, Argentina|Novartis Investigative Site, San Luis, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santiago del Estero, Argentina|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Baudour, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Heusden-Zolder, Belgium|Novartis Investigative Site, La Louvière, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Ronse, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Sao Luis, MA, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Uberlândia, MG, Brazil|Novartis Investigative Site, Belem, PA, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Passo Fundo, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Marilia, SP, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Votuporanga, SP, Brazil|Novartis Investigative Site, Burgas, Bulgaria|Novartis Investigative Site, Haskovo, Bulgaria|Novartis Investigative Site, Pazardzhik, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Russe, Bulgaria|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Silistra, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Stara Zagora, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Veliko Tarnovo, Bulgaria|Novartis Investigative Site, New Westminster, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Granby, Quebec, Canada|Novartis Investigative Site, Lachine, Quebec, Canada|Novartis Investigative Site, Laval, Quebec, Canada|Novartis Investigative Site, Longueuil, Quebec, Canada|Novartis Investigative Site, Lévis, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, St-Georges Beauce, Quebec, Canada|Novartis Investigative Site, Thetford Mines, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Los Angeles, Bio Bio, Chile|Novartis Investigative Site, Temuco, Cautin, Chile|Novartis Investigative Site, Santiago, Region Metropolitana, Chile|Novartis Investigative Site, San Miguel, Santiago, Chile|Novartis Investigative Site, Vitacura, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Talcahuano, Chile|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Baotou, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Chongqing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Cartagena, Bolivar, Colombia|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Bucaramanga, Santander, Colombia|Novartis Investigative Site, Floridablanca, Santander, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Cartegena, Colombia|Novartis Investigative Site, Florida Blanca, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Bilovec, CZE, Czech Republic|Novartis Investigative Site, Praha 2, CZE, Czech Republic|Novartis Investigative Site, Beroun, Czech Republic|Novartis Investigative Site, Brandys nad Labem, Czech Republic|Novartis Investigative Site, Horovice, Czech Republic|Novartis Investigative Site, Jablonec nad Nisou, Czech Republic|Novartis Investigative Site, Karlovy Vary, Czech Republic|Novartis Investigative Site, Kladno, Czech Republic|Novartis Investigative Site, Klatovy, Czech Republic|Novartis Investigative Site, Kolin, Czech Republic|Novartis Investigative Site, Liberec V Kristianova, Czech Republic|Novartis Investigative Site, Melnik, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Plzen, Czech Republic|Novartis Investigative Site, Prague 10, Vrsovice, Czech Republic|Novartis Investigative Site, Prague 1, Czech Republic|Novartis Investigative Site, Prague 5, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Praha 4, Czech Republic|Novartis Investigative Site, Semily, Czech Republic|Novartis Investigative Site, Strakonice, Czech Republic|Novartis Investigative Site, Trebic, Czech Republic|Novartis Investigative Site, Uherske Hradiste, Czech Republic|Novartis Investigative Site, Uherske Hradiste, Czech Republic|Novartis Investigative Site, Usti nad Labem, Czech Republic|Novartis Investigative Site, Aarhus C, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Herning, Denmark|Novartis Investigative Site, Randers NØ, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Santo Domingo, Republica Dominicana, Dominican Republic|Novartis Investigative Site, Santo Domingo, Dominican Republic|Novartis Investigative Site, Guayaquil, Guayas, Ecuador|Novartis Investigative Site, Guayaquil, Guayas, Ecuador|Novartis Investigative Site, Guayaquil, Guayas, Ecuador|Novartis Investigative Site, Quito, Pichincha, Ecuador|Novartis Investigative Site, Haabneeme, Viimsi vald, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, HUS, Finland|Novartis Investigative Site, Kemi, Finland|Novartis Investigative Site, Kuopio, Finland|Novartis Investigative Site, Oulu, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Strasbourg, Cedex, France|Novartis Investigative Site, Abbeville, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Beziers Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Cholet, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Essey Les Nancy, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lagny sur Marne, France|Novartis Investigative Site, Langres, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Le Plessis Robinson, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lomme, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nice Cedex 1, France|Novartis Investigative Site, Paris cedex 10, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, St Aubin Lès Elbeuf, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Valencienne, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Ahrensfelde, Germany|Novartis Investigative Site, Bad Homburg, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Bad Salzuflen, Germany|Novartis Investigative Site, Bad Schwartau, Germany|Novartis Investigative Site, Barsinghausen, Germany|Novartis Investigative Site, Berlin-Buch, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bernau, Germany|Novartis Investigative Site, Bitburg, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Darmstadt, Germany|Novartis Investigative Site, Dessau-Roßlau, Germany|Novartis Investigative Site, Dietzenbach, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Eilenburg, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Georgsmarienhütte, Germany|Novartis Investigative Site, Giengen, Germany|Novartis Investigative Site, Goch, Germany|Novartis Investigative Site, Graben-Neudorf, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamminkeln, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Hoppegarten-Dahlwitz, Germany|Novartis Investigative Site, Huy / OT Anderbeck, Germany|Novartis Investigative Site, Ingelheim, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kallstadt, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kelkheim, Germany|Novartis Investigative Site, Koethen, Germany|Novartis Investigative Site, Künzelsau, Germany|Novartis Investigative Site, Langen, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Loehne, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Lütjenburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Meissen, Germany|Novartis Investigative Site, Meißen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Mönchengladbach, Germany|Novartis Investigative Site, Mühldorf, Germany|Novartis Investigative Site, Mühlheim, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Münster, Germany|Novartis Investigative Site, Neunkirchen, Germany|Novartis Investigative Site, Neunkirchen, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Oldenburg i.H., Germany|Novartis Investigative Site, Osnabrück, Germany|Novartis Investigative Site, Papenburg, Germany|Novartis Investigative Site, Rhaunen, Germany|Novartis Investigative Site, Riesa, Germany|Novartis Investigative Site, Rodgau, Germany|Novartis Investigative Site, Schenklengsfeld, Germany|Novartis Investigative Site, Schkeuditz, Germany|Novartis Investigative Site, Schwäbisch Hall, Germany|Novartis Investigative Site, St. Ingbert - Oberwuerzbach, Germany|Novartis Investigative Site, Unterschneidheim, Germany|Novartis Investigative Site, Wangen, Germany|Novartis Investigative Site, Wardenburg, Germany|Novartis Investigative Site, Weeze, Germany|Novartis Investigative Site, Wermsdorf, Germany|Novartis Investigative Site, Westhofen, Germany|Novartis Investigative Site, Wetzlar-Naunheim, Germany|Novartis Investigative Site, Weyhe, Germany|Novartis Investigative Site, Wolmirstedt, Germany|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Pecs, Baranya, Hungary|Novartis Investigative Site, Baja, Hungary|Novartis Investigative Site, Balatonfured, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Cegled, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Eger, Hungary|Novartis Investigative Site, Hodmezovasarhely, Hungary|Novartis Investigative Site, Kaposvár, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Nagykanizsa, Hungary|Novartis Investigative Site, Nyiregyháza, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Sopron, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Zalaegerszeg, Hungary|Novartis Investigative Site, Kopavogur, Iceland|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Hyderabad, Andhra Pradesh, INDIA, India|Novartis Investigative Site, Guntur, Andhra Pradesh, India|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Tirupati, Andhra Pradesh, India|Novartis Investigative Site, Vishakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, Vishakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, Dehli, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Anand, Gujarat, India|Novartis Investigative Site, Surat, Gujarat, India|Novartis Investigative Site, Rajkot, Gujrat, India|Novartis Investigative Site, Vadodara, Gujrat, India|Novartis Investigative Site, Gurgaon, Haryana, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Banglaore, Karnataka, India|Novartis Investigative Site, Mangalore, Karnataka, India|Novartis Investigative Site, Mysore, Karnataka, India|Novartis Investigative Site, Cochin, Kerala, India|Novartis Investigative Site, Trivandrum, Kerala, India|Novartis Investigative Site, Trivandrum, Kerala, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Kota, Rajasthan, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Varanasi, Uttar Pradesh, India|Novartis Investigative Site, Ahmedabad, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Indore, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Safed, Israel|Novartis Investigative Site, Aosta, AO, Italy|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Seriate, BG, Italy|Novartis Investigative Site, Treviglio, BG, Italy|Novartis Investigative Site, San Pietro Vernotico, BR, Italy|Novartis Investigative Site, Bolzano, BZ, Italy|Novartis Investigative Site, Cosenza, CS, Italy|Novartis Investigative Site, Catanzaro, CZ, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Lido di Camaiore, LU, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milazzo, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Piove di Sacco, PD, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pescia, PT, Italy|Novartis Investigative Site, Casorate Primo, PV, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Stradella, PV, Italy|Novartis Investigative Site, Albano Laziale, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Battipaglia, SA, Italy|Novartis Investigative Site, Cava De' Tirreni, SA, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Thiesi, SS, Italy|Novartis Investigative Site, Palmanova, UD, Italy|Novartis Investigative Site, San Daniele Del Friuli, UD, Italy|Novartis Investigative Site, Tradate, VA, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Vibo Valentia, VV, Italy|Novartis Investigative Site, Wonju, Gangwon-Do, Korea, Republic of|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Gwangju, Korea, Republic of|Novartis Investigative Site, Pusan, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Liepaja, LV, Latvia|Novartis Investigative Site, Daugavplis, Latvia|Novartis Investigative Site, Kuldiga, Latvia|Novartis Investigative Site, Preili, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Ventspils, Latvia|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Kedainiai, Lithuania|Novartis Investigative Site, Siauliai, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Pulau Pinang, Penang, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Mexico City, Distrito Federal, Mexico|Novartis Investigative Site, Mexico D.F, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Zapopan, Jalisco, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, San Juan del Rio, Queretaro, Mexico|Novartis Investigative Site, Aguascalientes, Mexico|Novartis Investigative Site, Queretaro, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, San Luis Potosí, Mexico|Novartis Investigative Site, San Luis Potosí, Mexico|Novartis Investigative Site, Oss, NL, Netherlands|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Bosch, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Goes, Netherlands|Novartis Investigative Site, Gorinchem, Netherlands|Novartis Investigative Site, Hardenberg, Netherlands|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, Heerenveen, Netherlands|Novartis Investigative Site, Hengelo, Netherlands|Novartis Investigative Site, Hoorn, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Sneek, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Veldhoven, Netherlands|Novartis Investigative Site, Panama City, Panamá, Panama|Novartis Investigative Site, Panama City, Panamá, Panama|Novartis Investigative Site, Bellavista, Lima, Peru|Novartis Investigative Site, Cercado de Lima, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, La Molina, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lipa City, Batangas, Philippines|Novartis Investigative Site, Quezon City, Manila, Philippines|Novartis Investigative Site, Quezon City, Metro Manila, Philippines|Novartis Investigative Site, Bulacan, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Pasig City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, San Juan City, Philippines|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Golub-Dobrzyn, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Kutno, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Olawa, Poland|Novartis Investigative Site, Skierniewice, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Zabrze, Poland|Novartis Investigative Site, Vila Real, Portuigal, Portugal|Novartis Investigative Site, Amadora, Portugal|Novartis Investigative Site, Covilha, Portugal|Novartis Investigative Site, Guimarães, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Penafiel, Portugal|Novartis Investigative Site, Portalegre, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Setubal, Portugal|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucuresti, District 1, Romania|Novartis Investigative Site, Bucuresti, District 2, Romania|Novartis Investigative Site, Bucharest, District 5, Romania|Novartis Investigative Site, Craiova, Jud. Dolj, Romania|Novartis Investigative Site, Timisoara, jud. Timis, Romania|Novartis Investigative Site, Craiova, Jud.Dolj, Romania|Novartis Investigative Site, Ploiesti, Jud.Prahova, Romania|Novartis Investigative Site, Arad, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Deva, Romania|Novartis Investigative Site, Pitesti, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Gatchina, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Izhevsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N. Novgorod, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk-117, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Penza, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Rostov-on-Don, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, Sankt-Peterburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St-Peterburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St.Petersburg, Russian Federation|Novartis Investigative Site, Syktyvkar, Russian Federation|Novartis Investigative Site, Tula, Russian Federation|Novartis Investigative Site, Tver, Russian Federation|Novartis Investigative Site, Vladimir, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Brezno, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Levice, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Svidnik, Slovak Republic, Slovakia|Novartis Investigative Site, Vranov nad Toplou, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Dolny Kubin, Slovakia|Novartis Investigative Site, Dunajska Streda, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Kralovsky Chlmec, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Mthatha, Eastern Cape, South Africa|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Middelburg, Mpumalanga, South Africa|Novartis Investigative Site, Paarl, Western Cape, South Africa|Novartis Investigative Site, Somerset West, Western Cape, South Africa|Novartis Investigative Site, Alberton, South Africa|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Breyton, South Africa|Novartis Investigative Site, Brits, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, East London, South Africa|Novartis Investigative Site, Gatesville, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Kempton Park, South Africa|Novartis Investigative Site, Port Elizabeth, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Umkomaas, South Africa|Novartis Investigative Site, Witbank, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sant Joan Despi, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Mérida, Extremadura, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, Ferrol, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Vigo, Galicia, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Alcala de Henares, Madrid, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Mostoles, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Härnösand, Sweden|Novartis Investigative Site, Karlshamn, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Motala, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Vällingby, Sweden|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Ilan, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taladkwan, Nonthaburi, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Muang, Thailand|Novartis Investigative Site, Muang, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Balcova / Izmir, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Etlik / Ankara, Turkey|Novartis Investigative Site, Haseki / Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Meselik / Eskisehir, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Bristol, Bs2 8hw, United Kingdom|Novartis Investigative Site, Cambridge, Cambrigdeshire, United Kingdom|Novartis Investigative Site, Durham, County Durham, United Kingdom|Novartis Investigative Site, Dorchester, Dorset, United Kingdom|Novartis Investigative Site, Brighton, East Sussex, United Kingdom|Novartis Investigative Site, Swansea, England, United Kingdom|Novartis Investigative Site, Romford, Essex, United Kingdom|Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom|Novartis Investigative Site, Portsmouth, Hampshire, United Kingdom|Novartis Investigative Site, Royal Bridge Wells, Kent, United Kingdom|Novartis Investigative Site, Oldham, Lancashire, United Kingdom|Novartis Investigative Site, Leicester, Leicestershire, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom|Novartis Investigative Site, Dundee, Perthshire, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, Yeovil, Somerset, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, Redhill, Surrey, United Kingdom|Novartis Investigative Site, South Shields, Tyne and Wear, United Kingdom|Novartis Investigative Site, Dudley, West Midlands, United Kingdom|Novartis Investigative Site, Sutton Coldfield, West Midlands, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Bradford, United Kingdom|Novartis Investigative Site, Cheshire, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Croydon, United Kingdom|Novartis Investigative Site, Darlington, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Inverness, United Kingdom|Novartis Investigative Site, Kent, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, Londonderry, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Middlesborough, United Kingdom|Novartis Investigative Site, Milton Keynes, United Kingdom|Novartis Investigative Site, Newport, United Kingdom|Novartis Investigative Site, Newport, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Poole, United Kingdom|Novartis Investigative Site, Rotherham, United Kingdom|Novartis Investigative Site, Stevenage, United Kingdom|Novartis Investigative Site, Sunderland, United Kingdom|Novartis Investigative Site, Surrey, United Kingdom|Novartis Investigative Site, Vale of Glamorgan, United Kingdom|Novartis Investigative Site, Worcester, United Kingdom|Novartis Investigative Site, York, United Kingdom|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Caracas, Estado Miranda, Venezuela|Novartis Investigative Site, Maturin, Estado Monagas, Venezuela|Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela|Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela",,"https://ClinicalTrials.gov/show/NCT01035255"
657,"NCT00984802","Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy","SUPPORT-1","Completed","No Results Available","Stable Coronary Artery Disease|Percutaneous Coronary Intervention","Drug: CMX-2043|Drug: Placebo control","Safety as measured by changes in CK-MB|Cardiac biomarkers|ST segment changes","Ischemix, LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMX-2043-2a","February 2010","March 2011","April 2011","September 25, 2009",,"June 20, 2011","St. Vincent Hospital, Worcester, Massachusetts, United States|Duke University Hospital, Durham, North Carolina, United States|Madras Medical Mission, Chennai, India|Hinduja Hospital, Mumbai, India|Poona Hospital, Pune, India",,"https://ClinicalTrials.gov/show/NCT00984802"
658,"NCT01452152","Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study","PAPI-2","Terminated","Has Results","Cardiovascular Diseases|Acute Coronary Syndrome","Drug: clopidogrel|Drug: prasugrel","Occurrence of Post-randomization Cardiovascular Events|Occurrence of Bleeding Events|Post-treatment Platelet Aggregation|Health Care Resource Utilization and Cost-effectiveness|Occurrence of Adverse Events|Composite of All-cause Death, Myocardial Infarction (MI), Stroke and Repeat Revascularization","University of Maryland, Baltimore|National Heart, Lung, and Blood Institute (NHLBI)","All","20 Years to 74 Years   (Adult, Older Adult)","Phase 4","9","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HP-00047385|9U01HL105198-06","February 2012","July 2013","July 2013","October 14, 2011","June 28, 2016","August 22, 2019","Christiana Care Health System, Newark, Delaware, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Sinai Center for Thrombosis Research, Baltimore, Maryland, United States|The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Geisinger Health System, Danville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01452152"
659,"NCT02513940","Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes",,"Completed","Has Results","Long QT Syndrome","Drug: Testosterone|Drug: Progesterone|Drug: Placebo|Drug: Ibutilide","Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF)|Maximum QTF Following Ibutilide 0.003 mg/kg|Maximum Percent Change From Pretreatment Value in QTF Following Ibutilide 0.003 mg/kg|Area Under the QTF Versus Time Curve for 0-1 Hour Following Ibutilide 0.003 mg/kg|Number of Participants With Adverse Effects Associated With Testosterone, Progesterone and Placebo","Indiana University|American Heart Association|Purdue University","Male","65 Years and older   (Older Adult)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1507526854","May 2016","October 19, 2017","October 19, 2017","August 3, 2015","March 6, 2019","August 28, 2019","Indiana University, Indianapolis, Indiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02513940/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02513940"
660,"NCT02443402","Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","SITACABG NonDM","Completed","Has Results","Coronary Artery Disease","Drug: Sitagliptin|Drug: Placebo|Drug: Regular Human Insulin|Drug: Insulin glargine|Drug: Supplemental insulin (Insulin lispro)|Drug: Supplemental insulin (Insulin aspart)","Number of Participants With Stress Hyperglycemic Events in the Intensive Care Unit (ICU)|Number of Subjects With Persistent Hyperglycemia|Need for Continuous Intravenous Insulin (CII) for Treatment of Hyperglycemia|Mean Daily Intensive Care Unit (ICU) Blood Glucose (BG) Concentration|Mean Amount of Insulin Therapy in the Intensive Care Unit (ICU)|Duration of Continuous Intravenous Insulin (CII)|Mean Units Subcutaneous (SQ) Insulin Required|Mean Blood Glucose (BG) Concentration After Transition From Intensive Care Unit (ICU)|Total Insulin Therapy in the Intensive Care Unit (ICU)|Number of Participants With Severe Hyperglycemic Events During Continuous Insulin Infusion (CII)|Number of Participants With Hyperglycemia After Transition From Intensive Care Unit (ICU)|Number of Participants With Hypoglycemia During Intensive Care Unit (ICU) Stay|Number of Participants With Hypoglycemia After Transition From Intensive Care Unit (ICU)|Number of Participants With Blood Glucose Less Than 40 mg/dl|Hospital Mortality Rate|Intensive Care Unit (ICU) Mortality Rate|Number of Participants With Cerebrovascular Events|Hospital Complication Rate|Length of Stay: Intensive Care Unit (ICU)|Length of Hospital Stay After Study Randomization|Number of Participants Re-admitted to the Hospital Due to Wound Infections|Number of Participants Re-admitted to the Hospital Not Due to Wound Infections|Number of Participants With Emergency Room (ER) Visits|Number of Participants With Infections Not Requiring Hospital Re-admission|Number of Subjects Requiring the Use of Inotropes for Greater Than 24 Hours|Number of Subjects Requiring Re-intubation|Number of Subjects Requiring Re-intubation Within 24 Hours|Number of Subject Requiring Surgical Re-Intervention","Emory University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","68","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","IRB00080209","January 2016","December 2016","December 2016","May 13, 2015","February 6, 2018","February 6, 2018","Grady Health System, Atlanta, Georgia, United States|Emory University Hospital - Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02443402"
661,"NCT01661634","Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure","TRUE-AHF","Completed","No Results Available","Acute Decompensated Heart Failure","Drug: Ularitide|Drug: Placebo","Two Co-primary Efficacy Endpoints|Length of stay of index hospitalization in hours after start of study drug infusion|Length of stay in intensive care (intensive care unit [ICU] or critical care unit [CCU])|Number of events of persistent or worsening HF requiring an intervention|Proportion of patients with persistent or worsening HF and requiring an intervention|Reduction in rehospitalization for heart failure|Changes of N-terminal pro brain natriuretic peptide (NT-pro BNP)|Time to completion of last dose of any IV drugs that can be used for the treatment of HF (e.g., diuretics, vasodilators, or positive inotropic agents)|Change in serum creatinine|180 days after start of study drug infusion, including patients still hospitalized at Day 30.","Cardiorentis|Quintiles, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","2157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ULA01|2010-024249-59","July 2012","November 2015","March 2016","August 9, 2012",,"October 23, 2018","Huntsville, Alabama, United States|Montgomery, Alabama, United States|Sacramento, California, United States|Littleton, Colorado, United States|Trumbull, Connecticut, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Lawrenceville, Georgia, United States|Peoria, Illinois, United States|Rockford, Illinois, United States|Kansas City, Kansas, United States|Alexandria, Louisiana, United States|Worcester, Massachusetts, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Royal Oak, Michigan, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|Lincoln, Nebraska, United States|Newark, New Jersey, United States|Bronx, New York, United States|Brooklyn, New York, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Middletown, Ohio, United States|Toledo, Ohio, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Midlothian, Virginia, United States|Norfolk, Virginia, United States|Salem, Virginia, United States|Ciudad Autonoma, Buenos Aires, Argentina|Coronel Suarez, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Córdoba, Cordoba, Argentina|San Vicente, Cordoba, Argentina|Rosario, Santa Fe, Argentina|San Miguel de Tucuman, Tucuman, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Corrientes, Argentina|San Miguel de Tucuman, Argentina|Santa Fe, Argentina|Santa Fe, Argentina|Aalst, Belgium|Kortrijk, Belgium|Goiânia, Goiás, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Campinas, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Halifax, Nova Scotia, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Brno, Czechia|Brno, Czechia|Frydek-Mistek, Czechia|Hradec Kralove, Czechia|Olomouc, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 5, Czechia|Znojmo, Czechia|Tallinn, Estonia|Tallinn, Estonia|Espoo, Finland|Besançon Cedex, Doubs, France|Toulouse Cedex 9, Haute Garonne, France|Paris cedex 10, Paris, France|Bayonne, Pyrenees Atlantiques, France|Bron cedex, Rhone, France|Poitiers, Vienne, France|Nuernberg, Bayern, Germany|Bad Nauheim, Hessen, Germany|Gross-Umstadt, Hessen, Germany|Langen, Hessen, Germany|Greifswald, Mecklenburg Vorpommern, Germany|Bochum, Nordrhein Westfalen, Germany|Erfurt, Thueringen, Germany|Jena, Thueringen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Debrecen, Hungary|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Holon, Israel|Kfar-Saba, Israel|Nahariya, Israel|Nazareth, Israel|Safed, Israel|San Fermo della Battaglia, Como, Italy|Legnano, Milano, Italy|Rozzano, Milano, Italy|Alessandria, Italy|Bari, Italy|Bologna, Italy|Como, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Novara, Italy|Roma, Italy|Varese, Italy|Riga, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Vilnius, Lithuania|Beverwijk, Netherlands|Ede, Netherlands|Gorinchem, Netherlands|Groningen, Netherlands|Leiderdorp, Netherlands|Sneek, Netherlands|Krakow, Poland|Krakow, Poland|Lodz, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Bucuresti, Romania|Bucuresti, Romania|Iasi, Romania|Oradea, Romania|Belgrade, Serbia|Belgrade, Serbia|Belgrade, Serbia|Niska Banja, Serbia|Nis, Serbia|Sremska Kamenica, Serbia|Zemun, Serbia|L'Hospitalet de Llobregat, Barcelona, Spain|Sant Joan Despí, Barcelona, Spain|Santiago de Compostela, La Coruña, Spain|Aranjuez, Madrid, Spain|Majadahonda, Madrid, Spain|Majadahonda, Madrid, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Basel, Switzerland|Lugano, Switzerland|Zuerich, Switzerland|Eskisehir, Turkey|Istanbul, Turkey|Kocaeli, Turkey|Sivas, Turkey",,"https://ClinicalTrials.gov/show/NCT01661634"
662,"NCT03541603","Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF","HELP","Completed","No Results Available","Hypertension Pulmonary Secondary|Heart Failure, Right Sided|Heart Failure With Normal Ejection Fraction","Drug: Levosimendan|Drug: Matching Placebo","Change from baseline Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise|Change in Cardiac Index (CI) at rest and with exercise|Change in Pulmonary Vascular Resistance (PVR) effect at rest and with exercise|Change in PCWP when supine and legs elevated|Patient global assessment|Exercise duration via 6 minute walk test|Physician's assessment of functional class|Composite incidence of death or hospitalization","Tenax Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TNX-LVO-04","November 14, 2018","April 7, 2020","April 7, 2020","May 30, 2018",,"April 10, 2020","Stanford Healthcare, Stanford, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Christ Hospital, Cincinnati, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UW Health University Hospital, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03541603"
663,"NCT03153111","A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","SERENADE","Recruiting","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: Macitentan|Drug: Placebo","Change in NT-proBNP (Percent of Baseline Assessed at Week 24)|Change From Baseline to Week 24 in the Clinical Summary Score (as Assessed by the Kansas City Cardiomyopathy Questionnaire [KCCQ])|Change from baseline to Week 24 in accelerometer-assessed physical activity|Time to worsening heart failure (WHF) event over 52 weeks","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-055G202|2016-003653-15","July 11, 2017","December 9, 2020","December 9, 2020","May 15, 2017",,"April 28, 2020","Alaska Heart Institute, Anchorage, Alaska, United States|Mdfirst Research, Chandler, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Cedars Sinai Heart Institute, Beverly Hills, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Harbor Ucla Medical Center, Torrance, California, United States|Orange Country Research Center, Tustin, California, United States|South Denver Cardiology Associates PC, Littleton, Colorado, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University Of Iowa - Hospitals & Clinics, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School Of Medicine, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Next Phase Research Alliance, Las Vegas, Nevada, United States|Advanced Heart Care, LLC, Bridgewater, New Jersey, United States|Weill Cornell Medicine, New York, New York, United States|Peak Clinical Trials, Apex, North Carolina, United States|University of North Carolina (UNC) - School of Medicine, Chapel Hill, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Metrohealth Heart & Vascular Center, Cleveland, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Allegheny, Pittsburgh, Pennsylvania, United States|Vascular Medicine Institute University Of Pittsburgh, Pittsburgh, Pennsylvania, United States|AnMed Health, Anderson, South Carolina, United States|North Dallas Research Associates, McKinney, Texas, United States|Baylor Scott & White Research Institute, Temple, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|MultiCare Health System, Tacoma, Washington, United States|Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin, United States|Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina|CCBR - Buenos Aires - AR, Buenos Aires, Argentina|Clínica Adventista Belgrano, Caba, Argentina|Centro Médico Dra. De Salvo, Ciudad Autónoma de Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Argentina|Medizinische Universität Wien, Vienna, Austria|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Brazil|Maestri E Kormann Consultoria Médico- Científica Ltda, Blumenau, Brazil|Hospital do Coração do Brasil, Brasília, Brazil|Instituto de Pesquisa Clinica de Campinas, Campinas, Brazil|Instituto do Coração de Marília, Marilia, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Fundacao Universitaria de Cardiologia, Porto Alegre, Brazil|Instituto de Moléstias Cardiovasculares Tatuí, Tatuí, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, Brazil|Specialized Hospital for Active Treatment in Cardiology - Pleven, Pleven, Bulgaria|Diagnostic - Consulting Center I-Sliven, Sliven, Bulgaria|Multiprofile Hospital for Active Treatment - National Heart Hospital, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD, Sofia, Bulgaria|Fakultni nemocnice Brno, Brno, Czechia|Fakultní nemocnice u sv. Anny v Brn, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia|University Hospital Plzeň-Lochotín, Plzen, Czechia|Fnkv Iii. Internal Cardiology Clinic 3. Lf Uk And Fnkv, Praha 10, Czechia|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|IKEM, Praha 4, Czechia|Aarhus Universitetshospital, Aarhus, Denmark|Bispebjerg Og Frederiksberg Hospital, Copenhagen, Denmark|Sydvestjysk Sygehus, Esbjerg, Denmark|Gentofte Herlev Hospital, Herlev, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Hopital Henri Mondor, Creteil Cedex, France|CHU de Grenoble - Hôpital Albert Michallon, Grenoble Cedex 9, France|Hopital de Bicetre, Le Kremlin Bicetre, France|Hopital Cardiologique, Lille Cedex, France|Hôpital Nord Laennec - CHU NANTES, Nantes Cedex 1, France|CHU Rouen - Hopital Charles Nicolle, Rouen Cedex, France|Kardiologische Gemeinschaftspraxis Praxis Rankestraße, Berlin, Germany|Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie, Dresden, Germany|Universitaetsklinikum Giessen, Giessen, Germany|Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie, Hannover, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Herzzentrum Uniklinik Köln Klinik III für Innere Medizin, Köln, Germany|Kardiologische Praxis Papenburg, Papenburg, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|Budai Irgalmasrendi Korhaz, Budapest, Hungary|Semmelweis Egyetem Városmajor Szív- és Érgyógyászati Klinika, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Barzilai Medical Center, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Bnai Zion Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Toruń, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, Poland|Institutul de urgenta pentru Boli Cardiovasculare Prof. Dr. C.C. Iliescu Sectia cardiologie III, Bucuresti, Romania|Cardiomed, Craiova, Romania|SAL MED Pitesti, Pitesti, Romania|Cmi Dr Podoleanu Cristian, Targu-Mures, Romania|Ekaterinburg City Clinical Hospital #14, Ekaterinburg, Russian Federation|Federal State Budget Scientific Institution, Kemerovo, Russian Federation|Krasnodar Regional Clinical Hospital, Krasnodar, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|State Healthcare Institution, Regional Clinical Cardiology Dispensary, Saratov, Russian Federation|Federal State Budgetary Institution, St Petersburg, Russian Federation|State Autonomous Healthcare Institution Of Yaroslavl Region, Yaroslavl, Russian Federation|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Sahlgrenska Universitetsjukhuset, Goteborg, Sweden|Linkoping University Hospital, Linköping, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Uppsala Akademiska Sjukhuset, Kardiologkliniken, Uppsala, Sweden|Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|Royal Free Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03153111"
664,"NCT01896440","Heart Safety Study of Ondansetron in Children Receiving Chemotherapy",,"Withdrawn","No Results Available","Malignant Childhood Neoplasm","Drug: Ondansetron","Change in QTc interval","University of Oklahoma","All","6 Months to 18 Years   (Child, Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pediatric ondansetron QTc","October 2013","October 2013","October 2013","July 11, 2013",,"October 8, 2013","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01896440"
665,"NCT02188784","Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure","IRONOUT","Completed","Has Results","Chronic Heart Failure","Drug: Polysaccharide Iron Complex 150 mg|Drug: Placebo (for Polysaccharide Iron Complex)","Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption)|Change From Baseline in Sub-maximal Exercise Capacity as Assessed by the 6 Minute Walk Test (6MWT)|Change in Plasma NT-pro BNP|Change in Health Status: Kansas City Cardiomyopathy Questionnaire (KCCQ) - Clinical Summary Score|Change From Baseline in O2 Uptake Kinetics as Assessed by Mean Response Time From CPET|Change From Baseline in Ventilatory Efficiency Defined by Ve/VCO2","Adrian Hernandez|National Heart, Lung, and Blood Institute (NHLBI)|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 3","225","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pro00054061|2U10HL084904","September 3, 2014","April 6, 2016","April 6, 2016","July 14, 2014","May 15, 2017","July 11, 2017","Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals-Case Medical Center, Cleveland, Ohio, United States|Metor Health System, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Utah Hospitals and Clinics, Murray, Utah, United States|The University of Vermont - Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02188784"
666,"NCT03759392","Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure","METEORIC-HF","Recruiting","No Results Available","Heart Failure With Reduced Ejection Fraction","Drug: Omecamtiv Mecarbil|Drug: Placebo","Change in peak oxygen uptake (VO2) on cardiopulmonary exercise testing from baseline to Week 20|Change in exercise capacity, as measured by the change in total workload during cardiopulmonary exercise testing (CPET) from baseline to Week 20|Change in ventilatory efficiency, as measured by the change in Ventilation (VE)/Carbon dioxide output (VCO2) slope during cardiopulmonary exercise testing (CPET) from baseline to Week 20|Change in the average daily activity units measured over a 2-week period from baseline (Week -2 to Day 1) to Week 18-20","Amgen|Cytokinetics|Servier","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CY 1031|2018-001233-40","April 9, 2019","February 15, 2021","March 15, 2021","November 30, 2018",,"March 4, 2020","Alaska Heart and Vascular Institute, Anchorage, Alaska, United States|Arkansas Cardiology Clinic, Little Rock, Arkansas, United States|Harbor-UCLA Medical Center, Torrance, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Hartford Hospital-University of Connecticut School of Medicine, Hartford, Connecticut, United States|Holy Cross Hospital - Fort Lauderdale, Fort Lauderdale, Florida, United States|Broward Research Center - Pembroke Pines, Pembroke Pines, Florida, United States|Emory University, Atlanta, Georgia, United States|Saint Vincent Medical Group Inc., Indianapolis, Indiana, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital (MGH) - Cardiac Unit Associates, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Heart & Vascular Institute, Detroit, Michigan, United States|McLaren Health Care Corporation, Petoskey, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Cardiovascular Associates Of The Delaware Valley (Cadv), P.A. - Elmer Physicians Care Center - Elmer, Elmer, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|Queens Heart Institute, Rosedale, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Med Health and Hospital, Raleigh, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health, Portland, Oregon, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Lancaster Heart And Stroke Foundation, Lancaster, Pennsylvania, United States|University of Texas - Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott and White Heart and Vascular Hospital, Dallas, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Ecogene-21, Chicoutimi, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03759392"
667,"NCT02025465","Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control",,"Unknown status","No Results Available","Atrial Fibrillation|Atrial Flutter","Drug: Metoprolol|Drug: Diltiazem","Conversion to sinus rhythm|Heart rate control|Home discharges from Emergency Department (ED)|Total hospital cost|Rehospitalization for Atrial Fibrillation","CAMC Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1997386","December 2013","December 2018","December 2018","January 1, 2014",,"August 9, 2017","Charleston Area Medical Center, Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02025465"
668,"NCT01644331","Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure","TACTICS-HF","Completed","Has Results","Heart Failure|Dyspnea","Drug: Tolvaptan|Drug: Placebo","Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours|Renal Function|Weight Loss|Fluid Loss|Dyspnea Likert|Hospital Stay|Worsening or Persistent Heart Failure or Death|Over-diuresis|Serum Sodium|Dyspnea 11 Point NRS|Freedom From Congestion|Development of Worsening Renal Function|Days Hospitalized or Deceased|All Cause Death or Rehospitalization","Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 3","257","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pro00037557","October 2012","February 2016","February 2016","July 19, 2012","April 27, 2017","April 27, 2017","University of Colorado at Denver and Health Sciences Center, Aurora, Colorado, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northeast Georgia Heart Center, Gainesville, Georgia, United States|Mercer University School of Medicine, Macon, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Heart and Vascular, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Regional Medical Center, Lumberton, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|Grand View - Lehigh Valley Health Services, Sellersville, Pennsylvania, United States|UT Southwestern Medical center, Dallas, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01644331"
669,"NCT01830920","A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)",,"Completed","Has Results","Acute Kidney Injury","Drug: THR-184|Drug: Placebo","Incidence of Acute Kidney Injury (AKI)|Incidence of AKI|Severity of AKI|Duration of AKI","Thrasos Innovation, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","452","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A-003|2741202","May 2013","September 2015","September 2015","April 12, 2013","April 20, 2017","April 20, 2017","University of Alabama-Birmingham, Birmingham, Alabama, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Harbor - University of California Los Angeles Medical Center, Torrance, California, United States|Danbury Hospital, Danbury, Connecticut, United States|River City Clinical Research, Jacksonville, Florida, United States|University of Chicago, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Indiana Ohio Heart, Fort Wayne, Indiana, United States|Indiana Heart-St. Vincent Medical Group, Indianapolis, Indiana, United States|Maine Medical Center, Portland, Maine, United States|John Hopkins University, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Cardiac and Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|Covenant Medical Center, Saginaw, Michigan, United States|Washington University, St. Louis, Missouri, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Columbia University, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Lindner Research Center-Christ Hospital, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Soltero Cardiovascular Research Center, Dallas, Texas, United States|University of Texas, Houston, Houston, Texas, United States|Cardiothoracic Surgical Associates, Richmond, Virginia, United States|Foothills Medical Centre, Calgary, Alberta, Canada|St-John Regional Hospital Facility, St-John, New Brunswick, Canada|Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Institut de Cardiologie de Montréal, Montréal, Quebec, Canada|Centre hospitalier de l'université de Montréal(CHUM)- Hôtel-Dieu, Montréal, Quebec, Canada|MUHC - Royal Victoria Hospital, Montréal, Quebec, Canada|Sacre Cœur Hospital, Montréal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01830920"
670,"NCT01460368","A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: LY2409021|Drug: Placebo|Drug: Moxifloxacin","Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (LY2409021)|Part B: Mean Change From Baseline in 12-lead Electrocardiogram (ECG) Corrected QT Intervals (Moxifloxacin)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","14149|I1R-FW-GLBP","October 2011","March 2012","March 2012","October 26, 2011","October 18, 2018","January 7, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01460368"
671,"NCT03756285","Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.","SATELLITE","Suspended","No Results Available","Heart Failure","Drug: AZD4831|Drug: Placebo","The change from baseline in MPO activity in % after AZD4831 treatment.|Change from baseline in CFVR measured in the mid-distal segment of the left anterior descending (LAD) coronary artery under adenosine infusion measured by Transthoracic Doppler Echocardiography (TDE).|Change from baseline in Walking distance|The pharmacokinetic assessment parameter to be reported is AUC|The Pharmacokinetic assessment parameter to be reported is CL/F.","AstraZeneca","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D6580C00003","December 11, 2018","October 13, 2020","October 13, 2020","November 28, 2018",,"May 1, 2020","Research Site, Fort Payne, Alabama, United States|Research Site, Tucker, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Aarhus N, Denmark|Research Site, Herlev, Denmark|Research Site, Hvidovre, Denmark|Research Site, Odense C, Denmark|Research Site, Turku, Finland|Research Site, Deventer, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Groningen, Netherlands|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03756285"
672,"NCT02929329","Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction","GALACTIC-HF","Active, not recruiting","No Results Available","Heart Failure","Drug: Omecamtiv Mecarbil|Drug: Placebo","Measure time to cardiovascular death or first heart failure event|Measure time to cardiovascular death|Measure changes in patient reported outcomes Kansas City Cardiomyopathy Questionnaire Total Symptom Score|Measure time to first heart failure hospitalization|Measure time to all-cause death","Amgen|Cytokinetics|Servier","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","8256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","20110203|2016-002299-28","January 6, 2017","August 7, 2020","August 7, 2020","October 11, 2016",,"April 1, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Fort Payne, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Scottsboro, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Carmichael, California, United States|Research Site, Fresno, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Loma Linda, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, San Pedro, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Stanford, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Ventura, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, West Haven, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Zephyrhills, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, 'Aiea, Hawaii, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Champaign, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Fairview Heights, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Oak Lawn, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Richmond, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, West Monroe, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Moorestown, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Kingston, New York, United States|Research Site, Laurelton, New York, United States|Research Site, Mineola, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Lumberton, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Wiloughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Butler, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Fort Mill, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Powell, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Denison, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Huntsville, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Murray, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, White River Junction, Vermont, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Leesburg, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Puyallup, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Manitowoc, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Waukesha, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Coronel Suarez, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Merlo, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Ramos Meija, Buenos Aires, Argentina|Research Site, San Fernando, Buenos Aires, Argentina|Research Site, San Isidro, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Villa Maria, Córdoba, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Venado Tuerto, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Garran, Australian Capital Territory, Australia|Research Site, Concord, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Bundoora, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Sankt Poelten, Austria|Research Site, Villach, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Roeselare, Belgium|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Uberlandia, Minas Gerais, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Londrina, Paraná, Brazil|Research Site, Natal, Rio Grande Do Norte, Brazil|Research Site, Canoas, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Aracaju, Sergipe, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Marilia, São Paulo, Brazil|Research Site, Ribeirao Preto, São Paulo, Brazil|Research Site, Sao Jose do Rio Preto, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São José do Rio Preto, São Paulo, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, North Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Jérôme, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Temuco, Cautín, Chile|Research Site, Talcahuano, Concepción, Chile|Research Site, San Miguel, Santiago, Chile|Research Site, Vina del Mar, Valparaíso, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Haikou, Hainan, China|Research Site, Harbin, Heilongjiang, China|Research Site, Luoyang, Henan, China|Research Site, Luoyang, Henan, China|Research Site, Xinxiang, Henan, China|Research Site, Zhengzhou, Henan, China|Research Site, Hengyang, Hunan, China|Research Site, Xiangtan, Hunan, China|Research Site, Huhehaote, Inner Mongolia, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Xuzhou, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Heze, Shandong, China|Research Site, Jinan, Shandong, China|Research Site, Jining, Shandong, China|Research Site, QingDao, Shandong, China|Research Site, Taiyuan, Shanxi, China|Research Site, Taiyuan, Shanxi, China|Research Site, Yuncheng, Shanxi, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Linhai, Zhejiang, China|Research Site, Ningbo, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Medellin, Antioquia, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Barranquilla, Atlántico, Colombia|Research Site, Cartagena, Bolívar, Colombia|Research Site, Manizales, Caldas, Colombia|Research Site, Armenia, Quindío, Colombia|Research Site, Bucaramanga, Santander, Colombia|Research Site, Bucaramanga, Santander, Colombia|Research Site, Cali, Valle Del Cauca, Colombia|Research Site, Santiago de Cali, Valle Del Cauca, Colombia|Research Site, Bogota D.C., Colombia|Research Site, Beroun, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Frydek Mistek, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kladno, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Kolin III, Czechia|Research Site, Liberec, Czechia|Research Site, Louny, Czechia|Research Site, Marianske Lazne, Czechia|Research Site, Mohelnice, Czechia|Research Site, Opava, Czechia|Research Site, Ostrava, Czechia|Research Site, Policka, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Zlin, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Esbjerg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hellerup, Denmark|Research Site, Hillerod, Denmark|Research Site, Køge, Denmark|Research Site, Odense, Denmark|Research Site, Svendborg, Denmark|Research Site, Beziers cedex, France|Research Site, Caen Cedex 9, France|Research Site, Chambray les Tours, France|Research Site, Corbeil Essonnes, France|Research Site, Créteil Cedex, France|Research Site, Dijon, France|Research Site, Grenoble Cedex 9, France|Research Site, Le Chesnay, France|Research Site, Lille Cedex, France|Research Site, Lille, France|Research Site, Limoges Cedex, France|Research Site, Lyon Cedex 03, France|Research Site, Montauban, France|Research Site, Montpellier cedex 05, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Nimes cedex 9, France|Research Site, Paris Cedex 13, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Poitiers, France|Research Site, Rennes Cedex 9, France|Research Site, Saint Denis, France|Research Site, Toulon Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Tourcoing cedex, France|Research Site, Valenciennes, France|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Düsseldorf, Germany|Research Site, Erfurt, Germany|Research Site, Erfurt, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Greifswald, Germany|Research Site, Göttingen, Germany|Research Site, Haßloch, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Langen, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigshafen, Germany|Research Site, Mainz, Germany|Research Site, Markleeberg, Germany|Research Site, Witten, Germany|Research Site, Würzburg, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chaidari, Athens, Greece|Research Site, Chalkida, Greece|Research Site, Heraklion, Greece|Research Site, Ioannina, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Dunaujvaros, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Komarom, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszard, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ariccia, Italy|Research Site, Arzignano, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Brescia, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Catanzaro, Italy|Research Site, Cona FE, Italy|Research Site, Cuneo, Italy|Research Site, Foggia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Monza (MB), Italy|Research Site, Monza, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Rimini, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Seriate, Italy|Research Site, Siena, Italy|Research Site, Torrette Di Ancona, Italy|Research Site, Trieste, Italy|Research Site, Vimercate MB, Italy|Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Nagakute-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Seto-shi, Aichi, Japan|Research Site, Asahi-shi, Chiba, Japan|Research Site, Chiba-shi, Chiba, Japan|Research Site, Funabashi-shi, Chiba, Japan|Research Site, Urayasu-shi, Chiba, Japan|Research Site, Imabari-shi, Ehime, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kasuya-gun, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Koga-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Onga-gun, Fukuoka, Japan|Research Site, Fukushima-shi, Fukushima, Japan|Research Site, Fukushima-shi, Fukushima, Japan|Research Site, Fukushima-shi, Fukushima, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Fukuyama-shi, Hiroshima, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Hakodate-shi, Hokkaido, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Amagasaki-shi, Hyogo, Japan|Research Site, Himeji-shi, Hyogo, Japan|Research Site, Kawanishi-shi, Hyogo, Japan|Research Site, Nishinomiya-shi, Hyogo, Japan|Research Site, Takarazuka-shi, Hyogo, Japan|Research Site, Higashiibaraki-gun, Ibaraki, Japan|Research Site, Kahoku-gun, Ishikawa, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Morioka-shi, Iwate, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Hayama, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Odawara-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Nankoku-shi, Kochi, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Nagano-shi, Nagano, Japan|Research Site, Kashihara-shi, Nara, Japan|Research Site, Oita-shi, Oita, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Naha-shi, Okinawa, Japan|Research Site, Shimajiri-gun, Okinawa, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Higashiosaka-shi, Osaka, Japan|Research Site, Matsubara-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Ureshino-shi, Saga, Japan|Research Site, Ageo-shi, Saitama, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Wako-shi, Saitama, Japan|Research Site, Kusatsu-shi, Shiga, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Akishima-shi, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Fussa-shi, Tokyo, Japan|Research Site, Hachioji-shi, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Kodaira-shi, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Torreon, Coahuila, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Pachuca, Hidalgo, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Xalapa, Veracruz, Mexico|Research Site, Aguascalientes, Mexico|Research Site, 's Hertogenbosch, Netherlands|Research Site, Almelo, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Capelle Aan De IJssel, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Emmen, Netherlands|Research Site, Goes, Netherlands|Research Site, Groningen, Netherlands|Research Site, Groningen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Papatoetoe, Auckland, New Zealand|Research Site, Takapuna, Auckland, New Zealand|Research Site, Bialystok, Poland|Research Site, Bytom, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gizycko, Poland|Research Site, Kazimierza Wielka, Poland|Research Site, Kielce, Poland|Research Site, Klodzko, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Miechow, Poland|Research Site, Olawa, Poland|Research Site, Piotrkow Trybunalski, Poland|Research Site, Poznan, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Stalowa Wola, Poland|Research Site, Swidnik, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Aveiro, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Setubal, Portugal|Research Site, San Juan, Puerto Rico|Research Site, Bucarest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Pitesti, Romania|Research Site, Targoviste, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Korolev, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Lomonosov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Village Novoseltsy, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Snina, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trnava, Slovakia|Research Site, Bloemfontein, Free State, South Africa|Research Site, Parktown, Gauteng, South Africa|Research Site, Soweto, Gauteng, South Africa|Research Site, Sunninghill, Gauteng, South Africa|Research Site, Durban, KwaZulu-Natal, South Africa|Research Site, Umhlanga, KwaZulu-Natal, South Africa|Research Site, Parow, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Worcester, Western Cape, South Africa|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Ubeda, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, La laguna, Canarias, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, El Palmar, Murcia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Falun, Sweden|Research Site, Jonkoping, Sweden|Research Site, Lidköping, Sweden|Research Site, Linkoping, Sweden|Research Site, Lund, Sweden|Research Site, Orebro, Sweden|Research Site, Skelleftea, Sweden|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Fribourg, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, Zurich, Switzerland|Research Site, Adana, Turkey|Research Site, Afyonkarahisar, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Corum, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kirikkale, Turkey|Research Site, Kocaeli, Turkey|Research Site, Konya, Turkey|Research Site, Mersin, Turkey|Research Site, Sakarya, Turkey|Research Site, Sivas, Turkey|Research Site, Van, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsya, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Ayr, United Kingdom|Research Site, Basingstoke, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Dudley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Gillingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harlow, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Merthyr Tydfil, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Shipley, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Solihull, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Sunderland, United Kingdom|Research Site, Swindon, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02929329"
673,"NCT00853658","Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure","ATMOSPHERE","Completed","Has Results","Chronic Heart Failure","Drug: Enalapril|Drug: Aliskiren","Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization|Change From Baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score|All Cause Death","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","7064","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CSPP100F2301|2008-004104-31","March 2009","October 2015","October 2015","March 2, 2009","November 25, 2016","November 25, 2016","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Hot Springs, Arkansas, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Pine Bluff, Arkansas, United States|Novartis Investigative Site, Searcy, Arkansas, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, French Camp, California, United States|Novartis Investigative Site, Inglewood, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Modesto, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Westlake Village, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Littleton, Colorado, United States|Novartis Investigative Site, Boynton Beach, Florida, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville Beach, Florida, United States|Novartis Investigative Site, Miami Lakes, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Wellington, Florida, United States|Novartis Investigative Site, Athens, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Gillespie, Illinois, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Auburn, Maine, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Elmer, New Jersey, United States|Novartis Investigative Site, Laurelton, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Wiliamsville, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Varnville, South Carolina, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Everett, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Bahia Blanca, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Coronel Suarez, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Ramos Mejia, Buenos Aires, Argentina|Novartis Investigative Site, San Isidro, Buenos Aires, Argentina|Novartis Investigative Site, San Nicolas, Buenos Aires, Argentina|Novartis Investigative Site, Córdoba, Cordoba, Argentina|Novartis Investigative Site, Va Allende, Cordoba, Argentina|Novartis Investigative Site, Villa Maria, Cordoba, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Tucuman, San Miguel de Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Salta, Argentina|Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Wollongong, New South Wales, Australia|Novartis Investigative Site, Auchenflower, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Launceston, Tasmania, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Anderlecht, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, De Pinte, Belgium|Novartis Investigative Site, Eupen, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Ieper, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Turnhout, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Campina Grande do Sul, PR, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Caxias do Sul, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Marilia, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Tatuí, SP, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, St. John, New Brunswick, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Joliette, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Fuzhou, Fujian, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shijiazhuang, Hebei, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Baotou, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guang zhou, China|Novartis Investigative Site, Jinan, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Xian, China|Novartis Investigative Site, Medellín, Antioquia, Colombia|Novartis Investigative Site, Baranquilla, Atlantico, Colombia|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Cartagena, Bolivar, Colombia|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Florida Blanca, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Goicoechea, San Jose, Costa Rica, Costa Rica|Novartis Investigative Site, Alajuela, Costa Rica|Novartis Investigative Site, San Jose, Costa Rica|Novartis Investigative Site, San Jose, Costa Rica|Novartis Investigative Site, Benesov, Czech Republic|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Cesky Krumlov, Czech Republic|Novartis Investigative Site, Jindrichuv Hradec, Czech Republic|Novartis Investigative Site, Kolín, Czech Republic|Novartis Investigative Site, Kromeriz, Czech Republic|Novartis Investigative Site, Louny, Czech Republic|Novartis Investigative Site, Louny, Czech Republic|Novartis Investigative Site, Marianske lazne, Czech Republic|Novartis Investigative Site, Ostrava, Czech Republic|Novartis Investigative Site, Plzen, Czech Republic|Novartis Investigative Site, Praha 11, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Praha 9, Czech Republic|Novartis Investigative Site, Pribram VIII, Czech Republic|Novartis Investigative Site, Teplice, Czech Republic|Novartis Investigative Site, Vyskov, Czech Republic|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Copenhagen NV, Denmark|Novartis Investigative Site, Copenhagen S, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Fredericia, Denmark|Novartis Investigative Site, Frederiksberg, Denmark|Novartis Investigative Site, Glostrup, Denmark|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Helsingoer, Denmark|Novartis Investigative Site, Hillerød, Denmark|Novartis Investigative Site, Hjørring, Denmark|Novartis Investigative Site, Holbæk, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Køge, Denmark|Novartis Investigative Site, Næstved, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Randers NØ, Denmark|Novartis Investigative Site, Silkeborg, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Århus N, Denmark|Novartis Investigative Site, Santo Domingo, Republica Dominicana, Dominican Republic|Novartis Investigative Site, San Cristobal, Dominican Republic|Novartis Investigative Site, Parnu, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Hyvinkää, Finland|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Seinajoki, Finland|Novartis Investigative Site, Tammisaari, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Albi, France|Novartis Investigative Site, Angers, France|Novartis Investigative Site, Becon Les Granits, France|Novartis Investigative Site, Clichy, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Saint-Etienne, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Winsen (Luhe), Lower Saxony, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Nauheim, Germany|Novartis Investigative Site, Bad Neustadt an der Saale, Germany|Novartis Investigative Site, Bensheim, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Brake, Germany|Novartis Investigative Site, Celle, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Coburg, Germany|Novartis Investigative Site, Darmstadt, Germany|Novartis Investigative Site, Dessau-Roßlau, Germany|Novartis Investigative Site, Dinkelsbühl, Germany|Novartis Investigative Site, Dorsten, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duisburg, Germany|Novartis Investigative Site, Duisburg, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Ebersbach, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Erkner, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Gotha, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Gütersloh, Germany|Novartis Investigative Site, Halle (Saale), Germany|Novartis Investigative Site, Halle/Saale, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hassloch, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Heilbronn, Germany|Novartis Investigative Site, Helmbrechts, Germany|Novartis Investigative Site, Heppenheim, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kleve, Germany|Novartis Investigative Site, Koblenz, Germany|Novartis Investigative Site, Krefeld, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Königsbrück, Germany|Novartis Investigative Site, Köthen, Germany|Novartis Investigative Site, Lambrecht, Germany|Novartis Investigative Site, Landshut, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Lichtentanne, Germany|Novartis Investigative Site, Lienen, Germany|Novartis Investigative Site, Ludwigsburg, Germany|Novartis Investigative Site, Lörrach, Germany|Novartis Investigative Site, Lüneburg, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Markkleeberg, Germany|Novartis Investigative Site, Mayen, Germany|Novartis Investigative Site, Melsungen, Germany|Novartis Investigative Site, Muehldorf am Inn, Germany|Novartis Investigative Site, Muehlheim an der Ruhr, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Mülheim, Germany|Novartis Investigative Site, Northeim, Germany|Novartis Investigative Site, Nürnberg, Germany|Novartis Investigative Site, Oelde, Germany|Novartis Investigative Site, Oelde, Germany|Novartis Investigative Site, Pirna, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Reinfeld, Germany|Novartis Investigative Site, Salzwedel, Germany|Novartis Investigative Site, Schwalmstadt, Germany|Novartis Investigative Site, Schwäbisch Hall, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Stade, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Wedel, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Zwickau, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Chios, Greece|Novartis Investigative Site, Edessa, Greece|Novartis Investigative Site, Guntur, Andhra Pradesh, India|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Secunderabad, Andhra Pradesh, India|Novartis Investigative Site, Vijayawada, Andhra Pradesh, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Manipal, Karnataka, India|Novartis Investigative Site, Trivandrum, Kerela, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Delhi, New Delhi, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Madurai, Tamil Nadu, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Lucknow, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Noida, India|Novartis Investigative Site, Co Dublin, Ireland|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Montescano, (pv), Italy|Novartis Investigative Site, Pavia, (pv), Italy|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Lumezzane, BS, Italy|Novartis Investigative Site, Chieti, CH, Italy|Novartis Investigative Site, Cosenza, CS, Italy|Novartis Investigative Site, Forlì, FC, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Casarano, LE, Italy|Novartis Investigative Site, Cecina, LI, Italy|Novartis Investigative Site, Castelnuovo di Garfagnana, LU, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Passirana di Rho, MI, Italy|Novartis Investigative Site, Pieve di Coriano, MN, Italy|Novartis Investigative Site, Massa, MS, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Cotignola, RA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Rimini, RN, Italy|Novartis Investigative Site, Cava De' Tirreni, SA, Italy|Novartis Investigative Site, Poggibonsi, SI, Italy|Novartis Investigative Site, Sondalo, SO, Italy|Novartis Investigative Site, Sarzana, SP, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Vittorio Veneto, TV, Italy|Novartis Investigative Site, San Daniele Del Friuli, UD, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Tradate, VA, Italy|Novartis Investigative Site, San Bonifacio, VR, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Seto-city, Aichi, Japan|Novartis Investigative Site, Chiba-city, Chiba, Japan|Novartis Investigative Site, Inba-gun, Chiba, Japan|Novartis Investigative Site, Chikushino-city, Fukuoka, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Iizuka-city, Fukuoka, Japan|Novartis Investigative Site, Kurume-city, Fukuoka, Japan|Novartis Investigative Site, Ogaki-city, Gifu, Japan|Novartis Investigative Site, Hiroshima-city, Hiroshima, Japan|Novartis Investigative Site, Kure, Hiroshima, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Amagasaki-city, Hyogo, Japan|Novartis Investigative Site, Higashiibaraki-gun, Ibaraki, Japan|Novartis Investigative Site, Hitachinaka, Ibaraki, Japan|Novartis Investigative Site, Tsukuba-city, Ibaraki, Japan|Novartis Investigative Site, Kanazawa, Ishikawa, Japan|Novartis Investigative Site, Kawasaki-city, Kanagawa, Japan|Novartis Investigative Site, Sagamihara-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Yokosuka, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Kashihara-city, Nara, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Izumisano-city, Osaka, Japan|Novartis Investigative Site, Kita-ku, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Ureshino, Saga, Japan|Novartis Investigative Site, Hamada, Shimane, Japan|Novartis Investigative Site, Komatsushima-city, Tokushima, Japan|Novartis Investigative Site, Tokushima-city, Tokushima, Japan|Novartis Investigative Site, Adachi-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Hofu, Yamaguchi, Japan|Novartis Investigative Site, Shunan-city, Yamaguchi, Japan|Novartis Investigative Site, Ube, Yamaguchi, Japan|Novartis Investigative Site, Fukushima, Japan|Novartis Investigative Site, Nagasaki, Japan|Novartis Investigative Site, Saga, Japan|Novartis Investigative Site, Toyama, Japan|Novartis Investigative Site, Seongnam, Gyeonggi, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Daejeon, Korea, Republic of|Novartis Investigative Site, Gwangju, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Klaipeda, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Zapopan, Jalisco, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Culiacan, Sinaloa, Mexico|Novartis Investigative Site, Aguascalientes, Mexico|Novartis Investigative Site, Querétaro, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Apeldoorn, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Dirksland, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Haarlem, Netherlands|Novartis Investigative Site, Heerlen, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiderdorp, Netherlands|Novartis Investigative Site, Meppel, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Wildervank, Netherlands|Novartis Investigative Site, Zutphen, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Tønsberg, Norway|Novartis Investigative Site, Trujillo, La Libertad, Peru|Novartis Investigative Site, Chiclayo, Lambayeque, Peru|Novartis Investigative Site, Bellavista, Lima, Peru|Novartis Investigative Site, Cercado de Lima, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Juan de Miraflores, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bytom, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Grodzisk Mazowiecki, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Klodzko, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Kraków, Poland|Novartis Investigative Site, Lomza, Poland|Novartis Investigative Site, Olawa, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Ostrow Wielkopolski, Poland|Novartis Investigative Site, Ostrowiec Swietokrzyski, Poland|Novartis Investigative Site, Piotrkow Trybunalski, Poland|Novartis Investigative Site, Plock, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Sandomierz, Poland|Novartis Investigative Site, Tarnow, Poland|Novartis Investigative Site, Torun, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Zabrze, Poland|Novartis Investigative Site, Amadora, Portugal|Novartis Investigative Site, Aveiro, Portugal|Novartis Investigative Site, Carnaxide, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Faro, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Penafiel, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Humacao, Puerto Rico|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucharest, District 2, Romania|Novartis Investigative Site, Iasi, Jud Iasi, Romania|Novartis Investigative Site, Targu Mures, jud Mures, Romania|Novartis Investigative Site, Iasi, Jud. Iasi, Romania|Novartis Investigative Site, Targu Mures, Mures, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Brasov, Romania|Novartis Investigative Site, Brasov, Romania|Novartis Investigative Site, Cluj Napoca, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Oradea, Romania|Novartis Investigative Site, Pitesti, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Izhevsk, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Lubertsi, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Pushkin,St-Petersburg, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Komarno, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak republic, Slovakia|Novartis Investigative Site, Levice, Slovak Republic, Slovakia|Novartis Investigative Site, Nitra, Slovak Republic, Slovakia|Novartis Investigative Site, Povazska Bystrica, Slovak republic, Slovakia|Novartis Investigative Site, Presov, Slovak republic, Slovakia|Novartis Investigative Site, Stropkov, Slovak republic, Slovakia|Novartis Investigative Site, Zilina, Slovak Republic, Slovakia|Novartis Investigative Site, Zilina, Slovak Republic, Slovakia|Novartis Investigative Site, Bardejov, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Piestany, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Trebisov, Slovakia|Novartis Investigative Site, Trencin, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Benoni, South Africa|Novartis Investigative Site, Boksburg, South Africa|Novartis Investigative Site, Centurion, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Sanlucar de Barrameda, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Utrera, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Tarragona, Catalunya, Spain|Novartis Investigative Site, Tortosa, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Valdemoro, Madrid, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Falun, Sweden|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Karlstad, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Malmö, Sweden|Novartis Investigative Site, Malmö, Sweden|Novartis Investigative Site, Mölndal, Sweden|Novartis Investigative Site, Nässjö, Sweden|Novartis Investigative Site, Skelleftea, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Sundsvall, Sweden|Novartis Investigative Site, Sundsvall, Sweden|Novartis Investigative Site, Umeå, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Västerås, Sweden|Novartis Investigative Site, Örebro, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Biel, Switzerland|Novartis Investigative Site, Bruderholz, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Olten, Switzerland|Novartis Investigative Site, Winterthur, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Yongkang, Tainan, Taiwan|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Aydin, Turkey|Novartis Investigative Site, Balcova / Izmir, Turkey|Novartis Investigative Site, Etlik / Ankara, Turkey|Novartis Investigative Site, Fatih / Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kinikli / Denizli, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Leicester, Leicestershire, United Kingdom|Novartis Investigative Site, Dafen, Llanelli, United Kingdom|Novartis Investigative Site, Addlestone, Surrey, United Kingdom|Novartis Investigative Site, Chichester, West Sussex, United Kingdom|Novartis Investigative Site, Worthing, West Sussex, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Chesterfield, United Kingdom|Novartis Investigative Site, Colchester, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Valencia, Edo. Carabobo, Venezuela|Novartis Investigative Site, Barcelona, Estado Anzoátegui, Venezuela|Novartis Investigative Site, Puerto Ordaz, Estado Bolívar, Venezuela|Novartis Investigative Site, Caracas, Estado Miranda, Venezuela|Novartis Investigative Site, Cumana, Estado Sucre, Venezuela|Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela",,"https://ClinicalTrials.gov/show/NCT00853658"
674,"NCT01929083","Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening",,"Completed","Has Results","Prolonged QT Interval in EKG and Sudden Death","Drug: Progesterone|Drug: Placebo|Drug: Ibutilide","Baseline (Pre-Ibutilide) QTcI Intervals|Maximum Individual-corrected QT Interval (QTcI)|Maximum % Change From Baseline in QTcI Intervals Following Ibutilide Administration|Area Under the QTcI - Time Curve (AUEC)|Incidence of Progesterone-associated Adverse Effects Compared to Placebo","Indiana University|American Heart Association","Female","21 Years to 40 Years   (Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12GRNT12060187","April 2013","June 2014","June 2014","August 27, 2013","September 28, 2015","October 30, 2015","Indiana Clinical Research Center, Indianapolis, Indiana, United States|Purdue University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01929083"
675,"NCT03547583","Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF","VITALITY-HFpEF","Completed","No Results Available","Chronic Heart Failure With Preserved Ejection Fraction","Drug: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Drug: Placebo","Change in KCCQ physical limitation score from baseline to week 24|Change in the Six-minute walk test (6MWT) from baseline to week 24","Bayer|Merck Sharp & Dohme Corp.|Canadian VIGOUR Centre|Duke Clinical Research Institute","All","45 Years and older   (Adult, Older Adult)","Phase 2","788","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","19334|2018-000298-65","June 15, 2018","October 15, 2019","November 4, 2019","June 6, 2018",,"December 18, 2019","WestSide Medical, Beverly Hills, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Interventional Cardiology Medical Group, West Hills, California, United States|Penrose-St. Francis Health Services, Colorado Springs, Colorado, United States|Cardiology Associates of Fairfield County, PC, Trumbull, Connecticut, United States|Cardiology Associates Of South Florida PA, Boynton Beach, Florida, United States|Cardiovascular and Vein Center of Florida, Bradenton, Florida, United States|Cardiology Associates Research Company, Daytona Beach, Florida, United States|Life Spring Research, Miami, Florida, United States|Southwest Florida Research, Naples, Florida, United States|East Coast Institute for Research, LLC, Saint Augustine, Florida, United States|Cardiology Partners, Wellington, Florida, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|Advocate Condell Medical Center, Libertyville, Illinois, United States|Reid Health, Richmond, Indiana, United States|Research Integrity, LLC, Owensboro, Kentucky, United States|Heart Clinic of Hammond, Hammond, Louisiana, United States|Anne Arundel Health System, Annapolis, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Riser Medical Associates, Picayune, Mississippi, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|Glacier View Research Institute-Cardiology, Kalispell, Montana, United States|Bryan Heart, Lincoln, Nebraska, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|Carolina Heart Specialists, Lancaster, South Carolina, United States|Stern Cardiovascular Center, Germantown, Tennessee, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Corporation Lane Research Center, Virginia Beach, Virginia, United States|Clínica DIM, Ramos Mejía, Buenos Aires, Argentina|Instituto de Investigaciones Clínicas San Nicolás, San Nicolás, Buenos Aires, Argentina|Centro de Investigaciones Clínicas, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Centro de Medicina Integral e Investigacion Clínica, Caba, Ciudad Auton. De Buenos Aires, Argentina|Centro de Especialidades Médicas, Villa Luro, Ciudad Auton. De Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Inst. de Cardiología de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina|Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria|Krankenhaus St. Josef Braunau, Braunau, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Ordination Dr. Hanusch, Wien, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Krankenhauses Nord - Klinik Floridsdorf, Wien, Austria|Algemeen Stedelijk Ziekenhuis Campus Aalst, Aalst, Belgium|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|UZ Antwerpen, Edegem, Belgium|H. Hartziekenhuis Mol, MOL, Belgium|AZ Delta, Roeselare, Belgium|Multiprofile Hospital for Active Treatment Pazardzhik, Pazardzhik, Bulgaria|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment Medline Clinic, Plovdiv, Bulgaria|MHAT Dr. Bratan Shukerov AD, Smolyan, Bulgaria|Second Medical Center Sofia EOOD, Sofia, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|V MHAT, Sofia, Bulgaria|MHAT Sveta Marina EAD, Varna, Bulgaria|University of Alberta, Edmonton, Alberta, Canada|SMH Cardiology Clinical Trials Inc, Surrey, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|PACE Cardiology Clinic, Newmarket, Ontario, Canada|Oakville Cardiologists, Inc., Oakville, Ontario, Canada|Cardiovascular CRO Ltd., Sudbury, Ontario, Canada|St. Michael's Hospital Health Centre, Toronto, Ontario, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Centre De Recherche Du (CRCHUM) - Hotel-Diu, Montreal, Quebec, Canada|CardioVasc HR, Inc., Saint-Jean-sur-Richelieu, Quebec, Canada|Hospital General de Medellin, Medellin, Antioquia, Colombia|IPS Centro Cientifico Asistencial S.A.S, Barranquilla, Atlántico, Colombia|Caja de Compensación Familiar CAFAM, Bogotá, Distrito Capital De Bogotá, Colombia|Mediservis del Tolima IPS S.A.S, Ibague, Tolima, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|Klinikum der Universität Würzburg, Würzburg, Bayern, Germany|Zentrum für Klinische Studien Südbrandenburg GmbH, Elsterwerda, Brandenburg, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen, Nordrhein-Westfalen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz, Mainz, Rheinland-Pfalz, Germany|Klinische Forschung Dresden GmbH, Dresden, Sachsen, Germany|Cardiologicum Hamburg - Praxen Wandsbek, Hamburg, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|University General Hospital of Larissa, Larissa, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|University General Hospital of Thessaloniki ""AHEPA"", Thessaloniki, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Budai Irgalmasrendi Korhaz, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont Honvedkorhaz, Budapest, Hungary|Pharma4Trial Kft., Gyongyos, Hungary|Kanizsai Dorottya Hospital, Nagykanizsa, Hungary|Medifarma-98 Egeszsegugyi, Kereskedelmi es Szolgaltato Kft., Nyiregyhaza, Hungary|HaEmek Medical Center, Afula, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Corporation, Haifa, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|The Baruch Padeh Medical Center, Poria, Tiberias, Israel|Health Corporation of the Ziv Medical Center (R.A.), Zefat, Israel|Shamir Medical Center (Assaf Harofeh), Zrifin, Israel|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|A.O.U. di Ferrara Arcispedale S.Anna, Ferrara, Emilia-Romagna, Italy|Asl Roma 6, Roma, Lazio, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|IRCCS Istituto Clinico Humanitas (ICH), Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Lombardia, Italy|A.O.U. di Sassari, Sassari, Sardegna, Italy|Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan|Matsuda Cardiovascular clinic, Sapporo, Hokkaido, Japan|National Hospital Organization Kobe Medical Center, Kobe, Hyogo, Japan|Higashi Takarazuka Satoh Hospital, Takarazuka, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Iwate Prefectural Central Hospital, Morioka, Iwate, Japan|Uji-Tokushukai Medical Center, Uji, Kyoto, Japan|Hirakata kohsai Hospital, Hirakata, Osaka, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|National Hospital Organization Hamada Medical Center, Hamada, Shimane, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|National Hospital Organization Iwakuni Clinical Center, Iwakuni, Yamaguchi, Japan|Fukui Prefectural Hospital, Fukui, Japan|Okayama Rosai Hospital, Okayama, Japan|Osaka General Medical Center, Osaka, Japan|Toyama Prefectural Central Hospital, Toyama, Japan|Hospital Raja Perempuan Zainab II, Kelantan, Malaysia|Institute Jantung Negara, Kuala Lumpur, Malaysia|Sarawak Heart Centre, Sarawak, Malaysia|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|10 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ, Bydgoszcz, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|SPZOZ Centralny Szpital Kliniczny UM w Lodzi, Lodz, Poland|Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin, Poland|Uniwersyteckie Centrum Kliniczne Warszawskiego UM, Warszawa, Poland|IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ, Wroclaw, Poland|Dolnoslaski Szp. Spec. im T.M. Centrum Medycyny Ratunkowej, Wroclaw, Poland|Hospital de Cascais, Alcabideche, Lisboa, Portugal|CHTS - Hospital Padre Americo, Guilhufe, Porto, Portugal|CHS - Hospital Sao Bernardo, Setubal, Setúbal, Portugal|Hospital Garcia de Orta, Almada, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Sci-Res. Institute of Complex Cardiovascular Disorders, Kemerovo, Russian Federation|State Sientific Research Center for Preventive Medicine, Moscow, Russian Federation|Moscow State University n.a. M.V. Lomonosov, Moscow, Russian Federation|Samara Regional Clinical Cardiology Dispensary, Samara, Russian Federation|City hospital #15, St. Petersburg, Russian Federation|City Pokrovskaya Hospital, St. Petersburg, Russian Federation|Singapore General Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Clinical Trial Systems, Pretoria, Gauteng, South Africa|Durban Medical Centre, Durban, Kwazulu-Natal, South Africa|Nash Ranjith Research Centre, Merebank, Kwazulu-Natal, South Africa|TREAD Research cc, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre, Cape Town, Western Cape, South Africa|Vergelegen Medi-Clinic, Somerset West, Western Cape, South Africa|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Ciutat Sanitària i Universitària de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Sant Joan Despi Moises Broggi, Sant Joan Despi, Barcelona, Spain|Hospital Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital Universitario Clinica Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Álvaro Cunqueiro, Babio - Beade, Pontevedra, Spain|Hospital del Mar, Barcelona, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Hospitalario Ntra. Sra. de Valme, Sevilla, Spain|Far Eastern Memorial Hospital, New Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03547583"
676,"NCT03775421","An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.","RUBATO OL","Enrolling by invitation","No Results Available","Congenital Heart Disease With Fontan Circulation","Drug: macitentan 10 mg","Frequency of treatment-emergent adverse events (AEs), serious AEs and AEs leading to death|Number of AEs leading to premature discontinuation of study treatment|Frequency of treatment-emergent marked laboratory abnormalities up to 30 days after study treatment discontinuation|Incident rate of changes in laboratory parameters over time|Change in pulse rate (PR) over time|Change in peripheral oxygen saturation (SpO2) over time|Change in blood pressure (BP) over time","Actelion|Covance|Henry Ford Health System|Almac Clinical Technologies|ActiGraph LLC|Medidata Solutions","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","134","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055H302|2018-002821-45","May 15, 2019","November 7, 2022","March 31, 2024","December 14, 2018",,"April 24, 2020","Massachusetts General Hospital Heart Center, Boston, Massachusetts, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|The Prince Charles Hospital, Adult Congenital Heart Disease Unit, Chermside, Australia|Royal Children's Hospital, Parkville, Australia|Royal Melbourne Hospital, Parkville, Australia|Queensland CHILDREN'S HOSPITAL, South Brisbane, Australia|Beijing Anzhen Hospital, Beijing, China|Beijing Fuwai Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Wuhan Asia Heart Hospital, Wuhan, China|Fakultni nemocnice v Motole, Praha 5, Czechia|Rigshospitalet Kardiologisk Klinisk, Copenhagen, Denmark|Hôpital Necker - Enfants Malades, Paris, France|Hôpital Cardiologique Du Haut-Lévêque, Pessac, France|Auckland City Hospital, Auckland, New Zealand|Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn, Krakow, Poland|Queen Elizabeth Hospital, Birmingham, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03775421"
677,"NCT03689244","A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery","SELECT","Recruiting","No Results Available","Chronic Thromboembolic Pulmonary Hypertension","Drug: Selexipag|Drug: Placebo","Percent of baseline Pulmonary vascular resistance (PVR) at Week 20|Change from baseline to Week 26 in 6-minute walk distance (6MWD)|Rate of pulmonary hypertension-related hospitalizations or death up to Week 52|Time to clinical worsening up to Week 52|Percentage of subjects with World Health Organization Functional Class (WHO FC) improvement at Week 26|Change from baseline to Week 26 in PAH-SYMPACT™ scores|Change from baseline to Week 26 in Borg dypnea index|Change from baseline to Week 26 in N-terminal pro b-type natriuretic peptide (NT pro-BNP)","Actelion","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","236","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065B302|2018-002823-41","January 23, 2019","March 26, 2021","October 31, 2024","September 28, 2018",,"March 18, 2020","Mayo Clinic Arizona, Phoenix, Arizona, United States|University of California San Diego Medical Center, La Jolla, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|UCSF, San Francisco, California, United States|University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States|Colorado Springs Pulmonary Consultants, Colorado Springs, Colorado, United States|South Denver Cardiology Associates PC, Littleton, Colorado, United States|St Vincents Lung, Sleep And Critical Care, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago Hospitals - Chicago, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|St. Mary's Cardiology, Reno, Nevada, United States|University of New Mexico Clinical & Translational Science Center, Albuquerque, New Mexico, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor Scott & White Research Institute at The Heart Hospital Baylor Plano, Plano, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Cardiovascular Center, Salt Lake City, Utah, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States|Aurora Saint Lukes Medical Center, Milwaukee, Wisconsin, United States|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Sanatorio Ramon Cereijo, Caba, Argentina|Instituto de Cardiología y Cirugía Cardiovascular - Fundación Favaloro, Caba, Argentina|Hospital General de Agudos Dr Cosme Argerich, Caba, Argentina|Hospital Britanico de Buenos Aires, Caba, Argentina|Hospital General de Agudos Dr. Juan A. Fernández, Caba, Argentina|Centro Médico Dra. De Salvo, Ciudad Autónoma de Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, Australia|Queensland Lung Transplant Service, Chermside, Australia|St Vincent's hospital, Darlinghurst, Australia|Pulmonary Arterial Hypertension Clinic, Hobart, Australia|The Alfred Hospital, Melbourne, Australia|Westmead Hospital, Westmead, Australia|Ordensklinikum Linz GmbH Elisabethinen, Linz, Austria|Medical University Vienna, Vienna, Austria|ULB Hôpital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Hospital das Clínicas - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Brazil|Faculdade de Medicina de Botucatu - Universidade Estadual Paulista, Botucatu, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Hospital das Clinicas - UFG, Goiania, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital São Lucas PUCRS, Porto Alegre, Brazil|Faculdade de Medicina Do Abc, Santo André, Brazil|Hospital São Paulo-UNIFESP, São Paulo, Brazil|Instituto do Coracao (INCOR) - HCFMUSP, São Paulo, Brazil|UMHAT 'Heart and Brain Center for Excellence', Pleven, Bulgaria|National Cardiology Hospital, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD, Sofia, Bulgaria|University Of Calgary - Peter Lougheed Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire De Cardiologie Et De Pneumologie De Québec, Quebec, Canada|China-Japan Friendship Hospital, Beijing, China|Cardiovascular institute & Fuwai Hospital- Thrombus Center, Beijing, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Shanghai Pulmonary Hospital, Shanghai, China|The General Hospital of Northern Theater Command, Shenyang, China|Wuhan Asia Heart Hospital, Wuhan, China|General University Hospital II.department of Internal Medicine-cardiology and angiology, Praha 2, Czechia|Århus Universitetshospital, Skejby, Hjertemedicinsk Afdeling B, Arhus, Denmark|Rigshospitalet Kardiologisk Klinisk, Copenhagen, Denmark|Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie, Dresden, Germany|Universitätsklinikum Giessen Medizinische Klinik Und Poliklinik Ii, Pneumologie, Giessen, Germany|Universität Greifswald - Klinik Für Innere Medizin Bereich Pneumologie/Infektiologie, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf - Pneumologie, Hamburg, Germany|Medizinische Hochschule Hannover Zentrum Innere Medizin Klinik für Pneumologie, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätskliniken des Saarlandes / Medizinische Klinik und Poliklinik, Innere Medizin V, Homburg/Saar, Germany|Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Abteilung für Pneumologie, Leipzig, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|Semmelweis Egyetem,Pulmonológiai Klinika, Budapest, Hungary|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|SE Pulmonológiai Klinika, Budapest, Hungary|Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pecs, Hungary|Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet és rendelő, Szeged, Hungary|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Italy|ISMETT Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Policlinico Umberto I, Roma, Italy|Ospedale di Cattinara - Struttura complessa di Pneumologia, Trieste, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Mexico|CICUM San Miguel, Guadalajara, Mexico|Unidad de Investigacion Clinica en Medicina S.C. (UDICEM), Monterrey, Mexico|VUMC Amsterdam, Amsterdam, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Krakowski Szpital Specjalistyczny im Jana Pawla II, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland|NZOZ Europejskie Centrum Zdrowia Otwock, Otwock, Poland|Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Warszawski Uniwersytet Medyczny, Szpital Kliniczny Dzieciątka Jezus, Warszawa, Poland|Wojewodzki Szpital Specjalist, Osrodek Badawczo-Rozwojowy, Wrocław, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospitais da universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar de Lisboa Norte, Lisbon, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|Altay Regional Cardiological Dispensary, Barnaul, Russian Federation|Irkutsk Regional Clinical Hospital, Irkutsk, Russian Federation|Cardiovascular Pathology Research Institute of Siberian Branch of RAMS, Kemerovo, Russian Federation|Moscow City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|Novosibirsk Research Institution of Circulation Pathology n.a. E.N. Meshalkin, Novosibirsk, Russian Federation|Omsk Regional Clinical Hospital, Omsk, Russian Federation|State Autonomous Healthcare Organization of Permsky Region ""City Clinical Hospital #4"", Perm, Russian Federation|National medical Research Center n.a. V.A.Almazov of MoH of Russian Federation, Saint-Petersburg, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Voronezh Regional Clinical Hospital #1, Voronezh, Russian Federation|National University Heart Centre, Singapore, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Narodny ustav srdcovych a cievnych chorob, Bratislava, Slovakia|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Vall D'Hebron, Barcelona, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Virgen Del Rocio, Sevilla, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Norrlands Universitetssjukhus, Umea, Sweden|Uppsala Akademiska Sjukhuset, Kardiologkliniken, Uppsala, Sweden|Universitatsspital Zurich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand|Hacettepe University Medical Faculty, Ankara, Turkey|Ankara University Medical Faculty, Ankara, Turkey|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Marmara University Medical Faculty, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Kartal Kosuyolu Yuksek Ihtisas Egitim Ve Arastirma Hastanesi, Kartal-Istanbul, Turkey|CI 'Dnipropetrovsk Regional Clinical Center of Cardiology and Cardiosurgery', Dnipro, Ukraine|Clinic of SI 'NSC 'The M.D.Strazhesko Institute of Cardiology' of NAMS of Ukraine', Kyiv, Ukraine|SI 'National Institute of Phtisiology and Pulmonology n.a. F.G. Yanovsky of NAMS of Ukraine', Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Papworth Hospital NHS Trust, Cambridge, United Kingdom|National Waiting Times Centre Board Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03689244"
678,"NCT01981837","Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",,"Completed","No Results Available","TTR-mediated Amyloidosis","Drug: ALN-TTRSC (revusiran) for subcutaneous administration","The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation.|Pharmacokinetics (PK) of ALN-TTRSC (revusiran) (Cmax, tmax, t1/2, AUC, CL, Vss, Vz)|Effect of ALN-TTRSC (revusiran) on transthyretin (TTR) (Determination of % Lowering of TTR to pretreatment/Baseline Levels)","Alnylam Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALN-TTRSC-002","December 2013","October 2014","January 2015","November 13, 2013",,"January 29, 2018","Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01981837"
679,"NCT01755949","Colchicine and CRP in Atrial Fibrillation and AF Ablation",,"Completed","Has Results","Atrial Fibrillation","Drug: Colchicine, 0.6 mg PO BID|Drug: Matching placebo","Change in C-reactive Protein|Number of Subjects With Atrial Fibrillation|Time Course of C-reactive Protein Levels","Mayo Clinic|Takeda|Detiger Funds","All","21 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-001686","March 2013","December 6, 2016","December 6, 2016","December 24, 2012","May 9, 2019","May 9, 2019","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01755949"
680,"NCT02554253","The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction",,"Active, not recruiting","No Results Available","Cognitive Disorders|Delirium|Acute Kidney Injury","Drug: Ketamine|Drug: Propofol","Number of patients with postoperative cognitive dysfunction|Number of patients with acute kidney injury|Number of patients who develop postoperative delirium","Mayo Clinic","All","75 Years and older   (Older Adult)","Not Applicable","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","14-007148","September 2015","December 2020","December 2020","September 18, 2015",,"April 6, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02554253"
681,"NCT01437878","Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)",,"Terminated","Has Results","Chronic Obstructive Pulmonary Disease|Pulmonary Hypertension","Drug: Iloprost|Drug: Placebo","Change in Endurance Time|Participants With Treatment-emergent Adverse Events|Change in Systolic Pulmonary Arterial Pressure|Change in Diastolic Pulmonary Arterial Pressure|Change in Mean Pulmonary Arterial Pressure|Change in Mean Right Atrial Pressure|Change in Cardiac Output|Change in Right Ventricular Pressure|Change in Pulmonary Vascular Resistance|Change in End Tidal Partial Pressure of Carbon Dioxide|Change in End Tidal Partial Pressure of Oxygen|Change in Oxygen Uptake|Change in Carbon Dioxide Output|Change in Oxygen Uptake Per Heartbeat|Change in Heart Rate|Change in Arterial Oxygen Saturation as Indicated by Pulse Oximetry|Change in Tidal Volume|Change in Minute Ventilation","Actelion","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AC-063B201","March 2012","November 2012","November 2012","September 21, 2011","January 6, 2015","November 20, 2015","Los Angeles Biomedical Research Institute, Torrance, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Hopital d'adultes de Brabois, Vandoeuvre-lès-Nancy, France|Hospital Clinic i Provincial, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01437878"
682,"NCT00987415","Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels","EXACT-HF","Completed","Has Results","Heart Failure|Elevated Serum Uric Acid","Drug: allopurinol|Drug: sugar pill","A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged.|Change in Quality of Life (KCCQ).|Change in Submaximal Exercise Capacity (6-MWT)|Change in Quality of Life (KCCQ)","Duke University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","253","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00020011|5U10HL084904","May 2010","December 2013","June 2014","October 1, 2009","October 20, 2014","November 4, 2014","Morehouse School of Medicine, Atlanta, Georgia, United States|Harvard University, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals-Case Medical Center, Cleveland, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Univ. of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|University of Montreal, Montreal PQ, Canada",,"https://ClinicalTrials.gov/show/NCT00987415"
683,"NCT02235077","Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure","ATHENA-HF","Completed","Has Results","Heart Failure","Drug: Spironolactone|Drug: Placebo","96 Hour Change in NT-proBNP|96 Hour Change in Clinical Congestion Score|96 Hour Change in Dyspnea Likert Score|96 Hour Change in Serum Creatinine|96 Hour Net Fluid Output|96 Hour Change in Body Weight|96 Hour Change in Serum Potassium Levels|Change in Loop Diuretics Requirements From Baseline to 30 Days|Presence of Outpatient Worsening Heart Failure Symptoms Through Day 30|96 Hour Change in Dyspnea Visual Analog Scale","Duke University|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years and older   (Adult, Older Adult)","Phase 2","360","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00057090|5U01HL084904","December 30, 2014","April 12, 2016","June 6, 2016","September 9, 2014","May 17, 2017","June 14, 2017","Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston VA Healtcare System, West Roxbury, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Duke University, Durham, North Carolina, United States|Southeastern Regional Medical Center, Lumberton, North Carolina, United States|University Hospitals - Case Medical Center, Cleveland, Ohio, United States|Metro Health System, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson Medical College, Philadelphia, Pennsylvania, United States|Michael Debakey VA Medical Center, Houston, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Utah VA Medical Center, Salt Lake City, Utah, United States|The University of Vermont- Fletcher Allen Health Care, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT02235077"
684,"NCT01537887","A Study of LY2484595 on the Electrical Activity of the Heart",,"Completed","Has Results","Healthy Volunteers","Drug: LY2484595|Drug: Placebo|Drug: Moxifloxacin","Change From Baseline to Day 10 in QT Interval Corrected for Heart Rate (QTc) for LY2484595 Versus Placebo|Pharmacokinetics: Maximum Drug Concentration (Cmax) of LY2484595 During One Dosing Interval at Steady State|Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2484595 During One Dosing Interval at Steady State|Percentage Change From Baseline to Day 11 in Fasting Lipids and Apolipoproteins","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","11947|I1V-MC-EIAK","February 2012","June 2012","June 2012","February 23, 2012","March 7, 2019","March 7, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01537887"
685,"NCT01772537","The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.",,"Terminated","Has Results","Thoracic Aneurysm|Aneurysm Stent|Cardiopulmonary Bypass|Abdominal Aneurysm","Drug: Propofol|Drug: isoflurane","Changes in Cerebrospinal Fluid (CSF) Levels of Tau|Changes in CSF Levels of Amyloid|Number of Participants With Delirium as Assessed by the Confusion Assessment Method (CAM)","Johns Hopkins University|National Center for Research Resources (NCRR)","All","21 Years to 100 Years   (Adult, Older Adult)","Not Applicable","14","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","NA_00067716|5KL2RR025006","May 2012","February 2014","February 2014","January 21, 2013","February 24, 2017","March 31, 2017","Johns Hopkins Hospital, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01772537"
686,"NCT02874664","A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer",,"Completed","No Results Available","Small Cell Lung Carcinoma","Drug: Rovalpituzumab Tesirine","Change in QTcF interval from baseline QTcF following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.|Change in RR interval from baseline RR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.|Change in PR interval from baseline PR following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.|Change in QRS duration interval from baseline QRS duration following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.|Change in waveform composition interval from baseline waveform composition following treatment with rovalpituzumab teserine as measured by extracting quantitative ECG parameters from ambulatory Holter monitors.|Relationship between plasma rovalpituzumab tesirine concentration and change in QTcF interval from baseline.|Incidence of proarrhythmic adverse events stratified by change in QTcF from baseline of less than 10 ms or greater than 10 ms.|Incidence of adverse events.|Objective response rate|Duration of response|Progression free survival|Overall survival|Clinical benefit ratio|Maximum Plasma Concentration (Cmax)|Area Under the Curve (AUC)","Stemcentrx","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRX001-007","September 2016","September 12, 2018","September 12, 2018","August 22, 2016",,"September 24, 2018","University of California Los Angeles, Los Angeles, California, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|The Ottawa Hospital-Cancer Centre, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02874664"
687,"NCT03624010","Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients",,"Active, not recruiting","No Results Available","Hypertension Pulmonary Secondary Heart Failure|Right Sided Heart Failure With Normal Ejection Fraction|Heart Failure With Normal Ejection Fraction","Drug: Levosimendan 2.5 mg/ml Injectable Solution","Clinical Safety measured by number of adverse events (AEs )|6-minute walk test (6MWT)|Patient global assessment|Physician's Assessment of Functional Class|Clinical Events: Death and hospitalizations","Tenax Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TNX-LVO-05","November 14, 2018","April 2022","April 2022","August 9, 2018",,"March 13, 2020","Stanford Healthcare, Stanford, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Christ Hospital, Cincinnati, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UW Health University Hospital, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03624010"
688,"NCT02780882","SOM230 Ectopic ACTH-producing Tumors",,"Withdrawn","No Results Available","Ectopic ACTH Syndrome","Drug: Pasireotide","Evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors|Number of participants with abnormal laboratory values for urine free cortisol|Number of participants with abnormal laboratory values for serum cortisol levels|Number of participants with abnormal laboratory values for salivary cortisol levels|Number of participants with abnormal laboratory values for Hemoglobin A1C (HbA1C)|Number of participants with abnormal laboratory values for fasting blood glucose|Number of participants with abnormal laboratory values for blood electrolytes|Number of participants with abnormal laboratory values for plasma adrenocorticotropic hormone (ACTH)|Number of participants with abnormal laboratory values for plasma beta-lipotropin|Number of participants with changes in clinical signs and symptoms|Changes in Tumor Size|Number of participants with changes in blood chemistry (safety)|Number of participants with changes in hematology (safety)|Number of participants with changes in cardiac activity|Number of participants with changes in liver health","Cedars-Sinai Medical Center|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro34493","December 2015","December 2018","June 2019","May 24, 2016",,"January 26, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT02780882"
689,"NCT01202110","Early Propranolol After Traumatic Brain Injury: Phase II","EPAT: Phase II","Terminated","Has Results","Traumatic Brain Injury","Drug: Propranolol","Determine in Patients With Traumatic Brain Injury (TBI) the Safe Dosing of Early Propranolol.","Cedars-Sinai Medical Center","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00020850","June 2010","February 2015","February 2015","September 15, 2010","May 13, 2016","May 13, 2016","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01202110"
690,"NCT00935012","Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122I Or Wild-Type ATTR-CM",,"Completed","No Results Available","ATTR-CM","Drug: tafamidis","Percentage of patients with a change from baseline through 10 years in Global Assessment Summary Score|Percentage of patients with a change from baseline through 10 years in New York Heart Association Classification|Percentage of patients with a change from baseline through 10 years in their 6-minute walk test distance|Percentage of patients with a change from baseline through 10 years in their Kansas City Cardiomyopathy Questionnaire Summary Score|Percentage of patients with a clinically significant change from baseline through 10 years in their echocardiography test|Percentage of all patients with a clinically significant change from baseline through 10 years in serum levels of NT-proBNP, troponin I or troponin T|Number or percentage of patients with a mortality or hospitalization event within 10 years of study participation|Incidence of Treatment-Emergent Adverse Events from baseline through 10 years","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FX1B-303|B3461026","September 22, 2009","November 20, 2019","November 20, 2019","July 8, 2009",,"March 27, 2020","Emory University School of Medicine, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00935012"
691,"NCT03532009","Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure","PRIORITIZE HF","Recruiting","No Results Available","Heart Failure","Drug: Sodium Zirconium Cyclosilicate|Drug: Placebo","Proportion of subjects in the following categories: • No ACEi/ARB/ARNI or at less than target dose and no MRA • ACEi/ARB/ARNI at target dose and no MRA • MRA at less than target dose • MRA at target dose","AstraZeneca","All","18 Years to 150 Years   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9484C00001","June 26, 2018","October 12, 2020","October 12, 2020","May 22, 2018",,"March 18, 2020","Research Site, National City, California, United States|Research Site, Stanford, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Gurnee, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Brooklyn, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Richmond Hill, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasillia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Marília, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Uberlandia, Brazil|Research Site, Votuporanga, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Hatvan, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szentes, Hungary|Research Site, Chorzów, Poland|Research Site, Chrzanów, Poland|Research Site, Gdańsk, Poland|Research Site, Legnica, Poland|Research Site, Poznań, Poland|Research Site, Rzeszów, Poland|Research Site, Tczew, Poland|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Targu Mures, Romania|Research Site, Tg Mures, Romania|Research Site, Timisoara, Romania|Research Site, Aramil, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Brezno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia",,"https://ClinicalTrials.gov/show/NCT03532009"
692,"NCT03187301","A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations ""OFF"" Episodes",,"Completed","No Results Available","Parkinson's Disease|Off Episodes of Parkinson Disease","Drug: APL-130277|Drug: Placebo|Drug: Moxifloxacin","Time-matched change from baseline in QTc, placebo-adjusted and corrected for HR based on the Fridericia correction method (QTcF) method (ΔΔQTcF). Assay sensitivity will be demonstrated by inclusion of a positive control, moxifloxacin.|Cmax|Tmax|AUC0-T|Safety and tolerability as measured primarily by number of subjects with treatment emergent AEs|ECG assessments including QTc with Bazett correction (QTcB), heart rate, PR interval, QRS interval, Uncorrected QT interval|MDS-UPDRS Part III change from pre-dose to 30, 60, 90 minutes after dosing during the Titration Phase at the highest tolerated APL-130277 dose level and the lowest APL-130277 dose resulting in a full ""ON""|Time to ""ON"" during Titration Phase at the highest tolerated APL-130277 dose level and the lowest APL-130277 dose resulting in a full ""ON""|Duration of ""ON"" during Titration Phase at the highest tolerated APL-130277 dose level and the lowest APL-130277 dose resulting in a full ""ON"".","Sunovion","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTH-201|2016-001762-29","August 3, 2017","December 21, 2017","December 21, 2017","June 14, 2017",,"November 19, 2018","Movement Disorders Center of Arizona, Scottsdale, Arizona, United States|Clinical Trials, Inc., Little Rock, Arkansas, United States|The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States|Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Bioclinica Reserach, Orlando, Florida, United States|Atlanta Center for Medical Research, Atlanta, Georgia, United States|The NeuroMedical Center, PC, Baton Rouge, Louisiana, United States|QUEST Research Institute, Farmington Hills, Michigan, United States|Central Texas Neurology Consultants, Round Rock, Texas, United States|Casa di Cura villa Margherita (Neurologia), Arcugnano, Italy|Centro Ricerche San Raffaele, Cassino, Italy|Agine Research Center, University Foundahon Chica-Pescara, Behavioral Neurology and Movement Disorders Unit, Chieti, Italy|Neurologia, Policlinico Tor Vergata, Rome, Italy|IRCCS San Raffaele Pisana,Clinical Trial Center, Rome, Italy",,"https://ClinicalTrials.gov/show/NCT03187301"
693,"NCT01467466","Prevention of Serious Adverse Events Following Angiography","PRESERVE","Completed","Has Results","Acute Renal Failure|Kidney Disease|Coronary Artery Disease","Drug: IV isotonic saline|Drug: IV isotonic bicarbonate|Drug: N-acetylcysteine|Drug: Placebo","Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Intravenous Sodium Bicarbonate With Intravenous Sodium Chloride.|Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo.","VA Office of Research and Development|The George Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","5177","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","578|1011387","October 7, 2013","September 29, 2017","October 17, 2017","November 8, 2011","November 9, 2018","May 14, 2019","Southern Arizona VA Health Care System, Tucson, Tucson, Arizona, United States|Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Charlie Norwood VA Medical Center, Augusta, GA, Augusta, Georgia, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States|Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States|VA Boston Healthcare System West Roxbury Campus, West Roxbury, MA, West Roxbury, Massachusetts, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States|VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|Portland VA Medical Center, Portland, OR, Portland, Oregon, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States|Memphis VA Medical Center, Memphis, TN, Memphis, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States|VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States|Canberra Hospital, Canberra, Australian Capital Territory, Australia|Concord Hospital, Concord, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Northern Health, Epping, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Penang Hospital, George Town, Penang, Malaysia|Hospital Serdang, Sepang, Selangor, Malaysia|University of Malaya Medical Center, Kuala Lumpur, Malaysia|Taranaki Base Hospital, Westown, New Plymouth, New Zealand|Wellington Hospital, Newtown, Wellington, New Zealand|Auckland City Hospital, Auckland, New Zealand","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01467466/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT01467466/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT01467466"
694,"NCT03714815","A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","SERENADE OL","Enrolling by invitation","No Results Available","Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","Drug: macitentan 10 mg","Number of All-cause Deaths Occurring up to 30 days After Study Treatment Discontinuation (End of Study Visit [EOS])|Number of All-cause Hospital Admissions up to 30 days after Study Treatment Discontinuation (EOS)|Number of Participants with Treatment-Emergent Adverse Events (AE's) After Study Treatment Discontinuation|Number of Participants with Treatment-Emergent Serious Adverse Events (SAE's) After Study Treatment Discontinuation|Number of Participants with Adverse Events (AEs) Leading to Premature Discontinuation of study Treatment|Change from Baseline in Systolic Arterial Blood Pressure|Change from Baseline in Diastolic Arterial Blood Pressure|Change from Baseline in Pulse Rate|Change from Baseline in Body Weight|Percentage of Participants with Abnormalities in Clinical Laboratory Parameters up to 30 days after study Treatment Discontinuation|Change from Baseline in Laboratory Parameter (Hemoglobin)|Change from Baseline in Laboratory Parameter (Hematocrit)|Change from Baseline in Laboratory Parameter (Erythrocyte Count)|Change from Baseline in Laboratory Parameters (Leukocyte Count and Platelet Count)|Change from Baseline in Laboratory Parameters (Alanine Aminotransferase [ALT], Alkaline Phosphatase and Aspartate Aminotransferase [AST])|Change from Baseline in Laboratory Parameters (Total and Direct Bilirubin, Creatinine, Blood Urea Nitrogen, Uric acid)|Change from Baseline in Laboratory Parameters (Sodium, Potassium, Chloride, Calcium, Magnesium)|Change from Baseline in Laboratory Parameters (Total Protein and Albumin)|Change from Baseline in Laboratory Parameter (Albumin / Globulins Ratio)|Change from Baseline in Laboratory Parameter (N-Terminal pro-Brain Natriuretic Peptide [NT-proBNP])|Change from Baseline in Laboratory Parameters (Mid-Regional pro-Atrial Natriuretic Peptide [MR-proANP])|Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)","Actelion|Almac Clinical Technologies, LLC|Frontier Science & Technology Research Foundation, Inc.|Covance Central Laboratory Services, LP|Chiltern International Ltd.|WorldCare Clinical, LLC|AcitGraph|Medidata Solutions","All","18 Years and older   (Adult, Older Adult)","Phase 2","112","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055G203|2018-001603-37","December 7, 2018","May 4, 2026","April 30, 2027","October 22, 2018",,"April 28, 2020","South Denver Cardiology Associates PC, Littleton, Colorado, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University Of Iowa - Hospitals & Clinics, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Allegheny, Pittsburgh, Pennsylvania, United States|North Dallas Research Associates, McKinney, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|MultiCare Health System, Tacoma, Washington, United States|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Argentina|Medizinische Universität Wien, Vienna, Austria|Specialized Hospital for Active Treatment in Cardiology - Pleven, Pleven, Bulgaria|Diagnostic - Consulting Center I-Sliven, Sliven, Bulgaria|Medical Centre Synexus, Sofia, Bulgaria|Bispebjerg Og Frederiksberg Hospital, Copenhagen, Denmark|CHU de Grenoble - Hôpital Albert Michallon, Grenoble Cedex 9, France|Hopital de Bicetre, Le Kremlin Bicetre, France|CHU Rouen - Hopital Charles Nicolle, Rouen Cedex, France|Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik 1-Pneumologie, Dresden, Germany|Universitaetsklinikum Giessen, Giessen, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Herzzentrum Uniklinik Köln Klinik III für Innere Medizin, Köln, Germany|Klinikum Würzburg Mitte gGmbH Standort Missioklinik, Würzburg, Germany|Semmelweis Egyetem Városmajor Szív- és Érgyógyászati Klinika, Budapest, Hungary|Barzilai Medical Center, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Bnai Zion Medical Center, Haifa, Israel|Galilee Medical Center, Nahariya, Israel|Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Stefana Kardynala Wyszynskiego SPZOZ, Lublin, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Wroclaw, Poland|Cardiomed, Craiova, Romania|SAL MED Pitesti, Pitesti, Romania|Cmi Dr Podoleanu Cristian, Targu-Mures, Romania|Ekaterinburg City Clinical Hospital #14, Ekaterinburg, Russian Federation|Federal State Budget Scientific Institution, Kemerovo, Russian Federation|Moscow City Clinical Hospital No.51, Moscow, Russian Federation|National Medical Research Center of Cardiology of MoH of Russian Federation, Moscow, Russian Federation|Federal State Budgetary Institution, St Petersburg, Russian Federation|Sahlgrenska Universitetsjukhuset, Goteborg, Sweden|Royal Free Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03714815"
695,"NCT01982292","Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure","RELAX-REPEAT","Completed","Has Results","Chronic Heart Failure","Drug: RLX030 (serelaxin)|Drug: Placebo","Percentage of Participants With Chronic Heart Failure (CHF) Who Develop Anti-serelaxin Antibodies at Any Time Following Repeat Administration of IV Continuous Infusions of Serelaxin Administered for up to 48 Hours in 16 Weeks|Percentage of Participants With Chronic Heart Failure Who Develop Positive Anti-serelaxin Antibodies After a Single Infusion of Serelaxin Over Time up to Week 16|Antibody Titers in Participants With Chronic Heart Failure Who Develop Positive Anti-serelaxin Antibodies (Neutralizing, Non-neutralizing or Both) at Any Time Following 3 Repeated Infusions and at Week 4, Week 8 and Week 12|Percentage of Participants With Chronic Heart Failure With Positive Antibody Status Who Develop Non-neutralizing Anti-serelaxin Antibodies Following 3 Repeated Infusions (i.e. at Week 4, Week 8, and Week 12)|Number of Participants With Adverse Events Such as Adjudicated Potential Hypersensitivity or Infusion Reactions|Pharmacokinetics of RLX030: Area Under the Plasma Concentration Time Curve From Time Zero up to 48 Hours Post Dose (AUC 0-48)|Pharmacokinetics of RLXL030: Actual Concentrations at Steady State (Css)|Pharmacokinetics of RLX030: Cmax Steady State (Cmaxss) Concentration at 48 Hours|Pharmacokinetics of RLX030: Clearance of Serelaxin (CL)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","321","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CRLX030A2209|2013-002781-39","May 2014","September 2015","September 2015","November 13, 2013","November 9, 2016","November 9, 2016","Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, South Miami, Florida, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Geelong, Australia|Novartis Investigative Site, Melbourne, Australia|Novartis Investigative Site, Brno - Bohunice, Czech Republic|Novartis Investigative Site, JIhlava, Czech Republic|Novartis Investigative Site, Praha 2, Czech Republic|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Grunstadt, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Luebeck, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Vimercate, MI, Italy|Novartis Investigative Site, Sneek, The Netherlands, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Targu Mures, Mures, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Sibiu, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Diskapi / Ankara, Turkey|Novartis Investigative Site, Haydarpasa/Istanbul, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Meselik / Eskisehir, Turkey|Novartis Investigative Site, Sivas, Turkey",,"https://ClinicalTrials.gov/show/NCT01982292"
696,"NCT01104870","A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension",,"Completed","Has Results","Pulmonary Hypertension","Drug: UT-15C","Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise From Baseline to Week 12|Change in Mean Pulmonary Artery Pressure (PAPm) From Baseline to Week 12|Change in Cardiac Index (CI) From Baseline to Week 12|Change in 6-minute Walk Distance (6MWD) From Baseline to Week 12|Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 12|Change in PH Symptoms From Baseline to Week 12|Number of Participants With a Change From Baseline World Health Organization (WHO) Functional Classification at Week 12|Change in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) Concentrations From Baseline to Week 12","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","TDE-PH-202","April 2010","January 2013","January 2013","April 16, 2010","December 30, 2015","May 27, 2016","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California Los Angeles Pulmonary Division, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of Rochester Medical Center, Mary Parkes Center, Rochester, New York, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01104870"
697,"NCT03016325","Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure","STANDUP AHF","Completed","No Results Available","Heart Failure","Drug: HNO Donor|Drug: Placebo","Clinically relevant hypotension|Change in NT-proBNP (N-terminal prohormone of brain natriuretic peptide)|Change in patient-reported resting dyspnea, as measured by the area under the curve (AUC) of the 11-point Numerical Rating Scale (NRS)","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","331","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CV013-011|2016-001685-29","January 13, 2017","June 23, 2019","November 12, 2019","January 10, 2017",,"February 17, 2020","University of Arizona Sarver Heart Center, Tucson, Arizona, United States|University of Florida, Gainesville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|DMC Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Sinai Grace Hospital, Detroit, Michigan, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina - PPDS, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Corrientes, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Edmonton, Alberta, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Plzen-Bory, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 4, Czechia|Local Institution, Slany, Czechia|Local Institution, Besancon, France|Local Institution, Beziers, France|Local Institution, Bobigny, France|Local Institution, Creteil, France|Local Institution, Evreux, France|Local Institution, La Tronche, France|Local Institution, Paris Cedex 10, France|Local Institution, Paris, France|Local Institution, Bad Nauheim, Germany|Local Institution, Frankfurt, Germany|Local Institution, Gottingen, Germany|Local Institution, Greifswald, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Homburg, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Mainz, Germany|Local Institution, Regensburg, Germany|Local Institution, Athens, Attiki, Greece|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Ioannina, Greece|Local Institution, Kallithea, Greece|Local Institution, Larisa, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Brescia, Italy|Local Institution, Ferrara, Italy|Local Institution, Foggia, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Seto, Aichi, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Amagasaki, Hyogo, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kawaguchi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Itabashi-ku, Tokyo, Japan|Local Institution, Osaka, Japan|Local Institution, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Amersfoort, Netherlands|Local Institution, Deventer, Netherlands|Local Institution, Hardenberg, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Bialystok, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Wroclaw, Poland|Local Institution, Zamosc, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, L'Hospitalet de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sant Joan Despi, Spain|Local Institution, Santiago de Compostela, Spain|Local Institution, Belfast, United Kingdom|Local Institution, Blackpool, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03016325"
698,"NCT01055912","Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Drug: Lixivaptan|Drug: Placebo","To assess the efficacy and safety of lixivaptan treatment in congestive heart failure (CHF) patients with volume expansion.|To assess the effects of lixivaptan treatment in CHF patients with volume expansion.","CardioKine Inc.|Cardiokine Biopharma, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CK-LX2401","January 2010","September 2010",,"January 26, 2010",,"June 28, 2011","Mobile Heart Specialists, PC, Mobile, Alabama, United States|Phoenix Clinical, Phoenix, Arizona, United States|Nea Clinic, Jonesboro, Arkansas, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Merced Heart Associates, Merced, California, United States|Orange County Heart Institute and Research Center, Orange, California, United States|Innovative Research of West Florida, Inc, Clearwater, Florida, United States|Edgewater Medical Research Inc, Edgewater, Florida, United States|Foundation/Research/Cardiovascular Specialists Lower Keys, Key West, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Tampa Clinical Research, Tampa, Florida, United States|Executive Health and Research Associates, Inc, Atlanta, Georgia, United States|In-Quest Medical Research, LLC, Duluth, Georgia, United States|Fox Valley Clinical Research Center, Aurora, Illinois, United States|Maine Research Associates, Auburn, Maine, United States|Primary Care Cardiology Research, Inc, Ayer, Massachusetts, United States|Horizon Research, St. Louis, Missouri, United States|Great Lakes Medical Research, Westfield, New York, United States|Raleigh Cardiology, Raleigh, North Carolina, United States|Clinical Research Limited, Canton, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|East Texas Cardiology, Houston, Texas, United States|National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States|National Clinical Research - Richmond, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01055912"
699,"NCT00879229","ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","ARTEMIS-PH","Terminated","Has Results","Idiopathic Pulmonary Fibrosis|Pulmonary Hypertension","Drug: Ambrisentan|Drug: Placebo","Change From Baseline in Six-minute Walk Distance (6MWD).|Long-term Survival|Transition Dyspnea Index (TDI)|Change From Baseline in WHO Functional Class|Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted|Change From Baseline in N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Change From Baseline in the Borg Dyspnea Index (BORG) Immediately Following Exercise|Hemoglobin-corrected Diffusing Capacity for Carbon Monoxide (DLCO) Percent Predicted|Change in Quality of Life (QOL) Score as Assessed by the Short-Form 36® (SF-36)|Change in QOL Score as Assessed by the St. George's Respiratory Questionnaire (SRGQ)","Gilead Sciences","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-300-0128","July 2009","February 2011","February 2011","April 9, 2009","April 22, 2014","May 15, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Arizona, Scottsdale, Arizona, United States|University of California Davis, Davis, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|University of California San Diego Medical Center, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado Heatlh Sciences Center, Aurora, Colorado, United States|Bay Area Chest Physicians, Clearwater, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Miami Medical Center, Miami, Florida, United States|Suncoast Lung Center, Sarasota, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Association, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deacones Medical Center, Boston, Massachusetts, United States|University of Michigan Health Systems, Ann Arbor, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University, St Louis, Missouri, United States|Creighton University Center for Allergy & Asthma, Omaha, Nebraska, United States|Dartmouth Medical School, Lebanon, New Hampshire, United States|Albany Medical Center, Albany, New York, United States|Winthrop University Hospital, Mineola, New York, United States|North Shore Health System, New Hyde Park, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States|University Hospitals of Cleveland Case Western, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Alleghany General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Inova Heart Institiute and Vascular Institute, Falls Church, Virginia, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Providence Everett Medical Center, Everett, Washington, United States|St. Vincents Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universität Graz, Graz, Austria|Universitatsklinikum Innsbruck, Innsbruck, Austria|Medizinische Universität Wien, Vienna, Austria|Peter Loughheed Center- Calgary General Hospital, Calgary, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite de Montreal, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Center, Montreal, Quebec, Canada|Centre de Pneumologie de L'Hospital Laval, Sainte foy, Quebec, Canada|Evangelische Lungenklinik Berlin, Berlin, Germany|Charite-Universitatsmedizin Berlin, Berlin, Germany|Krankenhaus Donaustauf der LVA, Donaustauf, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitat Greifswald, Greifswald, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Thorax Klinik, Heidelberg, Germany|LMU Klinikum der Universitat, Munchen, Germany|Azienda Ospedaliero Universitaria, Catania, Italy|Presidio Ospedaliero G.B. Morgagni, Forli, Italy|Unita Funzionale di Pneumologia e Fisiopatologia Respiratoria, Milano, Italy|Ospedale S.Giuseppe Fatebenefratelli, Milan, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Instituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy|Policlinico Universitario Tor Vergata, Rome, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Centro delle Interstiziopatie Polmonari e Malattie Rare del Polmone, Torino, Italy|Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom|University Hospital Aintree, Liverpool, United Kingdom|University College Hosptial, London, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00879229"
700,"NCT01263808","Cardiac Safety of Indacaterol",,"Completed","No Results Available","Healthy Volunteers|Chronic Obstructive Pulmonary Disease","Drug: Indacaterol 150 µg|Drug: Indacaterol 300 µg|Drug: Indacaterol 600 µg|Drug: Placebo|Drug: Placebo/moxifloxacin","Change from baseline in QTc interval (Fridericia's)|Change from baseline in uncorrected QT interval","Novartis Pharmaceuticals|Novartis","All","18 Years to 55 Years   (Adult)","Phase 1","404","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQAB149B2339","April 2008","August 2008",,"December 21, 2010",,"December 21, 2010","Novartis investigative site, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01263808"
701,"NCT01922089","Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients","TITRATION","Completed","Has Results","Heart Failure With Reduced Ejection Fraction","Drug: LCZ696","Number of Participants Experiencing Hypotension, Renal Dysfunction, Hyperkalemia and Angioedema and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)|Number of Participants Who Achieved Treatment Success Over the 12 Weeks and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low)|Number of Participants Who Tolerated Study Medication for at Least the Last Two Weeks of the Study and by Renin-Angiotensin-Aldosterone System (RAAS) Stratum (High vs. Low).","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","498","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCZ696B2228|2013-001835-33","November 2013","August 2014","August 2014","August 14, 2013","October 15, 2015","October 15, 2015","Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Chiefland, Florida, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Evansville, Indiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Laurelton, New York, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Oak Ridge, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Livingston, Texas, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Gabrovo, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Smolian, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Berlin-Buch, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dietzenbach, Germany|Novartis Investigative Site, Ebersbach, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Hassloch, Germany|Novartis Investigative Site, Huy / OT Anderbeck, Germany|Novartis Investigative Site, Ingelheim, Germany|Novartis Investigative Site, Kelkheim, Germany|Novartis Investigative Site, Kleve, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mühlheim, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Straubing, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Mosonmagyarovar, Hungary|Novartis Investigative Site, Nyiregyháza, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, Aosta, AO, Italy|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Albano Laziale, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Vittorio Veneto, TV, Italy|Novartis Investigative Site, San Daniele Del Friuli, UD, Italy|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Brezno, Slovak Republic, Slovakia|Novartis Investigative Site, Nitra, Slovak Republic, Slovakia|Novartis Investigative Site, Svidnik, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Trebisov, Slovakia|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sanlucar de Barrameda, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Haydarpasa/Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Dorchester, Dorset, United Kingdom|Novartis Investigative Site, St Leonards on Sea, East Sussex, United Kingdom|Novartis Investigative Site, Oldham, Lancashire, United Kingdom|Novartis Investigative Site, Gateshead, Tyne and Wear, United Kingdom|Novartis Investigative Site, Bath, United Kingdom|Novartis Investigative Site, Bradford, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Harrow, United Kingdom|Novartis Investigative Site, Nuneaton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01922089"
702,"NCT02910635","A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers",,"Completed","No Results Available","Abnormalities, Cardiovascular","Drug: Volanesorsen|Drug: Moxifloxacin|Drug: Placebo","Placebo corrected change from baseline in QTcF (corrected Frederica's CT Interval)|Placebo corrected change from baseline heart rate (HR, PR and QRS)","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics","All","18 Years to 55 Years   (Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","ISIS 304801-CS13","September 19, 2016","December 20, 2016","December 20, 2016","September 22, 2016",,"July 28, 2017","Covance, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02910635"
703,"NCT02157506","A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure",,"Completed","Has Results","Heart Failure|Decompensated Heart Failure|Acute Heart Failure","Drug: CXL-1427|Drug: Placebo","Number of Participants With Treatment-Emergent Adverse Events|Mean Time Averaged Change From Baseline in Adjudicated Pulmonary Capillary Wedge Pressure (PCWP) During Infusion|Mean Time-Averaged Change From Baseline in Adjudicated Pulmonary Artery Diastolic Pressure (PAD) During the Infusion|Mean Time-Averaged Percent Change From Baseline in Cardiac Index (Fick)|Mean Time-Averaged Change From Baseline in Adjudicated Pulmonary Artery Systolic Pressure (PAS) During the Infusion|Mean Time-Averaged Change From Baseline in Adjudicated Right Atrial Pressure (RAP) During the Infusion|Mean Time-Averaged Change From Baseline in Mean Arterial Blood Pressure (MAP) During the Infusion|Mean Time-Averaged Change From Baseline in Systolic Blood Pressure (SBP) During the Infusion|Mean Time-Averaged Change From Baseline in Diastolic Blood Pressure (DBP) During the Infusion|Mean Time-Averaged Change From Baseline in Heart Rate (HR) During the Infusion","Bristol-Myers Squibb|Cardioxyl Pharmaceuticals, Inc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CXL-1427-02|CV013-006","June 30, 2014","May 31, 2015","July 31, 2015","June 6, 2014","May 20, 2019","July 31, 2019","Cardioxyl Study Site, Gainesville, Florida, United States|Cardioxyl Study Site, Jacksonville, Florida, United States|Cardioxyl Study Site, Jacksonville, Florida, United States|Cardioxyl Study Site, Macon, Georgia, United States|Cardioxyl Study Site, Baltimore, Maryland, United States|Cardioxyl Study Site, Detroit, Michigan, United States|Cardioxyl Study Site, Newark, New Jersey, United States|Cardioxyl Study Site, Chapel Hill, North Carolina, United States|Cardioxyl Study Site, Cincinnati, Ohio, United States|Cardioxyl Study Site, Columbus, Ohio, United States|Cardioxyl Study Site, Charleston, South Carolina, United States|Cardioxyl Study Site, Nashville, Tennessee, United States|Cardioxyl Study Site, Salt Lake City, Utah, United States|Cardioxyl Study Site, Richmond, Virginia, United States|Cardioxyl Study Site, Bad Neuheim, Germany|Cardioxyl Study Site, Cologne, Germany|Cardioxyl Study Site, Frankfurt, Germany|Cardioxyl Study Site, Gottingen, Germany|Cardioxyl Study Site, Greifswald, Germany|Cardioxyl Study Site, Kiel, Germany|Cardioxyl Study Site, Regensberg, Germany|Cardioxyl Study Site, Amman, Jordan|Cardioxyl Study Site, Irbid, Jordan|Cardioxyl Study Site, Lodz, Poland|Cardioxyl Study SIte, Warsaw, Poland|Cardioxyl Study Site, Warsaw, Poland|Cardioxyl Study Site, Wroclaw, Poland|Cardioxyl Study Site, Kemerovo, Russian Federation|Cardioxyl Study Site, Moscow, Russian Federation|Cardioxyl Study Site, Moscow, Russian Federation|Cardioxyl Study Site, Moscow, Russian Federation|Cardioxyl Study Site, Moscow, Russian Federation|Cardioxyl Study Site, St. Petersburg, Russian Federation|Cardioxyl Study Site, St. Petersburg, Russian Federation|Cardioxyl Study Site, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02157506"
704,"NCT00887588","LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction",,"Completed","Has Results","Chronic Heart Failure","Drug: LCZ696|Drug: Valsartan|Drug: Placebo","Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in NT-proBNP and Brain Natriuretic Peptide (BNP)|Change From Baseline in Plasma Cyclic Guanine Monophosphate (cGMP)|Change From Baseline in Echocardiography (ECHO) Parameters: Left Ventricular End (LVE) Diastolic Diameter, LVE Systolic Diameter, Septal End Diastolic Thickness, Posterior LV Wall End Diastolic Thickness, Relative Wall Thickness, Left Atrial Dimension|Change From Baseline in Echocardiography Parameters: LVE Diastolic Volume, LVE Systolic Volume, Left Ventricular Stroke Volume, Left Atrial Volume|Change From Baseline in Echocardiography Parameters: Left Ventricular Ejection Fraction|Change From Baseline in Echocardiography Parameters: Left Ventricular Mass|Change From Baseline in Echocardiography Parameters: Left Ventricular Mass Index|Change From Baseline in Echocardiography Parameters: Left Atrial Volume Index|Change From Baseline in Echocardiography Parameters: Ewave Velocity, A Wave Velocity, e' at Septal Mitral Annulus, e' at Lateral Mitral Annulus|Change From Baseline in Echocardiography Parameters: Ratio of E to A Velocity, E/e' Ratio|Change in Echocardiography Parameters: Isovolumic Relaxation Time|Change From Baseline in Echocardiography Parameters: Tricuspid Regurgitation Velocity|Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score and Individual Domain Summary Scores|Percentage of Participants With Clinical Composite Assessment of Improved, Unchanged or Worsened|Percentage of Participants With New York Heart Association (NYHA) Class I, II, II or IV|Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)|Change From Baseline in Serum Creatinine|Change From Baseline in Albumin/Creatinine Ratio|Change From Baseline in Arterial Stiffness Parameters: Brachial Systolic Blood Pressure (SBP), Brachial Diastolic Blood Pressure (DBP), Central Augmentation Pressure, Central Pressure at T1-DP, Central SBP, Central DBP, Central Mean Pressure|Change From Baseline in Arterial Stiffness Parameters: Heart Rate Correct Cen Aug/Pulse Ht|Change From Baseline in Arterial Stiffness Parameters: Heart Rate|Change From Baseline in Arterial Stiffness Parameters: Pulse Wave Velocity|Change From Baseline in Sitting SBP, Sitting DBP and Sitting Pulse Pressure (PP)","Novartis Pharmaceuticals|Novartis","All","40 Years and older   (Adult, Older Adult)","Phase 2","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CLCZ696B2214|2009-010208-27","November 2009","December 2011","December 2011","April 24, 2009","August 13, 2015","August 25, 2015","Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Hillsboro, Oregon, United States|Novartis Investigative Site, Wyomissing, Pennsylvania, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Ramos Mejia, Buenos Aires, Argentina|Novartis Investigative Site, San Martin, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Hyderabad, Andhra Pradesh, INDIA, India|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Mangalore, Karnataka, India|Novartis Investigative Site, Manipal, Karnataka, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Cosenza, CS, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Casorate Primo, PV, Italy|Novartis Investigative Site, Sarzana, SP, Italy|Novartis Investigative Site, San Daniele Del Friuli, UD, Italy|Novartis Investigative Site, Somma Lombardo, VA, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Goes, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Heerenveen, Netherlands|Novartis Investigative Site, Heerlen, Netherlands|Novartis Investigative Site, Hengelo, Netherlands|Novartis Investigative Site, Piotrkow Trybunalski, Poland|Novartis Investigative Site, Sieradz, Poland|Novartis Investigative Site, Warszawa/Anin, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Craiova, Jud. Dolj, Romania|Novartis Investigative Site, Craiova, Jud.Dolj, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Pitesti, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela",,"https://ClinicalTrials.gov/show/NCT00887588"
705,"NCT01558830","Safety of Amiodarone and Ranolazine Together in Patients With Angina","SARA","Unknown status","No Results Available","Chronic Stable Angina|Coronary Artery Disease|Atrial Fibrillation|Ventricular Tachycardia","Drug: ranolazine|Drug: placebo","ventricular arrhythmia|atrial arrhythmia burden|Electrocardiogram (EKG) corrected QT (QTc) interval measurement|hospitalization|syncope hospitalization|liver function assay","Cardiovascular Consultants of Nevada|Gilead Sciences","All","35 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IN-US-259-0121","January 2012","April 2013","July 2013","March 20, 2012",,"March 21, 2012","Cardiovascular Consultants of Nevada, Henderson, Nevada, United States|Cardiovascular Consultants of Nevada, Las Vegas, Nevada, United States|Cardiovascular Consultants of Nevada, Las Vegas, Nevada, United States",,"https://ClinicalTrials.gov/show/NCT01558830"
706,"NCT01323153","A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)",,"Completed","Has Results","Coronary Heart Disease","Drug: dalcetrapib|Drug: placebo","Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment|Similarity in Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment in Studies WC25501 and NC20971|Percent Change of High-density Lipoprotein C (HDL-C) Treatment Levels After 8, 12 and 20 Weeks of Treatment|Percent Change From Baseline in Blood Lipid Levels|Percent Change From Baseline in Lipoprotein Levels|Percent Change From Baseline in Apolipoprotein Levels|Safety: Incidence of Adverse Events","Hoffmann-La Roche","All","45 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WC25501","March 2011","March 2012","March 2012","March 25, 2011","August 6, 2018","July 30, 2019","Pensacola, Florida, United States|Pensacola, Florida, United States|Saginaw, Michigan, United States|Saint Cloud, Minnesota, United States|Syracuse, New York, United States|Rapid City, South Dakota, United States|Ceske Budejovice, Czechia|Chrudim, Czechia|Hradec Kralove, Czechia|Jihlava, Czechia|Jindrichuv Hradec, Czechia|Praha, Czechia|Semily, Czechia|Teplice, Czechia|Zlin, Czechia|Znojmo, Czechia|Amsterdam, Netherlands|Arnhem, Netherlands|Beverwijk, Netherlands|Breda, Netherlands|Den Helder, Netherlands|Eindhoven, Netherlands|Gouda, Netherlands|Heerlen, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Sneek, Netherlands|Edinburgh, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Stoke-on-Trent, United Kingdom|Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01323153"
707,"NCT01263223","A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: Placebo","Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 1|Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 4|Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 1|Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Heart Rate During Treatment With 36-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Systolic and Diastolic Blood Pressure During Treatment With 36-mg LY2216684 or Placebo on Day 4|Maximum and Mean Change From Baseline in ABPM Heart Rate During Treatment With 18-mg LY2216684 or 36-mg LY2216684 on Day 4|Maximum and Mean Change From Baseline in ABPM Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or 36-mg LY2216684 on Day 4","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12607|H9P-EW-LNCP","December 2010","March 2011","March 2011","December 20, 2010","October 23, 2018","October 23, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01263223"
708,"NCT01096043","A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: Placebo|Drug: Strata 1 CXL-1020|Drug: Strata 2 CXL-1020|Drug: Strata 3 CXL-1020","Safety and Hemodynamic Effects|Measurement of Plasma BNP Levels|Assessment of the dose/plasma concentration/effect relationship of CXL-1020|Effects of CXL-1020 on Renal Function|Signs and Symptoms of Heart failure|Evaluation of all Adverse Events","Bristol-Myers Squibb|Cardioxyl Pharmaceuticals, Inc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CXL-1020-02","April 2010","February 2012","February 2012","March 30, 2010",,"November 15, 2016","University of Florida, Gainesville, Florida, United States|University of Florida, Jacksonville, Florida, United States|Florida Hospital Transplant Center, Orlando, Florida, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|DMC Cardiovascular Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Medicine & Dentistry of New Jersey - New Jersey Medical School, South Orange, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Davis Heart & Lung Research Institute, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Stern Cardiovascular Center PA, Germantown, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01096043"
709,"NCT01363323","Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization",,"Completed","No Results Available","Healthy Volunteers","Drug: Methylnaltrexone (MNTX)|Drug: Placebo|Drug: Moxifloxacin","Effects of MNTX on QTcI duration","Bausch Health Americas, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MNTX 1106","November 2004","January 2005","February 2005","June 1, 2011",,"November 29, 2019","Progenics Pharmaceuticals, Tarrytown, New York, United States",,"https://ClinicalTrials.gov/show/NCT01363323"
710,"NCT01357850","A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure",,"Completed","Has Results","Heart Failure, Congestive","Drug: GSK716155|Drug: Placebo","Change From Baseline in Myocardial Glucose Utilization as Assessed by [18F]Fluoro-2-deoxy-glucose Positron Emission Tomography (FDG-PET) Imaging|Change From Baseline in Myocardial Efficiency (Work Performed/Myocardial Oxygen Consumption [MVO2]) Assessed at Rest|Change From Baseline in Peak Oxygen Uptake (Peak VO2) as Assessed by Bicycle Cardiopulmonary Exercise Testing|Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Assessed by Echocardiogram|Change From Baseline in Left Ventricular (LV) Volumes in Systole and Diastole as Assessed by Echocardiogram|Change From Baseline in LV and RV Function Assessed by Cardiac Magnetic Resonance (CMR) (LVEF), Myocardial Strain Assessed by Myocardial Tagging Indices|Change From Baseline in LV and RV Function Assessed by CMR (LV and RV Volumes in Systole and Diastole), Myocardial Strain Assessed by Myocardial Tagging Indices|Change From Baseline in LV and RV Function Assessed by CMR (LV Mass), Myocardial Strain Assessed by Myocardial Tagging Indices|Change From Baseline in Cardiac Energetics (PCr/ATP) Measured by 31P Magnetic Resonance Spectroscopy (MRS)|Change From Baseline in Cardiac and Liver Fat by Proton Spectroscopy (1H MRS)|Change From Baseline in Exercise Capacity Assessed by 6-minute Walk Test|Change From Baseline in Serum N-terminal Fragment Brain Natriuretic Peptide (NT-BNP) Level|Change From Baseline in Plasma Levels of Glucose, and Free Fatty Acids (FFA)|Change From Baseline in Plasma Levels of Insulin|Change From Baseline in Quality of Life as Assessed by the Minnesota Living With Heart Failure Questionnaire|Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Adverse Events by the Indicated Severity","GlaxoSmithKline","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","112670","September 15, 2010","September 18, 2012","September 18, 2012","May 23, 2011","October 1, 2014","August 17, 2017","GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Auburn, Maine, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Newark, New Jersey, United States|GSK Investigational Site, Stony Brook, New York, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, New York, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01357850"
711,"NCT01300013","Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)",,"Completed","No Results Available","Heart Failure","Drug: Placebo|Drug: Omecamtiv mecarbil","The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.|To characterize pharmacokinetics of omecamtiv mecarbil including metabolites following IV infusion and to evaluate the relationship between omecamtiv mecarbil plasma concentration and echocardiographic parameters in subjects with AHF|To assess the safety and tolerability of 3 dose levels of IV omecamtiv mecarbil compared with placebo in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure|To evaluate the effects of 48 hours treatment with IV omecamtiv mecarbil on additional measures of dyspnea, patient global assessment (PGA), change in NT-proBNP, incidence of worsening heart failure, and short term clinical outcomes","Amgen|Cytokinetics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","614","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20100754","April 2011","April 2013","September 2013","February 21, 2011",,"April 21, 2014","Research Site, Moblie, Alabama, United States|Research Site, Inglewood, California, United States|Research Site, La Jolla, California, United States|Research Site, San Francisco, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Atlantis, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Novi, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Newark, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Fairfield, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Gent, Belgium|Research Site, Roeselare, Belgium|Research Site, Blagoevgrad, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, QuÃ©bec, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Helsinki, Finland|Research Site, Turku, Finland|Research Site, Caen Cedex 9, France|Research Site, Lille Cedex, France|Research Site, Montpellier cedex 05, France|Research Site, Paris Cedex 13, France|Research Site, Paris, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 09, France|Research Site, Bad Nauheim, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Greifswald, Germany|Research Site, Halle/Saale, Germany|Research Site, Hamburg, Germany|Research Site, Homburg, Germany|Research Site, Langen, Germany|Research Site, Regensburg, Germany|Research Site, Stuttgart, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Haidari, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Pecs, Hungary|Research Site, Szolnok, Hungary|Research Site, Brescia, Italy|Research Site, Cagliari, Italy|Research Site, Pavia, Italy|Research Site, Udine, Italy|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Delft, Netherlands|Research Site, Deventer, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petrsburg, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Bristol, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01300013"
712,"NCT03442764","A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)","MAVERICK-HCM","Completed","No Results Available","Non-obstructive Hypertrophic Cardiomyopathy","Drug: mavacamten|Drug: Placebo","Frequency and severity of treatment-emergent adverse events and serious adverse events.","MyoKardia, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MYK-461-006","March 30, 2018","January 7, 2020","January 7, 2020","February 22, 2018",,"April 6, 2020","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States|Stanford Hospital and Clinics/Stanford University, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Northwestern University, Evanston, Illinois, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|University of Iowa Hospitals and clinics, Iowa City, Iowa, United States|University of Maryland Medical System, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Michigan Medicine, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Winthrop Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Cardiology at Southpoint, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Luke's Cardiology Associates, Bethlehem, Pennsylvania, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor St. Luke Medical Center at Houston, Texas Heart Institute Out-patient Clinic, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Medical Center, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Unity Point Health Meriter Heart and Vascular Institute, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03442764"
713,"NCT03685149","Pilot Randomized Trial With Flecainide in ARVC Patients",,"Recruiting","No Results Available","Arrhythmogenic Right Ventricular Cardiomyopathy","Drug: Flecainide Pill|Drug: Placebo","Number of ventricular premature beats (VPBs)|Proarrhythmic response to Flecainide|VT burden|Number of atrial premature beats (APBs)|Ratio of eligible to enrolled participants","Wojciech Zareba|University of Rochester","All","18 Years and older   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HL143372-01","July 31, 2019","August 31, 2021","August 31, 2021","September 26, 2018",,"January 18, 2020","University of Colorado, Denver, Colorado, United States|John Hopkins University, Baltimore, Maryland, United States|New York University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|University of Pensylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03685149"
714,"NCT03528902","Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension","T3PAH","Recruiting","No Results Available","Hypertension|Pulmonary Arterial Hypertension|Familial Primary Pulmonary Hypertension|Primary Pulmonary Hypertension|Lung Diseases|Tamoxifen|Estrogen Receptor Antagonist|Hormone Antagonists|Estrogens","Drug: Tamoxifen|Drug: Placebo Oral Tablet","Transthoracic echocardiogram (ECHO)-based change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) measurement|Six minute walk test distance (6MWTD)|Quality of life will be assessed using the SF36 questionnaire. This will be administered at baseline and 12 and 24 weeks.|Quality of life will be assessed using emPHasis-10 questionnaire. This will be administered at baseline and 12 and 24 weeks.","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","180241","October 1, 2018","June 30, 2022","June 30, 2023","May 18, 2018",,"January 18, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03528902"
715,"NCT03472495","Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial","OVID RAF","Active, not recruiting","No Results Available","Atrial Fibrillation and Flutter","Drug: Diltiazem Oral Product|Drug: Diltiazem Injectable Product","Heart rate control|Adverse event rate","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 4","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20009559","June 1, 2018","March 2021","March 2021","March 21, 2018",,"April 2, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03472495"
716,"NCT02057341","A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy",,"Completed","No Results Available","LMNA-Related Dilated Cardiomyopathy","Drug: ARRY-371797, p38 inhibitor; oral","Assess the efficacy of the study drug in terms of change from Baseline in 6-minute walk test.|Assess the efficacy of study drug in terms of left ventricular function.|Assess the efficacy of study drug in terms of right ventricular function.|Assess the safety of study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.|Characterize the pharmacokinetics (PK) of study drug and metabolites in terms of plasma concentration-time profiles and model-based PK parameters.","Array BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARRAY-797-231","February 2014","May 2016","May 2016","February 7, 2014",,"May 16, 2017","Stanford University School of Medicine, Stanford, California, United States|University of Colorado School of Medicine, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|The Ohio State University, Columbus, Ohio, United States|Meriter Wisconsin Heart, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02057341"
717,"NCT03057028","Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Anakinra","Change in exercise capacity, as determined by peak oxygen consumption and ventilatory efficiency on cardiopulmonary exercise testing|Effect of anakinra on serum high sensitivity C-reactive protein|Effect of anakinra on serum NT-pro-BNP.|Effect of anakinra on serum interleukin-6|Change in symptoms of heart failure (as assessed by questionnaire with the Duke Activity Status Index and Minnesota Living With Heart Failure Questionnaire).|Correlate between biomarkers (serum high sensitivity C reactive protein, interluekin-6, and NT-pro BNP) and measures of exercise capacity (peak oxygen consumption and ventilatory efficiency on cardiopulmonary exercise testing)|Number of patients with treatment related adverse events related to anakinra in patients with pulmonary arterial hypertension","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20005870","April 2016","June 7, 2018","June 7, 2018","February 17, 2017",,"April 5, 2019","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03057028"
718,"NCT01187836","Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure",,"Completed","No Results Available","Heart Failure","Drug: TRV120027|Drug: Placebo","Pulmonary Capillary Wedge Pressure (PCWP)|Safety and Tolerability|Pharmacokinetics of TRV120027|Additional Hemodynamics|Laboratory Evaluations","Trevena Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP120027.2001|2010-020376-37","December 2010","March 2012","March 2012","August 24, 2010",,"July 11, 2017","Miami, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Utah, Salt Lake City, Utah, United States|CZ05, Brno, Czechia|CZ04, Olomouc, Czechia|CZ06, Prague, Czechia|PL01, Warsaw, Poland|PL05, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT01187836"
719,"NCT02385877","Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines",,"Completed","No Results Available","Autonomic Peripheral Nervous System Diseases","Drug: [18F]4F-MHPG|Drug: [18F]3F-PHPG","Composite measure based on radiotracer tissue uptake ratios (heart-to-lung ratio, heart-to-liver ratio, heart-to-blood ratio) and rates of metabolism in plasma (half-time, in minutes) of [18F]4F-MHPG and [18F]3F-PHPG in healthy subjects.|Radiation Dose|Number of Adverse Events","University of Michigan","All","18 Years to 55 Years   (Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00088601","March 2015","August 2016","August 2016","March 11, 2015",,"July 2, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT02385877"
720,"NCT01107925","Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease","FEATHER","Completed","Has Results","Coronary Artery Disease","Drug: prasugrel|Drug: clopidogrel","Change From Baseline in Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12 (Period 1)|Change From Baseline in Vasodilator-Associated Stimulated Phosphoprotein (VASP) at Day 12 of Therapy|Change From Baseline in VerifyNow® P2Y12 Reaction Units (PRU) at Day 12 of Therapy|Pharmacokinetic (PK) Analysis of the Concentration-Time Curve (AUC)|Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) at Day 12 of Therapy","Eli Lilly and Company|Daiichi Sankyo Co., Ltd.","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12921|H7T-MC-TADI","March 2010","August 2011","August 2011","April 21, 2010","August 30, 2012","August 30, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nieuwegein, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01107925"
721,"NCT02101047","Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension",,"Withdrawn","No Results Available","Complications; Cesarean Section|Spinal Anesthetics Causing Adverse Effects in Therapeutic Use","Drug: Phenylephrine","Magnitude of cardiac output changes|provider intervention|vasopressor requirement|Emetic symptoms|hypertension|hypotension|bradycardia|Anesthetic time","Wake Forest University Health Sciences","Female","18 Years to 45 Years   (Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB 26872","August 2015","December 31, 2016","December 31, 2016","April 1, 2014",,"November 8, 2017","Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02101047"
722,"NCT01603082","Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients",,"Completed","Has Results","Acute Coronary Syndrome","Drug: Ticagrelor|Drug: Clopidogrel","Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™|Inhibition of the P2Y12 Receptor at 0.5 Hours, End of PCI, and 8 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by PRU From VerifyNow™","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 4","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5130L00014","July 2012","June 2014","June 2014","May 22, 2012","December 11, 2015","December 11, 2015","Research Site, Birmingham, Alabama, United States|Research Site, San Francisco, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, North Kansas, Missouri, United States|Research Site, Belleville, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tyler, Texas, United States|Research Site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01603082"
723,"NCT01757808","A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Ranolazine|Drug: Placebo","Change in pulmonary vascular resistance (PVR)|Change in CPET (VE/VCO2, PETCO2, peak VO2, peak HR, peak RER, work max (MET or Watt), sub maximum exercise time|Change in RV echo parameters: 2D, 3D|Change in 6MWD|Safety/SAE","University of Chicago","All","18 Years to 72 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11-0301","August 2011","January 2015","January 2015","December 31, 2012",,"March 3, 2017","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01757808"
724,"NCT01982695","Cardiomyopathy in DMD: Lisinopril vs. Losartan",,"Completed","Has Results","Duchenne Muscular Dystrophy (DMD)|Cardiomyopathy","Drug: Losartan|Drug: Lisinopril","Cardiac Ejection Fraction as Measured by Echocardiogram","Nationwide Children's Hospital|Boston Children’s Hospital|University of California, Davis|Unverisity of Kansas Medical Center|University of Minnesota|St. Louis Children's Hospital","Male","Child, Adult, Older Adult","Not Applicable","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB12-00149","March 2009","August 2012","September 2013","November 13, 2013","March 21, 2017","March 21, 2017","University of California Davis, Davis, California, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Minnesota, St. Paul, Minnesota, United States|St. Louis Children's Hospital, St. Louise, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01982695"
725,"NCT02291237","Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy","LIBERTY-HCM","Terminated","Has Results","Hypertrophic Cardiomyopathy","Drug: Eleclazine|Drug: Placebo","Change in Peak Oxygen Uptake (VO2) Achieved During Cardiopulmonary Exercise Testing (CPET) From Baseline to Week 24|Change in Peak Oxygen Uptake (VO2) Achieved During Cardiopulmonary Exercise Testing (CPET) From Baseline to Week 12|Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to Week 24|Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to Week 12|Change in Treadmill Exercise Time From Baseline to Week 24|Change in Treadmill Exercise Time From Baseline to Week 12","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-361-1157|2013-004429-97","February 5, 2015","January 20, 2017","February 17, 2017","November 14, 2014","March 22, 2018","September 24, 2018","Cedars-Sinai Heart Institute, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Athens Regional Medical Center, Athens, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University Medical Center/ New York Presbyterian, New York, New York, United States|NYU School of Medicine Pediatrics, New York, New York, United States|Duke Health Center at Southpoint, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|St. Thomas Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|Texas Heart Institute, Houston, Texas, United States|UT Southwestern Medical Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|Marshfield Clinic Research Institute, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Alfred Hospital, Melbourne, Victoria, Australia|Hôpital Européen Georges Pompidou, Paris, France|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Ein Kerem-Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat-Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Madonna del Soccorso Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Florence, Italy|Ospedale San Raffaele S.r.l., Milan, Italy|Azienda Ospedaliera Monaldi, Naples, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Academisch Medisch Centrum Amsterdam, Amsterdam, Noord-Holland, Netherlands|Erasmus MC, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|University Hospital of Wales, Cardiff, South Glamergon, United Kingdom|Northern General Hospital, Sheffield, Yorkshire, United Kingdom","""Study Protocol: Original"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02291237/Prot_005.pdf|""Study Protocol: Amendment 1"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02291237/Prot_006.pdf|""Study Protocol: Amendment 2"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02291237/Prot_007.pdf|""Study Protocol: Amendment 3"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02291237/Prot_008.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02291237/SAP_009.pdf","https://ClinicalTrials.gov/show/NCT02291237"
726,"NCT03794583","Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)","PERFECTOLE","Enrolling by invitation","No Results Available","Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease","Drug: Inhaled treprostinil solution","Incidence of treatment-related adverse events|Severity of treatment-related adverse events|6 Minute Walk Distance (6MWD)|Borg Dyspnea Score|N-terminal pro-brain natriuretic peptide (NT-pro-BNP)|Pulse Oximetry","United Therapeutics|Lung Biotechnology PBC","All","18 Years and older   (Adult, Older Adult)","Phase 3","136","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIN-PH-305","December 21, 2018","December 31, 2020","December 31, 2020","January 7, 2019",,"April 30, 2020","St. Vincent's Lung, Sleep, and Criticial Care Specialists, Jacksonville, Florida, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Albany Medical Center, Albany, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03794583"
727,"NCT03351738","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease",,"Completed","Has Results","Stable Coronary Heart Disease","Drug: MEDI5884|Drug: Placebo","Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)|Number of Participants With Clinically Important Changes in Electrocardiograms (ECGs) From Baseline|Number of Participants With Clinically Important Changes in Vital Signs From Baseline|Number of Participants With Clinically Important Changes in Laboratory Parameters From Baseline|Number of Participants With Clinically Important Changes in Physical Examinations From Baseline|Change From Baseline in Apolipoprotein B|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)|Area Under the Concentration-time Curve for 30 Days (AUC30d) After the Last Dose of MEDI5884|Maximum Observed Serum Concentration (Cmax) of MEDI5884 After the Last Dose|Terminal Elimination Half-life (t½) of MEDI5884 After the Last Dose|Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to MEDI5884","MedImmune LLC","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D7870C00002","December 13, 2017","November 9, 2018","November 9, 2018","November 24, 2017","December 19, 2019","March 23, 2020","Research Site, Anniston, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, El Cajon, California, United States|Research Site, Lincoln, California, United States|Research Site, Northridge, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Fleming Island, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Stow, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Kingsport, Tennessee, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03351738/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03351738/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03351738"
728,"NCT04136171","CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)",,"Recruiting","No Results Available","Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM)","Drug: AKCEA-TTR-LRx|Drug: Placebo","Composite Outcome of Cardiovascular (CV) Mortality and frequency of CV clinical events at Week 120|Change From Baseline on the 6-Minute Walk Test (6MWT) at Week 61|Change From Baseline in the 6MWT Distance at Week 120|Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores at Week 120|Rate of CV Mortality at Week 120|Rate of CV Clinical Events at Week 120|Rate of All-Cause Mortality at Week 120","Ionis Pharmaceuticals, Inc.|Akcea Therapeutics","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ION-682884-CS2|2019-002835-27","March 13, 2020","January 2024","June 2024","October 23, 2019",,"March 16, 2020","University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory Heart and Vascular Center - Emory Clifton Campus, Atlanta, Georgia, United States|Piedmont Heart of Fayetteville, Fayetteville, Georgia, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Boston University School of Medicine, Boston, Massachusetts, United States|New York University Langone Cardiology Associates, New York, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04136171"
729,"NCT03152552","A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure",,"Terminated","Has Results","Diabetes Mellitus and Heart Failure","Drug: LIK066|Drug: Placebo|Drug: Empagliflozin","Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 12|Change From Baseline in Glycated Hemoglobin (HbA1c) at Weeks 12 and 36|Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 36|Change From Baseline in Body Weight at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by Bio-impedance (Total Body Fat Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by Bio-impedance (Visceral Fat Level) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by Bio-impedance (Lean Body Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Total Body Fat Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Visceral Fat Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Lean Body Mass) at Weeks 12 and 36|Change From Baseline in Body Composition Assessed by DXA (Total Body Water) at Weeks 12 and 36|Change From Baseline in Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 12 and 36|Change From Baseline in Fasting Lipid Profile (Triglycerides (TG)) at Weeks 12 and 36|Change From Baseline in Fasting Lipid Profile (Lipoproteins) at Weeks 12 and 36|Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Weeks 12 and 36|Change From Baseline in High Sensitive C-reactive Protein (hsCRP) at Weeks 12 and 36|Change From Baseline in 24 Hour Urinary Glucose Excretion (UGE) at Weeks 12 and 36|Change From Baseline in 24 Hour Sodium Excretion at Weeks 12 and 36|Change From Baseline in Left Atrial Size at Weeks 12 and 36|Change From Baseline in Left Atrial Volume at Weeks 12 and 36|Number of Participants With New York Heart Association (NYHA) Class I, II, II or IV|Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at Week 12 and 36|Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 36|Change From Baseline in 24 Hour Urinary Calcium Excretion at Weeks 12 and 36|24 Hour Urinary Phosphate Excretion at Weeks 12 and 36|Change From Baseline in Bone Mineral Density (BMD) at Weeks 12 and 36","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLIK066B2204|2016-003084-19","July 25, 2017","June 6, 2018","June 6, 2018","May 15, 2017","August 28, 2019","August 28, 2019","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Carmichael, California, United States|Novartis Investigative Site, Concord, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Delray Beach, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Bogalusa, Louisiana, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Lennik, Brussels, Belgium|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, St-Jerome, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Krapinske toplice, Croatia|Novartis Investigative Site, Rijeka, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brandys nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Svitavy, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Karvina, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Prerov, Czechia|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Bad Oeynhausen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, San Donato Milanese, MI, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Rimini, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Wonju, Gangwon-Do, Korea, Republic of|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Loerenskog, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Paarl, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, London, GBR, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03152552/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT03152552/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03152552"
730,"NCT04062565","Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil Injectable Product|Drug: Riociguat Pill","Change in stroke volume/end systolic volume (SV/ESV)|Change in pulmonary and cardiac pressures|Change in pulmonary blood flow|Change in end-systolic elastance/arterial elastance (Ees/Ea)|Change in Right Ventricle (RV) diastolic stiffness (Beta)|Change in 6 minute walk distance|Change in brain natriuretic peptide (BNP)|Change in magnetic resonance imaging (MRI) right ventricle volumes|Change in Cardio pulmonary Exercise Testing (CPET)|Change in derived VO2 max|Change in derived Ve/VCO2|Change in adverse event profile|Change in composite time to clinical worsening","University of Arizona","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1812168816","March 25, 2019","December 2020","December 2021","August 20, 2019",,"August 20, 2019","University of Arizona, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04062565"
731,"NCT02603068","Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis",,"Withdrawn","No Results Available","Pulmonary Hypertension|Pulmonary Fibrosis","Drug: Oral treprostinil","Change in pulmonary vascular resistance (PVR)|Change in Six-minute walk distance (6MWD)|Change in N-terminal pro-brain natriuretic peptide (NT-ProBNP)","United Therapeutics","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-204","February 2016","April 2018","July 2018","November 11, 2015",,"February 9, 2016","Banner University Medical Center Phoenix Advanced Lung Disease, Phoenix, Arizona, United States|University of California, Los Angeles - Pulmonary Division, Los Angeles, California, United States|University of California - Davis Medical Group, Sacramento, California, United States|Emory University Hospital, Atlanta, Georgia, United States|Johns Hopkins University, Baltiomore, Maryland, United States|Oregon Health and Science University, Portland, Oregon, United States|CLC Pulmonary Hypertension Clinic Division of Pulmonary, Allergy and Critical Care Medicine UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02603068"
732,"NCT03961048","Ideal Initial Bolus and Infusion Rate for Erector Spinae Plane Block Catheters",,"Withdrawn","No Results Available","Pain, Postoperative|Pain, Chest","Drug: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Drug: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally","Median Effective Dose|Change in pain rating|Change in heart rate|Blood pressure|Change in percent oxygen saturation of hemoglobin|Changes in electrocardiogram tracing|Dermatomal coverage|Opioid consumption|Non-narcotic pain medication consumption","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","HM20014242","July 23, 2019","September 2020","September 2020","May 23, 2019",,"January 27, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03961048"
733,"NCT01870778","Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF","RELAX-AHF-2","Completed","Has Results","Acute Heart Failure","Drug: RLX030|Drug: Placebo","Percentage of Participants With Confirmed Cardiovascular (CV) Death Through Day 180|Percentage of Participants With Worsening of Heart Failure (WHF) Through Day 5|Percentage of Participants With All-cause Death Through Day 180|Length of Total Hospital Stay (LOS) During the Index Acute Heart Failure (AHF) Hospitalization|Percentage of Participants With First Occurrence of Adjudicated CV Death or Adjudicated Re-hospitalization|Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization|Percentage of Participants With First Improvement Since Baseline in Congestive Signs and Symptoms of Heart Failure|Change From Baseline in hsTroponin T Biomarker|Change From Baseline in NT-proBNP Biomarker|Change From Baseline in Cystatin C Biomarker","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","6600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRLX030A2301|2013-001498-25","October 2, 2013","January 23, 2017","February 1, 2017","June 6, 2013","March 30, 2018","March 30, 2018","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Montgomery, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Sylmar, California, United States|Novartis Investigative Site, Walnut Creek, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Sanford, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Winter Haven, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Oakbrook Terrace, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Annapolis, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Kingston, New York, United States|Novartis Investigative Site, New Hyde Park, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Natrona Heights, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Wynnewood, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Warwick, Rhode Island, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Galveston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Lynchburg, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Morgantown, West Virginia, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Carapachay, Buenos Aires, Argentina|Novartis Investigative Site, Coronel Suarez, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, San Martin, Buenos Aires, Argentina|Novartis Investigative Site, San Salvador de Jujuy, Jujuy, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Salta, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Braunau, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Villach, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Curitiba, Parana, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Pazardzhik, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Smolian, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, Thetford Mines, Quebec, Canada|Novartis Investigative Site, Las Condes, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Florida Blanca, Colombia|Novartis Investigative Site, Brno - Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Frydek Mistek, Czech Republic, Czechia|Novartis Investigative Site, Kladno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Pardubice, Czech Republic, Czechia|Novartis Investigative Site, Praha 6, Czech Republic, Czechia|Novartis Investigative Site, Slany, Czech Republic, Czechia|Novartis Investigative Site, Usti nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Usti nad Orlici, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Benesov, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, JIhlava, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Plzen, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Copenhagen NV, Denmark|Novartis Investigative Site, Glostrup, Denmark|Novartis Investigative Site, Glostrup, Denmark|Novartis Investigative Site, Randers, Denmark|Novartis Investigative Site, Amiens, France|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Beziers Cedex, France|Novartis Investigative Site, Bobigny, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Chambray-lès-Tours, France|Novartis Investigative Site, La Tronche, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Paris cedex 10, France|Novartis Investigative Site, Paris cedex 18, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac cedex, France|Novartis Investigative Site, Pontoise, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Saint Herblain - Nantes, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bitburg, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Coburg, Germany|Novartis Investigative Site, Detmold, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Friedberg, Germany|Novartis Investigative Site, Füssen, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heilbronn, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Kleve, Germany|Novartis Investigative Site, Koeln-Nippes, Germany|Novartis Investigative Site, Langen, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leverkusen, Germany|Novartis Investigative Site, Limburg, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Merseburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Mönchengladbach, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Ruesselsheim, Germany|Novartis Investigative Site, Tuebingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Villingen-Schwenningen, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Wuppertal, Germany|Novartis Investigative Site, Zwickau, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Chaidari, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Balatonfured, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Cegled, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Mateszalka, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Zalaegerszeg, Hungary|Novartis Investigative Site, Dublin 24, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Lower Galilee, Israel|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Sefad, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Tel Giborim, Holon, Israel|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Gavardo, BS, Italy|Novartis Investigative Site, Bolzano, BZ, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Vimercate, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Albano Laziale, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Rimini, RN, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, San Luis Potosi, San Luis Potosí, Mexico|Novartis Investigative Site, Culiacán, Sinaloa, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Sneek, The Netherlands, Netherlands|Novartis Investigative Site, Almelo, Netherlands|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Gorinchem, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Haarlem, Netherlands|Novartis Investigative Site, Hardenberg, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Zutphen, Netherlands|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, Krakow, POL, Poland|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Grodzisk Mazowiecki, Poland|Novartis Investigative Site, Klodzko, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Lódz, Poland|Novartis Investigative Site, Olawa, Poland|Novartis Investigative Site, Pulawy, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wloclawek, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Carnaxide - Linda-A-Velha, Lisboa, Portugal|Novartis Investigative Site, Vila Real, Portuigal, Portugal|Novartis Investigative Site, Amadora, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Covilha, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Penafiel, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Viana Do Castelo, Portugal|Novartis Investigative Site, Vila Nova de Gaia, Portugal|Novartis Investigative Site, Mayaguez, Puerto Rico|Novartis Investigative Site, Targu Mures, Mures, Romania|Novartis Investigative Site, Tg. Mures, Mures, Romania|Novartis Investigative Site, Arad, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Braila, Romania|Novartis Investigative Site, Brasov, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Oradea, Romania|Novartis Investigative Site, Pitesti, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tomsk, Russian Federation|Novartis Investigative Site, Vladimir, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Liptovsky Mikulas, Slovak Republic, Slovakia|Novartis Investigative Site, Topolcany, Slovak Republic, Slovakia|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Umhlanga, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Sanlucar de Barrameda, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Leon, Castilla Y Leon, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Getafe, Madrid, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Joenkoeping, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Molndal, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Haydarpasa/Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, High Wycombe, Buckinghamshire, United Kingdom|Novartis Investigative Site, Torquay, Devon, United Kingdom|Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom|Novartis Investigative Site, Nottingham, Hampshire, United Kingdom|Novartis Investigative Site, Blackburn, Lancashire, United Kingdom|Novartis Investigative Site, Hardwick,, Stockton On Tees, United Kingdom|Novartis Investigative Site, Dudley, West Midlands, United Kingdom|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Kettering, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT01870778/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT01870778/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01870778"
734,"NCT01060293","Dopamine in Acute Decompensated Heart Failure II","DAD-HF II","Terminated","No Results Available","Acute Decompensated Heart Failure","Drug: High-dose furosemide|Drug: Low-dose furosemide|Drug: Low-dose furosemide combined with low-dose dopamine","1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).|60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).|Novel indices of acute renal ischemia/injury (cystatin-C, KIM-1, NGAL)","Larissa University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3975","July 2009","December 2013","December 2013","February 2, 2010",,"September 11, 2013","Division of Cardiology, Emory University Hospital, Atlanta, Georgia, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|First Department of Cardiology, University of Athens, Athens, Attiki, Greece|Department of Cardiology, Volos General Hospital, Volos, Magnesia, Greece|Department of Cardiology, Larissa University Hospital, Larissa, Greece|AHEPA University Hospital, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT01060293"
735,"NCT03470545","Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy","EXPLORER-HCM","Active, not recruiting","No Results Available","Obstructive Hypertrophic Cardiomyopathy","Drug: mavacamten|Drug: Placebo","Percentage of Participants Achieving A Clinical Response","MyoKardia, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MYK-461-005","May 29, 2018","June 2020","June 2020","March 20, 2018",,"April 10, 2020","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center (Smidt Heart Institute), Los Angeles, California, United States|UCSF School of Medicine, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Cardiology at Southpoint, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Cardiology Associates, Bethlehem, Pennsylvania, United States|University of Pennsylvania (Penn Heart and Vascular Center), Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Presbyterian, Pittsburgh, Pennsylvania, United States|Methodist University Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Houston Medical School, Houston, Texas, United States|Intermountain Medical Center, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|UZ Antwerpen, Edegem, Antwerpen, Belgium|Onze-Lieve-Vrouwziekenhuis, Aalst, Oost-Vlaanderen, Belgium|Hôpital Erasme, Brussels, Belgium|Institut Klinicke a Experimentalni Mediciny, Prague, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Aarhus Universitetshospital, Aarhus N, Denmark|Bispebjerg Hospital, København NV, Denmark|Odense Universitetshospital, Odense, Denmark|CHRU Nantes, Nantes, Loire-Atlantique, France|Groupe Hospitalier Pitié Salpétrière, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hôpital de Rangueil, Toulouse, France|University Medicine Göttingen, Göttingen, Neidersachsen, Germany|Kerckhoff-Klinik-Forschungs-GmbH, Bad Nauheim, Germany|Charité Campus Buch - Experimental and Clinical Research Center, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Cardiologicum Dresden und Pirna, Dresden, Germany|University Clinic Heidelberg - PPDS, Heidelberg, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Tel-Aviv, Israel|Barzilai Medical Center, Ashkelon, Israel|Hadassah Medical Center PPDS -, Jerusalem, Israel|Rabin Medical Center - PPDS, Petach Tikva, Israel|The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital, Ramat-Gan, Israel|Kaplan Medical Center, Reẖovot, Israel|ZIV Medical Center, Safed, Israel|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Maastricht University Medical Center, Maastricht, Limburg, Netherlands|Academisch Medisch Centrum Amsterdam, Amsterdam, Noord-Holland, Netherlands|Erasmus MC, Rotterdam, Zuid-Holland, Netherlands|Collegium Medicum Uniwersytetu Jagiellonskiego, Kraków, Malopolskie, Poland|Kardio Klinika Brynów, Katowice, Slaskie, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwesytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego, Warsaw, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospital da Luz, Lisboa, Portugal|Hospital Universitario Virgen de La Arrixaca, El Palmar, Murcia, Spain|Hospital Universitario A Coruña, La Coruña, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|University Hospital of Wales, Cardiff, South Glamergon, United Kingdom|St Bartholomew's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03470545"
736,"NCT03037931","Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency","HEART-FID","Recruiting","No Results Available","Heart Failure|Iron-deficiency","Drug: Ferric carboxymaltose|Drug: Placebos","Incidence of Death|Incidence of hospitalization for heart failure|Change in 6MWT distance","American Regent, Inc.|Duke Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","3014","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1VIT15043","March 15, 2017","January 2021","June 2022","January 31, 2017",,"February 10, 2020","Advanced Cardiovascular LLC, Alexander City, Alabama, United States|Advanced Cardiovascular, LLC, Auburn, Alabama, United States|IMC/Diagnostic & Medical Clinic, Mobile, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Alaska Heart & Vascular Institute, Anchorage, Alaska, United States|Verde Valley Medical Center, Cottonwood, Arizona, United States|Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States|Carondelet Heart and Vascular Institute - Cardiology East, Tucson, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|NEA Baptist Clinic, Jonesboro, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|Harbor-UCLA Medical Center, Carson, California, United States|Valley Clinical Trials, Inc., Covina, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|California Heart Specialists, Huntington Beach, California, United States|First Valley Medical Group, Lancaster, California, United States|Healthcare Partners Affiliation Medical Group, Long Beach, California, United States|Axis Clinical Trials, Los Angeles, California, United States|St. Joseph Heritage-Healthcare, Mission Viejo, California, United States|Radin Cardiovascular Medical Group, Inc., Newport Beach, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Pasadena Clinical Research, Pasadena, California, United States|Eugene Soroka, MD Inc., Port Hueneme, California, United States|VA San Diego Health Care System, San Diego, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Western Connecticut Health Network, Danbury, Connecticut, United States|Stamford Hospital, Stamford, Connecticut, United States|Christiana Care, Newark, Delaware, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Cardiology Associates of South Florida, Boynton Beach, Florida, United States|Cardiovascular & Vein Center of Florida, Bradenton, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|St. Vincent's Healthcare - Riverside, Jacksonville, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States|St. Vincent's Healthcare - Southside Recruiting, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Empire Clinical Research, LLC, Miami Lakes, Florida, United States|ProLive Medical Research, Miami, Florida, United States|Cordova Research Institute, LLC, Miami, Florida, United States|Med-Care Research, Miami, Florida, United States|ITB Research, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|Cardiology Partners Clinical Research Institute, Palm Beach Gardens, Florida, United States|Misal Khan, MD, Panama City, Florida, United States|Broward Research Center, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|Avanza Medical Research Center, Pensacola, Florida, United States|Professional Health Care of Pinellas, Saint Petersburg, Florida, United States|Indian River Medical Center, Vero Beach, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|University Cardiology Associates, LLC, Augusta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont Heart Institute Fayetteville, Fayetteville, Georgia, United States|Georgia Arrhythmia Consultants and Research Institute, Macon, Georgia, United States|Mercer University, Macon, Georgia, United States|Atlanta Vanguard Research Institute, Smyrna, Georgia, United States|Medicoricium, LLC, Fairview Heights, Illinois, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Franciscan Physician Network - Indiana Heart Physicians, Indianapolis, Indiana, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|Indiana University Health Ball Memorial Hospital, Inc., Muncie, Indiana, United States|Reid Physician Associates / Reid Health, Richmond, Indiana, United States|Beacon Medical Group Advanced Cardiovascular Specialists, South Bend, Indiana, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Heart Clinic of Hammond, Hammond, Louisiana, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Tulane Heart & Vascular Institute, New Orleans, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Louisiana Heart Center, Slidell, Louisiana, United States|Maine Medical Partners Maine Health Cardiology, Scarborough, Maine, United States|Anne Arundel Health System Research Institute, Annapolis, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|NECCR Prima Care Research, LLC, Fall River, Massachusetts, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, Michigan, United States|Michigan CardioVascular Institute at Covenant Medical Center, Saginaw, Michigan, United States|Allina Health System, dba Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Cardiology Associates Research, LLC, Tupelo, Mississippi, United States|North Kansas City Hospital, North Kansas City, Missouri, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|Nebraska Heart Institute, Lincoln, Nebraska, United States|CHI Health Research Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Red Rock Clinical Research, LLC, Las Vegas, Nevada, United States|Monmouth Cardiology Associates, LLC, Eatontown, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Advanced Heart & Vascular Institute of Hunterdon, Flemington, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|AtlantiCare Regional Medical Center, Pomona, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Trinity Medical WNY, PC, Cheektowaga, New York, United States|Mount Sinai Hospital, New York, New York, United States|Richmond University Medical Center, Staten Island, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Circuit Clinical, West Seneca, New York, United States|Northtowns Cardiology, PLLC, Williamsville, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Duke University Heart Failure Research, Durham, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Wake Forest University Health Sciences, High Point, North Carolina, United States|Monroe Biomedical Research, Monroe, North Carolina, United States|Crossroads Clinical Research, Inc., Mooresville, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|NC Heart & Vascular Research, Raleigh, North Carolina, United States|WakeMed Health and Hospitals, Raleigh, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Trinity Health Center - Medical Arts, Minot, North Dakota, United States|Aultman Cardiology Clinical Trials, Canton, Ohio, United States|The MetroHealth System, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|North Ohio Heart Center, Elyria, Ohio, United States|North Ohio Heart Center, Sandusky, Ohio, United States|Heart House Research Foundation, Springfield, Ohio, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Geisinger Holy Spirit Cardiology, Camp Hill, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|V.A. Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Prisma Health, Columbia, South Carolina, United States|Self Regional Hospital Research Center, Greenwood, South Carolina, United States|Carolina Heart Specialists, Lancaster, South Carolina, United States|Black Hills Cardiovascular Research, a department of Rapid City Regional Hospital, Inc., Rapid City, South Dakota, United States|Tennova Healthcare-Turkey Creek Medical Center, Knoxville, Tennessee, United States|Parkway Cardiology Associates, PC, Oak Ridge, Tennessee, United States|Amarillo Hearth Clinical Research Institute, Inc., Amarillo, Texas, United States|PharmaTex Research, Amarillo, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|Southwest Family Medicine Associates, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Texas Health Research & Education Institute, Fort Worth, Texas, United States|Texas Heart Institute, Houston, Texas, United States|Houston Heart & Vascular Associates, Kingwood, Texas, United States|Caprock Cardiac Center Research Institute, Inc., Lubbock, Texas, United States|Angelina Medical Research, LLC, Lufkin, Texas, United States|North Dallas Research Associates, McKinney, Texas, United States|North Texas Research Associates, McKinney, Texas, United States|South Texas Cardiovascular Consultants, PLLC, San Antonio, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|PharmaTex Research, Tyler, Texas, United States|The University of Texas Health Center at Tyler, Tyler, Texas, United States|Wichita Falls Heart Clinic, Wichita Falls, Texas, United States|Advanced Clinical Research/Intermountain Heart Center PC, West Jordan, Utah, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|Stroobants Cardiovascular Center, Lynchburg, Virginia, United States|Riverside Cardiology Specialists, Newport News, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Swedish Heart & Vascular-Advanced Cardiac Support Program, Seattle, Washington, United States|Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington, United States|CHI Franciscan Research Center, Tacoma, Washington, United States|Walla Walla Clinic, Walla Walla, Washington, United States|Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|ProHealth Care Inc / Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|SWSLHD-Liverpool Hospital, Liverpool, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Cairns Hospital, Cairns, Queensland, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Core Research Group, Milton, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|SA Heart, Ashford, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Heart Lung Clinic, Darlinghurst, Sydney, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Royal Adelaide Hospital, Adelaide, Australia|University of Calbary, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|South Edmonton Cardiology Consultants, Edmonton, Alberta, Canada|Royal Alexandria Hospital, Edmonton, Alberta, Canada|Fraser Clinical Trials, New Westminster, British Columbia, Canada|SMH Cardiology Clinical Trials, Surrey, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|G.A. Research Associates, Ltd., Moncton, New Brunswick, Canada|Health Sciences Centre, Saint John's, Newfoundland and Labrador, Canada|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|Manna Research Inc., Burlington South, Burlington, Ontario, Canada|Cambridge Cardiac Care Center, Cambridge, Ontario, Canada|Vizel Cardiac Research, Cambridge, Ontario, Canada|London Health Sciences Center (LHSC), London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System - Mount Sinai Hospital, Toronto, Ontario, Canada|Clinique de Cardiologie de Lévis, Lévis, Quebec, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|McGill University Health Centre (MUHC), Montréal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Université Laval, Québec, Quebec, Canada|CISSS de Chaudière-Appalaches (CISSS-CA), site Hôpital St-Georges, Saint-Georges, Quebec, Canada|Recherche Medical St-Jerome Inc., Saint-Jérôme, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-et-du-centre-du-Quebec, Trois-Rivières, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Wellington Hospital, Newton, Wellington, New Zealand|North Shore Hospital, Auckland, New Zealand|Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Heart Institute, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Hawke's Bay Hospital, Hastings, New Zealand|Hutt Hospital, Lower Hutt, New Zealand|Nelson Hospital, Nelson, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Clinical Horizons NEW ZEALAND LTD, Tauranga, New Zealand|4th Military Hospital, Wrocław, Poland",,"https://ClinicalTrials.gov/show/NCT03037931"
737,"NCT02053909","Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis","TARGET","Recruiting","No Results Available","Saphenous Vein Graft Disease","Drug: Aspirin|Drug: Ticagrelor","Saphenous vein graft occlusion|Saphenous vein graft stenosis","Boca Raton Regional Hospital|AstraZeneca|Ottawa Heart Institute Research Corporation","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","300","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Brilinta ISSBRIL0220","September 2014","August 2022","August 2023","February 4, 2014",,"July 9, 2019","Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02053909"
738,"NCT02239146","Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass",,"Completed","No Results Available","Acquired Bleeding Disorder|Cardiac Surgery Requiring Cardiopulmonary Bypass","Drug: catridecacog|Drug: placebo","Incidence and severity of adverse events|Incidence and magnitude of laboratory abnormalities following administration of rFXIII|Incidence of antibodies to FXIII-A subunit|Incidence of anti-yeast antibodies","Novo Nordisk A/S","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","43","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F13CARD-1660|2005-000729-40","October 2005","January 2008","January 2008","September 12, 2014",,"January 11, 2017","Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, San Francisco, California, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Indianapolis, Indiana, United States|Novo Nordisk Investigational Site, Camden, New Jersey, United States|Novo Nordisk Investigational Site, Bronx, New York, United States|Novo Nordisk Investigational Site, Bronx, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Allentown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Toronto, Canada|Novo Nordisk Investigational Site, København ø, Denmark|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Lahr, Germany|Novo Nordisk Investigational Site, Mainz, Germany|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Middlesborough, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02239146"
739,"NCT01523392","A Pharmacodynamic Study With Ticagrelor in African American Patients",,"Completed","Has Results","Stable Coronary Artery Disease","Drug: Ticagrelor|Drug: Clopidogrel","Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose|Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 Hour and 8 Hours After Loading Dose|Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 Hours and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8|Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses|AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5130L00013","March 2012","September 2013","September 2013","February 1, 2012","September 26, 2014","October 8, 2014","Research Site, Newark, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Towson, Maryland, United States|Research Site, Beaumont, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01523392"
740,"NCT02885012","Crossover Study From Macitentan or Bosentan Over to Ambrisentan","Letairis","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Ambrisentan","Change in Stroke Volume|Change in EmPHasis-10 Score|Disease Status as Measured by Change in Biomarker","Medical University of South Carolina|Ochsner Health System","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00046009","June 2016","July 7, 2017","July 7, 2017","August 31, 2016","April 8, 2019","April 8, 2019","Ochsner Medical Center, New Orleans, Louisiana, United States|Medical University of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02885012/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02885012"
741,"NCT01076764","Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","TAO","Completed","No Results Available","Acute Coronary Syndrome","Drug: Otamixaban|Drug: Placebo (for Otamixaban)|Drug: UFH|Drug: Placebo (for UFH)|Drug: Eptifibatide|Drug: Placebo (for Eptifibatide)","Efficacy: Adjudicated double composite of all-cause of death and new myocardial infarction|Safety: Adjudicated Thrombolysis In Myocardial Infarction (TIMI) significant bleeding (composite of TIMI major and minor)|Adjudicated Triple efficacy composite of all-cause death, new myocardial infarction and any stroke|Rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction|Adjudicated all-cause death|Adjudicated Procedural thrombotic complications during the index PCI","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","13220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC6204|2009-016568-36","April 2010","May 2013","May 2013","February 26, 2010",,"May 4, 2016","Investigational Site Number 840015, Huntsville, Alabama, United States|Investigational Site Number 840569, Phoenix, Arizona, United States|Investigational Site Number 840703, Phoenix, Arizona, United States|Investigational Site Number 840101, Anaheim, California, United States|Investigational Site Number 840151, Anaheim, California, United States|Investigational Site Number 840213, Beverley Hills, California, United States|Investigational Site Number 840572, Huntington Beach, California, United States|Investigational Site Number 840201, Long Beach, California, United States|Investigational Site Number 840071, Los Angeles, California, United States|Investigational Site Number 840557, Los Angeles, California, United States|Investigational Site Number 840903, Northridge, California, United States|Investigational Site Number 840065, San Francisco, California, United States|Investigational Site Number 840561, Santa Rosa, California, United States|Investigational Site Number 840721, Littleton, Colorado, United States|Investigational Site Number 840551, Bridgeport, Connecticut, United States|Investigational Site Number 840166, New Haven, Connecticut, United States|Investigational Site Number 840520, Washington, District of Columbia, United States|Investigational Site Number 840185, Fort Lauderdale, Florida, United States|Investigational Site Number 840028, Jacksonville, Florida, United States|Investigational Site Number 840047, Lake Mary, Florida, United States|Investigational Site Number 840500, Melbourne, Florida, United States|Investigational Site Number 840706, Miami, Florida, United States|Investigational Site Number 840009, Ocala, Florida, United States|Investigational Site Number 840146, Ocala, Florida, United States|Investigational Site Number 840577, Orlando, Florida, United States|Investigational Site Number 840021, Sarasota, Florida, United States|Investigational Site Number 840902, St. Petersburg, Florida, United States|Investigational Site Number 840508, Tampa, Florida, United States|Investigational Site Number 840719, Gainesville, Georgia, United States|Investigational Site Number 840532, Boise, Idaho, United States|Investigational Site Number 840105, Aurora, Illinois, United States|Investigational Site Number 840190, Chicago, Illinois, United States|Investigational Site Number 840205, Chicago, Illinois, United States|Investigational Site Number 840521, Harvey, Illinois, United States|Investigational Site Number 840148, Joliet, Illinois, United States|Investigational Site Number 840042, Hammond, Indiana, United States|Investigational Site Number 840554, Indianapolis, Indiana, United States|Investigational Site Number 840560, Muncie, Indiana, United States|Investigational Site Number 840904, Ames, Iowa, United States|Investigational Site Number 840058, West Des Moines, Iowa, United States|Investigational Site Number 840912, Overland, Kansas, United States|Investigational Site Number 840568, Louisville, Kentucky, United States|Investigational Site Number 840534, Alexandria, Louisiana, United States|Investigational Site Number 840564, Lake Charles, Louisiana, United States|Investigational Site Number 840533, New Orleans, Louisiana, United States|Investigational Site Number 840517, Dearborn, Michigan, United States|Investigational Site Number 840544, Kalamazoo, Michigan, United States|Investigational Site Number 840531, Saginaw, Michigan, United States|Investigational Site Number 840525, Minneapolis, Minnesota, United States|Investigational Site Number 840510, Minneapolis, Minnesota, United States|Investigational Site Number 840527, Tupelo, Mississippi, United States|Investigational Site Number 840208, Bridgeton, Missouri, United States|Investigational Site Number 840209, Independence, Missouri, United States|Investigational Site Number 840194, Kansas City, Missouri, United States|Investigational Site Number 840138, Kansas City, Missouri, United States|Investigational Site Number 840056, Kansas City, Missouri, United States|Investigational Site Number 840530, St Louis, Missouri, United States|Investigational Site Number 840580, St Louis, Missouri, United States|Investigational Site Number 840210, St. Louis, Missouri, United States|Investigational Site Number 840052, St. Louis, Missouri, United States|Investigational Site Number 840529, Kalispell, Montana, United States|Investigational Site Number 840059, Omaha, Nebraska, United States|Investigational Site Number 840727, Omaha, Nebraska, United States|Investigational Site Number 840079, Omaha, Nebraska, United States|Investigational Site Number 840157, Reno, Nevada, United States|Investigational Site Number 840518, Brooklyn, New York, United States|Investigational Site Number 840539, New York, New York, United States|Investigational Site Number 840585, Charlotte, North Carolina, United States|Investigational Site Number 840515, Greenville, North Carolina, United States|Investigational Site Number 840566, Raleigh, North Carolina, United States|Investigational Site Number 840908, Winston Salem, North Carolina, United States|Investigational Site Number 840136, Minot, North Dakota, United States|Investigational Site Number 840082, Toledo, Ohio, United States|Investigational Site Number 840025, Midwest City, Oklahoma, United States|Investigational Site Number 840049, Oklahoma City, Oklahoma, United States|Investigational Site Number 840905, Oklahoma City, Oklahoma, United States|Investigational Site Number 840193, Oklahoma City, Oklahoma, United States|Investigational Site Number 840901, Tulsa, Oklahoma, United States|Investigational Site Number 840206, Eugene, Oregon, United States|Investigational Site Number 840540, Chambersburg, Pennsylvania, United States|Investigational Site Number 840519, Doylestown, Pennsylvania, United States|Investigational Site Number 840003, Erie, Pennsylvania, United States|Investigational Site Number 840098, Harrisburg, Pennsylvania, United States|Investigational Site Number 840573, Philadelphia, Pennsylvania, United States|Investigational Site Number 840075, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840911, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840211, Washington, Pennsylvania, United States|Investigational Site Number 840072, Oak Ridge, Tennessee, United States|Investigational Site Number 840023, Amarillo, Texas, United States|Investigational Site Number 840203, Austin, Texas, United States|Investigational Site Number 840574, Austin, Texas, United States|Investigational Site Number 840060, Dallas, Texas, United States|Investigational Site Number 840578, Dallas, Texas, United States|Investigational Site Number 840715, Fort Worth, Texas, United States|Investigational Site Number 840090, Houston, Texas, United States|Investigational Site Number 840207, Houston, Texas, United States|Investigational Site Number 840559, Houston, Texas, United States|Investigational Site Number 840586, Houston, Texas, United States|Investigational Site Number 840087, Tyler, Texas, United States|Investigational Site Number 840910, Victoria, Texas, United States|Investigational Site Number 840555, Wichita Falls, Texas, United States|Investigational Site Number 840553, Richmond, Virginia, United States|Investigational Site Number 840188, Richmond, Virginia, United States|Investigational Site Number 840165, Salem, Virginia, United States|Investigational Site Number 840565, Winchester, Virginia, United States|Investigational Site Number 840121, Tacoma, Washington, United States|Investigational Site Number 840513, Manitowoc, Wisconsin, United States|Investigational Site Number 032048, Adrogue, Argentina|Investigational Site Number 032013, Avellaneda, Argentina|Investigational Site Number 032046, Buenos Aires, Argentina|Investigational Site Number 032043, Buenos Aires, Argentina|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032032, Buenos Aires, Argentina|Investigational Site Number 032014, Caba, Argentina|Investigational Site Number 032007, Capital Federal, Argentina|Investigational Site Number 032039, Capital Federal, Argentina|Investigational Site Number 032045, Capital Federal, Argentina|Investigational Site Number 032029, Ciudad Autonoma De Bs.As, Argentina|Investigational Site Number 032036, Ciudad De Buenos Aires, Argentina|Investigational Site Number 032044, Cordoba, Argentina|Investigational Site Number 032010, Cordoba, Argentina|Investigational Site Number 032001, Corrientes, Argentina|Investigational Site Number 032035, Florencio Varela, Argentina|Investigational Site Number 032018, La Plata, Argentina|Investigational Site Number 032027, La Plata, Argentina|Investigational Site Number 032020, Mendoza, Argentina|Investigational Site Number 032033, Olivos, Argentina|Investigational Site Number 032022, Pilar, Argentina|Investigational Site Number 032023, Resistencia, Argentina|Investigational Site Number 032002, Resistencia, Argentina|Investigational Site Number 032004, Rosario, Argentina|Investigational Site Number 032005, Rosario, Argentina|Investigational Site Number 032021, Rosario, Argentina|Investigational Site Number 032028, Rosario, Argentina|Investigational Site Number 032040, Rosario, Argentina|Investigational Site Number 032025, San Luis, Argentina|Investigational Site Number 032024, San Martin, Argentina|Investigational Site Number 032008, San Miguel De Tucuman, Argentina|Investigational Site Number 032041, Santa Fe, Argentina|Investigational Site Number 032006, Santa Fe, Argentina|Investigational Site Number 036008, Adelaide, Australia|Investigational Site Number 036004, Ballarat, Australia|Investigational Site Number 036010, Concord, Australia|Investigational Site Number 036001, Herston, Australia|Investigational Site Number 036913, Hobart, Australia|Investigational Site Number 036011, Liverpool, Australia|Investigational Site Number 036003, Prahran, Australia|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 112004, Gomel, Belarus|Investigational Site Number 112003, Minsk, Belarus|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056001, Bonheiden, Belgium|Investigational Site Number 056007, Brugge, Belgium|Investigational Site Number 056003, Brussels, Belgium|Investigational Site Number 056006, Haine-Saint-Paul, Belgium|Investigational Site Number 056008, Leuven, Belgium|Investigational Site Number 076025, Campinas, Brazil|Investigational Site Number 076011, Fortaleza, Brazil|Investigational Site Number 076015, Marilia, Brazil|Investigational Site Number 076016, Maringa, Brazil|Investigational Site Number 076013, Passo Fundo, Brazil|Investigational Site Number 076009, Porto Alegre, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076022, Porto Alegre, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076023, Recife, Brazil|Investigational Site Number 076030, Recife, Brazil|Investigational Site Number 076027, Rio De Janeiro, Brazil|Investigational Site Number 076029, Salvador, Brazil|Investigational Site Number 076014, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076002, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076012, Sao Paulo, Brazil|Investigational Site Number 076020, Sao Paulo, Brazil|Investigational Site Number 076007, Sao Paulo, Brazil|Investigational Site Number 076008, Uberlandia, Brazil|Investigational Site Number 076024, Votuporanga, Brazil|Investigational Site Number 100511, Blagoevgrad, Bulgaria|Investigational Site Number 100508, Kazanlak, Bulgaria|Investigational Site Number 100512, Pazardjik, Bulgaria|Investigational Site Number 100505, Pleven, Bulgaria|Investigational Site Number 100509, Ruse, Bulgaria|Investigational Site Number 100510, Sandanski, Bulgaria|Investigational Site Number 100501, Sofia, Bulgaria|Investigational Site Number 100502, Sofia, Bulgaria|Investigational Site Number 100503, Sofia, Bulgaria|Investigational Site Number 100507, Varna, Bulgaria|Investigational Site Number 100504, Veliko Tarnovo, Bulgaria|Investigational Site Number 100506, Yambol, Bulgaria|Investigational Site Number 124005, Gatineau, Canada|Investigational Site Number 124006, Hamilton, Canada|Investigational Site Number 124004, Montreal, Canada|Investigational Site Number 124001, Quebec, Canada|Investigational Site Number 124007, Sherbrooke, Canada|Investigational Site Number 124009, St. John, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 152003, Antofagasta, Chile|Investigational Site Number 152906, Concepcion, Chile|Investigational Site Number 152005, Iquique, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152902, Santiago, Chile|Investigational Site Number 152901, Santiago, Chile|Investigational Site Number 152903, Santiago, Chile|Investigational Site Number 152010, Santiago, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152011, Talcahuano, Chile|Investigational Site Number 152908, Temuco, Chile|Investigational Site Number 152913, Temuco, Chile|Investigational Site Number 152016, Valdivia, Chile|Investigational Site Number 152912, Valparaíso, Chile|Investigational Site Number 152907, Vina Del Mar, Chile|Investigational Site Number 152910, Viña Del Mar, Chile|Investigational Site Number 170016, Barranquilla, Colombia|Investigational Site Number 170009, Bogota, Colombia|Investigational Site Number 170011, Bogotá, Colombia|Investigational Site Number 170002, Bucaramanga, Colombia|Investigational Site Number 170012, Cali, Colombia|Investigational Site Number 170001, Medellin, Colombia|Investigational Site Number 170003, Medellin, Colombia|Investigational Site Number 170017, Medellin, Colombia|Investigational Site Number 191502, Slavonski Brod, Croatia|Investigational Site Number 191503, Zagreb, Croatia|Investigational Site Number 191505, Zagreb, Croatia|Investigational Site Number 191506, Zagreb, Croatia|Investigational Site Number 203005, Brno, Czech Republic|Investigational Site Number 203903, Hradec Kralove, Czech Republic|Investigational Site Number 203902, Liberec, Czech Republic|Investigational Site Number 203009, Olomouc, Czech Republic|Investigational Site Number 203010, Ostrava - Poruba, Czech Republic|Investigational Site Number 203001, Praha 10, Czech Republic|Investigational Site Number 203901, Praha 2, Czech Republic|Investigational Site Number 203007, Praha 5, Czech Republic|Investigational Site Number 203003, Praha 5, Czech Republic|Investigational Site Number 203002, Usti Nad Labem, Czech Republic|Investigational Site Number 203006, Zlin, Czech Republic|Investigational Site Number 818504, Cairo, Egypt|Investigational Site Number 818501, Cairo, Egypt|Investigational Site Number 818502, Cairo, Egypt|Investigational Site Number 818503, Giza, Egypt|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233901, Tallinn, Estonia|Investigational Site Number 250016, Avignon Cedex 2, France|Investigational Site Number 250010, Bayonne, France|Investigational Site Number 250002, Belfort Cedex, France|Investigational Site Number 250001, Besancon, France|Investigational Site Number 250006, Creteil, France|Investigational Site Number 250003, Dijon Cedex, France|Investigational Site Number 250013, Le Chesnay Cedex, France|Investigational Site Number 250012, Montfermeil, France|Investigational Site Number 250005, Mulhouse, France|Investigational Site Number 250015, Mulhouse, France|Investigational Site Number 250009, Paris, France|Investigational Site Number 250011, Pau, France|Investigational Site Number 250007, Rouen, France|Investigational Site Number 250014, Strasbourg, France|Investigational Site Number 250008, Toulouse Cedex 9, France|Investigational Site Number 276022, Berlin, Germany|Investigational Site Number 276004, Berlin, Germany|Investigational Site Number 276024, Berlin, Germany|Investigational Site Number 276023, Bonn, Germany|Investigational Site Number 276006, Frankfurt Am Main, Germany|Investigational Site Number 276901, Freiburg, Germany|Investigational Site Number 276003, Hamburg, Germany|Investigational Site Number 276902, Hamburg, Germany|Investigational Site Number 276009, Heidelberg, Germany|Investigational Site Number 276904, Heidenheim, Germany|Investigational Site Number 276002, Kassel, Germany|Investigational Site Number 276013, Langen, Germany|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 276905, Mönchengladbach, Germany|Investigational Site Number 276005, München, Germany|Investigational Site Number 276018, Rostock, Germany|Investigational Site Number 300009, Alexandroupolis, Greece|Investigational Site Number 300004, Athens, Greece|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300011, Athens, Greece|Investigational Site Number 300007, Chios, Greece|Investigational Site Number 300008, Larissa, Greece|Investigational Site Number 300003, Melissia, Greece|Investigational Site Number 300005, N. Ionia, Greece|Investigational Site Number 300002, Patras, Greece|Investigational Site Number 300010, Thessaloniki, Greece|Investigational Site Number 300006, Thessaloniki, Greece|Investigational Site Number 344001, Chai Wan, Hong Kong|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348008, Budapest, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348009, Szeged, Hungary|Investigational Site Number 348007, Szekesfehervar, Hungary|Investigational Site Number 348001, Szolnok, Hungary|Investigational Site Number 348005, Szombathely, Hungary|Investigational Site Number 348006, Zalaegerszeg, Hungary|Investigational Site Number 356019, Ahmedabad, India|Investigational Site Number 356004, Ahmedabad, India|Investigational Site Number 356007, Ahmedabad, India|Investigational Site Number 356012, Allahabad, India|Investigational Site Number 356008, Bangalore, India|Investigational Site Number 356020, Chandigarh, India|Investigational Site Number 356029, Gurgaon, India|Investigational Site Number 356027, Gurgaon, India|Investigational Site Number 356040, Hyderabad, India|Investigational Site Number 356046, Hyderabad, India|Investigational Site Number 356014, Jaipur, India|Investigational Site Number 356003, Karamsad, India|Investigational Site Number 356037, Kochi, India|Investigational Site Number 356034, Kolkata, India|Investigational Site Number 356039, Madurai, India|Investigational Site Number 356018, Mangalore, India|Investigational Site Number 356021, Mumbai, India|Investigational Site Number 356016, Mumbai, India|Investigational Site Number 356031, Mumbai, India|Investigational Site Number 356032, Mumbai, India|Investigational Site Number 356011, Mysore, India|Investigational Site Number 356022, Nagpur, India|Investigational Site Number 356035, Nagpur, India|Investigational Site Number 356023, Nagpur, India|Investigational Site Number 356036, Nashik, India|Investigational Site Number 356025, New Delhi, India|Investigational Site Number 356001, New Delhi, India|Investigational Site Number 356026, New Delhi, India|Investigational Site Number 356010, Pune, India|Investigational Site Number 356033, Pune, India|Investigational Site Number 356024, Secunderabad, India|Investigational Site Number 356002, Varanasi, India|Investigational Site Number 356044, Vijaywada, India|Investigational Site Number 360505, Bandung, Indonesia|Investigational Site Number 360501, Depok, Indonesia|Investigational Site Number 360506, Jakarta, Indonesia|Investigational Site Number 360503, Jakarta, Indonesia|Investigational Site Number 360502, Jakarta, Indonesia|Investigational Site Number 376005, Afula, Israel|Investigational Site Number 376003, Ashkelon, Israel|Investigational Site Number 376011, Hadera, Israel|Investigational Site Number 376004, Haifa, Israel|Investigational Site Number 376009, Haifa, Israel|Investigational Site Number 376010, Holon, Israel|Investigational Site Number 376002, Jerusalem, Israel|Investigational Site Number 376013, Jerusalem, Israel|Investigational Site Number 376007, Safed, Israel|Investigational Site Number 376008, Tel Aviv, Israel|Investigational Site Number 376001, Tel Hashomer, Israel|Investigational Site Number 376012, Tzrifin, Israel|Investigational Site Number 380902, Bergamo, Italy|Investigational Site Number 380918, Bologna, Italy|Investigational Site Number 380904, Brescia, Italy|Investigational Site Number 380928, Brescia, Italy|Investigational Site Number 380929, Castellanza, Italy|Investigational Site Number 380930, Catania, Italy|Investigational Site Number 380912, Catania, Italy|Investigational Site Number 380932, Cittadella, Italy|Investigational Site Number 380926, Conegliano, Italy|Investigational Site Number 380909, Empoli, Italy|Investigational Site Number 380924, Forlì, Italy|Investigational Site Number 380908, Livorno, Italy|Investigational Site Number 380923, Massa, Italy|Investigational Site Number 380935, Massa, Italy|Investigational Site Number 380933, Messina, Italy|Investigational Site Number 380910, Milano, Italy|Investigational Site Number 380905, Modena, Italy|Investigational Site Number 380936, Napoli, Italy|Investigational Site Number 380901, Perugia, Italy|Investigational Site Number 380907, Pescara, Italy|Investigational Site Number 380919, Pordenone, Italy|Investigational Site Number 380916, Reggio Emilia, Italy|Investigational Site Number 380931, Roma, Italy|Investigational Site Number 380917, Roma, Italy|Investigational Site Number 380927, Rovigo, Italy|Investigational Site Number 380921, Rozzano, Italy|Investigational Site Number 380914, Seriate, Italy|Investigational Site Number 380925, Treviso, Italy|Investigational Site Number 400501, Amman, Jordan|Investigational Site Number 400502, Irbid, Jordan|Investigational Site Number 410005, Busan, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410002, Daegu, Korea, Republic of|Investigational Site Number 410014, Daegu, Korea, Republic of|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410004, Goyang, Korea, Republic of|Investigational Site Number 410018, Guri, Korea, Republic of|Investigational Site Number 410016, Gwangju, Korea, Republic of|Investigational Site Number 410007, Seongnam, Korea, Republic of|Investigational Site Number 410008, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410011, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410009, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410013, Suwon, Korea, Republic of|Investigational Site Number 410015, Wonju, Korea, Republic of|Investigational Site Number 428004, Daugavpils, Latvia|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 428003, Riga, Latvia|Investigational Site Number 422502, Beirut, Lebanon|Investigational Site Number 422505, Beirut, Lebanon|Investigational Site Number 440003, Kaunas, Lithuania|Investigational Site Number 440001, Siauliai, Lithuania|Investigational Site Number 440904, Vilnius, Lithuania|Investigational Site Number 807501, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 458001, Kuching, Malaysia|Investigational Site Number 484009, Aguascalientes, Mexico|Investigational Site Number 484907, Aguascalientes, Mexico|Investigational Site Number 484902, Guadalajara, Mexico|Investigational Site Number 484015, Guadalajara, Mexico|Investigational Site Number 484901, Guadalajara, Mexico|Investigational Site Number 484019, Merida, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484004, Monterrey, Mexico|Investigational Site Number 484910, Morelia, Michoacan, Mexico|Investigational Site Number 484914, México Df, Mexico|Investigational Site Number 484020, Puebla, Mexico|Investigational Site Number 484017, Queretaro, Mexico|Investigational Site Number 484012, San Luis Potosi, Mexico|Investigational Site Number 484911, San Luis Potosi, Mexico|Investigational Site Number 484013, Xalapa, Mexico|Investigational Site Number 499501, Podgorica, Montenegro|Investigational Site Number 528003, Alkmaar, Netherlands|Investigational Site Number 528005, Arnhem, Netherlands|Investigational Site Number 528007, Leeuwarden, Netherlands|Investigational Site Number 528004, Nieuwegein, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 554004, Auckland, New Zealand|Investigational Site Number 554001, Hamilton, New Zealand|Investigational Site Number 554002, Nelson, New Zealand|Investigational Site Number 578903, Arendal, Norway|Investigational Site Number 578901, Bergen, Norway|Investigational Site Number 578902, Stavanger, Norway|Investigational Site Number 591504, Panama, Panama|Investigational Site Number 591502, Panamá, Panama|Investigational Site Number 604005, Lambayeque, Peru|Investigational Site Number 604002, Lima, Peru|Investigational Site Number 604011, Lima, Peru|Investigational Site Number 604014, Lima, Peru|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 604017, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 616005, Bialystok, Poland|Investigational Site Number 616038, Bialystok, Poland|Investigational Site Number 616017, Bydgoszcz, Poland|Investigational Site Number 616009, Bytom, Poland|Investigational Site Number 616040, Elblag, Poland|Investigational Site Number 616027, Elk, Poland|Investigational Site Number 616023, Gdansk, Poland|Investigational Site Number 616032, Jelenia Gora, Poland|Investigational Site Number 616037, Katowice, Poland|Investigational Site Number 616046, Katowice, Poland|Investigational Site Number 616034, Klodzko, Poland|Investigational Site Number 616045, Krakow, Poland|Investigational Site Number 616002, Krakow, Poland|Investigational Site Number 616029, Lodz, Poland|Investigational Site Number 616004, Lomza, Poland|Investigational Site Number 616024, Lubin, Poland|Investigational Site Number 616041, Lublin, Poland|Investigational Site Number 616016, Ostroleka, Poland|Investigational Site Number 616003, Radom, Poland|Investigational Site Number 616047, Radom, Poland|Investigational Site Number 616033, Rybnik, Poland|Investigational Site Number 616019, Tarnów, Poland|Investigational Site Number 616022, Torun, Poland|Investigational Site Number 616018, Walbrzych, Poland|Investigational Site Number 616014, Warszawa, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 616031, Wloclawek, Poland|Investigational Site Number 616015, Wroclaw, Poland|Investigational Site Number 616020, Zamosc, Poland|Investigational Site Number 620010, Almada, Portugal|Investigational Site Number 620006, Amadora, Portugal|Investigational Site Number 620001, Coimbra, Portugal|Investigational Site Number 620002, Coimbra, Portugal|Investigational Site Number 620003, Lisboa, Portugal|Investigational Site Number 620015, Ponta Delgada, Portugal|Investigational Site Number 620004, Setúbal, Portugal|Investigational Site Number 620011, Évora, Portugal|Investigational Site Number 642002, Brasov, Romania|Investigational Site Number 642004, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642005, Cluj Napoca, Romania|Investigational Site Number 642003, Targu-Mures, Romania|Investigational Site Number 643018, Barnaul, Russian Federation|Investigational Site Number 643015, Ekaterinburg, Russian Federation|Investigational Site Number 643011, Kemerovo, Russian Federation|Investigational Site Number 643014, Krasnodar, Russian Federation|Investigational Site Number 643021, Krasnoyarsk, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643016, Nizniy Novgorod, Russian Federation|Investigational Site Number 643024, Novosibirsk, Russian Federation|Investigational Site Number 643008, Saint-Peterburg, Russian Federation|Investigational Site Number 643019, Saint-Petersburg, Russian Federation|Investigational Site Number 643013, Samara, Russian Federation|Investigational Site Number 643006, St-Petersburg, Russian Federation|Investigational Site Number 643025, St-Petersburg, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643012, Tomsk, Russian Federation|Investigational Site Number 643023, Volgograd, Russian Federation|Investigational Site Number 643017, Yaroslavl, Russian Federation|Investigational Site Number 688505, Belgrade, Serbia|Investigational Site Number 688501, Kragujevac, Serbia|Investigational Site Number 688503, Nis, Serbia|Investigational Site Number 688502, Sremska Kamenica, Serbia|Investigational Site Number 688504, Zemun, Serbia|Investigational Site Number 688506, Zemun, Serbia|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 703003, Banska Bystrica, Slovakia|Investigational Site Number 703002, Martin, Slovakia|Investigational Site Number 703001, Nitra, Slovakia|Investigational Site Number 710004, Alberton, South Africa|Investigational Site Number 710005, Cape Town, South Africa|Investigational Site Number 710001, Cape Town, South Africa|Investigational Site Number 710003, Centurion, South Africa|Investigational Site Number 710002, Kuils River, South Africa|Investigational Site Number 710007, Pretoria, South Africa|Investigational Site Number 724013, Alcorcón, Spain|Investigational Site Number 724001, Alicante, Spain|Investigational Site Number 724014, Badalona, Spain|Investigational Site Number 724022, Barcelona, Spain|Investigational Site Number 724021, Barcelona, Spain|Investigational Site Number 724025, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724901, Barcelona, Spain|Investigational Site Number 724007, Cáceres, Spain|Investigational Site Number 724026, Elche, Spain|Investigational Site Number 724016, Galdakao, Spain|Investigational Site Number 724023, Girona, Spain|Investigational Site Number 724006, La Laguna, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724902, Madrid, Spain|Investigational Site Number 724027, Madrid, Spain|Investigational Site Number 724904, Murcia, Spain|Investigational Site Number 724017, Málaga, Spain|Investigational Site Number 724018, San Juan De Alicante, Spain|Investigational Site Number 724005, Santander, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724903, Terrassa, Spain|Investigational Site Number 724010, Torrevieja, Spain|Investigational Site Number 724024, Valencia, Spain|Investigational Site Number 756001, Lugano, Switzerland|Investigational Site Number 756002, Zürich, Switzerland|Investigational Site Number 158007, Kaohsiung, Taiwan|Investigational Site Number 158002, Kaohsiung, Taiwan|Investigational Site Number 158003, Linkou, Taiwan|Investigational Site Number 158008, Taichung, Taiwan|Investigational Site Number 158904, Taipei, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158009, Taipei, Taiwan|Investigational Site Number 764002, Bangkok, Thailand|Investigational Site Number 764901, Bangkok, Thailand|Investigational Site Number 764005, Bangkok, Thailand|Investigational Site Number 764004, Khon Kaen, Thailand|Investigational Site Number 764007, Klong Luang, Thailand|Investigational Site Number 764903, Muang, Thailand|Investigational Site Number 764006, Rajathavee, Thailand|Investigational Site Number 788002, Ariana, Tunisia|Investigational Site Number 788005, Monastir, Tunisia|Investigational Site Number 788006, Monastir, Tunisia|Investigational Site Number 788001, Tunis, Tunisia|Investigational Site Number 788004, Tunis, Tunisia|Investigational Site Number 792010, Adana, Turkey|Investigational Site Number 792023, Ankara, Turkey|Investigational Site Number 792009, Antalya, Turkey|Investigational Site Number 792008, Bursa, Turkey|Investigational Site Number 792022, Bursa, Turkey|Investigational Site Number 792030, Edirne, Turkey|Investigational Site Number 792006, Erzurum, Turkey|Investigational Site Number 792020, Eskisehir, Turkey|Investigational Site Number 792004, Gaziantep, Turkey|Investigational Site Number 792018, Istanbul, Turkey|Investigational Site Number 792032, Istanbul, Turkey|Investigational Site Number 792028, Istanbul, Turkey|Investigational Site Number 792016, Istanbul, Turkey|Investigational Site Number 792029, Istanbul, Turkey|Investigational Site Number 792011, Izmir, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792012, Kayseri, Turkey|Investigational Site Number 792014, Kocaeli, Turkey|Investigational Site Number 792015, Konya, Turkey|Investigational Site Number 792025, Malatya, Turkey|Investigational Site Number 792019, Mersin, Turkey|Investigational Site Number 792021, Samsun, Turkey|Investigational Site Number 792026, Sivas, Turkey|Investigational Site Number 804004, Cherkasy, Ukraine|Investigational Site Number 804001, Kharkiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804003, Zaporozhie, Ukraine|Investigational Site Number 826008, Bournemouth, United Kingdom|Investigational Site Number 826007, Bradford, United Kingdom|Investigational Site Number 826001, Craigavon, United Kingdom|Investigational Site Number 826005, East Kilbride, United Kingdom|Investigational Site Number 826002, Hull, United Kingdom|Investigational Site Number 826006, Manchester, United Kingdom|Investigational Site Number 826003, St Leonards, United Kingdom|Investigational Site Number 704006, Hanoi, Vietnam|Investigational Site Number 704001, Ho Chi Minh City, Vietnam|Investigational Site Number 704003, Ho Chi Minh City, Vietnam|Investigational Site Number 704004, Ho Chi Minh City, Vietnam|Investigational Site Number 704005, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT01076764"
742,"NCT01966302","Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: BPS-314d-MR","Number of participants experiencing Adverse Events","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Lung Biotechnology PBC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Compassionate use BPS-314d-MR","November 2013","June 2, 2019","June 2, 2019","October 21, 2013",,"June 19, 2019","Los Angeles Biomedical research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT01966302"
743,"NCT02070991","Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction","MELODY-1","Completed","Has Results","Pulmonary Hypertension","Drug: Macitentan|Drug: Placebo","Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment|NT-proBNP at Week 12 Expressed as Percent of Baseline NT-proBNP at Rest|PVR at Rest at Week 12 Expressed as Percent of Baseline PVR at Rest|Change From Baseline to Week 12 in Mean Pulmonary Arterial Pressure (mPAP)|Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP)|Change From Baseline to Week 12 in Pulmonary Artery Wedge Pressure (PAWP)|Change From Baseline to Week 12 in Cardiac Index (CI)|Change From Baseline to Week 12 in Diastolic Pulmonary Vascular Pressure Gradient (DPG)","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-055G201","July 1, 2014","November 1, 2015","November 1, 2015","February 25, 2014","May 15, 2019","May 15, 2019","Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan Internal Medicine Cardiology, Pulmonary Hypertension Program, Ann Arbor, Michigan, United States|Washington University School of Medicine - Center for Advanced Med, Saint Louis, Missouri, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Houston Methodist Hospital - Heart Failure/Pulm Hypertension, Houston, Texas, United States|Krankenhaus der Elisabethinen Linz, 2. Interne Abteilung, Linz, Austria|Medical University of Vienna and AKH Cardiology, Vienna, Austria|Hôpital Erasme, Cliniques Universitaires de Bruxelles, Cardiologie, Brussels, Belgium|University Hospital Gasthuisberg / Interne Geneeskunde - I.G. Pneumologie, Leuven, Belgium|Vancouver General Hospital - The Lung, Vancouver, Canada|FN Brno-Bohunice, I. interní kardiologická klinika, Brno, Czechia|FN Olomouc, 1. Interní klinika - kardiologická, Olomouc, Czechia|IKEM (Institut klinické a experimentální medicíny, Institute for Clinical and Experimental Medicine), Praha, Czechia|Lékařská fakulta a Všeobecná fakultní nemocnice v Praze, II. Interní klinika kardiologie a angiologie, Praha, Czechia|Hôpital Charles Nicolle Service de Cardiologie, Rouen cedex, France|DRK Klinken Berlin Kopenick Klinik für Innere Medizin Kardiologie, Berlin, Germany|Universitätsklinik Schleswig-Holstein Campus Kiel Klinik für Innere Medizin III Kardiologie und Angiologie, Kiel, Germany|Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin), Köln, Germany|Klinikum der Universität München Medizinische Klinik und Poliklinik 1 - Großhadern Schwerpunkt Pneumologie, Munich, Germany|Carmel Medical Center, Pulmonary Unit, Haifa, Israel|Institute of Pulmonology Hadassah Medical Centre : Ein Karem, Jerusalem, Israel|Kaplan Medical Centre / Pulmonary Institute and Department of Medicine, Rehovot, Israel|The Chaim Sheba Medical Center / The Institute of Pulmonology, Physiology and Exercise, Tel-Hashomer, Israel|A.O. Universitaria Policlinico S. Orsola-Malpighi - Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Unità Operativa di Cardiologia, Bologna, Italy|Ospedali Riuniti Di Trieste, Trieste, Italy|Hospital Vall d´Hebron Servicio de Cardiologia, Barcelona, Spain|Hospital Clinic Servicio de Cardiologia, Barcelona, Spain|Hospital Reina Sofia Servicio de Cardiologia, Cordoba, Spain|Hospital Universitario 12 Octubre Servicio de Cardiología, Madrid, Spain|Universitätsklinik für Kardiologie Schweizer Herz- und Gefässzentrum Bern, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois Service de Cardiologie, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT02070991"
744,"NCT03536767","Open-Label Study of AG10 in Patients With Cardiomyopathy",,"Enrolling by invitation","No Results Available","Amyloid Cardiomyopathy","Drug: AG10","Assessment of long-term safety and tolerability: Incidence of each treatment-emergent adverse events|AG10 Pharmacokinetics AUC|AG10 Pharmacodynamic Assessments of TTR stabilization by Fluorescent Polarization Exclusion Assay|AG10 Pharmacodynamic Assessments of TTR stabilization by Western Blot|AG10 Pharmacodynamic Assessments: prealbumin","Eidos Therapeutics","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG10-202","August 8, 2018","July 2023","July 2023","May 25, 2018",,"November 18, 2019","Stanford University, Palo Alto, California, United States|University of California San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03536767"
745,"NCT01107912","Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease","GENERATIONS","Completed","Has Results","Coronary Artery Disease","Drug: prasugrel|Drug: clopidogrel","Change in Maximum Platelet Aggregation (MPA) to 20 Micromoles (μM) Adenosine Diphosphate (ADP) as Measured by Light Transmission Aggregometry (LTA) From Baseline to 12 Days of Therapy in the First Treatment Period|Change in Vasodilator-associated Stimulated Phosphoprotein (VASP) From Baseline to 12 Days of Therapy|Change in VerifyNow P2Y12 Reaction Units (PRU) From Baseline to 12 Days of Therapy|Active Metabolite Blood Levels to Drug Exposure as Measured by Pharmacokinetics (PK) Through 4 Hours After Dosing|Change From Baseline in Maximum Platelet Aggregation (MPA) as Measured by Light Transmission Aggregometry (LTA) From Baseline at Day 12 of Therapy","Eli Lilly and Company|Daiichi Sankyo Co., Ltd.","All","45 Years and older   (Adult, Older Adult)","Phase 1","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12835|H7T-MC-TACY","March 2010","October 2011","October 2011","April 21, 2010","October 26, 2012","October 26, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nieuwegein, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Malmo, Sweden",,"https://ClinicalTrials.gov/show/NCT01107912"
746,"NCT02666742","Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation","STROKE-VT","Terminated","No Results Available","Ventricular Tachycardia","Drug: Apixaban|Drug: Aspirin","Incidence of asymptomatic or symptomatic cerebrovascular embolic and systemic thromboembolic events|Incidence of major periprocedural bleeding|Incidence of minor periprocedural bleeding|All cause mortality","Kansas City Heart Rhythm Institute|Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","4","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STUDY00003241|CV185-415","February 16, 2017","May 1, 2018","May 1, 2018","January 28, 2016",,"May 2, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02666742"
747,"NCT00839007","Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure",,"Completed","No Results Available","Acute Decompensated Heart Failure","Drug: CD-NP","The occurence of hypotensive events, clinical symptoms, and renal function change with CD-NP infusion.","Nile Therapeutics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NIL-CDNP-CT005","June 2009","June 2010","July 2010","February 9, 2009",,"September 17, 2010","Los Angeles, California, United States|Torrance, California, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Bronx, New York, United States|Houston, Texas, United States|Berlin, Germany|Berlin, Germany|Dortmund, Germany|Neuss, Germany|Wuerzberg, Germany|Ashkelon, Israel|Haifa, Israel|Nazareth, Israel|Petach-Tikva, Israel|Safed, Israel|Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00839007"
748,"NCT03384966","A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease",,"Completed","No Results Available","Stable Coronary Artery Disease","Drug: ACT-246475|Drug: Placebo","Inhibition of platelet aggregation|Maximum plasma concentration - Cmax|Time to reach maximum plasma concentration - tmax|Area under the plasma concentration-time curve from time zero to 24 h time point - AUC0-24","Idorsia Pharmaceuticals Ltd.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ID-076A201","February 7, 2018","August 18, 2018","September 18, 2018","December 28, 2017",,"December 24, 2019","University of Florida (UF) Jacksonville, Jacksonville, Florida, United States|Florida Hospital Tampa - Pepin Heart Institute, Tampa, Florida, United States|NorthShore University, Chicago, Illinois, United States|Indiana University School of Medicine - Krannert Institute of Cardiology, Indianapolis, Indiana, United States|Inova Cardiology, Lutherville, Maryland, United States|MOUNT SINAI HOSPITAL (New York), New York, New York, United States|Inova Center For Thrombosis Research and Translational Medic, Falls Church, Virginia, United States|Institut de Cardiologie de Montréal, Montréal, Quebec, Canada|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|University Medical Center Groningen, Groningen, Netherlands|Maastricht UMC, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|National Heart Centre Singapore, Singapore, Singapore|Sahlgrenska University Hospital, Göteborg, Sweden|Uppsala University Hospital, Uppsala, Sweden|Freeman Hospital - Cardiothoracic Dept, Newcastle Upon Tyne, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom|East & North Hertfordshire NHS Trust - Lister Hospital, Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03384966"
749,"NCT01390181","The Effect of Losartan in Bicuspid Aortic Valve Patients",,"Terminated","Has Results","Bicuspid Aortic Valve|Thoracic Aortic Aneurysm","Drug: Cozaar","Inflammatory Markers Levels","University of Michigan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00048364","September 2011","January 2014","January 2014","July 8, 2011","April 14, 2017","April 14, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01390181"
750,"NCT01951625","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)",,"Completed","No Results Available","Heart Failure","Drug: Vericiguat (BAY1021189) (1.25 mg)|Drug: Vericiguat (BAY1021189) (5 mg)|Drug: Placebo","Change in log-transformed N-terminal pro-brain natriuretic peptide (NT-proBNP)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","456","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15371|2013-002287-11","November 2013","May 2015","June 2015","September 26, 2013",,"October 17, 2016","Fountain Valley, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Wilmington, Delaware, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Naples, Florida, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Jackson, Mississippi, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Buffalo, New York, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Burlington, Vermont, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Hobart, Tasmania, Australia|Prahran, Victoria, Australia|St. Pölten, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Salzburg, Austria|Wien, Austria|Brugge, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Gilly, Belgium|Hasselt, Belgium|HUY, Belgium|Ieper, Belgium|Mechelen, Belgium|MOL, Belgium|Roeselare, Belgium|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brampton, Ontario, Canada|Cambridge, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jean-sur-Richelieu, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Hradec kralove, Czech Republic|Kromeriz, Czech Republic|Fakultni nemocnice Ostrava, Ostrava, Czech Republic|Praha 10, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 6, Czech Republic|Slany, Czech Republic|Aalborg, Denmark|Aarhus N, Denmark|Hellerup, Denmark|Vejle, Denmark|Viborg, Denmark|Brest, France|BRON Cedex, France|La Tronche, France|Lille Cedex, France|Paris Cedex 15, France|Pessac, France|Rouen, France|Bad Krozingen, Baden-Württemberg, Germany|München, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt, Hessen, Germany|Limburg, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Hamburg, Germany|Athens, Greece|Haidari, Greece|Nea Ionia, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Eger, Hungary|Hodmezovasarhely, Hungary|Jaszbereny, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Szekesfehervar, Hungary|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Tiberias, Israel|Zrifin, Israel|San Fermo della Battaglia, Como, Italy|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Arezzo, Toscana, Italy|Verona, Veneto, Italy|Seto, Aichi, Japan|Iizuka, Fukuoka, Japan|Shirakawa, Fukushima, Japan|Himeji, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Takamatsu, Kagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Sendai, Miyagi, Japan|Naha, Okinawa, Japan|Sakai, Osaka, Japan|Takatsuki, Osaka, Japan|Yao, Osaka, Japan|Ureshino, Saga, Japan|Shimada, Shizuoka, Japan|Komatsushima, Tokushima, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Fukui, Japan|Hiroshima, Japan|Kumamoto, Japan|Nagasaki, Japan|Tokushima, Japan|Toyama, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Apeldoorn, Netherlands|Deventer, Netherlands|Groningen, Netherlands|Heerenveen, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Sneek, Netherlands|Veldhoven, Netherlands|Weert, Netherlands|Bialystok, Poland|Katowice, Poland|Krakow, Poland|Legnica, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|L'Hospitalet de Llobregat, Barcelona, Spain|Santander, Cantabria, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Malmö, Sweden|Stockholm, Sweden|Örebro, Sweden|Liestal, Basel-Landschaft, Switzerland|Basel, Basel-Stadt, Switzerland|Bruderholz, Switzerland|Genève, Switzerland|Lugano, Switzerland|Zürich, Switzerland|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Chesterfield, Derbyshire, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Northampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01951625"
751,"NCT01951638","Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)",,"Completed","No Results Available","Heart Failure","Drug: Vericiguat (BAY1021189) (1.25 mg)|Drug: Vericiguat (BAY1021189) (5 mg)|Drug: Placebo","Change of log-transformed N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change of left atrial volume (LAV)|Number of participants with adverse events as a measure of safety and tolerability","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","477","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15829|2013-002288-25","November 2013","August 2015","September 2015","September 26, 2013",,"November 3, 2015","Fountain Valley, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Wilmington, Delaware, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Naples, Florida, United States|Atlanta, Georgia, United States|Macon, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Jackson, Mississippi, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Buffalo, New York, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Burlington, Vermont, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Hobart, Tasmania, Australia|Prahran, Victoria, Australia|St. Pölten, Niederösterreich, Austria|Linz, Oberösterreich, Austria|Linz, Oberösterreich, Austria|Graz, Steiermark, Austria|Salzburg, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Brugge, Belgium|Bruxelles - Brussel, Belgium|Edegem, Belgium|Gent, Belgium|Gilly, Belgium|Hasselt, Belgium|HUY, Belgium|Ieper, Belgium|Mechelen, Belgium|MOL, Belgium|Roeselare, Belgium|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brampton, Ontario, Canada|Cambridge, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jean-sur-Richelieu, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Hradec kralove, Czech Republic|Kromeriz, Czech Republic|Ostrava, Czech Republic|Praha 10, Czech Republic|Praha 2, Czech Republic|Praha 4, Czech Republic|Praha 6 - Stresovice, Czech Republic|Slany, Czech Republic|Aalborg, Denmark|Aarhus N, Denmark|Hellerup, Denmark|Holbaek, Denmark|Randers, Denmark|Vejle, Denmark|Viborg, Denmark|Brest, France|BRON Cedex, France|La Tronche, France|Lille Cedex, France|PARIS cedex 10, France|Paris Cedex 15, France|Pessac, France|Rouen, France|Toulouse, France|Bad Krozingen, Baden-Württemberg, Germany|München, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Hamburg, Germany|Athens, Attica, Greece|Haidari, Attica, Greece|Nea Ionia / Athens, Greece|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Eger, Hungary|Hodmezovasarhely, Hungary|Jaszbereny, Hungary|Kaposvar, Hungary|Kistarcsa, Hungary|Szekesfehervar, Hungary|Afula, Israel|Ashkelon, Israel|Hadera, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Tiberias, Israel|Zrifin, Israel|Cortona, Arezzo, Italy|San Fermo della Battaglia, Como, Italy|Rho, Milano, Italy|Legnago, Verona, Italy|Ancona, Italy|Bergamo, Italy|Brescia, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Pavia, Italy|Seto, Aichi, Japan|Toyota, Aichi, Japan|Iizuka, Fukuoka, Japan|Himeji, Hyogo, Japan|Higashiibaraki, Ibaraki, Japan|Kanazawa, Ishikawa, Japan|Takamatsu, Kagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Yokosuka, Kanagawa, Japan|Uji, Kyoto, Japan|Sendai, Miyagi, Japan|Naha, Okinawa, Japan|Sakai, Osaka, Japan|Takatsuki, Osaka, Japan|Yao, Osaka, Japan|Ureshino, Saga, Japan|Komatsushima, Tokushima, Japan|Meguro-ku, Tokyo, Japan|Minato-ku, Tokyo, Japan|Fukui, Japan|Gifu, Japan|Hiroshima, Japan|Kumamoto, Japan|Nagasaki, Japan|Osaka, Japan|Tokushima, Japan|Toyama, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Apeldoorn, Netherlands|Deventer, Netherlands|Groningen, Netherlands|Heerenveen, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Sneek, Netherlands|Veldhoven, Netherlands|Weert, Netherlands|Bialystok, Poland|Katowice, Poland|Krakow, Poland|Krakow, Poland|Legnica, Poland|Lodz, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Almada, Portugal|Lisboa, Portugal|Lisboa, Portugal|Lisboa, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|L'Hospitalet de Llobregat, Barcelona, Spain|Santander, Cantabria, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Valencia, Spain|Helsingborg, Sweden|Karlstad, Sweden|Linköping, Sweden|Malmö, Sweden|Stockholm, Sweden|Örebro, Sweden|Liestal, Basel-Landschaft, Switzerland|Basel, Basel-Stadt, Switzerland|Lugano, Ticino, Switzerland|Bruderholz, Switzerland|Genève, Switzerland|Zürich, Switzerland|Kaohsiung, Taiwan|New Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Chesterfield, Derbyshire, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Northampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01951638"
752,"NCT03860935","Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy","ATTRIBUTE-CM","Recruiting","No Results Available","Amyloidosis|Amyloid Cardiomyopathy|Transthyretin Amyloidosis|Cardiomyopathies|Heart Diseases","Drug: AG10|Drug: Placebo Oral Tablet","6 Minute Walk Test (6MWT) at Month 12|Total number of deaths due to all-cause and frequency of cardiovascular-related hospitalization|Kansas City Cardiomyopathy Questionnaire (KCCQ) at Month 12|6 Minute Walk Test (6MWT) at Month 30|Kansas City Cardiomyopathy Questionnaire (KCCQ) at Month 30|Incidence of treatment-emergent events|AG10 Pharmacodynamic Assessments of TTR stabilization by Fluorescent Probe Exclusion Assay at Day 28|AG10 Pharmacodynamic Assessments of TTR stabilization by Fluorescent Probe Exclusion Assay through Month 30|AG10 Pharmacodynamic Assessments of TTR stabilization by Western Blot at Day 28|AG10 Pharmacodynamic Assessments of TTR stabilization by Western Blot through Month 30|All-cause mortality|Frequency of cardiovascular-related hospitalization|Cardiovascular-related mortality","Eidos Therapeutics","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","510","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG10-301|2018-004280-32","March 19, 2019","April 2023","May 2023","March 4, 2019",,"April 6, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Emory Heart and Vascular Center, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Luke's Hospital - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|New York University Langone Health, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Laurelton Heart Specialist, Rosedale, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Saint Thomas Heart - Saint Thomas West Hospital, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Carilion Clinic Roanoke Heart Institute, Roanoke, Virginia, United States|University of Washington School of Medicine, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Royal Adelaide Hospital, Adelaide, Australia|Box Hill Hospital, Box Hill, Australia|Royal Hobart Hospital, Hobart, Australia|Fiona Stanley Hospital, Murdoch, Australia|Saint Vincent's Hospital Sydney, Sydney, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Ziekenhuis Oost-Limburg - Campus Sint-Jan, Genk, Limburg, Belgium|Onze-Lieve-Vrouw Ziekenhuis Aalst, Aalst, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|University of Calgary, Calgary, Alberta, Canada|Montreal Heart Institute, Montréal, Canada|Aarhus Universitetshospital, Aarhus, Dinamarca, Denmark|Mater Misericordiae University Hospital, Dublin, Ireland|Saint Vincents University Hospital, Dublin, Ireland|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Ospedale San Donato, Arezzo, Italy|Azienda Ospedaliero - Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale degli Infermi, Rimini, Italy|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-Do, Korea, Republic of|Seoul National University Hospital, Seoul, Gyeonggi-Do, Korea, Republic of|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Middlemore Hospital, Otahuhu, Auckland, New Zealand|Waikato Hospital, Hamilton, Waikato, New Zealand|Centro Hospitalar de Lisboa Norte EPE- Hospital Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto, Porto, Portugal|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Son Llàtzer, Palma De Mallorca, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Royal Free Hospital, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03860935"
753,"NCT04153149","HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",,"Recruiting","No Results Available","Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","Drug: Vutrisiran|Drug: Sterile Normal Saline (0.9% NaCl)","Composite Endpoint of All-Cause Mortality and Frequency of Recurrent Cardiovascular (CV) Hospitalizations|Change from Baseline in 6-Minute Walk Test (6-MWT) at Month 30|Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) at Month 30|Change from Baseline in Mean Left Ventricular (LV) Wall Thickness by Echocardiographic Assessment at Month 30|Change from Baseline in Global Longitudinal Strain by Echocardiographic Assessment at Month 30|Composite Endpoint of All-Cause Mortality and Recurrent All-cause Hospitalizations|All-cause Mortality|Frequency of Recurrent CV Hospitalizations|Change from Baseline in N-terminal prohormone B-type Natriuretic Peptide (NTproBNP) at Month 30","Alnylam Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALN-TTRSC02-003|2019-003153-28","November 26, 2019","June 2024","June 2025","November 6, 2019",,"April 8, 2020","Clinical Trial Site, La Mesa, California, United States|Clinical Trial Site, Stanford, California, United States|Clinical Trial Site, Washington, District of Columbia, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Rochester, Minnesota, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Riga, Latvia",,"https://ClinicalTrials.gov/show/NCT04153149"
754,"NCT02525939","Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS","dal-GenE","Active, not recruiting","No Results Available","Acute Coronary Syndrome","Drug: dalcetrapib|Drug: Placebo","Composite of Major Cardiovascular Adverse Events (MACE), death, MI and stroke","DalCor Pharmaceuticals|The Montreal Health Innovations Coordinating Center (MHICC)|Medpace, Inc.|Roche Molecular Systems, Inc","All","45 Years and older   (Adult, Older Adult)","Phase 3","6000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAL-301","April 2016","January 2021","January 2021","August 18, 2015",,"January 30, 2020","Research Site, Alexander City, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Cottonwood, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Huntington Beach, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, Hartford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Clearwater, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Hudson, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miramar, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Covington, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Newburgh, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Lewiston, Maine, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Hyannis, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Bay City, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Mount Clemens, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Saint Joseph, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Coon Rapids, Minnesota, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Washington, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Linden, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Minot, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Butler, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Greeneville, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, La Crosse, Wisconsin, United States|Research Site, Bahía Blanca, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Coronel Suarez, Argentina|Research Site, Corrientes, Argentina|Research Site, Esperanza, Argentina|Research Site, Junin, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Moron, Argentina|Research Site, Quilmes, Argentina|Research Site, Rosario, Argentina|Research Site, San Juan, Argentina|Research Site, San Luis, Argentina|Research Site, San Martin, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolas, Argentina|Research Site, Santa Fe, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Tucuman, Argentina|Research Site, Venado Tuerto, Argentina|Research Site, Vicente Lopez, Argentina|Research Site, Villa Allende, Argentina|Research Site, Villa Maria, Argentina|Research Site, Bruce, New South Wales, Australia|Research Site, Gosford, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, Saint Leonards, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Douglas, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Milton, Queensland, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Elizabeth Vale, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Joondalup, Western Australia, Australia|Research Site, Murdoch, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Braunau Am Inn, Austria|Research Site, Feldkirch, Austria|Research Site, Krems, Austria|Research Site, Linz, Austria|Research Site, Vienna, Austria|Research Site, Wiener Neustadt, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brussels, Belgium|Research Site, Genk, Belgium|Research Site, Liege, Belgium|Research Site, Maaseik, Belgium|Research Site, Mechelen, Belgium|Research Site, Ottignies, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasilia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiania, Brazil|Research Site, Marilia, Brazil|Research Site, Maringa, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Salvador, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Jose do Rio Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Uberlandia, Brazil|Research Site, Vitoria, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Granby, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Institut de Cardiologie de Montreal, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, St-Charles-Borromee, Quebec, Canada|Research Site, St-Jean-sur-Richelieu, Quebec, Canada|Research Site, St-Jerome, Quebec, Canada|Research Site, St. George, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Thetford Mines, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Québec, Canada|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Bilina, Czechia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Kladno, Czechia|Research Site, Kromeriz, Czechia|Research Site, Liberec, Czechia|Research Site, Nachod, Czechia|Research Site, Pisek, Czechia|Research Site, Plzen, Czechia|Research Site, Prague 2, Czechia|Research Site, Prague 5, Czechia|Research Site, Prague 6, Czechia|Research Site, Prague, Czechia|Research Site, Slany, Czechia|Research Site, Trutnov, Czechia|Research Site, Zlin, Czechia|Research Site, Aalborg, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Glostrup, Denmark|Research Site, Hellerup, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Naestved, Denmark|Research Site, Silkeborg, Denmark|Research Site, Jyvaskyla, Finland|Research Site, Oulu, Finland|Research Site, Pori, Finland|Research Site, Turku, Finland|Research Site, Besancon, France|Research Site, Bron, France|Research Site, Clermont-Ferrand, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, Limoges, France|Research Site, Lyon, France|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Toulouse, France|Research Site, Tourcoing, France|Research Site, Valenciennes, France|Research Site, Aachen, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bremen, Germany|Research Site, Chemnitz, Germany|Research Site, Coburg, Germany|Research Site, Dresden, Germany|Research Site, Erfurt, Germany|Research Site, Fuerth, Germany|Research Site, Heidelberg, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Monchengladbach, Germany|Research Site, Munich, Germany|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Bnei Brak, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Nahariya, Israel|Research Site, Nazareth, Israel|Research Site, Petach-Tikva, Israel|Research Site, Poriyya 'Illit, Israel|Research Site, Rehovot, Israel|Research Site, Safed, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, Italy|Research Site, Ascoli Piceno, Italy|Research Site, Cagliari, Italy|Research Site, Casarano, Italy|Research Site, Cortona, Italy|Research Site, Empoli, Italy|Research Site, Firenze, Italy|Research Site, Foggia, Italy|Research Site, Giugliano in Campania, Italy|Research Site, Gubbio, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Sanremo, Italy|Research Site, Saronno, Italy|Research Site, Scorrano, Italy|Research Site, Seriate, Italy|Research Site, Torino, Italy|Research Site, Treviglio, Italy|Research Site, 's-Hertogenbosch, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Capelle Aan Den IJssel, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Deventer, Netherlands|Research Site, Doetinchem, Netherlands|Research Site, Ede, Netherlands|Research Site, Goes, Netherlands|Research Site, Gouda, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zaandam, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Grafton, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Hastings, New Zealand|Research Site, Lower Hutt, New Zealand|Research Site, Nelson, New Zealand|Research Site, New Plymouth, New Zealand|Research Site, Rotorua, New Zealand|Research Site, Takapuna, New Zealand|Research Site, Wellington, New Zealand|Research Site, Bydgoszcz, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Mragowo, Poland|Research Site, Olawa, Poland|Research Site, Oswiecim, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszow, Poland|Research Site, Sopot, Poland|Research Site, Sroda Wielkopolska, Poland|Research Site, Szczecin, Poland|Research Site, Torun, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Zamosc, Poland|Research Site, Almada, Portugal|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Faro, Portugal|Research Site, Leiria, Portugal|Research Site, Lisboa, Portugal|Research Site, Senhora da Hora, Portugal|Research Site, Setubal, Portugal|Research Site, Bayamon, Puerto Rico|Research Site, Caguas, Puerto Rico|Research Site, Ponce, Puerto Rico|Research Site, Arad, Romania|Research Site, Baia Mare, Romania|Research Site, Braila, Romania|Research Site, Bucharest, Romania|Research Site, Buzau, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Oradea, Romania|Research Site, Pitesti, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirovsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tula, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Nitra, Slovakia|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Gatong, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kuils River, South Africa|Research Site, Paarl, South Africa|Research Site, Parow, South Africa|Research Site, Somerset West, South Africa|Research Site, Worcester, South Africa|Research Site, A Coruna, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet del Llobregat, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Sabadell, Spain|Research Site, Salamanca, Spain|Research Site, Sant Joan, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Seville, Spain|Research Site, Tarragona, Spain|Research Site, Valencia, Spain|Research Site, Vigo, Spain|Research Site, Falun, Sweden|Research Site, Karlshamn, Sweden|Research Site, Koping, Sweden|Research Site, Linkoping, Sweden|Research Site, Malmo, Sweden|Research Site, Orebro, Sweden|Research Site, Umea, Sweden|Research Site, Uppsala, Sweden|Research Site, Vasteras, Sweden|Research Site, Geneva, Switzerland|Research Site, Lugano, Switzerland|Research Site, Afyonkarahisar, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kadikoy, Turkey|Research Site, Kayseri, Turkey|Research Site, Mersin, Turkey|Research Site, Samsun, Turkey|Research Site, Sivas, Turkey|Research Site, Dubai, United Arab Emirates|Research Site, Sharjah, United Arab Emirates|Research Site, Ayr, United Kingdom|Research Site, Barnet, United Kingdom|Research Site, Basildon, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Burton Upon Trent, United Kingdom|Research Site, Chelmsford, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Clydebank, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Craigavon, United Kingdom|Research Site, Dartford, United Kingdom|Research Site, Dudley, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Kirkcaldy, United Kingdom|Research Site, Lanark, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Lincoln, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Londonderry, United Kingdom|Research Site, London, United Kingdom|Research Site, Luton, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Paisley, United Kingdom|Research Site, Redhill, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stockport, United Kingdom|Research Site, Stockton on Tees, United Kingdom|Research Site, Swindon, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Telford, United Kingdom|Research Site, Truro, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Westcliff on Sea, United Kingdom|Research Site, Wigan, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Worthing, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02525939"
755,"NCT03997383","APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)",,"Recruiting","No Results Available","Transthyretin Amyloidosis (ATTR) With Cardiomyopathy","Drug: Placebo|Drug: Patisiran","Change from Baseline at Month 12 in Six-Minute Walk Test (6-MWT)|Change from Baseline at Month 12 in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) Score|Composite Endpoint of All-Cause Mortality, Frequency of Cardiovascular (CV)-Related Hospitalizations and Change from Baseline in 6-MWT|Composite Endpoint of All-Cause Mortality and Frequency of All-Cause Hospitalizations|Change from Baseline in Serum Transthyretin (TTR) Levels|Maximum Plasma Concentration at End of Infusion (Cmax) of Patisiran|Thirty-minute Post-infusion Concentration (Cp[30min]) of Patisiran|Pre-infusion Concentration (Cmin) of Patisiran|Number of Participants with Anti-drug Antibodies (ADAs)|Frequency of Adverse Events","Alnylam Pharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALN-TTR02-011|2019-001458-24","September 4, 2019","October 1, 2021","November 1, 2022","June 25, 2019",,"April 9, 2020","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Kansas City, Kansas, United States|Clinical Trial Site, Baltimore, Maryland, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Rochester, Minnesota, United States|Clinical Trial Site, Saint Louis, Missouri, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Florencio Varela, Argentina|Clinical Trial Site, São Paulo, Brazil|Clinical Trial Site, São Paulo, Brazil|Clinical Trial Site, Brno, Czechia|Clinical Trial Site, Prague, Czechia|Clinical Trial Site, Praha, Czechia|Clinical Trial Site, Aarhus, Denmark|Clinical Trial Site, Copenhagen, Denmark|Clinical Trial Site, Odense, Denmark|Clinical Trial Site, Paris, France|Clinical Trial Site, Messina, Italy|Clinical Trial Site, Pavia, Italy|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Warszawa, Poland|Clinical Trial Site, Stockholm, Sweden|Clinical Trial Site, Taipei, Taiwan|Clinical Trial Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03997383"
756,"NCT02507011","Beta-blockers in Pulmonary Arterial Hypertension",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Carvedilol|Drug: Placebo","Mean change in Right Ventricular Ejection Fraction as measured by cardiac MRI","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","4","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1504M69361","January 31, 2016","July 1, 2019","July 1, 2019","July 23, 2015",,"April 24, 2020","University of Minnesota Medical Center, Minneapolis, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02507011/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT02507011"
757,"NCT03510897","QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery",,"Recruiting","No Results Available","Cardiac Surgery","Drug: QPI-1002|Drug: Placebo","Proportion of subjects through day 90 who develop major adverse kidney events|Proportion of subjects developing AKI overall by modified AKIN criteria within 5 days post-surgery|Renal function as estimated by glomerular filtration rate|Proportion of subjects who die or initiate dialysis through day 90","Quark Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","1088","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","QRK309","May 25, 2018","July 2021","July 2021","April 27, 2018",,"April 14, 2020","University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Keck Hospital of USC, Los Angeles, California, United States|Cedar-Sinai Heart Institute, Los Angeles, California, United States|Ronald Regan UCLA Medical Center, Los Angeles, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|River City Clinical Research, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Northwestern University, Evanston, Illinois, United States|Indiana/ Ohio Heart, a division of Luthern Medical Group, LLC, Fort Wayne, Indiana, United States|Indiana University Health-Methodist Hospital, Indianapolis, Indiana, United States|University of Kentucky Healthcare, Lexington, Kentucky, United States|University of Louisville Physicians (ULP), Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MidMichigan Medical Center Midland, Midland, Michigan, United States|Cardiac & Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Bryan Heart, Lincoln, Nebraska, United States|Nebraska Heart Hospital, Lincoln, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Mission Hospital, Inc., Asheville, North Carolina, United States|Duke University Hospital Medical Center, Durham, North Carolina, United States|East Carolina Heart Institute at East Carolina University, Greenville, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor Jack and Jane Hamilton Heart and Vascular Hospital - Soltero Cardiovasular, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Swedish Medical Center - Cherry Hill, Seattle, Washington, United States|University Hospital, Madison, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Westmead Hospital, Westmead, New South Wales, Australia|The Prince Charles Hospital, Chermside, Qeensland, Australia|Princess Alexandra Hospital, Woolloongabba, Qeensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Medizinische Universitat Innsbruck, Innsbruck, Tyrol, Austria|Kepler Universitatsklinikum GmbH, Linz, Upper Austria, Austria|Medizinische Universitat Wien, Wien, Austria|University Hospital Leuven, Campus Gasthuisberg, Leuven, Belgium|Foothills Medical Centre, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospital / Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada|Royal Jubilee Hospital (Victoria Island Health Authority), Victoria, British Columbia, Canada|St. Boniface Hospital, Winnipeg, Manitoba, Canada|Horizon Health Network, Saint John Regional Hospital, Saint John, New Brunswick, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|London Health Sciences Center, University Hospital, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|McGill University Health Center - Royal Victoria Hospital, Montréal, Quebec, Canada|Institut Universitaire de cardiologie et de pneomologie de Quebec, Universite Laval, Québec, Quebec, Canada|Fakulni nemocnice Hradec Kralove, Kardiochirurgicka klinika, Hradec Králové, Czechia|Institut klinicke a experimenalni mediciny, Klinika kardiovaskularni chirurgie, Praha 4, Czechia|Fakultni nemocnice Motol a 2. LF UK, Klinika kariovaskularni chirurgie 2. LF. UK, Praha 5, Czechia|CHU Besancon-Service de Chirurgie Thoracique et Cardiovasculaire, Besançon, France|CHU - Grenoble Alpes, Grenoble Cedex 9, France|CHU Bordeaux, Pessac Cedex, France|Hospital Robert Debre, Reims, France|Chu Pontchaillou Rennes, Rennes, France|Hopitaux Universitaires de Strasbourg - Service de Chirurgie Cardiovasculaire, Strasbourg Cedex, France|CHU Toulouse - Hospital Rangueil-Service de Chirurgie Cadriovasculaire, Toulouse, France|Deutsches Herzzentrum Munchen, München, Bavaria, Germany|Charite-Universitatsmedizin Berlin, Berlin, Brandenburg, Germany|Klinikum der Friedrich-Schiller-Universitat Jena, Jena, Deutschland, Germany|Universitatsklinikum Frankfurt am Main, Frankfurt am main, Hesse, Germany|Universitasklinikum Giessen und Marburg GmbH, Geißen, Hesse, Germany|Herz-Und Gefasszentrum Bad Bevensen, Bad Bevensen, Lower Saxony, Germany|Krankenhaus der Barmherzigen Bruder Trier, Trier, Rhineland-Palatinate, Germany|Herzzentrum Leipzig, Leipzig, Saxony, Germany|Universitats-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany|RHON-KLINIKUM Campus Bad Neustadt, Bad Neustadt An Der Saale, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|Universitatsklinikum Bonn, Bonn, Germany|Universitatsklinikum ""Carl Gustav Carus"" der Technischen Universitat Dresden Klinik fur Herzchirurgle, Dresden, Germany|Universitatklinicum Essen Westdeutsches Herzzentrum Essen, Essen, Germany|Universitatsklinikum Heidelberg und Medizinische Fakultat, Heidelberg, Germany|Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Germany|Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Germany|Herzchirurgische Klinik und Poliklinik, München, Germany|Auckland City Hospital, Auckland, New Zealand|Waikato Hospital, Hamilton, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Hospital Clinico Universitario de Santiago-CHUS, Santiago De Compostela, A Coruña, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Cordoba, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Clinic Universitario de Valencia, Valencia, Spain|Royal Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom|Guy's and St Thomas Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03510897"
758,"NCT02108743","Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Idiopathic Pulmonary Arterial Hypertension.","Drug: Albuterol.|Drug: Normal saline placebo","End-expiratory lung volume:total lung capacity (EELV/TLC) ratio at matched metabolic isowork.|Change in peak oxygen consumption with albuterol|Change in O2 pulse with albuterol.|Exercise time|Borg dyspnea score","American Medical Association Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB8603","June 2014","July 2016","October 2016","April 9, 2014",,"December 30, 2015","LSUHSC Interim Louisiana Hospital, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02108743"
759,"NCT00853827","Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients","AQUARIUS","Completed","Has Results","Coronary Artery Disease (CAD)|Coronary Atherosclerosis","Drug: Placebo|Drug: Aliskiren","Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment|Change in Normalized Total Atheroma Volume (TAV) as Assessed by IVUS|Patients That Demonstrated Evidence of Atheroma Regression|Number of Patients With Adverse Events, Serious Adverse Events, and Death","Novartis Pharmaceuticals|The Cleveland Clinic|Novartis","All","35 Years and older   (Adult, Older Adult)","Phase 3","613","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CSPP100A2366|2008-006447-40","March 2009","January 2013","January 2013","March 2, 2009","May 7, 2014","June 3, 2014","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Torrance, California, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Farmington, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Hudson, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Safety Harbor, Florida, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Lexington, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Columbia, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Midland, Michigan, United States|Novartis Investigative Site, Petoskey, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, St. Paul, Minnesota, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Williamsville, New York, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Bend, Oregon, United States|Novartis Investigative Site, Hillsboro, Oregon, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Johnson City, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Oak Ridge, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Katy, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Buenos Aires, Capital Federal, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, New Lambton Heights, New South Wales, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Anderlecht, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Chicoutimi, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Le Plessis Robinson, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Coburg, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Neuss, Germany|Novartis Investigative Site, Pecs, Baranya, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Sesto San Giovanni, MI, Italy|Novartis Investigative Site, Massa, MS, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Kraków, Poland|Novartis Investigative Site, Lódz, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Hospitalet de Llobregat, Cataluña, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Vigo, Galicia, Spain|Novartis Investigative Site, Majadanonda, Madrid, Spain|Novartis Investigative Site, Galdakano, Pais Vasco, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00853827"
760,"NCT01280994","Hyperpolarized 129Xe MRI for Imaging Pulmonary Function",,"Suspended","No Results Available","Interstitial Lung Disease|Cystic Fibrosis|Pulmonary Hypertension|NSIP","Drug: Xenon","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Bastiaan Driehuys|Duke University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","445","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00025110","January 2011","December 2020","December 2021","January 21, 2011",,"April 27, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01280994"
761,"NCT00831441","Phase III Acute Coronary Syndrome","APPRAISE-2","Terminated","Has Results","Acute Coronary Syndrome","Drug: Apixaban|Drug: Placebo","Event Rate of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants|Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants|Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants|Event Rate of Stroke During the Intended Treatment Period - Randomized Participants|Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants|Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants|Event Rate of Composite of Cardiovascular Death, Myocardial Infarction, Unstable Angina, or Ischemic Stroke During the Intended Treatment Period - Randomized Participants|Event Rate of Composite of Cardiovascular Death, Fatal Bleed, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants|Event Rate of Composite of All-Cause Death, Myocardial Infarction, or Stroke During the Intended Treatment Period - Randomized Participants|Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants|Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants|Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants","Bristol-Myers Squibb|Pfizer|Duke Clinical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","7484","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CV185-068|EUDRACT# 2008-008298-77","March 2009","March 2011","March 2011","January 29, 2009","January 27, 2016","January 27, 2016","Uab Medical Center, Birmingham, Alabama, United States|University Of Alabama At Birmingham, Birmingham, Alabama, United States|Heart Center Research, Llc, Huntsville, Alabama, United States|North Phoenix Heart Center, Phoenix, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Nea Baptist Clinic, Jonesboro, Arkansas, United States|Phase Care, Llc, Alameda, California, United States|Cardiology Consultants Of Orange County, Anaheim, California, United States|Beaver Medical Group, Banning, California, United States|Local Institution, Chula Vista, California, United States|Escondido Cardiology Associates, Inc., Escondido, California, United States|William D. Bowden, D.O., Healdsburg, California, United States|California Heart Specialists, Inc., Huntington Beach, California, United States|Caring Clinical Research Corporation, Laguna Hills, California, United States|Eisenstein, Isaac, Lakewood, California, United States|Arvind J. Mehta, Md, Long Beach, California, United States|Local Institution, Los Alamitos, California, United States|Preciado Cardiology Incorporated, Los Angeles, California, United States|East Bay Physicians Medical Group, Oakland, California, United States|St. Joseph Heritage Medical Group, Orange, California, United States|A.R.I. Clinical Trials, Inc., Redondo Beach, California, United States|Coastal Multi-Specialty Research, Santa Ana, California, United States|Radiant Research, Inc, Santa Rosa, California, United States|Harbbor-Ucla Medical Center, Torrance, California, United States|Rocky Mountain Cardiology, Boulder, Colorado, United States|South Denver Cardiology Associates Pc, Littleton, Colorado, United States|Drogue Medical, Llc, Wheat Ridge, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Alfieri Cardiology, Newark, Delaware, United States|Orlando Heart Specialists, Altamonte Springs, Florida, United States|Palm Beach Heart Institute, Llc, Atlantis, Florida, United States|Ronald L. Walsh, Do, Clearwater, Florida, United States|The Heart And Vascular Institute Of Florida, Clearwater, Florida, United States|Cardiovascular Specialist Of South Florida, Davie, Florida, United States|David E. Perloff, Md, Ft. Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Jacksonville Heart Center, Pa, Jacksonville, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|East Coast Institute For Research, Jacksonville, Florida, United States|The Cardio Vascular Center P.A., Lake Mary, Florida, United States|Alpha Medical Research, Llc, Melbourne, Florida, United States|Melbourne Internal Medicine Associates (Mima), Melbourne, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Glenn J. Barquet, Md, Miami, Florida, United States|Miami Cardiology Clinical Research, L.L.C., Miami, Florida, United States|Advanced Pharma Clinical Research, Miami, Florida, United States|Mediquest Research Group Inc., Ocala, Florida, United States|Ocala Research Institute, Inc, Ocala, Florida, United States|Florida Heart Group, Orlando, Florida, United States|Orlando Heart Center, Orlando, Florida, United States|Palm Beach Gardens Research Center Llc, Palm Beach Gardens, Florida, United States|Local Institution, Pembroke Pines, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|Advent Clinical Research Centers, Inc., Pinellas Park, Florida, United States|Cardio-Pulmonary Associates, Plantation, Florida, United States|Avivo Clin Clinical Services, Port Orange, Florida, United States|Heartcare Research, Sarasota, Florida, United States|St. Augustine Cardiology Associates, St. Augustine, Florida, United States|Dr Kiran C Patel Research Institute At Pepin Heart Hospital, Tampa, Florida, United States|Howard T. Tee, M.D., F.A.C.P., F.A.C.C., Vero Beach, Florida, United States|Indian River Cardiovascular Associates, Inc, Vero Beach, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|Cardiovascular Physicians Of North Atlanta, Atlanta, Georgia, United States|Medical College Of Georgia, Augusta, Georgia, United States|Columbus Cardiology Associates Pc, Columbus, Georgia, United States|Georgia Heart Specialists, Covington, Georgia, United States|Atlanta Institute For Medical Research, Inc, Decatur, Georgia, United States|In-Quest Medical Research, Llc, Duluth, Georgia, United States|Alta Pharmaceutical Research Center, Inc., Dunwoody, Georgia, United States|North Georgia Medical Research, Ellijay, Georgia, United States|Northeast Georgia Heart Cntr, Pc, Gainesville, Georgia, United States|Mercer University School Of Medicine, Macon, Georgia, United States|Well Star Cardiovascular Medicine, Pc, Marietta, Georgia, United States|Southern Heart Research Institute, Llc, Riverdale, Georgia, United States|Memorial Hospital Of Carbondale, Carbondale, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University Of Chicago Hospitals, Chicago, Illinois, United States|Clinical Investigation Specialists, Inc, Gurnee, Illinois, United States|Gateway Cardiology. P.C, Jerseyville, Illinois, United States|Midwest Heart Foundation, Lombard, Illinois, United States|Local Institution, Moline, Illinois, United States|Illinois Heart & Lung Research, Normal, Illinois, United States|Heartcare Midwest, Peoria, Illinois, United States|Elkhart Clinic, Llc, Elkhart, Indiana, United States|St Margaret Mercy Healthcare Centers, Hammond, Indiana, United States|Krannertt Institute Of Cardiology, Indianapolis, Indiana, United States|R. L.Roudebush Va Medical Center, Indianapolis, Indiana, United States|The Care Group, Llc, Indianapolis, Indiana, United States|Medical Consultants, Pc, Muncie, Indiana, United States|Local Institution, Valparaiso, Indiana, United States|Mcfarland Clinic Pc, Ames, Iowa, United States|Iowa Heart Center, West Des Moines, Iowa, United States|Midwest Cardiology Associates , P.C., Overland Park, Kansas, United States|Kentucky Heart & Vascular Physicians, Ashland, Kentucky, United States|Local Institution, Hazard, Kentucky, United States|Cardiovascular Associates, Psc, Louisville, Kentucky, United States|Research Integrity, Llc, Owensboro, Kentucky, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Clinical Research Network, Alexandria, Louisiana, United States|Tulane University Hospital And Clinic, New Orleans, Louisiana, United States|Overton Brooks V.A.M.C., Shreveport, Louisiana, United States|Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, United States|Louisiana Heart Center, Slidell, Louisiana, United States|Local Institution, Annapolis, Maryland, United States|Delmarva Heart Research Foundation, Salisbury, Maryland, United States|Peninsula Cardiology Associates, P.A., Salisbury, Maryland, United States|Endeavor Medical Research, Plc, Alpena, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Local Institution, Detroit, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Thoracic And Cardiovascular Healthcare Foundation, Lansing, Michigan, United States|Local Institution, Mt. Pleasant, Michigan, United States|Covenant Medical Center, Inc, Saginaw, Michigan, United States|Great Lakes Heart & Vascular Institute, Pc, St. Joseph, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Va Medical Center, Minneapolis, Minnesota, United States|University Of Minnesota, Medical School, Minneapolis, Minnesota, United States|St Cloud Hospital, St. Cloud, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Local Institution, Jackson, Mississippi, United States|Missouri Cardiovascular Specialists, Columbia, Missouri, United States|Washington University School Of Medicine, St. Louis, Missouri, United States|Gateway Cardiology, P.C., St. Louis, Missouri, United States|Bryanlgh Heart Institute, Lincoln, Nebraska, United States|Heart Consultants, Omaha, Nebraska, United States|Alegent Health Clinic Heart & Vascular Specialists, Omaha, Nebraska, United States|Local Institution, Brick, New Jersey, United States|Central Jersey Medical Research Center, Elizabeth, New Jersey, United States|Hamilton Cardiology Associates, Hamilton, New Jersey, United States|Local Institution, Linden, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Central New Jersey Cardiology, South Plainfield, New Jersey, United States|New York Methodist Hospital, Brooklyn, New York, United States|Buffalo General Hospital, Buffalo, New York, United States|Dr. Michael Sacher, Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|The University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina Heart Institute At East Carolina University, Greenville, North Carolina, United States|Wake Med Heart Center, Raleigh, North Carolina, United States|Wilmington Medical Research, Wilmington, North Carolina, United States|Azalea Research Center, Wilmington, North Carolina, United States|Local Institution, Fargo, North Dakota, United States|Otfried N. Niedermaier, Md, Akron, Ohio, United States|City Cardiology Associates, Barberton, Ohio, United States|Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, United States|Fairfield Cardiac Cath Lab, Llc, Fairfield, Ohio, United States|Genoa Medical Center, Genoa, Ohio, United States|Middletown Cardiovascular Associates, Middletown, Ohio, United States|Toledo Cardiology Consultants, Toledo, Ohio, United States|Local Institution, Youngstown, Ohio, United States|Cardiology Associates Of Southeastern Ohio, Zanesville, Ohio, United States|Blue Stem Cardiology, Bartlesville, Oklahoma, United States|Cor Clinical Research, Llc, Oklahoma City, Oklahoma, United States|University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cardiovascular Associates, Oklahoma City, Oklahoma, United States|St. Charles Health System, Inc., Bend, Oregon, United States|Portland Preventive Cardiology, L.L.C., Portland, Oregon, United States|Blair Medical Associates, Inc., Altoona, Pennsylvania, United States|St. Lukes Cardiology Associates, Bethlehem, Pennsylvania, United States|Consultants In Cardiovascular Diseases, Inc., Erie, Pennsylvania, United States|Hamot Medical Center, Erie, Pennsylvania, United States|Richard M. Kastelic M.D. & Associates, P.C., Johnstown, Pennsylvania, United States|The Heart Group, Lancaster, Pennsylvania, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Pennsylvania Cardiology Associates, Philadelphia, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Pottstown Medical Specialists, Inc, Pottstown, Pennsylvania, United States|Local Institution, Scranton, Pennsylvania, United States|Buxmont Cardiology Associates, Pc, Sellersville, Pennsylvania, United States|Moffit Heart & Vascular Group, Wormleysburg, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Anmed Health, Anderson, South Carolina, United States|Carl Wilson Sofley, Jr., Md, Anderson, South Carolina, United States|Lowcountry Medical Group, Beaufort, South Carolina, United States|Columbia Cardiology, Columbia, South Carolina, United States|Cardiology Assoicates, Pc/Black Hills Clinical Research Ctr, Rapid City, South Dakota, United States|North Central Heart Institute, Sioux Falls, South Dakota, United States|The Chattanooga Heart Institute, Chattanooga, Tennessee, United States|The Stern Cardiovascular Center, Pa, Germantown, Tennessee, United States|Research Associates Of Jackson, Jackson, Tennessee, United States|Mountain State Health Alliance, Johnson City, Tennessee, United States|Knoxville Heart Group, Knoxville, Tennessee, United States|Access Clinical Trials, Nashville, Tennessee, United States|Parkway Cardiology Associates, Pc, Oak Ridge, Tennessee, United States|Amarillo Heart Clinical Research Institute Inc., Amarillo, Texas, United States|Dallas Va Medical Center, Dallas, Texas, United States|Cardiovascular Research Institute Of Dallas, Dallas, Texas, United States|Heart Consultants Of North Texas, Dallas, Texas, United States|Texas Health Research & Education Institute, Fort Worth, Texas, United States|T&R Clinic, Fort Worth, Texas, United States|Med Tech, Inc., Houston, Texas, United States|Methodist Debakey Heart & Vascular Center, Houston, Texas, United States|Centex Research, Pineloch Medical Clinic, Houston, Texas, United States|Heart Care Center, Houston, Texas, United States|Northwest Houston Cardiology, Pa, Houston, Texas, United States|Texas Cardiac Center, Lubbock, Texas, United States|Central Cardiovascular Institute Of San Antonio, San Antonio, Texas, United States|Jose A. Perez, M.D., San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|Sugarland Cardiology Associates, Sugarland, Texas, United States|Scott&White Memorial Hospital, Temple, Texas, United States|Northwest Heart Center, Tomball, Texas, United States|Tyler Cardiovascular Consultants, Tyler, Texas, United States|Utah Cardiology P.C, Layton, Utah, United States|Bermisa Family Practice & Research Center, Chesapeake, Virginia, United States|Zakhary, Bosh, Danville, Virginia, United States|Heart Care Associates P.C., Hopewell, Virginia, United States|The Cardiology Group Centra., Lynchburg, Virginia, United States|Virginia Cardiolovascular Associates, Manassas, Virginia, United States|Local Institution, Midlothian, Virginia, United States|Sendara Cardiovasular Research Institute, Norfolk, Virginia, United States|Virgina Commonwealth Universitymedical Center, Richmond, Virginia, United States|Inland Cardiology Associates, Spokane, Washington, United States|Franciscan Research Center, Tacoma, Washington, United States|Dean And St. Mary'S Outpatient Center, Madison, Wisconsin, United States|Wheaton Franciscan Healthcare St. Joseph, Milwaukee, Wisconsin, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Beunos Aire, Buenos Aires, Argentina|Local Institution, Coronel Suarez, Buenos Aires, Argentina|Local Institution, Gaba, Buenos Aires, Argentina|Local Institution, Haedo, Buenos Aires, Argentina|Local Institution, Junin, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Lanus Oeste, Buenos Aires, Argentina|Local Institution, Moron, Buenos Aires, Argentina|Local Institution, Quilmes, Buenos Aires, Argentina|Local Institution, Ramos Mejia, Buenos Aires, Argentina|Local Institution, San Isidro, Buenos Aires, Argentina|Local Institution, San Martin, Buenos Aires, Argentina|Local Institution, Resistencia, Chaco, Argentina|Local Institution, Villa Cabrera, Cordoba, Argentina|Local Institution, Villa Carlos Paz, Cordoba, Argentina|Local Institution, Villa Maria, Cordoba, Argentina|Local Institution, Corrientes Capital, Corrientes, Argentina|Local Institution, San Salvador De Jujuy, Jujuy, Argentina|Local Institution, Capital, Mendoza, Argentina|Local Institution, Posadas, Misiones, Argentina|Local Institution, Cipolletti, Rio Negro, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Corrientes, Argentina|Local Institution, Salta, Argentina|Local Institution, San Luis, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Bruce, Australian Capital Territory, Australia|Local Institution, Broken Hill, New South Wales, Australia|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Lismore, New South Wales, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Milton, Queensland, Australia|Local Institution, Ashford, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Woodville, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Geelong, Victoria, Australia|Local Institution, Richmond, Victoria, Australia|Local Institution, Feldkirch, Austria|Local Institution, Graz, Austria|Local Institution, Linz, Austria|Local Institution, Oberpullendorf, Austria|Local Institution, Vienna, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Aalst, Belgium|Local Institution, Anderlecht, Belgium|Local Institution, Antwerpen, Belgium|Local Institution, Bonheiden, Belgium|Local Institution, Brasschaat, Belgium|Local Institution, Brugge, Belgium|Local Institution, Gent, Belgium|Local Institution, Huy, Belgium|Local Institution, Ieper, Belgium|Local Institution, Mechelen, Belgium|Local Institution, Mol, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Maceio, Alagoas, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Sobral, Ceara, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Juiz De Fora, Mato Grosso, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belo Horzonte, Minas Gerais, Brazil|Local Institution, Uberlandia, Minas Gerais, Brazil|Local Institution, Uberlandia, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Londrina, Parana, Brazil|Local Institution, Belem, Para, Brazil|Local Institution, Recife, Pernambuco, Brazil|Local Institution, Rio Janeiro, Rio De Janeiro, Brazil|Local Institution, Natal, Rio Grande Do Norte, Brazil|Local Institution, Passo Fundo, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Sao Jose, Santa Catarina, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Limeira, Sao Paulo, Brazil|Local Institution, Marilia, Sao Paulo, Brazil|Local Institution, Marilia, Sao Paulo, Brazil|Local Institution, Santo Andre, Sao Paulo, Brazil|Local Institution, Santo Andre, Sao Paulo, Brazil|Local Institution, Sao Caetano Do Sul, Sao Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Burgas, Bulgaria|Local Institution, Dimitrovgrad, Bulgaria|Local Institution, Pazardzhik, Bulgaria|Local Institution, Pleven, Bulgaria|Local Institution, Plovdiv, Bulgaria|Local Institution, Plovdiv, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Sofia, Bulgaria|Local Institution, Stara Zagora, Bulgaria|Local Institution, Varna, Bulgaria|Local Institution, Edmonton, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, New Westminster, British Columbia, Canada|Local Institution, Penticton, British Columbia, Canada|Local Institution, Victoria, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, St-John, Newfoundland and Labrador, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Sydney, Nova Scotia, Canada|Local Institution, Cambridge, Ontario, Canada|Local Institution, Cambridge, Ontario, Canada|Local Institution, Grimsby, Ontario, Canada|Local Institution, Kitchener, Ontario, Canada|Local Institution, London, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Parry Sound, Ontario, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Scarborough, Ontario, Canada|Local Institution, Scarborough, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Chiccutimi, Quebec, Canada|Local Institution, Levis, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Sorel-Tracy, Quebec, Canada|Local Institution, St-Foy, Quebec, Canada|Local Institution, St. Charles Borromee, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Terrebonne, Quebec, Canada|Local Institution, Temuco, Araucania, Chile|Local Institution, Concepcion, Biobio, Chile|Local Institution, Talcahuano, Biobio, Chile|Local Institution, Osorno, Los Lagos, Chile|Local Institution, Punta Arenas, Magallanes Antartica, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Puerto Montt, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Lanzhou, Gansu, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Shijiazhuang, Hebei, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Dalian, Liaoning, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Jinan, Shandong, China|Local Institution, Beijing, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chongqing, Sichuan, China|Local Institution, Kunming, Yunnan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Xian, China|Local Institution, Cartagena, Bolivar, Colombia|Local Institution, Bogota, Cundinamaral, Colombia|Local Institution, Cali, Valle, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution, Floridablanca, Colombia|Local Institution, Manizales, Colombia|Local Institution, Medelin, Colombia|Local Institution, Medellin, Colombia|Local Institution, Brno, Czech Republic|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Novy Jicin, Czech Republic|Local Institution, Olomouc, Czech Republic|Local Institution, Ostrava, Czech Republic|Local Institution, Praha 10, Czech Republic|Local Institution, Rakovnik, Czech Republic|Local Institution, Usti Nad Orlici, Czech Republic|Local Institution, Arhus C, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, Esbjerg, Denmark|Local Institution, Haderslev, Denmark|Local Institution, Hellerup, Denmark|Local Institution, Hillerod, Denmark|Local Institution, Hvidovre, Denmark|Local Institution, Naestved, Denmark|Local Institution, Silkeborg, Denmark|Local Institution, Slagelse, Denmark|Local Institution, Espoo, Finland|Local Institution, Helsinki, Finland|Local Institution, Rovaniemi, Finland|Local Institution, Tampere, Finland|Local Institution, Albi Cedex 09, France|Local Institution, Amiens Cedex 1, France|Local Institution, Avignon, France|Local Institution, Cholet, France|Local Institution, Lagny Sur Marne, France|Local Institution, Langres Cedex, France|Local Institution, Montpellier, France|Local Institution, Paris Cedex 13, France|Local Institution, Pau Universite Cedex, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse Cedex 03, France|Local Institution, Bad Berka, Germany|Local Institution, Bad Nauheim, Germany|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Bernau, Germany|Local Institution, Bonn, Germany|Local Institution, Bonn, Germany|Local Institution, Chemnitz, Germany|Local Institution, Coswig, Germany|Local Institution, Cottbus, Germany|Local Institution, Dachau, Germany|Local Institution, Essen, Germany|Local Institution, Flensburg, Germany|Local Institution, Halle/Saale, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hoyerswerda, Germany|Local Institution, Jena, Germany|Local Institution, Leverkusen, Germany|Local Institution, Limburg, Germany|Local Institution, Luebeck, Germany|Local Institution, Mainz, Germany|Local Institution, Muenster, Germany|Local Institution, Neuss, Germany|Local Institution, Paderborn, Germany|Local Institution, Pirna, Germany|Local Institution, Regensburg, Germany|Local Institution, Rostock, Germany|Local Institution, Wesel, Germany|Local Institution, Baja, Hungary|Local Institution, Balatonfured, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budpest, Hungary|Local Institution, Cegled, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Dunaujvaros, Hungary|Local Institution, Hodmezovasarhely, Hungary|Local Institution, Kecskemet, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Szekszard, Hungary|Local Institution, Szentes, Hungary|Local Institution, Szombathely, Hungary|Local Institution, Zalaegerszeg, Hungary|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Vijayawada, Andhra Pradesh, India|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Ahmedabad, Gujarat, India|Local Institution, Vadodara, Gujarat, India|Local Institution, Gurgaon, Haryana, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Mysore, Karnataka, India|Local Institution, Shivamogga, Karnataka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Pune, Maharastra, India|Local Institution, Jalandhar, Punjab, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Coimbatore, Tamil Nadu, India|Local Institution, Chennai, Tamilnadu, India|Local Institution, Lucknow, Uttar Pradesh, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bikaner, India|Local Institution, Mangalore, India|Local Institution, New Delhi, India|Local Institution, New Delhi, India|Local Institution, Pune, India|Local Institution, Afula, Israel|Local Institution, Ashkelon, Israel|Local Institution, Hadera, Israel|Local Institution, Haifa, Israel|Local Institution, Haifa, Israel|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Jerusalem, Israel|Local Institution, Jerusalem, Israel|Local Institution, Jerusalem, Israel|Local Institution, Kfar-Saba, Israel|Local Institution, Nahariya, Israel|Local Institution, Nazareth, Israel|Local Institution, Nazareth, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Rehovot, Israel|Local Institution, Safed, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tiberias, Israel|Local Institution, Ascoli Piceno, Italy|Local Institution, Bergamo, Italy|Local Institution, Chieti, Italy|Local Institution, Foggia, Italy|Local Institution, Gravedona (Co), Italy|Local Institution, Grosseto, Italy|Local Institution, Massa, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Naples, Italy|Local Institution, Novara, Italy|Local Institution, Pavia, Italy|Local Institution, Perugia, Italy|Local Institution, Roma, Italy|Local Institution, San Daniele Del Friuli (Udine), Italy|Local Institution, Saronno (Va), Italy|Local Institution, Verona, Italy|Local Institution, Nagoya-Shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Seto-Shi, Aichi, Japan|Local Institution, Matsudo, Chiba, Japan|Local Institution, Kasuga, Fukuoka, Japan|Local Institution, Kurume, Fukuoka, Japan|Local Institution, Gifu-Shi, Gifu, Japan|Local Institution, Ogaki-Shi, Gifu, Japan|Local Institution, Kure, Hiroshima, Japan|Local Institution, Obihiro, Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kasama, Ibaraki, Japan|Local Institution, Tsuchiura-Shi, Ibaraki, Japan|Local Institution, Tsukuba, Ibaraki, Japan|Local Institution, Kanazawa, Ishikawa, Japan|Local Institution, Kanoya, Kagoshima, Japan|Local Institution, Yokohama Sakae-Ku, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Yokosuka, Kanagawa, Japan|Local Institution, Ueda, Nagano, Japan|Local Institution, Beppu, Oita, Japan|Local Institution, Sakai, Osaka, Japan|Local Institution, Ureshino, Saga, Japan|Local Institution, Ageo, Saitama, Japan|Local Institution, Koshigaya, Saitama, Japan|Local Institution, Toda, Saitama, Japan|Local Institution, Komatsushima, Tokushima, Japan|Local Institution, Chiyoda-Ku, Tokyo, Japan|Local Institution, Chuo-Ku, Tokyo, Japan|Local Institution, Hachioji, Tokyo, Japan|Local Institution, Meguro-Ku, Tokyo, Japan|Local Institution, Meguro, Tokyo, Japan|Local Institution, Iwakuni, Yamaguchi, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Fukuoka, Japan|Local Institution, Gifu, Japan|Local Institution, Kochi, Japan|Local Institution, Kumamoto, Japan|Local Institution, Kumamoto, Japan|Local Institution, Kumamoto, Japan|Local Institution, Kumamoto, Japan|Local Institution, Kyoto, Japan|Local Institution, Oita, Japan|Local Institution, Osaka, Japan|Local Institution, Saga, Japan|Local Institution, Tokyo, Japan|Local Institution, Wonju, Gangwon-Do, Korea, Republic of|Local Institution, Yangsan, Gyeongangnam-Do, Korea, Republic of|Local Institution, Anyang, Gyeonggi-Do, Korea, Republic of|Local Institution, Guri-Si, Gyeonggi-Do, Korea, Republic of|Local Institution, Jinju, Gyeongsangam-Do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Goyang, Korea, Republic of|Local Institution, Gwangju, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Jeonbuk, Korea, Republic of|Local Institution, Pusan, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Cabo San Lucas, Baja Californa Sur, Mexico|Local Institution, Tijuana, Baja California, Mexico|Local Institution, Monclova, Coahuila, Mexico|Local Institution, Metepec, Estado De Mexico, Mexico|Local Institution, Tlalnepantla, Estado De Mexico, Mexico|Local Institution, Acapulco, Guerrero, Mexico|Local Institution, Acapulco, Guerrero, Mexico|Local Institution, Pachuca, Hidalgo, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Xalapa, Veracruz, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Durango, Mexico|Local Institution, Queretaro, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Alkmaar, Netherlands|Local Institution, Almere, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Beverwijk, Netherlands|Local Institution, Boxmeer, Netherlands|Local Institution, Den Haag, Netherlands|Local Institution, Dirksland, Netherlands|Local Institution, Ede, Netherlands|Local Institution, Goes, Netherlands|Local Institution, Gouda, Netherlands|Local Institution, Heerlen, Netherlands|Local Institution, Hilversum, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Meppel, Netherlands|Local Institution, Purmerend, Netherlands|Local Institution, Sneek, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Weert, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Auckland, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Hastings, New Zealand|Local Institution, Nelson, New Zealand|Local Institution, Palmerston North, New Zealand|Local Institution, Bergen, Norway|Local Institution, Bodo, Norway|Local Institution, Drammen, Norway|Local Institution, Hamar, Norway|Local Institution, Kongsvinger, Norway|Local Institution, Kristiansund, Norway|Local Institution, Lillehammer, Norway|Local Institution, Oslo, Norway|Local Institution, Oslo, Norway|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Tynset, Norway|Local Institution, Bellavista, Callao, Peru|Local Institution, Chiclayo, Lambayeque, Peru|Local Institution, Callao, Peru|Local Institution, Cusco, Peru|Local Institution, Ica, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Wegrow, Mazowiekie, Poland|Local Institution, Bialystok, Poland|Local Institution, Bydgoszcz, Poland|Local Institution, Bytom, Poland|Local Institution, Czestochowa, Poland|Local Institution, Elblag, Poland|Local Institution, Gdynia, Poland|Local Institution, Grodzisk Mazowiecki, Poland|Local Institution, Inowroclaw, Poland|Local Institution, Kielce, Poland|Local Institution, Koscierzyna, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Lublin, Poland|Local Institution, Opole, Poland|Local Institution, Ostrowiec Swietokrzyski, Poland|Local Institution, Plock, Poland|Local Institution, Poznan, Poland|Local Institution, Radom, Poland|Local Institution, Rzeszow, Poland|Local Institution, Slupsk, Poland|Local Institution, Szczecin, Poland|Local Institution, Tarnow, Poland|Local Institution, Torun, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wloclawek, Poland|Local Institution, Zabrze, Poland|Local Institution, Zielona Gora, Poland|Local Institution, Cidra, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Arad, Romania|Local Institution, Baia Mare, Romania|Local Institution, Braila, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Oradea, Romania|Local Institution, Pitesti, Romania|Local Institution, Sibiu, Romania|Local Institution, Targu Mures, Romania|Local Institution, Timisoara, Romania|Local Institution, Barnaul, Russian Federation|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Ekaterinburg, Russian Federation|Local Institution, Ekaterinburg, Russian Federation|Local Institution, Kaluga, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Kemerovo, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow Reg. Zhekeznodorozhniy, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhni Novgorod, Russian Federation|Local Institution, Nizhny Novgorod, Russian Federation|Local Institution, Nizhny Novgorod, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Odintsovo, Russian Federation|Local Institution, Penza, Russian Federation|Local Institution, Perm, Russian Federation|Local Institution, Rostov-On-Don, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Tomsk, Russian Federation|Local Institution, Tver, Russian Federation|Local Institution, Tyumen, Russian Federation|Local Institution, Vasilievsky Island, Russian Federation|Local Institution, Voronezh, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Zhukovskiy, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Banska Bystrica, Slovakia|Local Institution, Bratislava, Slovakia|Local Institution, Kosice, Slovakia|Local Institution, Kosice, Slovakia|Local Institution, Kosice, Slovakia|Local Institution, Kralovsky Chlmec, Slovakia|Local Institution, Liptovsky Hradok, Slovakia|Local Institution, Lucenec, Slovakia|Local Institution, Martin, Slovakia|Local Institution, Nitra, Slovakia|Local Institution, Port Elizabeth, Eastern Cape, South Africa|Local Institution, Port Elizabeth, Eastern Cape, South Africa|Local Institution, Bloemfontein, Free State, South Africa|Local Institution, Bloemfontein, Free State, South Africa|Local Institution, Centurion, Gauteng, South Africa|Local Institution, Wapadrand - Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Umhlanga, Kwa Zulu Natal, South Africa|Local Institution, Bellville, Western Cape, South Africa|Local Institution, Kuils River, Western Cape, South Africa|Local Institution, Pinelands, Western Cape, South Africa|Local Institution, Somerset West, Western Cape, South Africa|Local Institution, Worcester, Western Cape, South Africa|Local Institution, Johannesburg, South Africa|Local Institution, Villajoyosa, Alicante, Spain|Local Institution, Oviedo, Asturas, Spain|Local Institution, Figueres, Gerona, Spain|Local Institution, San Sebastian De Los Reyes, Madrid, Spain|Local Institution, Almeria, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Caceres, Spain|Local Institution, El Ejido, Spain|Local Institution, Granada, Spain|Local Institution, Lleida, Spain|Local Institution, Lugo, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Tarragona, Spain|Local Institution, Torrevieja, Spain|Local Institution, Valencia, Spain|Local Institution, Valladolid, Spain|Local Institution, Zaragoza, Spain|Local Institution, Eskilstuna, Sweden|Local Institution, Halmstad, Sweden|Local Institution, Helsingborg, Sweden|Local Institution, Karlskoga, Sweden|Local Institution, Karlstad, Sweden|Local Institution, Koping, Sweden|Local Institution, Lidkoping, Sweden|Local Institution, Molndal, Sweden|Local Institution, Skovde, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Lugano, Ticino, Switzerland|Local Institution, Geneve, Switzerland|Local Institution, St Gallen, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Besevler, Ankara, Turkey|Local Institution, Isanbul, Haseki, Turkey|Local Institution, Bornova, Izmir, Turkey|Local Institution, Ankara, Turkey|Local Institution, Diyarbakir, Turkey|Local Institution, Isparta, Turkey|Local Institution, Kirikkale, Turkey|Local Institution, Konya, Turkey|Local Institution, Chernivtsy, Ukraine|Local Institution, Dnipropetrovsk, Ukraine|Local Institution, Dnipropetrovsk, Ukraine|Local Institution, Donetsk, Ukraine|Local Institution, Donetsk, Ukraine|Local Institution, Donetsk, Ukraine|Local Institution, Ivano-Frankivsk, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Lugansk, Ukraine|Local Institution, Lutsk, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Mykolayiv, Ukraine|Local Institution, Odessa, Ukraine|Local Institution, Odessa, Ukraine|Local Institution, Simferopol, Ukraine|Local Institution, Vinnitsa, Ukraine|Local Institution, Zhaporizhzhya, Ukraine|Local Institution, Belfast, Antrim, United Kingdom|Local Institution, Belfast, Armagh, United Kingdom|Local Institution, Portadown, Armagh, United Kingdom|Local Institution, Ayr, Ayrshire, United Kingdom|Local Institution, Kilmarnock, Ayrshire, United Kingdom|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Chesterfield, Derbyshire, United Kingdom|Local Institution, Dumfries, Dumfriesshire, United Kingdom|Local Institution, Cottingham, East Yorkshire, United Kingdom|Local Institution, Basildon, Essex, United Kingdom|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, Romford, Essex, United Kingdom|Local Institution, Tunbridge Wells, Kent, United Kingdom|Local Institution, Blackpool, Lancashire, United Kingdom|Local Institution, Scunthorpe, Lincolnshire, United Kingdom|Local Institution, Harrow, Middlesex, United Kingdom|Local Institution, Worksop, Nottinghamshire, United Kingdom|Local Institution, Doncaster, South Yorkshire, United Kingdom|Local Institution, New Castle Upon Tyne, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00831441"
762,"NCT00968708","Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome","EXAMINE","Completed","Has Results","Diabetes Mellitus, Type 2|Acute Coronary Syndrome","Drug: Alogliptin|Drug: Placebo","Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)|Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE)","Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","5380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SYR-322_402|U1111-1111-6825|2009-011222-34|JapicCTI-101246|DOH-27-0310-3047|09/H0709/63|CTRI/2010/091/000046|NMRR-09-872-4471","September 2009","April 2013","June 2013","August 31, 2009","April 15, 2014","May 2, 2014","Birmingham, Alabama, United States|Dothan, Alabama, United States|Mobile, Alabama, United States|Muscle Shoals, Alabama, United States|Cottonwood, Arizona, United States|Goodyear, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Malvern, Arkansas, United States|Searcy, Arkansas, United States|White Hall, Arkansas, United States|Alameda, California, United States|Aliso Viejo, California, United States|Anaheim, California, United States|Bell Gardens, California, United States|Beverly Hills, California, United States|Chula Vista, California, United States|Corona, California, United States|Downey, California, United States|Escondido, California, United States|Fullerton, California, United States|Huntington Beach, California, United States|Huntington Park, California, United States|Inglewood, California, United States|La Mirada, California, United States|Lakewood, California, United States|Lancaster, California, United States|Lomita, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Gatos, California, United States|Merced, California, United States|Newport Beach, California, United States|Northridge, California, United States|Oakland, California, United States|Palm Springs, California, United States|Pomona, California, United States|San Diego, California, United States|San Dimas, California, United States|Santa Ana, California, United States|Santa Clarita, California, United States|Stockton, California, United States|Tarzana, California, United States|Torrence, California, United States|Van Nuys, California, United States|Ventura, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Bridgeport, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Brandon, Florida, United States|Davie, Florida, United States|Daytona Beach, Florida, United States|DelRay Beach, Florida, United States|Doral, Florida, United States|Fleming Island, Florida, United States|Ft Lauderdale, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Lake Mary, Florida, United States|Largo, Florida, United States|Melbourne, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Naples, Florida, United States|New Smyrna Beach, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Panama City, Florida, United States|Pembroke Pines, Florida, United States|Pensacola, Florida, United States|Sarasota, Florida, United States|St. Cloud, Florida, United States|St. Petersburg, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Cartersville, Georgia, United States|Conyers, Georgia, United States|Dunwoody, Georgia, United States|Marietta, Georgia, United States|Savannah, Georgia, United States|Tucker, Georgia, United States|Waycross, Georgia, United States|Nampa, Idaho, United States|Aurora, Illinois, United States|Boilingbrook, Illinois, United States|Bolingbrook, Illinois, United States|Burr Ridge, Illinois, United States|Chicago, Illinois, United States|Jerseyville, Illinois, United States|Melrose Park, Illinois, United States|Moline, Illinois, United States|Peoria, Illinois, United States|Quincy, Illinois, United States|Springfield, Illinois, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Muncie, Indiana, United States|Munster, Indiana, United States|New Albany, Indiana, United States|Valparaiso, Indiana, United States|Council Bluffs, Iowa, United States|Shawnee Mission, Kansas, United States|Elizabethtown, Kentucky, United States|Lexington, Kentucky, United States|Madisonville, Kentucky, United States|Owensboro, Kentucky, United States|Alexandria, Louisiana, United States|Houma, Louisiana, United States|Lafayette, Louisiana, United States|Natchitoches, Louisiana, United States|New Orleans, Louisiana, United States|Slidell, Louisiana, United States|Biddeford, Maine, United States|Rockport, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Oxon Hill, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Brockton, Massachusetts, United States|Fall River, Massachusetts, United States|Alpena, Michigan, United States|Bridgman, Michigan, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Kalamazoo, Michigan, United States|Lapeer, Michigan, United States|Livonia, Michigan, United States|MIdland, Michigan, United States|Muskegon, Michigan, United States|Saginaw, Michigan, United States|Troy, Michigan, United States|Warren, Michigan, United States|Waterford, Michigan, United States|Ypsilanti, Michigan, United States|Duluth, Minnesota, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Chesterfield, Missouri, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|St. Joseph, Missouri, United States|St. Louis, Missouri, United States|Great Falls, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Pahrump, Nevada, United States|Brick, New Jersey, United States|Bridgewater, New Jersey, United States|Camden, New Jersey, United States|Fort Lee, New Jersey, United States|Haddon Heights, New Jersey, United States|Linden, New Jersey, United States|New Brunswick, New Jersey, United States|Newark, New Jersey, United States|Ridgewood, New Jersey, United States|Sewell, New Jersey, United States|Sicklerville, New Jersey, United States|South Plainfield, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Cortlandt Manor, New York, United States|Freeport, New York, United States|Huntington, New York, United States|Johnson City, New York, United States|Kingston, New York, United States|New Hartford, New York, United States|New York, New York, United States|Rochester, New York, United States|Saratoga Springs, New York, United States|Springfield Gardens, New York, United States|Valhalla, New York, United States|Williamsville, New York, United States|Asheville, North Carolina, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Elizabeth City, North Carolina, United States|Forsyth, North Carolina, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|Lenoir, North Carolina, United States|Smithfield, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Minot, North Dakota, United States|Akron, Ohio, United States|Athens, Ohio, United States|Berea, Ohio, United States|Boardman, Ohio, United States|Carlisle, Ohio, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Franklin, Ohio, United States|Lorain, Ohio, United States|Marion, Ohio, United States|Maumee, Ohio, United States|Middleburg Heights, Ohio, United States|Springfield, Ohio, United States|Toledo, Ohio, United States|Westlake, Ohio, United States|Zanesville, Ohio, United States|Bartlesville, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Yukon, Oklahoma, United States|Bend, Oregon, United States|Corvallis, Oregon, United States|Hillsboro, Oregon, United States|Portland, Oregon, United States|Altoona, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Clymer, Pennsylvania, United States|Fleetwood, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Schwenksville, Pennsylvania, United States|Scotland, Pennsylvania, United States|Sellersville, Pennsylvania, United States|Yardley, Pennsylvania, United States|East Providence, Rhode Island, United States|Beaufort, South Carolina, United States|Easley, South Carolina, United States|Florence, South Carolina, United States|Spartanburg, South Carolina, United States|Taylors, South Carolina, United States|Sioux Falls, South Dakota, United States|Bartlett, Tennessee, United States|Bristol, Tennessee, United States|Cleveland, Tennessee, United States|Franklin, Tennessee, United States|Germantown, Tennessee, United States|Jackson, Tennessee, United States|Johnson City, Tennessee, United States|Kingsport, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Oak Ridge, Tennessee, United States|Austin, Texas, United States|Beaumont, Texas, United States|Carrollton, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|Edinburg, Texas, United States|Fort Worth, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|McKinney, Texas, United States|North Richland Hills, Texas, United States|Plano, Texas, United States|Saginaw, Texas, United States|San Antonio, Texas, United States|Southlake, Texas, United States|Temple, Texas, United States|Tomball, Texas, United States|Bountiful, Utah, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Bennington, Vermont, United States|South Burlington, Vermont, United States|Burke, Virginia, United States|Charlottesville, Virginia, United States|Galax, Virginia, United States|Lakeridge, Virginia, United States|Manassas, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Suffolk, Virginia, United States|Virginia Beach, Virginia, United States|Everett, Washington, United States|Tacoma, Washington, United States|Beloit, Wisconsin, United States|Green Bay, Wisconsin, United States|Madison, Wisconsin, United States|Manitowoc, Wisconsin, United States|Milwaukee, Wisconsin, United States|Waukesha, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|C0rdoba, Argentina|Capital Federal, Buenos Aires, Argentina|Capital Federal, Argentina|Carlos Paz, C0rdoba, Argentina|Ciudad Aut0noma de Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Ciudad de C0rdoba, Argentina|Cordoba - Cordoba, Argentina|Cordoba, Argentina|Corrientes, Argentina|Derqui Pilar, Buenos Aires, Argentina|Formosa, Argentina|Haedo, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Argentina|Mar del Plata, Provincia de Buenos Aires, Argentina|Mar del Plata, Argentina|Mendoza, Argentina|Moron, Buenos Aires, Argentina|Olivos, Argentina|Quilmes, Argentina|Ramos Mejia, Buenos Aries, Argentina|Ramos Mejia, Argentina|Rosario - Santa Fe, Argentina|Rosario, Provincia de Santa Fe, Argentina|Rosario, Argentina|Salta, Argentina|San Isidro, Argentina|San Juan, San Juan, Argentina|San Justo, Argentina|San Luis, Argentina|San Miguel de Tucuman, Argentina|San Salvador, de Jujuy, Argentina|Santa Fe, Argentina|Trelew, Chubut, Argentina|Villa Maria, Argentina|Broken Hill, New South Wales, Australia|Kogarah, New South Wales, Australia|Milton, Queensland, Australia|Nambour, Queensland, Australia|Hobart, Tasmania, Australia|Fitzroy, Victoria, Australia|Frankston, Victoria, Australia|Heidelberg, Victoria, Australia|Prahran, Victoria, Australia|Adelaide, SA, Australia|Bruce, Australia|Feldkirch, Austria|Graz, Austria|Salzburg, Austria|Wien, Austria|Antwerpen, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brussel, Belgium|Bruxelles, Belgium|Gent, Belgium|La Louviere, Belgium|Curitiba, PR, Brazil|Rio de Janeiro, RJ, Brazil|Sao Paulo, SP, Brazil|Tatui, SP, Brazil|Aracaju, Sergipe, Brazil|Belem - PA, Brazil|Belo Horizonte - MG, Brazil|Belo Horizonte, Minas Gerais, Brazil|Blumenau, Brazil|Brasilia - DF, Brazil|Brasilia, Distrito Federal, Brazil|Campina Grande do Sul, Brazil|Campinas, Sao Paulo, Brazil|Campo Grande, Mato Grosso do Sul, Brazil|Curitiba, Parana, Brazil|Fortaleza - CE, Brazil|Fortaleza, Ceara, Brazil|Goiania, Goias, Brazil|Goiania, Brazil|Joinville, Brazil|Londrina/PR, Brazil|Macei0, Brazil|Marilia, Sao Paulo, Brazil|Marilia, Brazil|Mogi das Cruzes, Brazil|Natal, RN, Brazil|Natal, Brazil|Passo Fundo, Rio Grande do Sul, Brazil|Porto Alegre - RS, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Brazil|Recife, Pernambuco, Brazil|Recife, PE, Brazil|Recife, Brazil|Rio de Janeiro - RJ, Brazil|Rio de Janeiro, Brazil|Salvador - BA, Brazil|Salvador, Bahia, Brazil|Santo Andre, Brazil|Sao Jose do Rio Preto, Sao Paulo, Brazil|Sao Jose do Rio Preto- SP, Brazil|Sao Jose do Rio Preto, Brazil|Sao Jose, Santa Catarina, Brazil|Sao Paulo, Sao Paulo, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, Brazil|Sobral, CE, Brazil|Taguatinga, Brazil|Uberlandia, Minas Gerais, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Dimitrovgrad, Bulgaria|Kazanlak, Bulgaria|Lovech, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sevlievo, Bulgaria|Smolian, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Abbotsford, British Columbia, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Grand Falls-Windsor, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Ajax, Ontario, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Newmarket, Ontario, Canada|Niagara Falls, Ontario, Canada|Oshawa, Ontario, Canada|Pickering, Ontario, Canada|Smiths Falls, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Greenfield, Quebec, Canada|Lachine, Quebec, Canada|Mont-Royal, Quebec, Canada|Pointe Claire, Quebec, Canada|Pointe-Claire, Quebec, Canada|Sainte-Foy, Quebec, Canada|Sherbrooke, Quebec, Canada|St. Jerome, Quebec, Canada|Terrebonne, Quebec, Canada|Ontario, Canada|Quebec, Canada|Antofagasta, Region II, Chile|Antofagasta, Chile|Iquique, Region I, Chile|Osorno, Chile|Rancagua, Chile|Santiago, Chile|Talcahuano, Chile|Temuco, Region de la Araucania, Chile|Temuco, Chile|Vina del Mar, Chile|Barranquilla, Colombia|Bogota, Colombia|Bucaramanga, Colombia|Medellin, Colombia|Cakovec, Croatia|Krapinske Toplice, Croatia|Osijek, Croatia|Rijeka, Croatia|Sisak, Croatia|Split, Croatia|Virovitica, Croatia|Zadar, Croatia|Zagreb, Croatia|Caslav, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Ostrava - Vitkovice, Czech Republic|Zlin, Czech Republic|Znojmo, Czech Republic|Herlev, Denmark|Herning, Denmark|Kobenhavn NV, Denmark|Alexandria, Egypt|Giza, Egypt|Monofia, Egypt|Helsinki, Finland|Jyvaskyla, Finland|Kokkola, Finland|Kuopio, Finland|Tampere, Finland|Turku, Finland|Bordeaux, France|Corbeil Essonnes, France|Corbeil-Essonnes, France|Creteil, France|Dijon, France|La Rochelle, France|Lille, France|Montpellier, France|Narbonne, France|Paris, France|Pau, France|Pessac, France|Rennes, France|Toulouse, France|Bad Nauheim, Germany|Bensheim, Germany|Berlin, Germany|Dortmund, Germany|Dresden, Germany|Essen, Germany|Halle (Saale), Germany|Jena, Germany|Kassel, Germany|Koln, Germany|Leipzig, Germany|Mainz, Germany|Mannheim, Germany|Muenchen, Germany|Munster, Germany|Neumuenster, Germany|Neuwied, Germany|Sankt Ingbert, Germany|Siegen, Germany|Wangen, Germany|Marousi, Greece|Guatemala City, Guatemala|Guatemala, Guatemala|Quetzaltenango, Guatemala|Hong Kong, Hong Kong|Kowloon, Hong Kong|Shatin, Hong Kong|Tsuen Wan, Hong Kong|Budaors, Hungary|Budapest, Hungary|Debrecen, Hungary|Dunaujvaros, Hungary|Gyula, Hungary|H0dmezovasarhely, Hungary|Kaposvar, Hungary|Kecskemet, Hungary|Nagykanizsa, Hungary|Pecs, Hungary|Sopron, Hungary|Szekesfehervar, Hungary|Szentes, Hungary|Szombathely, Hungary|Zalaegerszeg, Hungary|Hyderabad, Andhra Pradesh, India|Nellore, Andhra Pradesh, India|Vijayawada, Andhra Pradesh, India|Visakhapatnam, Andhra Pradesh, India|Perumbakkam, Chennai, India|New Delhi, Delhi, India|Ahmedabad, Gujarat, India|Anand, Gujarat, India|Surat, Gujarat, India|Vadodara, Gujarat, India|Bangalore, Karnataka, India|Belgaum, Karnataka, India|Mangalore, Karnataka, India|Manipal, Karnataka, India|Mysore, Karnataka, India|Cochin, Kerala, India|Kochi, Kerala, India|Thiruvananthapuram, Kerala, India|Thrissur, Kerala, India|Trivandrum, Kerala, India|Aurangabad, Maharashtra, India|Mumbai, Maharashtra, India|Nagpur, Maharashtra, India|Nashik, Maharashtra, India|Pune, Maharashtra, India|Jalandhar, Punjab, India|Ludhiana, Punjab, India|Jaipur, Rajasthan, India|Chennai, Tamil Nadu, India|Coimbatore, Tamil Nadu, India|Madurai, Tamil Nadu, India|Kolkatta, West Bengal, India|Delhi, India|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Nahariya, Israel|Nazareth, Israel|Petach Tikva, Israel|Rehovot, Israel|Rishon Lezion, Israel|Safed, Israel|Tel Aviv, Israel|Tiberias, Israel|Cosenza, Italy|Isernia, Italy|Milano, Italy|Napoli, Italy|Palermo, Italy|Pavia, Italy|Ravenna, Italy|Roma, Italy|Sesto San Giovanni, Italy|Aichi-gun, Aichi, Japan|Nagoya,, Aichi, Japan|Seto city, Aichi, Japan|Funabashi-city, Chiba, Japan|Kashiwa city, Chiba, Japan|Imabari, Ehime, Japan|Fukuoka-shi, Fukuoka, Japan|Kasuga-city, Fukuoka, Japan|Kitakyusyu, Fukuoka, Japan|Ohkawa-city, Fukuoka, Japan|Fukushima-shi, Fukushima, Japan|Gifu-city, Gifu, Japan|Shibukawa, Gunma, Japan|Takasaki, Gunma, Japan|Higashihiroshima-city, Hiroshima, Japan|Tomakomai-city, Hokkaido, Japan|Amagasaki-city, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Sakaide City, Kagawa, Japan|Kawasaki, Kanagawa, Japan|Sagamihara-shi, Kanagawa, Japan|Nankoku-city, Kochi, Japan|Kumamoto-city, Kumamoto, Japan|Uji-shi, Kyoto, Japan|Matsusaka City, Mie, Japan|Nagasaki-city, Nagasaki, Japan|Nagasaki-shi, Nagasaki, Japan|Oita-city, Oita, Japan|Okayama-city, Okayama, Japan|Shimajiri-gun, Okinawa, Japan|Tomigusuku City, Okinawa, Japan|Kishiwada-city, Osaka, Japan|Matsubara-city, Osaka, Japan|Yao-shi, Osaka, Japan|Ageo, Saitama, Japan|Wako-city, Saitama, Japan|Hamada-city, Shimane, Japan|Suntou-gun, Shizuoka, Japan|Komatsushima-city, Tokushima, Japan|Tokushima-city, Tokushima, Japan|Hino, Tokyo, Japan|Tachikawa-city, Tokyo, Japan|Iwakuni-shi, Yamaguchi, Japan|Niigata, Japan|Saga, Japan|Tokyo, Japan|Anyang, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Goyang-Si, Korea, Republic of|Guri, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Jeonju-si, Korea, Republic of|Kangwon-do, Korea, Republic of|Pusan, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Yangsan, Korea, Republic of|Dasman, Kuwait|Daugavpils, Latvia|Ogre, Latvia|Riga, Latvia|Tukums, Latvia|Valmiera, Latvia|Kaunas, Lithuania|Kedainiai, Lithuania|Klaipeda, Lithuania|Palanga, Lithuania|Panevezys, Lithuania|Vilnius, Lithuania|Alor Setar, Malaysia|Batu Caves, Malaysia|Georgetown, Malaysia|Kuala Lumpur, Malaysia|Kuantan, Malaysia|Kubang Kerian, Malaysia|Pulau Pinang, Malaysia|Selangor, Malaysia|Acapulco, Guerrero, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Chihuhua, Chihuhua, Mexico|Ciudad Obregon, Sonora, Mexico|Cuernavaca, Morelos, Mexico|Cuernavaca, Mexico|Culiacan, Mexico|Durango, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Mexico|Merida, Yucatan, Mexico|Metepec, Mexico|Mexicali, Baja California, Mexico|Mexico City, Mexico, Mexico|Mexico City, Mexico|Mexico, Mexico|Monclova, Coahuila, Mexico|Monterrey, NL, Mexico|Monterrey, Nuevo Le0n, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Mexico|Morelia, Michoacan, Mexico|Pachuca, Mexico|Saltillo, Coahuila, Mexico|Saltillo, Mexico|San Luis Potosi.SLP, Mexico|San Luis Potosi, Mexico|Tijuana, Baja California Norte, Mexico|Tlalnepantla, Edo de Mexico, Mexico|Tlalnepantla, Mexico|Xalapa, Veracruz, Mexico|Zapopan, Mexico|Auckland, New Zealand|Christchurch, New Zealand|Otahuhu, New Zealand|Palmerston North, New Zealand|Takapuna, New Zealand|Tauranga, New Zealand|Arequipa, Peru|Bellavista, Peru|Callao, Peru|Cusco, Peru|Huacho, Peru|Ica, Peru|La Victoria, Lima, Peru|Lima San Isidro, Peru|Lima, Peru|Los Olivos, Peru|Miraflores, Lima, Peru|Piura, Peru|San Isidro, Lima, Peru|San Miguel, Lima, Peru|Trujillo, La Libertad, Peru|Trujillo, Peru|Baguio, Philippines|Dasmarinas, Philippines|Davao City, Philippines|Iloilo City, Philippines|Laoag City, Philippines|Makati City, Philippines|Manila, Philippines|Marikina City, Philippines|Pasig City, Philippines|Quezon City, Philippines|Bialystok, Poland|Bydgoszcz, Poland|Czestochowa, Poland|Dabrowa Gornicza, Poland|Elblag, Poland|Gdansk, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Inowroclaw, Poland|Katowice, Poland|Kielce, Poland|Krakow, Poland|Legnica, Poland|Lodz, Poland|Lubartow, Poland|Lublin, Poland|Plock, Poland|Pulawy, Poland|Radom, Poland|Ruda Slaska, Poland|Skierniewice, Poland|Slupsk, Poland|Szczecin, Poland|Torun, Poland|Warsaw, Poland|Warszawa, Poland|Wroclaw, Poland|Zabrze, Poland|Zgierz, Poland|Coimbra, Portugal|Faro, Portugal|Lisboa, Portugal|Vila Real, Portugal|Aibonito, Puerto Rico|Carolina, Puerto Rico|Cidra, Puerto Rico|Halo Rey, Puerto Rico|Levittown, Puerto Rico|Manati, Puerto Rico|Mayaguez, Puerto Rico|Ponce, Puerto Rico|Salinas, Puerto Rico|San Juan, Puerto Rico|Santurce, Puerto Rico|Bacau, Romania|Baia Mare, Romania|Braila, Romania|Brasov, Romania|Bucharest, Romania|Bucuresti, Romania|Buzau, Romania|Galati, Romania|Iasi, Romania|Oradea, Romania|Ploiesti, Romania|Satu Mare, Romania|Targu Mures, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Novosibirsk, Russian Federation|Rostov-on-Don, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Ufa, Russian Federation|Volgograd, Russian Federation|Vsevolozhsk, Russian Federation|Belgrade, Serbia|Beograd, Serbia|Nis, Serbia|Bardejov, Slovakia|Bratislava, Slovakia|Dolny Kubin, Slovakia|Komarno, Slovakia|Kosice - Saca, Slovakia|Kosice, Slovakia|Levice, Slovakia|Liptovsky Hradok, Slovakia|Nove Mesto nad Vahom, Slovakia|Nove Zamky, Slovakia|Povazska Bystrica, Slovakia|Rimavska Sobota, Slovakia|Ruzomberok, Slovakia|Svidnik, Slovakia|Zilina, Slovakia|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Paarl, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Tygerberg, Western Cape, South Africa|Worcester, Western Cape, South Africa|Durban, South Africa|Pretoria, South Africa|Zaragoza, Arag0n, Spain|Oviedo, Asturias, Spain|Cuenca, Castilla-La Mancha, Spain|Barcelona, Cataluna, Spain|Figueres, Cataluna, Spain|Torrevieja, Comunidad Valenciana, Spain|A Coruna, Galicia, Spain|Santiago de Compostela, Galicia, Spain|Bacarot, Spain|Merida, Spain|Palma de Mallorca, Spain|Dalby, Sweden|Falkoping, Sweden|Goteborg, Sweden|Harnosand, Sweden|Kristianstad, Sweden|Malmo, Sweden|Motala, Sweden|Stockholm, Sweden|Kaohsiung, Taiwan|Taipei County, Taiwan|Taoyuan, Taiwan|Amphure Muang, Thailand|Bangkojk, Thailand|Bangkok, Thailand|Chiang Rai, Thailand|Chiangmai, Thailand|Muang, Thailand|Nakhon Ratchasima, Thailand|Pathumwan, Thailand|Patumthani, Thailand|Phitsanulok, Thailand|Phrae, Thailand|Ankara, Balgat, Turkey|Antalya, Turkey|Istanbul, Turkey|Kayseri, Turkey|Konya, Turkey|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Vinnytsya, Ukraine|Zaporizhzhya, Ukraine|Abu Dhabi, United Arab Emirates|Barnsley, United Kingdom|Bath, United Kingdom|Birmingham, United Kingdom|Bournemouth, United Kingdom|Carshalton, United Kingdom|Chertsey, United Kingdom|Chichester, United Kingdom|Colchester, United Kingdom|Coventry, United Kingdom|Croydon, United Kingdom|Doncaster, United Kingdom|Glasgow, United Kingdom|Hull, United Kingdom|Inverness, United Kingdom|Kirkcaldy, United Kingdom|Liverpool, United Kingdom|Livingston, United Kingdom|London, United Kingdom|Nuneaton, United Kingdom|Stevenage, United Kingdom|Sunderland, United Kingdom|Torquay, United Kingdom|Wakefield, United Kingdom|West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00968708"
763,"NCT01130246","VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome","VISTA-16","Terminated","No Results Available","Acute Coronary Syndrome","Drug: A-002, varespladib methyl|Drug: Placebo","Primary Objective of the Study|Secondary Objective of the Study","Anthera Pharmaceuticals","All","40 Years and older   (Adult, Older Adult)","Phase 3","5189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AN-CVD2233","May 2010","March 2012","March 2012","May 25, 2010",,"October 31, 2012","Investigator Site 1064, Birmingham, Alabama, United States|Investigator Site 1063, Birmingham, Alabama, United States|Investigator Site 1065, Birmingham, Alabama, United States|Investigator Site 1020, Huntsville, Alabama, United States|Investigator Site 1133, Mobile, Alabama, United States|Investigator Site 1019, Tucson, Arizona, United States|Investigator Site 1132, Escondido, California, United States|Investigator Site 1087, Mission Viejo, California, United States|Investigator Site 1005, Torrance, California, United States|Investigator Site 1079, Aurora, Colorado, United States|Investigator Site 1006, Colorado Springs, Colorado, United States|Investigator Site 1050, Denver, Colorado, United States|Investigator Site 1045, Denver, Colorado, United States|Investigator Site 1061, Fort Collins, Colorado, United States|Investigator Site 1054, Littleton, Colorado, United States|Investigator Site 1140, Wheat Ridge, Colorado, United States|Investigator Site 1111, Hartford, Connecticut, United States|Investigator Site 1028, Newark, Delaware, United States|Inevestigator Site 1074, Washington, District of Columbia, United States|Investigator Site 1030, Washington, District of Columbia, United States|Investigator Site 1117, Washington, District of Columbia, United States|Investigator Site 1022, Clearwater, Florida, United States|Investigator Site 1051, Clearwater, Florida, United States|Investigator Site 1112, Ft. Lauderdale, Florida, United States|Investigator Site 1049, Lakeland, Florida, United States|Investigator Site 1124, Miami Beach, Florida, United States|Investigator Site 1095, Tallahassee, Florida, United States|Investigator Site 1058, Tampa, Florida, United States|Investigator Site1110, Atlanta, Georgia, United States|Investigator Site 1011, Augusta, Georgia, United States|Investigator Site 1114, Macon, Georgia, United States|Investigator Site 1086, Naperville, Illinois, United States|Investigator Site 1125, Oak Lawn, Illinois, United States|Investigator Site 1044, Covington, Louisiana, United States|Investigator Site 1069, New Orleans, Louisiana, United States|Investigator Site 1066, New Orleans, Louisiana, United States|Investigator Site 1144, Shreveport, Louisiana, United States|Investigator Site 1060, Flint, Michigan, United States|Investigator Site 1136, Novi, Michigan, United States|Investigator Site 1137, Petoskey, Michigan, United States|Investigator Site 1048, Traverse City, Michigan, United States|Investigator Site 1034, Duluth, Minnesota, United States|Investigator Site 1046, Minneapolis, Minnesota, United States|Investigator Site 1033, Minneapolis, Minnesota, United States|Investigator Site 1016, Tupelo, Mississippi, United States|Investigator Site 1027, Kalispell, Montana, United States|Investigator Site 1092, Missoula, Montana, United States|Investigator Site 1032, Omaha, Nebraska, United States|Investigator Site 1031, Ridgewood, New Jersey, United States|Investigator Site 1057, Johnson City, New York, United States|Investigator Site 1101, Charlotte, North Carolina, United States|Investigator Site 1100, Gastonia, North Carolina, United States|Investigator Site 1121, Raleigh, North Carolina, United States|Investigator Site 1088, Raleigh, North Carolina, United States|Investigator Site 1123, Wilmington, North Carolina, United States|Investigator Site 1075, Winston-Salem, North Carolina, United States|Investigator Site 1108, Fargo, North Dakota, United States|Investigator Site 1024, Canton, Ohio, United States|Investigator Site 1143, Cleveland, Ohio, United States|Investigator 1141, Cleveland, Ohio, United States|Investigator Site 1131, Mansfield, Ohio, United States|Investigator Site 1004, Oklahoma City, Oklahoma, United States|Investigator Site 1026, Oklahoma City, Oklahoma, United States|Investigator Site 1122, Portland, Oregon, United States|Investigator Site 1107, Danville, Pennsylvania, United States|Investigator Site 1029, Doylestown, Pennsylvania, United States|Investigator Site 1134, Lancaster, Pennsylvania, United States|Investigator Site 1018, York, Pennsylvania, United States|Investigator Site 1072, Providence, Rhode Island, United States|Investigator Site 1038, Rapid City, South Dakota, United States|Investigator Site 1138, Sioux Falls, South Dakota, United States|Investigator Site 1014, Jackson, Tennessee, United States|Investigator Site 1047, Knoxville, Tennessee, United States|Investigator Site 1115, Dallas, Texas, United States|Investigator Site 1040, Dallas, Texas, United States|Investigator Site 1037, Houston, Texas, United States|Investigator Site 1130, Houston, Texas, United States|Investigator Site 1025, Tyler, Texas, United States|Investigator Site 1139, Layton, Utah, United States|Investigator Site 1056, Harrisonburg, Virginia, United States|Investigator Site 1083, Norfolk, Virginia, United States|Investigator Site 1043, Richmond, Virginia, United States|Investigator Site 1042, Marshfield, Wisconsin, United States|Investigator Site 6106, Canberra, Australian Capital Territory, Australia|Investigator Site 6114, Gosford, New South Wales, Australia|Investigator Site 6120, Kingswood, New South Wales, Australia|Investigator Site 6113, Cairns, Queensland, Australia|Investigator Site 6112, Douglas, Queensland, Australia|Investigator Site 6123, Nambour, Queensland, Australia|Investigator Site 6111, Adelaide, South Australia, Australia|Investigator Site 6124, Bedford Park, South Australia, Australia|Investigator Site 6103, Elizabeth Vale, South Australia, Australia|Investigator Site 6122, Hobart, Tasmania, Australia|Investigator Site 6129, Epping, Victoria, Australia|Investigator Site 6127, Heidelberg, Victoria, Australia|Investigator Site 6125, Perth, Western Australia, Australia|Investigator Site 6130, Perth, Western Australia, Australia|Investigator Site 6118, Brisbane, Australia|Investigator Site 6126, Geelong, Australia|Investigator Site 6101, Kogarah, Australia|Investigator Site 6105, Melbourne, Australia|Investigator Site 6110, Nedlands, Australia|Investigator Site 6121, New Lambton, Australia|Investigator Site 6108, So Australia, Australia|Investigator Site 6119, South Port, Australia|Investigator Site 2069, Calgary, Alberta, Canada|Investigator Site 2065, Edmonton, Alberta, Canada|Investigator Site 2064, Edmonton, Alberta, Canada|Investigator Site 2073, Red Deer, Alberta, Canada|Investigator Site 2059, Kelowna, British Columbia, Canada|Investigator Site 2068, New Westminister, British Columbia, Canada|Investigator Site 2066, Surrey, British Columbia, Canada|Investigator Site 2057, Vancouver, British Columbia, Canada|Investigator Site 2063, Victoria, British Columbia, Canada|Investigator Site 2070, Saint John, Newfoundland and Labrador, Canada|Investigator Site 2048, Halifax, Nova Scotia, Canada|Investigator Site 2072, Sydney, Nova Scotia, Canada|Investigator Site 2067, Hamilton, Ontario, Canada|Investigator Site 2075, Kitchener, Ontario, Canada|Investigator Site 2058, London, Ontario, Canada|Investigator Site 2004, Newmarket, Ontario, Canada|Investigator Site 2008, Scarborough, Ontario, Canada|Investigator Site 2030, Thunder Bay, Ontario, Canada|Investigator Site 2011, Toronto, Ontario, Canada|Investigator Site 2012, Toronto, Ontario, Canada|Investigator Site 2074, Laval, Quebec, Canada|Investigator Site 2020, Lévis, Quebec, Canada|Investigator Site 2009, Montreal, Quebec, Canada|Investigator Site 2052, Montreal, Quebec, Canada|Investigator Site 2001, Montreal, Quebec, Canada|Investigator Site 2071, St. Jerome, Quebec, Canada|Investigator Site 2006, Terrebonne, Quebec, Canada|Investigator Site 2053, Quebec, Canada|Investigator Site 2007, Quebec, Canada|Investigator Site 2010, Saint John, Canada|Investigator Site 4212, Jihlavska, Brno, Czech Republic|Investigator Site 4201, Usti nad Labem, Labem, Czech Republic|Investigator Site 4216, Liberec, Stare Mesto, Czech Republic|Investigator Site 4210, Brno, Czech Republic|Investigator Site 4206, Hradec Kralove, Czech Republic|Investigator Site 4208, Jihlava, Czech Republic|Investigator Site 4214, Mlada Boleslav, Czech Republic|Investigator Site 4218, Nymburk, Czech Republic|Investigator 4218, Nymburk, Czech Republic|Investigator Site 4207, Olomouc, Czech Republic|Investigator Site 4209, Ostrava, Czech Republic|Investigator Site 4205, Plzen, Czech Republic|Investigator Site 4204, Praha 2, Czech Republic|Investigator Site 4217, Praha 5, Czech Republic|Investigator Site 4213, Praha, Czech Republic|Investigator Site 4220, Praha, Czech Republic|Investigator Site 4202, Usti nad Labem, Czech Republic|Investigator Site 4203, Znojmo, Czech Republic|Investigator Site 9502, Tbilisi, Georgia|Investigator Site 9508, Tbilisi, Georgia|Investigator Site 9504, Tbilisi, Georgia|Investigator Site 9509, Tbilisi, Georgia|Investigator Site 9510, Tbilisi, Georgia|Investigator Site 9501, Tbilisi, Georgia|Investigator Site 9505, Tbilisi, Georgia|Investigator Site 9506, Tbilisi, Georgia|Investigator Site 9503, Tbilisi, Georgia|Investigator Site 9507, Tbilisi, Georgia|Investigator Site 4921, Warendorf, Am Krankenhaus, Germany|Investigator Site 4932, Bad Friedrichshall, Germany|Investigator Site 4930, Bad Nauheim, Germany|Investigator Site 4928, Berlin, Germany|Investigator Site 4904, Bielefeld, Germany|Investigator Site 4905, Bonn, Germany|Investigator Site 4923, Dortmund, Germany|Investigator Site 4912, Erfurt, Germany|Investigator Site 4907, Goettingen, Germany|Investigator Site 4922, Hamburg, Germany|Investigator Site 4929, Kassel, Germany|Investigator Site 4911, Kiel, Germany|Investigator Site 4901, Limburg, Germany|Investigator Site 4927, Lubeck, Germany|Investigator Site 4908, Magdeburg, Germany|Investigator Site 4902, Mainz, Germany|Investigator Site 4917, Munchen, Germany|Investigator Site 4925, Nauen, Germany|Investigator Site 4915, Regensburg, Germany|Investigator Site 4906, Ulm, Germany|Investigator Site 3626, Pecs, Baranya Megye, Hungary|Investigator Site 3606, Szekesfehervar, Fejer Megye, Hungary|Investigator Site 3602, Budapest, Gaal Jozsef, Hungary|Investigator Site 3605, Debrecen, Hajdu-Bihar, Hungary|Investigator Site 3614, Semmelweis, Kistarcsa, Hungary|Investigator Site 3616, Budapest, Pest Megye, Hungary|Investigator Site 3612, Budapest, Pest Megye, Hungary|Investigator Site 3607, Szolnok, Szolnok Megye, Hungary|Investigator Site 3603, Zalaegerszeg, Zala Megye, Hungary|Investigator Site 3625, Balatonfured, Hungary|Investigator Site 3604, Budapest, Hungary|Investigator Site 3622, Budapest, Hungary|Investigator Site 3619, Eger, Hungary|Investigator Site 3624, Hodmezovasarhely, Hungary|Investigator Site 3629, Sopron, Hungary|Investigator Site 3623, Szombathely, Hungary|Investigator Site 9110, Hyderabad, Andhra Pradesh, India|Investigator Site 9109, Secunderabad, Andhra Pradesh, India|Investigator Site 9119, Secunderabad, Andhra Pradesh, India|Investigator Site 9105, New Delhi, Delhi, India|Investigator Site 9104, Ahmedabad, Gujarat, India|Investigator Site 9111, Ahmedabad, Gujarat, India|Investigator Site 9108, Ahmedabad, Gujarat, India|Investigator Site 9117, Surat, Gujarat, India|Investigator Site 9115, Vadodara, Gujarat, India|Investigator Site 9102, Vadodara, Gujarat, India|Investigator Site 9114, Bangalore, Karanataka, India|Investigator Site 9121, Bangalore, Karnataka, India|Investigator Site 9113, Indore, Madhya Pradesh, India|Investigator Site 9101, Nagpur, Maharashtra, India|Investigator Site 9103, Lucknow, Uttar Pradesh, India|Investigator Site 9118, Kolkata, West Bengal, India|Investigator Site 9107, Kolkata, West Bengal, India|Investigator Site 3921, Brescia, Via L Bissolati, Italy|Investigator Site 3908, Cecina, Italy|Investigator Site 3912, Colleferro, Italy|Investigator Site 3910, Ferrara, Italy|Investigator Site 3916, Massa, Italy|Investigator Site 3906, Milano, Italy|Investigator Site 3901, Monza, Italy|Investigator Site 3907, Napoli, Italy|Investigator Site 3920, Novara, Italy|Investigator Site 3918, Roma, Italy|Investigator Site 3902, Rome, Italy|Investigator Site 3909, Rome, Italy|Investigator Site 3903, Rozzano (MI), Italy|Investigator Site 3904, Siena, Italy|Investigator Site 8205, Busan, Korea, Republic of|Investigator Site 8206, Busan, Korea, Republic of|Investigator Site 8202, Cheongju, Korea, Republic of|Investigator Site 8214, Daegu, Korea, Republic of|Investigator Site 8213, Daejeon, Korea, Republic of|Investigator Site 8203, Gwangju, Korea, Republic of|Investigator Site 8204, Gyeonggi-do, Korea, Republic of|Investigator Site 8210, Kangwon-do, Korea, Republic of|Investigator Site 8209, Seoul, Korea, Republic of|Investigator Site 8215, Seoul, Korea, Republic of|Investigator Site 8212, Seoul, Korea, Republic of|Investigator Site 8207, Seoul, Korea, Republic of|Investigator Site 8201, Seoul, Korea, Republic of|Investigator Site 8208, Suwon, Korea, Republic of|Investigator Site 8211, Suwon, Korea, Republic of|Investigator Site 9603, Bir Hassan, Jnah, Lebanon|Investigator Site 9601, Beirut, Lebanon|Investigator Site 9603, Beirut, Lebanon|Investigator Site 3126, Nieuwegein, CM, Netherlands|Investigator Site 3129, Goes, RA, Netherlands|Investigator Site 3120, Amstelveen, Netherlands|Investigator Site 3128, Amsterdam, Netherlands|Investigator Site 3117, Amsterdam, Netherlands|Investigator Site 3125, Amsterdam, Netherlands|Investigator Site 3136, Breda, Netherlands|Investigator Site 3130, Delft, Netherlands|Investigator Site 3108, Den Helder, Netherlands|Investigator Site 3105, Deventer, Netherlands|Investigator Site 3102, Ede, Netherlands|Investigator Site 3134, Heerlen, Netherlands|Investigator Site 3109, Hoogeveen, Netherlands|Investigator Site 3101, Leeuwarden, Netherlands|Investigator Site 3118, Leiden, Netherlands|Investigator Site 3112, Purmerend, Netherlands|Investigator Site 3107, Roosendaal, Netherlands|Investigator Site 3104, Rotterdam, Netherlands|Investigator Site 3106, Rotterdam, Netherlands|Investigator Site 3123, Rotterdam, Netherlands|Investigator Site 3131, Schiedam, Netherlands|Investigator Site 3135, Sneek, Netherlands|Investigator Site 3103, Tilburg, Netherlands|Investigator Site 3116, Utrecht, Netherlands|Investigator Site 3124, Venlo, Netherlands|Investigator Site 3113, Zaandam, Netherlands|Investigator Site 6402, Takapuna, Auckland, New Zealand|Investigator Site 6405, Christchurch, New Zealand|Investigator Site 6404, Dunedin, New Zealand|Investigator Site 6401, Hamilton, New Zealand|Investigator Site 6406, Wellington, New Zealand|Investigator Site 4825, Wroc³aw, Dolnoslaskie, Poland|Investigator Site 4804, Inowroclaw, Kujawsko-pomorskie, Poland|Investigator Site4819, Pulawy, Podkarpackie, Poland|Investigator Site 4828, Gdansk, Pomorskie, Poland|Investigator Site 4809, Bialystok, Poland|Investigator Site 4813, Bialystok, Poland|Investigator Site 4801, Bytom, Poland|Investigator Site 4816, Stalowa Wola, Poland|Investigator Site 4827, Szczecin, Poland|Investigator Site 4812, Warszawa, Poland|Investigator Site 4815, Warszawa, Poland|Investigator Site 4806, Warszawa, Poland|Investigator Site 4823, Warszawa, Poland|Investigator Site 4824, Wroclaw, Poland|Investigator Site 7026, Barnaui, Russian Federation|Investigator Site 7021, Chelyabinsk, Russian Federation|Investigator Site 7001, Ekaterinburg, Russian Federation|Investigator Site 7023, Irkutsk, Russian Federation|Investigator Site 7020, Kazan, Russian Federation|Investigator Site 7002, Kemerovo, Russian Federation|Investigator Site 7017, Krasnoyarsk, Russian Federation|Investigator Site 7024, Kursk, Russian Federation|Investigator Site 7007, Leningrad, Russian Federation|Investigator Site 7003, Moscow, Russian Federation|Investigator Site 7015, Moscow, Russian Federation|Investigator Site 7019, Moscow, Russian Federation|Investigator Site 7018, Murmansk, Russian Federation|Investigator Site 7004, Novosibirsk, Russian Federation|Investigator Site 7027, Novosibirsk, Russian Federation|Investigator Site 7022, Orenburg, Russian Federation|Investigator Site 7016, Rostov-on-Don, Russian Federation|Investigator Site 7005, Samara, Russian Federation|Investigator Site 7006, Saratov, Russian Federation|Investigator Site 7028, Saratov, Russian Federation|Investigator Site 7008, St. Petersburg, Russian Federation|Investigator Site 7010, St. Petersburg, Russian Federation|Investigator Site 7013, St. Petersburg, Russian Federation|Investigator Site 7025, St. Petersburg, Russian Federation|Investigator Site 7009, St.Petersburg, Russian Federation|Investigator Site 7011, Tomsk, Russian Federation|Investigator Site 7012, Tyumen, Russian Federation|Investigator Site 3404, Oviedo, Asturias, Spain|Investigator Site 3432, Badalona, Barcelona, Spain|Investigator Site 3420, Coslada, Madrid, Spain|Investigator Site 3419, Fuenlabrada, Madrid, Spain|Investigator Site 3413, Majadahonda, Madrid, Spain|Investigator Site 3411, Lorca, Murcia, Spain|Investigator Site 3416, Pamplona, Navarra, Spain|Investigator Site 3408, Vigo, Pontevedra, Spain|Investigator Site 3410, Vigo, Pontevedra, Spain|Investigator Site 3425, Galdakao, Vizcaya, Spain|Investigator Site 3435, Albacete, Spain|Investigator Site 3428, Barcelona, Spain|Investigator Site 3418, Barcelona, Spain|Investigator Site 3406, Girona, Spain|Investigator Site 3407, Huelva, Spain|Investigator Site 3430, Leganes, Spain|Investigator Site 3402, Lleida, Spain|Investigator Site 3409, Madrid, Spain|Investigator Site 3423, Madrid, Spain|Investigator Site 3401, Madrid, Spain|Investigator Site 3415, Malaga, Spain|Investigator Site 3421, Malaga, Spain|Investigator Site 3431, Pontevedra, Spain|Investigator Site 3424, Reus, Spain|Investigator Site 3414, Santa Cruz de Tenerife, Spain|Investigator Site 3434, Sevilla, Spain|Investigator Site 3422, Utrera, Spain|Investigator Site 3403, Valencia, Spain|Investigator Site 3809, Dnipropetrovsk, Ukraine|Investigator Site 3807, Ivano-Frankivsk, Ukraine|Investigator Site 3806, Kharkiv, Ukraine|Investigator Site 3802, Kharkiv, Ukraine|Investigator Site 3803, Kharkiv, Ukraine|Investigator Site, Kharkiv, Ukraine|Investigator Site 3810, Kharkiv, Ukraine|Investigator Site 3801, Kiev, Ukraine|Investigator Site 3805, Kiev, Ukraine|Investigator Site 3808, Kiev, Ukraine|Investigator Site 3811, Lviv, Ukraine|Investigator Site 3813, Odessa, Ukraine|Investigator Site 3815, Odessa, Ukraine|Investigator Site 3814, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01130246"
764,"NCT01712620","Spironolactone for Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Spironolactone|Drug: Placebo","Change in placebo corrected 6-minute walk distance|Change in placebo corrected VO2 max|Change in right ventricular function|Biomarkers of vascular inflammation|Rate of study drug discontinuation due to hyperkalemia, renal insufficiency, or other side effects such as breast pain and gynecomastia","National Institutes of Health Clinical Center (CC)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania|University of Maryland, College Park|Washington Hospital Center|New England Medical Center, Tufts University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","120211|12-CC-0211","January 10, 2014","October 1, 2021","October 1, 2021","October 23, 2012",,"May 1, 2020","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01712620"
765,"NCT02009631","A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors",,"Completed","No Results Available","Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors","Drug: Veliparib (ABT-888)|Drug: Placebo","To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF)|Pharmacokinetic sampling maximum observed plasma concentration (Cmax)|Pharmacokinetic sampling - time to maximum observed plasma concentration (Tmax)|Pharmacokinetic sampling - the area under the plasma concentration-time curve (AUC) from time 0-24 hours (AUC 0-24)|The number of subjects with adverse events|Vital Signs|Clinical Laboratory Tests|Tumor Assessment","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","M12-020|2013-002028-18","November 2013","December 2014","December 2014","December 12, 2013",,"November 20, 2017","Site Reference ID/Investigator# 116015, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 116016, San Antonio, Texas, United States|Site Reference ID/Investigator# 117320, Groningn, Netherlands|Site Reference ID/Investigator# 117336, Maastricht, Netherlands|Site Reference ID/Investigator# 117517, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02009631"
766,"NCT02138825","Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)","RISE-IIP","Terminated","Has Results","Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Mean Change in 6 Minute Walking Distance (6MWD) From Baseline to Week 26|Number of Participants With Clinical Worsening","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13605|2010-024332-42","June 4, 2014","May 5, 2016","September 14, 2016","May 15, 2014","June 5, 2017","December 4, 2017","University of California, Los Angeles, Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Miami, Florida, United States|Orlando, Florida, United States|Via Christi Clinic, Wichita, Kansas, United States|Louisville, Kentucky, United States|Columbia University Medical Center, New York, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Falls Church, Virginia, United States|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Godoy Cruz, Mendoza, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Camperdown, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Sydney, New South Wales, Australia|Chermside, Queensland, Australia|Adelaide, South Australia, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Leuven, Belgium|Vancouver, British Columbia, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Quebec, Canada|Bogotá, Distrito Capital de Bogotá, Colombia|Floridablanca-Bucaramanga, Santander, Colombia|Cali, Valle del Cauca, Colombia|Bogotá, Colombia|Santafe de Bogotá, Colombia|Aarhus N, Denmark|Bron, France|Lille Cedex, France|Marseille, France|Paris Cedex 15, France|München, Bayern, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Grosshansdorf, Germany|Athens, Greece|Haidari, Greece|Ioannina, Greece|Thessaloniki, Greece|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Forlì-Cesena, Emilia-Romagna, Italy|Roma, Lazio, Italy|Monza-Brianza, Lombardia, Italy|Palermo, Sicilia, Italy|Siena, Toscana, Italy|Seto, Aichi, Japan|Yokohama, Kanagawa, Japan|Sakai, Osaka, Japan|Shibuya-ku, Tokyo, Japan|Chiba, Japan|Auckland, New Zealand|Christchurch, New Zealand|Coimbra, Portugal|Porto, Portugal|Vila Nova de Gaia, Portugal|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Vladimir, Russian Federation|Riyadh, Saudi Arabia|Riyadh, Saudi Arabia|Riyadh, Saudi Arabia|Barcelona, Spain|Barcelona, Spain|Valencia, Spain|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Denizli, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Clydebank, West Dunbartonshire, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02138825"
767,"NCT01245634","A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery",,"Completed","No Results Available","Coronary Heart Disease, Graft Occlusion, Vascular","Drug: Placebo|Drug: RO4905417","Proportion of patients with diameter stenosis >50% (including total occlusion) of at least one saphenous vein graft, as assessed by invasive angiography|Lumen diameter of saphenous vein grafts, as assessed by invasive angiography|Proportion of patients needing revascularization|Safety: Incidence of adverse events (including major adverse cardiovascular events)","Hoffmann-La Roche","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","384","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","BP25601","December 2010","May 2013","May 2013","November 22, 2010",,"November 2, 2016","Huntsville, Alabama, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Los Angeles, California, United States|Atlantis, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Macon, Georgia, United States|Springfield, Illinois, United States|Springfield, Illinois, United States|Fort Wayne, Indiana, United States|Lexington, Kentucky, United States|Dearborn, Michigan, United States|Petoskey, Michigan, United States|Royal Oak, Michigan, United States|Troy, Michigan, United States|Duluth, Minnesota, United States|Saint Paul, Minnesota, United States|Washington, Missouri, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|Toledo, Ohio, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01245634"
768,"NCT03571672","DEF-314 Better Accuracy in EF Assessment With DEFINITY","BENEFIT1","Completed","No Results Available","Cardiac Disease","Drug: DEFINITY","Demonstrate improvements in left ventricular ejection fraction measurement accuracy from unenhanced 2D echo imaging to imaging with DEFINITY® contrast-enhanced 2D echo using cardiac magnetic resonance imaging as the truth standard.|Demonstrate improvement in accuracy in left ventricular ejection fraction measurement assessment using DEFINITY® contrast-enhanced over unenhanced echocardiography in subjects with suboptimal echocardiograms.|Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction measurement using DEFINITY® contrast-enhanced versus unenhanced echocardiography|Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volume measurements using DEFINITY® contrast-enhanced versus unenhanced echocardiography.|Demonstrate a reduction in inter-reader variability for the assessment of left ventricular ejection fraction measurements using DEFINITY® contrast-enhanced versus unenhanced echocardiography in subjects with suboptimal echocardiograms.|Demonstrate a reduction in inter-reader variability for the assessment of end-diastolic/systolic volume measurements using DEFINITY® contrast-enhanced versus unenhanced echocardiography in subjects with suboptimal echocardiograms.","Lantheus Medical Imaging|Syneos Health","All","18 Years and older   (Adult, Older Adult)","Phase 3","158","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DEF-314","October 24, 2018","August 30, 2019","August 30, 2019","June 27, 2018",,"November 15, 2019","Banner University of Arizona Medical Center, Tucson, Arizona, United States|University of California-San Diego, San Diego, California, United States|Alfieri Cardiology, Wilmington, Delaware, United States|Henry Ford Hospital, Detroit, Michigan, United States|Weill Cornell Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|University Hospital/Cleveland Medical Center, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|West Virginia University Medical Center, Morgantown, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03571672"
769,"NCT02791230","Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy",,"Recruiting","No Results Available","Transthyretin (TTR) Amyloid Cardiomyopathy","Drug: Tafamidis","All-cause mortality and incidence of treatment emergent adverse events","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2000","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B3461045|2016-000868-42","June 13, 2016","December 24, 2026","January 2, 2027","June 6, 2016",,"April 28, 2020","The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States|Cardiovascular Clinical Trials Unit (CCTU), Birmingham, Alabama, United States|University Hospital, University of Alabama at Birmingham, Birmingham, Alabama, United States|California Heart Center, Beverly Hills, California, United States|Cedars-Sinai Heart Institute, Beverly Hills, California, United States|Altman Clinical Translational Research Institute, La Jolla, California, United States|UCSD Sulpizio Cardiovascular Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, San Diego Medical Center - Hillcrest, San Diego, California, United States|UCSF Ambulatory Care Center, San Francisco, California, United States|University of California, San Francisco, California, United States|UCSF Cardiovascular Care and Prevention Center, San Francisco, California, United States|Stanford Hospital and Clinics Investigational Pharmacy, Stanford, California, United States|Stanford University Hospital and Clinics, Stanford, California, United States|Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Northwestern Medical Group, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital IDS Pharmacy, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Boston Medical Center Investigational Pharmacy, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Michigan Medicine - Research Pharmacy, Ann Arbor, Michigan, United States|Michigan Medicine,University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic Hospital-Rochester, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|NYU Langone Health, New York, New York, United States|Columbia University Medical Center- Clinical Cardiovascular Research Laboratory for the Elderly, New York, New York, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|OHSU Center for Health and Healing, Portland, Oregon, United States|OHSU Research Pharmacy Services, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Vanderbilt Univ. Med. Ctr, Nashville, Tennessee, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Utah Hospitals & Clinics, Salt Lake City, Utah, United States|University of Utah, Division of Cardiovascular Medicine, Salt Lake City, Utah, United States|Instituto Cardiovascular de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|UZ Leuven, Leuven, Belgium|Hospital Universitário Clementino Fraga Filho (UFRJ), Rio de Janeiro, RJ, Brazil|University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Toronto General Hospital, Toronto, Ontario, Canada|University health network-Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute-Research Center, Montreal, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|Hopitaux de La Timone, Marseille, Provence, France|CHU Henri Mondor, Creteil, France|Hôpital De La Timone, Marseille, France|Hopital Bichat, Paris, France|CHU de Rennes - Hopital Pontchaillou, Rennes, France|CHU de Rennes - Hôpital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Rangueil, Toulouse, France|Medical University of Heidelberg, Heidelberg, Germany|Universitätsklinikum Münster, Münster, Germany|Clinical Trial Pharmacy, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Kurume University Hospital, Kurume-shi, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto-city, Kumamoto, Japan|Shinshu University Hospital, Nagano, Japan|University Medical Center Groningen, Groningen, Netherlands|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Skellefteå Lasarett, Skellefteå, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Investigational Drug Services, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Clinical Trial Pharmacy, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02791230"
770,"NCT01890434","Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","GadaCAD 2","Completed","Has Results","Coronary Artery Disease","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' Assessment|Absence of Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Specificity Based on Blinded Readers' Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Secondary Analysis of Sensitivity Comparison Based on the Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus GSPECT - Secondary Analysis of Sensitivity Comparison Based on Majority Blinded Reader's and Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity Based on Majority Blinded Reader's and Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus GSPECT -- Secondary Analysis of Specificity Comparison Based on Majority Blinded Reader's and Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Specificity Based on Majority Blinded Reader's and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to LAD and Non-LAD Territory on GSPECT - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to LAD and Non-LAD Territory on GSPECT - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment|Localization of a Myocardial Perfusion Defect to Each Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessment|Detection of Myocardial Perfusion Defect(s) on Gadobutrol-enhanced CMRI in Participants With Significant LMS Stenosis - Based on Blinded Readers' and Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Single or Multi-vessel Disease Evaluated on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Single-vessel Disease Evaluated on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity by Majority Blinded Reader and Investigator|Presence of a Myocardial Perfusion Defect Indicating Significant CAD in Participants With Multi-vessel Disease Evaluated on Gadobutrol-enhanced CMRI and GSPECT - Additional Secondary Analysis of Sensitivity by Majority Blinded Reader and Investigator|Number of Participants by Their Lowest Confidence in Diagnosis Obtained on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI - Based on Blinded Readers' and Investigator's Assessment","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","478","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15962|2013-000066-11","August 26, 2013","August 6, 2016","November 10, 2016","July 1, 2013","May 16, 2018","July 31, 2019","Tucson, Arizona, United States|Los Angeles, California, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Bethesda, Maryland, United States|Bethesda, Maryland, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Adelaide, South Australia, Australia|Perth, Western Australia, Australia|Chermside, Australia|North Adelaide, Australia|London, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Singapore, Singapore|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01890434"
771,"NCT02292186","A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",,"Completed","Has Results","TTR-mediated Amyloidosis","Drug: Revusiran (ALN-TTRSC)","Safety and Tolerability Results of Long-term Dosing With ALN-TTRSC (Revusiran) Transthyretin (TTR) Cardiac Amyloidosis Patients.|Serum TTR Levels|Mortality|Clinical Effects of Long-term Dosing of ALN-TTRSC on Hospitalization|6-minute Walk Test Performance","Alnylam Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALN-TTRSC-003","October 2014","February 22, 2017","February 22, 2017","November 17, 2014","June 15, 2018","February 13, 2020","Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Calgary, Alberta, Canada|Clinical Trial Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02292186/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02292186/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02292186"
772,"NCT01442038","Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)","RIVER-PCI","Completed","Has Results","Coronary Artery Disease|Angina Pectoris","Drug: Ranolazine|Drug: Placebo","Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization|Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death|Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death|Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","2651","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GS-US-259-0116|2011-002507-15","October 2011","February 2015","February 2015","September 28, 2011","July 15, 2016","July 15, 2016","Cardiology, PC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Heart Center Research, LLC, Huntsville, Alabama, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States|Scottsdale Healthcare, Scottsdale, Arizona, United States|University of California San Diego, La Jolla, California, United States|Spectrum Clinical Research Institute, Inc, Moreno Valley, California, United States|Veterans Affairs San Diego Healthcare System, San Diego, California, United States|John Muir Medical Center Concord Campus, Walnut Creek, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Cardiology Associates of Fairfield County, PC, Stamford, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|Zasa Clinical Research, Atlantis, Florida, United States|Cardiology Research Associates, Daytona Beach, Florida, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Michigan Heart, PC, Hialeah, Florida, United States|Jacksonville Heart Center, Jacksonville, Florida, United States|University of Florida Health Sciences Center-Jacksonville, Jacksonville, Florida, United States|East Coast Institute for Research, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Heart Institute, Orlando, Florida, United States|Cardiovascular Institute of Northwest Florida, Panama City, Florida, United States|Tallahassee Research Institute, Tallahassee, Florida, United States|Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Gateway Cardiology, PC, Jerseyville, Illinois, United States|Indiana Heart Physicians, Inc., Indianapolis, Indiana, United States|The Indiana Heart Hospital, Indianapolis, Indiana, United States|Northwest Indiana Cardiovascular Physicians, Valparaiso, Indiana, United States|Iowa Heart Center, West De Moines, Iowa, United States|Saint Joseph Cardiology Associates, Lexington, Kentucky, United States|Clinical Trials of America, Inc., Minden, Louisiana, United States|Clinical Trials of America, Inc., Shreveport, Louisiana, United States|Northeast Cardiology Associates, Bangor, Maine, United States|Baltimore Heart Associates, Baltimore, Maryland, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Saint Elizabeth's Medical Center, Boston, Massachusetts, United States|Cape Cod Research Institute, Hyannis, Massachusetts, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Essentia Health, Duluth, Minnesota, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Cardiology Associates of North Mississippi, Tupelo, Mississippi, United States|Gateway Cardiology, PC, Saint Louis, Missouri, United States|Saint John's Regional Medical Center, Springfield, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|New York Methodist Hospital, Brooklyn, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|SJH Cardiology Associates, Liverpool, New York, United States|Columbia University Medical Center, New York, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Central New York Cardiology, Utica, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Buffalo Cardiology and Pulmonary Associates, PC, Williamsville, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|Mid Carolina Cardiology, Charlotte, North Carolina, United States|Veterans Affairs Medical Center, Duke University Medical Center, Durham, North Carolina, United States|Carolina Cardiology Associates, High Point, North Carolina, United States|Wake Heart Research, Raleigh, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|Cardiology Associates of Southeast Ohio, Inc., Zanesville, Ohio, United States|Oklahoma City Veterans' Affairs Medical Center, Oklahoma City, Oklahoma, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|The Heart and Vascular Center, Beaver, Pennsylvania, United States|Central Bucks Cardiology, Doylestown, Pennsylvania, United States|Saint Vincent Health Care Center, Erie, Pennsylvania, United States|Veterans Administration Medical Center, Pittsburgh, Pennsylvania, United States|Pinnacle Health System, Wormleysburg, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Research Associates of Jackson, Jackson, Tennessee, United States|University of Tennessee, Knoxville, Tennessee, United States|Centennial Heart Cardiovascular Consultants, LLC, Nashville, Tennessee, United States|North Texas Healthcare System, Dept. of Veteran's Affairs, Dallas, Texas, United States|Humble Cardiology Associates, Humble, Texas, United States|Gamma Medical Research Inc., Mission, Texas, United States|San Antonio Endovascular and Heart Institute, San Antonio, Texas, United States|Victoria Heart and Vascular Center, Victoria, Texas, United States|Utah Cardiology, PC, Layton, Utah, United States|University of Vermont Medical Center, Fletcher Allen Health Care, Burlington, Vermont, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Landesklinikum Sankt Pölten, Saint Pölten, Lower Austria, Austria|Landeskrankenhaus Graz West, Graz, Styria, Austria|Innsbruck Universitaetsklinik, Innsbruck, Tyrol, Austria|Allgemeines Krankenhaus der Stadt Linz, Linz, Upper Austria, Austria|Medizinische Universität Wien, Wien, Vienna, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Antwerpen, Belgium|Imelda Ziekenhuis, Bonheiden, Antwerpen, Belgium|ZOL Genk, Campus Saint Jan, Genk, Limburg, Belgium|Algemeen Ziekenhuis Sint-Jan, Brugge, West-Vlaanderen, Belgium|Centre Hospitalier Universitaire Sart Tilman Liège, Liege, Belgium|Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|New Brunswick Heart Centre, Saint John, New Brunswick, Canada|Hamilton Health Sciences, General Site, Hamilton, Ontario, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|Scarborough Cardiology Research Associates, Scarborough, Ontario, Canada|Saint Michael's Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Karlovarská krajská nemocnice a.s., Karlovy Vary, Karlovarský kraj, Czech Republic|Krajská nemocnice Liberec a.s., Liberec, Liberecký kraj, Czech Republic|Fakultní nemocnice Brno, Brno, Czech Republic|Fakultní nemocnice u sv. Anny v Brne, Brno, Czech Republic|Fakultní nemocnice Olomouc, Olomoucký kraj, Czech Republic|Fakultní nemocnice Královské Vinohrady, Praha, Czech Republic|Všeobecná fakultní nemocnice v Praze, Praha, Czech Republic|Fakultní Nemocnice v Motole, Praha, Czech Republic|Hôpital Bichat-Claude Bernard, Paris, Ile-de-France, France|Hôpital Rangueil, Toulouse Cedex 9, Midi-Pyrenees, France|Centre Hospitalier d'Arras, Arras, Nord Pas-De-Calais, France|Centre Hospitalier d'Annecy, Pringy, Rhone-Alpes, France|Groupe hospitalier La Pitié Salpêtrière, Paris, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany|Kerckhoff-Klinik GmbH, Bad Nauheim, Hessen, Germany|Asklepios-Kliniken Langen, Langen, Hessen, Germany|Städtische Kliniken Bielefeld gGmbH, Bielefeld, Nordrhein-westfalen, Germany|Sankt Johannes Hospital, Dortmund, Nordrhein-westfalen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Nordrhein-westfalen, Germany|Krankenhaus Der Barmherzigen Brüder Trier, Trier, Rheinland-pfalz, Germany|Vivantes Klinikum im Friedrichshain, Berlin, Germany|Kaplan Medical Center, Rehovot, Reheoboth, Israel|HaEmek Medical Center, Afula, Israel|Barzilai Medical Center, Ashkelon, Israel|Assaf Harofeh Medical Centre, Beer Yahkov, Israel|Rambam Medical Center, Haifa, Israel|Bnai Zion Medical Center, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Ein-Kerem Medical Centre, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Western Galilee Hospital, Nahariya, Israel|Hillel Yaffe Medical Center, Ramat Gan, Israel|Tel Aviv Souraski Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel Hashomer, Israel|ZIV Medical Center, Zafed, Israel|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera S. Sebastiano di Caserta, Caserta, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Fondazione Centro S. Raffaele del Monte Tabor, Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera ""Maggiore della Carita"" di Novara, Novara, Italy|A.R.N.A.S. Civico G. Di Cristina Benfratelli, Palermo, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Ospedale Civile SS Annunziata ASL 1, Sassari, Italy|Catharina Ziekenhuis, Eindhoven, Noord-brabant, Netherlands|TweeSteden Ziekenhuis, Tilburg, Noord-brabant, Netherlands|Academisch Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, Zuid-holland, Netherlands|Ziekenhuis Rijnstate Arnhem, Gelderland, Netherlands|4th Wojskowy Szpital Kliniczny z Poliklinika, Klinika Kardiologii, Wroclaw, Dolnoslaskie, Poland|American Heart of Poland S.A., Belchatów, Lodzkie, Poland|American Heart of Poland S.A., Chrzanów, Malopolskie, Poland|Szpital Uniwersytecki w Krakowie, Kraków, Malopolskie, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Warszawa, Mazowieckie, Poland|Instytut Kardiologii, Warszawa, Mazowieckie, Poland|American Heart of Poland S.A., Kedzierzyn Kozle, Opolskie, Poland|American Heart of Poland S.A., Mielec, Podkarpackie, Poland|American Heart of Poland S.A., Bielsko-Biala, Slaskie, Poland|American Heart of Poland S.A., Dabrowa Górnicza, Slaskie, Poland|SPZOZ, SPSK nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach, Górnoslaskie Centrum Medyczne, Katowice, Slaskie, Poland|American Heart of Poland S.A., Tychy, Slaskie, Poland|American Heart of Poland S.A., Ustron, Slaskie, Poland|SPZOZ, Szpital Wojewódzki we Wloclawku, Kujawsko-pomorskie, Poland|Samodzielny Publiczny Szpital Kliniczny nr. 1 im. Przemienienia Panskiego, Poznan, Poland|Wojewódzki Szpital Zespolony im. Ludwika Rydygiera w Toruniu, Torun, Poland|SPZOZ, Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warszawa, Poland|Altai Regional Cardiological Dispensary, Barnaul, Russian Federation|Regional Clinical Hospital №3, Chelyabinsk, Russian Federation|Ural Institute of Cardiology, Ekaterinburg, Russian Federation|Cardiological Dispensary, Ivanovo, Russian Federation|Republic Clinical Hospital № 2, Kazan, Russian Federation|Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation|Medical Center ""Alliance"", Kirovsk, Leningradskaya Region, Russian Federation|Regional Clinical Hospital, Krasnoyarsk, Russian Federation|National Research Center For Preventive Medicine, Moscow, Russian Federation|City Clinical Hospital # 23 n.a.""Medsantrud"", Moscow, Russian Federation|City Clinical Hospital #15 named after O.M. Filatov, Moscow, Russian Federation|University Clinical Hospital #1, Moscow, Russian Federation|City Clinical Hospital n.a. S.P.Botkin, Moscow, Russian Federation|City Clinical Hospital #5, Nizhni Novgorod, Russian Federation|City Clinical Emergency Hospital # 2, Novosibirsk, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|Federal Center of Heart, Blood and Endocrinology n.a. V.A.Almazov, Saint-Petersburg, Russian Federation|Scientific and Research Institution Of Cardiology, Tomsk, Russian Federation|Volgograd Regional Clinical Cardiological Center, Volgograd, Russian Federation|Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitario de Bellvitge, L´Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Vigo, Meixoeiro Hospital, Vigo, Pontevedra, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Universitetssjukhuset Örebro, Örebro, Orebro, Sweden|Falu lasarett, Falun, Sweden|Sahlgrenska Universitetsjukhuset, Göteborg, Sweden|Karlstad Central Hospital, Karlstad, Sweden|Uppsala University Hospital, Uppsala, Sweden|Royal Sussex County Hospital, Brighton, England, United Kingdom|The James Cook University Hospital, Middlesbrough, England, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, England, United Kingdom|Ashford and Saint Peter's Hospital NHS Trust, Surrey, England, United Kingdom|Saint Richards Hospital, West Sussex, England, United Kingdom|Royal Victoria Hospital, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01442038"
773,"NCT03593759","Cardiac Sarcoidosis Randomized Trial","CHASM-CS-RCT","Recruiting","No Results Available","Cardiac Sarcoidosis|Sarcoidosis","Drug: Prednisone|Drug: Methotrexate","Summed perfusion rest score (SPRS) on FDG-PET scan|Mortality|Cardiovascular hospitalizations|Medication related adverse events|Modified Cleveland Clinic Glucocorticoid Toxicity Score|Glucocorticoid Toxicity Index|Patient reported symptoms related to medication|Medication compliance|Generic Quality of Life (SF 36)|Disease Specific Quality of Life (KSQ and SAT)|BMI|Blood pressure|HbA1C|T-score on bone density scan|FDG-PET and myocardial perfusion|Ventricular arrhythmia burden|Complete heart block|LVEF and RVEF assessed on echocardiogram|Highly sensitive Troponin I levels and BNP levels|CMR Endpoints","Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 3","194","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UOttawaHI","January 15, 2019","December 2022","December 2023","July 20, 2018",,"February 21, 2020","University of Michigan-Michigan Medicine Cardiovascular Center, Ann Arbor, Michigan, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Eastern Health Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada|St. Joseph's Healthcare Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|CIUSSS-Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval, Quebec City, Quebec, Canada|CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont, Sherbrooke, Quebec, Canada|Imperial College Healthcare Trust-NHS-Hammersmith Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03593759"
774,"NCT03525860","Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting",,"Active, not recruiting","No Results Available","Post-Operative Atrial Fibrillation|Acupuncture Therapy","Procedure: Acupuncture","Acupuncture treatment in the hospital setting|Number of patients with recurrent atrial fibrillation","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-006095","July 26, 2018","December 2020","December 2020","May 16, 2018",,"March 13, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03525860"
775,"NCT01769443","Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation",,"Terminated","Has Results","Primary Heart Transplant|Heart Transplantation|Heart Transplant","Drug: bortezomib|Procedure: plasmapheresis","Composite of Incidence of the Following Events in Subjects|Time From Wait Listing to Heart Transplantation|Change in Calculated PRA (cPRA) From Wait Listing to Transplantation|Incidence of Death|Incidence of Removal From Transplant Waiting List for Any Reason Except Improvement of Cardiac Function|Incidence of Initiation of Any Mechanical Circulatory Support Device|Incidence of Severe Infection Requiring Intravenous Antibiotics|Incidence of Cerebral Vascular Accident|Incidence of Acute Renal Failure Requiring Hemodialysis|Incidence of Administering Desensitization Therapy Beyond 90 Days After Randomization|Development of Angiographically Evident Cardiac Allograft Vasculopathy at 1 Year|Incidence of Serious Infections Requiring Intravenous Antimicrobial Therapy|Number of Subjects on Left Ventricular Assist Devices (LVAD) Compared to Those Not on LVADs|Cardiac Dysfunction as Reflected in the Left Ventricular Ejection Fractions < 40% by Echocardiography, Angiogram or Nuclear Testing.|Incidence of Post-Transplant Lymphoproliferative Disorder (PTLD)|Death|Re-transplantation or Re-listed for Transplantation|Incidence of Hospitalizations|Incidence of Rejection Episodes Per Subject and Freedom From Rejection","National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAIT CTOT-13|U01AI063594","June 2013","July 2014","July 2014","January 16, 2013","November 11, 2015","November 11, 2015","Cedars Sinai Heart Institute, Beverly Hills, California, United States|University of California at San Francisco, San Francisco, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Methodist Hospital, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01769443"
776,"NCT01067859","A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)","COMPOSE 2","Terminated","No Results Available","Acute Heart Failure","Drug: Cinaciguat (BAY58-2667)|Drug: Placebo","Pulmonary Capillary Wedge Pressure|Cardiac index (CI)|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Right atrial pressure (RAP)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14663|2009-014378-16","March 2010","September 2010","November 2010","February 12, 2010",,"October 8, 2015","Birmingham, Alabama, United States|Jacksonville, Florida, United States|Boston, Massachusetts, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Quilmes, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Graz, Steiermark, Austria|Innsbruck, Tirol, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Leuven, Belgium|Creteil, France|PARIS cedex 10, France|Toulouse, France|Bad Krozingen, Baden-Württemberg, Germany|Bad Nauheim, Hessen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Düsseldorf, Nordrhein-Westfalen, Germany|Berlin, Germany|Dublin, Ireland|Guadalajara, Jalisco, Mexico|Guadalajara, Jalisco, Mexico|Mexico D.F., México, Mexico|México D.F., Mexico|Quezon City, Philippines",,"https://ClinicalTrials.gov/show/NCT01067859"
777,"NCT03224585","Treatment of Acute Pericarditis With Anakinra",,"Active, not recruiting","No Results Available","Acute Pericarditis","Drug: Anakinra|Drug: Placebo","Pain Score","Virginia Commonwealth University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20008638","May 11, 2018","February 2021","March 2021","July 21, 2017",,"March 25, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03224585"
778,"NCT01251406","Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure","ZS-01-210","Completed","No Results Available","Chronic Heart Failure","Drug: Placebo|Drug: rhNRG-1 Dose 1|Drug: rhNRG-1 Dose 2","Change from baseline in LVEF|Six (6) minute walk test|Quality of Life Questionnaire (Kansas City Cardiomyopathy Questionnaire)|NYHA class status|All cause mortality and all cause hospitalization|Change in LVESV and LVEDV","Zensun Sci. & Tech. Co., Ltd.|Zensun USA Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ZS-01-210","January 2012","December 2012","March 2014","December 1, 2010",,"August 6, 2014","University of California, San Diego, La Jolla, California, United States|Metabolic Clinic and Research Center, Los Angeles, California, United States|USC Cardiovascular Division, Los Angeles, California, United States|Orange County Research Center, Tustin, California, United States|University of Colorado Denver, Denver, Colorado, United States|Clearwater Cardiovascular & Interventional Consultants, MD, PA, Clearwater, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|MedPharmics, LLC., Kenner, Louisiana, United States|Benchmark Research, Metairie, Louisiana, United States|East Texas Cardiology, Houston, Texas, United States|The Medical Center of Plano, Plano, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01251406"
779,"NCT01313572","Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI","ASPECT2","Terminated","No Results Available","Coronary Artery Disease","Drug: Apadenoson SPECT-MPI|Drug: Adenosine SPECT-MPI","Presence of myocardial perfusion defect based on SPECT-MPI|Incidence and subject rated intensity of most commonly reported side effects associated with use of adenosine compared to apadenoson in SPECT-MPI","Forest Laboratories|PPD","All","18 Years and older   (Adult, Older Adult)","Phase 3","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","PGX-III-AP-002","August 2011","April 2012","April 2012","March 11, 2011",,"May 1, 2012","Forest Investigative Site 138, Phoenix, Arizona, United States|Forest Investigative Site 146, Phoenix, Arizona, United States|Forest Investigative Site 113, Little Rock, Arkansas, United States|Forest Investigative Site 148, Beverly Hills, California, United States|Forest Investigative Site 154, Los Angeles, California, United States|Forest Investigative Site 131, Mission Viejo, California, United States|Forest Investigative Site 156, Denver, Colorado, United States|Forest Investigative Site 108, New Haven, Connecticut, United States|Forest Investigative Site 111, Newark, Delaware, United States|Forest Investigative Site 101, Clearwater, Florida, United States|Forest Investigative Site 163, Daytona Beach, Florida, United States|Forest Investigative Site 135, Edgewater, Florida, United States|Forest Investigative Site 102, Inverness, Florida, United States|Forest Investigative Site 151, Jacksonville, Florida, United States|Forest Investigative Site 105, Melbourne, Florida, United States|Forest Investigative Site 143, Melbourne, Florida, United States|Forest Investigative Site 137, Miami, Florida, United States|Forest Investigative Site 103, Miami, Florida, United States|Forest Investigative Site 123, Naples, Florida, United States|Forest Investigative Site 161, Safety Harbor, Florida, United States|Forest Investigative Site 118, Cumming, Georgia, United States|Forest Investigative Site 119, Tucker, Georgia, United States|Forest Investigative Site 166, Covington, Louisiana, United States|Forest Investigative Site 109, Hammond, Louisiana, United States|Forest Investigative Site 122, Slidell, Louisiana, United States|Forest Investigative Site 121, Auburn, Maine, United States|Forest Investigative Site 124, Annapolis, Maryland, United States|Forest Investigative Site 149, Hollywood, Maryland, United States|Forest Investigative Site 104, Detroit, Michigan, United States|Forest Investigative Site 134, Detroit, Michigan, United States|Forest Investigative Site 159, Rochester, Minnesota, United States|Forest Investigative Site 142, Kansas City, Missouri, United States|Forest Investigative Site 162, New Brunswick, New Jersey, United States|Forest Investigative Site 125, Albuquerque, New Mexico, United States|Forest Investigative Site 110, New York, New York, United States|Forest Investigative Site 153, Camp Hill, Pennsylvania, United States|Forest Investigative Site 152, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 120, Wyomissing, Pennsylvania, United States|Forest Investigative Site 145, Johnson City,, Tennessee, United States|Forest Investigative Site 140, Nashville, Tennessee, United States|Forest Investigative Site 107, Houston, Texas, United States|Forest Investigative Site 129, Houston, Texas, United States|Forest Investigative Site 115, Plano, Texas, United States|Forest Investigative Site 150, Tomball, Texas, United States|Forest Investigative Site 144, Provo, Utah, United States|Forest Investigative Site 205, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Forest Investigative Site 208, Rosario, Santa Fe, Argentina|Forest Investigative Site 204, Rosario, Santa Fé, Argentina|Forest Investigative Site 209, Buenos Aires, Argentina|Forest Investigative Site 212, Ciudad Autonoma de Buenos Aires, Argentina|Forest Investigative Site 207, Cordoba, Argentina|Forest Investigative Site 203, Cordoba, Argentina|Forest Investigative Site 211, Córdoba, Argentina|Forest Investigative Site 201, Godoy Cruz,, Argentina|Forest Investigative Site 202, Godoy Cruz, Argentina|Forest Investigative Site 214, La Plata, Argentina|Forest Investigative Site 210, Mar del Plata, Argentina|Forest Investigative Site 213, San Isidro, Argentina|Forest Investigative Site 206, Santa fe, Argentina|Forest Investigative Site 501, Aalst, Belgium|Forest Investigative Site 503, Bruxelles, Belgium|Forest Investigative Site 314, Curitiba, Parana, Brazil|Forest Investigative Site 312, Curitiba, Paraná, Brazil|Forest Investigative Site 309, São José do Rio Preto, São Paulo, Brazil|Forest Investigative Site 307, Belo Horizonte, Brazil|Forest Investigative Site 308, Belo Horizonte, Brazil|Forest Investigatie Site 301, Curitiba, Brazil|Forest Investigative Site 306, Goiânia, Brazil|Forest Investigative Site 310, Maceió, Brazil|Forest Investigative Site 302, Porto Alegre, Brazil|Forest Investigative Site 304, Recife, Brazil|Forest Investigative Site 315, Rio de Janeiro, Brazil|Forest Investigative Site 311, Rio de Janeiro, Brazil|Forest Investigative Site 303, Salvador, Brazil|Forest Investigative Site 313, Sao Paulo, Brazil|Forest Investigative Site 305, São José do Rio Preto, Brazil|Forest Investigative Site 316, São Paulo, Brazil|Forest Investigative Site 402, Gouda, Bleuland, Netherlands|Forest Investigative Site 403, Apeldoorn, Lukas, Netherlands|Forest Investigative Site 407, Amsterdam, Netherlands|Forest Investigative Site 405, Delft, Netherlands|Forest Investigative Site 401, Doetinchem, Netherlands|Forest Investigative Site 408, Hengelo, Netherlands|Forest Investigative Site 404, Hoogeveen, Netherlands|Forest Investigative Site 406, Maastricht, Netherlands|Forest Investigative Site 409, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01313572"
780,"NCT01198873","Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement","ODYSSEUS","Terminated","Has Results","Atrial Fibrillation","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","Change From Baseline in Left Atrial Volume Index (LAVi)|Changes From Baseline in Left Atrial Function|Changes From Baseline in Left Atrial Dimension|Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)|Changes From Baseline in Left Ventricular Function","Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRONE_L_04315","September 2010","January 2012","January 2012","September 10, 2010","February 12, 2013","February 12, 2013","Investigational Site Number 840072, Phoenix, Arizona, United States|Investigational Site Number 840015, Little Rock, Arkansas, United States|Investigational Site Number 840086, Beverly Hills, California, United States|Investigational Site Number 840018, Loma Linda, California, United States|Investigational Site Number 840029, Merced, California, United States|Investigational Site Number 840044, Redwood City, California, United States|Investigational Site Number 840042, Santa Ana, California, United States|Investigational Site Number 840060, Vista, California, United States|Investigational Site Number 840057, Stamford, Connecticut, United States|Investigational Site Number 840002, Newark, Delaware, United States|Investigational Site Number 840063, Wilmington, Delaware, United States|Investigational Site Number 840070, Bradenton, Florida, United States|Investigational Site Number 840010, Jacksonville, Florida, United States|Investigational Site Number 840071, Jupiter, Florida, United States|Investigational Site Number 840061, Lakeland, Florida, United States|Investigational Site Number 840096, Lauderdale Lakes, Florida, United States|Investigational Site Number 840031, Ocala, Florida, United States|Investigational Site Number 840074, Orlando, Florida, United States|Investigational Site Number 840016, Ormond Beach, Florida, United States|Investigational Site Number 840051, St Petersburg, Florida, United States|Investigational Site Number 840081, Roswell, Georgia, United States|Investigational Site Number 840103, Jerseyville, Illinois, United States|Investigational Site Number 840106, Peoria, Illinois, United States|Investigational Site Number 840066, Elkhart, Indiana, United States|Investigational Site Number 840099, Lexington, Kentucky, United States|Investigational Site Number 840039, Owensboro, Kentucky, United States|Investigational Site Number 840092, Baton Rouge, Louisiana, United States|Investigational Site Number 840040, Auburn, Maine, United States|Investigational Site Number 840077, Ayer, Massachusetts, United States|Investigational Site Number 840050, Alpena, Michigan, United States|Investigational Site Number 840041, Saginaw, Michigan, United States|Investigational Site Number 840058, Minneapolis, Minnesota, United States|Investigational Site Number 840101, Picayune, Mississippi, United States|Investigational Site Number 840078, St Louis, Missouri, United States|Investigational Site Number 840038, St Louis, Missouri, United States|Investigational Site Number 840102, St. Louis, Missouri, United States|Investigational Site Number 840012, Kalispell, Montana, United States|Investigational Site Number 840090, Lincoln, Nebraska, United States|Investigational Site Number 840003, Bronx, New York, United States|Investigational Site Number 840045, Buffalo, New York, United States|Investigational Site Number 840055, Manhasset, New York, United States|Investigational Site Number 840004, Troy, New York, United States|Investigational Site Number 840009, Maumee, Ohio, United States|Investigational Site Number 840028, Camp Hill, Pennsylvania, United States|Investigational Site Number 840067, Wyomissing, Pennsylvania, United States|Investigational Site Number 840027, Wakefield, Rhode Island, United States|Investigational Site Number 840046, Knoxville, Tennessee, United States|Investigational Site Number 840014, Longview, Texas, United States|Investigational Site Number 840068, Danville, Virginia, United States|Investigational Site Number 840069, Manassas, Virginia, United States|Investigational Site Number 840087, Richmond, Virginia, United States|Investigational Site Number 840085, Winchester, Virginia, United States|Investigational Site Number 840013, Burien, Washington, United States|Investigational Site Number 840091, Spokane, Washington, United States|Investigational Site Number 840080, Madison, Wisconsin, United States|Investigational Site Number 840023, Milwaukee, Wisconsin, United States|Investigational Site Number 124003, Cambridge, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01198873"
781,"NCT02226120","Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction",,"Completed","Has Results","Chronic Heart Failure With Reduced Ejection Fraction","Drug: LCZ696","Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Older Adult","Phase 3","1980","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLCZ696B2317|2014-001971-30","October 16, 2014","December 28, 2017","December 28, 2017","August 27, 2014","February 20, 2019","February 20, 2019","Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Muscle Shoals, Alabama, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Santa Rosa, California, United States|Novartis Investigative Site, Boynton Beach, Florida, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Columbia, Maryland, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Fremont, Nebraska, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Rosedale, New York, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Livingston, Texas, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Waukesha, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Capital Federal, Argentina|Novartis Investigative Site, San Salvador de Jujuy, Jujuy, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, San Luis, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santiago del Estero, Argentina|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, La Louviere, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Ronse, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Sao Luis, MA, Brazil|Novartis Investigative Site, Uberlandia, Mg-cep, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belem, PA, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Marilia, SP, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Santo Andre, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Votuporanga, SP, Brazil|Novartis Investigative Site, Haskovo, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Levis, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, St-Georges Beauce, Quebec, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Beroun, Czech Republic, Czechia|Novartis Investigative Site, Brandys nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Liberec V Kristianova, Czech Republic, Czechia|Novartis Investigative Site, Olomouc, Czech Republic, Czechia|Novartis Investigative Site, Prague 10, Vrsovice, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Bilovec, CZE, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Uherske Hradiste, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Randers, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Montpellier cedex 5, Herault, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Bad Homburg, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Berlin-Buch, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dessau-Roßlau, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Huy / OT Anderbeck, Germany|Novartis Investigative Site, Ingelheim, Germany|Novartis Investigative Site, Kelkheim, Germany|Novartis Investigative Site, Koethen, Germany|Novartis Investigative Site, Künzelsau, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Loehne, Germany|Novartis Investigative Site, Muehldorf, Germany|Novartis Investigative Site, Muehlheim An Der Ruhr, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Wermsdorf, Germany|Novartis Investigative Site, Wetzlar-Naunheim, Germany|Novartis Investigative Site, Weyhe, Germany|Novartis Investigative Site, Guatemala, Ciudad, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Hong Kong SAR, Hong Kong|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Nyiregyháza, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Zalaegerszeg, Hungary|Novartis Investigative Site, Guntur, Andhra Pradesh, India|Novartis Investigative Site, Dehli, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Anand, Gujarat, India|Novartis Investigative Site, Surat, Gujarat, India|Novartis Investigative Site, Surat, Gujrat, India|Novartis Investigative Site, Vadodara, Gujrat, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Indore, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Safed, Israel|Novartis Investigative Site, Aosta, AO, Italy|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Treviglio, BG, Italy|Novartis Investigative Site, Cosenza, CS, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Lido di Camaiore, LU, Italy|Novartis Investigative Site, Milazzo, ME, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pescia, Point, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Ariccia, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Wonju, Gangwon-Do, Korea, Republic of|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho-gu, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Ventspils, Latvia|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Kedainiai, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, San Juan del Rio, Queretaro, Mexico|Novartis Investigative Site, Aguascalientes, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, San Luis Potosí, Mexico|Novartis Investigative Site, Breda, CK, Netherlands|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Bosch, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Gorinchem, Netherlands|Novartis Investigative Site, Hardenberg, Netherlands|Novartis Investigative Site, Harderwijk, Netherlands|Novartis Investigative Site, Heerenveen, Netherlands|Novartis Investigative Site, Hengelo, Netherlands|Novartis Investigative Site, Sneek, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Veldhoven, Netherlands|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Bellavista, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, La Molina, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lipa City, Batangas, Philippines|Novartis Investigative Site, Quezon City, Manila, Philippines|Novartis Investigative Site, Pasig City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Vila Real, Portuigal, Portugal|Novartis Investigative Site, Covilha, Portugal|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Portalegre, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Setubal, Portugal|Novartis Investigative Site, Bucharest, District 1, Romania|Novartis Investigative Site, Bucuresti, District 1, Romania|Novartis Investigative Site, Craiova, Jud. Dolj, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Deva, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N. Novgorod, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk-117, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Rostov-on-Don, Russian Federation|Novartis Investigative Site, S-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Tula, Russian Federation|Novartis Investigative Site, Vladimir, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Brezno, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Levice, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Svidnik, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Martin, Slovakia|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Durban, Kwa-Zulu Natal, South Africa|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, Alberton, South Africa|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Kempton Park, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sant Joan Despi, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Vigo, Galicia, Spain|Novartis Investigative Site, Alcala de Henares, Madrid, Spain|Novartis Investigative Site, Mostoles, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Stockholm, SE, Sweden|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Karlshamn, Sweden|Novartis Investigative Site, Motala, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Yilan, Taiwan|Novartis Investigative Site, Taladkwan, Nonthaburi, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Muang, Thailand|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Durham, County Durham, United Kingdom|Novartis Investigative Site, Dorchester, Dorset, United Kingdom|Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom|Novartis Investigative Site, Portsmouth, Hampshire, United Kingdom|Novartis Investigative Site, Inverness, Invernesshire, United Kingdom|Novartis Investigative Site, Oldham, Lancashire, United Kingdom|Novartis Investigative Site, Leicester, Leicestershire, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom|Novartis Investigative Site, Dundee, Perthshire, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, Yeovil, Somerset, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, Redhill, Surrey, United Kingdom|Novartis Investigative Site, South Shields, Tyne And Wear, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Dudley, West Midlands, United Kingdom|Novartis Investigative Site, Cheshire, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Kent, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Milton Keynes, United Kingdom|Novartis Investigative Site, Newport, United Kingdom|Novartis Investigative Site, Newport, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Poole, United Kingdom|Novartis Investigative Site, Rotherham, United Kingdom|Novartis Investigative Site, Worcester, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02226120/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02226120/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02226120"
782,"NCT01347710","A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.",,"Completed","Has Results","Coronary Artery Disease","Drug: Flurpiridaz F18|Drug: 99mTechnicium (sestamibi or tetrofosmin)","Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity|Diagnostic Efficacy of Flurpiridaz PET MPI Specificity Versus SPECT MPI Specificity|Diagnostic Efficacy of Flurpiridaz F18 PET MPI Sensitivity Versus SPECT MPI Sensitivity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.|Diagnostic Efficacy of Flurpiridaz F18 PET MPI Specificity Versus SPECT Specificity in Subgroups: Pharmacologic Stress, Females and BMI>/=30.|Diagnostic Performance Evaluation of Localization of CAD for Sensitivity (PETVsSPECT).|Diagnostic Performance Evaluation of Localization of CAD for Specificity (PETVsSPECT).|Diagnositic Performance Evaluation of Multivessel Disease (PETvsSPECT).|Overall Summary of Sensitivity of PET MPI vs SPECT MPI; Image Quality Excellent or Good|Overall Summary of Specificity of PET MPI vs SPECT MPI; Image Quality of Excellent or Good|Image Quality of Rest and Stress (PET vs SPECT).|Diagnostic Certainty in PET MPI and SPECT MPI","Lantheus Medical Imaging","All","18 Years and older   (Adult, Older Adult)","Phase 3","795","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BMS747158-301","June 2011","July 2013","September 2013","May 4, 2011","April 5, 2016","April 5, 2016","Cardiology Associates of Mobile, Inc., Mobile, Alabama, United States|Scottsdale Medical Imaging, Ltd., Scottsdale, Arizona, United States|West Side Medical Associates of Los Angeles, Beverly Hills, California, United States|USC PET Imaging Science Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA West Los Angeles Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States|Cardiovascular Consultants Medical Group, Pleasant Hill, California, United States|Northern California PET Imaging Center-Palo Alto, Sacramento, California, United States|VA San Diego Healthcare System, San Diego, California, United States|UCSF Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Alfieri Cardiology, Newark, Delaware, United States|Christiana Care Health System, Newark, Delaware, United States|Elite Research and Clinical Trials, Aventura, Florida, United States|Independent Imaging, LLC, Boynton Beach, Florida, United States|Coastal Cardiology Consultants dba The Heart & Vascular Institute of Florida, Clearwater, Florida, United States|Florida Heart Associates, Fort Myers, Florida, United States|St. Luke's Cardiology Associates, Jacksonville, Florida, United States|The Cardiovascular Center, PA, Lake Mary, Florida, United States|Florida Hospital/Cardiovascular Institute (Florida Heart Group), Orlando, Florida, United States|South Florida Research Solutions, Pembroke Pines, Florida, United States|Memorial Hospital of Tampa, Tampa, Florida, United States|Georgia Health Sciences Univ/Med College of GA, Augusta, Georgia, United States|South Coast Imaging Center, Savannah, Georgia, United States|Gateway Cardiology, PC, Jerseyville, Illinois, United States|Norton Cardiovascular Associates, Louisville, Kentucky, United States|Biomedical Research Foundation of Northwest Louisiana, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Mass General Hospital (MGH), Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University - Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. Mary's Healthcare (Trinity Health), Grand Rapids, Michigan, United States|McLaren Macomb, Mount Clemens, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Missouri Cardiovascular Specialists, LLP, Columbia, Missouri, United States|Cardiovascular Imaging Technologies (CVIT), Kansas City, Missouri, United States|Saint Louis University School of Medicine, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|St. Francis Hospital, Roslyn, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Pinnacle Health Cardiovascular Institute/ Associated Cardiologists, Harrisburg, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Presbyterian University Hospital, Pittsburgh, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|York Hospital /Wellspan Health, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Wellmont CVA Heart Institute, Kingsport, Tennessee, United States|Center for Biomedical Research, Knoxville, Tennessee, United States|Cardiovascular Research of Knoxville - St. Mary's Health Care System, Inc., Knoxville, Tennessee, United States|Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States|Katy Cardiology, Katy, Texas, United States|West Houston Area Clinical Trial Consultants, LLC, Tomball, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|McGuire Veteran Affairs Medical Center, Richmond, Virginia, United States|Carilion Cardiology Clinic, Roanoke, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|University of Western Ontario, London, Ontario, Canada|KMH Cardiology and Diagnostic and MRI Centres, Mississauga, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada|Helsinki University Hospital, Helsinki, Finland|Turku PET Centre, Turku, Finland|San Patricio MEDFLIX (San Patricio MRI & CT Center), Guaynabo, Puerto Rico|VA Caribbean Healthcare System, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01347710"
783,"NCT00990327","Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI","ASPECT","Terminated","No Results Available","Coronary Artery Disease","Drug: Apadenoson SPECT-MPI|Drug: Adenosine SPECT-MPI","Presence of myocardial perfusion defect as based on SPECT-MPI|Incidence and patient rated intensity of most commonly reported side effects (e.g. dyspnea, flushing, chest pain, headache) associated with use of adenosine compared to apadenoson in SPECT-MPI","Forest Laboratories|PPD","All","18 Years and older   (Adult, Older Adult)","Phase 3","863","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","PGX-III-AP-001","November 2009","April 2012","April 2012","October 6, 2009",,"May 1, 2012","Forest Investigative Site 152, Birmingham, Alabama, United States|Forest Investigative Site 250, Mobile, Alabama, United States|Forest Investigative Site 223, Phoenix, Arizona, United States|Forest Investigative Site 191, Phoenix, Arizona, United States|Forest Investigative Site 230, Jonesboro, Arkansas, United States|Forest Investigative Site 153, Little Rock, Arkansas, United States|Forest Investigative Site 108, La Mesa, California, United States|Forest Investigative Site 111, Mission Viejo, California, United States|Forest Investigative Site 234, Murrieta, California, United States|Forest Investigative Site 146, Roseville, California, United States|Forest Investigative Site 225, Sacramento, California, United States|Forest Investigative Site 122, Sacramento, California, United States|Forest Investigative Site 105, Santa Rosa, California, United States|Forest Investigative Site 196, Walnut Creek, California, United States|Forest Investigative Site 132, Hartford, Connecticut, United States|Forest Investigative Site 102, Newark, Delaware, United States|Forest Investigative Site 205, Daytona Beach, Florida, United States|Forest Investigative Site 233, Edgewater, Florida, United States|Forest Investigative Site 164, Gainesville, Florida, United States|Forest Investigative Site 126, Jacksonville Beach, Florida, United States|Forest Investigative Site 120, Jacksonville, Florida, United States|Forest Investigative Site 198, Jacksonville, Florida, United States|Forest Investigative Site 118, Jacksonville, Florida, United States|Forest Investigative Site 124, Jacksonville, Florida, United States|Forest Investigative Site 125, Jacksonville, Florida, United States|Forest Investigative Site 180, Melbourne, Florida, United States|Forest Investigative Site 183, Miami, Florida, United States|Forest Investigative Site 106, Miami, Florida, United States|Forest Investigative Site 201, Naples, Florida, United States|Forest Investigative Site 240, Tampa, Florida, United States|Forest Investigative Site 238, Wellington, Florida, United States|Forest Investigative Site 155, Augusta, Georgia, United States|Forest Investigative Site 199, Cumming, Georgia, United States|Forest Investigative Site 204, Tucker, Georgia, United States|Forest Investigative Site 116, Honolulu, Hawaii, United States|Forest Investigative Site 137, Boise, Idaho, United States|Forest Investigative Site 138, Boise, Idaho, United States|Forest Investigative Site 227, Chicago, Illinois, United States|Forest Investigative Site 228, Joliet, Illinois, United States|Forest Investigative Site 173, Winfield, Illinois, United States|Forest Investigative Site 113, Indianapolis, Indiana, United States|Forest Investigative Site 168, Valparaiso, Indiana, United States|Forest Investigative Site 171, West Des Moines, Iowa, United States|Forest Investigative Site 133, Overland Park, Kansas, United States|Forest Investigative Site 248, Crestview Hills, Kentucky, United States|Forest Investigative Site 241, Owensboro, Kentucky, United States|Forest Investigative Site 202, Alexandria, Louisiana, United States|Forest Investigative Site 257, Covington, Louisiana, United States|Forest Investigative Site 114, Auburn, Maine, United States|Forest Investigative Site 107, Scarborough, Maine, United States|Forest Investigative Site 109, South Portland, Maine, United States|Forest Investigative Site 193, Baltimore, Maryland, United States|Forest investigative Site 197, Westminster, Maryland, United States|Forest Investigative Site 143, Detroit, Michigan, United States|Forest Investigative Site 207, Petoskey, Michigan, United States|Forest Investigative Site 177, Saint Louis Park, Minnesota, United States|Forest Investigative Site 131, Tupelo, Mississippi, United States|Forest Investigative Site 176, Kansas City, Missouri, United States|Forest Investigative Site 159, St. Louis, Missouri, United States|Forest Investigative Site 188, Missoula, Montana, United States|Forest Investigative Site 115, Albany, New York, United States|Forest Investigative Site 212, Buffalo, New York, United States|Forest Investigative Site 165, Kingston, New York, United States|Forest Investigative Site 224, Manhasset, New York, United States|Forest Investigative Site 139, Massapequa, New York, United States|Forest Investigative Site 208, Raleigh, North Carolina, United States|Forest Investigative Site 249, Sanford, North Carolina, United States|Forest Investigative Site 214, Fargo, North Dakota, United States|Forest Investigative Site 235, Akron, Ohio, United States|Forest Investigative Site163, Columbus, Ohio, United States|Forest Investigative Site 161, Columbus, Ohio, United States|Forest Investigative Site 156, Lorain, Ohio, United States|Forest Investigative Site 185, Sandusky, Ohio, United States|Forest Investigative Site 101, Westlake, Ohio, United States|Forest Investigative Site 182, Oklahoma City, Oklahoma, United States|Forest Investigative Site 190, Bend, Oregon, United States|Forest Investigative Site 217, Portland, Oregon, United States|Forest Investigative Site 213, Camp Hill, Pennsylvania, United States|Forest Investigative Site 154, Philadelphia, Pennsylvania, United States|Forest Investigative Site 134, Philadelphia, Pennsylvania, United States|Forest Investigative Site 218, Philadelphia, Pennsylvania, United States|Forest Investigative Site 160, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 187, Sellersville, Pennsylvania, United States|Forest Investigative Site 117, Wyomissing, Pennsylvania, United States|Forest Investigative Site 149, Charleston, South Carolina, United States|Forest Investigative Site 172, Simpsonville, South Carolina, United States|Forest Investigative Site 229, Spartanburg, South Carolina, United States|Forest Investigative Site 167, Johnson City, Tennessee, United States|Forest Investigative Site 192, Johnson City, Tennessee, United States|Forest Investigative Site 128, Amarillo, Texas, United States|Forest Investigative Site 252, Grapevine, Texas, United States|Forest Investigative Site 200, McKinney, Texas, United States|Forest Investigative Site 181, Plano, Texas, United States|Forest Investigative Site 253, San Antonio, Texas, United States|Forest Investigative Site 186, Sugar Land, Texas, United States|Forest Investigative Site 231, Tomball, Texas, United States|Forest Investigative Site 232, Tomball, Texas, United States|Forest Investigative Site 236, Provo, Utah, United States|Forest Investigative Site 210, Charlottesville, Virginia, United States|Forest Investigative Site 110, Roanoke, Virginia, United States|Forest Investigative Site 151, Seattle, Washington, United States|Forest Investigative Site 142, Spokane, Washington, United States|Forest Investigative Site 144, Madison, Wisconsin, United States|Forest Investigative Site 306, Salvador, Bahia, Brazil|Forest Investigative Site 307, Curitiba, Parana, Brazil|Forest Investigative Site 308, Belo Horizonte - MG, Brazil|Forest Investigative Site 317, Brasília - DF, Brazil|Forest Investigative Site 311, Campinas, Brazil|Forest Investigative Site 314, Curitiba - PR, Brazil|Forest Investigative Site 313, Curitiba, Brazil|Forest Investigative Site 305, Curitiba, Brazil|Forest Investigative Site 316, Niteroi, Brazil|Forest Investigative Site 309, Passo Fundo - RS, Brazil|Forest Investigative Site 318, Porto Alegre - RS, Brazil|Forest Investigative Site 310, Porto Alegre - RS, Brazil|Forest Investigative Site 319, Rio de Janeiro - RJ, Brazil|Forest Investigative Site 304, Rio de Janeiro - RJ, Brazil|Forest Investigative Site 315, Rio de Janeiro, Brazil|Forest Investigative Site 301, Salvador - BA, Brazil|Forest Investigative Site 303, São José, Brazil|Forest Investigative Site 302, São Paulo - SP, Brazil|Forest Investigative Site 312, São Paulo - SP, Brazil",,"https://ClinicalTrials.gov/show/NCT00990327"
784,"NCT03068130","Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER","RANGER","Recruiting","No Results Available","Pulmonary Hypertension","Drug: Bardoxolone methyl","Long-term Safety","Reata Pharmaceuticals, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","414","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTA 402-C-1602","April 18, 2017","December 2021","December 2021","March 1, 2017",,"August 28, 2019","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|University of California San Diego, La Jolla, California, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|University of California Davis Medical Center - Division of Pulmonary and Critical Care, Sacramento, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver - Division of Pulmonary Sciences, Aurora, Colorado, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Augusta University, Augusta, Georgia, United States|Piedmont-Georgia Lung, Austell, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Maine Medical Center - Division of Pulmonary and Critical Care Medicine, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|BreatheAmerica El Paso, El Paso, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, United States|University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Aurora Health Care, Milwaukee, Wisconsin, United States|Centro Médico Dra de Salvo, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Buenos Aires, Mar Del Plata, Argentina|Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Instituto Cardiovascular de Rosario, Rosario, Argentina|Hospital Provincial Dr Jose Maria Cullen, Santa Fe, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Hospital Erasme, Brussels, Belgium|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Peter Lougheed Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de l'Université Laval, Sainte Foy, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Prague, Czechia|Institut klinicke a experimentalni mediciny, Prague, Czechia|Universitatsklinkum Carl Gustav Carus an der Tu, Dresden, Germany|Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany|Thorax Klinik, Heidelberg, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Kyorin University Hospital, Tokyo, Mitaka-shi, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan|Chiba University Hospital, Chiba, Japan|Hokkaido University Hospital, Sapporo, Japan|Kurume University Medical Center, Sendai-shi, Japan|National Cerebral and Cardiovascular Center, Suita, Japan|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Nuevo León, Monterrey, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Nuevo Leon, Mexico|Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands|Philippine Heart Center, Quezon City, Metro Manila, Philippines|Makati Medical Center, Makati, Philippines|Philippine General Hospital (PGH), Manila, Philippines|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de La Salud, Toledo, Spain|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03068130"
785,"NCT00964678","Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Carvedilol","Absolute Change in Right Ventricular Ejection Fraction|Change in Right Ventricular End Systolic Volume|Change in 6 Minute Walk Distance|Change in Tricuspid Annular Plane Systolic Excursion","Virginia Commonwealth University|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM12120","June 2010","May 2014","May 2014","August 25, 2009","June 8, 2017","June 8, 2017","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00964678"
786,"NCT03458130","Study of AG10 in Amyloid Cardiomyopathy",,"Completed","No Results Available","Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM)","Drug: AG10|Drug: Placebo Oral Tablet","Assessment of safety and tolerability|AG10 Pharmacokinetics AUC|AG10 Pharmacodynamic Assessments of TTR stabilization by Fluorescent Polarization Exclusion Assay|AG10 Pharmacodynamic Assessments of TTR stabilization by Western Blot|AG10 Pharmacodynamic Assessments: prealbumin","Eidos Therapeutics","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AG10-201","April 27, 2018","October 5, 2018","October 5, 2018","March 8, 2018",,"November 20, 2019","Cedars-Sinai Medical Center, Beverly Hills, California, United States|Stanford University, Palo Alto, California, United States|University of California San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Northwestern University, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03458130"
787,"NCT02842242","A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction","PIONEER-HCM","Completed","Has Results","Cardiomyopathy, Hypertrophic Obstructive|Left Ventricular Outflow Tract Obstruction","Drug: MYK-461","Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12|Number of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg|Change in Dyspnea Symptom Score From Baseline to Week 12|Change in Peak VO2 From Baseline to Week 12|Change in VE/VCO2 From Baseline to Week 12|Change in Resting LVEF From Baseline to Week 12|Change in LV Fractional Shortening (LVFS) From Baseline to Week 12|Change in Global Longitudinal Strain (GLS) From Baseline to Week 12|Change in Post-exercise Peak LVOT Gradient From Week 12 to Week 16","MyoKardia, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MYK-461-004","August 2016","November 2017","November 2017","July 22, 2016","February 5, 2020","February 5, 2020","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Tufts Medical Center, Boston, Massachusetts, United States|Washington University St. Louis, Saint Louis, Missouri, United States|Duke Health Center at Southpoint, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania (Penn Heart and Vascular Center), Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02842242/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02842242/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02842242"
788,"NCT02833948","Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)","GALILEO-4D","Completed","Has Results","Aortic Valve Stenosis|Cardiovascular Diseases|Heart Valve Diseases|Ventricular Outflow Obstruction|Thrombosis","Drug: Acetylsalicylic acid|Drug: Clopidogrel|Drug: Rivaroxaban","Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan|The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan|The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan|The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan|Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.|Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.|Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.|Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.|Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.|Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.","ECRI bv|Rigshospitalet, Denmark|Bayer|Cardialysis BV","All","18 Years and older   (Adult, Older Adult)","Phase 3","231","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","ECRI 006 - H-15016807","May 2016","December 2018","March 6, 2019","July 14, 2016","January 18, 2020","January 18, 2020","Cedars Sinai Medical Center, Los Angeles, California, United States|Mount Sinai M.C, New York, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas, Health Science Center, Houston, Texas, United States|University of Alberta Hospital, Edmonton, Canada|Providence Health Care, Vancouver, Canada|Aarhus university hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark|Kerckhoff Klinik GmbH, Bad Nauheim, Germany|Charité- Universitätsmedizin Berlin - Campus Mitte, Berlin, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany|St. Johannes Hospital, Dortmund, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Medicin Herzzentrum Lahr/Baden, Lahr, Germany|Herzzentrum Leipzig - Universitätsklinik, Leipzig, Germany|Deutsches Herzzentrum München, München, Germany|Academic Medical Center, Amsterdam, Netherlands|Amphia Zienkenhuis, Breda, Netherlands|Erasmus M.C, Rotterdam, Netherlands|Skåne University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital Basel, Basel, Switzerland|Inselspital, Bern, Switzerland","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02833948/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02833948"
789,"NCT00918866","A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure",,"Completed","Has Results","Pulmonary Heart Disease","Drug: Definity","Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose|Immunology Panel- Complement 3A (C3A)|Immunology Panel- Complement 5A(C5A)|Immunology Panel- Interleuken-6|Immunology Panel- Tryptase","Lantheus Medical Imaging","All","18 Years and older   (Adult, Older Adult)","Phase 4","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DMP 115-416","July 2009","December 2009","December 2009","June 11, 2009","July 11, 2011","April 17, 2015","Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Methodist Hospital, St. Louis Park, Minnesota, United States|Cardiovascular Consultants, Kansas City, Missouri, United States|Holy Name Hospital, Teaneck, New Jersey, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|The University of Texas Medical Branch at Galveston, Galveston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00918866"
790,"NCT02104583","Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator","TEMPO","Completed","Has Results","Ventricular Arrhythmia","Drug: Eleclazine|Drug: Placebo to match eleclazine","Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24|Overall Occurrence (Total Number) of Appropriate ICD Interventions (ATP or Shock) Through End of Study|Change From Baseline in Premature Ventricular Complex (PVC) Count as Assessed by Continuous Electrocardiogram (cECG) Monitoring|Change From Baseline in Nonsustained Ventricular Tachycardia (nsVT) Count as Assessed by Continuous cECG Monitoring|Overall Occurrence (Total Number) of Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) (Treated or Untreated) Through Week 24 and End of Study|Overall Occurrence (Total Number) of Electrical Storm Through Week 24 and End of Study|Overall Occurrence (Total Number) of Inappropriate ICD Interventions Through Week 24 and End of Study|Change in Left Ventricular Systolic and Diastolic Function as Assessed by Left Ventricular Ejection Fraction (LVEF)|Time From First Dose of Study Drug to the First Occurrence of Appropriate ICD Interventions (ATP or Shock) or Cardiovascular (CV) Death|Time From First Dose of Study Drug to the First Occurrence of CV Hospitalization, Emergency Room (ER) Visit, or CV Death","Gilead Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","313","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-356-0101|2013-004430-15","September 2014","September 2016","October 2016","April 4, 2014","April 9, 2019","April 9, 2019","Cardiovascular Associates of Mesa, Mesa, Arizona, United States|Long Beach Memorial Hospital, Long Beach, California, United States|Good Samaritan Hospital, Los Angeles, California, United States|Radin Cardiovascular Medical Associates, Newport Beach, California, United States|Regional Cardiology Associates, Sacramento, California, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Atlantic Clinical Research Collaborative, Atlantis, Florida, United States|Clearwater Cardiovascular and Interventional Consultants, Clearwater, Florida, United States|Coastal Cardiology Consultants PA dba Heart and Vascular Institute of Florida, Clearwater, Florida, United States|The Heart Institute at Largo, Largo, Florida, United States|Charlotte Heart and Vascular Institute, Port Charlotte, Florida, United States|Florida Medical Clinic PA, Zephyrhills, Florida, United States|Athens Regional Specialty Services, Athens, Georgia, United States|Washington Adventist Hospital, Takoma Park, Maryland, United States|Mid Michigan Medical Center - Midland, Midland, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Great Falls Clinic, Great Falls, Montana, United States|Methodist Physicians Clinic Heart Consultants, Omaha, Nebraska, United States|New Mexico Hear Institute, Albuquerque, New Mexico, United States|New York Methodist Hospital, Brooklyn, New York, United States|Durham VA Medical Center, Durham, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Ohiohealth Corporation, Columbus, Ohio, United States|Capital Area Research, Camp Hill, Pennsylvania, United States|CardioVascular Institute, Wormleysburg, Pennsylvania, United States|Care New England Health Care, Kent Hospital, Warwick, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Volunteer Research Group, Knoxville, Tennessee, United States|Seton Heart Institute, Austin, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|West Houston Area Clinical Trial Consultants, Houston, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Virginia Heart Group Ltd, Falls Church, Virginia, United States|Stroobants Cardiovascular Center, Lynchburg, Virginia, United States|Carilion Roanoke Memorial Hospital, Roanoke, Virginia, United States|Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States|Kingston General Hospital, Kingston, Ontario, Canada|Chum Hotel Dieu, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke CHUS, Sherbrooke, Quebec, Canada|QEII Health Sciences Centre, Halifax, Canada|Fakultni nemocnice Olomouc, Olomouc, Czechia|Charles University Hospital Královské Vinohrady, Prague, Czechia|Aalborg University Hospital, Aalborg, Denmark|Rigshospitalet, The Heart Center, Copenhagen, Denmark|Gentofte Hospitak, Deparment of Cardiology, Hellerup, Denmark|Odense University Hospital/Department of Cardiology, Odense C, Denmark|Vivantes Humboldt Klinikum, Berlin, Germany|University Medical Center Goettingen, Goettingen, Germany|University of Heidelberg, Heidelberg, Germany|Medizinische Klinik und Poliklinik I Abteilung für Kardiologie, Munich, Germany|Klinikum der Universität Regensburg, Regensburg, Germany|Gemeinschaftspraxis für Innere Medizin, Riesa, Germany|State Hospital for Cardiology, Balatonfüred, Hungary|Budai Irgalmasrendi Kórház, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Zala Megyei Kórház, Zalaegerszeg, Hungary|HaEmek Medical Center, Afula, Israel|Rambam Health Care Campus, Haifa, Israel|Tel Aviv University/Meir Medical Center, Israel, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Catharina ziekenhuis, Eindhoven, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|St.Antonius Hospital, Nieuwegein, Netherlands|Isala, Zwolle, Netherlands|Samodzielny Publiczny Szpital Kliniczny nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach Górnosla, Katowice, Poland|Collegium Medicum Uniwersytetu Jagiellonskiego, Kraków, Poland|Medical University of Lodz, Lodz, Poland|Mc Tronik Specjalistyczny Gabinet Kontroli Stymulatorow Serca Dr N. Med. Michal Chudzik, Lódz, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Andrzej Lubinski, Lódz, Poland|NZOZ Sopockie Centrum badan Kardiolog.ProCordis pawel Miekus, Sopot, Poland|Indywidualna Specjalistyczna Praktyka Lekarska Jarosław Kaźmierczak, Szczecin, Poland|Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego, Warsaw, Poland|Szpital Wolski im Dr Anny Gostynskiej SP ZOZ, Warszawa, Poland|Warszawski Uniwersytet Medyczny, Warszawa, Poland|Medical University Wroclaw, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT02104583"
791,"NCT01149421","A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: LY2189265|Drug: Placebo","Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)|Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)|Change From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)|Change From Baseline to 16 and 26 Weeks in Mean 24-Hour Heart Rate (HR)|Change From Baseline to 16 and 26 Weeks in Mean 24-hour Pulse Pressure|Change From Baseline to 16 and 26 Weeks in Mean 24-hour Mean Arterial Pressure (MAP)|Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Systolic Blood Pressure (SBP)|Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Diastolic Blood Pressure (DBP)|Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Heart Rate (HR)|Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Pulse Pressure|Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Mean Arterial Pressure (MAP)|Change From Baseline to 16 and 26 Weeks in Glycosylated Hemoglobin (HbA1c)|Change From Baseline to 16 and 26 Weeks in Fasting Blood Glucose (FBG)|Percentage of Participants Achieving an Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%|Number of Participants With Treatment Emergent Adverse Events at 26 Weeks|Change From Baseline to 16 and 26 Weeks on Pancreatic Enzymes|Change From Baseline to 16 and 26 Weeks on Serum Calcitonin|Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)|Change From Baseline to 16 and 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval|Number of Events of Adjudicated Pancreatitis up to 26 Weeks|Number of Participants With Adjudicated Cardiovascular Events up to 26 Weeks|Anti-LY2189265 Antibodies|Rate of Hypoglycemic Episodes|Change From Baseline to 16 and 26 Weeks in Body Weight|Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","755","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13631|H9X-MC-GBDN|CTRI/2010/091/001444","June 2010","September 2011","January 2012","June 23, 2010","February 2, 2015","February 2, 2015","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anaheim, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lancaster, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spring Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coral Gables, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winter Haven, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cartersville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucker, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Idaho Falls, Idaho, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloomington, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paducah, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auburn, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haverhill, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jackson, Mississippi, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jefferson City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garden City, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dayton, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jefferson Hills, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Johnstown, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Georgetown, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Renton, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mar Del Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mendoza, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Red Deer, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winnipeg, Manitoba, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Johns, Newfoundland and Labrador, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamilton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oakville, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Laval, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ville St-Laurent, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ceske Budejovice, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cesky Krumlov, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prerov, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalborg, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ballerup, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vejle, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbatore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludhiana, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio Piedras, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01149421"
792,"NCT02436512","Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide","EAGLE","Withdrawn","No Results Available","Pulmonary Arterial Hypertension","Drug: Inhaled Nitric Oxide","Wean Success vs Wean Failure","Geno LLC","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P-2014-001","June 2015","August 2015","August 2015","May 6, 2015",,"September 7, 2015","University of Alabama, Birmingham, Alabama, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02436512"
793,"NCT00910429","BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension","CHEST-2","Completed","No Results Available","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)","Safety and tolerability (e.g. adverse event collection)|Change in 6-Minute Walking Distance (6MWD) from baseline","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","237","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11349|2008-003539-19","July 1, 2009","August 19, 2019","August 19, 2019","May 29, 2009",,"August 29, 2019","La Jolla, California, United States|Sacramento, California, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dallas, Texas, United States|Corrientes, Argentina|Prahran, Victoria, Australia|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande Do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|Calgary, Alberta, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Beijing, China|Beijing, China|Shanghai, China|Praha 2, Czechia|Aarhus N, Denmark|Brest, France|Le Kremlin Bicetre Cedex, France|Rouen, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Rabin Medical Center - Beilinson Campus, Petach Tikva, Israel|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Komatsu, Ishikawa, Japan|Fujisawa, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Suwa, Nagano, Japan|Bunkyo-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Monterrey, Nuevo Leon, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Krakow, Poland|Otwock, Poland|Coimbra, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Santa Maria, Lisboa, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bratislava 37, Slovakia|Barcelona, Spain|Zürich, Switzerland|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00910429"
794,"NCT01328054","A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval",,"Completed","Has Results","Cancer","Drug: lapatinib|Drug: placebo matching lapatinib","Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo and Lapatinib 2000mg|Change From Baseline in the Holter ECG Parameters of QT Interval, Corrected QT Interval (QTc), Bazett Corrected QTc Interval (QTcB), Individual-corrected QT Interval (QTcI), RR Interval, PR Interval, and QRS Duration at Indicated Time Points|Number of Participants With 12-lead Holter ECG Findings at the Indicated Time Points|Number of Participants With the Worst-case Post-Baseline 12-lead Holter ECG Findings With Significant ST, T Wave, and U Wave Abnormalities|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Mean Albumin, and Hemoglobin at the Indicated Time Points|Mean Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at the Indicated Time Points|Mean Direct Bilirubin, Total Bilirubin, and Creatinine at the Indicated Time Points|Mean Calcium, Chloride, Carbon Dioxide (CO2), Potassium, Sodium, Magnesium and Urea at the Indicated Time Points|Mean Total Neutrophils (ANC [Absolute Neutrophil Count]), Platelets and Leukocyte Count at the Indicated Time Points|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points|Change From Baseline in Heart Rate at the Indicated Time Points|Number of Participants With 12-lead ECG Findings at Indicated Time Points|Mean Area Under the Plasma Drug Concentration-time Curve (AUC) From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC[0-t]) and From Time Zero (Pre-dose) to 24 Hours Post Dose (AUC[0-24]) for Lapatinib|Mean Maximum Plasma Concentration (Cmax) and Observed Plasma Concentration at 24 Hours Post-dose (C24) of Lapatinib|Median Time to Cmax (Tmax) and the Time Prior to the First Quantifiable (Non-zero) Lapatinib Plasma Concentration (Tlag) Following the Last (3rd) Lapatinib Dose","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 4","58","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","114271","December 2011","March 2015","March 2015","April 4, 2011","June 8, 2016","June 8, 2016","GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01328054"
795,"NCT01026233","Cardiac Safety Study of Brentuximab Vedotin (SGN-35)",,"Completed","No Results Available","Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin","Drug: brentuximab vedotin","QTc interval|ECG parameters|Blood MMAE levels|Incidence of proarrhythmic adverse events|Incidence of adverse events and laboratory abnormalities","Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGN35-007","January 2010","August 2010","August 2011","December 4, 2009",,"December 12, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Miami Hospital and Clinics, Miller School of Medicine, Miami, Florida, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|New York University Cancer Institute, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|University Hospital of Cologne, Koln, Germany",,"https://ClinicalTrials.gov/show/NCT01026233"
796,"NCT01275339","Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study","ASPEN","Terminated","Has Results","Aortic Stenosis|LV Remodeling, Hypertrophy","Drug: Tadalafil|Drug: Placebo","Diastolic Function as Measured by Tissue Doppler e'|Change in Myocardial Fibrosis (ECV) on MRI|Change in Other Echocardiographic Indices of Diastolic Function|Safety and Tolerability|Change in Indices of Systolic Function|Change in LV Hypertrophic Remodeling|Change in Novel Echocardiographic Indices of Diastolic Function|Change in 6 Minute Walk Distance|Change in Circulating Neurohormonal Markers|Change in Quality of Life|Change in Pulmonary Artery Pressure and Pulmonary Vascular Resistance as Assessed by Echo|Change in Systemic Blood Pressure|Change in RV Function|Change in AS Severity","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-1334b","December 2012","April 14, 2017","April 14, 2017","January 12, 2011","April 17, 2019","April 17, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01275339/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01275339"
797,"NCT01272388","Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study","ASPEN-AVR","Terminated","Has Results","Aortic Stenosis","Drug: Tadalafil|Drug: Placebo","Quality of Life as Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)|6 Minute Walk Distance","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10-1334a","January 2011","April 2011","April 2012","January 7, 2011","September 12, 2018","September 12, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01272388"
798,"NCT03980522","A Pilot Study of KPL-914 in Recurrent Pericarditis",,"Completed","No Results Available","Recurrent Pericarditis","Drug: KPL-914","To collect inter- and intra-subject variability data on Numeric Rating Scale (NRS)|To collect inter- and intra-subject variability data on C-reactive protein (CRP) measurements|To explore the time course to improvement of pericarditis parameters in symptomatic subjects with recurrent idiopathic pericarditis (RIP). treated with KPL-914.","Kiniksa Pharmaceuticals, Ltd.","All","6 Years to 75 Years   (Child, Adult, Older Adult)","Phase 2","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KPL-914-C001","January 24, 2018","May 17, 2019","May 17, 2019","June 10, 2019",,"June 10, 2019","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03980522"
799,"NCT02329184","Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461",,"Completed","No Results Available","Hypertrophic Cardiomyopathy","Drug: MYK-461","Safety: Incidence of adverse events|Determination of pharmacokinetics parameters as measured by Cmax|Determination of pharmacokinetics parameters as measured by Tmax|Determination of pharmacokinetics parameters as measured by AUC|Determination of pharmacokinetics parameters as measured by t1/2","MyoKardia, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MYK-461-001","December 2014","March 2016","April 2016","December 31, 2014",,"September 14, 2016","Scottsdale, Arizona, United States|Cypress, California, United States|Stanford, California, United States|Boston, Massachusetts, United States|Kalamazoo, Michigan, United States|Durham, North Carolina, United States|Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02329184"
800,"NCT00887978","Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension","FREEDOM-C2","Completed","Has Results","Pulmonary Hypertension","Drug: UT-15C SR|Drug: Placebo","6-minute Walk Distance (6MWD)|Clinical Worsening Assessment|Borg Dyspnea Score|World Health Organization (WHO) Functional Class|Symptoms of PAH|Dyspnea Fatigue Index|N-terminal proBNP (NT-proBNP)|Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDE-PH-308","June 2009","July 2011","July 2011","April 24, 2009","January 15, 2013","January 15, 2013","University of Alabama-Birmingham, Birmingham, Alabama, United States|Arizona Pulmonary Specialist, LTD, Phoenix, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|UCSD Medical Center, La Jolla, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Health Science Center, Aurora, Colorado, United States|University of Florida-Jacksonville, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Chicago Hospitals, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Pulmonary Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Hospital, St. Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Columbia University Presbyterian Medical Center, New York, New York, United States|Mary M Parkes Center for Asthma, Allergy and Pulmonary Care, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Lindner Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|The University of Toledo, Toledo, Ohio, United States|Legacy Pulmonary Northwest, Portland, Oregon, United States|OHSU, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Inova Transplant Center, Falls Church, Virginia, United States|University Hospital Gasthuisberg, Leuven, Belgium|University of Calgary, Calgary, Alberta, Canada|University of Alberta Hospitals, Edmonton, Alberta, Canada|Vancouver Coastal Health Respiratory Clinic, Vancouver, British Columbia, Canada|London Health Sciences Center, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Hospital Claude Huriez, Lille, Cedex, France|Hospital Haut Leveque, Pessac, Cedex, France|Hospital Cavale Blanche, Brest, France|Universitaetsklinikum Dresden, Dresden, Germany|University Hospital Greifswald, Greifswald, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Pulmonology Department Rambam Medical Center, Haifa, Israel|Lady Davis Carmel Medical Centre, Haifa, Israel|Pulmonary institute, Ramat Gan, Israel|Azienda Ospedaliera Universitaria, Naples, Italy|VUMC, Amsterdam, Netherlands|Hospital de Santa Marta, Lisboa, Portugal|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Lund University Hospital, Lund, Sweden|Royal Free Hospital NHS Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00887978"
801,"NCT01516255","Effect of Liraglutide on Heart Frequency in Healthy Volunteers",,"Completed","No Results Available","Diabetes|Diabetes Mellitus, Type 2","Drug: liraglutide|Drug: placebo|Drug: moxifloxacin|Procedure: electrocardiogram (ECG)","Maximum time-matched mean difference between the baseline subtracted QTci intervals|QTc at liraglutide tmax (time to reach maximum concentration)|Percentage subjects with QTc at least 450, 480 and 500 milliseconds|Moxifloxacin maximum time-matched mean change QTc and QTci|Cmax, maximum concentration of liraglutide|tmax, time to reach Cmax of liraglutide|Vitals signs: Blood pressure|Vital signs: Pulse|Serial electrocardiography","Novo Nordisk A/S","All","18 Years to 45 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NN2211-1644","July 2006","November 2006","November 2006","January 24, 2012",,"January 25, 2017","Novo Nordisk Investigational Site, Fargo, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01516255"
802,"NCT00855465","A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.","CHEST-1","Completed","Has Results","Pulmonary Hypertension","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 16|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16|N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) - Change From Baseline to Week 16|World Health Organization (WHO) Functional Class - Change From Baseline to Week 16|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 16|EQ-5D Utility Score - Change From Baseline to Week 16|Living With Pulmonary Hypertension (LPH) Questionnaire - Change From Baseline to Week 16","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","262","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11348|2007-000072-16","February 2009","June 2012","June 2012","March 4, 2009","March 11, 2014","November 28, 2016","Birmingham, Alabama, United States|La Jolla, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Miami, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Fairfield, Ohio, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|Houston, Texas, United States|Murray, Utah, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Capital Federal, Argentina|Corrientes, Argentina|Camperdown, New South Wales, Australia|Auchenflower, Queensland, Australia|Chermside, Queensland, Australia|Prahran, Victoria, Australia|Innsbruck, Austria|Wien, Austria|Bruxelles - Brussel, Belgium|Leuven, Belgium|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|Rio de Janeiro, Brazil|São Paulo, Brazil|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Qingdao, Shandong, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Vseobecna fakultni nemocnice, Praha 2, Czech Republic|Aarhus N, Denmark|Besancon, France|Brest, France|Caen, France|Hopital Antoine Beclere, Clamart Cedex, France|GRENOBLE Cedex 09, France|Lille Cedex, France|Montpellier, France|Nice, France|Pessac, France|Rouen, France|Tours, France|Vandoeuvre Les Nancy, France|Heidelberg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Würzburg, Bayern, Germany|Gießen, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Hannover, Niedersachsen, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Hamburg, Germany|Dublin, Ireland|Petah Tikva, Israel|Roma, Lazio, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Kitakyushu, Fukuoka, Japan|Komatsu, Ishikawa, Japan|Fujisawa, Kanagawa, Japan|Isehara, Kanagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Suwa, Nagano, Japan|Suita, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Chiba, Japan|Fukuoka, Japan|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Jalisco, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mexico D.F., Mexico|Querétaro, Mexico|Amsterdam, Netherlands|Amsterdam, Netherlands|Nieuwegein, Netherlands|Krakow, Poland|Otwock, Poland|Wroclaw, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Bratislava 37, Slovakia|Barcelona, Spain|Madrid, Spain|Zürich, Switzerland|Kaohsiung, Taiwan|Taipei, Taiwan|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Cambridge, Cambridgeshire, United Kingdom|Glasgow, West Dunbartonshire, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00855465"
803,"NCT02484378","CER-001 Atherosclerosis Regression ACS Trial","CARAT","Completed","No Results Available","Acute Coronary Syndromes","Drug: CER-001|Drug: Placebo","Nominal Change in Percent Atheroma Volume (PAV)|Nominal Change in Normalized Total Atheroma Volume (TAV)","Cerenis Therapeutics, SA|South Australian Health and Medical Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 2","301","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CER-001-CLIN-010","August 2015","November 2016","December 2016","June 29, 2015",,"February 11, 2019","Heart Center Research, LLC, Huntsville, Alabama, United States|VA San Diego Healthcare System, San Diego, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|VA Eastern Colorado Health Care System, Denver, Colorado, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Cardiovascular Associates Research LLC, Covington, Louisiana, United States|Cardiac and Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|University of Missouri Health System, Columbia, Missouri, United States|Buffalo Heart Group LLP, Buffalo, New York, United States|Veterans Affairs WNY Healthcare System, Buffalo, New York, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States|Dallas VA Medical Center, Dallas, Texas, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford park, South Australia, Australia|Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Peninsula Heart Centre, Frankston, Victoria, Australia|Epworth Research Institute, Richmond, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Semmelweiss University, Budapest, Hungary|Military Hospital, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Pándy Kálmán County Hospital, Gyula, Hungary|County Hospital of Kecskemet, Kecskemet, Hungary|University of Szeged, Szeged, Hungary|Meander Medisch Centrum, Amersfoort, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Scheper Ziekenhuis, Emmen, Netherlands|Medisch Centrum Haaglanden, Leidschendam, Netherlands|Canisius-Wilhelmina hospital, Nijmegen, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Twee Steden hospital (Tilburg), Tilburg, Netherlands|VieCuri Medisch Centrum, Venlo, Netherlands",,"https://ClinicalTrials.gov/show/NCT02484378"
804,"NCT02931253","Metformin as an Upstream Therapy in Atrial Fibrillation",,"Terminated","No Results Available","Atrial Fibrillation","Drug: Metformin","Number of participants who maintain sinus rhythm|Hospitalization|Number of antiarrhythmic medications|Number of repeat ablations|BMI|Hemoglobin A1c|Number of thromboembolic events","The Guthrie Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1602-01","April 11, 2017","July 10, 2018","July 10, 2018","October 13, 2016",,"August 1, 2018","The Guthrie Clinic, Sayre, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02931253"
805,"NCT00979316","Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects",,"Completed","No Results Available","Alzheimer Disease","Drug: BMS-708163|Drug: Placebo|Drug: Moxifloxacin","Effect on the electrocardiographic QT interval corrected for heart rate (QTc) in healthy subjects|To assess the effects of BMS-708163 on other ECG endpoints (heart rate [HR], QRS and PR intervals), and changes in waveform morphology","Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Phase 1","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","CN156-020","September 2009","February 2010","February 2010","September 18, 2009",,"January 7, 2011","Mds Pharma Services (Us), Inc, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00979316"
806,"NCT01528709","Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)","ACTIVE","Completed","Has Results","Saphenous Vein Graft Disease","Drug: Atorvastatin 80 mg daily|Drug: Atorvastatin 10 mg daily","Saphenous Vein Graft Occlusion (Percentage of Vein Grafts Occluded) Based on CT Coronary Angiography at 1 Year|Vein Graft Stenosis 1 Year After CABG Based on CT Coronary Angiography","Boca Raton Regional Hospital|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","173","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2011.02","March 2012","January 2017","January 2017","February 8, 2012","August 9, 2018","September 7, 2018","Lynn Heart and Vascular Institute, Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01528709"
807,"NCT01511029","Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: Dexpramipexole|Drug: Dexpramipexole Placebo|Drug: Moxifloxacin","To evaluate whether a single dose of dexpramipexole prolongs the QTC interval as measured by frequent ECG measurements (using Holter monitoring) of individually corrected QT intervals (QTcI)|Area Under Curve (AUC) of dexpramipexole|Change in ECG measurements|Cmax of dexpramipexole|Tmax of dexpramipexole","Knopp Biosciences","All","18 Years to 60 Years   (Adult)","Phase 1","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","223HV102","January 2012","May 2012","May 2012","January 18, 2012",,"November 25, 2014","Research Site, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01511029"
808,"NCT02816736","EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)","HFN-LIFE","Active, not recruiting","No Results Available","Heart Failure","Drug: LCZ696|Drug: valsartan|Drug: LCZ696 placebo|Drug: valsartan placebo","Change in NT-proBNP|Composite endpoint of the effects of LCZ696 (number of days)|Tolerability - target dose|Tolerability - hypotension|Tolerability - renal function|Tolerability - hyperkalemia|Tolerability - inotropic therapy|Tolerability - use of IV diuretics|Tolerability - change in eGFR and cystatin C levels","Duke University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00071722|5U01HL084904","March 2, 2017","September 30, 2020","October 21, 2020","June 29, 2016",,"April 2, 2020","Cedars-Sinai Heart Institute, Beverly Hills, California, United States|Sutter Health Mills-Peninsula Health Services, Sacramento, California, United States|San Diego Cardiac Center, San Diego, California, United States|MedStar Washington Hospital Center, Washington, District of Columbia, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Mount Sinai Hospital, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States|Duke UMC, Durham, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Case Western Medical Center, Cleveland, Ohio, United States|Metro Health System, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Geisinger Medical Center, Wilkes-Barre, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Research Institute, Houston, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|Inova Heart and Vascular Insititute, Falls Church, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02816736"
809,"NCT04125745","Oral CXA-10 in Pulmonary Arterial Hypertension","PAH","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: CXA-10","Number of Treatment-Related Adverse Events as assessed by CTCAE v4.0 in 12 Weeks|Change from Baseline in Pulmonary Vascular Resistance is measured at baseline and 12 weeks by Right Heart Catheterization|Change from Baseline in Mean Pulmonary Artery Pressure is measured at baseline and 12 weeks by Right Heart Catheterization|Change from baseline in RV function as measured by tricuspid annular plane systolic excursion (TAPSE) as assessed by echocardiograms at 12 weeks|Changes from baseline in functional exercise capacity by assessing 6 minute walk distance test|Change from Baseline in levels of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) at 12 Weeks|Change from Baseline in Functional Status of Patients as Assessed by New York Heart Association Functional Class|Change from Baseline in Daily Physical Activity as Measured by a Accelerometer","Gladwin, Mark, MD|National Heart, Lung, and Blood Institute (NHLBI)|Complexa, Inc.|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY19010004|P01HL103455","October 31, 2019","June 30, 2023","December 31, 2023","October 14, 2019",,"April 3, 2020","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04125745"
810,"NCT00910962","A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation","Solstice","Completed","Has Results","Acute Coronary Syndrome","Drug: GW856553|Drug: Placebo","Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Any Major Adverse Cardiovascular Events (MACE)|Number of Participants With Any Pure MACE|Number of Participants With Hematology Data of Potential Clinical Importance (PCI) at Any Visit Post-Baseline|Number of Participants With Clinical Chemistry Data of PCI at Any Visit Post-Baseline|Number of Participants With Liver Function Test Elevations at Any Time Post-Baseline|Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Any Time Post-Baseline|Number of Participants With Vital Signs of PCI at Any Visit Post-Baseline|Mean High-sensitive C-Reactive Protein (hsCRP) Value at Week 12|Mean Cardiac Troponin I (cTnI) Area Under Concentration-time Curve (AUC) Over 72 Hours Post-randomization or Until Hospital Discharge (Whichever Comes First)|Mean hsCRP Over Hospitalization Period and Through Week 14|Mean Interleukin-6 (IL-6) Value at 24 Hours Post-randomization and at Weeks 2 and 12|Mean Creatine Kinase (MB Isoenzyme) (CK-MB) AUC Over 72 Hours Post-randomization or Until Hospital Discharge (Whichever Comes First)|Peak cTnI Over 72 Hours Post-randomization or Until Hospital Discharge (Whichever Comes First)|Mean Brain Natriuretic Peptide (BNP) at Discharge and Week 12|Mean Infarct Size Prior to Discharge From Hospital (Approximately Day 3) and at Week 12|Mean Percent Left Ventricular Ejection Fraction (LVEF) at Week 12|Mean Left Ventricular End-diastolic Volume (LVEDV) and Left Ventricular End-systolic Volume (LVESV) at Week 12|Mean Left Ventricular Mass at Week 12|Mean Regional Wall Motion Score Index at Week 12|Mean Hyperenhancement Score Index at Week 12","GlaxoSmithKline","All","45 Years and older   (Adult, Older Adult)","Phase 2","526","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","111810","October 8, 2009","March 6, 2012","March 6, 2012","June 1, 2009","October 27, 2017","December 7, 2017","GSK Investigational Site, Anchorage, Alaska, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Brooklyn, New York, United States|GSK Investigational Site, Stony Brook, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Elyria, Ohio, United States|GSK Investigational Site, Allentown, Pennsylvania, United States|GSK Investigational Site, Camp Hill, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Oak Ridge, Tennessee, United States|GSK Investigational Site, Amarillo, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Round Rock, Texas, United States|GSK Investigational Site, Victoria, Texas, United States|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, Brisbane, Queensland, Australia|GSK Investigational Site, Bedford Park, South Australia, Australia|GSK Investigational Site, Woodville South, South Australia, Australia|GSK Investigational Site, Launceston, Tasmania, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada|GSK Investigational Site, Terrebonne, Quebec, Canada|GSK Investigational Site, Bad Krozingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Rastatt, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Bad Nauheim, Hessen, Germany|GSK Investigational Site, Darmstadt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Fulda, Hessen, Germany|GSK Investigational Site, Limburg, Hessen, Germany|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Oldenburg, Niedersachsen, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dortmund, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leverkusen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany|GSK Investigational Site, Wuppertal, Nordrhein-Westfalen, Germany|GSK Investigational Site, Worms, Rheinland-Pfalz, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Pirna, Sachsen, Germany|GSK Investigational Site, Bad Berka, Thueringen, Germany|GSK Investigational Site, Erfurt, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Calicut, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Arnhem, Netherlands|GSK Investigational Site, Nieuwegein, Netherlands|GSK Investigational Site, Tilburg, Netherlands|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Radom, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Jerez (Cadiz), Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Brighton, East Sussex, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Clydebank, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Leicester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Paddington, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00910962"
811,"NCT01994889","Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy","ATTR-ACT","Completed","Has Results","Transthyretin (TTR) Amyloid Cardiomyopathy","Drug: Tafamidis|Drug: Placebo","Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations|All-Cause Mortality|Frequency of Cardiovascular-Related Hospitalizations|Change From Baseline in the Total Distance Walked During 6 Minute Walk Test (6MWT) at Month 30|Change From Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS) at Month 30|Number of Participants With Cardiovascular-Related Mortality|Percentage of Participants With Stabilized Transthyretin (TTR) at Month 1","Pfizer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","441","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B3461028|2012-002465-35|ATTR-ACT","December 9, 2013","February 7, 2018","February 7, 2018","November 26, 2013","April 3, 2019","April 24, 2019","The Kirklin Clinic, Birmingham, Alabama, United States|UAB Hospital Department of Pharmacy IDS, Birmingham, Alabama, United States|University Hospital, University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Arizona - Mayo Clinic Speciality Building, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic Arizona - Mayo Clinic Building, Scottsdale, Arizona, United States|UCSD Clinical and Translational Research Institute, Investigational Drug Service, La Jolla, California, United States|Altman Clinical Translational Research institute, La Jolla, California, United States|Altman Clinical Translational Research Institute, La Jolla, California, United States|UCSD Sulpizio Cardiovascular Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Investigational Drug Pharmacy Services, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Care Foundation, Los Angeles, California, United States|UCSF Cardiovascular Care and Prevention Center, San Francisco, California, United States|Stanford University Hospital and Clinics, Stanford, California, United States|UM Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|Northwestern Medical Group, Chicago, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Advocate Christ Medical Centre, Oak Lawn, Illinois, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland, School of Medicine, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|The Johns Hopkins Hospital IDS Pharmacy, Baltimore, Maryland, United States|Boston Medical Center - Cardiovascular Center, Outpatient Clinic, Boston, Massachusetts, United States|Boston Medical Center Investigational Pharmacy Services, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Boston University Medical Center General Clinical Research Unit, Boston, Massachusetts, United States|Michigan Medicine,University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic Pharmacy Research Supp, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|New York University Hospitals, New York, New York, United States|Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, New York, New York, United States|Mount Sinai Doctors Faculty Practice, New York, New York, United States|The Mount Sinai Hospital Department of Pharmacy, New York, New York, United States|Columbia University Medical Center Research Pharmacy, New York, New York, United States|Columbia University Medical Center/Clinical Cardiovascular Research Laboratory for the Elderly, New York, New York, United States|Duke University Health System, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|OHSU Center for Health and Healing, Portland, Oregon, United States|OHSU Research Pharmacy Services, Portland, Oregon, United States|Oregon Health and Science University (OHSU), Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Utah,Health Sciences Center, Salt Lake City, Utah, United States|VCU Medical Center - Ambulatory Care Clinic, Richmond, Virginia, United States|VCU Medical Center - Main Hospital, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Unidade de Pesquisa Clinica / Hospital Universitario Clementino Fraga Filho / UFRJ, Rio de Janeiro, RJ, Brazil|University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Fakultni nemocnice u sv. Anny, Nemocnicni lekarna, Brno, Czechia|Nemocnice u sv. Anny v Brne, Brno, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Vseobecna fakultni nemocnice v Praze, Nemocnicni lekarna, Praha 2, Czechia|IKEM, Ustavni lekarna, Praha 4, Czechia|IKEM, Praha 4, Czechia|Hopital Antoine Beclere, Clamart, France|CHU Henri Mondor, Creteil, France|Medical University of Heidelberg, Heidelberg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|U.O. Cardiologia- Prof. Rapezzi, Bologna, Italy|Unita Operativa di Cardiologia, Brescia, Italy|S.O.D. Cardiologia Generale 1 - D.A.I. del Cuore e dei Vasi, Firenze, Italy|Centro per lo Studio e la Cura Delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Kurume University Hospital, Kurume-shi, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto-city, Kumamoto, Japan|Shinshu University Hospital, Nagano, Japan|University Medical Center Groningen, Groningen, Netherlands|Hospital Universitario Puerta De Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Universitario A Coruna, A Coruna, Spain|Medicin-Geriatrik kliniken-Skelleftea lasarett, Skelleftea, Sweden|Sjukhusvägen, Akademiska sjukhuset, Uppsala, Sweden|St Bartholomew's Hospital-Barts Health NHS Trust, London, United Kingdom|St. George's Hospital (St George's Healthcare NHS Trust), London, United Kingdom|St. George's University of London, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01994889/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01994889/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01994889"
812,"NCT00914589","Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery",,"Completed","Has Results","Acquired Bleeding Disorder|Cardiac Surgery Requiring Cardiopulmonary Bypass","Drug: catridecacog|Drug: placebo","Percentage of Subjects Avoiding Any Allogeneic Transfusions for Seven Days Post-operative or Until Discharge, Whichever Came First|Percentage of Subjects With Thromboembolic Events|Percentage of Subjects With rFXIII Antibody Reaction|Percentage of Subjects With Critical Adverse Events|Percentage of Subjects With Serious Adverse Events","Novo Nordisk A/S","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","479","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NN1810-3540|JapicCTI-101078|2008-006324-62","July 2009","February 2011","February 2011","June 5, 2009","November 13, 2014","March 7, 2017","Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Durham, North Carolina, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Allentown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Providence, Rhode Island, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Canada|Novo Nordisk Investigational Site, Ottawa, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Toronto, Canada|Novo Nordisk Investigational Site, København ø, Denmark|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Frankfurt am Main, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, München, Germany|Novo Nordisk Investigational Site, Petach Tikva, Israel|Novo Nordisk Investigational Site, Ramat Gan, Israel|Novo Nordisk Investigational Site, Bologna, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, San Donato Milanese (MI), Italy|Novo Nordisk Investigational Site, Iwate, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00914589"
813,"NCT02587325","ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Hypertension","Drug: ABI-009, nab-rapamycin, albumin-bound rapamycin","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","Aadi, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PAH-001","April 1, 2017","December 2020","December 2020","October 27, 2015",,"December 10, 2019","University of Arizona, Tucson, Arizona, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Indiana University, Indianapolis, Indiana, United States|National Institutes of Health, Bethesda, Maryland, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02587325"
814,"NCT02319005","ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)",,"Completed","Has Results","Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related|Familial Transthyretin Cardiac Amyloidosis","Drug: Revusiran (ALN-TTRSC)|Drug: Sterile Normal Saline (0.9% NaCl)","6 Minute Walk Distance (6-MWD)|Serum TTR Levels|Composite Cardiovascular (CV) Mortality and Cardiovascular (CV) Hospitalization|New York Heart Association (NYHA) Class|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Cardiovascular (CV) Mortality|Cardiovascular (CV) Hospitalization|All-cause Mortality","Alnylam Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALN-TTRSC-004","December 2014","March 30, 2017","March 30, 2017","December 18, 2014","July 18, 2018","July 18, 2018","Clinical Trial Site, Bakersfield, California, United States|Clinical Trial Site, Beverly Hills, California, United States|Clinical Trial Site, La Mesa, California, United States|Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, San Francisco, California, United States|Clinical Trial Site, Stanford, California, United States|Clinical Trial Site, Torrance, California, United States|Clinical Trial Site, Aurora, Colorado, United States|Clinical Trial Site, Washington, District of Columbia, United States|Clinical Trial Site, Washington, District of Columbia, United States|Clinical Trial Site, Tampa, Florida, United States|Clinical Trial Site, Atlanta, Georgia, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, New Orleans, Louisiana, United States|Clinical Trial Site, Baltimore, Maryland, United States|Clinical Trial Site, Baltimore, Maryland, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Detroit, Michigan, United States|Clinical Trial Site, Rochester, Minnesota, United States|Clinical Trial Site, Saint Louis, Missouri, United States|Clinical Trial Site, Newark, New Jersey, United States|Clinical Trial Site, Bronx, New York, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Rosedale, New York, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Charleston, South Carolina, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Fort Worth, Texas, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Richmond, Virginia, United States|Clinical Trial Site, Seattle, Washington, United States|Clinical Trial Site, Anderlecht, Belgium|Clinical Trial Site, Hasselt, Belgium|Clinical Trial Site, Roeselare, Belgium|Clinical Trial Site, Toronto, Canada|Clinical Trial Site, Bordeaux, Aquitaine, France|Clinical Trial Site, Creteil, France|Clinical Trial Site, Marseille, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Muenster, Germany|Clinical Trial Site, Bologna, Italy|Clinical Trial Site, Messina, Italy|Clinical Trial Site, Pavia, Italy|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Umea, Sweden|Clinical Trial Site, Croydon, England, United Kingdom|Clinical Trial Site, London, England, United Kingdom|Clinical Trial Site, Tooting, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02319005/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02319005/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02319005"
815,"NCT02970669","Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.","AWAKE-HF","Completed","Has Results","Heart Failure, Reduced Ejection Fraction","Drug: sacubitril/valsartan (LCZ696)|Drug: enalapril|Drug: matching placebo sacubitril/valsartan (LCZ696)|Drug: matching placebo enalapril","Ratio of Mean Activity Counts Collected During the Most Active 30 Minutes of the Subject's Day Between Week 8 and Baseline|Change in Mean Activity Counts During Most Active 30 Minutes of Day From Baseline to Week 1|Change in Mean Activity Counts During Most Active 30 Minutes of Day From Baseline to Week 9 and 16|Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 8|Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 1|Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 9 and 16","Novartis Pharmaceuticals|Novartis","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","CLCZ696BUS14","December 16, 2016","March 19, 2018","March 19, 2018","November 22, 2016","April 8, 2019","April 8, 2019","Novartis Investigative Site, Fort Payne, Alabama, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, West Hills, California, United States|Novartis Investigative Site, Doral, Florida, United States|Novartis Investigative Site, Inverness, Florida, United States|Novartis Investigative Site, Ormond Beach, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Novartis Investigative Site, Lutherville, Maryland, United States|Novartis Investigative Site, East Brunswick, New Jersey, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Lancaster, South Carolina, United States|Novartis Investigative Site, Allen, Texas, United States|Novartis Investigative Site, McKinney, Texas, United States|Novartis Investigative Site, New Braunfels, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Marcos, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Tomball, Texas, United States|Novartis Investigative Site, Midlothian, Virginia, United States|Novartis Investigative Site, Tacoma, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02970669/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02970669/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02970669"
816,"NCT02763735","Right Ventricular Metabolism in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension|Healthy","Drug: 11C acetate","Right ventricular oxygen consumption divided by the rate pressure product|Right ventricular oxygen consumption (kmono)|Right ventricular glucose uptake (standardized uptake value)|Percent myocardial triglyceride content|Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with right ventricular function|Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with six minute walk distance|Correlation of kmono, kmono/RPP, FDG uptake, and myocardial triglyceride content with plasma metabolic profile","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","131271","June 2014","June 2019","June 2019","May 5, 2016",,"July 17, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02763735"
817,"NCT01278745","Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation",,"Terminated","Has Results","Cardiac Allograft Vasculopathy|Heart Transplant Recipients","Biological: Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|Drug: Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)","Change in Percent Atheroma Volume (PAV)|Death|Re-transplantation or Re-listed for Transplantation|Number of Episodes of Biopsy Proven Acute Rejection (BPAR) of Any Grade Per Participant|Incidence of BPAR (Any Grade)|Incidence of AMR|Incidence of Cellular Rejection|Incidence of Any Treated Rejection|Number of Participants With Episodes of Rejection Associated With Hemodynamic Compromise (HDC)|Number of Participants With Development of Angiographically Evident Cardiac Allograft Vasculopathy|Number of Participants With Post-transplant Serious Infections Requiring Intravenous Antimicrobial Therapy|Number of Participants With Post-transplant Incidence of PTLD|Post-transplant Safety Outcomes Among Participants: Safety and Tolerability of Rituximab","National Institute of Allergy and Infectious Diseases (NIAID)|National Heart, Lung, and Blood Institute (NHLBI)|Clinical Trials in Organ Transplantation|Genentech, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","362","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DAIT CTOT-11","September 2011","October 2015","October 2015","January 19, 2011","April 11, 2017","April 11, 2017","Cedars Sinai Heart Institute, Beverly Hills, California, United States|Ronald Regan UCLA Medical Center, Los Angeles, California, United States|Stanford University/Palo Alto VA, Palo Alto, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Northwestern University, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical City Dallas Hospital/CRSTI, Dallas, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01278745"
818,"NCT01880866","(-)-Epicatechin and Pulmonary Arterial Hypertension",,"Withdrawn","No Results Available","Pulmonary Arterial Hypertension","Drug: (-)-Epicatechin","Pulmonary Vascular Resistance Index|Endothelial function and hemodynamics","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPI","July 2013","January 2014","January 2014","June 19, 2013",,"September 10, 2014","UCSF, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01880866"
819,"NCT02874794","Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction","EVALUATE-HF","Completed","Has Results","Heart Failure and Reduced Ejection Fraction","Drug: LCZ696 (sacubitril/valsartan)|Drug: Enalapril|Drug: Placebo of Enalapril|Drug: Placebo of LCZ696","Change From Baseline in Aortic Characteristic Impedance at Week 12|Pearson Correlation Coefficient Between Change From Baseline in Aortic Characteristic Impedance and Biomarker Levels: B-type Natriuretic Peptide (BNP) During Both Trough and 4 Hours Post-dose at Week 4|Pearson Correlation Coefficient Between Change From Baseline in Aortic Characteristic Impedance and Biomarker Levels: cGMP/U-creatinine During Both Trough and 4 Hours Post-dose at Week 4|Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in Echocardiographic Measure: Global Longitudinal Strain|Change From Baseline in Echocardiographic Measure: Left Atrial Volume Index (LAVi)|Change From Baseline in Echocardiographic Measure: Mitral Annular E' Velocity (Doppler Tissue Imaging)|Change From Basekine in Echocardiographic Measure: Mitral E/E'|Change From Baseline in Echocardiographic Measure: Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Echocardiographic Measure: Ventricular-vascular Coupling (Ea/Ees)|Change From Baseline in Echocardiographic Measure: Left Ventricular End Systolic Volume Index (LVESVi)|Change From Baseline in Echocardiographic Measure: Left Ventricular End Diastolic Volume Index (LVEDVi)","Novartis Pharmaceuticals|Novartis","All","50 Years and older   (Adult, Older Adult)","Phase 4","465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CLCZ696BUS08","August 17, 2016","December 13, 2018","January 26, 2019","August 22, 2016","March 19, 2020","March 19, 2020","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Huntington Beach, California, United States|Novartis Investigative Site, Newport Beach, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, Van Nuys, California, United States|Novartis Investigative Site, Greenwich, Connecticut, United States|Novartis Investigative Site, Norwalk, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Trumbull, Connecticut, United States|Novartis Investigative Site, Newark, Delaware, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Aventura, Florida, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Coral Gables, Florida, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Doral, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Hialeah, Florida, United States|Novartis Investigative Site, Inverness, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Naples, Florida, United States|Novartis Investigative Site, Saint Augustine, Florida, United States|Novartis Investigative Site, Athens, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Blue Ridge, Georgia, United States|Novartis Investigative Site, Eatonton, Georgia, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Coeur d'Alene, Idaho, United States|Novartis Investigative Site, Fairview Heights, Illinois, United States|Novartis Investigative Site, Gurnee, Illinois, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Owensboro, Kentucky, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Eunice, Louisiana, United States|Novartis Investigative Site, Minden, Louisiana, United States|Novartis Investigative Site, Monroe, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Alpena, Michigan, United States|Novartis Investigative Site, Owosso, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Hillsborough, New Jersey, United States|Novartis Investigative Site, Linden, New Jersey, United States|Novartis Investigative Site, Manalapan, New Jersey, United States|Novartis Investigative Site, Mountain Lakes, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Lake Success, New York, United States|Novartis Investigative Site, Rosedale, New York, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Greenville, North Carolina, United States|Novartis Investigative Site, Lenoir, North Carolina, United States|Novartis Investigative Site, Yardley, Pennsylvania, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Amarillo, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, McKinney, Texas, United States|Novartis Investigative Site, McKinney, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Tomball, Texas, United States|Novartis Investigative Site, Webster, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richland, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Manitowoc, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02874794/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02874794/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02874794"
820,"NCT00825188","A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives",,"Terminated","No Results Available","Obesity|Hypertension","Drug: eplerenone, amlodipine|Drug: eplerenone|Drug: amlodipine","Basal metabolic rate","University of Mississippi Medical Center","All","21 Years to 100 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-0035","January 2009","March 2014","March 2014","January 19, 2009",,"May 29, 2018","The University of Mississippi Clinical Research Program, Jackson, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT00825188"
821,"NCT03267108","A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed iNO in Subjects With Pulmonary Fibrosis",,"Active, not recruiting","No Results Available","Pulmonary Fibrosis|Pulmonary Hypertension","Drug: iNO|Drug: Placebo","Change in 6-Minute Walking Distance|Clinically meaningful reduction in 6MWD|Change in right ventricular function|Change in left ventricular function|Change in Nadir SpO2 during 6MWT|Change in Oxygen desaturation during 6MWT|Patients who remain above 88% SPO2 during 6MWT|Change in Oxygen during the 6MWT|Increase in supplemental oxygen|Change in Distance Saturation Product (DSP)|Decrease in Distance Saturation Product (DSP)|Change in Integral Distance Saturation Product (IDSP)|Decrease in Integral Distance Saturation Product (IDSP)|Change in Activity Monitoring Measurement|Decrease in Activity Monitoring Measurment|Difference in Dyspnea|Change in St. George Respiratory Questionnaire (SGRQ)|Change in Disease-specific quality of life|Change in Borg Dyspnea Score|Change in Composite of Borg Dyspnea and 6MWD|Change in Pulmonary Hemodynamics|Pulmonary Hemodynamics Change ≥20%|Change in NT-ProBNP|Time to Clinical Improvement|Time to Clinical Worsening|Percent of Responders|Change in REVEAL RISK","Bellerophon Pulse Technologies|Bellerophon","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PULSE-PHPF-001","December 29, 2017","November 2021","May 2022","August 30, 2017",,"January 14, 2020","Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|University of California Davis Health, Sacramento, California, United States|UC Denver Anschutz Medical Center, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Avanza Medical Research Center, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare, Austell, Georgia, United States|Wellstar Medical Group - Pulmonary Medicine, Marietta, Georgia, United States|Loyola University, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|The Lung Research Center, LLC, Chesterfield, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The University of North Carolina at Chapel Hill Marsico Clinical Research Center, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Thomas Jefferson University Korman Respiratory Institute, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Utah Health Sciences, Salt Lake City, Utah, United States|Inova Heart and Vascular Institute Advanced Lung Disease Clinic, Falls Church, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03267108"
822,"NCT00993382","Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death","ALPHEE","Completed","No Results Available","Arrhythmia Prophylaxis|Ventricular Arrhythmia","Drug: Celivarone|Drug: Amiodarone|Drug: Matching placebo","Time to Ventricular Tachycardia or Ventricular Fibrillation (VT/VF) triggered ICD interventions or sudden death|Time to ICD shocks (appropriate or inappropriate) or death from any cause|Time to Cardiovascular hospitalization or death","Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 2","486","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DRI10936|2008-008412-47","September 2009","May 2011","May 2011","October 12, 2009",,"May 30, 2016","Investigational Site Number 840006, Huntsville, Alabama, United States|Investigational Site Number 840042, Mobile, Alabama, United States|Investigational Site Number 840014, Mesa, Arizona, United States|Investigational Site Number 840032, Phoenix, Arizona, United States|Investigational Site Number 840033, Tucson, Arizona, United States|Investigational Site Number 840054, Redondo Beach, California, United States|Investigational Site Number 840007, Redwood City, California, United States|Investigational Site Number 840039, Colorado Springs, Colorado, United States|Investigational Site Number 840002, Fort Myers, Florida, United States|Investigational Site Number 840010, Orlando, Florida, United States|Investigational Site Number 840005, Port Charlotte, Florida, United States|Investigational Site Number 840013, St. Petersburg, Florida, United States|Investigational Site Number 840043, St. Petersburg, Florida, United States|Investigational Site Number 840004, Augusta, Georgia, United States|Investigational Site Number 840045, Chicago, Illinois, United States|Investigational Site Number 840035, Lombard, Illinois, United States|Investigational Site Number 840017, Kansas City, Kansas, United States|Investigational Site Number 840022, Scarborough, Maine, United States|Investigational Site Number 840009, Ann Arbor, Michigan, United States|Investigational Site Number 840026, Detroit, Michigan, United States|Investigational Site Number 840003, Petoskey, Michigan, United States|Investigational Site Number 840015, Ypsilanti, Michigan, United States|Investigational Site Number 840049, Columbia, Missouri, United States|Investigational Site Number 840019, Kansas City, Missouri, United States|Investigational Site Number 840031, New York, New York, United States|Investigational Site Number 840029, Tulsa, Oklahoma, United States|Investigational Site Number 840037, Portland, Oregon, United States|Investigational Site Number 840024, Camp Hill, Pennsylvania, United States|Investigational Site Number 840030, Doylestown, Pennsylvania, United States|Investigational Site Number 840034, Upland, Pennsylvania, United States|Investigational Site Number 840020, Charleston, South Carolina, United States|Investigational Site Number 840048, Rapid City, South Dakota, United States|Investigational Site Number 840011, Tullahoma, Tennessee, United States|Investigational Site Number 840025, Chesapeake, Virginia, United States|Investigational Site Number 840012, Norfolk, Virginia, United States|Investigational Site Number 840038, Richmond, Virginia, United States|Investigational Site Number 840016, Spokane, Washington, United States|Investigational Site Number 032002, Ciudad Autonoma De Bs.As, Argentina|Investigational Site Number 032003, Corrientes, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 036012, Adelaide, Australia|Investigational Site Number 036006, Auchenflower, Australia|Investigational Site Number 036004, Bedford Park, Australia|Investigational Site Number 036014, Camperdown, Australia|Investigational Site Number 036013, Garran, Australia|Investigational Site Number 036010, Gosford, Australia|Investigational Site Number 036005, Herston, Australia|Investigational Site Number 036008, Nedlands, Australia|Investigational Site Number 036009, New Lambton, Australia|Investigational Site Number 036007, Perth, Australia|Investigational Site Number 036003, Woolloongabba, Australia|Investigational Site Number 056005, Aalst, Belgium|Investigational Site Number 056007, Brugge, Belgium|Investigational Site Number 056001, Brussel, Belgium|Investigational Site Number 056002, Gilly, Belgium|Investigational Site Number 056004, Hasselt, Belgium|Investigational Site Number 056003, Roeselare, Belgium|Investigational Site Number 124009, Calgary, Canada|Investigational Site Number 124010, Hamilton, Canada|Investigational Site Number 124004, London, Canada|Investigational Site Number 124008, Montreal, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124005, Ste-Foy, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124006, Vancouver, Canada|Investigational Site Number 124007, Victoria, Canada|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 203004, Brno, Czech Republic|Investigational Site Number 203002, Ceske Budejovice, Czech Republic|Investigational Site Number 203005, Hradec Kralove, Czech Republic|Investigational Site Number 203001, Liberec, Czech Republic|Investigational Site Number 203003, Olomouc, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 208002, Aarhus, Denmark|Investigational Site Number 208004, Hellerup, Denmark|Investigational Site Number 208005, København Ø, Denmark|Investigational Site Number 208001, Odense C, Denmark|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246004, Tampere, Finland|Investigational Site Number 250004, Brest, France|Investigational Site Number 250006, Grenoble, France|Investigational Site Number 250005, Lille, France|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250001, Paris Cedex 15, France|Investigational Site Number 250007, Rennes, France|Investigational Site Number 250003, Vandoeuvre Les Nancy Cedex, France|Investigational Site Number 276005, Bad Neustadt, Germany|Investigational Site Number 276002, Bernau, Germany|Investigational Site Number 276003, Dresden, Germany|Investigational Site Number 276001, Frankfurt Am Main, Germany|Investigational Site Number 276006, Hamburg, Germany|Investigational Site Number 348001, Balatonfüred, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348005, Pécs, Hungary|Investigational Site Number 348003, Zalaegerszeg, Hungary|Investigational Site Number 376002, Afula, Israel|Investigational Site Number 376003, Ashkelon, Israel|Investigational Site Number 376004, Haifa, Israel|Investigational Site Number 376001, Tel Aviv, Israel|Investigational Site Number 380004, Bari, Italy|Investigational Site Number 380008, Bergamo, Italy|Investigational Site Number 380002, Como, Italy|Investigational Site Number 380001, Firenze, Italy|Investigational Site Number 380007, Roma, Italy|Investigational Site Number 392004, Meguro-Ku, Japan|Investigational Site Number 392005, Niigata-Shi, Japan|Investigational Site Number 392001, Osaka Sayama-Shi, Japan|Investigational Site Number 392006, Osaka-Shi, Japan|Investigational Site Number 392003, Shinjuku-Ku, Japan|Investigational Site Number 392002, Suita-Shi, Japan|Investigational Site Number 484002, Mexico City, Mexico|Investigational Site Number 528001, Alkmaar, Netherlands|Investigational Site Number 528005, Amsterdam, Netherlands|Investigational Site Number 528002, Breda, Netherlands|Investigational Site Number 528003, Maastricht, Netherlands|Investigational Site Number 528007, Rotterdam, Netherlands|Investigational Site Number 528004, Zwolle, Netherlands|Investigational Site Number 578003, Drammen, Norway|Investigational Site Number 616007, Bydgoszcz, Poland|Investigational Site Number 616011, Gdynia, Poland|Investigational Site Number 616006, Lodz, Poland|Investigational Site Number 616003, Lodz, Poland|Investigational Site Number 616002, Szczecin, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 620004, Coimbra, Portugal|Investigational Site Number 620003, Lisboa, Portugal|Investigational Site Number 620005, Vila Nova De Gaia, Portugal|Investigational Site Number 643006, Ekaterinburg, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643008, Samara, Russian Federation|Investigational Site Number 643003, St-Petersburg, Russian Federation|Investigational Site Number 643011, St-Petersburg, Russian Federation|Investigational Site Number 643004, Tomsk, Russian Federation|Investigational Site Number 643007, Tyumen, Russian Federation|Investigational Site Number 703001, Bratislava, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 710002, Pretoria, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724006, Santiago De Compostela, Spain|Investigational Site Number 724009, Sevilla, Spain|Investigational Site Number 724007, Valencia, Spain|Investigational Site Number 752002, Stockholm, Sweden|Investigational Site Number 752003, Umeå, Sweden|Investigational Site Number 752001, Uppsala, Sweden|Investigational Site Number 792001, Ankara, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792002, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00993382"
823,"NCT03723655","A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM",,"Enrolling by invitation","No Results Available","Hypertrophic Cardiomyopathy|Obstructive Hypertrophic Cardiomyopathy|Non-obstructive Hypertrophic Cardiomyopathy","Drug: mavacamten","Frequency and severity of treatment-emergent adverse events and serious adverse events","MyoKardia, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","310","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MYK-461-007","October 5, 2018","June 2022","June 2022","October 29, 2018",,"April 10, 2020","Mayo Clinic Arizona, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|St. Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Oregon Health & Sciences University, Portland, Oregon, United States|St. Luke's University Health Network, Danville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor St Luke's Medical Center, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Intermountain Medical Center, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|UZ Antwerpen, Edegem, Antwerpen, Belgium|Onze-Lieve-Vrouwziekenhuis, Aalst, Oost-Vlaanderen, Belgium|Hôpital Erasme, Bruxelles, Belgium|Vseobecna Fakultni Nemocnice V Praze, Praha 2, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|Aarhus Universitetshospital, Aarhus N, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Odense Universitetshospital, Odense, Denmark|CHRU Nantes, Nantes Cedex 1, France|Groupe Hospitalier Pitié Salpétrière, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hôpital de Rangueil, Toulouse, France|Kerckhoff-Klinik-Forschungs-GmbH, Bad Nauheim, Hessen, Germany|University Medicine Göttingen Germany, Göttingen, Niedersachsen, Germany|Cardiologicum Dresden und Pirna, Dresden, Germany|University Clinic Heidelberg - PPDS, Heidelberg, Germany|Hadassah Medical Center PPDS, Jerusalem, Israel|Rabin Medical Center - PPDS, Petah Tikva, Israel|Sheba Medical Center - PPDS, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|ZIV Medical Center, Safed, Israel|Tel Aviv Sourasky Medical Center PPDS, Tel-Aviv, Israel|Azienda Ospedaliera Universitaria Careggi, Florence, Italy|Maastricht University Medical Center, Maastricht, Limburg, Netherlands|Erasmus MC, Rotterdam, Netherlands|Kardio Klinika Brynów, Katowice, Poland|Instytut Kardiologii im Prymasa Tysiaclecia Kardynala Stefana Wyszynskiego, Warsaw, Poland|Hospital Garcia de Orta, Almada, Portugal|Hospital da Luz, Lisboa, Portugal|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario A Coruña, A Coruña, Spain|Hospital Universitario Virgen de La Arrixaca, El Palmar, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|St Bartholomew's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03723655"
824,"NCT03872401","Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke","VESALIUS-CV","Recruiting","No Results Available","Coronary Heart Disease (CHD)","Drug: Evolocumab|Drug: Placebo","Time to Coronary Heart Disease Death, Myocardial Infarction, or Ischemic Stroke|Time to Coronary Heart Disease Death, Myocardial Infarction, Ischemic Stroke, or Any Ischemia-driven Arterial Sroke|Time to MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization|Time to CHD Death, MI, or Any Ischemia-driven Arterial Revascularization|Time to Cardiovascular Death, MI, or Stroke|Time to Myocardial Infarction|Time to Any Ischemia-driven Arterial Revascularization|Time to CHD Death|Time to Cardiovascular Death|Time to All Cause of Death|Time to Ischemic Stroke","Amgen","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 3","12000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20170625|2018-004565-14","June 11, 2019","May 29, 2024","May 29, 2024","March 13, 2019",,"April 7, 2020","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, Torrance, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boca Raton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Cumming, Georgia, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Covington, Kentucky, United States|Research Site, Eunice, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Great Barrington, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Southampton, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Jersey Shore, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, East Greenwich, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Little River, South Carolina, United States|Research Site, Murrells Inlet, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Suffolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Caba, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Mar del Plata, Buenos Aires, Argentina|Research Site, Moron, Buenos Aires, Argentina|Research Site, San Nicolas, Buenos Aires, Argentina|Research Site, Zarate, Buenos Aires, Argentina|Research Site, Santa Rosa, La Pampa, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Juan, Argentina|Research Site, San Luis, Argentina|Research Site, Garran, Australian Capital Territory, Australia|Research Site, Camperdown, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Bundaberg, Queensland, Australia|Research Site, Milton, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Fullarton, South Australia, Australia|Research Site, Leabrook, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Joondalup, Western Australia, Australia|Research Site, Woolloongabba, Australia|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Nepean, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Jerome, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Broumov, Czechia|Research Site, Havirov - Mesto, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Klatovy IV, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 3, Czechia|Research Site, Praha 5 - Smichov, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Svitavy, Czechia|Research Site, Trinec, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Znojmo, Czechia|Research Site, Aalborg, Denmark|Research Site, Aarhus N, Denmark|Research Site, Ballerup, Denmark|Research Site, Esbjerg, Denmark|Research Site, Gentofte, Denmark|Research Site, Herlev, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, Kobenhavn O, Denmark|Research Site, Kobenhavn S, Denmark|Research Site, Kolding, Denmark|Research Site, Silkeborg, Denmark|Research Site, Svendborg, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Bron, France|Research Site, Grenoble, France|Research Site, Le Coudray, France|Research Site, Marseille Cedex 08, France|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Krozingen, Germany|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Fulda, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Markleeberg, Germany|Research Site, Papenburg, Germany|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Balatonkeresztur, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Berettyoujfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Miskolc, Hungary|Research Site, Pecs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Bergamo, Italy|Research Site, Catanzaro, Italy|Research Site, Chieti, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Roma, Italy|Research Site, San Donato Milanese, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Almere, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dirksland, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Ede, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Goes, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Leiden, Netherlands|Research Site, Meppel, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sneek, Netherlands|Research Site, The Hague, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Uden, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zaandam, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krosno, Poland|Research Site, Leczna, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lodz, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Miechow, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Pulawy, Poland|Research Site, Ruda Slaska, Poland|Research Site, Siedlce, Poland|Research Site, Skierniewice, Poland|Research Site, Staszow, Poland|Research Site, Swidnik, Poland|Research Site, Szczecin, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wegrow, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sait-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Almeria, Andalucía, Spain|Research Site, Cordoba, Andalucía, Spain|Research Site, Granada, Andalucía, Spain|Research Site, Malaga, Andalucía, Spain|Research Site, Sevilla, Andalucía, Spain|Research Site, Zaragoza, Aragón, Spain|Research Site, Valladolid, Castilla León, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruña, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Falun, Sweden|Research Site, Goteborg, Sweden|Research Site, Harnosand, Sweden|Research Site, Jonkoping, Sweden|Research Site, Lidkoping, Sweden|Research Site, Malmo, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden|Research Site, Hualien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Barnsley, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Bollington, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Burton-on-Trent, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Cleveleys, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Corby, United Kingdom|Research Site, Crawley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Kenilworth, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newport, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Nuneaton, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sandbach, United Kingdom|Research Site, Scunthorpe, United Kingdom|Research Site, Shipley, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Thetford, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Watford, United Kingdom|Research Site, West Bromwich, United Kingdom|Research Site, Whitby, United Kingdom|Research Site, Wokingham, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Yeovil, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03872401"
825,"NCT01201837","Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial","CHI SQUARE","Completed","No Results Available","Acute Coronary Syndrome","Drug: Placebo|Drug: CER-001","Change in Total Plaque Volume|Percent Change in Plaque Volume","Cerenis Therapeutics, SA","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","507","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CER-001-CLIN-002","March 2011","October 2012","March 2013","September 15, 2010",,"March 3, 2014","Heart Center Research LLC, Huntsville, Alabama, United States|Mayo Clinic - Arizona, Phoenix, Arizona, United States|VA San Diego Health Care Center, San Diego, California, United States|Palm Beach Heart Institute, LLC - Zasa Clinical Research, Boynton Beach, Florida, United States|Heart and Vascular Institute of Florida, Clearwater, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Saint Joseph Research Institute, Atlanta, Georgia, United States|The Care Group, LLC, Indianapolis, Indiana, United States|Suburban Hospital, Bethesda, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Detroit Medical Center (DMC) Cardiovascular Institute, Detroit, Michigan, United States|Cardiac and Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|Alegent Research Center, Omaha, Nebraska, United States|Buffalo Heart Group, Buffalo, New York, United States|Buffalo Cardiology & Pulmonary Associates, Williamsville, New York, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina, United States|Sanford Heart Center, Fargo, North Dakota, United States|South Oklahoma Heart Research, Oklahoma City, Oklahoma, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Sanford Research / USD, Sioux Falls, South Dakota, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|MultiCare Health System Research Institute / Cardiac Study Center, Tacoma, Washington, United States|Foothills Medical Centre, Calgary, Alberta, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|St. John Health Center, St. John's, Newfoundland and Labrador, Canada|London Health Sciences Center, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Centre de Santé et de Services Sociaux de Laval, Laval, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Montreal General Hospital Research Institute, Montreal, Quebec, Canada|CSSS du Nord de Lanaudière, St-Charles-Borromée, Quebec, Canada|Centre Hospitalier Régional de Trois-Rivières, Trois-Rivières, Quebec, Canada|Institut Universitaire de Cardiologie et Pneumologie de Québec (IUCPQ), Quebec, Canada|Hôpital Cardiologique du Haut-Lévesque, Bordeaux, PESSAC Cedex, France|Clinique Pasteur, Toulouse, France|Centre Hospitalier Universitaire de Toulouse Rangueil, Toulouse, France|Onze Lieve Vrouwe Gasthius, Amsterdam, AC, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, AD, Netherlands|Medisch Centrum Alkmaar, Alkmaar, Amsterdam, Netherlands|Academic Medical Center, Amsterdam, AZ, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, CM, Netherlands|Maassstadziekenhuis Cardiology Research, Rotterdam, DZ, Netherlands|Catharina Ziekenhuis Eindhoven, Eindhoven, EJ, Netherlands|Medisch Spectrum Twente, Enschede, ER, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, SZ, Netherlands",,"https://ClinicalTrials.gov/show/NCT01201837"
826,"NCT04083833","A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects",,"Completed","No Results Available","TQT Study","Drug: Tetrodotoxin|Drug: Placebos","Cardiodynamic|ECG Paramenters|Assay Sensitivity","Wex Pharmaceuticals Inc.|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","TTX-TQT-101","February 7, 2018","March 24, 2018","March 24, 2018","September 10, 2019",,"September 10, 2019","Celerion, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04083833"
827,"NCT03315507","A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: PB1046 Subcutaneous Injection","Adverse Events|Vital Signs (Blood pressure)|Vital Signs (Heart rate)|Laboratory Parameters (Lipids)|Laboratory Parameters (Serum chemistry)|Laboratory Parameters (Urinalysis)|Laboratory Parameters (NT-pro-BNP)|Mean Pulmonary Artery Pressure|Cardiac Index|Total pulmonary resistance|Laboratory Parameters (Fasting Plasma Glucose)|Laboratory Parameters (Hematology)|Pharmacokinetic Dose Exposures (AUC (0-t))|Pharmacokinetic Dose Exposures (AUC (0-tmax))|Pharmacokinetic Dose Exposures (Cmax)|Pharmacokinetic Dose Exposures (Tmax)|Pharmacokinetic Dose Exposures (Ctrough)|Pharmacokinetic Dose Exposures (t1/2)|Pharmacokinetic Dose Exposures (Lambda z)|Pharmacokinetic Dose Exposures (Cl/F)|Pharmacokinetic Dose Exposures (Vd/F)|Immunogenicity","PhaseBio Pharmaceuticals Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PB1046-PT-CL-0005","October 20, 2017","August 8, 2019","August 8, 2019","October 20, 2017",,"October 8, 2019","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03315507"
828,"NCT01996943","The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study","HOLIDAY","Active, not recruiting","No Results Available","Atrial Fibrillation|Alcohol","Drug: Ethanol|Drug: Placebo","Atrial Fibrillation Induction|Change in Conduction Time|Change in Atrial Effective Refractory Period (AERP)","University of California, San Francisco","All","21 Years to 81 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","12-08579","September 2012","November 2020","November 2021","November 27, 2013",,"April 1, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01996943"
829,"NCT01764711","Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)",,"Active, not recruiting","No Results Available","Postural Tachycardia Syndrome","Drug: Cosyntropin administration","Adrenal responsiveness to adrenocorticotropin hormone. (ACTH)","Vanderbilt University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","18 Years to 50 Years   (Adult)","Not Applicable","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","120612|R01HL102387","January 2013","December 2020","December 2020","January 9, 2013",,"February 7, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01764711"
830,"NCT03785405","CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF",,"Recruiting","No Results Available","Heart Failure","Drug: sacubitril/valsartan","Number of participants with Adverse Events (AEs) as a measure of safety and tolerability|Number of participants with Serious Adverse Events (SAEs) as a measure of safety and tolerability","Novartis Pharmaceuticals|Novartis","All","1 Year to 18 Years   (Child, Adult)","Phase 3","240","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLCZ696B2319E1","May 2, 2019","April 21, 2022","May 19, 2022","December 24, 2018",,"February 27, 2020","Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, Saint Petersburg, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Be'er-Sheva, Israel|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Obu, Aichi, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, Japan|Novartis Investigative Site, Omura, Nagasaki, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku ku, Tokyo, Japan|Novartis Investigative Site, Yangsan Si, Gyeongsangnam Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Carnaxide, Lisboa, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkoknoi, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Konak/Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT03785405"
831,"NCT02630316","Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE",,"Completed","No Results Available","Pulmonary Hypertension|Interstitial Lung Disease|Combined Pulmonary Fibrosis and Emphysema","Drug: Inhaled Treprostinil|Drug: Placebo","Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure from Baseline to Week 16|Change in Peak 6-minute Walk Distance (6MWD) from Baseline to Week 12|Change in Trough 6-minute Walk Distance (6MWD) from Baseline to Week 15|Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to Week 16","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RIN-PH-201","May 2016","December 23, 2019","December 23, 2019","December 15, 2015",,"February 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|IMC-Diagnostic & Medical Clinic, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California San Francisco - Fresno, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|Pacific Pulmonary Medical Group, Riverside, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Kaiser Permanente, San Francisco, California, United States|University of Colorado Hospital - Cardiac and Vascular Center, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Heart & Vascular Institute, Washington, District of Columbia, United States|Florida Lung, Asthma & Sleep Specialists, P.A., Celebration, Florida, United States|St. Francis Sleep, Allergy and Lung Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|Wellstar Medical Group, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Maine Medical Center, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Spectrum Health Medical Center, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|The University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Northwell Health, New Hyde Park, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Vermont Lung Center, Colchester, Vermont, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|Alliance Cardio Pulmonary Research Group, Inc., Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02630316"
832,"NCT01847014","Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument","SYMPHONYext","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan","Incident Rate of Adverse Events (AEs).","Actelion","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-402","September 1, 2013","October 1, 2015","November 30, 2017","May 6, 2013","August 22, 2018","August 22, 2018","Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01847014"
833,"NCT01351753","Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity","REVIVE","Suspended","No Results Available","Obesity|Metabolic Syndrome X","Drug: Metformin|Drug: Orlistat|Drug: Topiramate|Drug: Placebo","Weight (change from baseline)|Brachial artery flow mediated dilatation (change from baseline)|Number of subjects with mild, moderate and serious adverse events.|Systolic and diastolic systemic arterial pressure (change from baseline)|Fasting lipids, glucose and other biomarkers of obesity risk (change from baseline)|Mood, anxiety, quality of life and cognitive function (change from baseline)|Body fat distribution (change from baseline)|Pulse wave velocity (PWV) and aortic augmentation pressure (change from baseline)|Peripheral arteriolar tonometry","University of Iowa","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201012738","March 2011","October 2019","October 2020","May 11, 2011",,"January 23, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01351753"
834,"NCT01545336","Anastrozole in Patients With Pulmonary Arterial Hypertension","AIPH","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Anastrozole|Drug: Placebo","Plasma Estradiol (E2) Level|Tricuspid Annular Plane Systolic Excursion (TAPSE)|Six Minute Walk Distance","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","815035","October 2012","June 2015","September 2015","March 6, 2012","August 9, 2016","October 27, 2016","University of Pennsylvania - Penn Presbyterian, Philadelphia, Pennsylvania, United States|University of Pennsylvania - Perelman Center, Philadelphia, Pennsylvania, United States|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01545336"
835,"NCT02554890","Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.","PIONEER-HF","Completed","Has Results","Acute Heart Failure","Drug: sacubitril/valsartan (LCZ696)|Drug: Enalapril|Drug: sacubitril/valsartan (LCZ696) matching placebo|Drug: enalapril matching placebo","N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline|Number of Patients With Incidences of Symptomatic Hypotension|Number of Patients With Incidences of Hyperkalemia|Number of Patients With Incidences of Angioedema|Change From Baseline in High Sensitivity Troponin (Hs-Troponin)|Change From Baseline in Urinary cGMP|Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio|Change From Baseline in BNP to NTproBNP Ratio|N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","887","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CLCZ696BUS01","April 29, 2016","June 29, 2018","July 24, 2018","September 18, 2015","September 24, 2019","September 24, 2019","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Fort Smith, Arkansas, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Bakersfield, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Pasadena, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Marino, California, United States|Novartis Investigative Site, San Pablo, California, United States|Novartis Investigative Site, Stanford, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Littleton, Colorado, United States|Novartis Investigative Site, Bridgeport, Connecticut, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, West Haven, Connecticut, United States|Novartis Investigative Site, Newark, Delaware, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Orange Park, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, Winter Haven, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Oakbrook Terrace, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Winfield, Illinois, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Annapolis, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Bay City, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Maplewood, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Reno, Nevada, United States|Novartis Investigative Site, Camden, New Jersey, United States|Novartis Investigative Site, Elmer, New Jersey, United States|Novartis Investigative Site, Haddon Heights, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Johnson City, New York, United States|Novartis Investigative Site, Manhasset, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Poughkeepsie, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Staten Island, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Greenville, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Camp Hill, Pennsylvania, United States|Novartis Investigative Site, Natrona Heights, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, White River Junction, Vermont, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Lynchburg, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Virginia Beach, Virginia, United States|Novartis Investigative Site, Charleston, West Virginia, United States|Novartis Investigative Site, Clarksburg, West Virginia, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Wausau, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02554890/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT02554890/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02554890"
836,"NCT03558958","Safety and Efficacy of P-188 NF in DMD Patients",,"Suspended","No Results Available","Duchenne Muscular Dystrophy","Drug: P-188 NF","Forced vital capacity (FVC)|Maximal inspiratory pressure (MIP)|Maximal expiratory pressure (MEP)|Peak cough flow (PCF)|Left ventricular end-diastolic volume (LVEDV)|Ejection Fraction (EF)|Degree of fibrosis as assessed by cardiac MRI|Performance of upper limb (PUL) test|Cardiac troponin I|Muscle creatine kinase","Phrixus Pharmaceuticals, Inc.|Charley's Fund","Male","12 Years to 25 Years   (Child, Adult)","Phase 2","10","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-004","August 8, 2018","September 2020","November 2020","June 15, 2018",,"August 30, 2019","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03558958"
837,"NCT01734694","Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","STOP-NT","Terminated","No Results Available","Health Care Associated Pneumonia|Osteomyelitis/Septic Arthritis|Endocarditis|Bacteremia|Acute Bacterial Skin and Skin Structure Infections","Drug: Vancomycin|Drug: Ceftaroline|Drug: Daptomycin|Drug: Linezolid","Nephrotoxicity|Acute Kidney Injury Network Modified Definition of Nephrotoxicity|Clinical Success","Henry Ford Health System","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","7089","October 2011","September 2013",,"November 28, 2012",,"July 9, 2013","Henry Ford Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01734694"
838,"NCT00825266","Insulin Resistance in Pulmonary Arterial Hypertension",,"Terminated","Has Results","Hypertension, Pulmonary","Drug: bosentan|Drug: Pioglitazone","Insulin Resistance Profile Change - Triglyceride:HDL Cholesterol Ratio|6 Minute Walk Test|NYHA (New York Heart Association Classification) Changes","Stanford University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SU-09052008-1295|IRB#7432","September 2008","May 2010","May 2010","January 21, 2009","March 31, 2017","March 31, 2017","Stanford University School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT00825266"
839,"NCT00907998","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180",,"Completed","No Results Available","Coronary Heart Disease","Drug: APL180|Drug: Placebo","Safety and tolerability of APL180|Pharmacokinetics of APL180|Evaluate effects of APL180 biomarkers|Pharmacokinetic-pharmacodynamic relationship of APL180|Effect of APL180 on exploratory biomarkers,","Novartis Pharmaceuticals|Novartis","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","CAPL180A2210B|EudraCT 2009-010877-19","June 2009","October 2009",,"May 25, 2009",,"November 20, 2009","Pinnacle Research Group, Anniston, Alabama, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Icon Clinical Research, San Antonio, Texas, United States|Novartis Investigator Site, Copenhagen, Denmark|Novartis Investigator Site, Mainz, Germany|Novartis Investigator Site, Mannheim, Germany|Novartis Investigator Site, Neuss, Germany|Novartis Investigator Site, Rehovot, Israel|Novartis Investigator Site, Tel Aviv, Israel|Novartis Investigator Site, Zrifin, Israel|Novartis Investigator Site, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT00907998"
840,"NCT02633293","An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE",,"Enrolling by invitation","No Results Available","Pulmonary Hypertension|Interstitial Lung Disease|Combined Pulmonary Fibrosis and Emphysema","Drug: Inhaled Treprostinil","Change in Peak 6-Minute Walk Distance (6MWD) from Baseline to the Week 48 Visit|Change in plasma concentration of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) from Baseline to the Week 48 Visit|Change in Forced Expiratory Volume (FEV1) in One Second from Baseline to Week 48|Change in Forced Vital Capacity (FVC) from Baseline to Week 48|Change in Total Lung Capacity (TLC) from Baseline to Week 48|Change in Lung Diffusion Capacity (DLCO) from Baseline to Week 48|Incidence of Adverse Events Among Participants through Week 108","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","266","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RIN-PH-202","September 2016","November 2022","November 2022","December 17, 2015",,"February 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|IMC-Diagnostic & Medical Clinic, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California, San Francisco-Fresno, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|Pacific Pulmonary Medical Group, Riverside, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Kaiser Permanente, San Francisco, California, United States|University of Colorado Hospital - Cardiac and Vascular Center, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Heart & Vascular Institute, Washington, District of Columbia, United States|Florida Lung, Asthma & Sleep Specialists, P.A., Celebration, Florida, United States|St. Francis Sleep, Allergy and Lung Institute, Clearwater, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|St. Vincent's Lung, Sleep, and Critical Care Specialists, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|Wellstar Medical Group, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Community Heart and Vascular Hospital, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville Physicians Outpatient Center, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center New Orleans, New Orleans, Louisiana, United States|Maine Medical Center, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Spectrum Health Medical Center, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University Hospital, Saint Louis, Missouri, United States|The University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Northwell Health, New Hyde Park, New York, United States|NYU Langone Medical Center, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|AnMed Health Pulmonary and Sleep Medicine, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Statcare Pulmonary Consultants, Knoxville, Tennessee, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Vermont Lung Center, Colchester, Vermont, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States|Alliance Cardio Pulmonary Research Group, Inc., Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02633293"
841,"NCT02917031","Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","MEASURE-HF","Completed","No Results Available","Type 2 Diabetes Mellitus|Heart Failure","Drug: Saxagliptin|Drug: Sitagliptin|Drug: Placebo to match saxagliptin|Drug: Placebo to match sitagliptin","The change in LVEDV index measured by MRI from baseline to Week 24|The change in LVESV index measured by MRI from baseline to Week 24|The change in LVEF measured by MRI from baseline to Week 24|The change in LVM measured by MRI from baseline to Week 24|The change from baseline in NT-proBNP after 24 weeks of treatment","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 4","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D1680C00016","January 10, 2017","August 23, 2019","August 23, 2019","September 28, 2016",,"February 19, 2020","Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Doral, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Houston, Texas, United States|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Chicoutimi, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Viña del Mar, Chile|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kisvárda, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Orosháza, Hungary|Research Site, Pécs, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Busan, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Hwaseong-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Brasov, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Rivne, Ukraine",,"https://ClinicalTrials.gov/show/NCT02917031"
842,"NCT03779841","Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open-chest Cardiac Surgery (NOVA)",,"Recruiting","No Results Available","Post-Operative Atrial Fibrillation","Drug: AGN-151607|Drug: Placebo","Percentage of participants with at least 1 continuous atrial fibrillation (AF) episode ≥ 30 seconds during the first 30 days post-surgery.|Percentage of time spent in AF (AF burden) during the first 30 days post-surgery|Percentage of participants with at least 1 event of symptomatic AF during the first 30 days post-surgery|Time to first occurrence of AF during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 2 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 5 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 30 minutes during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 1 hour during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 4 hours during the first 30 days post-surgery|Percentage of participants with at least 1 continuous AF episode ≥ 24 hours during the first 30 days post-surgery","Allergan","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1925-201-008|2017-004399-68","March 1, 2019","October 15, 2020","October 14, 2021","December 19, 2018",,"March 31, 2020","Stanford University School of Medicine, Stanford, California, United States|Medstar Heart and Vascular Institute, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|The University of Michigan, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Duke University, Durham, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Medical Center Heart and Vascular Research Organization, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor Scott & White Research Institute The Heart Hospital Plano, Plano, Texas, United States|University of Utah Division of Cardiothoracic Surgery, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Allgemeines Krankenhaus Wien Universitätsklinik für Chirurgie Klinische Abteilung für Herzchirurgie, Vienna, Austria|London Health Sciences Centre, University Hospital, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec Universié Laval, Laval, Quebec, Canada|Montreal Heart University, Montreal, Quebec, Canada|CHUM, Montreal, Quebec, Canada|CIUSS North of Montreal Island Sacré-Cœur Hospital Montreal, Montreal, Quebec, Canada|Asklepios Klinik Harburg-Hamburg, Hamburg, Germany|Leipzig Heart Institute, Leipzig, Germany|Asst degli Spegali Civili di Brescia, Brescia, Italy|Amsterdam UMC, Amsterdam, Noord Holland, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Utrecht, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Karolinska University Hospital, Solna, Stockholm, Sweden|Orebro University Hospital, Orebro, Sweden|Derriford Hospital, Plymouth, Devon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03779841"
843,"NCT03929718","Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation",,"Recruiting","No Results Available","AFib","Drug: Spironolactone|Drug: No Spironolactone","Long-Term incidence of new-onset AF after CTI ablation|Rates of new-onset AF between standard therapy and spironolactone","Piedmont Healthcare","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVOID-AF","April 24, 2019","May 2022","May 2022","April 29, 2019",,"April 29, 2019","Piedmont Heart Institute, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03929718"
844,"NCT02251509","Rate Control in Atrial Fibrillation",,"Unknown status","No Results Available","Atrial Fibrillation","Drug: Carvedilol|Drug: Metoprolol tartrate","Resting heart rate","Creighton University","All","19 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","624918","December 2016","September 2017","September 2017","September 29, 2014",,"June 16, 2016","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02251509"
845,"NCT04187196","Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion",,"Not yet recruiting","No Results Available","Atrial Fibrillation|Atrial Flutter","Drug: Propofol|Drug: Methohexital","Time from initiation of sedation to full recovery|Time from end of injection to loss of conscious|Time to first shock|Time to eyes opening|Systolic Blood Pressure|Diastolic Blood Pressure|Mean arterial Blood Pressure|Respiratory Rate|SpO2|Heart rate|Recall of pain at injection site - visual analog scale|Recall of anything unpleasant about the procedure - visual analog scale","Wake Forest University Health Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00061732","May 2020","November 2020","November 2020","December 5, 2019",,"April 21, 2020","Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04187196"
846,"NCT01884675","Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.","AMBER I","Terminated","Has Results","Hypertension","Drug: Ambrisentan 5 mg|Drug: Placebo","Change From Baseline in Six Minutes Walking Distance (6MWD) at Week 16|Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16|Change From Baseline in WHO Functional Class (FC) at Weeks 4, 8, 12 and 16/Early Withdrawal|Change From Baseline in Borg CR10 Scale (BCR10S) Immediately Following Exercise at Weeks 4, 8, 12 and 16/Early Withdrawal|Number of Participants With Clinical Worsening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Change From Baseline in Mean Right Atrial Pressure (mRAP) and Mean Pulmonary Artery Pressure (mPAP) at Week 16|Change From Baseline in Cardiac Index at Week 16|Percent Change From Baseline in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Change From Baseline in Quality of Life as Measured by Short Form 36 Health Survey (SF-36)|Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)|Change From Baseline in Haemoglobin Levels at Weeks 4, 8, 12, and 16/Early Withdrawal|Change From Baseline in Haematocrit Levels at Weeks 4, 8, 12, and 16/Early Withdrawal|Number of Participants With Significant Liver Events at Weeks 4, 8, 12, and 16/Early Withdrawal|Change From Baseline in Supine Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Assessed at Weeks 4, 8, 12, and 16/Early Withdrawal|Change From Baseline in Heart Rate Assessed at Weeks 4, 8, 12, and 16/Early Withdrawal|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern Any Time Post Baseline|Number of Participants With Hematology Parameters of Potential Clinical Concern Any Time Post Baseline|Number of Participants With Testicular Function (Males Only) of Potential Clinical Concern Any Time Post Baseline","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","115811","September 2013","March 2015","March 2015","June 24, 2013","December 16, 2015","March 6, 2017","GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Xian, Shaanxi, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Monterrey NL, Nuevo León, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Riyadh, Saudi Arabia|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Clydebank, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01884675"
847,"NCT02365415","Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement",,"Withdrawn","No Results Available","Peripheral Pulmonary Stenosis|In-stent Stenosis","Drug: Sirolimus","Percent change in in-stent stenosis|RV pressure|Adverse drug event","Boston Children’s Hospital","All","6 Months and older   (Child, Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-P00005257","February 2015","April 2018","April 2018","February 19, 2015",,"April 5, 2018","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02365415"
848,"NCT03229499","Pulmonary Hypertension and Anastrozole Trial","PHANTOM","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Anastrozole|Drug: Placebo Oral Tablet","Difference in changes in distance walked in six minutes between anastrozole and placebo groups|Difference in right ventricular function between anastrozole and placebo groups|Difference in changes in plasma NT-proBNP level between anastrozole and placebo groups|Difference in changes in biomarkers between anastrozole and placebo groups|Difference in changes in SF36 between anastrozole and placebo groups|Difference in changes in emPHasis-10 between anastrozole and placebo groups|Difference in changes in actigraphy-measured physical activity between anastrozole and placebo groups|Difference in time-to-clinical worsening (TTCW) between anastrozole and placebo groups|Difference in changes in bone mineral density between anastrozole and placebo groups|Difference in side effects between anastrozole and placebo groups at twelve months","University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University|University of Colorado, Denver|Rhode Island Hospital|Stanford University|Vanderbilt University|Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","84","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","827486|R01HL134905","December 7, 2017","September 2021","September 2021","July 25, 2017",,"April 24, 2020","Stanford University, Stanford, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03229499"
849,"NCT01117987","Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)","IMPRES Extn","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Imatinib|Drug: Placebo","Number of Participants With Adverse Events, Serious Adverse Events and Deaths|Change From Core Study Baseline in Six-Minute Walk Distance (6MWD)|Percentage of Participants With Incidence of Clinical Worsening Events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","144","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQTI571A2301E1|2009-018167-26","April 2010","April 2014","April 2014","May 6, 2010","May 21, 2015","August 13, 2015","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tualatin, Oregon, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Milwaulkee, Wisconsin, United States|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Clamart Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Pavia, (pv), Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Hamamatsu, Shizuoka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Mitaka-city, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, Newcastle, United Kingdom|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01117987"
850,"NCT02029534","Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)",,"Unknown status","No Results Available","Cardiothoracic Surgery|Post-operative Atrial Fibrillation","Drug: Atorvastatin 20 mg|Drug: Atorvastatin 80 mg","Occurrence of atrial fibrillation by hospital discharge|Length of hospital stay|Incidence of major adverse cardiac and cardiovascular events (MACCE) at 30 days","Creighton University","All","19 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","13-16729","August 2013","June 2017","June 2017","January 8, 2014",,"June 16, 2016","Creighton University, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02029534"
851,"NCT01042769","A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus",,"Completed","No Results Available","Diabetes Mellitus Type 2","Drug: Aleglitazar|Drug: Placebo","Effect on cardiovascular death, non-fatal myocardial infarction and non-fatal stroke|Effects on other cardiovascular endpoints|Glycemic control, lipoprotein profile, blood pressure, biomarkers of cardiovascular risk|Tolerability and long-term safety profile","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","7226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BC22140|2009-012269-71","February 2010","November 2013","November 2013","January 6, 2010",,"November 2, 2016","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Mobile, Alabama, United States|Mobile, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Banning, California, United States|Carmichael, California, United States|Fresno, California, United States|Fullerton, California, United States|Glendale, California, United States|Hawaiian Gardens, California, United States|Inglewood, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Northridge, California, United States|Orange, California, United States|Pomona, California, United States|Redondo Beach, California, United States|Salinas, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Sylmar, California, United States|Thousand Oaks, California, United States|Torrance, California, United States|Ventura, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|Bridgeport, Connecticut, United States|Hartford, Connecticut, United States|Stamford, Connecticut, United States|Seaford, Delaware, United States|Aventura, Florida, United States|Boynton Beach, Florida, United States|Clearwater, Florida, United States|Coral Springs, Florida, United States|Doral, Florida, United States|Edgewater, Florida, United States|Elizabeth, Florida, United States|Ft. Lauderdale, Florida, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville Beach, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miramar, Florida, United States|Naples, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Panama City, Florida, United States|Sarasota, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Trinity, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Macon, Georgia, United States|Gurnee, Illinois, United States|Elkhart, Indiana, United States|Indianapolis, Indiana, United States|Lafayette, Indiana, United States|Ames, Iowa, United States|Council Bluffs, Iowa, United States|Davenport, Iowa, United States|Des Moines, Iowa, United States|Elizabethtown, Kentucky, United States|Owensboro, Kentucky, United States|Alexandria, Louisiana, United States|Convington, Louisiana, United States|Hammond, Louisiana, United States|Houma, Louisiana, United States|Lafayette, Louisiana, United States|LaPlace, Louisiana, United States|Metarie, Louisiana, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Opelousas, Louisiana, United States|Shreveport, Louisiana, United States|Shreveport, Louisiana, United States|Slidell, Louisiana, United States|Zachary, Louisiana, United States|Bangor, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Columbia, Maryland, United States|Oxon Hill, Maryland, United States|Salisbury, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Fall River, Massachusetts, United States|Hyannis, Massachusetts, United States|Worcester, Massachusetts, United States|Alpena, Michigan, United States|Ann Arbor, Michigan, United States|Bay City, Michigan, United States|Flint, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Petoskey, Michigan, United States|Royal Oak, Michigan, United States|Saginaw, Michigan, United States|Saginaw, Michigan, United States|Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Paul, Minnesota, United States|St. Cloud, Minnesota, United States|Jackson, Mississippi, United States|Picayune, Mississippi, United States|Chesterfield, Missouri, United States|Washington, Missouri, United States|Great Falls, Montana, United States|Freemont, Nebraska, United States|Omaha, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Bridgewater, New Jersey, United States|Mine Hill, New Jersey, United States|Newark, New Jersey, United States|Somerset, New Jersey, United States|Albuquerque, New Mexico, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Albany, New York, United States|Bronx, New York, United States|Brooklyn, New York, United States|Buffalo, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Suffern, New York, United States|Syracuse, New York, United States|Troy, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Durham, North Carolina, United States|Greenville, North Carolina, United States|Rocky Mount, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Kettering, Ohio, United States|Marion, Ohio, United States|Middleburg Heights, Ohio, United States|Springfield, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Chambersburg, Pennsylvania, United States|Danville, Pennsylvania, United States|Harrisburg, Pennsylvania, United States|Natrona Heights, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pottstown, Pennsylvania, United States|Upper Darby, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Providence, Rhode Island, United States|Providence, Rhode Island, United States|Greer, South Carolina, United States|Johnson City, Tennessee, United States|Kingsport, Tennessee, United States|Lexington, Tennessee, United States|Nashville, Tennessee, United States|Tullahoma, Tennessee, United States|Amarillo, Texas, United States|Austin, Texas, United States|Bellaire, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Kerrville, Texas, United States|Kingwood, Texas, United States|Lubbock, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Tomball, Texas, United States|Victoria, Texas, United States|Layton, Utah, United States|Murray, Utah, United States|Danville, Virginia, United States|Roanoke, Virginia, United States|Huntington, West Virginia, United States|Beloit, Wisconsin, United States|Burlington, Wisconsin, United States|Green Bay, Wisconsin, United States|LaCrosse, Wisconsin, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Caba, Argentina|Caba, Argentina|Caba, Argentina|Capital Federal, Argentina|Ciudad Autonoma Bs As, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Coronel Suarez, Argentina|Corrientes, Argentina|Haedo, Argentina|Mendoza, Argentina|Moron, Argentina|Rosario, Argentina|Rosario, Argentina|Rosario, Argentina|Salta, Argentina|Santa Fe, Argentina|Santiago del Estero, Argentina|Tucuman, Argentina|Zarate, Argentina|Garran, Australian Capital Territory, Australia|Bankstown, New South Wales, Australia|Concord, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Liverpool BC, New South Wales, Australia|New Lambton, New South Wales, Australia|Penrith, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Wollongong, New South Wales, Australia|Douglas, Queensland, Australia|Milton, Queensland, Australia|Redcliffe, Queensland, Australia|Southport, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Elizabeth Vale, South Australia, Australia|Woodville, South Australia, Australia|Ballarat, Victoria, Australia|Geelong, Victoria, Australia|Richmond, Victoria, Australia|Shepparton, Victoria, Australia|Salvador, BA, Brazil|Fortaleza, CE, Brazil|Fortaleza, CE, Brazil|Fortaleza, CE, Brazil|Fortaleza, CE, Brazil|Brasilia, DF, Brazil|Cariacica, ES, Brazil|Goiania, GO, Brazil|Belo Horizonte, MG, Brazil|Belo Horizonte, MG, Brazil|Belo Horizonte, MG, Brazil|Uberlandia, MG, Brazil|Campo grande, MS, Brazil|Recife, PE, Brazil|Campina Grande do Sul, PR, Brazil|Curitiba, PR, Brazil|Curitiba, PR, Brazil|Curitiba, PR, Brazil|Rio de Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Natal, RN, Brazil|Passo Fundo, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Sao Jose do Rio Preto, SC, Brazil|Sao Jose, SC, Brazil|Campinas, SP, Brazil|Campinas, SP, Brazil|Sao Jose do Rio Preto, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Red Deer, Alberta, Canada|New Westminster, British Columbia, Canada|Surrey, British Columbia, Canada|Bathurst, New Brunswick, Canada|Moncton, New Brunswick, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|St Johns, Newfoundland and Labrador, Canada|Bridgewater, Nova Scotia, Canada|Halifax, Nova Scotia, Canada|Brampton, Ontario, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Burlington, Ontario, Canada|Cambridge, Ontario, Canada|Cambridge, Ontario, Canada|Fort Eire, Ontario, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|MIssissauga, Ontario, Canada|NewMarket, Ontario, Canada|Oshawa, Ontario, Canada|Smiths Falls, Ontario, Canada|Sudbury, Ontario, Canada|Sudbury, Ontario, Canada|Sudbury, Ontario, Canada|Thunder Bay, Ontario, Canada|Toronto, Ontario, Canada|Charlottetown, Prince Edward Island, Canada|Chicoutimi, Quebec, Canada|Chicoutimi, Quebec, Canada|Gatineau, Quebec, Canada|Granby, Quebec, Canada|Granby, Quebec, Canada|Laval, Quebec, Canada|Longueuil, Quebec, Canada|Lévis, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Quebec city, Quebec, Canada|Quebec city, Quebec, Canada|Saint-Laurent, Quebec, Canada|Sherbrooke, Quebec, Canada|Sherbrooke, Quebec, Canada|St-Charles-Borromée, Quebec, Canada|St-jerome, Quebec, Canada|St-Lambert, Quebec, Canada|St-Léonard, Quebec, Canada|Ste. Foy, Quebec, Canada|Terrebonne, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Val DOr, Quebec, Canada|Vaudreuil-Dorion, Quebec, Canada|Baotou, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijng, China|Changsha, China|Changsha, China|Changsha, China|Chengdu, China|Dalian, China|Daqing, China|Guangzhou, China|Guangzhou, China|Hangzhou, China|Hangzhou, China|Hangzhou, China|Jinan, China|Nanjing, China|Nanning, China|Qingdao, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|ShenYang, China|Shenyang, China|Shijiazhuang, China|Tianjin, China|Wuhan, China|Xi'an, China|Brno, Czech Republic|Brno, Czech Republic|Hradec Kralove, Czech Republic|Jindrichuv Hradec, Czech Republic|Kladno, Czech Republic|Olomouc, Czech Republic|Prague 2, Czech Republic|Prague 2, Czech Republic|Prague, Czech Republic|Tabor, Czech Republic|Teplice, Czech Republic|Trutnov, Czech Republic|Znojmo, Czech Republic|Aalborg, Denmark|Copenhagen, Denmark|Fredericia, Denmark|Herning, Denmark|Odense, Denmark|Slagelse, Denmark|Albi, France|Besancon, France|Bron, France|Cambrai, France|Creteil, France|Dijon, France|Lagny-sur-marne, France|Le Coudray, France|Le Plessis Robinson, France|Marseille, France|Montfermeil, France|Montpellier, France|Paris, France|Paris, France|Pessac, France|St Herblain, France|Valenciennes, France|Bad Krozingen, Germany|Bad Nauheim, Germany|Bad Oeynhausen, Germany|Bad Rothenfelde, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bernried, Germany|Bochum, Germany|Bonn, Germany|Brandenburg, Germany|Burg, Germany|Cologne, Germany|Dortmund, Germany|Düsseldorf, Germany|Essen, Germany|Frankfurt, Germany|Fulda, Germany|Fürth, Germany|Halle, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Homburg/Saar, Germany|Kiel, Germany|Lahr, Germany|Langen, Germany|Mainz, Germany|Mannheim, Germany|Muenchen, Germany|Mönchengladbach, Germany|Münster, Germany|Nienburg, Germany|Pirna, Germany|Regensburg, Germany|Rotenburg, Germany|Ruedersdorf, Germany|Wuppertal, Germany|Toulouse, Grenada|Balatonfuered, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyula, Hungary|Kaposvár, Hungary|Kecskemet, Hungary|Miskolc, Hungary|Pécs, Hungary|Szolnok, Hungary|Szombathely, Hungary|Székeshehérvár, Hungary|Zalaegerszeg, Hungary|Kochi, Kerala, India|Pune, Maharashtra, India|Ahmedabad, India|Ahmedabad, India|Ahmedabad, India|Ahmedabad, India|Bangalore, India|Bangalore, India|Bangalore, India|Banglore, India|Belgaum, India|Belgaum, India|Chennai, India|Cochin, India|Gurgaon, India|Hyderabad, India|Hyderabad, India|Hyderabad, India|Hyderabad, India|Hyderabad, India|Indore, India|Jaipur, India|Kolkata, India|Lucknow, India|Madhurai, India|Mangalore, India|Mangalore, India|Mangalore, India|Mumbai, India|Mumbai, India|Mysore, India|Nagpur, India|Nagpur, India|New Delhi, India|Palakkad, India|Pune, India|Pune, India|Pune, India|Secunderabad, India|Trivandeum, India|Ballinasloe, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Tallaght Dublin, Ireland|Napoli, Campania, Italy|Pozzuoli, Campania, Italy|Bentivoglio, Emilia-Romagna, Italy|Ferrara, Emilia-Romagna, Italy|Reggio Emilia, Emilia-Romagna, Italy|Udine, Friuli-Venezia Giulia, Italy|Rome, Lazio, Italy|Bergamo, Lombardia, Italy|Legnano, Lombardia, Italy|Mantova, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Pavia, Lombardia, Italy|Perugia, Umbria, Italy|Cittadella, Veneto, Italy|Rovigo, Veneto, Italy|Busan, Korea, Republic of|Busan, Korea, Republic of|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Incheon, Korea, Republic of|Jeollabuk-do, Korea, Republic of|Kyonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Uijongbu, Korea, Republic of|Ulsan, Korea, Republic of|Wonju, Korea, Republic of|Kelantan, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Kuantan, Malaysia|Penang, Malaysia|Sarawak, Malaysia|Serdang, Malaysia|Acapulco, Mexico|Aguascalientes, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Chihuahua, Mexico|Ciudad Juárez, Mexico|Cuernavaca, Mexico|Culiacan, Mexico|Durango, Mexico|Durango, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Pachuca, Mexico|Puebla, Mexico|Puerto Vallarta, Mexico|Queretaro, Mexico|San Luis Potosi S.L.P., Mexico|Tampico, Mexico|Tijuana, Mexico|Tlalnepantla, Mexico|Veracruz, Mexico|Xalapa, Mexico|Zapopan, Mexico|AC Amsterdam, Netherlands|Amstelveen, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Hoorn, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Purmerend, Netherlands|Tilburg, Netherlands|Weert, Netherlands|Zaandam, Netherlands|Zwolle, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Hamiton, New Zealand|Lower Hutt, New Zealand|Nelson, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Bialystok, Poland|Bielsko-Biala, Poland|Bydgoszcz, Poland|Bydgoszcz, Poland|Bytom, Poland|Bêdzin, Poland|Cracow, Poland|Gdansk, Poland|Gdansk, Poland|Gdynia, Poland|Gdynia, Poland|Gdynia, Poland|Gdynia, Poland|Gorlice, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Kedzierzyn-Kozle, Poland|Kielce, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Kutno, Poland|Libiaz, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Lublin, Poland|Nowa Sol, Poland|Nysa, Poland|Olawa, Poland|Olesnica, Spalice, Poland|Olsztyn, Poland|Poznan, Poland|Pulawy, Poland|Radom, Poland|Rzeszow, Poland|Swidnica, Poland|Tarnow, Poland|Tarnów, Poland|Torun, Poland|Ustron, Poland|Ustroñ, Poland|Warsaw, Poland|Warsaw, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wola, Poland|Wroclaw, Poland|Zamosc, Poland|Zarow, Poland|Zgorzelec, Poland|£ódx, Poland|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Buzau, Romania|Cluj-Napoca, Romania|Craiova, Romania|Galati, Romania|Oradea, Romania|Ploiesti, Romania|Targu-Mures, Romania|Timisoara, Romania|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Vitoria, Alava, Spain|Torrevieja, Alicante, Spain|Oviedo, Asturias, Spain|Granollers, Barcelona, Spain|Hospitalet de Llobregat, Barcelona, Spain|Sabadell, Barcelona, Spain|Terrassa, Barcelona, Spain|Jerez de La Frontera, Cadiz, Spain|Figueres, Girona, Spain|Coruna, La Coruña, Spain|Ferrol, La Coruña, Spain|Santiago de Compostela, La Coruña, Spain|Alcorcon, Madrid, Spain|San Sebastian de los Reyes, Madrid, Spain|Seville, Sevilla, Spain|Reus, Tarragona, Spain|Bilbao, Vizcaya, Spain|Alicante, Spain|Almeria, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Guadalajara, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Salamanca, Spain|Tarragona, Spain|Valencia, Spain|Valencia, Spain|Danderyd Stockholm, Sweden|Goteborg, Sweden|Halmstad, Sweden|Kalmar, Sweden|Karlstad, Sweden|Kristianstad, Sweden|Malmö, Sweden|Ostersund, Sweden|Skellefteå, Sweden|Skovde, Sweden|Stockholm, Sweden|Stockholm, Sweden|Amphur Mae-Rim, Thailand|Amphur Muang, Thailand|Amphur Muang, Thailand|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|ChiangMai, Thailand|Chonburi, Thailand|Khon Kaen, Thailand|Khonkaen, Thailand|Klong Luang, Thailand|Phitsanulok, Thailand|Saraburi, Thailand|Abano Terme, United Kingdom|Antrim, United Kingdom|AYR, United Kingdom|Basildon, United Kingdom|Bath, United Kingdom|Belfast, United Kingdom|Belfast, United Kingdom|Brighton, United Kingdom|Cambridge, United Kingdom|Craigavon, United Kingdom|Derby, United Kingdom|Glasgow, United Kingdom|Harrow, United Kingdom|Inverness, United Kingdom|Isle of Wight, United Kingdom|Isleworth, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesex, United Kingdom|Newcastle upon Tyne, United Kingdom|Northampton, United Kingdom|Paddington, United Kingdom|Plymouth, United Kingdom|Poole, United Kingdom|Romford, United Kingdom|Stoker on Trent, United Kingdom|West Bromwich, United Kingdom|Wrexham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01042769"
852,"NCT01440881","Does Nesiritide Provide Renal Protection",,"Completed","Has Results","Renal Failure","Drug: Nesiritide|Drug: Placebo","Measure Neutrophils to Measure Kidney Injury|The Examine and Measure Cytokines to Measure Kidney Injury|The Examine and Measure Endothelin-1 to Measure Kidney Injury|The Examine and Measure Urinary NGAL to Measure Kidney Injury","University of Florida","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","70-2010|09KW-03","April 2010","December 2012","December 2012","September 27, 2011","March 6, 2014","June 6, 2014","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01440881"
853,"NCT02293395","A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome","GEMINI ACS 1","Completed","Has Results","Acute Coronary Syndrome","Drug: Acetylsalicylic acid|Drug: Rivaroxaban|Drug: Clopidogrel|Drug: Ticagrelor","Number of Participants With Non Coronary Artery Bypass Graft-Related (Non CABG-related) Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events","Janssen Research & Development, LLC|Bayer|Duke Clinical Research Institute|Harvard Medical School","All","18 Years and older   (Adult, Older Adult)","Phase 2","3037","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CR106261|RIVAROXACS2002|2014-004266-26","April 20, 2015","October 14, 2016","October 14, 2016","November 18, 2014","November 13, 2017","December 26, 2017","Alexander City, Alabama, United States|Banning, California, United States|Sylmar, California, United States|Aurora, Colorado, United States|Littleton, Colorado, United States|Jupiter, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Athens, Georgia, United States|Cumming, Georgia, United States|Macon, Georgia, United States|Tucker, Georgia, United States|Boise, Idaho, United States|Coeur d'Alene, Idaho, United States|Jerseyville, Illinois, United States|Indianapolis, Indiana, United States|Munster, Indiana, United States|Bay City, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Ypsilanti, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Stony Brook, New York, United States|Rocky Mount, North Carolina, United States|Sanford, North Carolina, United States|Cincinnati, Ohio, United States|Zanesville, Ohio, United States|Bartlesville, Oklahoma, United States|Tulsa, Oklahoma, United States|Abington, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|York, Pennsylvania, United States|Rapid City, South Dakota, United States|Oak Ridge, Tennessee, United States|Amarillo, Texas, United States|Fort Sam Houston, Texas, United States|Houston, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Danville, Virginia, United States|Puyallup, Washington, United States|Buenos Aires, Argentina|Caba, Argentina|Ciudad De Buenos Aires, Argentina|Cordooba, Argentina|Corrientes, Argentina|Córdoba, Argentina|La Plata, Argentina|Mar Del Plata, Argentina|Resistencia, Argentina|Rosario, Argentina|Salta, Argentina|San Martín, Argentina|Santa Fe, Argentina|Brisbane, Australia|Cairns, Australia|Chermside, Australia|Elizabeth Vale, Australia|Herston, Australia|Hobart, Australia|Launceston, Australia|Liverpool, Australia|Murdoch, Australia|Nambour, Australia|New Lambton Heights, Australia|Antwerpen, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brugge, Belgium|Edegem, Belgium|Genk, Belgium|Gent, Belgium|Huy, Belgium|Liège, Belgium|Mol, Belgium|Roeselare, Belgium|Ronse, Belgium|Turnhout, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Curitiba, Brazil|Marília, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Salvador, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Tatuí, Brazil|Uberlândia, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Haskovo, Bulgaria|Lovech, Bulgaria|Pazardzhik, Bulgaria|Pleven, Bulgaria|Ruse, Bulgaria|Sandanski, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|New West Minister, British Columbia, Canada|Victoria, British Columbia, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saint-Charles-Borromée, Quebec, Canada|Sherbrooke, Quebec, Canada|Québec, Canada|Brno, Czechia|Kolin Iii., Czechia|Ostrava, Czechia|Plzen-Bory, Czechia|Praha 1, Czechia|Praha 2, Czechia|Trebic, Czechia|Znojmo, Czechia|Herlev, Denmark|Koge, Denmark|Silkeborg, Denmark|Besançon, France|Chambray Les Tours, France|Jossigny, France|Le Coudray, France|Lyon, France|Montauban, France|Nantes Cedex 1, France|Nantes, France|Périgueux, France|Balatonfüred, Hungary|Budapest, Hungary|Debrecen, Hungary|Gyula, Hungary|Győr, Hungary|Kaposvar, Hungary|Kecskemét, Hungary|Nyíregyháza, Hungary|Szolnok, Hungary|Székesfehérvár, Hungary|Gifu, Japan|Kagawa, Japan|Kitakyushu-City, Japan|Kobe-Shi, Japan|Kumamoto-Shi, Japan|Kumamoto, Japan|Matsue-Shi, Japan|Nagano-Shi, Japan|Osaka-Shi, Japan|Sayama-Shi, Japan|Tokyo, Japan|Uwajima-Shi, Japan|Yokohama, Japan|Yonago, Japan|Yotsui 2-8-1, Japan|Gwangju, Korea, Republic of|Incheon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Amersfoort, Netherlands|Amsterdam, Netherlands|Blaricum, Netherlands|Den Haag, Netherlands|Den Helder, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Hoofddorp, Netherlands|Hoogeveen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|S-Hertogenbosch, Netherlands|Schiedam, Netherlands|Bielsko-Biala, Poland|Bytom, Poland|Chrzanow, Poland|Dabrowa Gornicza, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Inowrocław, Poland|Kedzierzyn-Kozle, Poland|Kielce, Poland|Koszalin, Poland|Krakow, Poland|Lodz, Poland|Nowy Targ, Poland|Nysa, Poland|Oswiecim, Poland|Polanica Zdroj, Poland|Pulawy, Poland|Tychy, Poland|Warszawa, Poland|Wloclawek, Poland|Barnaul, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Kaliningrad, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorod, Russian Federation|Orenburg, Russian Federation|Penza, Russian Federation|Perm, Russian Federation|Rostov On Don, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Syktyvkar, Russian Federation|Tyumen, Russian Federation|A Coruña, Spain|Almería, Spain|Barcelona, Spain|Madrid, Spain|Murcia, Spain|Málaga, Spain|Sant Boi De Llobregat, Spain|Tarragona, Spain|Ávila, Spain|Falun, Sweden|Jönköping, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Sundsvall, Sweden|Uppsala, Sweden|Örebro, Sweden|Östersund, Sweden|Adana, Turkey|Ankara, Turkey|Aydin, Turkey|Bursa, Turkey|Diyarbakir, Turkey|Eskisehir, Turkey|Istanbul, Turkey|Kahramanmaras, Turkey|Kocaeli, Turkey|Konya, Turkey|Sivas, Turkey|Cherkasy, Ukraine|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Ternopil, Ukraine|Zaporizhzhia, Ukraine|Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT02293395"
854,"NCT01275352","CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression",,"Withdrawn","No Results Available","Hypertension","Drug: Eplerenone|Drug: placebo","Change in LV mass index (g/m2) in ClC-Ka Gly/Gly83 patients and ClC-Ka Gly/Gly83 patients|Change in LV relative wall thickness|Change in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change in LV mass index (g/m2)","Washington University School of Medicine|University of Pennsylvania","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLNCKA-1","December 2011","December 2014","June 2015","January 12, 2011",,"June 3, 2015","Barnes Jewish Hospital, St. Louis, Missouri, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01275352"
855,"NCT01336959","Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery",,"Terminated","Has Results","Acute Kidney Injury","Drug: BCT197 Part A|Drug: Placebo|Drug: BCT197 Part B","Renal Function Measured at 48 Hours Post Cardiac Surgery With Cardiopulmonary Bypass Pump.|Pharmacokinetic Measurements of Drug in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass Pump. Pharmacokinetics Will be Measured Using Cmax","Mereo BioPharma|Novartis","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBCT197A2202|2011-002735-25","September 2011","November 2013","November 2013","April 18, 2011","November 8, 2018","November 8, 2018","Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Wynnewood, Pennsylvania, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Be'er Sheva, Israel|Novartis Investigative Site, Herzliya, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01336959"
856,"NCT01173809","Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation","SPECULATE","Completed","No Results Available","Atrial Fibrillation","Drug: Amiodarone","Recurrence of atrial arrhythmia|Relapse of AF","Texas Cardiac Arrhythmia Research Foundation|University of Kansas|California Pacific Medical Center|Stanford University|Case Western Reserve University|Southlake Regional Health Centre|Catholic University, Italy","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCAI-SPECULATE","October 2010","May 2014","July 2014","August 2, 2010",,"August 21, 2014","St.David's Medical Center, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01173809"
857,"NCT02090075","Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque",,"Completed","Has Results","Atrial Fibrillation","Drug: apixaban|Drug: warfarin","Coronary Artery Calcium (CAC) Score|Coronary Plaque on CT Angiography","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21183-01","September 2014","December 27, 2016","April 5, 2017","March 18, 2014","April 23, 2019","April 23, 2019","Los Angeles Biomedical Research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT02090075"
858,"NCT01302444","Treprostinil Combined With Tadalafil for Pulmonary Hypertension","T2","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Tadalafil|Drug: Placebo","All Cause Mortality|Adverse Events Are no Greater Than With Treprostinil Infusion Alone|WHO Functional Class Will Improve or Remain Stable|Hospitalizations|6 Minute Walking Distance Change Will Improve|Tei Index Change by Transthoracic Echocardiography|Plasma BNP (Brain Natriuretic Peptide)Level Change|Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)as Assessed by Transthoracic Echocardiography Using Doppler Ultrasound","Rhode Island Hospital|United Therapeutics","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","T2 Trial","March 2011","March 2012","March 2012","February 24, 2011","July 18, 2013","July 26, 2013","Maine Medical Center, Portland, Maine, United States|Tuft's New England Medical Center, Boston, Massachusetts, United States|Brigham & Womens Hospital, Boston, Massachusetts, United States|Saint Barnabas Health Care System, Newark Beth Israel Medical Center, Newark, New Jersey, United States|Beth Israel Medical Center, new York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01302444"
859,"NCT01064037","A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)","COMPOSE EARLY","Terminated","No Results Available","Heart Failure|Heart Decompensation","Drug: Cinaciguat (BAY58-2667)|Drug: Placebo","Dyspnea VAS (using a visual analogue scale)|Dyspnea assessment (Likert Scale)|Overall health status assessment (EQ-5D)|Changes in the dyspnea VAS at other time points|Dyspnea assessment through Likert scale|Overall health status assessment through EQ-5D Health Questionnaire|Global clinical assessment by the physician|Change in concomitant medications|Safety variables","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14836|2009-017082-39","April 2010","February 2011","March 2011","February 8, 2010",,"October 8, 2015","Chicago, Illinois, United States|Detroit, Michigan, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Quebec, Canada|Brno, Czech Republic|Pardubice, Czech Republic|Praha 10, Czech Republic|Praha 5, Czech Republic|Praha 5, Czech Republic|Jyväskylä, Finland|Turku, Finland|Dommartin-les-toul, France|Paris Cedex 04, France|Paris cedex 13, France|Paris, France|POITIERS Cedex, France|Nürnberg, Bayern, Germany|Melsungen, Hessen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Kiel, Schleswig-Holstein, Germany|Erfurt, Thüringen, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Kecskemet, Hungary|Szekesfehervar, Hungary|Ballinasloe, Co. Galway, Ireland|Dublin, Ireland|Dublin, Ireland|Haifa, Israel|Nahariya, Israel|Rehovot, Israel|Safed, Israel|Pontedecimo, Genova, Italy|Casarano, Lecce, Italy|Cotignola, Ravenna, Italy|Bari, Italy|Ferrara, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Kanazawa, Ishikawa, Japan|Chigasaki, Kanagawa, Japan|Matsumoto, Nagano, Japan|Sunto, Shizuoka, Japan|Tanabe, Wakayama, Japan|Kagoshima, Japan|Shizuoka, Japan|Seoul, Jongno-gu,, Korea, Republic of|Seoul, Songpa-gu, Korea, Republic of|Bydgoszcz, Poland|Krakow, Poland|Olsztyn, Poland|Szczecin, Poland|Johannesburg, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Kuils River, Western Cape, South Africa|Worcester, Western Cape, South Africa|Torrevieja, Alicante, Spain|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Barcelona, Spain|Harrow, London, United Kingdom|Northampton, Northamptonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01064037"
860,"NCT03153137","Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects","RUBATO","Recruiting","No Results Available","Congenital Heart Disease","Drug: Macitentan 10 mg|Drug: Placebo","Change in peak VO2 (oxygen uptake)|Change in peak VO2|Physical activity measured by accelerometer|Treatment-emergent AEs and SAEs|Trough (pre dose) plasma concentrations","Actelion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-055H301|2016-003320-23","August 14, 2017","June 11, 2021","December 31, 2021","May 15, 2017",,"March 18, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Cardiology Group, Phoenix, Arizona, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|UCLA, Los Angeles, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Congenital Heart Center of the University of Florida, Gainesville, Florida, United States|Advocate Children's Hospital, Oak Lawn, Illinois, United States|University of Iowa Hospital, Iowa City, Iowa, United States|University of Maryland Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital Heart Center, Boston, Massachusetts, United States|University of Nebraska Medical Center & Childrens Hospital, Omaha, Nebraska, United States|Columbia University Medical Center, New York, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Pennsylvania State University College Of Medicine, Hershey, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States|University of Utah Primary Childrens Medical Center, Salt Lake City, Utah, United States|Providence Medical Research Providence Health Care, Spokane, Washington, United States|Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Royal Adelaide Hospital, Adelaide, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|The Prince Charles Hospital, Adult Congenital Heart Disease Unit, Chermside, Australia|Royal Children's Hospital, Parkville, Australia|Royal Melbourne Hospital, Parkville, Australia|Queensland CHILDREN'S HOSPITAL, South Brisbane, Australia|Westmead Hospital, Westmead, Australia|Westmead Private Cardiology, Westmead, Australia|Hospital Pequeno Principe, Curitiba, Brazil|Hospital de Messejana dr. Carlos Alberto Studart Gomes, Fortaleza, Brazil|Fundacao Universitaria de Cardiologia, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de Sao Paulo, Sao Paulo, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, São Paulo, Brazil|Montreal Heart Institute, Montreal, Quebec, Canada|Centre Hospitalier Sainte Justine, Montreal, Quebec, Canada|CHU de Québec Université Laval, Quebec, Canada|Beijing Anzhen Hospital, Beijing, China|Beijing Fuwai Hospital, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Wuhan Asia Heart Hospital, Wuhan, China|Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Homolce - Roentgenova 2, Praha 5, Czechia|Nemocnice na Homolce, Praha 5, Czechia|Rigshospitalet Kardiologisk Klinisk, Copenhagen, Denmark|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital Cardiologique Du Haut-Lévêque, Pessac, France|Deutsches Herzzentrum Berlinklinik Für Angeborene Herzfehler, Berlin, Germany|Deutsches Herzzentrum München, München, Germany|Our Lady's Children's Hospital, Dublin, Ireland|Auckland City Hospital, Auckland, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Krakowski Szpital Specjalityczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn, Krakow, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Wojewódzki Szpital Specjalistyczny We Wrocławiu, Wrocław, Poland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Queen Elizabeth Hospital, Birmingham, United Kingdom|Birmingham Children's Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03153137"
861,"NCT01777165","A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery",,"Completed","No Results Available","Acute Kidney Injury","Drug: ABT-719|Drug: Placebo","Number of patients developing acute kidney injury based on the Acute Kidney Injury Network (AKIN) scoring criteria by comparing the ABT-719 dose groups versus placebo group.|Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in estimated glomerular filtration rate or measured glomerular filtration rate|Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in serum creatinine based estimated glomerular filtration rate (GFR)|Proportion of subjects developing AKI as defined by the Risk, Injury, Failure, Loss, or ESRD (RIFLE) model|Proportion of subjects developing AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) model|Changes from baseline (defined as within 24 hours of day 0) in serum creatinine (SCr) and S-Cystatin C at all study visits from baseline to Day 90","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","M13-796|2012-003942-33","February 2013","March 2014","March 2014","January 28, 2013",,"April 16, 2015","Site Reference ID/Investigator# 83739, Danbury, Connecticut, United States|Site Reference ID/Investigator# 87720, Gainesville, Florida, United States|Site Reference ID/Investigator# 83746, Jacksonville, Florida, United States|Site Reference ID/Investigator# 83733, Jacksonville, Florida, United States|Site Reference ID/Investigator# 89178, Tampa, Florida, United States|Site Reference ID/Investigator# 87693, Atlanta, Georgia, United States|Site Reference ID/Investigator# 87717, Augusta, Georgia, United States|Site Reference ID/Investigator# 89180, Fort Wayne, Indiana, United States|Site Reference ID/Investigator# 101942, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 85917, Lexington, Kentucky, United States|Site Reference ID/Investigator# 83732, Bethesda, Maryland, United States|Site Reference ID/Investigator# 83724, Boston, Massachusetts, United States|Site Reference ID/Investigator# 83745, Boston, Massachusetts, United States|Site Reference ID/Investigator# 83750, Grand Blanc, Michigan, United States|Site Reference ID/Investigator# 83747, Petoskey, Michigan, United States|Site Reference ID/Investigator# 83744, Royal Oak, Michigan, United States|Site Reference ID/Investigator# 85913, St. Paul, Minnesota, United States|Site Reference ID/Investigator# 96455, St. Louis, Missouri, United States|Site Reference ID/Investigator# 91253, Omaha, Nebraska, United States|Site Reference ID/Investigator# 93673, Newark, New Jersey, United States|Site Reference ID/Investigator# 83722, New York, New York, United States|Site Reference ID/Investigator# 89176, Ashville, North Carolina, United States|Site Reference ID/Investigator# 83723, Durham, North Carolina, United States|Site Reference ID/Investigator# 92413, Gastonia, North Carolina, United States|Site Reference ID/Investigator# 87733, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 83735, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 91813, Columbus, Ohio, United States|Site Reference ID/Investigator# 83738, Toledo, Ohio, United States|Site Reference ID/Investigator# 91693, Portland, Oregon, United States|Site Reference ID/Investigator# 89182, Springfield, Oregon, United States|Site Reference ID/Investigator# 83734, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 83730, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 101876, Memphis, Tennessee, United States|Site Reference ID/Investigator# 90614, Charlottesville, Virginia, United States|Site Reference ID/Investigator# 83725, Richmond, Virginia, United States|Site Reference ID/Investigator# 87714, Tacoma, Washington, United States|Site Reference ID/Investigator# 91814, Madison, Wisconsin, United States|Site Reference ID/Investigator# 87739, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 94956, Aarhus N, Denmark|Site Reference ID/Investigator# 109295, Copenhagen O, Denmark|Site Reference ID/Investigator# 94955, Odense C, Denmark",,"https://ClinicalTrials.gov/show/NCT01777165"
862,"NCT01065077","BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)","COMPOSE 1","Terminated","No Results Available","Acute Heart Failure","Drug: Cinaciguat (BAY58-2667)|Drug: Placebo","Pulmonary Capillary Wedge Pressure|Cardiac index (CI)|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Right atrial pressure (RAP)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14560|2009-014377-40","March 2010","January 2011","February 2011","February 9, 2010",,"October 8, 2015","Ridgewood, New Jersey, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Fairfield, Ohio, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Linz, Oberösterreich, Austria|Wien, Austria|Zagreb, Croatia|Helsinki, Finland|Oulu, Finland|Greifswald, Mecklenburg-Vorpommern, Germany|Köln, Nordrhein-Westfalen, Germany|Homburg, Saarland, Germany|Erfurt, Thüringen, Germany|Jena, Thüringen, Germany|Haifa, Israel|Jerusalem, Israel|Tiberias, Israel|San Fermo della Battaglia, Como, Italy|Brescia, Italy|Ferrara, Italy|Mantova, Italy|Torino, Italy|Nagoya, Aichi, Japan|Kure, Hiroshima, Japan|Higashiibaraki, Ibaraki, Japan|Kawasaki, Kanagawa, Japan|Omura, Nagasaki, Japan|Bunkyo-ku, Tokyo, Japan|Shinagawa, Tokyo, Japan|Osaka, Japan|Gdansk, Poland|Lodz, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Zabrze, Poland|Zgorzelec, Poland|Bucharest, Romania|Cluj-Napoca, Romania|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Beograd, Serbia|Nis, Serbia|Sremska Kamenica, Serbia|Lucenec, Slovakia|Martin, Slovakia|Celje, Slovenia|Golnik, Slovenia|Ljubljana, Slovenia|Göteborg, Sweden|Uppsala, Sweden|Lugano, Ticino, Switzerland|Zürich, Switzerland|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01065077"
863,"NCT01546532","Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)",,"Completed","No Results Available","Chronic Heart Failure (CHF)","Drug: RLX030|Drug: Placebo","Change from baseline in renal plasma flow (RPF) measured by Para-aminohippuric acid (PAH) clearance in subjects with CHF after 24 hours intravenous (i.v) infusion of RLX030|Change from baseline in glomerular filtration rate (GFR) as measured by Iothalamate (IOTH) clearance in subjects with CHF after 24 hours i.v. infusion of RLX030|Change from baseline in filtration fraction (FF) in subjects with CHF after 24 hours infusion of RLX030|Change over time in Diuresis|Change over time in calculated creatinine clearance|Change over time on fractional sodium excretion(natriuresis)|Central aortic systolic pressure-time curve|Radial augmentation index-time curve|Number of patients with adverse events, serious adverse events and death|Pharmacokinetics of RLX030: area under the serum concentration-time curve from time zero to infinity (AUCinf)Time|Pharmacokinetics of RLX030: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)|Pharmacokinetics of RLX030: serum concentration over 20 hours of infusion (C24h)|Pharmacokinetics of RLX030: terminal elimination half-life (T1/2)following intravenous administration|Pharmacokinetics of RLX030: mean residence time (MRT)intravenous administration|Pharmacokinetics of RLX030: volume of distribution at steady state (Vss) following intravenous administration|Pharmacokinetics of RLX030: systemic clearance from serum (CL) following intravenous administration(natriuresis)|Corrected QT (QTc) Interval Using Fridericia's and Bazett's Formula","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRLX030A2202|2011-001588-37","February 2012","December 2012","December 2012","March 7, 2012",,"June 15, 2015","Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Sneek, Netherlands|Novartis Investigative Site, Grodzisk Mazowiecki, Poland|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Kraków, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Walbrzych, Poland|Novartis Investigative Site, Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT01546532"
864,"NCT01894022","A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","AMBER II","Terminated","Has Results","Hypertension","Drug: Ambrisentan 5 mg","Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Change From Study AMB115811 Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Absolute Neutrophil Count [ANC]), Platelet Count, and White Blood Cell (WBC) Count at the Indicated Time Points|Change From Study AMB115811 Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points|Change From Study AMB115811 Baseline in Hematocrit at the Indicated Time Points|Change From Study AMB115811 Baseline in Mean Corpuscle Volume at the Indicated Time Points|Change From Study AMB115811 Baseline in Red Blood Cell Count and Reticulocytes at the Indicated Time Points|Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern at Any Time Post Entry Visit|Number of Participants With Creatinine Values of Potential Clinical Concern at Any Time Post Entry Visit|Change From Study AMB115811 Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Assessed at the Indicated Time Points|Change From Study AMB115811 Baseline in Heart Rate at the Indicated Time Points|Change From Study AMB115811 Baseline in Weight at the Indicated Time Points|Time to First Change in Dose of Open-label Ambrisentan Due to Tolerability Issues in Any Participant|Change From Study AMB115811 Baseline in the 6 Minutes Walking Distance (6MWD) at the Indicated Time Points|Change From Study AMB115811 Baseline (BL) in World Health Organization (WHO) Functional Class (FC) at the Indicated Time Points|Change From Study AMB115811 Baseline in Borg CR10 Scale (BCR10S) Immediately Following Exercise at the Indicated Time Points|Number of Participants With Clinical Worsening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Change From Study AMB115811 Baseline in Quality of Life as Measured by Short Form 36 Health Survey (SF-36)|Percent Change From Study AMB115811 Baseline in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Change From Start of Ambrisentan Treatment in 6 Minutes Walking Distance at the Indicated Time Points|Change From Start of Ambrisentan Treatment in World Health Organization (WHO) Functional Class (FC) at the Indicated Time Points|Change From Start of Ambrisentan Treatment in Borg CR10 Scale (BCR10S) Immediately Following Exercise at the Indicated Time Points|Percent Change From Start of Ambrisentan Treatment in Plasma N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP)|Time to First Change in Dose of Open-label Ambrisentan Due to Deterioration of Clinical Conditions in Any Participant|Time to First Addition of Another Targeted PAH Therapeutic Agent Due to Deterioration of Clinical Condition or Lack of Beneficial Effect With Previous Therapy in Any Participant","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116457","January 23, 2014","November 18, 2015","November 18, 2015","July 9, 2013","June 8, 2017","September 11, 2017","GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Corrientes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Xian, Shaanxi, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Monterrey NL, Nuevo León, Mexico|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Riyadh, Saudi Arabia|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Clydebank, United Kingdom|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01894022"
865,"NCT00863707","A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment",,"Completed","Has Results","Kidney Diseases|Coronary Artery Disease","Drug: Regadenoson|Drug: Placebo","Number of Subject With Serious Treatment Emergent Adverse Events (TEAE)","Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 4","511","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","3606-CL-3010","April 2009","December 2009","December 2009","March 18, 2009","January 31, 2011","May 18, 2012","Anniston, Alabama, United States|Little Rock, Arkansas, United States|Bell Gardens, California, United States|Fullerton, California, United States|Garden Grove, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Oakland, California, United States|Roseville, California, United States|Santa Ana, California, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Trinity, Florida, United States|Winter Park, Florida, United States|Ellijay, Georgia, United States|Chicago, Illinois, United States|Auburn, Maine, United States|Detroit, Michigan, United States|Flint, Michigan, United States|Minneapolis, Minnesota, United States|Ridgewood, New Jersey, United States|Somerset, New Jersey, United States|New York, New York, United States|Springfield Gardens, New York, United States|Springfield, Ohio, United States|Oklahoma City, Oklahoma, United States|Bend, Oregon, United States|Duncansville, Pennsylvania, United States|Indiana, Pennsylvania, United States|Tyrone, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Charleston, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Houston, Texas, United States|Houston, Texas, United States|Sugar Grove, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00863707"
866,"NCT01912534","Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM","VANISH","Active, not recruiting","No Results Available","Hypertrophic Cardiomyopathy","Drug: Valsartan|Drug: Placebo","A combined single composite z-score (described below) will serve as primary surrogate endpoint to monitor response to valsartan treatment|Impact of valsartan treatment on disease pathology|Clinical outcomes and assessment of symptom burden|Incidence of adverse drug reactions, frequency of subject drop-out, and responses to validated quality of life metrics between valsartan and placebo-treated group","HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI)","All","8 Years to 45 Years   (Child, Adult)","Phase 2","211","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VANISH|5P50HL112349","April 2014","July 2019","July 2020","July 31, 2013",,"March 13, 2020","Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School Medicine, Saint Louis, Missouri, United States|Cinncinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Sick Kids, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01912534"
867,"NCT02036970","Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT",,"Completed","No Results Available","Pulmonary Arterial Hypertension|Pulmonary Hypertension|Interstitial Lung Disease|Idiopathic Interstitial Pneumonia|Idiopathic Pulmonary Fibrosis|Sarcoidosis|Respiratory Bronchiolitis Associated Interstitial Lung Disease|Desquamative Interstitial Pneumonia|Cryptogenic Organizing Pneumonia|Acute Interstitial Pneumonitis|Idiopathic Lymphoid Interstitial Pneumonia|Idiopathic Pleuroparenchymal Fibroelastosis","Drug: Bardoxolone methyl|Drug: Placebo","Change from baseline in 6-Minute Walk Distance (6MWD)","Reata Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 402-C-1302","May 2014","January 19, 2018","May 16, 2018","January 15, 2014",,"January 3, 2019","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|VA Healthcare System of Greater Los Angeles, Los Angeles, California, United States|University of California Davis Medical Center - Division of Pulmonary and Critical Care, Sacramento, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver - Division of Pulmonary Sciences, Aurora, Colorado, United States|South Denver Cardiology Associates, P.C, Littleton, Colorado, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|Cleveland Clinic of Florida, Weston, Florida, United States|University of Chicago, Chicago, Illinois, United States|Maine Medical Center - Division of Pulmonary and Critical Care Medicine, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai, Beth Israel Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|BreatheAmerica El Paso, Inc., El Paso, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, United States|University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University Clinic Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02036970"
868,"NCT01738451","A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors",,"Completed","No Results Available","Cancer","Drug: GSK2118436 75 mg|Drug: Placebo","Part 1: Safety and tolerability of GSK2118436 as assessed by changes in physical examination findings|Part 1: Safety and tolerability of GSK2118436 as assessed by changes in vital signs measurements|Part 1: Safety and tolerability of GSK2118436 as assessed by changes in ECG readings|Part 1: Safety and tolerability of GSK2118436 as assessed by changes in clinical laboratory assessments|Part 2: Change from Baseline in QTcF interval at each time point for GSK2118436|Part 1: Plasma concentration of GSK2118436 and its metabolites|Part 1: The AUC(0-t)) of GSK2118436 and its metabolites|Part 1: The Cmax of GSK2118436 and its metabolites|The Ctrough of GSK2118436 and its metabolites|The tmax of GSK2118436 and its metabolites|Part 2: Change from Baseline in slope of the relationships between the baseline-adjusted, placebo-corrected change in QTc interval and the plasma concentrations of GSK2118436 or its metabolites and predicted change in QTc|Part 2: ECG parameters: and morphology assessments|Part 2: Plasma concentrations of GSK2118436 and its metabolites|The AUC(0-10) and AUC(0 t) of GSK2118436 and its metabolites (GSK2285403, GSK2298683 and GSK2167542)|The AUC(0-infinity) of GSK2118436 and its metabolites (GSK2285403, GSK2298683 and GSK2167542)|The t½ of GSK2167542 and its metabolites|Part 2: The Ctrough of GSK2167542 and its metabolites|Part 2: The Cmax, of GSK2167542 and its metabolites|Part 2: The tmax, of GSK2167542 and its metabolites|Part 2: Safety of GSK2118436 as assessed by number of subjects with adverse events (AE)s|Part 2: Safety of GSK2118436 as assessed by changes in vital signs measurements|Part 2: Safety of GSK2118436 as assessed by changes in ECG readings|Part 2: Safety of GSK2118436 as assessed by changes in clinical laboratory assessments","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","113773","January 22, 2013","November 28, 2014","November 28, 2014","November 30, 2012",,"November 13, 2017","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01738451"
869,"NCT01719367","Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation",,"Completed","Has Results","Atrial Fibrillation","Drug: Atenolol","Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise|Change in Pre- and Post-atenolol Ventricular Rate Response After 10 and 15 Minutes of Exercise","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130298","January 2013","September 2016","September 2016","November 1, 2012","June 17, 2019","June 17, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01719367"
870,"NCT01590875","Validation Durability Adenosine Effect in Verification Pulmonary Vein Isolation",,"Completed","Has Results","Atrial Fibrillation","Drug: Adenosine arm","Pulmonary Vein Reconnection","Medical College of Wisconsin","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MCWPRO00016186","May 2012","June 2015","June 2015","May 3, 2012","May 3, 2017","November 6, 2017","Froedtert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01590875"
871,"NCT02017171","A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes",,"Completed","No Results Available","Diabetic Nephropathies|Coronary Artery Disease","Drug: Allopurinol|Drug: Placebo","iGFR at the end of the wash-out period|eGFR at 4 months of treatment|iGFR the end of treatment period|iGFR time trajectory|eGFR time trajectory|Time to serum creatinine doubling or end stage renal disease (ESRD)|AER at the end of the wash-out period|AER at the end of the treatment period|Time to fatal or non-fatal cardiovascular events","Alessandro Doria|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Juvenile Diabetes Research Foundation|Joslin Diabetes Center|University of Minnesota|University of Colorado, Denver|University of Michigan|University of Toronto|Feinberg School of Medicine, Northwestern University|Albert Einstein College of Medicine|Steno Diabetes Center Copenhagen|Washington University School of Medicine|University of Washington|Emory University|University of Calgary|University of Alberta|University of Texas Southwestern Medical Center|BCDiabetes.Ca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","530","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","DK101108|UC4DK101108-01","February 2014","July 15, 2019","August 31, 2019","December 20, 2013",,"February 20, 2020","Barbara Davis Center / University of Colorado Denver, Aurora, Colorado, United States|Kaiser Permanente Colorado Institute of Health Research, Denver, Colorado, United States|Emory University - Grady Memorial Hospital, Atlanta, Georgia, United States|Atlanta Diabetes Associates, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|Brehm Center for Diabetes Research / University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Albert Einstein College of Medicine / Montefiore Medical Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Winthrop-University Hospital, Mineola, New York, United States|ICAHN School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Texas Southwestern, Dallas, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Gunderson Health System, La Crosse, Wisconsin, United States|University of Calgary, Calgary, Alberta, Canada|Alberta Diabetes Institute, Edmonton, Alberta, Canada|BC Diabetes, Vancouver, British Columbia, Canada|LMC Diabetes and Endocrinology, Toronto, Ontario, Canada|Mount Sinai Hospital / University of Toronto, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Steno Diabetes Center, Gentofte, Denmark",,"https://ClinicalTrials.gov/show/NCT02017171"
872,"NCT01002118","Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients",,"Terminated","Has Results","Cardiovascular Disease","Drug: Omega-3 Acid Ethyl Esters|Drug: Placebo","Determine Recruitment Rates|Assess the Effectiveness of Omega-3 Fatty Acid Compared to Placebo on Electrocardiographic Parameters.|Medication Adherence","University of Iowa|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","1","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","200801761","January 25, 2008","February 23, 2011","February 23, 2011","October 27, 2009","August 9, 2017","August 9, 2017","University of Iowa, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01002118"
873,"NCT01966601","A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure","BLAST-AHF","Completed","No Results Available","Acute Decompensated Heart Failure","Drug: TRV027 Dose #1|Drug: TRV027 Dose #2|Drug: TRV027 Dose #3|Drug: Placebo","composite z score","Trevena Inc.","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 2","620","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CP027.2002","December 2013","March 2016","September 2016","October 21, 2013",,"July 26, 2018","Wayne State University, Detroit, Michigan, United States|University of Cincinnati, Cincinnati, Ohio, United States|Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States|Michael E Debakey VA Medical Center, Houston, Texas, United States|Research Site, Ciudad Autónoma de Buenos Aires, Argentina|Research Site, Ciudad De Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Coronel Suarez, Argentina|Research Site, Corrientes, Argentina|Research Site, La Plata, Argentina|Research Site, Moron, Argentina|Research Site, Quilmes, Argentina|Research Site, Rosario, Argentina|Research Site, San Martin, Argentina|Research Site, San Miguel de Tucumán, Argentina|Research Site, Santa Fe, Argentina|Research Site, Dimitrovgrad, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Sites, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Prague, Czechia|Research Site, Praha, Czechia|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Greifswald, Germany|Research Site, Budapest, Hungary|Research Site, Kaposvar, Hungary|Research Site, Pecs, Hungary|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Nahariya, Israel|Research Site, Nazareth, Israel|Research Site, Safed, Israel|Research Site, Bad Nauheim, Poland|Research Site, Bialystok, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Klodzko, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Ruda Slaska, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Baia Mare, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Targu Mures, Romania|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kocise, Slovakia|Research Site, Martin, Slovakia",,"https://ClinicalTrials.gov/show/NCT01966601"
874,"NCT02071602","CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function","BELIEVE III","Completed","No Results Available","ST Elevation (STEMI) Myocardial Infarction of Anterior Wall","Drug: CD-NP","Number of subjects with symptomatic hypotension|Comparison of LV function improvement between placebo vs. CD-NP groups|Exploratory analyses of Major Adverse Cardiovascular Events (MACE)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12-006317","October 2013","May 2018","November 2018","February 26, 2014",,"January 4, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02071602"
875,"NCT03042910","A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors",,"Completed","Has Results","Solid Tumor","Drug: Talazoparib","Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF)|Intercept of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22|Concentration Slope of Predicted Linear Mixed Effects Models for Change From Baseline in QTcF Versus Plasma Talazoparib Concentrations at Day 22|Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Bazett's Correction Fomulation (QTcB)|Time-matched Mean Change From Baseline in Heart Rate|Time-matched Mean Change From Baseline in PR Interval|Time-matched Mean Change From Baseline in QRS Interval|Time-matched Mean Change From Baseline in QT Interval|Time-matched Mean Change From Baseline in RR Interval|Number of Participants With Treatment-emergent Abnormalities in 12-lead Electrocardiogram (ECG) Morphpology|Number of Participants With Clinically Significant Findings in 12-lead Electrocardiogram (ECG) Parameters Meeting Predefined Criteria|Number of Participants With Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, AEs of Special Interest, and Deaths|Number of Participants With Clinically Notable Changes in Vital Signs Measurements|Number of Participants With Clinically Significant Laboratory Test Abnormalities|Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours After Dosing (AUC24) of Plasma Talazoparib on Day 1 and Day 22|Maximum Plasma Concentration (Cmax) of Plasma Talazoparib on Day 1 and Day 22|Time for Cmax (Tmax) of Plasma Talazoparib on Day 1 and Day 22|Predose Concentration (Ctrough) of Plasma Talazoparib on Day 22|Apparent Clearance After Oral Dose (CL/F) of Plasma Talazoparib on Day 22|Accumulation Ratio (Rac) of Plasma Talazoparib on Day 22","Pfizer|Medivation, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","38","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MDV3800-14|C3441005","October 13, 2016","May 30, 2017","June 22, 2017","February 3, 2017","December 17, 2019","December 17, 2019","CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|UCLA Hematology/Oncology - Burbank, Burbank, California, United States|St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States|UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States|TRIO-US Central Administration, Los Angeles, California, United States|UCLA Hematology/Oncology, Los Angeles, California, United States|UCLA West Medical Pharmacy. Attn: Steven L. Wong, Pharm.D., Los Angeles, California, United States|UCLA Hematology/Oncology - Pasadena, Pasadena, California, United States|UCLA Hematology/Oncology - Porter Ranch, Porter Ranch, California, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, United States|UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States|Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03042910/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT03042910/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03042910"
876,"NCT01936896","Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction","VCU-Alpha1RT","Completed","Has Results","Acute Myocardial Infarction","Drug: Alpha 1-Antitrypsin","C Reactive Protein (Area Under the Curve)|Left Ventricular End-systolic Volume Change","Virginia Commonwealth University","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM15342","December 2013","June 2014","July 2014","September 6, 2013","February 12, 2016","February 12, 2016","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01936896"
877,"NCT00951301","Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation","MRI-AF","Terminated","No Results Available","Atrial Fibrillation","Drug: mangosteen juice|Drug: placebo juice","Test the hypothesis that the addition of mangosteen juice as a dietary supplement may reduce the measured levels of inflammatory biomarkers interleukin 1, interleukin 6, C-reactive protein (CRP), and tumor necrosis factor alpha (TNF a) etc).|attenuation of markers of endothelial cell dysfunction including endothelial progenitor cell (EPCs).|Clinical levels of anticoagulation (INR), digoxin, CBC, lipids, and glycosylated hemoglobin (Hgb A1c).|Quality of life|AF recurrence rates between the mangosteen group and the placebo group|Associated levels of inflammatory markers with those experiencing recurrent AF","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","07-007749","July 2009","June 2013","June 2013","August 4, 2009",,"March 16, 2016","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00951301"
878,"NCT01618669","A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","EXERRT","Completed","Has Results","Coronary Artery Disease (CAD)","Drug: Regadenoson|Procedure: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)","Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans|Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events|Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans|Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans|Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans|Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans|Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan|Overall Assessment of Image Quality|Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans|Percentage of Scans With Subdiaphragmatic Interference|Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity|Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson","Astellas Pharma Global Development, Inc.|Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","1147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","3606-CL-3004","June 2012","December 2014","December 2014","June 13, 2012","February 8, 2016","February 8, 2016","Mobile Heart Specialists, PC, Mobile, Alabama, United States|Silicon Valley Medical Imaging, Fremont, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Westside Medical Associates of Los Angeles, Los Angeles, California, United States|Ventura Clinical Trials, Malibu, California, United States|Mission Internal Medical Group, Mission Viejo, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Santa Rosa Cardiology Medical Group, Inc., Santa Rosa, California, United States|Los Angeles Biomedical Research Institute, Torrance, California, United States|HOCC - New Britain Campus, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfieri Cardiology, Newark, Delaware, United States|Delaware Clinical Trials, Wilmington, Delaware, United States|Elite Research and Clinical Trials, Aventura, Florida, United States|S & W Clinical Research, Fort Lauderdale, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Florida Heart Associates, Fort Myers, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|St. Luke's Cardiology St. Vincent's HealthCare, Jacksonville, Florida, United States|Watson Medical Clinic/Lakeland Regional Medical Clinic, Lakeland, Florida, United States|MIMA Century Research Associates, Melbourne, Florida, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|Florida Hospital/Cardiovascular Institute, Orlando, Florida, United States|University of South Florida, Tampa, Florida, United States|Cardiology Partners Clinical Research Institute, Wellington, Florida, United States|St. Joseph's Hospital, Atlanta, Georgia, United States|University Cardiology Associates, LLC, Augusta, Georgia, United States|South Coast Medical Group, Savannah, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|I U School of Medicine/ Krannert Institute of Cardiology, Indianapolis, Indiana, United States|Midwest Cardiology Associates, Overland Park, Kansas, United States|Maine Research Associates, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Berkshire Medical Center, Pittsfield, Massachusetts, United States|Henry Ford Hospital, Detriot, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Michigan Heart, Ypsilanti, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Cardiology Associates of North Mississippi, Tupelo, Mississippi, United States|Cardiovascular Imaging Technologies, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Alegent Health Heart and Vascular Specialists, Omaha, Nebraska, United States|Alegent Health Research Center, Omaha, Nebraska, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Laurelton Medical center, Laurelton, New York, United States|Columbia University Medical Center, New York, New York, United States|Westchester Medical Center-New York Medical College, Valhalla, New York, United States|Buffalo Cardiology & Pulmonary Associates, P.C., Williamsville, New York, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Berks Cardiologists, Ltd., Wyomissing, Pennsylvania, United States|Katy Cardiology Associates, Katy, Texas, United States|Mission Research Institute LLC, New Braunfels, Texas, United States|West Houston Area Clinical Trial Consultants, LLC, Tomball, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Roanoke Heart Institute, PC, Roanoke, Virginia, United States|University of Washington, Seattle, Washington, United States|Hospital Italiano Garibaldi, Rosario, Santa Fé, Argentina|Instituto Oulton, Cordoba, Argentina|Instituto de Cardiologia la Plata, La Plata, Argentina|Hospital Italiano de La Plata, Provincia de Buenos Aires, Argentina|Sanatorio San Geronimo, Santa Fe, Argentina|Clinica Anglo Americana, Lima, Peru|Hospital Arzobispo Loayza, Lima, Peru|Instituto Nacional Cardiovascular de EsSalud, Lima, Peru|VA Caribbean Healthcare System (672), San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01618669"
879,"NCT01464476","Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)","SHIELD-2","Terminated","No Results Available","Arrhythmias, Cardiac|Heart Diseases|Cardiovascular Diseases|Implantable Cardioverter Defibrillator","Drug: Azimilide Dihydrochloride|Drug: Placebo","Time to first cardiovascular event|Time to first all-cause shock by the ICD|Time to first unplanned physician-office visit.","Forest Laboratories","All","18 Years and older   (Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZM-MD-302","November 2011","May 2013","June 2013","November 3, 2011",,"May 6, 2013","Forest Investigative Site 053, Birmingham, Alabama, United States|Forest Investigative Site 048, Huntsville, Alabama, United States|Forest Investigative Site 013, Phoenix, Arizona, United States|Forest Investigative Site 110, Los Angeles, California, United States|Forest Investigative Site 022, Merced, California, United States|Forest Investigative Site 060, Colorado Springs, Colorado, United States|Forest Investigative Site 090, Littleton, Colorado, United States|Forest Investigative Site 041, Newark, Delaware, United States|Forest Investigative Site 113, Hollywood, Florida, United States|Forest Investigative Site 010, Jacksonville, Florida, United States|Forest Investigative Site 035, Lakeland, Florida, United States|Forest Investigative Site 044, Port Charlotte, Florida, United States|Forest Investigative Site 062, Rockledge, Florida, United States|Forest Investigative Site 082, Safety Harbor, Florida, United States|Forest Investigative Site 006, Zephyrhills, Florida, United States|Forest Investigative Site 123, Augusta, Georgia, United States|Forest Investigative Site 092, Boise, Idaho, United States|Forest Investigative Site 012, Bloomington, Indiana, United States|Forest Investigative Site 068, Indianapolis, Indiana, United States|Forest Investigative Site 087, South Bend, Indiana, United States|Forest Investigative Site 063, Houma, Louisiana, United States|Forest Investigative Site 050, Auburn, Maine, United States|Forest Investigative Site 030, Baltimore, Maryland, United States|Forest Investigative Site 058, Baltimore, Maryland, United States|Forest Investigative Site 052, Lanham, Maryland, United States|Forest Investigative Site 118, Silver Spring, Maryland, United States|Forest Investigative Site 015, Boston, Massachusetts, United States|Forest Investigative Site 091, Brighton, Massachusetts, United States|Forest Investigative Site 020, Saginaw, Michigan, United States|Forest Investigative Site 085, Southfield, Michigan, United States|Forest Investigative Site 079, Troy, Michigan, United States|Forest Investigative Site 034, Ypsilanti, Michigan, United States|Forest Investigative Site 121, Tupelo, Mississippi, United States|Forest Investigative Site 088, St. Louis, Missouri, United States|Forest Investigative Site 100, St. Louis, Missouri, United States|Forest Investigative Site 055, Englewood,, New Jersey, United States|Forest Investigative Site 059, Ridgewood, New Jersey, United States|Forest Investigative Site 106, Warren, New Jersey, United States|Forest Investigative Site 112, Albuquerque, New Mexico, United States|Forest Investigative Site 018, Albany, New York, United States|Forest Investigative Site 069, Albany, New York, United States|Forest Investigative Site 045, New York, New York, United States|Forest Investigative Site 122, New York, New York, United States|Forest Investigative Site 075, Williamsville, New York, United States|Forest Investigative Site 089, Chapel Hill, North Carolina, United States|Forest Investigative Site 116, Greensboro, North Carolina, United States|Forest Investigative Site 070, Canton, Ohio, United States|Forest Investigative Site 064, Cincinnati, Ohio, United States|Forest Investigative Site 124, Cincinnati, Ohio, United States|Forest Investigative Site 043, Columbus, Ohio, United States|Forest Investigative Site 083, Kettering, Ohio, United States|Forest Investigative Site 109, Toledo, Ohio, United States|Forest Investigative Site 119, Oklahoma City, Oklahoma, United States|Forest Investigative Site 003, Tulsa, Oklahoma, United States|Forest Investigative Site 056, Camp Hill, Pennsylvania, United States|Forest Investigative Site 081, Erie, Pennsylvania, United States|Forest Investigative Site 008, Erie, Pennsylvania, United States|Forest Investigative Site 024, Hershey, Pennsylvania, United States|Forest Investigative Site 095, Philadelphia, Pennsylvania, United States|Forest Investigative Site 005, Wilkes-Barre, Pennsylvania, United States|Forest Investigative Site 107, Yardley, Pennsylvania, United States|Forest Investigative Site 046, York, Pennsylvania, United States|Forest Investigative Site 084, Providence, Rhode Island, United States|Forest Investigative Site 066, Florence, South Carolina, United States|Forest Investigative Site 073, Greenville, South Carolina, United States|Forest Investigative Site 014, Rapid City, South Dakota, United States|Forest Investigative Site 094, Sioux Falls, South Dakota, United States|Forest Investigative Site 029, Corpus Christi, Texas, United States|Forest Investigative Site 028, Dallas, Texas, United States|Forest Investigative Site 007, Fort Worth,, Texas, United States|Forest Investigative Site 111, Fort Worth, Texas, United States|Forest Investigative Site 125, Houston, Texas, United States|Forest Investigative Site 076, Houston, Texas, United States|Forest Investigative Site 074, San Antonio, Texas, United States|Forest Investigative Site 016, Chesapeake, Virginia, United States|Forest Investigative Site 004, Falls Church, Virginia, United States|Forest Investigative Site 117, Lynchburg, Virginia, United States|Forest Investigative Site 065, Newport News, Virginia, United States|Forest Investigative Site 072, Richmond, Virginia, United States|Forest Investigative Site 023, Roanoke, Virginia, United States|Forest Investigative Site 071, Green Bay, Wisconsin, United States|Forest Investigative Site 042, Madison, Wisconsin, United States|Forest Investigative Site 049, Milwaukee, Wisconsin, United States|Forest Investigative Site 302, Brugge, Belgium|Forest Investigative Site 303, Charleroi, Belgium|Forest Investigative Site 300, Leuven, Belgium|Forest Investigative Site 304, Liège, Belgium|Forest Investigative Site 301, Yvoir, Belgium|Forest Investigative Site 264, Edmonton, Alberta, Canada|Forest Investigative Site 269, Vancouver, British Columbia, Canada|Forest Investigative Site 252, Victoria, British Columbia, Canada|Forest Investigative Site 267, Hamilton, Ontario, Canada|Forest Investigative Site 253, Kingston, Ontario, Canada|Forest Investigative Site 259, Toronto, Ontario, Canada|Forest Investigative Site 263, Toronto, Ontario, Canada|Forest Investigative Site 254, Montreal, Quebec, Canada|Forest Investigative Site 250, Montreal, Quebec, Canada|Forest Investigative Site 270, Sherbrooke, Quebec, Canada|Forest Investigative Site 262, Saskatoon, Saskatchewan, Canada|Forest Investigative Site 750, Brno, Czech Republic|Forest Investigative Site 753, Ceské Budejovice, Czech Republic|Forest Investigative Site 751, Olomouc, Czech Republic|Forest Investigative Site 754, Prague, Czech Republic|Forest Investigative Site 752, Sokolska, Czech Republic|Forest Investigative Site 852, Aalborg, Denmark|Forest Investigative Site 850, Copenhagen, Denmark|Forest Investigative Site 854, Esbjerg, Denmark|Forest Investigative Site 853, Hellerup, Denmark|Forest Investigative Site 851, Odense, Denmark|Forest Investigative Site 353, Grenoble, France|Forest Investigative Site 354, Lille, France|Forest Investigative Site 350, Montpellier, France|Forest Investigative Site 358, Nantes, France|Forest Investigative Site 357, Pessac, France|Forest Investigative Site 405, Berlin, Germany|Forest Investigative Site 402, Gottingen, Germany|Forest Investigative Site 410, Heidelberg, Germany|Forest Investigative Site 406, Ludwigshafen, Germany|Forest Investigative Site 401, Mannheim, Germany|Forest Investigative Site 450, Ashkelon, Israel|Forest Investigative Site 453, Jerusalem, Israel|Forest Investigative Site 452, Tel Aviv, Israel|Forest Investigative Site 451, Tel Hashomer, Israel|Forest Investigative Site 504, Ancona, Italy|Forest Investigative Site 502, Catania, Italy|Forest Investigative Site 552, Breda, Netherlands|Forest Investigative Site 550, Eindhoven, Netherlands|Forest Investigative Site 555, Zwolle, Netherlands|Forest Investigative Site 706, Gdansk, Poland|Forest Investigative Site 705, Gdynia, Poland|Forest Investigative Site 604, Barcelona, Spain|Forest Investigative Site 601, Malaga, Spain|Forest Investigative Site 800, Lund, Sweden|Forest Investigative Site 805, Orebro, Sweden|Forest Investigative Site 804, Stockholm, Sweden|Forest Investigative Site 802, Stockholm, Sweden|Forest Investigative Site 801, Uppsala, Sweden|Forest Investigative Site 803, Vasteras, Sweden",,"https://ClinicalTrials.gov/show/NCT01464476"
880,"NCT01647945","FK506 (Tacrolimus) in Pulmonary Arterial Hypertension","TransformPAH","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: FK506 level < 2 ng/ml|Drug: FK506 level 2-3 ng/ml|Drug: FK506 level 3-5 ng/ml","Safety of Low-dose FK-506 in PAH|Number of Combined Clinical Events|Efficacy of Low-dose FK-506 in Pulmonary Arterial Hypertension (PAH) Measured by Change in 6-min Walk Distance (6MWD)","Edda Spiekerkoetter|Stanford University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PAH-70522","July 2012","May 2014","August 2014","July 24, 2012","October 5, 2016","October 5, 2016","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01647945"
881,"NCT03370887","AZD8601 Study in CABG Patients",,"Recruiting","No Results Available","Heart Failure","Drug: AZD8601|Drug: Placebo","Serious Adverse Events|Adverse event|Electrocardiogram (ECG, number of patients with ECG results exceeding ICH reference ranges)|Left ventricular ejection fraction (LVEF) change from baseline (%)|Changes in physical examination (number of abnormal findings in physical examination)|Changes in vital signs - blood pressure (mmHg)|Changes in vital signs - pulse (bpm)|Changes in laboratory values - hematology|Changes in laboratory values - clinical chemistry|Changes in laboratory values - urinalysis","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D9150C00003","February 5, 2018","March 30, 2022","March 30, 2022","December 13, 2017",,"April 15, 2020","Research Site, New Haven, Connecticut, United States|Research Site, Kuopio, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, München, Germany|Research Site, München, Germany|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Göteborg, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT03370887"
882,"NCT02471586","ILUMIEN III: OPTIMIZE PCI",,"Completed","No Results Available","Coronary Artery Disease","Procedure: Coronary PCI guided by IVUS|Procedure: Coronary PCI guided by OCT|Procedure: Coronary PCI guided by Angiography","Primary Efficacy Endpoint (powered)|Primary Safety Endpoint (non-powered)|Acute procedural success|Post-PCI stent expansion (%)|Mean stent expansion (%)|Intra-stent plaque protrusion and thrombus|Untreated reference segment disease|Edge dissections|Stent Malapposition|Border detection (OCT arm only)|Altered clinical decision making on the basis of the post-stent imaging run|Intra-stent Lumen Area (Intra-stent Flow Area)|Effective Lumen Area (Total Flow Area)|IVUS Secondary Endpoints (IVUS Arm Only): Comparison to Blinded OCT Run (not-powered)|Non OCT Secondary Endpoints (Angiographic Endpoints (QCA))|Procedural Endpoints (site reported)|Additional Procedural and Clinical Endpoints","Abbott Medical Devices|Cardiovascular Research Foundation, New York","All","18 Years and older   (Adult, Older Adult)","Not Applicable","450","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SJM-CIP-10034","May 2015","April 5, 2016","May 25, 2017","June 15, 2015",,"November 22, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Scottsdale Healthcare Hospitals, Scottsdale, Arizona, United States|Scripps Green Hospital, La Jolla, California, United States|University of California at San Diego (UCSD) Medical Center, San Diego, California, United States|Heart Institute of Colorado, Broomfield, Colorado, United States|Orlando Health, Orlando, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|North Georgia Heart Foundation, Inc., Gainesville, Georgia, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Massachusetts, Worcester, Massachusetts, United States|North Shore/LIJ, Manhasset, New York, United States|New York Presbyterian Hospital/Columbia University, New York, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Eastern Cardiology, Greenville, North Carolina, United States|INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma, United States|St. Charles Medical Center, Bend, Oregon, United States|Austin Heart, Austin, Texas, United States|Houston Cardiovascular Institute, Houston, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Onze-Lieve-Vrouwziekenhuis Campus Aalst, Aalst, East Flanders, Belgium|UZ Gasthuisberg, Leuven, Flemish Brabant, Belgium|Klinikum der Justus-Liebig-Universität, Giessen, Hesse, Germany|Osp. S. Giovanni Addolorata, Roma, Latium, Italy|Ospedale Papa Giovanni XXIII, Bergamo, Lombardy, Italy|Centro Cardiologico Monzino, Milan, Lombardy, Italy|Kobe University Hospital, Chuo-ku, Hyogo, Japan|Nara Medical University Hospital, Kashihara-shi, Nara, Japan|Osaka Saiseikai Nakatsu Hospital, Osaka-shi, Osaka, Japan|Wakayama Medical University Hospital, Wakayama City, Wakayama, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan|Erasmus MC - Thoraxcenter, Rotterdam, Zuid-Holland, Netherlands|Hospital Universitario de la Princesa, Madrid, Spain|Kings College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02471586"
883,"NCT02981082","Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension",,"Terminated","No Results Available","Systemic Sclerosis|Pulmonary; Hypertension","Drug: Dimethyl Fumarate (DMF)|Drug: Placebo Oral Tablet","6 minute walk distance (6MWD).|Clinical Worsening|Borg Dyspnea Index (BDI)|Serum markers of oxidative stress|Proteomic biomarkers","Robert Lafyatis|Biogen|University of Pittsburgh","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRO16070614","December 2016","February 10, 2020","February 10, 2020","December 2, 2016",,"April 7, 2020","National Jewish, Denver, Colorado, United States|John Hopkins, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02981082"
884,"NCT01765270","Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery","MAPSS","Terminated","Has Results","Type 2 Diabetes Mellitus|Cardiovascular Disease","Drug: Saxagliptin|Drug: Placebo","Troponin I (TnI) Area Under the Curve (AUC)|High Sensitive Troponin-I (hsTnT) Area Under the Curve|Creatine Kinase-Myocardial Bands (CK-MB) Area Under the Curve|Number of Major Adverse Cardiac Events (MACE)|Duration of Inotropic Support|Number of Participants Who Had an Episode of Hypoglycemia|Number of Participants Who Required Intraaortic Balloon Pump (IABP) Support|Need for Antiarrhythmic Therapy","Duke University","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","Pro00041744","March 2013","June 2014","June 2014","January 10, 2013","May 8, 2015","May 29, 2015","Cardiology, PC, Birmingham, Alabama, United States|Cardio-Thoracic Surgeons PC, Birmingham, Alabama, United States|Heart Center Research, LLC, Huntsville, Alabama, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Stanford University Medical Center, Palo Alto, California, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Duke University Medical Center (DUMC), Durham, North Carolina, United States|Chippenham Medical Center, Richmond, Virginia, United States|Charleston Area Medical Center (CAMC), Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01765270"
885,"NCT03678116","Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses",,"Completed","No Results Available","Energy Metabolism|Heart Rate|Blood Pressure|Mood","Drug: Sugar Pill (placebo)|Dietary Supplement: Caffeine (plus Teacrine and Cayenne)|Dietary Supplement: Caffeine (plus Teacrine)","Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Resting Energy Expenditure (REE)|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Heart Rate|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Blood Pressure|Effects of Ingestion of a Commercially Available Thermogenic Dietary Supplement on Mood Responses","University of Mary Hardin-Baylor|Dymatize Inc.","All","18 Years to 35 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","AMP-1","July 23, 2018","October 31, 2018","October 31, 2018","September 19, 2018",,"March 28, 2019","UMHB Human Performance Lab, Belton, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03678116"
886,"NCT03644667","Tocilizumab in Cardiac Transplantation",,"Recruiting","No Results Available","Heart Transplant","Biological: tocilizumab|Biological: Placebo|Drug: Standard of Care Triple IS","Proportion of Participants Positive for Event of dnDSA, ACR, AMR, Hemodynamic Compromise, Death or Re-Transplantation - By Treatment Group|Freedom of Detection of de Novo Donor-Specific Antibodies (dnDSA) - by Treatment Group|Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Rejection - by Treatment Group|Freedom from Antibody Mediated Rejection (AMR) ≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1 - by Treatment Group|Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection - by Treatment Group|Freedom from Any-Treated Rejection - by Treatment Group|Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Per Patient - by Treatment Group|Freedom from Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group|Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection Per Participant - by Treatment Group|Occurrence of Death - by Treatment Group|Occurrence of Re-Listed for Transplantation - by Treatment Group|Occurrence of Re-Transplantation - by Treatment Group|Number of Acute Cellular Rejection (≥ International Society of Heart and Lung Transplantation (ISHLT) 2R) Per Patient - by Treatment Group|Number of Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group|Number of Rejection Episodes Associated with Hemodynamic Compromise (HDC) Per Participant - by Treatment Group|Change in Intravascular Ultrasound (IVUS) Measurements From Baseline to 1 Year Post-Transplant- by Treatment Group|Angiographic Evidence of Cardiac Allograft Vasculopathy (CAV) - by Treatment Group|Participant Loss to follow up - by Treatment Group|Occurrence of Serious Infections Requiring Intravenous Antimicrobial Therapy and Need for Hospitalization - by Treatment Group|Incidence of Tuberculosis - by Treatment Group|Incidence of Cytomegalovirus (CMV) Infection - by Treatment Group|Incidence of Post-Transplant Lymphoproliferative Disease (PTLD) - by Treatment Group|Tolerability (Discontinuation of Study Drug) of Tocilizumab (TCZ) - by Treatment Group","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","200","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAIT RTB-004|ALL IN","December 20, 2018","August 2022","August 2023","August 23, 2018",,"April 24, 2020","Cedars Sinai Medical Center (CACS), Beverly Hills, California, United States|University of California, Los Angeles (UCLA), Los Angeles, California, United States|Stanford University (CASU), Stanford, California, United States|Tampa General Hospital (FLTG), Tampa, Florida, United States|Tufts Medical Center (MANM), Boston, Massachusetts, United States|Massachusetts General Hospital (MAMG), Boston, Massachusetts, United States|St. Luke's Hospital of Kansas City (MOLH), Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Mount Sinai SOM (NYMS), New York, New York, United States|Columbia University Medical Center (NYCP), New York, New York, United States|Duke University Medical Center (NCDU), Durham, North Carolina, United States|Cleveland Clinic (OHCC), Cleveland, Ohio, United States|Penn State Health: Milton S. Hershey Medical Center (PAHE), Hershey, Pennsylvania, United States|University of Pennsylvania School of Medicine (PAUP), Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center (TNVU), Nashville, Tennessee, United States|Baylor University Medical Center (TXTX), Dallas, Texas, United States|University of Utah (UTMC), Salt Lake City, Utah, United States|University of Washington Medical Center (WAUW), Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03644667"
887,"NCT01349491","Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion","GILEAD","Terminated","Has Results","Atrial Fibrillation","Drug: Ranolazine|Drug: Matching placebo","Primary Outcome - Number of Participants With Atrial Fibrillation","University of Oklahoma|Gilead Sciences","All","21 Years and older   (Adult, Older Adult)","Phase 3","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2399","March 2012","June 2014","June 2014","May 6, 2011","April 27, 2017","April 27, 2017","Oklahoma City VA Medical Center, Oklahoma City, Oklahoma, United States|OU Medical Center, Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT01349491"
888,"NCT02610283","A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery",,"Completed","No Results Available","Acute Kidney Injury","Drug: QPI-1002|Drug: Placebo","Proportion of subjects developing AKI as defined by the AKIN criteria|Proportion of subjects developing at least on of the following events: death, needing renal replacement therapy (RRT) during the 90-day post-operative period, or having a ≥ 25% reduction in SCr based eGFR at the Day 90 visit","Quark Pharmaceuticals","All","45 Years and older   (Adult, Older Adult)","Phase 2","341","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","QRK209","December 2015","February 2018","April 2018","November 20, 2015",,"January 10, 2019","University of Arizona Sarver Heart Center, Tucson, Arizona, United States|University of Florida, Gainesville, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|River City Clinical Research, Jacksonville, Florida, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Indiana Ohio Heart, Fort Wayne, Indiana, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Mid Michigan Cardiovascular Research, Midland, Michigan, United States|Cardiac & Vascular Research Center of Northern Michigan, Petoskey, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Bryan Heart, Lincoln, Nebraska, United States|Columbia University, New York, New York, United States|Duke University, Durham, North Carolina, United States|Lindner Research Center, The Christ Hospital, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Baylor University, Dallas, Texas, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. John Regional Hospital, Saint John, New Brunswick, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Centre hospitalier de l'universite de Montreal, Montreal, Quebec, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Instiut Universitaire de Cardiologie et Pneumologie de Quebec, Quebec City, Quebec, Canada|Charité - Universitätsmedizin Berlin, Berlin, Germany|Herzzentrum Dresden GmbH, Dresden, Germany|Westdeutsches Herzzentrum Essen / Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Giessen und Marburg / Standort Giessen / Zentrum für Chirurgie, Giessen, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum der Universität zu Köln, Köln, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT02610283"
889,"NCT03236311","A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI",,"Terminated","Has Results","Microvascular Coronary Artery Disease","Drug: SAR407899|Drug: Placebo|Drug: Adenosine|Drug: Regadenoson|Drug: 13N-ammonia|Drug: 82Rubidium","Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4|Change From Baseline in Angina-induced Physical Limitation Assessed Using Seattle Angina Questionnaire Physical Limitation Scale (SAQ-PL) at Week 4|Pharmacokinetic Parameter: SAR407899 Plasma Concentration","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT14656|2016-000629-38|U1111-1182-1709","October 12, 2017","July 23, 2018","July 23, 2018","August 1, 2017","July 11, 2019","July 11, 2019","Investigational Site Number 8400003, Los Angeles, California, United States|Investigational Site Number 8400001, Jacksonville, Florida, United States|Investigational Site Number 8400013, Wellington, Florida, United States|Investigational Site Number 8400008, Baltimore, Maryland, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 8400010, Philadelphia, Pennsylvania, United States|Investigational Site Number 2080001, København Nv, Denmark|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 5280001, Nijmegen, Netherlands|Investigational Site Number 7520001, Lund, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03236311/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT03236311/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03236311"
890,"NCT03987204","Ivabradine for Rate Control in Permanent Atrial Fibrillation",,"Recruiting","No Results Available","Atrial Fibrillation|Atrial Fibrillation, Persistent","Drug: Ivabradine","Heart Rate in Daily Life|Percent Pacing in Daily Life|Heart Rate on Treadmill|Symptoms and Exercise Tolerance|Blood Pressure","Yale University","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000022064","June 15, 2019","June 1, 2020","January 1, 2021","June 14, 2019",,"September 27, 2019","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03987204"
891,"NCT02147067","Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)","MARINA","Completed","Has Results","Microvascular Angina","Drug: Ranolazine|Drug: Placebo","Change in Seattle Angina Questionnaire Score Regarding Angina Frequency|Change in Seattle Angina Questionnaire Score Regarding Physical Limitation|Change in Seattle Angina Questionnaire Score Regarding Angina Stability|Change in Seattle Angina Questionnaire Score Regarding Treatment Satisfaction|Change in Seattle Angina Questionnaire Score Regarding Disease Perception|Change in Peak Rate of Oxygen Consumption (VO2 Max)|Change in Time to Angina|Change in Metabolic Equivalents of Task (METs) at Peak|Change in Coronary Flow Reserve (CFR)|Change in Hyperemic Microcirculatory Resistance (HMR)|Percent Change in Coronary Blood Flow","Emory University|Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00072996","September 2014","March 2018","June 2018","May 26, 2014","May 21, 2019","May 21, 2019","Emory University, Atlanta, Georgia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02147067/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02147067"
892,"NCT02100722","A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease","FAME 3","Active, not recruiting","No Results Available","Coronary Disease|Coronary Stenosis","Procedure: FFR guided PCI|Procedure: CABG","MACCE|Death, MI, and stroke","Stanford University|VZW Cardiovascular Research Center Aalst|Catharina Ziekenhuis Eindhoven|Golden Jubilee National Hospital|University of California, Irvine|Medtronic|Abbott Medical Devices|Genae|King's College Hospital, London|Houston Methodist DeBakey Heart and Vascular Center, Houston","All","21 Years and older   (Adult, Older Adult)","Phase 4","1500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FAME 3","August 2014","December 2020","December 2024","April 1, 2014",,"January 18, 2020","Palo Alto VA, Palo Alto, California, United States|Stanford University, Stanford, California, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Jesse Brown VA Medical Center, Chicago, Illinois, United States|University of Kansas Medical Center, Lawrence, Kansas, United States|Lexinton VA, Lexington, Kentucky, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Baystate Medical Center, Springfield, Massachusetts, United States|HealthEast St. Joseph's Hospital, Saint Paul, Minnesota, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Centennial Heart, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Peninsula Health, Frankston, Australia|St. Vincent's Hospital Melbourne, Melbourne, Australia|Concord Hospital, Sydney, Australia|Royal North Shore, Sydney, Australia|University of Sydney, Sydney, Australia|Cardiovascular Center Aalst, Aalst, Belgium|Le'Centre Hospitalier de l'Universite de Montreal, Montreal, Canada|York PCI Group INC, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Canada|Masaryk University and University Hospital Brno, Brno, Czechia|Rigshospitalet University Hospital, Copenhagen, Denmark|Cardiovascular Hospital, Lyon, France|Hungarian Institute of Cardiology, Budapest, Hungary|Asan Medical Center, Seoul, Korea, Republic of|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Catharina Hospital Eindhoven, Eindhoven, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Isala Klinieken, Zwolle, Netherlands|Waikato Hospital, Hamilton, New Zealand|Stavanger University Hospital, Stavanger, Norway|University Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Sahlgrenska University Hospital, Goteborg, Sweden|Danderyds Sjukhus, Stockholm, Sweden|Karolinska Institutet, Dep of clinical science and education, Södersjukhuset, Stockholm, Sweden|Wales Heart Research Institute, Cardiff, United Kingdom|University Hospitals Coventry and Warwickshire, Coventry And Warwickshire, United Kingdom|Golden Jubilee National Hospital, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|St. Thomas' Hospital, London, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Oxford University Hospital NHS Trust, Oxford, United Kingdom|Southampton University Hospitals NHS Trust, Southhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02100722"
893,"NCT00888940","Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery","CONSERV-2","Completed","Has Results","Bloodloss|Surgical Procedures, Operative","Drug: Ecallantide|Drug: Cyklokapron(R)","Cumulative Volume of Packed Red Blood Cells Transfused|Treatment-emergent Adverse Events.","Cubist Pharmaceuticals LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ECAL-CCPB-08-07","June 2009","December 2009","January 2010","April 28, 2009","January 17, 2011","August 10, 2015","Cardio-Thoracic Surgeons PC, Birmingham, Alabama, United States|Universitaetsklinikum Aachen AoeR, Aachen, Germany|Klinikum Augsburg, Augsburg, Germany|Herz- und Gefaesszentrum Bad Bevensen, Bad Bevensen, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Klinik und Poliklinik fuer Herz- und Thoraxchirurgie der Universitaet zu Koeln, Cologne, Germany|St. Johannes Hospital, Dortmund, Germany|Herzzentrum Dresden GmbH Universitaetsklinik, Dresden, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Universitaetsklinikum Frankfurt, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsmedizin Goettingen, Goettingen, Germany|Universitaetsklinikum Halle (Saale), Halle, Germany|Universitaeres Herzzentrum Hamburg GmbH, Hamburg, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Klinikum der Stadt Ludwigshafen gGmbH, Ludwigshafen, Germany|Klinik fuer Herzchirurgie des Universitaetsklinikum SH, Luebeck, Germany|Deutsches Herzzentrum Muenchen, Munich, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|HELIOS Klinik Wuppertal, Wuppertal, Germany|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Uniwersytecki im. Dr. Antoniego Jurasza w Bydgoszczy, Bydgoszcz, Poland|Akademickie Centrum Kliniczne, Szpital AM w Gdansku, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Kraków, Poland|Uniwersytecki Szpital Kliniczny Nr. 3 im. Dr Seweryna Sterlinga, Lódz, Poland|Katedra Chorób Serca AM, Szpital Miejski im. J Strusia, Poznan, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 2 Pomorskiej Akademii Medycznej, Szczecin, Poland|Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON, Warszawa, Poland|Instytut Kardiologii im. Prymasa Tysiclecia Stefana Kardynała Wyszyńskiego, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu, Wroclaw, Poland|4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ, Centrum Chorób Serca, Wroclaw, Poland|Slaskie Centrum Chorób Serca, Zabrze, Poland",,"https://ClinicalTrials.gov/show/NCT00888940"
894,"NCT04050410","Autonomic Determinants of POTS - Pilot1",,"Suspended","No Results Available","Postural Tachycardia Syndrome","Drug: Moxonidine|Drug: Placebo","Change in Orthostatic Symptom Burden [delta (delta VOSS)]|Change in Orthostatic Change in Heart Rate [delta (delta HR)]","Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI)","Female","18 Years to 55 Years   (Adult)","Early Phase 1","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","VANDERBILT_IRB_190703|R56HL142583","August 27, 2019","July 31, 2024","December 31, 2025","August 8, 2019",,"April 9, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04050410"
895,"NCT01059682","A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease",,"Terminated","Has Results","Cardiovascular Disease","Drug: Dalcetrapib|Drug: Placebo","Nominal Change From Baseline to Study End in Coronary Percent Atheroma Volume (PAV) of the Target Coronary Artery Assessed by IVUS.|Rate of Change From Baseline to Study End in Carotid Intima-media Thickness (CIMT) Using B-mode Ultrasound|Nominal Changes From Baseline in Minimal Lumen Diameter as Assessed by Quantitative Coronary Angiography|Blood Lipids, Lipoproteins|Nominal Changes in Percent Diameter Stenosis as Assessed by Quantitative Coronary Angiography","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","936","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NC22703","January 2010","September 2011","September 2011","February 1, 2010","March 24, 2020","March 24, 2020","Los Angeles, California, United States|Los Angeles, California, United States|Torrance, California, United States|Boulder, Colorado, United States|Greeley, Colorado, United States|Littleton, Colorado, United States|Hartford, Connecticut, United States|Atlantis, Florida, United States|Fort Lauderdale, Florida, United States|Fort Lauderdale, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Elkhart, Indiana, United States|Louisville, Kentucky, United States|Columbia, Maryland, United States|Salisbury, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|Midland, Michigan, United States|Muskegon, Michigan, United States|Petoskey, Michigan, United States|Duluth, Minnesota, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|Paramus, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Chapel Hill, North Carolina, United States|Toledo, Ohio, United States|Hershey, Pennsylvania, United States|Providence, Rhode Island, United States|Germantown, Tennessee, United States|Oak Ridge, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Saint John, New Brunswick, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Cambridge, Ontario, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Newmarket, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Fleurimont, Quebec, Canada|Gatineau, Quebec, Canada|Greenfield Park, Quebec, Canada|Lachine, Quebec, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Montréal, Quebec, Canada|Saint Georges-de-beauce, Quebec, Canada|St-Charles-Borromée, Quebec, Canada|St-jerome, Quebec, Canada|St-Lambert, Quebec, Canada|Ste. Foy, Quebec, Canada|Sudbury, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Val D'or, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Aachen, Germany|Berlin, Germany|Darmstadt, Germany|Essen, Germany|Hamburg, Germany|Hamburg, Germany|Heidelberg, Germany|Leipzig, Germany|Muenchen, Germany|München, Germany|Regensburg, Germany|Ulm, Germany|Elblag, Poland|Gdańsk, Poland|Krakow, Poland|Kraków, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Geneve, Switzerland|Kreuzlingen, Switzerland|Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01059682"
896,"NCT04134845","Feasibility of Dantrolene to Study RyR2 Inhibition to Prevent Ventricular Arrhythmias",,"Completed","No Results Available","Ventricular Tachycardia","Drug: Dantrolene","Inducibility of sustained VT/VF by standardized ventricular stimulation protocol","Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190797","October 7, 2019","February 10, 2020","February 10, 2020","October 22, 2019",,"April 9, 2020","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04134845"
897,"NCT01392469","Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Imatinib","Measure: To evaluate the effect of QTI571 on pharmacokinetics of of sildenafil and bosentan in terms of the changes in AUCtau and Cmax in patients with Pulmonary Arterial Hypertension|Measure: Number of patients with adverse events as a measure of the safety and tolerability of QTI571 when co-administered with sildenafil and bosentan.|Measure: To evaluate the pharmacokinetics of QTI571 and its active metabolite in terms of AUCtau and Cmax in patients with Pulmonary Arterial Hypertension","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQTI571A2102|2010-021344-17","April 20, 2011","October 25, 2012","October 25, 2012","July 12, 2011",,"June 13, 2018","Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01392469"
898,"NCT03589729","Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers",,"Recruiting","No Results Available","Acute Myeloid Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts 10 Percent or More of Bone Marrow Nucleated Cells|High Risk Myelodysplastic Syndrome|Myeloid Sarcoma|Myeloproliferative Neoplasm|Philadelphia Chromosome Positive","Drug: Cladribine|Drug: Cytarabine|Drug: Dexrazoxane Hydrochloride|Drug: Gemtuzumab Ozogamicin|Drug: Idarubicin","Percentage of patients experiencing a decrease in left ventricular ejection fraction (LVEF)|Incidence of cardiac symptoms|Assessment of change in troponin I and high-sensitivity troponin T|Incidence of adverse events|Complete remission (CR) /complete remission with incomplete blood count recovery (CRi) rates (Cohorts 1-3)|Overall response (Cohorts 1-3)|Overall survival (Cohorts 1-3)|Event-free survival (Cohorts 1-3)|Remission duration (Cohorts 1-3)|Recurrence-free survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2017-0937|NCI-2018-01108|P30CA016672","September 19, 2018","December 31, 2020","December 31, 2020","July 18, 2018",,"December 16, 2019","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03589729"
899,"NCT01546883","Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation","DEPAF","Terminated","Has Results","Atrial Fibrillation","Drug: Dabigatran etexilate (Pradaxa)","Percentage of Fibrosis","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 4","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB # 43119","February 2012","December 2013","December 2013","March 7, 2012","October 12, 2015","October 12, 2015","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01546883"
900,"NCT01580813","Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes","AcT2","Active, not recruiting","No Results Available","Type 2 Diabetes","Drug: Acipimox|Drug: Placebo","Evaluating the Effect of Acipimox on Insulin Sensitivity and Cardiovascular Function|Evaluate the Impact of Acipimox on Exercise Parameters in People with Type 2 Diabetes","University of Colorado, Denver|US Department of Veterans Affairs|Pfizer","All","30 Years to 60 Years   (Adult)","Not Applicable","50","Other|U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10-1393","June 2011","December 2019","December 2019","April 19, 2012",,"April 26, 2019","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01580813"
901,"NCT02710669","New Formulations of Propafenone to Treat Atrial Fibrillation",,"Suspended","No Results Available","Atrial Fibrillation","Drug: (R)-propafenone|Drug: (S)-Propafenone|Drug: Placebo","Induction of atrial fibrillation (yes or no)|Inducibility of atrial fibrillation expressed as an ordinal variable based on stage of the induction protocol|Induction of atrial flutter (yes or no)","Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","243","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","151952|1R01HL124935-01A1","October 2016","December 2020","December 2020","March 17, 2016",,"April 9, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02710669"
902,"NCT01529502","Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting",,"Completed","Has Results","Blood Transfusion|Endothelial Physiopathology|Nitric Oxide|Pulmonary Hypertension","Procedure: Red blood Cells auto-transfusion|Drug: Inhaled Nitric Oxide (iNO) administration","Systolic Pulmonary Artery Pressure|Endothelial Function: Reactive Hyperemia Index","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","Blood Study Overweight","March 2012","December 2013","December 2013","February 8, 2012","March 29, 2017","May 22, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01529502"
903,"NCT02365506","Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome",,"Completed","No Results Available","LQT2 Syndrome","Drug: Eleclazine|Drug: Placebo","Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)|Change in daily QT interval|Maximal QT shortening","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-394-1658|2015-002413-30","July 2015","May 2016","June 2016","February 19, 2015",,"July 12, 2016","University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT02365506"
904,"NCT02632786","The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis","PRONTO","Completed","Has Results","AL Amyloidosis","Drug: NEOD001|Drug: Placebo","Number of Participants With Cardiac Response and Non-Response|SF-36v2 PCS Score|6MWT Distance|Number of Participants With Renal Best Response and Non-Response|NIS-LL Total Score|NT-proBNP Slope|Hepatic Best Response","Prothena Therapeutics Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NEOD001-201","March 2016","March 2018","March 2018","December 17, 2015","April 5, 2019","April 5, 2019","City of Hope, Duarte, California, United States|Stanford Cancer Institute (SCI), Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Chicago Medicine, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas; MD Anderson Cancer Center, Houston, Texas, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The University of Queensland - Princess Alexandra Hospital (PAH), Woolloongabba, Queensland, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien, Vienna, Austria|Hôpital Dupuytren - CHU Limoges, Limoges, France|Hôpital Pitié-Salpêtrière, Paris, France|Hopitaux Lyon Sud, Pierre-Benite Cedex, France|CHU Rennes, Service de Medecine Interne, Rennes Cedex 2, France|Charite-Universitatsmedizin, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Universitatsklinikum Hamburg-Eppendorf (UKE, Hamburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Alexandra General Hospital of Athens, Athens, Greece|University Hospital of Patras, Patras, Greece|Hadassah University Medical Center, Jerusalem, Israel|Policlinica San Matteo, Pavia, Italy|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Spain|Centre for Clinical Haematology, Birmingham, United Kingdom|The Royal Free London NHS Foundation Trust - The Royal Free Hospital, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02632786/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02632786/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02632786"
905,"NCT02251431","Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome",,"Recruiting","No Results Available","Type 2 Diabetes Mellitus|Chronic Kidney Disease|Left Ventricular Diastolic Dysfunction","Drug: BYDUREON|Drug: Placebo","Myocardial injury summary score (MISS)|Kidney Injury Summary Score (KISS)|Cardiac fibrosis|Left ventricular strain","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","014-149|D5551L00004/ISSEXEN0013","February 2016","June 2020","June 2020","September 29, 2014",,"September 17, 2019","Baylor Scott and White Research Institute- Baylor Heart and Vascular Hospital, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02251431"
906,"NCT01890421","Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)","GadaCAD 1","Completed","Has Results","Coronary Artery Disease","Drug: Gadobutrol (Gadovist, Gadavist, BAY86-4875)","Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based on Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Sensitivity Based on the Blinded Readers' Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Specificity Based on the Blinded Readers' Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Additional Secondary Analysis of Specificity Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Sensitivity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Investigator's Assessment|Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment|Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on Investigator's Assessment|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-Enhanced CMRI - Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessments|Localization of a Myocardial Perfusion Defect to a Coronary Territory on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' and Investigator's Assessments|Detection of Myocardial Perfusion Defect(s) on Gadobutrol-enhanced CMRI in Participants With Significant LMS Stenosis - Based on Blinded Readers' and Investigator's Assessments|Presence/Absence of a MPD Indicating/Excluding Significant CAD in Participants With Multi Versus Single Vessel Disease Evaluated on Gadobutrol-enhanced CMRI-Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Presence/Absence of a MPD Indicating/Excluding Significant CAD in Participants With Multi Vs Single Vessel Disease Evaluated on Gadobutrol-enhanced CMRI-Additional Secondary Analysis of Sensitivity Based on Blinded Readers' and Investigator's Assessments|Percentage of Participants by Their Lowest Confidence in Diagnosis Obtained on Gadobutrol-enhanced CMRI and Unenhanced Wall Motion CMRI - Based on Blinded Readers' and Investigator's Assessments","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","426","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15961|2012-002563-10","July 19, 2013","April 10, 2015","August 31, 2017","July 1, 2013","May 16, 2018","May 16, 2018","Minneapolis, Minnesota, United States|Marseille, France|Saint-Etienne, France|Bad Krozingen, Baden-Württemberg, Germany|Stuttgart, Baden-Württemberg, Germany|Tuebingen, Baden-Württemberg, Germany|Darmstadt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Yangsan-si, Korea, Republic of|Auckland, New Zealand|Lugano, Ticino, Switzerland|Leicester, United Kingdom|Liverpool, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01890421"
907,"NCT01210846","A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: tivozanib","Change from baseline in QTcF|Change from baseline in QTc with Bazett correction method (QTcB)|Change from baseline in heart rate (HR)|Change from baseline in PR interval|Change from baseline in QRS interval|Change from baseline in Uncorrected QT interval|Change from baseline in ECG morphological patterns|Correlation between the QTcF change from baseline and serum concentrations of tivozanib","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","AV-951-10-112","October 2010","March 2011","July 2011","September 29, 2010",,"September 26, 2011","TGEN Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC, Metairie, Louisiana, United States|Associates in Oncology/Hematology, Rockville, Maryland, United States|Oklahoma University Cancer Institute (OUCI), Oklahoma City, Oklahoma, United States|Tennessee Onocology, Nashville, Tennessee, United States|Multicare Research Institute/Tacoma General Hospital, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01210846"
908,"NCT01327183","A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention",,"Completed","No Results Available","Myocardial Infarction","Procedure: Percutaneous Coronary Intervention (PCI)|Drug: RO4905417|Drug: placebo","Reduction of procedural damage during percutaneous coronary intervention (PCI): Change from baseline in troponin I levels early after PCI|Change from baseline in troponin I at 8 hours post PCI|Peak and AUC for troponin I|Change from baseline in Creatine Kinase-Myocardial Band (CK-MB) after PCI|Change form baseline in Growth Differentiation Factor 15 (GDF-15) at 120 days post PCI|Change from baseline in cystatin C biomarker at 24 hours and 30 days post PCI|Safety: Incidence of adverse events and major adverse cardiovascular events (MACEs)","Hoffmann-La Roche","All","19 Years to 74 Years   (Adult, Older Adult)","Phase 2","532","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BP25619","May 2011","October 2012","October 2012","April 1, 2011",,"November 2, 2016","Huntsville, Alabama, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Salinas, California, United States|Littleton, Colorado, United States|Farmington, Connecticut, United States|Boynton Beach, Florida, United States|Kissimmee, Florida, United States|Ocala, Florida, United States|Sarasota, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Columbus, Georgia, United States|Aurora, Illinois, United States|Fort Wayne, Indiana, United States|Iowa City, Iowa, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Shreveport, Louisiana, United States|Baltimore, Massachusetts, United States|Hyannis, Massachusetts, United States|Bay City, Michigan, United States|Petoskey, Michigan, United States|St. Paul, Minnesota, United States|Ridgewood, New Jersey, United States|Johnson City, New York, United States|Raleigh, North Carolina, United States|Bismarck, North Dakota, United States|Springfield, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Chambersburg, Pennsylvania, United States|Houston, Texas, United States|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Hamilton, Ontario, Canada|Newmarket, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Quebec City, Quebec, Canada|St-Charles Borromee, Quebec, Canada|Heerlen, Netherlands|Leeuwarden, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Gdynia, Poland|Jozefow, Poland|Katowice, Poland|Krakow, Poland|Kraków, Poland|Starogard Gdanski, Poland|Torun, Poland|Warszawa, Poland|Warszawa, Poland|Wejherowo, Poland|Wroclaw, Poland|Łodz, Poland",,"https://ClinicalTrials.gov/show/NCT01327183"
909,"NCT03661385","Nitric Oxide During Bypass for Arterial Switch Operation","NASO","Recruiting","No Results Available","Low Cardiac Output Syndrome|Transposition of Great Vessels","Drug: Nitric Oxide","Major adverse events|Length of stay in ICU (hours)|Length of stay in hospital (days)|Ventilator-free days|Inotrope hours|Dialysis-free days|Inhaled NO hours|ECMO-free days|Closed sternum days|Composite free-day score","Warwick Butt|Murdoch Childrens Research Institute","All","Child, Adult, Older Adult","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","38017|ACTRN12618000089235p","July 11, 2018","December 31, 2021","December 31, 2021","September 7, 2018",,"June 21, 2019","Texas Children's Hospital, Houston, Texas, United States|Royal Children's Hospital, Melbourne, Victoria, Australia|Harapan Kita Children and Women's Hospital, Jakarta, Indonesia|Schneider Children's medical center, Petach Tikvah, Israel|Institut Jantung Negara, Kuala Lumpur, Malaysia|Alder Hey Hospital, Liverpool, United Kingdom","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03661385/ICF_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03661385/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03661385"
910,"NCT00848731","Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism",,"Completed","No Results Available","Pulmonary Embolism","Drug: nitric oxide","Borg score|vital signs","Atrium Health","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CMC_kline_iNO1.1","February 2009","May 2011","May 2011","February 20, 2009",,"June 27, 2011","Carolinas Medical Center, Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00848731"
911,"NCT02197065","Pilot Study of Atorvastatin for Orthopedic Surgery Patients","POST-OP Pilot","Completed","Has Results","Hip Fracture|Myocardial Ischemia|Inflammation","Drug: Atorvastatin|Drug: Placebo","Percentage of All Enrolled Patients With a Peri-operative Rise in High-sensitivity Cardiac Troponin I|Peri-operative Rise in High Sensitivity C-reactive Protein (Hs-CRP)|Peri-operative Rise in Interleukin-6 (IL-6) Levels","Hospital for Special Surgery, New York|Weill Medical College of Cornell University|Washington University School of Medicine|University of Utah","All","65 Years to 99 Years   (Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EPAR4398|UL1TR000457-06","September 2014","July 2016","January 2017","July 22, 2014","July 2, 2017","July 2, 2017","Hospital for Special Surgery, New York, New York, United States|New York Presbyterian Hospital (Cornell), New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02197065"
912,"NCT03044353","Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698",,"Terminated","Has Results","Amyloidosis","Drug: GSK2315698 (CPHPC)|Biological: GSK2398852 (anti-SAP mAb)","Change From Baseline in Left Ventricular (LV) Mass Over Time up to 8-week Follow-up|Number of Participants With Any On-treatment Adverse Events (AEs)|Number of Participants With Any Serious Adverse Events (SAEs)|Number of Participants With Abnormal Hematology Values|Number of Participants With Abnormal Clinical Chemistry Values|Number of Participants With Abnormal Urinalysis Results|Number of Participants With Abnormal Urinalysis Results for Character Parameters|Number of Participants With Body Temperature Shifts From Baseline Relative to Potential Clinical Importance (PCI) Criteria|Number of Participants With Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Shifts From Baseline Relative to PCI Criteria|Number of Participants With Pulse Rate Shifts From Baseline Relative to PCI Criteria|Number of Participants With Abnormal Electrocardiogram (ECG) Findings|Number of Participants With Abnormalities During Cardiac Monitoring|Number of Participants for Which Unscheduled Echocardiography (ECHO) Was Performed for Safety Reasons|Number of Participants With Skin Rashes|Number of Participants With Skin Rashes Classified Using CTCAE|Number of Participants With Abnormalities in Histopathological Examination of Skin Biopsies|Number of Participants With Abnormalities in Immunohistochemical Examination of Skin Biopsies|Number of Participants With Abnormalities in Histopathological Examination of Blood Biomarkers|Number of Participants With Abnormalities in Immunohistochemical Examination of Blood Biomarkers|Change From Baseline in Plasma Cytokines Over Time|Change From Baseline in Fluid Phase Complement Marker-Complement 3 (C3) Over Time|Change From Baseline in Fluid Phase Complement Marker-Complement 4 (C4) Over Time|Change From Baseline in Fluid Phase Complement Marker-Total Complement (CH50) Over Time|Change From Baseline in Inflammatory Biomarkers Over Time|Maximum Concentration (Cmax) of GSK2398852|Time Associated With Cmax (Tmax) of GSK2398852|Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC 0-t) of GSK2398852|Cmax of GSK2315698 for Newly Diagnosed Mayo Stage II/IIIa AL Amyloidosis Participants|Tmax of GSK2315698 for Newly Diagnosed Mayo Stage II/IIIa AL Amyloidosis Participants|AUC 0-t of GSK2315698 for Newly Diagnosed Mayo Stage II/IIIa AL Amyloidosis Participants|Change From Baseline in Global Longitudinal Strain (GLS) by CMR|Change From Baseline in GLS by ECHO|Change From Baseline in LV Twist Over Time|Change From Baseline in Stroke Volume (SV) by CMR|Change From Baseline in SV by ECHO|Change From Baseline in Left Ventricular Ejection Fraction (EF) by CMR|Change From Baseline in Left Ventricular EF by ECHO|Change From Baseline in Left Ventricle End Diastolic Volume (EDV) by CMR|Change From Baseline in Left Ventricle End Diastolic Volume (EDV) by ECHO|Change From Baseline in Ratio of Mitral Peak Velocity of Early Filling to Early Diastolic Mitral Annual Velocity (E/e' Ratio)","GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201464|2016-000276-23","July 10, 2017","January 3, 2019","January 3, 2019","February 7, 2017","October 16, 2019","October 16, 2019","GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03044353/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/53/NCT03044353/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03044353"
913,"NCT00927459","Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol",,"Terminated","No Results Available","Hypercholesterolemia","Drug: PRO-040201|Drug: Placebo","Safety and tolerability of PRO-040201|Pharmacokinetics of PRO-040201 in Humans|Pharmacodynamics of PRO-040201 in Humans","Arbutus Biopharma Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TKM-ApoB-001","June 2009","December 2009","January 2010","June 25, 2009",,"January 22, 2010","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00927459"
914,"NCT03907046","Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","ASPIRE","Suspended","No Results Available","Intracerebral Hemorrhage|Atrial Fibrillation","Drug: Apixaban|Drug: Aspirin","Stroke or death|Modified Rankin Scale (mRS) score","Yale University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2000026409|1U01NS106513-01A1","January 28, 2020","April 2024","April 2024","April 8, 2019",,"April 7, 2020","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT03907046"
915,"NCT00833703","Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation","CLARINET LT","Completed","Has Results","Heart Defects, Congenital","Drug: Clopidogrel|Drug: placebo","Number of Participants With Bleeding Events|Number of Participants According to Bleeding Type/Etiology|Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths","Sanofi|Bristol-Myers Squibb","All","12 Months and older   (Child, Adult, Older Adult)","Phase 3","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LTS10916|2008-004999-53","January 2009","July 2010","July 2010","February 2, 2009","August 16, 2011","August 22, 2011","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00833703"
916,"NCT03941483","Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery",,"Recruiting","No Results Available","Acute Kidney Injury (AKI)","Drug: ASP1128|Drug: Placebo","Proportion of participants developing acute kidney injury based on serum creatinine (SCr) criteria within 72 hrs (AKI-SCr72h)|Proportion of participants developing AKI based on SCr criteria within 7 days (AKI-SCr7d)|Proportion of participants developing AKI based on all captured criteria within 72 hours (AKI-KDIGO72h)|Proportion of participants developing AKI based on all criteria within 7 days (AKI-KDIGO7d)|Proportion of participants with major adverse kidney events (MAKE) within 30 days (MAKE30)|Proportion of participants with MAKE within 90 days (MAKE90)","Astellas Pharma Inc","All","35 Years and older   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1128-CL-0201","November 1, 2019","July 2020","September 2020","May 8, 2019",,"April 3, 2020","Heart Center Research, LLC, Huntsville, Alabama, United States|Sarver Heart Center, Tucson, Arizona, United States|Keck School of Medicine USC, Los Angeles, California, United States|JEHM clinical Research Group, Palm Springs, California, United States|Hartford Hospital, Hartford, Connecticut, United States|HealthPark Medical Center, Fort Myers, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|University of Florida- Jacksonville, Jacksonville, Florida, United States|Florida Hospital Pepin Heart Institute, Tampa, Florida, United States|Southern Illinois University, Springfield, Illinois, United States|St. Vincent Heart Center, Indianapolis, Indiana, United States|Indiana University Health Ball Memorial Hospital, Muncie, Indiana, United States|Maine Medical Center, Portland, Maine, United States|Delmarva Heart, LLC, Salisbury, Maryland, United States|Ascension Genesys Hospital, Grand Blanc, Michigan, United States|Baptist Medical Center, Jackson, Mississippi, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Lourdes Cardiology Services, Voorhees, New Jersey, United States|Duke Hospital and Health Center, Durham, North Carolina, United States|Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States|Fairview Hospital - Cleveland Clinic, Cleveland, Ohio, United States|ProMedica Toledo Hospital, Toledo, Ohio, United States|Vanderbilt University, Nashville, Tennessee, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Baylor Scott & White Heart Hospital, Plano, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03941483"
917,"NCT01988883","Modafinil and Cognitive Function in POTS",,"Active, not recruiting","No Results Available","Postural Tachycardia Syndrome","Drug: Placebo|Drug: Modafinil|Drug: Propranolol","Visual Attention Performance Speed|Executive Function|Blood Pressure|Heart Rate","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","131371|5UL1TR000445-07","October 2014","December 2020","December 2020","November 20, 2013",,"February 7, 2020","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01988883"
918,"NCT00826280","Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)",,"Completed","Has Results","Coronary Artery Disease (CAD)","Drug: regadenoson|Drug: overencapsulated caffeine|Radiation: technetium|Drug: placebo","Change in Number of Reversible Defects|Change in Summed Difference Score (SDS) Across All 17 Segments|Change in Number of Reversible Defects Assessed by Computerized Quantitation|Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation|Change From Baseline in Heart Rate|Change From Baseline in Systolic Blood Pressure|Change From Baseline in Diastolic Blood Pressure","Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","347","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","3606-CL-3002","March 24, 2009","July 15, 2010","July 15, 2010","January 22, 2009","October 21, 2011","December 18, 2017","Birmingham, Alabama, United States|Huntsville, Alabama, United States|La Mesa, California, United States|Mission Viejo, California, United States|Roseville, California, United States|Sacramento, California, United States|Santa Rosa, California, United States|Hartford, Connecticut, United States|Newark, Delaware, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Tamarac, Florida, United States|Aurora, Illinois, United States|Overland Park, Kansas, United States|Auburn, Maine, United States|Pittsfield, Massachusetts, United States|Detroit, Michigan, United States|Ypsilanti, Michigan, United States|Kansas City, Missouri, United States|Albany, New York, United States|Rochester, New York, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00826280"
919,"NCT02365532","Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults",,"Completed","No Results Available","Long QT Syndrome","Drug: GS-6615|Drug: Placebo to match GS-6615|Drug: Placebo to match dofetilide|Drug: Dofetilide","Change in daytime QT interval corrected for heart rate using the Fridericia formula (QTcF)|Pharmacokinetic (PK) profiles of GS-6615 and dofetilide|Incidence of adverse events, clinical laboratory test results, vital sign measurements, and electrocardiogram (ECG) data","Gilead Sciences","All","18 Years to 40 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-372-1666","February 2015","May 2015","May 2015","February 19, 2015",,"May 20, 2015","Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02365532"
920,"NCT01725256","A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: AIR001 (sodium nitrite inhalation solution)","Change in pulmonary vascular resistance (PVR)from baseline to week 16 assessed at peak AIR001|Time to Clinical Worsening (TTCW), other hemodynamics, and safety","Aires Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIR001-CS05","November 2012","February 2014","February 2014","November 12, 2012",,"April 9, 2014","UCSD Medical Center, La Jolla, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Gottsegen Gyorgy Hungarian, Budapest, Hungary|Semmelweis Karlocai, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|University of Szeged, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT01725256"
921,"NCT00862641","A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease",,"Completed","Has Results","Asthma|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive","Drug: Regadenoson|Drug: Placebo","Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline Assessment|Use of Short-acting Bronchodilators for Treatment of Symptoms After Study Drug Administration|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Absolute Values|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1 Percent Predicted|Change From Baseline to the 2 Hour Post-dose Assessment for Forced Vital Capacity (FVC)|Change From Baseline to the 2 Hour Post-dose Assessment for FEV1/ FVC Ratio|Change From Baseline to the 2 Hour Post-dose Assessment for Oxygen Saturation Measured by Pulse Oximetry|Percentage of Selected Respiratory Adverse Events","Astellas Pharma Inc","All","18 Years and older   (Adult, Older Adult)","Phase 4","1009","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","3606-CL-3001","April 2009","October 2009","October 2009","March 17, 2009","December 15, 2010","September 18, 2012","Montgomery, Alabama, United States|Anaheim, California, United States|Encinitas, California, United States|Fullerton, California, United States|Huntington Beach, California, United States|Long Beach, California, United States|Mission Viejo, California, United States|Roseville, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Waterbury, Connecticut, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Deland, Florida, United States|Miami, Florida, United States|Trinity, Florida, United States|Winter Park, Florida, United States|Stockbridge, Georgia, United States|Aurora, Illinois, United States|Topeka, Kansas, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|No. Dartmouth, Massachusetts, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|Papillion, Nebraska, United States|Brick, New Jersey, United States|Raleigh, North Carolina, United States|Chardon, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Oklahoma, Oklahoma, United States|Medford, Oregon, United States|Upland, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Easley, South Carolina, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00862641"
922,"NCT03602781","Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric",,"Withdrawn","No Results Available","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: iNO","Time to clinical worsening during iNO withdrawal for up to 8 weeks|Difference in clinical worsening events that occur during iNO withdrawal for up to 8 weeks between those treated with iNO ≥ 10 months prior to the start of withdrawal of iNO vs. those treated < 10 months prior to initiation of withdrawal to iNO.","Bellerophon Pulse Technologies|Worldwide Clinical Trials|Bellerophon","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PULSE-PAH-007","August 2018","June 2019","June 2020","July 27, 2018",,"August 10, 2018","Bluhm Cardiovascular Institute, Clinical Trials Unit, Chicago, Illinois, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Peter Lougheed Centre, Calgary, Alberta, Canada|Toronto General Hospital, University Health Network, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03602781"
923,"NCT01901575","Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia","IVPCA","Completed","Has Results","Tachycardia, Ventricular","Drug: Remifentanil","Inhibition of Idiopathic Ventricular Tachycardia|PVC Suppression With Remifentanil Sedation","NYU Langone Health","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-00800","July 2011","April 2013","April 2013","July 17, 2013","December 19, 2014","January 2, 2018","NYU Langone Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01901575"
924,"NCT03404180","Peripheral Nerve Blocks for Above-the-knee Amputations",,"Recruiting","No Results Available","Peripheral Vascular Diseases|Hyperglycaemia (Diabetic)|Hypertension|Coronary Artery Disease|Pulmonary Disease, Chronic Obstructive","Procedure: Peripheral nerve block|Drug: Intravenous Sedatives|Procedure: Lateral femoral cutaneous nerve blocks|Procedure: Obturator nerve blocks","Chi-squared tests of peripheral nerve block success as a primary anesthetic|Analysis of pain scores|Mortality","University of Florida|US Department of Veterans Affairs","All","18 Years and older   (Adult, Older Adult)","Phase 4","36","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB201702402|OCR18952","February 9, 2018","October 2020","October 2020","January 19, 2018",,"March 9, 2020","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03404180"
925,"NCT03273257","Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)",,"Recruiting","No Results Available","Chronic Thromboembolic Pulmonary Hypertension|CTEPH","Drug: Riociguat|Drug: Placebo|Procedure: Pulmonary endarterectomy","Change from baseline in pulmonary vascular resistance (PVR) to immediately before pulmonary endarterectomy (pre-PEA)|Change from baseline in pulmonary vascular resistance (PVR) to 6 months post pulmonary endarterectomy (PEA)|Number of patients with either all-cause death, PH-related hospitalisation, need for PAH-targeted therapy or WHO functional class unchanged or worse between randomisation and 6 months post pulmonary endarterectomy (composite endpoint)|Intraoperative circulatory arrest time|Frequency of intraoperative surgery-related complications (composite endpoint)|Surgical evaluation of specimen: ease of dissection plane|Surgical evaluation of specimen: completeness of disease clearance|Surgical evaluation of specimen: appearance of clot and vessel wall|Frequency of all-cause death|Frequency of withdrawal during randomised treatment phase","International CTEPH Association","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PEA Bridging Study","August 17, 2018","July 2020","July 2020","September 6, 2017",,"January 27, 2020","UC San Diego, La Jolla, California, United States|Hopital de Bicêtre, Paris, France|Kerckhoff-Klinik GmbH, Bad Nauheim, Germany|Papworth Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03273257"
926,"NCT01778218","A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)",,"Completed","No Results Available","Coronary Artery Disease","Radiation: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose","Safety: The number of participants with Adverse Events","Cell>Point LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CP-ECDG-C2","January 2013","February 2013","March 2013","January 29, 2013",,"July 12, 2013","Cardiovascular Imaging Technologies, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01778218"
927,"NCT03498586","Half-normal Saline in Atrial Fibrillation Ablation",,"Recruiting","No Results Available","Atrial Fibrillation","Drug: Half-normal saline|Drug: Normal saline","total radiofrequency ablation time, and total procedure time|acute pulmonary veins, and left atrial appendage (if applicable) reconnection|freedom from atrial tachycardia/atrial fibrillation > 30 seconds without antiarrhythmic drugs|freedom from atrial tachycardia/atrial fibrillation > 30 seconds with or without antiarrhythmic drugs|long-term pulmonary veins, left atrial appendage (if applicable), and coronary sinus (if applicable) reconnection","Texas Cardiac Arrhythmia Research Foundation","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","TCAI_HNS_AF","May 2, 2018","December 2020","December 2020","April 13, 2018",,"December 11, 2019","Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03498586"
928,"NCT02943785","Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)",,"Active, not recruiting","No Results Available","Atrial Fibrillation","Drug: Edoxaban-based Regimen|Drug: VKA-based Regimen","Number of participants experiencing the described adverse event composite within 36 months (ISTH definition)|Number of participants experiencing major bleeding (ISTH definition)|Number of participants experiencing the described adverse event composite within 36 months (non-ISTH definition)|Percentage of participants experiencing major bleeding per other than ISTH definition|Percentage of participants experiencing stroke (ischemic, hemorrhagic, or undetermined)|Percentage of participants experiencing systemic embolic events (SEE)","Daiichi Sankyo, Inc.|Chiltern International Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DU176B-C-U4001|2016-003930-26","March 21, 2017","May 2020","November 2020","October 25, 2016",,"February 20, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Sarver Heart Center, Tucson, Arizona, United States|Arkansas Site Management Services, Little Rock, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Cedar-Sinai Heart Institute, Los Angeles, California, United States|UCLA Cardiovascular Center, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Medical Facility Associates, Washington, District of Columbia, United States|Cardiology Associate Research, Daytona Beach, Florida, United States|International Research Partners, LLC., Doral, Florida, United States|Memorial Healthcare Systems, Hollywood, Florida, United States|UF Health Jacksonville, Jacksonville, Florida, United States|Watson Clinic Center for Research, Lakeland, Florida, United States|Tallahassee Research Institute, Inc., Tallahassee, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|St. Vincent Heart Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Maine Medical Center, Scarborough, Maine, United States|Washington Adventist Hospital, Takoma Park, Maryland, United States|Baystate Health, Springfield, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|MidMichigan Medical Center Midland, Midland, Michigan, United States|Michigan Heart, St. Joseph Mercy Health System, Ypsilanti, Michigan, United States|Essentia Health, Duluth, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|Jackson Heart Clinic, Jackson, Mississippi, United States|Clinical Investigators LLC, Saint Louis, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|New Mexico Heart Institute, Albuquerque, New Mexico, United States|NY Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States|St. Francis Hospital, East Hills, New York, United States|St. Joseph's Physicians, East Syracuse, New York, United States|Rochester General Hospital, Geneva, New York, United States|Northshore Community Hospital, Manhasset, New York, United States|Mt. Sinai Hospital, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Moses H. Cone Memorial Hospital Operating Corporation d/b/a Cone Health, Greensboro, North Carolina, United States|East Carolina Heart Institute, Greenville, North Carolina, United States|Promedica Toledo Hospital, Toledo, Ohio, United States|Oklahoma Heart Hospital Research Foundation, Oklahoma City, Oklahoma, United States|Southern Oregon Cardiology, Medford, Oregon, United States|Providence Heart and Vascular Institute, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Doylestown Health Cardiothoracic Surgery, Doylestown, Pennsylvania, United States|Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Pinnacle Health, Wormleysburg, Pennsylvania, United States|WellSpan York Hospital, York, Pennsylvania, United States|Black Hills Cardiovascular Research, Rapid City, South Dakota, United States|SCRI - Centennial Medical Center, Nashville, Tennessee, United States|Seton Heart Institute, Austin, Texas, United States|Houston Methodist Research Institute, Houston, Texas, United States|University of Texas Health Science Center Houston, Houston, Texas, United States|Legacy Heart Center, Plano, Texas, United States|Inova Heart and Vascular Institute, Falls Church, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Providence Sacred Heart Medical Research Center, Spokane, Washington, United States|CAMC Memorial Hospital, Charleston, West Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medizinische Universitaet Graz, Graz, Austria|Clinic Wels-Grieskirchen GmbH, Grieskirchen, Austria|Universitaetsklinik fuer Innere Medizin III, Innsbruck, Austria|Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria|Universitätsklinik für Innere Medizin II, Vienna, Austria|Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel, Vienna, Austria|Wilhelminenspital, Wien, Austria|ASZ Aalst - Aalst campus, Aalst, Belgium|ZNA - Stuivenberg Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|Hospital Erasme, Brussels, Belgium|UZA - Universtiair Ziekenhuis Antwerpen, Edegem, Belgium|ZOL Genk, Campus Sint-Jan, Genk, Belgium|Jessa Ziekenhuis- Campus Virga Jessa, Hasselt, Belgium|CHU de Liege, Liège, Belgium|AZ Delta Roeselare, Roeselare, Belgium|University of Alberta Hospital, Edmonton, Alberta, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Newmarket Cardiac Surgery Research Incorporated, Newmarket, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|Hamilton General Hospital, Hamilton, Canada|Universitè Laval, Québec, Canada|Horizon Health Network, Saint John, Canada|CHU d'Angers, Angers, France|Clinique Saint Augustin, Bordeaux, France|Hopital Henri Mondor, Créteil, France|Institut Coeur Poumon - CHRU de Lille, Lille, France|CHU Arnaud de Villeneuve, Montpellier, France|Clinique du Millenaire Service de Cardiologie Interventionelle, Montpellier, France|Institut Mutualiste Montsouris, Paris, France|Hopital Bichat, Paris, France|CHU de Bordeaux Hopital du Haut Leveque, Pessac, France|CHU de Rouen, Rouen, France|Clinique Saint-Hilaire, Rouen, France|Nouvel Hopital Civil, Strasbourg, France|Clinique Pasteur / GCVI, Toulouse, France|Kerckhoff-Klinik, Bad Nauheim, Germany|Herz und Gefaess Klinik, Bad Neustadt An Der Saale, Germany|Segeberger Kliniken, Bad Segeberg, Germany|Charite Universitatsmedizin Berlin, Berlin, Germany|Immanuel Klinikum Bernau Herzzentrum Brandenburg, Berlin, Germany|Gesundheit Nord gGmbH, Bremen, Germany|Klinikum der Stadt Ludwigshafen, Dortmund, Germany|St. Johannes - Hospital, Dortmund, Germany|Heart Center Dresden, University Clinic Technical University Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Elisabeth Krankenhaus Essen Klinik fur Kardiologie und Angiologie, Essen, Germany|Klinikum Fulda gAG, Fulda, Germany|Universitatsklinikum Halle (Saale), Halle, Germany|Asklepios St. Georg Abteilung fuer Kardiologie, Hamburg, Germany|Heidelberg University Hospital, Heidelberg, Germany|Universitaetsklinik Schleswig-Holstein Campus Kiel, Kiel, Germany|MediClin Herzzentrum Lahr/Baden, Lahr, Germany|Herzzentrum Leipzig, Leipzig, Germany|Universitatsmedizin Mainz, Zentrum fur Kardiologie, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Muenchen, Germany|Deutsches Herzzentrum Munchen, München, Germany|Universitatsklinikum Essen, Klinik fur Kardiologie, München, Germany|Klinikum Oldenburg AöR, Oldenburg, Germany|Uniklinikum Regensburg, Med II, Regensburg, Germany|Krankenhaus der Barmherzigen, Trier, Germany|Universitaetsklinikum Tuebingen Medizinische Klinik, Abteilung III, Tuebingen, Germany|Universitatsklinikum Ulm, Ulm, Germany|Helios Herzzentrum Wuppertal, Wuppertal, Germany|Universitatsklinikum Wurzburg, Würzburg, Germany|Ospedali Riuniti Torrette Di Ancona, Ancona, Italy|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|ASST Spedali Civili di Brescia-UO Cardiologia, Brescia, Italy|AOU Policlinico Vittorio Emanuele, Catania, Italy|Magna Graecia University, Catanzaro, Italy|Ospedale S. Croce e Carle, Cuneo, Italy|Citta di Lecce Hospital, Lecce, Italy|Azienda Socio Sanitaria Territoriale di Lecco, Lecco, Italy|ASST Ovest Milanese - Presidio Ospedallero di Legnana, Legnano, Italy|Fondazione Toscana Gabriele Monasterio, Massa, Italy|Ospedale San Raffaele, Milano, Italy|Centro Cardiologico Monzino IRCCS, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Clinica Mediterranea, Napoli, Italy|A.A Dei Colli Monaldi UOC Cardiologia Interventistica, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Centro Cuore Morgagni, Pedara, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|IRCCS-ASMN Reggio Emilia, Reggio Emilia, Italy|AO San Camillo Forlanini, Rome, Italy|Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy|AOU Careggi, Interventistica Cardiologica Strutturale, Rome, Italy|Ospedale Sant'Andrea - U.O.S. Emodinamica Cardiologia Interventistica, Rome, Italy|Istituto Clinico Humanitas, Rozzano, Italy|AOU S.Giovanni Di Dio e Ruggi D'Aragona, Salerno, Italy|IRCCS Policlinico San Donato, San Donato Milanese, Italy|UOC Emodinamica III, Siena, Italy|Azienda Ospedaliera Integrata di Verona, Verona, Italy|Nagoya Heart Center, Toyohashi, Aichi, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Ogaki Municipal Hospital, Ōgaki, Gifu, Japan|Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan|Tsukuba Medical Center Hospital, Amakubo, Ibaraki, Japan|Teikyo University Hospital, Tokyo, Itabashi, Japan|Iwate Medical University Hospital, Morioka, Iwate Prefecture, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka City University Hospital, Abeno Ward, Osaka, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Keio University Hospital, Shinjuku City, Tokyo, Japan|Toyohashi Heart Center, Aichi, Japan|New Tokyo Hospital, Chiba, Japan|Shonan Kamakura General Hospital, Kanagawa, Japan|Toyama University Hospital, Toyama, Japan|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of|Yonsei University Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of|Korean University Anam Hospital, Seoul, Seongbuk-gu, Korea, Republic of|Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of|Academic Medical Center, Amsterdam, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Białystok, Poland|University Clinical Centre in Gdańsk, Gdańsk, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland|Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain|Complexo hospitalario universitario de Santiago de Compostela, A Coruña, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinico y Provincial de Barcelona, Barcelona, Spain|Complejo Asistencial de Granada, Grenada, Spain|Complexo Hospitalario Universitario de A Coruna, La Coruña, Spain|Hospital La Luz QuironSalud, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Valdecilla Hospital, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Alvaro Cunqueiro, Vigo, Spain|Universitatsspital Basel, Basel, Switzerland|Bern University Hospital, Bern, Switzerland|Hopitaux Universitaires de Geneve, Geneve, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|BSUH, Cardiac Research Unit, Brighton, England, United Kingdom|Papworth Hospital NHS Foundation Trust, Cambridge, England, United Kingdom|Royal Edinburgh Infirmary, Edinburgh, England, United Kingdom|Guys St Thomas Hospital, London, England, United Kingdom|Trent Cardiac Centre, Nottingham, England, United Kingdom|Oxford University Hospitals, John Radcliffe Hospital, Oxford, England, United Kingdom|Northern General Hospital, Sheffield, England, United Kingdom|University Hospital of Wales, Heath Park, Cardiff, Wales, United Kingdom|University Hospitals of Leicester NHS Trust, Leicester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02943785"
929,"NCT01050361","Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery","EGHEM","Completed","No Results Available","Cardiovascular Risk Factors","Procedure: Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)","To use standard cardiac ultrasound-generated data points in addition to systemic blood pressure and ECG signal to assess, manage, modify, and optimize the patient cardiac preload, afterload, heart rate and contractility in the perioperative period.|To reduce perioperative morbidity and mortality associated with congestive heart failure for non-cardiac surgeries.|To evaluate and support the conclusion that echocardiography is a superior technology for identifying these changes and managing the unique cardiovascular challenges of the UNMC patient population.","University of Nebraska","All","19 Years to 100 Years   (Adult, Older Adult)","Phase 3","35","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","321-09-FB","June 2010","January 2013","January 2013","January 15, 2010",,"May 17, 2016","University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01050361"
930,"NCT03386539","Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score","TEAMMATE","Recruiting","No Results Available","Pediatric Heart Transplantation|Immunosuppression|Chronic Kidney Diseases|Cardiac Allograft Vasculopathy|Heart Transplant Failure and Rejection|Post-transplant Lymphoproliferative Disorder|Heart Transplant Infection","Drug: Everolimus|Drug: Tacrolimus|Drug: Mycophenolate Mofetil","EFFICACY: MATE-3 Score|SAFETY: MATE-6 Score|Efficacy: Overall patient survival|Efficacy: Overall allograft survival|Efficacy: Change in kidney function|Efficacy: Freedom from CKD event|Efficacy: Freedom from CAV event|Efficacy: Freedom from BP-ACR event|Efficacy: Freedom from composite failure|Efficacy: Lansky and Karnofsky scores|Efficacy: EuroQOL EQ-5D Y (Youth Version)|Safety: Freedom from AMR|Safety: Freedom from infection|Safety: Freedom from PTLD|Safety: Frequency and incidence of adverse events including, but not limited to, hyperlipidemia, anemia, thrombocytopenia, interstitial lung disease, aphthous stomatitis, proteinuria, and rash|Safety: Freedom from Major Transplant Events (Composite)|Safety: Freedom from Level 2 severity CKD Event|Safety: Freedom from Level 2 severity CAV Event|Safety: Freedom from Level 2 severity ACR Event|Safety: Freedom from Level 2 severity AMR Event|Safety: Freedom from Level 2 severity Infection Event|Safety: Freedom from Level 2 severity PTLD Event","Boston Children’s Hospital|Stanford University|United States Department of Defense","All","up to 21 Years   (Child, Adult)","Phase 3","210","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P00025970|PR160574|IND 127980","January 29, 2018","September 2022","September 2022","December 29, 2017",,"February 10, 2020","Children's of Alabama, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Loma Linda University, Loma Linda, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|UCLA Mattel Children's Hospital, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Congenital Heart Center, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Children's Healthcare of Atlanta Emory, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Children's Hospital of New York, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Children's Health Dallas University of Texas Southwestern, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03386539"
931,"NCT01808456","Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.",,"Completed","No Results Available","Influenza, Human|Transplantation Infection","Biological: influenza trivalent inactive vaccine|Biological: influenza trivalent inactive vaccine high dose","Number of patients with local or systemic reactions|Measurement of strain-specific hemagglutination inhibition (HI) antibody titers|All cause hospitalization|All cause ED visits/unscheduled clinic visits|Evaluate seroconversion and seroprotection rates","Inova Health Care Services","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","IFH20132015","October 2013","December 2016","December 2016","March 11, 2013",,"March 13, 2018","Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01808456"
932,"NCT01263197","A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",,"Completed","Has Results","Major Depressive Disorder","Drug: LY2216684|Drug: albuterol|Drug: propranolol|Drug: placebo for LY2216684|Drug: placebo for albuterol|Drug: placebo for propranolol","Maximum, Minimum and Average Changes in Heart Rate|Maximum, Minimum and Average Changes in Systolic Blood Pressure|Maximum, Minimum and Average Changes in Diastolic Blood Pressure","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12598|H9P-EW-LNCI","December 2010","March 2011","March 2011","December 20, 2010","October 22, 2018","January 29, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01263197"
933,"NCT02471183","Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension","TRANSIT-1","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Selexipag","Percentage of Subjects With Sustained Treatment Transition|Percentage of Subjects With Treatment-emergent Adverse Events (AEs),|Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag|Absolute Change From Baseline Over Time in Blood Pressure|Absolute Change From Baseline Over Time in Heart Rate (HR)|Maximal Tolerated Dose|Time to Discontinuation of Inhaled Treprostinil.|Percentage of Subjects With WHO Functional Class (FC) Change From Baseline|Absolute Change in 6-minute Walk Distance (6MWD) at Trough|Percentage of Patients With Change in 6-minute Walk Distance (6MWD)|Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A304","October 12, 2015","December 5, 2016","December 5, 2016","June 15, 2015","December 28, 2017","January 23, 2018","UCSD Medical Center -La Jolla, La Jolla, California, United States|UCSF Medical Center, San Francisco, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Emory University, Atlanta, Georgia, United States|Piedmont Healthcare Research Institute, Austell, Georgia, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke Unversity, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Sentara Cardiovascular Research Instistute, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02471183"
934,"NCT03924154","A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: RVT-1201|Drug: Placebo","Adverse events (AEs) and discontinuations due to AEs|Concentration of biomarkers of serotonin biosynthesis in plasma|Concentration of biomarkers of serotonin biosynthesis in urine|Study drug (RVT-1201) and active metabolite (KAR5417) plasma concentrations|Area under the plasma concentration versus time curve (AUC) of KAR5417 (the active metabolite of RVT-1201)|Relationship between KAR5417 exposure and percent change from baseline in plasma concentrations of the serotonin-related biomarkers|Relationship between KAR5417 exposure and percent change from baseline in urine concentrations of the serotonin-related biomarkers","Altavant Sciences GmbH|Altavant Sciences, Inc.|PPD","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","3","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RVT-1201-2001","August 1, 2019","February 24, 2020","February 24, 2020","April 23, 2019",,"March 9, 2020","Pulmonary Associates, PA, Phoenix, Arizona, United States|University of California Davis Medical Center, Sacramento, California, United States|SBPA Research LLC, Santa Barbara, California, United States|University of Colorado, Aurora, Colorado, United States|George Washington Medical Faculty Associates - Pulmonary Hypertension Program, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States|Central Florida Pulmonary Group, P.A., Orlando, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States|University of Calgary, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03924154"
935,"NCT01665508","Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease","NIRVANA","Completed","Has Results","Microvascular Angina","Drug: Nebivolol","Seattle Angina Questionnaire Score|Peak VO2 Measured by Cardiopulmonary Exercise Testing|Resource Utilization Questionnaire|SF36|Exercise Duration|Peak Heart Rate as Measured by Cardiopulmonary Exercise Testing|Peak O2 Pulse","Massachusetts General Hospital|Forest Laboratories","Female","40 Years to 80 Years   (Adult, Older Adult)","Phase 4","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BYS-IT-75","April 2013","May 2015","May 2015","August 15, 2012","April 20, 2017","April 20, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01665508"
936,"NCT02924727","Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","PARADISE-MI","Recruiting","No Results Available","Acute Myocardial Infarction","Drug: LCZ696 (sacubitril/valsartan)|Drug: Ramipril|Drug: Placebo of LCZ696|Drug: Placebo of ramipril|Drug: Valsartan|Drug: Placebo of valsartan","Time to the first occurrence of a confirmed composite endpoint|Time to the first occurrence of a confirmed composite of CV death or HF hospitalization|Time to the first occurrence of a confirmed composite of HF hospitalization or outpatient HF|Time to the first occurrence of a confirmed composite of CV death, non-fatal spontaneous myocardial infarction or non-fatal stroke|Total number of recurrent confirmed composite endpoints|Time to all-cause mortality","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","5650","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCZ696G2301|2016-002154-20","December 9, 2016","May 14, 2021","May 14, 2021","October 5, 2016",,"April 10, 2020","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Bakersfield, California, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Carmichael, California, United States|Novartis Investigative Site, Huntington Beach, California, United States|Novartis Investigative Site, Los Alamitos, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Santa Rosa, California, United States|Novartis Investigative Site, Sylmar, California, United States|Novartis Investigative Site, Brandon, Florida, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Daytona Beach, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville Beach, Florida, United States|Novartis Investigative Site, Jacksonville Beach, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Cumming, Georgia, United States|Novartis Investigative Site, Thomasville, Georgia, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Coeur d'Alene, Idaho, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Merrillville, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Munster, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, Davenport, Iowa, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Hammond, Louisiana, United States|Novartis Investigative Site, Slidell, Louisiana, United States|Novartis Investigative Site, Bangor, Maine, United States|Novartis Investigative Site, Annapolis, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Rockville, Maryland, United States|Novartis Investigative Site, Springfield, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Grand Blanc, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Midland, Michigan, United States|Novartis Investigative Site, Petoskey, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Flushing, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Poughkeepsie, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Valhalla, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Greenville, North Carolina, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Clackamas, Oregon, United States|Novartis Investigative Site, Medford, Oregon, United States|Novartis Investigative Site, Camp Hill, Pennsylvania, United States|Novartis Investigative Site, Erie, Pennsylvania, United States|Novartis Investigative Site, Hershey, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, York, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Webster, Texas, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Danville, Virginia, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Lynchburg, Virginia, United States|Novartis Investigative Site, Manassas, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Bellevue, Washington, United States|Novartis Investigative Site, Everett, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Manitowoc, Wisconsin, United States|Novartis Investigative Site, Waukesha, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, Argentina|Novartis Investigative Site, Tucuman, San Miguel De Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, San Luis, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Chemside, Queensland, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Braunau, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, St Poelten, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Turnhout, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Uberlandia, Minas Gerais, Brazil|Novartis Investigative Site, Curitiba, Parana, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Blumenau, SC, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Campina Grande do Sul, Brazil|Novartis Investigative Site, Sao Jose, Brazil|Novartis Investigative Site, Burgas, BGR, Bulgaria|Novartis Investigative Site, Sofia, BGR, Bulgaria|Novartis Investigative Site, Blagoevgrad, Bulgaria|Novartis Investigative Site, Burgas, Bulgaria|Novartis Investigative Site, Gabrovo, Bulgaria|Novartis Investigative Site, Kardzhali, Bulgaria|Novartis Investigative Site, Pernik, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Ruse, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, Terrebonne, Quebec, Canada|Novartis Investigative Site, Trois Rivieres, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Xicheng, Beijing, China|Novartis Investigative Site, Lanzhou, Gansu, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shijiazhuang, Hebei, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Yanji, Jilin, China|Novartis Investigative Site, Shengyang, Liaoning, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Jinshan, Shanghai, China|Novartis Investigative Site, Shanghai City, Shanghai, China|Novartis Investigative Site, Xian, Shanxi, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Wenzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Wuhan, China|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Bucaramanga, Santander, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Zagreb, HRV, Croatia|Novartis Investigative Site, Cakovec, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Kladno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Ostrava, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Brno Bohunice, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Plzen-Bory, Czechia|Novartis Investigative Site, Prague 4, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Slany, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Glostrup, Denmark|Novartis Investigative Site, Hellerup, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Svendborg, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, HUS, Finland|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Kaupio, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Chambray les Tours, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Marseille Cedex 8, France|Novartis Investigative Site, Paris cedex 18, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Coburg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Guetersloh, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Hennigsdorf, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln-Nippes, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Langen, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leverkusen, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Moenchengladbach, Germany|Novartis Investigative Site, Neuss, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Riesa, Germany|Novartis Investigative Site, Ruesselsheim, Germany|Novartis Investigative Site, Stadtlohn, Germany|Novartis Investigative Site, Vechta, Germany|Novartis Investigative Site, Villingen-Schwenningen, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Alexandroupolis, Evros, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Pecs, Baranya, Hungary|Novartis Investigative Site, Zalaegerszeg, Zala, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szekesfehervar, Hungary|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Vadodara, Gujarat, India|Novartis Investigative Site, Karamsad, Gujrat, India|Novartis Investigative Site, Gurgaon, Haryana, India|Novartis Investigative Site, Kochi, Kerala, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Madurai, Tamil NADU, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Secunderabad, Telangana, India|Novartis Investigative Site, DehraDun, Uttarakhand, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Lower Galilee, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Sefad, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Catanzaro, CZ, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Sanremo, IM, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Rimini, RN, Italy|Novartis Investigative Site, Trieste, TS, Italy|Novartis Investigative Site, Saronno, VA, Italy|Novartis Investigative Site, Grosseto, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Wonju, Gangwon-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Gwangju, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Torreon, Coahulia, Mexico|Novartis Investigative Site, Culiacan Sinaloa, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Zapopan, Jalisco, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico|Novartis Investigative Site, Queretaro, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Sneek, The Netherlands, Netherlands|Novartis Investigative Site, Alkmaar, Netherlands|Novartis Investigative Site, Almelo, Netherlands|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Beverwijk, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Heemstede, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiderdorp, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Schiedam, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Uden, Netherlands|Novartis Investigative Site, Veldhoven, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Zutphen, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Gralum, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Bellavista, Lima, Peru|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Iloilo city, Iloilo, Philippines|Novartis Investigative Site, Quezon City, Manila, Philippines|Novartis Investigative Site, Manila, Metro Manila, Philippines|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Lubin, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Carnaxide, Lisboa, Portugal|Novartis Investigative Site, Almada, Portugal|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Covilha, Portugal|Novartis Investigative Site, Faro, Portugal|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Leiria, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Vila Real, Portugal|Novartis Investigative Site, Pitesti, Arges, Romania|Novartis Investigative Site, Bucuresti, District 4, Romania|Novartis Investigative Site, Oradea, Jud Bihor, Romania|Novartis Investigative Site, Cluj Napoca, Jud Cluj, Romania|Novartis Investigative Site, Iasi, Jud Iasi, Romania|Novartis Investigative Site, Targu Mures, Mures, Romania|Novartis Investigative Site, Braila, ROM, Romania|Novartis Investigative Site, Suceava, ROM, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Arad, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Brasov, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Sibiu, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Murmansk, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, Rostov on Don, Russian Federation|Novartis Investigative Site, S.-Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Sestroretsk, Russian Federation|Novartis Investigative Site, Sochy, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tomsk, Russian Federation|Novartis Investigative Site, Yekaterinburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Liptovsky Mikulas, Slovak Republic, Slovakia|Novartis Investigative Site, Nitra, Slovak Republic, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovak Republic, Slovakia|Novartis Investigative Site, Banska Bystrica, SVK, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Pinelands, Cape Town, South Africa|Novartis Investigative Site, Bloemfontein, Free State, South Africa|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, Worcester, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Badalona, Barcelona, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Leon, Castilla Y Leon, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, El Palmar (Murcia), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Stockholm, SE, Sweden|Novartis Investigative Site, Falun, Sweden|Novartis Investigative Site, Gothenburg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Malmo, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Luzern 16, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, New Taipei, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Yilan, Taiwan|Novartis Investigative Site, Bangkok, THA, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Eskisehir, Meselik, Turkey|Novartis Investigative Site, Ankara-Cankaya, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Kucukcekmece/Istanbul, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Basingstoke, Hampshire, United Kingdom|Novartis Investigative Site, Blackburn, Lancashire, United Kingdom|Novartis Investigative Site, Lincoln, Lincolnshire, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom|Novartis Investigative Site, Paisley, Renfrewshire, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Clydebank, West Dumbartonshire, United Kingdom|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, Middlesborough, United Kingdom|Novartis Investigative Site, Middlesex, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02924727"
937,"NCT02132767","Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation",,"Completed","Has Results","Postoperative Atrial Fibrillation","Drug: Amiodarone|Procedure: DC-cardioversion|Drug: Rate Control","Total Number of Days in Hospital|Time to Conversion to Sustained, Stable Non-AF Rhythm|Heart Rhythm Comparison|Length of Stay (Index Hospitalization)|Length of Stay (Rehospitalization, Including ED Visits)|Outpatient Interventions|AF- or Treatment-related Events|Cost (Hospital)","Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Neurological Disorders and Stroke (NINDS)|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 3","523","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 08-1078-00007|5U01HL088942-08","May 2014","September 2015","September 2015","May 7, 2014","January 18, 2017","March 15, 2019","University of Southern California, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Maryland, Baltimore, Maryland, United States|NIH Heart Center at Suburban Hospital, Bethesda, Maryland, United States|University of Michigan Health Services, Ann Arbor, Michigan, United States|Montefiore Einstein Heart Center, Bronx, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor Research Institute, Plano, Texas, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|Institut Universitaire de Cardiologie de Quebec (Hopital Laval), Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02132767"
938,"NCT03556020","Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC PB1046 in Subjects With Symptomatic PAH","VIP","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: PB1046","Incidence and severity of AEs|Incidence of Clinical Laboratory Abnormalities|Changes in Diastolic Blood Pressure|Changes in Systolic Blood Pressure|Changes in Oral Body Temperature|Changes in Respiratory Rate|Changes in Heart Rate|12-Lead ECG - Incidence of clinically significant findings|Immunogenicity|Change in baseline in pulmonary vascular resistance (PVR)|Change from baseline in 6MWD|Change from baseline in NT-proBNP|Change from baseline in cardiac index (CI)|Change from baseline in mean pulmonary artery pressure (mPAP)|Change from baseline in mean right atrial pressure (mRAP)|Change from baseline in wedge pressure|Change from baseline in mixed venous oxygen saturation (SvO2)|Change from baseline in pulmonary artery compliance","PhaseBio Pharmaceuticals Inc.","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PB1046-PT-CL-0004","July 15, 2018","December 31, 2021","December 31, 2021","June 14, 2018",,"February 25, 2020","IMC - Diagnostic & Medical Clinic, LLC, Mobile, Alabama, United States|University of California, San Diego (UCSD), La Jolla, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of California-Davis, Sacramento, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|The University Miami Health Hospital, Miami, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Dept of Internal Medicine, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Tufts University, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|The Linder Center for Resarch and Education at The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Memorial Hermann Hospital CRU affiliated with University of Texas Health Science Center at Houston - McGovern Medical School, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03556020"
939,"NCT03180593","Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH","BVreduce","Completed","No Results Available","Hypertension Complicated|Hypertrophy, Left Ventricular|Blood Pressure","Drug: Valsartan 80 mg","LVH reduction at 4 weeks.|24hr-ABPM measurement Change from baseline in mean 24 hour ABPM SBP|LVH reduction at 8 weeks.|24hr-Systolic ABPM measurement|24hr- DBP ABPM measurements|Office Blood Pressure measurements","Trinity Hypertension & Metabolic Research Institute|Allergan Sales, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","BYS-IT-78","February 7, 2017","January 25, 2018","January 25, 2018","June 8, 2017",,"April 11, 2018","Trinity Hypertension & Metabolic Research Institute, Carrollton, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03180593"
940,"NCT02451007","Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors",,"Completed","Has Results","Solid Tumors","Drug: lurbinectedin (PM01183)","Change in QTcF (QT Corrected According to Fridericia's Formula)|Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Plasma Concentration)|Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Predicted ΔQTcF)|Relationship Between ΔQTcF and Time-matched Lurbinectedin Plasma Concentrations (Intercept)","PharmaMar","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2","39","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","PM1183-B-005-14-QT","August 12, 2015","August 19, 2016","August 19, 2016","May 21, 2015","February 18, 2019","November 19, 2019","Sarcoma Oncology Research Center, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Dana Farber Cancer lnstitute, Boston, Massachusetts, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain|Complejo Hospitalario de Especialidades Virgen de La Victoria, Málaga, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02451007"
941,"NCT01264783","Safety and Tolerability of RNS60 Given by IV to Healthy Subjects",,"Completed","No Results Available","Myocardial Infarct","Drug: RNS60|Drug: Placebo","Tolerability|Biomarkers","Revalesio Corporation","Male","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11.1.1.H1","July 2011","September 2011","September 2011","December 22, 2010",,"October 4, 2011","Quintiles, Inc., Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01264783"
942,"NCT03066804","A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","PARALLAX","Completed","No Results Available","Heart Failure With Preserved Ejection Fraction","Drug: sacubitril/valsartan|Drug: Enalapril|Drug: Valsartan|Drug: Placebo to match sacubitril/valsartan|Drug: Placebo to match enalapril|Drug: Placebo to match valsartan","Change from baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP) at Week 12|Change from baseline in 6 minute walk distance (6MWD) at Week 24|Mean change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24|Percentage of patients with ≥ 5-points deterioration in KCCQ CSS at Week 24|Percentage of patients with ≥ 5-points improvement in KCCQ CSS at Week 24|Change from baseline in NYHA functional class at Week 24|Change from baseline in SF-36 physical component summary (PCS) score score at week 24","Novartis Pharmaceuticals|Novartis","All","45 Years and older   (Adult, Older Adult)","Phase 3","2569","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCZ696D2302|2016-003410-28","August 22, 2017","October 28, 2019","November 5, 2019","February 28, 2017",,"March 16, 2020","Novartis Investigative Site, Andalusia, Alabama, United States|Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Santa Ana, California, United States|Novartis Investigative Site, Sylmar, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Novartis Investigative Site, Covington, Georgia, United States|Novartis Investigative Site, Thomasville, Georgia, United States|Novartis Investigative Site, Arlington Heights, Illinois, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Alexandria, Louisiana, United States|Novartis Investigative Site, Chalmette, Louisiana, United States|Novartis Investigative Site, Houma, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Hattiesburg, Mississippi, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Nashua, New Hampshire, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Kettering, Ohio, United States|Novartis Investigative Site, Marion, Ohio, United States|Novartis Investigative Site, Corvallis, Oregon, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Lufkin, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Tomball, Texas, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, Argentina|Novartis Investigative Site, Tucuman, San Miguel De Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, San Luis, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Braunau, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Hall in Tirol, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Heusden-Zolder, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Curitiba, Parana, Brazil|Novartis Investigative Site, Canoas, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Blumenau, SC, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Burgas, Bulgaria|Novartis Investigative Site, Pazardzhik, Bulgaria|Novartis Investigative Site, Pernik, Bulgaria|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Veliko Tarnovo, Bulgaria|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Oakville, Ontario, Canada|Novartis Investigative Site, Levis, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, St-Georges Beauce, Quebec, Canada|Novartis Investigative Site, Medellin, Antioquia, Colombia|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogota DC, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, San Gil, Colombia|Novartis Investigative Site, Brandys nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Cesky Krumlov, Czech Republic, Czechia|Novartis Investigative Site, Jablonec nad Nisou, Czech Republic, Czechia|Novartis Investigative Site, Kromeriz, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Louny, Czech Republic, Czechia|Novartis Investigative Site, Ostrava, Czech Republic, Czechia|Novartis Investigative Site, Pardubice, Czech Republic, Czechia|Novartis Investigative Site, Plzen, Czech Republic, Czechia|Novartis Investigative Site, Roznov pod Radhostem, Czech Republic, Czechia|Novartis Investigative Site, Svitavy, Czech Republic, Czechia|Novartis Investigative Site, Tabor, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, JIhlava, CZE, Czechia|Novartis Investigative Site, Policska, CZE, Czechia|Novartis Investigative Site, Karvina, Czechia|Novartis Investigative Site, Kolin, Czechia|Novartis Investigative Site, Olomouc Lazce, Czechia|Novartis Investigative Site, Prerov, Czechia|Novartis Investigative Site, Valasske Mezirici, Czechia|Novartis Investigative Site, Copenhagen NV, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Randers, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, CAEN Cedex, France|Novartis Investigative Site, Chambray les Tours, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Le Coudray, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Rennes Cedex 9, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Winnenden, Baden Wuerttemberg, Germany|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Dachau, DEU, Germany|Novartis Investigative Site, Essen, DEU, Germany|Novartis Investigative Site, Detmold, NRW, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Bad Homburg, Germany|Novartis Investigative Site, Bad Oeynhausen, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Berlin Buch, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum Wattenscheid, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Brueel, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Coburg, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Fuerth, Germany|Novartis Investigative Site, Fulda, Germany|Novartis Investigative Site, Halle Saale, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hassloch, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln-Nippes, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Lüneburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muehldorf, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Munich, Germany|Novartis Investigative Site, Neuruppin, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Nuremberg, Germany|Novartis Investigative Site, Papenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Riesa, Germany|Novartis Investigative Site, Riesa, Germany|Novartis Investigative Site, Rodgau, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Rotenburg an der Fulda, Germany|Novartis Investigative Site, Ruesselsheim, Germany|Novartis Investigative Site, Schwaebisch Hall, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Stadtlohn, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wallerfing, Germany|Novartis Investigative Site, Wedel, Germany|Novartis Investigative Site, Wismar, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Guatemala, Guatemala|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Mosanmagyarovar, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Vadodara, Gujarat, India|Novartis Investigative Site, Manipal, Karnataka, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Nashik, Maharastra, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, India, India|Novartis Investigative Site, Ashkelon, Israel|Novartis Investigative Site, Be'er Sheva, Israel|Novartis Investigative Site, Hadera, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Cortona, AR, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Legnano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Sesto San Giovanni, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Rovigo, RO, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Saronno, Va, Italy|Novartis Investigative Site, Cona, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, San Vito al Tagliamento, Italy|Novartis Investigative Site, Liepaja, LVA, Latvia|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Ogre, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Klaipeda, Klaipedos Apskritis, Lithuania|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Queretaro, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Almelo, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Doetinchem, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hardenberg, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Stadskanaal, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Venlo, Netherlands|Novartis Investigative Site, Trujillo, La Libertad, Peru|Novartis Investigative Site, Cercado De Lima, Lima, Peru|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Callao, Peru|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Penafiel, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Viana do Castelo, Portugal|Novartis Investigative Site, Vila Real, Portugal|Novartis Investigative Site, Ponce, Puerto Rico|Novartis Investigative Site, Bucuresti, District 4, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Timisoara, Timis, Romania|Novartis Investigative Site, Bacau, Romania|Novartis Investigative Site, Baia Mare, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Pitesti, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Targu Mures, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Tirgoviste, Romania|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Gatchina, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Rostov on Don, Russian Federation|Novartis Investigative Site, Rostov on Don, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Yekaterinburg, Russian Federation|Novartis Investigative Site, Belgrade, Serbia|Novartis Investigative Site, Kragujevac, Serbia|Novartis Investigative Site, Niska Banja, Serbia|Novartis Investigative Site, Nis, Serbia|Novartis Investigative Site, Sremska Kamenica, Serbia|Novartis Investigative Site, Namestovo, Slovak Republic, Slovakia|Novartis Investigative Site, Presov, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, SVK, Slovakia|Novartis Investigative Site, Handlova, SVK, Slovakia|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bardejov, Slovakia|Novartis Investigative Site, Bardejov, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Dolny Kubin, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Lucenec, Slovakia|Novartis Investigative Site, Moldava nad Bodvou, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Nove Zamky, Slovakia|Novartis Investigative Site, Povazska Bystrica, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Snina, Slovakia|Novartis Investigative Site, Svidnik, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Huelva, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Puerto Real, Cadiz, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Lerida, Cataluna, Spain|Novartis Investigative Site, Torrevieja (Alicante), Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, A Coruna, Galicia, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Manises, Valencia, Spain|Novartis Investigative Site, Alicante, Spain|Novartis Investigative Site, Las Palmas De Gran Canarias, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Muang, Thailand|Novartis Investigative Site, Ubon Ratchathani, Thailand|Novartis Investigative Site, Eskisehir, Meselik, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Aydin, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mersin, Turkey|Novartis Investigative Site, Sivas, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, High Wycombe, Buckinghamshire, United Kingdom|Novartis Investigative Site, Stockton on Tees, Cleveland, United Kingdom|Novartis Investigative Site, Chesterfield, Derbyshire, United Kingdom|Novartis Investigative Site, Craigavon, Northern Ireland, United Kingdom|Novartis Investigative Site, Wansford, Peterborough, United Kingdom|Novartis Investigative Site, Addlestone, Surrey, United Kingdom|Novartis Investigative Site, Sunderland, Tyne And Wear, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03066804"
943,"NCT03594110","EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)",,"Recruiting","No Results Available","Chronic Kidney Disease","Drug: Empagliflozin|Drug: Matching placebo","Composite primary outcome:Time to first occurrence of (i) kidney disease progression (defined as ESKD, a sustained decline in eGFR to <10 mL/min/1.73m², renal death, or a sustained decline of ≥40% in eGFR from randomization) or (ii) Cardiovascular death|Time to first hospitalization for heart failure or cardiovascular death|Time to occurrences of all-cause hospitalizations (first and recurrent combined)|Time to death from any cause|Time to first occurrence of kidney disease progression|Time to cardiovascular death|Time to cardiovascular death or ESKD","Boehringer Ingelheim|Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","6000","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1245-0137|2017-002971-24","January 25, 2019","June 2, 2022","June 30, 2022","July 20, 2018",,"April 15, 2020","Nephrology Consultants, LLC, Huntsville, Alabama, United States|Southern California Permanente Medical Group, San Diego, California, United States|University of California Los Angeles, Sylmar, California, United States|University of California Los Angeles, Torrance, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|East Coast Clinical Research, Inc, Lake City, Florida, United States|Hanson Clinical Research Center, Port Charlotte, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States|The Jones Center for Diabetes and Endocrine Wellness, Macon, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Saint Elizabeth Healthcare, Covington, Kentucky, United States|Lexington VA Health Care System - Troy Bowling Campus, Lexington, Kentucky, United States|Kidney Care and Transplant Services of New England, PC, Springfield, Massachusetts, United States|Saint Clair Specialty Physicians, Roseville, Michigan, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Seacoast Kidney and Hypertension Specialists, Portsmouth, New Hampshire, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Mountain Kidney and Hypertension Associates, PA, Asheville, North Carolina, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Brookview Hills Research Associates LLC, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Carolina Diabetes & Kidney Center, Sumter, South Carolina, United States|Regional Health Clinical Research, Rapid City, South Dakota, United States|Research Institute of Dallas, Dallas, Texas, United States|Renal Disease Research Institute, Dallas, Texas, United States|Academy Of Diabetes, Thyroid And Endocrine, PA, El Paso, Texas, United States|Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, United States|Clinical Advancement Center PLLC, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|Kelowna General Hospital, Kelowna, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|LMC Clinical Research Inc. (Brampton), Brampton, Ontario, Canada|Cambridge Cardiac Care Inc., Cambridge, Ontario, Canada|LMC Clinical Research Inc. (Thornhill), Concord, Ontario, Canada|Clinical Research Solutions Inc., Kitchener, Ontario, Canada|London Health Science Centre, University Campus, London, Ontario, Canada|LMC Clinical Research Inc. (Ottawa), Nepean, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Fadia El Boreky Medicine Professional, Waterloo, Ontario, Canada|Montreal Clinical Research Institute (IRCM), Montreal, Quebec, Canada|Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval Research Centre, Quebec, Canada|IUCPQ (Laval University), Quebec, Canada|Jinling Hospital, Nanjing, China|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Universitätsklinikum Augsburg, Augsburg, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Bad Oeynhausen, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Ärztezentrum Helle Mitte, Berlin, Germany|Klinikum Bielefeld gGmbH, Bielefeld, Germany|Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Frankfurt, Germany|Nierenzentrum Freiburg, Freiburg, Germany|Nephrologisches Zentrum Göttingen, Göttingen, Germany|Universitätsklinikum Halle/S., Halle, Germany|Zentrum für Nieren-, Hochdruck und Stoffwechselerkrankungen, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Dialysezentrum Heilbronn ÜBAG für Nephrologie und Dialyse, Heilbronn, Germany|Nephrologisches Zentrum Hoyerswerda, Hoyerswerda, Germany|Universitätsklinikum Jena, Jena, Germany|Städt. Klinikum, Karlsruhe, Moltkestr., Karlsruhe, Germany|Klinikum St. Georg gGmbH, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Nephrologisches Zentrum Mettmann, Mettmann, Germany|Klinikum der Universität München - Campus Innenstadt, München, Germany|Dialysezentrum Neckarsulm, Neckarsulm, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Nürnberg, Germany|MVZ Diaverum Potsdam, Potsdam, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Nephrologisches Zentrum Velbert, Velbert, Germany|MVZ DaVita Viersen GmbH, Viersen, Germany|Nephrologisches Zentrum Villingen-Schwenningen, Villingen-Schwenningen, Germany|Gemeinschaftspraxis für Nephrologie und Rheumatologie, Wiesbaden, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Chubu Rosai Hospital, Aichi, Nagoya, Japan|Aichi Medical University Hospital, Aichi, Japan|Fukui Prefectural Hospital, Fukui City, Japan|Fukuoka University Hospital, Fukuoka, Fukuoka, Japan|Maebashi Hirosegawa Clinic, Gunma, Japan|Ota Diabetes Clinic, Gunma, Japan|University of Tsukuba Hospital, Ibaraki, Tsukuba, Japan|Medical Corporation Seijinkai Ikeda Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|Koukan Clinic, Kawasaki, Japan|Kobe University Hospital, Kobe, Japan|Tohoku University Hospital, Miyagi, Sendai, Japan|Nagoya University Hospital, Nagoya, Japan|Kawasaki Medical School Hospital, Okayama, Kurashiki, Japan|Okayama University Hospital, Okayama, Okayama, Japan|AMC Nishi-umeda Clinic, Osaka, Japan|Kansai Electric Power Hospital, Osaka, Japan|Iwasaki Internal Medicine Clinic, Osaka, Japan|Shiga University of Medical Science Hospital, Shiga, Otsu, Japan|Juntendo University Hospital, Tokyo, Bunkyo-ku, Japan|The University of Tokyo Hospital, Tokyo, Bunkyo-ku, Japan|Shin Clinic, Tokyo, Ota-ku, Japan|Global Health and Medicine Ctr, Tokyo, Shinjuku-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Japan|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Ampang, Ampang, Malaysia|University Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia|Hospital Pulau Pinang, Georgetown, Pulau Pinang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Sultanah Aminah, Johor Bahru, Malaysia|Hospital Kajang, Kajang, Selangor, Malaysia|Hospital Serdang, Kajang, Selangor, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Trengganu, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Kulim, Kulim, Kedah, Malaysia|Hospital Melaka, Melaka, Malaysia|Hospital Pakar Sultanah Fatimah, Muar, Malaysia|Hospital Selayang, Selangor, Malaysia|Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan, Malaysia|Pusat Perubatan UiTM Jalan Hospital, Sungai Buloh, Malaysia|Hospital Sultan Abdul Halim, Sungai Petani, Malaysia|Hospital Taiping, Taiping, Perak, Malaysia|Antrim Area Hospital, Antrim, United Kingdom|Ulster Hospital, Belfast, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Oakenhurst Medical Practice, Blackburn, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Southmead Hospital, Bristol, United Kingdom|West Suffolk Hospital, Bury St Edmunds, United Kingdom|Kent & Canterbury Hospital, Oncology Department, Canterbury, Canterbury, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|St Helier Hospital, Carshalton, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darent Valley Hospital, Chemotherapy Unit, Dartford, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Queen Elizabeth Hospital, King's Lynn, United Kingdom|Victoria Hospital, Kirkcaldy, United Kingdom|St James's University Hospital, Leeds, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|Royal London Hospital, London, United Kingdom|North Middlesex Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Newcastle Urology & Renal Research Office, Newcastle, United Kingdom|Daisy Hill Hospital, Newry, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|St Bartholomew's Medical Centre (OxFed), Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Wessex Kidney Centre, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Queen's Hospital, Romford, United Kingdom|Salford Royal Hospital, Salford, United Kingdom|Northern General Hospital, Sheffield, United Kingdom|University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom|Great Western Hospital, Swindon, United Kingdom|Princess Royal Hospital, Telford, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03594110"
944,"NCT03483051","Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)","PULSE-AS","Completed","Has Results","Aortic Valve Stenosis","Drug: Potassium Nitrate|Drug: Potassium Chloride","Total Work Performed During a Maximal-effort Exercise Test|Peak Oxygen Uptake (VO2) During a Maximal Effort Exercise Test|Quality of Life Score|Systemic Vasodilator Response to Exercise|Left Ventricle Diastolic Function|Myocardial Systolic Strain|Late Systolic Left Ventricle Load","University of Pennsylvania","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","828994","May 1, 2018","March 13, 2019","May 23, 2019","March 29, 2018","February 26, 2020","March 11, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03483051/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03483051/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03483051"
945,"NCT01225562","Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","PEGASUS","Completed","Has Results","Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke","Drug: Ticagrelor 90 mg|Drug: Ticagrelor 60 mg|Drug: Ticagrelor Placebo","Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization|Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","21379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D5132C00001|2009-017242-30","October 2010","December 2014","December 2014","October 21, 2010","December 9, 2015","January 25, 2016","Research Site, Alexander City, Alabama, United States|Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site, Fountain Valley, California, United States|Research Site, La Mesa, California, United States|Research Site, Larkspur, California, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Modesto, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oakland, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, San Marino, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Ventura, California, United States|Research Site, Westlake Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Davie, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona, Florida, United States|Research Site, Ft Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pannama City, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, The Villages, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Aurora, Illinois, United States|Research Site, Bannockburn, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Minden, Louisiana, United States|Research Site, New Iberia, Louisiana, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, S Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Lapeer, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Baxter, Minnesota, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, St Cloud, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Papillion, Nebraska, United States|Research Site, Reno, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Linden, New Jersey, United States|Research Site, Mine Hill, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Southampton, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Fairfield, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, West Chester, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Florence, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Grapevine, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, MC Allen, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Provo, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Everett, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Bahia Blanca, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de BA, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Coronel Suarez, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Haedo, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario Santa Fe, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolas, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Santa Fe, Argentina|Research Site, Santa Fé, Argentina|Research Site, Tucuman, Argentina|Research Site, Tucumán, Argentina|Research Site, Zarate, Argentina|Research Site, Adelaide, Australia|Research Site, Ashford, Australia|Research Site, Auchenflower, Australia|Research Site, Ballarat, Australia|Research Site, Bruce, Australia|Research Site, Chermside, Australia|Research Site, Clayton, Australia|Research Site, Concord, Australia|Research Site, East St Kilda, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Epping, Australia|Research Site, Fremantle, Australia|Research Site, Geelong, Australia|Research Site, Gosford, Australia|Research Site, Greenslopes, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Kingswood, Australia|Research Site, Kogorah, Australia|Research Site, Launceston, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton Heights, Australia|Research Site, Richmond, Australia|Research Site, St Leonards, Australia|Research Site, Wollongong, Australia|Research Site, Woodville, Australia|Research Site, Woolloongabba, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Bouge, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Mechelen, Belgium|Research Site, Mol, Belgium|Research Site, Ottignies, Belgium|Research Site, Roeselare, Belgium|Research Site, Tienen, Belgium|Research Site, Turnhout, Belgium|Research Site, Yvoir, Belgium|Research Site, Zottegem, Belgium|Research Site, Aracaju, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasília, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Maceio, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S.J.Rio Preto, Brazil|Research Site, Salvador, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Uberlândia, Brazil|Research Site, Votuporanga, Brazil|Research Site, Dimitrovgrad, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, St-Lambert, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Thetford Mines, Quebec, Canada|Research Site, Val d'Or, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Osorno, Chile|Research Site, Rancagua, Chile|Research Site, Santiago Centro, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chongqing, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Hang Zhou, China|Research Site, Lanzhou, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shengyang, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogotá D.C., Colombia|Research Site, Bucaramanga, Colombia|Research Site, Cali, Colombia|Research Site, Cartagena, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Medillin, Colombia|Research Site, Brno, Czech Republic|Research Site, Caslav, Czech Republic|Research Site, Ceska Lipa, Czech Republic|Research Site, Cesky Krumlov, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Havirov, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Kyjov, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Marianske Lazne, Czech Republic|Research Site, Ostrava-Poruba, Czech Republic|Research Site, Ostrava-Zabreh, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pelhrimov, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Pribram, Czech Republic|Research Site, Slany, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Usti nad Orlici, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, ABBEVILLE cedex, France|Research Site, Albi, France|Research Site, ANGERS Cedex 9, France|Research Site, Angers, France|Research Site, Avignon Cedex, France|Research Site, Bayonne, France|Research Site, Cannes, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Jossigny, France|Research Site, La Rochelle Cedex, France|Research Site, Le Chesnay, France|Research Site, Le Coudray Cedex, France|Research Site, Limoges Cedex, France|Research Site, MARSEILLE Cedex 5, France|Research Site, Metz Cedex 1, France|Research Site, NICE Cedex 01, France|Research Site, NIMES Cedex 9, France|Research Site, Orléans Cedex 2, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Toulouse Cedex, France|Research Site, TOURCOING cedex, France|Research Site, Bad Krozingen, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Coburg, Germany|Research Site, Deggingen, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Esslingen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Limburg, Germany|Research Site, Ludwigshafen, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Mönchengladbach, Germany|Research Site, Ulm, Germany|Research Site, Warendorf, Germany|Research Site, Witten, Germany|Research Site, Ballasagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Békéscsaba, Hungary|Research Site, Cegléd, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemét, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Albano Laziale, Italy|Research Site, Bari, Italy|Research Site, Benevento, Italy|Research Site, Brescia, Italy|Research Site, Carpi, Italy|Research Site, Catania, Italy|Research Site, Genova, Italy|Research Site, Legnano, Italy|Research Site, Lucca, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Osio Sotto frazione di Zingoni, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pescara, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, S Maria Capua Vetere, Italy|Research Site, San Remo, Italy|Research Site, Sassari, Italy|Research Site, Sessa Aurunca, Italy|Research Site, Siena, Italy|Research Site, Sorrento NA, Italy|Research Site, Vimercate, Italy|Research Site, Akishima-shi, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kamogawa-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kawachinagano-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Komatsushima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kusatsu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saitama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Shimada-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Takarazuka-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Tomakomai-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yatsushiro-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Jeonju, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Almere, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Drachten, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Goes, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Heerenveen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, OSS, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Shertogenbosch, Netherlands|Research Site, Sittardgeleen, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bergen, Norway|Research Site, Bodo, Norway|Research Site, Bodø, Norway|Research Site, Flekkefjord, Norway|Research Site, Hamar, Norway|Research Site, Levanger, Norway|Research Site, Lillehammer, Norway|Research Site, Nesttun, Norway|Research Site, Oslo, Norway|Research Site, Skien, Norway|Research Site, Tromsø, Norway|Research Site, Tynset, Norway|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, San Borja, Peru|Research Site, Trujillo, Peru|Research Site, Cebu City, Philippines|Research Site, Fuente Osmena Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Las Pinas City, Philippines|Research Site, Lipa City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, San Juan, Philippines|Research Site, Białystok, Poland|Research Site, Bielsko Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chorzow, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Kraków, Poland|Research Site, Legnica, Poland|Research Site, Lubin, Poland|Research Site, Nowa Sól, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Oława, Poland|Research Site, Piotrkow, Poland|Research Site, Poznań, Poland|Research Site, Płock, Poland|Research Site, Skierniewice, Poland|Research Site, Sobótka, Poland|Research Site, Sokolka, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Włocławek, Poland|Research Site, Łańcut, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Deva, Romania|Research Site, Focsani, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Tg. Mures, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Liptovsky Hradok, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Partizanske, Slovakia|Research Site, Piestany, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Gatesville, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempron Park, South Africa|Research Site, Panorama, South Africa|Research Site, Parow, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Soweto, South Africa|Research Site, Worcester, South Africa|Research Site, Almeria, Spain|Research Site, Aviles, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Don Benito (Badajoz), Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Sabadell, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Eksjö, Sweden|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Linkoping, Sweden|Research Site, Ljungby, Sweden|Research Site, Lund, Sweden|Research Site, Molndal, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umea, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Östersund, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Mersin, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozye, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Antrim, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, East Kilbride, United Kingdom|Research Site, Ely, United Kingdom|Research Site, Hastings, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01225562"
946,"NCT02049203","Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis",,"Completed","No Results Available","Aortic Valve Stenosis","Drug: Ataciguat|Drug: Placebo","Number of patients experiencing orthostatic hypotension|The change in blood pressure following the transition from sitting to standing|The change in blood pressure following progressive head-up tilt|Subject self-reports of light-headedness/orthostatic intolerance during the standing test and the head-up tilt testing","Jordan D. Miller, Ph.D.|National Center for Advancing Translational Science (NCATS)|Sanofi-Synthelabo|National Center for Research Resources (NCRR)|Mayo Clinic","All","50 Years and older   (Adult, Older Adult)","Phase 1","44","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","13-005387|UL1RR024150","January 2014","March 2015","March 2015","January 30, 2014",,"July 7, 2016","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02049203"
947,"NCT01060020","Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis",,"Completed","Has Results","Aortic Stenosis","Drug: Sildenafil","Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort.|Percent Change in Pulmonary Vascular Resistance in the Whole Cohort.|Percent Change in Cardiac Index.|Load Independent Index of Diastolic Filling.|Global Longitudinal Strain","Washington University School of Medicine|Barnes-Jewish Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-1780","January 2010","September 2011","October 2011","February 1, 2010","April 25, 2018","April 25, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT01060020"
948,"NCT03187678","Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: i.v. selexipag|Drug: oral selexipag (Uptravi)","Number of Participants With at Least One Adverse Event (AE)|Number of Participants With Prostacyclin-associated Adverse Events|Number of Participants With Adverse Event Related to Injection Site Reactions|Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation|Number of Participants With PAH-related Adverse Events","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A309|2016-004035-21","December 4, 2017","May 29, 2018","May 29, 2018","June 15, 2017","May 21, 2019","May 21, 2019","University of California San Diego Medical center - PULM VASCULAR DIV, La Jolla, California, United States|TUFTS New England Medical Center - PULM / CRITICAL CARE & SLEEP, Boston, Massachusetts, United States|Cleveland Clin Foundation - Dept of Pulm & Critical Care Med, Cleveland, Ohio, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Universitätsklinikum Giessen und Marburg GmbH, Medizinische Klinik und Poliklinik II, Pneumologie, Giessen, Germany|Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B, Greifswald, Germany|Universitätsklinikum Hamburg-Eppendorf, II. Medizinische Klinik und Poliklinik, Pneumologie, Hamburg, Germany|Universitätsklinikum Leipzig / Medizinischen Klinik und Poliklinik I, Pneumologie, Leipzig, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03187678/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03187678/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03187678"
949,"NCT03619876","Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","AMiRA","Recruiting","No Results Available","Rheumatoid Arthritis|Myocardial Inflammation","Drug: Abatacept|Drug: Adalimumab","Change in myocardial FDG uptake in RA patients treated with abatacept vs adalimumab.|Prevalence of T cell subpopulations associated with myocardial FDG uptake in RA patients treated with abatacept vs adalimumab.","Columbia University|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAS2235","July 10, 2019","July 2021","July 2021","August 8, 2018",,"December 9, 2019","Columbia University Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03619876"
950,"NCT01065454","A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction","LEPHT","Active, not recruiting","Has Results","Hypertension, Pulmonary|Ventricular Dysfunction, Left","Drug: Riociguat (Adempas, BAY63-2521)|Drug: Placebo","Pulmonary Artery Mean Pressure (PAPmean) at Rest - Change From Baseline to Week 16|Venous Oxygen Saturation (SvO2) - Change From Baseline to Week 16|Pulmonary Vascular Resistance (PVR) - Change From Baseline to Week 16|Pulmonary Vascular Resistance Index (PVRi) - Change From Baseline to Week 16|Systemic Vascular Resistance (SVR) - Change From Baseline to Week 16|Systemic Vascular Resistance Index (SVRi) - Change From Baseline to Week 16|Transpulmonary Pressure Gradient (TPG) - Change From Baseline to Week 16|Pulmonary Capillary Wedge Pressure (PCWP) - Change From Baseline to Week 16|Tricuspid Annular Plane Systolic Excursion (TAPSE) - Change From Baseline to Week 16|Systolic Pulmonary Arterial Pressure (PAPsyst) - Change From Baseline to Week 16|Left Ventricular Ejection Fraction (LVEF) - Change From Baseline to Week 16|Left Ventricular End-systolic Volume (LVESV) - Change From Baseline to Week 16|Left Ventricular End-diastolic Volume (LVEDV) - Change From Baseline to Week 16|E-wave Deceleration Time - Change From Baseline to Week 16|Ratio of Mitral Peak Velocity of Early Filling to Mitral Peak Velocity of Late Filling (E/A) - Change From Baseline to Week 16|6-minute Walking Distance (6MWD) - Change From Baseline to Week 16|WHO (World Health Organization) Functional Class - Change From Baseline to Week 16|Percentage of Participants With Clinical Worsening|Borg CR 10 Scale - Change From Baseline to Week 16|EQ-5D Utility Score - Change From Baseline to Week 16|Minnesota Living With Heart Failure Questionnaire (MLHF) Score - Change From Baseline to Week 16|Cystatin C - Change From Baseline to Week 16|N-terminal Pro-brain Natriuretic Peptide (NT-pro BNP) - Change From Baseline to Week 16|Troponin T - Change From Baseline to Week 16|Asymmetric Dimethylarginine (ADMA) - Change From Baseline to Week 16|Osteopontin - Change From Baseline to Week 16","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14308|2009-015878-35","April 14, 2010","June 6, 2012","December 31, 2023","February 9, 2010","December 25, 2013","March 23, 2020","Fountain Valley, California, United States|Los Angeles, California, United States|San Diego, California, United States|Torrance, California, United States|Miami, Florida, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Cincinnati, Ohio, United States|Fairfield, Ohio, United States|Falls Church, Virginia, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Chermside, Queensland, Australia|Prahran, Victoria, Australia|Innsbruck, Tirol, Austria|Wien, Austria|Aalst, Belgium|Bruxelles - Brussel, Belgium|Gent, Belgium|Leuven, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Montreal, Quebec, Canada|Quebec, Canada|Beijing, China|Shanghai, China|Shanghai, China|Brno, Czechia|Olomouc, Czechia|Praha 2, Czechia|Praha 4, Czechia|Aarhus N, Denmark|Bron, France|Lille Cedex, France|Nantes, France|Pessac, France|Rouen, France|Toulouse, France|Heidelberg, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Köln, Nordrhein-Westfalen, Germany|Erfurt, Thüringen, Germany|Napoli, Campania, Italy|Pavia, Lombardia, Italy|Nagoya, Aichi, Japan|Seto, Aichi, Japan|Ogaki, Gifu, Japan|Higashiibaraki, Ibaraki, Japan|Tsu, Mie, Japan|Sendai, Miyagi, Japan|Suita, Osaka, Japan|Kusatsu, Shiga, Japan|Sunto, Shizuoka, Japan|Arakawa-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Tanabe, Wakayama, Japan|Osaka, Japan|Osaka, Japan|Amsterdam, Netherlands|Amsterdam, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Warszawa, Poland|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Majadahonda, Madrid, Spain|El Palmar, Murcia, Spain|Son Ferriol, Palma De Mallorca, Spain|A Coruña, Spain|Barcelona, Spain|Madrid, Spain|Valencia, Spain|Lugano, Ticino, Switzerland|Genève, Switzerland|Zürich, Switzerland|Cambridge, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01065454"
951,"NCT03009266","Ischemic Memory Imaging With Myocardial Contrast Echocardiography",,"Recruiting","No Results Available","Myocardial Ischemia","Drug: Sonazoid","Dose optimization|Detection of Ischemia","Oregon Health and Science University","All","19 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00016794","July 7, 2018","December 2019","December 2019","January 4, 2017",,"August 23, 2018","OHSU, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT03009266"
952,"NCT04039087","Sildenafil Exercise: Role of PDE5 Inhibition",,"Active, not recruiting","No Results Available","Cystic Fibrosis","Drug: Sildenafil 40mg oral capsule|Drug: Placebo Oral capsule","6 Minute Walk Distance (6MWD)|CFQ-R respiratory domain score|Cardiac strain|Flow-Mediated Dilation (FMD)|Skeletal muscle function","National Jewish Health|Augusta University|Cystic Fibrosis Foundation","All","9 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Sildenafil Exercise","September 5, 2019","June 2022","June 2023","July 31, 2019",,"April 8, 2020","National Jewish Health, Denver, Colorado, United States|Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04039087"
953,"NCT03919773","IVIG (Gamunex-C) Treatment Study for POTS Subjects","iSTAND","Enrolling by invitation","No Results Available","Postural Tachycardia Syndrome","Drug: IVIG|Drug: Albumin","Improvement in symptoms measured by change in COMPASS-31 score.","University of Texas Southwestern Medical Center|Grifols Biologicals, LLC|Dysautonomia International","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STU-2018-0005","October 29, 2018","July 2020","December 2020","April 18, 2019",,"May 13, 2019","UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03919773"
954,"NCT03657095","BPS-314d-MR-PAH-303 (BEAT OLE)","BEAT OLE","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium 314d Modified Release tablets","Incidence of treatment-related adverse events|Severity of treatment-related adverse events|6 Minute Walk Distance (6MWD)|Borg Dyspnea Score|World Health Organization (WHO) Functional Class (FC)|N-terminal pro-brain natriuretic peptide (NT-pro-BNP)","Lung Biotechnology PBC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","112","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BPS-314d-MR-PAH-303","December 10, 2018","July 20, 2019","July 20, 2019","September 4, 2018",,"November 4, 2019","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|University of California Los Angeles UCLA, Los Angeles, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Allianz Research Institute, Westminster, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Aurora Denver Cardiology Associates, Denver, Colorado, United States|South Denver Cardiology Associates, Littleton, Colorado, United States|Bay Area Cardiology Research, Brandon, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Florida Hospital, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Indiana University Health North Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health, Troy, Michigan, United States|Albany Medical Center, Albany, New York, United States|The Mount Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The University of Toledo, Toledo, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Anderson Pharmaceutical Research, LLC, Anderson, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Rabin Medical Center, Petah Tikva, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel",,"https://ClinicalTrials.gov/show/NCT03657095"
955,"NCT01208402","Esmolol for Treatment of Perioperative Tachycardia",,"Terminated","Has Results","High-risk, Non-cardiovascular Surgeries","Drug: Esmolol","Percentage of Intraoperative Case Time With Heart Rate (HR) <60 or >80 Bpm|Percentage of Postoperative First Three Hours With Heart Rate (HR) <60 or >80 Bpm|Percentage of Postoperative Hours 4 to 12 With Heart Rate (HR) <60 or >80 Bpm.|Percentage of Intraoperative Case Time With Systolic Blood Pressure <95 mmHg|Percentage of Postoperative First Three Hours With Systolic Blood Pressure <95 mmHg|Percentage of Postoperative Hours 4 to 12 With Systolic Blood Pressure <95 mmHg","Duke University|Baxter Healthcare Corporation","All","41 Years and older   (Adult, Older Adult)","Phase 3","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Pro00024224","September 2010","July 2013","July 2013","September 24, 2010","November 19, 2014","December 12, 2014","Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01208402"
956,"NCT01077297","Tezosentan in Pulmonary Arterial Hypertension",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Tezosentan","Change in PVR from Baseline to 30 minutes expresses as percent of the Baseline value.|Change in mean right arterial pressure (mRAP) from Baseline to 30 minutes|Change in mPAP from Baseline to 30 min|Change in total pulmonary resistance (TPR) from Baseline to 30 min|Change in PCWP from Baseline to 30 min|Change in cardiac output (CO) from Baseline to 30 min|Change in cardiac index (CI) from Baseline to 30 min","Idorsia Pharmaceuticals Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-051-206","August 2010","November 2010","September 2011","March 1, 2010",,"July 9, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States|Baylor College of Medicine, Houston, Texas, United States|Hopital Antoine Béclère, Paris, Clamart, France|University Hospital of Basel, Clinic of Pneumology, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT01077297"
957,"NCT01843426","Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan",,"Completed","No Results Available","Aortic Valve Stenosis","Drug: Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan","Clinically Diagnostic CT Assessments|Image Quality|Safety|Long-term Follow-Up","Medical University of South Carolina|General Electric","All","18 Years to 90 Years   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro19770","February 2013","September 25, 2017","September 25, 2017","April 30, 2013",,"August 2, 2018","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01843426"
958,"NCT01495481","Dexmedetomidine and Adenosine: Therapeutic Use for SVT",,"Completed","Has Results","Supraventricular Tachycardia","Drug: Dexmedetomidine|Drug: Adenosine","Termination of SVT|Number of Participants With Sinus Pause >2.5 Sec After Termination of SVT|Number of Participants With Tachyarrhythmias After Medication Administration|Number of Participants With Hypotension by Non-invasive Cuff in First 10 Minutes After Medication Administration","University of Pittsburgh","All","5 Years to 30 Years   (Child, Adult)","Not Applicable","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO11070129|PRE-11-010","January 2012","July 2014","July 2014","December 20, 2011","March 28, 2017","March 28, 2017","Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01495481"
959,"NCT02992288","A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction","PANTHEON","Completed","Has Results","Heart Failure","Drug: Neladenoson bialanate (BAY1067197)|Drug: Placebo","Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) (%) at Week 20 Measured by Echocardiography|Absolute Change From Baseline in Log-transformed NT-pro B-type Natriuretic Peptide (BNP) at Week 20|Change From Baseline in Left Ventricular End-Systolic Volume (LVESV) at Week 20|Change From Baseline in Left Ventricular End-Diastolic Volume (LVEDV) at Week 20|Change From Baseline in High Sensitivity Troponin T (Hs-TNT) at Week 20|Number of Participants With Composite Efficacy Outcome|Number of Participants With Cardiovascular (CV) Mortality|Number of Participants With Heart Failure (HF) Hospitalization and Urgent Visits for Heart Failure (HF)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","427","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15128|2016-003839-38","February 22, 2017","March 28, 2018","May 16, 2018","December 14, 2016","April 23, 2019","April 23, 2019","Southwest Florida Research, Naples, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|Glacier View Research Institute-Cardiology, Kalispell, Montana, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|St. Elizabeth Youngstown Hospital, Youngstown, Ohio, United States|Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States|East Texas Cardiology, Houston, Texas, United States|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Grand Hôpital de Charleroi, Gilly, Belgium|AZ Delta, Roeselare, Belgium|AZ Turnhout, Turnhout, Belgium|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Sofia, Sofia, Bulgaria|MHAT Dr Stefan Cherkezov, Veliko Tarnovo, Bulgaria|Medizinische Hochschule Hannover (MHH), Hannover, Niedersachsen, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Bad Oeynhausen, Nordrhein-Westfalen, Germany|St.-Johannes-Hospital Dortmund, Dortmund, Nordrhein-Westfalen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Rheinland-Pfalz, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|Thriassio General Hospital of Elefsina, Elefsina, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Barzilai Medical Center, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Corporation, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zrifin, Israel|A.O.U. Policlinico Federico II Napoli, Napoli, Campania, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|IRCCS Centro Cardiologico Fondazione Monzino, Milano, Lombardia, Italy|AUSL 8 Arezzo, Arezzo, Toscana, Italy|Gunma University Hospital, Maebashi, Gunma, Japan|National Hospital Organization Takasaki General Medical C, Takasaki, Gunma, Japan|Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|National hospital Organization Mito Medical Center, Higashiibaraki, Ibaraki, Japan|R.I.A.C Naha City Hospital, Naha, Okinawa, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Okayama Rosai Hospital, Okayama, Japan|Osaka General Medical Center, Osaka, Japan|Toyama Prefectural Central Hospital, Toyama, Japan|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|KLIMED Marek Klimkiewicz, Bialystok, Poland|CLINICAL MEDICAL RESEARCH Sp. z o. o., Katowice, Poland|Szpital Specjalistyczny im. J. Dietla, Krakow, Poland|Nzoz Salus, Lodz, Poland|Szpital Kliniczny Przemienienia Panskiego, Poznan, Poland|Twoja Przychodnia - Szczecinskie Centrum Medyczne, Szczecin, Poland|IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ, Wroclaw, Poland|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02992288/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT02992288/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02992288"
960,"NCT00989963","Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium Modified Release","Right Heart Catheterization|Exercise Capacity|World Health Organization(WHO)Functional Class.|Clinical Laboratory Parameters|Electrocardiogram (ECG) Findings","Lung Biotechnology PBC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BPS-MR-PAH-203","November 2009","December 2011","December 2011","October 6, 2009",,"April 24, 2013","Harbor-UCLA Medical Center, Torrance, California, United States|Edward Heart Hospital, Naperville, Illinois, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Beth Israel Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Universite Libre de Bruxelles, Bruxellas, Belgium|Catholic University of Leuven, Leuven, Belgium|General Teaching Hospital, Praha, Czech Republic|Klinikum der Universitat zu Koln, Cologne, Germany|Medizinische Klinik und Poliklinik, Dresden, Germany|Abt. Innere Medizin III, Medizinische Universitatsklinik, Heidelberg, Germany|Universitatsklinik Leipzig Abteilung Pulmologie, Leipzig, Germany|Mater Misericordiae University Hospital Ltd., Dublin, Ireland|Institutul de Urgenta pentru Boli, Bucuresti, Romania|Institutul National de Pneumologie, Bucuresti, Romania|Institutul de Boli Cardiovasculare, Lasi, Romania",,"https://ClinicalTrials.gov/show/NCT00989963"
961,"NCT02310672","REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension","REPAIR","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Macitentan","To evaluate the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension (PAH).|To investigate the effect of macitentan on ventriculo-arterial coupling in patients with symptomatic PAH.|To evaluate the safety and tolerability of macitentan in patients with symptomatic PAH.","Actelion","All","18 Years to 64 Years   (Adult)","Phase 4","89","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-403","June 1, 2015","September 10, 2019","September 10, 2019","December 8, 2014",,"October 2, 2019","Massachussetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rudgers New Jersey Medical School, New Brunswick, New Jersey, United States|Cornell University, New York, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical, Dallas, Texas, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Prince Charles Hospital, Chermside, Queensland, Australia|Hopital Gabriel Montpied, Clermont-Ferrand, France|Hôpital Michallon, La Tronche, France|""CHRU de Lille - Hôpital Albert Calmette "", Lille Cedex, France|Hopital de Brabois, Nancy, France|Hôpital Laennec, Nantes Cedex 01, France|Hôpital Pasteur, Nice, France|Hôpital Européen Georges-Pompidou, Paris, France|Medizinische Klinik und Poliklinik II Universitätsklinik Bonn, Bonn, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz Centrum für Thrombose und Hämostase, Mainz, Germany|Grantham Hospital, Cardiac Medical Unit, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Pulmonology institute, Soroka Medical Center, Beer-Sheva, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS Policlinico San Matteo Ambulatorio Scompenso Cardiaco e Trapianti, Pavia, Italy|Hospital Pulau Pinang, George Town, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|VU University Medical Center (VUMC), Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|Erasmus University medical Center, Rotterdam, Netherlands|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|Almazov Federal North-West Medical Research Centre of Department of Health, Saint Petersburg, Russian Federation|National University Hospital - The Heart Institute - Cardiac Department, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Golden Jubilee National Hospital, Glasgow, United Kingdom|The Royal Free Hospital, London, United Kingdom|""Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital"", Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02310672"
962,"NCT00874354","Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction","REVITALIZE","Completed","No Results Available","Myocardial Infarction","Drug: Intracoronary Transplantation of Bone Marrow Stem Cells","Safety and feasibility of intracoronary administration of autologous bone marrow-derived mononuclear cells; Improvement of global left ventricular ejection fraction by cardiac MRI and echocardiography after 4 months.|Freedom from Major Adverse Cardiac Event (MACE)","Cedars-Sinai Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4441","July 2005","June 2013","June 2013","April 2, 2009",,"February 2, 2017","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00874354"
963,"NCT03914326","A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes","SOUL","Recruiting","No Results Available","Diabetes Mellitus, Type 2","Drug: Semaglutide|Drug: Placebo (semaglutide)","Time to first occurrence of a major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death/non-fatal myocardial infarction/non-fatal stroke|Time to first occurrence of a composite endpoint|Time to occurrence of CV death|Time to first occurrence of major adverse limb events (MALE), a composite endpoint consisting of: acute limb ischemia hospitalisation/chronic limb ischemia hospitalisation|Time to first occurrence of an expanded MACE composite endpoint consisting of: CV death/non-fatal myocardial infarction/ non-fatal stroke/coronary revascularisation/unstable angina requiring hospitalisation|Time to first occurrence of a composite heart failure endpoint consisting of: CV death/heart failure requiring hospitalisation/urgent heart failure visit|Time to first occurrence of a composite CKD endpoint|Time to occurrence of all-cause death|Time to first occurrence of non-fatal myocardial infarction (MI)|Time to first occurrence of non-fatal stroke|Time to first occurrence of heart failure requiring hospitalisation|Time to first occurrence of urgent heart failure visit|Time to first occurrence of coronary revascularisation|Time to first occurrence of unstable angina requiring hospitalisation|Time to occurrence of renal death|Time to first occurrence of onset of persistent 50% or more reduction in eGFR|Time to first occurrence of onset of persistent eGFR (CKD-EPI) below 15 mL/min/1.73 m^2|Time to first occurrence of initiation of chronic renal replacement therapy (dialysis or kidney transplantation)|Time to first occurrence of a composite endpoint consisting of: all-cause death/non-fatal myocardial infarction/non-fatal stroke|Time to first occurrence of acute limb ischemia|Time to first occurrence of chronic limb ischemia|Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)|Change in glycosylated haemoglobin (HbA1c)|Change in body weight|Number of severe hypoglycaemic episodes|Time to first occurrence of a severe hypoglycaemic episode","Novo Nordisk A/S","All","50 Years and older   (Adult, Older Adult)","Phase 3","9642","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EX9924-4473|2018-003141-42|U1111-1218-5368","June 17, 2019","July 29, 2024","July 29, 2024","April 16, 2019",,"April 28, 2020","Novo Nordisk Investigational Site, Montgomery, Alabama, United States|Novo Nordisk Investigational Site, Little Rock, Arkansas, United States|Novo Nordisk Investigational Site, Searcy, Arkansas, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Los Alamitos, California, United States|Novo Nordisk Investigational Site, Mission Hills, California, United States|Novo Nordisk Investigational Site, Monterey, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Denver, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, New Port Richey, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Lawrenceville, Georgia, United States|Novo Nordisk Investigational Site, Roswell, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Gurnee, Illinois, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, West Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, New Orleans, Louisiana, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Buckley, Michigan, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Lebanon, New Hampshire, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Burlington, North Carolina, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, New Bern, North Carolina, United States|Novo Nordisk Investigational Site, Whiteville, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, United States|Novo Nordisk Investigational Site, Marion, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Twinsburg, Ohio, United States|Novo Nordisk Investigational Site, Norman, Oklahoma, United States|Novo Nordisk Investigational Site, Beaver, Pennsylvania, United States|Novo Nordisk Investigational Site, McMurray, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Murrells Inlet, South Carolina, United States|Novo Nordisk Investigational Site, Myrtle Beach, South Carolina, United States|Novo Nordisk Investigational Site, Spartanburg, South Carolina, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Fort Worth, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, Round Rock, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Constantine, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Setif, Algeria|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Buenos Aires, Argentina|Novo Nordisk Investigational Site, Capital Federal, Argentina|Novo Nordisk Investigational Site, Cordoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Lanus Este, Argentina|Novo Nordisk Investigational Site, Mar del Plata, Argentina|Novo Nordisk Investigational Site, Rosario, Santa Fe, Argentina|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Saint Stefan, Austria|Novo Nordisk Investigational Site, Vienna, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Kortrijk, Belgium|Novo Nordisk Investigational Site, Leuven, Belgium|Novo Nordisk Investigational Site, Roeselare, Belgium|Novo Nordisk Investigational Site, Brasilia, Distrito Federal, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Vancouver, British Columbia, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Barrie, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Concord, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, Markham, Ontario, Canada|Novo Nordisk Investigational Site, Sarnia, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Mirabel, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Cangzhou, Hebei, China|Novo Nordisk Investigational Site, Changzhou, Jiangsu, China|Novo Nordisk Investigational Site, Zhenjiang, Jiangsu, China|Novo Nordisk Investigational Site, Jinan, Shandong, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Barranquilla, Colombia|Novo Nordisk Investigational Site, Bucaramanga, Colombia|Novo Nordisk Investigational Site, Cali, Colombia|Novo Nordisk Investigational Site, San Juan De Pasto, Colombia|Novo Nordisk Investigational Site, Soledad, Colombia|Novo Nordisk Investigational Site, Krapinske Toplice, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Pula, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Split, Croatia|Novo Nordisk Investigational Site, Varazdin, Croatia|Novo Nordisk Investigational Site, Zadar, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Brno, Czechia|Novo Nordisk Investigational Site, Chrudim, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Moravska Ostrava, Czechia|Novo Nordisk Investigational Site, Ostrava, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzen, Czechia|Novo Nordisk Investigational Site, Plzeň, Czechia|Novo Nordisk Investigational Site, Praha, Czechia|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, København, Denmark|Novo Nordisk Investigational Site, Slagelse, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Besançon cedex, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Marseille, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Falkensee, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Jerichow, Germany|Novo Nordisk Investigational Site, Lingen, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Münster, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Rehlingen-Siersburg, Germany|Novo Nordisk Investigational Site, Stuttgart, Germany|Novo Nordisk Investigational Site, Witten, Germany|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Guwahati, Assam, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Rohtak, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Kozhikode, Kerala, India|Novo Nordisk Investigational Site, Indore, Madhya Pradesh, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Ludhiana, Punjab, India|Novo Nordisk Investigational Site, Jaipur, Rajasthan, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Hyderabad, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Thriruvananthapuram, India|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Bari, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Chieti, Italy|Novo Nordisk Investigational Site, Lucca, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Ehime, Japan|Novo Nordisk Investigational Site, Fukui, Japan|Novo Nordisk Investigational Site, Fukuoka, Japan|Novo Nordisk Investigational Site, Ibaraki, Japan|Novo Nordisk Investigational Site, Kumamoto, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Miyagi, Japan|Novo Nordisk Investigational Site, Miyazaki, Japan|Novo Nordisk Investigational Site, Nagano, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Takamatsu-shi, Kagawa, Japan|Novo Nordisk Investigational Site, Tochigi, Japan|Novo Nordisk Investigational Site, Tokorozawa-shi, Saitama, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Seoul, Korea, Republic of|Novo Nordisk Investigational Site, Alor Setar, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Malaysia|Novo Nordisk Investigational Site, Kota Samarahan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuching, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Sarawak, Malaysia|Novo Nordisk Investigational Site, Seremban, Malaysia|Novo Nordisk Investigational Site, Sungai Buloh, Malaysia|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Tlalpan, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Nicolas de los Garza, Nuevo León, Mexico|Novo Nordisk Investigational Site, Hermosillo, Sonora, Mexico|Novo Nordisk Investigational Site, Merida, Yucatan, Mexico|Novo Nordisk Investigational Site, Mérida, Yucatan, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Amersfoort, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Delft, Netherlands|Novo Nordisk Investigational Site, Eindhoven, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Hoogeveen, Netherlands|Novo Nordisk Investigational Site, Maastricht, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, Utrecht, Netherlands|Novo Nordisk Investigational Site, Targoviste, Dambovita, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Tirgu Mures, Mures, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Ploiesti, Prahova, Romania|Novo Nordisk Investigational Site, Bacau, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Sibiu, Romania|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Kragujevac, Serbia|Novo Nordisk Investigational Site, Nis, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Bratislava, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Kosice, Slovakia|Novo Nordisk Investigational Site, Krompachy, Slovakia|Novo Nordisk Investigational Site, Nitra, Slovakia|Novo Nordisk Investigational Site, Poprad, Slovakia|Novo Nordisk Investigational Site, Prievidza, Slovakia|Novo Nordisk Investigational Site, Rimavska Sobota, Slovakia|Novo Nordisk Investigational Site, Roznava, Slovakia|Novo Nordisk Investigational Site, Vrutky, Slovakia|Novo Nordisk Investigational Site, Benoni, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Berea, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Alcorcón, Spain|Novo Nordisk Investigational Site, Antequera, Spain|Novo Nordisk Investigational Site, Barcelona, Spain|Novo Nordisk Investigational Site, Burela, Spain|Novo Nordisk Investigational Site, Córdoba, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Las Palmas de Gran Canaria, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain|Novo Nordisk Investigational Site, Sanlúcar De Barrameda - Cádiz-, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Santiago de Compostela, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Changhua City, Taiwan|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Taoyuan, Taiwan|Novo Nordisk Investigational Site, Bangkoknoi, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Nakhon Ratchasima, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Bursa, Turkey|Novo Nordisk Investigational Site, Erzurum, Turkey|Novo Nordisk Investigational Site, Eskisehir, Turkey|Novo Nordisk Investigational Site, Hatay, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Sivas, Turkey|Novo Nordisk Investigational Site, Trabzon, Turkey|Novo Nordisk Investigational Site, Cherkasy, Ukraine|Novo Nordisk Investigational Site, Chernivtsi, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Poltava, Ukraine|Novo Nordisk Investigational Site, Uzhhorod, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Addlestone, United Kingdom|Novo Nordisk Investigational Site, Belfast, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Chippenham, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Harrogate, United Kingdom|Novo Nordisk Investigational Site, Hinckley, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Norfolk, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Redhill, United Kingdom|Novo Nordisk Investigational Site, Soham, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03914326"
964,"NCT03098979","A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction","PANACHE","Completed","Has Results","Heart Failure","Drug: Neladenoson bialanate (BAY1067197)|Drug: Placebo","Absolute Change From Baseline in 6-minute Walking Distance (6MWD) After 20 Weeks of Treatment|Change From Baseline in Average Weekly Percentage of Maximum Possible Recorded Activity Intensity|Measured Values (Log Transformed) and Absolute Change in NT-proBNP From Baseline to 20 Weeks|Measured Values (Log-transformed) and Absolute Change in High Sensitivity Troponin T (Hs-TNT) From Baseline to 20 Weeks|Measured Values and Absolute Change in 3 Scores From Kansas City Cardiomyopathy Questionnaire (KCCQ) From Baseline to 20 Weeks: Overall Summary Score, Physical Limitation Score and Total Symptom Score","Bayer","All","45 Years and older   (Adult, Older Adult)","Phase 2","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17582|2016-004062-26","May 10, 2017","May 23, 2018","June 20, 2018","April 4, 2017","July 23, 2019","July 23, 2019","Northwestern University, Chicago, Illinois, United States|St. Louis Heart & Vascular, PC, Saint Louis, Missouri, United States|BryanLGH Medical Center East, Lincoln, Nebraska, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Universitätsklinikum St. Pölten, St. Pölten, Niederösterreich, Austria|Krankenhaus St. Josef Braunau, Braunau, Oberösterreich, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|Krankenhaus Hietzing, Wien, Austria|Jessa Ziekenhuis, Hasselt, Belgium|CHR de la Citadelle, Liege, Belgium|AZ Delta, Roeselare, Belgium|Spec Hosp for Active Treatm in Cardiology Sv Georgi Pernik, Pernik, Bulgaria|Specialized Hospital for Actrive Treatm of Card - Pleven, Pleven, Bulgaria|Medical Center Cardiohelp, Sofia, Bulgaria|NMTH Tzar Boris III, Sofia, Bulgaria|UMHAT Tsaritsa Joanna-ISUL EAD Sofia, Sofia, Bulgaria|MCOMH Preventsia-2000, Stara Zagora, Bulgaria|St. Vincenz und Elisabeth Hospital, Kathol. Klinikum Mainz, Mainz, Rheinland-Pfalz, Germany|Klinische Forschung Dresden GmbH, Dresden, Sachsen, Germany|HELIOS Klinikum Erfurt GmbH, Erfurt, Thüringen, Germany|Charité Campus Virchow-Klinikum (CVK), Berlin, Germany|KAT General Hospital of Athens, Kifisia / Athens, Attica, Greece|G. Gennimatas General State Hospital of Athens, Athens, Greece|General Hospital of Chalkida, Chalkida, Greece|Konstantopoulio General Hospital of Nea Ionia - Agia Olga, Nea Ionia / Athens, Greece|Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece|Asklipieion General Hospital of Voulas, Voula, Greece|Barzilai Medical Center, Ashkelon, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Corporation, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zrifin, Israel|AAS 3 Friuli Alto Medio Collin, Udine, Friuli-Venezia Giulia, Italy|A.O.U. Sant'Andrea, Roma, Lazio, Italy|ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|ASST Spedali Civili di Brescia, Brescia, Lombardia, Italy|A.O. Ordine Mauriziano, Torino, Piemonte, Italy|A.O.U. di Sassari, Sassari, Sardegna, Italy|AUSL Toscana Sud-Est, Arezzo, Toscana, Italy|Chuno kosei Hospital, Seki, Gifu, Japan|Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan|R.I.A.C Naha City Hospital, Naha, Okinawa, Japan|Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Minamino Cardiovascular Hospital, Hachioji, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Fukui Prefectural Hospital, Fukui, Japan|Okayama Rosai Hospital, Okayama, Japan|Osaka General Medical Center, Osaka, Japan|Tokushima Prefectural Central Hospital, Tokushima, Japan|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Zachodni w Grodzisku Mazowieckim, Grodzisk Mazowiecki, Poland|Szpital Specjalistyczny im. J. Dietla, Krakow, Poland|Wojewodzki Specjalistyczny Szpital im. dr Wl. Bieganskiego, Lodz, Poland|109 Szpital Wojskowy z przychodnia SPZOZ, Szczecin, Poland|Szpital Wolski im. dr Anny Gostynskiej SPZOZ, Warszawa, Poland|IV Wojskowy Szpital Kliniczny z Poliklinika, SPZOZ, Wroclaw, Poland|CHUC - Hospitais da Universidade de Coimbra, Coimbra, Portugal|CHLO - Hospital São Francisco Xavier, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|CHUP, EPE - Hospital de Santo Antonio, Porto, Portugal|Hospital Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Hospital del Mar, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03098979/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03098979/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03098979"
965,"NCT03161678","CES1 Crossover Trial of Clopidogrel and Ticagrelor",,"Recruiting","No Results Available","Myocardial Infarction|Thrombosis|Platelet Dysfunction","Drug: Clopidogrel|Drug: Ticagrelor","CES1 genotype-dependent effect of clopidogrel or ticagrelor on inhibition of platelet aggregation|Impact of alternative drug choice on CES1 genotype-dependent maximal platelet aggregation","University of Maryland, Baltimore","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","90","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HP-00074967","August 22, 2017","October 2020","October 2020","May 22, 2017",,"November 12, 2019","Amish Research Clinic, Lancaster, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03161678"
966,"NCT03574597","Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity","SELECT","Recruiting","No Results Available","Overweight|Obesity","Drug: Semaglutide|Drug: Placebo (semaglutide)","Time to first occurrence of a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke|Time to CV death|Time to all-cause death|Time to first occurrence of an expanded composite CV endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation or unstable angina requiring hospitalisation|Time to first occurrence of a composite heart failure endpoint consisting of: heart failure hospitalisation, urgent heartfailure visit or CV death|Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction, or non-fatal stroke|Time to first occurrence of non-fatal myocardial infarction|Time to first occurrence of non-fatal stroke|Time to first occurrence of coronary revascularisation|Time to first occurrence of unstable angina requiring hospitalisation|Time to first occurrence of heart failure hospitalisation or urgent heart failure visit|Time to first occurrence of HbA1c greater than or equal to 48 mmol/mol (6.5%)|Time to first occurrence of a 5-component composite nephropathy endpoint|Time to HbA1c greater than or equal to 39 mmol/mol (5.7%) for subjects with a screening HbA1c less than 39 mmol/mol (5.7%)|Subjects with HbA1c less than 39 mmol/mol (5.7%) at each visit where HbA1c is assessed for subjects with a screening HbA1c greater than or equal to 39 mmol/mol (5.7%)|Change in systolic blood pressure|Change in diastolic blood pressure|Change in pulse|Change in High sensitivity C-Reactive Protein (hsCRP)|Change in total cholesterol|Change in high density lipoprotein (HDL) cholesterol|Change in low density lipoprotein (LDL) cholesterol|Change in triglycerides|Change in body weight|Change in waist circumference|Change in EuroQol five dimensions five level (EQ-5D-5L) questionnaire|Change in total score weight related sign and symptom measure|Change in haemoglobin A1c (HbA1c)|Change in HbA1c","Novo Nordisk A/S","All","45 Years and older   (Adult, Older Adult)","Phase 3","17500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EX9536-4388|2017-003380-35|U1111-1200-5564","October 24, 2018","September 28, 2023","September 28, 2023","July 2, 2018",,"April 2, 2020","Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Montgomery, Alabama, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Phoenix, Arizona, United States|Novo Nordisk Investigational Site, Beverly Hills, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, Covina, California, United States|Novo Nordisk Investigational Site, El Cajon, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Lancaster, California, United States|Novo Nordisk Investigational Site, Lomita, California, United States|Novo Nordisk Investigational Site, Long Beach, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Moreno Valley, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Oxnard, California, United States|Novo Nordisk Investigational Site, Palm Springs, California, United States|Novo Nordisk Investigational Site, Pomona, California, United States|Novo Nordisk Investigational Site, Quartz Hill, California, United States|Novo Nordisk Investigational Site, San Diego, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, San Ramon, California, United States|Novo Nordisk Investigational Site, Spring Valley, California, United States|Novo Nordisk Investigational Site, Torrance, California, United States|Novo Nordisk Investigational Site, Ventura, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, Golden, Colorado, United States|Novo Nordisk Investigational Site, Monument, Colorado, United States|Novo Nordisk Investigational Site, Bridgeport, Connecticut, United States|Novo Nordisk Investigational Site, New Haven, Connecticut, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Boynton Beach, Florida, United States|Novo Nordisk Investigational Site, Bradenton, Florida, United States|Novo Nordisk Investigational Site, Clearwater, Florida, United States|Novo Nordisk Investigational Site, Crystal River, Florida, United States|Novo Nordisk Investigational Site, Fleming Island, Florida, United States|Novo Nordisk Investigational Site, Fort Lauderdale, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Jacksonville Beach, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Orlando, Florida, United States|Novo Nordisk Investigational Site, Oviedo, Florida, United States|Novo Nordisk Investigational Site, Panama City, Florida, United States|Novo Nordisk Investigational Site, Saint Augustine, Florida, United States|Novo Nordisk Investigational Site, Sarasota, Florida, United States|Novo Nordisk Investigational Site, Tampa, Florida, United States|Novo Nordisk Investigational Site, Wellington, Florida, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Cumming, Georgia, United States|Novo Nordisk Investigational Site, Statesboro, Georgia, United States|Novo Nordisk Investigational Site, Suwanee, Georgia, United States|Novo Nordisk Investigational Site, Tucker, Georgia, United States|Novo Nordisk Investigational Site, Arlington Heights, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Evanston, Illinois, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, United States|Novo Nordisk Investigational Site, Hazel Crest, Illinois, United States|Novo Nordisk Investigational Site, Oakbrook Terrace, Illinois, United States|Novo Nordisk Investigational Site, Skokie, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Anderson, Indiana, United States|Novo Nordisk Investigational Site, Avon, Indiana, United States|Novo Nordisk Investigational Site, Evansville, Indiana, United States|Novo Nordisk Investigational Site, Franklin, Indiana, United States|Novo Nordisk Investigational Site, Greenfield, Indiana, United States|Novo Nordisk Investigational Site, Michigan City, Indiana, United States|Novo Nordisk Investigational Site, Muncie, Indiana, United States|Novo Nordisk Investigational Site, New Albany, Indiana, United States|Novo Nordisk Investigational Site, Valparaiso, Indiana, United States|Novo Nordisk Investigational Site, Iowa City, Iowa, United States|Novo Nordisk Investigational Site, Kansas City, Kansas, United States|Novo Nordisk Investigational Site, Overland Park, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Louisville, Kentucky, United States|Novo Nordisk Investigational Site, Alexandria, Louisiana, United States|Novo Nordisk Investigational Site, Hammond, Louisiana, United States|Novo Nordisk Investigational Site, Natchitoches, Louisiana, United States|Novo Nordisk Investigational Site, Slidell, Louisiana, United States|Novo Nordisk Investigational Site, Annapolis, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Elkridge, Maryland, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, United States|Novo Nordisk Investigational Site, Rockville, Maryland, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Boston, Massachusetts, United States|Novo Nordisk Investigational Site, Ann Arbor, Michigan, United States|Novo Nordisk Investigational Site, Canton, Michigan, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Flint, Michigan, United States|Novo Nordisk Investigational Site, Ypsilanti, Michigan, United States|Novo Nordisk Investigational Site, Belzoni, Mississippi, United States|Novo Nordisk Investigational Site, Festus, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Henderson, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Nashua, New Hampshire, United States|Novo Nordisk Investigational Site, East Brunswick, New Jersey, United States|Novo Nordisk Investigational Site, Raritan, New Jersey, United States|Novo Nordisk Investigational Site, Teaneck, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, Brooklyn, New York, United States|Novo Nordisk Investigational Site, Great Neck, New York, United States|Novo Nordisk Investigational Site, Lake Success, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, New York, New York, United States|Novo Nordisk Investigational Site, Saratoga Springs, New York, United States|Novo Nordisk Investigational Site, West Seneca, New York, United States|Novo Nordisk Investigational Site, Westfield, New York, United States|Novo Nordisk Investigational Site, Chapel Hill, North Carolina, United States|Novo Nordisk Investigational Site, Charlotte, North Carolina, United States|Novo Nordisk Investigational Site, Durham, North Carolina, United States|Novo Nordisk Investigational Site, Garner, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Lumberton, North Carolina, United States|Novo Nordisk Investigational Site, Morganton, North Carolina, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, United States|Novo Nordisk Investigational Site, Winston-Salem, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Maumee, Ohio, United States|Novo Nordisk Investigational Site, Wadsworth, Ohio, United States|Novo Nordisk Investigational Site, Corvallis, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Portland, Oregon, United States|Novo Nordisk Investigational Site, Danville, Pennsylvania, United States|Novo Nordisk Investigational Site, Doylestown, Pennsylvania, United States|Novo Nordisk Investigational Site, Duncansville, Pennsylvania, United States|Novo Nordisk Investigational Site, Harleysville, Pennsylvania, United States|Novo Nordisk Investigational Site, Johnstown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Anderson, South Carolina, United States|Novo Nordisk Investigational Site, Charleston, South Carolina, United States|Novo Nordisk Investigational Site, Greenville, South Carolina, United States|Novo Nordisk Investigational Site, Mount Pleasant, South Carolina, United States|Novo Nordisk Investigational Site, Bristol, Tennessee, United States|Novo Nordisk Investigational Site, Germantown, Tennessee, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, United States|Novo Nordisk Investigational Site, Memphis, Tennessee, United States|Novo Nordisk Investigational Site, Nashville, Tennessee, United States|Novo Nordisk Investigational Site, Tullahoma, Tennessee, United States|Novo Nordisk Investigational Site, Amarillo, Texas, United States|Novo Nordisk Investigational Site, Arlington, Texas, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Bellaire, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Longview, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Sugar Land, Texas, United States|Novo Nordisk Investigational Site, Tyler, Texas, United States|Novo Nordisk Investigational Site, Waco, Texas, United States|Novo Nordisk Investigational Site, Bountiful, Utah, United States|Novo Nordisk Investigational Site, Salt Lake City, Utah, United States|Novo Nordisk Investigational Site, South Burlington, Vermont, United States|Novo Nordisk Investigational Site, Danville, Virginia, United States|Novo Nordisk Investigational Site, Fairfax, Virginia, United States|Novo Nordisk Investigational Site, Midlothian, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Norfolk, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Salem, Virginia, United States|Novo Nordisk Investigational Site, Virginia Beach, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Winchester, Virginia, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Wenatchee, Washington, United States|Novo Nordisk Investigational Site, Green Bay, Wisconsin, United States|Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States|Novo Nordisk Investigational Site, Wausau, Wisconsin, United States|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Algiers, Algeria|Novo Nordisk Investigational Site, Oran, Algeria|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Caba, Argentina|Novo Nordisk Investigational Site, Corrientes, Argentina|Novo Nordisk Investigational Site, Córdoba, Argentina|Novo Nordisk Investigational Site, Rosario, Argentina|Novo Nordisk Investigational Site, Garran, Australian Capital Territory, Australia|Novo Nordisk Investigational Site, Gosford, New South Wales, Australia|Novo Nordisk Investigational Site, Liverpool, New South Wales, Australia|Novo Nordisk Investigational Site, Merewether, New South Wales, Australia|Novo Nordisk Investigational Site, Auchenflower, Queensland, Australia|Novo Nordisk Investigational Site, Milton, Queensland, Australia|Novo Nordisk Investigational Site, Wollongabba, Queensland, Australia|Novo Nordisk Investigational Site, Adelaide, South Australia, Australia|Novo Nordisk Investigational Site, Elizabeth Vale, South Australia, Australia|Novo Nordisk Investigational Site, Clayton, Victoria, Australia|Novo Nordisk Investigational Site, Geelong, Victoria, Australia|Novo Nordisk Investigational Site, Heidelberg Heights, Victoria, Australia|Novo Nordisk Investigational Site, Melbourne, Victoria, Australia|Novo Nordisk Investigational Site, Joondalup, Western Australia, Australia|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Innsbruck, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Aalst, Belgium|Novo Nordisk Investigational Site, Bonheiden, Belgium|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Genk, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Hasselt, Belgium|Novo Nordisk Investigational Site, Salvador, Bahia, Brazil|Novo Nordisk Investigational Site, Brasilia, Distrito Federal, Brazil|Novo Nordisk Investigational Site, Uberlândia, Minas Gerais, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Curitiba, Parana, Brazil|Novo Nordisk Investigational Site, Passo Fundo, Rio Grande Do Sul, Brazil|Novo Nordisk Investigational Site, Blumenau, Santa Catarina, Brazil|Novo Nordisk Investigational Site, Campinas, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São José do Rio Preto, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, São Paulo, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Rio de Janeiro, Brazil|Novo Nordisk Investigational Site, Dimitrovgrad, Bulgaria|Novo Nordisk Investigational Site, Pleven, Bulgaria|Novo Nordisk Investigational Site, Plovdiv, Bulgaria|Novo Nordisk Investigational Site, Razgrad, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Varna, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Sherwood Park, Alberta, Canada|Novo Nordisk Investigational Site, Moncton, New Brunswick, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Burlington, Ontario, Canada|Novo Nordisk Investigational Site, Cambridge, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Nepean, Ontario, Canada|Novo Nordisk Investigational Site, North York, Ontario, Canada|Novo Nordisk Investigational Site, Oshawa, Ontario, Canada|Novo Nordisk Investigational Site, Peterborough, Ontario, Canada|Novo Nordisk Investigational Site, Port Perry, Ontario, Canada|Novo Nordisk Investigational Site, Scarborough, Ontario, Canada|Novo Nordisk Investigational Site, Stoney Creek, Ontario, Canada|Novo Nordisk Investigational Site, Thunder Bay, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, greenfield Park, Quebec, Canada|Novo Nordisk Investigational Site, Levis, Quebec, Canada|Novo Nordisk Investigational Site, Mirabel, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Québec, Quebec, Canada|Novo Nordisk Investigational Site, Sherbrooke, Quebec, Canada|Novo Nordisk Investigational Site, St-Marc-des-Carrières, Quebec, Canada|Novo Nordisk Investigational Site, Terrebonne, Quebec, Canada|Novo Nordisk Investigational Site, Pointe Claire, Canada|Novo Nordisk Investigational Site, Quebec, Canada|Novo Nordisk Investigational Site, Barranquilla, Colombia|Novo Nordisk Investigational Site, Barranquilla, Colombia|Novo Nordisk Investigational Site, Barranquilla, Colombia|Novo Nordisk Investigational Site, Bucaramanga, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Medellin, Colombia|Novo Nordisk Investigational Site, Krapinske Toplice, Croatia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Rijeka, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Chomutov, Czechia|Novo Nordisk Investigational Site, Hradec Kralove, Czechia|Novo Nordisk Investigational Site, Jihlava, Czechia|Novo Nordisk Investigational Site, Liberec, Czechia|Novo Nordisk Investigational Site, Olomouc, Czechia|Novo Nordisk Investigational Site, Policka, Czechia|Novo Nordisk Investigational Site, Praha 2, Czechia|Novo Nordisk Investigational Site, Praha 4, Czechia|Novo Nordisk Investigational Site, Praha 8, Czechia|Novo Nordisk Investigational Site, Slany, Czechia|Novo Nordisk Investigational Site, Svitavy, Czechia|Novo Nordisk Investigational Site, Tabor, Czechia|Novo Nordisk Investigational Site, Aalborg, Denmark|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Hellerup, Denmark|Novo Nordisk Investigational Site, Herning, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, Svendborg, Denmark|Novo Nordisk Investigational Site, Jyväskylä, Finland|Novo Nordisk Investigational Site, Kuopio, Finland|Novo Nordisk Investigational Site, Lahti, Finland|Novo Nordisk Investigational Site, Oulu, Finland|Novo Nordisk Investigational Site, Seinäjoki, Finland|Novo Nordisk Investigational Site, Tampere, Finland|Novo Nordisk Investigational Site, Turku, Finland|Novo Nordisk Investigational Site, Besançon, France|Novo Nordisk Investigational Site, Bondy, France|Novo Nordisk Investigational Site, Corbeil Essonnes, France|Novo Nordisk Investigational Site, DIJON cedex, France|Novo Nordisk Investigational Site, La Tronche, France|Novo Nordisk Investigational Site, Le Coudray, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, Nice, France|Novo Nordisk Investigational Site, Paris Cedex 18, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Reims, France|Novo Nordisk Investigational Site, Saint Herblain, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Aachen, Germany|Novo Nordisk Investigational Site, Bad Homburg, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Berlin, Germany|Novo Nordisk Investigational Site, Bochum, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Elsterwerda, Germany|Novo Nordisk Investigational Site, Essen, Germany|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Frankfurt, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hannover, Germany|Novo Nordisk Investigational Site, Karlsruhe, Germany|Novo Nordisk Investigational Site, Kassel, Germany|Novo Nordisk Investigational Site, Leipzig, Germany|Novo Nordisk Investigational Site, Leipzig, Germany|Novo Nordisk Investigational Site, Ludwigshafen, Germany|Novo Nordisk Investigational Site, Lübeck, Germany|Novo Nordisk Investigational Site, Oldenburg I. Holst, Germany|Novo Nordisk Investigational Site, Pirna, Germany|Novo Nordisk Investigational Site, Saint Ingbert-Oberwürzbach, Germany|Novo Nordisk Investigational Site, Schkeuditz, Germany|Novo Nordisk Investigational Site, Schwerin, Germany|Novo Nordisk Investigational Site, Villingen-Schwenningen, Germany|Novo Nordisk Investigational Site, Wangen, Germany|Novo Nordisk Investigational Site, Wermsdorf, Germany|Novo Nordisk Investigational Site, Witten, Germany|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Chios, Greece|Novo Nordisk Investigational Site, Haidari-Athens, Greece|Novo Nordisk Investigational Site, Ioannina, Greece|Novo Nordisk Investigational Site, Lamia, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Budapest, Hungary|Novo Nordisk Investigational Site, Gyöngyös, Hungary|Novo Nordisk Investigational Site, Szeged, Hungary|Novo Nordisk Investigational Site, Szombathely, Hungary|Novo Nordisk Investigational Site, Zalaegerszeg, Hungary|Novo Nordisk Investigational Site, Hyderabad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Hyderbad, Andhra Pradesh, India|Novo Nordisk Investigational Site, Vijayawada, Andhra Pradesh, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Ahmedabad, Gujarat, India|Novo Nordisk Investigational Site, Surat, Gujarat, India|Novo Nordisk Investigational Site, Surat, Gujarat, India|Novo Nordisk Investigational Site, Gurgaon, Haryana, India|Novo Nordisk Investigational Site, Bangalore, Karnataka, India|Novo Nordisk Investigational Site, Manipal, Karnataka, India|Novo Nordisk Investigational Site, Aurangabad, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Mumbai, Maharashtra, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Nagpur, Maharashtra, India|Novo Nordisk Investigational Site, Nashik, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Pune, Maharashtra, India|Novo Nordisk Investigational Site, Delhi, New Delhi, India|Novo Nordisk Investigational Site, New Dehli, New Delhi, India|Novo Nordisk Investigational Site, Amritsar, Punjab, India|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Coimbatore, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Lucknow, Uttar Pradesh, India|Novo Nordisk Investigational Site, Kolkata, West Bengal, India|Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Ludhiana, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, New Delhi, India|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Dublin, Ireland|Novo Nordisk Investigational Site, Galway, Ireland|Novo Nordisk Investigational Site, Mallow, Ireland|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Haifa, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Kfar Saba, Israel|Novo Nordisk Investigational Site, Nahariya, Israel|Novo Nordisk Investigational Site, Petah-Tikva, Israel|Novo Nordisk Investigational Site, Rehovot, Israel|Novo Nordisk Investigational Site, Tel Aviv, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel Hashomer, Israel|Novo Nordisk Investigational Site, Tel-Aviv, Israel|Novo Nordisk Investigational Site, Bergamo, Italy|Novo Nordisk Investigational Site, Bologna, Italy|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Chieti Scalo, Italy|Novo Nordisk Investigational Site, Como, Italy|Novo Nordisk Investigational Site, Cona - Ferrara, Italy|Novo Nordisk Investigational Site, Firenze, Italy|Novo Nordisk Investigational Site, Genova, Italy|Novo Nordisk Investigational Site, Latina, Italy|Novo Nordisk Investigational Site, Napoli, Italy|Novo Nordisk Investigational Site, Padova, Italy|Novo Nordisk Investigational Site, Palermo, Italy|Novo Nordisk Investigational Site, Pavia, Italy|Novo Nordisk Investigational Site, Pisa, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Rome, Italy|Novo Nordisk Investigational Site, San Donato Milanese (MI), Italy|Novo Nordisk Investigational Site, Savigliano (CN), Italy|Novo Nordisk Investigational Site, Siena, Italy|Novo Nordisk Investigational Site, Torino, Italy|Novo Nordisk Investigational Site, Adachi-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Asahikawa, Hokkaido, Japan|Novo Nordisk Investigational Site, Bunkyo-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Chiba, Japan|Novo Nordisk Investigational Site, Chikushino-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Ehime, Japan|Novo Nordisk Investigational Site, Funabashi-shi, Chiba, Japan|Novo Nordisk Investigational Site, Gifu-city, Gifu, Japan|Novo Nordisk Investigational Site, Hirakata-shi, Osaka, Japan|Novo Nordisk Investigational Site, Hiroshima-shi, Hiroshima, Japan|Novo Nordisk Investigational Site, Kagoshima-shi, Kagoshima, Japan|Novo Nordisk Investigational Site, Kanagawa, Japan|Novo Nordisk Investigational Site, Kasugai-shi, Aichi, Japan|Novo Nordisk Investigational Site, Kawaguchi-shi, Saitama, Japan|Novo Nordisk Investigational Site, Kitakyushu-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Kochi-shi, Kochi, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Kyoto-shi, Kyoto, Japan|Novo Nordisk Investigational Site, Kyoto-shi,Kyoto, Japan|Novo Nordisk Investigational Site, Kyoto, Japan|Novo Nordisk Investigational Site, Matsuyama-shi, Ehime, Japan|Novo Nordisk Investigational Site, Miyagi, Japan|Novo Nordisk Investigational Site, Moriyama-shi, Shiga, Japan|Novo Nordisk Investigational Site, Nagoya-shi, Aichi, Japan|Novo Nordisk Investigational Site, Naha-shi, Okinawa, Japan|Novo Nordisk Investigational Site, Okawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Okayama-shi, Okayama, Japan|Novo Nordisk Investigational Site, Osaka-city、Osaka, Japan|Novo Nordisk Investigational Site, Osaka, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Sendai-shi, Miyagi, Japan|Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo, Japan|Novo Nordisk Investigational Site, Takamatsu-shi, Kagawa, Japan|Novo Nordisk Investigational Site, Takamatsu-shi, Kagawa, Japan|Novo Nordisk Investigational Site, Takasaki-shi, Gunma, Japan|Novo Nordisk Investigational Site, Tokorozawa-shi, Saitama, Japan|Novo Nordisk Investigational Site, Tokorozawa-shi,Saitama, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Tokyo, Japan|Novo Nordisk Investigational Site, Wako-city, Saitama, Japan|Novo Nordisk Investigational Site, Yanagawa-shi, Fukuoka, Japan|Novo Nordisk Investigational Site, Yokosuka-shi, Kanagawa, Japan|Novo Nordisk Investigational Site, Daugavpils, Latvia|Novo Nordisk Investigational Site, Liepaja, Latvia|Novo Nordisk Investigational Site, Ogre, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Riga, Latvia|Novo Nordisk Investigational Site, Ventspils, Latvia|Novo Nordisk Investigational Site, Alor Gajah, Malaysia|Novo Nordisk Investigational Site, Alor Setar, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Kelantan, Malaysia|Novo Nordisk Investigational Site, Kota Bharu, Malaysia|Novo Nordisk Investigational Site, Kota Samarahan, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuala Lumpur, Malaysia|Novo Nordisk Investigational Site, Kuantan, Malaysia|Novo Nordisk Investigational Site, Putrajaya, Malaysia|Novo Nordisk Investigational Site, Seri Manjung, Malaysia|Novo Nordisk Investigational Site, Sungai Buloh, Malaysia|Novo Nordisk Investigational Site, Torreon, Coahuila, Mexico|Novo Nordisk Investigational Site, Guadalajara, Jalisco, Mexico|Novo Nordisk Investigational Site, Ciudad de Mexico, México, D.F., Mexico|Novo Nordisk Investigational Site, Ciudad de Mexico, México, D.F., Mexico|Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico|Novo Nordisk Investigational Site, San Luis Potosí, San Luis Potosi, Mexico|Novo Nordisk Investigational Site, Culiacán, Sinaloa, Mexico|Novo Nordisk Investigational Site, Aguascalientes, Mexico|Novo Nordisk Investigational Site, Durango, Mexico|Novo Nordisk Investigational Site, Apeldoorn, Netherlands|Novo Nordisk Investigational Site, Breda, Netherlands|Novo Nordisk Investigational Site, Deventer, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Leeuwarden, Netherlands|Novo Nordisk Investigational Site, Leiderdorp, Netherlands|Novo Nordisk Investigational Site, Roosendaal, Netherlands|Novo Nordisk Investigational Site, Rotterdam, Netherlands|Novo Nordisk Investigational Site, Sneek, Netherlands|Novo Nordisk Investigational Site, Tiel, Netherlands|Novo Nordisk Investigational Site, Bergen, Norway|Novo Nordisk Investigational Site, Hamar, Norway|Novo Nordisk Investigational Site, Lillehammer, Norway|Novo Nordisk Investigational Site, Nordbyhagen, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Oslo, Norway|Novo Nordisk Investigational Site, Tønsberg, Norway|Novo Nordisk Investigational Site, Ålesund, Norway|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Bialystok, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdansk, Poland|Novo Nordisk Investigational Site, Gdynia, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Krakow, Poland|Novo Nordisk Investigational Site, Lodz, Poland|Novo Nordisk Investigational Site, Lomza, Poland|Novo Nordisk Investigational Site, Lowicz, Poland|Novo Nordisk Investigational Site, Lublin, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Poznan, Poland|Novo Nordisk Investigational Site, Pulawy, Poland|Novo Nordisk Investigational Site, Siedlce, Poland|Novo Nordisk Investigational Site, Skierniewice, Poland|Novo Nordisk Investigational Site, Szczecin, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Warszawa, Poland|Novo Nordisk Investigational Site, Zamosc, Poland|Novo Nordisk Investigational Site, Almada, Portugal|Novo Nordisk Investigational Site, Coimbra, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Lisboa, Portugal|Novo Nordisk Investigational Site, Matosinhos, Portugal|Novo Nordisk Investigational Site, Porto, Portugal|Novo Nordisk Investigational Site, Trujillo Alto, Puerto Rico|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Oradea, Bihor, Romania|Novo Nordisk Investigational Site, Clarasi, Calaras, Romania|Novo Nordisk Investigational Site, Cluj Napoca, Cluj, Romania|Novo Nordisk Investigational Site, Craiova, Dolj, Romania|Novo Nordisk Investigational Site, Baia Mare, Maramures, Romania|Novo Nordisk Investigational Site, Targu Mures, Mures, Romania|Novo Nordisk Investigational Site, Timisoara, Timis, Romania|Novo Nordisk Investigational Site, Bacau, Romania|Novo Nordisk Investigational Site, Brasov, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucharest, Romania|Novo Nordisk Investigational Site, Bucuresti, Romania|Novo Nordisk Investigational Site, Buzau, Romania|Novo Nordisk Investigational Site, Deva, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Galati, Romania|Novo Nordisk Investigational Site, Iasi, Romania|Novo Nordisk Investigational Site, Iasi, Romania|Novo Nordisk Investigational Site, Iasi, Romania|Novo Nordisk Investigational Site, Pascani, Romania|Novo Nordisk Investigational Site, Ploiesti, Romania|Novo Nordisk Investigational Site, Satu Mare, Romania|Novo Nordisk Investigational Site, Sibiu, Romania|Novo Nordisk Investigational Site, Suceava, Romania|Novo Nordisk Investigational Site, Arkhangelsk, Russian Federation|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Belgorod, Russian Federation|Novo Nordisk Investigational Site, Ekaterinburg, Russian Federation|Novo Nordisk Investigational Site, Ivanovo, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Orenburg, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Rostov-on-Don, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Pushkin, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Sochi, Russian Federation|Novo Nordisk Investigational Site, St. Petersburg, Russian Federation|Novo Nordisk Investigational Site, Syktyvkar, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Tumen, Russian Federation|Novo Nordisk Investigational Site, Tver, Russian Federation|Novo Nordisk Investigational Site, Tyumen, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Voronezh, Russian Federation|Novo Nordisk Investigational Site, Yaroslavl, Russian Federation|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Belgrade, Serbia|Novo Nordisk Investigational Site, Novi Sad, Serbia|Novo Nordisk Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Novo Nordisk Investigational Site, Bloemfontein, Free State, South Africa|Novo Nordisk Investigational Site, Alberton, Gauteng, South Africa|Novo Nordisk Investigational Site, Centurion, Gauteng, South Africa|Novo Nordisk Investigational Site, Germiston, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Johannesburg, Gauteng, South Africa|Novo Nordisk Investigational Site, Lenasia, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Pretoria, Gauteng, South Africa|Novo Nordisk Investigational Site, Roodepoort, Gauteng, South Africa|Novo Nordisk Investigational Site, Durban, KwaZulu-Natal, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa|Novo Nordisk Investigational Site, Kuilsriver, Western Cape, South Africa|Novo Nordisk Investigational Site, Paarl, Western Cape, South Africa|Novo Nordisk Investigational Site, Worcester, Western Cape, South Africa|Novo Nordisk Investigational Site, Almeria, Spain|Novo Nordisk Investigational Site, La Coruña, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Málaga, Spain|Novo Nordisk Investigational Site, Palma de Mallorca, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Kristianstad, Sweden|Novo Nordisk Investigational Site, Lund, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Örebro, Sweden|Novo Nordisk Investigational Site, Östersund, Sweden|Novo Nordisk Investigational Site, Hsinchu City, Taiwan|Novo Nordisk Investigational Site, Kaohsiung City, Taiwan|Novo Nordisk Investigational Site, New Taipei City, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taoyuan City, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Chiang Mai, Thailand|Novo Nordisk Investigational Site, Khon kaen, Thailand|Novo Nordisk Investigational Site, Klong Luang, Pathumthani, Thailand|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Adana, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Ankara, Turkey|Novo Nordisk Investigational Site, Antalya, Turkey|Novo Nordisk Investigational Site, Aydin, Turkey|Novo Nordisk Investigational Site, Eskisehir, Turkey|Novo Nordisk Investigational Site, Gaziantep, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Izmir, Turkey|Novo Nordisk Investigational Site, Kayseri, Turkey|Novo Nordisk Investigational Site, Mersin, Turkey|Novo Nordisk Investigational Site, Sivas, Turkey|Novo Nordisk Investigational Site, Chernivtsi, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kharkiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Kyiv, Ukraine|Novo Nordisk Investigational Site, Lviv, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Odesa, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Vinnytsia, Ukraine|Novo Nordisk Investigational Site, Zhytomyr, Ukraine|Novo Nordisk Investigational Site, Addlestone, United Kingdom|Novo Nordisk Investigational Site, Airdrie, United Kingdom|Novo Nordisk Investigational Site, Antrim, United Kingdom|Novo Nordisk Investigational Site, Axbridge, United Kingdom|Novo Nordisk Investigational Site, Basingstoke, United Kingdom|Novo Nordisk Investigational Site, Bexhill-on-Sea, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Blackpool, United Kingdom|Novo Nordisk Investigational Site, Bollington, United Kingdom|Novo Nordisk Investigational Site, Bradford-on-Avon, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cardiff, United Kingdom|Novo Nordisk Investigational Site, Chertsey, United Kingdom|Novo Nordisk Investigational Site, Chester, United Kingdom|Novo Nordisk Investigational Site, Coventry, United Kingdom|Novo Nordisk Investigational Site, Denmark Hill, London, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Exeter, United Kingdom|Novo Nordisk Investigational Site, Harrogate, North Yorkshire, United Kingdom|Novo Nordisk Investigational Site, Harrow, United Kingdom|Novo Nordisk Investigational Site, High Wycombe, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Leicester, United Kingdom|Novo Nordisk Investigational Site, Lincoln, United Kingdom|Novo Nordisk Investigational Site, Liverpool, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Manchester, United Kingdom|Novo Nordisk Investigational Site, Middlesbrough, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Rhyl, United Kingdom|Novo Nordisk Investigational Site, Rotherham, United Kingdom|Novo Nordisk Investigational Site, Sandbach, United Kingdom|Novo Nordisk Investigational Site, Somerset, United Kingdom|Novo Nordisk Investigational Site, Southampton, United Kingdom|Novo Nordisk Investigational Site, Stevenage, United Kingdom|Novo Nordisk Investigational Site, Sunderland, United Kingdom|Novo Nordisk Investigational Site, Taunton, United Kingdom|Novo Nordisk Investigational Site, Torquay, United Kingdom|Novo Nordisk Investigational Site, Truro, United Kingdom|Novo Nordisk Investigational Site, West Sussex, United Kingdom|Novo Nordisk Investigational Site, Wishaw, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03574597"
967,"NCT03893734","Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery",,"Recruiting","No Results Available","EKG-QT Prolongation","Drug: methadone|Drug: Hydromorphone","QT prolongation on the EKG 30 minutes after postanesthesia care unit admission|QT prolongation on the EKG on the morning of postoperative day one|Level of pain on on a 0-10 scale 30 minutes after postanesthesia care unit admission|Level of pain on a 0-10 scale on the morning of postoperative day one","NorthShore University HealthSystem","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","EH17-264","May 1, 2018","August 12, 2020","December 23, 2020","March 28, 2019",,"September 13, 2019","NorthShore University HealthSystem, Evanston, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03893734"
968,"NCT01786512","COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.","COSMIC-HF","Completed","No Results Available","Modified Release Oral Formulation|Left Ventricular Systolic Dysfunction|Chronic Heart Failure|History of Chronic Heart Failure|Left Ventricular Ejection Fraction|Pharmacokinetics|Echocardiogram","Drug: Omecamtiv Mecarbil|Drug: Placebo","Dose Escalation - Characterize Pharmacokinetics - Cmax|Dose Escalation - Characterize Pharmacokinetics -Cmin|Dose Escalation - Characterize Pharmacokinetics-Tmax|Dose Escalation - Characterize Pharmacokinetics - AUC12h|Dose Expansion - Characterize Pharmacokinetics - Cmax|Dose Expansion - Characterize Pharmacokinetics - Cpredose|Systolic Ejection Time(SET) (msec)|Left Ventricular End-Systolic Diameter (LVESD) (cm)|Left Ventricular End-Diastolic Diameter (LVEDD) (cm)|Heart Rate (beats per minute)|Stroke Volume (ml)|Effect of omecamtiv mecarbil on NT-proBNP (pg/mL)|Dose Escalation - Safety and tolerability of oral omecamtiv mecarbil|Dose Expansion - Safety and tolerability of oral omecamtiv mecarbil","Amgen|Cytokinetics","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","544","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20110151","February 26, 2013","July 22, 2015","August 19, 2015","February 8, 2013",,"August 16, 2017","Research Site, Mobile, Alabama, United States|Research Site, Costa Mesa, California, United States|Research Site, Fresno, California, United States|Research Site, Inglewood, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Tustin, California, United States|Research Site, Danbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Atlantis, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Peekskill, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Gent, Belgium|Research Site, Ieper, Belgium|Research Site, Liege, Belgium|Research Site, Kazanlak, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Trois Rivieres, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Svitavy, Czechia|Research Site, Teplice, Czechia|Research Site, Bad Krozingen, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Greifswald, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Jaszbereny, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Brescia, Italy|Research Site, Pavia, Italy|Research Site, Verona, Italy|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Amersfoort, Netherlands|Research Site, Groningen, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Bialystok, Poland|Research Site, Klodzko, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Ruda Slaska, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Dudley, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01786512"
969,"NCT02939599","Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: QCC374","Number of Participants Who Experienced Adverse Events (AEs), Serious Adverse Events (SAEs) in Patients With PAH Over a Two Year Period|Maximum Observed Plasma Concentration (Cmax)|Time to Reach the Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast)|Area Under the Plasma Concentration Time Curve From 0 to the End of a Dosing Interval (AUCtau)|Change From Baseline in Six Minute Walk Distance (6MWD)|Change in Tricuspid Annular Peak Systolic Velocity (TA S') at Week 16 (Day 112) Using Echocardiography|Change From Baseline in RV Tei Index at Week 16 (Day 112) Using Echocardiography|Change From Baseline in RV Fractional Area Change at Week 16 (Day 112) Using Echocardiography","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQCC374X2201E1","February 1, 2018","November 6, 2018","November 6, 2018","October 20, 2016","February 28, 2020","February 28, 2020","Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02939599/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02939599/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02939599"
970,"NCT01477333","Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: UT-15C SR|Drug: Tyvaso Inhalation Solution","Change in Hemodynamic Parameters From Baseline to Week 24.|Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.|Change in Hemodynamic Parameters (Arterial and Venous Oxygen Saturation) From Baseline to Week 24.|Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.|Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.|Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.|Change in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Over the 24-week Treatment Period.|Time to Clinical Worsening Over the Treatment Period.|Shift From Baseline in World Health Organization (WHO) Functional Class Over the 24-week Treatment Period.|N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Over the 24-week Treatment Period.","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-203","October 2011","November 2013","November 2013","November 22, 2011","March 6, 2017","March 6, 2017","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Allegheny General Hospital, Pittsburg, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01477333"
971,"NCT01458405","Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration","ALLSTAR","Terminated","No Results Available","Myocardial Infarction","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells|Drug: Placebo","Infarct size assessed by MRI","Capricor Inc.|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|California Institute for Regenerative Medicine (CIRM)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","156","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1002-01|RC3HL103356-01","November 13, 2012","July 3, 2017","February 28, 2019","October 24, 2011",,"April 9, 2019","Cardiology, P.C., Birmingham, Alabama, United States|Heart Center Research, Huntsville, Alabama, United States|Scripps, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Florida - Shands Hospital, Gainesville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Prairie Heart - St. John's Hospital, Springfield, Illinois, United States|Kansas University Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|Michigan CardioVascular Institute, Saginaw, Michigan, United States|Metropolitan Heart and Vascular Institute / Mercy Hospital, Coon Rapids, Minnesota, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|University at Buffalo, Buffalo, New York, United States|Lenox Hill Hospital, New York, New York, United States|Carolinas HealthCare System, Charlotte, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|NC Heart & Vascular Research, Raleigh, North Carolina, United States|SUMMA Health System, Akron, Ohio, United States|Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Austin Heart, Austin, Texas, United States|University of Texas Memorial Hermann Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Swedish Medical Center - Heart and Vascular Research, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Aurora Research Institute, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01458405"
972,"NCT02153437","Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers",,"Terminated","No Results Available","Atrial Fibrillation","Drug: BMS-919373|Drug: Sotalol|Drug: Placebo for BMS-919373","The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker|The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests|Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline|Safety assessments based on Atrioventricular interval (AVI) and change from baseline|Safety assessments based on Wenckebach cycle length (WCL) and change from baseline|Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline","Bristol-Myers Squibb","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","CV205-006","October 2014","October 2016","October 2016","June 3, 2014",,"February 15, 2017","Local Institution, Austin, Texas, United States|The University Of Calgary, Calgary, Alberta, Canada|University Of Ottawa Heart Institute, Ottawa, Ontario, Canada|St. Michael'S Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02153437"
973,"NCT01560624","Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy","FREEDOM-EV","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Treprostinil Diolamine|Drug: Placebo","Time to First Clinical Worsening Event|Change in 6-Minute Walk Distance|Change in Plasma N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 24|Change in World Health Organization Functional Class (WHO FC) From Baseline to Week 48","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","690","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDE-PH-310","June 26, 2012","June 24, 2018","June 24, 2018","March 22, 2012","February 13, 2020","February 13, 2020","Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program, Sacramento, California, United States|David Geffen School of Medicine, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine, Jacksonville, Florida, United States|University of Florida College of Medicine Jacksonville, Jacksonville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|HeartCare Midwest, Peoria, Illinois, United States|Indiana University Hospital, Carmel, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Beaumont Health, Troy, Michigan, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|University of Rochester, Rochester, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospital, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Legacy Research Institute, Portland, Oregon, United States|Perelman Center for Advanced Medicine; University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Sanatorio San José, Caba, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Hospital Italiano Garibaldi, Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Dr. José María Cullen, Santa Fe, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Saint Vincents Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Krankenhaus Elisabethinen Linz, Linz, Upper Austria, Austria|Medizinische Universität Wien, Wien, Austria|Hospital das Clinicas da Universidade Federal de Goias, Goiania, Goias, Brazil|Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital das Clínicas da Faculdade de Medicina de Botucatu- UNESP, Botucatu, SAO Paulo, Brazil|Hospital da Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SAO Paulo, Brazil|Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SAO Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Respiratory Research Foundation, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Coastal Health, Vancouver, British Columbia, Canada|Lawson Health Research Institute, London, Ontario, Canada|Centro de Investigaciones TASOL, Santiago, Region Metropolitana, Chile|Clínica Tabancura, Vitacura, Santiago, Chile|Beijing Chao-Yang Hospital, Beijing, Beijing, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Xiangya Hospital, Changsha, Hunan, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China|Peking Union Medical College Hospital, Beijing, China|Beijing Shijitan Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Renji Hospital of Shanghai Jiaotong University, Shanghai, China|Shanghai Pulmonary Hospital of Tongji University, Shanghai, China|Shenyang General Hospital of Shenyang Military Command, Shenyang, China|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark|Hopital Haut-Leveque, CHU Bordeaux, Pessac, Aquitaine, France|Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon, Besancon, Franche-comte, France|CHU de Montpellier, Montpellier Cedex 5, Languedoc-roussillon, France|Hopital Brabois, Vandoeuvre-Les-Nancy, Limousin, Lorraine, France|Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille, NORD Pas-de-calais, France|Centre Hospitalier Universitaire Hopital Nord, Marseille, Provence Alpes COTE D'azur, France|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Missionsarztliche Klinik Wurzburg gGmbH, Wurzburg, Bayern, Germany|Universitätsmedizin Greifswald, Greifswald, Mecklenburg-vorpommern, Germany|Bergmannsheil Berufsgenossenschaftliche Universitätsklinik GmbH, Bochum, Nordrhein-westfalen, Germany|Herzzentrum Duisburg, Duisburg, Nordrhein-westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Technische Universität Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätskrankenhaus Hamburg-Eppendorf, Hamburg, Germany|Technische Universität Dresden, Sachsen, Germany|University General Hospital of Attikon, Athens, Attica, Greece|General Hospital of Thessaloniki, ""G.Papanikolaou"", Thessaloniki, Macedoni, Greece|CARE Hospital, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Care Institute Medical Sciences, Ahmedabad, Gujarat, India|Apollo Hospitals International, Ltd., Gandhinagar, Gujarat, India|Medanta - The Medicity, Gurgaon, Haryana, India|Narayana Institute of Cardiac Sciences, Bangalore, Karnataka, India|KEM Hospital, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Apollo Hospital, Chennai, Tamil NADU, India|G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil NADU, India|Rabin Medical Center, Petach Tikvah, Petah Tiqwa, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Tel Aviv, Israel|Rambam Health Corp., Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Azienda Ospedaliera Universitaria, Napoli, Italy|Istituto Mediterraneo Trapianti e Terapia Alta Specializzazione (ISMETT), Palermo, Italy|Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Tlalpan, Distrito Federal, Mexico|Unidad de Investigacion Clinica en Medicina S.C., Monterrey, Nuevo LEON, Mexico|Universitair Medisch Centrum Sint Radboud, Nijmegen, Gelderland, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Krakow, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Malogoskie, Poland|Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina, Otwock, Poland|National University Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Sahlgrenska University Hospital, Göteborg, Vastra Gotaland, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|National Cheng Kung University Hospital, Tainan, Tainan CITY, Taiwan|Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Papworth Hospital, Papworth Everard, Cambridgshire, United Kingdom|Royal Free Hospital, London, England, United Kingdom|Freeman Hospital, Newcastle upon Tyne, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01560624/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01560624/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01560624"
974,"NCT01212900","Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression",,"Completed","Has Results","Atherosclerosis|Hypercholesterolemia","Drug: Statins, HMG CoA","Change in Mean of Wall Volume of Internal Carotid Arteries","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","50 Years to 99 Years   (Adult, Older Adult)","Phase 4","230","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","100214|10-H-0214","September 30, 2010","November 30, 2016","February 22, 2017","October 1, 2010","October 31, 2018","November 30, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01212900/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01212900"
975,"NCT01206062","Systolic Blood Pressure Intervention Trial","SPRINT","Active, not recruiting","Has Results","Hypertension","Drug: Intensive control of SBP|Drug: Standard control of SBP","Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death|Number of Participants With All-cause Mortality|Number of CKD Participants Who Experienced a 50% Decline From Baseline eGFR|Participants Who Developed End Stage Renal Disease|Dementia|Decline in Cognitive Function|Small Vessel Cerebral Ischemic Disease","National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Neurological Disorders and Stroke (NINDS)|Wake Forest University Health Sciences","All","50 Years and older   (Adult, Older Adult)","Not Applicable","9361","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","SPRINT|268200900040C-1-0-1","October 2010","July 2016","November 2018","September 21, 2010","December 4, 2017","October 18, 2018","Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01206062/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01206062/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01206062"
976,"NCT02927223","Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)",,"Completed","Has Results","Catecholaminergic Polymorphic Ventricular Tachycardia","Drug: Atropine|Procedure: Exercise treadmill test","Number of Ventricular Ectopic Beats Recorded During Exercise (and Recovery)","Vanderbilt University|Vanderbilt University Medical Center","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","VUMC-161398","October 2016","February 2019","February 2019","October 6, 2016","January 28, 2020","January 28, 2020","Vanderbilt University, Nashville, Tennessee, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02927223/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02927223"
977,"NCT01833455","Premature Ventricular Contractions (PVCs) and Blood Pressure Control",,"Terminated","Has Results","Ventricular Premature Complexes|Blood Pressure","Drug: PVC Suppression using Flecainide|Drug: No PVC Suppression using Placebo","Change in Mean Arterial Pressure|Change in Muscle Sympathetic Nerve Activity","University of Wisconsin, Madison","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","UW-PVC-2012-0510","February 2013","June 2016","June 2016","April 16, 2013","February 22, 2019","February 22, 2019","University of Wisconsin, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01833455"
978,"NCT04169100","Novel Form of Acquired Long QT Syndrome",,"Recruiting","No Results Available","Long QT Syndrome|Connective Tissue Diseases|Rheumatoid Arthritis","Drug: Prednisone","Change in Corrected QT Interval|Change in Cytokine Levels|Change in ESR|Change in CRP","Narrows Institute for Biomedical Research|VA New York Harbor Healthcare System","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 4","25","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ORD01372","September 28, 2011","March 31, 2024","September 30, 2024","November 19, 2019",,"November 19, 2019","VA New York Harbor Healthcare System, NY and Brooklyn Campuses, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04169100"
979,"NCT02285920","Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial","SPin-D","Completed","Has Results","End-Stage Renal Disease","Drug: Spironolactone","Safety - Number of Participants With Serum Potassium >6.5 mEq/L|Safety - Participants With Serious Hypotension|Study Drug Tolerability|Efficacy - Change in Mitral Annular E' Velocity|Feasibility of Conducting a Full-scale Mortality-powered Trial|Safety - Number of Participants With Serious Hyperkalemia|Safety - Hyperkalemia Requiring Adjustment in Treatment|Safety - Inter- or Intra-dialytic Hypotension|Safety - Cardiovascular Death|Efficacy - Secondary Cardiac Outcome Measure - Left Ventricular Ejection Fraction (LVEF)|Efficacy - Secondary Cardiac Outcome Measures Left Ventricular Mass Index (LVMI)|Efficacy - Secondary Cardiac Outcome Measures - Ratio of Mitral Peak Velocity to Diastolic Mitral Annular Velocity (E/E')|Efficacy - Secondary Cardiac Outcome Measures - Left Ventricular Global Longitudinal Strain (LVGLS)|Safety - Combined Incidence of Potassium >6.5 mEq/L or Serious Hyperkalemia","University of Pennsylvania|Brigham and Women's Hospital|George Washington University|Vanderbilt University|University of Washington","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","129","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","821193","November 2014","June 2017","July 30, 2017","November 7, 2014","July 23, 2019","July 23, 2019","The George Washington University, Washington, District of Columbia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Kidney Research Institute, University of Washington, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02285920/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02285920"
980,"NCT01648205","Efficacy Study of Sodium Channel Blocker in LQT3 Patients",,"Completed","No Results Available","Long QT Syndrome","Drug: Placebo|Drug: Ranolazine","QTc duration|Change in Novel ECG, Echo, and Holter-derived markers from baseline at 2 and 6 months","University of Rochester|Gilead Sciences","All","21 Years and older   (Adult, Older Adult)","Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IN-US-259-0128","September 2012","July 20, 2018","July 20, 2018","July 24, 2012",,"February 19, 2019","University of Rochester, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01648205"
981,"NCT01572909","Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events","EMBRACE","Completed","No Results Available","Reperfusion Injury|STEMI","Drug: Bendavia (MTP-131)|Drug: Placebo","Comparison between treatment groups of the infarct size measured by the area under the creatine kinase-MB (CK-MB)enzyme curve.|Comparison between treatment groups of the measurement of the cardiac infarct size calculated by the area under the troponin I enzyme curve.|Comparison between treatment groups of the measurement of the cardiac infarct size calculated by the volume of infarcted myocardium.|Comparison between treatment groups of the infarct size as measured by the ratio of the volume of infarcted myocardium to the volume of edematous myocardium.|Comparison between treatment groups of the degree and incidence of ""no-reflow"".|Comparison between treatment groups of the myocardial function and structure.|Comparison between treatment groups of the incidence of immediate myocardial complications.|The pharmacokinetics of Bendavia in acute STEMI.|Comparison between treatment groups of the myocardial infarct size|Comparison between treatment groups of the laboratory markers of congestive heart failure and systemic inflammation.|Comparison between treatment groups of the comparative impact of Bendavia through 30 days and 6 months on the incidence of the composite endpoint.|Comparison between treatment groups of renal function.","Stealth BioTherapeutics Inc.|ICON Clinical Research","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SPIRI-201","April 2012","November 2014","February 2015","April 6, 2012",,"December 10, 2015","Advanced Medical Research Center, Port Orange, Florida, United States|Henry Ford Hospital, Detroit, Michigan, United States|Creighton Cardiac Center, Omaha, Nebraska, United States|Universitätsmedizin Berlin, Charité Campus Benjamin Franklin, Berlin, Germany|Staedtische Kliniken Bielefeld, Bielefeld, Germany|Marienhaus Klinikum Eifel, Bitburg, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Klinikum Herford, Herford, Germany|Robert-Bosch-Krankenhaus Kardiologie, Stuttgart, Germany|Helios Klinikum Wuppertal, Herzzentrum Elberfeld, Wuppertal, Germany|Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Budapest, Hungary|Semmelweis Egyetem Kardiológiai Központ, Városmajor u. 68, Budapest, Hungary|Honvédkórház-Állami Egészségügyi Központ, Budapest, Hungary|PTE Klinikai Központ Szívgyógyászati Klinika, Pecs, Hungary|Szent György Kórház, II. Belgyógyászati Osztály, Szekesfehervar, Hungary|Zala Megyei Kórház, Kardiológiai Osztály, Zrínyi Miklós út 1., Zalaegerszeg, Hungary|Krakowski Szpital Specjalistyczny im. Jana Pwla II, Centrum Interwencyjnego Leczenia Chorob Serca i Naczyn z Pododdzialem Kariologii Interwencyjnej, ul. Pradnicka 80, Krakow, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Pracownia Kardiologii Inwazyjnej, ul. Banacha 1A, Warsaw, Poland|Medical University of Bialystok, Bialystok, Poland|SPSK Nr 7 Klaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszka Gieca, III Oddzial Kardiologii, Zklad Kardiologii Inwazjnejul, Ziolowa 45-47, Katowice, Poland|SPSK Nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszaka Gieca, I Oddzial Kardiologii, ul. Ziolowa 45-47, Katowice, Poland|Wojewodzki Szpital Zespolony w Kielcach, Swietokrzyskie Centrum Kardiologii, Kielce, Poland|Wojewodzki Specjalistyczny Szpital im WI. Bieganskiego, II Katedra i Klinika Kardiologii Uniwersytetu Medycznego w Lodzi, Pracownia Kardiologii Inwazyinej, ul. Kniaziewicza 1/5, Lodz, Poland|SP ZOZ Wojewodzkie Centrum Medyczne, Zaklad Diagnostyki Obrazowej, AI. W. Witosa 26, Opole, Poland|Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii, Oswiecim, Poland|Szpital Bielanski im. ks. Jerzego Popieluszki, Warsaw, Poland|Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego, Warsaw, Poland|Dolnoslaski Szpital Specjalistyczny im. T. Marciniaka, Centrum Medycyny Ratunkowe, Wroclaw, Poland|Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny, ul. H. Kamieskiego 73a, Wroclaw, Poland|Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II w Zamosciu, Oddzial Kardiologii z Pododdzialem Intensywnej Terapil Kardiologicznej, ul. Aleje Jana Pawta II 10, Zamosc, Poland",,"https://ClinicalTrials.gov/show/NCT01572909"
982,"NCT01265888","Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.","PHiano","Completed","No Results Available","Pulmonary Arterial Hypertension|Idiopathic Pulmonary Fibrosis","Drug: Inhaled Nitric Oxide","Identify the minimally and maximum effective doses of inhaled nitric oxide generated by the GeNOsyl® System compared to placebo.|Assess the safety and tolerability of nitric oxide generated by the GeNOsyl® System in subjects with WHO Group 1 PAH and WHO Group 3 PH-IPF.|Evaluate the pharmacokinetics of total nitrates/nitrites and methemoglobin produced following inhalation of nitric oxide via the GeNOsyl® System.","Geno LLC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Protocol # GeNO-P-2010-002|PHiano","March 2011","September 2016","September 2016","December 23, 2010",,"September 19, 2016","University of Alabama @ Birmingham, Birmingham, Alabama, United States|VA Greater LA Health Care System-UCLA, Los Angeles, California, United States|University of California- Davis Medical Center, Sacramento, California, United States|National Jewish Health, Denver, Colorado, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States|Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01265888"
983,"NCT02008461","Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias",,"Unknown status","No Results Available","Supra-ventricular Tachyarrhythmias","Procedure: radiofrequency ablation|Drug: botulinum toxin injection","number of episodes of atrial fibrillation|serious adverse events","Meshalkin Research Institute of Pathology of Circulation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BT_SVT","June 2013","December 2015","February 2016","December 11, 2013",,"September 23, 2015","University of Rochester, Rochester, New York, United States|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02008461"
984,"NCT03789552","Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina",,"Recruiting","No Results Available","Chronic Stable Angina Pectoris","Drug: T89 capsule|Drug: Placebo capsule","Change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 57|The trend of TED changes over time (Slop) from Day 1 to Day 57|Percent change in the average frequency of angina episodes (average over 14 days) from baseline [Day -14 to 1] to end of double-blind treatment period [Day 43 to 57]|Percent change in the average on-demand consumption of short-acting nitroglycerin (average over 14 days) from baseline [Day -14 to 1] to end of double-blind treatment period [Day 43 to 57].|Change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 43|Percent change in the average frequency of angina episodes (average over 14 days) from baseline [Day -14 to 1] to Week-6 visit of double-blind treatment period [Day 29 to 43]|Change in time to onset of angina during ETT from baseline to Day 57|Change in time to 1 mm ST depression during ETT from baseline to Day 57","Tasly Pharmaceuticals, Inc.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 3","765","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T89-08-ORESA","August 1, 2019","April 1, 2022","September 1, 2022","December 28, 2018",,"April 9, 2020","Southwest Florida Research LLC, Naples, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03789552"
985,"NCT00902174","Imatinib (QTI571) in Pulmonary Arterial Hypertension","IMPRES","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: imatinib mesylate|Drug: Placebo","Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks|Clinical Worsening Comparing Imatinib Versus Placebo for Adjudicated Cases|Change From Baseline in Right Atrial Pressure|Change From Baseline in Mean Pulmonary Arterial Pressure|Change From Baseline in Mean Pulmonary Capillary Wedge Pressure|Change From Baseline in Systemic Vascular Resistance|Change From Baseline in Pulmonary Vascular Resistance|Change From Baseline in Pulmonary Resistance Index|Change From Baseline in Cardiac Output|Change From Baseline in Systolic Arterial Blood Pressure|Change From Baseline in Diastolic Arterial Blood Pressure|Change From Baseline in Heart Rate|Change in Borg Dyspnea Score During 6-minute Walk Test|Covariance of End of Study CAMPHOR Score|Plasma Concentration of QTI571 200 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant|Plasma Concentration of QTI571 400 mg and Its Metabolite (GCP74588) Pre-dose and Between 0 Hour to 3 Hour Post-dose Per Participant","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CQTI571A2301","September 2009","May 2011","May 2011","May 15, 2009","July 16, 2013","February 17, 2016","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Clearwater, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Rochester, Minnesota, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Minneola, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis investigative site, Innsbruck, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Calgary, Canada|Novartis Investigative Site, Edmonton, Canada|Novartis Investigative Site, London, Canada|Novartis Investigative Site, Montreal, Canada|Novartis Investigative Site, Ottawa, Canada|Novartis investigative site, Toronto, Canada|Novartis Investigative Site, Vancouver, Canada|Novartis Investigative Site, Clamart Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Giessen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Koln, Germany|Novartis investigative site, Lowenstein, Germany|Novartis Investigative Site, Munchen, Germany|Novartis Investigative Site, Regensberg, Germany|Novartis Investigative Site, Wurzberg, Germany|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Pisa, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Bunkyo-ku, Japan|Novartis Investigative Site, Hamamatsu, Japan|Novartis Investigative Site, Mitaka, Japan|Novartis Investigative Site, Okayama, Japan|Novartis Investigative Site, Sendai, Japan|Novartis Investigative Site, Suita, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Caceras, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis investigative site, La Laguna, Spain|Novartis Investigative Site, Las Palmas de Gran Canarias, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis investigative site, Valencia, Spain|Novartis Investigative Site, Valladolid, Spain|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Umea, Sweden|Novartis Investigative Site, Uppsala, Sweden|University Hospital Basel, Basel, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Clydebank, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00902174"
986,"NCT01609140","A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease",,"Completed","No Results Available","Coronary Heart Disease","Drug: MPSK3169A|Drug: Placebo","Absolute change from baseline in LDL-c concentration|Absolute change from baseline in LDL-c concentration for each arm at the nadir for that arm|Average value over time of the change in LDL-c (absolute and percent change) for each arm, up to Day 169, weighted by the number of weeks between consecutive LDL-c measurements|Percent change from baseline in LDL-c concentration at Day 169 and at the nadir for each arm|Percent and absolute change from baseline in LDL-c concentration at all other designated timepoints|Percent and absolute change from baseline in total cholesterol, non-HDL-c, and apolipoprotein B (ApoB) at Day 169 and at the nadir for each arm","Genentech, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GC28210","May 2012","May 2013","July 2013","May 31, 2012",,"November 2, 2016","Goodyear, Arizona, United States|Carmichael, California, United States|Spring Valley, California, United States|Walnut Creek, California, United States|Wildomar, California, United States|Jacksonville, Florida, United States|Ponte Verde, Florida, United States|Boise, Idaho, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Auburn, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Wilmington, North Carolina, United States|Fargo, North Dakota, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Springdale, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Greer, South Carolina, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Knoxville, Tennessee, United States|Boerne, Texas, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Richmond, Virginia, United States|Wenatchee, Washington, United States|Mount Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Sarnia, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sainte-foy, Quebec, Canada|St-jerome, Quebec, Canada|Trois-Rivières, Quebec, Canada|Hodonin, Czech Republic|Jičícin, Czech Republic|Marianske Lazne, Czech Republic|Ostrava - Poruba, Czech Republic|Rakovník, Czech Republic|Berlin, Germany|Köln, Germany|Komarom, Hungary|Nagykanizsa, Hungary|Nyíregyháza, Hungary|Sopron, Hungary|Auckland, New Zealand|Auckland, New Zealand|Christchurch, New Zealand|Nelson, New Zealand|Tauranga, New Zealand|Elverum, Norway|Hamar, Norway|Oslo, Norway|Oslo, Norway|Sandnes, Norway|Bardejov, Slovakia|Bratislava, Slovakia|Presov, Slovakia|Rimavska Sobota, Slovakia|Cape Town, South Africa|Cape Town, South Africa|Centurion, South Africa|Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT01609140"
987,"NCT01830543","A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","PIONEER AF-PCI","Completed","Has Results","Atrial Fibrillation|Percutaneous Coronary Intervention","Drug: rivaroxaban 2.5 mg|Drug: rivaroxaban 15 mg|Drug: rivaroxaban 10 mg|Drug: aspirin (ASA)|Drug: vitamin K antagonist (VKA)|Drug: clopidogrel|Drug: prasugrel|Drug: ticagrelor","Percentage of Participants With Clinically Significant Bleeding|Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding|Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding|Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)|Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)|Percentage of Participants With Cardiovascular Death|Percentage of Participants With Myocardial Infarction|Percentage of Participants With Stroke|Percentage of Participants With Stent Thrombosis","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","2124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100758|RIVAROXAFL3003|2012-001491-11","May 10, 2013","July 28, 2016","July 28, 2016","April 12, 2013","July 31, 2017","September 19, 2017","Huntsville, Alabama, United States|Los Alamitos, California, United States|Mission Viejo, California, United States|Oceanside, California, United States|Riverside, California, United States|Sacramento, California, United States|San Francisco, California, United States|Stockton, California, United States|Thousand Oaks, California, United States|Torrance, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Danbury, Connecticut, United States|Washington, D.C., District of Columbia, United States|Atlantis, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Jacksonville, Florida, United States|Port Charlotte, Florida, United States|Safety Harbor, Florida, United States|Saint Petersburg, Florida, United States|Tallahassee, Florida, United States|Tampa, Florida, United States|Columbus, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Hazel Crest, Illinois, United States|Indianapolis, Indiana, United States|Munster, Indiana, United States|Hammond, Louisiana, United States|Lake Charles, Louisiana, United States|Slidell, Louisiana, United States|Auburn, Maine, United States|Bangor, Maine, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Lansing, Michigan, United States|Mount Clemens, Michigan, United States|Petoskey, Michigan, United States|Ypsilanti, Michigan, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Haddon Heights, New Jersey, United States|New Brunswick, New Jersey, United States|Newark, New Jersey, United States|Ridgewood, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Peekskill, New York, United States|Sanford, North Carolina, United States|Bartlesville, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Bend, Oregon, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Erie, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|York, Pennsylvania, United States|Greenville, South Carolina, United States|Mount Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Humble, Texas, United States|Odessa, Texas, United States|Plano, Texas, United States|Layton, Utah, United States|Charlottesville, Virginia, United States|Manassas, Virginia, United States|Midlothian, Virginia, United States|Richmond, Virginia, United States|Bellevue, Washington, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Weston, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|C.a.b.a., Argentina|Cordoba, Argentina|Corrientes, Argentina|La Plata, Argentina|Resistencia, Argentina|Rosario, Argentina|Santa Fe, Argentina|Vicente Lopez, Argentina|Chermside N/A, Australia|Epping, Australia|Hobart, Australia|Kogarah, Australia|Liverpool, Australia|New Lambton, Australia|Wollongong, Australia|Aalst, Belgium|Bonheiden, Belgium|Brasschaat, Belgium|Brugge, Belgium|Bruxelles, Belgium|Genk, Belgium|Gent, Belgium|Liège, Belgium|Mechelen, Belgium|Mol, Belgium|Roeselare, Belgium|Turnhout, Belgium|Belo Horizonte, Brazil|Blumenau, Brazil|Brasilia, Brazil|Campina Grande Do Sul, Brazil|Campinas, Brazil|Curitiba, Brazil|Marilia, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Uberlandia, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Pazardjik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Edmonton, Alberta, Canada|Maple Ridge, British Columbia, Canada|New Westminster, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|St. John'S, Newfoundland and Labrador, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Chicoutimi, Canada|Quebec, Canada|Saint John, Canada|Alto, Chile|Concepcion, Chile|Punta Arenas, Chile|Santiago, Chile|Temuco, Chile|Brno 2, Czechia|Brno, Czechia|Hradec Kralove, Czechia|Jablonec Na Nisou, Czechia|Karlovy Vary, Czechia|Kladno, Czechia|Litomysl, Czechia|Olomouc, Czechia|Plzen, Czechia|Praha 10 N/A, Czechia|Praha 2, Czechia|Praha, Czechia|Slany, Czechia|Uherske Hradiste, Czechia|Aalborg, Denmark|Copenhagen, Denmark|Esbjerg, Denmark|Herlev, Denmark|Herning, Denmark|Hvidovre, Denmark|Koege, Denmark|Naestved, Denmark|Odense, Denmark|Roskilde, Denmark|Svendborg N/A, Denmark|Vejle, Denmark|Besancon Cedex Franche-Comté, France|Caen Cedex 9, France|Centres, France|Chartres, France|Lille, France|Limoges Cedex, France|Marseille Cedex 05, France|Montfermeil, France|Nantes Cedex 1, France|Nimes, France|Paris 75, France|Paris, France|Pau, France|Pessac, France|Poitiers, France|Toulouse, France|Bad Friedrichshall, Germany|Bad Nauheim, Germany|Berlin, Germany|Dresden, Germany|Esslingen, Germany|Frankfurt Am Main, Germany|Freiburg, Germany|Greifswald, Germany|Göttingen, Germany|Hamburg, Germany|Heidelberg, Germany|Köln, Germany|Limburg, Germany|Mannheim, Germany|Ulm, Germany|Witten, Germany|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Gyeonggi-Do, Korea, Republic of|Incheon, Korea, Republic of|Seongnam, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Uijeongbu, Korea, Republic of|Wonju, Korea, Republic of|Georgetown, Malaysia|Johor Bahru, Malaysia|Kajang, Malaysia|Kuala Lumpur, Malaysia|Aguascalientes, Mexico|Guadalajara, Mexico|Leon, Mexico|Mexico, Mexico|Pachuca, Mexico|Puebla, Mexico|Queretaro, Mexico|Villahermosa, Mexico|Zapopan, Mexico|Alkmaar, Netherlands|Amsterdam Zuidoost, Netherlands|Amsterdam, Netherlands|Breda, Netherlands|Delft, Netherlands|Den Bosch, Netherlands|Gorinchem, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Sneek, Netherlands|Uden, Netherlands|Bedzin, Poland|Bielsko-Biala, Poland|Chrzanow, Poland|Gdynia, Poland|Grodzisk Mazowiecki, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Mielec, Poland|Nowy Targ, Poland|Ostrowiec Swietokrzyski, Poland|Oswiecim, Poland|Plock, Poland|Rzeszow Poland, Poland|Starachowice, Poland|Starogard Gdanski, Poland|Szczecin, Poland|Torun, Poland|Tychy, Poland|Ustron, Poland|Warszawa, Poland|Zamosc, Poland|Bucharest, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Targu-Mures, Romania|Tg Mures, Romania|Arkhangelsk, Russian Federation|Barnaul, Russian Federation|Chita, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Perm, Russian Federation|Rostov On Don, Russian Federation|Samara, Russian Federation|Saratov, Russian Federation|St. Petersburg, Russian Federation|Syktyvkar, Russian Federation|Tumen, Russian Federation|Tyumen, Russian Federation|Cape Town, South Africa|Centurion, South Africa|Linksfield West, Johannesburg, South Africa|Somerset West, South Africa|Falun, Sweden|Göteborg, Sweden|Jönköping, Sweden|Lund, Sweden|Malmö, Sweden|Stockholm N/A, Sweden|Stockholm, Sweden|Umeå, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Antalya, Turkey|Bursa, Turkey|Gaziantep, Turkey|Istanbul Nap, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Sivas, Turkey|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kharkov, Ukraine|Khemelnitskiy, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Rivne, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Bath, United Kingdom|Birmingham, United Kingdom|Blackburn, United Kingdom|Bradford, United Kingdom|Clydebank, United Kingdom|Cottingham, United Kingdom|Coventry, United Kingdom|Dorchester, United Kingdom|Dundee, United Kingdom|Edinburgh, United Kingdom|Exeter, United Kingdom|Hampshire, United Kingdom|Harrow, United Kingdom|High Wycombe, United Kingdom|London, United Kingdom|Middlesbrough N/A, United Kingdom|Norwich, United Kingdom|Nottingham, United Kingdom|Plymouth, United Kingdom|Portsmouth, United Kingdom|Torquay, United Kingdom|Truro, United Kingdom|Worcester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01830543"
988,"NCT01976507","Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism",,"Completed","Has Results","Atrial Fibrillation|Atrial Flutter","Drug: dabigatran etexilate mesylate","Frequency of Major Bleeding Complications in Patients Administered Dabigatran Following RF Ablation.|Frequency of Major Thrombo-embolic Events in Patients Administered Dabigatran Following RF Ablation.|Dabigatran Serum Drug Levels in Patients Experiencing a Major Bleeding or Thrombo-embolic Event.|Number of Participants With Minor Bleeding Events","Vanderbilt University Medical Center|Boehringer Ingelheim","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","101","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","121204","October 2013","December 2016","December 2016","November 5, 2013","September 12, 2017","September 12, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01976507"
989,"NCT02111564","A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","MARINER","Completed","Has Results","Heart Failure|Respiratory Insufficiency|Stroke Acute|Infectious Diseases|Rheumatic Diseases","Drug: Rivaroxaban, 10 mg|Drug: Rivaroxaban, 7.5 mg|Drug: Placebo","Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee (CEC)|Event Rate Based on Time From Randomization to the First Occurrence of Major Bleeding Adjudicated by CEC|Event Rate Based on Time From Randomization to First Occurrence of VTE-Related Death Adjudicated by CEC|Event Rate Based on Time From Randomization to the First Occurrence of a Symptomatic Venous Thromboembolism Event (VTE) Adjudicated by CEC|Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE and All-Cause Mortality (ACM) Adjudicated by CEC|Event Rate Based on Time From Randomization to the First Occurrence of a Composite of Symptomatic VTE, Myocardial Infarction (MI), Non-Hemorrhagic Stroke, and Cardiovascular (CV) Death Adjudicated by CEC|Event Rate Based on Time From Randomization to First Occurrence of All-Cause Mortality (ACM) Adjudicated by CEC","Janssen Research & Development, LLC|Bayer","All","40 Years and older   (Adult, Older Adult)","Phase 3","12024","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","CR103834|2014-000305-13|RIVAROXDVT3002","January 7, 2014","March 6, 2018","May 3, 2018","April 11, 2014","November 25, 2019","November 25, 2019","Birmingham, Alabama, United States|Mobile, Alabama, United States|Sheffield, Alabama, United States|Scottsdale, Arizona, United States|Fort Smith, Arkansas, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Fullerton, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Orange, California, United States|Sacramento, California, United States|San Jose, California, United States|San Marino, California, United States|Santa Ana, California, United States|Colorado Springs, Colorado, United States|Bridgeport, Connecticut, United States|Danbury, Connecticut, United States|New Haven, Connecticut, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Atlantis, Florida, United States|Bay Pines, Florida, United States|Bradenton, Florida, United States|Brandon, Florida, United States|Celebration, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Jacksonville Beach, Florida, United States|Jacksonville, Florida, United States|Largo, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Saint Cloud, Florida, United States|Sebring, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Wellington, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Normal, Illinois, United States|North Chicago, Illinois, United States|Hammond, Indiana, United States|Lafayette, Indiana, United States|Michigan City, Indiana, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Topeka, Kansas, United States|Alexandria, Louisiana, United States|Lafayette, Louisiana, United States|Metairie, Louisiana, United States|Minden, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Slidell, Louisiana, United States|Rockport, Maine, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Royal Oak, Michigan, United States|Saginaw, Michigan, United States|Troy, Michigan, United States|Minneapolis, Minnesota, United States|Saint Paul, Minnesota, United States|Bridgeton, Missouri, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Atlantic City, New Jersey, United States|Bridgewater, New Jersey, United States|Marlton, New Jersey, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Buffalo, New York, United States|Cortlandt Manor, New York, United States|Jamaica, New York, United States|Johnson City, New York, United States|Manhasset, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Staten Island, New York, United States|Valhalla, New York, United States|Durham, North Carolina, United States|Greensboro, North Carolina, United States|Raleigh, North Carolina, United States|Statesville, North Carolina, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Maumee, Ohio, United States|Springfield, Ohio, United States|Willoughby, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Abington, Pennsylvania, United States|Camp Hill, Pennsylvania, United States|Chambersburg, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Jefferson Hills, Pennsylvania, United States|Johnstown, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Shippensburg, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Columbia, South Carolina, United States|Summerville, South Carolina, United States|Athens, Tennessee, United States|Amarillo, Texas, United States|Austin, Texas, United States|Channelview, Texas, United States|Corsicana, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Tyler, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Richland, Washington, United States|Seattle, Washington, United States|Huntington, West Virginia, United States|La Crosse, Wisconsin, United States|Marshfield, Wisconsin, United States|Bahia Blanca, Argentina|Buenos Aires, Argentina|Ciudad de Buenos Aires, Argentina|Cordoba, Argentina|Coronel Suarez, Argentina|Corrientes, Argentina|Córdoba, Argentina|Esperanza, Argentina|La Plata, Argentina|Merlo, Argentina|Moron, Argentina|Munro, Argentina|Rosario, Argentina|Santa Fe, Argentina|Santa Fé, Argentina|Tucuman, Argentina|Bedford Park, Australia|Box Hill, Australia|Caboolture, Australia|Cairns, Australia|Chermside, Australia|East Saint Kilda, Australia|Kogarah, Australia|Launceston, Australia|Lismore, Australia|Meadowbrook, Australia|Milton, Australia|Nedlands, Australia|Parkwood, Australia|Penrith, Australia|Redcliffe, Australia|South Brisbane, Australia|Sydney, Australia|VIC, Parkville, Australia|Feldkirch, Austria|Graz, Austria|Linz, Austria|Salzburg, Austria|Wien, Austria|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Mogilev, Belarus|Vitebsk, Belarus|Vychulki, Brest Region, Brest, Belarus|Banja Luka, Bosnia and Herzegovina|Bihac, Bosnia and Herzegovina|Foca, Bosnia and Herzegovina|Mostar, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Zenica, Bosnia and Herzegovina|Belo Horizonte, Brazil|Blumenau, Brazil|Brasília, Brazil|Campina Grande do Sul, Brazil|Campinas, Brazil|Canoas, Brazil|Curitiba, Brazil|Itajaí, Brazil|Natal, Brazil|Passo Fundo, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirão Preto, Brazil|Salvador, Brazil|San Paulo, Brazil|Santo André, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulo, Brazil|Votuporanga, Brazil|Blagoevgrad, Bulgaria|Burgas, Bulgaria|Dimitrovgrad, Bulgaria|Gabrovo, Bulgaria|Kozlodui, Bulgaria|Lom, Bulgaria|Lovech, Bulgaria|Montana, Bulgaria|Pernik, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Razlog, Bulgaria|Ruse, Bulgaria|Sandanski, Bulgaria|Sliven, Bulgaria|Sofia, Bulgaria|Veliko Tarnovo, Bulgaria|Vidin, Bulgaria|Edmonton, Alberta, Canada|Saint John, New Brunswick, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Saint-Jerome, Quebec, Canada|Sherbrooke, Quebec, Canada|Quebec, Canada|Armenia, Colombia|Barranquilla, Colombia|Bogota, Colombia|Bogotá, Colombia|Cali, Colombia|Chia, Colombia|Floridablanca, Colombia|Medellin, Colombia|Medellín, Colombia|Villavicencio, Colombia|Cakovec, Croatia|Karlovac, Croatia|Krapinske Toplice, Croatia|Osijek, Croatia|Pula, Croatia|Rijeka, Croatia|Sibenik, Croatia|Virovitica, Croatia|Zabok, Croatia|Zadar, Croatia|Zagreb, Croatia|Boskovice, Czechia|Brno, Czechia|Cesky Krumlov, Czechia|Jablonec Na Nisou, Czechia|Karvina, Czechia|Kladno, Czechia|Krnov, Czechia|Kyjov, Czechia|Liberec, Czechia|Litomysl, Czechia|Mestec Kralove, Czechia|Nove Mesto na Morave, Czechia|Nymburk N/a, Czechia|Olomouc, Czechia|Opava, Czechia|Ostrava, Czechia|Pardubice, Czechia|Praha 10, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 8, Czechia|Pribram, Czechia|Písek, Czechia|Slany, Czechia|Sternberk, Czechia|Svitavy, Czechia|Teplice, Czechia|Trinec, Czechia|Trutnov, Czechia|Uherske Hradiste, Czechia|Usti Nad Labem, Czechia|Usti nad Orlici, Czechia|Zlin, Czechia|Aalborg, Denmark|Copenhagen, Denmark|Esbjerg, Denmark|Frederiksberg, Denmark|Hellerup, Denmark|Hilleroed, Denmark|Hvidovre, Denmark|København S, Denmark|Roskilde, Denmark|Tallinn, Estonia|Batumi, Georgia|Kutaisi, Georgia|Marneuli, Georgia|Rustavi, Georgia|T'bilisi, Georgia|Tbilisi, Georgia|Telavi, Georgia|Berlin, Germany|Coburg, Germany|Dresden, Germany|Esslingen, Germany|Frankfurt, Germany|Heidelberg, Germany|Jülich, Germany|Karlsbad, Germany|Leipzig, Germany|Limburg, Germany|Mannheim, Germany|Minden, Germany|Mönchengladbach, Germany|Neuwied, Germany|Troisdorf, Germany|Witten, Germany|Achaïa, Greece|Alexandroupolis, Greece|Athens, Greece|Heraklion, Greece|Ioannina, Greece|Kifisia, Athens, Greece|Magoula, Greece|Patra, Greece|Thessalonikis, Greece|Thessaloniki, Greece|Voula, Greece|Ajka, Hungary|Baja, Hungary|Balassagyarmat, Hungary|Berettyóújfalú, Hungary|Budapest, Hungary|Cegléd, Hungary|Debrecen, Hungary|Eger, Hungary|Farkasgyepü, Hungary|Gyula, Hungary|Gyõr, Hungary|Gödöllő, Hungary|Hodmezovasarhely, Hungary|Kalocsa, Hungary|Kaposvar, Hungary|Kecskemet N/a, Hungary|Kecskemet, Hungary|Keszthely, Hungary|Kistarcsa, Hungary|Komarom, Hungary|Miskolc, Hungary|Nagykanizsa, Hungary|Orosháza, Hungary|Pecs, Hungary|Pécs, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szekszárd, Hungary|Szentes, Hungary|Szolnok, Hungary|Szombathely, Hungary|Székesfehérvár, Hungary|Sátoraljaújhely, Hungary|Zalaegerszeg, Hungary|Beersheba, Israel|Hadera, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Kfar-Saba, Israel|Modi'in, Israel|Nahariya, Israel|Petah Tikva, Israel|Petah Tiqwa, Israel|Rehovot, Israel|Safed, Israel|Tel-Hashomer, Israel|Tiberias, Israel|Zefat, Israel|Balvi, Latvia|Daugavpils, Latvia|Jekabpils, Latvia|Jelgava, Latvia|Krāslavas Apriņķis, Latvia|Kuldiga, Latvia|Liepaja, Latvia|Riga, Latvia|Ventspils, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Panevezys, Lithuania|Siauliai, Lithuania|Taurage, Lithuania|Utena, Lithuania|Vilniaus Apskritis, Lithuania|Vilnius, Lithuania|Aguascalientes, Mexico|Cuernavaca, Mexico|Guadalajara, Mexico|Merida, Mexico|Monterrey, Mexico|San Pedro Garza Garcia, Mexico|Alkmaar, Netherlands|Almelo, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Den Haag, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Hoorn, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|s-Hertogenbosch, Netherlands|Sittard-Geleen, Netherlands|Sneek, Netherlands|Tilburg, Netherlands|Veldhoven, Netherlands|Zutphen, Netherlands|Zwolle, Netherlands|Bitola, North Macedonia|Ohrid, North Macedonia|Skopje, North Macedonia|Struga, North Macedonia|Štip, North Macedonia|Callao, Peru|Lima, Peru|Bialystok, Poland|Bielsko-Biala, Poland|Bydgoszcz, Poland|Bystra, Poland|Czeladz, Poland|Gdynia, Poland|Kielce, Poland|Klodzko, Poland|Krakow, Poland|Kraków, Poland|Leczna, Poland|Lodz, Poland|Lublin, Poland|Olawa, Poland|Ostroleka, Poland|Ostrow Mazowiecka, Poland|Pabianice, Poland|Plock, Poland|Poznan, Poland|Proszowice, Poland|Pulawy, Poland|Rabka-Zdroj, Poland|Siedlce, Poland|Sopot,Gdynia, Poland|Sosnowiec, Poland|Szczecin, Poland|Tarn W N/a, Poland|Torun, Poland|Warszawa N/a, Poland|Warszawa, Poland|Wegrow, Poland|Wroclaw, Poland|Braga, Portugal|Coimbra, Portugal|Covilhã, Portugal|Figueira da Foz, Portugal|Guimarães, Portugal|Lisboa, Portugal|Porto, Portugal|Vila Nova de Gaia, Portugal|San Juan, Puerto Rico|Bacau, Romania|Baia Mare, Romania|Braila, Romania|Brasov, Romania|Bucuresti, Romania|Bucureşti, Romania|Cluj-Napoca, Romania|Craiova, Romania|Focsani, Romania|Iasi, Romania|Iaşi, Romania|Oradea, Romania|Pitesti, Romania|Tg Mures, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Irkutsk, Russian Federation|Kazan, Russian Federation|Kemerovo, Russian Federation|Krasnodar, Russian Federation|Krasnoyarsk, Russian Federation|Moscow, Russian Federation|Moskva, Russian Federation|Novosibirsk, Russian Federation|Orenburg, Russian Federation|Penza, Russian Federation|Rostov on Don, Russian Federation|Saint Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Saratov, Russian Federation|Smolensk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ulyanovsk, Russian Federation|Vsevolzhsk, Russian Federation|Yaroslavl, Russian Federation|Belgrade, Serbia|Beograd, Serbia|Cacak, Serbia|Cuprija, Serbia|Dedinje, Serbia|Kragujevac, Serbia|Leskovac, Serbia|Nis, Serbia|Novi Sad, Serbia|Sabac, Serbia|Smederevo, Serbia|Sremska Kamenica, Serbia|Subotica, Serbia|Valjevo, Serbia|Vranje, Serbia|Zaječar, Serbia|Kosice, Slovakia|Martin, Slovakia|Nitra, Slovakia|Bellville, South Africa|Bloemfontein, South Africa|Cape Town, South Africa|Durban Kwa Zulu Natal, South Africa|Durban, South Africa|Gatesville Cape Town, South Africa|Groenkloof, Pretoria, South Africa|Johannesburg, South Africa|Kempton Park, South Africa|Kuils River, South Africa|Pretoria, South Africa|Somerset West, South Africa|Stellenbosch, South Africa|Worcester, South Africa|Alcalá de Henares, Spain|Alicante, Spain|Almeria, Spain|Alzira, Spain|Aranjuez, Spain|Avila, Spain|Balea, Spain|Barcelona, Spain|Burgos, Spain|Cartagena, Spain|Cáceres, Spain|Don Benito, Spain|Elche, Spain|Getafe, Spain|Granada, Spain|Huelva N/a, Spain|La Laguna, Spain|Las Palmas de Gran Canaria, Spain|Logroño, Spain|Madrid, Spain|Majadahonda-Madrid, Spain|Malaga, Spain|Murcia, Spain|Móstoles, Spain|Olot, Spain|Oviedo, Spain|Palma de Mallorca, Spain|Pamplona, Spain|Sabadell, Spain|San Sebastian de los Reyes, Spain|Sanchinarro, Spain|Sant Boi de Llobregat, Spain|Sant Joan d'Alacant, Spain|Santander N/a, Spain|Sarrià, Spain|Sevilla, Spain|Torrelavega Cantabria, Spain|Valencia, Spain|Zaragoza, Spain|Adana, Turkey|Ankara, Turkey|Antalya, Turkey|Istanbul, Turkey|Izmir, Turkey|Konya, Turkey|Rize, Turkey|Samsun, Turkey|Cherkasy, Ukraine|Chernihiv, Ukraine|Dnipropetrovsk, Ukraine|Ivano-Frankivsky, Ukraine|Kharkiv, Ukraine|Kherson, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Uzhgorod, Ukraine|Vinnytsia, Ukraine|Zaporizhzhia, Ukraine|Zaporizhzhya, Ukraine|Zhytomyr, Ukraine|Angus, United Kingdom|Cardiff, United Kingdom|Craigavon, United Kingdom|Glasgow, United Kingdom|Leeds, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom|Plymouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02111564/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02111564/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02111564"
990,"NCT03182725","Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome","POTS","Active, not recruiting","No Results Available","Postural Orthostatic Tachycardia Syndrome","Drug: Ivabradine|Drug: Placebo","Change in Heart Rate|Change in Quality of Life","University of California, San Diego|Amgen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","170694","February 6, 2018","April 2020","June 2020","June 9, 2017",,"April 17, 2020","University of California, San Diego, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT03182725"
991,"NCT03078907","Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.","TRACE","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: Selexipag|Drug: Placebo","Change from baseline to Week 24 in daily time spent in non-sedentary activity|Change from baseline to Week 24 in percentage of daily time spent in non-sedentary activity|Change from baseline to Week 24 in total daily life physical activity|Change from baseline to Week 24 in total sleep time (TST)|Change from baseline to Week 24 in wake after sleep onset (WASO)|Change from baseline to Week 24 in number of awakenings|Change from baseline to Week 24 in sleep efficiency (SE)|Change from baseline to Week 24 in World Health Organization Functional Class (WHO FC)|Change from baseline to Week 24 in 6-minute walk distance (6MWD)|Change from baseline to Week 24 in Borg dyspnea score|Change from baseline to Week 24in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change from baseline to Week 24 in cardiovascular symptom domain score of PAH-SYMPACT®|Change from baseline to Week 24 in cardiopulmonary symptom domain score of PAH-SYMPACT®|Change from baseline to Week 24 in physical impact domain score of PAH-SYMPACT®|Change from baseline to Week 24 in cognitive/emotional impact domain score of PAH-SYMPACT®","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","108","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","AC-065A404","November 8, 2017","February 10, 2020","February 10, 2020","March 14, 2017",,"March 18, 2020","LA Biomedical Research Institute, Torrance, California, United States|Northside Hospital, Atlanta, Georgia, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Tufts Medical Center, Pulmonary/Critical Care & Sleep, Boston, Massachusetts, United States|University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division, Omaha, Nebraska, United States|NYU Winthrop Hospital, Mineola, New York, United States|UNC Pulmonary Speciality Clinic, Chapel Hill, North Carolina, United States|Duke University School of Medicine, Duke Pulmonary Vascular Disease center, Durham, North Carolina, United States|University of Cincinnati, Heart, Lung and Vascular Institute, Cincinnati, Ohio, United States|CCF- Akron General Medical Hospital, Cleveland, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Pulmonary Vascular Disease Program, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Care Medicine, Nashville, Tennessee, United States|Methodist Clinical Trials, San Antonio, Texas, United States|University of Texas Health Science Center (San Antonio), San Antonio, Texas, United States|Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2, Innsbruck, Austria|Krankenhaus der Elisabethinen, Servicestelle Klinische Studien, Linz, Austria|Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire, Le Kremlin-Bicêtre, France|CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie, Lille, France|Hospital Larrey CHU de Toulouse, Toulouse, France|Universitätsklinikum Giessen, Giessen, Germany|Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin, Köln, Germany|Universitätsklinikum Leipzig AöR, Abteilung Pneumologie, Leipzig, Germany|Katholisches Klinikum Lünen/Werne GmbH, Haus E, Lünen, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|Oslo University Hospital, dept of cardiology, Oslo, Norway|Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia, Coimbra, Portugal|Hospital Geral de Santo António-DEFI, Porto, Portugal|Sahlgrenska University Hospital, Gothenburg, Gothenburg, Sweden|Skåne University Hospital, VO Hjärt och Lungmedicin, Lund, Sweden|Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin, St. Gallen, Switzerland|Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11, Zurich, Switzerland|Papworth Hospital, Pulmonary Vascular Disease Unit, Cambridge, United Kingdom|Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit, Clydebank, United Kingdom|The Royal Free Hospital, Cardiology Department, London, United Kingdom|Royal Brompton Hospital, Hypertension, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Cardiothoracic Department, Newcastle Upon Tyne, United Kingdom|Royal Hallamshire Hospital, Pulmonary Vascular Medicine, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03078907"
992,"NCT01179737","Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Nilotinib|Drug: Placebo to nilotinib","Change in Pulmonary Vascular Resistance (PVR)|Change in Six-Minute Walk Distance (6MWD) From Baseline|Total Number of Adverse Events and Serious Adverse Events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CAMN107X2201|2010-019883-36","July 2010","January 2013","January 2013","August 11, 2010","February 27, 2014","May 1, 2014","Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT01179737"
993,"NCT01106014","Selexipag (ACT-293987) in Pulmonary Arterial Hypertension","GRIPHON","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Selexipag|Drug: Placebo","Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake|Change From Baseline to Week 26 in 6-minute Walk Distance (6MWD) at Trough|Absence of Worsening From Baseline to Week 26 in Modified NYHA/WHO Functional Class (WHO FC)","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065A302","December 1, 2009","April 1, 2014","October 1, 2014","April 19, 2010","March 1, 2016","January 11, 2018","University of South Alabama, Mobile, Alabama, United States|The University of Arizona, Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|University of California San Diego Medical Center (La Jolla), La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|GLVA Healthcare Center, Los Angeles, California, United States|University of California, Davis, UC Davis Medical Center, Sacramento, California, United States|LIU Center for Pulmonary Hypertension, Torrance, California, United States|Lung Health & Sleep Emhancement Center, LLC, Newark, Delaware, United States|Emory University School of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Atlanta, Georgia, United States|Georgia Health Sciences University, Augusta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Clarian North Hospital, Carmel, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|LSU Health Science Center - New Orleans, New Orleans, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital - Pulmonary Critical Care Unit, Boston, Massachusetts, United States|Massachusetts General Hospital-Pulmonary Critical Care Unit, Boston, Massachusetts, United States|Boston University School of Medicine / Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Hospital, Troy, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Newark Beth Isreal Medical Center-Department of Pulmonary Medicine, Newark, New Jersey, United States|Montefiore Medical Center, Weiler Division, Bronx, New York, United States|Columbia University Medical Center, Pediatric Cardiology, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Pulmonary Associates, PC, Portland, Oregon, United States|Central Bucks Specialists, Doylestown, Pennsylvania, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas-Houston Health Center Department of Pulmonary & Critical Care, Houston, Texas, United States|University of Wisconsin Hospital-Department of Medicine, Madison, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Froedtert Hospital - Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Centro de Investigacion y Prevencion Cardiovascular (CIPREC), Buenos Aires, Argentina|Sanatorio Otamendi y Miroli S.A., Buenos Aires, Argentina|Hospital Britanico-Pneumology, Buenos Aires, Argentina|Sanatorio San Jose, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba S.A., Cordoba, Argentina|Instituto De Cardiologia de Corrientes, Corrientes, Argentina|St. Vincent's Hospital / Heart and Lung Transplant Unit, Darlinghurst, New South Wales, Australia|Prince Charles Hospital Lung Transplant, Thoracic Department, Chermside, Queensland, Australia|Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU), Adelaide, South Australia, Australia|Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology, Bedford Park, South Australia, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Royal Hobart Hospital, Centre for Clinical Research, Hobart, Australia|John Hunter Hospital Autoimmune Resource and Research Centre, New Lambton, Australia|Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine, Parkville, Australia|Royal Perth Hospital, Perth, Australia|Medizinische Universität Graz, Graz, Austria|Medical University of Vienna and AKH Cardiology, Vienna, Austria|The Republican Scientific-Practical Center ""Cardiology"", Minsk, Belarus|Minsk City Hospital No. 9, Minsk, Belarus|Minsk Regional Clinical Hospital of the Red Banner of Labour, Minsk, Belarus|Ulb Erasme, Cardiology, Brussels, Belgium|University Hospital Gasthuisberg - Pneumologie, Leuven, Belgium|University of Alberta Hospital - Children's Centre, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Hopital General Juif (Jewish General Hospital), Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada|Instituto Nacional del Torax Teaching Dept, Santiago, Chile|Clinica Tabancura- Cardiology Unit, Santiago, Chile|Pontificia Universidad Catolica de Chile-Departmento De Enfermedades Cardiovasculares, Santiago, Chile|Peking Union Medical College Hospital, Rheumatology Department, Beijing, China|Cardiovascular Institute & Fuwai Hospital-Pulmonary Vascular Center, Beijing, China|Beijing Shijitan Hospital, Beijing, China|Guangdong General Hospital, Cardiology Department, Guangzhou, China|Renji Hospital, Rheumatology Department, Shanghai, China|Renji Hospital, Cardiology Department, Shanghai, China|Shanghai Pulmonary Hospital, Department of Pulmonary Circulation, Shanghai, China|Fundacion Cardio Infantil, Bogota, Colombia|Fundacion Clinica Shaio, Bogota, Colombia|Gen Faculty Hosp Prague Cardiology Clin, Praha 2, Czechia|Aarhus University Hospital , Cardiology, Arhus, Denmark|Rigshospitalet, Hjertemedicinsk klinik - Cardiology, Copenhagen, Denmark|Hosp Pradel Lyon - Dpt Pneumology, Bron cedex, France|Hosp Cote de Nacre - Dpt Pneumology, Caen Cedex, France|Hosp A. Beclere - Dept Pulmo & Resp Intensive Care, Clamart, France|Hosp Huriez - Dpt Internal Medecine, Lille Cedex, France|Hosp Civil - Dpt Pneumology, Strasbourg, France|Hosp Larrey - Dpt Pneumology, Toulouse Cedex 9, France|DRK Kliniken Köpenick, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13, Dresden, Germany|""Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"", Giessen, Germany|Universität Greifswald / Klinik für Innere Medizin B, Greifswald, Germany|Medizinische Hochschule Hannover / Klinik für Pneumologie, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|""Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"", Köln, Germany|Praxis für Pneumologie und Allergologie, Leipzig, Germany|Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie, Löwenstein, Germany|Universitätsklinkum Regensburg / Innere Medizin II, Regensburg, Germany|Onasseio Cardiosurgical Hospital, Athens, Greece|""Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály"", Budapest, Hungary|""Semmelweis Egyetem, Pulmonológiai Klinika"", Budapest, Hungary|Egészségügyi Járóbeteg Központ Kardiológiai Intézete - Debrecen, Debrecen, Hungary|""Pécsi Tudományegyetem Klinikai Központ,, Pécs, Hungary|""Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ, II. sz. Belgyógyászati klinika és Kardiológiai központ"", Szeged, Hungary|Sanjivani Hospitals - Department of Cardiology, Ahmedabad, India|Apollo Hospitals, Chennai, Chennai, India|Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai, Chennai, India|CARE Hospitals Nampally, Cardiology Dep. Hyderabad, Hyderabad, India|Apollo Indraprastha Hospitals, New Delhi, India|Mater Miscordiae University Hospital, Dublin, Ireland|Carmel Medical Center, Pulmonary Unit, Haifa, Israel|Pulmonology Institute, Hadassah University Hospital at Ein Karem, Jerusalem, Israel|Rabin Medical Centre - Pulmonology, Petach Tikvah, Israel|Kaplan Medical - Pulmonary Institute, Rehovot, Israel|The Chaim Sheba Med Ctr -Pulmonology, Tel-Hashomer, Israel|Policlinico S. Orsola-Malpighi - Dipartimento Cardio-Toraco-Vascolare, Bologna, Italy|Seconda Università Degli Studi di Napoli - Azienda Universitaria Policlinico - Dipartimento Assistenziale di medicina Generale, Angiologia, Endocrinologia, Epatogastroenterologia e Reumatologia - Unità Operativa di Reumatologia, Napoli, Italy|ISMETT - Istituto Mediterraneo Trapianti e Terapie ad Alta Specializzazione - Dipartimento di Medicina - Divisione di Pneumologia, Palermo, Italy|Gil Medical Centre, Incheon, Korea, Republic of|Seoul Nathional University Hospital, Seoul, Korea, Republic of|Yonsei University Health System Dept of Cardiology, Seoul, Korea, Republic of|Samsung Medical Center, Division of Cardiology, Seoul, Korea, Republic of|""The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology"", Seoul, Korea, Republic of|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubrian, Mexico City, Mexico|Instituto Nacional de Cardiologia (INC) Ignacio Chavez, Mexico City, Mexico|VU Medisch Centrum / Afdeling longziekten, secretariaat 4A 48, Amsterdam, Netherlands|Academisch Ziekenhuis Maastricht / Department of Pulmonary Diseases, Maastricht, Netherlands|St. Antonius Ziekenhuis afdeling Longziekten, Nieuwegein, Netherlands|Erasmus Medisch Centrum Rotterdam afdeling longziekten, Rotterdam, Netherlands|Hospital Nacional Edgardo Rebagliati / Unidad de Investigacion Cardiologia 2, Lima, Peru|Instituto de Enfermedades Respiratorias Clinica San Gabriel, Lima, Peru|""Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca"", Gdańsk, Poland|""Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń"", Krakow, Poland|""Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej"", Warszawa, Poland|""Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM"", Łódź, Poland|""Institutul de Pneumologie ""Marius Nasta"", I. Clinica de Pneumoftiziologie"", Bucharest, Romania|""Spitalul Clinic de Pneumoftiziologie Iasi Sectia Clinica I de Pneumoftiziologie"", Iasi, Romania|Municipal Medical Institution City Hospital #5, Barnaul, Russian Federation|Regional Clinical Hospital # 1, Ekaterinburg, Russian Federation|Kemerovo Cardiology Dispensary / Kemerovo Regional Hospital, Kemerovo, Russian Federation|Scientific Research Institute of Pulmonology of the Federal Medical and Biological Agency of Russia, Moscow, Russian Federation|State Institution, ""Institute fo Rheumatology of RAMS"", Moscow, Russian Federation|The Institution of the Clinical Cardiology named after A. L. Myaskinov, Moscow, Russian Federation|Limited liability company, Consultative diagnostic centre Healthy Joints, Novosibirsk, Russian Federation|V. A. Almazov Institute of Cardiology, Russian Ministry of Healthcare and Social Development / Medical Treatment and Rehabilitation Complex, St Petersburg, Russian Federation|Cardiology Scientific Research Institute of Tomsk Scientific Center of RAMs, Siberian Branch / Cardiovascular Surgery Department, Tomsk, Russian Federation|Tomsk Regional Clinical Hospital/ Pulmonology Unit, Tomsk, Russian Federation|""Klinički Centar Srbije, Klinika za pulmologiju"", Belgrade, Serbia|""Kliničko-bolnički centar Zemun, Kardiološko odeljenje"", Belgrade, Serbia|National Heart Centre (NHC) Singapore, Singapore, Singapore|Národný ústav srdcových a cievnych chorôb, a.s. - NÚSCH a.s., Bratislava, Slovakia|Hosp Vall D'Hebron - Barcelona - Pneumology, Barcelona, Spain|Clinic-Barcelona, Barcelona, Spain|Hospital 12 Octubre, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Kardiologi, Goteborg, Sweden|Linköping University Hospital, Cardiology, Linköping, Sweden|Umeå University Hospital, Cardiology (Umeå), Umea, Sweden|Uppsala Akademiska Sjukhuset, Kardiologkliniken 50F, Uppsala, Sweden|University Hospital Basel Division of Pneumology, Basel, Switzerland|Universitätsspital Bern, Clinic for Pneumology (Inselspital), Bern, Switzerland|HUG Hôpitaux Universitaires de Genève; Pneumology, PAH, Genève 14, Switzerland|Kantonsspital St. Gallen Klinik für Pneumologie, St. Gallen, Switzerland|Kaohsiung Veterans General Hospital (KVGH), Kaohsiung, Taiwan|National Taiwan University Hospital / Department of Surgery, Taipei, Taiwan|Srinagarind Hospital, Khon Kaen University, Division of Allergy-Immunology and Rheumatology, Department of Medicine, Khon Kaen, Thailand|Çukurova Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı, Adana, Turkey|Istanbul Üniversitesi Kardiyoloji Enstitisü, Istanbul, Turkey|Marmara Üniversitesi Tip Fakultesi Kardiyoloji Anabilim Dali, Istanbul, Turkey|Dokuz Eylül Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı, İzmir, Turkey|""Dnipropetrovsk State Medical Academy, Municipal Institution """"Dnipropetrovsk Regional Clinic Diagnostic Center"""", Dnipropetrovsk, Ukraine|Health Care Municipal Institution, City Clinical Hospital #13, Kharkiv, Ukraine|Public Institution ""F.H. Yanovski Phthisiology and Pulmonology National Institute Under Ukrainian Academy of Medical Sciences"", Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Golden Jubilee - Pulm Vascular Unit, Glasgow, United Kingdom|Royal Free & Ucms Rheumatology Unit, London, United Kingdom|Hammersmith, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01106014"
994,"NCT00860847","Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)",,"Completed","Has Results","Coronary Atherosclerosis|Coronary Artery Calcification|Coronary Stenosis","Dietary Supplement: Aged garlic extract and Coenzyme Q10","Rate of Change in Total Coronary Calcium Scores by Computed Tomography|1.Plasma Lipids: Total Plasma Cholesterol and Triglycerides, LDL-Cholesterol, HDL-Cholesterol, and VLDL-Cholesterol Determined by the Precipitation Method; 2. Endothelial Markers and Inflammation: C-reactive Protein and Homocysteine, as Well as GSH","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","Male","35 Years to 84 Years   (Adult, Older Adult)","Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Wakunaga of America Co., Ltd.","May 2009","August 2010","September 2010","March 12, 2009","March 12, 2015","March 12, 2015","Los Angeles Biomedical Research Institute, Torrance, California, United States",,"https://ClinicalTrials.gov/show/NCT00860847"
995,"NCT01849003","Study of the Effect of GS-6615 in Subjects With LQT-3",,"Completed","No Results Available","Long QT Syndrome","Drug: GS-6615","Changes in QTc intervals (Fridericia formula)|Incidence of Adverse Events (AEs)|Changes in ECHO parameters|Area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable concentration of GS-6615|Maximum observed plasma concentration (Cmax) of GS-6615|Time to maximum observed concentration (Tmax) of GS-6615|Changes in ECG parameters|Changes in QTc interval (Bazett [QTcB])","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-279-0110","May 2013","November 2014","November 2014","May 8, 2013",,"November 17, 2014","University of Rochester Medical Center/Strong Memorial Hospital, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT01849003"
996,"NCT03276728","Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Subjects and Heart Failure Patients",,"Terminated","No Results Available","Heart Failure","Drug: AMG 986 IV Dose Level A or matching Placebo|Drug: AMG 986 IV Dose Level B or matching Placebo|Drug: AMG 986 IV Dose Level C or matching placebo|Drug: AMG 986 IV Dose Level D or matching placebo|Drug: AMG 986 IV Dose Level E or matching Placebo|Drug: AMG 986 IV Dose Level F or matching Placebo|Drug: AMG 986 IV Dose Level G or matching Placebo|Drug: AMG 986 Oral Dose Level A or matching Placebo|Drug: AMG 986 Oral Dose Level B or matching Placebo|Drug: AMG 986 Oral Dose Level C or matching Placebo|Drug: AMG 986 Oral Dose Level D or matching Placebo|Drug: AMG 986 Oral Dose Level E or matching Placebo|Drug: AMG 986 Oral Dose Level F or matching Placebo|Drug: AMG 986 Oral Dose Regimen or matching placebo - R|Drug: AMG 986 Oral Dose Regimen or matching placebo - P","Subject incidence of treatment-emergent adverse events.|Oral bioavailability for AMG 986|Area under the plasma concentration versus time curve (AUC) for AMG 986|Peak Plasma Concentration (Cmax) for AMG 986|the time of maximum observed concentration (tmax) for AMG 986","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150183","August 12, 2016","April 18, 2019","April 18, 2019","September 8, 2017",,"October 30, 2019","Research Site, Anaheim, California, United States|Research Site, Tustin, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Metairie, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Durham, North Carolina, United States|Research Site, Auchenflower, Queensland, Australia|Research Site, Bundaberg, Queensland, Australia|Research Site, Leabrook, South Australia, Australia|Research Site, Berwick, Victoria, Australia|Research Site, Bundoora, Victoria, Australia|Research Site, Sherbrooke, Quebec, Canada|Research Site, Nantes Cedex 1, France|Research Site, Paris, France|Research Site, Rennes Cedex 9, France|Research Site, Toulouse Cedex 9, France|Research Site, Bad Neuheim, Germany|Research Site, Berlin, Germany|Research Site, Groningen, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Jozefow, Poland|Research Site, Wroclaw, Poland|Research Site, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03276728"
997,"NCT02300558","Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3",,"Terminated","Has Results","Long QT Syndrome Type 3","Drug: Eleclazine|Drug: Eleclazine placebo","Change From Baseline in Mean Daytime QT Interval in Lead V5 Corrected for Heart Rate Using the Fridericia Formula (QTcF) Interval to Week 24 (Based on Standard 12-lead ECG Data)|Change From Baseline in Mean Daytime QTcF Interval (AUC0-6/6) to Week 12 (Lead V5; Standard 12-lead ECG)|Change From Baseline in Mean Daily (Daytime and Nocturnal) QTcF Interval to Week 24 (Lead V5; Holter)|Change From Baseline in Mean Nocturnal QTcF Interval to Week 24 (Lead V5; Holter)","Gilead Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GS-US-372-1234|2014-000042-30","December 17, 2014","December 12, 2016","February 15, 2017","November 25, 2014","January 12, 2018","January 12, 2018","Mayo Clinic Rochester, Rochester, Minnesota, United States|NYU Langone Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|L'institut Du Thorax Nantes, Nantes, France|Groupe Hospitalier Bichat Claude Bernard, Paris, France|CHU Réunion Sud, Saint-Pierre, France|LMU Klinikum der Universität München, München, Germany|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|Fondazione Salvatore Maugeri IRCCS, Pavia, Italy|Academisch Medisch Centrum Amsterdam, Amsterdam, Netherlands|Barts and The London School of Medicine and Dentistry, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02300558"
998,"NCT03359161","Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload",,"Recruiting","No Results Available","Heart Failure","Combination Product: sc2Wear Furosemide Infusor","% weight loss between enrollment/screening compared to Post Visit #1 and Post Visit #2|Reduction in pro-BNP between enrollment/screening compared to Post Visit #1 and Post Visit #2|% of patients alive 30 days post enrollment|% of patients without hospitalization for worsening HF within 30 days after enrollment|% of patients without a significant Heart Failure related medical events within 30 days after enrollment.|Proportion of patients requiring additional 4 days of diuresis|Discontinuation due to presence of skin reaction to drug or device/adhesive.","Steward St. Elizabeth's Medical Center of Boston, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Clinical Protocol Version 4.0","April 5, 2018","January 2019","June 2019","December 2, 2017",,"April 18, 2018","St ELizabeth's Medical Center, Brighton, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03359161"
999,"NCT01908699","Beraprost-314d Added-on to Tyvaso® (BEAT)","BEAT","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium 314d Modified Release Tablets|Drug: Placebo","Number of Participants That Experienced Clinical Worsening|Mean Change From Baseline in Borg Dyspnea Score at Week 24|Mean Change From Baseline in NT-pro-BNP Levels at Week 24|Change in WHO Functional Class From Baseline to Week 24|Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 24|Number of Participants With TEAEs, Serious TEAEs, Investigations SOC TEAEs, and Serious Investigations SOC TEAEs","Lung Biotechnology PBC","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","273","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BPS-314d-MR-PAH-302","May 31, 2013","February 19, 2019","February 19, 2019","July 26, 2013","February 28, 2020","February 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center Heart Institute, Beverly Hills, California, United States|Allianz Research Institute Inc., Fountain Valley, California, United States|University of California San Francisco - Fresno, Fresno, California, United States|University of California - San Diego, La Jolla, California, United States|University of California Los Angeles, Los Angeles, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|Center for Advanced Pulmonary Medicine, Rancho Mirage, California, United States|University of California - San Francisco, San Francisco, California, United States|Cottage Pulmonary Hypertension Center, Santa Barbara, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Aurora Denver Cardiology Associates, Denver, Colorado, United States|South Denver Cardiology Associates P.C., Littleton, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|Florida Lung, Asthma, and Sleep Institute, Celebration, Florida, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Orlando Health Heart Institute, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Gwinnett Biomedical Research, Lawrenceville, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|Advocate Health and Hospitals Corporation, Oakbrook Terrace, Illinois, United States|Indiana University - Health Physicians, Carmel, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville Department of Medicine, Louisville, Kentucky, United States|John Ochsner Heart & Vascular Institute, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health Systems, Troy, Michigan, United States|Rutgers University Hospital, Newark, New Jersey, United States|Albany Medical College, Albany, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Beth Israel Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Pulmonary Health Physicians, PC, Syracuse, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Anderson Pharmaceutical Research, Anderson, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Methodist Healthcare Clinical Trials Office, San Antonio, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Soroka Medical Center, Beer-sheva, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Rabin Medical Center-Beilinson Campus, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center, Rechovot, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01908699/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01908699/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01908699"
1000,"NCT01729871","A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","VENTURE-AF","Completed","Has Results","Atrial Fibrillation","Drug: rivaroxaban|Drug: uninterrupted vitamin K antagonist (VKA)","Number of Participants With Incidence of Post-Procedure Major Bleeding Events|Number of Participants With Composite Endpoint of Myocardial Infarction (MI), Ischemic Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism and Vascular Death|Number of Participants With Myocardial Infarction (MI)|Number of Participants With Ischemic Stroke|Number of Participants With Non-Central Nervous System (Non-CNS) Systemic Embolism|Number of Participants With Vascular Death","Janssen Scientific Affairs, LLC|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR100732|RIVAROXAFL3002|2012-001484-79","February 2013","October 2014","October 2014","November 20, 2012","November 10, 2015","March 6, 2017","Beverly Hills, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|Jacksonville, Florida, United States|Maywood, Illinois, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|St Louis Park, Minnesota, United States|Ridgewood, New Jersey, United States|Flushing, New York, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Erie, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Tyler, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Aalst, Belgium|Antwerpen, Belgium|Brugge, Belgium|Genk, Belgium|Hasselt, Belgium|Brest Cedex 2, France|Montpellier, France|Pessac Cedex, France|Toulouse Cedex 9 N/A, France|Vandoeuvre Les Nancy, France|Bad Krozingen, Germany|Bad Nauheim, Germany|Berlin, Germany|Dresden, Germany|Jena, Germany|Mönchengladbach, Germany|Neuwied, Germany|Bournemouth, United Kingdom|Cottingham, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01729871"
1001,"NCT03950739","Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso","BREEZE","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Treprostinil Inhalation Powder","Number of subjects with treatment-emergent adverse events [Safety and Tolerability]|Analysis of treprostinil plasma concentration (pharmacokinetics [PK])|Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 3|Number of subjects with treatment-emergent adverse events [Long-term Safety and Tolerability] during an Optional Extension Phase|Subject satisfaction with and preference for inhaled treprostinil devices|Patient-reported PAH symptoms and impact","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TIP-PH-101","September 17, 2019","May 2020","August 2020","May 15, 2019",,"March 2, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|USC, Department of Medicine, Los Angeles, California, United States|Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Ascension/ St. Vincent's Lung Institute, Jacksonville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville Pulmonary Research, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03950739"
1002,"NCT01105117","Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401","EPITOME-1 Ext","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: ACT-385781A (Actelion Epoprostenol)|Drug: Flolan®","Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) - Number of Patients With Adverse Events Leading Discontinuation of Study Treatment|Safety and Tolerability of ACT-385781A and Flolan in Injectable Prostanoid Treatment-naïve Patients With PAH - Number of Deaths","Actelion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-066A402","May 2010","July 2011","December 2011","April 16, 2010","August 23, 2012","December 3, 2012","University of California - San Diego, La Jolla, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania-Penn Presybyterian Medical Center, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01105117"
1003,"NCT01105091","Epoprostenol for Injection in Pulmonary Arterial Hypertension","EPITOME-1","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: ACT-385781A (Actelion Epoprostenol)|Drug: Flolan®","Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 2 ng/kg/Min|Dose Normalized Pharmacokinetics of 6,15-diketo-13,14-dihydro-Prostacyclin F1alpha at 4 ng/kg/Min|Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 2 ng/kg/Min|Dose Normalized Pharmacokinetics of 6-keto-Prostacyclin F1alpha at 4 ng/kg/Min|Six-minute Walk Distance (6MWD) - Baseline and Day 28|Patients With New York Heart Association (NYHA) Functional Class Change (Improved or Worsened) From Baseline to Day 28|Percentage Central Venous Blood Oxygen Saturation (ScVO2) - Baseline and Day 28|Blood Pressure - Baseline and Day 28|Heart Rate - Baseline and Day 28|Body Weight - Baseline and Day 28","Actelion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-066A401","March 2010","May 2011","July 2011","April 16, 2010","August 23, 2012","December 3, 2012","University of California - San Diego, La Jolla, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01105091"
1004,"NCT01363193","Safety and Efficacy of Lean Body Weight-based IV Heparin Dosing in Obese/Morbidly Obese Patients",,"Unknown status","No Results Available","Obesity|Morbid Obesity|Venous Thromboembolism|Atrial Fibrillation|Angina|Chest Pain","Drug: Lean Body Weight-based heparin dose","Percent of study patients achieving therapeutic aPTT within first 24 hours on a hospital based IV heparin protocol using Lean Body Weight|Evaluation of side effects and/or complications during the index hospitalization","Nazareth Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LBW Heparin study","July 2011","December 2014","December 2014","June 1, 2011",,"May 14, 2013","Nazareth Hospital - Mercy Health System, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01363193"
1005,"NCT00964392","NAVISTAR® THERMOCOOL® Catheter Post Approval Registry","AF Registry","Completed","Has Results","Paroxysmal Atrial Fibrillation","Procedure: Atrial fibrillation ablation","The Percentage of Subjects Experiencing Primary Adverse Events Within Seven Days of the Ablation Procedure.|Percentage of Subjects Experienced Serious Adverse Events.","Biosense Webster, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","437","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMA #P030031/S014","September 1, 2009","September 1, 2013","January 5, 2018","August 24, 2009","April 26, 2017","October 17, 2018","Diagnostic Cardiology Associates PA, Jacksonville, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|Central Baptist Hospital, Lexington, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Washington Adventist Hospital, Silver Spring, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Park Nicollet Institute, Minneapolis, Minnesota, United States|St. Luke's Roosevelt Hospital, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|Austin Heart PA, Austin, Texas, United States|Inova Fairfax Hospital, Fairfax, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Montreal Heart Institute (Institut de Cardiologie de Montreal), Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00964392"
1006,"NCT01594333","Cardiovascular Inflammation Reduction Trial","CIRT","Completed","No Results Available","Cardiovascular Disease","Drug: Methotrexate|Drug: Placebo","Rate of major cardiovascular events|Rate of all-cause mortality|Rate of the primary endpoint plus coronary revascularization|Rate of hospitalization for congestive heart failure|Rate of primary endpoint plus all-cause mortality plus coronary revascularization plus congestive heart failure|Rate of new onset type 2 diabetes among those with metabolic syndrome but not diabetes at study entry","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","4786","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2012P-000857|U01HL101422|U01HL101389","April 2013","December 2018","June 2019","May 9, 2012",,"July 12, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Appalachian Research Associates, Fort Payne, Alabama, United States|Avant Research Associates, LLC, Guntersville, Alabama, United States|Saadat Ansari MD LLC, Huntsville, Alabama, United States|University of South Alabama: Division of Clinical Research, Mobile, Alabama, United States|Heart Vascular of Northern Arizona, Cottonwood, Arizona, United States|CardioVascular Associates of Mesa, Mesa, Arizona, United States|Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States|Scottsdale Medical Imaging, Scottsdale, Arizona, United States|The Heart Clinic, Scottsdale, Arizona, United States|Pima Heart, Tucson, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|Arkansas Cardiology, Little Rock, Arkansas, United States|Arkansas Heart Hospital, Little Rock, Arkansas, United States|Oracle Clinical Research, Inc., Anaheim, California, United States|Medical Group of Culver City, Culver City, California, United States|Touro University California- Solano County Affiliated Clinics, Fairfield, California, United States|University Of California San Francisco, Fresno, California, United States|VACCHCS, Fresno, California, United States|UCSD Sulpizio Cardiovascular Center, La Jolla, California, United States|University Of California San Diego, La Jolla, California, United States|Desert Medical Care & Wellness, La Quinta, California, United States|Kumar Medical Corporation, Lancaster, California, United States|Loma Linda University Health, Loma Linda, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|Cardiovascular Innovation and Research, Long Beach, California, United States|Los Alamitos Cardiovascular, Los Alamitos, California, United States|Faye Montegrande Md. Clinical Research, Los Angeles, California, United States|Eastside Clinical Research Associates, Los Angeles, California, United States|Salman Khan A. Medical Corporation, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|West LA VA Medical Center, Los Angeles, California, United States|VA Northern California Health Care, Mather, California, United States|Valley Clinical Trials, Inc., Northridge, California, United States|Orange County Heart Institute & Research, Orange, California, United States|University of CA Irvine Medical Center, Orange, California, United States|Diverse Research Solutions, Oxnard, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Central Coast Cardiology, Salinas, California, United States|Richard G. Friedman, MD, San Diego, California, United States|Ritchken and First MDs, San Diego, California, United States|Foundation for Cardiovascular Medicine, San Diego, California, United States|San Diego Cardiac Center, San Diego, California, United States|Veterans Affairs San Diego Healthcare System, San Diego, California, United States|UCSF at Zuckerberg SF General Hospital, San Francisco, California, United States|Coastal Heart Medical Group, Inc., Santa Ana, California, United States|Comprehensive Cardiovascular Care, Santa Maria, California, United States|Pacific Heart and Vascular Medical Group, Stockton, California, United States|Manoj D. Aswani M.D., Thousand Oaks, California, United States|Touro University California- Solano Public Health Affiliated Clinics, Vallejo, California, United States|Munni R. Selagamsetty, Md, Pc, Colorado Springs, Colorado, United States|Vijay - Aurora Denver Cardiology, Denver, Colorado, United States|Colorado Health Medical Group Heart Center of the Rockies, Fort Collins, Colorado, United States|Medical Center of the Rockies Research, Fort Collins, Colorado, United States|Unrein - Rocky Vista University Health Center, Parker, Colorado, United States|Connecticut Heart and Vascular Center, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Cardiology Physicians/Red Clay Research, Newark, Delaware, United States|Boisey Barnes MD, PC, Washington, District of Columbia, United States|GWU Medical Faculty Associatin, Inc., Washington, District of Columbia, United States|Pianko - Aventura Research Center, LLC, Aventura, Florida, United States|North Ridge Heart Associates, Boca Raton, Florida, United States|St. Francis Medical Institute, Clearwater, Florida, United States|Gonzalez MD & Aswad MD Health Ser, Coral Gables, Florida, United States|American Research Institute, Inc., Cutler Bay, Florida, United States|Daytona Heart Group, Daytona Beach, Florida, United States|Daytona Heart Group, DeLand, Florida, United States|Seidman Clinical Trials, Delray Beach, Florida, United States|Steven Cohen MD, Delray Beach, Florida, United States|Infinite Clinical Research, Doral, Florida, United States|International Research Partners, LLC, Doral, Florida, United States|Medical Research Institute at Doral, Inc., Doral, Florida, United States|Lake Internal Medicine Assocaties, Eustis, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|Primary Care Associates, Fort Myers, Florida, United States|Lee Physician Group, Fort Myers, Florida, United States|The Cardiac and Vascular Institute, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Qway Research, Hialeah, Florida, United States|State of the Art Research, Hialeah, Florida, United States|Healing Touch C&C Research, Hialeah, Florida, United States|Luzmed Clinical Research Institute, Hialeah, Florida, United States|Viviana Perez MD Research & Cosmetics, Hialeah, Florida, United States|Elite Cardiac Research Center LLC, Hialeah, Florida, United States|Nova Clinical Research Clinic, Hialeah, Florida, United States|Best Quality Research, Inc., Hialeah, Florida, United States|South Florida Research Solutions, LLC, Hollywood, Florida, United States|John Gutleber Medical Research Office, Homestead, Florida, United States|Cardiovascular Medical Associates of Palm Beach, Jupiter, Florida, United States|Hope Clinical Research, Kissimmee, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Lakes Research, LLC, Miami Lakes, Florida, United States|Veritas Research Corp., Miami Lakes, Florida, United States|Ocean Blue Medical Research Center, Miami Springs, Florida, United States|Medical Research Center of Florida, Miami, Florida, United States|LG Diagnostics, Inc., Miami, Florida, United States|St. Paul Medical Research Center, Inc., Miami, Florida, United States|Team Medical Research, Miami, Florida, United States|Paradise Clinical Research, LLC, Miami, Florida, United States|GAD Research Center, Miami, Florida, United States|Innovation Research Institute, Inc., Miami, Florida, United States|Sanitas Research, Miami, Florida, United States|Segui - Med Care Research, Miami, Florida, United States|South Florida Research Group, LLC, Miami, Florida, United States|Vista Health Research, LLC, Miami, Florida, United States|D De La Vega MD Research Group, Miami, Florida, United States|Southwest Florida Research, LLC, Naples, Florida, United States|Orlando Healthy Heart Institute, Orlando, Florida, United States|Palm Beach Gardens Research Center, LLC, Palm Beach Gardens, Florida, United States|Broward Research Center, Pembroke Pines, Florida, United States|Pioneer Clinical Research, Pembroke Pines, Florida, United States|Sandoval - Broward Research Center, Pembroke Pines, Florida, United States|Bay Area Heart Center: 49th Street, Saint Petersburg, Florida, United States|Bay Area Heart Center: 7th Avenue, Saint Petersburg, Florida, United States|Lenus Research & Medical Group, Sweetwater, Florida, United States|DBC Research, Tamarac, Florida, United States|Asclepes Research Centers, Weeki Wachee, Florida, United States|Gupta - Premier Heart and Vascular Center, Wesley Chapel, Florida, United States|Athens Regional Medical Center, Athens, Georgia, United States|Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, United States|Laureate Medical Group at Northside, Atlanta, Georgia, United States|Synergy Therapeutic Partners, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Atlanta Heart Specialists, LLC, Cumming, Georgia, United States|Heart and Rhythm Specialists, Dalton, Georgia, United States|Albert F. Johary MD, PC, Dunwoody, Georgia, United States|Infinite Clinical Trials, Riverdale, Georgia, United States|Atlanta Vanguard Medical Associates, Smyrna, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Atlanta Heart Specialists, LLC, Tucker, Georgia, United States|Cardiology Associates of Vidalia, P.C., Vidalia, Georgia, United States|VA Pacific Islands Health Care System, Honolulu, Hawaii, United States|St. Luke's Idaho Cardiology Associates, Boise, Idaho, United States|Clinical Research Prime, Idaho Falls, Idaho, United States|Northwest Heart Clinical Research, Arlington Heights, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Advocate Med Group-Heart & Vascular Of Illinois, Chicago, Illinois, United States|Illinois Heart & Lung Research Center, SC, Normal, Illinois, United States|Captain James A. Lovell Federal Health, North Chicago, Illinois, United States|Specialty Physicians of Illinois, LLC, Olympia Fields, Illinois, United States|Advanced CardioVascular Consultants, Rock Island, Illinois, United States|Cardiospecialists, LTD, Dyer, Indiana, United States|Martin - Martin Family Practice and Research, Evansville, Indiana, United States|Krannert Institute Of Cardiology, Indianapolis, Indiana, United States|Community Hospital South, Indianapolis, Indiana, United States|Indiana Heart Physicians, Indianapolis, Indiana, United States|Medical Consultants, PC, Muncie, Indiana, United States|Iowa Heart Center, West Des Moines, Iowa, United States|Stahl - Midwest Heart & Vascular Specialists, Overland Park, Kansas, United States|Professional Research Network of KS, Wichita, Kansas, United States|Robert J. Dole VAMC, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Robley Rex VAMC, Louisville, Kentucky, United States|Stoddard - University of Louisville, Louisville, Kentucky, United States|Bays - L-MARC Research Center, Louisville, Kentucky, United States|Research Integrity LLC, Owensboro, Kentucky, United States|Dorothy H. Banish, MD, APMC Study Group, Covington, Louisiana, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|North Oaks Cardiology, Hammond, Louisiana, United States|American Clinical Research, LLC, Marrero, Louisiana, United States|Otis Barnum D.O.P.C., Natchitoches, Louisiana, United States|Tulane University Office of Health Research, New Orleans, Louisiana, United States|Veterans Affairs Medical Center Shreveport, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Paul A. Shapero, M.D., Bangor, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|InterMed, PA, Portland, Maine, United States|Maine Medical Partners Maine Health Cardiology, South Portland, Maine, United States|Maine Centers for Healthcare, Westbrook, Maine, United States|Sinai Center for Thrombosis Research, Baltimore, Maryland, United States|St. Mary's Medical Center, Charlotte Hall, Maryland, United States|Calvert Memorial Hospital, Clinton, Maryland, United States|Shah Associates, MD, LLC, Prince Frederick, Maryland, United States|Peninsula Cardiology Associates, Salisbury, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|MGH Cardiology, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Massachusetts General Hospital - Chelsea Health Care Center, Chelsea, Massachusetts, United States|Pentucket Medical Associates, Inc., Haverhill, Massachusetts, United States|VA Central Western Massachusetts Healthca, Leeds, Massachusetts, United States|South Shore Internal Medicine, Milton, Massachusetts, United States|Lahey Medical Center, Peabody, Massachusetts, United States|North Shore Cardiovascular Associates, Salem, Massachusetts, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Endeavor Medical Research, Alpena, Michigan, United States|John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan, United States|Trace Research Group at Wayne State University, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Flint Clinical Research, Flint, Michigan, United States|Apex Medical Research MI, Inc., Flint, Michigan, United States|Garden City Hospital, Garden City, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|National Clinical LLC, Hamtramck, Michigan, United States|Academic Cardiology Associates PC, Rochester Hills, Michigan, United States|Beaumont Health Center, Royal Oak, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Mid-Michigan Heart & Vascular Center, Saginaw, Michigan, United States|Centra Care Heart & Vascular Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|United Heart and Vascular Clinic, Saint Paul, Minnesota, United States|Gulfside Clinical Research, LLC, Gulfport, Mississippi, United States|University of MS Medical Center, Jackson, Mississippi, United States|David M. Headley M.D. PA Planters Clinic, Port Gibson, Mississippi, United States|Stern Cardiovascular Foundation, Inc., Southaven, Mississippi, United States|Center for Advanced Medicine and Research LLC, Bridgeton, Missouri, United States|Clinical Research Center University of Missouri, Columbia, Missouri, United States|Quantum Research LLC, Festus, Missouri, United States|Midwest Cardiology Associates, Independence, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|VA Medical Center Kansas City, Kansas City, Missouri, United States|Lake Regional Cardiovascular Institute, Osage Beach, Missouri, United States|VA St. Louis Health Care System (VASTLHCS), Saint Louis, Missouri, United States|SLUCare Cardiology, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Clinical Investigators LLC, Saint Louis, Missouri, United States|Consult and Research Associates, Saint Louis, Missouri, United States|Center for Advanced Medicine and Research, Saint Peters, Missouri, United States|CoxHealth: Wheeler Heart & Vascular Center, Springfield, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Great Falls Clinic Clinical Research Deptartment, Great Falls, Montana, United States|Cone - Montana Medical Research, Missoula, Montana, United States|Barrett Clinic, P.C., La Vista, Nebraska, United States|Heart Consultants, Omaha, Nebraska, United States|Alegent Creighton Health, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Internal Medicine Clinic, Las Vegas, Nevada, United States|Red Rock Clinical Research, LLC, Las Vegas, Nevada, United States|Sierra Nevada Health Care System, Reno, Nevada, United States|Renown Inst for Heart & Vasc Health, Reno, Nevada, United States|Lahey Cardiology, Nashua, New Hampshire, United States|Family Health at Mount Olive, Flanders, New Jersey, United States|Cardiocare, Hillsborough, New Jersey, United States|New Jersey Heart, Linden, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Cardiovascular Institute, New Brunswick, New Jersey, United States|Palisade Medical Center, North Bergen, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Mercer Bucks Cardiology, Robbinsville, New Jersey, United States|Cardio Metabolic Institute, Somerset, New Jersey, United States|Holy Name Medical Center, Inc., Teaneck, New Jersey, United States|Total Cardiology Care, LLC, Wayne, New Jersey, United States|Westwood Cardiology Associates, Westwood, New Jersey, United States|Presbyterian Heart Group, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Albany Stratton VA Medical Center, Albany, New York, United States|Novel Research of New York, LLC, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Brown - SUNY Downstate Medical Center, Brooklyn, New York, United States|Buffalo Heart Group, Buffalo, New York, United States|Bassett Healthcare Network, Cooperstown, New York, United States|NYU Hudson Valley Cardiology, Cortlandt Manor, New York, United States|NYHQ, Flushing, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Long Island Heart Associates, Mineola, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Queens Long Island Medical Group, New Hyde Park, New York, United States|Chinatown Cardiology, PC, New York, New York, United States|Weill Cornell Medical College and NY Presbyterian, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|DiGiovanna Institute for Medical Education and Research, North Massapequa, New York, United States|Champlain Valley Physician Hospital, Plattsburgh, New York, United States|Cardiology Associates of Schenectady, Schenectady, New York, United States|Clinical Study Center of Asheville, Asheville, North Carolina, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Gaffney Health Services, Charlotte, North Carolina, United States|Carolinas Research Center, Charlotte, North Carolina, United States|Eastern Carolina Cardiovascular, PA, Elizabeth City, North Carolina, United States|Eastern Cardiology, Greenville, North Carolina, United States|Northside Clinical Research, Lenoir, North Carolina, United States|Lake Shore Clinical Research, LLC., Mooresville, North Carolina, United States|Carteret Medical Group, Morehead City, North Carolina, United States|Cardiology Associates of Carolinas, PA, Morganton, North Carolina, United States|Eastern Nephrology Associates, PLLC, New Bern, North Carolina, United States|Boice Willis Clinic, Rocky Mount, North Carolina, United States|Sanford Cardiology, Sanford, North Carolina, United States|Natalie A. Doyle, MD, PA, Wilson, North Carolina, United States|Altru Health System Rehab Center, Grand Forks, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Ohio University Heritage College of Osteopathic Medicine, Athens, Ohio, United States|Diabetes and Endocrinology Associates of Stark Cit, Canton, Ohio, United States|The Lindner Research Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Optimed Research, LTD, Columbus, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|Dayton Veteran Affairs Medical Center, Dayton, Ohio, United States|Colonnade Medical Group, Lancaster, Ohio, United States|Middletown Cardiovascular Associates, Middletown, Ohio, United States|Comprehensive Heart Care, Inc., Toledo, Ohio, United States|Mount Carmel Clinical Cardiovascular Care, Westerville, Ohio, United States|Premier Physicians, Westlake, Ohio, United States|Wooster Heart Group, Wooster, Ohio, United States|Unity Clinical Research, Lindsay, Oklahoma, United States|COR Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Thadani - VA Medical Center Oklahoma City, OK, Oklahoma City, Oklahoma, United States|Today Clinical Research, Oklahoma City, Oklahoma, United States|Cardiovascular Health Clinic, Oklahoma City, Oklahoma, United States|Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States|Samaritan Health Services, Corvallis, Oregon, United States|Southern Oregon Cardiology, LLC, Medford, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Center for Clinical Res. Abington Health, Abington, Pennsylvania, United States|St. Luke's University Hospital, Bethlehem, Pennsylvania, United States|Renu-Ca Research Institute, Lower Bucks Hospital, Bristol, Pennsylvania, United States|Main Line Health Center, Broomall, Broomall, Pennsylvania, United States|Spirit Physician Services, Inc, Camp Hill, Pennsylvania, United States|The Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Central Bucks Cardiology, Doylestown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Heart Specialists of Lancaster County, Ephrata, Pennsylvania, United States|Saint Vincent Consultants in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Feasterville Family Healthcare Center, Feasterville, Pennsylvania, United States|Christiana Care Health System, Glen Mills, Pennsylvania, United States|Pinnacle Health Cardiovascular Institute, Harrisburg, Pennsylvania, United States|George Isajiw, MD, Lansdowne, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lehigh Valley Health Services, Sellersville, Pennsylvania, United States|Pish Medical Associates, Inc., Uniontown, Pennsylvania, United States|Lehigh Valley Family Practice, Whitehall, Pennsylvania, United States|Wilkes-Barre VA Medical Center, Wilkes-Barre, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Ocean State Clinical Research Prtnr, Lincoln, Rhode Island, United States|Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Ocean State Research Institute, Inc, Providence, Rhode Island, United States|South Carolina Heart Center, Columbia, South Carolina, United States|Amistad Research Center, LLC, Columbia, South Carolina, United States|Charlotte Hearts, Indian Land, South Carolina, United States|Miller - SC Internal Medicine Associates.: Irmo, Irmo, South Carolina, United States|Inlet Cardiopulmonary & Associates, Pawleys Island, South Carolina, United States|Fusion Clinical Research of Spartanburg, Spartanburg, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|New Phase Research & Development, Chattanooga, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, Inc., Germantown, Tennessee, United States|Kore Cardiovascular Research Institutue, Jackson, Tennessee, United States|New Phase Research & Development, Knoxville, Tennessee, United States|Cardiovascular Research of Knoxville, Knoxville, Tennessee, United States|Ramanathan - VAMC Memphis, Memphis, Tennessee, United States|Clinical Research Center Meharry Medical College, Nashville, Tennessee, United States|Avant Research Associates LLC, Austin, Texas, United States|Texas Heart and Vascular Research, LLC, Austin, Texas, United States|Southeast TX Clinical Research Center, Beaumont, Texas, United States|Cornerstone Family Medicine, Big Spring, Texas, United States|IMD Medical Center, Carrollton, Texas, United States|Texas Health Physicians Group, Carrollton, Texas, United States|Cardiovascular Research Institute of Dallas, Dallas, Texas, United States|North Texas Health Center, Dallas, Texas, United States|The Heart Center of Dallas, Dallas, Texas, United States|Global Medical Research, DeSoto, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T&R Clinic, P.A., Haltom City, Texas, United States|Michele P. Sartori, MD, Houston, Texas, United States|Grand Medical Care, Katy, Texas, United States|Team Research Of Central Texas, Killeen, Texas, United States|Houston Heart and Vascular Associates, Kingwood, Texas, United States|Grace Research, LLC, Marshall, Texas, United States|Valley Heart Consultants, McAllen, Texas, United States|Heart Center, Palo Pinto General Hospital, Mineral Wells, Texas, United States|Valley Central Research Inc, Mission, Texas, United States|North Hills Medical Research, Inc, North Richland Hills, Texas, United States|Grace Research, LLC, Palestine, Texas, United States|Avant Research Associates, LLC, Port Arthur, Texas, United States|Santoscoy - Health Texas Research Institute, San Antonio, Texas, United States|Element Research Group, San Antonio, Texas, United States|Schnitzler Cardiovascular Consultants, San Antonio, Texas, United States|San Antonio Endovascular & Heart Institute, San Antonio, Texas, United States|Acacia Medical Research Institute, Sugar Land, Texas, United States|Health Plus Clinical Research, Sugar Land, Texas, United States|Lone Star Heart and Vascular Center, Tomball, Texas, United States|Northwest Houston Clinical Research, Tomball, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Utah Cardiology, P.C., Layton, Utah, United States|Utah Diabetes Center, Salt Lake City, Utah, United States|VA Medical Center, White River Junction, White River Junction, Vermont, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice Research, Hampton, Virginia, United States|Tidewater Physicians Multispecialty Group, Hampton, Virginia, United States|Virginia Cardiovascular Associates, Manassas, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Tucker Cardiology Associates, P.C., Mechanicsville, Virginia, United States|TPMG Clinical Research, Newport News, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Roanoke Heart Institute PLC, Roanoke, Virginia, United States|Cardinal Internal Medicine Associates, Woodbridge, Virginia, United States|Tidewater Physicians Multispecialty Group, Yorktown, Virginia, United States|Frandsen Family Medicine DBA Sound Medi, Port Orchard, Washington, United States|Premier Clinical Research, Spokane, Washington, United States|Kootenai Heart Clinics, LLC, Spokane, Washington, United States|Northside Internal Medicine, Spokane, Washington, United States|Northwest Medical Associates, P.S., Vancouver, Washington, United States|Cardiology Associates of Bellin Health, Green Bay, Wisconsin, United States|Dean Foundation, Madison, Wisconsin, United States|University Of Wisconsin, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Columbia St. Mary's, Milwaukee, Wisconsin, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Medical Arts Health Research Group, North Vancouver, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Winnipeg Clinic, Winnipeg, Manitoba, Canada|Bramalea Medical Centre, Brampton, Ontario, Canada|Brampton Research Associates, Brampton, Ontario, Canada|Philippe R Beaudry Medicine Professional Corporation, Burlington, Ontario, Canada|Vizel Cardiac Research, Cambridge, Ontario, Canada|Dr. Linda Sinnaeve's Office, Chatham, Ontario, Canada|Scisco Clinical Research, Cornwall, Ontario, Canada|Dr. Peter Spadafora Health Center, Guelph, Ontario, Canada|John Stimac, MD, Hamilton, Ontario, Canada|KMH Cardiology & Diagnostics: Hamilton, Hamilton, Ontario, Canada|Dr. William Liang, Hamilton, Ontario, Canada|Source Unique Clinic, Hawkesbury, Ontario, Canada|Dr. Ronald Fowlis, Kitchener, Ontario, Canada|University Hospital, London, Ontario, Canada|Malton Medical Research, Mississauga, Ontario, Canada|KMH Cardiology & Diagnostics: Mississauga, Mississauga, Ontario, Canada|Sewa Ram Singal Medicine Professional Corporation, Mississauga, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|Newmarket Cardiology Research Group, Newmarket, Ontario, Canada|Portage Medical Centre, Niagra Falls, Ontario, Canada|Humber River Regional Hospital, North York, Ontario, Canada|Bakbak Medicine Professional Corporation, Oshawa, Ontario, Canada|Dr. James Y. Cha, Oshawa, Ontario, Canada|University Of Ottawa Heart Institute, Ottawa, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Steeple Hill Medical Centre, Pickering, Ontario, Canada|Sarnia Institute Of Clinical Research, Sarnia, Ontario, Canada|Scarborough Cardiology Research, Scarborough, Ontario, Canada|Scarborough General Hospital Cardiology Research Associates, Scarborough, Ontario, Canada|Milliken Medical Centre, Scarborough, Ontario, Canada|Canadian Centre for Research on Diabetes, Smith Falls, Ontario, Canada|Lake Shore Cardiology, St. Catharines, Ontario, Canada|Sardar Medical Clinic, St. Thomas, Ontario, Canada|G.S. Cardiac Lab Medicine Professional Corp, Sudbury, Ontario, Canada|Dr. R. Labonte Professional Med Corp, Sudbury, Ontario, Canada|Dr. G. Garrioch, Independent Practice, Sudbury, Ontario, Canada|Dr. Laurence Gibbs Medicine Professional Corp., Thedford, Ontario, Canada|Tillsonburg Medical Centre, Tillsonburg, Ontario, Canada|Humber River Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Weston Road Medical Clinic, Toronto, Ontario, Canada|Dr. Nigel Jagan Medicine Professional Corporation, Whitby, Ontario, Canada|Dr. Nwadiaro Medicine Professional Corp, Windsor, Ontario, Canada|Viacar Recherche Clinique Inc., Brossard, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Q&T Research Chicoutimi, Chicoutimi, Quebec, Canada|Viacar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|CHUM Hotel-Dieu, Montreal, Quebec, Canada|Iucpq, Quebec City, Quebec, Canada|ALPHA Recherche Clinique, Québec, Quebec, Canada|CardioVasc HR, Saint-Jean-sur-Richelieu, Quebec, Canada|ViaCar Recherche Clinique Inc, Saint-Lambert, Quebec, Canada|Viacar Recherche Clinique, St. Lambert, Quebec, Canada|Hopital Pierre-Le Gardeur, Terrebonne, Quebec, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Instituto Sanacoop, Bayamón, Puerto Rico|San Juan Bautista School of Medicine, Caguas, Puerto Rico|Norma S. Severino-Pacheco, MD, Canovanas, Puerto Rico|Cardiometabolic Research Center, Ponce, Puerto Rico|Miguel Sosa-Padilla, MD, San Juan, Puerto Rico|Yolanda Sierra Quinones, MD, Toa Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01594333"
1007,"NCT01560637","An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension",,"Enrolling by invitation","No Results Available","Pulmonary Arterial Hypertension","Drug: UT-15C (treprostinil diethanolamine)","Safety (e.g.number and frequency of adverse events, changes in laboratory parameters from Baseline)","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","850","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-311","May 2012","May 2021","August 2021","March 22, 2012",,"April 7, 2020","Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program, Sacramento, California, United States|David Geffen School of Medicine, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Piedmont - Georgia Lung Associates, Austell, Georgia, United States|HeartCare Midwest, Peoria, Illinois, United States|Indiana University Hospital, Carmel, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Beaumont Health, Troy, Michigan, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|University of Rochester, Rochester, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospital, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Legacy Research Institute, Portland, Oregon, United States|Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Sanatorio San José, Caba, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Hospital Italiano Garibaldi, Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Dr. José María Cullen, Santa Fe, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Saint Vincents Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Krankenhaus Elisabethinen Linz, Linz, Upper Austria, Austria|Medizinische Universität Wien, Wien, Austria|Hospital das Clinicas da Universidade Federal de Goias, Goiania, Goias, Brazil|Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital das Clínicas da Faculdade de Medicina de Botucatu- UNESP, Botucatu, SAO Paulo, Brazil|Hospital da Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SAO Paulo, Brazil|Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SAO Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Respiratory Research Foundation, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Vancouver Coastal Health, Vancouver, British Columbia, Canada|Lawson Health Research Institute, London, Ontario, Canada|Centro de Investigaciones TASOL, Santiago, Region Metropolitana, Chile|Clínica Tabancura, Vitacura, Santiago, Chile|Beijing Chao-Yang Hospital, Beijing, Beijing, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Wuhan Asia Heart Hospital, Wuhan, Hubei, China|Xiangya Hospital, Changsha, Hunan, China|The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China|The Second Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, China|Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China|Peking Union Medical College Hospital, Beijing, China|Beijing Shijitan Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Renji Hospital of Shanghai Jiaotong University, Shanghai, China|Shanghai Pulmonary Hospital of Tongji University, Shanghai, China|Shenyang General Hospital of Shenyang Military Command, Shenyang, China|Aarhus Universitetshospital, Skejby, Aarhus, Denmark|Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark|Hopital Haut-Leveque, CHU Bordeaux, Pessac, Aquitaine, France|Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon, Besancon, Franche-comte, France|CHU de Montpellier, Montpellier cedex 5, Languedoc-roussillon, France|Hopital Brabois, Vandoeuvre-Les-Nancy, Limousin, Lorraine, France|Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille, NORD Pas-de-calais, France|Centre Hospitalier Universitaire Hopital Nord, Marseille, Provence Alpes COTE D'azur, France|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Baden-wuerttemberg, Germany|Ludwig-Maximilians-Universitat Munchen, Munchen, Bayern, Germany|Universitätsklinikum Regensburg, Regensburg, Bayern, Germany|Missionsarztliche Klinik Wurzburg gGmbH, Wurzburg, Bayern, Germany|Universitätsmedizin Greifswald, Greifswald, Mecklenburg-vorpommern, Germany|Bergmannsheil Berufsgenossenschaftliche Universitätsklinik GmbH, Bochum, Nordrhein-westfalen, Germany|Herzzentrum Duisburg, Duisburg, Nordrhein-westfalen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Rheinland-pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Technische Universität Dresden, Dresden, Sachsen, Germany|Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany|Universitätskrankenhaus Hamburg-Eppendorf, Hamburg, Germany|University General Hospital of Attikon, Athens, Attica, Greece|General Hospital of Thessaloniki, ""G.Papanikolaou"", Thessaloniki, Macedoni, Greece|CARE Hospital, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Care Institute Medical Sciences, Ahmedabad, Gujarat, India|Apollo Hospitals International, Ltd., Gandhinagar, Gujarat, India|Medanta - The Medicity, Gurgaon, Haryana, India|Narayana Institute of Cardiac Sciences, Bangalore, Karnataka, India|KEM Hospital, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Apollo Hospital, Chennai, Tamil NADU, India|G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil NADU, India|Rabin Medical Center, Petach Tikvah, Petah Tiqwa, Israel|The Chaim Sheba Medical Center at Tel Hashomer, Tel Hashomer, Tel Aviv, Israel|Rambam Health Corp., Haifa, Israel|Carmel Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Azienda Ospedaliera Universitaria, Napoli, Italy|Istituto Mediterraneo Trapianti e Terapia Alta Specializzazione (ISMETT), Palermo, Italy|Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy|Azienda Policlinico Umberto I di Roma, Roma, Italy|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cardiologia Ignacio Chavez, Tlalpan, Distrito Federal, Mexico|Unidad de Investigacion Clinica en Medicina S.C., Monterrey, Nuevo LEON, Mexico|Universitair Medisch Centrum Sint Radboud, Nijmegen, Gelderland, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Noord-holland, Netherlands|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu, Krakow, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Malogoskie, Poland|Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina, Otwock, Poland|National University Hospital, Singapore, Singapore|National Heart Centre Singapore, Singapore, Singapore|Sahlgrenska University Hospital, Göteborg, Vastra Gotaland, Sweden|Karolinska University Hospital Solna, Stockholm, Sweden|National Cheng Kung University Hospital, Tainan, Tainan CITY, Taiwan|Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Papworth Hospital, Papworth Everard, Cambridgshire, United Kingdom|Royal Free Hospital, London, England, United Kingdom|Freeman Hospital, Newcastle upon Tyne, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01560637"
1008,"NCT03839355","Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation","ARISTA","Recruiting","No Results Available","Atrial Fibrillation","Drug: Apixaban|Drug: Warfarin","Standardized neurocognitive function score|MRI evidence of silent cerebral infarct|MRI evidence of new cerebral micro-bleeds","Mayo Clinic|Pfizer|Bristol-Myers Squibb","All","60 Years and older   (Adult, Older Adult)","Phase 3","280","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","17-010544","December 19, 2018","December 2022","December 2022","February 15, 2019",,"February 15, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03839355"
1009,"NCT03988842","Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism","SAFE-LYSE","Not yet recruiting","No Results Available","Pulmonary Embolism With Acute Cor Pulmonale|Pulmonary Embolism|Pulmonary Embolism With Pulmonary Infarction|Pulmonary Embolism Subacute Massive|Right Ventricular Dysfunction|Right Ventricular Failure","Drug: Alteplase|Drug: Unfractionated heparin|Drug: Placebo|Drug: Apixaban","Change in extent of clot lysis in the Experimental Arm|Change in extent of clot lysis between the Experimental Arm and the Active Comparator Arm|Change in right ventricular to left ventricular diameter (RV/LV) ratio|Change in RV/LV ratio from baseline Echocardiogram|Change in tricuspid annular plane systolic excursion (TAPSE) from baseline Echocardiogram|Change in right ventricular systolic pressure (RVSP) from baseline Echocardiogram|Change in the collapse of the inferior vena cava (IVC) from baseline Echocardiogram|Change in the requirement for oxygen therapy after 6 Minute Walk Test (6MWT)|Change in Borg Dyspnea Scale score after 6 Minute Walk Test (6MWT)|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) questionnaire|Change in Pulmonary Embolism Quality of Life (PEmb-QOL) questionnaire|Number of recurrent deep vein thrombosis (DVT) and/or pulmonary embolism (PE) events","Victor Tapson, MD|Bristol-Myers Squibb|Cedars-Sinai Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00054951","June 2019","April 2021","April 2022","June 18, 2019",,"June 18, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03988842"
1010,"NCT01112306","ACT-293987 in Pulmonary Arterial Hypertension",,"Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: ACT-293987","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 3","1193","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A303|2009-014992-31","July 7, 2010","December 31, 2020","October 31, 2023","April 28, 2010",,"March 18, 2020","Mobile, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Sacramento, California, United States|Torrance, California, United States|Newark, Delaware, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Carmel, Indiana, United States|Iowa City, Iowa, United States|Kansas, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Rochester, Minnesota, United States|Chesterfield, Missouri, United States|Saint Louis, Missouri, United States|Newark, New Jersey, United States|Bronx, New York, United States|Islandia, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Bend, Oregon, United States|Portland, Oregon, United States|Doylestown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|York, Pennsylvania, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Buenos Aires, Argentina|Cordoba, Argentina|Corrientes, Argentina|Adelaide, Australia|Bedford Park, Australia|Chermside, Australia|Concord, Australia|Darlinghurst, Australia|Fitzroy, Australia|Hobart, Australia|Murdoch, Australia|New Lambton, Australia|Parkville, Australia|Graz, Austria|Vienna, Austria|Minsk, Belarus|Brussels, Belgium|Leuven, Belgium|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Santiago De Chile, Chile|Beijing, China|Guangzhou, China|Shanghai, China|Bogota, Colombia|Bogotá, Colombia|Praha 2, Czechia|Arhus, Denmark|Copenhagen, Denmark|Bron Cedex, France|Le Kremlin-Bicêtre Cedex, France|Lille Cedex, France|Toulouse Cedex 9, France|Berlin, Germany|Dresden, Germany|Giessen, Germany|Greifswald, Germany|Hannover, Germany|Heidelberg, Germany|Köln, Germany|Leipzig, Germany|Löwenstein, Germany|Regensburg, Germany|Alexandroupoli, Greece|Athens, Greece|Thessaloniki, Greece|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szeged, Hungary|Ahmedabad, India|Chennai, India|Hyderabad, India|Dublin, Ireland|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel-Hashomer, Israel|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Kuala Lumpur, Malaysia|Ciudad de Mexico, Mexico|Amsterdam, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Lima, Peru|Gdańsk, Poland|Krakow, Poland|Otwock, Poland|Łódź, Poland|Bucharest, Romania|Iasi, Romania|Barnaul, Russian Federation|Ekaterinburg, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St Petersburg, Russian Federation|Tomsk, Russian Federation|Belgrade, Serbia|Singapore, Singapore|Bratislava, Slovakia|Košice, Slovakia|Barcelona, Spain|Madrid, Spain|Göteborg, Sweden|Linköping, Sweden|Umea, Sweden|Uppsala, Sweden|Basel, Switzerland|Bern, Switzerland|Genève 14, Switzerland|Lausanne, Switzerland|Kaohsiung, Taiwan|Taipei, Taiwan|Khon Kaen, Thailand|Adana, Turkey|Istanbul, Turkey|İzmir, Turkey|Dnipro, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Glasgow, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01112306"
1011,"NCT03282669","TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia",,"Withdrawn","No Results Available","Pain, Postoperative|Obesity|Respiratory Insufficiency","Drug: Intrathecal Morphine|Drug: Intravenous hydromorphone","Incidence of hypercapnia|Opioid consumption|NSAID consumption|Respiratory rate|Sedation scores|Pain Scores|Pulse oximetry","Northwestern University","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STU00203985","August 2019","December 2021","December 2021","September 14, 2017",,"July 15, 2019","Prentice Womens Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03282669"
1012,"NCT02927366","Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: QCC374|Drug: Placebo Matching","Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 16 (Day 111)|Change From Baseline in Six Minute Walk Distance (6MWD) Over Time|Change From Baseline in Cardiac Output (CO) at Week 16 (Day 111)|Change From Baseline in Cardiac Index at Week 16 (Day 111)|Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 16 (Day 111)|Change From Baseline in Systemic Vascular Resistance (SVR) at Week 16 (Day 111)|Change From Baseline in RV Fractional Area Change and RV Free Wall Average Peak Long Strain at Week 16 (Day 111) Using Echocardiography|Change From Baseline in RV Tei Index at Week 16 (Day 111) Using Echocardiography|Change From Baseline in Tricuspid Annular Peak Systolic Velocity (TA S') at Week 16 (Day 111) Using Echocardiography|Change From Baseline in Tricuspid Annular Plane Sys Excursion (TAPSE) at Week 16 (Day 111) Using Echocardiography|Maximum Observed Plasma Concentration (Cmax) for QCC374 and Its Metabolite QCM441|Time to Reach the Maximum Plasma Concentration (Tmax) for QCC374 and Its Metabolite QCM441|Area Under the Plasma Concentration-time Curve From 0 to the Last Measurable Concentration (AUClast) for QCC374 and Its Metabolite QCM441|Area Under the Plasma Concentration Time Curve From 0 to the End of a Dosing Interval (AUCtau) for QCC374 and Its Metabolite QCM441","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CQCC374X2201|2016-001412-38","September 19, 2017","June 7, 2018","June 7, 2018","October 7, 2016","August 7, 2019","February 28, 2020","Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02927366/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02927366/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02927366"
1013,"NCT02668432","Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock",,"Terminated","Has Results","New Onset Atrial Fibrillation|Severe Sepsis|Septic Shock","Drug: Amiodarone","Mean HR Every 6 Hours Within the First 7 Days|Percentage of Time Spent Hemodynamically Unstable After Initiation of Amiodarone Infusion to Day 7 or Death|Percentage of Time of Conversion to Normal Sinus Rhythm|Percentage of Time Patients Spent in Atrial Fibrillation|Mean Arterial Pressure (MAP)|Systolic Blood Pressure (SBP)|Heart Rate (HR)|Percentage Time of Vasopressor Norepinephrine Use|Percentage Time of Vasopressor Vasopressin Use|Percentage of Time of Vasopressor Phenylephrine Use|Percentage of Time of Corticosteroid Use|Percentage of Time of Dobutamine Use|Percentage of Time of Concomitant Rate Control Medication Use|Concomitant Rhythm Control Medication or Intervention Use|28-day Mortality|Intensive Care Unit Length of Stay (ICU LOS)","The University of Texas Health Science Center at San Antonio","All","18 Years and older   (Adult, Older Adult)","Phase 4","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC20150864H","May 2016","September 20, 2018","September 20, 2018","January 29, 2016","April 2, 2019","April 2, 2019","University Hospital, San Antonio, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02668432/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02668432"
1014,"NCT02486367","Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)",,"Completed","No Results Available","Aortic Stenosis|Inflammation|Thrombosis","Drug: Clopidogrel|Drug: Ticagrelor","Platelet reactivity|Inflammatory monocyte proportion","University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","UH IRB # 06-14-33","June 2015","January 2019","January 2019","July 1, 2015",,"July 17, 2019","UH Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02486367"
1015,"NCT00980031","Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension","Aldosterone","Terminated","No Results Available","Myocardial Remodeling","Drug: Eplerenone|Drug: Lactose Tablet","Myocardial Remodeling (cardiac chamber sizes, wall thickness, left ventricular ejection fraction, left atrial volumes, and diastolic function) assessed by transthoracic echocardiogram|Blood Pressure","Creighton University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","07-14634","April 2007","September 2011","September 2011","September 18, 2009",,"March 28, 2014","Creighton University Medical Center (including ambulatory centers), Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT00980031"
1016,"NCT01588405","Remodulin® to Oral Treprostinil Transition",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: UT-15C SR","Number of Participants That Were Succesfully Transitioned From Parenteral Remodulin to UT-15C.|Change From Baseline in Six-minute Walk Distance at Week 24|Change in Borg Dyspnea Score (Following 6MWT) From Baseline to Week 24|Change in Quality of Life (QoL) Assessment: Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) From Baseline to Week 24|Change in World Health Organization (WHO) Functional Classification From Baseline to Week 24|Change in Dyspnea-fatigue Index From Baseline to Week 24|Change From Baseline to Week 24 in Pharmacokinetic Parameters: Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), and Trough Plasma Concentration (Cmin)|Change From Baseline to Week 24 in Pharmacokinetics Parameter: Peak Time to Reach Peak Plasma Concentration [Tmax (h)]|Change From Baseline to Week 24 in Pharmacokinetics Parameters: Area Under the Plasma Concentration Curve (AUC) [h(ng/mL)]|Change From Baseline to Week 24 in Hemodynamics Parameters: Mean Pulmonary Artery Pressure (PAPm), Mean Right Atrial Pressure (RAPm) and Mean Pulmonary Capillary Wedge Pressure (PCWPm)|Change From Baseline to Week 24 in Hemodynamics Parameters: Arterial Oxygen Saturation (SaO2) (%) and Mixed Venous Oxygen Saturation (SvO2) (%)|Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Output (CO) (L/Min)|Change From Baseline to Week 24 in Hemodynamics Parameters: Cardiac Index (CI) (L/Min/m^2)|Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance Index (PVRI) (mmHg*Min*m^2/L)|Change From Baseline to Week 24 in Hemodynamics Parameters: Pulmonary Vascular Resistance (PVR) (mmHg*Min/L)","United Therapeutics","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-205","April 2012","July 2014","December 2014","May 1, 2012","May 16, 2016","May 16, 2016","Arizona Pulmonary Specialists, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|Washington University School of Medicine, St. Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|The Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01588405"
1017,"NCT00962949","The Renin-Aldosterone Axis in Postural Tachycardia Syndrome",,"Completed","Has Results","Postural Orthostatic Tachycardia Syndrome (POTS)","Drug: Angiotensin II","Mean Arterial Blood Pressure Change|Plasma Renin Activity|Aldosterone Level|Cortisol Level","Vanderbilt University Medical Center","All","18 Years to 64 Years   (Adult)","Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","081398|PF334","April 2009","December 2012","December 2012","August 20, 2009","August 17, 2018","August 17, 2018","Vanderbilt University, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00962949"
1018,"NCT03497689","EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil","Oral treprostinil dose|Prostanoid Adverse Events (AEs)|Echocardiograms|Change in 6-minute walk distance (6MWD)|Change in Borg dyspnea score|Change in World Health Organization (WHO) functional class (FC)|Change in serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels|Impact of pulmonary hypertension on a person's life (health-related quality of life)|Treatment satisfaction","United Therapeutics","All","17 Years to 85 Years   (Child, Adult, Older Adult)","Phase 4","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDE-PH-402","September 21, 2018","July 2020","July 2020","April 13, 2018",,"March 6, 2020","University of California San Francisco - Fresno, Fresno, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Florida Hospital, Orlando, Florida, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|UPMC Presbytarian Hospital, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03497689"
1019,"NCT01125436","A Trial of Vitamin D Therapy in Patients With Heart Failure",,"Unknown status","No Results Available","Heart Failure|Aerobic Capacity|Strength","Dietary Supplement: Cholecalciferol","Peak VO2|muscle strength","University Hospitals Cleveland Medical Center","All","50 Years and older   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1KL2RR024990","July 2008","September 2011","September 2011","May 18, 2010",,"July 4, 2011","University Hospitals/Case Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01125436"
1020,"NCT01877473","Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF",,"Withdrawn","No Results Available","Persistent Atrial Fibrillation","Procedure: Ablation","Freedom of atrial fibrillation/flutter","Valley Health System","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VHS 12.0031","May 2013","September 2013","September 2013","June 13, 2013",,"June 17, 2014","Valley Hospital, Ridgewood, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01877473"
1021,"NCT00990314","Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Beraprost Sodium Modified Release","Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)|Number of Reported Treatment-Emergent Adverse Events|Change in Six-Minute-Walk Distance (6MWD)|Change in Borg Dyspnea Score|Number of Participants That Experienced Clinical Worsening|Number of Participants With a Change in WHO Functional Class","Lung Biotechnology PBC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BPS-MR-PAH-204","November 30, 2009","November 30, 2013","November 30, 2013","October 6, 2009","September 16, 2019","September 16, 2019","Harbor-UCLA Medical Center, Torrance, California, United States|Midwest Heart Foundation - Advocate Medical Group, Oakbrook Terrace, Illinois, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Beth Israel Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Universite Libre de Bruxelles, Bruxelles, Belgium|Catholic University of Leuven, Leuven, Belgium|General Teaching Hospital, Praha, Czechia|Klinikum der Universitat zu Koln, Cologne, Germany|Medizinische Klinik und Poliklinik, Dresden, Germany|Abt Innere Medizin III, Medizinische Universitatsklinik, Heidelberg, Germany|Universitatsklinik Leipzig Abteilung Pulmologie, Leipzig, Germany|Mater Misericordiae University Hospital Ltd., Dublin, Ireland|Institutul de Urgenta pentru Boli, Bucuresti, Romania|Institutul National de Pneumologie, Bucuresti, Romania|Institutul de Boli Cardiovasculare, Lasi, Romania",,"https://ClinicalTrials.gov/show/NCT00990314"
1022,"NCT01976091","Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA",,"Completed","No Results Available","Limb Girdle Muscular Dystrophy Type 2D (LGMD2D)","Drug: scAAVrh74.tMCK.hSGCA","Safety with fewer than one grade 3 adverse events or fewer than two grade 2 adverse events|Change in Six-Minute-Walk-Test (6MWT) distance from baseline over two years","Jerry R. Mendell|Nationwide Children's Hospital","All","7 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5U01AR060911","February 2015","March 14, 2019","March 14, 2019","November 5, 2013",,"July 24, 2019","Nationwide Children's Hospital, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01976091"
1023,"NCT01334918","A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)",,"Completed","Has Results","Coronary Artery Disease (CAD)","Drug: regadenoson|Radiation: technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Radiation: Contrast|Procedure: Single Photon Emission Computed Tomography|Procedure: Multidetector Computed Tomography","Number of Participants With Reversible Defects|Overall Image Quality of Scans by Modality and Reviewer|Number of Participants With Reversible Defects in the Left Anterior Descending Coronary Artery (LAD)|Number of Participants With Reversible Defects in the Right Coronary Artery (RCA)|Number of Participants With Reversible Defects in the Left Circumflex Coronary Artery (LCX)|Number of Participants With Fixed Defects|Percentage of Participants With Two or More Ischemic Segments on SPECT, But Less on CT","Astellas Pharma Inc","All","45 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","3606-CL-2001","April 26, 2011","July 2, 2012","July 2, 2012","April 13, 2011","September 18, 2013","December 19, 2017","Sutter Roseville Medical Center, Roseville, California, United States|Harbor UCLA Medical Center, Torrance, California, United States|Cardiovascular Research Center of South Florida, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Midwest Cardiology Associates, P.C., Overland Park, Kansas, United States|Maine Research Associates, Auburn, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Berkshire Medical Center, Pittsfield, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Oregon Health and Science University, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT01334918"
1024,"NCT01323582","Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis","AZI","Terminated","Has Results","Gastroparesis","Drug: Erythromycin|Drug: Azithromycin","Time in Minutes for 50% of the Ingested Meal to Empty the Stomach With a Standardized Breath Test: Half the of the Week 11 Value (Period 2) Less Half the of the Week 4 Value (Period 1). This Estimates the Effect Size.|Gastroparesis Cardinal Symptom Index (GCSI) Score|NDI Score|TLAG (Time From Ingestion of Meal to Start of Gastric Emptying)|Change in Time to 50% Gastric Emptying: Post Test Less Baseline Pooled Over Orderings|Change in Time to 50% Emptying: Post Test Less Baseline Pooled Over Orderings|Gastroparesis Cardinal Symptom Index (GCSI) Score Change From Baseline to Post Treatment|Does GCSI Score Improve (Lower) on Treatment, Pooling the AZ Patients Over Their Treatment Periods? Endpoint is Difference in Post-test Less Baseline","University of Florida|Metabolic Solutions Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","645-2008","February 2009","December 2012","December 2012","March 25, 2011","December 5, 2014","December 5, 2014","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01323582"
1025,"NCT02060487","Effects of Oral Sildenafil on Mortality in Adults With PAH","AFFILIATE","Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: sildenafil citrate","Overall Survival (OS)|Time to first clinical worsening (TTCW) event|6 Minute Walk Distance (6MWD) at Months 6 & 12","Pfizer","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 4","429","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A1481324|2013-004362-34|AFFILIATE","September 22, 2014","June 30, 2023","June 30, 2023","February 12, 2014",,"February 21, 2020","Emory University Investigational Drug Services, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Frederik Meijer Heart & Vascular Institute Cardiovascular Research, Grand Rapids, Michigan, United States|Spectrum Health Butterworth Hospital IDS Pharmacy, Grand Rapids, Michigan, United States|Spectrum Health Heart & Lung Specialized Care Clinic, Grand Rapids, Michigan, United States|Spectrum Health Hospitals, Grand Rapids, Michigan, United States|Spectrum Health Medical Group - Pulmonary Division, Grand Rapids, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Robert V. Sibilia MD, Inc., Wooster, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Australian Respiratory and Sleep Medicine Institute, Bedford Park, South Australia, Australia|University Hospital of Mont-Godinne, Yvoir, Belgium|BH Heart Center Tuzla, Tuzla, B&h/canton Tuzla, Bosnia and Herzegovina|University Clinical Center of the Republic of Srpska, Banja Luka, B&h/republic OF Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia AND Herzegovina/canton Sarajevo, Bosnia and Herzegovina|Clinical Center University Sarajevo, Sarajevo, Bosnia AND Herzegovina/canton Sarajevo, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Herzegovina-neretva Canton, Bosnia and Herzegovina|University Hospital Center Zagreb, Zagreb, Croatia|University Hospital Dubrava, Zagreb, Croatia|Fakultni nemocnice Olomouc, Olomouc, Czech Republic, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czech Republic, Czechia|Institut klinicke a experimentalni mediciny, Praha 4, Czechia|DRK Kliniken Berlin, Westend, Berlin, Germany|Universitaetsklinikum der TU Dresden, Dresden, Germany|Universitaetsmedizin Greifswald, Greifswald, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Thoraxklinik am Universitaetsklinikum Heidelberg, Heidelberg, Germany|Universitaetsklinikum Schleswig-Holstein, Luebeck, Germany|University General Hospital of Athens ""Attikon"", Athens, Attiki, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece|University General Hospital of Patras, Patras, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|The Chaim Sheba Medical Center, Tel-Hashomer, Israel|Pauls Stradins Clinical University Hospital, Riga, Latvia|Sultanah Aminah Hospital, Johor Bahru, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Serdang, Kajang, Selangor, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Centro De Prevencion Y Rehabilitacion De Enfermedades Pulmonares Crónicas, Monterrey, Nuevo LEÓN, Mexico|Centro de Desarrollo Biomedico, Merida, Yucatan, Mexico|Centro de Estudios Clinicos de Queretaro S.C., Queretaro, Mexico|Samodzielny Publiczny Szpital Kliniczny nr 4, Lublin, Poland|Institutul Inimii ,,Niculae Stancioiu"" Cluj Napoca, Cluj-Napoca, Romania|Institutul de Urgenta pentru Boli Cardiovasculare si Transplant Targu-Mures, Targu-Mures, Romania|FSBI ""Research Institute of complex problems of cardiovascular diseases"", Kemerovo, Russian Federation|FSBI Scientific Research Institute of Pulmonology of FMBA, Moscow, Russian Federation|FSBI ""E.Meshalkin National medical research center"", Novosibirsk, Russian Federation|FSBI ""V.A. Almazov National Medical Research Center"", St. Petersburg, Russian Federation|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Vojvodina/serbia, Serbia|Institute for Cardiovascular disease of Vojvodina, Sremska Kamenica, Vojvodina, Serbia|Clinical Center of Serbia, Belgrade, Serbia|University Medical Center Zvezdara, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|National University Heart Centre, National University Hospital Singapore (NUHS), Singapore, Singapore|Khoo Teck Puat Hospital, Singapore, Singapore|Center of Chest Diseases, Johannesburg, Gauteng, South Africa|Dr PG Williams Practice, Johannesburg, Gauteng, South Africa|Hospital Universitario Val d´Hebrón, Barcelona, Cataluña, Spain|King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok, Thailand|Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Sripoom Sub-district, Muang, Chiang MAI, Thailand|Division of Cardiology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Muang District, KHON KAEN , Thailand, Thailand|Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Muang District, Khon Kaen, Thailand|Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Bakirkoy, Turkey|Ege Üniversitesi Tıp Fakültesi Kardiyoloji Bilim Dalı, Izmir, Bornova, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Fatih, Turkey|Istanbul University Haseki Cardiology Institute, Istanbul, Fatih, Turkey|Uludağ Universitesi Tıp Fakültesi Kardiyoloji Bilim Dalı, Bursa, Görükle, Turkey|Dokuz Eylul Üniversitesi Tıp Fakültesi Kardiyoloji Bilim Dalı, Izmir, Inciralti, Turkey|Marmara University Pendik Training and Research Hospital, Istanbul, Pendik, Turkey|KZ ""Dnipropetrovskyi oblasnyi klinichnyi tsentr kardiolohii ta kardiokhirurhii"" DOR"", viddilennia ka, Dnipropetrovsk, Ukraine|Komunalnyi zaklad okhorony zdorovia, Kharkiv, Ukraine|Oleksandrivska klinichna likarnia m. Kyieva, Kyiv, Ukraine|Kyivska miska klinichna likarnia No 5, kardiolohichne viddilennia, Kyiv, Ukraine|Derzhavna ustanova ""Natsionalnyi naukovyi tsentr ""Instytut kardiolohii, Kyiv, Ukraine|Zakarpatskyi oblasnyi klinichnyi kardiolohichnyi dyspanser, infarktne viddilennia, m. Uzhhorod, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT02060487"
1026,"NCT02164864","Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)",,"Completed","Has Results","Atrial Fibrillation|Percutaneous Coronary Intervention","Drug: Dabigatran Etexilate 110mg|Drug: Warfarin 3mg|Drug: Aspirin|Drug: Dabigatran Etexilate 150mg|Drug: Clopidogrel or Ticagrelor|Drug: Warfarin 5mg|Drug: Warfarin 1mg","Time to First Adjudicated ISTH MBE or CRNMBE|Time to Adjudicated Undetermined Cause of Death|Time to Adjudicated Non-CV|Time to Adjudicated CV|Time to Adjudicated All Cause Death|Time to First Adjudicated MI|Time to First Adjudicated Stroke|Time to First Adjudicated SE|Time to First Adjudicated ST|Time to Composite Endpoint of Death + MI + Stroke|Time to Composite Endpoint of Death or First Thrombotic Event|Time to First Adjudicated Unplanned Revascularisation by PCI/CABG|Time to Death or First Thrombotic Event or Unplanned Revascularisation by PCI/CABG","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","2725","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160.186|2013-003201-26","July 22, 2014","June 5, 2017","June 5, 2017","June 17, 2014","July 31, 2018","July 31, 2018","Cardiology P.C., Birmingham, Alabama, United States|Verde Valley Medical Center, Cottonwood, Arizona, United States|Cardiovascular Associates of Mesa, Mesa, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Mission Cardiovascular Research Institute, Fremont, California, United States|Aurora Denver Cardiology Associates, PC, Aurora, Colorado, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|Watson Clinic, LLP, Lakeland, Florida, United States|Community Clinical Research Center, Anderson, Indiana, United States|Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana, United States|Ball Memorial Hospital, Muncie, Indiana, United States|Richmond Cardiology Associates Research, LLC, Richmond, Indiana, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Cape Cod Research Institute, Hyannis, Massachusetts, United States|Mid Michigan Medical Center, Midland, Michigan, United States|Covenant Medical Center, Inc., Saginaw, Michigan, United States|Saint Mary's Medical Center dba Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|CentraCare Heart and Vascular Center, Saint Cloud, Minnesota, United States|Kansas City Veterans Administration Medical Center, Kansas City, Missouri, United States|Saint Anthony's Medical Center, Saint Louis, Missouri, United States|St. Michaels Medical Center, Newark, New Jersey, United States|Lourdes Cardiology Services, Voorhees, New Jersey, United States|VA Western New York Healthcare System, Buffalo, New York, United States|Novant Health Heart and Vascular Institute, Charlotte, North Carolina, United States|Altru Health System, Grand Forks, North Dakota, United States|Cardiovascular Research Center, Toledo, Ohio, United States|Chambersburg Hospital, Chambersburg, Pennsylvania, United States|Pinnacle Health Harrisburg Hospital, Harrisburg, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Chattanooga Heart Institute, Chattanooga, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Dallas VA Medical Center, Dallas, Texas, United States|North Dallas Research Associates, McKinney, Texas, United States|Scott and White Healthcare, Round Rock, Texas, United States|South Texas Cardiovascular Consultants, San Antonio, Texas, United States|Wichita Falls Heart Clinic, Wichita Falls, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Bayview Physicians Services PC dba Cardiovascular Associates, Virginia Beach, Virginia, United States|Holy Family Memorial, Inc, Manitowoc, Wisconsin, United States|Fundación Favaloro, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Instituto Cardiovascular de Buenos Aires, Caba, Argentina|Consultorios Asociados de Endocrinología e Invest Clínica, Capital Federal, Argentina|Instituto de Cardiología de Corrientes, Corrientes, Argentina|Sanatorio Allende, Córdoba, Argentina|Instituto CER, Quilmes, Argentina|Inst.Cardiovascular San Luis, San Luis, Argentina|Investigaciones Clinicas Tucumán, San Miguel de Tucumán, Argentina|Pendlebury Research, Adamstown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Heartcare Victoria, Bundoora, Victoria, Australia|The Geelong Hospital, Geelong, Victoria, Australia|Order Hospital Elisabethinen Linz, Linz, Austria|LKH Salzburg, Univ. Clinic, Salzburg, Austria|Wilhelminenspital, Wien, Austria|Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|AZ Sint-Lucas - Campus Sint Lucas, Gent, Belgium|Charleroi - HOSP St-Joseph, Gilly, Belgium|Ziekenhuis Netwerk Antwerpen (ZNA) - Campus Middelheim, Middelheim, Belgium|Sint-Niklaas - HOSP AZ Nikolaas (Campus St-Niklaas), Sint-Niklaas, Belgium|Tienen - PRAC De Wolf, Axel, Tienen, Belgium|Brussels - HOSP Europe (Ste-Elisabeth), Ukkel, Belgium|Hospital Santa Isabel, Blumenau, Brazil|Irmandade da Santa Casa de Misericordia de Curitiba, Campina Grande do Sul, Brazil|Instituto de Cardiologia Rio Grande do Sul, Porto Alegre, Brazil|Hospital de Base - Fac Med de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil|Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil|Hospital Sao Paulo - UNIFESP, Sao Paulo, Brazil|INCOR e Hospital das Clínicas da Universidade de São Paulo, Sao Paulo, Brazil|Eurolatino pesquisas Médicas Ltda, Uberlandia, Brazil|MHAT ""Deva Maria"", Dept. of Cardiology, Burgas, Burgas, Bulgaria|SHAT in Cardiology EAD, Pleven, Pleven, Bulgaria|MHAT""Sv.Georgi"",Cardi.Clin., Plovdiv, Bulgaria|MHAT ""Sv. Vrach"" EOOD, Cardiology Dept., Sandanski, Sandanski, Bulgaria|City Clin.Univ.MPHAT EOOD,Clin.of Cardiology, Sofia, Sofia, Bulgaria|Specialized Hosp.f.Active Treatment, Cardiology Dept, Yambol, Yambol, Bulgaria|Calgary Heart Centre, Calgary, Alberta, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|Kawartha Cardiology Clinical Trials, Peterborough, Ontario, Canada|Dr. R. Labonte Prof. Med. Corp, Sudbury, Ontario, Canada|Thunder Bay Regional Health Science Centre, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|IUCPQ (Laval University), Ste-Foy, Quebec, Canada|Hospital San Juan de Dios, Santiago, Chile|Centro de Estudios Clinicos Barros Luco, Santiago, Chile|Hospital Las Higueras, Talcahuano, Chile|CECMI Ltda, Temuco, Chile|Fundación Clínica Abood Shaio, Bogotá, Colombia|Fundación Santa Fe de Bogotá, Bogotá, Colombia|Centro Médico Imbanaco de Cali S.A., Cali, Colombia|Fundación Valle de Lili, Cali, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|Hospital Pablo Tobón Uribe, Medellin, Colombia|Clincal Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hosp.Merkur,Clin.Internal Med,Cardiology Dep,Zagreb, Zagreb, Croatia|Clinical Hospital Sstre Milosrdnice, Cardiology Dept, Zagreb, Zagreb, Croatia|University hospital center Zagreb, Zagreb, Croatia|University Hospital Dubrava, Zagreb, Croatia|Amkardia, s.r.o. Brno, Brno, Czechia|Hospital Jihlava, Jihlava, Czechia|Karlovarska Reg.Hosp, Cardiology Dept, Karlovy Vary, Karlovy Vary, Czechia|University Hospital Olomouc, Olomouc, Czechia|Municipal Hospital Ostrava, Ostrava, Czechia|Institute for Clinical and Experimental Medicine, Praha 4, Czechia|General Faculty Hospital, Prague, Praha, Czechia|University Hospital Motol, Praha, Czechia|Hospital Slany, Internal Department, Slany, Czechia|Hospitals of Pardubice Region, Internal Department, Svitavy, Svitavy, Czechia|Masaryk Hospital, Usti nad Labem, Usti nad Labem, Czechia|Hosp.of Pardubice Reg,Orlickoustecka,Internal Dept, Ustinad, Usti nad Orlici, Czechia|Aarhus Universitetshospital, Århus N, Denmark|HYKS, Kardiologian klinikka, Sydän- ja keuhkokeskus, Helsinki, Finland|StudyCor Oy, Jyväskylä, Finland|Keski-Pohjanmaan keskussairaala, Kardiologian pkl, Kokkola, Kokkola, Finland|TYKS, Turku, Finland|HOP Ambroise Paré, Boulogne-Billancourt, France|HOP de la Cavale Blanche, Brest Cedex 2, France|HOP Gabriel-Montpied, Clermont-Ferrand, France|HOP CHU de Grenoble, Grenoble, France|HOP St Joseph, Marseille, France|CLI du Pont de Chaume, Montauban, France|HOP Arnaud de Villeneuve, Montpellier cedex 5, France|HOP Pasteur, Nice, France|HOP Salpêtrière, Cardio, Paris, Paris cedex 13, France|HOP Lariboisière, Paris, France|CLI Saint-Hilaire, Rouen, France|HOP Rangueil, Toulouse, France|SLK-Kliniken Heilbronn GmbH, Bad Friedrichshall, Germany|Kerckhoff-Klinik, Bad Nauheim, Bad Nauheim, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Bad Oeynhausen, Germany|CIMS Studienzentrum Bamberg GmbH, Bamberg, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Bielefeld gGmbH, Bielefeld, Germany|St. Josef- und St. Elisabeth-Hospital gGmbH, Bochum, Germany|Universitätsklinikum Bonn AöR, Bonn, Germany|Allgemeines Krankenhaus, Celle, Celle, Germany|Klinikum Coburg gGmbH, Coburg, Germany|Helios Amper-Klinikum Dachau, Dachau, Germany|St. Johannes Hospital Dortmund, Dortmund, Germany|Städtisches Klinikum Dresden, Dresden, Germany|Praxisklinik Herz und Gefäße, Dresden, Germany|Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Städtisches Klinikum, Fulda, Fulda, Germany|Herz- und Gefäßzentrum (HGZ-Göttingen) am Krankenhaus Neu Bethlehem, Göttingen, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Cardiologicum Hamburg, Hamburg, Germany|HPK-Heidelberger Praxisklinik, Heidelberg, Germany|Westküstenkliniken Brunsbüttel und Heide gGmbH, Heide, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Asklepios Klinik Langen-Seligenstadt GmbH, Langen, Germany|Herzzentrum Leipzig GmbH, Leipzig, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Märkische Gesundheitsholding GmbH & Co. KG, Klinikum Lüdenscheid, Lüdenscheid, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Carl-von-Basedow Klinikum Saalekreis gGmgH, Merseburg, Germany|Klinikum der Universität München - Campus Großhadern, München, Germany|Städtisches Klinikum München GmbH, München, Germany|Städtisches Klinikum München GmbH, München, Germany|Universitätsklinikum Münster, Münster, Germany|St. Vincenz-Krankenhaus GmbH, Paderborn, Germany|Sana-Klinikum Remscheid GmbH, Remscheid, Germany|Universitätsmedizin Rostock, Rostock, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Marien-Hospital-Wesel gGmbH, Wesel, Germany|Helios Universitätsklinikum Wuppertal, Wuppertal, Germany|University Hospital of Alexandroupolis, Alexandroupoli, Greece|Hippokration Hospital, Univ Clinic of Cardiology, Athens, Greece|General Hospital of Athens ""Alexandra"", Athens, Greece|General Hospital of Athens Konstantopoulio-Agia Olga, Athens, Greece|General Hospital of Attica ""Sismanoglio - Amalia Fleming"", Athens, Greece|General Hospital of Chios, Department of Cardiology, Chios, Greece|University General Hospital of Heraklion, Heraklion, Crete, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|University Hospital of Patras, Patras, Greece|University Hospital of Thessaloniki AHEPA, Thessaloniki, Greece|Prince of Wales Hosp, Dept of Med & Therapeutics, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Gottsegen Gyorgy Hungarian Instit.of Cardiology,Budapest, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Milit.Hosp.-State Health Cent., Budapest, Hungary|University Debrecen Hospital, Debrecen, Hungary|Bacs-Kiskun Megyei Onkormanyzat Hospital, Kecskemet, Hungary|University of Pecs, Invasive Cardiology, Pecs, Hungary|Univ. of Szeged, 2nd Dept. of Internal Med., Haematology, Szeged, Hungary|Care Institute Of Medical Sciences, Ahmedabad, India|Medanta- The Medicity, Gurgaon, India|Nizam's Institute of Medical Sciences, Hyderabad, India|B and M Patel Cardiac Centre, Shree Krishna Hospital,, Karamsad, India|Shri Krishna Hrudayalaya and Critical Care, Nagpur, India|Vijan Cardiac and Critical Care Centre, Nasik, India|Fortis Escorts Heart Institute, New Delhi, India|Byramjee Jeejeebhoy Medical College, Pune, India|King George's Hospital,, Seemandhra, India|Mater Misericordiae University Hospital, Dublin, Ireland|St James's Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Hillel Yaffe Medical Center, Hadera, Hadera, Israel|Rambam Medical Center, Haifa, Israel|Wolfson Medical Center, Holon, Israel|Shaare Zedek Medical Center, Jerusalem 91031, Jerusalem, Israel|West.Galilee Med.Cent.Naharia, Naharia, Israel|Rabin Medical Center Beilinson, Petah Tikva, Israel|Ospedale San Donato di Arezzo, Arezzo, Italy|ASST Papa Giovanni XXIII - A.O. Papa Giovanni XXIII, Bergamo, Italy|Fond. Poliambulanza Istituto, Brescia, Italy|A.O.U. Policlinico Vittorio Emanuele, Catania, Italy|Osp. Clin. SS. Anunziata, Chieti, Italy|Ospedale ""Fabrizio Spaziani"", Frosinone, Italy|Ospedale della Misericordia, Grosseto, Italy|Azienda Ospedaliera Vito Fazzi, Lecce, Italy|Osp. Pediatrico Aprano Pasquinucci, Massa, Italy|Ospedale Cardarelli, Napoli, Italy|Pol. Universitario Tor Vergata, Roma, Italy|Policlinico Gemelli, Roma, Italy|Presidio Ospedaliero di Saronno, Saronno (VA), Italy|Ospedale Bolognini, Seriate, Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Hirosaki University Hospital, Aomori, Hirosaki, Japan|Chiba University Hospital, Chiba, Chiba, Japan|Kokura Memorial Hospital, Fukuoka, Kitakyushu, Japan|Fukuoka-Higashi Med. Ctr. Fukuoka, CV, Fukuoka, Koga, Japan|Shin Koga Hospital, Fukuoka, Kurume, Japan|Gumma Prefectural Cardiovascular Center, Gunma, Maebashi, Japan|National Hospital Organization Takasaki General Medical Center, Gunma, Takasaki, Japan|Fukuyama Cardiovascular Hospital, Hiroshima, Fukuyama, Japan|Tokeidai Memorial Hospital, Hokkaido, Sapporo, Japan|National Hospital Organization Hokkaido Medical Center, Hokkaido, Sapporo, Japan|Hyogo Brain and Heart Center, Hyogo, Himeji, Japan|The Veritas Hospital, Hyogo, Kawanishi, Japan|Kobe University Hospital, Hyogo, Kobe, Japan|Takahashi Hospital, Hyogo, Kobe, Japan|National Hospital Organization Kanazawa Medical Center, Ishikawa, Kanazawa, Japan|Iwate Medical University Hospital, Iwate, Morioka, Japan|Kagawa Prefectural Central Hospital, Kagawa, Takamatsu, Japan|Shonan Fujisawa Tokushukai Hospital, Kanagawa, Fujisawa, Japan|Kitasato University Hospital, Kanagawa, Sagamihara, Japan|Yokohama City Minato Red Cross Hospital, Kanagawa, Yokohama, Japan|Kyoto University Hospital, Kyoto, Kyoto, Japan|Miyazaki Medical Association Hospital, Miyazaki, Miyazaki, Japan|Sakurabashi Watanabe Hospital, Osaka, Osaka, Japan|Osaka City Hospital Organization Osaka City General Hospital, Osaka, Osaka, Japan|Sayama General Clinic, Saitama, Sayama, Japan|National Hospital Organization Saitama National Hospital, Saitama, Wako, Japan|Kusatsu General Hospital, Shiga, Kusatsu, Japan|Omihachiman Community Medical Center, Shiga, Omihachiman, Japan|Tokushima Red Cross Hospital, Tokushima, Komatsushima, Japan|Nishiarai Heart Center Hospital, Tokyo, Adachi-ku, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Minamino Heart Clinic, Tokyo, Hachioji, Japan|Teikyo University Hospital, Tokyo, Itabashi-Ku, Japan|Nihon University Itabashi Hospital, Tokyo, Itabashi-Ku, Japan|Itabashi Chuo Medical Center, Tokyo, Itabashi-Ku, Japan|Global Health and Medicine Ctr, Tokyo, Shinjuku-ku, Japan|Tokyo Women's Medical University Hospital, Tokyo, Shinjuku-ku, Japan|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Kyungpook National Univ. Hosp, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Pusan National Univ. Hosp, Pusan, Korea, Republic of|Kyung Hee University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|St.Carollo Hospital, Suncheon, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Wonju Severance Christian Hosp, Wonju, Korea, Republic of|Hospital Cardiologica Aguascalientes, Aguascalientes, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico, Mexico|H. Central Dr Ignacio M. P., San Luis Potosi, Mexico|Centro Especializado en Terapia Endovascular (CETEN), Zapopan, Jalisco, Mexico|Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Scheper Ziekenhuis, Emmen, Netherlands|Admiraal de Ruyter Ziekenhuis, Goes, Netherlands|UMCG, Groningen, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Canisius-Wilhelmina ziekenhuis, Nijmegen, Netherlands|Ziekenhuis Bernhoven Uden, Uden, Netherlands|Waikato Hospital, Hamilton, New Zealand|Sørlandet sykehus HF, Avd. Arendal, Arendal, Norway|Oslo Universitetssykehus HF, Ullevål sykehus, Oslo, Norway|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Stavanger Helseforskning, Stavanger, Norway|Universitetssykehuset Nord-Norge, Tromsø, Tromsø, Norway|Univ. Clinic Hosp, Bialystok, Bialystok, Poland|10.Military Clin.Hospital&Polyclinic, Bydgoszcz, Poland|Swissmed Vascular Sp. Z.o.o Hosp., Cardiology Dept., Gdansk, Gdansk, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Reg.Hosp Kielce,Swietokrzyskie,1.Clinic of Cardiology,Kielce, Kielce, Poland|Independent Public Clin.Hosp.#4, Cardiology Clinic,Lubilin, Lublin, Poland|Independent Public Healthcare, Dept. of Cardiology, Pulawy, Pulawy, Poland|Central Hospital of Medical Academy, Warsaw, Warsaw, Poland|Lower Silesian Spec.Hosp.T.Marciniaka,Cardiology Dep,Wroclaw, Wroclaw, Poland|John Paul II Regional Hospital, Zamosc, Zamosc, Poland|Hospital Garcia de Orta, EPE, Almada, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Centro Hosp. de Leiria-Pombal, Leiria, Portugal|CHLC, EPE - Hospital de Santa Marta, Lisboa, Portugal|CHLO, EPE - Hospital de Santa Cruz, Lisboa, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|CHUC,EPE - Hospital Geral dos Covões, S. Martinho Do Bispo,Coimbra, Portugal|Altaiskyi Reg.Cardiologic Dispensary,Cardiology Dept,Barnaul, Barnaul, Russian Federation|Regional Clinical Hospital No.3, Cardiology Dept,Chelyabinsk, Chelyabinsk, Russian Federation|Cent.f.Spec.Med.C.U.Cardi.Inst, Ekaterinburg, Russian Federation|State Instit.Kazan Fed.Univ., Kazan, Russian Federation|State Autonomous Healthc Insti City Clin Hosp#7,Cardio,Kazan, Kazan, Russian Federation|Res.Inst.-Compl.Iss.Cardi.Dis., Kemerovo, Russian Federation|Clin.Hosp.#1na S.V.Ochapovskiy, Krasnodar, Russian Federation|City Clin.Hosp.#15 n.a.O.M.Filatov,Cardiology Dept.#2,Moscow, Moscow, Russian Federation|City Clin.Hosp#51,Moscow Healthcare Dep.X-ray surgery method, Moscow, Russian Federation|Cntr of CV Surgery na Bakulev,Surg.Treatm of Inter.Path.dept, Moscow, Russian Federation|City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg, Saint Petersburg, Russian Federation|State Budg.Healthc.Instit.Samara Reg.Clin.Cardiology Dispens, Samara, Russian Federation|North-Western Fed.Med.Resear.Centr na V.I.Almazov,Cardio.dep, St.Petersburg, Russian Federation|State Budg.Healthc.Instit Volgograd RegClin.Cardiology Centr, Volgograd, Russian Federation|National University Hospital, Singapore, Singapore|National Heart Center, Singapore, Singapore|Slov.Ins.Crdi.Dise.,Cor.C.U., Banska Bystrica, Slovakia|Nat.Instit.Cardiov.Diseas,Arryhythmias&Cardiac Pacing,Bratis, Bratislava, Slovakia|East Slovak Inst.Cardi.Disea., Kosice, Slovakia|Kardiocentrum Nitra,Internal Medicine Dept, Nitra, Nitra, Slovakia|General Hospital Celje, Celje, Slovenia|General Hospital Izola, Cardiology Department, Izola, Slovenia|University Medical Center Ljubljana, Ljubljana, Slovenia|Univ. Medical Center Maribor, Maribor, Slovenia|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de Bellvitge, L'Hospitalet Llobregat (bcn), Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital de Manises, Manises, Spain|CS Parc Taulí, Sabadell (Barcelona), Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital de Galdakao, Vizcaya, Spain|Hospital Miguel Servet, Zaragoza, Spain|Länssjukhuset, Gävle, Gävle, Sweden|Sahlgrenska Universitetssjukhuset, Östra, Göteborg, Sweden|Länssjukhuset, Halmstad, Halmstad, Sweden|Lasarettet, Helsingborg, Helsingborg, Sweden|Universitetssjukhuset, Linköping, Linköping, Sweden|Skånes universitetssjukhus, Lund, Lund, Sweden|Skånes universitetssjukhus, Malmö, Malmö, Sweden|Danderyds Sjukhus, Stockholm, Sweden|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|E-Da Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Siriraj Hospital, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Cukurova Universitesi Tip Fakultesi Kardiyoloji AnabilimDali, Adana, Turkey|Türkiye Yüksek Ihtisas Egitim ve Arastirma Hastanesi, Ankara, Turkey|Diskapi Yildirim Beyazit EAH, Ankara, Turkey|Bursa Yuksek Ihtisas EAH, Bursa, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul Universitesi Kardiyoloji Enstitusu, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Bagcilar Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Medipol Mega Üniversitesi Hastanesi, Istanbul, Turkey|Istanbul Mehmet Akif Ersoy Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Siyami Ersek Gogus Kalp ve Damar Cerrahisi Hastanesi, Istanbul, Turkey|Kartal Kosuyolu Yuksek Ihtisas EAH, Istanbul, Turkey|Dokuz Eylul Unv. Tip Fakultesi, Izmir, Turkey|Izmir Katip Celebi Univ. EAH, Izmir, Turkey|Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali, Kayseri, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|Birmingham City Hospital, Birmingham, United Kingdom|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|Grantham District Hospital, Grantham, United Kingdom|Wycombe General Hospital, High Wycombe, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02164864/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02164864/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02164864"
1027,"NCT03061006","Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation","CAF","Recruiting","No Results Available","Dementia|Cognition Disorders|Cerebral Ischemic Events","Drug: Dabigatran Etexilate|Drug: Warfarin","Incident dementia determined by a formal diagnosis of dementia by a neurologist|Moderate decline in cognitive function based on results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.|Stroke or Transient ischemic attack (TIA), intracranial bleed|Changes from baseline scores on the mini-mental status evaluation and the Hachinski Ischemic Scale.","Intermountain Health Care, Inc.|Boehringer Ingelheim","All","65 Years and older   (Older Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1050164","April 3, 2017","April 2021","April 2021","February 23, 2017",,"June 4, 2019","Intermountain Heart Institute, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03061006"
1028,"NCT01384448","Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain",,"Completed","No Results Available","Chest Pain|Angina|Angina Pectoris|Coronary Artery Disease","Procedure: Stress Echocardiography|Procedure: Coronary CT Angiography","Hospital admission|Emergency Department length of stay|Hospital length of stay|Estimated cost of initial care|Repeat visits to the Emergency Department|Death|Non-fatal myocardial infarction","Montefiore Medical Center|American Heart Association","All","30 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MMC-11-03-107|11SDG7380006","August 2011","February 2016","February 2017","June 29, 2011",,"October 11, 2018","Montefiore Medical Center - Weiler / Einstein Division, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT01384448"
1029,"NCT01863134","Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up",,"Completed","Has Results","Non ST Elevation Myocardial Infarction","Drug: Eptifibatide|Drug: Placebo","Major Adverse Cardiac and Cerebrovascular Events (MACCE)","Medical University of Silesia","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2 P05C 023 27","January 2005","December 2010","December 2010","May 27, 2013","October 31, 2013","October 31, 2013","Albert Einstein College of Medicine, New York, New York, United States|First Department of Cardiac Surgery, Medical University of Silesia, Katowice, Slaskie, Poland|Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland|Department of Internal Medicine and Clinical Pharmacology, Katowice, Poland|First Department of Cardiology, Medical University of Silesia, Katowice, Poland|Division of Molecular Biology and Clinical Genetics, Jagiellonian University Medical College, Krakow, Poland",,"https://ClinicalTrials.gov/show/NCT01863134"
1030,"NCT02558972","Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)",,"Recruiting","No Results Available","Postural Tachycardia Syndrome (POTS)|Vasovagal Syncope (VVS)|Fainting","Drug: Northera (Droxidopa)|Drug: Placebo","Study #1 and Study #2 - Splanchnic and lower extremity pooling (physiological parameter)|Study #2 -Quality of Life measured by self reporting questionnaire (RAND-36)|Study #2 -Quality of Life measured by self reporting questionnaire (COMPASS 31)|Study #1 and Study #2 -Blood pressure (BP)|Study #1 and Study #2 -Heart rate (HR)","New York Medical College|Lundbeck LLC","All","18 Years to 35 Years   (Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","L-11,388","September 2015","December 2020","December 2020","September 24, 2015",,"January 14, 2020","New York Medical College/Bradhurst building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT02558972"
1031,"NCT01110031","Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects",,"Completed","No Results Available","Leukaemia, Lymphocytic, Chronic","Biological: Ofatumumab","Cardiac Repolarization (Fredericia's QTc)|Plasma concentrations of ofatumumab and electrocardiogram (ECG) parameters|Vital signs, weight, adverse events|Flow cytometry|Cytokine, chemokine, human anti-human antibodies","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","112855","May 13, 2010","April 12, 2012","June 26, 2012","April 23, 2010",,"November 13, 2017","GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Randwick, New South Wales, Australia|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT01110031"
1032,"NCT02496221","A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Albiglutide 50 mg|Drug: Placebo|Drug: CCK (Kinevac)","Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum Effect|Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF)|Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK Infusion|Maximum Gallbladder Ejection Fraction Value During CCK Infusion|Area Under the Effect Curve for Gallbladder Volume (AUEC VL)|Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum Effect|Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK Infusion|Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK Infusion|Maximum Change From Baseline in Common Bile Duct Diameter During CCK Infusion|Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Change From Baseline in Heart Rate|Number of Participants With Clinical Chemistry and Hematology Abnormalities of Potential Clinical Importance|Change From Baseline in Electrocardiogram (ECG) Parameters|Part A: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event|Number of Participants for the Indicated Urinalysis Parameters Tested by Dipstick","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","201834","June 11, 2015","October 13, 2015","October 13, 2015","July 14, 2015","July 21, 2016","April 5, 2018","GSK Investigational Site, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02496221"
1033,"NCT00832507","Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: Cicletanine|Drug: Cicletanine Placebo","Change from baseline in six-minute walk distance (6MWD) evaluated after 12 weeks of treatment|Change from baseline in BDI, WHO Functional Class, BNP, cardiac hemodynamics and SF-36 physical functioning scale following 12 weeks of treatment. In addition, time to clinical worsening (TTCW) will be evaluated.","Gilead Sciences","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","162","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-235-0101","January 2009","October 2011","March 2012","January 30, 2009",,"February 4, 2014","University of South Alabama, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|VA Greater LA Healthcare System, Los Angeles, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Harish H. K. Murthy, MD, San Jose, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Cleveland Clinic, Ft. Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|University of Chicago Hospital, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Louisiana State University, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Case Medical Center, Cleveland, Ohio, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University Of Virginia, Charlottesville, Virginia, United States|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|University Klinik Graz, Graz, Austria|University Klinik Wien, Wien, Austria|ULB Hôpital Erasme, Bruxelles, Belgium|Peter Lougheed Centre, Calgary, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Ludwig-Maximilians-Universitaet, Muenchen, BY, Germany|Universitaetsklinikum Giessen und Marburg, Giessen, HE, Germany|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Unidad de Investigación Clínica en Medicina S.C., Monterrey, NL, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico|H Clinic i Provincial, Barcelona, Spain|HU 12 de Octubre, Madrid, Spain|Royal Free Hospital, London, Gt Lon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00832507"
1034,"NCT02008448","Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation",,"Unknown status","No Results Available","Persistent Atrial Fibrillation","Procedure: Pulmonary vein isolation|Procedure: Linear Lesion Ablation|Drug: BT injection","freedom of atrial tachyarrhythmia, including AF and atrial flutter/tachycardia|serious adverse events","Meshalkin Research Institute of Pathology of Circulation","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","BT_AFPers","June 2013","December 2015","January 2016","December 11, 2013",,"September 23, 2015","University of Rochester, Rochester, New York, United States|State Research Institute of Circulation Pathology, Novosibirsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02008448"
1035,"NCT00924118","Sodium Nitrite in Acute Myocardial Infarction",,"Completed","Has Results","Acute Myocardial Infarction","Drug: Sodium Nitrite","Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.|Left Ventricular Infarct Size","Johns Hopkins University|Hope Pharmaceuticals","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00023049","July 2009","June 2016","June 2016","June 18, 2009","September 25, 2017","May 14, 2018","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT00924118"
1036,"NCT02736149","Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)","LIBERTY2","Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: ubenimex","Treatment-emergent adverse events recorded on the Adverse Event Case Report Form|Change in pulmonary vascular resistance (PVR)|Change in exercise capacity as measured by 6-minute walk distance (6MWD)|Change in World Health Organization/New York Heart Association Functional Classification|Change in disease biomarkers brain natriuretic peptide (BNP) /N-terminal pro-brain natriuretic peptide (NT-proBNP )","Eiger BioPharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EIG-UBX-002","December 2016","March 2018","August 2018","April 13, 2016",,"July 18, 2019","California Heart Center Foundation, An Affiliate of Cedars-Sinai Heart Institute, Cedars-Sinai Medical Care Foundation, Beverly Hills, California, United States|UCSD Medical Center, La Jolla, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Cleveland Clinic, Florida, Weston, Florida, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic College of Medicine, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Respiratory Institute, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pennsylvania Medical Center, Pittsburgh, Pennsylvania, United States|Alpert Medical School of Brown University Rhode Island Hospital, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University Texas Health Science Center, San Antonio, Texas, United States|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02736149"
1037,"NCT03737110","RHAPSODY Phase 3 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis","RHAPSODY","Active, not recruiting","No Results Available","Recurrent Pericarditis","Drug: Rilonacept|Drug: Placebo","Time to pericarditis recurrence|Proportion of subjects who maintained Clinical Response|Percentage of days with no or minimal pain|Proportion of subjects with absent or minimal pericarditis symptoms|Proportion of subjects with adverse events","Kiniksa Pharmaceuticals, Ltd.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KPL-914-C002|2018-002719-87","December 6, 2018","June 2020","June 2021","November 9, 2018",,"March 13, 2020","Cedars-Sinai Heart Institute, Los Angeles, California, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Loretto Hospital, Chicago, Illinois, United States|Beth Israel Deaconness MC, Boston, Massachusetts, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|Stony Brook University School of Medicine, Stony Brook, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cardiology Consultants of Philadelphia, Yardley, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cardiovoyage, McKinney, Texas, United States|Orion Medical, Pasadena, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|University Of Vermont Medical Center, Burlington, Vermont, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Seattle Children's Hosptial, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Core Research Group, Milton, Queensland, Australia|HeartCare Partners Clinical Research Unit, Milton, Queensland, Australia|The Queen Elizabeth Hospital, Woodville, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Health, Monash Medical Centre, Clayton, Victoria, Australia|GenesisCare - Cardiology Research, Doncaster East, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western, Australia|HaEmek Medical Center, Afula, Israel|Bnai Zion Medical Center, Haifa, Israel|Rambam Health Corporation, Haifa, Israel|Edith Wolfson Medical Center, Holon, Israel|Hadassah University Hospital Mount Scopus, Jerusalem, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Rabin Medical Center - PPDS, Petach Tiqwa, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Assaf Harofe Medical Center, Tzrifin, Israel|ZIV Medical Center, Zefat, Israel|Istituto G Gaslini Ospedale Pediatrico IRCCS, Genova, Liguria, Italy|ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico, Milano, Lombardia, Italy|Ospedale Pediatrico Bambino Gesù, Roma, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT03737110"
1038,"NCT02787044","INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure","INVESTED","Active, not recruiting","No Results Available","Heart Failure|Myocardial Infarction","Biological: High Dose Trivalent Influenza Vaccine|Biological: Standard Dose Quadrivalent Influenza Vaccine","All-Cause Death or Cardiopulmonary Hospitalization|Total cardiopulmonary hospitalizations or death|Death or cardiopulmonary hospitalization within each influenza season|Death or cardiopulmonary hospitalizations across all influenza seasons|All-Cause Mortality|Cardiopulmonary Hospitalization|Number of participants with treatment-related adverse events","Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI)|University of Wisconsin, Madison|University of Toronto|Boston VA Research Institute, Inc.|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 4","5388","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2015P001823|U01HL130163","August 2016","August 2020","February 2021","June 1, 2016",,"October 9, 2019","Birmingham VAMC, Birmingham, Alabama, United States|University of Alabama Hypertension Program, Birmingham, Alabama, United States|Heart Center Research, LLC, Huntsville, Alabama, United States|Alaska Heart & Vascular Institute, Anchorage, Alaska, United States|Banner University Medicine North, Tucson, Arizona, United States|University of Arizona- Sarver Heart Center, Tucson, Arizona, United States|CAVHS, Little Rock, Arkansas, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Long Beach VAMC, Long Beach, California, United States|University of California Davis Medical Center, Sacramento, California, United States|VA San Diego Healthcare System, San Diego, California, United States|UCSF Medical Center, San Francisco, California, United States|VA West Haven, West Haven, Connecticut, United States|Washington DC VAMC, Washington, District of Columbia, United States|Clearwater Cardiovascular Consultants, Clearwater, Florida, United States|N FL/S GA Veterans Health System, Gainesville, Florida, United States|OneFlorida CDRN, Gainesville, Florida, United States|Clearwater Cardiovascular Consultants-Largo, Largo, Florida, United States|Inpatient Research Corporation, Miami, Florida, United States|ITB Research, Miami, Florida, United States|Charlotte Heart Group Research Center, Port Charlotte, Florida, United States|Clearwater Cardiovascular Consultants-SH, Safety Harbor, Florida, United States|Bond Community Health Center, Inc., Tallahassee, Florida, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States|Peidmont Fayette, Fayetteville, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Jesse Brown VA Medical Center, Chicago, Illinois, United States|University of Chicago Medicine, Chicago, Illinois, United States|Chicago Medical Research, Hazel Crest, Illinois, United States|Northwester Medicine Lake Forest, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois, United States|UnityPoint Health Methodist, Peoria, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|Krannert Institute of Cardiology, Indianapolis, Indiana, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|VA Eastern Kansas Health Care System, Leavenworth, Kansas, United States|Robley Rex VA, Louisville, Kentucky, United States|The Heart Clinic of Hamond, Hammond, Louisiana, United States|Southeast Louisiana Veterans Healthcare System, New Orleans, Louisiana, United States|Ochsner Health System- Baton Rouge, New Orleans, Louisiana, United States|ENRM VA Hospital, Bedford, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Pentucket Medical Associates, Haverhill, Massachusetts, United States|Charles River Medical Associates, Natick, Massachusetts, United States|Boston/West Roxbury VA Hospital, West Roxbury, Massachusetts, United States|VA Boston Healthcase System, West Roxbury, Massachusetts, United States|VA Ann Harbor Healthcare System, Ann Arbor, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|HealthPartners - Riverside Research, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|HealthEast Medical Research Institute, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|VA St. Louis Health Care System, Saint Louis, Missouri, United States|St. Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Heart Institute- Grand Island, Grand Island, Nebraska, United States|Darthmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cardio Assoc. of the Del. Valley- Elmer, Elmer, New Jersey, United States|Cardio. Assoc. of the Del. Valley- Haddon Heights, Haddon Heights, New Jersey, United States|Cardio. Assoc. of the Del. Valley- Sewell, Sewell, New Jersey, United States|Lourdes Cardiology Services, Voorhees, New Jersey, United States|New Mexico VA Health Care System, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|New York Presbyterian Queens Bayside/Whitestone, Flushing, New York, United States|New York Presbyterian/Queens, Flushing, New York, United States|NYPQ - Cardiology Outpatient Clinic, Flushing, New York, United States|Winthrop University Hospital, Mineola, New York, United States|New York VA, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|New York Presbyterian, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Charles George VA, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke, Durham, North Carolina, United States|Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Heart House Research Foundation, Springfield, Ohio, United States|Oregon Health & Science, Portland, Oregon, United States|VA Portland Health Care Systems (VAPHCS), Portland, Oregon, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Providence VA Medical Center, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|WJB Dorn VAMC, Columbia, South Carolina, United States|Palmetto Research Center, LLC, Spartanburg, South Carolina, United States|VAMC Memphis, Memphis, Tennessee, United States|Meharry Medical College, Nashville, Tennessee, United States|Tennessee Valley Healthcare Systems-Nashville, Nashville, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Austin Heart- Heart Hospital, Austin, Texas, United States|Baylor Scott and White Heart and Vascular Hospital, Dallas, Texas, United States|Michael E. DeBakey VAMC, Houston, Houston, Texas, United States|Houston Heart & Vascular Associates, Kingwood, Texas, United States|Houston Methodist Research Institute-CCAT Pearland, Pearland, Texas, United States|St. David's Heath & Vascular PLLC, Round Rock, Texas, United States|South Texas Veterans Healthcare System, San Antonio, Texas, United States|STAR Clinical Trials, San Antonio, Texas, United States|Austin Heart San Marcos, San Marcos, Texas, United States|Baylor Scott and White Research Institute, Temple, Texas, United States|University of Utah, Salt Lake City, Utah, United States|George E. Wahlen Dept of VA Affairs Medical Center, Salt Lake City, Utah, United States|VA Medical Center White River Junction, White River Junction, Vermont, United States|Inova Heart and Vascular Institute, Alexandria, Virginia, United States|Carient Heart & Vascular, Manassas, Virginia, United States|Louis A Johnson VAMC, Clarksburg, West Virginia, United States|Gundersen Clinic, La Crosse, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|Willam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States|University of Wisconsin Madison, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Research Institute, LLC, Milwaukee, Wisconsin, United States|Celement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|TotalCardiology, Calgary, Alberta, Canada|University of Calgary, Calgary, Alberta, Canada|CK Hui Heart Centre, Royal Alexandra Hospital, Edmonton, Alberta, Canada|Dr. MPJ Senaratne Professional Corporation, Edmonton, Alberta, Canada|Northwest Echocardiolography, Grande Prairie, Alberta, Canada|The CARe Clinic (Central Alberta Research), Red Deer, Alberta, Canada|University of Alberta Hospital- Mazankoski Heart Institute, Edmonton, British Columbia, Canada|Kelowna General Hospital, Kelowna, British Columbia, Canada|SMH Cardiology Clinical, Surrey, British Columbia, Canada|Manna Research Inc. (Vancouver), Vancouver, British Columbia, Canada|Vancouver General Hospital - Gordon Leslie Diamond Centre, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|St. Boniface Hospital/University of Manitoba, Winnipeg, Manitoba, Canada|University of Sherbrooke, Dieppe, New Brunswick, Canada|G.A Research Associates Ltd., Moncton, New Brunswick, Canada|QEII Health Sciences, Halifax, Nova Scotia, Canada|Brampton Research Assocaites, Brampton, Ontario, Canada|Manna Research Inc. (Burlington North), Burlington, Ontario, Canada|Manna Research Inc. (Burlington South), Burlington, Ontario, Canada|Cambridge Cardiac Care Center, Cambridge, Ontario, Canada|Vizel Cardiac Research, Cambridge, Ontario, Canada|Dr. Alan David Bell, Downsview, Ontario, Canada|Hamilton Health Sciences General Hospital/ McMaste, Hamilton, Ontario, Canada|Queen's University CardioPulmonary Unit, Kingston, Ontario, Canada|St. Joseph's Health Care, London, Ontario, Canada|Dixie Medical Group, Mississauga, Ontario, Canada|Apple Hills Medical Associates, Mississauga, Ontario, Canada|PACE, Newmarket, Ontario, Canada|North York General Hospital, North York, Ontario, Canada|Sewa Ram Singal Med Prof Corporation, North York, Ontario, Canada|Heart Care Research, Oshawa, Ontario, Canada|Dr. James Cha, Oshawa, Ontario, Canada|Montfort Hospital and Ottawa Cardiovascular Centre, Ottawa, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Heart Function Clinic Queensway Carleton, Ottawa, Ontario, Canada|Kawartha Cardiology, Peterborough, Ontario, Canada|Scarborough General Hospital, Scarborough, Ontario, Canada|St. Catherines Hospital, St. Catherines, Ontario, Canada|Manna Research (Stoney Creek), Stoney Creek, Ontario, Canada|Health Sciences North Research Institute, Sudbury, Ontario, Canada|Dr. D. Shukla Professional Medicine Corporation, Sudbury, Ontario, Canada|Dr. R. Labonte Professional Medicine Corporation, Sudbury, Ontario, Canada|Thunder Bay Regional Health Sciences Center, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Women's College Hospital, Toronto, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|iHealthCentre, Vaughan, Ontario, Canada|CISSS de Laval, Hopital Cite de la Sante, Laval, Quebec, Canada|Montreal Heart Institute, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CIUSSS NÎM Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|Manna Research Inc. (Montreal), Montréal, Quebec, Canada|IUCPQ, Quebec City, Quebec, Canada|Centre hospitalier régional de Lanaudière, St-Charles Borromee, Quebec, Canada|CISSSI- Hopital Pierre-Le Gardeur, Terrebonne, Quebec, Canada|Centre Hospitalier de Regional Trois-Rivieres, Trois-Rivières, Quebec, Canada|Prairie Vascular Research Inc., Regina, Saskatchewan, Canada|VA Caribbean Healthcare System, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02787044"
1039,"NCT01961453","Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function","ISMN","Withdrawn","No Results Available","Hypertension","Drug: Isosorbide Mononitrate, sustained release|Drug: Placebo capsule","Change in left ventricular mass|Change in extracellular volume fraction|Change in peak myocardial systolic longitudinal strain measured by MRI|Change in peak early diastolic intraventricular pressure gradient measured by MRI|Change in late systolic hypertension derived from pulse wave analysis","Corporal Michael J. Crescenz VA Medical Center","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 2","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","01442","August 2013","January 2016","January 2016","October 11, 2013",,"August 11, 2016","Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01961453"
1040,"NCT03496207","A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)","PULSAR","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: Sotatercept","Change from baseline in Pulmonary Vascular Resistance (PVR) as measured by right heart catheterization|Change from baseline in 6-Minute Walk Distance (6MWD)|Change from baseline in amino-terminal brain natriuretic propeptide (NT-proBNP)|Change from baseline in tricuspid annular plane systolic excursion (TAPSE) by echocardiography (ECHO)|Change from baseline in Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) patient-reported outcome (PRO) score|Change from baseline in 36-Item Short Form Health Survey (SF-36) patient-reported outcome (PRO) score","Acceleron Pharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A011-09|2017-004738-27","June 27, 2018","March 2020","November 2021","April 12, 2018",,"August 28, 2019","Pulmonary Associates, PA, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Banner-University Medical Center Phoenix, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California, San Francisco Medical Center, San Francisco, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Michigan, Ann Arbor, Michigan, United States|Center for Outpatient Health, Saint Louis, Missouri, United States|Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Houston Methodist Hospital, Houston, Texas, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Whales, Australia|Prince Charles Hospital, Chermside, Queensland, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Riogrande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Hospital São Paulo, Sao Paulo, Brazil|Hôpital Arnaud de Villeneuve, Montpellier, Hérault, France|Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Klinikum der Universität Regensburg, Regensburg, Bayern,, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitatsklinikum Halle (Saale), Halle, Sachsen-Anhalt, Germany|Otto-von-Guericke-Universität Magdeburg, Magdeburg, Sachsen-Anhalt, Germany|Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Barzilai Medical Center, Ashkelon, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Rabin Medical Center - PPDS, Petach-Tikva, Israel|ZIV Medical Center, Safed, Israel|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain|Hospital Complejo Hospitalario Universitario de Pontevedra, Santander, Pontevedra, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital de Montecel, Pontevedra, Spain|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03496207"
1041,"NCT04072835","Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303",,"Recruiting","No Results Available","Paroxysmal Supraventricular Tachycardia","Drug: Etripamil NS","Safety of etripamil NS 70mg for the patient-administered treatment of acute episodes of PSVT outside of the clinical setting.|Efficacy of etripamil NS 70mg for the patient-administered treatment of acute episodes of PSVT outside of the clinical setting measured by median time to conversion post etripamil NS administration|Improvement in patient quality of life measured by the Treatment Satisfaction Questionnaire for Medication and/or the Patient Reported Outcomes (PRO) System .","Milestone Pharmaceuticals Inc.|IQVIA Biotech","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NODE-303","September 2, 2019","August 31, 2021","August 31, 2021","August 28, 2019",,"December 17, 2019","1046, Cottonwood, Arizona, United States|1098, Anaheim, California, United States|1121, Fremont, California, United States|1023, Vista, California, United States|1083, West Hills, California, United States|1042, Bradenton, Florida, United States|1075, Cutler Bay, Florida, United States|1106, Daytona Beach, Florida, United States|1054, Doral, Florida, United States|1107, Edgewater, Florida, United States|1027, Hialeah, Florida, United States|1032, Hialeah, Florida, United States|1061, Jacksonville, Florida, United States|1026, Miami, Florida, United States|1055, Miami, Florida, United States|1064, Naples, Florida, United States|1071, North Miami Beach, Florida, United States|1009, Orlando, Florida, United States|1030, Orlando, Florida, United States|Site 1022, Cumming, Georgia, United States|1053, Tucker, Georgia, United States|1045, Peoria, Illinois, United States|1025, West Des Moines, Iowa, United States|1015, Louisville, Kentucky, United States|1073, Bossier City, Louisiana, United States|1008, Monroe, Louisiana, United States|1070, Shreveport, Louisiana, United States|1007, Salisbury, Maryland, United States|1088, Flint, Michigan, United States|1126, Columbia Falls, Montana, United States|1005, Charlotte, North Carolina, United States|1065, Charlotte, North Carolina, United States|1072, Lenoir, North Carolina, United States|1074, Morganton, North Carolina, United States|1079, Mount Airy, North Carolina, United States|1024, Canton, Ohio, United States|1091, Cincinnati, Ohio, United States|1069, Dayton, Ohio, United States|1002, Rapid City, South Dakota, United States|1062, Jackson, Tennessee, United States|1047, Austin, Texas, United States|1104, Beaumont, Texas, United States|1013, Dallas, Texas, United States|1016, Fort Worth, Texas, United States|1001, Houston, Texas, United States|1017, Houston, Texas, United States|1048, Plano, Texas, United States|Site 1004, Riverton, Utah, United States|5129, Ciudad Autónoma de Buenos Aires, Argentina|3007, Bruxelles, Belgium|5215, Campinas, SP, Brazil|2010, North Vancouver, British Columbia, Canada|2005, Burlington, Ontario, Canada|2006, Oshawa, Ontario, Canada|2009, Scarborough, Ontario, Canada|2007, Sudbury, Ontario, Canada|2011, Greenfield Park, Quebec, Canada|2002, Saint-Jean-sur-Richelieu, Quebec, Canada|5307, Santiago, Chile|5407, Punta de Cartagena, Colombia|4006, Prague, Czechia|3701, Copenhagen NV, Denmark|3101, Brest Cedex, France|3201, Dortmund, Germany|4101, Budapest, Hungary|6001, Afula, Israel|3301, Torrette, Ancona, Italy|5018, Monterrey, Aguascalientes, Mexico|3416, Leiden, Netherlands|4201, Gdańsk, Poland|4301, Cluj-Napoca, Romania|4503, Novosibirsk, Central, Russian Federation|4601, Považská Bystrica, Slovakia|7001, Somerset West, South Africa|3503, Madrid, Spain|4401, Odesa, Ukraine|3602, London, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04072835"
1042,"NCT02279160","Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension",,"Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: APD811|Drug: Placebo","Change from baseline in pulmonary vascular resistance (PVR)|Change from baseline in 6-min walk distance (6MWD) in patients with PAH","Arena Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","APD811-003","December 2014","June 2017","June 2017","October 30, 2014",,"December 11, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCLA Medical Center, Torrance, California, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, United States|UT Southwestern, Dallas, Texas, United States|University of Texas, Houston Center for Clinical and Translational Sciences, Houston, Texas, United States|The Prince Charles Hospital, Chermside, Australia|St Vincent's Hospital, Darlinghurst NSW, Australia|St Vincent's Hospital, Fitzroy, Australia|Royal Hobart Hospital, Hobart, Australia|Fiona Stanley Hospital, Murdoch, Australia|""Многопрофилната болница за активно лечение ""Национална кардиологична болница """" ЕАД, Sofia, Bulgaria|Многопрофилна болница за активно лечение ""Света Анна"" София АД, Клиника по кардиология, Sofia, Bulgaria|II. interní klinika - klinika kardiologie a angiologie, 1. lékařská fakulta, Univerzita Karlova v Praze a Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Gottsegen György Országos Kardiologiai Intézet, Felnőtt Kardiológia, Budapest, Hungary|Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary|Pécsi Tudományegyetem Klinikai Központ, Szívgyógyászati Klinika, Pecs, Hungary|Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok, Poland|Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie, Krakow, Poland|Wojewódzki Szpital Specjalistyczny im. W. Biegańskiego w Łodzi, Lodz, Poland|Institutul de Urgență pentru Boli Cardiovasculare, Secția Clinică Cardiologie III, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Secția Clinică Pneumoftiziologie IV, Bucharest, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie, Sectia Clinica Pneumologie II, Timisoara, Romania|Klinički Centar Srbije (KCS), Klinika za kardiologiju, Belgrade, Serbia|Kliničko-bolnički centar (KBC) Zemun,Klinika za internu medicinu,Sluzba kardiologije, Belgrade, Serbia|Institut za plućne bolesti Vojvodine Sremska Kamenica (IPBVSK),, Sremska Kamenica, Serbia|Hospital Universitari General Vall d'Hebron, Servicio de Neumología, Barcelona, Spain|Hospital Clinic de Barcelona, Departamento de Pneumologia, Barcelona, Spain|Hospital 12 de Octubre, Departamento de Cardiologia, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02279160"
1043,"NCT02234141","Selonsertib in Adults With Pulmonary Arterial Hypertension","ARROW","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Placebo|Drug: Selonsertib","Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC)|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: Cardiac Index|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: mPAP|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: mRAP|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: Mixed Venous Oxygen Saturation (SVO2) (%)|Change From Baseline at Week 24 in Other Cardiopulmonary Hemodynamic Measures: Right Ventricular Cardiac Power (RVCP)|Change From Baseline at Week 24 in 6MWD Test|Change From Baseline at Week 24 in BDI After the 6MWD Test|Number of Participants Experiencing Change From Baseline at Week 24 in WHO Functional Class|Change From Baseline at Week 24 in NT-proBNP|Change From Baseline at Week 24 in Short Form (SF-36) Physical Functioning Scale|Change From Baseline at Week 24 in emPHasis-10 Questionnaire Score|Change From Baseline at Week 24 in Heart Rate Recovery (HRR) After the 6MWD Test|Kaplan-Meier Estimate of Time to Clinical Worsening (TTCW) Evaluated in Period 1|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: TAPSE|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Right Ventricular Myocardial Strain (%)|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Tricuspid Annular Peak Sys Myocard Velocity (TAS)|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Right Ventricular Tei Index (RVTI)|Change From Baseline in Echocardiographic Measures of Right Ventricular Function at Week 24: Right Ventricular Fractional Area Change (RVFAC)","Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-357-1394|2014-002131-34","November 2014","April 2016","December 2016","September 9, 2014","April 10, 2019","April 10, 2019","University of South Alabama Medical Center, Mobile, Alabama, United States|Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialist, Ltd, Phoenix, Arizona, United States|University of Arizona Clinical and Translational Science (CATS) Research Center, Tucson, Arizona, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|LA Biomedical Research Institute Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Cardiac and Vascular Center, Anschutz Inpatient Pavillion, Aurora, Colorado, United States|The Emory Clinic, Atlanta, Georgia, United States|University of Chicago Medicine, Chicago, Illinois, United States|Boston University Medical Center, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mary M. Parkes Center // University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Martha Morehouse Medical Pavilion, Columbus, Ohio, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Peter Lougheed Center, Calgary, Alberta, Canada|Vancouver General Hospital, The Lung Centre // Vancouver Coastal Health, Vancouver General Hospital, Vancouver, British Columbia, Canada|Victoria Hospital - London Health Sciences Centre, London, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Institut Universitaire de caridologie et de pneumologie de Quebee (IUCPQ), Sainte Foy, Quebec, Canada|CHU de Grenoble Clinique Universitaire de Pneumologie, Grenoble Cedex 9, France|CHU de Bicetre, Service de Pneumologie-Reanimation Respiratoire, Le Kremlin Bicetre Cedex, France|Hopital Cardiologique-CHRU Lille, Service de cardiologie, Lille Cedex, France|Universitatsklinikul Giessen und Marburg GmbH, Giessen, Hessen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinik III fur Innere Medizin, Herzzentrum Uniklinik Koln, Koln, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Klinik und Poliklinik fur Innere Medizin II, Universitatsklinikum Regensburg, Regensburg, Germany|Universita ""Sapienza""-Azienda Policlinico Umberto 1, Rome, Italy|VU University Medical Center, Amsterdam, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Doce (12) de Octubre, Madrid, Spain|Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, Clydebank, West Dunbartonshire, United Kingdom|Royal Free Hampstead NHS Trust, London, United Kingdom|Clinical Research Facility, Royal Hallamshrie Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02234141"
1044,"NCT01776424","Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease","COMPASS","Active, not recruiting","Has Results","Prevention & Control","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Aspirin|Drug: Aspirin placebo|Drug: Rivaroxaban placebo|Drug: Pantoprazole","The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death|The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria|The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death|The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death|All-cause Mortality","Bayer|Population Health Research Institute|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","27395","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","15786|2012-004180-43","February 28, 2013","July 21, 2017","October 10, 2021","January 28, 2013","October 5, 2018","April 13, 2020","Birmingham, Alabama, United States|Mobile, Alabama, United States|Anaheim, California, United States|Laguna Hills, California, United States|Northridge, California, United States|Palo Alto, California, United States|Santa Rosa, California, United States|Sylmar, California, United States|Torrance, California, United States|Norwalk, Connecticut, United States|Stamford, Connecticut, United States|Trumbull, Connecticut, United States|Atlantis, Florida, United States|Clearwater, Florida, United States|Coral Springs, Florida, United States|Jacksonville Beach, Florida, United States|Largo, Florida, United States|New Port Richey, Florida, United States|Safety Harbor, Florida, United States|Sarasota, Florida, United States|Meridian, Idaho, United States|Arlington Heights, Illinois, United States|Hazel Crest, Illinois, United States|Davenport, Iowa, United States|West Des Moines, Iowa, United States|Crestview Hills, Kentucky, United States|Baltimore, Maryland, United States|Haverhill, Massachusetts, United States|Alpena, Michigan, United States|Jackson, Michigan, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|New Brunswick, New Jersey, United States|Cortlandt Manor, New York, United States|Kingston, New York, United States|Saratoga Springs, New York, United States|Durham, North Carolina, United States|Pinehurst, North Carolina, United States|Elyria, Ohio, United States|Sandusky, Ohio, United States|Toledo, Ohio, United States|Doylestown, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Yardley, Pennsylvania, United States|Sioux Falls, South Dakota, United States|Dallas, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Bellevue, Washington, United States|Puyallup, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Adrogue, Buenos Aires, Argentina|Bahía Blanca, Buenos Aires, Argentina|Coronel Suarez, Buenos Aires, Argentina|Junín, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Merlo, Buenos Aires, Argentina|Munro, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Ramos Mejía, Buenos Aires, Argentina|San Martín, Buenos Aires, Argentina|San Nicolás, Buenos Aires, Argentina|Vicente López, Buenos Aires, Argentina|Zárate, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Ciudad Autón. de Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Villa Allende, Córdoba, Argentina|Villa María, Córdoba, Argentina|Santa Rosa, La Pampa, Argentina|Rafaela, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Venado Tuerto, Santa Fe, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Ciudad Auton. de Buenos Aires, Argentina|Corrientes, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Salta, Argentina|San Juan, Argentina|San luis, Argentina|Santa Fe, Argentina|Bruce, Australian Capital Territory, Australia|Gosford, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|Birtinya, Queensland, Australia|Brisbane, Queensland, Australia|Brisbane, Queensland, Australia|Redcliffe, Queensland, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Hobart, Tasmania, Australia|Launceston, Tasmania, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Murdoch, Western Australia, Australia|Nedlands, Western Australia, Australia|Taree, Australia|Antwerpen, Belgium|Bonheiden, Belgium|Brugge, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Genk, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liege, Belgium|Roeselare, Belgium|Goiania, Goiás, Brazil|Belo Horizonte, Minas Gerais, Brazil|Uberaba, Minas Gerais, Brazil|Uberlândia, Minas Gerais, Brazil|Campina Grande do Sul, Parana, Brazil|Curitiba, Parana, Brazil|Canoas, Rio Grande Do Sul, Brazil|Pelotas, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Porto Alegre, Rio Grande Do Sul, Brazil|Blumenau, Santa Catarina, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Matão, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São José do Rio Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Votuporanga, Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|New Westminster, British Columbia, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|Saint John, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Burlington, Ontario, Canada|Cambridge, Ontario, Canada|Cambridge, Ontario, Canada|Grimsby, Ontario, Canada|Hamilton, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Newmarket, Ontario, Canada|Newmarket, Ontario, Canada|Oakville, Ontario, Canada|Oshawa, Ontario, Canada|Oshawa, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Scarborough, Ontario, Canada|Sudbury, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Chicoutimi, Quebec, Canada|Laval, Quebec, Canada|Levis, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Terrebonne, Quebec, Canada|Thetford Mines, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Ontario, Canada|Quebec, Canada|Temuco, Araucanía, Chile|Temuco, Araucanía, Chile|Temuco, Araucanía, Chile|Concepción, Bío-Bío, Chile|Osorno, Los Lagos, Chile|Valdivia, Los Lagos, Chile|Viña del Mar, Valparaíso, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Wudan, Hubei, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanjing, Jiangsu, China|Nanjing, Jiangsu, China|Changchun, Jilin, China|Changchun, Jilin, China|Shenyang, Liaoning, China|Xi'an, Shanxi, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Barranquilla, Atlántico, Colombia|Cartagena, Bolívar, Colombia|Manizales, Caldas, Colombia|Montería, Córdoba, Colombia|Pasto, Nariño, Colombia|Armenia, Quindío, Colombia|Pereira, Risaralda, Colombia|Bucaramanga, Santander, Colombia|Floridablanca, Santander, Colombia|Espinal, Tolima, Colombia|Cali, Valle Del Cauca, Colombia|Barranquilla, Colombia|Santafe de Bogotá, Colombia|Brno, Czechia|Brno, Czechia|Ceske Budejovice, Czechia|Cesky Krumlov, Czechia|Hodonin, Czechia|Hradec Kralove, Czechia|Jablonec nad Nisou, Czechia|Kolin, Czechia|Liberec, Czechia|Olomouc, Czechia|Ostrava, Czechia|Ostrava, Czechia|Pardubice, Czechia|Praha 10, Czechia|Praha 13, Czechia|Praha 2, Czechia|Praha 4, Czechia|Praha 5, Czechia|Praha 5, Czechia|Praha 6, Czechia|Slany, Czechia|Susice, Czechia|Trebic, Czechia|Trinec, Czechia|Uherske Hradiste, Czechia|Zlin, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Hellerup, Denmark|Holbaek, Denmark|Hvidovre, Denmark|Kolding, Denmark|København Ø, Denmark|København, Denmark|Viborg, Denmark|Guayaquil, Guayas, Ecuador|Quito, Pichincha, Ecuador|Quito, Ecuador|Kuopio, Finland|Kuusankoski, Finland|Tampere, Finland|Turku, Finland|Vantaa, Finland|Amiens, France|Clermont Ferrand, France|Limoges Cedex, France|Montpellier, France|Nice, France|NIMES cedex 9, France|Paris Cedex 15, France|Paris, France|Paris, France|Saint-priest-en-jarez, France|Nürnberg, Bayern, Germany|Würzburg, Bayern, Germany|Bad Homburg, Hessen, Germany|Frankfurt, Hessen, Germany|Kassel, Hessen, Germany|Bielefeld, Nordrhein-Westfalen, Germany|Dortmund, Nordrhein-Westfalen, Germany|Wuppertal, Nordrhein-Westfalen, Germany|Magdeburg, Sachsen-Anhalt, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bottrop, Germany|Frankfurt, Germany|Hamburg, Germany|Warendorf, Germany|Balatonfured, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Mosonmagyarovar, Hungary|Pecs, Hungary|Sopron, Hungary|Szekesfehervar, Hungary|Szekszard, Hungary|Ballinasloe, Co. Galway, Ireland|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Afula, Israel|Ashkelon, Israel|Bnei Brak, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Nahariya, Israel|Tel Aviv, Israel|Tel Aviv, Israel|Zefat, Israel|Caserta, Campania, Italy|Bologna, Emilia-Romagna, Italy|Forlì-Cesena, Emilia-Romagna, Italy|Ravenna, Emilia-Romagna, Italy|Trieste, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Udine, Friuli-Venezia Giulia, Italy|Brescia, Lombardia, Italy|Cremona, Lombardia, Italy|Pavia, Lombardia, Italy|Ancona, Marche, Italy|Isernia, Molise, Italy|Foggia, Puglia, Italy|Lecce, Puglia, Italy|Catania, Sicilia, Italy|Palermo, Sicilia, Italy|Arezzo, Toscana, Italy|Firenze, Toscana, Italy|Perugia, Umbria, Italy|Terni, Umbria, Italy|Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Kisarazu, Chiba, Japan|Matsudo, Chiba, Japan|Imabari, Ehime, Japan|Matsuyama, Ehime, Japan|Kasuga, Fukuoka, Japan|Kitakyushu, Fukuoka, Japan|Miyako-gun, Fukuoka, Japan|Onga-gun, Fukuoka, Japan|Maebashi, Gunma, Japan|Onomichi, Hiroshima, Japan|Asahikawa, Hokkaido, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Spporo, Hokkaido, Japan|Tomakomai, Hokkaido, Japan|Kobe, Hyogo, Japan|Takarazuka, Hyogo, Japan|Kaga, Ishikawa, Japan|Miura-gun, Kanagawa, Japan|Sagamihara, Kanagawa, Japan|Yokohama, Kanagawa, Japan|Naha, Okinawa, Japan|Kishiwada, Osaka, Japan|Takatsuki, Osaka, Japan|Tokorozawa, Saitama, Japan|Komatsushima, Tokushima, Japan|Akishima, Tokyo, Japan|Bunkyo-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Shimonoseki, Yamaguchi, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Gifu, Japan|Gifu, Japan|Kumamoto, Japan|Kyoto, Japan|Kyoto, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Osaka, Japan|Wonju-si, Gang''weondo, Korea, Republic of|Goyang-si, Gyeonggido, Korea, Republic of|Seongnam-si, Gyeonggido, Korea, Republic of|Jeju, Jejudo, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Busan, Korea, Republic of|Daejeon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Batu Caves, Selangor, Malaysia|Kedah, Malaysia|Kuala Lumpur, Malaysia|Kuala Lumpur, Malaysia|Selangor, Malaysia|Sungai Buloh Selangor, Malaysia|Amsterdam, Netherlands|Apeldoorn, Netherlands|Arnhem, Netherlands|Breda, Netherlands|Delft, Netherlands|Den Bosch, Netherlands|Deventer, Netherlands|Doetinchem, Netherlands|Drachten, Netherlands|EDE, Netherlands|Gorinchem, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Hoogeveen, Netherlands|Hoorn, Netherlands|Leeuwarden, Netherlands|Meppel, Netherlands|Nijmegen, Netherlands|Roermond, Netherlands|Roosendaal, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Sneek, Netherlands|Tiel, Netherlands|Zwolle, Netherlands|Batangas, Philippines|Cebu City, Philippines|Dagupan City, Philippines|Dasmarinas, Philippines|Iloilo City, Philippines|Laoag City, Philippines|Manila, Philippines|Manila, Philippines|Metro Manila, Philippines|Muntinlupa City, Philippines|Palawan, Philippines|Pasig city, Philippines|Quezon City, Philippines|Quezon City, Philippines|Quezon City, Philippines|Tacloban City, Philippines|Gdansk, Poland|Kielce, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Tarnow, Poland|Wroclaw, Poland|Timisoara, Timis, Romania|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Bucuresti, Romania|Cluj Napoca, Romania|Iasi, Romania|Iasi, Romania|Targu Mures, Romania|Targu Mures, Romania|Timisoara, Romania|Barnaul, Russian Federation|Kemerovo, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Tomsk, Russian Federation|Zhukovskiy, Russian Federation|Bratislava, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Presov, Slovakia|Vrable, Slovakia|Pinelands, Eastern Cape, South Africa|Port Elizabeth, Eastern Cape, South Africa|Bloemfontein, Freestate, South Africa|Johannesburg, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Observatory, Western Cape, South Africa|Pinelands, Western Cape, South Africa|Worcester, Western Cape, South Africa|Somerset West, South Africa|Göteborg, Sweden|Helsingborg, Sweden|Kristianstad, Sweden|Skellefteå, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Stockholm, Sweden|Vällingby, Sweden|Örebro, Sweden|Östersund, Sweden|Lugano, Ticino, Switzerland|Dnipropetrovsk, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Lviv, Ukraine|Lviv, Ukraine|Simferopol, Ukraine|Vinnitsa, Ukraine|Zaporozhye, Ukraine|Zaporozhye, Ukraine|Belfast, Antrim, United Kingdom|Londonderry Co. Londonderry, Derry, United Kingdom|Basildon, Essex, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Blackpool, Lancashire, United Kingdom|Harrow, London, United Kingdom|Portadown, North Ireland, United Kingdom|Middlesborough, North Yorkshire, United Kingdom|Northampton, Northamptonshire, United Kingdom|Hardwick, Stockton-on-Tees, United Kingdom|Nuneaton, Warwickshire, United Kingdom|West Bromich, West Midlands, United Kingdom|Wolverhampton, West Midlands, United Kingdom|Worcester, Worcestershire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01776424/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT01776424/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01776424"
1045,"NCT01791816","Mechanisms of Vasovagal Syncope",,"Active, not recruiting","No Results Available","Vasovagal Syncope|Postural Tachycardia Syndrome","Drug: Phenylephrine|Drug: L-Ng-monomethyl Arginine (L-NMMA)","Heart rate and blood pressure in response to Lower Body Negative Pressure(LBNP)|Adrenergic neurotransmission as measured by Muscle Sympathetic Nerve Activity(MSNA), doppler ultrasound blood flow, venous Norepinephrine in response to Phenylephrine infusion","New York Medical College","All","14 Years to 29 Years   (Child, Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1R01HL112736-01A1","February 2013","December 2020","December 2020","February 15, 2013",,"January 14, 2020","New York Medical College/Bradhurst Building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT01791816"
1046,"NCT03148756","Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis",,"Terminated","Has Results","Endocarditis|Bacteremia","Drug: Dalbavancin|Drug: Standard of Care","Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population|Percentage of Participants With Clinical Outcome of Success at Day 42 in the ITT Population|Percentage of Participants With Clinical Outcome of Success at Day 42 in the Clinically Evaluable (CE) Population|Number of Participants With Day 84 Mortality in the Safety Population|Percentage of Participants With Clinical Outcome of Success at Day 84 in the CE Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the ITT Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the ITT Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the CE Population|Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the CE Population|Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the ITT Population|Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the ITT Population|Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the CE Population|Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the CE Population","Allergan","All","18 Years and older   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DAL-MD-09","May 12, 2017","August 4, 2017","August 4, 2017","May 11, 2017","September 10, 2018","September 10, 2018","Midway Immunology and Research Center, Fort Pierce, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03148756/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03148756"
1047,"NCT00952627","Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects",,"Terminated","No Results Available","Cardiac Fibrosis|Diastolic Dysfunction","Dietary Supplement: Pycnogenol|Dietary Supplement: Placebo","cardiac fibrosis (by measuring the serum markers of myocardial fibrosis and collagen turnover) and diastolic dysfunction (by transthoracic echocardiogram)|liver and kidney function tests|Immunological measurements including the cytokine profile in serum (interleukin (IL)-4, IL-10, interferon-gamma, C-reactive protein).","University of Arizona|Horphag Research","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UofAFRS 439130","July 2009","July 2011","July 2011","August 6, 2009",,"December 17, 2013","University of Arizona, Sarver Heart Center, Tucson, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT00952627"
1048,"NCT01978535","Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)",,"Terminated","Has Results","Postural Orthostatic Tachycardia Syndrome","Drug: Iron infusion|Drug: Normal saline infusion","Cardiovascular Indices-interval Change in Heart Rate During 10-minute Head up Tilt Table Test","Mayo Clinic","All","12 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12-009963","December 17, 2014","September 8, 2017","September 8, 2017","November 7, 2013","November 17, 2017","November 17, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01978535/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01978535"
1049,"NCT04092621","Rapid Atrial Fibrillation Treatment Strategy","RAFTS","Not yet recruiting","No Results Available","New Onset Atrial Fibrillation|Sepsis|Respiratory Failure","Drug: Amiodarone in Parenteral Dosage Form|Drug: Amiodarone Pill|Procedure: Direct Current Cardioversion (DCC)|Drug: Rate-control therapy","ICU Length of Stay (LOS)|Ventilation-free days|Vasopressor days","Our Lady of the Lake Regional Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-106","September 16, 2019","September 15, 2020","September 15, 2020","September 17, 2019",,"September 17, 2019","Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT04092621"
1050,"NCT02083510","Apolipoprotein CIII Reduction Via Colchicine",,"Completed","No Results Available","Hypertriglyceridemia|Gout|Pericarditis","Drug: Colchicine","Reduction in ApoCIII levels|Reduction of triglycerides and very low density lipoprotein (VLDL) levels|Measurement of Apolipoprotein A and Apolipoprotein B via Vertical Auto Profile (VAP)","Scripps Translational Science Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-6293|1UL1TR001114-01","February 2014","May 2014","May 2014","March 11, 2014",,"May 30, 2014","Scripps Translational Science Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT02083510"
1051,"NCT03761953","Oritavancin for Staphylococcus Aureus Infections in Opioid Users",,"Recruiting","No Results Available","Staphylococcus Aureus Bacteremia|Staphylococcus Aureus Endocarditis","Drug: Oritavancin Injection","Frequency of grade 3 or 4 systemic (i.e., not a local reaction) adverse events associated with the administration of oritavancin|Frequency of relapse of infection|Duration of hospitalization|Relapse of systemic S. aureus infections|Pharmacokinetic parameters of oritavancin: Cmin (μg/ml)|Patient satisfaction when using oritavancin measured using the Patient Satisfaction Questionnaire Short Form (PSQ-18)","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","831334","July 1, 2019","December 31, 2019","December 31, 2019","December 3, 2018",,"July 11, 2019","Clinical Trials Unit. University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03761953"
1052,"NCT02279745","Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension",,"Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Ralinepag","Long-term safety assessed by adverse events up to 28 days following discontinuation of study drug","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APD811-007","July 2015","May 2020","May 2020","October 31, 2014",,"December 4, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Cardiac and Vascular Center, Anschutz Inpatient Pavilion, Aurora, Colorado, United States|Cleveland Clinic Florida, Weston, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Chest Medicine Associates, Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston University Medical Center General Clinical Research Unit (GCRU), Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|UC Health, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center - Martha Morehouse Medical Pavilion, Columbus, Ohio, United States|UPMC, Presbytarian, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|The Prince Charles Hospital, Chermside, Australia|St. Vincent's Hospital/Lung Transplant Unit, Darlinghurst, Australia|St Vincent's Hospital, Fitzroy, Australia|Royal Hobart Hospital, Hobart, Australia|Fiona Stanley Hospital, Murdoch, Australia|Multiprofile Hospital for Active Treatment in Cardiology EAD, Department of Cardiology, Pleven, Bulgaria|Multiprofile Hospital for Active Treatment ""National Heart Hospital"" EAD, Clinic of Cardiology, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment "" St. Anna"", Sofia AD, Cardiology Clinic, Sofia, Bulgaria|Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czechia|Second Internal Clinic - Clinic of Cardiology and Angiology, 1st Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Prague, Czechia|Gottsegen Gyorgy Orszagos Kardiológiai lntézet National Institute of Cardiology, Department of Adult Cardiology, Budapest, Hungary|Semmelweis University, Department of Pulmonology - Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary|University of Derecen Clinical Research Center Cardiology and Cardiac Surgery Department - Debreceni Egyetem Klinikai Kozpont Kardiologiai es Szivsebeszeti Klinika, Debrecen, Hungary|University of Pecs, Medical School, Heart Institute - Pécsi Tudományegyetem, Klinikai Központ, Szívgyógyászati Klinika, Pécs, Hungary|University of Szeged Faculty of Medicine, 2nd Department of Medicine and Cardiology Center, Albert Szent-Györyi Clinical Center - SZTE ÁOK Szent-Györgyi A lbert Klinikai Központ I I. sz. Belgyógyászati Klini ka és Kard ilógiai Központ, Szeged, Hungary|Medical University of Bialystok Clinical Hospital Cardiology Clinic - Uniwersytecki Szpital Kliniczny, Klinika Kardiologii z Oddziałem Intensywnego Nadzoru Kardiologicznego, Białystok, Poland|John Paul II Hospital in Cracov Department of Cardiac and Vascular Diseases - Krakowski Szpital Specjalistyczny im. Jana Pawła II, Oddział Kliniczny Chorób Serca i Naczyń, Krakow, Poland|Biegański Provincial Specialist Hospital Department of Cardiology - Wojewódzki Szpital Specjalistyczny im. dr Wł. Biegańskiego w Lodzi, Oddział Kardiologiczny, Lodz, Poland|""Prof. Dr. C.C. Iliescu"" Institute of Cardiovascular Diseases, Department of Clinic Cardiology III - Institutul de Urgenţă pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Secţia Clinica Cardiologie fIJ, Bucharest, Romania|""Marius Nasta"" Institute of Pneumoftiziology, Department of Pneumoftiziology IV - Institutul de Pneumoftiziologie ""Marius Nasta"", Sectia Clinica Pneumoftiziologie IV, Bucharest, Romania|""Dr. Victor Babes"" Clinic Hospital for Infesctious Diseases and Pneumoftiziology, Department of Clinic Pneumology II, Timisoara, Romania|Clinical Centre of Serbia (CCS), Cardiology Clinic - Klinicki Centar SrЬije, Klinika za kardiologiju, Belgrade, Serbia|Кlinjcko-bolnicki centar Zemun, Кlinika za internu medicmu, Sluzba za kardiologiju, Belgrade, Serbia|Institute of Pulmonary Diseases of Vojvodina Sremska Kamenica (IPDVSK), The Clinic for Urgent Pulmonology, ICU - Intensive Care Unit - Klinicki Centar SrЬije, Klinika za kardiologiju, Sremska Kamenica, Serbia|Department of Heart Failure and Transplantation, National Institute of Cardiovascular Diseases - Oddelenie zlyhávania a transplantácie srdca, Národný ústav srdcových a cievnych chorôb, a.s., Bratislava, Slovakia|Cardiology department, East Slovak Institute for Cardiovascular Diseases - Kardiologické oddelenie Klinika kardiológie , Východoslovenský ústav srdcových a cievnych chorôb, a.s, Košice, Slovakia|General Universitary Hospital Vall d'Hebron, Department of Pneumology, Barcelona, Spain|Clinic Hospital of Barcelona, Department of Pneumology, Barcelona, Spain|Hospital 12th of October, Department of Cardiology, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02279745"
1053,"NCT01135017","Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers","HESTIA","Terminated","Has Results","Atrial Fibrillation","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","Atrial Fibrillation (AF) Burden During the 12-week Treatment Period|AF Burden During the First 4 Weeks of Treatment and After 4-week Treatment|Average Ventricular Rate During AF Episodes|Atrial Fibrillation Severity Scale (AFSS) Scores|Incidence Rate of Electrical Cardioversion (or Overdrive Pacing)","Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRONE_L_04316|U1111-1117-0024","July 2010","February 2012","February 2012","June 2, 2010","April 1, 2013","April 11, 2013","Investigational Site Number 840015, Birmingham, Alabama, United States|Investigational Site Number 840087, Huntsville, Alabama, United States|Investigational Site Number 840018, Mobile, Alabama, United States|Investigational Site Number 840030, Mesa, Arizona, United States|Investigational Site Number 840048, Phoenix, Arizona, United States|Investigational Site Number 840072, Phoenix, Arizona, United States|Investigational Site Number 840013, Tucson, Arizona, United States|Investigational Site Number 840069, Hot Springs, Arkansas, United States|Investigational Site Number 840121, Beverly Hills, California, United States|Investigational Site Number 840090, Laguna Hills, California, United States|Investigational Site Number 840068, Los Angeles, California, United States|Investigational Site Number 840062, Mission Hills, California, United States|Investigational Site Number 840070, Orange, California, United States|Investigational Site Number 840021, Riverside, California, United States|Investigational Site Number 840024, San Diego, California, United States|Investigational Site Number 840001, Aurora, Colorado, United States|Investigational Site Number 840089, Littleton, Colorado, United States|Investigational Site Number 840029, Loveland, Colorado, United States|Investigational Site Number 840108, Newark, Delaware, United States|Investigational Site Number 840045, Washington, District of Columbia, United States|Investigational Site Number 840106, Washington, District of Columbia, United States|Investigational Site Number 840010, Clearwater, Florida, United States|Investigational Site Number 840020, Ft. Myers, Florida, United States|Investigational Site Number 840058, Inverness, Florida, United States|Investigational Site Number 840044, Jacksonville Beach, Florida, United States|Investigational Site Number 840043, Jacksonville, Florida, United States|Investigational Site Number 840066, Jacksonville, Florida, United States|Investigational Site Number 840128, Jacksonville, Florida, United States|Investigational Site Number 840042, Orlando, Florida, United States|Investigational Site Number 840016, Port Charlotte, Florida, United States|Investigational Site Number 840080, Wellington, Florida, United States|Investigational Site Number 840056, Gainesville, Georgia, United States|Investigational Site Number 840092, Normal, Illinois, United States|Investigational Site Number 840032, Oak Lawn, Illinois, United States|Investigational Site Number 840046, Rockford, Illinois, United States|Investigational Site Number 840051, Bloomington, Indiana, United States|Investigational Site Number 840053, Kansas City, Kansas, United States|Investigational Site Number 840110, Owensboro, Kentucky, United States|Investigational Site Number 840102, Columbia, Maryland, United States|Investigational Site Number 840017, Lansing, Michigan, United States|Investigational Site Number 840081, Lapeer, Michigan, United States|Investigational Site Number 840075, Petoskey, Michigan, United States|Investigational Site Number 840027, Troy, Michigan, United States|Investigational Site Number 840104, St Cloud, Minnesota, United States|Investigational Site Number 840097, Tupelo, Mississippi, United States|Investigational Site Number 840037, Columbia, Missouri, United States|Investigational Site Number 840035, Kansas City, Missouri, United States|Investigational Site Number 840060, St Louis, Missouri, United States|Investigational Site Number 840055, St. Louis, Missouri, United States|Investigational Site Number 840067, Missoula, Montana, United States|Investigational Site Number 840049, Reno, Nevada, United States|Investigational Site Number 840054, Reno, Nevada, United States|Investigational Site Number 840026, Bridgewater, New Jersey, United States|Investigational Site Number 840093, Englewood, New Jersey, United States|Investigational Site Number 840036, Bronx, New York, United States|Investigational Site Number 840006, Buffalo, New York, United States|Investigational Site Number 840077, Kingston, New York, United States|Investigational Site Number 840096, Mineola, New York, United States|Investigational Site Number 840041, Syracuse, New York, United States|Investigational Site Number 840086, Troy, New York, United States|Investigational Site Number 840007, Williamsville, New York, United States|Investigational Site Number 840084, Raleigh, North Carolina, United States|Investigational Site Number 840061, Wilmington, North Carolina, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840008, Camp Hill, Pennsylvania, United States|Investigational Site Number 840009, Doylestown, Pennsylvania, United States|Investigational Site Number 840004, Philadelphia, Pennsylvania, United States|Investigational Site Number 840078, Phoenixville, Pennsylvania, United States|Investigational Site Number 840105, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840130, Scranton, Pennsylvania, United States|Investigational Site Number 840019, Unionville, Pennsylvania, United States|Investigational Site Number 840023, Wyomissing, Pennsylvania, United States|Investigational Site Number 840119, Greenville, South Carolina, United States|Investigational Site Number 840002, Rapid City, South Dakota, United States|Investigational Site Number 840114, Germantown, Tennessee, United States|Investigational Site Number 840118, Corpus Christi, Texas, United States|Investigational Site Number 840014, Dallas, Texas, United States|Investigational Site Number 840012, San Antonio, Texas, United States|Investigational Site Number 840125, Tyler, Texas, United States|Investigational Site Number 840083, Salt Lake City, Utah, United States|Investigational Site Number 840113, Danville, Virginia, United States|Investigational Site Number 840082, Lynchburg, Virginia, United States|Investigational Site Number 840088, Manassas, Virginia, United States|Investigational Site Number 840099, Richmond, Virginia, United States|Investigational Site Number 840112, Richmond, Virginia, United States|Investigational Site Number 840003, Tacoma, Washington, United States|Investigational Site Number 840107, Tacoma, Washington, United States|Investigational Site Number 840123, Green Bay, Wisconsin, United States|Investigational Site Number 840022, Madison, Wisconsin, United States|Investigational Site Number 840033, Milwaukee, Wisconsin, United States|Investigational Site Number 840047, Milwaukee, Wisconsin, United States|Investigational Site Number 840076, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01135017"
1054,"NCT01841762","Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument",,"Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan","Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT)|Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), With Reliability Assessed Via Test-retest Reliability.|Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Assessing Internal Consistency Reliability.|Number of Participants With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events Resulting in Patient Study Drug Discontinuation Between Time Periods, BL to End of Study Visit (EoS, Week 16+30 Days for Follow-up Safety Visits)","Actelion","All","18 Years and older   (Adult, Older Adult)","Phase 3","284","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-401","April 1, 2013","November 1, 2015","November 1, 2015","April 29, 2013","October 31, 2018","February 26, 2019","Cardiovascular Associates of the Southeast, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Pulmonary Associates, PA, Phoenix, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|UCSF Fresno, Fresno, California, United States|UCSD Medical Center, Pulmonary Department, La Jolla, California, United States|VAGLAHS, VA Greater LA Healthcare System, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Los Angeles Biomedical Research Institute, Torrance, California, United States|University of Colorado, Aurora, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Bay Area Cardiology Associates, P.A., Brandon, Florida, United States|University of Florida Academic Health Center, Gainesville, Florida, United States|University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Medical, Chicago, Illinois, United States|Advocate Health and Hospitals Corporation, Oakbrook Terrace, Illinois, United States|Chest Infectious Diseases and Critical Care Associates, PC, Des Moines, Iowa, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Iowa City Heart Center, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Veritas Clinical Specialties, Topeka, Kansas, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Beaumont Hospital, Troy, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Midwest Pulmonary Consultants, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Clinic Pulmonology, Saint Louis, Missouri, United States|Clayton Sleep Institute, Saint Louis, Missouri, United States|Ferrell-Duncan Clinic, Springfield, Missouri, United States|Nebraska Pulmonary Specialties, Lincoln, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Pulmonary and Critical Care Associates, Union, New Jersey, United States|Montefiore Medical Center, Weiler Division, Bronx, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|North Shore-LIJ/Advance Lung Disease Clinic, New Hyde Park, New York, United States|Beth Israel Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Pulmonary and Critical Care, Matthews, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|UC Health/University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Davis Heart & Lung Research Institute, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|The Oregon Clinic, Portland, Oregon, United States|CDA for Oregon Pulmonary Associate, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Division on Pulmonary and Critical Care, Philadelphia, Pennsylvania, United States|Temple Lung Center, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Berks Schuylkill Respiratory Specialists, Ltd., Wyomissing, Pennsylvania, United States|Wellspan Lung, Sleep and Critical Care, York, Pennsylvania, United States|Sioux Falls Cardiovascular, PC, Sioux Falls, South Dakota, United States|Baylor Research Institute (BRI), Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Inova Heart and Vascular Institue / Inova Fairfax Hospital, Falls Church, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Pulmonary & Sleep Research, Spokane, Washington, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|Aurora Cardiovascular Services, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01841762"
1055,"NCT01813422","GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound","GLAGOV","Completed","Has Results","Hypercholesterolemia","Biological: Evolocumab|Drug: Placebo","Change From Baseline in Percent Atheroma Volume at Week 78|Change From Baseline in Total Atheroma Volume at Week 78|Percentage of Participants With Regression in Percent Atheroma Volume|Percentage of Participants With Regression in Total Atheroma Volume","Amgen","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","970","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20120153|2012-004208-37","April 18, 2013","July 12, 2016","July 29, 2016","March 19, 2013","January 4, 2018","February 20, 2019","Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Monica, California, United States|Research Site, Torrance, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Hammond, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bay City, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Springfield, Oregon, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Concord, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Lodelinsart, Belgium|Research Site, Cariacica, Espírito Santo, Brazil|Research Site, Goiania, Goiás, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Aarhus N, Denmark|Research Site, Odense C, Denmark|Research Site, Besançon Cedex, France|Research Site, Chambray les Tours, France|Research Site, Creteil, France|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Aachen, Germany|Research Site, Essen, Germany|Research Site, München, Germany|Research Site, Neuss, Germany|Research Site, Regensburg, Germany|Research Site, Ulm, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Reykjavik, Iceland|Research Site, Dublin, Ireland|Research Site, Galway, Ireland|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Rehovot, Israel|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Sesto San Giovanni (MI), Italy|Research Site, Torino, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuantan, Pahang, Malaysia|Research Site, Penang, Malaysia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Culiacan, Sinaloa, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Puebla, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Oslo, Norway|Research Site, Tromso, Norway|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Chrzanow, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Singapore, Singapore|Research Site, Boksburg, Gauteng, South Africa|Research Site, Centurion, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kuils River, Western Cape, South Africa|Research Site, Pinelands, Cape Town, Western Cape, South Africa|Research Site, Somerset West, Western Cape, South Africa|Research Site, Malaga, Andalucía, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, L Hospitalet De Llobregat, Cataluña, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Lund, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden|Research Site, Örebro, Sweden|Research Site, Geneva 14, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01813422"
1056,"NCT01725269","Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05",,"Terminated","No Results Available","Pulmonary Arterial Hypertension","Drug: AIR001","To evaluate the intermediate/long-term safety of inhaled nebulized AIR001|To assess the effect of inhaled AIR001 on Time to Clinical Worsening, 6MWD, Functional Class, and Quality of Life","Aires Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIR001-CS06","March 2013","April 2014","April 2014","November 12, 2012",,"April 9, 2014","UCSD Medical Center, La Jolla, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Adaani Frost, M.D., Houston, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Gottsegen Gyorgy Hungarian, Budapest, Hungary|Semmelweis University, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|University of Szeged, Szeged, Hungary",,"https://ClinicalTrials.gov/show/NCT01725269"
1057,"NCT01014741","Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation","MAGIC-AF","Completed","Has Results","Persistent Atrial Fibrillation","Drug: Ibutilide|Drug: Placebo","Number of Participants With 1 Year Freedom From AF / AT|Procedure Time|AF Termination|Radiofrequency Ablation Time","Vivek Reddy|Abbott Medical Devices|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 09-0906","October 2009","January 2015","January 2015","November 17, 2009","May 24, 2017","February 14, 2018","Regional Cardiology Associates, Sacramento, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Republic of Korea University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01014741"
1058,"NCT01894555","Pharmacogenomics of Antiplatelet Response - II (PARes-II)","PARes-II","Completed","Has Results","Atherothrombosis","Drug: Aspirin","Changes in Platelet Transcriptome","Johns Hopkins University","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 4","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","K23HL105897-PARes-II|K23HL105897","January 2013","August 2014","August 2014","July 10, 2013","January 9, 2017","January 9, 2017","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01894555"
1059,"NCT02558231","The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","TRITON","Active, not recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: Macitentan|Drug: Tadalafil|Drug: Selexipag","Pulmonary vascular resistance","Actelion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","247","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-065A308","May 1, 2016","August 29, 2019","March 31, 2020","September 23, 2015",,"February 19, 2020","Arizona Pulmonary Specialists, LTD, Phoenix, Arizona, United States|UCSD Health Sciences, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Piedmont Pulmonary and Critical Care Research, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|LSU Health Sciences Center, New Orleans, Louisiana, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Michigan, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|The Christ Hospital, Cincinnati, Ohio, United States|Allegheny General Hospital of Research, Pittsburgh, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Royal Prince Albert Hospital, Camperdown, New South Wales, Australia|St. Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia|LKH -Universität Klinkum Graz, Graz, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|AKH Wien, Wien, Austria|Hôpital Erasme, Brussels, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Belgium|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec, Canada|University of Calgary, Calgary, Canada|University of Ottawa Heart Institute, Ottawa, Canada|Aarhus University Hospital Skejby, Aarhus, Denmark|Rigshospitalet Copenhagen, Copenhagen, Denmark|CHU de Bicêtre, Le Kremlin-Bicêtre, France|Unversitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Giessen, Giessen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|Ospedale Sant'Orsola, Bologna, Italy|VUmc Amsterdam, Amsterdam, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Skånes universitetssjukhus Lund, Lund, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Kardiologkliniken, Uppsala, Sweden|Universiätsspital Zürich, Zürich, Switzerland|Golden Jubilee National Hospital, Clydebank, United Kingdom|The Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02558231"
1060,"NCT00837616","Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism",,"Completed","Has Results","Turner Syndrome|Hypogonadism|Premature Ovarian Failure","Drug: 17 B estradiol orally|Drug: 17 B estradiol","Change in Weight From Baseline at 12 Months|Change in Body Mass Index From Baseline at 12 Months|Change in Percent Fat Mass From Baseline in 12 Months|Change in Fat Free Mass From Baseline at 12 Months|Characterize PK/PD and Relative Biological Potency of Different Oral vs TD Estrogen Preparations|Changes in Insulin Growth Factor-I From Baseline at 12 Months|Lipids Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Rates of Lipid Oxidation After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Serum 17B Estradiol Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Serum Estrone Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months|Serum Estrone Sulfate Concentrations After Using Oral Versus Transdermal 17B Estradiol Replacement for 12 Months","Nemours Children's Clinic|Genentech, Inc.","Female","13 Years to 20 Years   (Child, Adult)","Phase 4","41","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","908-M01","January 2009","June 2012","December 2012","February 5, 2009","February 10, 2014","March 27, 2014","Nemours Children's Clinic, Jacksonville, Florida, United States|Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Chile/Clinica las Condes, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT00837616"
1061,"NCT02501811","Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure","CONCERT-HF","Active, not recruiting","No Results Available","Ischemic Cardiomyopathy","Biological: Mesenchymal Stem Cells (MSC)|Biological: c-kit+ cells|Biological: Placebo (Plasmalyte A)","Left Ventricular Ejection Fraction (LVEF)|Global Strain (HARP MRI)|Regional Strain (HARP MRI)|Left Ventricular End Diastolic Volume Index (LVEDVI)|Left Ventricular End Systolic Volume Index (LVESVI)|Left Ventricular Sphericity Index|Infarct/scar Volume (DEMRI)|Maximal Oxygen Consumption (VO2 max)|Exercise Tolerance|Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score|N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP)|Incidence of major adverse cardiac events (MACE)|Incidence of other significant clinical events|Cumulative Days alive and out of hospital for heart failure","The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 2","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-SPH-15-0413|5UM1HL087318","October 2015","May 2020","May 2020","July 17, 2015",,"January 29, 2020","Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdisciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02501811"
1062,"NCT02657356","Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST",,"Active, not recruiting","No Results Available","Connective Tissue Disease-Associated Pulmonary Arterial Hypertension","Drug: Placebo capsules|Drug: Bardoxolone methyl capsules","Change from baseline in six-minute-walk distance (6MWD)","Reata Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 402-C-1504","October 4, 2016","May 2020","June 2020","January 15, 2016",,"December 4, 2019","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|Regents of The University of California, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Pacific Pulmonary Research, Inc., San Diego, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Augusta University, Augusta, Georgia, United States|Piedmont-Georgia Lung, Austell, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico, Albuquerque, New Mexico, United States|NYU Langone Health, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|Integris Nazih Zuhdi Transplant Institute, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fundación Favaloro, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Hospital Británico de Buenos Aires, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Centro Médico Dra de Salvo, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Buenos Aires, Mar Del Plata, Argentina|Instituto De Enfermedades Respiratorias E Investigacion Medica, Buenos Aires, Villa Vatteone, Argentina|Hospital Cordoba, Cordoba, Argentina|Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Hospital de Alta Complejidad ""Pte. J. D. Perón"", Formosa, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Hôpital Erasme, Brussels, Belgium|Hospital de Messejana, Fortaleza, Ceara, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Hospital São Paulo, Sao Paulo, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Peter Lougheed Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de l'Université Laval, Sainte Foy, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Prague, Czechia|Institut klinicke a experimentalni mediciny, Prague, Czechia|Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany|Universitatsklinkum Erlangen, Erlangen, Bayern, Germany|Universität Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Thorax Klinik, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan|Chiba University Hospital, Chiba, Japan|Gunma University School of Medicine, Gunma, Japan|Kobe University Hospital, Kobe, Japan|Nagoya Medical Center, Nagoya, Japan|Hokkaido University Hospital, Sapporo, Japan|Kurume University Medical Center, Sendai-shi, Japan|National Cerebral and Cardiovascular Center, Suita, Japan|Fujita Health University Hospital, Toyoake, Japan|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio González, Monterrey, Nuevo Leon, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Nuevo Leon, Mexico|Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands|Angeles University Foundation Medical Center (AUFMC), Angeles City, Philippines|Mary Mediatrix Medical Center (MMMC), Lipa, Philippines|Makati Medical Center (MMC), Makati, Philippines|Philippine General Hospital (PGH), Manila, Philippines|Philippine Heart Center (PHC), Quezon City, Philippines|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de La Salud, Toledo, Spain|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02657356"
1063,"NCT03781440","Regional Anesthesia for Cardiothoracic Enhanced Recovery","RACER","Not yet recruiting","No Results Available","Opioid Use|Anesthesia, Local|Cardiac Disease|Pain, Acute","Procedure: Bilateral ESP catheter with lidocaine|Procedure: Bilateral ESP catheter with saline","Median time to extubation in patients with ESPB|Length of stay in ICU|Opioid Consumption|Determine average post-operative pain scores in patients with ESPB","Stanford University","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","47647","June 30, 2019","October 30, 2020","October 30, 2022","December 19, 2018",,"May 9, 2019","Stanford University, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT03781440"
1064,"NCT02283294","Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation","AREST","Completed","No Results Available","Transient Ischemic Attack|Stroke|Atrial Fibrillation","Drug: Apixaban|Drug: Warfarin","Composite endpoint of fatal stroke, recurrent ischemic stroke, or TIA|Intracranial hemorrhage assessed by MRI/CT","University of South Florida|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","91","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRO00019754","April 2015","June 2019","June 2019","November 5, 2014",,"August 19, 2019","Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Bayfront Health St Petersburg, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Louisville, Louisville, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT02283294"
1065,"NCT00839501","Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome",,"Terminated","No Results Available","Andersen-Tawil Syndrome","Dietary Supplement: Potassium|Drug: Acetazolamide","Sum of the attack durations across the entire treatment period, reported by the participants via interactive voice response (IVR)","University of Rochester|Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network|National Institute of Neurological Disorders and Stroke (NINDS)","All","10 Years and older   (Child, Adult, Older Adult)","Phase 1","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RDCRN 5305|U54NS059065","December 2008","January 2011","January 2011","February 9, 2009",,"January 20, 2012","University of Rochester School of Medicine, Rochester, New York, United States",,"https://ClinicalTrials.gov/show/NCT00839501"
1066,"NCT03626688","A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients",,"Recruiting","No Results Available","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Drug: Ralinepag|Drug: Placebo","Time from randomization to the first adjudicated protocol-defined clinical worsening event|Change from Baseline in N-terminal pro-brain natriuretic peptide (NT-proBNP)|Change from Baseline in 6-minute walk distance (6MWD)|Change from Baseline in WHO/New York Heart Association (NYHA) Functional Class|Shift and proportion of subjects who attain all 3 of the following: NT-proBNP level <300 pg/mL, 6MWD >440 meters, and WHO/NYHA Functional Class I or II|Change from Baseline in health-related quality of life as measured by patient-reported outcomes.|Change from Baseline in heart rate recovery (HRR) following completion of the 6MWT|Time to all-cause nonelective hospitalization|Time to all-cause mortality|Safety and tolerability of ralinepag in subjects with PAH","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ROR-PH-301|APD811-301","August 30, 2018","December 2021","December 2021","August 13, 2018",,"May 1, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Chest Medicine Associates, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|Winthrop Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati-Medical Science Building, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NewSTAT, PLLC, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Hospital Italiano, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Respirar, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|Hospital Italiano de Cordoba, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Instituto de Investigaciones Clinicas, Mar Del Plata, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|Cliniques Universitaires de Bruxelles Hopital Erasme, Bruxelles, Belgium|UZ Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, Leuven, Belgium|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, MG, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, R.S, Brazil|MHAT - ""National Heart Hospital"" EAD, 65, Konyovitza Str., Sofia, Bulgaria|Peter Lougheed Centre, Calgary, Alberta, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|SMBD Jewish General Hospital d/b/a Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec, Quebec, Canada|Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China|Clinical Hospital Dubrava Zagreb, Avenija G.Šuška 6, Zagreb, Croatia|University Clinic for Pulmonary Diseases, Jordanovac 104, Zagreb, Croatia|Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark|Århus Universitetshospital, Århus, Denmark|CHU de Strasbourg - Nouvel Hôpital Civil, Ctre de competence Hypertension Arterielle Pulmona, 1 place de l Hopital, Strasbourg, Bas Rhin, France|CHU de Grenoble - Hôpital Albert Michallon, Clinique de Cardiologie, Boulevrad de la Chantourne, Grenoble, Isere, France|CHU de Saint-Etienne - Hopital Nord, Service de Medecine vasculaire et therapeutique, 81 Avenue A. Raimond, Saint-Étienne, Loire, France|CHU Nancy - Hôpital de Brabois Adultes, Pneumologie- Oncologie Médicale, Rue du Morvan, Vandoeuvre les Nancy, Meurthe Et Moselle, France|CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Service de Pneumologie, 59 Boulevard Pinel, Bron cedex, Rhone, France|Groupement Hospitalier Sud - Hôpital Bicêtre, Le Kremlin-Bicêtre, Val De Marne, France|University General Hospital Attikon, 1 Rimini Street, Chaidari, Athens, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|""Onasseio"" Cardiosurgery Hospital, Hemodynamic Research and Interventional Cardiology Dept., 356, Syggrou Avenue, Athens, Greece|AHEPA General Hospital of Thessaloniki, A' Cardiology Clinic, 1 St. Kyriakidi Street, Thessaloniki, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, S.C. di Cardiologia, Viale Luigi Pinto, 1, Foggia, Italy|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Gachon University Hospital Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddział Kliniczny Chorób Serca i Naczyń z Pododdziałem Intensywnego Nadzoru Kardiologicznego, Pradnicka 80, Krakow, Poland|NZOZ Europejskie Centrum Zdrowia, ul. Borowa 14/18, Otwock, Poland|Premium Clinic Wrocław CM, Podwale 83/17, Wroclaw, Poland|Institutul de Urgenta pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Sos. Fundeni nr. 258, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Sos. Viilor nr. 90, Sector 5, Bucuresti, Romania|Institutul Inimii ""Niculae Stancioiu"" Cluj-Napoca, Cardiologie, Str. Motilor nr. 19-21, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie ""Dr. Victor Babes"" Timisoara, Str. Gheorghe Adam nr. 13, Timisoara, Romania|Hospital Universitari Vall d'Hebron, Respiratory Dept., Passeig Vall d'Hebron,119-129, Neumologia, Barcelona, Spain|Hospital Clinic de Barcelona, C/ Villarroel, 170, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Linköping Universitetssjukhuset, Linköping, Sweden|Norrlands Universitetssjukhus, Hjärtcentrum, Umeå, Sweden|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|CE Dniprop RCC&C Center of Dniprop RC Dept of Card SI DMA of MOHU, Chair of Internal Medicine 3, 28, Knyazya Volodymyra Velykogo St., Dnipro, Ukraine|SI F.H.Yanovskyi National Institute of Phthisiology and Pulmonology of NAMSU, Clinical and Functional Dept, 10, Amosova St., Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council Lviv Clinical Hospital, Dept of Cardiology, D.Halytskyi Lviv NMU, Ch of Internal Medicine #1, 7, Chernihivska str., Lviv, Ukraine|Golden Jubilee National Hospital, Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03626688"
1067,"NCT01127503","Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome",,"Terminated","Has Results","Velo-cardio-facial Syndrome|Psychosis","Drug: Metyrosine|Drug: Placebo","To Evaluate the Safety of Metyrosine (Demser®) for the Treatment of Psychosis in Patients With VCFS|To Evaluate the Efficacy of Metyrosine (Demser®) for the Treatment of Psychosis in Patients With VCFS","Bausch Health Americas, Inc.","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","09-MET-101","June 2010","November 2010","September 2011","May 21, 2010","May 8, 2018","November 22, 2019","VCFS International Center, Syracuse, New York, United States",,"https://ClinicalTrials.gov/show/NCT01127503"
1068,"NCT02803073","Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction",,"Withdrawn","No Results Available","Hypogonadism|Acute Myocardial Infarction: Rehabilitation Phase","Drug: Testosterone|Drug: Normal Saline","Metabolic Equivalent|6 minute walk test","Texas Tech University Health Sciences Center","Male","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","L16-116","August 2016","March 2017","May 2017","June 16, 2016",,"November 21, 2019","Mission Fitness-Medical Center Hospital, Odessa, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02803073"
1069,"NCT03492177","A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","Pulmonary Arterial Hypertension","Drug: selexipag (Uptravi)","Area under the plasma concentration-time curve over a dose interval at steady state of selexipag and its metabolite ACT-333679 combined (AUCτ,ss, combined)|Area under the plasma concentration-time curve over a dose interval at steady state (AUCτ,ss) of selexipag|Area under the plasma concentration-time curve over a dose interval at steady state (AUCτ,ss) of ACT-333679|Maximum observed plasma concentration (Cmax,ss) of selexipag at steady state|Maximum observed plasma concentration (Cmax,ss) of ACT-333679 at steady state|Time to the maximum observed plasma concentration (tmax,ss) of selexipag at steady state|Time to the maximum observed plasma concentration (tmax,ss) of ACT-333679 at steady state|Trough concentration of selexipag at steady state (Ctrough,ss)|Trough concentration of ACT-333679 at steady state (Ctrough,ss)|Treatment-emergent adverse events (TEAEs)|Change from baseline in Tanner stage up to end of treatment (EOT + 3 days)|Change from baseline over time in body mass index (BMI) up to end of treatment (EOT + 3 days)|Change from baseline in thyroid stimulating hormone (TSH) up to end of treatment (EOT + 3 days)","Actelion","All","2 Years to 18 Years   (Child, Adult)","Phase 2","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-065A203|2018-000145-39","July 23, 2018","February 11, 2026","May 31, 2026","April 10, 2018",,"April 24, 2020","Children'S Hospital Cardiac Care Center University Of Colorado, Aurora, Colorado, United States|University of Iowa Hospital, Iowa City, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seattle Children's Hospital, Seattle, Washington, United States|State Institution Republican Scientific And Practical Center For Pediatric Surgery, Minsk, Belarus|Health Institution 4Th City Children'S Clinical Hospital, Minsk, Belarus|Centre Hospitalier Sainte Justine, Montreal, Quebec, Canada|Stollery Children's Hospital, Edmonton, Canada|Beijing Anzhen Hospital, Beijing, China|Cardiovascular institute & Fuwai Hospital- Thrombus Center, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, China|Shanghai Children's Medical Center, Shanghai, China|Wuhan Asia Heart Hospital, Wuhan, China|CHU Arnaud de Villeneuve, Montpellier Cedex 5, France|Hôpital Necker - Enfants Malades, Paris, France|Chu Hopital Des Enfants, Toulouse Cedex 9, France|Universitätsklinikum Freiburg Zentrum, Freiburg, Germany|Justus-Liebig-Universität Gießen, Kinderherzzentrum, Giessen, Germany|Universitäres Herzzentrum Hamburg, Hamburg, Germany|Universitätsklinikum Münster, Münster, Germany|Gottsegen György Országos Kardiológiai Intézet, Felnőtt kardiológiai osztály, Budapest, Hungary|Schneider Children's Medical Center, Petach Tikvah, Israel|Sheba Medical Center, Ramat Gan, Israel|Sarawak General Hospital, Kota Samarahan, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Kraków, Poland|Szpital Kliniczny im. Karola Jonschera, Poznan, Poland|Wojewódzki Szpital Specjalistyczny We Wrocławiu, Wrocław, Poland|Kazan State Medical University, Kazan, Russian Federation|Federal State Budget Scientific Institution, Kemerovo, Russian Federation|Moscow Scientific Research Institute For Pediatrics And Childrens Surgery Of Rosmedtechnologies, Moscow, Russian Federation|Samara Regional Clinical Cardiological Dispensary, Samara, Russian Federation|Federal State Budgetary Institution, St Petersburg, Russian Federation|Univerzitetska Dečja Klinika, Belgrade, Serbia|Institut Za Zdravstvenu Zaštitu Majke I Deteta Srbije ''Dr Vukan Čupić'', Belgrade, Serbia|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Municipal Enterprise Of The Dnipropetrovsk Regional Council, Dnipro, Ukraine|State Institution Of The Ministry Of Health Of Ukraine, Kiev, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Municipal Institution Of The Zaporizhzhya Regional Council, Zaporizhzhya, Ukraine|Great Ormond Street Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03492177"
1070,"NCT02791906","Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease",,"Terminated","No Results Available","Renal Insufficiency, Chronic","Drug: ISMN|Dietary Supplement: Vitamin C","Change in LV mass|Changes in Diffuse Myocardial Fibrosis|Changes in myocardial systolic and diastolic function|Pulse Wave Reflection Magnitude|Aerobic Capacity|Vasodilatory Reserve to Exercise|Physical Activity","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","823665","May 2016","March 2019","March 2019","June 7, 2016",,"July 29, 2019","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT02791906"
1071,"NCT01630213","Impact of Vitamin D Supplementation on Cardiac Structure and Function","VITAL-Echo","Active, not recruiting","No Results Available","Cardiovascular Disease","Dietary Supplement: Vitamin D3 + fish oil/fish oil placebo|Dietary Supplement: Vitamin D3 placebo + fish oil/fish oil placebo","Change in left ventricular (LV) mass|Change in LV systolic/diastolic function|Change in LV mass","Massachusetts General Hospital|Brigham and Women's Hospital","All","50 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2009P-001217","July 2010","October 2020","December 2020","June 28, 2012",,"March 22, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01630213"
1072,"NCT03623256","Comparison of Intrathecal Versus Epidural Fentanyl on Fetal Bradycardia in Labor Combined Spinal Epidural Analgesia",,"Recruiting","No Results Available","Labor Pain|Obstetric Pain","Drug: Spinal fentanyl|Drug: Spinal bupivacaine|Drug: Spinal Fentanyl and Bupivacaine|Drug: Epidural fentanyl /spinal bupivacaine","Fetal heart rate|Blood pressure|Dermatomal level|Maternal Pain level: visual analogue scale|Patient satisfaction level: Likert Scale|Uterine tone","Augusta University","Female","18 Years and older   (Adult, Older Adult)","Phase 4","558","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","1238162","October 28, 2019","October 1, 2023","October 31, 2023","August 9, 2018",,"March 25, 2020","Augusta University, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03623256"
1073,"NCT03261570","Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS",,"Recruiting","No Results Available","Postural Orthostatic Tachycardia Syndrome (POTS)|POTS|Orthostatic Intolerance","Drug: Pyridostigmine|Drug: Digoxin|Drug: Placebo","Cardiovagal Baroreflex during orthostatic stress|Cognitive ability during orthostatic stress|Cardiac output measure by inert gas breathing technique|Arterial blood pressure, and mean arterial pressure defined by the time average blood pressure over the cardiac cycle|Heart rate|systemic vascular resistance defined by the ratio of mean arterial pressure to cardiac output","New York Medical College|National Institutes of Health (NIH)","Female","15 Years to 30 Years   (Child, Adult)","Early Phase 1","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","1R01HL134674-01A1","July 1, 2017","June 30, 2021","September 1, 2021","August 25, 2017",,"January 14, 2020","New York Medical College/Bradhurst building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT03261570"
1074,"NCT02315898","Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis","PLATyPuS","Suspended","No Results Available","Plastic Bronchitis|Protein-Losing Enteropathies|Healthy","Drug: Treatment-inhaled tPA","Primary Endpoint: Number of subjects that develop new, active bleeding|Arterial oxygen saturation|Forced expiratory volume in one second (FEV1)|Forced expiratory flow 25-75% (FEF25-75)|Forced vital capacity (FVC)|Frequency of production/expectoration and size of airway casts|Changes in the chest x-ray (CXR)|Requirement for urgent or emergent bronchoscopy|Requirement for mechanical ventilation|Fibrin and mucin content of airway casts|Detection of fibrin degradation product (FDP) in the systemic circulation|Assessment of patient centered outcomes","University of Michigan|Genentech, Inc.","All","5 Years to 24 Years   (Child, Adult)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMich Inhaled tPA119678|R01FD005393","March 19, 2018","August 2021","December 2021","December 12, 2014",,"March 23, 2020","Lucile Packard Children's Hospital, Stanford University, Palo Alto, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Michigan Mott Children's Hospital, Ann Arbor, Michigan, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Medical University of South Caroline, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02315898"
1075,"NCT03333824","Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer",,"Completed","No Results Available","Solid Tumours","Drug: CYP1A2 (caffeine)|Drug: CYP2C19 (omeprazole)|Drug: CYP3A (midazolam)|Drug: Kytril (granisetron)|Drug: Wee-1 kinase inhibitor AZD1775","Part A: Area under the plasma concentration-time curve from zero to infinity for cocktail parent compounds (midazolam, omeprazole and caffeine)|Part A: Area under the plasma concentration-time curve from time zero to the time ""t"" of the last quantifiable concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Part A: maximum plasma drug concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Part B: dECG intervals (QTcF) for absolute values and time-matched change from baseline|Time to reach maximum plasma concentration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Terminal half-life for cocktail parent compounds (midazolam, omeprazole and caffeine)|Elimination rate constant for cocktail parent compounds (midazolam, omeprazole and caffeine)|Apparent clearance following oral administration for cocktail parent compounds (midazolam, omeprazole and caffeine)|Apparent volume of distribution for cocktail parent compounds (midazolam, omeprazole and caffeine)|Area under the plasma concentration-time curve from zero to infinity for cocktail metabolites|Area under the plasma concentration-time curve from time zero to the time ""t"" of the last quantifiable concentration for cocktail metabolites|Time to reach maximum plasma concentration for cocktail metabolites|Maximum plasma drug concentration for cocktail metabolites|Terminal half-life for cocktail metabolites|Elimination rate constant for cocktail metabolites|Day 1, Part B Only: Area under the plasma concentration-time curve from time zero to 12 hours for AZD1775|Day 1, Part B only: Time to reach maximum plasma concentration for AZD1775|Day 1, Part B only: Maximum plasma drug concentration for AZD1775|Day 3, Parts A & B: Area under the plasma concentration-time curve from time zero to 12 hours for AZD1775|Day 3, Parts A & B: Time to reach maximum plasma concentration for AZD1775|Day 3, Parts A & B: Maximum plasma drug concentration for AZD1775|Day 3, Parts A & B: Minimum plasma drug concentration for AZD1775|Day 3, Parts A & B: Average concentration over a dosing interval for AZD1775|Day 3, Parts A & B: Apparent clearance at steady state for AZD1775|Day 3, Parts A & B: Fluctuation index (FI) over a dosing interval for AZD1775|Part B only: Accumulation ratio for area under the plasma concentration-time curve from time zero to twelve hours for AZD1775|Part B only: Accumulation ratio for maximum plasma drug concentration for AZD1775|dECG intervals (heart rate, RR, PR, QRS, QTcB, QTcF and QT) for absolute values and time-matched change from baseline|Changes in dECG morphology|Area under the plasma concentration-time curve from time zero to infinity ratios in relation to parent compound|Maximum plasma drug concentration ratios in relation to parent compound","AstraZeneca|Quintiles, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6014C00006","December 1, 2017","January 22, 2019","January 22, 2019","November 7, 2017",,"March 25, 2019","Research Site, Bingham Farms, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Providence, Rhode Island, United States|Research Site, Greenville, South Carolina, United States|Research Site, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03333824"
1076,"NCT01210430","Local Vasoconstriction in Postural Tachycardia Syndrome",,"Completed","No Results Available","Postural Tachycardia Syndrome","Drug: Losartan|Drug: Ascorbic Acid (Vitamin C)|Drug: Normal Saline","Orthostatic tolerance measured by the heart rate and blood pressure response to upright tilt|Sympathetic activation and blood flow measured by sympathetic nerve recordings and Doppler blood flow in the leg","New York Medical College","All","14 Years to 29 Years   (Child, Adult)","Early Phase 1","74","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","2R01HL074873-06A2","July 2010","June 2015","June 2015","September 28, 2010",,"January 14, 2020","New York Medical College/Bradhurst building, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT01210430"
1077,"NCT03098797","A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome","TAZPOWER","Active, not recruiting","No Results Available","Barth Syndrome","Drug: Elamipretide","Change in distance walked during the 6-minute walk test (6MWT)|Change in muscle strength as measured by handheld dynamometry|Change in five times sit-to-stand test|Change in 2-D and 3-D echocardiographic measurements|Change in accelerometry counts|Change in SWAY application balance assessments|Change in Patient Reported Outcomes|Change in Clinician Global Impression|Change in biomarkers|Number of participants with treatment related adverse events","Stealth BioTherapeutics Inc.","Male","12 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SPIBA-201","May 1, 2017","April 2021","June 2021","April 4, 2017",,"April 14, 2020","McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03098797"
1078,"NCT01963728","Comparison of Insulin Therapy in Treating Post-Transplant Diabetes",,"Terminated","No Results Available","Diabetes Mellitus","Drug: Insulin, Isophane|Drug: insulin glargine","change in Hemoglobin A1C (glycosylated hemoglobin)|change in hemoglobin A1C (glycosylated hemoglobin)|Mean blood glucose values|weight change|incidence of hypoglycemic episodes per subject","Inova Health Care Services","All","18 Years and older   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Inova NODAT-001","May 2014","March 2015","March 2015","October 16, 2013",,"March 24, 2015","Inova Fairfax Hospital, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01963728"
1079,"NCT03762096","Short Interval Resveratrol Trial in Cardiovascular Surgery","SIRT-CVS","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Coronary Artery Disease","Dietary Supplement: Trans-resveratrol|Dietary Supplement: Placebo","Change in endothelial function|Effects of resveratrol on caveolar function|Effects of resveratrol on molecular signaling","Maine Medical Center|American Heart Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","1095584","March 6, 2018","December 31, 2020","December 31, 2021","December 3, 2018",,"April 7, 2020","Maine Medical Center, Portland, Maine, United States",,"https://ClinicalTrials.gov/show/NCT03762096"
1080,"NCT03044964","Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)","REPTAR","Unknown status","No Results Available","Angina","Drug: Ranolazine|Drug: Placebo","Within-patient comparison of accelerometer-assessed physical activity utilizing the Actigraph accelerpmeter from baseline to end of study between Ranolazine and placebo.","Amit Malhotra, MD|Gilead Sciences|Stern Cardiovascular Foundation, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","REPTAR","January 10, 2017","October 2017","October 2017","February 7, 2017",,"February 7, 2017","Stern Cardiovascular Foundation, Inc, Southaven, Mississippi, United States",,"https://ClinicalTrials.gov/show/NCT03044964"
1081,"NCT01950299","Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)","VCU-ART3","Completed","Has Results","Acute Myocardial Infarction","Drug: Anakinra 100 mg|Drug: Placebo","Acute Phase Response (CRP Levels)|Left Ventricular End-systolic Volume|Left Ventricular Ejection Fraction|Heart Failure","Virginia Commonwealth University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","99","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20000024|1R34HL121402-01","July 1, 2014","December 23, 2018","December 23, 2018","September 25, 2013","December 18, 2019","December 18, 2019","Washington Hospital Center, Washington, District of Columbia, United States|Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT01950299/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01950299"
1082,"NCT01674647","Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","X-VERT","Completed","Has Results","Atrial Fibrillation","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Vitamin K antagonist (VKA)","Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death|Number of Participants With Major Bleedings as Per Central Adjudication|Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms|Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality|Number of Participants With Strokes|Number of Participants With Transient Ischemic Attacks|Number of Participants With Non-central Nervous System Systemic Embolisms|Number of Participants With Myocardial Infarctions|Number of Participants With Cardiovascular Deaths|Number of Participants With All-cause Mortality|Number of Participants With Composite of Major and Non-major Bleeding Events","Bayer|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","1504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","15693|2011-002234-39","October 2012","January 2014","January 2014","August 29, 2012","February 3, 2015","April 30, 2015","Mobile, Alabama, United States|Scottsdale, Arizona, United States|East Palo Alto, California, United States|El Cajon, California, United States|National City, California, United States|Sacramento, California, United States|Santa Rosa, California, United States|Torrance, California, United States|New Haven, Connecticut, United States|Stamford, Connecticut, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Deltona, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Augustine, Florida, United States|Tallahassee, Florida, United States|Savannah, Georgia, United States|Aurora, Illinois, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Elk Grove Village, Illinois, United States|Joliet, Illinois, United States|Rockford, Illinois, United States|Annapolis, Maryland, United States|Columbia, Maryland, United States|Rockville, Maryland, United States|Lincoln, Nebraska, United States|North Las Vegas, Nevada, United States|Bridgewater, New Jersey, United States|Manalapan, New Jersey, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|New York, New York, United States|New York, New York, United States|Troy, New York, United States|Asheville, North Carolina, United States|Cantan, Ohio, United States|Cleveland, Ohio, United States|Mansfield, Ohio, United States|Toledo, Ohio, United States|Beaver, Pennsylvania, United States|Butler, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Rapid City, South Dakota, United States|Johnson City, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Tyler, Texas, United States|Layton, Utah, United States|Bellingham, Washington, United States|Burien, Washington, United States|Wausau, Wisconsin, United States|Leuven, Vlaams Brabant, Belgium|Bruxelles - Brussel, Belgium|Gilly, Belgium|Hasselt, Belgium|Liege, Belgium|MOL, Belgium|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Campinas, Sao Paulo, Brazil|Campinas, Sao Paulo, Brazil|Sao Paulo, Brazil|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Saint John, New Brunswick, Canada|St. John's, Newfoundland and Labrador, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec, Canada|Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Nanchang, Jiangxi, China|Changchun, Jilin, China|Xi'an, Shaanxi, China|Urumqi, Xinjiang, China|Beijing, China|Shanghai, China|Shenyang, China|Hellerup, Denmark|Herning, Denmark|København NV, Denmark|Viborg, Denmark|Helsinki, Finland|Jyväskylä, Finland|Lappeenranta, Finland|Oulu, Finland|Pori, Finland|Rovaniemi, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Arras, France|Lille Cedex, France|Paris cedex 13, France|Paris, France|Paris, France|Pessac, France|TOULOUSE cedex, France|Tours, France|Vandoeuvre-les-nancy, France|Freiburg, Baden-Württemberg, Germany|Nürnberg, Bayern, Germany|Frankfurt, Hessen, Germany|Bad Oeynhausen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Hamburg, Germany|Alexandroupolis, Greece|Attica / Athens, Greece|Heraklion, Greece|Thessaloniki, Greece|Acquaviva delle Fonti, Bari, Italy|San Fermo della Battaglia, Como, Italy|San Donato Milanese, Milano, Italy|Mestre, Venezia, Italy|Ancona, Italy|Catania, Italy|Roma, Italy|Torino, Italy|Arnhem, Netherlands|Haarlem, Netherlands|Heerlen, Netherlands|Leeuwarden, Netherlands|Maastricht, Netherlands|Martinho do Bispo, Coimbra, Portugal|Carnaxide, Lisboa, Portugal|Almada, Portugal|Faro, Portugal|Lisboa, Portugal|Vila Nova de Gaia, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Alberton, Gauteng, South Africa|Soweto, Gauteng, South Africa|Cape Town, Western Cape, South Africa|Cape Town, Western Cape, South Africa|Kuils River, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Worcester, Western Cape, South Africa|Bloemfontein, South Africa|Sabadell, Barcelona, Spain|Majadahonda, Madrid, Spain|Barcelona, Spain|Granada, Spain|Madrid, Spain|Pamplona, Spain|Chesterfield, Derbyshire, United Kingdom|Bournemouth, Dorset, United Kingdom|Welwyn Garden City, Hertfordshire, United Kingdom|Leicester, Leicestershire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Cliftonville, United Kingdom|London, United Kingdom|Portsmouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01674647"
1083,"NCT02454283","Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm","RESTORE SR","Terminated","Has Results","Atrial Fibrillation or Flutter","Drug: Vanoxerine HCl|Drug: Placebo","Conversion to Sinus Rhythm|Length of Stay (From Time of Study Drug Administration)","Laguna Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LGN-VN-003","September 2015","November 2015","November 2015","May 27, 2015","October 17, 2016","October 17, 2016","Littleton, Colorado, United States|Washington, District of Columbia, United States|Iowa City, Iowa, United States|Saint Louis, Missouri, United States|Plovdiv, Bulgaria|Sofia, Bulgaria|Budapest, Hungary|Hodmezovasarhely, Hungary|Pecs, Hungary|Rokus, Hungary|Zalaegerszeg, Hungary|Ashkelon, Israel|Safed, Israel|Moscow, Russian Federation|Saint Petersburg, Russian Federation|Vladimir, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02454283"
1084,"NCT03043274","Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size",,"Terminated","No Results Available","STEMI - ST Elevation Myocardial Infarction","Drug: Cangrelor","Change in Myocardial Infarction Size|Platelet reactivity|Peripheral blood count quantification|Interleukin-1β|Interleukin-6|Interleukin-10|Tumor Necrosis factor-α|In-hospital mortality|30-Day mortality|Major bleeding|Composite outcome: Incidence of a composite of in-hospital mortality, 30-day mortality, major bleeding, and access complications will be reported.","Khaled Ziada, MD|University of Kentucky","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","16-0990-F6A","January 2017","May 2019","May 2019","February 6, 2017",,"March 9, 2020","University of Kentucky, Lexington, Kentucky, United States",,"https://ClinicalTrials.gov/show/NCT03043274"
1085,"NCT02102802","Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD",,"Completed","No Results Available","Posttraumatic Stress Disorder","Drug: Low or Medium dose MDMA|Drug: Full dose MDMA","Change in brain activity measured via fMRI while listening to trauma scripts|Change in heart rate variability in response to trauma script|Change in Self Compassion Scale Score","Multidisciplinary Association for Psychedelic Studies","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","MP8-S1","January 2014","September 2016","April 2017","April 3, 2014",,"June 6, 2017","Offices of Michael Mithoefer, Mount Pleasant, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02102802"
1086,"NCT03683186","A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension",,"Enrolling by invitation","No Results Available","PAH|Pulmonary Hypertension|Pulmonary Arterial Hypertension|Hypertension|Connective Tissue Diseases|Familial Primary Pulmonary Hypertension|Vascular Diseases|Cardiovascular Diseases|Hypertension, Pulmonary|Lung Diseases|Respiratory Tract Disease","Drug: Ralinepag","Number of subjects with treatment-emergent adverse events [Safety and Tolerability]","United Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ROR-PH-303|APD811-303","September 23, 2019","September 2024","September 2024","September 25, 2018",,"May 1, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Central Florida Pulmonary Group, Orlando, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Vincent Medical Group, Inc., Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Chest Medicine Associates, South Portland, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|Winthrop Hospital, Mineola, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati-Medical Science Building, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The Oregon Clinic, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NewSTAT, PLLC, Knoxville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|Hospital Italiano, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Sanatorio Parque S.A., Rosario, Santa Fe, Argentina|Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Fundacion Favaloro, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba S.A, Cordoba, Argentina|Instituto de Cardiologia de Corrientes, Corrientes, Argentina|Hospital Italiano de Cordoba, Córdoba, Argentina|Instituto de Investigaciones Clinicas, Mar Del Plata, Argentina|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Macquarie University, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|Cliniques Universitaires de Bruxelles Hopital Erasme, Bruxelles, Belgium|UZ Leuven, UZ Leuven Campus Gasthuisberg, Herestraat 49, Leuven, Belgium|Instituto das Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, MG, Brazil|Hospital Sao Lucas da PUC-RS, Porto Alegre, R.S, Brazil|MHAT - ""National Heart Hospital"" EAD, 65, Konyovitza Str., Sofia, Bulgaria|Peter Lougheed Centre, Calgary, Alberta, Canada|LHSC - Victoria Hospital, London, Ontario, Canada|SMBD Jewish General Hospital d/b/a Jewish General Hospital, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec, Quebec, Canada|Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China|Clinical Hospital Dubrava Zagreb, Avenija G.Šuška 6, Zagreb, Croatia|University Clinic for Pulmonary Diseases, Jordanovac 104, Zagreb, Croatia|Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark|Århus Universitetshospital, Århus, Denmark|CHU de Strasbourg - Nouvel Hôpital Civil, Ctre de competence Hypertension Arterielle Pulmona, 1 place de l Hopital, Strasbourg, Bas Rhin, France|CHU de Grenoble - Hôpital Albert Michallon, Clinique de Cardiologie, Boulevrad de la Chantourne, Grenoble, Isere, France|CHU de Saint-Etienne - Hopital Nord, Service de Medecine vasculaire et therapeutique, 81 Avenue A. Raimond, Saint-Étienne, Loire, France|CHU Nancy - Hôpital de Brabois Adultes, Pneumologie- Oncologie Médicale, Rue du Morvan, Vandoeuvre les Nancy, Meurthe Et Moselle, France|CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Pradel, Service de Pneumologie, 59 Boulevard Pinel, Bron cedex, Rhone, France|Groupement Hospitalier Sud - Hôpital Bicêtre, Service de Pneumologie, 78 Avenue du General Leclerc, Le Kremlin-Bicêtre, Val De Marne, France|University General Hospital Attikon, 1 Rimini Street, Chaidari, Athens, Greece|University General Hospital of Alexandroupolis, Alexandroupolis, Greece|""Onasseio"" Cardiosurgery Hospital, Hemodynamic Research and Interventional Cardiology Dept., 356, Syggrou Avenue, Athens, Greece|AHEPA General Hospital of Thessaloniki, A' Cardiology Clinic, 1 St. Kyriakidi Street, Thessaloniki, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia, S.C. di Cardiologia, Viale Luigi Pinto, 1, Foggia, Italy|Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Gachon University Hospital Gil Medical Center, Incheon, Namdong-gu, Korea, Republic of|Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddział Kliniczny Chorób Serca i Naczyń z Pododdziałem Intensywnego Nadzoru Kardiologicznego, Pradnicka 80, Krakow, Poland|NZOZ Europejskie Centrum Zdrowia, ul. Borowa 14/18, Otwock, Poland|Premium Clinic Wrocław CM, Podwale 83/17, Wroclaw, Poland|Institutul de Urgenta pentru Boli Cardiovasculare ""Prof. Dr. C.C. Iliescu"", Sos. Fundeni nr. 258, Bucharest, Romania|Institutul de Pneumoftiziologie ""Marius Nasta"", Sos. Viilor nr. 90, Sector 5, Bucuresti, Romania|Institutul Inimii ""Niculae Stancioiu"" Cluj-Napoca, Cardiologie, Str. Motilor nr. 19-21, Cluj-Napoca, Romania|Spitalul Clinic de Boli Infectioase si Pneumoftiziologie ""Dr. Victor Babes"" Timisoara, Str. Gheorghe Adam nr. 13, Timisoara, Romania|Hospital Universitari Vall d'Hebron, Respiratory Dept., Passeig Vall d'Hebron,119-129, Neumologia, Barcelona, Spain|Hospital Clinic de Barcelona, C/ Villarroel, 170, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|CE Dniprop RCC&C Center of Dniprop RC Dept of Card SI DMA of MOHU, Chair of Internal Medicine 3, 28, Knyazya Volodymyra Velykogo St., Dnipro, Ukraine|SI F.H.Yanovskyi National Institute of Phthisiology and Pulmonology of NAMSU, Clinical and Functional Dept, 10, Amosova St., Kyiv, Ukraine|Communal Noncommercial Enterprise of Lviv Regional Council Lviv Clinical Hospital, Dept of Cardiology, D.Halytskyi Lviv NMU, Ch of Internal Medicine #1, 7, Chernihivska str., Lviv, Ukraine|Golden Jubilee National Hospital, Glasgow, West Dunbartonshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03683186"
1087,"NCT02052011","Ranolazine and Microvascular Angina by PET in the Emergency Department","RAMP-ED","Completed","Has Results","Microvascular Angina","Drug: Ranolazine|Drug: Placebo","Coronary Flow Reserve","Yale University|Gilead Sciences","All","30 Years and older   (Adult, Older Adult)","Phase 4","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1312013144","April 2014","November 2015","November 2015","January 31, 2014","May 16, 2017","May 16, 2017","Yale New Haven Hospital, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT02052011"
1088,"NCT02938949","Alirocumab in Patients With Acute Myocardial Infarction",,"Completed","Has Results","Myocardial Infarction|Hypercholesterolemia","Drug: alirocumab|Drug: placebo","Changes in Low-density Lipoprotein (LDL) Cholesterol|Change in Inflammatory Markers (hsCRP)","Virginia Commonwealth University|Regeneron Pharmaceuticals|Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HM20008008","January 2017","August 2018","August 16, 2018","October 19, 2016","September 6, 2019","September 6, 2019","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02938949/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02938949"
1089,"NCT02419937","Short-Term Application of Tocilizumab Following Myocardial Infarction","STAT-MI","Completed","Has Results","Myocardial Infarction","Drug: Tocilizumab|Drug: Placebo","Number of Participants With Major Adverse Cardiovascular Events (MACE)","Keesler Air Force Base Medical Center","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","28","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FKE20140029H","May 2015","August 2017","August 2017","April 17, 2015","November 17, 2017","November 17, 2017","Keesler Medical Center, Keesler Air Force Base, Mississippi, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02419937/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02419937/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02419937"
1090,"NCT03310125","Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)","COP-AF","Recruiting","No Results Available","Atrial Fibrillation|Atrial Flutter|Thoracic Surgery","Drug: Colchicine|Drug: Placebo","Clinically important atrial fibrillation|First occurrence of the composite of all-cause mortality, nonfatal myocardial infarction, or nonfatal stroke|Duration of stay in ICU, step-down, and in-hospital|All-cause mortality|Myocardial infarction|Myocardial injury after noncardiac surgery (MINS)|Time to chest tube removal","McMaster University|Hamilton Health Sciences Corporation|Population Health Research Institute","All","55 Years and older   (Adult, Older Adult)","Phase 3","2800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2017-001-COPAF","February 14, 2018","January 2022","June 2022","October 16, 2017",,"March 16, 2020","Cleveland Clinic Florida, Weston, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|MD Anderson Cancer Center, Houston, Texas, United States|Foothills Medical Centre, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, Canada|St. Joseph Healthcare, St. Joseph Hospital, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Prince of Wales Hospital, Hong-Kong, China|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03310125"
1091,"NCT01126697","Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies",,"Completed","No Results Available","Duchenne Muscular Dystrophy|Becker Muscular Dystrophy|Limb Girdle Muscular Dystrophy","Drug: Coenzyme Q10 and Lisinopril","myocardial performance index (MPI)","Cooperative International Neuromuscular Research Group|United States Department of Defense","All","8 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","63","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PITT0908","February 2010","December 2017","December 2017","May 20, 2010",,"June 15, 2018","Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Tennessee, Memphis, Tennessee, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|National Center of Neurology and Psychiatry, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01126697"
1092,"NCT04045665","Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","PACES","Recruiting","No Results Available","Atrial Fibrillation|Stroke|Bleeding","Drug: Antiplatelet-only strategy|Drug: Oral Anticoagulant plus background antiplatelet therapy","Composite of death, stroke, TIA, MI, systemic arterial thromboembolism or venous thromboembolism (DVT and/or PE)|Any BARC type 3 or 5|Net clinical benefit (NCB)|Number of participants with Stroke event|Number of participants with TIA event|Number of participants with MI event|Number of participants with systematic arterial thromboembolism event|Number of participants with venous thromboembolism event|Number of cardiovascular mortalities|Number of non-cardiovascular mortalities|The incidence of BARC 2 bleeding at 90 days after randomization|Number of cardiac arrhythmias","Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","3200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 08-1078|2U01HL088942-12","December 13, 2019","December 2022","December 1, 2023","August 5, 2019",,"February 20, 2020","CHI St. Vincent, Arkansas, Little Rock, Arkansas, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Western Connecticut Hospital Systems, Danbury, Connecticut, United States|Yale New Haven, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Lutheran Medical Center, Fort Wayne, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|University of Maryland, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mid America Health Institute, Kansas City, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Northwell Health System, Great Neck, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|WakeMed, Raleigh, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Hermitage, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor Research Institute, Plano, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Health, Falls Church, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada|Hôpital Laval, Quebec, Canada|University Heart Center Hamburg, Berlin, Brandenburg, Germany|Heart Center Leipzig, Berlin, Brandenburg, Germany|University Medical Center Göttingen, Göttingen, Lower Saxony, Germany|University Medical Center Jena, Jena, Thuringia, Germany|Clinic Bad Neustadt - Medical Center for Heart and Vascular Diseases, Bad Neustadt An Der Saale, Germany|HDZ-NRW Bad Oeynhausen, Bad Oeynhausen, Germany|Charité Berlin - Benjamin Franklin Campus, Berlin, Germany|Charité Berlin - Rudolf Virchow Campus, Berlin, Germany|German Heart Center Berlin, Berlin, Germany|Medical Center Braunschweig, Braunschweig, Germany|University Medical Center Frankfurt, Frankfurt, Germany|Heart Center, University of Freiburg, Freiburg, Germany|University Medical Center Heidelberg, Heidelberg, Germany|University Medical Center Schleswig-Holstein Kiel, Kiel, Germany|University Medical Center Schleswig-Holstein Lübeck, Lübeck, Germany|German Heart Center Munich, Munich, Germany|Medical Center of the Ludwig-Maximilians-University Munich, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT04045665"
1093,"NCT01052272","Impact of Diabetes on Left Ventricular Remodeling","P3","Completed","Has Results","Diabetes","Drug: Ramipril|Drug: Candesartan cilexetil|Drug: Allopurinol","Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA)|Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness)|Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV)|Left Ventricular Ejection Fraction (LVEF)|Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA)|LV End Systolic Maximum Shortening (LVES Max Shortening)|Peak Early Filling Rate Normalized to EDV","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","72","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F040105007","July 2005","November 2010","November 2010","January 20, 2010","December 17, 2012","December 17, 2012","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01052272"
1094,"NCT01360476","Vitamin D Therapy to Reduce Cardiac Damage Among Vulnerable Hypertensive Patients","AdDReaCH","Completed","No Results Available","Hypertension|Left Ventricular Hypertrophy","Dietary Supplement: cholecalciferol (Vitamin D)|Dietary Supplement: Placebo","Change from Baseline in left ventricular hypertrophy at 1 year","Wayne State University|National Institute on Minority Health and Health Disparities (NIMHD)","All","30 Years to 74 Years   (Adult, Older Adult)","Not Applicable","354","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1R01MD005849-01A1","August 2011","November 2015","November 2015","May 25, 2011",,"December 9, 2015","Detroit Receiving Hospital, Detroit, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01360476"
1095,"NCT02348723","Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)",,"Completed","Has Results","Atrial Fibrillation","Drug: Warfarin|Drug: Dabigatran Etexilate 150mg","Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH)|Incidence of the Composite of Stroke, Systemic Embolism, or Transient Ischemic Attack (TIA)|Incidence of Minor Bleeding Events|Incidence of ISTH MBE, Stroke, Systemic Embolism, or TIA (Composite Endpoint Combining Safety and Efficacy","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 4","678","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1160.204|2014-003890-40","April 28, 2015","November 11, 2016","November 14, 2016","January 28, 2015","November 14, 2017","January 29, 2018","Arkansas Cardiology, PA, Little Rock, Arkansas, United States|Mission Cardiovascular Research Institute, Fremont, California, United States|University of California, Sacramento, California, United States|Mercy Medical Group, a service of Dignity Health Medical Foundation, Sacramento, California, United States|University of California, San Francisco, California, United States|Southwest Florida Research, LLC, Naples, Florida, United States|University of South Florida, Tampa, Florida, United States|Elkhart General Healthcare System, Elkhart, Indiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|St. Louis Heart and Vascular, P.C., Saint Louis, Missouri, United States|New York Methodist Hospital, Brooklyn, New York, United States|University at Buffalo, The State University of New York, Buffalo, New York, United States|Staten Island University Hospital, Staten Island, New York, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Tennessee Methodist Physicians, Memphis, Tennessee, United States|North Texas Heart Center, Dallas, Texas, United States|St Luke's Health Baylor College of Medicine Med Center, Houston, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Providence Regional Medical Center, Everett, Washington, United States|Bonheiden - HOSP Imelda, Bonheiden, Belgium|Brussels - UNIV UZ Brussel, Brussel, Belgium|UNIV UZ Gent, Gent, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Antwerpen - HOSP ZNA Middelheim - Pneumo, Middelheim, Belgium|Brussels - HOSP Europe (Ste-Elisabeth), Ukkel, Belgium|Royal Alexandra Hospital, Edmonton, Alberta, Canada|Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|IUCPQ (Laval University), Quebec, Canada|HOP Nord Michallon, La Tronche, France|HOP Timone, Marseille, France|CLI Nouvelles Cliniques Nantaises,Cardio,Nantes Cedex 2, Nantes, France|HOP Salpêtrière, Cardio, Paris, Paris cedex 13, France|HOP Européen G. Pompidou, Paris, France|HOP Haut-Lévêque, Pessac, France|HOP CHU Nancy Brabois, Cardiologie, Vandoeuvre les Nancy, France|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Universitätsklinikum Ulm, Ulm, Germany|Ospedale Generale Regionale ""Miulli"", Acquaviva Delle Fonti (BA), Italy|A.S.O.S. Croce e Carle, Cuneo, Italy|Osp.dell'Angelo, Mestre-Venezia, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Centro Cardiologico Monzino-IRCCS, Milano, Italy|Policlinico Casilino U.O. Cardiologia, Roma, Italy|Anjo-kosei Hospital, Aichi, Anjo, Japan|Nagoya City East Medical Center, Aichi, Nagoya, Japan|Nagoya University Hospital, Aichi, Nagoya, Japan|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Hirosaki University Hospital, Aomori, Hirosaki, Japan|New Tokyo Heart Clinic, Chiba, Matsudo, Japan|Shonan Kamakura General Hospital, Kanagawa, Kamakura, Japan|Sakurabashi Watanabe Hospital, Osaka, Osaka, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-Ku, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji, Japan|VU Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Heart&Vessels Diseases,Cardiol&Cardiovas.SurgeryDep,Kamerovo, Kemerovo, Russian Federation|Instit.of Surgery na Vishnevskiy,Treatm.of comp.arrhythm.dep, Moscow, Russian Federation|City Pokrovskiy Hospital, Cardiology Dept., Saint Petersburg, Saint Petersburg, Russian Federation|North-Westrn Fed.med.res.cntr,Almazov Interven.arrhythmo.dep, St. Petersburg, Russian Federation|Tyumen Cardiology Center, Dept.of Cardiac Arrhythmia, Tyumen, Russian Federation|Yaroslavl Regional Clin. Hospital, Dept. Endocrinology, Yaroslavl, Russian Federation|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Álvaro Cunqueiro, Vigo (Pontevedra), Spain|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Papworth Hospital, Cambridge, United Kingdom|Golden Jubilee National Hospital, Clydebank, Clydebank, United Kingdom|Castle Hill Hopsital, Cottingham, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02348723"
1096,"NCT01483183","Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation","CADENCE 215","Terminated","Has Results","Atrial Fibrillation|Paroxysmal Atrial Fibrillation|Persistent Atrial Fibrillation","Drug: OPC-108459|Drug: Placebo","Part 1: Maximum (Peak) Plasma Concentration (Cmax)|Part 1: Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUCτ)|Part 1:Maximal Change From Baseline in QT Interval Corrected for Heart Rate Using the Fridericia Formula (QTcF) Within 24 Hour Infusion|Part 1: Maximal Change From Baseline in Ventricular Rate Within 24 Hour Infusion|Part 1: Maximal Change From Baseline in Blood Pressure Within 24 Hour Infusion|Part 2/1 Infusion: Cmax|Part 2/2 Infusions: Cmax|Part 2/1 Infusion: AUCt|Part 2/2 Infusions: AUCt|Part 2: QTcF|Part 2: Ventricular Rate|Part 2: Diastolic and Systolic Blood Pressure|Part 2: Percentage of Subjects With Normal Sinus Rhythm (NSR)|Part 1: Percentage of Participants With NSR|Part 2: Time to NSR|Part 2: Duration of NSR","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","269-11-215","November 2011","October 2015","October 2015","December 1, 2011","April 10, 2017","April 10, 2017","Otsuka Investigational Site, Washington, District of Columbia, United States|Otsuka Investigational Site, Hollywood, Florida, United States|Otsuka Investigational Site, Jacksonville, Florida, United States|Otsuka Investigational Site, Sarasota, Florida, United States|Otsuka Investigational Site, Lexington, Kentucky, United States|Otsuka Investigational Site, New Orleans, Louisiana, United States|Otsuka Investigational Site, Johnson City, New York, United States|Otsuka Investigational Site, Germantown, Tennessee, United States|Otsuka Investigational Site, Houston, Texas, United States|Otsuka Investigational Site, Berlin, Germany|Otsuka Investigational Site, Hamburg, Germany|Otsuka Investigational Site, Leipzig, Germany|Otsuka Investigational Site, Pirna, Germany|Otsuka Investigational Site, San Fermo, Como, Italy|Otsuka Investigational Site, Ancona, Italy|Otsuka Investigational Site, Bologna, Italy|Otsuka Investigational Site, Cremona, Italy|Otsuka Investigational Site, Amsterdam, Netherlands|Otsuka Investigational Site, Groningen, Netherlands|Otsuka Investigational Site, Fuenlabrada, Madrid, Spain|Otsuka Investigational Site, Barcelona, Spain|Otsuka Investigational Site, Granada, Spain|Otsuka Investigational Site, Madrid, Spain|Otsuka Investigational Site, Madrid, Spain|Otsuka Investigational Site, Chertsey, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01483183"
1097,"NCT01821781","Immune Disorder HSCT Protocol",,"Recruiting","No Results Available","Immune Deficiency Disorders|Severe Combined Immunodeficiency|Chronic Granulomatous Disease|X-linked Agammaglobulinemia|Wiskott-Aldrich Syndrome|Hyper-IgM|DiGeorge Syndrome|Chediak-Higashi Syndrome|Common Variable Immune Deficiency|Immune Dysregulatory Disorders|Hemophagocytic Lymphohistiocytosis|IPEX|Autoimmune Lymphoproliferative Syndrome|X-linked Lymphoproliferative Syndrome","Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan","Number of participants with donor engraftment|Major Transplant Related Toxicities|Time to neutrophil recovery|Number of patient with acute GVHD|Number of participants with infectious complications|Time to immune reconstitution|Overall survival|Time to platelet recovery|Number of patients with chronic GVHD|Disease free survival","Washington University School of Medicine","All","up to 21 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201301135","March 2013","March 2022","March 2024","April 1, 2013",,"March 26, 2019","Washington University, Saint Louis, Missouri, United States|Methodist Heathcare, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01821781"
1098,"NCT03968445","Neuroinflammation After Myocardial Infarction - Imaging Substudy",,"Recruiting","No Results Available","Myocardial Infarction","Drug: [18F]DPA-714-PET/MRI","TPSO-PET measurement of neuroinflammation after acute myocardial infarction","University of Alabama at Birmingham","All","50 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-300003221 R19-045","July 24, 2019","July 24, 2021","July 24, 2021","May 30, 2019",,"November 15, 2019","University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03968445"
1099,"NCT01586975","Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events",,"Completed","Has Results","Stroke|Myocardial Infarctions","Drug: Clopidogrel|Drug: Aspirin 81 mg|Drug: Aspirin >300 mg","PFA1","Northwestern University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","93","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Aspirin Resistance and Stroke|IRB#0996-007 FUND#7810","July 2007","April 2010","December 2011","April 27, 2012","December 3, 2015","December 31, 2015","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT01586975"
1100,"NCT02966028","Effect of SNF472 on Progression of Cardiovascular Calicification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)",,"Completed","No Results Available","Cardiovascular Diseases|Cardiovascular Abnormalities|Calcifications, Vascular|Endstage Renal Disease|ESRD|Coronary Artery Calcification","Drug: SNF472|Drug: Placebo","Absolute change in coronary artery calcium volume scores","Sanifit Therapeutics S. A.|Clinipace Worldwide","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","274","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNFCT2015-05","November 2016","August 2019","September 2019","November 17, 2016",,"September 25, 2019","Bakersfield, California, United States|Chula Vista, California, United States|Escondido, California, United States|Granada Hills, California, United States|La Palma, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Lynwood, California, United States|Northridge, California, United States|Riverside, California, United States|San Diego, California, United States|San Dimas, California, United States|Simi Valley, California, United States|Tarzana, California, United States|Whittier, California, United States|Arvada, Colorado, United States|Westminster, Colorado, United States|Middlebury, Connecticut, United States|Orange, Connecticut, United States|Hollywood, Florida, United States|Lauderdale Lakes, Florida, United States|Miami Gardens, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Tampa, Florida, United States|Evanston, Illinois, United States|Shreveport, Louisiana, United States|Pontiac, Michigan, United States|Roseville, Michigan, United States|Brookhaven, Mississippi, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|North Brunswick, New Jersey, United States|Bronx, New York, United States|College Point, New York, United States|Asheville, North Carolina, United States|Cincinnati, Ohio, United States|Bethlehem, Pennsylvania, United States|Knoxville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|Richardson, Texas, United States|San Antonio, Texas, United States|Chesapeake, Virginia, United States|Wauwatosa, Wisconsin, United States|Palma de Mallorca, Balearic Islands, Spain|Barcelona, Catalonia, Spain|Palma, Illes Balears, Spain|Palma, Islas Baleares, Spain|Galdakao, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Córdoba, Spain|Lleida, Spain|Lleida, Spain|Lugo, Spain|Madrid, Spain|Navarro, Spain|Oviedo, Spain|Palma, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain|Bradford, United Kingdom|Manchester, United Kingdom|Salford, United Kingdom|Shrewsbury, United Kingdom|Swansea, United Kingdom|Westcliff-on-Sea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02966028"
1101,"NCT02750319","Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery",,"Active, not recruiting","No Results Available","Thoracic Surgery|Atrial Fibrillation in High Risk Patients","Drug: Amiodarone|Drug: N-Acetylcysteine|Drug: Placebo","rate of sustained (lasting >30 seconds) or clinically significant post-operative atrial fibrillation (POAF)","Memorial Sloan Kettering Cancer Center|Washington University School of Medicine|The Cleveland Clinic|Vanderbilt University School of Medicine","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16-307","April 2016","April 2021","April 2021","April 25, 2016",,"March 23, 2020","University of Washington School of Medicine in St. Louis, Saint Louis, Missouri, United States|Memoral Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States|Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre (Consent only), Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau (Consent only), Uniondale, New York, United States",,"https://ClinicalTrials.gov/show/NCT02750319"
1102,"NCT01549977","Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina",,"Terminated","Has Results","Angina","Drug: Febuxostat|Drug: Placebo","Change From Baseline in Exercise Treadmill Testing (ETT) Duration at Week 12|Change From Baseline in Time to Onset of Angina During ETT at Week 12|Change From Baseline in Time to Onset of ≥1 mm ST-segment Depression During ETT at Week 12|Change From Baseline in Maximum ST-segment Depression During ETT at Week 12|Percentage of Participants Stopping ETT Due to Angina at Week 12","Takeda","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMX-67_207|U1111-1125-1278","July 2012","November 2012","November 2012","March 9, 2012","December 20, 2013","December 20, 2013","Carmichael, California, United States|Fresno, California, United States|Irvine, California, United States|Paramount, California, United States|Sacramento, California, United States|San Diego, California, United States|Tampa, Florida, United States|Dunwoody, Georgia, United States|Suwanee, Georgia, United States|Lexington, Kentucky, United States|St. Louis, Missouri, United States|St. Peters, Missouri, United States|Salisbury, North Carolina, United States|Columbus, Ohio, United States|Lyndhurst, Ohio, United States|Oklahoma City, Oklahoma, United States|Tipton, Pennsylvania, United States|San Antonio, Texas, United States|Manassas, Virginia, United States|Port Orchard, Washington, United States|Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01549977"
1103,"NCT02854683","Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients",,"Active, not recruiting","No Results Available","Chronic Fatigue Syndrome|Myalgic Encephalomyelitis|Systemic Exertion Intolerance Disease (SEID)|Postural Tachycardia Syndrome (POTS)|Neurally Mediated Syncope (NMS)","Drug: Normal Saline|Dietary Supplement: Oral Rehydration Solution","To test whether 1 Liter volumes of intravenous or oral rehydration solution increase total blood volume and cardiac output, comparably improving the threshold for orthostatic intolerance","New York Medical College|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)","All","15 Years to 29 Years   (Child, Adult)","Phase 1","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L-11-531-101|1R21NS094644-01","February 2016","December 2020","December 2020","August 3, 2016",,"January 14, 2020","NewYork Medical College, Hawthorne, New York, United States",,"https://ClinicalTrials.gov/show/NCT02854683"
1104,"NCT02191137","Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)",,"Completed","Has Results","Hypertension, Pulmonary","Drug: Riociguat (Adempas, BAY63-2521)","Change From Baseline to Week 24 in the Living With Pulmonary Hypertension (LPH) Questionnaire Total Score|Change From Baseline to Weeks 4 and 16 in the LPH Total Score|Change From Week 16 to Week 24 in the LPH Total Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the LPH Physical Dimension Score|Change From Week 16 to Week 24 in the LPH Physical Dimension Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the LPH Emotional Dimension Score|Change From Week 16 to Week 24 in the LPH Emotional Dimension Score (Completers Analysis Set Only)|Percentage of Patients With a Minimal Clinically Significant Important Difference (MCID) From Baseline in LPH Total Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Baseline in LPH Physical Dimension Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Baseline in LPH Emotional Dimension Score at Weeks 4, 16, and 24|Percentage of Patients With an MCID From Week 16 in LPH Total Score at Week 24 (Completers Analysis Set Only)|Percentage of Patients With an MCID From Week 16 in Physical Dimension Score at Week 24 (Completers Analysis Set Only)|Percentage of Patients With an MCID From Week 16 in Emotional Dimension Score at Week 24 (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the WLQ Time Management, Physical Demands, Mental-Interpersonal Demands and Output Demands Scores|Change From Baseline to Weeks 4, 16, and 24 in the WLQ Percentage of Productivity Loss|Change From Week 16 to Week 24 in the WLQ Time Management, Physical Demands, Mental-Interpersonal Demands, and Output Demands Scores (Completers Analysis Set Only)|Change From Week 16 to Week 24 in the WLQ Percentage of Productivity Loss (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the Short Form-12 Health Survey (SF-12) Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Score|Change From Week 16 to Week 24 in the SF-12 PCS Score and MCS Score (Completers Analysis Set Only)|Change From Baseline to Weeks 4, 16, and 24 in the WHO Functional Class|Change From Week 16 to Week 24 in the WHO Functional Class (Completers Analysis Set Only)|Change From Baseline to Weeks 16 and 24 in the Modified Borg Dyspnea Scale|Change From Week 16 to Week 24 in the Modified Borg Dyspnea Scale (Completers Analysis Set Only)|Change From Baseline to Weeks 16 and 24 in the 6MWD|Change From Week 16 to Week 24 in the 6MWD (Completers Analysis Set Only)","Bayer","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17407","September 23, 2014","July 16, 2016","July 16, 2016","July 16, 2014","October 13, 2017","October 13, 2017","Tucson, Arizona, United States|La Jolla, California, United States|Moreno Valley, California, United States|Pomona, California, United States|Sacramento, California, United States|San Juan Capistrano, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|Celebration, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Pascagoula, Mississippi, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Liverpool, New York, United States|Mineola, New York, United States|New Hyde Park, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Sioux Falls, South Dakota, United States|El Paso, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Guaynabo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02191137"
1105,"NCT01417104","Aliskiren Effect on Aortic Plaque Progression","ALPINE","Terminated","Has Results","Atherosclerosis","Drug: Aliskiren|Drug: Placebo","Change in Normalized Total Aortic Wall Volume (TWV) Between the Trial Arms at the End of the Treatment|Change in the Percentage Wall Volume (PWV) Between Baseline and End of Treatment","Ohio State University|Novartis","All","45 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","71","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPP100AUS33T","October 2009","December 2011","January 2012","August 16, 2011","December 31, 2012","May 11, 2017","Ohio State University, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01417104"
1106,"NCT02156076","A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation",,"Terminated","Has Results","Paroxysmal Atrial Fibrillation","Drug: BMS-919373|Drug: Placebo (Matching with BMS-919373)","Percent Change From Baseline in Atrial Fibrillation Burden (AFB) as Assessed by SEEQ Mobile Cardiac Telemetry (MCT) System|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-related AEs and Death|Maximum Observed Concentarion (Cmax) of BMS-919373|Trough Observed Concentration (Cmin) of BMS-919373|Oral Clearance (CL/F) of BMS-919373|Central Volume of Distribution (Vc/F) of BMS-919373|Absorption Rate Constant (Ka) of BMS-919373|Average Concentration (Cavg) of BMS-919373 at Steady State|Area Under the Concentration-time Curve (AUC) at Steady State of BMS-919373|Time to First Atrial Fibrillation Recurrence (TTFR) (Symptomatic or Asymptomatic)|Total Number of Atrial Fibrillation Episodes|Average Duration of Atrial Fibrillation Per Episode","Bristol-Myers Squibb","All","Child, Adult, Older Adult","Phase 2","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","CV205-005","July 25, 2014","June 1, 2016","June 1, 2016","June 5, 2014","May 22, 2019","July 31, 2019","Cardiology Consultants Of Orange County Med. Group Inc, Anaheim, California, United States|Oracle Clinical Research, Inc., Anaheim, California, United States|Wcct Global, Llc, Costa Mesa, California, United States|Long Beach Va Medical Center, Long Beach, California, United States|Spectrum Clinical Research, Moreno Valley, California, United States|Chase Medical Research, Llc, Waterbury, Connecticut, United States|All Medical Research, Llc, Cooper City, Florida, United States|The Cardiac And Vascular Institute Research Foundation, Llc, Gainesville, Florida, United States|Acrc Cardiology, Lake Worth, Florida, United States|The Heart Institute At Largo, Largo, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Community Clinical Research Center, Anderson, Indiana, United States|Midwest Heart And Vascular Specialists, Llc., Overland Park, Kansas, United States|Cambridge Medical Trials, Alexandria, Louisiana, United States|Castlerock Clinical Research Consultants, Llc, Tulsa, Oklahoma, United States|Capital Area Research, Llc, Camp Hill, Pennsylvania, United States|Tennessee Center For Clinical Trials, Tullahoma, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Austin, Texas, United States|Utah Cardiology P.C, Layton, Utah, United States|Local Institution, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc., New Westminster, British Columbia, Canada|Local Institution, Cambridge, Ontario, Canada|Dr. Andy S.C. Lam Medicine Professional, Grimsby, Ontario, Canada|Stroke Prevention & Artherosclerosis Research Centre, London, Ontario, Canada|Local Institution, Newmarket, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|King Street Cardiology, Oshawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Waterloo, Ontario, Canada|Viacar Recherche Clinique, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Csss Du Sud De Lanaudiere-Hopital Pierre-Le Gardeur, Terrebonne, Quebec, Canada|Local Institution, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02156076"
1107,"NCT01314586","Flax Lignans and Heart Health","ISULignan","Completed","No Results Available","Hypercholesterolemia","Dietary Supplement: secoisolariciresinol diglucoside-containing extract of flaxseed","Change in serum total cholesterol from baseline to 12 weeks after intervention treatments|Change in serum glucose from baseline to 12 weeks after intervention treatments|Change in blood pressure from baseline to end of treatment|Changes in serum clinical chemistry from baseline to end of treatment","Iowa State University|Archer Daniels Midland Co.","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","93","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","ADM Beneflax ISU-1","December 2007","July 2009","November 2009","March 14, 2011",,"March 14, 2011","Nutrition & Wellness Research Center, Ames, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT01314586"
1108,"NCT03696758","Improving Right Ventricular Function in Young Adults Born Preterm",,"Suspended","No Results Available","Infant,Premature","Procedure: Pulmonary Function Testing|Procedure: Electrocardiogram|Procedure: Cardiac Magnetic Resonance Imaging|Drug: Metoprolol|Drug: Sildenafil","Right ventricular energetic efficiency|left ventricular energetic efficiency","University of Wisconsin, Madison|National Center for Advancing Translational Science (NCATS)","All","18 Years to 35 Years   (Adult)","Phase 2","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-0796|1UL1TR002373-01|A534285|SMPH/MEDICINE/PULMON MED","October 30, 2018","September 2020","September 2020","October 5, 2018",,"April 3, 2020","University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03696758"
1109,"NCT02545933","Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor","VORA-PRATIC","Active, not recruiting","No Results Available","Myocardial Infarction","Drug: Prasugrel|Drug: Vorapaxar|Drug: Aspirin|Drug: Ticagrelor","Maximal platelet aggregation|Comparison of maximal Platelet aggregation measured by light transmittance aggregometry","University of Florida|Merck Sharp & Dohme Corp.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","126","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS 53376","February 2016","May 2019","August 2020","September 10, 2015",,"April 30, 2020","University of Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02545933"
1110,"NCT03070470","CiPA Phase 1 ECG Biomarker Validation Study",,"Completed","Has Results","Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics","Drug: Ranolazine|Drug: Verapamil|Drug: Lopinavir / Ritonavir|Drug: Chloroquine|Drug: Placebo|Drug: Dofetilide and Diltiazem","Change From Baseline J-Tpeakc With ""Balanced Ion Channel"" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)|Change From Baseline QTc With ""Predominant hERG"" Blocking Drug (Chloroquine)|QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)","Food and Drug Administration (FDA)|Spaulding Clinical Research LLC","All","18 Years to 50 Years   (Adult)","Phase 1","60","U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","16-086D|SCR-004","March 14, 2017","June 26, 2017","June 26, 2017","March 3, 2017","January 18, 2020","January 18, 2020","Spaulding Clinical Research, West Bend, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03070470/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/70/NCT03070470/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03070470"
1111,"NCT01941225","Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients",,"Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Inhaled iloprost 5.0 mcg|Drug: Placebo","Dynamic hyperinflation during maximal cardiopulmonary exercise test|Blood markers of oxidative stress|Blood markers of inflammation|Dead space fraction|B-type natriuretic peptide|Partial pressure of oxygen|Metabolic and gas exchange parameters during cardiopulmonary exercise test|Blood cyclic AMP levels|Blood iloprost levels|Exercise time and external work performed|Borg dyspnea and leg scores","Louisiana State University Health Sciences Center in New Orleans","All","40 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","GM104940-50346-S","September 2013","November 2016","November 2016","September 13, 2013",,"December 16, 2016","LSU Health Sciences Center, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01941225"
1112,"NCT01392495","Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)",,"Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Imatinib","Number of Patients With Adverse Events, Serious Adverse Events and Deaths|Change From Baseline in the Six Minute Walk Distance (6MWD)|Time to Clinical Worsening (TTCW) Endpoints|Medical Resource Utilization","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Older Adult","Phase 3","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CQTI571A2102E1|2010-021960-14","June 2011","March 2014","March 2014","July 12, 2011","July 13, 2015","August 10, 2015","Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01392495"
1113,"NCT01151137","Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy","PALLAS","Terminated","Has Results","Atrial Fibrillation","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","Overview of the Two Co-primary Outcomes|Time to First Co-primary Outcome (Cumulative Incidence Function)|Time to Second Co-primary Outcome (Cumulative Incidence Function)|Deaths|Time to Cardiovascular Death (Cumulative Incidence Function)","Sanofi","All","65 Years and older   (Older Adult)","Phase 3","3236","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11405|2010-019791-73|U1111-1116-5566","July 2010","September 2011","September 2011","June 25, 2010","October 26, 2012","October 26, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Providencia Santiago, Chile|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Frankfurt, Germany|Sanofi-Aventis Administrative Office, Kallithea, Greece|Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Auckland, New Zealand|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-Aventis Administrative Office, Warsaw, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Bratislava, Slovakia|Sanofi-Aventis Administrative Office, Gauteng, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Geneva, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Kiev, Ukraine|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01151137"
1114,"NCT00871377","Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures","FOS","Completed","Has Results","Epilepsy","Drug: Placebo|Drug: High Dose Fish Oil|Drug: Low Dose Fish Oil","Seizure Frequency","National Center for Complementary and Integrative Health (NCCIH)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","24","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R21AT003420-01A2","May 2008","May 2011","August 2011","March 30, 2009","January 10, 2014","February 7, 2014","UCLA General Clinical Research Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00871377"
1115,"NCT02733185","Trial to Assess Chelation Therapy 2","TACT2","Suspended","No Results Available","Diabetes|Myocardial Infarction","Drug: disodium EDTA|Dietary Supplement: Oral Multi Vitamins/Minerals (OMVM)|Drug: Placebo disodium EDTA|Dietary Supplement: Placebo Oral Multi Vitamins/Minerals (OMVM)","A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina","Mt. Sinai Medical Center, Miami|National Center for Complementary and Integrative Health (NCCIH)|National Heart, Lung, and Blood Institute (NHLBI)|Duke Clinical Research Institute","All","50 Years and older   (Adult, Older Adult)","Phase 3","1100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","AT009149-01|UH3AT009149","October 2016","December 2022","December 2022","April 11, 2016",,"March 20, 2020","Mount Sinai Medical Center, Miami Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02733185"
1116,"NCT02981407","Myocardial Ischemia and Transfusion","MINT","Recruiting","No Results Available","Myocardial Infarction|Anemia","Biological: Red Blood Cell Transfusion","Composite outcome of all-cause mortality or nonfatal myocardial reinfarction|All-cause mortality|Myocardial reinfarction|Composite of all-cause mortality, nonfatal myocardial reinfarction, ischemia driven unscheduled coronary revascularization, or readmission to the hospital for ischemic cardiac diagnosis","Rutgers, The State University of New Jersey|University of Pittsburgh|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","3500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro20160000722|1U01HL133817-01","April 25, 2017","March 2021","April 2021","December 5, 2016",,"May 22, 2019","Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|University of Arkansas Medical Sciences (UAMS) Hospital, Little Rock, Arkansas, United States|VAGLAHS, Los Angeles, California, United States|Danbury Hospital, Danbury, Connecticut, United States|Mount Sinai Medical Center, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Alexian Brothers Medical Center, Elk Grove Village, Illinois, United States|AMITA Health, Hinsdale, Illinois, United States|Saint Luke's Mid America Heart, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Hospital, Burlington, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|St. Joseph Mercy Health System, Ypsilanti, Michigan, United States|Essentia Health, Duluth, Minnesota, United States|University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States|Minneapolis Heart Institute (Foundation), Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Hospital at Gulfport, Gulfport, Mississippi, United States|Washington University, Saint Louis, Missouri, United States|Copper University Hospital, Camden, New Jersey, United States|Hackensacjk University Medical Center, Hackensack, New Jersey, United States|Jersey Shore University Medical, Neptune, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Southside Hospital, Bay Shore, New York, United States|Montefiore Medical Center, Bronx, New York, United States|NYP Brooklyn Methodist, Brooklyn, New York, United States|New York Presbyterian/Queens, Flushing, New York, United States|Westchester Medical Center, Hawthorne, New York, United States|NYU Langone Medical Center, Bellevue Hospital, New York, New York, United States|Lenox Hilll Hospital, New York, New York, United States|Rochester General Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Northwell Staten Island Hopsital, Staten Island, New York, United States|Stony Brook Medicine, Stony Brook, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Durham Va, Durham, North Carolina, United States|WakeMed Health and Hospital, Raleigh, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|University of Toledo Medical Center, Toledo, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|PENN Presbyterian Medical Cente, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Greenville Health System, Greenville, South Carolina, United States|The Memphis VAMC, Memphis, Tennessee, United States|Baylor St Luke's Medical Center, Houston, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Medical College of Wisconsin - Froedtert Hospital, Milwaukee, Wisconsin, United States|Foothills Medical Centre, Calgary, Alberta, Canada|Grey Nuns Community Hospital, Edmonton, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|QE II Health Sciences Center, Halifax, Nova Scotia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|Hamilton St. Joseph's Health, Hamilton, Ontario, Canada|St. Joseph's Health Centre, Hamilton, Ontario, Canada|University Hospital - LHSC, London, Ontario, Canada|Victoria Hospital - LHSC, London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Victoria Heart Institute, Victoria, Ontario, Canada|Hôpital Charles Lemoyne, Greenfield Park, Quebec, Canada|Hotel-Dieu de Levis, Levis, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Centre Hosp. Universitaire de Montréal, Montréal, Quebec, Canada|Montreal General Hospital, Montréal, Quebec, Canada|Royal Victoria Hospital, Montréal, Quebec, Canada|Quebec Heart and Lung Institute, Québec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|General Hospital Trois-Rivièrs, Trois-Rivières, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT02981407"
1117,"NCT01685372","Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults",,"Completed","Has Results","Solid Organ Transplant Recipient (Liver, Kidney, Heart)|Rheumatologic Disorder|Human Immunodeficiency Virus (HIV)|Bone Marrow Transplant (BMT)|Dialysis","Biological: Fluzone High Dose|Biological: Fluzone","Number of Episodes of Influenza and Influenza-Like-Illness Reported in High Dose and Standard Dose Vaccination Groups|Number of Subjects Seroprotected at Timepoint 2 in High Dose and Standard Dose Vaccination Groups|Number of Adverse Events Definitely or Possibly Related to Vaccination Reported Within 14 Days of Vaccination|Number of Subjects With Seroconversion From T1 to T2 in the High Dose and Standard Dose Vaccine Groups|Number of Participants Seroprotected at Timepoint 3 in High Dose and Standard Dose Vaccination Groups|Change in Disease Status From Vaccination Through June of the Following Year|Number of Adverse Events Considered Definitely or Possibly Related to Vaccination Through Sept 30 of the Year Following Vaccination.","University of Colorado, Denver|Colorado Clinical & Translational Sciences Institute","All","5 Years to 35 Years   (Child, Adult)","Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","12-0829","September 2012","September 2015","September 2017","September 14, 2012","November 30, 2017","January 23, 2018","Children's Hospital Colorado, Aurora, Colorado, United States",,"https://ClinicalTrials.gov/show/NCT01685372"
1118,"NCT00974025","Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients",,"Completed","No Results Available","Fontan Procedure|Hypoplastic Left Heart Syndrome|Tricuspid Atresia","Dietary Supplement: Vitamin C|Dietary Supplement: Placebo","Change in peak oxygen consumption (from baseline to post-study drug testing)|Oxygen Pulse|Peak Work|Endo-PAT score|Framingham Modified Endothelial Function Score|PedsQL 4.0 - quality of life assessment|BNP","University of Michigan|Griese-Hutchinson Champions for Children's Hearts Investigator Award","All","8 Years to 25 Years   (Child, Adult)","Not Applicable","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00029464","June 2009","November 2009","March 2010","September 10, 2009",,"June 1, 2017","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT00974025"
1119,"NCT01097330","Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia","CEASE-VT","Terminated","Has Results","Defibrillators, Implantable|Tachycardia, Ventricular","Procedure: Ablation|Drug: Amiodarone","Number of Participants With Appropriate ICD Therapy, Slow VT or Sudden Cardiac Death|Number of Participants With (a) Ablation or Amiodarone Complications, (b) Inappropriate Shocks From ICD, or (c) Need for Concomitant Use of Sotalol, Dofetilide, Azimilide or Class 1 Antiarrhythmic Agents in Either Arm of the Trial.|Quality of Life Score","Population Health Research Institute|Abbott Medical Devices|Hamilton Health Sciences Corporation","All","19 Years to 84 Years   (Adult, Older Adult)","Phase 3","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CEASE-VT","August 2010","March 2012","March 2012","April 1, 2010","January 29, 2020","January 29, 2020","Northwestern University, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Cardiac Arrhythmia Research Foundation, Austin, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Hamilton Health Sciences, Hamilton, Ontario, Canada|Southlake Regional Health Centre, Newmarket, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada|Institut Universitaire de Cardiologie et Pneumologie de Québec, Quebec, Canada|Beijng Fuwai Heart Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01097330"
1120,"NCT01951339","Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes|Cardiovascular Disease","Drug: Sitagliptin|Drug: Glimepiride|Drug: Placebo","Peak Oxygen Consumption (VO2peak).|Changes From Baseline in 31P Measurement: Phosphocreatine Time Constant|Change in Oxygen Uptake Kinetics (VO2 Kinetics)|Changes From Baseline in 31P Measurement: Free Pi Time Constant|Changes From Baseline in 31P Measurement: Adenosine Triphosphate (ATP) Peaks|Changes From Baseline in 31P Measurement: Adenosine Diphosphate (ADP) Time Constant|Changes From Baseline in 31P Measurement: pH|Changes From Baseline in Echocardiographic Measures (Stroke Volume)|Change in (Non-invasively Measured) Deoxygenated Hemoglobin Concentration in the Vastus Lateralis During Exercise","University of Colorado, Denver|Merck Sharp & Dohme Corp.","All","22 Years to 70 Years   (Adult, Older Adult)","Not Applicable","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","13-2015","October 2013","June 2018","June 2018","September 26, 2013","May 22, 2019","May 22, 2019","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT01951339/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01951339"
1121,"NCT01322048","DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury",,"Completed","Has Results","Brain Injuries|Craniocerebral Trauma|Trauma, Nervous System|Traumatic Brain Injury","Drug: IV Propranolol and Per Tube Clonidine|Drug: Placebo","Ventilator-free Days|Plasma Norepinephrine Levels","Vanderbilt University|Vanderbilt Institute for Clinical and Translational Research (CTSA)|Eastern Association for the Surgery of Trauma (EAST)|Vanderbilt University Medical Center","All","16 Years to 64 Years   (Child, Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","110429","August 2011","January 2015","December 2016","March 24, 2011","June 8, 2017","August 17, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01322048"
1122,"NCT03542240","Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome",,"Active, not recruiting","No Results Available","Obesity|High Blood Pressure|High Cholesterol|Type2 Diabetes|Heart Diseases","Dietary Supplement: Curcumin","Change inintestinal permeability|Change in intestinal barrier function","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HM20012060","September 19, 2018","November 2020","November 2020","May 31, 2018",,"February 19, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03542240"
1123,"NCT01522651","A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)",,"Completed","No Results Available","Atrial Fibrillation","Drug: Ranolazine|Drug: Dronedarone low dose 1|Drug: Dronedarone low dose 2|Drug: Ranolazine placebo|Drug: Dronedarone placebo","The effect of ranolazine and of low dose dronedarone when given alone and in combination at different dose levels on atrial fibrillation burden (AFB) over 12 weeks of treatment|AFB for each visit period (Weeks 4, 8 and 12)|Number of atrial fibrillation (AF) episodes, duration of AF episodes, and ventricular rate during AF episodes|Ventricular rate over 12 weeks of treatment and for each visit period (Weeks 4, 8, and 12)|Percentage of ventricular pacing|Percentage of atrial pacing|Incidence of persistent AF|Incidence of electrical cardioversion|Incidence of symptomatic episodes|The percentage of subjects who have ≥ 30% (≥ 50%) reduction from baseline in AFB|The percentage of subjects who have total duration of AF episodes ≥ 5.5 hours per day at any point during the Treatment period","Gilead Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GS-US-291-0102|2011-001134-42","January 2012","March 2014","March 2014","January 31, 2012",,"August 12, 2014","Investigational Site, Beverly Hills, California, United States|Investigational Site, Newport Beach, California, United States|Investigational Site, San Francisco, California, United States|Investigational Site, Aurora, Colorado, United States|Investigational Site, Washington DC, District of Columbia, United States|Investigational Site, Lakeland, Florida, United States|Investigational Site, Takoma Park, Maryland, United States|Investigational Site, Towson, Maryland, United States|Investigational Site, Utica, New York, United States|Investigational Site, Cleveland, Ohio, United States|Investigational Site, Warwick, Rhode Island, United States|Investigational Site, Houston, Texas, United States|Investigational Site, Murray, Utah, United States|Investigational Site, Seattle, Washington, United States|Investigational Site, Wausau, Wisconsin, United States|Investigational Site, München, Bayern, Germany|Investigational Site, Würzburg, Bayern, Germany|Investigational Site, Bonn, Germany|Investigational Site, Coburg, Germany|Investigational Site, Frankfurt, Germany|Investigational Site, Goettingen, Germany|Investigational Site, Ingolstadt, Germany|Investigational Site, Lubeck, Germany|Investigational Site, Ashkelon, Ashqelon, Israel|Investigational Site, Afula, Zefat, Israel|Investigational Site, Hadera, Israel|Investigational Site, Haifa, Israel|Investigational Site, Holon, Israel|Investigational Site, Jerusalem, Israel|Investigational Site, Nahariya, Israel|Investigational Site, Rehovot, Israel|Investigational Site, Como, Italy|Investigational Site, Firenze, Italy|Investigational Site, Maastricht, Limburg, Netherlands|Investigational Site, Groningen, Netherlands|Investigational Site, Torun, Kujawsko-pomorskie, Poland|Investigational Site, Lodz, Lodzkie, Poland|Investigational Site, Lódz, Lodzkie, Poland|Investigational Site, Kraków, Malopolskie, Poland|Investigational Site, Warsaw, Mazowieckie, Poland|Investigational Site, Warsaw, Mazowieckie, Poland|Investigational Site, Bialystok, Podlaskie, Poland|Investigational Site, Gdansk, Pomorskie, Poland|Investigational Site, Sopot, Pomorskie, Poland|Investigational Site, Katowice, Slaskie, Poland|Investigational Site, Zabrze, Slaskie, Poland|Investigational Site, Posnan, Wielkopolskie, Poland|Investigational Site, Szczecin, Zachodniop, Poland|Investigational Site, Lodz, Poland|Investigational Site, Warszawa, Poland|Investigational Site, London, England, United Kingdom|Investigational Site, Cardiff, United Kingdom|Investigational Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01522651"
1124,"NCT00877903","Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)",,"Completed","No Results Available","Myocardial Infarction","Drug: Prochymal®|Drug: Placebo","Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3|Left Ventricular End Systolic Volume|Infarct Size|Left Ventricular Ejection Fraction|Left Ventricular End Diastolic Volume|Number of Participants with Ventricular Arrhythmias|Duke Activity Status Index (DASI) Assessment|New York Heart Association (NYHA) Congestive Heart Failure Classification Status|Maximal Symptom-limited Exercise Test (Treadmill)|Number of Participants with Major Adverse Cardiac Events (MACE)|Overall Survival|Number of Participants with Adverse Events","Mesoblast, Inc.|Mesoblast, Ltd.","All","21 Years to 85 Years   (Adult, Older Adult)","Phase 2","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","403","March 30, 2009","May 18, 2011","March 14, 2016","April 8, 2009",,"April 2, 2020","Mercy Gilbert Medical Center / Catholic Health Care West, Gilbert, Arizona, United States|University of Arizona, Tucson, Arizona, United States|UC Davis Medical Center, Sacramento, California, United States|University of California - San Diego (UCSD), San Diego, California, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The Care Group, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Research Center, Topeka, Kansas, United States|University of Maryland Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Minneapolis Heart Institute, Minneapolis, Minnesota, United States|UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|University at Buffalo - Buffalo General Hospital, Buffalo, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The Lindner Research Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn State University - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|The Stern Cardiovascular Center, Germantown, Tennessee, United States|Austin Heart P.A., Austin, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Wisconsin School of Medicine, Madison, Wisconsin, United States|McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00877903"
1125,"NCT03176186","Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest","XePOHCAS","Recruiting","No Results Available","Post-Cardiac Arrest Syndrome","Combination Product: Xenon","functional outcome: degree of functional independence measured using a modified Rankin Scale (mRS)|survival: number of survivors","NeuroproteXeon, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1436","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XePOHCAS Ph III","December 20, 2018","October 15, 2020","December 15, 2020","June 5, 2017",,"March 8, 2019","Hartford Hospital, Hartford, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Memorial Hospital at Gulfport, Gulfport, Mississippi, United States|University Nebraska Medical Center, Omaha, Nebraska, United States|University at Buffalo, Buffalo, New York, United States|Wexner Medical Center, Ohio State University, Columbus, Ohio, United States|Baptist Memorial Hospital, Baptist Clinical Research Institute, Memphis, Tennessee, United States|Houston Methodist Research Institute, Houston, Texas, United States|Aalborg University Hospital, Aalborg, Denmark|University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03176186"
1126,"NCT01492361","A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.","REDUCE-IT","Completed","No Results Available","Cardiovascular Diseases","Drug: AMR101|Drug: Placebo","Composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, and unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization.|Composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke.|Composite of CV death or nonfatal MI (including silent MI).|Fatal or nonfatal MI (including silent MI).|Non-elective coronary revascularization represented as the composite of emergent or urgent classifications.|CV death.|Unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization.|Fatal or nonfatal stroke.|Total mortality, nonfatal MI (including silent MI), or nonfatal stroke.|Total mortality.","Amarin Pharma Inc.","All","45 Years and older   (Adult, Older Adult)","Phase 3","8179","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AMR-01-01-0019","November 2011","May 2018","May 2018","December 15, 2011",,"June 6, 2019","Amarin Investigational Site, Birmingham, Alabama, United States|Amarin Investigational Site, Birmingham, Alabama, United States|Amarin Investigational Site, Huntsville, Alabama, United States|Amarin Investigational Site, Mobile, Alabama, United States|Amarin Investigational Site, Muscle Shoals, Alabama, United States|Amarin Investigational Site, Mesa, Arizona, United States|Amarin Investigational Site, Phoenix, Arizona, United States|Amarin Investigational Site, Tucson, Arizona, United States|Amarin Investigational Site, Little Rock, Arkansas, United States|Amarin Investigational Site, Beverly Hills, California, United States|Amarin Investigational Site, Chino, California, United States|Amarin Investigational Site, Concord, California, United States|Amarin Investigational Site, El Cajon, California, United States|Amarin Investigational Site, Encino, California, United States|Amarin Investigational Site, Fair Oaks, California, United States|Amarin Investigational Site, Hawaiian Gardens, California, United States|Amarin Investigational Site, Lancaster, California, United States|Amarin Investigational Site, Lincoln, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, Los Angeles, California, United States|Amarin Investigational Site, National City, California, United States|Amarin Investigational Site, Orange, California, United States|Amarin Investigational Site, Paramount, California, United States|Amarin Investigational Site, Roseville, California, United States|Amarin Investigational Site, San Diego, California, United States|Amarin Investigational Site, Torrance, California, United States|Amarin Investigational Site, Ventura, California, United States|Amarin Investigational Site, Walnut Creek, California, United States|Amarin Investigational Site, Aurora, Colorado, United States|Amarin Investigational Site, Colorado Springs, Colorado, United States|Amarin Investigational Site, Golden, Colorado, United States|Amarin Investigational Site, Guilford, Connecticut, United States|Amarin Investigational Site, Hartford, Connecticut, United States|Amarin Investigational Site, Newark, Delaware, United States|Amarin Investigational Site, Wilmington, Delaware, United States|Amarin Investigational Site, Washington, District of Columbia, United States|Amarin Investigational Site, Boynton Beach, Florida, United States|Amarin Investigational Site, Bradenton, Florida, United States|Amarin Investigational Site, Clearwater, Florida, United States|Amarin Investigational Site, Edgewater, Florida, United States|Amarin Investigational Site, Fleming Island, Florida, United States|Amarin Investigational Site, Fort Lauderdale, Florida, United States|Amarin Investigational Site, Fort Lauderdale, Florida, United States|Amarin Investigational Site, Inverness, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Jacksonville, Florida, United States|Amarin Investigational Site, Miami Beach, Florida, United States|Amarin Investigational Site, Miami Lakes, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Miami, Florida, United States|Amarin Investigational Site, Ocala, Florida, United States|Amarin Investigational Site, Orlando, Florida, United States|Amarin Investigational Site, Pembroke Pines, Florida, United States|Amarin Investigational Site, Plantation, Florida, United States|Amarin Investigational Site, Safety Harbor, Florida, United States|Amarin Investigational Site, Saint Petersburg, Florida, United States|Amarin Investigational Site, Sarasota, Florida, United States|Amarin Investigational Site, Vero Beach, Florida, United States|Amarin Investigational Site, West Palm Beach, Florida, United States|Amarin Investigational Site, Conyers, Georgia, United States|Amarin Investigational Site, Covington, Georgia, United States|Amarin Investigational Site, Cumming, Georgia, United States|Amarin Investigational Site, Roswell, Georgia, United States|Amarin Investigational Site, Honolulu, Hawaii, United States|Amarin Investigational Site, Addison, Illinois, United States|Amarin Investigational Site, Chicago, Illinois, United States|Amarin Investigational Site, Norman, Illinois, United States|Amarin Investigational Site, North Chicago, Illinois, United States|Amarin Investigational Site, Peoria, Illinois, United States|Amarin Investigational Site, Winfield, Illinois, United States|Amarin Investigational Site, Evansville, Indiana, United States|Amarin Investigational Site, Iowa City, Iowa, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Wichita, Kansas, United States|Amarin Investigational Site, Louisville, Kentucky, United States|Amarin Investigational Site, Alexandria, Louisiana, United States|Amarin Investigational Site, Eunice, Louisiana, United States|Amarin Investigational Site, Marrero, Louisiana, United States|Amarin Investigational Site, Auburn, Maine, United States|Amarin Investigational Site, Baltimore, Maryland, United States|Amarin Investigational Site, Lutherville, Maryland, United States|Amarin Investigational Site, Takoma Park, Maryland, United States|Amarin Investigational Site, Boston, Massachusetts, United States|Amarin Investigational Site, Boston, Massachusetts, United States|Amarin Investigational Site, Fall River, Massachusetts, United States|Amarin Investigational Site, Lansing, Michigan, United States|Amarin Investigational Site, Marquette, Michigan, United States|Amarin Investigational Site, Troy, Michigan, United States|Amarin Investigational Site, Saint Cloud, Minnesota, United States|Amarin Investigational Site, Biloxi, Mississippi, United States|Amarin Investigational Site, Tupelo, Mississippi, United States|Amarin Investigational Site, Chesterfield, Missouri, United States|Amarin Investigational Site, Florissant, Missouri, United States|Amarin Investigational Site, Jefferson City, Missouri, United States|Amarin Investigational Site, Kansas City, Missouri, United States|Amarin Investigational Site, Saint Louis, Missouri, United States|Amarin Investigational Site, Saint Peters, Missouri, United States|Amarin Investigational Site, Hastings, Nebraska, United States|Amarin Investigational Site, Omaha, Nebraska, United States|Amarin Investigational Site, Omaha, Nebraska, United States|Amarin Investigational Site, Henderson, Nevada, United States|Amarin Investigational Site, Las Vegas, Nevada, United States|Amarin Investigational Site, Ocean City, New Jersey, United States|Amarin Investigational Site, Albuquerque, New Mexico, United States|Amarin Investigational Site, Albany, New York, United States|Amarin Investigational Site, Brooklyn, New York, United States|Amarin Investigational Site, Great Neck, New York, United States|Amarin Investigational Site, Liverpool, New York, United States|Amarin Investigational Site, New York, New York, United States|Amarin Investigational Site, New York, New York, United States|Amarin Investigational Site, North Massapequa, New York, United States|Amarin Investigational Site, Smithtown, New York, United States|Amarin Investigational Site, Vestal, New York, United States|Amarin Investigational Site, West Seneca, New York, United States|Amarin Investigational Site, Charlotte, North Carolina, United States|Amarin Investigational Site, Durham, North Carolina, United States|Amarin Investigational Site, Gastonia, North Carolina, United States|Amarin Investigational Site, Kernersville, North Carolina, United States|Amarin Investigational Site, Raleigh, North Carolina, United States|Amarin Investigational Site, Winston-Salem, North Carolina, United States|Amarin Investigational Site, Fargo, North Dakota, United States|Amarin Investigational Site, Cincinnati, Ohio, United States|Amarin Investigational Site, Dayton, Ohio, United States|Amarin Investigational Site, Lorain, Ohio, United States|Amarin Investigational Site, Sandusky, Ohio, United States|Amarin Investigational Site, Tulsa, Oklahoma, United States|Amarin Investigational Site, Bend, Oregon, United States|Amarin Investigational Site, Portland, Oregon, United States|Amarin Investigational Site, Beaver, Pennsylvania, United States|Amarin Investigational Site, Doylestown, Pennsylvania, United States|Amarin Investigational Site, Jersey Shore, Pennsylvania, United States|Amarin Investigational Site, Newport, Pennsylvania, United States|Amarin Investigational Site, Philadelphia, Pennsylvania, United States|Amarin Investigational Site, Phoenixville, Pennsylvania, United States|Amarin Investigational Site, Sellersville, Pennsylvania, United States|Amarin Investigational Site, Tipton, Pennsylvania, United States|Amarin Investigational Site, Wyomissing, Pennsylvania, United States|Amarin Investigational Site, Yardley, Pennsylvania, United States|Amarin Investigational Site, Lancaster, South Carolina, United States|Amarin Investigational Site, Simpsonville, South Carolina, United States|Amarin Investigational Site, Rapid City, South Dakota, United States|Amarin Investigational Site, Bristol, Tennessee, United States|Amarin Investigational Site, Columbia, Tennessee, United States|Amarin Investigational Site, Germantown, Tennessee, United States|Amarin Investigational Site, Jackson, Tennessee, United States|Amarin Investigational Site, Knoxville, Tennessee, United States|Amarin Investigational Site, Smyrna, Tennessee, United States|Amarin Investigational Site, Austin, Texas, United States|Amarin Investigational Site, Beaumont, Texas, United States|Amarin Investigational Site, Carrollton, Texas, United States|Amarin Investigational Site, Dallas, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Houston, Texas, United States|Amarin Investigational Site, Hurst, Texas, United States|Amarin Investigational Site, New Braunfels, Texas, United States|Amarin Investigational Site, Plano, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, San Antonio, Texas, United States|Amarin Investigational Site, Splendora, Texas, United States|Amarin Investigational Site, Tomball, Texas, United States|Amarin Investigational Site, West Jordan, Utah, United States|Amarin Investigational Site, Falls Church, Virginia, United States|Amarin Investigational Site, Manassas, Virginia, United States|Amarin Investigational Site, Midlothian, Virginia, United States|Amarin Investigational Site, Newport News, Virginia, United States|Amarin Investigational Site, Burien, Washington, United States|Amarin Investigational Site, Tacoma, Washington, United States|Amarin Investigational Site, Huntington, West Virginia, United States|Amarin Investigational Site, Camperdown, New South Wales, Australia|Amarin Investigational Site, Lismore, New South Wales, Australia|Amarin Investigational Site, Brisbane, Queensland, Australia|Amarin Investigational Site, Chermside, Queensland, Australia|Amarin Investigational Site, Bedford Park, South Australia, Australia|Amarin Investigational Site, Launceston, Tasmania, Australia|Amarin Investigational Site, Fitzroy, Victoria, Australia|Amarin Investigational Site, Geelong, Victoria, Australia|Amarin Investigational Site, Heidelberg Heights, Victoria, Australia|Amarin Investigational Site, Melbourne, Victoria, Australia|Amarin Investigational Site, Fremantle, Western Australia, Australia|Amarin Investigational Site, Joondalup, Western Australia, Australia|Amarin Investigational Site, Murdoch, Western Australia, Australia|Amarin Investigational Site, Nedlands, Western Australia, Australia|Amarin Investigational Site, Perth, Western Australia, Australia|Amarin Investigational Site, Edmonton, Alberta, Canada|Amarin Investigational Site, Coquitlam, British Columbia, Canada|Amarin Investigational Site, Vancouver, British Columbia, Canada|Amarin Investigational Site, Vancouver, British Columbia, Canada|Amarin Investigational Site, Brampton, Ontario, Canada|Amarin Investigational Site, Collingwood, Ontario, Canada|Amarin Investigational Site, Corunna, Ontario, Canada|Amarin Investigational Site, Newmarket, Ontario, Canada|Amarin Investigational Site, Sarnia, Ontario, Canada|Amarin Investigational Site, Strathroy, Ontario, Canada|Amarin Investigational Site, Laval, Quebec, Canada|Amarin Investigational Site, Montreal, Quebec, Canada|Amarin Investigational Site, Montreal, Quebec, Canada|Amarin Investigational Site, Sherbrooke, Quebec, Canada|Amarin Investigational Site, St. Charles-Borromée, Quebec, Canada|Amarin Investigational Site, Québec, Canada|Amarin Investigational Site, Québec, Canada|Amarin Investigational Site, Hyderabad, Andhra Pradesh, India|Amarin Investigational Site, Hyderabad, Andhra Pradesh, India|Amarin Investigational Site, Secunderabad, Andhra Pradesh, India|Amarin Investigational Site, Visakhapatnam, Andhra Pradesh, India|Amarin Investigational Site, New Delhi, Delhi, India|Amarin Investigational Site, New Delhi, Delhi, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Bangalore, Karnataka, India|Amarin Investigational Site, Mysore, Karnataka, India|Amarin Investigational Site, Mysore, Karnataka, India|Amarin Investigational Site, Kottayam, Kerala, India|Amarin Investigational Site, Mumbai, Maharashtra, India|Amarin Investigational Site, Nashik, Maharashtra, India|Amarin Investigational Site, Pune, Maharashtra, India|Amarin Investigational Site, Chennai, Tamil Nadu, India|Amarin Investigational Site, Coimbatore, Tamil Nadu, India|Amarin Investigational Site, Almelo, Netherlands|Amarin Investigational Site, Amersfoort, Netherlands|Amarin Investigational Site, Blaricum, Netherlands|Amarin Investigational Site, Capelle aan den Ijssel, Netherlands|Amarin Investigational Site, Den Haag, Netherlands|Amarin Investigational Site, Den Helder, Netherlands|Amarin Investigational Site, Deventer, Netherlands|Amarin Investigational Site, Ede, Netherlands|Amarin Investigational Site, Eindhoven, Netherlands|Amarin Investigational Site, Enschede, Netherlands|Amarin Investigational Site, Goes, Netherlands|Amarin Investigational Site, Gorinchem, Netherlands|Amarin Investigational Site, Gouda, Netherlands|Amarin Investigational Site, Groningen, Netherlands|Amarin Investigational Site, Haarlem, Netherlands|Amarin Investigational Site, Harderwijk, Netherlands|Amarin Investigational Site, Heerenveen, Netherlands|Amarin Investigational Site, Heerlen, Netherlands|Amarin Investigational Site, Hoofddorp, Netherlands|Amarin Investigational Site, Leeuwarden, Netherlands|Amarin Investigational Site, Leiderdorp, Netherlands|Amarin Investigational Site, Nijmegen, Netherlands|Amarin Investigational Site, Roosendaal, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, Rotterdam, Netherlands|Amarin Investigational Site, s'Hertogenbosch, Netherlands|Amarin Investigational Site, Schiedam, Netherlands|Amarin Investigational Site, Sneek, Netherlands|Amarin Investigational Site, Tilburg, Netherlands|Amarin Investigational Site, Tilburg, Netherlands|Amarin Investigational Site, Uden, Netherlands|Amarin Investigational Site, Veldhoven, Netherlands|Amarin Investigational Site, Zoetermeer, Netherlands|Amarin Investigational Site, Zutphen, Netherlands|Amarin Investigational Site, Takapuna, Auckland, New Zealand|Amarin Investigational Site, Christchurch, New Zealand|Amarin Investigational Site, Dunedin, New Zealand|Amarin Investigational Site, Hamilton, New Zealand|Amarin Investigational Site, Hastings, New Zealand|Amarin Investigational Site, Nelson, New Zealand|Amarin Investigational Site, New Plymouth, New Zealand|Amarin Investigational Site, Takapuna, Auckland, New Zealand|Amarin Investigational Site, Tauranga, New Zealand|Amarin Investigational Site, Whangarei, New Zealand|Amarin Investigational Site, Bialystok, Poland|Amarin Investigational Site, Bialystok, Poland|Amarin Investigational Site, Katowice, Poland|Amarin Investigational Site, Katowice, Poland|Amarin Investigational Site, Kraków, Poland|Amarin Investigational Site, Mikolów, Poland|Amarin Investigational Site, Skierniewice, Poland|Amarin Investigational Site, Tarnów, Poland|Amarin Investigational Site, Warszawa, Poland|Amarin Investigational Site, Warszawa, Poland|Amarin Investigational Site, Warszawska, Poland|Amarin Investigational Site, Wroclaw, Poland|Amarin Investigational Site, Wroclaw, Poland|Amarin Investigational Site, Zgierz, Poland|Amarin Investigational Site, Argeş, Romania|Amarin Investigational Site, Brăila, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucharest, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Bucuresti, Romania|Amarin Investigational Site, Cluj-Napoca, Romania|Amarin Investigational Site, Constanţa, Romania|Amarin Investigational Site, Craiova, Dolj, Romania|Amarin Investigational Site, Iaşi, Romania|Amarin Investigational Site, Maramureş, Romania|Amarin Investigational Site, Mureş, Romania|Amarin Investigational Site, Sibiu, Romania|Amarin Investigational Site, Timişoara, Romania|Amarin Investigational Site, Târgu Mureş, Romania|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Arkhangelsk, Russian Federation|Amarin Investigational Site, Ekaterinburg, Russian Federation|Amarin Investigational Site, Ekaterinburg, Russian Federation|Amarin Investigational Site, Kazan, Russian Federation|Amarin Investigational Site, Kazan, Russian Federation|Amarin Investigational Site, Kemerovo, Russian Federation|Amarin Investigational Site, Kemerovo, Russian Federation|Amarin Investigational Site, Kirovsk, Leningradskaya Region, Russian Federation|Amarin Investigational Site, Krasnodar, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Moscow, Russian Federation|Amarin Investigational Site, Nizhny Novgorod, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Novosibirsk, Russian Federation|Amarin Investigational Site, Petrozavodsk, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Saratov, Russian Federation|Amarin Investigational Site, Saratov, Russian Federation|Amarin Investigational Site, Sestroretsk, Saint-Petersburg, Russian Federation|Amarin Investigational Site, Tomsk, Russian Federation|Amarin Investigational Site, Tomsk, Russian Federation|Amarin Investigational Site, Volgograd, Russian Federation|Amarin Investigational Site, Voronezh, Russian Federation|Amarin Investigational Site, Voronezh, Russian Federation|Amarin Investigational Site, Yaroslavl, Russian Federation|Amarin Investigational Site, Yaroslavl, Russian Federation|Amarin Investigational Site, Bloemfontein, Freestate, South Africa|Amarin Investigational Site, Benoni, Gauteng, South Africa|Amarin Investigational Site, Pretorio, Gauteng, South Africa|Amarin Investigational Site, Soweto, Gauteng, South Africa|Amarin Investigational Site, Witbank, Gauteng, South Africa|Amarin Investigational Site, Durban, KwaZulu-Natal, South Africa|Amarin Investigational Site, Newlands, KwaZulu-Natal, South Africa|Amarin Investigational Site, Bellville, Western Cape, South Africa|Amarin Investigational Site, Cape Town, Western Cape, South Africa|Amarin Investigational Site, Durbanville, Western Cape, South Africa|Amarin Investigational Site, Goodwood, Western Cape, South Africa|Amarin Investigational Site, Kraaifontein, Western Cape, South Africa|Amarin Investigational Site, Paarl, Western Cape, South Africa|Amarin Investigational Site, Panorama, Western Cape, South Africa|Amarin Investigational Site, Parow, Western Cape, South Africa|Amarin Investigational Site, Pinelands, Western Cape, South Africa|Amarin Investigational Site, Somerset West, Western Cape, South Africa|Amarin Investigational Site, Worcester, Western Cape, South Africa|Amarin Investigational Site, Lutsk, Volyn Region, Ukraine|Amarin Investigational Site, Cherkasy, Ukraine|Amarin Investigational Site, Chernivtsi, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Dnipropetrovsk, Ukraine|Amarin Investigational Site, Donetsk, Ukraine|Amarin Investigational Site, Donetsk, Ukraine|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Ivano-Frankivsk, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kharkiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Kyiv, Ukraine|Amarin Investigational Site, Luhansk, Ukraine|Amarin Investigational Site, Lutsk, Ukraine|Amarin Investigational Site, Lviv, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Odesa, Ukraine|Amarin Investigational Site, Poltava, Ukraine|Amarin Investigational Site, Ternopil, Ukraine|Amarin Investigational Site, Uzhgorod, Ukraine|Amarin Investigational Site, Uzhgorod, Ukraine|Amarin Investigational Site, Vinnytsya, Ukraine|Amarin Investigational Site, Vinnytsya, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine|Amarin Investigational Site, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01492361"
1127,"NCT02412098","Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function",,"Completed","Has Results","Long QT Syndrome","Drug: Eleclazine","PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine|PK Parameter: AUCinf of GS-623134 (Metabolite of Eleclazine)|PK Parameter: Cmax of Eleclazine|PK Parameter: Cmax of GS-623134 (Metabolite of Eleclazine)|Number of Participants Experiencing Treatment-Emergent Adverse Events|Number of Participants Experiencing Clinical Laboratory Abnormalities","Gilead Sciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-372-1048|2014-005266-30","March 19, 2015","April 22, 2016","April 22, 2016","April 8, 2015","July 29, 2019","July 29, 2019","Miami, Florida, United States|Orlando, Florida, United States|Minneapolis, Minnesota, United States|Kansas City, Missouri, United States|München, Germany|Auckland, New Zealand|Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02412098"
1128,"NCT02441829","Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function",,"Completed","No Results Available","Long QT Syndrome","Drug: Eleclazine","Plasma pharmacokinetics (PK) profiles of eleclazine and its metabolite GS-623134: AUC_0-inf and Cmax|Safety profile of eleclazine as measured by incidence of adverse events and laboratory abnormalities","Gilead Sciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-372-1589|2014-005267-32","May 2015","December 2015","December 2015","May 12, 2015",,"December 22, 2015","DeLand, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|St. Paul, Minnesota, United States|Kansas City, Missouri, United States|Chisinau, Moldova, Republic of|Bucharest, Romania",,"https://ClinicalTrials.gov/show/NCT02441829"
1129,"NCT01219010","A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma",,"Completed","No Results Available","Monoclonal Gammopathy of Undetermined Significance|Multiple Myeloma|Plasma Cell Neoplasm","Biological: Siltuximab","QTc interval|Additional safety evaluations|Efficacy evaluations|Pharmacokinetic and Pharmacodynamic evaluations","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR017452|CNTO328SMM1001","October 2010","June 2012","March 2014","October 13, 2010",,"January 19, 2015","Chicago, Illinois, United States|Dallas, Texas, United States|Houston, Texas, United States|Antwerpen, Belgium|Gent, Belgium|Izhevsk, Russian Federation|Moscow N/A, Russian Federation|Nizhni Novgorod, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01219010"
1130,"NCT02117713","An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome","IMAGINE-II","Active, not recruiting","No Results Available","Alagille Syndrome","Drug: LUM001","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Change From Baseline in the Pruritus Associated with ALGS|Change From Baseline in the Fasting Serum Bile Acid Levels Associated with ALGS|Change From Baseline in the Biochemical Markers of Cholestasis and Liver Disease|Change From Baseline in the Xanthomas as Measured by Clinician Xanthoma Scale Associated with ALGS|Expanded Dosing Range","Mirum Pharmaceuticals, Inc.|Lumena Pharmaceuticals, Inc.|Childhood Liver Disease Research and Education Network","All","1 Year to 18 Years   (Child, Adult)","Phase 2","36","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LUM001-305|SHP625-305","March 16, 2015","April 30, 2020","April 30, 2020","April 21, 2014",,"November 13, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California at San Francisco Children's Hospital, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02117713"
1131,"NCT04053543","CXA-10 Study in Subjects With Pulmonary Arterial Hypertension",,"Recruiting","No Results Available","PAH","Drug: CXA-10","Incidence of AEs|Changes in respiration|Changes in heart rate|Changes in blood pressure|PAH-specific medication changes|6 Minute Walk Distance|Who Classification of Functional Status|Clinical worsening","Complexa, Inc.|Medpace, Inc.|Innovative Analytics|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","All","18 Years and older   (Adult, Older Adult)","Phase 2","96","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CXA-10-2302","August 9, 2019","February 28, 2021","February 28, 2021","August 12, 2019",,"January 6, 2020","University of Alabama, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|University of California San Diego, La Jolla, California, United States|University of California San Francisco, San Francisco, California, United States|National Jewish Health, Denver, Colorado, United States|Washington Hospital (Medstar), Washington, District of Columbia, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Health, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Minnesotta, Minneapolis, Minnesota, United States|Washington University and Barnes Jewish Hospital, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Christ Hospital-Lindner Research Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Vanderbuilt University, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Virginia School of Medicine, Charlottesville, Virginia, United States|Inova Medical Campus, Falls Church, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Froedert Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free, London, United Kingdom|Royal Brompton, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04053543"
1132,"NCT02942407","Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation","RENAL-AF","Completed","No Results Available","Atrial Fibrillation|End Stage Renal Disease","Drug: apixaban|Drug: warfarin","Time (measured in days) from randomization to the onset of first major bleeding/clinically relevant non-major bleeding event, as described by International Society of Thrombosis and Haemostasis (ISTH)|stroke or systemic embolism|mortality|adherence to treatment with apixaban or with warfarin, measured by pill count for patients randomized to apixaban, and by time in therapeutic range (TTR) for warfarin|apixaban plasma concentration.|plasma apixaban concentration, Cmax|plasma apixaban concentration, Cmin|plasma apixaban concentration, area under the curve (AUC)|apixaban pharmacodynamics, chromogenic factor Xa assay","Christopher Granger, MD|Bristol-Myers Squibb|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 4","155","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00068545","December 2016","July 10, 2019","August 12, 2019","October 24, 2016",,"October 8, 2019","Nephrology Consultants, Huntsville, Alabama, United States|The Medical Research Group, Inc., Fresno, California, United States|DaVita Clinical Trials, LLC, Long Beach, California, United States|Southland Renal Medical Group, Long Beach, California, United States|Valley Renal Medical Group Research, Northridge, California, United States|Summit Nephrology Medical Group, Inc., Roseville, California, United States|Satellite Healthcare, San Jose, California, United States|Washington Nephrology Associates, Washington, District of Columbia, United States|South Florida Nephrology Group PA, Research Division, Coral Springs, Florida, United States|LG. Diagnostic, Inc. & Cosmetic Center, Miami, Florida, United States|Nuren Medical and Research Center, Miami, Florida, United States|Medical Professional Clinical Research Center, Miami, Florida, United States|Boise Kidney and Hypertension Institute, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|NANI Research, Crystal Lake, Illinois, United States|NANI Research, River Forest, Illinois, United States|NANI Research, Fort Wayne, Indiana, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Washington Nephrology Associates, Takoma Park, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|South Shore Nephrology, Plymouth, Massachusetts, United States|Renal and Transplant Associates of New England, Springfield, Massachusetts, United States|Paragon Health Neprhology Centre, Kalamazoo, Michigan, United States|St. Clair Nephrology, Port Huron, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Southwest Mississippi Nephrology, PLLC, Brookhaven, Mississippi, United States|Southern Clinical Research Group, LLC, Gulfport, Mississippi, United States|Nephrology & Hypertension Associates, Tupelo, Mississippi, United States|Polack Renal, LLC, Saint Louis, Missouri, United States|Sierra Nevada Nephrology Consultants, Reno, Nevada, United States|Renal Medicine Associates, Albuquerque, New Mexico, United States|Advanced Kidney Care of Hudson Valley, Poughkeepsie, New York, United States|Durham Nephrology Associates, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Eastern Nephrology Associates, PLLC., Kinston, North Carolina, United States|Eastern Nephrology Associates, PLLC, New Bern, North Carolina, United States|HNC Dialysis, Ltd., Columbus, Ohio, United States|Northeast Clinical Research Ctr, Bethlehem, Pennsylvania, United States|Penn State Health - Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Columbia Nephrology Associates, Columbia, South Carolina, United States|South Carolina Nephrology and Hypertension, Orangeburg, South Carolina, United States|Sumter Medical Specialists, Sumter, South Carolina, United States|Regional Health Clinical Research, Rapid City, South Dakota, United States|Knoxville Kidney Center, Knoxville, Tennessee, United States|Southwest Houston Research, Ltd., Houston, Texas, United States|Lubbock Vascular Access Center, Lubbock, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Washington Nephrology Associates, Alexandria, Virginia, United States|University of Virgina Health System, Charlottesville, Virginia, United States|TPMG Clinical Research, Newport News, Virginia, United States|Valley Nephrology Associates, Roanoke, Virginia, United States|University of Washington, Seattle, Washington, United States|Nephrology and Hypertension Associates, Bluefield, West Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Aspirius Research Institute, Wausau, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02942407"
1133,"NCT01855334","L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD","LAST-D","Withdrawn","No Results Available","End Stage Renal Disease|Hemodialysis","Drug: Spironolactone|Dietary Supplement: L-arginine|Drug: Placebo","Change in coronary Flow Reserve (PET)|Change in left ventricular diastolic function|Association between coronary flow reserve (CFR) and tissue doppler index (E')|Change in resting myocardial blood flow|Change in left ventricular mass index|Change in coronary vascular resistance|Association between change in coronary flow reserve (CFR) and change in diastolic function-tissue doppler index (E')|Change in early diastolic function (E')|Combined cardiovascular safety|Cardiovascular death|Hyperkalemia|Hypotension|Change in early coronary flow reserve|Change in hyperemic myocardial blood flow","Brigham and Women's Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Joslin Diabetes Center","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","0","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1R01DK096189","September 2013","July 2018","July 2018","May 16, 2013",,"May 4, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01855334"
1134,"NCT01743001","Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome","MAESTRO","Completed","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan 10 mg|Drug: Placebo","Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)|Change From Baseline to Week 16 in WHO Functional Class|Change From Baseline to Week 16 in Dyspnea, Assessed by the Borg Dyspnea Index|Change From Baseline to Week 16 in Quality of Life (QoL), Assessed by the Short Form-36 (SF-36) Questionnaire","Actelion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","226","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-055-305","May 21, 2013","December 1, 2016","December 1, 2016","December 6, 2012","January 30, 2018","February 23, 2018","Ahmanson/UCLA Heart Disease Center, Los Angeles, California, United States|Stanford Hospital and Clinic, Palo Alto, California, United States|Emory University Hospital/the Emory Clinic, Atlanta, Georgia, United States|Barnes-Jewish Hosp/Wash Univ School of Med, Saint Louis, Missouri, United States|Children'S Heart Center Nevada, Las Vegas, Nevada, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Texas Children'S Hosp - Dept of Cardiology, Houston, Texas, United States|Gen Hosp Univ Vienna Dept Cardiology, Vienna, Austria|Mhat Nat Card Hosp - Cardiology Clinic, Sofia, Bulgaria|Mhat Nat Card Hosp - Pediatric Clin / Ped Card Dept, Sofia, Bulgaria|Mhat Sveta Anna Clin Card, Sofia, Bulgaria|Inst Nat Torax, Unidad Cardiopatia Congenitas Del Adulto, Providencia, Chile|Clinica Tabancura - Cardio Unit, Santiago, Chile|Guangdong General Hospital, Cardiology Dpt, Guangzhou, Guangdong, China|Wu Han Asia Heart Hosp, Wuhan, Hubei, China|The General Hosp of Shenyang Military Region, Shenyang, Liaoning, China|Beijing Anzhen Hospital, Cardiology Dpt, Beijing, China|Cardiovascular Institute&Fuwai Hospital, Beijing, China|Shanghai Pulmonary Hospital, Dept of Pulmonary Circulation, Shanghai, China|Hosp La Timone - Dept Pediatric Cardiology, Marseille Cedex 5, France|Hosp Laennec - Dept Cardiology, Nantes Cedex 1, France|Hosp Pompidou - Dept Congenital Cardiac Diseases, Paris Cedex 15, France|Hosp Cardiology Haut Leveque - Dept Congenital Diseases, Pessac, France|Herzzentrum Berlin, Ped Cardiology, Berlin, Germany|Universitätsklinikum Giessen - Pediatric Heart Center, Giessen, Germany|Uni Heidelberg - Kinderkardiologie, Heidelberg, Germany|Ahepa University General Hospital, Thessaloniki, Greece|Rabin Medical Centre - Pulmonology, Petach Tikvah, Israel|Institut Jantung Negara, Kuala Lumpur, Malaysia|Unidad de Investigacion Clin En Med, Sc (Udicem), Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Cardiologia (Inc) Ignacio Chavez, Mexico City, Mexico|Instituto de Corazon de Querètaro, Querétaro, Mexico|PHC, MAB, Manila, Philippines|Cardiology Gdańsk Univ, Gdańsk, Poland|Cardiology Kraków Univ, Krakow, Poland|Cardiology Wrocław, Wrocław, Poland|Hosp Univ Coimbra - Dpt Cardiology, Coimbra, Portugal|Hosp Sta Marta - Dept Cardiology, Lisboa, Portugal|Er Inst For Cardvasc Dis ""Prof Dr Cc Iliescu"" - Card Ii, Bucuresti, Romania|Cardio Med Srl, Targu-Mures, Romania|Clin Hosp For Inf and Pulm Dis Victor Babes - Ii Pulm, Timisoara, Romania|Sci Institute Systemic Problems Cardio Diseases Kemerovo, Kemerovo, Russian Federation|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|V. A. Almazov Institute of Cardiology, St Petersburg, Russian Federation|Dedinje Cardiovasc Inst - Cardiovasc Research Ctr, Belgrade, Serbia|Mother and Child Health Care Inst ""Dr Vukan Cupic"", Belgrade, Serbia|Clin Hosp Ctr Zemun - Cardiology Dept, Belgrade, Serbia|Hosp Univ Vall D'Hebron - Dpt Congenital Heart Disease Adult, Barcelona, Spain|Hosp Univ Virgen Macarena - Dpt Cardiology, Sevilla, Spain|Hosp Universitario La Fe Dpt Cardiology, Valencia, Spain|Omu Pediatry, Samsun, Turkey|Bristol Univ Hosp Congenital Heart Centre, Bristol, United Kingdom|Hanoi Medical University Hospital, Hanoi, Vietnam|Children's Hospital, Ho Chi Minh, Ho Chi Minh, Vietnam|Tam Duc Hospital, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01743001"
1135,"NCT02915198","Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes","VA-IMPACT","Recruiting","No Results Available","Prediabetic State|Atherosclerosis|Metformin","Drug: Metformin XR|Drug: Placebo","Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization|Time in days to Cardiovascular Outcomes|Time in days to Oncologic Outcome|Time in days to Diabetes Outcome","VA Office of Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 4","7868","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2002","February 21, 2019","August 21, 2024","August 21, 2024","September 26, 2016",,"April 16, 2020","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02915198"
1136,"NCT01148836","Coenzyme Q-10 and Pulmonary Arterial Hypertension",,"Completed","Has Results","Pulmonary Arterial Hypertension","Dietary Supplement: Coenzyme Q-10 in Pulmonary Hypertension subjects|Dietary Supplement: Coenzyme Q-10 in Normal Control subjects","Left Ventricular End Diastolic Volume|Right Ventricular Outflow|Right Ventricle Myocardial Performance|Tricuspid Regurgitation Grade|Right Atrial Pressure|Red Blood Cells|Hemoglobin|Hematocrit|Mean Corpuscular Hemoglobin|Red Blood Cell Distribution Width","The Cleveland Clinic","All","18 Years to 55 Years   (Adult)","Not Applicable","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-497","January 2010","January 2014","January 2014","June 22, 2010","March 20, 2015","March 20, 2015","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01148836"
1137,"NCT01739400","Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome","MAESTRO-OL","Terminated","Has Results","Pulmonary Arterial Hypertension","Drug: Macitentan 10 mg tablet, once daily.","Change in Exercise Capacity as Measured by 6-minute Walking Distance (6MWD) Month 6 and 12|Change in WHO Functional Class (FC) at Month 6 and 12|Change in Borg Dyspnea Score at Month 6 and 12|Change in Peripheral Oxygen Saturation (SpO2) at Rest at Month 6 and 12","Actelion","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","217","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AC-055-308","September 10, 2013","January 12, 2018","January 12, 2018","December 3, 2012","April 16, 2019","April 16, 2019","Emory University Hospital/the Emory Clinic, Atlanta, Georgia, United States|Barnes-Jewish Hosp/Wash Univ School of Med, Saint Louis, Missouri, United States|Children'S Heart Center Nevada, Las Vegas, Nevada, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Texas Children'S Hosp - Dept of Cardiology, Houston, Texas, United States|Gen Hosp Univ Vienna Dept Cardiology, Vienna, Austria|Mhat Nat Card Hosp - Cardiology Clinic, Sofia, Bulgaria|Mhat Nat Card Hosp - Pediatric Clin / Ped Card Dept, Sofia, Bulgaria|Mhat Sveta Anna Clin Card, Sofia, Bulgaria|Instituto Nacional del Torax, Providencia, Santiago RCH, Chile|Clinica Tabancura - Cardio Unit, Santiago, Chile|Guangdong General Hospital, Cardiology Dpt, Guangzhou, Guangdong, China|Wu Han Asia Heart Hosp, Wuhan, Hubei, China|The General Hosp of Shenyang Military Region, Shenyang, Liaoning, China|Beijing Anzhen Hospital, Cardiology Dpt, Beijing, China|Cardiovascular Institute&Fuwai Hospital, Beijing, China|Shanghai Pulmonary Hospital, Dept of Pulmonary Circulation, Shanghai, China|Hosp La Timone - Dept Pediatric Cardiology, Marseille Cedex 5, France|Hosp Laennec - Dept Cardiology, Nantes Cedex 1, France|Hosp Pompidou - Dept Congenital Cardiac Diseases, Paris cedex 15, France|Hosp Cardiology Haut Leveque - Dept Congenital Diseases, Pessac, France|Herzzentrum Berlin, Ped Cardiology, Berlin, Germany|Universitätsklinikum Giessen - Pediatric Heart Center, Giessen, Germany|Uni Heidelberg - Kinderkardiologie, Heidelberg, Germany|Ahepa University General Hospital, Thessaloniki, Greece|Institut Jantung Negara, Kuala Lumpur, Malaysia|Unidad de Investigacion Clin En Med, Sc (Udicem), Monterrey, Nuevo Leon, Mexico|Instituto Nacional de Cardiologia (Inc) Ignacio Chavez, Mexico City, Mexico|Instituto de Corazon de Querètaro, Querétaro, Mexico|PHC, MAB, Manila, Philippines|Cardiology Gdańsk Univ, Gdańsk, Poland|Cardiology Kraków Univ, Krakow, Poland|Cardiology Wrocław, Wrocław, Poland|Hosp Univ Coimbra - Dpt Cardiology, Coimbra, Portugal|Hosp Sta Marta - Dept Cardiology, Lisboa, Portugal|Er Inst For Cardvasc Dis ""Prof Dr Cc Iliescu"" - Card Ii, Bucaresti, Romania|Cardio Med Srl, Targu-Mures, Romania|Clin Hosp For Inf and Pulm Dis Victor Babes - Ii Pulm, Timisoara, Romania|Sci Institute Systemic Poriblems Cardio Diseases Kemerovo, Kemerovo, Russian Federation|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|V. A. Almazov Institute of Cardiology, St Petersburg, Russian Federation|Dedinje Cardiovasc Inst - Cardiovasc Research Ctr, Belgrade, Serbia|Mother and Child Health Care Institute Dr. Vukan Cupic, Belgrade, Serbia|Clin Hosp Ctr Zemun - Cardiology Dept, Belgrade, Serbia|Hosp Univ Vall D'Hebron - Dpt Congenital Heart Disease Adult, Barcelona, Spain|Hosp Univ Virgen Macarena - Dpt Cardiology, Sevilla, Spain|Hosp Universitario La Fe Dpt Cardiology, Valencia, Spain|Bristol Univ Hosp Congenital Heart Centre, Bristol, United Kingdom|Hanoi Medical University Hospital, Hanoi, Vietnam|Children'S Hospital, Ho Chi Minh, Ho Chi Minh, Vietnam|Tam Duc Hospital, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01739400/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01739400/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01739400"
1138,"NCT02227368","Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR","TI-PAD EVR","Terminated","Has Results","Peripheral Artery Disease (PAD)","Drug: Ticagrelor|Drug: Comparator","Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)|Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)","AstraZeneca|CPC Clinical Research","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5135L00003","October 20, 2014","May 23, 2016","May 23, 2016","August 28, 2014","June 14, 2017","July 19, 2017","Research Site, Daytona Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Munster, Indiana, United States|Research Site, New York, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02227368"
1139,"NCT01991795","A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","THEMIS","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Ticagrelor 60 mg|Drug: Ticagrelor placebo","Composite of Cardiovascular (CV) Death, MI or Stroke|CV Death|MI|Ischaemic Stroke|All-cause Death","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","19271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D513BC00001","February 10, 2014","January 25, 2019","January 25, 2019","November 25, 2013","March 18, 2020","March 18, 2020","Research Site, Alexander City, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Fairhope, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Cottonwood, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Fremont, California, United States|Research Site, Fresno, California, United States|Research Site, Irvine, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Hills, California, United States|Research Site, Newport Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Stockton, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Greenwich, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Cooper City, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Merritt Island, Florida, United States|Research Site, Miami Gardens, Florida, United States|Research Site, Miami Shores, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, North Miami Beach, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Cloud, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Nampa, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Crystal Lake, Illinois, United States|Research Site, Elmhurst, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Moline, Illinois, United States|Research Site, North Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Bossier City, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Crowley, Louisiana, United States|Research Site, Minden, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bowie, Maryland, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, North Attleboro, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Mount Clemens, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Joplin, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lee's Summit, Missouri, United States|Research Site, North Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Helena, Montana, United States|Research Site, Hastings, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, East Brunswick, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Binghamton, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Hawthorne, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Utica, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Clayton, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Butler, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Harleysville, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Port Matilda, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenwood, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Varnville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Channelview, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Huntsville, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Pharr, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Shavano Park, Texas, United States|Research Site, Bountiful, Utah, United States|Research Site, Draper, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Arlington, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Port Orchard, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Kenosha, Wisconsin, United States|Research Site, Waukesha, Wisconsin, United States|Research Site, Buenos aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad Autonomade Buenos Aires, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ranelagh, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Venado Tuerto, Argentina|Research Site, Villa Maria, Argentina|Research Site, Adelaide, Australia|Research Site, Ashford, Australia|Research Site, Coffs Harbour, Australia|Research Site, Fitzroy, Australia|Research Site, Fullarton, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Merewether, Australia|Research Site, Milton, Australia|Research Site, Murdoch, Australia|Research Site, Braunau, Austria|Research Site, Eisenstadt, Austria|Research Site, Feldkirch, Austria|Research Site, Innsbruck, Austria|Research Site, Saint Stefan/Stainz, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Bouge, Belgium|Research Site, Bruges, Belgium|Research Site, De Pinte, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Mechelen, Belgium|Research Site, Mol, Belgium|Research Site, Overpelt, Belgium|Research Site, Roeselare, Belgium|Research Site, Yvoir, Belgium|Research Site, Zottegem, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasilia, Brazil|Research Site, Brasillia, Brazil|Research Site, Brasillia, Brazil|Research Site, Brasília, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Cariacica, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Goiânia, Brazil|Research Site, Marilia, Brazil|Research Site, Maringa, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S.J.Rio Preto, Brazil|Research Site, Sao Jose dos Campos, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Tatui, Brazil|Research Site, Uberlândia, Brazil|Research Site, Vitoria, Brazil|Research Site, Vitória, Brazil|Research Site, Votuporanga, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Burgas, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Red Deer, Alberta, Canada|Research Site, Spruce Grove, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Jarvis, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Lambert, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Chicoutimi, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Los Angeles, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Cangzhou, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Yinchuan, China|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogotá, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Cali, Colombia|Research Site, Cali, Colombia|Research Site, Cartagena, Colombia|Research Site, Floridablanca, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellin, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceska Lipa, Czechia|Research Site, Chomutov, Czechia|Research Site, Frydek-Mistek, Czechia|Research Site, Jablonec nad Nisou, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kolin, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Louny, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Zabreh, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Ostrava, Czechia|Research Site, Pelhrimov, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 9, Czechia|Research Site, Praha, Czechia|Research Site, Praha, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Slany, Czechia|Research Site, Trebic, Czechia|Research Site, Turnov, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aarhus N, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hjørring, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kolding, Denmark|Research Site, Købehhavn Ø, Denmark|Research Site, København NV, Denmark|Research Site, Næstved, Denmark|Research Site, Odense C, Denmark|Research Site, Roslev, Denmark|Research Site, Svendborg, Denmark|Research Site, Viborg, Denmark|Research Site, Værløse, Denmark|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Jyväskylä, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Avignon Cedex, France|Research Site, Bayonne, France|Research Site, Bobigny, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, La Rochelle Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Lyon, France|Research Site, Montauban, France|Research Site, NICE Cedex 01, France|Research Site, Nimes, France|Research Site, PARIS Cedex 15, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Toulouse Cedex, France|Research Site, TOURCOING cedex, France|Research Site, TOURS Cedex 9, France|Research Site, Altdorf, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Markkleeberg, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf Am Inn, Germany|Research Site, München, Germany|Research Site, Neuwied, Germany|Research Site, Nürnberg, Germany|Research Site, Papenburg, Germany|Research Site, Schwerin, Germany|Research Site, Wangen, Germany|Research Site, Wermsdorf, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Kisvárda, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pásztó, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Naharia, Israel|Research Site, Petach Tikva, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Pavia, Italy|Research Site, Rivoli, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Udine, Italy|Research Site, Viterbo, Italy|Research Site, Adachi-ku, Japan|Research Site, Beppu-shi, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Edogawa-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Fussa-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kawanishi-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Otaru-shi, Japan|Research Site, Sanyoonoda-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Shimajiri-gun, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takayama-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Toyota-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Urasoe-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Changwon-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Iksan-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, Culiacán, Mexico|Research Site, D.F, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, México, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Pachuca, Mexico|Research Site, Querétaro, Mexico|Research Site, Tijuana, Mexico|Research Site, Xalapa, Mexico|Research Site, Zapopan, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Blaricum, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Goes, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Stadskanaal, Netherlands|Research Site, Tiel, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bergen, Norway|Research Site, Bodø, Norway|Research Site, Bodø, Norway|Research Site, Kongsvinger, Norway|Research Site, Lillehammer, Norway|Research Site, Oslo, Norway|Research Site, Oslo, Norway|Research Site, Oslo, Norway|Research Site, Sandefjord, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Svelvik, Norway|Research Site, Tromsø, Norway|Research Site, Trondheim, Norway|Research Site, Ålesund, Norway|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Callao, Peru|Research Site, Chiclayo, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Miraflores, Peru|Research Site, Cebu City, Philippines|Research Site, Cebu, Philippines|Research Site, Davao City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Biała Rawska, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Bielsko-Biała, Poland|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chojnice, Poland|Research Site, Chorzów, Poland|Research Site, Chrzanow, Poland|Research Site, Chrzanów, Poland|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Koszalin, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kędzierzyn Koźle, Poland|Research Site, Legnica, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Mikołów, Poland|Research Site, Myszków, Poland|Research Site, Nakło nad Notecią, Poland|Research Site, Nowogard, Poland|Research Site, Nysa, Poland|Research Site, Opole, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Oświęcim, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Puławy, Poland|Research Site, Płock, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Siedlce, Poland|Research Site, Sobótka, Poland|Research Site, Sokółka, Poland|Research Site, Staszów, Poland|Research Site, Szczecin, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Tychy, Poland|Research Site, Ustroń, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Włocławek, Poland|Research Site, Zabrze, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Zielona Góra, Poland|Research Site, Łódź, Poland|Research Site, Żnin, Poland|Research Site, Canovanas, Puerto Rico|Research Site, Cidra, Puerto Rico|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Suceava, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Khanty-Mansiysk, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Khobar, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Benoni, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Greenbury, Phoenix, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Soweto, South Africa|Research Site, Stanger, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, A Coruña, Spain|Research Site, Alcalá de Henares, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Cáceres, Spain|Research Site, El Palmar, Spain|Research Site, Ferrol (A Coruña), Spain|Research Site, Girona, Spain|Research Site, Granada, Spain|Research Site, Hospitalet de Llobregat, Spain|Research Site, Huelva, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Móstoles, Spain|Research Site, Pontevedra, Spain|Research Site, Sabadell, Spain|Research Site, San Juan de Alicante, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Santander, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Son Ferriol, Spain|Research Site, Valdemoro, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Lessebo, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Malmö, Sweden|Research Site, Rättvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Changhua City, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, Pingtung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Muang, Thailand|Research Site, Naimuang, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Antalya, Turkey|Research Site, Aydin, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Mersin, Turkey|Research Site, Belo Horizonte, Ukraine|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Rivne, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Antrim, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Durham, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Faringdon, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrogate, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, London, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Newcastle-Upon-Tyne, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Paisley, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Rothwell, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, York, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01991795/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01991795/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01991795"
1140,"NCT02575833","Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)",,"Completed","Has Results","Stable Angina","Drug: Erenumab|Drug: Placebo","Change From Baseline in Total Exercise Time|Time to Onset of Exercise-induced Angina|Time to Onset of ≥ 1 mm ST-segment Depression","Amgen","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140254|2015-002322-40","November 23, 2015","January 23, 2017","April 13, 2017","October 15, 2015","July 5, 2018","August 24, 2018","Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Jackson, Tennessee, United States|Research Site, New Braunfels, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Haskovo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Brandys nad Labem, Czechia|Research Site, Chomutov, Czechia|Research Site, Praha 4, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Riga, Latvia|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Zabrze, Poland|Research Site, Timisoara, Romania|Research Site, Bardejov, Slovakia|Research Site, Brezno, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Piestany, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Zilina, Slovakia|Research Site, Parow, Western Cape, South Africa|Research Site, Geneva 14, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02575833/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02575833/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02575833"
1141,"NCT00853112","A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension",,"Terminated","Has Results","Hypertension, Pulmonary","Drug: PF-00489791|Drug: placebo|Drug: sildenafil","Mean Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) Over 4 Hours Post Dose|Greatest Reduction From Baseline in Pulmonary Vascular Resistance Index (PVRI) and Systemic Vascular Resistance Index (SVRI) Over 4 Hours Post Dose|Mean Change From Baseline in Systemic Vascular Resistance Index (SVRI) Over 4 Hours Post Dose|Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Systemic Vascular Resistance Index (SVRI) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Cardiac Index (CI) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Mean Pulmonary Artery Pressure (mPAP), Systolic Pulmonary Artery Pressure (sPAP), Diastolic Pulmonary Artery Pressure (dPAP), Right Atrial Pressure (RAP) at Hour 1, 2, 3 and 4 Post Dose|Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP), Mean Systemic Arterial Pressure (SAP), Systolic Systemic Arterial Pressure (sSAP) and Diastolic Systemic Arterial Pressure (dSAP) at Hour 1, 2, 3 and 4 Post Dose|Mean Change From Baseline in Pulmonary Vascular Resistance (PVR) and Systemic Vascular Resistance (SVR) at Hour 1, 2, 3 and 4 Post Dose|Mean Change From Baseline in Heart Rate (HR) at Hour 1, 2, 3 and 4 Post Dose|Number of Participants With Clinically Significant Laboratory Values|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Values|Change From Baseline in Mean Partial Pressure of Oxygen (PaO2) and Carbon Dioxide (PaCO2) at Hour 1 and 4 Post Dose|Plasma Concentration of PF-00489791 and Sildenafil","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A7331009|2008-003572-21","April 2009","July 2010","July 2010","March 2, 2009","October 24, 2017","October 24, 2017","Pulmonary Associates, PA, Phoenix, Arizona, United States|John C. Lincoln Hospital, North Mountain, Phoenix, Arizona, United States|Pulmonary Associates, PA, Phoenix, Arizona, United States|Shands at University of Florida, Gainesville, Florida, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center - Department of Internal Medicine Pulmonary, Dallas, Texas, United States|UT Southwestern St. Paul Hospital, Dallas, Texas, United States|Lawson Health Research Institute, London, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada|Thoraxklinik am Universitaetsklinikum, Heidelberg, Germany|Department Of Cardiology, MediCiti Hospital,, Hyderabad, Andhra Pardesh, India|Department Of Cardiology, Sri Venkateswara Institute Of Medical Sciences, Tirupati, Andhra Pardesh, India|Bankers Heart Institute, Vadodara, Gujarat, India|Omega Hospital, Mangalore, Karnataka, India|Moscow Healthcare Institution ""City Clinical Hospital No. 57"", Moscow, Russian Federation|Institute of Cardiosurgery n.a. V.I.Burakovsky, Moscow, Russian Federation|Hospital General Universitari Vall D´Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Universitetssjukhuset i Lund, Hjart- och Lungdivisionen, Lund, Sweden|Norrlands Universitetssjukhus, Kliniskt Forsknings Centrum, Umea, Sweden|Akademiska Sjukhuset, Kardiologen 50F/Forskningsenheten, Uppsala, Sweden|Universitaetsspittal Zuerich, Medizinische Klinik A, Zuerich, Switzerland",,"https://ClinicalTrials.gov/show/NCT00853112"
1142,"NCT01101035","Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)","CARES","Completed","Has Results","Cardiovascular Disease","Drug: Febuxostat|Drug: Allopurinol","Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)|Percentage of Participants With Primary MACE Composite (Final Analysis)|Percentage of Participants With Antiplatelet Trialists' Collaborative (APTC) Event|Percentage of Participants With Cardiovascular (CV) Death|Percentage of Participants With Non-fatal Myocardial Infarction (MI)|Percentage of Participants With Non-fatal Stroke|Percentage of Participants With Unstable Angina With Urgent Coronary Revascularization","Takeda","All","50 Years and older   (Adult, Older Adult)","Phase 3","6198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TMX-67_301|U1111-1114-4194","April 23, 2010","May 15, 2017","July 18, 2017","April 9, 2010","June 14, 2018","June 14, 2018","Decatur, Georgia, United States|Dunwoody, Georgia, United States|Marietta, Georgia, United States|Norcross, Georgia, United States|Roswell, Georgia, United States|Suwanee, Georgia, United States|Waycross, Georgia, United States|Honolulu, Hawaii, United States|Boise, Idaho, United States|Coeur d'Alene, Idaho, United States|Nampa, Idaho, United States|Addison, Illinois, United States|Arlington Heights, Illinois, United States|Evanston, Illinois, United States|Evergreen Park, Illinois, United States|Flossmoor, Illinois, United States|Melrose Park, Illinois, United States|Morton, Illinois, United States|Naperville, Illinois, United States|Quincy, Illinois, United States|Rockford, Illinois, United States|Bloomington, Indiana, United States|Brownsburg, Indiana, United States|Lafayette, Indiana, United States|Valparaiso, Indiana, United States|Iowa City, Iowa, United States|Lenexa, Kansas, United States|Overland Park, Kansas, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Elizabethtown, Kentucky, United States|Lexington, Kentucky, United States|Owensboro, Kentucky, United States|Paducah, Kentucky, United States|Mer Rouge, Louisiana, United States|Monroe, Louisiana, United States|Shreveport, Louisiana, United States|Biddeford, Maine, United States|Rockport, Maine, United States|Baltimore, Maryland, United States|Cumberland, Maryland, United States|Hagerstown, Maryland, United States|Lutherville, Maryland, United States|Wheaton, Maryland, United States|Brockton, Massachusetts, United States|Fall River, Massachusetts, United States|Hyannis, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Bingham Farms, Michigan, United States|Chelsea, Michigan, United States|Detroit, Michigan, United States|Flint, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Chaska, Minnesota, United States|Duluth, Minnesota, United States|Edina, Minnesota, United States|Saint Paul, Minnesota, United States|Jackson, Mississippi, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|Clarkson Valley, Missouri, United States|Hazelwood, Missouri, United States|Kansas City, Missouri, United States|Saint Charles, Missouri, United States|Saint Louis, Missouri, United States|Washington, Missouri, United States|Billings, Montana, United States|Butte, Montana, United States|Bellevue, Nebraska, United States|Grand Island, Nebraska, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Brick, New Jersey, United States|Edison, New Jersey, United States|Oradell, New Jersey, United States|Albuquerque, New Mexico, United States|Las Vegas, New Mexico, United States|Endwell, New York, United States|Freeport, New York, United States|Glens Falls, New York, United States|Mineola, New York, United States|New Windsor, New York, United States|New York, New York, United States|Rochester, New York, United States|West Seneca, New York, United States|Westfield, New York, United States|Asheboro, North Carolina, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Columbia, North Carolina, United States|Greensboro, North Carolina, United States|Huntersville, North Carolina, United States|Lenoir, North Carolina, United States|Monroe, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Shelby, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Akron, Ohio, United States|Centerville, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Delaware, Ohio, United States|Franklin, Ohio, United States|Kettering, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Mentor, Ohio, United States|Middleburg Heights, Ohio, United States|Toledo, Ohio, United States|Willoughby Hills, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Ashland, Oregon, United States|Bend, Oregon, United States|Eugene, Oregon, United States|Portland, Oregon, United States|Altoona, Pennsylvania, United States|Bensalem, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Downingtown, Pennsylvania, United States|Duncansville, Pennsylvania, United States|Ephrata, Pennsylvania, United States|Harleysville, Pennsylvania, United States|Lansdale, Pennsylvania, United States|McMurray, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Quakertown, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Cumberland, Rhode Island, United States|East Providence, Rhode Island, United States|Providence, Rhode Island, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|Greenwood, South Carolina, United States|Greer, South Carolina, United States|Myrtle Beach, South Carolina, United States|Orangeburg, South Carolina, United States|Pelzer, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Athens, Tennessee, United States|Chattanooga, Tennessee, United States|Clarksville, Tennessee, United States|Collierville, Tennessee, United States|Fayetteville, Tennessee, United States|Jackson, Tennessee, United States|Kingsport, Tennessee, United States|Memphis, Tennessee, United States|New Tazewell, Tennessee, United States|Bellaire, Texas, United States|Carrollton, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Fort Worth, Texas, United States|Grapevine, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|McKinney, Texas, United States|New Braunfels, Texas, United States|Odessa, Texas, United States|Pearland, Texas, United States|Plano, Texas, United States|Richardson, Texas, United States|San Antonio, Texas, United States|Southlake, Texas, United States|Sugar Land, Texas, United States|Tomball, Texas, United States|Waco, Texas, United States|Bountiful, Utah, United States|Draper, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Alexandria, Virginia, United States|Arlington, Virginia, United States|Burke, Virginia, United States|Danville, Virginia, United States|McLean, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Salem, Virginia, United States|Virginia Beach, Virginia, United States|Port Orchard, Washington, United States|Tacoma, Washington, United States|Clarksburg, West Virginia, United States|Green Bay, Wisconsin, United States|Milwaukee, Wisconsin, United States|New Berlin, Wisconsin, United States|Oregon, Wisconsin, United States|Verona, Wisconsin, United States|Waukesha, Wisconsin, United States|Weston, Wisconsin, United States|Jalisco, Distrito Federal, Mexico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01101035/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01101035/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01101035"
1143,"NCT04160468","Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase","DISRUPT","Recruiting","No Results Available","Staphylococcus Aureus Bacteremia|Staphylococcus Aureus Endocarditis","Drug: Exebacase|Drug: Placebo","Clinical responder rate at Day 14 in the methicillin-resistant Staphylococcus aureus (MRSA) population|Treatment-emergent adverse events (TEAEs) through Day 60|Clinical responder rate at Day 14 in all S. aureus patients|30-day survival in the MRSA population|Clinical responder rate at Day 60 in the MRSA population|Clinical responder rate at Day 60 in all S. aureus patients|Clinical responder rate at Day 60 in right-sided IE patients (all S. aureus and MRSA populations)","ContraFect","All","18 Years and older   (Adult, Older Adult)","Phase 3","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CF-301-105","December 20, 2019","August 2021","October 2021","November 13, 2019",,"April 17, 2020","Cf 301-105, Augusta, Georgia, United States|CF-301-105 Study Site, Idaho Falls, Idaho, United States|CF-301-105 Study Site, Burlington, Massachusetts, United States|CF-301-105 Study Site, Columbia, Missouri, United States|CF-301-105 Study Site, Butte, Montana, United States|Cf 301-105, Omaha, Nebraska, United States|CF-301-105 Study Site, Englewood, New Jersey, United States|CF-301-105 Study Site, Bronx, New York, United States|CF-301-105 Study Site, Greenville, North Carolina, United States|CF-301-105 Study Site, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04160468"
1144,"NCT01672346","PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation","ZODIAC","Recruiting","No Results Available","Paroxysmal Atrial Fibrillation","Procedure: PVAI followed by adenosine provocation","AF recurrence","Texas Cardiac Arrhythmia Research Foundation|California Pacific Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","188","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZODIAC_TCAI","May 2013","December 2019","December 2020","August 24, 2012",,"April 10, 2019","St. david's Medical Center, Austin, Texas, United States|Texas Cardiac arrhythmia Institute, St. David's Hospital, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01672346"
1145,"NCT01227629","PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin",,"Completed","Has Results","Atrial Fibrillation","Drug: dabigatran with ASA|Drug: warfarin|Drug: dabigatran without ASA","Number of Participants With Fatal or Life-threatening Major Bleeding Events|Number of Participants With Minor/Relevant Bleeding Events|Number of Participants With Minor/Nuisance Bleeding Events|Number of Participants With Thromboembolic Events: Composite Endpoint|Number of Participants With Thromboembolic Events: Ischemic Stroke|Thromboembolic Events: Number of Participants With Transient Ischemic Attack|Thromboembolic Events: Number of Participants With Systemic Thromboembolism|Thromboembolic Events: Number of Participants With Myocardial Infarction|Thromboembolic Events: Number of Participants With Other Major Cardiac Events|Thromboembolic Events: Number of Participants Who Died|D-dimer: Difference From Baseline|Soluble Fibrin: Difference From Baseline|11-dehydrothromboxane B2 (TXB2): Difference From Baseline|Ecarin Clotting Time (ECT): Difference From Baseline|Activated Partial Thromboplastin Time (aPTT): Difference From Baseline|Trough Plasma Concentration of Dabigatran (BIBR 953)|Number of Participants With Increase of Aspartat-Aminotransferase (AST) to >2*Baseline|Number of Participants With Increase of Alkaline Phosphatase (AP) to >2*Baseline|Number of Participants With Increase of Bilirubin to >2*Baseline|Number of Participants With Increase of Alanine-Aminotransferase (ALT) to >2*Baseline|Severity of Adverse Events","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","502","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention","1160.20|PETRO trial","September 2003","November 2004",,"October 25, 2010","February 10, 2011","May 5, 2014","1160.20.10010, Fayetteville, Arkansas, United States|1160.20.10003 La Mesa Cardiac, La Mesa, California, United States|1160.20.10006 The Ford Research Institute, PA, Pensacola, Florida, United States|1160.20.10004, Port Charlotte, Florida, United States|1160.20.10002, St. Petersburg, Florida, United States|1160.20.10015, Baltimore, Maryland, United States|1160.20.10008, Westminister, Maryland, United States|1160.20.10012, Pittsfield, Massachusetts, United States|1160.20.10007, Troy, Michigan, United States|1160.20.10014, Hawthorne, New York, United States|1160.20.10013, New Hyde Park, New York, United States|1160.20.10009, North Durham, North Carolina, United States|1160.20.10001, Philadelphia, Pennsylvania, United States|1160.20.10005, Germantown, Tennessee, United States|1160.20.45010, Aalborg, Denmark|1160.20.45005 Aarhus Sygehus, Aarhus C, Denmark|1160.20.45007 Medicinsk afdeling, Brædstrup, Denmark|1160.20.45011 Medicinsk afd., Esbjerg, Denmark|1160.20.45012 Afdeling B3, Frederikssund, Denmark|1160.20.45003 Forskningscentret plan 3, Helsingør, Denmark|1160.20.45004 Herlev Hospital, Herlev, Denmark|1160.20.45009 Medicinsk amb. B8, Holbæk, Denmark|1160.20.45002 Kardiologisk afdeling, Hvidovre, Denmark|1160.20.45014 Hjertemedicinsk afd., Køge, Denmark|1160.20.45001 Kardiologisk Laboratorium, Odense, Denmark|1160.20.45013 Kardiologisk afd., Roskilde, Denmark|1160.20.45006 Medicinsk afdeling, Svendborg, Denmark|1160.20.46013 HIA, Mälarsjukhuset, Eskilstuna, Sweden|1160.20.46007 Falu Lasarett, Falun, Sweden|1160.20.46005 Ryhovs Länssjukhus, Jönköping, Sweden|1160.20.46010 Länssjukhuset Kalmar, Kalmar, Sweden|1160.20.46009 Universitetssjukhuset MAS, Malmö, Sweden|1160.20.46008 Vrinnevisjukhuset, Norrköping, Sweden|1160.20.46002 Södersjukhuset, Stockholm, Sweden|1160.20.46011 Arytmienheten, Med klin, Stockholm, Sweden|1160.20.46006 Norrlands Universitetssjukhus, Umeå, Sweden|1160.20.46003 Centrallasarettet, Västerås, Sweden|1160.20.46004 Universitetssjukhuset, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT01227629"
1146,"NCT03385239","Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)",,"Active, not recruiting","No Results Available","Hypertriglyceridemia|Cardiovascular Diseases","Drug: ISIS 678354|Drug: Placebo","Efficacy of different doses and dosing regimens of ISIS 678354 on the reduction in serum triglyceride (TG) levels from baseline at the primary analysis time point.|The safety of ISIS 678354 by the incidence of treatment-emergent adverse events.|Efficacy of different doses and dosing regimens of ISIS 678354 on serum triglyceride (TG) levels from baseline at the primary analysis time point.|To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein C-III (apoC-III).|To evaluate the efficacy of ISIS 678354 on serum levels of cholesterol parameters.|To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein B100 (apoB).|To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein A-1 (apoA-I).|Plasma Cmax of ISIS 678354 across different doses and dose regimens.|Plasma Tmax of ISIS 678354 across different doses and dose regimens.|Plasma AUC values of ISIS 678354 across different doses and dose regimens.","Akcea Therapeutics|Ionis Pharmaceuticals, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISIS 678354-CS2","January 5, 2018","November 25, 2019","February 28, 2020","December 28, 2017",,"February 17, 2020","Clinical Site, Cottonwood, Arizona, United States|Clinical Site, Little Rock, Arkansas, United States|Clinical Site, Carmichael, California, United States|Clinical Site, Fresno, California, United States|Clinical Site, La Jolla, California, United States|Clinical Site, Long Beach, California, United States|Clinical Site, Montclair, California, United States|Clinical Site, Wilmington, Delaware, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jacksonville, Florida, United States|Clinical Site, New Port Richey, Florida, United States|Clinical Site, Munster, Indiana, United States|Clinical Site, Ames, Iowa, United States|Clinical Site, Kansas City, Kansas, United States|Clinical Site, Louisville, Kentucky, United States|Clinical Site, Fall River, Massachusetts, United States|Clinical Site, Cooperstown, New York, United States|Clinical Site, High Point, North Carolina, United States|Clinical Site, Portland, Oregon, United States|Clinical Site, Lansdale, Pennsylvania, United States|Clinical Site, Providence, Rhode Island, United States|Clinical Site, Greer, South Carolina, United States|Clinical Site, Houston, Texas, United States|Clinical Site, Milwaukee, Wisconsin, United States|Clinical Site, Cambridge, Ontario, Canada|Clinical Site, Sudbury, Ontario, Canada|Clinical Site, Brossard, Quebec, Canada|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Gatineau, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada|Clinical Site, Québec, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03385239"
1147,"NCT03163446","Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia",,"Completed","No Results Available","Staphylococcus Aureus Bacteremia|Staphylococcus Aureus Endocarditis","Biological: CF-301|Drug: Placebo","Incidence of adverse events [Safety and Tolerability]|Clinical outcome at Day 14 (improvement, response, non-response)|CF-301 Maximum plasma concentration (Cmax) and time to Cmax|CF-301 time to clearance|Clinical outcome at Day 7 (improvement, response, non-response)|Clinical outcome at End of Standard of Care Therapy (EOT) (response, non-response)|Clinical outcome at Test of Cure (TOC) (response, non-response)|Clearance of bacteremia at Day 7 after CF-301/placebo administration|Clearance of bacteremia at Day 14 after CF-301/placebo administration|Microbiological eradication at end of standard-of-care antibacterial therapy (EOT)|Microbiological eradication at test of cure (TOC)","ContraFect","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CF-301-102","May 23, 2017","March 7, 2019","March 7, 2019","May 23, 2017",,"May 20, 2019","CF-301-102 Study Site, Birmingham, Alabama, United States|CF-301-102 Study Site, Sacramento, California, United States|CF301-102 Study Site, Sylmar, California, United States|CF-301-102 Study Site, New Haven, Connecticut, United States|CF-301-102 Study Site, Newark, Delaware, United States|CF-301-102 Study Site, Atlanta, Georgia, United States|CF-301-102 Study Site, Augusta, Georgia, United States|CF0301-102 Study Site, Decatur, Georgia, United States|CF-301 Study Site, Idaho Falls, Idaho, United States|CF301-102 Study Site, Chicago, Illinois, United States|CF301-102 Study Site, Burlington, Massachusetts, United States|CF-301-102 Study Site, Detroit, Michigan, United States|CF301-102 Study Site, Royal Oak, Michigan, United States|CF301-102 Study Site, Saint Louis, Missouri, United States|CF301-102 Study site, Butte, Montana, United States|CF301-102 Study Site, Omaha, Nebraska, United States|CF-301-102 Study Site, Omaha, Nebraska, United States|CF-301-102 Study Site, Englewood, New Jersey, United States|CF301-102 Study Site, Paterson, New Jersey, United States|CF-301-102 Study Site, New York, New York, United States|CF-301-102 Study Site, New York, New York, United States|CF-301-102 Study Site, Valhalla, New York, United States|CF-301-102 Study Site, Cleveland, Ohio, United States|CF301-102 Study Site, Columbus, Ohio, United States|Cf-301-102, Columbus, Ohio, United States|CF-301 Study Site, Toledo, Ohio, United States|CF-301-102 Study Site, Bethlehem, Pennsylvania, United States|Cf-301-102, Richmond, Virginia, United States|CF-301-102 Study Site, Roanoke, Virginia, United States|CF-301-102 Study Site, Seattle, Washington, United States|CF-301-102 Study Site, Milwaukee, Wisconsin, United States|CF-301-102 Study Site #2, Brussels, Belgium|CF301-102 Study Site, Brussels, Belgium|CF301-102 Study Site, Edegem, Belgium|CF301-102 Study Site, Ghent, Belgium|CF301-102 Study Site, Leuven, Belgium|CF301-102 Study Site, Ruse, Bulgaria|CF301-102 Study Site, Sofia, Bulgaria|CF-301-102 Study Site, Santiago, Chile|CF-301-102 Study Site, Viña Del Mar, Chile|CF301-102 Study Site, Brno, Czechia|CF301-102 Study Site #2, Prague, Czechia|CF301-102 Study Site, Prague, Czechia|CF301-102 Study Site, Limoges, France|CF301-102 Study Site, Lyon, France|CF301-102 Study Site, Paris, France|CF301-102 Study Site, Toulon, France|CF-301-102 Study Site #2, Berlin, Germany|CF-301-102 Study Site, Berlin, Germany|CF-301-102 Study Site, Cologne, Germany|CF-301-102 Study Site, Freiburg, Germany|CF301-102 Study Site #3, Athens, Greece|CF301-102 Study Site, Athens, Greece|Study Site #2, Athens, Greece|CF301-102 Study Site, Larissa, Greece|CF-301-102 Study Site, Guatemala City, Guatemala|CF-301-102 Study Site, Santa Rosita, Guatemala|CF301-102 Study Site, Be'er Sheva, Israel|CF301-102 Study Site, Nazareth, Israel|CF301-102 Study Site, Safed, Israel|CF301-102 Study Site, Tel HaShomer, Israel|CF301-102 Study Site, Bergamo, Italy|CF-301-102 Study Site, Busto Arsizio, Italy|CF-301-102 Study Site, Genoa, Italy|CF-301-102 Study Site, Krasnodar, Russian Federation|CF-301-102 Study Site, Moscow, Russian Federation|CF-301-102 Study Site, St. Pertersburg, Russian Federation|CF-301-102 Study Site #2, St. Petersburg, Russian Federation|Cf301-102, Barcellona, Spain|CF-301-102 Study Site #2, Barcelona, Spain|CF301-102 Study Site, Córdoba, Spain|CF301-102 Study Site, Seville, Spain|CF301-102 Study Site, Terrassa, Spain|CF301-102 Study Site, Chelmsford, United Kingdom|CF301-102 Study Site, Liverpool, United Kingdom|CF-301-102 Study Site, London, United Kingdom|CF301-102 Study Site #2, London, United Kingdom|CF301-102 Study Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03163446"
1148,"NCT02871778","Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia","CLEAN-PCD","Completed","No Results Available","Primary Ciliary Dyskinesia","Drug: VX-371|Drug: Hypertonic Saline|Drug: Placebo (0.17% saline)|Drug: Ivacaftor","Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs) in Part A and Part B|Absolute change in percent predicted FEV1 in Part A and Part B|Change in Quality of Life (QOL), as determined by mean change in QOL-PCD and SGRQ (St. George's Respiratory Questionnaire) scores in Part A and Part B","Vertex Pharmaceuticals Incorporated|Parion Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PS-G202|2015-004917-26","August 2016","November 20, 2018","November 20, 2018","August 18, 2016",,"November 25, 2019","Birmingham, Alabama, United States|Palo Alto, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Miami, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Minneapolis, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Columbia, South Carolina, United States|Seattle, Washington, United States|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Copenhagen, Denmark|Munster, North Rhine-Westphalia, Germany|Hannover, Germany|Heidelberg, Germany|Pisa, Italy|Amsterdam, Netherlands|Rotterdam, Netherlands|Rabka-Zdroj, Poland|Cambridge, United Kingdom|London, United Kingdom|Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02871778"
1149,"NCT02460211","Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D","ASSESS-D","Active, not recruiting","No Results Available","Cardiovascular Disease|Vitamin D Deficiency","Dietary Supplement: Vitamin D3|Dietary Supplement: Placebo","Changes in 25(OH) vitamin D levels (ng/ml) between baseline (pre-surgery) and 72 hours post-surgery.|Comparison of 25(OH) vitamin D levels (ng/ml) between baseline and other time points.|Percent differences in adverse clinical outcomes between the vitamin D3 supplementation treatment and placebo arms.|Time to adverse clinical events stratified by vitamin D3 supplementation and placebo arms.","Intermountain Health Care, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1040458","July 2015","October 1, 2018","October 2019","June 2, 2015",,"February 1, 2019","Intermountain Heart Institute, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02460211"
1150,"NCT02057692","Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome","ITCH","Completed","Has Results","Alagille Syndrome","Drug: LUM001|Drug: Placebo","Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus|Change From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level|Change From Baseline to Endpoint (Week 13/Early Termination) in Liver Enzyme Levels|Change From Baseline to Endpoint (Week 13/Early Termination) in Total and Direct Bilirubin Concentrations","Mirum Pharmaceuticals, Inc.|Childhood Liver Disease Research and Education Network","All","12 Months to 18 Years   (Child, Adult)","Phase 2","37","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LUM001-301","November 24, 2014","November 16, 2016","November 16, 2016","February 7, 2014","January 23, 2018","March 26, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02057692"
1151,"NCT01090310","Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis","ENDURE","Terminated","Has Results","Non-infectious Uveitis","Drug: AIN457|Drug: Placebo","The Time to the First Recurrence in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline|Change in Vitreous Haze Score for the Study Eye From Baseline to the Highest Post-baseline Value|Mean Change in Best Corrected Visual Acuity From Baseline, Core and Extension|Number of Participants With First Recurrence in in Any Eye of Active Intermediate, Posterior, or Panuveitis From Baseline During the Core and Extension Studies|Composite Immunosuppressive Medication Score From Baseline to Week 52, Core and Extension","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAIN457C2301E1|2009-015508-24","August 2010","July 2011","July 2011","March 19, 2010","January 14, 2016","January 14, 2016","Novartis Investigative Site, Beverly Hills, California, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Cambridge, Massachusetts, United States|Novartis Investigative Site, Teaneck, New Jersey, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Lausanne, CHE, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Luzern, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01090310"
1152,"NCT01659580","Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina","CAESA","Completed","No Results Available","Angina Pectoris","Drug: T89 high dose|Drug: T89 Low dose|Drug: Sanqi+Bingpian|Drug: Placebo","The change of symptom-limited TED from baseline compared to placebo at the end of week 4.|The change of symptom-limited TED at trough drug levels at the end of the 2nd and 6th weeks|Frequency of weekly angina episodes","Tasly Pharmaceuticals, Inc.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 3","1004","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","T89-07-CAESA|T89-07-GL","August 2012","December 2016","December 2016","August 8, 2012",,"March 9, 2017","Cardiology and Medicine Clinic, Little Rock, Arkansas, United States|Beaver Medical Clinic, Banning, California, United States|Foundation for Cardiovascular Medicine, La Jolla, California, United States|Precision Research Institute, National City, California, United States|Paradigm Clinical Research Institute, Inc., Torrance, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Brevard Cardiovascular Research Associates, Merritt, Florida, United States|NewPhase Clinical Trials, Inc., Miami Beach, Florida, United States|SouthCoast Research Center, Inc, Miami, Florida, United States|Molecular Imaging Research and Clinical Trials, Miami, Florida, United States|Integrity Clinical Trials, Miami, Florida, United States|Peninsula Research, Inc., Ormond Beach, Florida, United States|Cardiovascular Center of Sarasota, Sarasota, Florida, United States|Jedidiah Clinical Research, Tampa, Florida, United States|Athens Heart Center, Athens, Georgia, United States|Atlanta Clinical Research Center, Atlanta, Georgia, United States|Ellipsis Research, Atlanta, Georgia, United States|Central Cardiology, Campbellsville, Kentucky, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Tulane University Health Science Center, Tulane University Heart & Vascular Institute, New Orleans, Louisiana, United States|Manhattan Medical Research Practice, New York, New York, United States|Cleveland Clinic, Medina, Ohio, United States|Hillsboro Cardiology, PC, Hillsboro, Oregon, United States|Kore CV Research, Jackson, Tennessee, United States|Tennessee Center for Clinical Trials, Tullahoma, Tennessee, United States|Angiocardiac Care of Texas, PA, Houston, Texas, United States|Northwest Houston Cardiology, Houston, Texas, United States|Cardiology Center of Houston, PA, Katy, Texas, United States|Northwest Heart Center, Tomball, Texas, United States|Minsk Regional Clinical Hospital, Minsk, Belarus|Dr. Petr Polasek, MD, Office of, Kelowna, British Columbia, Canada|The Medical Arts Health Research Group, North Vancouver, British Columbia, Canada|Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Dixie Medical Group, Mississauga, Ontario, Canada|Bakbak Medicine Professional Corporation, Oshawa, Ontario, Canada|Heart Care Research, Oshawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|ViaCar Recherche Clinique Inc., Brossard, Quebec, Canada|ViaCar Recherche Clinique Inc., Greenfield Park, Quebec, Canada|Centre Cardiovasculaire De La Rive-Sud (Ccrs), Longueuil, Quebec, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Clinique Sante Cardio MC, Montreal, Quebec, Canada|Centre de Sante et de Services Sociaux de Trois-Rivieres, Trois-Rivieres, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada|The ""Unimed Ajara"", Batumi, Georgia|Cardiological CLinic ""Guli"" Ltd, Tbilisi, Georgia|Archangel St. Michael Multiprofile Clinical Hospital, Tbilisi, Georgia|Cardio-Reanimation Centre, Tbilisi, Georgia|Emergency Cardiology Center named by Academician G. Chapidze Ltd, Tbilisi, Georgia|Tbilis Heart and vascular clinic Ltd., Tbilisi, Georgia|Center of Vascular and Heart Diseases Ltd., Tbilisi, Georgia|""Clinic L J"" Ltd, Tbilisi, Georgia|Consultorio Medico de Especialidad, Tijuana, Baja California, Mexico|Centro para el Desarrollo de la Medicina y Asistencia Médica Especializada SC sede Torreon Coahuila, Torreón, Coahuila, Mexico|Cardiocen de Guadalajara, S.C., Guadalajara, Jalisco, Mexico|Centro de Investigación Clínica Chapultepec, Morelia, Michoacán, Mexico|Centro para el Desarollo de la Medicina y de Asistencia Medica Esp. S.C., Culiacan, Sinaloa, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosí, SLP, Mexico|Hospital de Cardiología de Aguascalientes, Aguascalientes, Mexico|OSMO, Oaxaca, Mexico|Regional Buegetary Healthcare Institution ""Cardiological Dispensary"", Ivanovslaya, Ivanovslaya Obl., Russian Federation|State Budgetary Healthcare Institution ""State Novosibirsk Regional Clinical Hospital"", Novosibirsk, Russia, Russian Federation|Regional Cardiology Center, Volgograd, Russia, Russian Federation|Smolensk State Medical Academy Of Roszdrav, Smolensk, Smoleskaya oblast, Russian Federation|Federal State Budgetary Institution Research Institution Of Cardiology Of Sibirsky, Tomsk, Tomskaya Obl., Russian Federation|Ural Medical Academy, Ekaterinburg, Russian Federation|Nonstate Healthcare Institution ""Departmental Clinical Hospital on Kemerovo Station of Public Corporation ""Russian Railroad"", Kemerovo, Russian Federation|Krasnodar regional hospital #1 n.a. Prof. Ochapovskiy S.V., Krasnodar, Russian Federation|Moscow State Healthcare Institution, City Clinical Hospital #15, Moscow, Russian Federation|First Moscow State Medical University, Moscow, Russian Federation|Almazov Federal Heart, Blood And Endocrinology Centre, Saint-Petersburg, Russian Federation|City Polyclinic # 109, St. Petersburg, Russian Federation|City Hospital #38 named after Semashko N.A., St. Petersburg, Russian Federation|Almazov Federal Heart, Blood And Endocrinology Centre, St. Petersburg, Russian Federation|St. Petersburg State Health Care, Institution Pokrovskaya City Hospital, St. Petersburg, Russian Federation|Tyumen Cardiology Center, Tyumen, Russian Federation|City Hospital #4, Vladimir, Russian Federation|Clinical Hospital n.a. N.V. Solovyov, Yaroslavl, Russian Federation|Regional medical center of cardiovascular diseases, Zaporizhzhya, Zaporizhzhya region, Ukraine|Department of internal diseases #2, Zaporizhzhya, Zaporizhzhya region, Ukraine|Ivano-Frankivsk Regional Clinical Cardiology Dispensary, department of anesthesiology with intensive care unit, Ivano-Frankivsk, Ukraine|L.T. Malaya Therapy Institute of National Academy of Medical Sciences of Ukraine, Head of Cardiopulmonology Department Government Institution, Kharkiv, Ukraine|L.T. Malaya Therapy Institute of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine|Institute Of Gerontology, Department Of Clinical Physiology And Pathology Of Internal Organs, Kiev, Ukraine|Kyiv Oleksandrivska Clinical Hospital, Kiev, Ukraine|Municipal Clinical Hospital #1, Kiev, Ukraine|National medical university named after O.O.Bogomolets, Kiev, Ukraine|Lviv Regional State Clinical Threatment-and-Diagnostic Cardiology Center, Lviv, Ukraine|Department of Family Medicine and General Practice of Odessa National Medical University, Odessa, Ukraine|City Clinical Hospital No. 3, Odessa, Ukraine|Odessa regional cardiological dispensary, Odessa, Ukraine|District Clinical Hospital Of Station ""Uzhgorod"", Dgto ""Lviv Railway Station"" Therapeutic Department, Uzhgorod, Ukraine|City Clinical Hospital # 1, Vinnitsa, Ukraine|Vinnytsya Regional Specialized Center for Radiation Protection of People, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01659580"
1153,"NCT02624765","FAST Therapy Trial of Fetal Tachyarrhythmia",,"Recruiting","No Results Available","Fetal Atrial Flutter Without Hydrops|Fetal Supraventricular Tachycardia Without Hydrops|Fetal Supraventricular Tachycardia With Hydrops","Drug: Digoxin (monotherapy)|Drug: Sotalol (monotherapy)|Drug: Flecainide (monotherapy)|Drug: Digoxin (dual therapy)|Drug: Sotalol (dual therapy)|Drug: Flecainide (dual therapy)","Proportion of live-born children with a delivery at term and a normal cardiac rhythm|Proportion of patients with cardioversion over time|Proportion of participants with treatment failure|Proportion of participants with arrhythmia-related death|Average gestational age at birth|Birth weight z-scores|Total days of treatment related maternal and neonatal hospitalizations|Maternal prevalence of adverse events and outcome","Edgar Jaeggi|Canadian Institutes of Health Research (CIHR)|St George's, University of London|The Hospital for Sick Children","Female","16 Years to 50 Years   (Child, Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000039945","February 2016","March 2021","June 30, 2021","December 8, 2015",,"August 14, 2019","Morgan Stanley Children's Hospital, UCSF, San Francisco, California, United States|Children's Hospital of Colorado, Denver, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|Cohen Children's Medical Center, New York, New York, United States|Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Monroe Carell Jr. Children's Hospital, Vanderbilt, Nashville, Tennessee, United States|Austin Children's Hospital, Austin, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|West Virginia University Hospitals, Morgantown, West Virginia, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|The Royal Women's Hospital, Melbourne, Australia|University of Alberta/WCCHN, Edmonton, Canada|Sainte-Justine Hospital, Montreal, Canada|Mount Sinai Hospital, Toronto, Canada|The Hospital for Sick Children, Toronto, Canada|British Columbia Children's Hospital, Vancouver, Canada|UKB Universitätsklinikum BONN, Bonn, Germany|Academic Medical Center - AMC, Amsterdam, Netherlands|Leiden University Medical Center - LUMC, Leiden, Netherlands|Erasmus Medical Center Rotterdam, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Belfast Health and Social Care Trust, Belfast, United Kingdom|Fetal Medicine Centre, Birmingham Women's Foundation Trust, Birmingham, United Kingdom|The Ian Donald Centre for Foetal Medicine, Southern General Hospital, Glasgow, United Kingdom|Liverpool Women's Hospital, Liverpool, United Kingdom|Chelsea and Westminster, London, United Kingdom|St George's University Hospital Foundation Trust, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02624765/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02624765"
1154,"NCT01259297","A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","APOLLO","Terminated","Has Results","Cardiovascular Events","Drug: Aliskiren|Drug: Amlodipine|Drug: Hydrochlorothiazide (HCTZ)|Drug: Placebo for Aliskiren|Drug: Placebo for Amlodipine|Drug: Placebo for Hydrochlorothiazide (HCTZ)","Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen|Number of Participants With Composite Cardiovascular Endpoints in Aliskiren+Amlodipine/HCTZ Group Versus All Placebo Group|Change From Baseline to End of Study in Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part I)|Percentage of Participants With Standard Assessment of Global Activities in the Elderly (SAGE) Dimensions (Part II)|Number of Participants With Renal Dysfunction in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen|Number of Participants With Total Mortality in Aliskiren Based Regimen Versus Non-aliskiren Based Regimen","Novartis Pharmaceuticals|Novartis","All","65 Years and older   (Older Adult)","Phase 3","2336","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSPP100G2301|2009-010170-38","January 2011","November 2012","November 2012","December 14, 2010","April 8, 2014","April 8, 2014","Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Sylmar, California, United States|Novartis Investigative Site, Tucker, Georgia, United States|Novartis Investigative Site, Pocatello, Idaho, United States|Novartis Investigative Site, Haverhill, Massachusetts, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Westfiled, New York, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Marshfield, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Coronel Suarez, Buenos Aires, Argentina|Novartis Investigative Site, Jenin, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Merlo, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, San Nicolas, Buenos Aires, Argentina|Novartis Investigative Site, Cipolletti, Rio Negro, Argentina|Novartis Investigative Site, Tucuman, San Miguel de Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Venado Tuerto, Santa Fe, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Salta, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Uberaba, MG, Brazil|Novartis Investigative Site, Campina Grande do Sul, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Marilia, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Votuporanga, SP, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Coquitlam, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, St. John's, Newfoundland and Labrador, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Markham, Ontario, Canada|Novartis Investigative Site, Missisauga, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Niagara Falls, Ontario, Canada|Novartis Investigative Site, North York, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, St Catherines, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Lévis, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sainte Foy, Quebec, Canada|Novartis Investigative Site, Sainte-Foy, Quebec, Canada|Novartis Investigative Site, St.Gorges de Beauce, Quebec, Canada|Novartis Investigative Site, Terrebonne, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Temuco, Cautin, Chile|Novartis Investigative Site, Vista Del Mar, I Region, Chile|Novartis Investigative Site, Temuca, TX, Chile|Novartis Investigative Site, Osorno, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Barranquilla, Atlantico, Colombia|Novartis Investigative Site, Cartagena, Bolivar, Colombia|Novartis Investigative Site, Manizoles, Caldas, Colombia|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Pereira, Risaralda, Colombia|Novartis Investigative Site, Floridablanca, Santander, Colombia|Novartis Investigative Site, Armenia, Colombia|Novartis Investigative Site, Baranquilla, Colombia|Novartis Investigative Site, Barranquilla, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Bogotá, Colombia|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Cartegena, Colombia|Novartis Investigative Site, Espinal, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Pasto, Colombia|Novartis Investigative Site, Beroun, Czech Republic|Novartis Investigative Site, Brandys nad Labem, Czech Republic|Novartis Investigative Site, Novy Jicin, Czech Republic|Novartis Investigative Site, Prague 4, Czech Republic|Novartis Investigative Site, Prague 6, Czech Republic|Novartis Investigative Site, Praha 9, Czech Republic|Novartis Investigative Site, Uherske Hradiste, Czech Republic|Novartis Investigative Site, Usti nad Orlici, Czech Republic|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Melsungen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyongyos, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Komarom, Hungary|Novartis Investigative Site, Mosonmagyarovar, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Sopron, Hungary|Novartis Investigative Site, Szentes, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Adoni, Andhra Pradesh, India|Novartis Investigative Site, Adoni, Andhra Pradesh, India|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Visakhapatnam, Andhra Pradesh, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Ahmedabad, Gujarat, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Belgaum, Karnataka, India|Novartis Investigative Site, Bengaluru, Karnataka, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Wardha, Maharashtra, India|Novartis Investigative Site, Jalandhar, Punjab, India|Novartis Investigative Site, Ludhiana, Punjab, India|Novartis Investigative Site, Bikaner, Rajasthan, India|Novartis Investigative Site, Tiruvannamalai, Tamil Nadu, India|Novartis Investigative Site, Trichy, Tamil Nadu, India|Novartis Investigative Site, Lucknow, Uttar Pradesh, India|Novartis Investigative Site, Chennai, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, Trichy, India|Novartis Investigative Site, Gorey, Co. Wexford, Ireland|Novartis Investigative Site, Ballinsloe, Galway, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Givatayim, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Safed, Israel|Novartis Investigative Site, Alor Setar, Kedah, Malaysia|Novartis Investigative Site, Kota Bahru, Kelantan, Malaysia|Novartis Investigative Site, Kota Bharu, Kelantan, Malaysia|Novartis Investigative Site, Kuantan, Pahang, Malaysia|Novartis Investigative Site, Batu Caves, Selangor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leiderdorp, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Velp, Netherlands|Novartis Investigative Site, Zoetermeer, Netherlands|Novartis Investigative Site, Dasmarinas, Cavite, Philippines|Novartis Investigative Site, Laoag City, Ilocos Norte, Philippines|Novartis Investigative Site, Quezon City, Metro Manila, Philippines|Novartis Investigative Site, Binan City, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Pasig City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Paarl, Western Province, South Africa|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Ferrol, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Puerto de Sagunto, Spain|Novartis Investigative Site, Dalby, Sweden|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Malmö, Sweden|Novartis Investigative Site, Rättvik, Sweden|Novartis Investigative Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01259297"
1155,"NCT01018849","Role of Vitamin D in Secondary Prevention of Cardiovascular Events",,"Completed","No Results Available","Cardiovascular Disease","Dietary Supplement: Cholecalciferol|Dietary Supplement: Placebo","To give oral vitamin D supplements and raise the blood levels of 25-OH D in the study subjects to >30ng/ml.|To see if raising the serum 25(OH) D levels reduces the incidence of cardiovascular events in patients with coronary artery disease (CAD).|To see if higher serum 25(OH) D levels will help in better control of blood pressure.|To perform proteomics analysis to: a) Extract total protein; b) Profile protein expression in 2-DE and /or 2-DLC and direct mass spectrometric analysis (dMS) on the serum of vitamin D supplemented and placebo subjects.|To compare protein expression profiles and/or MS spectrum pattern recognition, and identify differentially expressed proteins in vitamin D supplemented and placebo subjects.|To obtain bone mineral density measurements (by DXA) and assess bone markers in subjects with known coronary artery disease","Creighton University","All","19 Years and older   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","08-15149","July 2009","July 2013","May 2015","November 25, 2009",,"January 15, 2016","The Cardiac Center at Creighton University, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT01018849"
